PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Coghill, D; Markovitch, H				Coghill, D; Markovitch, H			Use of stimulants for attention deficit hyperactivity disorder	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Definitive diagnosis of attention deficit hyperactivity disorder is complex. David Coghill believes the condition is undertreated, but Harvey Markovitch argues that cut rent uncertainties about diagnosis and treatment mean doctors should be cautious	Univ Dundee, Ctr Child Hlth, Div Pathol & Neurosci Psychiat, Dundee DD3 6HH, Scotland	University of Dundee	Coghill, D (corresponding author), Univ Dundee, Ctr Child Hlth, Div Pathol & Neurosci Psychiat, Dundee DD3 6HH, Scotland.	david.coghill@tpct.scot.nhs.uk; h.marcovitch@btinternet.com	Coghill, David R/B-7244-2009; Coghill, David/ABF-5213-2020; Coghill, David R/X-6449-2018	Coghill, David R/0000-0003-3017-9737; Coghill, David/0000-0003-3017-9737; Coghill, David R/0000-0003-3017-9737				CASTELLANOS FX, 2002, HYPERACTIVITY ATTENT, P336; Hill P, 2001, ARCH DIS CHILD, V84, P404, DOI 10.1136/adc.84.5.404; Huss M, 2002, J Atten Disord, V6 Suppl 1, pS65; Jadad AR, 1999, CAN J PSYCHIAT, V44, P1025, DOI 10.1177/070674379904401009; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Jureidini JN, 2004, BMJ-BRIT MED J, V328, P879, DOI 10.1136/bmj.328.7444.879; National Institute for Clinical Excellence, 13 NAT I CLIN EXC; Perrin JM, 2001, PEDIATRICS, V108, P1033; Rey JM, 2003, BRIT J PSYCHIAT, V182, P284, DOI 10.1192/bjp.182.4.284; Rieppi R, 2002, J AM ACAD CHILD PSY, V41, P269, DOI 10.1097/00004583-200203000-00006; *SCOTT INT GUID NE, 2001, ATT DEF HYP DIS CHIL; Taylor E, 2004, EUR CHILD ADOLES PSY, V13, P7, DOI 10.1007/s00787-004-1002-x; Taylor E, 1996, J AM ACAD CHILD PSY, V35, P1213, DOI 10.1097/00004583-199609000-00019	13	18	18	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	2004	329	7471					907	909		10.1136/bmj.329.7471.907	http://dx.doi.org/10.1136/bmj.329.7471.907			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	863MU	15485976	Green Published			2022-12-28	WOS:000224566800027
J	Beck, M; Forster, F; Ecke, M; Plitzko, JM; Melchior, F; Gerisch, G; Baumeister, W; Medalia, O				Beck, M; Forster, F; Ecke, M; Plitzko, JM; Melchior, F; Gerisch, G; Baumeister, W; Medalia, O			Nuclear pore complex structure and dynamics revealed by cryoelectron tomography	SCIENCE			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; ARCHITECTURE; MICROSCOPY; IMPORT	Nuclear pore complexes (NPCs) are gateways for nucleocytoplasmic exchange. To analyze their structure in a close-to-life state, we studied transport-active, intact nuclei from Dictyostelium discoideum by means of cryoelectron tomography. Subvolumes of the tomograms containing individual NPCs were extracted in silico and subjected to three-dimensional classification and averaging, whereby distinct structural states were observed. The central plug/transporter (CP/T) was variable in volume and could occupy different positions, along the nucleocytoplasmic axis, which supports the notion that it essentially represents cargo in transit. Changes in the position of the CP/T were accompanied by structural rearrangements in the NPC scaffold.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Baumeister, W (corresponding author), Max Planck Inst Biochem, D-82152 Martinsried, Germany.	baumeist@biochem.mpg.de; omedatia@biochem.mpg.de	Beck, Martin/B-5589-2011; Plitzko, Juergen M/H-9576-2014; Melchior, Frauke/E-2014-2014; Foerster, Friedrich/D-3710-2009	Beck, Martin/0000-0002-7397-1321; Plitzko, Juergen M/0000-0002-6402-8315; Melchior, Frauke/0000-0001-9546-8797; Foerster, Friedrich/0000-0002-6044-2746; Medalia, Ohad/0000-0003-0994-2937				AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; Baumeister W, 2002, CURR OPIN STRUC BIOL, V12, P679, DOI 10.1016/S0959-440X(02)00378-0; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; Goldberg MW, 1996, J MOL BIOL, V257, P848, DOI 10.1006/jmbi.1996.0206; Grunewald K, 2003, BIOPHYS CHEM, V100, P577, DOI 10.1016/S0301-4622(02)00307-1; Kiseleva E, 2004, J STRUCT BIOL, V145, P272, DOI 10.1016/j.jsb.2003.11.010; Kiseleva E, 1998, J CELL SCI, V111, P223; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Pante N, 1996, SCIENCE, V273, P1729, DOI 10.1126/science.273.5282.1729; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Siebrasse JP, 2002, EMBO REP, V3, P887, DOI 10.1093/embo-reports/kvf171; Stoffler D, 2003, J MOL BIOL, V328, P119, DOI 10.1016/S0022-2836(03)00266-3; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4; Yang WD, 2004, P NATL ACAD SCI USA, V101, P12887, DOI 10.1073/pnas.0403675101	16	371	381	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1387	1390		10.1126/science.1104808	http://dx.doi.org/10.1126/science.1104808			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15514115				2022-12-28	WOS:000225301600056
J	Ferriero, DM				Ferriero, DM			Medical progress - Neonatal brain injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NITRIC-OXIDE SYNTHASE; CEREBRAL FUNCTION MONITOR; SELECTIVE VULNERABILITY; INTRAVENTRICULAR HEMORRHAGE; HYPOXIA-ISCHEMIA; SUBPLATE NEURONS; RISK-FACTORS; SCHOOL-AGE; CELL-DEATH; CHILDREN		Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ferriero, DM (corresponding author), Univ Calif San Francisco, Dept Neurol, 521 Parnassus Ave,C215, San Francisco, CA 94143 USA.	dmf@itsa.ucsf.edu						Aarts MM, 2003, BIOCHEM PHARMACOL, V66, P877, DOI 10.1016/S0006-2952(03)00297-1; American College of Obstetricians and Gynecologists & American Academy of Pediatrics, 2003, NEON ENC CER PALS DE; Back SA, 2001, J NEUROSCI, V21, P1302; Badawi N, 1998, BMJ-BRIT MED J, V317, P1554, DOI 10.1136/bmj.317.7172.1554; Barker DJP, 1999, ANN MED, V31, P3, DOI 10.1080/07853890.1999.11904392; Barkovich AJ, 1997, AM J NEURORADIOL, V18, P1816; Barkovich AJ, 2002, BRAIN DEV-JPN, V24, P2, DOI 10.1016/S0387-7604(01)00327-8; Barnett A, 2002, NEUROPEDIATRICS, V33, P242, DOI 10.1055/s-2002-36737; Baud O, 2004, J NEUROSCI, V24, P1531, DOI 10.1523/JNEUROSCI.3989-03.2004; Beckman JS, 2000, SEMIN PERINATOL, V24, P37, DOI 10.1016/S0146-0005(00)80053-1; BELLINGER DC, 1995, NEW ENGL J MED, V332, P549, DOI 10.1056/NEJM199503023320901; Black SM, 1995, NEUROBIOL DIS, V2, P145, DOI 10.1006/nbdi.1995.0016; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; Cowan F, 2003, LANCET, V361, P736, DOI 10.1016/S0140-6736(03)12658-X; Dammann O, 2002, MENT RETARD DEV D R, V8, P46, DOI 10.1002/mrdd.10005; Deng WB, 2004, P NATL ACAD SCI USA, V101, P7751, DOI 10.1073/pnas.0307850101; deVeber G, 2001, NEW ENGL J MED, V345, P417, DOI 10.1056/NEJM200108093450604; deVeber G, 2003, SEMIN THROMB HEMOST, V29, P567; DUMOULIN CL, 2002, MAGN RESON ENG, V15, P117; Erberich SG, 2003, NEUROIMAGE, V20, P683, DOI 10.1016/S1053-8119(03)00370-7; Feigin V, 2003, LANCET NEUROL, V2, P529, DOI 10.1016/S1474-4422(03)00500-3; Felderhoff-Mueser U, 2003, PEDIATR RES, V54, P659, DOI 10.1203/01.PDR.0000084114.83724.65; Ferriero DM, 1996, NEUROBIOL DIS, V3, P64, DOI 10.1006/nbdi.1996.0006; FERRIERO DM, 1990, NEUROSCIENCE, V36, P417, DOI 10.1016/0306-4522(90)90437-9; FERRIERO DM, 1988, ANN NEUROL, V24, P670, DOI 10.1002/ana.410240512; Ferriero DM, 2002, DEV NEUROSCI-BASEL, V24, P349, DOI 10.1159/000069048; FERRIERO DM, 2002, BIRTH ASPHYXIA BRAIN, P153; Fullerton HJ, 2002, NEUROLOGY, V59, P34, DOI 10.1212/WNL.59.1.34; Gluckman PD, 2004, PEDIATR RES, V55, p582A; Golomb MR, 2001, ANN NEUROL, V50, P163, DOI 10.1002/ana.1078; Graham EM, 2004, NEUROBIOL DIS, V17, P89, DOI 10.1016/j.nbd.2004.05.007; Gressens P, 2002, J PEDIATR-US, V140, P646, DOI 10.1067/mpd.2002.123214; Gunther, 2001, STROKE, V32, P279; Gunther G, 2000, STROKE, V31, P2437, DOI 10.1161/01.STR.31.10.2437; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HAMRICK SE, IN PRESS J PEDIAT; Haynes RL, 2003, J NEUROPATH EXP NEUR, V62, P441, DOI 10.1093/jnen/62.5.441; Heller C, 2003, CIRCULATION, V108, P1362, DOI 10.1161/01.CIR.0000087598.05977.45; Hoppe C, 2004, BLOOD, V103, P2391, DOI 10.1182/blood-2003-09-3015; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; Hyland K, 2003, ANN NEUROL, V54, pS13, DOI 10.1002/ana.10627; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Juul SE, 2000, CLIN PERINATOL, V27, P527, DOI 10.1016/S0095-5108(05)70037-3; Kadri Munaf, 2003, J Perinatol, V23, P181, DOI 10.1038/sj.jp.7210913; Kanold PO, 2003, SCIENCE, V301, P521, DOI 10.1126/science.1084152; Kaufman SA, 2003, PEDIATR NEUROL, V28, P342, DOI 10.1016/S0887-8994(03)00015-8; Kaukola T, 2004, ANN NEUROL, V55, P186, DOI 10.1002/ana.10809; Khong TY, 2000, HUM PATHOL, V31, P292; Kurnik K, 2003, STROKE, V34, P2887, DOI 10.1161/01.STR.0000103745.03393.39; Liu YQ, 2004, STROKE, V35, P1460, DOI 10.1161/01.STR.0000128029.50221.fa; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; MAYTAL J, 1989, PEDIATRICS, V83, P323; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; McKinstry RC, 2002, NEUROLOGY, V59, P824, DOI 10.1212/WNL.59.6.824; McQuillen PS, 2003, J NEUROSCI, V23, P3308; McQuillen PS, 2004, PEDIATR NEUROL, V30, P227, DOI 10.1016/j.pediatrneurol.2003.10.001; Mercuri E, 2004, ARCH DIS CHILD-FETAL, V89, pF258, DOI 10.1136/adc.2002.025387; Mercuri E, 2003, J PEDIATR-US, V142, P647, DOI 10.1067/mpd.2003.215; Mercuri E, 2001, PEDIATRICS, V107, P1400, DOI 10.1542/peds.107.6.1400; Miller SP, 2004, ANN THORAC SURG, V77, P1698, DOI 10.1016/j.athoracsur.2003.10.084; Miller SP, 2004, AM J OBSTET GYNECOL, V190, P93, DOI 10.1016/S0002-9378(03)00908-6; Miller SP, 2002, J MAGN RESON IMAGING, V16, P621, DOI 10.1002/jmri.10205; Miller SP, 2002, PEDIATR RES, V52, P71, DOI 10.1203/00006450-200207000-00014; Nakajima W, 2000, J NEUROSCI, V20, P7994; Nelson KB, 2004, LANCET NEUROL, V3, P150, DOI 10.1016/S1474-4422(04)00679-9; Nelson KB, 1998, ANN NEUROL, V44, P665, DOI 10.1002/ana.410440413; NELSON KB, IN PRESS PEDIAT RES; Olney JW, 2003, CURR OPIN PHARMACOL, V3, P101, DOI 10.1016/S1471-4892(02)00002-4; Ozduman K, 2004, PEDIATR NEUROL, V30, P151, DOI 10.1016/j.pediatrneurol.2003.08.004; Painter MJ, 1999, NEW ENGL J MED, V341, P485, DOI 10.1056/NEJM199908123410704; Partridge SC, 2004, NEUROIMAGE, V22, P1302, DOI 10.1016/j.neuroimage.2004.02.038; Peeters-Scholte C, 2003, PEDIATR RES, V54, P516, DOI 10.1203/01.PDR.0000081297.53793.C6; Peeters-Scholte C, 2002, STROKE, V33, P2304, DOI 10.1161/01.STR.0000028343.25901.09; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Rennie JM, 2004, ARCH DIS CHILD-FETAL, V89, pF37, DOI 10.1136/fn.89.1.F37; Roelants-van Rijn AM, 2001, NEUROPEDIATRICS, V32, P286; Roland EP, 1998, ANN NEUROL, V44, P161, DOI 10.1002/ana.410440205; Rutherford MA, 1998, PEDIATRICS, V102, P323, DOI 10.1542/peds.102.2.323; Sarco DP, 2000, NEUROSCI LETT, V282, P113, DOI 10.1016/S0304-3940(00)00878-8; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Shankaran S, 2004, PEDIATR RES, V55, p582A; Sheldon RA, 1998, BRAIN RES, V810, P114, DOI 10.1016/S0006-8993(98)00892-0; Sie LTL, 2000, NEUROPEDIATRICS, V31, P128, DOI 10.1055/s-2000-7496; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Takanashi J, 2003, NEUROLOGY, V61, P531, DOI 10.1212/01.WNL.0000079370.28310.EA; Toet MC, 2002, PEDIATRICS, V109, P772, DOI 10.1542/peds.109.5.772; Van Landeghem FKH, 2002, PEDIATR RES, V51, P129, DOI 10.1203/00006450-200202000-00003; Vigneron DB, 2001, AM J NEURORADIOL, V22, P1424; Vohr BR, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.4.e340; VOLPE JJ, 2001, NEUROLOGY NEWBORN, P912; WESTMARK KD, 1995, AM J NEURORADIOL, V16, P685; Winter S, 2002, PEDIATRICS, V110, P1220, DOI 10.1542/peds.110.6.1220; Wu YW, 2004, PEDIATRICS, V114, P612, DOI 10.1542/peds.2004-0385; Wu YW, 2003, ANN NEUROL, V54, P123, DOI 10.1002/ana.10619; Wu YW, 2000, JAMA-J AM MED ASSOC, V284, P1417, DOI 10.1001/jama.284.11.1417; Wu YW, 2003, JAMA-J AM MED ASSOC, V290, P2677, DOI 10.1001/jama.290.20.2677	97	837	876	4	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1985	1995		10.1056/NEJMra041996	http://dx.doi.org/10.1056/NEJMra041996			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525724				2022-12-28	WOS:000224851300011
J	Ruggenenti, P; Fassi, A; Ilieva, AP; Bruno, S; Iliev, IP; Brusegan, V; Rubis, N; Gherardi, G; Arnoldi, F; Ganeva, M; Ene-Iordache, B; Gaspari, F; Perna, A; Bossi, A; Trevisan, R; Dodesini, AR; Remuzzi, G				Ruggenenti, P; Fassi, A; Ilieva, AP; Bruno, S; Iliev, IP; Brusegan, V; Rubis, N; Gherardi, G; Arnoldi, F; Ganeva, M; Ene-Iordache, B; Gaspari, F; Perna, A; Bossi, A; Trevisan, R; Dodesini, AR; Remuzzi, G		BENEDICT Investigators	Preventing microalbuminuria in type 2 diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL PROTEINURIA; ALBUMIN EXCRETION; RENAL-DISEASE; NEPHROPATHY; MELLITUS; MORTALITY; PROGRESSION; IRBESARTAN; INHIBITORS; LOSARTAN	BACKGROUND: The multicenter double-blind, randomized Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) was designed to assess whether angiotensin-converting-enzyme inhibitors and non-dihydropyridine calcium-channel blockers, alone or in combination, prevent microalbuminuria in subjects with hypertension, type 2 diabetes mellitus, and normal urinary albumin excretion. METHODS: We studied 1204 subjects, who were randomly assigned to receive at least three years of treatment with trandolapril (at a dose of 2 mg per day) plus verapamil (sustained-release formulation, 180 mg per day), trandolapril alone (2 mg per day), verapamil alone (sustained-release formulation, 240 mg per day), or placebo. The target blood pressure was 120/80 mm Hg. The primary end point was the development of persistent microalbuminuria (overnight albumin excretion, greater/equal 20 microg per minute at two consecutive visits). RESULTS: The primary outcome was reached in 5.7 percent of the subjects receiving trandolapril plus verapamil, 6.0 percent of the subjects receiving trandolapril, 11.9 percent of the subjects receiving verapamil, and 10.0 percent of control subjects receiving placebo. The estimated acceleration factor (which quantifies the effect of one treatment relative to another in accelerating or slowing disease progression) adjusted for predefined baseline characteristics was 0.39 for the comparison between verapamil plus trandolapril and placebo (P=0.01), 0.47 for the comparison between trandolapril and placebo (P=0.01), and 0.83 for the comparison between verapamil and placebo (P=0.54). Trandolapril plus verapamil and trandolapril alone delayed the onset of microalbuminuria by factors of 2.6 and 2.1, respectively. Serious adverse events were similar in all treatment groups. CONCLUSIONS: In subjects with type 2 diabetes and hypertension but with normoalbuminuria, the use of trandolapril plus verapamil and trandolapril alone decreased the incidence of microalbuminuria to a similar extent. The effect of verapamil alone was similar to that of placebo.	Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis, I-24125 Bergamo, Italy; Osped Riuniti Bergamo, Azienda Osped, Nephrol Unit, I-24100 Bergamo, Italy; Treviglio Hosp, Unit Diabetol, Treviglio, Italy; Bergamo Hosp, Unit Diabetol, Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo	Ruggenenti, P (corresponding author), Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis, Via Gavazzeni 11, I-24125 Bergamo, Italy.	manuelap@marionegri.it	Parvanova, Aneliya Ilieva/ABH-3290-2020; TREVISAN, ROBERTO/Q-8706-2016; Rubis, Nadia/ABF-4293-2020; Perna, Annalisa/AAC-1323-2020; Gherardi, Giulia/ABH-4861-2020; Ene-Iordache, Bogdan/C-6824-2018; Remuzzi, Giuseppe/V-9766-2017	Parvanova, Aneliya Ilieva/0000-0002-7820-720X; TREVISAN, ROBERTO/0000-0003-0420-4468; Perna, Annalisa/0000-0002-9257-0283; Gherardi, Giulia/0000-0001-7700-8324; Ene-Iordache, Bogdan/0000-0002-4011-9343; Remuzzi, Giuseppe/0000-0002-6194-3446; Bossi, Antonio Carlo/0000-0001-8900-1787				Adler AI, 2003, KIDNEY INT, V63, P225, DOI 10.1046/j.1523-1755.2003.00712.x; Allison P. D., 1995, SURVIVAL ANAL USING; American Diabetes Association, 1998, DIABETES CARE, V21, pS23, DOI [10.2337/diacare.21.1.S23, DOI 10.2337/DIACARE.21.1.S23]; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Bakris GL, 1998, KIDNEY INT, V54, P1283, DOI 10.1046/j.1523-1755.1998.00083.x; Bakris GL, 1996, KIDNEY INT, V50, P1641, DOI 10.1038/ki.1996.480; Black HR, 1998, ARCH INTERN MED, V158, P573; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Collett D, 1994, MODELLING SURVIVAL D; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; Dinneen SF, 1997, ARCH INTERN MED, V157, P1413, DOI 10.1001/archinte.157.13.1413; Eurich DT, 2004, DIABETES CARE, V27, P1330, DOI 10.2337/diacare.27.6.1330; FIORETTO P, 1992, AM J HYPERTENS, V5, P837, DOI 10.1093/ajh/5.11.837; Gall MA, 1997, BMJ-BRIT MED J, V314, P783, DOI 10.1136/bmj.314.7083.783; Gerstein HC, 2000, LANCET, V355, P253; Heart Outcomes Prevention Evaluation Study Investigators, 2000, LANCET, V356, P860; KILPATRICK ES, 1994, BMJ-BRIT MED J, V309, P983, DOI 10.1136/bmj.309.6960.983; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1994, NEW ENGL J MED, V330, P152; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; Mattock MB, 1998, DIABETES, V47, P1786, DOI 10.2337/diabetes.47.11.1786; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; MOGENSEN CE, 1995, LANCET, V346, P1080, DOI 10.1016/S0140-6736(95)91747-0; NELSON RG, 1991, ARCH INTERN MED, V151, P1761, DOI 10.1001/archinte.151.9.1761; NELSON RG, 1988, DIABETOLOGIA, V31, P730, DOI 10.1007/BF00274774; Parving H., 2004, BRENNER RECTORS KIDN, P1777; Parving HH, 1996, KIDNEY INT, V49, P1778, DOI 10.1038/ki.1996.266; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; Perkins BA, 2003, NEW ENGL J MED, V348, P2285, DOI 10.1056/NEJMoa021835; Perna A, 2003, CONTROL CLIN TRIALS, V24, P442, DOI 10.1016/S0197-2456(03)00028-X; Ravid M, 1998, ANN INTERN MED, V128, P982, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00004; Ravid M, 1996, ARCH INTERN MED, V156, P286, DOI 10.1001/archinte.156.3.286; Remuzzi G, 2002, NEW ENGL J MED, V346, P1145, DOI 10.1056/NEJMcp011773; Ritz E, 2003, NEW ENGL J MED, V348, P2349, DOI 10.1056/NEJMe030066; Ruggenenti P, 1997, CURR OPIN NEPHROL HY, V6, P141, DOI 10.1097/00041552-199703000-00006; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *UKPDS GROUP, 1999, BMJ-BRIT MED J, V318, P29; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; *WHO, 2004, DIAB PROGR	40	730	772	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1941	1951		10.1056/NEJMoa042167	http://dx.doi.org/10.1056/NEJMoa042167			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15516697	Green Published			2022-12-28	WOS:000224851300006
J	Shen, J; Hirschtick, R				Shen, J; Hirschtick, R			Getting the lead out	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Shen, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.								0	4	5	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1996	1996		10.1056/NEJMicm030114	http://dx.doi.org/10.1056/NEJMicm030114			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525725				2022-12-28	WOS:000224851300012
J	Wang, RC; Smogorzewska, A; de Lange, T				Wang, RC; Smogorzewska, A; de Lange, T			Homologous recombination generates T-loop-sized deletions at human telomeres	CELL			English	Article							SENESCENT HUMAN-CELLS; DNA-DAMAGE; DYSKERATOSIS-CONGENITA; MAMMALIAN TELOMERES; SACCHAROMYCES-CEREVISIAE; STOCHASTIC MECHANISM; HUMAN CANCER; LIFE-SPAN; TRF2; MAINTENANCE	The t-loop structure of mammalian telomeres is thought to repress nonhomologous end joining (NHEJ) at natural chromosome ends. Telomere NHEJ occurs upon loss of TRF2, a telomeric protein implicated in t-loop formation. Here we describe a mutant allele of TRF2, TRF2(DeltaB), that suppressed NHEJ but induced catastrophic deletions of telomeric DNA. The deletion events were stochastic and occurred rapidly, generating dramatically shortened telomeres that were accompanied by a DNA damage response and induction of senescence. TRF2(DeltaB)-induced deletions depended on XRCC3, a protein implicated in Holliday junction resolution, and created t-loop-sized telomeric circles. These telomeric circles were also detected in unperturbed cells and suggested that t-loop deletion by homologous recombination (HR) might contribute to telomere attrition. Human ALT cells had abundant-telomeric circles, pointing to frequent t-loop HR events that could promote rolling circle replication of telomeres in the absence of telomerase. These findings show that t-loop deletion by HR influences the integrity and dynamics of mammalian telomeres.	Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, Cell Biol & Genet Lab, 1230 York Ave, New York, NY 10021 USA.	delange@mail.rockefeller.edu	de Lange, Titia/B-8263-2011; Wang, Richard/AAW-3066-2021; Smogorzewska, Agata/B-8891-2011	de Lange, Titia/0000-0002-9267-367X; Wang, Richard/0000-0003-4543-8295; Smogorzewska, Agata/0000-0001-6285-1562	NCI NIH HHS [K08 CA164047] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA164047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailey SM, 1996, MUTAGENESIS, V11, P139, DOI 10.1093/mutage/11.2.139; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; Bakkenist CJ, 2004, CANCER RES, V64, P3748, DOI 10.1158/0008-5472.CAN-04-0453; Bechter OE, 2004, CELL CYCLE, V3, P547; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bucholc M, 2001, MOL CELL BIOL, V21, P6559, DOI 10.1128/MCB.21.19.6559-6573.2001; Cesare AJ, 2003, PLANT J, V36, P271, DOI 10.1046/j.1365-313X.2003.01882.x; Cohen S, 1996, MOL CELL BIOL, V16, P2002; de Lange T, 2004, NAT REV MOL CELL BIO, V5, P323, DOI 10.1038/nrm1359; De Lange T, 2000, COLD SPRING HARB SYM, V65, P265, DOI 10.1101/sqb.2000.65.265; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Fairall L, 2001, MOL CELL, V8, P351, DOI 10.1016/S1097-2765(01)00321-5; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hakin-Smith V, 2003, LANCET, V361, P836, DOI 10.1016/S0140-6736(03)12681-5; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Jaco I, 2003, MOL CELL BIOL, V23, P5572, DOI 10.1128/MCB.23.16.5572-5580.2003; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Lee JH, 2003, MOL CANCER RES, V1, P674; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Li BB, 1996, GENE DEV, V10, P1310, DOI 10.1101/gad.10.11.1310; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu YL, 2004, SCIENCE, V303, P243, DOI 10.1126/science.1093037; Londono-Vallejo JA, 2004, CANCER RES, V64, P2324, DOI 10.1158/0008-5472.CAN-03-4035; Lundblad V, 2002, ONCOGENE, V21, P522, DOI 10.1038/sj.onc.1205079; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Lustig AJ, 2003, NAT REV GENET, V4, P916, DOI 10.1038/nrg1207; Marciniak RA, 2000, TRENDS GENET, V16, P193, DOI 10.1016/S0168-9525(00)01984-3; Martin-Ruiz C, 2004, J BIOL CHEM, V279, P17826, DOI 10.1074/jbc.M311980200; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Murti KG, 1999, P NATL ACAD SCI USA, V96, P14436, DOI 10.1073/pnas.96.25.14436; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Natarajan S, 2002, MOL CELL BIOL, V22, P4512, DOI 10.1128/MCB.22.13.4512-4521.2002; Nikitina T, 2004, J CELL BIOL, V166, P161, DOI 10.1083/jcb.200403118; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Regev A, 1998, ONCOGENE, V17, P3455, DOI 10.1038/sj.onc.1202250; Rubelj I, 1999, J THEOR BIOL, V197, P425, DOI 10.1006/jtbi.1998.0886; Shay JW, 2002, CANCER CELL, V2, P257, DOI 10.1016/S1535-6108(02)00159-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SMITH JR, 1980, SCIENCE, V207, P82; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stansel RM, 2001, EMBO J, V20, P5532; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tarsounas M, 2004, CELL, V117, P337, DOI 10.1016/S0092-8674(04)00337-X; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tokutake Y, 1998, BIOCHEM BIOPH RES CO, V247, P765, DOI 10.1006/bbrc.1998.8876; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Yoshihara T, 2004, EMBO J, V23, P670, DOI 10.1038/sj.emboj.7600087; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	72	414	433	0	25	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	2004	119	3					355	368		10.1016/j.cell.2004.10.011	http://dx.doi.org/10.1016/j.cell.2004.10.011			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	868IW	15507207	Bronze			2022-12-28	WOS:000224908300007
J	Wennberg, R; Zimmermann, C				Wennberg, R; Zimmermann, C			The PROGRESS trial three years later: time for a balanced report of effectiveness	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; STROKE		Univ Toronto, Univ Hlth Network, Dept Med, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Wennberg, R (corresponding author), Univ Toronto, Univ Hlth Network, Dept Med, Toronto, ON M5T 2S8, Canada.	Richard.Wennberg@uhn.on.ca		Zimmermann, Camilla/0000-0003-4889-0244				Britov A N, 2002, Klin Med (Mosk), V80, P53; Cates C, 2001, LANCET, V358, P1993, DOI 10.1016/S0140-6736(01)06978-1; Chalmers J, 2003, STROKE, V34, P2333, DOI 10.1161/01.STR.0000091397.81767.40; Chapman N, 2004, STROKE, V35, P116, DOI 10.1161/01.STR.0000106480.76217.6F; Chaturvedi V, 2003, EUR HEART J, V24, P475, DOI 10.1016/S0195-668X(02)00804-7; Jackson G, 2003, INT J CLIN PRACT, V57, P385; LIU LS, 1995, CHINESE MED J-PEKING, V108, P710; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Neal B, 2000, LANCET, V356, P1955; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Psaty BM, 2002, AM J HYPERTENS, V15, P472, DOI 10.1016/S0895-7061(02)02928-X; Staessen JA, 2001, LANCET, V358, P1305, DOI 10.1016/S0140-6736(01)06411-X; Staessen JA, 2001, LANCET, V358, P1026, DOI 10.1016/S0140-6736(01)06226-2; Tirschwell David, 2002, ACP J Club, V136, P51; Tonkin AM, 2002, MED J AUSTRALIA, V176, P283, DOI 10.5694/j.1326-5377.2002.tb04410.x; Turnbull F, 2003, LANCET, V362, P1527; Tzourio C, 2003, ARCH INTERN MED, V163, P1069	17	20	20	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 23	2004	329	7472					968	970		10.1136/bmj.329.7472.968	http://dx.doi.org/10.1136/bmj.329.7472.968			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866KU	15499116	Green Published			2022-12-28	WOS:000224773200023
J	Heuschmann, PU; Kolominsky-Rabas, PL; Roether, J; Misselwitz, B; Lowitzsch, K; Heidrich, J; Hermanek, P; Leffmann, C; Sitzer, M; Biegler, M; Buecker-Nott, HJ; Berger, K				Heuschmann, PU; Kolominsky-Rabas, PL; Roether, J; Misselwitz, B; Lowitzsch, K; Heidrich, J; Hermanek, P; Leffmann, C; Sitzer, M; Biegler, M; Buecker-Nott, HJ; Berger, K		German Stroke Registers Study Grp	Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; ACUTE MYOCARDIAL-INFARCTION; EXPERIENCE; SURVIVAL; QUALITY; VOLUME; RISK; TPA	Context Data are limited regarding the risks and benefits of thrombolytic therapy for acute ischemic stroke outside of clinical trials. Objective To investigate predictors of in-hospital mortality in patients with ischemic stroke treated with intravenous tissue plasminogen activator (tPA) within a pooled analysis of large German stroke registers. Design and Setting Prospective, observational cohort study conducted at 225 community and academic hospitals throughout Germany cooperating within the German Stroke Registers Study Group. Patients A total of 1658 patients with acute ischemic stroke who were admitted to study hospitals between 2000 and 2002 and were treated with tPA. Main Outcome Measure In-hospital mortality. Results One hundred sixty-six patients (10%) who received tPA died during hospitalization, with 67.5% of these deaths occurring within 7 days. Factors predicting inhospital death after tPA use were older age (for each 10-year increment in age, adjusted odds ratio [OR], 1.6; 95% confidence interval [0], 1.3-1.9) and altered level of consciousness (adjusted OR, 3.4 95% Cl, 2.4-4.7). The overall rate of symptomatic intracranial hemorrhage was 7.1 % and increased with age. One or more serious complications was observed in 27.2% of all patients and in 83.9% of patients who died after tPA treatment. An inverse relation between the number of patients treated with tPA in the respective hospital and the risk of in-hospital death was observed (adjusted OR, 0.97; 95% Cl, 0.96-0.99 for each additional patient treated with tPA per year). Conclusion In patients with ischemic stroke who are treated with tPA, disturbances of consciousness and increasing age are associated with increased in-hospital mortality.	Univ Munster, Inst Epidemiol & Social Med, D-48149 Munster, Germany; Westphalian Board Phys, Dept Qual Assurance, Munster, Germany; Univ Erlangen Nurnberg, Dept Neurol, Unit Stroke Res & Publ Hlth Med, D-8520 Erlangen, Germany; Univ Hamburg Eppendorf, Dept Neurol, Hamburg, Germany; Hamburg Hosp Federat, Coordinat Ctr Qual Management Projects, Hamburg, Germany; Inst Qual Assurance Hesse, Eschborn, Germany; Stroke Register Rhineland Palatine SQMed, Mainz, Germany; Inst Qual Assurance Rhineland Palatine SQMed, Mainz, Germany; Bavarian Permanent Working Party Qual Assurance, Munich, Germany; Goethe Univ Frankfurt, Dept Neurol, D-6000 Frankfurt, Germany	University of Munster; University of Erlangen Nuremberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Goethe University Frankfurt	Heuschmann, PU (corresponding author), Univ Munster, Inst Epidemiol & Social Med, Domagkstr 3, D-48149 Munster, Germany.	heuschma@uni-muenster.de						Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; [Anonymous], 2003, STAT YB 2003 FED REP; *ARB SCHL HESS, 1999, AKTUEL NEUROL, V26, P8; Canto JG, 2000, NEW ENGL J MED, V342, P1573, DOI 10.1056/NEJM200005253422106; CHRISTIANSEN W, 1998, CEREBROVASC DIS, V8, P38; Graham GD, 2003, STROKE, V34, P2847, DOI 10.1161/01.STR.0000101752.23813.C3; Handschu R, 2003, STROKE, V34, P2842, DOI 10.1161/01.STR.0000102043.70312.E9; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; Heuschmann PU, 2000, GESUNDHEITSWESEN, V62, P547, DOI 10.1055/s-2000-13039; Heuschmann PU, 2003, STROKE, V34, P1106, DOI 10.1161/01.STR.0000065198.80347.C5; Johnston SC, 2001, STROKE, V32, P1061, DOI 10.1161/01.STR.32.5.1061; Katzan IL, 2003, STROKE, V34, P799, DOI 10.1161/01.STR.0000056944.42686.1E; Katzan IL, 2000, JAMA-J AM MED ASSOC, V283, P1151, DOI 10.1001/jama.283.9.1151; Kleindorfer D, 2004, STROKE, V35, pE27, DOI 10.1161/01.STR.0000109767.11426.17; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Reed SD, 2001, STROKE, V32, P1832, DOI 10.1161/01.STR.32.8.1832; Schmidt WP, 2003, CEREBROVASC DIS, V16, P247, DOI 10.1159/000071123; Soumerai SB, 2002, ARCH INTERN MED, V162, P561, DOI 10.1001/archinte.162.5.561; Tanne D, 1999, NEUROLOGY, V53, P424, DOI 10.1212/WNL.53.2.424; Tanne D, 2002, CIRCULATION, V105, P1679, DOI 10.1161/01.CIR.0000012747.53592.6A; Tanne D, 2000, STROKE, V31, P370, DOI 10.1161/01.STR.31.2.370; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Wang DZ, 2000, STROKE, V31, P77, DOI 10.1161/01.STR.31.1.77; Wardlaw JM, 2003, STROKE, V34, P1437, DOI 10.1161/01.STR.0000072513.72262.7E; Warlow C, 2003, BMJ-BRIT MED J, V326, P233, DOI 10.1136/bmj.326.7383.233; Weimar C, 2004, STROKE, V35, P158, DOI 10.1161/01.STR.0000106761.94985.8B; Weir NU, 2001, STROKE, V32, P1370, DOI 10.1161/01.STR.32.6.1370	27	179	183	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2004	292	15					1831	1838		10.1001/jama.292.15.1831	http://dx.doi.org/10.1001/jama.292.15.1831			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IV	15494580	Bronze			2022-12-28	WOS:000224485100021
J	Lindsberg, PJ; Soinne, L; Tatlisumak, T; Roine, RO; Kallela, M; Happola, O; Kaste, M				Lindsberg, PJ; Soinne, L; Tatlisumak, T; Roine, RO; Kallela, M; Happola, O; Kaste, M			Long-term outcome after intravenous thrombolysis of basilar artery occlusion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE ISCHEMIC-STROKE; THERAPY; ASSOCIATION; QUALITY; LIFE; CARE	Context Basilar artery occlusion (BAO) is an infrequent disease with high morbidity and mortality. Intra-arterial thrombolysis is advocated for treatment but is limited to use at specialized centers. Objective To evaluate outcomes for patients with BAO treated with intravenous thrombolytic therapy. Design, Setting, and Participants During 1995 to 2003, 50 consecutive patients with angiographically proven BAO were treated according to an institutional therapy protocol based on intravenous thrombolysis with recombinant tissue plasminogen activator (alteplase). Patients were treated at an urban university teaching hospital receiving all patients with ischemic stroke who were considered for thrombolysis in a catchment area of 1.5 million inhabitants in Helsinki, Finland. Intervention Intravenous administration of alteplase (0.9 mg/kg) during a 1-hour infusion. Main Outcome Measures Basilar artery recanalization determined by magnetic resonance angiography and clinical outcomes at 3 months and at 1 year or longer determined by modified Rankin Scale and Barthel index scores. Results Recanalization was studied in 43 patients and verified in 26 (52%) of all patients. By 3 months, 20 patients (40%) had died while 11 had good outcomes (modified Rankin Scale score, 0-2); 12 (24%) reached independence in activities of daily living (Barthel Index score, 95-100), and 6 (16%) were severely disabled (Barthel Index score, 0-50). in the long term (median follow-up 2.8 years), 15 patients (30%) reached good outcomes (modified Rankin Scale score, 0-2) while 23 (46%) died. Conclusions Intravenous administration of alteplase for patients with BAO appears to be associated with rates of survival, recanalization, and independent functional outcome comparable with those reported with endovascular approaches. These data suggest that a randomized trial is needed to compare these approaches for treatment of BAO.	Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki 00029, Finland; Biomedicum Helsinki, Program Neurosci, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Lindsberg, PJ (corresponding author), Univ Helsinki, Cent Hosp, Dept Neurol, POB 340, Helsinki 00029, Finland.	perttu.lindsberg@hus.fi	Soinne, Lauri/E-3703-2019; Lindsberg, Perttu J/F-1271-2010	Lindsberg, Perttu/0000-0001-7690-811X				Adams HP, 1996, STROKE, V27, P1711; Brandt T, 1996, STROKE, V27, P875, DOI 10.1161/01.STR.27.5.875; Cross DT, 1997, AM J NEURORADIOL, V18, P1221; Devuyst G, 2002, ARCH NEUROL-CHICAGO, V59, P567, DOI 10.1001/archneur.59.4.567; Eckert B, 2002, CEREBROVASC DIS, V14, P42, DOI 10.1159/000063722; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; Hacke W, 2004, LANCET, V363, P768; Levy EI, 1999, NEUROSURGERY, V45, P539, DOI 10.1097/00006123-199909000-00025; Lindsberg P J, 1998, Duodecim, V114, P889; Lindsberg PJ, 2003, STROKE, V34, P1443, DOI 10.1161/01.STR.0000071111.98505.C7; Lindsberg PJ, 2003, CURR OPIN NEUROL, V16, P73, DOI 10.1097/00019052-200302000-00010; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Patrick DL, 2000, J CLIN EPIDEMIOL, V53, P779, DOI 10.1016/S0895-4356(00)00205-5; Richardson P G, 2001, Emerg Med (Fremantle), V13, P367, DOI 10.1046/j.1035-6851.2001.00242.x; Wijdicks EFM, 1997, MAYO CLIN PROC, V72, P1005, DOI 10.4065/72.11.1005	15	141	153	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2004	292	15					1862	1866		10.1001/jama.292.15.1862	http://dx.doi.org/10.1001/jama.292.15.1862			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IV	15494584	Bronze			2022-12-28	WOS:000224485100025
J	Barish, GD; Evans, RM				Barish, GD; Evans, RM			A nuclear strike against Listeria - The evolving life of LXR	CELL			English	Editorial Material							LIVER-X-RECEPTORS; PPAR-DELTA; ATHEROSCLEROSIS; INFLAMMATION; LIGAND; MICE	LXRs are members of the nuclear receptor superfamily and function as master regulators of cholesterol metabolism. In the macrophage, they control cholesterol efflux and inhibit the transcription factor NF-kappaB-mediated proinflammatory responses. In this issue of Cell, Joseph et al. (2004) discover surprising, protective functions for LXRalpha in innate immunity.	Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA; Univ Calif San Francisco, Dept Med, Div Endocrinol & Metab, San Francisco, CA 94121 USA	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Francisco	Barish, GD (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NCI NIH HHS [CA09370] Funding Source: Medline; NHLBI NIH HHS [5P50HL56989] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009370] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056989] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032; Lee CH, 2003, SCIENCE, V302, P453, DOI 10.1126/science.1087344; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Terasaka N, 2003, FEBS LETT, V536, P6, DOI 10.1016/S0014-5793(02)03578-0; Vazquez-Boland JA, 2001, CLIN MICROBIOL REV, V14, P584, DOI 10.1128/CMR.14.3.584-640.2001; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Welch JS, 2003, P NATL ACAD SCI USA, V100, P6712, DOI 10.1073/pnas.1031789100	10	10	10	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	2004	119	2					149	151		10.1016/j.cell.2004.10.003	http://dx.doi.org/10.1016/j.cell.2004.10.003			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479632	Bronze			2022-12-28	WOS:000224577200003
J	Belenkaya, TY; Han, C; Yan, D; Opoka, RJ; Khodoun, M; Liu, HZ; Lin, XH				Belenkaya, TY; Han, C; Yan, D; Opoka, RJ; Khodoun, M; Liu, HZ; Lin, XH			Drosophila Dpp morphogen movement is independent of dynamin-mediated endocytosis but regulated by the glypican members of heparan sulfate proteoglycans	CELL			English	Article							GRADIENT FORMATION; TOUT-VELU; HEDGEHOG; GENE; PATTERN; PROTEIN; WINGLESS; DISTINCT; INTERNALIZATION; TRANSDUCTION	The Drosophila transforming growth factor beta(TGF-beta) homolog Decapentaplegic (Dpp) acts as a morphogen that forms a long-range concentration gradient to direct the anteroposterior patterning of the wing. Both planar transcytosis initiated by Dynamin-mediated endocytosis and extracellular diffusion have been proposed for Dpp movement across cells. In this work, we found that Dpp is mainly extracellular, and its extracellular gradient coincides with its activity gradient. We demonstrate that a blockage of endocytosis by the dynamin mutant shibire does not block Dpp movement but rather inhibits Dpp signal transduction, suggesting that endocytosis is not essential for Dpp movement but is involved in Dpp signaling. Furthermore, we show that Dpp fails to move across cells mutant for daily and daily-like (dly), two Drosophila glypican members of heparin sulfate proteoglycan (HSPG). Our results support a model in which Dpp moves along the cell surface by restricted extracellular diffusion involving the glypicans Daily and Dly.	Univ Cincinnati, Coll Med, Div Dev Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Childrens Hosp, Coll Med, Med Ctr,Grad Program Mol & Dev Biol, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Lin, XH (corresponding author), Univ Cincinnati, Coll Med, Div Dev Biol, Cincinnati, OH 45229 USA.	linyby@chmcc.org		Han, Chun/0000-0001-7319-8095	NHLBI NIH HHS [R01 HL-071898] Funding Source: Medline; NIGMS NIH HHS [R01 GM-63891] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063891] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baeg GH, 2001, DEVELOPMENT, V128, P87; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Belenkaya TY, 2002, DEVELOPMENT, V129, P4089; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bornemann DJ, 2004, DEVELOPMENT, V131, P1927, DOI 10.1242/dev.01061; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cadigan KM, 2002, SEMIN CELL DEV BIOL, V13, P83, DOI 10.1016/S1084-9521(02)00014-9; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Entchev EV, 2000, CELL, V103, P981, DOI 10.1016/S0092-8674(00)00200-2; Fujise M, 2003, DEVELOPMENT, V130, P1515, DOI 10.1242/dev.00379; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; Han C, 2004, DEVELOPMENT, V131, P1563, DOI 10.1242/dev.01051; Han C, 2004, DEVELOPMENT, V131, P601, DOI 10.1242/dev.00958; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Jazwinska A, 1999, DEVELOPMENT, V126, P3323; Johnson KG, 2004, CURR BIOL, V14, P499, DOI 10.1016/j.cub.2004.02.005; Lander AD, 2002, DEV CELL, V2, P785, DOI 10.1016/S1534-5807(02)00179-X; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lecuit T, 1998, DEVELOPMENT, V125, P4901; Lin XH, 2002, GLYCOCONJUGATE J, V19, P363, DOI 10.1023/A:1025329323438; Lin XH, 2000, MATRIX BIOL, V19, P303, DOI 10.1016/S0945-053X(00)00073-1; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; Muller B, 2003, CELL, V113, P221, DOI 10.1016/S0092-8674(03)00241-1; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Nybakken K, 2002, BBA-GEN SUBJECTS, V1573, P280, DOI 10.1016/S0304-4165(02)00395-1; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; Raftery LA, 1999, DEV BIOL, V210, P251, DOI 10.1006/dbio.1999.9282; Seto ES, 2002, GENE DEV, V16, P1314, DOI 10.1101/gad.989602; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; Steigemann P, 2004, CURR BIOL, V14, P225, DOI 10.1016/j.cub.2004.01.006; Strigini M, 2000, CURR BIOL, V10, P293, DOI 10.1016/S0960-9822(00)00378-X; Tabata T, 2004, DEVELOPMENT, V131, P703, DOI 10.1242/dev.01043; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Takei Y, 2004, DEVELOPMENT, V131, P73, DOI 10.1242/dev.00913; Tanimoto H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7; Teleman AA, 2000, CELL, V103, P971, DOI 10.1016/S0092-8674(00)00199-9; Teleman AA, 2001, CELL, V105, P559, DOI 10.1016/S0092-8674(01)00377-4; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; Vincent JP, 2002, DEV CELL, V3, P615, DOI 10.1016/S1534-5807(02)00323-4; Voigt A, 2002, DEV DYNAM, V224, P403, DOI 10.1002/dvdy.10120; XU T, 1993, DEVELOPMENT, V117, P1223	58	239	246	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2004	119	2					231	244		10.1016/j.cell.2004.09.031	http://dx.doi.org/10.1016/j.cell.2004.09.031			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479640	Bronze			2022-12-28	WOS:000224577200011
J	Bode, M				Bode, M			The environment matters - Even on the atomic scale	SCIENCE			English	Editorial Material							NANOPARTICLES; MICROSCOPY		Univ Hamburg, Inst Appl Phys, D-20355 Hamburg, Germany; Univ Hamburg, Microstruct Res Ctr, D-20355 Hamburg, Germany	University of Hamburg; University of Hamburg	Bode, M (corresponding author), Univ Hamburg, Inst Appl Phys, Jungiusstr 11, D-20355 Hamburg, Germany.	mbode@physnet.uni-hamburg.de	Bode, Matthias/S-3249-2016	Bode, Matthias/0000-0001-7514-5560				Bode M, 2003, REP PROG PHYS, V66, P523, DOI 10.1088/0034-4885/66/4/203; Cho A, 2002, SCIENCE, V296, P246, DOI 10.1126/science.296.5566.246; Gambardella P, 2003, SCIENCE, V300, P1130, DOI 10.1126/science.1082857; Grochowski E, 2003, IBM SYST J, V42, P338, DOI 10.1147/sj.422.0338; Heinrich AJ, 2004, SCIENCE, V306, P466, DOI 10.1126/science.1101077; Heinze S, 2000, SCIENCE, V288, P1805, DOI 10.1126/science.288.5472.1805; HILLEBRANDS B, 2003, SPINDYNAMICS CONFINE, V2; Ho W, 2002, J CHEM PHYS, V117, P11033, DOI 10.1063/1.1521153; Jamneala T, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.256804; Rugar D, 2004, NATURE, V430, P329, DOI 10.1038/nature02658; Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989; Wiesendanger R, 1999, CURR OPIN SOLID ST M, V4, P435, DOI 10.1016/S1359-0286(99)00045-5	12	2	3	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2004	306	5695					423	+		10.1126/science.1103196	http://dx.doi.org/10.1126/science.1103196			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486282				2022-12-28	WOS:000224626500034
J	Pang, PT; Teng, HK; Zaitsev, E; Woo, NT; Sakata, K; Zhen, SH; Teng, KK; Yung, WH; Hempstead, BL; Lu, B				Pang, PT; Teng, HK; Zaitsev, E; Woo, NT; Sakata, K; Zhen, SH; Teng, KK; Yung, WH; Hempstead, BL; Lu, B			Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity	SCIENCE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; ACTIVITY-DEPENDENT SECRETION; NEUROTROPHIC FACTOR; LATE-PHASE; LASTING POTENTIATION; EXCITATORY SYNAPSES; BDNF; GROWTH; MEMORY; MICE	Long-term memory is thought to be mediated by protein synthesis-dependent, late-phase tong-term potentiation (L-LTP). Two secretory proteins, tissue plasminogen activator (tPA) and brain-derived neurotrophic factor (BDNF), have been implicated in this process, but their relationship is unclear. Here we report that tPA, by activating the extracellular protease plasmin, converts the precursor proBDNF to the mature BDNF (mBDNF), and that such conversion is critical for L-LTP expression in mouse hippocampus. Moreover, application of mBDNF is sufficient to rescue L-LTP when protein synthesis is inhibited, which suggests that mBDNF is a key protein synthesis product for L-LTP expression.	NICHD, Sect Neural Dev & Plast, Lab Cellular & Synapt Neurophysiol, Bethesda, MD 20892 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Hematol, New York, NY 10021 USA; Chinese Univ Hong Kong, Fac Med, Dept Physiol, Shatin, Hong Kong, Peoples R China	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Cornell University; Chinese University of Hong Kong	Lu, B (corresponding author), NICHD, Sect Neural Dev & Plast, Lab Cellular & Synapt Neurophysiol, Bethesda, MD 20892 USA.	bailu@mail.nih.gov	Lu, Bai/A-4018-2012; Yung, Ho/R-6161-2018; Sakata, Kazuko/I-2351-2017	Yung, Ho/0000-0002-5542-8173; Teng, Kenneth/0000-0002-9392-2172; Lu, Bai/0000-0001-5418-9759	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000714] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30658] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Calabresi P, 2000, EUR J NEUROSCI, V12, P1002, DOI 10.1046/j.1460-9568.2000.00991.x; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Frey U, 1996, J NEUROSCI, V16, P2057; Gualandris A, 1996, J NEUROSCI, V16, P2220; Hoffman KB, 1998, BRAIN RES, V811, P29, DOI 10.1016/S0006-8993(98)00906-8; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Korte M, 1998, NEUROPHARMACOLOGY, V37, P553, DOI 10.1016/S0028-3908(98)00035-5; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Li TS, 2002, BIOPOLYMERS, V67, P10, DOI 10.1002/bip.10038; Lu B, 2003, NEURON, V39, P735, DOI 10.1016/S0896-6273(03)00538-5; Madani R, 1999, EMBO J, V18, P3007, DOI 10.1093/emboj/18.11.3007; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; Mowla SJ, 1999, J NEUROSCI, V19, P2069; Mowla SJ, 2001, J BIOL CHEM, V276, P12660, DOI 10.1074/jbc.M008104200; Nakagami Y, 2000, J NEUROSCI, V20, P2003; Patterson SL, 2001, NEURON, V32, P123, DOI 10.1016/S0896-6273(01)00443-3; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; Pawlak R, 2002, NEUROSCIENCE, V113, P995, DOI 10.1016/S0306-4522(02)00166-5; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Tsirka SE, 1997, J NEUROSCI, V17, P543; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Wu YP, 2000, J CELL BIOL, V148, P1295, DOI 10.1083/jcb.148.6.1295	31	852	895	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					487	491		10.1126/science.1100135	http://dx.doi.org/10.1126/science.1100135			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486301				2022-12-28	WOS:000224626500054
J	Ginsburg, PB				Ginsburg, PB			Election 2004: Controlling health care costs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ctr Studying Hlth Syst Change, Washington, DC USA		Ginsburg, PB (corresponding author), Ctr Studying Hlth Syst Change, Washington, DC USA.							Kaiser Family Foundation, 2004, KAIS HLTH POLL REP; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; STRUNK BC, 2004, TRACKING HLTH CARE C	3	41	41	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1591	1593		10.1056/NEJMp048159	http://dx.doi.org/10.1056/NEJMp048159			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483273				2022-12-28	WOS:000224427300001
J	Kansagra, SM; Curtis, LH; Schulman, KA				Kansagra, SM; Curtis, LH; Schulman, KA			Regionalization of percutaneous transluminal coronary angioplasty and implications for patient travel distance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Alpha Omega Alpha Symposium	MAY 11, 2004	Duke Univ, Sch Med, Durham, NC		Duke Univ, Sch Med		ACUTE MYOCARDIAL-INFARCTION; CARDIAC-SURGERY; VOLUME; HOSPITALS; OUTCOMES; EXPERIENCE; MORBIDITY; MORTALITY; OPERATOR; TIME	Context Minimum procedure volume thresholds have been proposed to improve outcomes among patients undergoing percutaneous transluminal coronary angioplasty (PTCA). How regionalization policies would affect patient travel distances is not known. Objective To examine the effect of regionalization of PTCA on patient travel distances. Design, Setting, and Participants A retrospective cohort study of discharge records, which were examined to determine hospital and operator procedure volumes, of 97401 patients undergoing PTCA in New York, New Jersey, and Florida in 2001. Travel distances were measured at baseline and under 2 regionalization scenarios in which hospital-operator pairs not meeting minimum volume standards stopped providing services. Main Outcome Measures Observed and expected patient travel distances, and risk-adjusted mortality. Results With a minimum volume standard of 175 per operator and 400 per hospital (class 1), 25% of patients had a shorter travel distance, 10% had a longer travel distance, and 65% experienced no change. Most patients with longer travel distances under this standard would travel no more than 25 miles farther, and most patients with shorter travel distances would save no more than 10 miles. With a minimum volume standard of 75 per operator and 400 per hospital (class 2), 11% of patients had a shorter travel distance, 2% had a longer travel distance, and 87% experienced no change. Under both standards, less than 1% of patients would travel more than 50 miles farther than their observed travel distance. Risk-adjusted mortality was higher for lower-volume hospital-operator pairs (1.2% for class 3 vs 0.9% for class 2 and 0.8% for class 1; P<.001 for both comparisons). Conclusion Regionalization of PTCA would not increase travel distance for most patients; however, potential costs of regionalization not related to travel must be examined before such policies can be recommended.	Duke Clin Res Inst, Ctr Clin & Genet Econ, Durham, NC 27715 USA; Duke Univ, Med Ctr, Sch Med, Durham, NC USA; Duke Univ, Fuqua Sch Business, Hlth Sector Management Program, Durham, NC 27706 USA	Duke University; Duke University; Duke University	Schulman, KA (corresponding author), Duke Clin Res Inst, Ctr Clin & Genet Econ, POB 17969, Durham, NC 27715 USA.	kevin.schulman@duke.edu						Birkmeyer JD, 2003, JAMA-J AM MED ASSOC, V290, P2703, DOI 10.1001/jama.290.20.2703; Chang RKR, 2002, PEDIATRICS, V109, P173, DOI 10.1542/peds.109.2.173; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cox JL, 1997, CAN MED ASSOC J, V156, P497; DHOORE W, 1993, METHOD INFORM MED, V32, P382; Ellis SG, 1997, CIRCULATION, V95, P2479, DOI 10.1161/01.CIR.95.11.2479; Goldberg RJ, 1998, AM J CARDIOL, V82, P259, DOI 10.1016/S0002-9149(98)00342-7; GRUMBACH K, 1995, JAMA-J AM MED ASSOC, V274, P1282, DOI 10.1001/jama.274.16.1282; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; Iezzoni LI, 1997, RISK ADJUSTMENT MEAS; Jollis JG, 1997, CIRCULATION, V95, P2485, DOI 10.1161/01.CIR.95.11.2485; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; KIMMEL SE, 1995, JAMA-J AM MED ASSOC, V274, P1137, DOI 10.1001/jama.274.14.1137; McGrath PD, 2000, JAMA-J AM MED ASSOC, V284, P3139, DOI 10.1001/jama.284.24.3139; Rill V, 1999, Circulation, V99, pe12; RITCHIE JL, 1993, CIRCULATION, V88, P2735, DOI 10.1161/01.CIR.88.6.2735; Schulman KA, 1997, JOINT COMM J QUAL IM, V23, P117, DOI 10.1016/S1070-3241(16)30304-2; Smith SC, 2001, J AM COLL CARDIOL, V37, P2215, DOI 10.1016/S0735-1097(01)01344-4; FACT SHEET EVIDENCE	19	27	27	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2004	292	14					1717	1723		10.1001/jama.292.14.1717	http://dx.doi.org/10.1001/jama.292.14.1717			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	861JS	15479937	Bronze			2022-12-28	WOS:000224413400031
J	Man, WDC; Polkey, MI; Donaldson, N; Gray, BJ; Moxham, J				Man, WDC; Polkey, MI; Donaldson, N; Gray, BJ; Moxham, J			Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-STATUS; TIME-COURSE; COPD; RECOVERY	Objective To evaluate the effects of an early, community based, pulmonary rehabilitation programme after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease (COPD). Design A single centre, randomised controlled trial. Setting An inner city, secondary and tertiary care hospital in London. Participants 42 patients admitted with an acute exacerbation of COPD. Intervention An eight week, pulmonary rehabilitation programme for outpatients, started within 10 days of hospital discharge, or usual care. Main outcome measures Incremental shuttle walk distance, disease specific health status (St George's respiratory questionnaire, SGRQ; chronic respiratory questionnaire, CRQ), and generic health status (medical outcomes short form 36 questionnaire, SF-36) at three months after hospital discharge. Results Early pulmonary rehabilitation, compared with usual care, led to significant improvements in median incremental shuttle walk distance (60 metres, 95% confidence interval 26.6 metres to 93.4 metres, P = 0.0002), mean SGRQ total score (-12.7, - 5.0 to - 20.3, P = 0.002), all four domains of the CRQ (dyspnoea 5.5, 2.0 to 9.0, P = 0.003; fatigue 5.3, 1.9 to 8.8, P=0.004; emotion 8.7, 2.4 to 15.0, P=0.008; and mastery 7.5, 4.2 to.10.7, P < 0.001), and the mental component score of the SF-36 (20.1, 3.3 to 36.8, P=0.02). Improvements in the physical component score of the SF-36 did not reach significance (10.6, -0.3 to 21.6,P=0.057). Conclusion Early pulmonary rehabilitation after admission to hospital for acute exacerbations of COPD is safe and leads to statistically and clinically significant improvements in exercise capacity and health status at three months.	Kings Coll Hosp London, Guys Kings & St Thomas Sch Med, Resp Muscle Lab, London SE5 9PJ, England; Kings Coll Hosp London, London SE5 9RS, England; Royal Brompton Hosp, London SW3 6NP, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; Royal Brompton Hospital	Man, WDC (corresponding author), Kings Coll Hosp London, Guys Kings & St Thomas Sch Med, Resp Muscle Lab, London SE5 9PJ, England.	william.man@kcl.ac.uk		Man, William/0000-0002-3782-659X				Aaron SD, 2003, NEW ENGL J MED, V348, P2618, DOI 10.1056/NEJMoa023161; Behnke M, 2000, RESP MED, V94, P1184, DOI 10.1053/rmed.2000.0949; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; *BRIT LUNG FDN, 2003, LUNG REP ILL CAST SH; *BRIT LUNG FDN, 2003, 3 BRIT LUNG FDN; Britton M, 2003, RESP MED, V97, pS71, DOI 10.1016/S0954-6111(03)80027-6; Garcia-Aymerich J, 2003, THORAX, V58, P100, DOI 10.1136/thorax.58.2.100; Griffiths TL, 2001, THORAX, V56, P779, DOI 10.1136/thorax.56.10.779; Griffiths TL, 2000, LANCET, V355, P362, DOI 10.1016/S0140-6736(99)07042-7; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Lacasse Y, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003793.PUB2; Man WDC, 2003, THORAX, V58, P665, DOI 10.1136/thorax.58.8.665; National Institute for Clinical Excellence (NICE), 2004, THORAX S1, V59; Seemungal TAR, 2000, AM J RESP CRIT CARE, V161, P1608, DOI 10.1164/ajrccm.161.5.9908022; SINGH SJ, 1992, THORAX, V47, P1019, DOI 10.1136/thx.47.12.1019; Spencer S, 2003, THORAX, V58, P589, DOI 10.1136/thorax.58.7.589; Spruit MA, 2003, THORAX, V58, P752, DOI 10.1136/thorax.58.9.752; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	19	215	224	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2004	329	7476					1209	1211		10.1136/bmj.38258.662720.3A	http://dx.doi.org/10.1136/bmj.38258.662720.3A			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874FG	15504763	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000225335700016
J	Aharonian, FA; Akhperjanian, AG; Aye, KM; Bazer-Bachi, AR; Beilicke, M; Benbow, W; Berge, D; Berghaus, P; Bernlohr, K; Bolz, O; Boisson, C; Borgmeier, C; Breitling, F; Brown, AM; Gordo, JB; Chadwick, PM; Chitnis, VR; Chounet, LM; Cornils, R; Costamante, L; Degrange, B; Djannati-Atai, A; Drury, LO; Ergin, T; Espigat, P; Feinstein, F; Fleury, P; Fontaine, G; Funk, S; Gallant, YA; Giebels, B; Gillessen, S; Goret, P; Guy, J; Hadjichristidis, C; Hauser, M; Heinzelmann, G; Henri, G; Hermann, G; Hinton, JA; Hofmann, W; Holleran, M; Horns, D; de Jager, OC; Jung, I; Kheilifi, B; Komin, N; Konopelko, A; Latham, IJ; Le Gallou, R; Lemoine, M; Lemiere, A; Leroy, N; Lohse, T; Marcowith, A; Masterson, C; McComb, TJL; de Naurois, M; Nolan, SJ; Noutsos, A; Orford, KJ; Osborne, JL; Ouchriff, M; Panter, M; Pelletier, G; Pita, S; Pohl, M; Puhlhofer, G; Punch, M; Raubenheimer, BC; Raue, M; Raux, J; Rayner, SM; Redondo, I; Reimer, A; Reimer, O; Ripken, J; Rivoal, M; Rob, L; Rolland, L; Rowell, G; Sahakian, V; Sauge, L; Schlenker, S; Schlickeiser, R; Schuster, C; Schwanke, U; Siewert, M; Sol, H; Steenkamp, R; Stegmann, C; Tavernet, JP; Theoret, CG; Tluczykont, M; van der Walt, DJ; Vasileiadis, G; Vincent, P; Visser, B; Volk, HJ; Wagner, SJ				Aharonian, FA; Akhperjanian, AG; Aye, KM; Bazer-Bachi, AR; Beilicke, M; Benbow, W; Berge, D; Berghaus, P; Bernlohr, K; Bolz, O; Boisson, C; Borgmeier, C; Breitling, F; Brown, AM; Gordo, JB; Chadwick, PM; Chitnis, VR; Chounet, LM; Cornils, R; Costamante, L; Degrange, B; Djannati-Atai, A; Drury, LO; Ergin, T; Espigat, P; Feinstein, F; Fleury, P; Fontaine, G; Funk, S; Gallant, YA; Giebels, B; Gillessen, S; Goret, P; Guy, J; Hadjichristidis, C; Hauser, M; Heinzelmann, G; Henri, G; Hermann, G; Hinton, JA; Hofmann, W; Holleran, M; Horns, D; de Jager, OC; Jung, I; Kheilifi, B; Komin, N; Konopelko, A; Latham, IJ; Le Gallou, R; Lemoine, M; Lemiere, A; Leroy, N; Lohse, T; Marcowith, A; Masterson, C; McComb, TJL; de Naurois, M; Nolan, SJ; Noutsos, A; Orford, KJ; Osborne, JL; Ouchriff, M; Panter, M; Pelletier, G; Pita, S; Pohl, M; Puhlhofer, G; Punch, M; Raubenheimer, BC; Raue, M; Raux, J; Rayner, SM; Redondo, I; Reimer, A; Reimer, O; Ripken, J; Rivoal, M; Rob, L; Rolland, L; Rowell, G; Sahakian, V; Sauge, L; Schlenker, S; Schlickeiser, R; Schuster, C; Schwanke, U; Siewert, M; Sol, H; Steenkamp, R; Stegmann, C; Tavernet, JP; Theoret, CG; Tluczykont, M; van der Walt, DJ; Vasileiadis, G; Vincent, P; Visser, B; Volk, HJ; Wagner, SJ			High-energy particle acceleration in the shell of a supernova remnant	NATURE			English	Article							GAMMA-RAY EMISSION; SNR RX-J1713.7-3946; CASSIOPEIA-A; COSMIC-RAYS; G347.3-0.5; DISCOVERY; SPECTRUM; SYSTEM; ORIGIN	A significant fraction of the energy density of the interstellar medium is in the form of high-energy charged particles ( cosmic rays)(1). The origin of these particles remains uncertain. Although it is generally accepted that the only sources capable of supplying the energy required to accelerate the bulk of Galactic cosmic rays are supernova explosions, and even though the mechanism of particle acceleration in expanding supernova remnant (SNR) shocks is thought to be well understood theoretically(2,3), unequivocal evidence for the production of high-energy particles in supernova shells has proven remarkably hard to find. Here we report on observations of the SNR RX J1713.7 - 3946 ( G347.3 - 0.5), which was discovered by ROSAT(4) in the X-ray spectrum and later claimed as a source of high-energy gamma-rays(5,6) of TeV energies (1 TeV = 10(12) eV). We present a TeV gamma-ray image of the SNR: the spatially resolved remnant has a shell morphology similar to that seen in X-rays, which demonstrates that very-high-energy particles are accelerated there. The energy spectrum indicates efficient acceleration of charged particles to energies beyond 100 TeV, consistent with current ideas of particle acceleration in young SNR shocks.	Max Planck Inst Kernphys, D-69029 Heidelberg, Germany; Yerevan Phys Inst, Yerevan 375036, Armenia; Univ Durham, Dept Phys, Durham DH1 3LE, England; UPS, CNRS, Ctr Etud Spatiale Rayonnements, F-31029 Toulouse 4, France; Univ Hamburg, Inst Expt Phys, D-22761 Hamburg, Germany; Coll France, CNRS, IN2P3, F-75231 Paris 05, France; Humboldt Univ, Inst Phys, D-12489 Berlin, Germany; Observ Paris, CNRS, UMR 8102, LUTH, F-92195 Meudon, France; Univ Montpellier 2, CNRS, IN2P3, Grp Astroparticules Montpellier, F-34095 Montpellier 5, France; Univ Paris 06, CNRS, IN2P3, Lab Phys Nucl & Hautes Energies, F-75231 Paris 05, France; Univ Paris 07, F-75231 Paris 05, France; Ecole Polytech, CNRS, IN2P3, Lab Leprince Ringuet, F-91128 Palaiseau, France; Dublin Inst Adv Studies, Dublin 2, Ireland; CE Saclay, CEA, DSM, DAPNIA,Serv Astrophys, F-91191 Gif Sur Yvette, France; Landessternwarte Heidelberg, D-69117 Heidelberg, Germany; Univ Grenoble 1, CNRS, INSU, Lab Astrophys Grenoble, F-38041 Grenoble 9, France; North West Univ, Unit Space Phys, ZA-2520 Potchefstroom, South Africa; Ruhr Univ Bochum, Inst Theoret Phys, Lehrstuhl Weltraum & Astrophys 4, D-44780 Bochum, Germany; Charles Univ, Inst Nucl & Particle Phys, CR-18000 Prague 8, Czech Republic; Univ Namibia, Windhoek, Namibia	Max Planck Society; Yerevan Physics Institute; Durham University; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Hamburg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; PSL Research University Paris; College de France; Humboldt University of Berlin; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); Institut Polytechnique de Paris; Dublin Institute for Advanced Studies; CEA; UDICE-French Research Universities; Universite Paris Saclay; Ruprecht Karls University Heidelberg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); North West University - South Africa; Ruhr University Bochum; Charles University Prague; University of Namibia	Berge, D (corresponding author), Max Planck Inst Kernphys, POB 103980, D-69029 Heidelberg, Germany.	David.Berge@mpi-hd.mpg.de	Ergin, Tulun/AAQ-1106-2021; Gordo, Javier Bussons/B-5572-2019; Pühlhofer, Gerd/Q-2336-2018; Aye, Klaus-Michael/D-2425-2009; Berge, David/P-2179-2017; Djannati-Atai, Arache/ABA-9249-2021; Drury, Luke O'C/B-1916-2017; Reimer, Olaf/A-3117-2013; Funk, Stefan/B-7629-2015; Funk, Stefan/AAI-1568-2021; Pohl, Martin/P-4920-2017; Hadjichristidis, Christos/G-7284-2012; Reimer, Anita/K-5822-2015; Jung-Richardt, Ira/AAT-8884-2020; Marcowith, Alexandre/ABH-1254-2020; Horns, Dieter/C-9727-2011; Fontaine, Gerard/D-6420-2014; Horns, Dieter/ABE-9516-2020; Redondo, Ignacio/K-8639-2014; Komin, Nukri/J-6781-2015; Aye, Klaus-Michael/W-1271-2018	Ergin, Tulun/0000-0003-2423-4656; Gordo, Javier Bussons/0000-0002-8275-592X; Berge, David/0000-0002-2918-1824; Drury, Luke O'C/0000-0002-9257-2270; Reimer, Olaf/0000-0001-6953-1385; Funk, Stefan/0000-0002-2012-0080; Funk, Stefan/0000-0002-2012-0080; Pohl, Martin/0000-0001-7861-1707; Hadjichristidis, Christos/0000-0002-5933-0755; Reimer, Anita/0000-0001-8604-7077; Marcowith, Alexandre/0000-0002-3971-0910; Fontaine, Gerard/0000-0002-6443-5025; Horns, Dieter/0000-0003-1945-0119; Hermann, German/0000-0002-4595-1032; Hinton, James/0000-0002-1031-7760; Redondo, Ignacio/0000-0003-3737-4121; Punch, Michael/0000-0002-4710-2165; Chadwick, Paula/0000-0002-1468-2685; Komin, Nukri/0000-0003-3280-0582; Aye, Klaus-Michael/0000-0002-4088-1928; Rowell, Gavin/0000-0002-9516-1581; Noutsos, Aristeidis/0000-0002-4151-3860; Bernlohr, Konrad/0000-0001-8065-3252; Benbow, Wystan/0000-0003-2098-170X; Brown, Anthony/0000-0003-0259-3148; van der Walt, Johan/0000-0001-6666-6866; Khelifi, Bruno/0000-0001-6876-5577				Aharonian F, 2001, ASTRON ASTROPHYS, V370, P112, DOI 10.1051/0004-6361:20010243; AHARONIAN FA, 1994, ASTRON ASTROPHYS, V285, P645; Aharonian FA, 1999, ASTRON ASTROPHYS, V349, P11; Berezhko EG, 2003, ASTRON ASTROPHYS, V400, P971, DOI 10.1051/0004-6361:20030033; Bernlohr K, 2003, ASTROPART PHYS, V20, P111, DOI 10.1016/S0927-6505(03)00171-3; CASSAMCHENAI A, IN PRESS ASTRON ASTR; DRURY LO, 1994, ASTRON ASTROPHYS, V287, P959; Ellison DC, 2001, ASTROPHYS J, V563, P191, DOI 10.1086/323687; Enomoto R, 2002, NATURE, V416, P823, DOI 10.1038/416823a; Fukui Y, 2003, PUBL ASTRON SOC JPN, V55, pL61, DOI 10.1093/pasj/55.5.L61; Hinton JA, 2004, NEW ASTRON REV, V48, P331, DOI 10.1016/j.newar.2003.12.004; HOFMANN W, 2003, P 28 ICRC TSUK, P2811; Koo BC, 2004, IAU SYMP, P85; Laming JM, 1998, ASTROPHYS J, V499, P309, DOI 10.1086/305647; LONGAIR MS, 2002, HIGH ENERGY ASTROPHY, V2; MASTERSON C, 2003, P 28 ICRC TSUK, P2323; Muraishi H, 2000, ASTRON ASTROPHYS, V354, pL57; NAITO T, 1994, J PHYS G NUCL PARTIC, V20, P477, DOI 10.1088/0954-3899/20/3/009; Pfeffermann E., 1996, Rontgenstrahlung from the Universe. International Conference on X-Ray Astronomy and Astrophysics. Conference Proceedings (MPE Report 263), P267; Slane P, 1999, ASTROPHYS J, V525, P357, DOI 10.1086/307893; Tanimori T, 1998, ASTROPHYS J, V497, pL25, DOI 10.1086/311267; Uchiyama Y, 2003, ASTRON ASTROPHYS, V400, P567, DOI 10.1051/0004-6361:20021824; Uchiyama Y, 2002, PUBL ASTRON SOC JPN, V54, pL73, DOI 10.1093/pasj/54.5.L73; VINCENT P, 2003, P 28 ICRC TSUK, P2887; WEEKES TC, 1989, ASTROPHYS J, V342, P379, DOI 10.1086/167599	25	422	428	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					75	77		10.1038/nature02960	http://dx.doi.org/10.1038/nature02960			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525982	Green Accepted, Green Submitted			2022-12-28	WOS:000224854900040
J	Pierce, JL; Meyer, GA; Jull, AJT				Pierce, JL; Meyer, GA; Jull, AJT			Fire-induced erosion and millennialscale climate change in northern ponderosa pine forests	NATURE			English	Article							YELLOWSTONE-NATIONAL-PARK; UNITED-STATES; VARIABILITY; AGE; TEMPERATURES; COLORADO; REGIMES; EVENTS; TIME; USA	Western US ponderosa pine forests have recently suffered extensive stand-replacing fires followed by hillslope erosion and sedimentation(1-4). These fires are usually attributed to increased stand density as a result of fire suppression, grazing and other land use, and are often considered uncharacteristic or unprecedented(1-3). Tree-ring records from the past 500 years indicate that before Euro-American settlement, frequent, low-severity fires maintained open stands(1-3). However, the pre-settlement period between about AD 1500 and AD 1900 was also generally colder than present(5-10), raising the possibility that rapid twentieth-century warming promoted recent catastrophic fires. Here we date fire-related sediment deposits in alluvial fans in central Idaho to reconstruct Holocene fire history in xeric ponderosa pine forests and examine links to climate. We find that colder periods experienced frequent low-severity fires, probably fuelled by increased understory growth. Warmer periods experienced severe droughts, stand-replacing fires and large debris-flow events that comprise a large component of long-term erosion(11) and coincide with similar events in sub-alpine forests of Yellowstone National Park(12). Our results suggest that given the powerful influence of climate, restoration of processes typical of pre-settlement times may be difficult in a warmer future that promotes severe fires.	Univ New Mexico, Dept Earth & Planetary Sci, Albuquerque, NM 87131 USA; Univ Arizona, NSF, Arizona AMS Facil, Tucson, AZ 85721 USA	University of New Mexico; National Science Foundation (NSF); University of Arizona	Pierce, JL (corresponding author), Univ New Mexico, Dept Earth & Planetary Sci, Albuquerque, NM 87131 USA.	jpierce@unm.edu						Adams KD, 2003, QUATERNARY RES, V60, P294, DOI 10.1016/j.yqres.2003.07.006; Agee, 1993, FIRE ECOLOGY PACIFIC; BARRETT SW, 1994, INT J WILDLAND FIRE, V4, P65, DOI 10.1071/WF9940065; Bradley RS, 2003, SCIENCE, V302, P404, DOI 10.1126/science.1090372; Brown PM, 1999, LANDSCAPE ECOL, V14, P513, DOI 10.1023/A:1008137005355; CARRARA PE, 1989, US GEOL SURV B, V1902, P1; Covington W. W., 1994, Journal of Sustainable Forestry, V2, P13, DOI 10.1300/J091v02n01_02; Crowley TJ, 2000, SCIENCE, V289, P270, DOI 10.1126/science.289.5477.270; Esper J, 2002, SCIENCE, V295, P2250, DOI 10.1126/science.1066208; Grove JM, 1988, LITTLE ICE AGE; Karl TR, 1996, B AM METEOROL SOC, V77, P279, DOI 10.1175/1520-0477(1996)077<0279:IOCCFT>2.0.CO;2; Kirchner JW, 2001, GEOLOGY, V29, P591, DOI 10.1130/0091-7613(2001)029<0591:MEOYKY>2.0.CO;2; LAVEE H, 1995, GEOMORPHOLOGY, V11, P227, DOI 10.1016/0169-555X(94)00059-Z; Luckman BH, 2000, GEOMORPHOLOGY, V32, P357, DOI 10.1016/S0169-555X(99)00104-X; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; MEYER GA, 1995, GEOL SOC AM BULL, V107, P1211, DOI 10.1130/0016-7606(1995)107<1211:FAACIY>2.3.CO;2; Meyer GA, 2001, HYDROL PROCESS, V15, P3025, DOI 10.1002/hyp.389; Moody JA, 2001, HYDROL PROCESS, V15, P2981, DOI 10.1002/hyp.386; Pollack HN, 1998, SCIENCE, V282, P279, DOI 10.1126/science.282.5387.279; Rollins MG, 2002, LANDSCAPE ECOL, V17, P539, DOI 10.1023/A:1021584519109; Schmidt KM, 2001, CAN GEOTECH J, V38, P995, DOI 10.1139/cgj-38-5-995; Shinneman DJ, 1997, CONSERV BIOL, V11, P1276, DOI 10.1046/j.1523-1739.1997.96198.x; Steele R., 1986, Western Journal of Applied Forestry, V1, P16; Stine S, 1998, WATER TRANS, V31, P43; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; Swetnam TW, 1998, J CLIMATE, V11, P3128, DOI 10.1175/1520-0442(1998)011<3128:MDAERT>2.0.CO;2; Veblen TT, 2000, ECOL APPL, V10, P1178, DOI 10.1890/1051-0761(2000)010[1178:CAHIOF]2.0.CO;2; Westerling AL, 2003, B AM METEOROL SOC, V84, P595, DOI 10.1175/BAMS-84-5-595; WHITLOCK C, 2003, FOREST ECOL MANAG, V178, P163; Woodhouse CA, 1998, B AM METEOROL SOC, V79, P2693, DOI 10.1175/1520-0477(1998)079<2693:YODVIT>2.0.CO;2	30	208	214	6	80	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	2004	432	7013					87	90		10.1038/nature03058	http://dx.doi.org/10.1038/nature03058			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525985				2022-12-28	WOS:000224854900044
J	Molyneux, E; Weber, MW				Molyneux, E; Weber, MW			Applying the right standards to improve hospital performance in Africa	LANCET			English	Editorial Material							DEVELOPING-COUNTRIES; GUIDELINES; QUALITY; ILLNESS; TRIAGE; CARE		Coll Med, Dept Paediat, Blantyre 3, Malawi; WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland	University of Malawi; University of Geneva; World Health Organization	Molyneux, E (corresponding author), Coll Med, Dept Paediat, Blantyre 3, Malawi.	emolyneux@malawi.net	Weber, Martin/GPW-6095-2022					Duke T, 2003, ARCH DIS CHILD, V88, P563, DOI 10.1136/adc.88.7.563; Gove S, 1999, ARCH DIS CHILD, V81, P473, DOI 10.1136/adc.81.6.473; MOLYNEUX E, 2001, MALAWI MED J, V13, P2; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; Robertson MA, 2001, ARCH DIS CHILD, V85, P208, DOI 10.1136/adc.85.3.208; Robertson MA, 2001, ARCH DIS CHILD, V85, P214, DOI 10.1136/adc.85.3.214; Saravia NG, 2004, B WORLD HEALTH ORGAN, V82, P608; SILIMPIRI D, 2004, 24 INT C PED CANC ME; Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0; Tulloch J., 1999, Lancet (British edition), V354, P16, DOI 10.1016/S0140-6736(99)90252-0; Weber MW, 1997, B WORLD HEALTH ORGAN, V75, P25; *WHO, 2004, CAH PROGR REP 2002 2; *WHO FCH CAH, 2001, IMPR QUAL PAED CAR S	13	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	2004	364	9445					1560	1561		10.1016/S0140-6736(04)17326-1	http://dx.doi.org/10.1016/S0140-6736(04)17326-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	866IQ	15519614				2022-12-28	WOS:000224767600005
J	Passegue, E; Wagner, EF; Weissman, IL				Passegue, E; Wagner, EF; Weissman, IL			JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells	CELL			English	Article							CHRONIC MYELOID-LEUKEMIA; MICE LACKING JUNB; MYELOGENOUS LEUKEMIA; GENE-EXPRESSION; SELF-RENEWAL; PROGENITORS; GRANULOCYTE; APOPTOSIS; CANCER; BMI-1	The AP-1 transcription factor JunB is a transcriptional regulator of myelopoiesis. Inactivation of JunB in postnatal mice results in a myeloproliferative disorder (MPD) resembling early human chronic myelogenous leukemia (CML). Here, we show that JunB regulates the numbers of hematopoietic stem cells (HSC). JunB overexpression decreases the frequency of long-term HSC (LT-HSC), while JunB inactivation specifically expands the numbers of LT-HSC and granulocyte/macrophage progenitors (GMP) resulting in chronic MPD. Further, we demonstrate that junB inactivation must take place in LT-HSC, and not at later stages of myelopoiesis, to induce MPD and that only junB-deficient LT-HSC are capable of transplanting the MPD to recipient mice. These results demonstrate a stem cell-specific role for JunB in normal and leukemic hematopoiesis and provide experimental evidence that leukemic stem cells (LSC) can reside at the LT-HSC stage of development in a mouse model of MPD.	Stanford Univ, Sch Med, Inst Canc & Stem Cell Biol & Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Inst Canc & Stem Cell Biol & Med, Dept Dev Biol, Stanford, CA 94305 USA; Res Inst Mol Pathol, A-1030 Vienna, Austria	Stanford University; Stanford University; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Passegue, E (corresponding author), Stanford Univ, Sch Med, Inst Canc & Stem Cell Biol & Med, Dept Pathol, Stanford, CA 94305 USA.	passegue@stanford.edu		Passegue, Emmanuelle/0000-0002-3516-297X; Wagner, Erwin F/0000-0001-7872-0196	NCI NIH HHS [CA55209, CA86017] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086017] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Allsopp RC, 2002, ONCOGENE, V21, P3270, DOI 10.1038/sj.onc.1205314; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bose S, 1998, BLOOD, V92, P3362, DOI 10.1182/blood.V92.9.3362; Bruchova H, 2002, LEUKEMIA LYMPHOMA, V43, P1289, DOI 10.1080/10428190290026358; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Clarkson B, 2003, LEUKEMIA, V17, P1211, DOI 10.1038/sj.leu.2402912; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Domen J, 2000, IMMUNOL RES, V22, P83, DOI 10.1385/IR:22:2-3:83; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; Dorsam ST, 2004, BLOOD, V103, P1676, DOI 10.1182/blood-2003-07-2202; Feldman E, 2003, EXP HEMATOL, V31, P702, DOI 10.1016/S0301-472X(03)00176-0; FIALKOW PJ, 1981, BLOOD, V58, P158, DOI 10.1182/blood.V58.1.158.158; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; Jaiswal S, 2003, P NATL ACAD SCI USA, V100, P10002, DOI 10.1073/pnas.1633833100; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kantarjian HM, 2003, CANCER, V98, P522, DOI 10.1002/cncr.11543; Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Matioli GT, 2002, MED HYPOTHESES, V59, P588, DOI 10.1016/S0306-9877(02)00220-7; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Nakorn TN, 2002, J CLIN INVEST, V109, P1579, DOI 10.1172/JCI200215272; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Tallquist MD, 2000, GENESIS, V26, P113, DOI 10.1002/(SICI)1526-968X(200002)26:2<113::AID-GENE3>3.0.CO;2-2; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Yang MY, 2003, BLOOD, V101, P3205, DOI 10.1182/blood-2002-05-1598	46	292	313	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2004	119	3					431	443		10.1016/j.cell.2004.10.010	http://dx.doi.org/10.1016/j.cell.2004.10.010			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	868IW	15507213	Bronze			2022-12-28	WOS:000224908300013
J	Yedavalli, VSRK; Neuveut, C; Chi, YH; Kleiman, L; Jeang, KT				Yedavalli, VSRK; Neuveut, C; Chi, YH; Kleiman, L; Jeang, KT			Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function	CELL			English	Article							CONSTITUTIVE TRANSPORT ELEMENT; IMMUNODEFICIENCY-VIRUS REV; NUCLEAR-PORE COMPLEX; MESSENGER-RNA; D RETROVIRUS; SACCHAROMYCES-CEREVISIAE; TRANSLATION INITIATION; CELLULAR-PROTEINS; CRM1; TYPE-1	A single transcript in its unspliced and spliced forms directs the synthesis of all HIV-1 proteins. Although nuclear export of intron-containing cellular transcripts is restricted in mammalian cells, HIV-1 has evolved the viral Rev protein to overcome this restriction for viral transcripts. Previously, CRM1 was identified as a cellular cofactor for Rev-dependent export of intron-containing HIV-1 RNA. Here, we present evidence that Rev/CRM1 activity utilizes the ATP-dependent DEAD box RNA helicase, DDX3. We show that DDX3 is a nucleo-cytoplasmic shuttling protein, which binds CRM1 and localizes to nuclear membrane pores. Knockdown of DDX3 using either antisense vector or dominant-negative mutants suppressed Rev-RRE-function in the export of incompletely spliced HIV-1 RNAs. Plausibly, DDX3 is the human RNA helicase which functions in the CRM1 RNA export pathway analogously to the postulated role for Dbp5p in yeast mRNA export.	NIAID, Mol Virol Sect, Mol Microbiol Lab, Bethesda, MD 20892 USA; McGill AIDS Ctr, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Lady Davis Institute; McGill University	Jeang, KT (corresponding author), NIAID, Mol Virol Sect, Mol Microbiol Lab, 9000 Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Chi, Ya-Hui/ABE-8550-2020; Chi, Ya-Hui/B-1080-2010; Jeang, Kuan-Teh/A-2424-2008	Chi, Ya-Hui/0000-0002-9216-0938; Neuveut, Christine/0000-0001-6520-271X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Bear J, 1999, MOL CELL BIOL, V19, P6306; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; Clouse KN, 2001, NAT CELL BIOL, V3, P97, DOI 10.1038/35050625; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; Gaits F, 1999, MOL BIOL CELL, V10, P1395, DOI 10.1091/mbc.10.5.1395; Gururajan R, 1997, BBA-GENE STRUCT EXPR, V1350, P169, DOI 10.1016/S0167-4781(96)00155-8; Harris ME, 2000, ESSAYS BIOCHEM, V36, P115, DOI 10.1042/bse0360115; Herold A, 2001, RNA, V7, P1768; Hodzic DM, 2004, J BIOL CHEM, V279, P25805, DOI 10.1074/jbc.M313157200; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; Iost I, 1999, J BIOL CHEM, V274, P17677, DOI 10.1074/jbc.274.25.17677; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JENSEN TH, 1995, GENE, V162, P235, DOI 10.1016/0378-1119(95)00328-4; Kadare G, 1997, J VIROL, V71, P2583; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; Linder P, 2001, CURR BIOL, V11, pR961, DOI 10.1016/S0960-9822(01)00574-7; Linder P, 2003, BIOL CELL, V95, P157, DOI 10.1016/S0248-4900(03)00032-7; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Linder P, 2001, TRENDS BIOCHEM SCI, V26, P339, DOI 10.1016/S0968-0004(01)01870-9; Lorsch JR, 2002, CELL, V109, P797, DOI 10.1016/S0092-8674(02)00804-8; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Neuveut C, 1996, J VIROL, V70, P5572, DOI 10.1128/JVI.70.8.5572-5581.1996; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Park SH, 1998, CYTOGENET CELL GENET, V81, P178, DOI 10.1159/000015022; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Saavedra C, 1997, CURR BIOL, V7, P619, DOI 10.1016/S0960-9822(06)00288-0; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; SODROSKI J, 1986, NATURE, V321, P410; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 2000, J BIOL CHEM, V275, P32694, DOI 10.1074/jbc.M003933200; Tang HL, 1997, VIROLOGY, V228, P333, DOI 10.1006/viro.1996.8407; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Van Baalen CA, 1998, J VIROL, V72, P6851, DOI 10.1128/JVI.72.8.6851-6857.1998; Westberg C, 2000, J BIOL CHEM, V275, P21396, DOI 10.1074/jbc.M909887199; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0; Zhang XF, 2003, J BIOCHEM, V134, P759, DOI 10.1093/jb/mvg197; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160; ZOLOTUKHIN AS, 1994, J VIROL, V68, P7944, DOI 10.1128/JVI.68.12.7944-7952.1994	61	410	428	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2004	119	3					381	392		10.1016/j.cell.2004.09.029	http://dx.doi.org/10.1016/j.cell.2004.09.029			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	868IW	15507209	Bronze			2022-12-28	WOS:000224908300009
J	Eskandar, EN; Loeffler, JS; O'Neill, AM; Hunter, GJ; Louis, DN; Batchelor, T				Eskandar, EN; Loeffler, JS; O'Neill, AM; Hunter, GJ; Louis, DN; Batchelor, T			A man with a seizure and a frontal-lobe brain lesion - Anaplastic oligodendroglioma with allelic loss of chromosomes 1p and 19q	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MOLECULAR-GENETIC-ANALYSIS; GROWTH-FACTOR RECEPTOR; GLIOBLASTOMA-MULTIFORME; CHEMOTHERAPY; SURVIVAL; P53; AMPLIFICATION; RADIOTHERAPY; PREDICTORS; GLIOMAS		Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Eskandar, EN (corresponding author), Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02114 USA.							Bauman GS, 2000, INT J RADIAT ONCOL, V48, P825, DOI 10.1016/S0360-3016(00)00703-3; Burger PC, 2001, J NEUROPATH EXP NEUR, V60, P1099, DOI 10.1093/jnen/60.11.1099; CAIRNCROSS G, 1994, J CLIN ONCOL, V12, P2013, DOI 10.1200/JCO.1994.12.10.2013; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; CAIRNCROSS JG, 1988, ANN NEUROL, V23, P360, DOI 10.1002/ana.410230408; Dehghani F, 1998, ACTA NEUROPATHOL, V95, P493, DOI 10.1007/s004010050830; Ino Y, 2001, CLIN CANCER RES, V7, P839; KOOY HM, 1994, INT J RADIAT ONCOL, V28, P1229, DOI 10.1016/0360-3016(94)90499-5; MeyerPuttlitz B, 1997, AM J PATHOL, V151, P853; Reifenberger J, 1996, J NEUROPATH EXP NEUR, V55, P822, DOI 10.1097/00005072-199607000-00007; Schiffer D, 1997, CAN J NEUROL SCI, V24, P313, DOI 10.1017/S0317167100032984; SHAW EG, 1992, J NEUROSURG, V76, P428, DOI 10.3171/jns.1992.76.3.0428; Simmons ML, 2001, CANCER RES, V61, P1122; Smith JS, 2000, J CLIN ONCOL, V18, P636, DOI 10.1200/JCO.2000.18.3.636; Tortosa A, 2000, NEUROPATH APPL NEURO, V26, P544, DOI 10.1046/j.0305-1846.2000.00290.x; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; WINGER MJ, 1989, J NEUROSURG, V71, P487, DOI 10.3171/jns.1989.71.4.0487	18	3	3	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1875	1882		10.1056/NEJMcpc049025	http://dx.doi.org/10.1056/NEJMcpc049025			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509821				2022-12-28	WOS:000224723100012
J	Ofri, D				Ofri, D			Becoming a physician: Residency regulations - Resisting our reflexes	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NYU, Sch Med, Dept Med, New York, NY 10003 USA; Bellevue Hosp, New York, NY USA	New York University; Bellevue Hospital Center	Ofri, D (corresponding author), NYU, Sch Med, Dept Med, New York, NY 10003 USA.			Ofri, Danielle/0000-0001-9865-7104					0	20	20	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1824	1826		10.1056/NEJMp038251	http://dx.doi.org/10.1056/NEJMp038251			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509814				2022-12-28	WOS:000224723100004
J	Budetti, PP				Budetti, PP			10 years beyond the health security act failure - Subsequent developments and persistent problems	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INSURANCE	Ten years after the failure of President Clinton's Health Security Act (HSA), the United States continues to face multiple stresses in health care, including large numbers of uninsured individuals, increasing costs, questions about quality, and dissatisfaction with managed care. Using the framework of the HSA-particularly universal coverage, spending and managed competition, insurance for low-income persons, and patients' rights-the post-HSA evolution and current status of the US health care system is traced and lessons to guide future actions are outlined. Neither incremental legislation nor private sector changes in health care organization and financing during the past decade have ameliorated the problems addressed by the HSA, and new troubles have emerged. These problems affect every group in the country and continue to deteriorate health care, yet there has been no political support for large-scale reform. The core components of a vision for future action - universal coverage, quality improvement, cost containment, and subsidies for the economically vulnerable-are essential. There is a pressing need to construct a clear vision that would tie together incremental steps into a rational approach to comprehensive reform and to actually move toward the realization of that vision.	Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Hlth Policy & Adm, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Budetti, PP (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Hlth Policy & Adm, 801 NE 13th St,CHB 343A, Oklahoma City, OK 73104 USA.	peter-budetti@ouhsc.edu						*AM HLTH INS PLANS, HLTH SAV ACC; [Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; BRUEN B, 2001, MEDICAID SPENDING GR; BRUEN B, 1999, SLOW GROWTH MEDICAID; Budetti PP, 1997, JAMA-J AM MED ASSOC, V277, P193; CARROLL W, 11 CTR COST FIN STUD; Centers for Medicare and Medicaid Services, TABL 1 NAT HLTH EXP; Congressional Budget Office, 1994, AN ADM HLTH PROP; *CTR MED MED SERV, TABL 1 NATL HLTH EXP; Davis K, 2000, ARCH INTERN MED, V160, P3357, DOI 10.1001/archinte.160.22.3357; FREUDENHEIM M, 2004, NY TIMES        0513; FUCHS BC, 1993, HLTH CARE REFORM PRE; GABEL JR, 2002, HLTH AFF MILLWOOD S, pW395; Hing E, 1999, MED CARE, V37, P692, DOI 10.1097/00005650-199907000-00009; HOLOHAN J, 2003, MEDICAID SPENDING FA; *KAIS COMM MED UN, 2003, HLTH INS COV AM 2002; *KAIS FAM FDN, TRENDS IND CHANG HLT; *KAIS FAM FDN HLTH, EMPL HLTH BEN 2003 A; *KAIS FAM FDN HLTH, 2004, EMPL HLTH BEN 2004 A; *KAIS FDN HLTH RES, EMPL HLTH BEN 2003 A; Kilbridge P, 2003, NEW ENGL J MED, V348, P1423, DOI 10.1056/NEJMp030020; KOHN LT, 1999, ERR HUMAN BUILDING S; Long SH, 2001, HEALTH AFFAIR, V20, P154, DOI 10.1377/hlthaff.20.1.154; MERLIS M, 2002, FAMILY POCKET SPENDI; MILLS RJ, 2002, HLTH INSURANCE COVER; *NAT ASS STAT BUDG, 2003, 2002 STAT EXP REP; Nichols LM, 2004, HEALTH AFFAIR, V23, P8, DOI 10.1377/hlthaff.23.2.8; President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry, 1998, QUAL 1 BETT HLTH CAR; Robinson JC, 2004, JAMA-J AM MED ASSOC, V291, P1880, DOI 10.1001/jama.291.15.1880; ROBINSON JC, 2002, HLTH AFFAIRS    0320; ROBINSON JC, 2004, HLTH AFFAIRS    0519; SHORT PF, 1995, JAMA-J AM MED ASSOC, V274, P1302; *US CENS BUR, 2004, HIST HLTH INS TABL H; *US DEP LAB, EMPL COST TRENDS WEB; Woolhandler S, 2003, NEW ENGL J MED, V349, P768, DOI 10.1056/NEJMsa022033; 2002, MANAGED CARE     DEC; 2002 EMPLOYER BENEFI	37	2	3	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2004	292	16					2000	2006		10.1001/jama.292.16.2000	http://dx.doi.org/10.1001/jama.292.16.2000			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865DO	15507586				2022-12-28	WOS:000224682900025
J	den Herder, C; Schmeck, J; Appelboom, DJK; de Vries, N				den Herder, C; Schmeck, J; Appelboom, DJK; de Vries, N			Risks of general anaesthesia in people with obstructive sleep apnoea	BRITISH MEDICAL JOURNAL			English	Review							PERIOPERATIVE COMPLICATIONS; UPPER AIRWAY; SURGERY; MANAGEMENT; INTUBATION; DISORDERS; MORPHINE; CHILDREN; SNORERS; MEN		St Lucas Andreas Hosp, Dept Otolaryngol Head & Neck Surg, NL-1006 AE Amsterdam, Netherlands; St Lucas Andreas Hosp, Dept Anaesthesiol, NL-1006 AE Amsterdam, Netherlands; Univ Heidelberg, Univ Hosp Mannheim, Dept Anaesthesiol & Operat Intens Care Med, D-68167 Mannheim, Germany	Sint Lucas Andreas Hospital; Sint Lucas Andreas Hospital; Ruprecht Karls University Heidelberg	den Herder, C (corresponding author), St Lucas Andreas Hosp, Dept Otolaryngol Head & Neck Surg, Tooropstr 164, NL-1006 AE Amsterdam, Netherlands.	c.denherder@slaz.nl						Baik UB, 2002, ANGLE ORTHOD, V72, P124; Barthel SW, 1999, MED CLIN N AM, V83, P85, DOI 10.1016/S0025-7125(05)70089-4; Boushra NN, 1996, CAN J ANAESTH, V43, P599, DOI 10.1007/BF03011774; BURGESS LPA, 1992, OTOLARYNG HEAD NECK, V106, P81, DOI 10.1177/019459989210600132; Caplan RA, 2003, ANESTHESIOLOGY, V98, P1269; CHAUVIN M, 1982, BRIT J ANAESTH, V54, P843, DOI 10.1093/bja/54.8.843; CHUNG F, 1982, CAN ANAESTH SOC J, V29, P439, DOI 10.1007/BF03009406; CHUNG F, 2002, CAN J ANESTH, V49, pR1; Connolly L A, 1991, J Clin Anesth, V3, P461, DOI 10.1016/0952-8180(91)90094-4; CRADDOCK M, 1989, GEN ANESTHESIA, P346; Do KL, 2000, LARYNGOSCOPE, V110, P1552, DOI 10.1097/00005537-200009000-00027; ESCLAMADO RM, 1989, LARYNGOSCOPE, V99, P1125; Friedman M, 1999, LARYNGOSCOPE, V109, P1901, DOI 10.1097/00005537-199912000-00002; GLEADHILL IC, 1991, AM REV RESPIR DIS, V143, P1300, DOI 10.1164/ajrccm/143.6.1300; Gupta RM, 2001, MAYO CLIN PROC, V76, P897, DOI 10.4065/76.9.897; Hoekema A, 2003, J ORAL REHABIL, V30, P690, DOI 10.1046/j.1365-2842.2003.01130.x; KAFER ER, 1983, ANESTHESIOLOGY, V58, P418, DOI 10.1097/00000542-198305000-00005; KNILL RL, 1990, ANESTHESIOLOGY, V73, P52, DOI 10.1097/00000542-199007000-00009; KRAVATH RE, 1980, J PEDIATR-US, V96, P645, DOI 10.1016/S0022-3476(80)80730-X; Liistro G, 2003, EUR RESPIR J, V21, P248, DOI 10.1183/09031936.03.00292403; Loadsman JA, 2001, BRIT J ANAESTH, V86, P254, DOI 10.1093/bja/86.2.254; MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357; MCCOLLEY SA, 1992, ARCH OTOLARYNGOL, V118, P940; Mortimore IL, 1998, AM J RESP CRIT CARE, V157, P280, DOI 10.1164/ajrccm.157.1.9703018; NUNN JF, 1993, NUNNS APPL RESP PHYS, P333; Ostermeier AM, 1997, ANESTH ANALG, V85, P452, DOI 10.1097/00000539-199708000-00037; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; RAFFERTY TD, 1980, BRIT J ANAESTH, V52, P619, DOI 10.1093/bja/52.6.619; Reimer MA, 2003, SLEEP MED REV, V7, P335, DOI 10.1053/smrv.2001.0220; Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008; SHAPIRO CM, ABC SLEEP DISORDERS, P5; SHEPPARD L, 1992, LASER SURG MED, V12, P137, DOI 10.1002/lsm.1900120205; Siyam MA, 2002, ANESTH ANALG, V95, P1098, DOI 10.1097/00000539-200210000-00058; STROHL KP, 1986, AM REV RESPIR DIS, V134, P791; TAASAN VC, 1981, AM J MED, V71, P240; VALNICEK SM, 1994, PLAST RECONSTR SURG, V93, P954, DOI 10.1097/00006534-199404001-00009; Verin E, 2002, RESP PHYSIOL, V129, P335, DOI 10.1016/S0034-5687(01)00324-3; Verse T, 2002, LARYNGOSCOPE, V112, P64, DOI 10.1097/00005537-200201000-00012; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 1997, SLEEP, V20, P705, DOI 10.1093/sleep/20.9.705; 2003, PHARM THERAPEUTIC CO, P51	41	56	81	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 23	2004	329	7472					955	959		10.1136/bmj.329.7472.955	http://dx.doi.org/10.1136/bmj.329.7472.955			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866KU	15499112	Green Published			2022-12-28	WOS:000224773200019
J	Tattersfield, AE; Hall, IP				Tattersfield, AE; Hall, IP			Are beta(2)-adrenoceptor polymorphisms important in asthma - an unravelling story	LANCET			English	Editorial Material							REGULAR INHALED SALBUTAMOL; BETA-AGONIST; ASSOCIATION; EXACERBATIONS; POPULATION; ALBUTEROL; RECEPTOR		Nottingham City Hosp NHS Trust, Div Resp, Nottingham NG5 1PB, England; Univ Hosp NHS Trust, Queens Med Ctr, Div Therapeut & Mol Med, Nottingham, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; Nottingham University Hospital NHS Trust; University of Nottingham	Tattersfield, AE (corresponding author), Nottingham City Hosp NHS Trust, Div Resp, Nottingham NG5 1PB, England.	anne.tattersfield@nottingham.ac.uk		Hall, Ian/0000-0001-9933-3216				D'Amato M, 1998, AM J RESP CRIT CARE, V158, P1968, DOI 10.1164/ajrccm.158.6.9804126; Dennis SM, 2000, LANCET, V355, P1675, DOI 10.1016/S0140-6736(00)02238-8; Dewar JC, 1998, CLIN EXP ALLERGY, V28, P442; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; Hall IP, 2004, LANCET, V363, P183, DOI 10.1016/S0140-6736(03)15369-X; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; Hancox RJ, 1998, EUR RESPIR J, V11, P589; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; Taylor DR, 1998, THORAX, V53, P744, DOI 10.1136/thx.53.9.744; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; VATHENEN AS, 1988, LANCET, V1, P554	15	22	24	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	2004	364	9444					1464	1466		10.1016/S0140-6736(04)17286-3	http://dx.doi.org/10.1016/S0140-6736(04)17286-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500871				2022-12-28	WOS:000224645500004
J	O'Connell, H; Chin, AV; Cunningham, C; Lawlor, BA				O'Connell, H; Chin, AV; Cunningham, C; Lawlor, BA			Recent developments: Suicide in older people	BMJ-BRITISH MEDICAL JOURNAL			English	Review							COMPLETED SUICIDE; ELDERLY SUICIDES; RISK-FACTORS; AGE		St James Hosp, Mercers Inst Res Ageing Hosp 4, Dublin 8, Ireland	Trinity College Dublin	O'Connell, H (corresponding author), St James Hosp, Mercers Inst Res Ageing Hosp 4, Dublin 8, Ireland.	henryoconnell@hotmail.com	Ai-Vyrn, Chin/E-4237-2013	Ai-Vyrn, Chin/0000-0002-0332-0048				BARRACLOUGH BM, 1971, BR J PSYCHIATRY S, V6, P87; Bertolote JM, 2003, BRIT J PSYCHIAT, V183, P382, DOI 10.1192/bjp.183.5.382; Cattell H., 2000, ADV PSYCHIAT TREATME, V6, P102, DOI DOI 10.1192/APT.6.2.102; Chiu HFK, 2004, ACTA PSYCHIAT SCAND, V109, P299, DOI 10.1046/j.1600-0447.2003.00263.x; Conwell Y, 2000, J AM GERIATR SOC, V48, P23, DOI 10.1111/j.1532-5415.2000.tb03024.x; Conwell Y, 2002, BIOL PSYCHIAT, V52, P193, DOI 10.1016/S0006-3223(02)01347-1; Conwell Y, 1996, AM J PSYCHIAT, V153, P1001; Conwell Y, 1991, Int Psychogeriatr, V3, P59, DOI 10.1017/S1041610291000522; DUBERSTEIN PR, 1994, PSYCHIATRY, V57, P213; Fischer LR, 2003, J AM GERIATR SOC, V51, P1554, DOI 10.1046/j.1532-5415.2003.51506.x; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; Hepple J, 1997, BRIT J PSYCHIAT, V171, P42, DOI 10.1192/bjp.171.1.42; Kirby M, 1997, IRISH J PSYCHOL MED, V14, P124, DOI 10.1017/S0790966700003311; McClain CS, 2003, LANCET, V361, P1603, DOI 10.1016/S0140-6736(03)13310-7; ROSS RK, 1990, PREV MED, V19, P323, DOI 10.1016/0091-7435(90)90032-F; Rubenowitz E, 2001, PSYCHOL MED, V31, P1193, DOI 10.1017/S0033291701004457; Suominen K, 2003, INT J GERIATR PSYCH, V18, P1095, DOI 10.1002/gps.1019; Uncapher H, 2000, J AM GERIATR SOC, V48, P188, DOI 10.1111/j.1532-5415.2000.tb03910.x; Waern M, 2003, GERONTOLOGY, V49, P328, DOI 10.1159/000071715; Waern M, 2003, ALCOHOL ALCOHOLISM, V38, P249, DOI 10.1093/alcalc/agg060; Waern M, 2002, AM J PSYCHIAT, V159, P450, DOI 10.1176/appi.ajp.159.3.450; WHO (World Health Organization), 2013, SCHIST PROGR REP 200	22	151	157	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	2004	329	7471					895	899		10.1136/bmj.329.7471.895	http://dx.doi.org/10.1136/bmj.329.7471.895			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	863MU	15485967	Green Published			2022-12-28	WOS:000224566800019
J	Kavanaugh, MP				Kavanaugh, MP			Neurobiology - Accessing a transporter structure	NATURE			English	Editorial Material							GLUTAMATE TRANSPORTER		Univ Montana, Ctr Struct & Funct Neurosci, Missoula, MT 59812 USA	University of Montana System; University of Montana	Kavanaugh, MP (corresponding author), Univ Montana, Ctr Struct & Funct Neurosci, 301 Skaggs Bldg, Missoula, MT 59812 USA.	michael.kavanaugh@umontana.edu						Bergles DE, 1999, CURR OPIN NEUROBIOL, V9, P293, DOI 10.1016/S0959-4388(99)80043-9; BORRE L, 2002, BIOCHIM BIOPHYS ACTA, V1555, P92; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; Larsson HP, 2004, P NATL ACAD SCI USA, V101, P3951, DOI 10.1073/pnas.0306737101; Locher KP, 2003, SCIENCE, V301, P603, DOI 10.1126/science.1088621; LOGAN WJ, 1971, NATURE, V234, P297, DOI 10.1038/234297b0; Ryan RM, 2004, J BIOL CHEM, V279, P20742, DOI 10.1074/jbc.M304433200; STERN JR, 1949, BIOCHEM J, V44, P410, DOI 10.1042/bj0440410; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018	11	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					752	753		10.1038/431752a	http://dx.doi.org/10.1038/431752a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483590				2022-12-28	WOS:000224435500025
J	Crawford, M; Patton, R; Touquet, R; Drummond, C; Byford, S; Barrett, B; Reece, B; Brown, A; Henry, JA				Crawford, M; Patton, R; Touquet, R; Drummond, C; Byford, S; Barrett, B; Reece, B; Brown, A; Henry, JA			Screening and referral for brief intervention of alcohol-misusing patients in an emergency department: a pragmatic randomised control led trial	LANCET			English	Article							COST DATA; ACCIDENT; DRINKERS	Background Alcohol misuse is highly prevalent among people attending emergency departments, but the effect of intervention by staff working in these departments is unclear. We investigated the effect of screening and referral of patients found to be misusing alcohol while attending an emergency department. Methods We undertook a single-blind pragmatic randomised controlled trial. Patients received either an information leaflet or an information leaflet plus an appointment with an alcohol health worker. Outcome data were collected by patient interview and examination of hospital records at 6 and 12 months. Findings 599 patients were randomised over a 12-month period. At 6 months, those referred to an alcohol health worker were consuming a mean of 59.7 units of alcohol per week compared with 83.1 units in the control group (t-2.4, p=0.02). At 12 months those referred were drinking 57.2 units per week compared with 70.8 in controls (t-1.7, p=0.09). Those referred to the alcohol health worker had a mean of 0.5 fewer visits to the emergency department over the following 12 months (1.2 compared with 1.7, t-2.0, p=0.046). Differences in quality of life were not found. Interpretation Opportunistic identification and referral for alcohol misuse in an emergency department is feasible, associated with lower levels of alcohol consumption over the following 6 months, and reduces reattendance at the department. Short-term reductions in alcohol consumption associated with referral for brief intervention for alcohol misuse benefit patients and reduce demand for accident and emergency department services.	Univ London Imperial Coll Sci Technol & Med, Dept Psychol Med, London, England; Univ London Imperial Coll Sci Technol & Med, Acad Dept Accid & Emergency Med, London, England; St Marys Hosp NHS Trust, Dept Accid & Emergency, London, England; Univ London St Georges Hosp, Sch Med, Dept Addict Behav & Psychol Med, London SW17 0RE, England; Kings Coll London, Inst Psychiat, Ctr Econ Mental Hlth, London WC2R 2LS, England; Cent & NW London Mental Hlth NHS Trust, London, England	Imperial College London; Imperial College London; St Georges University London; University of London; King's College London	Crawford, M (corresponding author), Paterson Ctr, Dept Psychol Med, 20 S Wharf Rd, London W2 1PD, England.	m.crawford@imperial.ac.uk	Barrett, Barbara M/F-7606-2010; Drummond, Colin/O-9141-2019; Patton, Robert/E-8354-2012; Byford, Sarah/D-1699-2010	Barrett, Barbara M/0000-0002-0270-6256; Drummond, Colin/0000-0001-9379-5452; Patton, Robert/0000-0002-0468-3406; Byford, Sarah/0000-0001-7084-1495; Crawford, Mike/0000-0003-3137-5772				Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; *CAB OFF, 2004, ALC HARM RED STRAT E; D'Onofrio G, 2002, ACAD EMERG MED, V9, P627, DOI 10.1197/aemj.9.6.627; *DEP HLTH, 2003, ATT ACC EM DEP MIN I; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Goldberg D.P, 1972, DETECTION PSYCHIAT I; GREEN M, 1993, J ROY SOC MED, V86, P393; *HLTH ED AUTH, 1995, THINK DRINK; Hodgson RJ, 2003, ADDICT BEHAV, V28, P1453, DOI 10.1016/S0306-4603(02)00246-0; Huntley JS, 2001, EMERG MED J, V18, P99, DOI 10.1136/emj.18.2.99; Longabaugh R, 2001, J STUD ALCOHOL, V62, P806, DOI 10.15288/jsa.2001.62.806; Miller W., 1996, FORM 90 STRUCTURED A; Monti PM, 1999, J CONSULT CLIN PSYCH, V67, P989, DOI 10.1037/0022-006X.67.6.989; Moyer A, 2002, ADDICTION, V97, P279, DOI 10.1046/j.1360-0443.2002.00018.x; Office of National Statistics, 2003, CENS 2001 NAT REP EN; Patton R, 2004, EMERG MED J, V21, P491, DOI 10.1136/emj.2003.011403; Patton R, 2004, ALCOHOL ALCOHOLISM, V39, P266, DOI 10.1093/alcalc/agh049; Patton R, 2003, EMERG MED J, V20, P451, DOI 10.1136/emj.20.5.451; Peters J, 1998, ADDICTION, V93, P589, DOI 10.1046/j.1360-0443.1998.93458914.x; *ROYAL COLL PHYS, 2001, ALC CAN NHS AFF IT; Smith SGT, 1996, J ACCID EMERG MED, V13, P308; SOBELL LC, 1979, ASSESSING ALCOHOL PR, P241; SPIVAK K, 1994, ADDICTION, V89, P1135, DOI 10.1111/j.1360-0443.1994.tb02790.x; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WILLIAMS S, IN PRESS ALCOHOL DRU; Wright S, 1998, ALCOHOL ALCOHOLISM, V33, P651, DOI 10.1093/alcalc/33.6.651	28	204	208	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2004	364	9442					1334	1339		10.1016/S0140-6736(04)17190-0	http://dx.doi.org/10.1016/S0140-6736(04)17190-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474136	Green Submitted			2022-12-28	WOS:000224349700029
J	Fotin, A; Cheng, YF; Sliz, P; Grigorieff, N; Harrison, SC; Kirchhausen, T; Walz, T				Fotin, A; Cheng, YF; Sliz, P; Grigorieff, N; Harrison, SC; Kirchhausen, T; Walz, T			Molecular model for a complete clathrin lattice from electron cryomicroscopy	NATURE			English	Article							LIGHT-CHAINS; 3-DIMENSIONAL STRUCTURE; LOCATION; COATS; TRIMERIZATION; STABILIZATION; ORGANIZATION; RESOLUTION; SOFTWARE	Clathrin-coated vesicles are important vehicles of membrane traffic in cells. We report the structure of a clathrin lattice at subnanometre resolution, obtained from electron cryomicroscopy of coats assembled in vitro. We trace most of the 1,675-residue clathrin heavy chain by fitting known crystal structures of two segments, and homology models of the rest, into the electron microscopy density map. We also define the position of the central helical segment of the light chain. A helical tripod, the carboxyterminal parts of three heavy chains, projects inward from the vertex of each three-legged clathrin triskelion, linking that vertex to 'ankles' of triskelions centred two vertices away. Analysis of coats with distinct diameters shows an invariant pattern of contacts in the neighbourhood of each vertex, with more variable interactions along the extended parts of the triskelion 'legs'. These invariant local interactions appear to stabilize the lattice, allowing assembly and uncoating to be controlled by events at a few specific sites.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Biophys Grad Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biochem, Waltham, MA 02454 USA; Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Brandeis University; Brandeis University; Howard Hughes Medical Institute	Harrison, SC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave, Boston, MA 02115 USA.	Harrison@crystal.harvard.edu	Gimenez, Luis E Diaz/D-9291-2011	Cheng, Yifan/0000-0001-9535-0369; Grigorieff, Nikolaus/0000-0002-1506-909X; Walz, Thomas/0000-0003-2606-2835; Sliz, Piotr/0000-0002-6522-0835				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Chen CY, 2002, EMBO J, V21, P6072, DOI 10.1093/emboj/cdf594; CROWTHER RA, 1976, J MOL BIOL, V103, P785, DOI 10.1016/0022-2836(76)90209-6; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Fotin A, 2004, NATURE, V432, P649, DOI 10.1038/nature03078; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, YAAP ASAP SET AVERAG; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; KIRCHHAUSEN T, 1993, J BIOL CHEM, V268, P10268; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; Mindell JA, 2003, J STRUCT BIOL, V142, P334, DOI 10.1016/S1047-8477(03)00069-8; Musacchio A, 1999, MOL CELL, V3, P761, DOI 10.1016/S1097-2765(01)80008-3; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCARMATO P, 1990, J BIOL CHEM, V265, P3661; Smith CJ, 1998, EMBO J, V17, P4943, DOI 10.1093/emboj/17.17.4943; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; THON F, 1966, Z NATURFORSCH PT A, VA 21, P476, DOI 10.1515/zna-1966-0417; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708	40	390	397	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	2004	432	7017					573	579		10.1038/nature03079	http://dx.doi.org/10.1038/nature03079			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875PL	15502812				2022-12-28	WOS:000225433200035
J	Powell, K				Powell, K			Age is no barrier ...	NATURE			English	News Item							CRYOPRESERVED OVARIAN TISSUE; TRANSPLANTATION											Battaglia DE, 1996, HUM REPROD, V11, P2217; Donnez J, 2004, LANCET, V364, P1405, DOI 10.1016/S0140-6736(04)17222-X; Gruijters MJG, 2003, MOL CELL ENDOCRINOL, V211, P85, DOI 10.1016/j.mce.2003.09.024; Johnson J, 2004, NATURE, V428, P145, DOI 10.1038/nature02316; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Oktay K, 2004, LANCET, V363, P837, DOI 10.1016/S0140-6736(04)15728-0; Paris F, 2002, NAT MED, V8, P901, DOI 10.1038/nm0902-901; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; Porcu E, 2004, EUR J OBSTET GYN R B, V113, pS14, DOI 10.1016/j.ejogrb.2003.11.004	9	6	6	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	2004	432	7013					40	42		10.1038/432040a	http://dx.doi.org/10.1038/432040a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525976	Bronze			2022-12-28	WOS:000224854900033
J	Horbar, JD; Carpenter, JH; Buzas, J; Soll, RF; Suresh, G; Bracken, MB; Leviton, LC; Plsek, PE; Sinclair, JC				Horbar, JD; Carpenter, JH; Buzas, J; Soll, RF; Suresh, G; Bracken, MB; Leviton, LC; Plsek, PE; Sinclair, JC			Collaborative quality improvement to promote evidence based surfactant for preterm infants: a cluster randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To test a multifaceted collaborative quality improvement intervention designed to promote evidence based surfactant treatment for preterm infants of 23-29 weeks' gestation. Design Cluster randomised controlled trial. Setting and participants 114 neonatal intensive care units (which treated 6039 infants of 23-29 weeks gestation born in 2001). Main outcome measures Process of care measures: proportion of infants receiving first surfactant in the delivery room, proportion receiving first surfactant more than two hours after birth, and median time from birth to first dose of surfactant. Clinical outcomes: death before discharge home, and pneumothorax. Intervention Multifaceted collaborative quality improvement advice including audit and feedback, evidence reviews, an interactive training workshop, and ongoing faculty support via conference calls and email. Results Compared with those in control hospitals, infants in intervention hospitals were more likely to receive surfactant in the delivery room (adjusted odds ratio 5.38 (95% confidence interval 2.84 to 10.20)), were less likely to receive the first dose more than two hours after birth (adjusted odds ratio 0.35 (0.24 to 0.53)), and received the first dose of surfactant sooner after birth (median of 21 minutes v 78 minutes, P<0.001). The intervention effect on timing of surfactant was larger for infants born in the participating hospitals than for infants transferred to a participating hospital after birth. There were no significant differences in mortality or pneumothorax. Conclusion A multifaceted intervention including audit and feedback, evidence reviews, quality improvement training, and follow up support changed the behaviour of health professionals and promoted evidence based practice.	Vermont Oxford Network, Burlington, VT 05401 USA; Univ Vermont, Burlington, VT USA; Med Univ S Carolina, Charleston, SC 29425 USA; Yale Univ, Ctr Perinatal Pediat & Environm Epidemiol, New Haven, CT USA; Robert Wood Johnson Fdn, Princeton, NJ 08540 USA; Paul E Plsek & Associates, Atlanta, GA USA; McMaster Univ, Dept Pediat, Hamilton, ON, Canada	University of Vermont; Medical University of South Carolina; Yale University; Robert Wood Johnson Foundation (RWJF); McMaster University	Horbar, JD (corresponding author), Vermont Oxford Network, 33 Kilburn St, Burlington, VT 05401 USA.	horbar@vtoxford.org			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010528] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS10528] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Berwick DM, 2003, JAMA-J AM MED ASSOC, V289, P1969, DOI 10.1001/jama.289.15.1969; Campbell Marion K, 2004, BMC Med Res Methodol, V4, P9, DOI 10.1186/1471-2288-4-9; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Collett, 2003, MODELLING SURVIVAL D; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; Horbar JD, 2004, PEDIATRICS, V113, P1593, DOI 10.1542/peds.113.6.1593; Horbar JD, 2003, PEDIATRICS, V111; Horbar JD, 2002, PEDIATRICS, V110, P143, DOI 10.1542/peds.110.1.143; Horbar JD, 2001, PEDIATRICS, V107, P14, DOI 10.1542/peds.107.1.14; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; Ivers N, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000259.PUB3; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Langley Gj., 1996, IMPROVEMENT GUIDE PR; LEE EW, 1994, STAT MED, V13, P1241, DOI 10.1002/sim.4780131206; OBRIEN MAT, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003030; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Plsek P E, 1999, Pediatrics, V103, P203; Puffer S, 2003, BMJ-BRIT MED J, V327, P785, DOI 10.1136/bmj.327.7418.785; PUFLIER S, 2003, BMJ-BRIT MED J, V327, P785; Sackett D., 2000, EVIDENCE BASED MED P, DOI DOI 10.1136/BMJ.H3089; Soll RF, 2000, COCHRANE DB SYST REV, V2; SOLL RF, 2001, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD000510, 10.1002/14651858.CD000510]; *VT OXF NETW, 1999, DAT MAN OP REL 4 0; Wilson Tim, 2003, Jt Comm J Qual Saf, V29, P85; Yost CC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001456; Zwarentein M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000072.pub2	26	120	124	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	2004	329	7473					1004	1007		10.1136/bmj.329.7473.1004	http://dx.doi.org/10.1136/bmj.329.7473.1004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514344	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000224852400017
J	Bonadonna, F; Nevitt, GA				Bonadonna, F; Nevitt, GA			Partner-specific odor recognition in an Antarctic seabird	SCIENCE			English	Article									CNRS, Ctr Ecol Fonct & Evolut, Behav Ecol Grp, F-34293 Montpellier 5, France; Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA	UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Institut Agro; Montpellier SupAgro; CIRAD; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Paul-Valery; Universite de Montpellier; University of California System; University of California Davis	Bonadonna, F (corresponding author), CNRS, Ctr Ecol Fonct & Evolut, Behav Ecol Grp, 1919 Route Mende, F-34293 Montpellier 5, France.	bonadonna@cefe.cnrs.fr	Bonadonna, Francesco/A-7456-2008	Bonadonna, Francesco/0000-0002-2702-5801				Bonadonna F, 2003, BEHAV ECOL SOCIOBIOL, V54, P174, DOI 10.1007/s00265-003-0610-7; De Leon A, 2003, BEHAVIOUR, V140, P925, DOI 10.1163/156853903770238382; Hagelin JC, 2003, P ROY SOC B-BIOL SCI, V270, P1323, DOI 10.1098/rspb.2003.2379; Mateo J, 2001, TRENDS ECOL EVOL, V16, P74, DOI 10.1016/S0169-5347(00)02042-5; Nevitt GA, 2000, BIOL BULL-US, V198, P245, DOI 10.2307/1542527; Warham J., 1996, BEHAV POPULATION BIO	6	193	196	30	1437	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					835	835		10.1126/science.1103001	http://dx.doi.org/10.1126/science.1103001			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514149				2022-12-28	WOS:000224969400036
J	Reznick, DN; Bryant, MJ; Roff, D; Ghalambor, CK; Ghalambor, DE				Reznick, DN; Bryant, MJ; Roff, D; Ghalambor, CK; Ghalambor, DE			Effect of extrinsic mortality on the evolution of senescence in guppies	NATURE			English	Article							LIFE-HISTORY EVOLUTION; POECILIA-RETICULATA; NATURAL-POPULATIONS; GENETIC-BASIS; REPRODUCTION; SPAN; PERFORMANCE; PREDATION; GROWTH	Classical theories(1,2) for the evolution of senescence predict that organisms that experience low mortality rates attributable to external factors, such as disease or predation, will evolve a later onset of senescence. Here we use patterns of senescence in guppies derived from natural populations that differ in mortality risk to evaluate the generality of these predictions. We have previously found that populations experiencing higher mortality rates evolve earlier maturity and invest more in reproduction, as predicted by evolutionary theory(3). We report here that these same populations do not have an earlier onset of senescence with respect to either mortality or reproduction but do with respect to swimming performance, which assesses neuromuscular function. This mosaic pattern of senescence challenges the generality of the association between decreased extrinsic mortality and delayed senescence and invites consideration of more derived theories for the evolution of senescence.	Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA; Calif Inst Arts, Sch Crit Studies, Valencia, CA 91355 USA; Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA	University of California System; University of California Riverside; Colorado State University	Reznick, DN (corresponding author), Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA.	david.reznick@ucr.edu	Ghalambor, Cameron/V-4486-2019; Ghalambor, Cameron/HGE-0411-2022	Ghalambor, Cameron/0000-0003-2515-4981; reznick, david/0000-0002-1144-0568				ABRAMS PA, 1993, EVOLUTION, V47, P877, DOI 10.1111/j.1558-5646.1993.tb01241.x; AUSTAD SN, 1991, J GERONTOL, V46, pB47, DOI 10.1093/geronj/46.2.B47; AUSTAD SN, 1993, J ZOOL, V229, P695, DOI 10.1111/j.1469-7998.1993.tb02665.x; CARVALHO GR, 1991, BIOL J LINN SOC, V42, P389, DOI 10.1111/j.1095-8312.1991.tb00571.x; Charlesworth B., 1994, EVOLUTION AGE STRUCT, V2nd ed, edited by C. Cannings, F. C. Hoppensteadt, and L. A. Segel.; Delbono O, 2003, AGING CELL, V2, P21, DOI 10.1046/j.1474-9728.2003.00011.x; Domenici P, 1997, J EXP BIOL, V200, P1165; Dudycha JL, 1999, EVOLUTION, V53, P1744, DOI 10.1111/j.1558-5646.1999.tb04559.x; FINCH CE, 1990, SCIENCE, V249, P902, DOI 10.1126/science.2392680; Ghalambor CK, 2004, AM NAT, V164, P38, DOI 10.1086/421412; Hendry AP, 2004, P ROY SOC B-BIOL SCI, V271, P259, DOI 10.1098/rspb.2003.2600; HOLMES DJ, 1995, AM ZOOL, V35, P307; *INS CORP, 2001, S PLUS 6 WIND GUID S, V3; Keller L, 1997, NATURE, V389, P958, DOI 10.1038/40130; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; LUCKINBILL LS, 1985, HEREDITY, V55, P9, DOI 10.1038/hdy.1985.66; MCMILLAN I, 1970, GENETICS, V65, P349; MEDAWAR PB, 2002, UNSOLVED PROBLEM BIO; OPPENHEIMER L, 1981, BIOCHEM J, V197, P721, DOI 10.1042/bj1970721; Partridge L, 2002, NAT REV GENET, V3, P165, DOI 10.1038/nrg753; PROMISLOW DEL, 1991, EVOLUTION, V45, P1869, DOI 10.1111/j.1558-5646.1991.tb02693.x; REZNICK D, 1982, EVOLUTION, V36, P1236, DOI 10.1111/j.1558-5646.1982.tb05493.x; Reznick D, 2002, MECH AGEING DEV, V123, P773, DOI 10.1016/S0047-6374(01)00423-7; Reznick D, 2001, EXP GERONTOL, V36, P791, DOI 10.1016/S0531-5565(00)00241-2; Reznick D, 2001, AM NAT, V157, P126, DOI 10.1086/318627; REZNICK DA, 1990, NATURE, V346, P357, DOI 10.1038/346357a0; Reznick DN, 1996, EVOLUTION, V50, P1651, DOI 10.1111/j.1558-5646.1996.tb03937.x; Ricklefs RE, 1998, AM NAT, V152, P24, DOI 10.1086/286147; Stearns SC, 2000, P NATL ACAD SCI USA, V97, P3309, DOI 10.1073/pnas.060289597; Tatar M, 1997, OECOLOGIA, V111, P357, DOI 10.1007/s004420050246; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Williams PD, 2003, EVOLUTION, V57, P1478	32	313	320	3	219	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1095	1099		10.1038/nature02936	http://dx.doi.org/10.1038/nature02936			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15510147				2022-12-28	WOS:000224730800040
J	Swartz, MN				Swartz, MN			Bacterial meningitis - A view of the past 90 years	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Swartz, MN (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.							DOWLING HF, 1949, AM J MED SCI, V217, P149, DOI 10.1097/00000441-194902000-00005; Flexner S, 1913, J EXP MED, V17, P553, DOI 10.1084/jem.17.5.553; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823	4	120	129	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1826	1828		10.1056/NEJMp048246	http://dx.doi.org/10.1056/NEJMp048246			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509815				2022-12-28	WOS:000224723100005
J	Benner, SA				Benner, SA			Redesigning genetics	SCIENCE			English	Editorial Material							NUCLEIC-ACID; ENZYMATIC INCORPORATION; DIRECTED EVOLUTION; DNA-POLYMERASE; BASE-PAIR; RNA; STABILITY; THYMIDINE; SYSTEMS; ABILITY		Univ Florida, Dept Chem, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Benner, SA (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.	benner@chem.ufl.edu						Ball P, 2004, NATURE, V431, P624, DOI 10.1038/431624a; Benner SA, 2002, BIOORG CHEM, V30, P62, DOI 10.1006/bioo.2001.1232; Collins ML, 1997, NUCLEIC ACIDS RES, V25, P2979, DOI 10.1093/nar/25.15.2979; Elbeik T, 2004, J CLIN MICROBIOL, V42, P563, DOI 10.1128/JCM.42.2.563-569.2004; Fa M, 2004, J AM CHEM SOC, V126, P1748, DOI 10.1021/ja038525p; Freier SM, 1997, NUCLEIC ACIDS RES, V25, P4429, DOI 10.1093/nar/25.22.4429; Geyer CR, 2003, STRUCTURE, V11, P1485, DOI 10.1016/j.str.2003.11.008; Ghadessy FJ, 2001, P NATL ACAD SCI USA, V98, P4552, DOI 10.1073/pnas.071052198; Gibbs WW, 2004, SCI AM, V290, P74; Goodman MF, 1999, NAT BIOTECHNOL, V17, P640, DOI 10.1038/10852; Lai JS, 2004, J AM CHEM SOC, V126, P3040, DOI 10.1021/ja039571s; Liu HB, 2004, J AM CHEM SOC, V126, P1102, DOI 10.1021/ja038384r; Martinot TA, 2004, J ORG CHEM, V69, P3972, DOI 10.1021/jo0497959; MILLER PS, 1977, BIOCHEMISTRY-US, V16, P1988, DOI 10.1021/bi00628a036; Minakawa N, 2003, J AM CHEM SOC, V125, P9970, DOI 10.1021/ja0347686; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; Nielsen PE, 2004, MOL BIOTECHNOL, V26, P233, DOI 10.1385/MB:26:3:233; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; Ricardo A, 2004, SCIENCE, V303, P196, DOI 10.1126/science.1092464; SWITZER C, 1989, J AM CHEM SOC, V111, P8322, DOI 10.1021/ja00203a067; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	21	33	33	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					625	626		10.1126/science.1101104	http://dx.doi.org/10.1126/science.1101104			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499002				2022-12-28	WOS:000224756700033
J	Della, M; Palmbos, PL; Tseng, HM; Tonkin, LM; Daley, JM; Topper, LM; Pitcher, RS; Tomkinson, AE; Wilson, TE; Doherty, AJ				Della, M; Palmbos, PL; Tseng, HM; Tonkin, LM; Daley, JM; Topper, LM; Pitcher, RS; Tomkinson, AE; Wilson, TE; Doherty, AJ			Mycobacterial Ku and ligase proteins constitute a two-component NHEJ repair machine	SCIENCE			English	Article							STRAND BREAK REPAIR; EUKARYOTIC DNA PRIMASE; SACCHAROMYCES-CEREVISIAE; POLYMERASE-LAMBDA; JOINING REPAIR; YEAST; COMPLEX; ENDS; IV; MU	In mammalian cells, repair of DNA double-strand. breaks (DSBs) by nonhomologous end-joining (NHEJ) is critical for genome stability. Although the end-bridging and ligation steps of NHEJ have been reconstituted in vitro, little is known about the end-processing reactions that occur before ligation. Recently, functionally homologous end-bridging and ligation activities have been identified in prokarya. Consistent with its homology to polymerases and nucleases, we demonstrate that DNA ligase D from Mycobacterium tuberculosis (Mt-Lig) possesses a unique variety of nucleotidyl transferase activities, including gap-filling polymerase, terminal transferase, and primase, and is also a 3' to 5' exonuclease. These enzyme activities allow the Mt-Ku and Mt-Lig proteins to join incompatible DSB ends in vitro, as well as to reconstitute NHEJ in vivo in yeast. These results demonstrate that prokaryotic Ku and ligase form a bona fide NHEJ system that encodes all the recognition, processing, and ligation activities required for DSB repair.	Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England; Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge, England; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Mol Med Grad Program, San Antonio, TX USA; Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Dept Radiat Oncol, Baltimore, MD 21201 USA	University of Sussex; University of Cambridge; University of Michigan System; University of Michigan; University of Texas System; University of Texas Health San Antonio; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Doherty, AJ (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.	AJD21@sussex.ac.uk		Doherty, Aidan/0000-0002-6370-1109	NATIONAL CANCER INSTITUTE [R01CA102563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102563, R01 CA102563-01A1] Funding Source: Medline; NIGMS NIH HHS [T32 GM007315] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2001, GENOME RES, V11, P1365, DOI 10.1101/gr.181001; Arezi B, 2000, TRENDS BIOCHEM SCI, V25, P572, DOI 10.1016/S0968-0004(00)01680-7; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; CHENG SN, 2000, P INT WORKSH ANN COM, V1, P275; Connelly JC, 2002, TRENDS BIOCHEM SCI, V27, P410, DOI 10.1016/S0968-0004(02)02144-8; Covo S, 2004, J BIOL CHEM, V279, P859, DOI 10.1074/jbc.M310447200; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; DELLA M, UNPUB; Garcia-Diaz M, 2004, MOL CELL, V13, P561, DOI 10.1016/S1097-2765(04)00061-9; Karathanasis E, 2002, GENETICS, V161, P1015; Koonin EV, 2000, J MOL MICROB BIOTECH, V2, P509; Krejci L, 2003, PROG NUCLEIC ACID RE, V74, P159, DOI 10.1016/S0079-6603(03)01013-4; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; McElhinny SAN, 2003, MOL CELL BIOL, V23, P2309, DOI 10.1128/MCB.23.7.2309-2315.2003; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; Rydberg B, 2002, P NATL ACAD SCI USA, V99, P16654, DOI 10.1073/pnas.262591699; Tseng HM, 2002, J BIOL CHEM, V277, P45630, DOI 10.1074/jbc.M206861200; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Weller GR, 2001, FEBS LETT, V505, P340, DOI 10.1016/S0014-5793(01)02831-9; Wilson TE, 2003, TRENDS BIOCHEM SCI, V28, P62, DOI 10.1016/S0968-0004(03)00005-7; Wilson TE, 2002, GENETICS, V162, P677; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599	29	166	174	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					683	685		10.1126/science.1099824	http://dx.doi.org/10.1126/science.1099824			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499016				2022-12-28	WOS:000224756700050
J	Siveter, DJ; Sutton, MD; Briggs, DEG; Siveter, DJ				Siveter, DJ; Sutton, MD; Briggs, DEG; Siveter, DJ			A Silurian sea spider	NATURE			English	Article							HEREFORDSHIRE; ARTHROPOD; PYCNOGONIDA; PHYLOGENETICS	Pycnogonids (sea spiders) are marine arthropods numbering some 1,160 extant species. They are globally distributed in depths of up to 6,000 metres, and locally abundant(1,2); however, their typically delicate form and non-biomineralized cuticle has resulted in an extremely sparse fossil record that is not accepted universally(3). There are two opposing views of their phylogenetic position: either within Chelicerata as sister group to the euchelicerates(4-7), or as a sister taxon to all other euarthropods(8). The Silurian Herefordshire Konservat-Lagerstatte(9) in England (similar to425 million years (Myr) BP) yields exceptionally preserved three-dimensional fossils that provide unrivalled insights into the palaeobiology of a variety of invertebrates(10-14). The fossils are preserved as calcitic void in-fills in carbonate concretions within a volcaniclastic horizon(15), and are reconstructed digitally(12). Here we describe a new pycnogonid from this deposit, which is the oldest adult sea spider by similar to35 Myr and the most completely known fossil species. The large chelate first appendage is consistent with a chelicerate affinity for the pycnogonids. Cladistic analyses place the new species near the base of the pycnogonid crown group, implying that the latter had arisen by the Silurian period.	Univ Oxford, Dept Earth Sci, Oxford OX1 3PS, England; Univ Museum Nat Hist, Geol Collect, Oxford OX1 3PW, England; Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; Univ Leicester, Dept Geol, Leicester LE1 7RH, Leics, England	University of Oxford; University of Oxford; Yale University; University of Leicester	Siveter, DJ (corresponding author), Univ Oxford, Dept Earth Sci, S Parks Rd, Oxford OX1 3PS, England.	derek.siveter@earth.ox.ac.uk	Sutton, Mark/A-4189-2010					[Anonymous], 1998, FOSSILS HUNSR CK SLA; Arango CP, 2003, MOL PHYLOGENET EVOL, V28, P588, DOI 10.1016/S1055-7903(03)00069-1; Arango CP, 2002, ORG DIVERS EVOL, V2, P107, DOI 10.1078/1439-6092-00035; ARNAUD F, 1987, ADV MAR BIOL, V24, P1; BERGSTROM J, 1980, Palaeontologische Zeitschrift, V54, P7; Boxshall GA, 2004, BIOL REV, V79, P253, DOI 10.1017/S1464793103006274; Briggs DEG, 2004, P ROY SOC B-BIOL SCI, V271, P131, DOI 10.1098/rspb.2003.2593; Briggs DEG, 1996, NATURE, V382, P248, DOI 10.1038/382248a0; Child C. Allan, 1998, NIWA Biodiversity Memoir, V109, P1; DUNLOP JA, IN PRESS J ZOOL SYST; Giribet G, 2001, NATURE, V413, P157, DOI 10.1038/35093097; King P., 1973, PYCNOGONIDS; Miyazaki K, 2002, J MAR BIOL ASSOC UK, V82, P1037, DOI 10.1017/S0025315402006628; Orr PJ, 2000, J GEOL SOC LONDON, V157, P173, DOI 10.1144/jgs.157.1.173; Siveter DJ, 2003, SCIENCE, V302, P1749, DOI 10.1126/science.1091376; Sutton MD, 2002, P ROY SOC B-BIOL SCI, V269, P1195, DOI 10.1098/rspb.2002.1986; Sutton MD, 2001, P ROY SOC B-BIOL SCI, V268, P2355, DOI 10.1098/rspb.2001.1788; Sutton MD, 2001, NATURE, V410, P461, DOI 10.1038/35068549; Vilpoux K, 2003, ARTHROPOD STRUCT DEV, V32, P349, DOI 10.1016/j.asd.2003.09.004; Waloszek D, 2002, PALAEONTOLOGY, V45, P421, DOI 10.1111/1475-4983.00244; Wilby PR, 1996, GEOLOGY, V24, P847, DOI 10.1130/0091-7613(1996)024<0847:MOSBII>2.3.CO;2	21	68	70	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					978	980		10.1038/nature02928	http://dx.doi.org/10.1038/nature02928			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496921				2022-12-28	WOS:000224585600042
J	Muzha, I; Filipi, N; Lede, R; Copertari, P; Traverso, C; Copertari, A; Vergara, EA; Montenegro, C; de Huidobro, RR; Saladino, P; Surt, K; Cizlzeta, J; Lazzeri, S; Lucero, L; Pinero, G; Ciccioli, F; Videtta, W; Barboza, MF; Svampa, S; Sciuto, V; Domeniconi, G; Bustamante, M; Waschbusch, M; Gullo, MP; Posadas, A; Linares, JCA; Camputaro, L; Penna, J; Troccoli, G; Galimberti, H; Tallott, M; Horn, S; Eybner, C; Buchinger, W; Fitzal, S; Oleffe, V; Grollinger, T; Delvaux, P; Carlier, L; Braet, V; Jacques, JM; de Knoop, D; Choi, HK; Schmitt, M; Gentil, A; Nacul, F; Barrios, PB; Chen, XK; Hua, LS; Tian, HH; Cai, XD; Gualteros, W; Otero, AA; Ciro, J; Jaramillo, H; Garcia, G; Gonzalez, I; Gomez, C; Arias, A; Fonseca, M; Mora, C; Cabrera, EGL; Betancurth, JL; Munoz, P; Quinonez, JA; Castillo, MEG; Lopez, O; Yepes, RP; Cuellar, DL; Paez, G; Chaves, HD; Ordonez, PE; Plata, R; Pineda, M; Pulido, LE; Britton, T; Jaramillo, JSV; Rebolledo, C; Palma, O; Cuadrado, AS; Pastrana, I; Falero, R; Castro, AM; Perera, MD; Garcia, AA; Oliva, R; Domenech, MA; Delgado, HL; Carnero, AM; Lopez, BL; Gallardo, AL; Morales, AO; de Cespedes, CM; Lezcano, H; Lima, GA; Ferrer, MI; Enriquez, M; Bess, IZ; Canino, GR; Ruiz, EMP; Cruz, OG; Kantorova, I; Ochmann, J; Scheer, P; Kozumplik, L; Marsova, J; Edelmann, K; Chytra, I; Bosman, R; Andrejsova, H; Pachl, I; Burger, J; Kramar, F; Vernaza, L; Ulloa, MI; Gonzalez, L; Daccach, A; Ortega, A; Cevallos, S; Cueva, BZ; Arteaga, JC; Ochoa, M; Tapia, JV; Hurtado, J; Wong, MCS; Carbo, TM; Santos, R; Khamis, H; Abaza, AH; Fekry, A; El Kordy, S; Shawky, T; El-Sayed, H; Khalil, N; Negm, N; Fisal, S; Alamin, M; Shokry, H; Elhusseny, AY; Radwan, A; Rashid, M; Gogichaisvili, T; Ingorokva, G; Gongadze, N; Otarashvili, A; Moritz, E; Kleist, W; Kalkum, M; Ulrich, P; Andrews, N; Nakos, G; Karavelis, A; Archontakis, G; Myrianthefs, P; Yadav, Y; Yadav, S; Khatri, R; Baghel, A; Husain, M; Jha, D; Chhang, WH; Dhandhania, M; Fonning, C; Iyengar, SN; Gupta, S; Ravi, RR; Bopiah, KS; Herur, A; Venkataramana, NK; Satish, A; Bhavadasan, K; Morris, R; S, R; Felcry, A; Tirschenreuth, K; Gupta, S; Dewan, Y; Singh, Y; Bhagchandani, R; Bhagchandani, S; Sethurayar, VU; Ipe, S; Sreekumar, G; Panigrahi, M; Reddy, A; Khosla, V; Pillay, H; Thomas, N; Sridhar, K; Jose, B; Kurian, N; Praharaj, S; Pillai, S; Kiyawat, D; Maheshwari, K; Panikar, D; Chawla, J; Shenoy, S; Raja, A; Rupayana, Y; Reddy, S; Mohan, N; Kelkar, S; Johri, M; Golden, N; Maliawan, S; Fauzi, A; Farouk, U; Fakharian, E; Aramesh, A; Ahmadzadeh, F; Gholami, A; Eghtedari, M; Plunkett, P; Redican, C; McMahon, G; Annetta, MG; Mouchaty, H; Bruzzone, E; Harding, A; Qureshi, M; Idris, Z; Abdullah, J; Ghazali, G; Ghani, ARI; Cheah, F; Cabrera, A; Gonzalez, JLM; Loria-Castellanos, J; Jackson, S; Hutchinson, R; Komolafe, E; Adeolu, A; Komolafe, M; Adeyemi-Doro, O; Bankole, F; Danfodiyo, U; Shehu, B; Danlami, V; Odebode, O; Oluwadiya, K; Sanni, A; Giebel, H; Kumar, S; Jooma, R; Guerrero, MA; Mezquita, JE; Ovelar, CO; Gonzalez-Portillo, M; Rodriguez, D; Balica, L; Oprita, B; Sklerniacof, M; Steflea, L; Bandut, L; Danil, A; Iliescu, R; Bagdasar, D; El-Dawlafly, A; Alwatidy, S; Al-Yafi, W; El-Dawlatly, M; Krunic-Protic, R; Janosevic, V; Tan, J; Seah, C; Trenkler, S; Humenansky, M; Stajancova, T; Poprad, N; Schwendt, I; Laincz, A; Bojnice, N; Julius, Z; Maros, S; Kosice, F; Firment, J; Trebisov, N; Cifranicova, M; Saniova, B; Ruzinov, N; Kalig, K; Zamky, NN; Medekova, S; Mikulas, NL; Wiszt, R; Roosevelt, FD; Zilina, N; Macuga, I; Hartzenberg, B; du Pleissis, G; Houlie, Z; Nathoo, N; Khumalo, S; Tracey, R; Munoz-Sanchez, A; Murillo-Cabezas, F; Flores-Cordero, J; Rincon-Ferrari, D; Rubi, M; Caler, L; del Campo, MM; Laguna, LB; de Terrassa, M; Nava, JM; Trueta, J; Haya, C; Lopez, AM; Ramos-Gomez, L; de la Torre-Prados, V; Pellejero, R; Laloe, VR; Mahendran, K; Stocker, R; Ludwig, S; Zimmermann, H; Schaffhausen, K; Denzier, U; Yutthakasemsunt, S; Kittiwattanagul, W; Piyavechvirat, P; Tapsai, P; Nanmang-jan, A; Chantapimpa, U; Watanachai, C; Subsompon, P; Pussanakawatin, W; Khunjan, P; Tangchitvittaya, S; Nilapong, S; Klangsang, T; Taechakosol, W; Srinat, A; Jerbi, Z; Borsali-Falfoul, N; Rezgui, M; Cakar, N; Ssenyonjo, H; Kobusingye, O; Lomas, G; Yates, D; Lecky, F; Bleetman, A; Baldwin, A; Jenkinson, E; Pantrini, S; Stewart, J; Contractor, N; Roberts, T; Butler, J; Pinto, A; Lee, D; Brayley, N; Robbshaw, K; Dix, C; Graham, S; Pye, S; Green, M; Kellins, A; Moulton, C; Fogg, B; Cottingham, R; Funnell, S; Shanker, U; Summers, C; Malek, L; Ashcroft, C; Powell, J; Moore, S; Buckley, S; Grocutt, M; Chambers, S; Morrice, A; Marshall, H; Harris, J; Matthews, W; Tippet, J; Mardell, S; MacMillan, F; Shaw, A; Luthra, P; Dixon, G; Ahmed, M; Young, M; Mason, S; Loveday, I; Clark, C; Taylor, S; Wilson, P; Ali, K; Greenwood, S; White, M; Perez, R; Eljamel, S; Wasserberg, J; Read, C; McCarron, J; Pennell, A; Ray, G; Thurston, J; Brown, E; Jaffey, L; Graves, M; Bailey, R; Loveridge, N; Evans, G; Hughes, S; Ahmed, K; Richardson, J; Gallagher, C; Odedun, T; Lees, K; Foley, D; Payne, N; Pennycock, A; Griffiths, C; Moore, D; Byrne, D; Dasan, S; Banerjee, A; McGuinness, S; Chikhani, C; Zoltie, N; Barlow, I; Stell, I; Hulse, W; Crossley, J; Watkins, L; Dorani, B; Van Viet, T; Baigent, C; Bracken, M; Chadwick, D; Curley, K; Duley, L; Farrell, B; Haegi, M; Nickson, G; Peto, R; Pickard, J; Roberts, I; Sandercock, P; Teasdale, G; Collins, R; Haines, S; MacMahon, S; Warlow, C; Edwards, P; Ritchie, N; Shakur, H; Ramos, M; Barnetson, L; Fernandes, J; Tooth, D; Free, C; Narayanan, L; Collander, J; Abernethy, J; Bardswell, J; Mashru, R; Godward, C; Afolabi, L; Ritchie, A; Hosford, T; Collingwood, A; Massey, S; Svoboda, P; Mazairac, G; Laloe, V; Arango, M; Olldashi, F				Muzha, I; Filipi, N; Lede, R; Copertari, P; Traverso, C; Copertari, A; Vergara, EA; Montenegro, C; de Huidobro, RR; Saladino, P; Surt, K; Cizlzeta, J; Lazzeri, S; Lucero, L; Pinero, G; Ciccioli, F; Videtta, W; Barboza, MF; Svampa, S; Sciuto, V; Domeniconi, G; Bustamante, M; Waschbusch, M; Gullo, MP; Posadas, A; Linares, JCA; Camputaro, L; Penna, J; Troccoli, G; Galimberti, H; Tallott, M; Horn, S; Eybner, C; Buchinger, W; Fitzal, S; Oleffe, V; Grollinger, T; Delvaux, P; Carlier, L; Braet, V; Jacques, JM; de Knoop, D; Choi, HK; Schmitt, M; Gentil, A; Nacul, F; Barrios, PB; Chen, XK; Hua, LS; Tian, HH; Cai, XD; Gualteros, W; Otero, AA; Ciro, J; Jaramillo, H; Garcia, G; Gonzalez, I; Gomez, C; Arias, A; Fonseca, M; Mora, C; Cabrera, EGL; Betancurth, JL; Munoz, P; Quinonez, JA; Castillo, MEG; Lopez, O; Yepes, RP; Cuellar, DL; Paez, G; Chaves, HD; Ordonez, PE; Plata, R; Pineda, M; Pulido, LE; Britton, T; Jaramillo, JSV; Rebolledo, C; Palma, O; Cuadrado, AS; Pastrana, I; Falero, R; Castro, AM; Perera, MD; Garcia, AA; Oliva, R; Domenech, MA; Delgado, HL; Carnero, AM; Lopez, BL; Gallardo, AL; Morales, AO; de Cespedes, CM; Lezcano, H; Lima, GA; Ferrer, MI; Enriquez, M; Bess, IZ; Canino, GR; Ruiz, EMP; Cruz, OG; Kantorova, I; Ochmann, J; Scheer, P; Kozumplik, L; Marsova, J; Edelmann, K; Chytra, I; Bosman, R; Andrejsova, H; Pachl, I; Burger, J; Kramar, F; Vernaza, L; Ulloa, MI; Gonzalez, L; Daccach, A; Ortega, A; Cevallos, S; Cueva, BZ; Arteaga, JC; Ochoa, M; Tapia, JV; Hurtado, J; Wong, MCS; Carbo, TM; Santos, R; Khamis, H; Abaza, AH; Fekry, A; El Kordy, S; Shawky, T; El-Sayed, H; Khalil, N; Negm, N; Fisal, S; Alamin, M; Shokry, H; Elhusseny, AY; Radwan, A; Rashid, M; Gogichaisvili, T; Ingorokva, G; Gongadze, N; Otarashvili, A; Moritz, E; Kleist, W; Kalkum, M; Ulrich, P; Andrews, N; Nakos, G; Karavelis, A; Archontakis, G; Myrianthefs, P; Yadav, Y; Yadav, S; Khatri, R; Baghel, A; Husain, M; Jha, D; Chhang, WH; Dhandhania, M; Fonning, C; Iyengar, SN; Gupta, S; Ravi, RR; Bopiah, KS; Herur, A; Venkataramana, NK; Satish, A; Bhavadasan, K; Morris, R; S, R; Felcry, A; Tirschenreuth, K; Gupta, S; Dewan, Y; Singh, Y; Bhagchandani, R; Bhagchandani, S; Sethurayar, VU; Ipe, S; Sreekumar, G; Panigrahi, M; Reddy, A; Khosla, V; Pillay, H; Thomas, N; Sridhar, K; Jose, B; Kurian, N; Praharaj, S; Pillai, S; Kiyawat, D; Maheshwari, K; Panikar, D; Chawla, J; Shenoy, S; Raja, A; Rupayana, Y; Reddy, S; Mohan, N; Kelkar, S; Johri, M; Golden, N; Maliawan, S; Fauzi, A; Farouk, U; Fakharian, E; Aramesh, A; Ahmadzadeh, F; Gholami, A; Eghtedari, M; Plunkett, P; Redican, C; McMahon, G; Annetta, MG; Mouchaty, H; Bruzzone, E; Harding, A; Qureshi, M; Idris, Z; Abdullah, J; Ghazali, G; Ghani, ARI; Cheah, F; Cabrera, A; Gonzalez, JLM; Loria-Castellanos, J; Jackson, S; Hutchinson, R; Komolafe, E; Adeolu, A; Komolafe, M; Adeyemi-Doro, O; Bankole, F; Danfodiyo, U; Shehu, B; Danlami, V; Odebode, O; Oluwadiya, K; Sanni, A; Giebel, H; Kumar, S; Jooma, R; Guerrero, MA; Mezquita, JE; Ovelar, CO; Gonzalez-Portillo, M; Rodriguez, D; Balica, L; Oprita, B; Sklerniacof, M; Steflea, L; Bandut, L; Danil, A; Iliescu, R; Bagdasar, D; El-Dawlafly, A; Alwatidy, S; Al-Yafi, W; El-Dawlatly, M; Krunic-Protic, R; Janosevic, V; Tan, J; Seah, C; Trenkler, S; Humenansky, M; Stajancova, T; Poprad, N; Schwendt, I; Laincz, A; Bojnice, N; Julius, Z; Maros, S; Kosice, F; Firment, J; Trebisov, N; Cifranicova, M; Saniova, B; Ruzinov, N; Kalig, K; Zamky, NN; Medekova, S; Mikulas, NL; Wiszt, R; Roosevelt, FD; Zilina, N; Macuga, I; Hartzenberg, B; du Pleissis, G; Houlie, Z; Nathoo, N; Khumalo, S; Tracey, R; Munoz-Sanchez, A; Murillo-Cabezas, F; Flores-Cordero, J; Rincon-Ferrari, D; Rubi, M; Caler, L; del Campo, MM; Laguna, LB; de Terrassa, M; Nava, JM; Trueta, J; Haya, C; Lopez, AM; Ramos-Gomez, L; de la Torre-Prados, V; Pellejero, R; Laloe, VR; Mahendran, K; Stocker, R; Ludwig, S; Zimmermann, H; Schaffhausen, K; Denzier, U; Yutthakasemsunt, S; Kittiwattanagul, W; Piyavechvirat, P; Tapsai, P; Nanmang-jan, A; Chantapimpa, U; Watanachai, C; Subsompon, P; Pussanakawatin, W; Khunjan, P; Tangchitvittaya, S; Nilapong, S; Klangsang, T; Taechakosol, W; Srinat, A; Jerbi, Z; Borsali-Falfoul, N; Rezgui, M; Cakar, N; Ssenyonjo, H; Kobusingye, O; Lomas, G; Yates, D; Lecky, F; Bleetman, A; Baldwin, A; Jenkinson, E; Pantrini, S; Stewart, J; Contractor, N; Roberts, T; Butler, J; Pinto, A; Lee, D; Brayley, N; Robbshaw, K; Dix, C; Graham, S; Pye, S; Green, M; Kellins, A; Moulton, C; Fogg, B; Cottingham, R; Funnell, S; Shanker, U; Summers, C; Malek, L; Ashcroft, C; Powell, J; Moore, S; Buckley, S; Grocutt, M; Chambers, S; Morrice, A; Marshall, H; Harris, J; Matthews, W; Tippet, J; Mardell, S; MacMillan, F; Shaw, A; Luthra, P; Dixon, G; Ahmed, M; Young, M; Mason, S; Loveday, I; Clark, C; Taylor, S; Wilson, P; Ali, K; Greenwood, S; White, M; Perez, R; Eljamel, S; Wasserberg, J; Read, C; McCarron, J; Pennell, A; Ray, G; Thurston, J; Brown, E; Jaffey, L; Graves, M; Bailey, R; Loveridge, N; Evans, G; Hughes, S; Ahmed, K; Richardson, J; Gallagher, C; Odedun, T; Lees, K; Foley, D; Payne, N; Pennycock, A; Griffiths, C; Moore, D; Byrne, D; Dasan, S; Banerjee, A; McGuinness, S; Chikhani, C; Zoltie, N; Barlow, I; Stell, I; Hulse, W; Crossley, J; Watkins, L; Dorani, B; Van Viet, T; Baigent, C; Bracken, M; Chadwick, D; Curley, K; Duley, L; Farrell, B; Haegi, M; Nickson, G; Peto, R; Pickard, J; Roberts, I; Sandercock, P; Teasdale, G; Collins, R; Haines, S; MacMahon, S; Warlow, C; Edwards, P; Ritchie, N; Shakur, H; Ramos, M; Barnetson, L; Fernandes, J; Tooth, D; Free, C; Narayanan, L; Collander, J; Abernethy, J; Bardswell, J; Mashru, R; Godward, C; Afolabi, L; Ritchie, A; Hosford, T; Collingwood, A; Massey, S; Svoboda, P; Mazairac, G; Laloe, V; Arango, M; Olldashi, F		CRASH Trial Collaborators	Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial	LANCET			English	Article							SPINAL-CORD-INJURY; CARE MANAGEMENT; INTENSIVE-CARE; BRAIN-INJURY; METHYLPREDNISOLONE	Background Corticosteroids have been used to treat head injuries for more than 30 years. In 1997, findings of a systematic review suggested that these drugs reduce risk of death by 1-2%. The CRASH trial-a multicentre international collaboration-aimed to confirm or refute such an effect by recruiting 20 000 patients. In May, 2004, the data monitoring committee disclosed the unmasked results to the steering committee, which stopped recruitment. Methods 10 008 adults with head injury and a Glasgow coma score (GCS) of 14 or less within 8 h of injury were randomly allocated 48 h infusion of corticosteroids (methylprednisolone) or placebo. Primary outcomes were death within 2 weeks of injury and death or disability at 6 months. Prespecified subgroup analyses were based on injury severity (GCS) at randomisation and on time from injury to randomisation. Analysis was by intention to treat. Effects on outcomes within 2 weeks of randomisation are presented in this report. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN74459797. Findings Compared with placebo, the risk of death from all causes within 2 weeks was higher in the group allocated corticosteroids (1052 [21.1%] vs 893 [17.9%] deaths; relative risk 1.18 [95% CI 1.09-1.27]; p=0.0001). The relative increase in deaths due to corticosteroids did not differ by injury severity (p=0.22) or time since injury (p=0.05). Interpretation Our results show there is no reduction in mortality with methylprednisolone in the 2 weeks after head injury. The cause of the rise in risk of death within 2 weeks is unclear.	Univ London London Sch Hyg & Trop Med, CRASH Trials Coordinating Ctr, Keppel St, London WC1E 7HT, England; Cent Mil Univ Hosp Natl Trauma Ctr, Tirana, Albania; Univ Hosp Mother Teresa, Tirana, Albania; IAMBE, Buenos Aires, DF, Argentina; Hosp San Bernardo, Salta, Argentina; Hosp Escuela Jose San Martin, Corrientes, Argentina; Hosp Municipal Leonidas Lucero, Buenos Aires, DF, Argentina; Hosp Ramon Carrillo, Buenos Aires, DF, Argentina; Hosp Castro Rendon, Neuquen, Argentina; Hosp Zonal Gen Agudos, Merlo, Buenos Aires, Argentina; Policlinico Sofia T Santamarina, Monte Grande, Buenos Aires, Argentina; Hosp Municipal Hector J DAgnillo, Marcos Paz, Buenos Aires, Argentina; Hosp Nacl Prof Alejandro Posadas, Buenos Aires, DF, Argentina; Hosp Espanol Mendoza, Mendoza, Argentina; Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina; Hosp Jose Penna, Bahia Blanca, Buenos Aires, Argentina; Hosp Aleman, Buenos Aires, DF, Argentina; Gold Coast Hosp, Southport, Qld, Australia; Waldviertelklinikum Standort Horn, Horn, Austria; Wilhelminenspital Stadt Wien, Vienna, Austria; Ctr Hosp Reg Namur, Namur, Belgium; AZ KLINA Hosp, Brasschaat, Belgium; Hosp Jolimont, Jolimont, Belgium; Clinique Saint-Luc, Brussels, Belgium; Hosp Pronto Socorro Porto Alegre, Porto Alegre, RS, Brazil; Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil; Clin Sao Vicente, Rio De Janeiro, Brazil; Hosp Reg Copiapo, Copiapo, Chile; Zhongshan City Peoples Hosp, Zhongshan, Peoples R China; Sheng Zheng Second Peoples Hosp, Sheng Zheng, Peoples R China; Hosp Univ San Jorge, Risaralda, Colombia; Clin Las Amer, Medellin, Colombia; Hosp Gen Medellin, Medellin, Colombia; Hosp Erasmo Meoz, Cucuta, Colombia; Hosp Dept Narino, Pasto, Colombia; Hosp San Andres, Tumaco, Colombia; Hosp Federico Lleras, Ibague, Colombia; Hosp El Tunal, Bogota, Colombia; Hosp Civil Ipiales, Ipiales, Nariono, Colombia; Hosp Univ Valle, Cali, Colombia; Hosp Reg Duitama, Boyaca, Colombia; Hosp Timothy Britton, San Andres, Colombia; Org Clin Gen Norte, Atlantico, Colombia; Hosp Mexico, Tijuana, Baja California, Mexico; Hosp Abel Santamaria Cuadrado, Pinar Del Rio, Cuba; Hosp Univ Arnaldo Milian Castro, Santa Clara, Villa Clara, Cuba; Hosp Prov Docente Manuel Ascunce Domenech, Camaguey, Cuba; Hosp VI Lenin, Holguin, Cuba; Hosp Gen Moron, Moron, Ciego de Avila, Cuba; Hosp Gen Univ Carlos Manuel de Cespedes, Bayamo, Cuba; Hosp Univ Dr Gustavo Aldereguia Lima, Cienfuegos, Cuba; Hosp Miguel Enriquez, Havana, Cuba; Hosp Clin Quirurg Docente Saturnino Lora, Santiago De Cuba, Cuba; Ctr Invest Med Quirurgicas, Havana, Cuba; Res Inst Special Surg & Trauma, Moravia, Czech Republic; Masaryk Hosp, Usti Nad Labem, Czech Republic; Charles Univ Hosp, Plzen, Czech Republic; Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic; Univ Karlovy Neurochirurg Klin, Prague, Czech Republic; Hosp Luis Vernaza, Guayaquil, Ecuador; Hosp Policia Guayaquil, Guayaquil, Ecuador; Hosp Jose Carrasco Arteaga, Cuenca, Ecuador; Hosp Naval, Buenos Aires, DF, Argentina; Clin Cent, Santiago, Reg Metropolita, Chile; Hosp Militar Guayaquil, Guayaquil, Guayas, Ecuador; Hosp Reg IESS Dr Teodoro Maldonado Carbo, Guayaquil, Ecuador; Mataria Teaching Hosp, Cairo, Egypt; Suez Canal Univ, Ismailia, Egypt; Aswan Teaching Hosp, Aswan, Egypt; Zagazig Univ Hosp, Sharkia, Egypt; Tbilisi State Med Univ, Neurosurg Dept, Tbilisi, Georgia; Tbilisi 4th Hosp, Tbilisi, Georgia; Ernst Moritz Arndt Univ Greifswald, Greifswald, Germany; Kreiskrankenhaus Tirschenreuth, Tirschenreuth, Germany; Klinikum Offenbach, Offenbach, Germany; Narh Bita Hosp, Tema, Ghana; Univ Hosp Ioannina, Ioannina, Greece; Univ Gen Hosp Larissa, Larisa, Greece; Chania Gen Hosp St George, Khania, Crete, Greece; KAT Hosp Athens, Athens, Greece; NSCB Med Coll, Jabalpur, Madhya Pradesh, India; King George Med Coll, Lucknow, Uttar Pradesh, India; North Bengal Neuro Res Ctr, Darjeeling, India; GR Med Coll, Gwalior, India; Med Trust Hosp Kochi, Kochi, Kerala, India; Manipal Hosp, Bangalore, Karnataka, India; Med Coll Hosp Trivandrum, Trivandrum, Kerala, India; Abhaya Hosp, Bangalore, Karnataka, India; Christian Med Coll & Hosp, Ludhiana, Punjab, India; Apex Hosp Bhopal, Bhopal, India; Meenakshi Mission Hosp & Res Ctr, Madurai, Tamil Nadu, India; MOSC Med Coll & Hosp, Ernakulam, Kerala, India; Nizams Inst Med Sci, Hyderabad, Andhra Pradesh, India; Postgrad Inst Med Educ & Res, Chandigarh, India; Baby Mem Hosp, Calicut, Kerala, India; VHS Hosp, Madras, Tamil Nadu, India; Jubilee Mission Hosp, Trichur, Kerala, India; Natl Inst Mental Hlth & Neurosci, Bangalore, Karnataka, India; Care Hosp, Hyderabad, Andhra Pradesh, India; Sri Sai Hosp, Hyderabad, Andhra Pradesh, India; Hirabi Cowasji Jehangir Med Res Inst, Pune, Maharashtra, India; Maheshwari Orthopaed Hosp, Jamnagar, Gujarat, India; Amrita Inst Med Sci, Ernakulam, India; Hartej Matern & Nursing Home, Amritsar, Punjab, India; Kasturba Med Coll & Hosp, Manipal, Karnataka, India; Choitram Hosp & Res Ctr, Indore, Madhya Pradesh, India; Gowri Gopal Superspecial Hosp, Kurnool, Andhra Pradesh, India; Apex Hosp Visakhapatnam, Visakhapatnam, Andhra Pradesh, India; Cent India Inst Med Sci, Nagpur, Maharashtra, India; Marble City Hosp & Res Ctr, Jabalpur, India; Govt Med Coll Amritsar, Amritsar, Punjab, India; Johri Hosp, Jabalpur, India; Natl Hosp Jabalpur, Jabalpur, India; Sanglah Gen Hosp, Denpasar, Bali, Indonesia; Sidoarjo Gen Hosp, E Java Province, Indonesia; Fatemeh Zahra Hosp, Sari, Iran; Social Secur Hosp, Bandar E Abbas, Iran; St James Hosp, Dublin, Ireland; Univ Cattolica Sacro Cuore, Piacenza, Italy; Univ Florence, Florence, Italy; Osped San Martino Genova, Genoa, Italy; CHU Cocody, Abidjan, Cote Ivoire; Aga Khan Hosp, Kisumu City, Kenya; Hosp Univ Sci Malaysia, Kelantan, Malaysia; Ipoh Specialist Hosp, Ipoh, Malaysia; Hosp Gen Reg 1, Cuernavaca, Morelos, Mexico; Hosp Gen Queretaro, Queretaro, Qro, Mexico; Hosp Gen Reg 25, Mexico City, DF, Mexico; Dunedin Publ Hosp, Dunedin, New Zealand; Obafemi Awolowo Univ Teaching Hosp, Ife, Nigeria; Lagos Univ Teaching Hosp, Idi Araba, Nigeria; Usmanu Danfodiyo Univ Teaching Hosp, Sokoto, Nigeria; Univ Ilorin Teaching Hosp, Ilorin, Nigeria; Lautech Teaching Hosp, Osogbo, Nigeria; Lagos State Univ Teaching Hosp, Lagos, Nigeria; Seventh Day Adventist Hosp, Ife, Nigeria; St Stephens Hosp, New Delhi, India; Jinnah Postgrad Med Ctr, Karachi, Pakistan; Complejo Hosp MA Guerrero, Colon, Panama; Inst Previs Social, Asuncion, Paraguay; Hosp Nacl Dos de Mayo, Lima, Peru; Hosp Nacl Arzobispo Loayza, Lima, Peru; Spitalul Clin Urgenta Bucuresti, Bucharest, Romania; Sfantum Pantelimon Hosp, Bucharest, Romania; Prof Dr D Bagdasar Clin Emergency Hosp, Bucharest, Romania; King Khalid Univ Hosp, Riyadh, Saudi Arabia; King Khalid Natl Guard Hosp, Jeddah, Saudi Arabia; Klin Ctr Srbije, Belgrade, Serbia; Natl Neurosci Inst, Singapore, Singapore; Changi Gen Hosp, Singapore, Singapore; Reiman Hosp, Presov, Slovakia; NsP Poprad, Poprad, Slovakia; Nemocnica Bojnice, Bojnice, Slovakia; FNsP Kosice, Kosice, Slovakia; NsP Trebisov, Trebisov, Slovakia; Fac Hosp Martinique, Martin, Slovakia; NsP Ruzinov, Bratislava, Slovakia; NsP Nove Zamky, Nove Zamky, Slovakia; NsP Liptovsky Mikulas, Liptovsky Mikulas, Slovakia; NsP FD Roosevelt, Banska Bystrica, Slovakia; NsP Zilina, Bratislava, Slovakia; Tygerberg Acad Hosp, Tygerberg, South Africa; Wentworth Provincial Hosp, Durban, South Africa; Curamed Kloof Hosp, Pretoria, South Africa; Hosp Univ Virgen del Rocio, Seville, Spain; Hosp Torrecardenas, Almeria, Spain; Hosp Univ Germans Trias i Pujol, Barcelona, Spain; Hosp Mutua Terrassa, Terrassa, Spain; Hosp Univ Girona Dr Josep Trueta, Girona, Spain; Hosp Carlos Haya, Malaga, Spain; Hosp Gen La Palma, La Palma, Spain; Hosp Univ Virgen Victoria, Malaga, Spain; Hosp Gen Yague, Burgos, Spain; Batticaloa Gen Hosp Medecins Sans Frontieres, Batticaloa, Sri Lanka; Natl Hosp Sri Lanka, Colombes, France; Point Pedro Base Hosp, Point Pedro, Sri Lanka; Univ Hosp Zurich, Zurich, Switzerland; Univ Hosp Bern, Bern, Switzerland; Kantonsspital Schaffhausen, Schaffhausen, Switzerland; Khon Kaen Reg Hosp, Khon Kaen, Thailand; Chiangrai Prachanuko Hosp, Chiang Rai, Thailand; Rayong Hosp, Rayong, Thailand; Krabi Hosp, Krabi, Thailand; Suratthani Hosp, Suratthani, Thailand; Roi Et Hosp, Roi Et, Thailand; Lampang Hosp, Lampang, Thailand; Hosp Habib Thameur, Tunis, Tunisia; Istanbul Med Fac, Istanbul, Turkey; Makerere Med Sch, Kampala, Uganda; Hope Hosp, Salford, Lancs, England; Birmingham Heartlands Hosp, Birmingham, W Midlands, England; North Manchester Gen Hosp, Manchester, Lancs, England; Royal Albert Edward Infirm, Wigan, Lancs, England; Colchester Gen Hosp, Colchester, Essex, England; Whiston Hosp, Liverpool, Merseyside, England; Selly Oak Hosp, Birmingham, W Midlands, England; Royal Bolton Hosp, Bolton, England; Eastbourne Dist Gen Hosp, Eastbourne, E Sussex, England; Trafford Gen Hosp, Manchester, Lancs, England; Royal Sussex Cty Hosp, Brighton, E Sussex, England; Countess Chester Hosp, Chester, Cheshire, England; Worthing Dist Hosp, Worthing, W Sussex, England; Medway Maritime Hosp, Gillingham, Kent, England; Chelsea & Westminster Hosp, London, England; Furness Gen Hosp, Barrow In Furness, Cumbria, England; Royal Oldham Hosp, Oldham, England; Stepping Hill Hosp, Stockport, Lancs, England; No Gen Hosp, Sheffield, S Yorkshire, England; Blackburn Royal Infirm, Blackburn, Lancs, England; Cheltenham Gen Hosp, Cheltenham, Glos, England; Fairfield Hosp, Manchester, Lancs, England; Queen Elizabeth Queen Mother Hosp, Margate, Kent, England; Ninewells Hosp & Med Sch, Dundee, Scotland; Queen Elizabeth Hosp Birmingham, Birmingham, W Midlands, England; Russells Hall Hosp, Dudley, England; Princess Alexandra Hosp, Harlow, Essex, England; Princess Royal Hosp, Haywards Heath, W Sussex, England; Darent Valley Hosp, Dartford, Kent, England; Royal Liverpool Univ Hosp, Liverpool, Merseyside, England; Chesterfield & N Derbyshire Royal Hosp, Chesterfield, Derby, England; Withybush Gen Hosp, Haverfordwest, Wales; Aberdeen Royal Infirm, Aberdeen, Scotland; Ormskirk & Dist Gen Hosp, Ormskirk, Lancs, England; Queen Marys Hosp, Sidcup, Kent, England; Arrowe Pk Hosp, Upton, Merseyside, England; City Hosp Birmingham, Birmingham, W Midlands, England; St Helier Hosp, Carshalton, Surrey, England; Whittington Hosp, London, England; Doncaster Royal Infirm, Doncaster, England; Leeds Gen Infirm, Leeds, W Yorkshire, England; Bromley Hosp, Bromley, Kent, England; Harrogate Dist Hosp, Harrogate, N Yorkshire, England; Inst Neurol, London, England; Queen Elizabeth Hosp Gateshead, Gateshead, Tyne & Wear, England	University of London; London School of Hygiene & Tropical Medicine; University Hospital Center Mother Teresa (QSUT); Hospital Italiano de Buenos Aires; University of Buenos Aires; Hospital Aleman; University of Buenos Aires; Gold Coast University Hospital; Wilhelminenspital; Groupe Jolimont; Universidade de Sao Paulo; Sun Yat Sen University; Universidad del Valle; Masaryk Hospital; Charles University Prague; University Hospital Hradec Kralove; Egyptian Knowledge Bank (EKB); General Organization of Teaching Hospitals & Institutes (GOTHI); Egyptian Knowledge Bank (EKB); Suez Canal University; Egyptian Knowledge Bank (EKB); Zagazig University; Tbilisi State Medical University; Ernst Moritz Arndt Universitat Greifswald; Sana Klinikum Offenbach; University Hospital Ioannina; General University Hospital of Larissa; King George's Medical University; Nizam's Institute of Medical Sciences; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; National Institute of Mental Health & Neurosciences - India; Amrita Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Kochi; Manipal Academy of Higher Education (MAHE); Kasturba Medical College, Manipal; Sanglah General Hospital; Trinity College Dublin; Catholic University of the Sacred Heart; University of Florence; University of Genoa; IRCCS AOU San Martino IST; Dunedin Public Hospital; Obafemi Awolowo University; University of Ilorin; Lagos State University; St. Stephen's Hospital; Instituto de Prevision Social (IPS); King Saud University; King Khalid University Hospital; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Jeddah; Clinical Centre of Serbia; National Neuroscience Institute (NNI); Changi General Hospital; Virgen del Rocio University Hospital; Hospital Torrecardenas; Hospital Germans Trias i Pujol; Hospital Universitario Mutua Terrassa; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Hospital Carlos Haya; Hospital Virgen de la Victoria; Hospital General Yague; University of Zurich; University Zurich Hospital; University of Bern; University Hospital of Bern; Universite de Tunis-El-Manar; Hopital Habib Thameur; Istanbul University; Makerere University; Heart of England NHS Foundation Trust; University of Birmingham; Whiston Hospital; Royal Bolton Hospital; University of Brighton; Medway Maritime Hospital; Imperial College London; Northern General Hospital; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital; University of Dundee; University of Birmingham; Russells Hall Hospital; Princess Alexandra Hospital NHS Trust; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of Aberdeen; St Helier Hospital; University of London; University College London; Leeds General Infirmary; University of Leeds; University of London; University College London	Muzha, I (corresponding author), Univ London London Sch Hyg & Trop Med, CRASH Trials Coordinating Ctr, Keppel St, London WC1E 7HT, England.	crash@lshtm.ac.uk	Scheer, Peter/F-9500-2015; Nacul, Flavio/AAK-5554-2020; Abdullah, J/C-2828-2011; Eghtedari, Masoomeh/H-4556-2011; Myrianthefs, Pavlos/AAF-4388-2019; LORIA-CASTELLANOS, JORGE/J-2410-2016; Dewan, Yashbir/C-6503-2013; Radwan, Ahmed F./X-1931-2019; Di Napoli, Mario/J-6418-2014; Duley, Lelia/E-8107-2015; Fakharian, Esmaeil/A-1338-2018; Gallardo, Angel Jesús Lacerda/AAZ-9478-2020; Ghani, Ali/AIE-2604-2022; Watkins, Laurence/AAH-6973-2021; Saniová, Beata/AAU-5751-2021; Murillo-Cabezas, Francisco/AAO-3348-2021; Wasserberg, Jonathan/AAB-7099-2020; Kalkum, Mathias/AAO-7093-2020; Calatrava, Isidro González/S-4410-2018; Negm, Nabel A./U-5647-2017; LORIA-CASTELLANOS, JORGE/N-2363-2019; Nabil H, khalil/A-9528-2015; IBIS, NEUROCRITICOS/C-1805-2016; Kramar, Filip/O-5860-2017; Chytra, Ivan/B-2075-2008	Scheer, Peter/0000-0002-4507-5474; Abdullah, J/0000-0002-0258-7410; Myrianthefs, Pavlos/0000-0002-8830-031X; LORIA-CASTELLANOS, JORGE/0000-0001-9269-0034; Dewan, Yashbir/0000-0002-7154-1301; Di Napoli, Mario/0000-0001-9609-4926; Duley, Lelia/0000-0001-6721-5178; Gallardo, Angel Jesús Lacerda/0000-0001-9171-2000; Watkins, Laurence/0000-0003-0678-3774; Wasserberg, Jonathan/0000-0002-3782-0390; Calatrava, Isidro González/0000-0003-4784-2582; Negm, Nabel A./0000-0002-7999-0179; LORIA-CASTELLANOS, JORGE/0000-0001-9269-0034; Nabil H, khalil/0000-0001-6293-7972; Kramar, Filip/0000-0003-0833-2360; Maliawan, Sri/0000-0003-2389-3481; Maliawan, Prof. Sri/0000-0002-6151-3155; komolafe, edward/0000-0003-1261-3501; Cakar, Nahit/0000-0002-1302-9596; Shakur-Still, Haleema/0000-0002-6511-109X; KOMOLAFE, MORENIKEJI/0000-0002-0592-5120; Chytra, Ivan/0000-0001-5342-5537; Edwards, Phil/0000-0003-4431-8822; Ochoa-Parra, Marcelo/0000-0003-0432-8962; MacMahon, Stephen/0000-0003-2064-7699				Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRACKEN MB, 1999, COCHRANE LIB; BTF Guidelines, 2000, J NEUROTRAUM, V17, P591; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; JENNETT B, 1975, LANCET, V1, P480; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Murray CJL., 1996, GLOBAL HLTH STAT COM, V1996; OTANI K, 1994, SEKITSUI SEKIZUI J, V7, P633; Pocock S, 1999, LANCET, V353, P943, DOI 10.1016/S0140-6736(98)00379-1; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Stevens RD, 2003, J NEUROSURG ANESTH, V15, P215, DOI 10.1097/00008506-200307000-00009; TEASDALE G, 1974, LANCET, V2, P81; Wang J, 1999, J INORG MATER, V14, P233; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; 1990, LANCET, V336, P279	22	645	684	0	116	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2004	364	9442					1321	1328		10.1016/s0140-6736(04)17188-2	http://dx.doi.org/10.1016/s0140-6736(04)17188-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474134				2022-12-28	WOS:000224349700027
J	Formisano, V; Atreya, S; Encrenaz, T; Ignatiev, N; Giuranna, M				Formisano, V; Atreya, S; Encrenaz, T; Ignatiev, N; Giuranna, M			Detection of methane in the atmosphere of Mars	SCIENCE			English	Article							SUBSURFACE LIFE; PHOTOCHEMISTRY; ECOSYSTEMS; STABILITY	We report a detection of methane in the martian atmosphere by the Planetary Fourier Spectrometer onboard the Mars Express spacecraft. The global average methane mixing ratio is found to be 10+/-5 parts per billion by volume (ppbv). However, the mixing ratio varies between 0 and 30 ppbv over the planet. The source of methane could be either biogenic or nonbiogenic, including past or present subsurface microorganisms, hydrothermal activity, or cometary impacts.	INAF IFSI, Ist Fis Spazio Interplanetario, I-00133 Rome, Italy; Univ Michigan, Dept Atmospher Ocean & Space Sci, Ann Arbor, MI 48109 USA; Observ Paris, Lab Etud Spatiales & Instrumentat Astrophys, Observ Paris, F-92195 Meudon, France; Russian Acad Sci IKI, Space Res Inst, Moscow 117810, Russia	Istituto Nazionale Astrofisica (INAF); University of Michigan System; University of Michigan; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite; Russian Academy of Sciences; Space Research Institute of the Russian Academy of Sciences	Formisano, V (corresponding author), INAF IFSI, Ist Fis Spazio Interplanetario, Via Fosso Cavaliere 100, I-00133 Rome, Italy.	formisan@nike.ifsi.rm.cnr.it	GIURANNA, Marco/S-9378-2017	GIURANNA, Marco/0000-0001-8967-9184; Ignatiev, Nikolay/0000-0002-6358-7094				[Anonymous], 1996, SOIL MICROBIOLOGY BI; ATREYA SK, 1995, ADV SPACE RES, V16, P57, DOI 10.1016/0273-1177(95)00250-I; ATREYA SK, 1994, J GEOPHYS RES-PLANET, V99, P13133, DOI 10.1029/94JE01085; BOSTON PJ, 1992, ICARUS, V95, P300, DOI 10.1016/0019-1035(92)90045-9; Chapelle FH, 2002, NATURE, V415, P312, DOI 10.1038/415312a; Clancy R. T., 2003, Journal of Geophysical Research, V108, P2, DOI 10.1029/2003JE002058; Cronin JR., 1988, ORGANIC MATTER CARBO, P819; Flynn GJ, 1996, EARTH MOON PLANETS, V72, P469, DOI 10.1007/BF00117551; FORMISANO V, UNPUB; Foustoukos DI, 2004, SCIENCE, V304, P1002, DOI 10.1126/science.1096033; Gibb EL, 2003, ICARUS, V165, P391, DOI 10.1016/S0019-1035(03)00201-X; GIURANNA M, UNPUB; Krasnopolsky VA, 1997, J GEOPHYS RES-PLANET, V102, P6525, DOI 10.1029/96JE03766; Krasnopolsky VA, 1998, SCIENCE, V280, P1576, DOI 10.1126/science.280.5369.1576; KRASNOPOLSKY VA, 2004, EUR GEOSC UN M NIC F; Kress ME, 2004, ICARUS, V168, P475, DOI 10.1016/j.icarus.2003.10.013; LELLOUCH E, 1991, PLANET SPACE SCI, V39, P219, DOI 10.1016/0032-0633(91)90145-Z; Levison HF, 2000, ICARUS, V143, P415, DOI 10.1006/icar.1999.6313; MAGUIRE WC, 1977, ICARUS, V32, P85, DOI 10.1016/0019-1035(77)90051-3; Max MD, 2000, J GEOPHYS RES-PLANET, V105, P4165, DOI 10.1029/1999JE001119; MUMMA MJ, 2003, AM ASS SCI DIV PLAN; NAIR H, 1994, ICARUS, V111, P124, DOI 10.1006/icar.1994.1137; PARKES RJ, 1994, NATURE, V371, P410, DOI 10.1038/371410a0; STEVENS TO, 1995, SCIENCE, V270, P450, DOI 10.1126/science.270.5235.450; Summers ME, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015377; WALLENDAHL A, 1999, LUN PLAN SCI C, V30; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; Weiss BP, 2000, P NATL ACAD SCI USA, V97, P1395, DOI 10.1073/pnas.030538097; Wong AS, 2004, ADV SPACE RES, V33, P2236, DOI 10.1016/S0273-1177(03)00524-6; Wong AS, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE002003; Yung Y.L., 1999, PHOTOCHEMISTRY PLANE	31	527	548	4	153	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	2004	306	5702					1758	1761		10.1126/science.1101732	http://dx.doi.org/10.1126/science.1101732			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878FA	15514118				2022-12-28	WOS:000225630800047
J	Kulathinal, RJ; Bettencourt, BR; Hartl, DL				Kulathinal, RJ; Bettencourt, BR; Hartl, DL			Compensated deleterious mutations in insect genomes	SCIENCE			English	Article							EVOLUTION	Relatively little is known about the importance of amino acid interactions in protein and phenotypic evolution. Here we examine whether mutations that are pathogenic in Drosophila melanogaster become fixed via epistasis in other Dipteran genomes. Overall divergence at pathogenic amino acid sites is reduced. However, similar to10% of the substitutions at these sites carry the exact same pathogenic amino acid found in D. melanogaster mutants. Hence compensatory mutation(s) must have evolved. Surprisingly, the fraction 10% is not affected by phylogenetic distance. These results support a selection-driven process that allows compensated amino acid substitutions to become rapidly fixed in taxa with large populations.	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Harvard University	Hartl, DL (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.	dhartl@oeb.harvard.edu			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P41HG000739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068465] Funding Source: NIH RePORTER; NHGRI NIH HHS [P41-HG00739] Funding Source: Medline; NIGMS NIH HHS [GM068465] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Dobzhansky T, 1970, GENETICS EVOLUTIONAR; Fay JC, 2002, NATURE, V415, P1024, DOI 10.1038/4151024a; Fisher R.A., 1930, GENETICAL THEORY NAT; Gelbart W, 2003, NUCLEIC ACIDS RES, V31, P172, DOI 10.1093/nar/gkg094; Kimura M., 1985, J GENET, V64, P7, DOI [10.1007/BF02923549, DOI 10.1007/BF02923549]; Kliman RM, 2000, GENETICS, V156, P1913; Kondrashov AS, 2002, P NATL ACAD SCI USA, V99, P14878, DOI 10.1073/pnas.232565499; RICHARDS S, IN PRESS GENOME RES; Sawyer SA, 2003, J MOL EVOL, V57, pS154, DOI 10.1007/s00239-003-0022-3; Smith NGC, 2002, NATURE, V415, P1022, DOI 10.1038/4151022a; Stephan W, 1996, GENETICS, V144, P419; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wilke CO, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-3; WRIGHT SEWALL, 1932, PROC SIXTH INTERNAT CONGR GENETICS ITHACA NEW YORK, V1, P356	14	84	87	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1553	1554		10.1126/science.1100522	http://dx.doi.org/10.1126/science.1100522			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15498973				2022-12-28	WOS:000225442700058
J	Vas, J; Mendez, C; Perea-Milla, E; Vega, E; Panadero, MD; Leon, JM; Borge, MA; Gaspar, O; Sanchez-Rodriguez, F; Aguilar, I; Jurado, R				Vas, J; Mendez, C; Perea-Milla, E; Vega, E; Panadero, MD; Leon, JM; Borge, MA; Gaspar, O; Sanchez-Rodriguez, F; Aguilar, I; Jurado, R			Acupuncture as a complementary therapy to the pharmacological treatment of osteoarthritis of the knee: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To analyse the efficacy of acupuncture as a complementary therapy to the pharmacological treatment of osteoarthritis of the knee, with respect to pain relief, reduction of stiffness, and increased physical function during treatment; modifications in the consumption of diclofenac during treatment; and changes in the patient's quality of life. Design Randomised, controlled, single blind trial, with blinded evaluation and statistical analysis of results. Setting Pain management unit in a public primary care centre in southern Spain, over a period of two years. Participants 97 outpatients presenting with osteoarthritis of the knee. Interventions Patients were randomly separated into two groups, one receiving acupuncture plus diclofenac (n=48) and the other placebo acupuncture plus diclofenac (n=49). Main outcome measures The clinical variables examined included intensity of pain as measured by a visual analogue scale; pain, stiffness, and physical function subscales of the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index; dosage of diclofenac taken during treatment; and the profile of quality of life in the chronically ill (PQLC) instrument, evaluated before and after the treatment programme. Results 88 patients completed the trial. In the intention to treat analysis, the WOMAC; index presented a greater reduction in the intervention group than in the control group (mean difference 23.9, 95% confidence interval 15.0 to 32.8) The reduction was greater in the subscale of functional activity. The same result was observed in the pain visual analogue scale, with a reduction of 26.6 (18.5 to 34.8). The PQLC results indicate that acupuncture treatment produces significant changes in physical capability (P=0.021) and psychological functioning (P=0.046). Three patients reported bruising after the acupuncture sessions. Conclusions Acupuncture plus diclofenac is more effective than placebo acupuncture plus diclofenac for the symptomatic treatment of osteoarthritis of the knee.	Ctr Salud Dos Hermanas A, Dist Sanitario Sevilla Sur, Pain Treatment Unit, Dos Hermanas 41700, Spain; Dist Sanitario Sevilla Sur, Alcala De Guadaira 41500, Spain; Hosp Costa Sol, Res Support Unit, Marbella 29600, Spain; Univ Seville, Dept Social Psychol, Seville 41018, Spain; Serv Ordenac Sanitaria, Serv Andaluz Salud, Seville 41001, Spain; Municipal Med Serv, Mairena Del Aljarafe 41927, Spain; Ctr Salud Castilleja De La Cuesta, Pain Treatment Unit, Castilleja de la Cuesta 41950, Spain	University of Sevilla	Vas, J (corresponding author), Ctr Salud Dos Hermanas A, Dist Sanitario Sevilla Sur, Pain Treatment Unit, Dos Hermanas 41700, Spain.	jvas@acmas.com	León-Rubio, José María/E-7734-2010; Vas, Jorge/P-7946-2016; Vas, Jorge/B-1138-2012	León-Rubio, José María/0000-0003-0197-5291; Vas, Jorge/0000-0003-1326-856X; Vas, Jorge/0000-0003-1326-856X				AHLBACK S, 1968, ACTA RADIOL DIAGN S, V72; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; AYZAGNER LCS, 1993, MUESTREO INVESTIGACI; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Berman BM, 1999, RHEUMATOLOGY, V38, P346, DOI 10.1093/rheumatology/38.4.346; BROWN BW, 2000, DSTPLAN CALCULATIONS; Cheng X, 1987, CHINESE ACUPUNCTURE; CHRISTENSEN BV, 1992, ACTA ANAESTH SCAND, V36, P519, DOI 10.1111/j.1399-6576.1992.tb03511.x; COBOS R, 2000, MANUAL ACUPUNCTURA M; Cobos R, 2000, MANUAL ACUPUNTURA MO; Creamer P, 1997, LANCET, V350, P503, DOI 10.1016/S0140-6736(97)07226-7; FELSON DT, 1990, SEMIN ARTHRITIS RHEU, V20, P42, DOI 10.1016/0049-0172(90)90046-I; FERRANDEZ IA, 2002, ATEN PRIMARIA, V30, P602; Perrot S, 1996, DRUGS, V52, P21, DOI 10.2165/00003495-199600523-00005; Siegrist J., 1996, PROFIL LEBENSQUALIT; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Takeda W, 1994, Arthritis Care Res, V7, P118, DOI 10.1002/art.1790070304; Vas Jorge, 2004, Acupunct Med, V22, P23; Yurtkuran M, 1999, Am J Acupunct, V27, P133	19	126	140	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2004	329	7476					1216	1219		10.1136/bmj.38238.601447.3A	http://dx.doi.org/10.1136/bmj.38238.601447.3A			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874FG	15494348	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000225335700018
J	Aharon-Peretz, J; Rosenbaum, H; Gershoni-Baruch, R				Aharon-Peretz, J; Rosenbaum, H; Gershoni-Baruch, R			Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GAUCHER-DISEASE; ALZHEIMERS-DISEASE; CLINICAL-DIAGNOSIS; MECHANISMS; PREVALENCE; SYSTEM	BACKGROUND: A clinical association has been reported between type 1 Gaucher's disease, which is caused by a glucocerebrosidase deficiency owing to mutations in the glucocerebrosidase gene (GBA), and parkinsonism. We examined whether mutations in the GBA gene are relevant to idiopathic Parkinson's disease. METHODS: A clinic-based case series of 99 Ashkenazi patients with idiopathic Parkinson's disease, 74 Ashkenazi patients with Alzheimer's disease, and 1543 healthy Ashkenazi Jews who underwent testing to identify heterozygosity for certain recessive diseases were screened for the six GBA mutations (N370S, L444P, 84GG, IVS+1, V394L, and R496H) that are most common among Ashkenazi Jews. RESULTS: Thirty-one patients with Parkinson's disease (31.3 percent; 95 percent confidence interval, 22.2 to 40.4 percent) had one or two mutant GBA alleles: 23 were heterozygous for N370S, 4 were heterozygous for 84GG, 3 were homozygous for N370S, and 1 was heterozygous for R496H. Among the 74 patients with Alzheimer's disease, 3 were identified as carriers of Gaucher's disease (4.1 percent; 95 percent confidence interval, 0.0 to 8.5 percent): 2 were heterozygous for N370S, and 1 was heterozygous for 84GG. Ninety-five carriers of Gaucher's disease were identified among the 1543 control subjects (6.2 percent; 95 percent confidence interval, 5.0 to 7.4 percent): 92 were heterozygous for N370S, and 3 were heterozygous for 84GG. Patients with Parkinson's disease had significantly greater odds of being carriers of Gaucher's disease than did patients with Alzheimer's disease (odds ratio, 10.8; 95 percent confidence interval, 3.0 to 46.6; P<0.001) or control subjects (odds ratio, 7.0; 95 percent confidence interval, 4.2 to 11.4; P<0.001). Among the patients with Parkinson's disease, patients who were carriers of Gaucher's disease were younger than those who were not carriers (mean [+/-SD] age at onset, 60.0+/-14.2 years vs. 64.2+/-11.7 years; P=0.04). CONCLUSIONS: Our results suggest that heterozygosity for a GBA mutation may predispose Ashkenazi Jews to Parkinson's disease.	Rambam Med Ctr, Dept Neurol, Haifa, Israel; Rambam Med Ctr, Cognit Neurol Unit, Haifa, Israel; Rambam Med Ctr, Dept Hematol & Bone Marrow Transplantat, Haifa, Israel; Rambam Med Ctr, Dept Human Genet, Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Gershoni-Baruch, R (corresponding author), Rambam Med Ctr, Dept Med Genet, IL-31096 Haifa, Israel.	rgershoni@rambam.health.gov.il						American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Anca M, 2002, NEUROEPIDEMIOLOGY, V21, P50, DOI 10.1159/000048614; ATSUMI S, 1992, ARCH BIOCHEM BIOPHYS, V297, P362, DOI 10.1016/0003-9861(92)90685-P; Bembi B, 2003, NEUROLOGY, V61, P99, DOI 10.1212/01.WNL.0000072482.70963.D7; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BEUTLER E, 1990, CLIN CHIM ACTA, V194, P161, DOI 10.1016/0009-8981(90)90130-K; Brugg B, 1996, J NEUROCHEM, V66, P733; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Fahn S., 1987, RECENT DEV PARKINSON, VVol. 2, P153; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; Gorrell JM, 1996, ENVIRON HEALTH PERSP, V104, P652, DOI 10.2307/3433095; GRABOWSKI GA, 1993, ADV HUM GENET, V21, P377; Horowitz M, 1998, HUM MUTAT, V12, P240, DOI 10.1002/(SICI)1098-1004(1998)12:4<240::AID-HUMU4>3.0.CO;2-J; Horowitz M, 1999, HUM MUTAT, V13, P255; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; LAZZARINI AM, 1994, NEUROLOGY, V44, P499, DOI 10.1212/WNL.44.3_Part_1.499; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lloyd-Evans E, 2003, J BIOL CHEM, V278, P23594, DOI 10.1074/jbc.M300212200; Machaczka M, 1999, AM J HEMATOL, V61, P216, DOI 10.1002/(SICI)1096-8652(199907)61:3<216::AID-AJH12>3.3.CO;2-2; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Neudorfer O, 1996, QJM-MON J ASSOC PHYS, V89, P691; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Nussbaum RL, 2003, NEW ENGL J MED, V348, P2588; Orvisky E, 2002, MOL GENET METAB, V76, P262, DOI 10.1016/S1096-7192(02)00117-8; Payami H, 1998, J GERIATR PSYCH NEUR, V11, P98, DOI 10.1177/089198879801100207; Piccini P, 1999, ANN NEUROL, V45, P577, DOI 10.1002/1531-8249(199905)45:5<577::AID-ANA5>3.0.CO;2-O; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Tayebi N, 2001, MOL GENET METAB, V73, P313, DOI 10.1006/mgme.2001.3201; Varkonyi J, 2003, AM J MED GENET A, V116A, P348, DOI 10.1002/ajmg.a.10028; Wong KD, 2004, MOL GENET METAB, V82, P192, DOI 10.1016/j.ymgme.2004.04.011; Yamao F, 1999, J BIOCHEM-TOKYO, V125, P223, DOI 10.1093/oxfordjournals.jbchem.a022277	32	424	446	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1972	1977		10.1056/NEJMoa033277	http://dx.doi.org/10.1056/NEJMoa033277			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525722				2022-12-28	WOS:000224851300009
J	Kapp, C				Kapp, C			Health and hunger in Zimbabwe	LANCET			English	Editorial Material																			0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	2004	364	9445					1569	1572		10.1016/S0140-6736(04)17331-5	http://dx.doi.org/10.1016/S0140-6736(04)17331-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	866IQ	15519619				2022-12-28	WOS:000224767600010
J	van der Hilst, RD				van der Hilst, RD			Geophysics - Changing views on Earth's deep mantle	SCIENCE			English	Editorial Material							MGSIO3 PEROVSKITE; CONVECTION; STRATIFICATION; HETEROGENEITY; GEOCHEMISTRY; TRANSITIONS; CONSTRAINTS; TOMOGRAPHY; STABILITY; VELOCITY		MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	van der Hilst, RD (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	hilst@mit.edu						Albarede F, 2002, PHILOS T R SOC A, V360, P2569, DOI 10.1098/rsta.2002.1081; Anderson DL, 2002, INT GEOL REV, V44, P97, DOI 10.2747/0020-6814.44.2.97; Badro J, 2003, SCIENCE, V300, P789, DOI 10.1126/science.1081311; Badro J, 2004, SCIENCE, V305, P383, DOI 10.1126/science.1098840; Becker TW, 1999, EARTH PLANET SC LETT, V171, P351, DOI 10.1016/S0012-821X(99)00160-0; Davies GF, 2002, GEOCHIM COSMOCHIM AC, V66, P3125, DOI 10.1016/S0016-7037(02)00915-8; Forte AM, 2001, NATURE, V410, P1049, DOI 10.1038/35074000; Fukao Y, 2001, REV GEOPHYS, V39, P291, DOI 10.1029/1999RG000068; Helffrich GR, 2001, NATURE, V412, P501, DOI 10.1038/35087500; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; Humayun M, 2004, SCIENCE, V306, P91, DOI 10.1126/science.1101050; Ishii M, 1999, SCIENCE, V285, P1231, DOI 10.1126/science.285.5431.1231; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; Kennett BLN, 1998, J GEOPHYS RES-SOL EA, V103, P12469, DOI 10.1029/98JB00150; Masters G., 2000, EARTHS DEEP INTERIOR, V117, P63, DOI DOI 10.1029/GM117P0063; Murakami M, 2004, SCIENCE, V304, P855, DOI 10.1126/science.1095932; Ni SD, 2002, SCIENCE, V296, P1850, DOI 10.1126/science.1070698; Saltzer RL, 2001, GEOPHYS RES LETT, V28, P1335, DOI 10.1029/2000GL012339; Schubert G, 2001, MANTLE CONVECTION EA; Shim SH, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019639; Shim SH, 2001, SCIENCE, V293, P2437, DOI 10.1126/science.1061235; Su WJ, 1997, PHYS EARTH PLANET IN, V100, P135, DOI 10.1016/S0031-9201(96)03236-0; Tackley PJ, 2000, SCIENCE, V288, P2002, DOI 10.1126/science.288.5473.2002; Trampert J, 2004, SCIENCE, V306, P853, DOI 10.1126/science.1101996; van der Hilst RD, 1999, SCIENCE, V283, P1885, DOI 10.1126/science.283.5409.1885; van Keken PE, 1999, J GEOPHYS RES-SOL EA, V104, P7137, DOI 10.1029/1999JB900003; VANDERHILST R, 1991, NATURE, V353, P37, DOI 10.1038/353037a0; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; VANDERHILST RD, UNPUB	29	17	17	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					817	818		10.1126/science.1104679	http://dx.doi.org/10.1126/science.1104679			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514143				2022-12-28	WOS:000224969400030
J	Murray, MJ; Tang, T; Ryder, C; Mabin, D; Nicholson, JC				Murray, MJ; Tang, T; Ryder, C; Mabin, D; Nicholson, JC			Lesson of the week - Childhood leukaemia masquerading as juvenile idiopathic arthritis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDREN; PAIN		Addenbrookes Hosp, Cambridge CB2 2QQ, England; W Suffolk Hosp, Bury St Edmunds IP33 2QZ, Suffolk, England; Birmingham Childrens Hosp, Birmingham B4 6NH, W Midlands, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Birmingham	Nicholson, JC (corresponding author), Addenbrookes Hosp, Hills Rd, Cambridge CB2 2QQ, England.	james.nicholson@addenbrookes.nhs.uk						Barbosa Cássia Maria Passarelli Lupoli, 2002, J. Pediatr. (Rio J.), V78, P481, DOI 10.1590/S0021-75572002000600007; BRADLOW A, 1991, POSTGRAD MED J, V67, P562, DOI 10.1136/pgmj.67.788.562; Cabral DA, 1999, J PEDIATR-US, V134, P53, DOI 10.1016/S0022-3476(99)70372-0; CABRAL DA, 1995, PEDIATR CLIN N AM, V42, P1051; JONSSON OG, 1990, J PEDIATR-US, V117, P233, DOI 10.1016/S0022-3476(05)80535-9; OSTROV BE, 1993, J PEDIATR-US, V122, P595, DOI 10.1016/S0022-3476(05)83543-7; REVESZ T, 1985, CANCER, V55, P1637, DOI 10.1002/1097-0142(19850415)55:8<1637::AID-CNCR2820550804>3.0.CO;2-H; Tsai Ming-Jer, 1995, Acta Paediatrica Sinica, V36, P274; Wallendal M, 1996, ARCH PEDIAT ADOL MED, V150, P70, DOI 10.1001/archpedi.1996.02170260074012	9	22	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 23	2004	329	7472					959	961		10.1136/bmj.329.7472.959	http://dx.doi.org/10.1136/bmj.329.7472.959			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866KU	15499113	Green Published			2022-12-28	WOS:000224773200020
J	Thwaites, GE; Bang, ND; Dung, NH; Quy, HT; Oanh, DTT; Thoa, NTC; Hien, NQ; Thuc, NT; Hai, NN; Lan, NTN; Lan, NN; Duc, NH; Tuan, VN; Hiep, CH; Chau, TTH; Mai, PP; Dung, NT; Stepniewska, K; White, NJ; Hien, TT; Farrar, JJ				Thwaites, GE; Bang, ND; Dung, NH; Quy, HT; Oanh, DTT; Thoa, NTC; Hien, NQ; Thuc, NT; Hai, NN; Lan, NTN; Lan, NN; Duc, NH; Tuan, VN; Hiep, CH; Chau, TTH; Mai, PP; Dung, NT; Stepniewska, K; White, NJ; Hien, TT; Farrar, JJ			Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND: Tuberculous meningitis kills or disables more than half of those affected with the disease. Previous studies have been too small to determine whether adjunctive treatment with corticosteroids can reduce the risk of disability or death among adults with tuberculous meningitis, and the effect of coinfection with the human immunodeficiency virus (HIV) is unclear. METHODS: We performed a randomized, double-blind, placebo-controlled trial in Vietnam in patients over 14 years of age who had tuberculous meningitis, with or without HIV infection, to determine whether adjunctive treatment with dexamethasone reduced the risk of death or severe disability after nine months of follow-up. We conducted prespecified subgroup analyses and intention-to-treat analyses. RESULTS: A total of 545 patients were randomly assigned to groups that received either dexamethasone (274 patients) or placebo (271 patients). Only 10 patients (1.8 percent) had been lost to follow-up at nine months of treatment. Treatment with dexamethasone was associated with a reduced risk of death (relative risk, 0.69; 95 percent confidence interval, 0.52 to 0.92; P=0.01).It was not associated with a significant reduction in the proportion of severely disabled patients (34 of 187 patients [18.2 percent] among survivors in the dexamethasone group vs. 22 of 159 patients [13.8 percent] in the placebo group, P=0.27) or in the proportion of patients who had either died or were severely disabled after nine months (odds ratio, 0.81; 95 percent confidence interval, 0.58 to 1.13; P=0.22).The treatment effect was consistent across subgroups that were defined by disease-severity grade (stratified relative risk of death, 0.68; 95 percent confidence interval, 0.52 to 0.91; P=0.007) and by HIV status (stratified relative risk of death, 0.78; 95 percent confidence interval, 0.59 to 1.04; P=0.08). Significantly fewer serious adverse events occurred in the dexamethasone group than in the placebo group (26 of 274 patients vs. 45 of 271 patients, P=0.02). CONCLUSIONS: Adjunctive treatment with dexamethasone improves survival in patients over 14 years of age with tuberculous meningitis but probably does not prevent severe disability.	Univ Oxford, Clin Res Unit, Hosp Trop Dis, Ho Chi Minh City, Vietnam; John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England; Pham Ngoc Thach Hosp TB & Lung Dis, Ho Chi Minh City, Vietnam	University of Oxford; University of Oxford	Thwaites, GE (corresponding author), Univ Oxford, Clin Res Unit, Hosp Trop Dis, 190 Ben Ham Tu,Quan 5, Ho Chi Minh City, Vietnam.	guy.thwaites@btinternet.com	White, Nicholas J/I-4629-2012; White, Nick/AAC-6527-2019; Farrar, Jeremy J./HGA-7610-2022; Thwaites, Guy E/R-4993-2019	White, Nick/0000-0002-1897-1978; Thwaites, Guy E/0000-0002-2858-2087; Farrar, Jeremy/0000-0002-2700-623X; Stepniewska, Kasia/0000-0002-1713-6209				ASHBY M, 1955, LANCET, V1, P65; Celani MG, 2002, STROKE, V33, P218, DOI 10.1161/hs0102.100532; ESCOBAR JA, 1975, PEDIATRICS, V56, P1050; GIRGIS NI, 1991, PEDIATR INFECT DIS J, V10, P179, DOI 10.1097/00006454-199103000-00002; Girgis NI, 1998, AM J TROP MED HYG, V58, P28, DOI 10.4269/ajtmh.1998.58.28; Horne N W, 1966, Bibl Tuberc, V22, P1; Hosoglu S, 2002, INT J TUBERC LUNG D, V6, P64; HOUGHTON LE, 1954, LANCET, V1, P595; LEPPER MH, 1963, ANN NY ACAD SCI, V106, P106, DOI 10.1111/j.1749-6632.1963.tb16629.x; MARSHALL G, 1948, LANCET, V254, P582; OTOOLE RD, 1969, ANN INTERN MED, V70, P39, DOI 10.7326/0003-4819-70-1-39; PARSONS M, 1989, TUBERCLE, V70, P79, DOI 10.1016/0041-3879(89)90031-7; PRASAD K, 2000, COCHRANE DB SYST REV, V3; Schoeman JF, 1997, PEDIATRICS, V99, P226, DOI 10.1542/peds.99.2.226; SHANE SJ, 1953, NEW ENGL J MED, V249, P829, DOI 10.1056/NEJM195311192492101; WOLFE CDA, 1991, STROKE, V22, P1242, DOI 10.1161/01.STR.22.10.1242	16	617	666	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2004	351	17					1741	1751		10.1056/NEJMoa040573	http://dx.doi.org/10.1056/NEJMoa040573			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863TH	15496623				2022-12-28	WOS:000224585200009
J	Paola, FA				Paola, FA			The secret	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												fpaola@hsc.usf.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2004	292	15					1795	1796		10.1001/jama.292.15.1795	http://dx.doi.org/10.1001/jama.292.15.1795			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IV	15494563				2022-12-28	WOS:000224485100001
J	Hongoro, C; McPake, B				Hongoro, C; McPake, B			How to bridge the gap in human resources for health	LANCET			English	Article							REIMBURSEMENT METHOD; DEVELOPING-COUNTRIES; BRAIN-DRAIN; CARE; WORKERS	Human resources are the crucial core of a health system, but they have been a neglected component of health-system development. The demands on health systems have escalated in low income countries, in the form of the Millennium Development Goals and new targets for more access to HIV/AIDS treatment. Human resources are in very short supply in health systems in low and middle income countries compared with high income countries or with the skill requirements of a minimum package of health interventions. Equally serious concerns exist about the quality and productivity of the health workforce in low income countries. Among available strategies to address the problems, expansion of the numbers of doctors and nurses through training is highly constrained. This is a difficult issue involving the interplay of multiple factors and forces.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	McPake, B (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.	barbara.mcpake@Ishtm.ac.uk	McPake, Barbara/AAE-8655-2021	McPake, Barbara/0000-0002-9904-1077; Hongoro, Charles/0000-0002-9715-4940				ANAND S, 2004, IN PRESS LANCET; [Anonymous], 1994, KEY ISSUES HLTH EC; Bach S., 2003, INT MIGRATION HLTH W; BIRCH S, 1988, FAM PRACT, V5, P265, DOI 10.1093/fampra/5.4.265; Buchan J. M. D., 2003, GLOBAL WORKFORCE STR, V21, P275; Buchan James, 2003, INT NURSE MOBILITY T; CARVEL J, 2004, GUARDIAN LONDON; Cook CT, 2002, EVAL PROGRAM PLANN, V25, P107, DOI 10.1016/S0149-7189(02)00003-4; Dickson-Tetteh K, 2002, INT FAM PLAN PERSPEC, V28, P144, DOI 10.2307/3088257; Dovlo Delanyo, 2004, Hum Resour Health, V2, P7, DOI 10.1186/1478-4491-2-7; Dussault Gilles, 2003, Hum Resour Health, V1, P1, DOI 10.1186/1478-4491-1-1; EICHLER R, 2001, 236 WORLD BANK; Ensor T, 2001, HEALTH POLICY, V57, P1, DOI 10.1016/S0168-8510(01)00125-7; Fenton PM, 2003, BRIT MED J, V327, P587, DOI 10.1136/bmj.327.7415.587; Gericke C. A., 2003, 13 DIS CONTR PRIOR P; GLENNGARD A, 2003, INVESTMENT HUMAN RES; Goddard M, 2000, HEALTH ECON, V9, P95, DOI 10.1002/(SICI)1099-1050(200003)9:2<95::AID-HEC488>3.3.CO;2-1; Hanson K, 2003, J INT DEV, V15, P1, DOI DOI 10.1002/JID.963; HOLMSTROM B, 1982, BELL J ECON, V13, P324, DOI 10.2307/3003457; HOLMSTROM B, 1990, 6 SITE STANF U; HONGORO C, IN PRESS DIS CONTROL; *JOINT LEARN IN, 2003, HUM RES HLTH DEV JOI; Kroneman M, 2001, HEALTH POLICY, V55, P19, DOI 10.1016/S0168-8510(00)00118-4; KUROWSKI C, 2004, 0104 HEFP LOND SCH H; Lang HC, 2004, HEALTH POLICY, V67, P195, DOI 10.1016/S0168-8510(03)00119-2; LEHMANN U, 2003, 41 HUM RES HLTH DEV; Marchal B, 2003, INT J HEALTH PLAN M, V18, pS89, DOI 10.1002/hpm.720; MATHESON A, 2002, ORG EC COOP DEV 26 S; MATLIN SA, 2004, 10 90 GAP HLTH RES M; McAuliffe M S, 1998, AANA J, V66, P273; McPake B, 1999, SOC SCI MED, V49, P849, DOI 10.1016/S0277-9536(99)00144-6; MEIKLE J, 2003, GUARDIAN LONDON 0919; Narasimhan V, 2004, LANCET, V363, P1469, DOI 10.1016/S0140-6736(04)16108-4; Oliveira-Cruz V., 2003, J INT DEV, V15, P41, DOI [10.1002/jid.965, DOI 10.1002/JID.965]; Pang T, 2002, BMJ-BRIT MED J, V324, P499, DOI 10.1136/bmj.324.7336.499; REVILL J, 2003, OBSERVER LONDON 0810; Rodrigues J, 1989, Int J Health Plann Manage, V4, P3, DOI 10.1002/hpm.4740040103; Saltman RB, 2002, SOC SCI MED, V54, P1677, DOI 10.1016/S0277-9536(01)00335-5; SANDERS D, 1992, COMMUNITY HLTH WORKE, P178; SSENGOOBA F, 2003, HSDWP0403 IPH; STEINWALD B, 1989, HEALTH AFFAIR, V8, P35, DOI 10.1377/hlthaff.8.2.35; Stilwell B, 2004, B WORLD HEALTH ORGAN, V82, P595; Van Damme W, 2001, SOTNIKUM NEW DEAL 1; Venning P, 2000, BMJ-BRIT MED J, V320, P1048, DOI 10.1136/bmj.320.7241.1048; Vujicic Marko, 2004, Hum Resour Health, V2, P3, DOI 10.1186/1478-4491-2-3; WALT G, 1988, EPC PUBLICATION, V16; Weiner R, 1998, S AFR J SCI, V94, P59; *WHO, 2002, WORK GROUP 5 COMM MA; Wibulpolprasert Suwit, 2003, Hum Resour Health, V1, P12, DOI 10.1186/1478-4491-1-12; World Health Organisation, 1999, RED MAT MORT JOINT W; World Health Organization, GLOB ATL HLTH WORKF; World Health Organization, 2004, WORLD HLTH REP 2004	52	253	258	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2004	364	9443					1451	1456		10.1016/S0140-6736(04)17229-2	http://dx.doi.org/10.1016/S0140-6736(04)17229-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	862IX	15488222				2022-12-28	WOS:000224485300033
J	John, BV; Subramanian, S; Mohan, D; Rao, A; Thomas, K				John, BV; Subramanian, S; Mohan, D; Rao, A; Thomas, K			A hint from the past	LANCET			English	Editorial Material									Christian Med Coll & Hosp, Dept Med, Unit 2, Vellore 632004, Tamil Nadu, India; Christian Med Coll & Hosp, Dept Radiodiag, Vellore 632004, Tamil Nadu, India	Christian Medical College & Hospital (CMCH) Vellore; Christian Medical College & Hospital (CMCH) Vellore	John, BV (corresponding author), Christian Med Coll & Hosp, Dept Med, Unit 2, Vellore 632004, Tamil Nadu, India.	binuvalsanjohn@hotmail.com	Mohan, Dinesh/E-3475-2010	Mohan, Dinesh/0000-0002-3251-2946; Swaminathan, Subramanian/0000-0001-7971-6842				Gray L, 2001, PEDIATRICS, V108, P116, DOI 10.1542/peds.108.1.116; VARDHAMAN S, 2003, INDIAN PEDIATR, V40, P230; CRITERIA MED CARE CH	3	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	2004	364	9443					1460	1460		10.1016/S0140-6736(04)17231-0	http://dx.doi.org/10.1016/S0140-6736(04)17231-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488224				2022-12-28	WOS:000224485300035
J	Pincock, S				Pincock, S			Herbert Bower - Obituary	LANCET			English	Biographical-Item												stephenpincock@blueyonder.co.uk		Pincock, Stephen/0000-0003-1655-2902					0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	2004	364	9443					1398	1398		10.1016/S0140-6736(04)17249-8	http://dx.doi.org/10.1016/S0140-6736(04)17249-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15517699				2022-12-28	WOS:000224485300015
J	Chihara, T; Luo, LQ				Chihara, T; Luo, LQ			Like poles repel: Molecular mechanisms of dendritic tiling	CELL			English	Editorial Material								To cover the entire sensory field once and only once, dendrites of some sensory system neurons avoid crossing other dendrites from the same type of neurons. In this issue of Cell, Emoto et al. (2004) provide first insight into the molecular mechanisms of dendritic tiling.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Chihara, T (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.		Chihara, Takahiro/G-7639-2019	Chihara, Takahiro/0000-0001-9989-3619; Luo, Liqun/0000-0001-5467-9264				Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Emoto K, 2004, CELL, V119, P245, DOI 10.1016/j.cell.2004.09.036; Gallegos ME, 2004, NEURON, V44, P239, DOI 10.1016/j.neuron.2004.09.021; Grueber WB, 2003, CURR BIOL, V13, P618, DOI 10.1016/S0960-9822(03)00207-0; Grueber WB, 2002, DEVELOPMENT, V129, P2867; Jan YN, 2003, NEURON, V40, P229, DOI 10.1016/S0896-6273(03)00631-7; Lin B, 2004, NEURON, V43, P475, DOI 10.1016/j.neuron.2004.08.002; Rockhill RL, 2002, J NEUROSCI, V22, P3831; Sugimura K, 2003, J NEUROSCI, V23, P3752	9	1	1	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2004	119	2					148	149		10.1016/j.cell.2004.10.002	http://dx.doi.org/10.1016/j.cell.2004.10.002			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479631	Bronze			2022-12-28	WOS:000224577200002
J	Glotzer, SC				Glotzer, SC			Some assembly required	SCIENCE			English	Editorial Material							GOLD NANOPARTICLES; BUILDING-BLOCKS		Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Glotzer, SC (corresponding author), Univ Michigan, Dept Chem Engn, 2300 Hayward St, Ann Arbor, MI 48109 USA.	sgtolzer@umich.edu						Blum AS, 2004, NANO LETT, V4, P867, DOI 10.1021/nl0497474; Cardoen G, 2004, MACROMOLECULES, V37, P5123, DOI 10.1021/ma049769c; Gracias DH, 2002, APPL PHYS LETT, V80, P2802, DOI 10.1063/1.1470222; Jackson AM, 2004, NAT MATER, V3, P330, DOI 10.1038/nmat1116; Laine RM, 1998, APPL ORGANOMET CHEM, V12, P715, DOI 10.1002/(SICI)1099-0739(199810/11)12:10/11<715::AID-AOC778>3.0.CO;2-0; Malikova N, 2002, LANGMUIR, V18, P3694, DOI 10.1021/la025563y; Manoharan VN, 2003, SCIENCE, V301, P483, DOI 10.1126/science.1086189; Milliron DJ, 2004, NATURE, V430, P190, DOI 10.1038/nature02695; Mokari T, 2004, SCIENCE, V304, P1787, DOI 10.1126/science.1097830; Nelson DR, 2002, NANO LETT, V2, P1125, DOI [10.1021/nl0202096, 10.1021/n10202096]; Song T, 2003, POLYMER, V44, P2529, DOI [10.1016/S0032-3861(03)00107-1, 10.1016/s0032-3861(03)00107-1]; Wang SP, 2002, NANO LETT, V2, P817, DOI [10.1021/nl0255193, 10.1021/n10255193]; Westenhoff S, 2002, J AM CHEM SOC, V124, P2448, DOI 10.1021/ja0173728; Whitesides GM, 2002, P NATL ACAD SCI USA, V99, P4769, DOI 10.1073/pnas.082065899; Zhang ZL, 2004, NANO LETT, V4, P1407, DOI 10.1021/nl0493500; Zhang ZL, 2003, NANO LETT, V3, P1341, DOI 10.1021/nl034454g	16	328	339	3	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2004	306	5695					419	420		10.1126/science.1099988	http://dx.doi.org/10.1126/science.1099988			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486279				2022-12-28	WOS:000224626500031
J	Mechelli, A; Crinion, JT; Noppeney, U; O'Doherty, J; Ashburner, J; Frackowiak, RS; Price, CJ				Mechelli, A; Crinion, JT; Noppeney, U; O'Doherty, J; Ashburner, J; Frackowiak, RS; Price, CJ			Structural plasticity in the bilingual brain - Proficiency in a second language and age at acquisition affect grey-matter density.	NATURE			English	Editorial Material							PET		Wellcome Dept Imaging Neurosci, London WC1N 3BG, England; Fdn Santa Lucia, I-00179 Rome, Italy	University of London; University College London; IRCCS Santa Lucia	Mechelli, A (corresponding author), Wellcome Dept Imaging Neurosci, 12 Queen Sq, London WC1N 3BG, England.	a.mechelli@fil.ion.ucl.ac.uk	Ashburner, John/I-3757-2013; O'Doherty, John P/F-1204-2013; Mechelli, Andrea/B-1114-2011; Frackowiak, Richard S/I-1809-2013; Crinion, Jennifer/A-1992-2019; Frackowiak, Richard/H-4383-2011	Ashburner, John/0000-0001-7605-2518; Crinion, Jennifer/0000-0001-8080-6562; Frackowiak, Richard/0000-0002-3151-822X; Price, Catherine/0000-0001-7448-4835; Noppeney, Uta/0000-0002-7697-2290	Wellcome Trust [051067] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; Golestani N, 2002, NEURON, V35, P997, DOI 10.1016/S0896-6273(02)00862-0; Good CD, 2002, NEUROIMAGE, V17, P29, DOI 10.1006/nimg.2002.1202; Kim KHS, 1997, NATURE, V388, P171, DOI 10.1038/40623; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Poline JB, 1996, NEUROIMAGE, V4, P34, DOI 10.1006/nimg.1996.0027; Warburton E, 1996, BRAIN, V119, P159, DOI 10.1093/brain/119.1.159	8	580	602	8	193	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	2004	431	7010					757	757		10.1038/431757a	http://dx.doi.org/10.1038/431757a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483594	Bronze			2022-12-28	WOS:000224435500027
J	Yernool, D; Boudker, O; Jin, Y; Gouaux, E				Yernool, D; Boudker, O; Jin, Y; Gouaux, E			Structure of a glutamate transporter homologue from Pyrococcus horikoshii	NATURE			English	Article							SCANNING MUTAGENESIS REVEALS; AMINO-ACID TRANSPORTERS; MEMBRANE TOPOLOGY; BACILLUS-STEAROTHERMOPHILUS; CONFORMATIONAL-CHANGES; ANOMALOUS DIFFRACTION; PERMEATION PATHWAY; ESCHERICHIA-COLI; REENTRANT LOOP; PROTON CURRENT	Glutamate transporters are integral membrane proteins that catalyse the concentrative uptake of glutamate from the synapse to intracellular spaces by harnessing pre-existing ion gradients. In the central nervous system glutamate transporters are essential for normal development and function, and are implicated in stroke, epilepsy and neurodegenerative diseases. Here we present the crystal structure of a eukaryotic glutamate transporter homologue from Pyrococcus horikoshii. The transporter is a bowl-shaped trimer with a solvent-filled extracellular basin extending halfway across the membrane bilayer. At the bottom of the basin are three independent binding sites, each cradled by two helical hairpins, reaching from opposite sides of the membrane. We propose that transport of glutamate is achieved by movements of the hairpins that allow alternating access to either side of the membrane.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute	Gouaux, E (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 650 W 168th St, New York, NY 10032 USA.	jeg52@columbia.edu	Gouaux, Eric/Y-4370-2019	Gouaux, Eric/0000-0002-8549-2360				Amara SG, 2002, NEUROCHEM INT, V41, P313, DOI 10.1016/S0197-0186(02)00018-9; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Bergles DE, 1999, CURR OPIN NEUROBIOL, V9, P293, DOI 10.1016/S0959-4388(99)80043-9; Borre L, 2002, J BIOL CHEM, V277, P13501, DOI 10.1074/jbc.M110861200; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dingledine R, 1999, PHARMACOL REV, V51, P7; Fairman WA, 1998, NAT NEUROSCI, V1, P105, DOI 10.1038/355; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Gendreau S, 2004, J BIOL CHEM, V279, P39505, DOI 10.1074/jbc.M408038200; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; JORDING D, 1993, MOL GEN GENET, V241, P106, DOI 10.1007/BF00280207; Kanai Y, 2003, EUR J PHARMACOL, V479, P237, DOI 10.1016/j.ejphar.2003.08.073; Kanner BI, 2002, BBA-BIOENERGETICS, V1555, P92, DOI 10.1016/S0005-2728(02)00260-8; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Larsson HP, 2004, P NATL ACAD SCI USA, V101, P3951, DOI 10.1073/pnas.0306737101; Leighton BH, 2002, J BIOL CHEM, V277, P29847, DOI 10.1074/jbc.M202508200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ryan RM, 2004, J BIOL CHEM, V279, P20742, DOI 10.1074/jbc.M304433200; Ryan RM, 2002, J BIOL CHEM, V277, P13494, DOI 10.1074/jbc.M109970200; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Seal RP, 2001, P NATL ACAD SCI USA, V98, P15324, DOI 10.1073/pnas.011400198; Slotboom DJ, 1999, MICROBIOL MOL BIOL R, V63, P293, DOI 10.1128/MMBR.63.2.293-307.1999; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 1996, J BIOL CHEM, V271, P31317, DOI 10.1074/jbc.271.49.31317; Slotboom DJ, 2001, TRENDS BIOCHEM SCI, V26, P534, DOI 10.1016/S0968-0004(01)01925-9; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOLNER B, 1995, MOL MICROBIOL, V18, P123, DOI 10.1111/j.1365-2958.1995.mmi_18010123.x; Tzingounis AV, 1998, J BIOL CHEM, V273, P17315, DOI 10.1074/jbc.273.28.17315; Wahle S, 1996, J CELL BIOL, V135, P1867, DOI 10.1083/jcb.135.6.1867; Wheal H.V., 1995, EXCITATORY AMINO ACI; Yernool D, 2003, BIOCHEMISTRY-US, V42, P12981, DOI 10.1021/bi030161q; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	50	633	643	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					811	818		10.1038/nature03018	http://dx.doi.org/10.1038/nature03018			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483603	Bronze			2022-12-28	WOS:000224435500038
J	Crown, J				Crown, J			Smart bombs versus blunderbusses: high-dose chemotherapy for breast cancer	LANCET			English	Editorial Material									St Vincents Univ Hosp, Dublin 4, Ireland	University College Dublin; Saint Vincent's University Hospital	Crown, J (corresponding author), St Vincents Univ Hosp, Elm Pk, Dublin 4, Ireland.	John.crown@icorg.ie	Crown, John/AAL-3367-2020	Crown, John/0000-0002-3125-7613				CROWN J, 2003, P AN M AM SOC CLIN, V22, pA23; DAVIDSON NE, 1992, J CLIN ONCOL, V10, P517, DOI 10.1200/JCO.1992.10.4.517; FARQUHAR C, 2003, COCHRANE LIB; Hortobagyi GN, 2004, J CLIN ONCOL, V22, P2263, DOI 10.1200/JCO.2004.02.927; NITZ UA, 2003, P AN M AM SOC CLIN, V22, pA832; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P759, DOI 10.1093/jnci/djh133; Weiss RB, 2003, J CLIN ONCOL, V21, P1825, DOI 10.1200/JCO.2003.09.006; Weiss RB, 2001, J CLIN ONCOL, V19, P2771, DOI 10.1200/JCO.2001.19.11.2771; Zander AR, 2004, J CLIN ONCOL, V22, P2273, DOI 10.1200/JCO.2004.07.026	9	10	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2004	364	9442					1299	1300		10.1016/S0140-6736(04)17207-3	http://dx.doi.org/10.1016/S0140-6736(04)17207-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474123				2022-12-28	WOS:000224349700010
J	Raoult, D; Audic, S; Robert, C; Abergel, C; Renesto, P; Ogata, H; La Scola, B; Suzan, M; Claverie, JM				Raoult, D; Audic, S; Robert, C; Abergel, C; Renesto, P; Ogata, H; La Scola, B; Suzan, M; Claverie, JM			The 1.2-megabase genome sequence of mimivirus	SCIENCE			English	Article							ORIGIN; EVOLUTION; PROTEIN; FAMILIES; DATABASE; VIRUSES	We recently reported the discovery and preliminary characterization of Mimivirus, the largest known virus, with a 400-nanometer particle size comparable to mycoplasma. Mimivirus is a double-stranded DNA virus growing in amoebae. We now present its 1,181,404-base pair genome sequence, consisting of 1262 putative open reading frames, 10% of which exhibit a similarity to proteins of known functions. In addition to exceptional genome size, Mimivirus exhibits many features that distinguish it from other nucleocytoplasmic large DNA viruses. The most unexpected is the presence of numerous genes encoding central protein-translation components, including four amino-acyl transfer RNA synthetases, peptide release factor 1, translation elongation factor EF-TU, and translation initiation factor 1. The genome also exhibits six tRNAs. Other notable features include the presence of both type I and type II topoisomerases, components of all DNA repair pathways, many polysaccharide synthesis enzymes, and one intein-containing gene. The size and complexity of the Mimivirus genome challenge the established frontier between viruses and parasitic cellular organisms. This new sequence data might help shed a new light on the origin of DNA viruses and their role in the early evolution of eukaryotes.	Univ Mediterranee, CNRS, UMR 6020, Unite Rickettsies, F-13385 Marseille 05, France; Inst Biol Struct & Microbiol, CNRS, UPR 2589, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS)	Raoult, D (corresponding author), Univ Mediterranee, CNRS, UMR 6020, Unite Rickettsies, F-13385 Marseille 05, France.	Didier.Raoult@medecine.univ-mrs.fr; Jean-Michel.Claverie@igs.cnrs-mrs.fr	renesto, patricia/T-6446-2019; Claverie, Jean Michel/Z-2183-2019; Renesto, patricia/M-6105-2014; RAOULT, Didier/A-8434-2008; Claverie, Jean-Michel/AAG-4889-2019; LA SCOLA, Bernard/P-6477-2016	renesto, patricia/0000-0002-6749-7862; RAOULT, Didier/0000-0002-0633-5974; Claverie, Jean-Michel/0000-0003-1424-0315; LA SCOLA, Bernard/0000-0001-8006-7704; Audic, Stephane/0000-0001-6193-4374; Abergel, Chantal/0000-0003-1875-4049				ABERGEL C, UNPUB; Afonso CL, 1999, J VIROL, V73, P533, DOI 10.1128/JVI.73.1.533-552.1999; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bell PJL, 2001, J MOL EVOL, V53, P251; Bresnahan WA, 2000, SCIENCE, V288, P2373, DOI 10.1126/science.288.5475.2373; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Forterre P, 2001, CR ACAD SCI III-VIE, V324, P1067, DOI 10.1016/S0764-4469(01)01403-2; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Iyer LM, 2001, J VIROL, V75, P11720, DOI 10.1128/JVI.75.23.11720-11734.2001; Kawasaki T, 2002, VIROLOGY, V302, P123, DOI 10.1006/viro.2002.1572; La Scola B, 2003, SCIENCE, V299, P2033; Lazarevic V, 1998, P NATL ACAD SCI USA, V95, P1692, DOI 10.1073/pnas.95.4.1692; LWOFF A, 1957, J GEN MICROBIOL, V17, P239, DOI 10.1099/00221287-17-2-239; Miller ES, 2003, MICROBIOL MOL BIOL R, V67, P86, DOI 10.1128/MMBR.67.1.86-156.2003; Mindell DP, 2003, SCIENCE, V302, P1677; Moran NA, 2002, CELL, V108, P583, DOI 10.1016/S0092-8674(02)00665-7; Nandhagopal N, 2002, P NATL ACAD SCI USA, V99, P14758, DOI 10.1073/pnas.232580699; OGATA H, UNPUB; Pedulla ML, 2003, CELL, V113, P171, DOI 10.1016/S0092-8674(03)00233-2; Pennisi E, 2004, SCIENCE, V305, P766, DOI 10.1126/science.305.5685.766; Pietrokovski S, 1998, CURR BIOL, V8, pR634, DOI 10.1016/S0960-9822(07)00409-5; Pietrokovski S, 2001, TRENDS GENET, V17, P465, DOI 10.1016/S0168-9525(01)02365-4; Raoult D, 2003, GENOME RES, V13, P1800, DOI 10.1101/gr.1474603; Takemura M, 2001, J MOL EVOL, V52, P419, DOI 10.1007/s002390010171; TARNAS I, 2002, SCIENCE, V296, P2376; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Van Etten JL, 2003, ANNU REV GENET, V37, P153, DOI 10.1146/annurev.genet.37.110801.143915; Van Etten JL, 1999, ANNU REV MICROBIOL, V53, P447, DOI 10.1146/annurev.micro.53.1.447; Villarreal LP, 2000, J VIROL, V74, P7079, DOI 10.1128/JVI.74.15.7079-7084.2000; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; Waters E, 2003, P NATL ACAD SCI USA, V100, P12984, DOI 10.1073/pnas.1735403100; Woese C, 1998, P NATL ACAD SCI USA, V95, P6854, DOI 10.1073/pnas.95.12.6854; YAMADA T, 1993, VIROLOGY, V197, P742, DOI 10.1006/viro.1993.1650; Zillig W, 1998, EXTREMOPHILES, V2, P131, DOI 10.1007/s007920050052	36	711	1657	4	154	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1344	1350		10.1126/science.1101485	http://dx.doi.org/10.1126/science.1101485			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15486256				2022-12-28	WOS:000225301600043
J	Benton, MJ; Tverdokhlebov, VP; Surkov, MV				Benton, MJ; Tverdokhlebov, VP; Surkov, MV			Ecosystem remodelling among vertebrates at the Permian-Triassic boundary in Russia	NATURE			English	Article							MASS EXTINCTION; BIOTIC CRISIS; SOUTH-AFRICA; BASIN; BIODIVERSITY; PATTERN; MARINE; SCALE; EVENT; LIFE	The mass extinction at the Permian - Triassic boundary, 251 million years (Myr) ago, is accepted as the most profound loss of life on record(1-3). Global data compilations indicate a loss of 50% of families or more, both in the sea(1,2,4) and on land(2,5), and these figures scale to a loss of 80 - 96% of species, based on rarefaction analyses(6,7). This level of loss is confirmed by local and regional-scale studies of marine sections(3,8), but the terrestrial record has been harder to analyse in such close detail. Here we document the nature of the event in Russia in a comprehensive survey of 675 specimens of amphibians and reptiles from 289 localities spanning 13 successive geological time zones in the South Urals basin. These changes in diversity and turnover cannot be explained simply by sampling effects. There was a profound loss of genera and families, and simplification of ecosystems, with the loss of small fish-eaters and insect-eaters, medium and large herbivores and large carnivores. Faunal dynamics also changed, from high rates of turnover through the Late Permian period to greater stability at low diversity through the Early Triassic period. Even after 15 Myr of ecosystem rebuilding, some guilds were apparently still absent - small fish-eaters, small insect-eaters, large herbivores and top carnivores.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Saratov NG Chernyshevskii State Univ, Inst Geol, Saratov 410075, Russia	University of Bristol; Saratov State University	Benton, MJ (corresponding author), Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England.	mike.benton@bris.ac.uk	Benton, Michael J/A-5639-2008	Benton, Michael J/0000-0002-4323-1824				Benton MJ, 1996, P ROY SOC B-BIOL SCI, V263, P641, DOI 10.1098/rspb.1996.0096; Benton MJ, 2003, TRENDS ECOL EVOL, V18, P358, DOI 10.1016/S0169-5347(03)00093-4; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; BENTON MJ, 2003, LIFE NEARLY DIED; Berner RA, 2002, P NATL ACAD SCI USA, V99, P4172, DOI 10.1073/pnas.032095199; Bowring SA, 1998, SCIENCE, V280, P1039, DOI 10.1126/science.280.5366.1039; CASSINIS G, 2002, PERMOPHILES, V40, P4; ERWIN DH, 1994, NATURE, V367, P231, DOI 10.1038/367231a0; GRADSTEIN FM, IN PRESS GEOLOGIC TI; Jablonski D., 1986, P183; Jin YG, 1997, EPISODES, V20, P10; Jin YG, 2000, SCIENCE, V289, P432, DOI 10.1126/science.289.5478.432; KOZUR HW, 2003, ALBERTIANA, V28, P570; MAXWELL WD, 1992, PALAEONTOLOGY, V35, P571; MCKINNEY ML, 1995, PALEOBIOLOGY, V21, P300, DOI 10.1017/S0094837300013312; Michaelsen P, 2002, PALAEOGEOGR PALAEOCL, V179, P173, DOI 10.1016/S0031-0182(01)00413-8; Mundil R, 2001, EARTH PLANET SC LETT, V187, P131, DOI 10.1016/S0012-821X(01)00274-6; Newell AJ, 1999, SEDIMENT GEOL, V127, P11, DOI 10.1016/S0037-0738(99)00009-3; Ogg JG, 2004, LETHAIA, V37, P183, DOI 10.1080/00241160410006492; Peters SE, 2001, PALEOBIOLOGY, V27, P583, DOI 10.1666/0094-8373(2001)027<0583:BITPAR>2.0.CO;2; RAUP DM, 1979, SCIENCE, V206, P217, DOI 10.1126/science.206.4415.217; RAUP DM, 1991, ANAL PALEOBIOLOGY SH, V4, P207; Sepkoski J.J., 1996, GLOBAL EVENT STRATIG, P35, DOI [10.1007/978-3-642-79634-0_4, DOI 10.1007/978-3-642-79634-0_4]; Smith AB, 2001, PHILOS T R SOC B, V356, P351, DOI 10.1098/rstb.2000.0768; Smith RMH, 2001, GEOLOGY, V29, P1147, DOI 10.1130/0091-7613(2001)029<1147:POVEAA>2.0.CO;2; Tverdokhlebov VP, 2003, EARTH-SCI REV, V60, P1, DOI 10.1016/S0012-8252(02)00076-4; TVERDOKHLEBOV VP, 2004, IN PRESS EARTH SCI R; Twitchett RJ, 2001, GEOLOGY, V29, P351, DOI 10.1130/0091-7613(2001)029<0351:RASCOM>2.0.CO;2; Ward PD, 2000, SCIENCE, V289, P1740, DOI 10.1126/science.289.5485.1740; Wignall PB, 1996, SCIENCE, V272, P1155, DOI 10.1126/science.272.5265.1155	30	213	222	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	2004	432	7013					97	100		10.1038/nature02950	http://dx.doi.org/10.1038/nature02950			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525988	Green Published			2022-12-28	WOS:000224854900047
J	Feany, MB				Feany, MB			New genetic insights into Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Dept Pathol, Div Neuropathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Feany, MB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Div Neuropathol, 75 Francis St, Boston, MA 02115 USA.			Feany, Mel/0000-0003-0315-7970				Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Nussbaum RL, 2003, NEW ENGL J MED, V348, P2588; Scherzer CR, 2004, TRENDS GENET, V20, P273, DOI 10.1016/j.tig.2004.05.005; Vila M, 2004, NAT MED, V10, pS58, DOI 10.1038/nm1068; Wong KD, 2004, MOL GENET METAB, V82, P192, DOI 10.1016/j.ymgme.2004.04.011	5	41	45	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1937	1940		10.1056/NEJMp048263	http://dx.doi.org/10.1056/NEJMp048263			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525720				2022-12-28	WOS:000224851300005
J	Ioannidis, JPA; Ralston, SH; Bennett, ST; Brandi, ML; Grinberg, D; Karassa, FB; Langdahl, B; van Meurs, JBJ; Mosekilde, L; Scollen, S; Albagha, OME; Bustamante, M; Carey, AH; Dunning, AM; Enjuanes, A; van Leeuwen, JPTM; Mavilia, C; Masi, L; McGuigan, FEA; Nogues, X; Pols, HAP; Reid, DM; Schuit, SCE; Sherlock, RE; Uitterlinden, AG				Ioannidis, JPA; Ralston, SH; Bennett, ST; Brandi, ML; Grinberg, D; Karassa, FB; Langdahl, B; van Meurs, JBJ; Mosekilde, L; Scollen, S; Albagha, OME; Bustamante, M; Carey, AH; Dunning, AM; Enjuanes, A; van Leeuwen, JPTM; Mavilia, C; Masi, L; McGuigan, FEA; Nogues, X; Pols, HAP; Reid, DM; Schuit, SCE; Sherlock, RE; Uitterlinden, AG		GENOMOS Study	Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MINERAL DENSITY; RECEPTOR-ALPHA GENE; MYOCARDIAL-INFARCTION; POSTMENOPAUSAL WOMEN; REPEAT POLYMORPHISM; FRACTURE RISK; METAANALYSIS; ASSOCIATION; SUSCEPTIBILITY; HAPLOTYPE	Context Both bone mineral density (BMD) and fracture risk have a strong genetic component. Estrogen receptor alpha (ESR1) is a candidate gene for osteoporosis, but previous studies of ESR1 polymorphisms in this field were hampered by small sample size, lack of standardization, and inconclusive results. Objective To generate large-scale evidence on whether 3 common ESR1 polymorphisms (intron 1 polymorphisms Xbal [dbSNP: rs9340799] and Pvull [dbSNP: rs2234693] and promoter TA repeats microsatellite) and haplotypes thereof are associated with BMD and fractures. Design and Setting Meta-analysis of individual-level data involving standardized genotyping of 18 917 individuals in 8 European centers. Main Outcome Measures BMD of femoral neck and lumbar spine; all fractures and vertebral fractures by genotype. Results No between-center heterogeneity was observed for any outcome in any genetic contrast. None of the 3 polymorphisms or haplotypes had any statistically significant effect on BMD in adjusted or unadjusted analyses, and estimated differences between genetic contrasts were 0.01 g/cm(2) or less. Conversely, we found significant reductions in fracture risk. In women homozygous for the absence of an Xbal recognition site, the adjusted odds of all fractures were reduced by 19% (odds ratio, 0.81 [95% Cl, 0.71-0.93]; P=.002) and vertebral fractures by 35% (odds ratio, 0.65 [95% Cl, 0.49-0.87]; P=.003). Effects on fractures were independent of BMD and unaltered in adjusted analyses. No significant effects on fracture risk were seen for Pvull and TA repeats. Conclusions ESR1 is a susceptibility gene for fractures, and Xbal determines fracture risk by mechanisms independent of BMD. Our study demonstrates the value of adequately powered studies with standardized genotyping and clinical outcomes in defining effects of common genetic variants on complex diseases.	Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin & Mol Epidemiol Unit, GR-45110 Ioannina, Greece; Fdn Res & Technol Hellas, Inst Biomed Res, Ioannina, Greece; Tufts Univ, Sch Med, Tufts New England Med Ctr, Dept Med, Boston, MA 02111 USA; Univ Aberdeen, Sch Med, Inst Med Sci, Aberdeen AB9 2ZD, Scotland; Oxagen Ltd, Abingdon, Oxon, England; Univ Florence, Dept Internal Med, Florence, Italy; Univ Barcelona, Fac Biol, Dept Genet, Barcelona, Spain; Aarhus Univ Hosp, Dept Endocrinol & Metab, DK-8000 Aarhus, Denmark; Erasmus Univ MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands; Erasmus Univ MC, Dept Internal Med, Rotterdam, Netherlands; Strangeways Res Lab, Cambridge CB1 4RN, England; UAB, Hosp del Mar, IMIM, Barcelona, Spain	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); Tufts Medical Center; Tufts University; University of Aberdeen; Oxagen Limited; University of Florence; University of Barcelona; Aarhus University; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin & Mol Epidemiol Unit, GR-45110 Ioannina, Greece.	jioannid@cc.uol.gr	Bustamante, Mariona/ABB-9142-2021; ENJUANES, Anna/H-3245-2015; Grinberg, Daniel/F-3641-2010; van Leeuwen, Johannes/D-5015-2014; Karassa, Fotini/AAG-5040-2020; Ioannidis, John P. A./G-9836-2011	Bustamante, Mariona/0000-0003-0127-2860; ENJUANES, Anna/0000-0002-4679-6687; Grinberg, Daniel/0000-0001-9859-2590; van Leeuwen, Johannes/0000-0002-2282-4006; van Meurs, Joyce/0000-0001-6245-2123; Nogues, Xavier/0000-0002-5537-1859; Dunning, Alison Margaret/0000-0001-6651-7166; Nogues, Xavier/0000-0001-8201-9933; Scollen, Serena/0000-0002-9311-1337				Albagha OME, 2001, J BONE MINER RES, V16, P128, DOI 10.1359/jbmr.2001.16.1.128; Becherini L, 2000, HUM MOL GENET, V9, P2043, DOI 10.1093/hmg/9.13.2043; Bergink AP, 2003, ARTHRITIS RHEUM, V48, P1913, DOI 10.1002/art.11046; Bogardus ST, 1999, JAMA-J AM MED ASSOC, V281, P1919, DOI 10.1001/jama.281.20.1919; Chen HY, 2001, MATURITAS, V40, P143, DOI 10.1016/S0378-5122(01)00233-X; Cooper GS, 1996, J BONE MINER RES, V11, P1841; Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001-2002; Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002-9343(01)01124-X; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Efstathiadou Z, 2001, J BONE MINER RES, V16, P1586, DOI 10.1359/jbmr.2001.16.9.1586; Herrington DM, 2002, CIRCULATION, V105, P1879, DOI 10.1161/01.CIR.0000016173.98826.88; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Ioannidis JPA, 2002, J BONE MINER RES, V17, P2048, DOI 10.1359/jbmr.2002.17.11.2048; Ioannidis JPA, 2001, ANN INTERN MED, V135, P782, DOI 10.7326/0003-4819-135-9-200111060-00008; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Ioannidis JPA, 2002, AM J EPIDEMIOL, V156, P204, DOI 10.1093/aje/kwf031; Ioannidis JPA, 2003, TRENDS MOL MED, V9, P135, DOI 10.1016/S1471-4914(03)00030-3; KALENDER WA, 1995, EUR J RADIOL, V20, P83, DOI 10.1016/0720-048X(95)00631-Y; Keavney B, 2003, LANCET, V361, P396, DOI 10.1016/S0140-6736(03)12386-0; Keavney B, 2000, LANCET, V355, P434; Langdahl BL, 2000, J BONE MINER RES, V15, P2222, DOI 10.1359/jbmr.2000.15.11.2222; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; MCCLOSKEY EV, 1993, OSTEOPOROSIS INT, V3, P138, DOI 10.1007/BF01623275; Nguyen TV, 2000, J BONE MINER RES, V15, P392, DOI 10.1359/jbmr.2000.15.3.392; PETTITI D, 1999, META ANAL DECISION A; Ralston SH, 2002, J CLIN ENDOCR METAB, V87, P2460, DOI 10.1210/jc.87.6.2460; SANO M, 1995, BIOCHEM BIOPH RES CO, V217, P378, DOI 10.1006/bbrc.1995.2787; Schuit SCE, 2004, JAMA-J AM MED ASSOC, V291, P2969, DOI 10.1001/jama.291.24.2969; Schuit SCE, 2004, J CLIN ENDOCR METAB, V89, P303, DOI 10.1210/jc.2003-031095; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Torgerson DJ, 1996, J BONE MINER RES, V11, P293; van Meurs JBJ, 2003, HUM MOL GENET, V12, P1745, DOI 10.1093/hmg/ddg176; Weel AEAM, 1999, J CLIN ENDOCR METAB, V84, P3146, DOI 10.1210/jc.84.9.3146	34	241	265	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2004	292	17					2105	2114		10.1001/jama.292.17.2105	http://dx.doi.org/10.1001/jama.292.17.2105			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868OC	15523071				2022-12-28	WOS:000224921900023
J	Cooper, RA				Cooper, RA			Weighing the evidence for expanding physician supply	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HEALTH-CARE; UNITED-STATES; NURSE-PRACTITIONERS; MEDICAL-SCHOOL; POSTSECONDARY EDUCATION; NONPHYSICIAN CLINICIAN; PROJECTED WORKFORCE; REGIONAL-VARIATIONS; PATIENT-CARE; SHORTAGE	For 2 decades, health planners have forecasted impending physician surpluses, and policy decisions related to medical schools and residency programs have been based on such expectations. However, these much-heralded surpluses never materialized, and a growing body of data and opinion now point in the other direction. The question at the forefront is whether the United States is instead headed for a physician shortage. What is the evidence? This paper reviews the trends that link economic growth to health care spending and to the demand for physicians. It assesses the current environment by examining trends in the characteristics of clinical practice, signals from the medical market, and recent experiences of physician shortages in other English-speaking countries; it also discusses why past forecasting approaches may have failed. Taken together, this body of information indicates that physician shortages are emerging and that they will probably worsen over the next 2 decades. By 2020 or 2025, the deficit could be as great as 200 000 physicians-20% of the needed workforce. If remedies are to be found, the nature of the problem must be appreciated, and a consensus to solve it must be reached.	Med Coll Wisconsin, Hlth Policy Inst, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Cooper, RA (corresponding author), Med Coll Wisconsin, Hlth Policy Inst, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	rcooper@mcw.edu						AARON HJ, 2003, HLTH AFFAIRS WE 0108, DOI DOI 10.1377/H6THAFF.W3.28; *ABT ASS INC, 1991, REEX AD PHYS S MAD 1; ALTMAN DE, 2002, HLTH AFFAIRS WE 0123, DOI DOI 10.1377/H6THAFF.W2.83; ALTMAN SH, 2003, HLTH AFFAIRS WE 0108; *AM ASS COLL OST M, 1997, CONS STAT PHYS WORKF; *AM MED ASS, 1997, MED DIR IND MED ED C; *AM MED ASS, 2003, AM REV POL ADDR CONT; *AM MED ASS, 2001, PHYS SOC STAT 2000 2; *AM OST ASS, 2002, STAT OST PHYS; Anderson GF, 2003, HEALTH AFFAIR, V22, P89, DOI 10.1377/hlthaff.22.3.89; Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762; *ASS AM MED COLL, 2002, PHYS WORKF POS STAT; Barer M, 2002, HEALTH AFFAIR, V21, P169, DOI 10.1377/hlthaff.21.1.169; Blumenthal D, 2004, NEW ENGL J MED, V350, P1780, DOI 10.1056/NEJMhpr033066; Brennan T., 1996, NEW RULES REGULATION; *BUR EC AN, 2002, NAT INC PROD ACC GRO; CHAN B, 2003, P 7 INT MED WORKF C; Chernew ME, 2003, HEALTH AFFAIR, V22, P15, DOI 10.1377/hlthaff.22.4.15; Cherry D. K., 2003, ADV DATA VITAL HLTH; COHEN JJ, 2004, COMMUNICATION   0712; Cooper R A, 1994, Internist, V35, P10; Cooper RA, 2003, MILBANK Q, V81, P107, DOI 10.1111/1468-0009.00040; COOPER RA, 1994, JAMA-J AM MED ASSOC, V272, P680, DOI 10.1001/jama.272.9.680; Cooper RA, 2002, HEALTH AFFAIR, V21, P140, DOI 10.1377/hlthaff.21.1.140; Cooper RA, 2003, ACAD MED, V78, P855, DOI 10.1097/00001888-200309000-00003; Cooper RA, 2003, ACAD MED, V78, P864, DOI 10.1097/00001888-200309000-00004; Cooper RA, 2003, HEALTH AFFAIR, V22, P71, DOI 10.1377/hlthaff.22.4.71; Cooper RA, 2003, HEALTH SERV RES, V38, P675, DOI 10.1111/1475-6773.00139; Cooper RA, 2002, HEALTH AFFAIR, V21, P279, DOI 10.1377/hlthaff.21.3.279; Cooper RA, 2002, ACAD MED, V77, P761, DOI 10.1097/00001888-200208000-00002; COOPER RA, 1995, JAMA-J AM MED ASSOC, V274, P1534, DOI 10.1001/jama.274.19.1534; Cooper RA, 1998, JAMA-J AM MED ASSOC, V280, P788, DOI 10.1001/jama.280.9.788; Cooper RA, 1998, JAMA-J AM MED ASSOC, V280, P795, DOI 10.1001/jama.280.9.795; COOPER RA, 2000, EVALUATION SPECIALTY; Cooper Richard, 2004, J Health Serv Res Policy, V9 Suppl 1, P39, DOI 10.1258/135581904322724121; *COUNC GRAD MED ED, 1994, 4 COUNC GRAD MED ED; *COUNC GRAD MED ED, 2003, REASS PHYS WORKF POL; *CTR HLTH WORKF ST, 2003, PHYS S DEM IND NEW Y; CUTLER DM, 2001, HEALTH AFFAIR, V20, P11; ERNST RL, 1985, PHYS LOCATION SPECIA; Evans R., 1974, EC HLTH MED CARE; Evans S, 2002, ARCH SURG-CHICAGO, V137, P274, DOI 10.1001/archsurg.137.3.274; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; FOLLAND S, 2000, EC HLTH HLTH CARE, P204; FUCHS VR, 1978, J HUM RESOUR, V13, P35, DOI 10.2307/145247; GAMLIEL S, 1995, HEALTH AFFAIR, V14, P131, DOI 10.1377/hlthaff.14.2.131; GAVEL P, 2003, P 7 INT MED WORKF C; Getzen T E, 1990, Adv Health Econ Health Serv Res, V11, P27; GETZEN TE, 1992, J GERONTOL, V47, pS98, DOI 10.1093/geronj/47.3.S98; Getzen TE, 2000, J HEALTH ECON, V19, P259, DOI 10.1016/S0167-6296(99)00032-6; GETZEN TE, 2000, J HLTH CARE FINANCIN, V263, P56; GINZBERG E, 1989, HEALTH AFFAIR, V8, P84, DOI 10.1377/hlthaff.8.2.84; GINZBERG E, 1966, NEW ENGL J MED, V275, P85, DOI 10.1056/NEJM196607142750207; *GRAD 7ED ED NAT C, 1908, DHHS PUBL; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; Grumbach K, 2002, HEALTH AFFAIR, V21, P155, DOI 10.1377/hlthaff.21.1.155; Hecker DE, 2004, MON LABOR REV, V127, P80; HEFFLER S, 2003, HLTH AFF S; HOLTZEAKIN D, 2004, MEDICARES LONG TERM; *I MED, 1996, NAT PHYS WORKF OPT B; Institute of Medicine, 2000, ERR IS HUM BUILD SAF; JOSIAH M, 1992, FDN REP J MACY JR FD; Lee R. I., 1933, FUNDAMENTALS GOOD ME; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; MCGUIRE TG, 1991, J HEALTH ECON, V10, P385, DOI 10.1016/0167-6296(91)90022-F; McNeil BJ, 2001, NEW ENGL J MED, V345, P1612, DOI 10.1056/NEJMsa011810; Mechanic D, 2001, NEW ENGL J MED, V344, P198, DOI 10.1056/NEJM200101183440307; *MED PAYM ADV COMM, 2002, 2002 SURV PHYS MED P; Merritt J, 2004, WILL LAST PHYS AM PL; Miller RD, 2001, MAYO CLIN PROC, V76, P969, DOI 10.4065/76.10.969; Mitchell JM, 2000, MED CARE, V38, P1029, DOI 10.1097/00005650-200010000-00007; Mullan F, 2002, HEALTH AFFAIR, V21, P158, DOI 10.1377/hlthaff.21.1.158; Mullan F, 1998, HEALTH AFFAIR, V17, P118, DOI 10.1377/hlthaff.17.2.118; Mundinger MO, 2000, JAMA-J AM MED ASSOC, V283, P59, DOI 10.1001/jama.283.1.59; *NAT CTR HLTH WORK, 2002, PROJ SUPPL DEM SHORT; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; Nordhaus WD, 2003, MEASURING THE GAINS FROM MEDICAL RESEARCH, P9; *OFF ACT, 2003, PROJ NAT HLTH EXP ME; PASKO T, 2003, PHYS CHARACTERISTICS; Pauly MV, 2003, HLTH AFFAIRS WE 0108, pw3, DOI [10.1377/hlthaff.w3.15, DOI 10.1377/HLTHAFF.W3.15]; Petersdorf R G, 1994, Internist, V35, P7; PETERSDORF RG, 1978, NEW ENGL J MED, V299, P628, DOI 10.1056/NEJM197809212991204; Pew Health Professions Commission, 1995, CRIT CHALL REV HLTH; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; *PHYS PAYM REV COM, 1994, ANN REP C 1994, P237; Politzer RM, 1996, INQUIRY-J HEALTH CAR, V33, P181; Reinhardt U, 1997, JAMA, V277, P69, DOI 10.1001/jama.277.1.69; Reinhardt UE, 2002, HEALTH AFFAIR, V21, P165, DOI 10.1377/hlthaff.21.1.165; Reinhardt UE, 2004, HEALTH AFFAIR, V23, P10, DOI 10.1377/hlthaff.23.3.10; Reinhardt UE, 2003, HEALTH AFFAIR, V22, P27, DOI 10.1377/hlthaff.22.6.27; Reinhardt UE, 1999, JAMA-J AM MED ASSOC, V281, P462, DOI 10.1001/jama.281.5.462; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; SCHWARTZ WB, 1988, NEW ENGL J MED, V318, P892, DOI 10.1056/NEJM198804073181405; Singer A, 2001, J Am Osteopath Assoc, V101, P646; SOX HC, 1979, ANN INTERN MED, V91, P459, DOI 10.7326/0003-4819-91-3-459; Sox HC, 2000, JAMA-J AM MED ASSOC, V283, P106, DOI 10.1001/jama.283.1.106; Stegemerten G. J., 1927, TIME MOTION STUDY FO; STRUNK BC, 2003, HLTH AFFAIRS WE 0611, DOI DOI 10.1377/H6THAFF.W3.266; STRUNK BG, 2003, DATA B, V26; Tarlov A R, 1986, Health Aff (Millwood), V5, P23, DOI 10.1377/hlthaff.5.1.23; Topel R, 2003, MEASURING GAINS MED; TRUDE S, 2002, GROW PHYS ACC PROBL; Wanless, 2002, SECURING OUR FUTURE; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENNBERG JE, 1992, TECHNOLOGY HLTH CARE; Wilensky G R, 1997, JAMA, V277, P73, DOI 10.1001/jama.277.1.73; *WORKF AN BRANCH B, 2003, CHANG DEM IMPL PHYS; Wynia MK, 2003, HEALTH AFFAIR, V22, P190, DOI 10.1377/hlthaff.22.4.190; YOUNG R, 2003, INT MARKET MED DOCT; Zuger A, 2004, NEW ENGL J MED, V350, P69, DOI 10.1056/NEJMsr031703; [No title captured]	113	137	137	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2004	141	9					705	714		10.7326/0003-4819-141-9-200411020-00012	http://dx.doi.org/10.7326/0003-4819-141-9-200411020-00012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867JT	15520427				2022-12-28	WOS:000224839600007
J	Gabbay, J; le May, A				Gabbay, J; le May, A			Evidence based guidelines or collectively constructed "mindlines?" - Ethnographic study of knowledge management in primary care	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; HEALTH; RULES; THUMB	Objective To explore in depth how primary care clinicians (general practitioners and practice nurses) derive their individual and collective healthcare decisions. Design Ethnographic study using standard methods (non-participant observation, semistructured interviews. and documentary review) over two years to collect data, which were analysed thematically. Setting Two general practices, one in the south of England and the other in the north of England. Participants Nine doctors, three nurses, one phlebotomist, and associated medical staff in one practice provided the initial data; the emerging model was checked for transferability with general practitioners in the second practice. Results Clinicians rarely accessed and used explicit evidence from research or other sources directly, but relied on "mindlines"-collectively reinforced, internalised, tacit guidelines. These were informed by brief reading but mainly by their own and their colleagues' experience, their interactions with each other and with opinion leaders, patients, and pharmaceutical representatives, and other Sources Of largely tacit knowledge. Mediated by organisational demands and constraints, mindlines were iteratively negotiated with a variety of key actors, often through a range of informal interactions in fluid "communities of practice," resulting in socially constructed "knowledge in practice." Conclusions These findings highlight the potential advantage of exploiting existing formal and informal networking as a key to conveying evidence to clinicians.	Univ Southampton, Wessex Inst Hlth Res & Dev, Southampton SO16 7PX, Hants, England; Univ Southampton, Sch Nursing & Midwifery, Southampton SO9 5NH, Hants, England	University of Southampton; University of Southampton	Gabbay, J (corresponding author), Univ Southampton, Wessex Inst Hlth Res & Dev, Southampton SO16 7PX, Hants, England.	j.gabbay@soton.ac.uk						Agar M., 1996, PROFESSIONAL STRANGE; Andre M, 2003, FAM PRACT, V20, P514, DOI 10.1093/fampra/cmg503; Andre M, 2002, FAM PRACT, V19, P617, DOI 10.1093/fampra/19.6.617; [Anonymous], 1988, SCI ACTION FOLLOW SC; Brown JS, 1991, ORGAN SCI, V2, P40, DOI 10.1287/orsc.2.1.40; BROWN JS, 2000, SOCIAL LIFE INFORMAT; CALLON M, 1986, SOCIOLOGICAL REV MON, V32; CATLON M, 1986, SOCIOLOGICAL REV MON, V32; Choo C.W., 1998, KNOWING ORG ORG USE; Coleman J. S., 1966, MED INNOVATION DIFFU; Davenport T., 1998, WORKING KNOWLEDGE; Dopson S, 2002, HEALTH CARE MANAGE R, V27, P35, DOI 10.1097/00004010-200207000-00005; Eriksen T. H., 2001, SMALL PLACES LARGE I; Ferlie E, 2000, J Health Serv Res Policy, V5, P96; Fitzgerald L, 2002, HUM RELAT, V55, P1429, DOI 10.1177/001872602128782213; Gabbay J, 2003, HEALTH, V7, P283, DOI 10.1177/1363459303007003003; Haines A., 1998, GETTING RES PRACTICE; Hamm RM, 2003, THINKING PSYCHOL PER, P315; LAVE J, 1986, SOCIOLOGICAL REV MON, V32; Le May A, 1998, J ADV NURS, V28, P428, DOI 10.1046/j.1365-2648.1998.00634.x; Lincoln Y, 1985, NATURALISTIC ENQUIRY; Locock L, 2001, SOC SCI MED, V53, P745, DOI 10.1016/S0277-9536(00)00387-7; Muir Gray JA, 1998, EVIDENCE BASED HEALT; Nonaka I., 1995, KNOWLEDGE CREATION C; Polanyi M., 2009, TACIT DIMENSION; Polanyi M., 2005, PERSONAL KNOWLEDGE P; Pope C, 2003, HEALTH-LONDON, V7, P267, DOI 10.1177/1363459303007003002; Spradley J., 1979, ETHNOGRAPHIC INTERVI; Trinder L., 2000, EVIDENCE BASED PRACT, P1; Weick K.E., 1995, SENSEMAKING ORG; Wenger Etienne., 1998, COMMUNITIES PRACTICE, V18th ed	31	557	563	3	87	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 30	2004	329	7473					1013	1016A		10.1136/bmj.329.7473.1013	http://dx.doi.org/10.1136/bmj.329.7473.1013			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514347	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000224852400022
J	Garner, P; Meremikwu, M; Volmink, J; Xu, Q; Smith, H				Garner, P; Meremikwu, M; Volmink, J; Xu, Q; Smith, H			Putting evidence into practice: how middle and low income countries "get it together"	BRITISH MEDICAL JOURNAL			English	Article							QUALITY; CARE; MALARIA		Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Res Grp, Liverpool L3 5QA, Merseyside, England; Univ Calabar, Inst Trop Dis Res & Prevent, Calabar, Cross River Sta, Nigeria; Univ Cape Town, Fac Hlth Sci, ZA-7925 Cape Town, South Africa; Fudan Univ, Med Ctr, Sch Publ Hlth, Dept Maternal & Child Hlth, Shanghai 200433, Peoples R China	Liverpool School of Tropical Medicine; University of Liverpool; University of Calabar; University of Cape Town; Fudan University	Garner, P (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Res Grp, Liverpool L3 5QA, Merseyside, England.	pgarner@liv.ac.uk	Garner, Paul/Y-8385-2019; Garner, Paul/HII-5856-2022; Meremikwu, Martin/AAO-6421-2020; smith, helen/F-4033-2014	Garner, Paul/0000-0002-0607-6941; smith, helen/0000-0002-6252-3793				Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Attaran A, 2004, LANCET, V363, P237, DOI 10.1016/S0140-6736(03)15330-5; Clarke M, 2000, JAMA-J AM MED ASSOC, V284, P1785, DOI 10.1001/jama.284.14.1785; Eisenberg JM, 2002, HEALTH AFFAIR, V21, P166, DOI 10.1377/hlthaff.21.3.166; *GLOB PROGR EV HLT, 2003, EIPGPEEQC20031; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Harvey G, 2003, QUAL SAF HEALTH CARE, V12, P210, DOI 10.1136/qhc.12.3.210; Ivers N, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000259.PUB3; Kim Y, 2001, COCHRANE DB SYST REV; McIntosh HM, 2000, COCHRANE DB SYST REV; Olliaro P., 2003, COCHRANE DB SYST REV, V2, pCD000016; Smith H, 2004, SAMJ S AFR MED J, V94, P117; SMITH H, 2003, BRIT J MIDWIFERY, V11, P502; Thomson O'Brien MA., 2000, COCHRANE DB SYST REV, V2; *WHO CHILD AD HLTH, OR REH SALTS ORS NEW	17	36	36	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 30	2004	329	7473					1036	1039		10.1136/bmj.329.7473.1036	http://dx.doi.org/10.1136/bmj.329.7473.1036			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514355	Green Accepted, Green Published			2022-12-28	WOS:000224852400032
J	Smith, JD; Cappa, CD; Wilson, KR; Messer, BM; Cohen, RC; Saykally, RJ				Smith, JD; Cappa, CD; Wilson, KR; Messer, BM; Cohen, RC; Saykally, RJ			Energetics of hydrogen bond network rearrangements in liquid water	SCIENCE			English	Article							ABSORPTION FINE-STRUCTURE; MOLECULAR-DYNAMICS; COMPUTER-SIMULATIONS; SPECTROSCOPY; TEMPERATURES; H2O	A strong temperature dependence of oxygen K-edge x-ray absorption fine structure features was observed for supercooled and normal liquid water droplets prepared from the breakup of a liquid microjet. Analysis of the data over the temperature range 251 to 288 kelvin (-22degrees to +15degreesC) yields a value of 1.5+/-0.5 kilocalories per mote for the average thermal energy required to effect an observable rearrangement between the fully coordinated ("ice-like") and distorted ("broken-donor") local hydrogen-bonding configurations responsible for the pre-edge and post-edge features, respectively. This energy equals the latent heat of melting of ice with hexagonal symmetry (ice 1=lh) and is consistent with the distribution of hydrogen bond strengths obtained for the "overstructured" ST2 model of water.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Saykally, RJ (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	saykally@berkeley.edu	Cohen, Ronald C/A-8842-2011	Cohen, Ronald C/0000-0001-6617-7691; Cappa, Christopher/0000-0002-3528-3368; SAYKALLY, RICHARD/0000-0001-8942-3656				Bergmann U, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.092107; Bluhm H, 2002, J PHYS-CONDENS MAT, V14, pL227, DOI 10.1088/0953-8984/14/8/108; BLUMBERG RL, 1984, J CHEM PHYS, V80, P5230, DOI 10.1063/1.446593; CORBAN R, 1992, BER BUNSEN PHYS CHEM, V96, P1463, DOI 10.1002/bbpc.19920961022; GEIGER A, 1982, PHYS REV LETT, V49, P1749, DOI 10.1103/PhysRevLett.49.1749; Guo JH, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.137402; HARE DE, 1990, J CHEM PHYS, V93, P6954, DOI 10.1063/1.459472; Hetenyi B, 2004, J CHEM PHYS, V120, P8632, DOI 10.1063/1.1703526; Jeffrey G. A., 1997, INTRO HYDROGEN BONDI, P11, DOI DOI 10.1246/CL.2012.65; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kuo IFW, 2004, SCIENCE, V303, P658, DOI 10.1126/science.1092787; LUZAR A, 1993, J CHEM PHYS, V98, P8160, DOI 10.1063/1.464521; Myneni S, 2002, J PHYS-CONDENS MAT, V14, pL213, DOI 10.1088/0953-8984/14/8/106; Sorenson JM, 2000, J CHEM PHYS, V113, P9149, DOI 10.1063/1.1319615; STANLEY HE, 1980, J CHEM PHYS, V73, P3404, DOI 10.1063/1.440538; STILLINGER FH, 1974, J CHEM PHYS, V60, P1545, DOI 10.1063/1.1681229; STILLINGER FH, 1980, SCIENCE, V209, P451, DOI 10.1126/science.209.4455.451; Suresh SJ, 2000, J CHEM PHYS, V113, P9727, DOI 10.1063/1.1320822; Wernet P, 2004, SCIENCE, V304, P995, DOI 10.1126/science.1096205; Wilson KR, 2004, REV SCI INSTRUM, V75, P725, DOI 10.1063/1.1645656; Wilson KR, 2002, J PHYS-CONDENS MAT, V14, pL221, DOI 10.1088/0953-8984/14/8/107	21	445	455	2	192	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					851	853		10.1126/science.1102560	http://dx.doi.org/10.1126/science.1102560			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514152				2022-12-28	WOS:000224969400040
J	Yarger, JL; Wolf, GH				Yarger, JL; Wolf, GH			Chemistry - Polymorphism in liquids	SCIENCE			English	Editorial Material									Univ Wyoming, Dept Chem, Laramie, WY 82071 USA; Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA	University of Wyoming; Arizona State University; Arizona State University-Tempe	Yarger, JL (corresponding author), Univ Wyoming, Dept Chem, Laramie, WY 82071 USA.	yarger@uwyo.edu; gwolf@asu.edu	Yarger, Jeffery L/L-8748-2014	Yarger, Jeffery L/0000-0002-7385-5400				AASLAND S, 1994, NATURE, V369, P633, DOI 10.1038/369633a0; Angell CA, 2004, ANNU REV PHYS CHEM, V55, P559, DOI 10.1146/annurev.physchem.55.091602.094156; BRAZHKIN VV, 2001, NATO SCI SERIES, V2; Buldyrev S, 2002, PHYSICA A, V304, P23, DOI 10.1016/S0378-4371(01)00566-0; Katayama Y, 2004, SCIENCE, V306, P848, DOI 10.1126/science.1102735; Kurita R, 2004, SCIENCE, V306, P845, DOI 10.1126/science.1103073; LANTZKY K, UNPUB; MCMILLAN PF, 2004, J MATER CHEM, V14, P1; Roberts CJ, 1996, J CHEM PHYS, V105, P658, DOI 10.1063/1.471922	9	47	47	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2004	306	5697					820	821		10.1126/science.1104417	http://dx.doi.org/10.1126/science.1104417			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514145				2022-12-28	WOS:000224969400032
J	Lockley, SW; Cronin, JW; Evans, EE; Cade, BE; Lee, CJ; Landrigan, CP; Rothschild, JM; Katz, JT; Lilly, CM; Stone, PH; Aeschbach, D; Czeisler, CA				Lockley, SW; Cronin, JW; Evans, EE; Cade, BE; Lee, CJ; Landrigan, CP; Rothschild, JM; Katz, JT; Lilly, CM; Stone, PH; Aeschbach, D; Czeisler, CA		Harvard Work Hours, Hlth Safety Gr	Effect of reducing interns' weekly work hours on sleep and attentional failures	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATIONAL-SURVEY; RESIDENT; FATIGUE; PERFORMANCE; LIMITATIONS; RESTRICTION; DEPRIVATION; WAKEFULNESS; IMPACT; LIGHT	BACKGROUND: Knowledge of the physiological effects of extended (24 hours or more) work shifts in postgraduate medical training is limited. We aimed to quantify work hours, sleep, and attentional failures among first-year residents (postgraduate year 1) during a traditional rotation schedule that included extended work shifts and during an intervention schedule that limited scheduled work hours to 16 or fewer consecutive hours. METHODS: Twenty interns were studied during two three-week rotations in intensive care units, each during both the traditional and the intervention schedule. Subjects completed daily sleep logs that were validated with regular weekly episodes (72 to 96 hours) of continuous polysomnography (r=0.94) and work logs that were validated by means of direct observation by study staff (r=0.98). RESULTS: Seventeen of 20 interns worked more than 80 hours per week during the traditional schedule (mean, 84.9; range, 74.2 to 92.1). All interns worked less than 80 hours per week during the intervention schedule (mean, 65.4; range, 57.6 to 76.3). On average, interns worked 19.5 hours per week less (P<0.001), slept 5.8 hours per week more (P<0.001), slept more in the 24 hours preceding each working hour (P<0.001), and had less than half the rate of attentional failures while working during on-call nights (P=0.02) on the intervention schedule as compared with the traditional schedule. CONCLUSIONS: Eliminating interns' extended work shifts in an intensive care unit significantly increased sleep and decreased attentional failures during night work hours.	Brigham & Womens Hosp, Dept Med, Div Sleep Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Cardiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Int Med Residency Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Sleep Med, Boston, MA USA; Childrens Hosp, Dept Med, Div Gen Pediat, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Czeisler, CA (corresponding author), Brigham & Womens Hosp, Dept Med, Div Sleep Med, 221 Longwood Ave, Boston, MA 02115 USA.	caczeisler@hms.harvard.edu	Lee, Clark J./M-4753-2019; Lee, Clark/GRR-3922-2022; Cade, Brian/J-6770-2019	Lee, Clark J./0000-0003-4931-2534; Lee, Clark/0000-0003-4931-2534; Cade, Brian/0000-0003-1424-0673; Lockley, Steven/0000-0001-5209-2881; Czeisler, Charles Andrew/0000-0002-7408-1849; Landrigan, Christopher/0000-0001-8386-4100	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS012032, K08HS013333, F32HS014130] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH007567] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS12032, K08 HS13333, F32 HS14130] Funding Source: Medline; NCRR NIH HHS [M01 RR02635] Funding Source: Medline; NHLBI NIH HHS [T32 HL079010] Funding Source: Medline; NIOSH CDC HHS [R01 OH07567] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIOSH CDC HHS		*AAMC, 2001, AAMC POL GUID GRAD M; *ACCR COUNC GRAD M, 2003, COMM PROGR REQ RES D; Baldwin DC, 2004, SLEEP, V27, P217, DOI 10.1093/sleep/27.2.217; Baldwin DC, 2003, ACAD MED, V78, P1154, DOI 10.1097/00001888-200311000-00018; Barden CB, 2002, J AM COLL SURGEONS, V195, P531, DOI 10.1016/S1072-7515(02)01242-5; Bartel P, 2004, OCCUP ENVIRON MED, V61, P167, DOI 10.1136/oem.2002.006197; Cajochen C, 1999, AM J PHYSIOL-REG I, V277, pR640, DOI 10.1152/ajpregu.1999.277.3.R640; Cajochen C, 2000, BEHAV BRAIN RES, V115, P75, DOI 10.1016/S0166-4328(00)00236-9; Cho KW, 2001, NAT NEUROSCI, V4, P567, DOI 10.1038/88384; Czeisler CA, 2004, SLEEP, V27, P371; Czeisler CA, 2002, JAMA-J AM MED ASSOC, V287, P1802; DIJK DJ, 1994, NEUROSCI LETT, V166, P63, DOI 10.1016/0304-3940(94)90841-9; Drazen JM, 2002, NEW ENGL J MED, V347, P1271, DOI 10.1056/NEJMe020110; Gaba DM, 2002, NEW ENGL J MED, V347, P1249, DOI 10.1056/NEJMsa020846; Halbach MM, 2003, AM J OBSTET GYNECOL, V188, P1198, DOI 10.1067/mob.2003.306; Howard SK, 2003, ANESTHESIOLOGY, V98, P1345, DOI 10.1097/00000542-200306000-00008; Howard SK, 2002, ACAD MED, V77, P1019, DOI 10.1097/00001888-200210000-00015; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; Jewett ME, 1997, THESIS HARVARD U CAM; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Leape L, 2002, NEW ENGL J MED, V347, P1272, DOI 10.1056/NEJMe020123; Lewis FR, 2003, ANN SURG, V237, P458, DOI 10.1097/00000658-200304000-00003; Lowenstein J, 2003, PERSPECT BIOL MED, V46, P273, DOI 10.1353/pbm.2003.0026; Monk TH, 2003, SLEEP, V26, P208, DOI 10.1093/sleep/26.2.208; Mullins MD, 2003, NEW ENGL J MED, V348, P665; Neri DF, 2002, AVIAT SPACE ENVIR MD, V73, P654; Niederee MJ, 2003, ARCH SURG-CHICAGO, V138, P663, DOI 10.1001/archsurg.138.6.663; Ohayon MM, 2002, J PSYCHOSOM RES, V53, P577, DOI 10.1016/S0022-3999(02)00438-5; Phipps-Nelson J, 2003, SLEEP, V26, P695, DOI 10.1093/sleep/26.6.695; Richardson GS, 1996, SLEEP, V19, P718; Rollinson DC, 2003, ANN EMERG MED, V41, P400, DOI 10.1067/mem.2003.77; Rosen IM, 2003, NEW ENGL J MED, V348, P665; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; Steinbrook R, 2002, NEW ENGL J MED, V347, P1296, DOI 10.1056/NEJMhpr022383; TORSVALL L, 1987, ELECTROEN CLIN NEURO, V66, P502, DOI 10.1016/0013-4694(87)90096-4; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Van Dongen HPA, 2004, SLEEP, V27, P423; Veasey S, 2002, JAMA-J AM MED ASSOC, V288, P1116, DOI 10.1001/jama.288.9.1116; Walker MP, 2002, NEURON, V35, P205, DOI 10.1016/S0896-6273(02)00746-8; Whang EE, 2003, ANN SURG, V237, P449, DOI 10.1097/00000658-200304000-00001	41	646	657	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1829	1837		10.1056/NEJMoa041404	http://dx.doi.org/10.1056/NEJMoa041404			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509816				2022-12-28	WOS:000224723100006
J	Luime, JJ; Verhagen, AP; Miedema, HS; Kuiper, JI; Burdorf, A; Verhaar, JAN; Koes, BW				Luime, JJ; Verhagen, AP; Miedema, HS; Kuiper, JI; Burdorf, A; Verhaar, JAN; Koes, BW			Does this patient have an instability of the shoulder or a labrum lesion?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ROTATOR-CUFF TEARS; SUBACROMIAL IMPINGEMENT SYNDROME; BICEPS LOAD TEST; CLINICAL-TEST; PHYSICAL-EXAMINATION; DIAGNOSTIC-ACCURACY; POSTERIOR LESIONS; PAINFUL SHOULDER; SLAP LESIONS; ANTERIOR	Context History taking and clinical tests are commonly used to diagnose shoulder pain. Unclear is whether tests and history accurately diagnose instability or intra-articular pathology (IAP). Objective To analyze the accuracy of clinical tests and history taking for shoulder instability or IAP. Data Sources Relevant studies identified through PubMed, EMBASF, CINAHL, and bibliographies of known primary and review articles. Study Selection Studies comparing the performance of history items or physical examination with a reference standard were included. Studies on fibromyalgia, fractures, or systemic disorders were excluded. Of 1449 articles, 35 were eligible, and 17 were selected. Data Extraction Data were extracted on study population, clinical tests, reference tests' and outcome. The studies' methodological quality (patient spectrum, verification, blinding, and replication) was assessed with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist. Data Synthesis Six tests showed positive likelihood ratios (LRs) and confidence intervals (CIs). Tests favoring the diagnosis for establishing instability included: relocation (LR, 6.5; 95% CI, 3.0-14.0) and anterior release (LR, 8.3; 95% CI, 3.6-19). Tests showing promise for establishing labral lesions included: the biceps load I and 11 (LR, 29; 95% CI, 7.3-115.0 and LR, 26; 95% CI, 8.6-80.0), respectively, pain provocation of Mimori (LR, 7.2; 95% CI, 1.6-32.0), and internal rotation resistance strength (LR, 25; 95% Cl, 8.1-76.0). The apprehension, clunk, release, load and shift, and sulcus sign tests proved less useful. Results should be cautiously interpreted because studies were completed in select populations in orthopedic practice, mostly assessed by the test designers, and evaluated in single studies only. No accuracy studies were found for history taking or for clinical tests in primary care. Conclusions Shoulder complaints are frequently recurrent. Instability might cause some of these complaints. Best evidence supports the value of the relocation and anterior release tests. Symptoms related to IAP (labral tears) remain unclear. Most promising for establishing labral tears are currently the biceps load I and II, pain provocation of Mimori, and the internal rotation resistance strength tests.	Univ Med Ctr Rotterdam, Erasmus MC, Dept Gen Practice, NL-3000 DR Rotterdam, Netherlands; Univ Med Ctr Rotterdam, Netherlands Expert Ctr Work Related Musculoskelet, Rotterdam, Netherlands; Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; Univ Med Ctr Rotterdam, Erasmus MC, Dept Orthoped, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Luime, JJ (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Gen Practice, POB 1738, NL-3000 DR Rotterdam, Netherlands.	b.koes@erasmusmc.nl	Koes, Bart w/K-4614-2016; Verhaar, Jan/AAH-1372-2020	Koes, Bart w/0000-0002-0450-9969; Verhaar, Jan/0000-0003-3016-9600; Verhagen, Arianne/0000-0002-6195-0128				ADOLFSSON L, 1989, Arthroscopy, V5, P315, DOI 10.1016/0749-8063(89)90148-5; BENKIBLER W, 1995, ARTHROSCOPY, V11, P296, DOI 10.1016/0749-8063(95)90006-3; Bennett WF, 1998, ARTHROSCOPY, V14, P789, DOI 10.1016/S0749-8063(98)70012-X; Berg EE, 1998, CLIN J SPORT MED, V8, P121, DOI 10.1097/00042752-199804000-00011; Calis M, 2000, ANN RHEUM DIS, V59, P44, DOI 10.1136/ard.59.1.44; COFIELD RH, 1993, CLIN ORTHOP RELAT R, V291, P45; Croft P, 1996, BRIT MED J, V313, P601; Deville Walter L, 2002, BMC Med Res Methodol, V2, P9, DOI 10.1186/1471-2288-2-9; Deville WLJM, 2000, J CLIN EPIDEMIOL, V53, P65, DOI 10.1016/S0895-4356(99)00144-4; GAZIELLY DF, 1995, REV CHIR ORTHOP, V81, P8; Gerber Christian, 1997, P9; Gross ML, 1997, CLIN ORTHOP RELAT R, P105; Guanche CA, 2003, ARTHROSCOPY, V19, P517, DOI 10.1053/jars.2003.50104; Hertel R, 1996, J Shoulder Elbow Surg, V5, P307, DOI 10.1016/S1058-2746(96)80058-9; HOVELIUS L, 1982, CLIN ORTHOP RELAT R, V166, P127; KANEKO K, 1995, CLIN IMAG, V19, P8, DOI 10.1016/0899-7071(94)00024-7; Kim SH, 2001, ARTHROSCOPY, V17, P160, DOI 10.1053/jars.2001.20665; Kim SH, 1999, AM J SPORT MED, V27, P300, DOI 10.1177/03635465990270030501; LERAT JL, 1994, REV CHIR ORTHOP, V80, P461; LEROUX JL, 1995, REV RHUM, V62, P423; Litaker D, 2000, J AM GERIATR SOC, V48, P1633, DOI 10.1111/j.1532-5415.2000.tb03875.x; Liu SH, 1996, AM J SPORT MED, V24, P721, DOI 10.1177/036354659602400604; LYONS AR, 1992, J BONE JOINT SURG BR, V74, P414, DOI 10.1302/0301-620X.74B3.1587891; MacDonald PB, 2000, J SHOULDER ELB SURG, V9, P299, DOI 10.1067/mse.2000.106918; Macfarlane GJ, 1998, J RHEUMATOL, V25, P1612; Makela M, 1999, RHEUMATOLOGY, V38, P656, DOI 10.1093/rheumatology/38.7.656; MATSEN FA, 1990, SHOULDER, P526; McFarland EG, 2002, AM J SPORT MED, V30, P810, DOI 10.1177/03635465020300061001; McFarland EG, 2001, ARTHROSCOPY, V17, P38, DOI 10.1053/jars.2001.19967; McFarland EG, 1996, SPORTS MED, V22, P264, DOI 10.2165/00007256-199622040-00005; Mimori K, 1999, AM J SPORT MED, V27, P137, DOI 10.1177/03635465990270020401; Natvig Bard, 1994, Tidsskrift for den Norske Laegeforening, V114, P323; NELSON MC, 1991, J BONE JOINT SURG AM, V73A, P707, DOI 10.2106/00004623-199173050-00009; NOVEJOSSERAND L, 1994, REV CHIR ORTHOP, V80, P595; O'Brien SJ, 1998, AM J SPORT MED, V26, P610, DOI 10.1177/03635465980260050201; Oliashirazi A, 1999, AM J SPORT MED, V27, P464, DOI 10.1177/03635465990270041001; Picavet HSJ, 2003, PAIN, V102, P167, DOI 10.1016/S0304-3959(02)00372-X; Pollock R, 1996, UNSTABLE SHOULDER, P25; Pope DP, 1997, ANN RHEUM DIS, V56, P308, DOI 10.1136/ard.56.5.308; Rahme H, 1998, SCAND J REHABIL MED, V30, P253; Read JW, 1998, J SHOULDER ELB SURG, V7, P264, DOI 10.1016/S1058-2746(98)90055-6; SNYDER S J, 1990, Arthroscopy, V6, P274, DOI 10.1016/0749-8063(90)90056-J; SNYDER SJ, 1994, SHOULDER ARTHROSCOPY, P115; SPEER KP, 1994, AM J SPORT MED, V22, P177, DOI 10.1177/036354659402200205; Stetson WB, 2002, AM J SPORT MED, V30, P806, DOI 10.1177/03635465020300060901; T'Jonck L. S. F., 2001, GENEESKUNDE SPORT, V34, P15; URE BM, 1993, UNFALLCHIRURG, V96, P382; Urwin M, 1998, ANN RHEUM DIS, V57, P649, DOI 10.1136/ard.57.11.649; VANDERHELM FCT, 1994, J BIOMECH, V27, P551, DOI 10.1016/0021-9290(94)90065-5; VANDERWINDT DAWM, 1995, ANN RHEUM DIS, V54, P959, DOI 10.1136/ard.54.12.959; Walch G, 1998, J BONE JOINT SURG BR, V80B, P624, DOI 10.1302/0301-620X.80B4.8651; Warner Jon J. P., 1997, P3; Westerberg CE, 1996, SCAND J REHABIL MED, V28, P63; Whiting P, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8250; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Zaslav KR, 2001, J SHOULDER ELB SURG, V10, P23, DOI 10.1067/mse.2001.111960	56	38	38	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2004	292	16					1989	1999		10.1001/jama.292.16.1989	http://dx.doi.org/10.1001/jama.292.16.1989			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865DO	15507585				2022-12-28	WOS:000224682900024
J	Pritchard-Jones, K; Pritchard, J				Pritchard-Jones, K; Pritchard, J			Success of clinical trials in childhood Wilms' tumour around the world	LANCET			English	Editorial Material							INTERNATIONAL-SOCIETY; MALIGNANT NEOPLASMS; RENAL TUMORS; STAGE-I; DURATION; CHILDREN; OLDER		Royal Marsden Hosp, Inst Canc Res, Sutton SM2 5PT, Surrey, England; Royal Hosp Sick Children, Edinburgh EH9 1LF, Midlothian, Scotland	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Pritchard-Jones, K (corresponding author), Royal Marsden Hosp, Inst Canc Res, Downs Rd, Sutton SM2 5PT, Surrey, England.	kathy.pritchard-jones@icr.ac.uk	Pritchard-Jones, Kathy/F-4286-2014	Pritchard-Jones, Kathy/0000-0002-2384-9475				BERGERON C, 2003, MED PEDIATR ONCOL, V41, P289; BRESLOW NE, 1995, J CLIN ONCOL, V13, P1851, DOI 10.1200/JCO.1995.13.8.1851; Carli M, 1997, MED PEDIATR ONCOL, V29, P239, DOI 10.1002/(SICI)1096-911X(199710)29:4<239::AID-MPO1>3.3.CO;2-P; de Kraker J, 2004, LANCET, V364, P1229, DOI 10.1016/S0140-6736(04)17139-0; DECAMARGO B, 1994, CANCER-AM CANCER SOC, V73, P3081, DOI 10.1002/1097-0142(19940615)73:12<3081::AID-CNCR2820731229>3.0.CO;2-1; Green DM, 1998, J CLIN ONCOL, V16, P3744, DOI 10.1200/JCO.1998.16.12.3744; Green DM, 2001, J CLIN ONCOL, V19, P1926, DOI 10.1200/JCO.2001.19.7.1926; MITCHELL C, 2003, MED PEDIATR ONCOL, V41, P287; Pritchard-Jones K, 2003, J CLIN ONCOL, V21, P3269, DOI 10.1200/JCO.2003.01.062; STILLER CA, 1990, BRIT J CANCER, V62, P1026, DOI 10.1038/bjc.1990.432; Tournade MF, 2001, J CLIN ONCOL, V19, P488, DOI 10.1200/JCO.2001.19.2.488; Vujanic GM, 2002, MED PEDIATR ONCOL, V38, P79, DOI 10.1002/mpo.1276; Weirich A, 2001, ANN ONCOL, V12, P311, DOI 10.1023/A:1011167924230	13	35	36	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	2004	364	9444					1468	1470		10.1016/S0140-6736(04)17289-9	http://dx.doi.org/10.1016/S0140-6736(04)17289-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500874				2022-12-28	WOS:000224645500007
J	Arteta-Bulos, R; Karim, SM				Arteta-Bulos, R; Karim, SM			Nontraumatic Clostridium septicum myonecrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Henry Ford Hosp, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	Arteta-Bulos, R (corresponding author), Henry Ford Hosp, Detroit, MI 48202 USA.								0	3	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2004	351	17					E15	E15		10.1056/ENEJMicm030714	http://dx.doi.org/10.1056/ENEJMicm030714			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863TH	15496616				2022-12-28	WOS:000224585200014
J	Nathan, C				Nathan, C			Antibiotics at the crossroads	NATURE			English	Editorial Material							DRUG DISCOVERY; MYCOBACTERIUM-TUBERCULOSIS; CHALLENGES		Cornell Univ, Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Immunol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Mol Biol, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Nathan, C (corresponding author), Cornell Univ, Weill Cornell Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10021 USA.							[Anonymous], 2004, SCIENCE, V303, P1798, DOI 10.1126/science.303.5665.1796; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; *CDCP, 2000, PUBL HLTH ACT PLAN C; Chopra I, 1996, JAMA-J AM MED ASSOC, V275, P401, DOI 10.1001/jama.275.5.401; Coates A, 2002, NAT REV DRUG DISCOV, V1, P895, DOI 10.1038/nrd940; Darwin KH, 2003, SCIENCE, V302, P1963, DOI 10.1126/science.1091176; Fidock DA, 2004, NAT REV DRUG DISCOV, V3, P509, DOI 10.1038/nrd1416; *GLOB ALL TUB DRUG, 2001, EC TB DRUG DEV; Infectious Diseases Society of America, 2004, BAD BUGS NO DRUGS; Keller M, 2004, NAT REV MICROBIOL, V2, P141, DOI 10.1038/nrmicro819; Liu J, 2004, NAT BIOTECHNOL, V22, P185, DOI 10.1038/nbt932; Manetsch R, 2004, J AM CHEM SOC, V126, P12809, DOI 10.1021/ja046382g; Miesel L, 2003, NAT REV GENET, V4, P442, DOI 10.1038/nrg1086; Nwaka S, 2003, NAT REV DRUG DISCOV, V2, P919, DOI 10.1038/nrd1230; Projan SJ, 2003, CURR OPIN MICROBIOL, V6, P427, DOI 10.1016/j.mib.2003.08.003; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Vennerstrom JL, 2004, NATURE, V430, P900, DOI 10.1038/nature02779; Walsh C, 2003, NAT REV MICROBIOL, V1, P65, DOI 10.1038/nrmicro727; Wenzel RP, 2004, NEW ENGL J MED, V351, P523, DOI 10.1056/NEJMp048093; *WHO, 2001, DRAFT GLOB STRAT CON; WHO Commission on Macroeconomics and Health, 2001, MACR HLTH INV HLTH E	23	301	315	4	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					899	902		10.1038/431899a	http://dx.doi.org/10.1038/431899a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496893				2022-12-28	WOS:000224585600016
J	Donnez, J; Dolmans, MM; Demylle, D; Jadoul, P; Pirard, C; Squifflet, J; Martinez-Madrid, B; Van Langendonckt, A				Donnez, J; Dolmans, MM; Demylle, D; Jadoul, P; Pirard, C; Squifflet, J; Martinez-Madrid, B; Van Langendonckt, A			Livebirth after orthotopic transplantation of cryopreserved ovarian tissue	LANCET			English	Article							CHILDHOOD-CANCER; CORTICAL STRIPS; FERTILITY; AUTOGRAFTS; FROZEN; SHEEP; LYMPHOMA; FRESH; RESTORATION; SURVIVORS	Background The lifesaving treatment endured by cancer patients leads, in many women, to early menopause and subsequent infertility. In clinical situations for which chemotherapy needs to be started, ovarian tissue cryopreservation looks to be a promising option to restore fertility. In 1997, biopsy samples of ovarian cortex were taken from a woman with stage IV Hodgkin's lymphoma and cryopreserved before chemotherapy was initiated. After her cancer treatment, the patient had premature ovarian failure. Methods In 2003, after freeze-thawing, orthotopic autotransplantation of ovarian cortical tissue was done by laparoscopy. Findings 5 months after reimplantation, basal body temperature, menstrual cycles, vaginal ultrasonography, and hormone concentrations indicated recovery of regular ovulatory cycles. Laparoscopy at 5 months confirmed the ultrasonographic data and showed the presence of a follicle at the site of reimplantation, clearly situated outside the ovaries, both of which appeared atrophic. From 5 to 9 months, the patient had menstrual bleeding and development of a follicle or corpus luteum with every cycle. 11 months after reimplantation, human chorionic gonadotrophin concentrations and vaginal echography confirmed a viable intrauterine pregnancy, which has resulted in a livebirth. Interpretation We have described a livebirth after orthotopic autotransplantation of cryopreserved ovarian tissue. Our findings suggest that cryopreservation of ovarian tissue should be offered to all young women diagnosed with cancer.	Univ Catholique Louvain, Clin Univ St Luc, Dept Gynaecol, B-1200 Brussels, Belgium; Univ Catholique Louvain, Gynaecol Res Unit, B-1200 Brussels, Belgium	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain	Donnez, J (corresponding author), Univ Catholique Louvain, Clin Univ St Luc, Dept Gynaecol, Ave Hippocrate 10, B-1200 Brussels, Belgium.	donnez@gyne.ud.ac.be	Dolmans, Marie-Madeleine/AAI-7167-2020; Martinez-Madrid, Belen/K-7493-2017	Martinez-Madrid, Belen/0000-0001-6852-4597				Aubard Y, 1999, HUM REPROD, V14, P2149, DOI 10.1093/humrep/14.8.2149; Baird DT, 1999, ENDOCRINOLOGY, V140, P462, DOI 10.1210/en.140.1.462; Blatt J, 1999, MED PEDIATR ONCOL, V33, P29, DOI 10.1002/(SICI)1096-911X(199907)33:1<29::AID-MPO6>3.0.CO;2-2; Callejo J, 2001, J CLIN ENDOCR METAB, V86, P4489, DOI 10.1210/jc.86.9.4489; Campbell BK, 2000, MOL CELL ENDOCRINOL, V163, P131, DOI 10.1016/S0303-7207(00)00217-3; CANDY CJ, 1995, HUM REPROD, V10, P2334; Candy CJ, 2000, HUM REPROD, V15, P1300, DOI 10.1093/humrep/15.6.1300; Cortvrindt RG, 2001, FERTIL STERIL, V75, P588, DOI 10.1016/S0015-0282(00)01754-4; Donnez J, 1998, HUM REPROD UPDATE, V4, P248, DOI 10.1093/humupd/4.3.248; Donnez J, 2000, CURR OPIN OBSTET GYN, V12, P1, DOI 10.1097/00001703-200002000-00001; Galant C, 2004, AM J PATHOL, V165, P83, DOI 10.1016/S0002-9440(10)63277-4; GOSDEN RG, 1994, HUM REPROD, V9, P597, DOI 10.1093/oxfordjournals.humrep.a138556; GOUGEON A, 1986, HUM REPROD, V1, P81, DOI 10.1093/oxfordjournals.humrep.a136365; Kim SS, 2001, HUM REPROD, V16, P2056, DOI 10.1093/humrep/16.10.2056; Kim SS, 2003, HUM REPROD, V18, P1759, DOI 10.1093/humrep/deg381; Kim SS, 2001, FERTIL STERIL, V75, P1049, DOI 10.1016/S0015-0282(01)01790-3; Larsen EC, 2004, ACTA OBSTET GYN SCAN, V83, P96, DOI 10.1111/j.1600-0412.2004.00332.x; Lee DM, 2004, NATURE, V428, P137, DOI 10.1038/428137a; Meirow D, 1999, FERTIL STERIL, V71, P948, DOI 10.1016/S0015-0282(99)00067-9; Meirow D, 1998, FERTIL STERIL, V69, P996; Nisolle M, 2000, FERTIL STERIL, V74, P122, DOI 10.1016/S0015-0282(00)00548-3; Oktay K, 2000, NEW ENGL J MED, V342, P1919, DOI 10.1056/NEJM200006223422516; Oktay K, 2004, LANCET, V363, P837, DOI 10.1016/S0140-6736(04)15728-0; Oktay K, 2001, JAMA-J AM MED ASSOC, V286, P1490, DOI 10.1001/jama.286.12.1490; Radford JA, 2001, LANCET, V357, P1172, DOI 10.1016/S0140-6736(00)04335-X; Rao GD, 2004, LANCET, V363, P1829, DOI 10.1016/S0140-6736(04)16320-4; Shaw JM, 1996, HUM REPROD, V11, P1668	27	1103	1195	3	65	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	2004	364	9443					1405	1410		10.1016/S0140-6736(04)17222-X	http://dx.doi.org/10.1016/S0140-6736(04)17222-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488215				2022-12-28	WOS:000224485300026
J	Forde, SE; Thompson, JN; Bohannan, BJM				Forde, SE; Thompson, JN; Bohannan, BJM			Adaptation varies through space and time in a coevolving host-parasitoid interaction	NATURE			English	Article							LOCAL ADAPTATION; ANTAGONISTIC COEVOLUTION; RESOURCE ENRICHMENT; GENE FLOW; MODEL; COMMUNITY; BACTERIA; PRODUCTIVITY; POPULATIONS; SELECTION	One of the central challenges of evolutionary biology is to understand how coevolution organizes biodiversity over complex geographic landscapes. Most species are collections of genetically differentiated populations, and these populations have the potential to become adapted to their local environments in different ways. The geographic mosaic theory of coevolution incorporates this idea by proposing that spatial variation in natural selection and gene flow across a landscape can shape local coevolutionary dynamics(1-7). These effects may be particularly strong when populations differ across productivity gradients, where gene flow will often be asymmetric among populations(8). Conclusive empirical tests of this theory have been particularly difficult to perform because they require knowledge of patterns of gene flow, historical population relationships and local selection pressures(2). We have tested these predictions empirically using a model community of bacteria and bacteriophage ( viral parasitoids of bacteria). We show that gene flow across a spatially structured landscape alters coevolution of parasitoids and their hosts and that the resulting patterns of adaptation can fluctuate in both space and time.	Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	University of California System; University of California Santa Cruz; Stanford University	Forde, SE (corresponding author), Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA.	forde@biology.ucsc.edu	Thompson, Jessica/GXW-0323-2022; Bohannan, Brendan J. M./R-1582-2017	Bohannan, Brendan J. M./0000-0003-2907-1016				Benkman CW, 2003, AM NAT, V162, P182, DOI 10.1086/376580; Bohannan BJM, 1999, AM NAT, V153, P73, DOI 10.1086/303151; Bohannan BJM, 1997, ECOLOGY, V78, P2303; Bohannan BJM, 2000, AM NAT, V156, P329, DOI 10.1086/303393; Brockhurst MA, 2003, ECOL LETT, V6, P975, DOI 10.1046/j.1461-0248.2003.00531.x; Brodie ED, 2002, EVOLUTION, V56, P2067; Buckling A, 2003, SCIENCE, V302, P2107, DOI 10.1126/science.1088848; Buckling A, 2002, P ROY SOC B-BIOL SCI, V269, P931, DOI 10.1098/rspb.2001.1945; Burdon JJ, 1999, AM NAT, V153, pS15, DOI 10.1086/303209; CHAO L, 1977, ECOLOGY, V58, P369, DOI 10.2307/1935611; Futuyma D. J., 1998, EVOLUTIONARY BIOL; Gandon S, 2002, ECOL LETT, V5, P246, DOI 10.1046/j.1461-0248.2002.00305.x; Gandon S, 1996, P ROY SOC B-BIOL SCI, V263, P1003, DOI 10.1098/rspb.1996.0148; Gandon S, 2002, J EVOLUTION BIOL, V15, P451, DOI 10.1046/j.1420-9101.2002.00402.x; Gomulkiewicz R, 2000, AM NAT, V156, P156, DOI 10.1086/303382; Hochberg ME, 1998, AM NAT, V152, P620, DOI 10.1086/286194; LENSKI RE, 1985, AM NAT, V125, P585, DOI 10.1086/284364; Nuismer SL, 1999, P ROY SOC B-BIOL SCI, V266, P605, DOI 10.1098/rspb.1999.0679; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; SHRAG SJ, 1996, AM NAT, V148, P348; SLATKIN M, 1985, ANNU REV ECOL SYST, V16, P393, DOI 10.1146/annurev.ecolsys.16.1.393; Thompson JD., 1994, COEVOLUTIONARY PROCE; Thompson JN, 2002, NATURE, V417, P735, DOI 10.1038/nature00810; Thompson JN, 1999, SCIENCE, V284, P2116, DOI 10.1126/science.284.5423.2116; Zangerl AR, 2003, EVOLUTION, V57, P806, DOI 10.1111/j.0014-3820.2003.tb00292.x	25	159	162	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	2004	431	7010					841	844		10.1038/nature02906	http://dx.doi.org/10.1038/nature02906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483611				2022-12-28	WOS:000224435500046
J	Sheridan, C; Wolfe, N				Sheridan, C; Wolfe, N			If only you hadn't, I would not have hit you: infant crying and abuse	LANCET			English	Editorial Material							CHILD		Loma Linda Univ, Childrens Hosp, Div Forens Pediat, Loma Linda, CA 92350 USA; Childrens Assessment Ctr, San Bernardino, CA USA	Children's Hospital Los Angeles; Loma Linda University	Sheridan, C (corresponding author), Loma Linda Univ, Childrens Hosp, Div Forens Pediat, Loma Linda, CA 92350 USA.	CSheridan@ahs.llumc.edu						Bograd M., 1988, COPING FAMILY VIOLEN, P60; BRAZELTON TB, 1962, PEDIATRICS, V29, P579; Briere J N, 1994, Future Child, V4, P54, DOI 10.2307/1602523; ELLIOTT M, 1995, CHILD ABUSE NEGLECT, V19, P579, DOI 10.1016/0145-2134(95)00017-3; Freeman-Longo R., 1998, SEXUAL ABUSE AM EPID; Langellier K. M., 1993, NARRATIVE SOCIAL CON, P49; SHIELDS NM, 1983, J APPL SOC PSYCHOL, V13, P515, DOI 10.1111/j.1559-1816.1983.tb02334.x; Sidebotham P, 2003, CHILD ABUSE NEGLECT, V27, P337, DOI 10.1016/S0145-2134(03)00010-3; Stamp GH, 1995, J APPL COMMUN RES, V23, P284, DOI 10.1080/00909889509365432; SUGARMAN DB, 1989, J APPL SOC PSYCHOL, V19, P1034, DOI 10.1111/j.1559-1816.1989.tb01237.x	10	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	2004	364	9442					1295	1296		10.1016/S0140-6736(04)17204-8	http://dx.doi.org/10.1016/S0140-6736(04)17204-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	860NG	15474120				2022-12-28	WOS:000224349700007
J	Cantor, J; Baum, K				Cantor, J; Baum, K			The limits of conscientious objection - May pharmacists refuse to fill prescriptions for emergency contraception?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Yale Univ, Sch Med, New Haven, CT 06510 USA; Wiggin & Dana, New Haven, CT USA	Yale University	Cantor, J (corresponding author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06510 USA.							*A GUTTM I, 2004, STAT POL BRIEF REF P; Alford S., 2001, TRANSITIONS, V12, P1; *AM PHARM ASS, COD ETH PHARM PREAMB; BRODY JE, 2004, NY TIMES        0921, pF7; Drazen JM, 2004, NEW ENGL J MED, V350, P1561, DOI 10.1056/NEJMe048057; ELLIOTT D, 2004, ALABAMA NURSES QUIT; FASSETT WE, 1996, ETHICAL ISSUES PHARM, P1; Foster DG, 2004, AM J OBSTET GYNECOL, V191, P150, DOI 10.1016/j.ajog.2004.01.004; Glasier A, 1997, NEW ENGL J MED, V337, P1058, DOI 10.1056/NEJM199710093371507; Hughes EC., 1972, OBSTET GYNECOLOGIC T; SAUER M, 1991, ST PETERSBURG T 1219, pB1; SEELEY RA, 1998, ADVICE CONSCIENTIOUS, P1; SIMON S, 2004, LOS ANGELES TIM 0320, pA18; Stanford JB, 2004, NEW ENGL J MED, V350, P2413; SWEENEY JF, 2004, PLAIN DEALER    0505, pE1; 2002, DAILY REPROD HLTH RE; 2004, CAPITAL TIMES   0513, pA16	17	78	79	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					2008	2012		10.1056/NEJMsb042263	http://dx.doi.org/10.1056/NEJMsb042263			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525728				2022-12-28	WOS:000224851300016
J	Mitch, WE				Mitch, WE			Treating diabetic nephropathy - Are there only economic issues?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TARGET		Univ Texas, Med Branch, Div Renal, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston	Mitch, WE (corresponding author), Univ Texas, Med Branch, Div Renal, Galveston, TX 77550 USA.							Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; de Zeeuw D, 2004, CIRCULATION, V110, P921, DOI 10.1161/01.CIR.0000139860.33974.28; de Zeeuw D, 2004, KIDNEY INT, V65, P2309, DOI 10.1111/j.1523-1755.2004.00653.x; Lewis EJ, 2004, J AM SOC NEPHROL, V15, P1358; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303	5	19	25	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1934	1936		10.1056/NEJMp048254	http://dx.doi.org/10.1056/NEJMp048254			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15516698				2022-12-28	WOS:000224851300004
J	Zhu, M; Ahlberg, PE				Zhu, M; Ahlberg, PE			The origin of the internal nostril of tetrapods	NATURE			English	Article							POROLEPIFORMES	The choana, a unique 'internal nostril' opening from the nasal sac into the roof of the mouth, is a key part of the tetrapod ( land vertebrate) respiratory system. It was the first component of the tetrapod body plan to evolve, well before the origin of limbs, and is therefore crucial to our understanding of the beginning of the fish - tetrapod transition. However, there is no consensus on the origin of the choana despite decades of heated debate(1-9); some have claimed that it represents a palatally displaced external nostril(4,6), but others have argued that this is implausible because it implies breaking and rejoining the maxillary - premaxillary dental arcade and the maxillary branch of nerve V(2,6). The fossil record has not resolved the dispute, because the choana is fully developed in known tetrapod stem-group members(8,10,11). Here we present new material of Kenichthys, a 395-million-year-old fossil fish from China(12-14), that provides direct evidence for the origin of the choana and establishes its homology: it is indeed a displaced posterior external nostril that, during a brief transitional stage illustrated by Kenichthys, separated the maxilla from the premaxilla.	Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China; Uppsala Univ, Evolutionary Biol Ctr, Dept Evolutionary Organismal Biol, SE-75236 Uppsala, Sweden	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS; Uppsala University	Zhu, M (corresponding author), Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, POB 643, Beijing 100044, Peoples R China.	zhumin@ivpp.ac.cn	Ahlberg, Per/E-8086-2013; Zhu, Min/E-8728-2012; min, zhu/AAL-6712-2021	Zhu, Min/0000-0002-4786-0898; Ahlberg, Per/0000-0001-9054-2900				Ahlberg PE, 1998, NATURE, V395, P792, DOI 10.1038/27421; AHLBERG PE, 1991, ZOOL J LINN SOC-LOND, V103, P241, DOI 10.1111/j.1096-3642.1991.tb00905.x; Ahlberg PE, 1996, NATURE, V381, P61, DOI 10.1038/381061a0; Ashique AM, 2002, DEVELOPMENT, V129, P4647; BEMIS WE, 1992, J MORPHOL, V213, P47, DOI 10.1002/jmor.1052130106; CHAN V, 1993, PEDIATR PULM, V15, P183, DOI 10.1002/ppul.1950150310; Chang M.M., 1984, Proceedings of the Linnean Society of New South Wales, V107, P171; Chang M.-M., 1982, THESIS STOCKHOLM U; Chang Mee-Mann, 1997, American Museum Novitates, V3189, P1; Clement G, 2001, J VERTEBR PALEONTOL, V21, P795, DOI 10.1671/0272-4634(2001)021[0795:EFLOCI]2.0.CO;2; FOREY PL, 1987, BIOL EVOLUTION LUNGF, P39; Hu D, 1999, DEVELOPMENT, V126, P4873; Jarvik E., 1942, ZOOL BIDR UPPS, V21, P235; Jarvik E., 1980, BASIC STRUCTURE EVOL, V1; Johanson Z, 1998, NATURE, V394, P569, DOI 10.1038/29058; Lebedev Oleg A., 1995, Bulletin du Museum National d'Histoire Naturelle Section C Sciences de la Terre Paleontologie Geologie Mineralogie, V17, P287; Long J.A., 1989, Journal of Vertebrate Paleontology, V9, P1; Long J.A., 1997, Records of the Western Australian Museum Supplement, V53, P1; MAISEY J G, 1986, Cladistics, V2, P201, DOI 10.1111/j.1096-0031.1986.tb00462.x; PANCHEN AL, 1967, BIOL REV, V42, P374, DOI 10.1111/j.1469-185X.1967.tb01478.x; PANCHEN AL, 1987, BIOL REV, V62, P341, DOI 10.1111/j.1469-185X.1987.tb01635.x; Rosen D. E., 1981, B AM MUS NAT HIST, V167, P157; Schultze H.-P., 1991, P29; Tong-Dzuy T., 1990, Bulletin du Museum National d'Histoire Naturelle Section C Sciences de la Terre Paleontologie Geologie Mineralogie, V12, P143; Zhang ZY, 2002, DEVELOPMENT, V129, P4135; Zhu M, 2001, NATURE, V410, P81, DOI 10.1038/35065078; ZHU M, 1996, ACTA STRATIGR SIN, V20, P58	27	63	69	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	2004	432	7013					94	97		10.1038/nature02843	http://dx.doi.org/10.1038/nature02843			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525987				2022-12-28	WOS:000224854900046
J	Anand, S; Barnighausen, T				Anand, S; Barnighausen, T			Human resources and health outcomes: cross-country econometric study	LANCET			English	Article							MATERNAL MORTALITY-RATES; GNP PER-CAPITA; INFANT-MORTALITY; CHILD-MORTALITY; CARE; POPULATION; EDUCATION	Background Only a few studies have investigated the link between human resources for health and health outcomes, and they arrive at different conclusions. We tested the strength and significance of density of human resources for health with improved methods and a new WHO dataset. Methods We did cross-country multiple regression analyses with maternal mortality rate, infant mortality rate, and under-five mortality rate as dependent variables. Aggregate density of human resources for health was an independent variable in one set of regressions; doctor and nurse densities separately were used in another set. We controlled for the effects of income, female adult literacy, and absolute income poverty. Findings Density of human resources for health is significant in accounting for maternal mortality rate, infant mortality rate, and under-five mortality rate (with elasticities ranging from -0.474 to -0.212, all p values <= 0.0036). The elasticities of the three mortality rates with respect to doctor density ranged from -0.386 to -0.174 (all p values <= 0.0029). Nurse density was not associated except in the maternal mortality rate regression without income poverty (p=0.0443). Interpretation In addition to other determinants, the density of human resources for health is important in accounting for the variation in rates of maternal mortality, infant mortality, and under-five mortality across countries. The effect of this density in reducing maternal mortality is greater than in reducing child mortality, possibly because qualified medical personnel can better address the illnesses that put mothers at risk. Investment in human resources for health must be considered as part of a strategy to achieve the Millennium Development Goals of improving maternal health and reducing child mortality.	Univ Oxford, Dept Econ, Oxford, England; Harvard Univ, Global Equ Initiat, Cambridge, MA USA; Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA	University of Oxford; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health	Anand, S (corresponding author), Univ Oxford St Catherines Coll, Oxford OX1 3UJ, England.	sudhir.anand@economics.ox.ac.uk	Bärnighausen, Till/Y-2388-2019					Adams O, 2003, HUMAN RESOURCES HLTH; Aiken LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI 10.1001/jama.288.16.1987; ANAND S, 1993, J ECON PERSPECT, V7, P133, DOI 10.1257/jep.7.1.133; Berman P, 2004, MULTIPLE PUBLIC PRIV; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; CALDWELL JC, 1990, ANN AM ACAD POLIT SS, V510, P44, DOI 10.1177/0002716290510001004; CALDWELL JC, 1986, POPUL DEV REV, V12, P171, DOI 10.2307/1973108; COCHRANE AL, 1978, J EPIDEMIOL COMMUN H, V32, P200, DOI 10.1136/jech.32.3.200; DIALLO K, 2004, METHODOLOGICAL NOTE; Donnay F, 2000, INT J GYNECOL OBSTET, V70, P89, DOI 10.1016/S0020-7292(00)00236-8; Dussault Gilles, 2003, Hum Resour Health, V1, P1, DOI 10.1186/1478-4491-1-1; Egan M, 1999, HEALTH SOC WORK, V24, P43, DOI 10.1093/hsw/24.1.43; Filmer D, 1999, SOC SCI MED, V49, P1309, DOI 10.1016/S0277-9536(99)00150-1; FLEGG AT, 1982, POP STUD-J DEMOG, V36, P441, DOI 10.2307/2174055; Frankenberg E, 1995, Health Transit Rev, V5, P143; Frankenberg E, 2001, DEMOGRAPHY, V38, P253, DOI 10.1353/dem.2001.0014; Gilling C M, 1989, Nurse Educ Today, V9, P82, DOI 10.1016/0260-6917(89)90058-0; Goodburn E, 2001, BRIT MED J, V322, P917, DOI 10.1136/bmj.322.7291.917; Gulliford MC, 2002, J PUBLIC HEALTH MED, V24, P252, DOI 10.1093/pubmed/24.4.252; HERTZ E, 1994, SOC SCI MED, V39, P105, DOI 10.1016/0277-9536(94)90170-8; *JLI, IN PRESS HUM RES HLT; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; KIM KK, 1992, SOC SCI MED, V34, P837, DOI 10.1016/0277-9536(92)90253-M; Koblinsky MA, 1999, B WORLD HEALTH ORGAN, V77, P399; Love Mary Beth, 2004, Health Promot Pract, V5, P418, DOI 10.1177/1524839903260142; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; Nolte A, 1995, Curationis, V18, P49; NUTTER DO, 1983, J MED EDUC, V58, P555; Robinson J, 2000, J ADV NURS, V32, P28, DOI 10.1046/j.1365-2648.2000.01458.x; Robinson JJA, 2001, J ADV NURS, V34, P445, DOI 10.1046/j.1365-2648.2001.01773.x; ROLSL C, 1996, AUST COLL MIDWIVES I, V9, P18; Rutstein SO, 2000, B WORLD HEALTH ORGAN, V78, P1256; SUBBARAO K, 1995, ECON DEV CULT CHANGE, V44, P105, DOI 10.1086/452202; Suleiman AB, 1999, B WORLD HEALTH ORGAN, V77, P190; THOMAS D, 1991, 89 WORLD BANK; *UNAID, 2003, HLTH SECT HUM RES  C; United Nations Development Programme (UNDP), 2003, HUM DEV REP 2003; *WHO, 2004, WHO EST HLTH PERS PH; *WHO, 2000, INF 5 MORT RAT WHO R; *WHO UNICEF UNFPA, 2001, MAT MORT 1995 EST DE; *WHOSIS, WHO EST HLTH PERS PH; Wooldridge J., 2002, ECONOMETRIC ANAL CRO; Wooldridge J.M., 2016, INTRO ECONOMETRICS M; *WORLD BANK, 2004, COUNTR CLASS CLASS E; World Bank, 2022, WORLD DEV IND; *WORLD BANK, 1981, DEV DIG, V19, P79; *WORLD BANK HNPSTA, 2003, WORLD BANK	47	359	370	1	59	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	2004	364	9445					1603	1609		10.1016/S0140-6736(04)17313-3	http://dx.doi.org/10.1016/S0140-6736(04)17313-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	866IQ	15519630				2022-12-28	WOS:000224767600025
J	Kotaska, AR				Kotaska, AR			Inappropriate use of randomised trials to evaluate complex phenomena: case study of vaginal breech delivery	BRITISH MEDICAL JOURNAL			English	Article							EVIDENCE-BASED MEDICINE; CESAREAN-SECTION; CAROTID-ENDARTERECTOMY; NEONATAL-MORTALITY; UNITED-STATES; SINGLE-CENTER; TERM; ROUTE; PRESENTATIONS; HYSTERECTOMY		Univ British Columbia, BC Womens Hosp, Dept Obstet & Gynaecol, Vancouver, BC V6H 3V5, Canada	University of British Columbia	Kotaska, AR (corresponding author), Univ British Columbia, BC Womens Hosp, Dept Obstet & Gynaecol, Vancouver, BC V6H 3V5, Canada.	kotaska@bulkley.net						Alarab M, 2004, OBSTET GYNECOL, V103, P407, DOI 10.1097/01.AOG.0000113625.29073.4c; Albrechtsen S, 1997, AM J OBSTET GYNECOL, V177, P586, DOI 10.1016/S0002-9378(97)70150-9; Albrechtsen S, 2000, ACTA OBSTET GYN SCAN, V79, P508, DOI 10.1034/j.1600-0412.2000.079006508.x; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; BRACHT E, 1938, ZENTRALBLATT GYNAECO, V31, P1735; Danielian PJ, 1996, BRIT MED J, V312, P1451, DOI 10.1136/bmj.312.7044.1451; Giuliani A, 2002, AM J OBSTET GYNECOL, V187, P1694, DOI 10.1067/mob.2002.127902; Halmesmaki E, 2001, ACTA OBSTET GYN SCAN, V80, P187, DOI 10.1034/j.1600-0412.2001.080003187.x; Hannah ME, 2000, LANCET, V356, P1375, DOI 10.1016/S0140-6736(00)02840-3; Hauth JC, 2002, OBSTET GYNECOL, V99, P1115, DOI 10.1016/S0029-7844(02)02031-8; Irion O, 1998, BRIT J OBSTET GYNAEC, V105, P710, DOI 10.1111/j.1471-0528.1998.tb10200.x; Julian DG, 2003, J CARDIOVASC ELECTR, V14, pS2, DOI 10.1046/j.1540-8167.14.s9.18.x; Kayem G, 2002, EUR J OBSTET GYN R B, V102, P137, DOI 10.1016/S0301-2115(01)00605-4; Keirse MJNC, 2002, BIRTH-ISS PERINAT C, V29, P55, DOI 10.1046/j.1523-536X.2002.00157.x; Lee KS, 1998, OBSTET GYNECOL, V92, P769, DOI 10.1016/S0029-7844(98)00291-9; Lindqvist A, 1997, BRIT J OBSTET GYNAEC, V104, P1288, DOI 10.1111/j.1471-0528.1997.tb10976.x; Maresh MJA, 2002, BJOG-INT J OBSTET GY, V109, P302, DOI 10.1111/j.1471-0528.2002.01282.x; MAYER AR, 1992, GYNECOL ONCOL, V47, P223, DOI 10.1016/0090-8258(92)90110-5; MENTICOGLOU SM, 1990, AUST NZ J OBSTET GYN, V30, P1, DOI 10.1111/j.1479-828X.1990.tb03185.x; Sanchez-Ramos L, 2001, INT J GYNECOL OBSTET, V73, P7, DOI 10.1016/S0020-7292(00)00384-2; Schiff E, 1996, AM J OBSTET GYNECOL, V175, P18, DOI 10.1016/S0002-9378(96)70244-2; Tingulstad S, 2003, OBSTET GYNECOL, V102, P499, DOI 10.1016/S0029-7844(03)00579-9; Tonelli MR, 1998, ACAD MED, V73, P1234, DOI 10.1097/00001888-199812000-00011; Tu JV, 1998, NEW ENGL J MED, V339, P1441, DOI 10.1056/NEJM199811123392006; University of Toronto Maternal Infant and Reproductive Health Research Unit, 1996, TERM BREECH TRIAL ST, P8; Varma R, 2001, OBSTET GYNECOL, V97, P613, DOI 10.1016/S0029-7844(00)01232-1; WHYTE H, 2003, AM J OBSTET GYNECO S, V189	27	114	114	1	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 30	2004	329	7473					1039	1042		10.1136/bmj.329.7473.1039	http://dx.doi.org/10.1136/bmj.329.7473.1039			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514356	Green Published, Green Submitted			2022-12-28	WOS:000224852400033
J	McCulloch, P				McCulloch, P			Half full or half empty VATS?	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England	University of Oxford	McCulloch, P (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England.	petermcculloch@doctors.org.uk		McCulloch, Peter/0000-0002-3210-8273				Chesterton G. K., 1910, WHATS WRONG WORLD; PLOUS S, 1993, PSYCHOL JUDGEMENT DE; SEDRAKYAN A, 2004, BMJ, V329; Timmermans S, 2003, GOLD STANDARD CHALLE	4	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 30	2004	329	7473					1012	1012		10.1136/bmj.329.7473.1012	http://dx.doi.org/10.1136/bmj.329.7473.1012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514346	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000224852400020
J	Ansorge, MS; Zhou, MM; Lira, A; Hen, R; Gingrich, JA				Ansorge, MS; Zhou, MM; Lira, A; Hen, R; Gingrich, JA			Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice	SCIENCE			English	Article							DORSAL RAPHE NUCLEUS; SEROTONIN TRANSPORTER; ENDOGENOUS-DEPRESSION; ANTIDEPRESSANT DRUGS; MONOAMINE-OXIDASE; RECEPTOR-BINDING; MATERNAL-CARE; BRAIN-REGIONS; ANIMAL-MODEL; ANXIETY	Reduced serotonin transporter (5-HTT)-expression is associated with abnormal affective and anxiety-like symptoms in humans and rodents, but the mechanism of this effect is unknown. Transient inhibition of 5-HTT during early development with ftuoxetine, a commonly used serotonin selective reuptake inhibitor, produced abnormal emotional behaviors in adult mice. This effect mimicked the behavioral phenotype of mice genetically deficient in 5-HTT expression. These findings indicate a critical rote of serotonin in the maturation of brain systems that modulate emotional function in the adult and suggest a developmental mechanism to explain how low-expressing 5-HTT promoter alleles increase vulnerability to psychiatric disorders.	Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Sackler Inst Dev Psychobiol, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, Dept Dev Psychobiol, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, Dept Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Columbia University; New York State Psychiatry Institute; New York State Psychiatry Institute	Gingrich, JA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Psychiat, 722 W 168th St, New York, NY 10032 USA.	jag46@columbia.edu	ansorge, mark s/L-1360-2014					BODNOFF SR, 1989, PSYCHOPHARMACOLOGY, V97, P277, DOI 10.1007/BF00442264; Caldji C, 2003, NEUROPSYCHOPHARMACOL, V28, P1950, DOI 10.1038/sj.npp.1300237; Casper RC, 2003, J PEDIATR-US, V142, P402, DOI 10.1067/mpd.2003.139; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Collier DA, 1996, MOL PSYCHIATR, V1, P453; Gaspar P, 2003, NAT REV NEUROSCI, V4, P1002, DOI 10.1038/nrn1256; Gingrich JA, 2003, CNS SPECTRUMS, V8, P572, DOI 10.1017/S1092852900018848; Gobbi G, 2001, J PHARMACOL EXP THER, V296, P987; Gross C, 2004, NAT REV NEUROSCI, V5, P545, DOI 10.1038/nrn1429; Gross C, 2002, NATURE, V416, P396, DOI 10.1038/416396a; Gutierrez B, 1998, HUM GENET, V103, P319, DOI 10.1007/s004390050823; Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829; Holmes A, 2003, GENES BRAIN BEHAV, V2, P365, DOI 10.1046/j.1601-1848.2003.00050.x; HRDINA PD, 1990, J PHARMACOL EXP THER, V252, P410; Kent JM, 2000, LANCET, V355, P911, DOI 10.1016/S0140-6736(99)11381-3; Kinney GG, 1997, BRAIN RES, V756, P68, DOI 10.1016/S0006-8993(97)00119-4; Koch S, 2002, NEUROPSYCHOPHARMACOL, V27, P949, DOI 10.1016/S0893-133X(02)00377-9; LAUDER JM, 1978, DEV NEUROSCI-BASEL, V1, P15, DOI 10.1159/000112549; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Lesch KP, 2003, BEHAVIORAL GENETICS IN THE POSTGENOMIC ERA, P389, DOI 10.1037/10480-020; Lira A, 2003, BIOL PSYCHIAT, V54, P960, DOI 10.1016/S0006-3223(03)00696-6; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; MOISEIWITSCH JRD, 1995, P NATL ACAD SCI USA, V92, P7182, DOI 10.1073/pnas.92.16.7182; Nulman I, 1997, NEW ENGL J MED, V336, P258, DOI 10.1056/NEJM199701233360404; Nulman I, 2002, AM J PSYCHIAT, V159, P1889, DOI 10.1176/appi.ajp.159.11.1889; Rumajogee P, 2004, EUR J NEUROSCI, V19, P937, DOI 10.1111/j.0953-816X.2004.03194.x; Salichon N, 2001, J NEUROSCI, V21, P884, DOI 10.1523/JNEUROSCI.21-03-00884.2001; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; SHUEY DL, 1992, TERATOLOGY, V46, P367, DOI 10.1002/tera.1420460407; SMYTHE JW, 1994, DEV BRAIN RES, V80, P183, DOI 10.1016/0165-3806(94)90103-1; Upton AL, 2002, NEUROSCIENCE, V111, P597, DOI 10.1016/S0306-4522(01)00602-9; Vitalis T, 1998, J COMP NEUROL, V393, P169, DOI 10.1002/(SICI)1096-9861(19980406)393:2<169::AID-CNE3>3.0.CO;2-0; VOGEL G, 1990, NEUROSCI BIOBEHAV R, V14, P85, DOI 10.1016/S0149-7634(05)80164-2; VORHEES CV, 1994, FUND APPL TOXICOL, V23, P194, DOI 10.1006/faat.1994.1098; Wisner KL, 1999, JAMA-J AM MED ASSOC, V282, P1264, DOI 10.1001/jama.282.13.1264; YAVARONE MS, 1993, TERATOLOGY, V47, P573, DOI 10.1002/tera.1420470609; Zeskind PS, 2004, PEDIATRICS, V113, P368, DOI 10.1542/peds.113.2.368	37	625	635	0	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					879	881		10.1126/science.1101678	http://dx.doi.org/10.1126/science.1101678			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514160				2022-12-28	WOS:000224969400049
J	Romero, S; Le Clainche, C; Didry, D; Egile, C; Pantaloni, D; Carlier, MF				Romero, S; Le Clainche, C; Didry, D; Egile, C; Pantaloni, D; Carlier, MF			Formin is a processive motor that requires profilin to accelerate actin assembly and associated ATP hydrolysis	CELL			English	Article							DIAPHANOUS-RELATED FORMIN; BARBED-END; INDUCED NUCLEATION; MAMMALIAN HOMOLOG; MITOTIC SPINDLE; CAPPING PROTEIN; MOUSE FORMIN; POLYMERIZATION; MDIA1; ELONGATION	Motile and morphogenetic cellular processes are driven by site-directed assembly of actin filaments. Formins, proteins characterized by formin homology domains FH1 and FH2, are initiators of actin assembly. How formins simply bind to filament barbed ends in rapid equilibrium or find free energy to become a processive motor of filament assembly remains enigmatic. Here we demonstrate that the FH1-FH2 domain accelerates hydrolysis of ATP coupled to profilin-actin polymerization and uses the derived free energy for processive polymerization, increasing 15-fold the rate constant for profilin-actin association to barbed ends. Profilin is required for and takes part in the processive function. Single filaments grow at least 10 mum long from formin bound beads without detaching. Transitory formin-associated processes are generated by poisoning of the processive cycle by barbed-end capping proteins. We successfully reconstitute formin-induced motility in vitro, demonstrating that this mechanism accounts for the puzzlingly rapid formin-induced actin processes observed in vivo.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Harvard University; Harvard Medical School	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave de La Terrasse, F-91198 Gif Sur Yvette, France.	carlier@lebs.cnrs-gif.fr	Le Clainche, Christophe/A-4782-2015; Romero, Stephane/GLR-3472-2022; Romero, Stephane/K-5998-2017	Le Clainche, Christophe/0000-0001-5659-677X; Romero, Stephane/0000-0002-7358-3871; Romero, Stephane/0000-0002-7358-3871				Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Arai R, 2002, J CELL SCI, V115, P887; Boquet I, 2000, CELL, V102, P797, DOI 10.1016/S0092-8674(00)00068-4; BRUNE D, 1994, P NATL ACAD SCI USA, V91, P2930, DOI 10.1073/pnas.91.8.2930; CARLIER MF, 1986, J BIOL CHEM, V261, P785; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Dickinson RB, 2002, BIOPHYS J, V82, P605, DOI 10.1016/S0006-3495(02)75425-8; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Dong YQ, 2003, J CELL BIOL, V161, P1081, DOI 10.1083/jcb.200212040; DRENCKHAHN D, 1986, J BIOL CHEM, V261, P2754; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Evangelista Marie, 2002, Nature Cell Biology, V4, P260; Frisch C, 2001, J MOL BIOL, V308, P69, DOI 10.1006/jmbi.2001.4577; Gasman S, 2003, NAT CELL BIOL, V5, P195, DOI 10.1038/ncb935; Gutsche-Perelroizen I, 1999, J BIOL CHEM, V274, P6234, DOI 10.1074/jbc.274.10.6234; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Hertzog M, 2004, CELL, V117, P611, DOI 10.1016/S0092-8674(04)00403-9; Higashida C, 2004, SCIENCE, V303, P2007, DOI 10.1126/science.1093923; ISAMBERT H, 1995, J BIOL CHEM, V270, P11437, DOI 10.1074/jbc.270.19.11437; Kato T, 2001, J CELL SCI, V114, P775; Kobielak A, 2004, NAT CELL BIOL, V6, P21, DOI 10.1038/ncb1075; Koka S, 2003, J CELL SCI, V116, P1745, DOI 10.1242/jcs.00386; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; Ozaki-Kuroda K, 2001, MOL CELL BIOL, V21, P827, DOI 10.1128/MCB.21.3.827-839.2001; PANTALONI D, 1985, P NATL ACAD SCI USA, V82, P7207, DOI 10.1073/pnas.82.21.7207; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Severson AF, 2002, CURR BIOL, V12, P2066, DOI 10.1016/S0960-9822(02)01355-6; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Tolliday N, 2002, CURR BIOL, V12, P1864, DOI 10.1016/S0960-9822(02)01238-1; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Wiesner S, 2003, J CELL BIOL, V160, P387, DOI 10.1083/jcb.200207148; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Yang HC, 2002, P NATL ACAD SCI USA, V99, P751, DOI 10.1073/pnas.022462899; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	54	416	428	0	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2004	119	3					419	429		10.1016/j.cell.2004.09.039	http://dx.doi.org/10.1016/j.cell.2004.09.039			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	868IW	15507212	Bronze			2022-12-28	WOS:000224908300012
J	Brown, P; Sutikna, T; Morwood, MJ; Soejono, RP; Jatmiko; Saptomo, EW; Due, RA				Brown, P; Sutikna, T; Morwood, MJ; Soejono, RP; Jatmiko; Saptomo, EW; Due, RA			A new small-bodied hominin from the Late Pleistocene of Flores, Indonesia	NATURE			English	Article							RELATIVE BRAIN SIZE; PLIOPLEISTOCENE HOMINIDS; DENTAL MORPHOLOGY; BODY PROPORTIONS; HOMO; AUSTRALOPITHECUS; ALLOMETRY; STATURE; DMANISI; ISLAND	Currently, it is widely accepted that only one hominin genus, Homo, was present in Pleistocene Asia, represented by two species, Homo erectus and Homo sapiens. Both species are characterized by greater brain size, increased body height and smaller teeth relative to Pliocene Australopithecus in Africa. Here we report the discovery, from the Late Pleistocene of Flores, Indonesia, of an adult hominin with stature and endocranial volume approximating 1 m and 380 cm(3), respectively - equal to the smallest-known australopithecines. The combination of primitive and derived features assigns this hominin to a new species, Homo floresiensis. The most likely explanation for its existence on Flores is long-term isolation, with subsequent endemic dwarfing, of an ancestral H. erectus population. Importantly, H. floresiensis shows that the genus Homo is morphologically more varied and flexible in its adaptive responses than previously thought.	Univ New England, Sch Human & Environm Studies, Armidale, NSW 2351, Australia; Indonesian Ctr Archaeol, Jakarta 12001, Indonesia	University of New England	Brown, P (corresponding author), Univ New England, Sch Human & Environm Studies, Armidale, NSW 2351, Australia.	pbrown3@pobox.une.edu.au	Brown, Peter/C-8763-2018; Sutikna, Thomas/C-4709-2018	Sutikna, Thomas/0000-0002-9742-4226				AIELLO A, 1990, INTRO HUMAN EVOLUTIO; Baba H, 2003, SCIENCE, V299, P1384, DOI 10.1126/science.1081676; BAILEY RC, 1991, HUM ECOL, V19, P261, DOI 10.1007/BF00888748; BEALS KL, 1984, CURR ANTHROPOL, V25, P301, DOI 10.1086/203138; BRAUER G, 1992, J HUM EVOL, V22, P79, DOI 10.1016/0047-2484(92)90032-5; Brown P, 2004, ANTHROPOL SCI, V112, P29, DOI 10.1537/ase.00072; Brown Peter, 1994, Courier Forschungsinstitut Senckenberg, V171, P33; Cavalli-Sforza L. L., 1986, AFRICAN PYGMIES; COUNT EW, 1947, ANN NY ACAD SCI, V46, P993, DOI 10.1111/j.1749-6632.1947.tb36165.x; Gabunia L, 2000, SCIENCE, V288, P1019, DOI 10.1126/science.288.5468.1019; GEFFNER ME, 1995, J CLIN ENDOCR METAB, V80, P3732, DOI 10.1210/jc.80.12.3732; Haeusler M, 2004, J HUM EVOL, V46, P433, DOI 10.1016/j.jhevol.2004.01.004; Hiernaux J., 1974, PEOPLE AFRICA; Jaffe H., 1972, METABOLIC DEGENERATI; Jeffery N, 2002, AM J MED GENET, V111, P260, DOI 10.1002/ajmg.10559; Jerison HJ., 1973, EVOLUTION BRAIN INTE; JOHANSON DC, 1979, SCIENCE, V203, P321, DOI 10.1126/science.104384; JUNGERS WL, 1982, NATURE, V297, P676, DOI 10.1038/297676a0; JUNGERS WL, 1988, AM J PHYS ANTHROPOL, V76, P227, DOI 10.1002/ajpa.1330760211; KAIFU Y, IN PRESS AM J PHYSL; KENNEDY GE, 1983, J HUM EVOL, V12, P587, DOI 10.1016/S0047-2484(83)80001-3; Kohler M, 2004, BRAIN BEHAV EVOLUT, V63, P125, DOI 10.1159/000076239; Lieberman DE, 2000, YEARB PHYS ANTHROPOL, V43, P117; LOMOLINO MV, 1985, AM NAT, V125, P310, DOI 10.1086/284343; LUCA APS, 1980, NGANDONG FOSSIL HOMI; MARTIN RD, 1981, NATURE, V293, P57, DOI 10.1038/293057a0; McHenry H.M., 1988, P133; McHenry HM, 2002, CAM S BIO EVOL ANTHR, V33, P401; McHenry HM, 2000, ANNU REV ANTHROPOL, V29, P125, DOI 10.1146/annurev.anthro.29.1.125; MERIMEE TJ, 1987, NEW ENGL J MED, V316, P906, DOI 10.1056/NEJM198704093161503; Morwood MJ, 2004, NATURE, V431, P1087, DOI 10.1038/nature02956; Morwood MJ, 1998, NATURE, V392, P173, DOI 10.1038/32401; Rak Y., 1983, AUSTRALOPITHECINE FA, DOI [10.1016/B978-0-12-576280-9.50006-7, DOI 10.1016/B978-0-12-576280-9.50006-7]; RIMOIN DL, 1966, SCIENCE, V152, P1635, DOI 10.1126/science.152.3729.1635; Roberts D. F., 1978, CLIMATE HUMAN VARIAB; Ruff Christopher B., 1994, Yearbook of Physical Anthropology, V37, P65; SECKEL HPG, 1960, BIRD HEADED DWARFS; Shea BT, 1996, AM J PHYS ANTHROPOL, V100, P311; Sondaar P.Y., 1977, MAJOR PATTERNS VERTE, P671, DOI DOI 10.1007/978-1-4684-8851-7; Spoor F, 1997, S AFR J SCI, V93, P182; STERN JT, 1983, AM J PHYS ANTHROPOL, V60, P279, DOI 10.1002/ajpa.1330600302; Tobias PV., 1992, S AFR ARCHAEOL B, V47, P137, DOI [10.2307/3889219, DOI 10.2307/3889219]; Vekua A, 2002, SCIENCE, V297, P85, DOI 10.1126/science.1072953; Walker A., 1993, NARIOKOTOME HOMO ERE; Weidenreich F., 1943, Palaeontologia Sinica, VD 10, P1; Wood B, 1999, SCIENCE, V284, P65, DOI 10.1126/science.284.5411.65; Wood B., 1991, HOMINID CRANIAL REMA, V4; WOOD BA, 1987, J ANAT, V154, P121; WOOD BA, 1988, J ANAT, V156, P107	49	549	578	13	443	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1055	1061		10.1038/nature02999	http://dx.doi.org/10.1038/nature02999			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	865VB	15514638	Green Published			2022-12-28	WOS:000224730800030
J	Xu, P; Widmer, G; Wang, YP; Ozaki, LS; Alves, JM; Serrano, MG; Puiu, D; Manque, P; Akiyoshi, D; Mackey, AJ; Pearson, WR; Dear, PH; Bankier, AT; Peterson, DL; Abrahamsen, MS; Kapur, V; Tzipori, S; Buck, GA				Xu, P; Widmer, G; Wang, YP; Ozaki, LS; Alves, JM; Serrano, MG; Puiu, D; Manque, P; Akiyoshi, D; Mackey, AJ; Pearson, WR; Dear, PH; Bankier, AT; Peterson, DL; Abrahamsen, MS; Kapur, V; Tzipori, S; Buck, GA			The genome of Cryptosporidium hominis	NATURE			English	Article							TOXOPLASMA-GONDII; PARVUM; SEQUENCE; GENE; BIOSYNTHESIS; APICOMPLEXAN; ENCODE	Cryptosporidium species cause acute gastroenteritis and diarrhoea worldwide. They are members of the Apicomplexa - protozoan pathogens that invade host cells by using a specialized apical complex and are usually transmitted by an invertebrate vector or intermediate host. In contrast to other Apicomplexans, Cryptosporidium is transmitted by ingestion of oocysts and completes its life cycle in a single host. No therapy is available, and control focuses on eliminating oocysts in water supplies(1). Two species, C. hominis and C. parvum, which differ in host range, genotype and pathogenicity, are most relevant to humans(1-3). C. hominis is restricted to humans, whereas C. parvum also infects other mammals(2). Here we describe the eight-chromosome similar to9.2-million-base genome of C. hominis(2). The complement of C. hominis protein-coding genes shows a striking concordance with the requirements imposed by the environmental niches the parasite inhabits. Energy metabolism is largely from glycolysis. Both aerobic and anaerobic metabolisms are available, the former requiring an alternative electron transport system in a simplified mitochondrion. Biosynthesis capabilities are limited, explaining an extensive array of transporters. Evidence of an apicoplast is absent, but genes associated with apical complex organelles are present. C. hominis and C. parvum exhibit very similar gene complements, and phenotypic differences between these parasites must be due to subtle sequence divergence.	Virginia Commonwealth Univ, Ctr Study Biol Complex, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Philips Inst Oral & Craniofacial Mol Biol, Richmond, VA 23298 USA; Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA; Univ Minnesota, Dept Vet & Biomed Sci, St Paul, MN 55108 USA; Univ Minnesota, Biomed Genom Ctr, St Paul, MN 55108 USA; Univ Minnesota, Dept Microbiol, St Paul, MN 55108 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Tufts University; University of Virginia; University of Virginia; MRC Laboratory Molecular Biology; Virginia Commonwealth University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Buck, GA (corresponding author), Virginia Commonwealth Univ, Ctr Study Biol Complex, Med Coll Virginia Campus, Richmond, VA 23284 USA.	saul.tzipori@tufts.edu; buck@mail2.vcu.edu	Alves, Joao M.P./G-8927-2011; Pearson, William/K-4908-2019; Dear, Paul H/A-1162-2012; Kapur, Vivek/F-7610-2013	Alves, Joao M.P./0000-0001-5914-2087; Pearson, William/0000-0002-0727-3680; manque, patricio/0000-0002-6606-0896; Kapur, Vivek/0000-0002-9648-0138				Abrahamsen MS, 2004, SCIENCE, V304, P441, DOI 10.1126/science.1094786; Akiyoshi DE, 2002, INFECT IMMUN, V70, P5670, DOI 10.1128/IAI.70.10.5670-5675.2002; Atreya CE, 2004, J BIOL CHEM, V279, P18314, DOI 10.1074/jbc.M400009200; Bankier AT, 2003, GENOME RES, V13, P1787, DOI 10.1101/gr.1555203; Beyer TV, 2002, CELL BIOL INT, V26, P861, DOI 10.1006/cbir.2002.0943; Chaturvedi S, 1999, J BIOL CHEM, V274, P2424, DOI 10.1074/jbc.274.4.2424; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Geer LY, 2002, GENOME RES, V12, P1619, DOI 10.1101/gr.278202; Jasso-Chavez R, 2003, EUR J BIOCHEM, V270, P4942, DOI 10.1046/j.1432-1033.2003.03896.x; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; Keithly JS, 1997, MOL BIOCHEM PARASIT, V88, P35, DOI 10.1016/S0166-6851(97)00063-7; LaGier MJ, 2003, MICROBIOL-SGM, V149, P3519, DOI 10.1099/mic.0.26365-0; Morgan-Ryan UM, 2002, J EUKARYOT MICROBIOL, V49, P433, DOI 10.1111/j.1550-7408.2002.tb00224.x; Muhia DK, 2003, J BIOL CHEM, V278, P22014, DOI 10.1074/jbc.M301639200; Muller M, 1998, SYST ASSOC SPEC VOL, V56, P109; Ngo HM, 2003, J BIOL CHEM, V278, P5343, DOI 10.1074/jbc.M208291200; Parsons M, 2000, PARASITOL TODAY, V16, P56, DOI 10.1016/S0169-4758(99)01590-2; Petry F, 1999, INT J PARASITOL, V29, P1249, DOI 10.1016/S0020-7519(99)00080-6; Priest JW, 2001, MOL BIOCHEM PARASIT, V113, P117, DOI 10.1016/S0166-6851(00)00386-8; Riordan CE, 2003, CURR GENET, V44, P138, DOI 10.1007/s00294-003-0432-1; Sanchez LB, 2000, J BIOL CHEM, V275, P5794, DOI 10.1074/jbc.275.8.5794; Simpson AGB, 2002, MOL BIOL EVOL, V19, P1782, DOI 10.1093/oxfordjournals.molbev.a004000; Stedman TT, 2003, J BIOL CHEM, V278, P5433, DOI 10.1074/jbc.M209390200; Striepen B, 2004, P NATL ACAD SCI USA, V101, P3154, DOI 10.1073/pnas.0304686101; Tetley L, 1998, MICROBIOL-SGM, V144, P3249, DOI 10.1099/00221287-144-12-3249; Tzipori S, 2002, MICROBES INFECT, V4, P1047, DOI 10.1016/S1286-4579(02)01629-5; Zhu G, 2004, MOL BIOCHEM PARASIT, V134, P127, DOI 10.1016/j.molbiopara.2003.11.011; Zhu G, 2000, MICROBIOL-SGM, V146, P315, DOI 10.1099/00221287-146-2-315; Zhu G, 2002, GENE, V298, P79, DOI 10.1016/S0378-1119(02)00931-9; Zuther E, 1999, P NATL ACAD SCI USA, V96, P13387, DOI 10.1073/pnas.96.23.13387	30	392	433	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1107	1112		10.1038/nature02977	http://dx.doi.org/10.1038/nature02977			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15510150	hybrid			2022-12-28	WOS:000224730800043
J	Homs, MYV; Steyerberg, EW; Eijkenboom, WMH; Tilanus, HW; Stalpers, LJA; Bartelsman, JFWM; van Lanschot, JJB; Wijrdeman, HK; Mulder, CJJ; Reinders, JG; Boot, H; Aleman, BMP; Kuipers, E; Siersema, PD				Homs, MYV; Steyerberg, EW; Eijkenboom, WMH; Tilanus, HW; Stalpers, LJA; Bartelsman, JFWM; van Lanschot, JJB; Wijrdeman, HK; Mulder, CJJ; Reinders, JG; Boot, H; Aleman, BMP; Kuipers, E; Siersema, PD		Dutch SIREC study grp	Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial	LANCET			English	Article							QUALITY-OF-LIFE; INTRALUMINAL BRACHYTHERAPY; ESOPHAGOGASTRIC NEOPLASMS; MALIGNANT DYSPHAGIA; CARCINOMA; ADENOCARCINOMA; OBSTRUCTION; IRRADIATION; GUIDELINES; CARDIA	Background Both single-dose brachytherapy and self-expanding metal stent placement are commonly used for palliation of oesophageal obstruction due to inoperable cancer, but their relative merits are unknown. We under-took a randomised trial to compare the outcomes of brachytherapy and stent placement in patients with oesophageal cancer. Methods Nine hospitals in the Netherlands participated in our study. Between December, 1999, and June, 2002, 209 patients with dysphagia from inoperable carcinoma of the oesophagus or oesophagogastric junction were randomly assigned to stent placement (n=108) or single-dose (12 Gy) brachytherapy (n=101), and were followed up after treatment. Primary outcome was relief of dysphagia during follow-up, and secondary outcomes were complications, treatment for persistent or recurrent dysphagia, health-related quality of life, and costs. Analysis was by intention to treat. Findings Nine patients (six [brachytherapy] vs three [stent placement]) did not receive their allocated treatments. None was lost to follow-up. Dysphagia improved more rapidly after stent placement than after brachytherapy, but long-term relief of dysphagia was better after brachytherapy. Stent placement had more complications than brachytherapy (36[33%] of 108 vs 21 [21%] of 101; p=0.02), which was mainly due to an increased incidence of late haemorrhage (14 [13%] of 108 vs five [5%] of 101; p=0.05). Groups did not differ for persistent or recurrent dysphagia (p=0.81), or for median survival (p=0.23). Quality-of-life scores were in favour of brachytherapy compared with stent placement. Total medical costs were also much the same for stent placement ((sic)8215) and brachytherapy ((sic)8135). Interpretation Despite slow improvement, single-dose brachytherapy gave better long-term relief of dysphagia than metal stent placement. Since brachytherapy was also associated with fewer complications than stent placement, we recommend it as the primary treatment for palliation of dysphagia from oesophageal cancer.	Univ Med Ctr Rotterdam, Erasmus MC, Dept Gastroenterol & Hepatol, NL-3000 CA Rotterdam, Netherlands; Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; Univ Med Ctr Rotterdam, Erasmus MC, Dept Radiotherapy, NL-3000 CA Rotterdam, Netherlands; Univ Med Ctr Rotterdam, Erasmus MC, Dept Surg, NL-3000 CA Rotterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Radiotherapy, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands; Univ Med Ctr Utrecht, Dept Radiotherapy, Utrecht, Netherlands; Rijnstate Hosp, Dept Gastroenterol, Arnhem, Netherlands; Arnhem Radiotherapeut Inst, Arnhem, Netherlands; Netherlands Canc Inst, Dept Gastroenterol, Amsterdam, Netherlands; Netherlands Canc Inst, Dept Radiotherapy, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center; Rijnstate Hospital; Netherlands Cancer Institute; Netherlands Cancer Institute	Siersema, PD (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Gastroenterol & Hepatol, POB 2040, NL-3000 CA Rotterdam, Netherlands.	p.siersema@erasmusmc.nl	Kuipers, Ernst J/H-3293-2019; Siersema, Peter/V-1636-2019; Stalpers, Lukas/AAP-1701-2020; Steyerberg, Ewout/C-1509-2018	Kuipers, Ernst J/0000-0002-0633-3098; Steyerberg, Ewout/0000-0002-7787-0122				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Allgaier HP, 1997, NEW ENGL J MED, V337, P1778, DOI 10.1056/NEJM199712113372417; Allum WH, 2002, GUT, V50, P1; Bartelsman JFW, 2000, GASTROINTEST ENDOSC, V51, P134, DOI 10.1016/S0016-5107(00)70407-X; Blazeby JM, 1996, EUR J CANCER, V32A, P1912, DOI 10.1016/0959-8049(96)00199-2; Blazeby JM, 2001, SURG ONCOL, V10, P127, DOI 10.1016/S0960-7404(01)00024-X; Blazeby JM, 2000, CANCER, V88, P1781; Botterweck AAM, 2000, INT J EPIDEMIOL, V29, P645, DOI 10.1093/ije/29.4.645; Brewster A E, 1995, Clin Oncol (R Coll Radiol), V7, P102, DOI 10.1016/S0936-6555(05)80810-6; Christie NA, 2001, ANN THORAC SURG, V71, P1797, DOI 10.1016/S0003-4975(01)02619-4; Dallal HJ, 2001, GASTROINTEST ENDOSC, V54, P549, DOI 10.1067/mge.2001.118947; DEPALMA GD, 1995, AM J GASTROENTEROL, V90, P2140; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Efron B., 1994, MONOGRAPHS STAT APPL; Fairclough DL, 2002, DESIGN ANAL QUALITY; Gaspar LE, 1997, INT J RADIAT ONCOL, V38, P127, DOI 10.1016/S0360-3016(97)00231-9; Gold MR, 1996, COST EFFECTIVENESS H; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; Homs MYV, 2003, RADIOTHER ONCOL, V66, P327, DOI 10.1016/S0167-8140(02)00410-3; Jager J, 1995, RADIOTHER ONCOL, V37, P237, DOI 10.1016/0167-8140(95)01667-8; Kozarek RA, 1996, GASTROINTEST ENDOSC, V44, P562, DOI 10.1016/S0016-5107(96)70009-3; OGILVIE AL, 1982, GUT, V23, P1060, DOI 10.1136/gut.23.12.1060; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Raijman I, 1998, GASTROINTEST ENDOSC, V48, P172, DOI 10.1016/S0016-5107(98)70159-2; Sabharwal T, 2003, GUT, V52, P922, DOI 10.1136/gut.52.7.922; Schraube P, 1997, RADIOTHER ONCOL, V44, P45, DOI 10.1016/S0167-8140(97)00083-2; Siersema PD, 2003, ENDOSCOPY, V35, P79, DOI 10.1055/s-2003-36418; Siersema PD, 2001, GASTROINTEST ENDOSC, V54, P145, DOI 10.1016/S0016-5107(01)70098-3; Siersema PD, 1997, ENDOSCOPY, V29, P416, DOI 10.1055/s-2007-1004227; Spencer GM, 2002, GUT, V50, P224, DOI 10.1136/gut.50.2.224; Sundelof M, 2002, INT J CANCER, V99, P751, DOI 10.1002/ijc.10420; Sur M, 1996, CANCER, V77, P2200, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2200::AID-CNCR3>3.0.CO;2-T; Sur RK, 2002, INT J RADIAT ONCOL, V53, P127, DOI 10.1016/S0360-3016(02)02702-5; Sur RK, 1998, INT J RADIAT ONCOL, V40, P447, DOI 10.1016/S0360-3016(97)00710-4; Taal BG, 1996, BRIT J CANCER, V74, P1452, DOI 10.1038/bjc.1996.564; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; Vakil N, 2001, AM J GASTROENTEROL, V96, P1791, DOI 10.1016/S0002-9270(01)02486-8	39	324	339	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1497	1504		10.1016/S0140-6736(04)17272-3	http://dx.doi.org/10.1016/S0140-6736(04)17272-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500894				2022-12-28	WOS:000224645500027
J	Kemner, KM; Kelly, SD; Lai, B; Maser, J; O'Loughlin, EJ; Sholto-Douglas, D; Cai, ZH; Schneegurt, MA; Kulpa, CF; Nealson, KH				Kemner, KM; Kelly, SD; Lai, B; Maser, J; O'Loughlin, EJ; Sholto-Douglas, D; Cai, ZH; Schneegurt, MA; Kulpa, CF; Nealson, KH			Elemental and redox analysis of single bacterial cells by X-ray microbeam analysis	SCIENCE			English	Article							PSEUDOMONAS-FLUORESCENS; ZONE PLATES; EXOPOLYSACCHARIDES; POLYSACCHARIDES; BIOFILMS; ALGINATE; CALCIUM; PUTIDA; IONS	High-energy x-ray fluorescence measurements were used to make elemental maps and qualitative chemical analyses of individual Pseudomonas fluorescens strain NCIMB 11764 cells. Marked differences between planktonic and adhered cells were seen in the morphology, elemental composition, and sensitivity to Cr(VI) of hydrated cells at spatial scales of 150 nm. This technology can be applied to natural geomicrobiological systems.	Argonne Natl Lab, Div Environm Res, Argonne, IL 60439 USA; Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA; Wichita State Univ, Dept Biol Sci, Wichita, KS 67260 USA; Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA	United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; Wichita State University; University of Notre Dame; University of Southern California	Kemner, KM (corresponding author), Argonne Natl Lab, Div Environm Res, 9700 S Cass Ave, Argonne, IL 60439 USA.	kemner@anl.gov	O'Loughlin, Edward/C-9565-2013; Maser, Jörg/K-6817-2013	O'Loughlin, Edward/0000-0003-1607-9529; 				BEVERIDGE TJ, 1989, ANNU REV MICROBIOL, V43, P147, DOI 10.1146/annurev.mi.43.100189.001051; Braccini I, 1999, CARBOHYD RES, V317, P119, DOI 10.1016/S0008-6215(99)00062-2; Cai Z, 2000, AIP CONF PROC, V507, P472, DOI 10.1063/1.1291193; CONTI E, 1994, MICROBIOL-UK, V140, P1125, DOI 10.1099/13500872-140-5-1125; COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431; COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251; FETT WF, 1989, APPL ENVIRON MICROB, V55, P579, DOI 10.1128/AEM.55.3.579-583.1989; GRANT GT, 1973, FEBS LETT, V32, P195, DOI 10.1016/0014-5793(73)80770-7; Gregor JE, 1996, WATER RES, V30, P1319, DOI 10.1016/0043-1354(95)00194-8; Kemner KM, 1999, J SYNCHROTRON RADIAT, V6, P639, DOI 10.1107/S0909049598016586; Langley S, 1999, CAN J MICROBIOL, V45, P616, DOI 10.1139/cjm-45-7-616; LOVLEY DR, 1991, MICROBIOL REV, V55, P259, DOI 10.1128/MMBR.55.2.259-287.1991; NEALSON KH, 1994, ANNU REV MICROBIOL, V48, P311, DOI 10.1146/annurev.mi.48.100194.001523; READ RR, 1987, CAN J MICROBIOL, V33, P1080, DOI 10.1139/m87-189; SKJAKBRAEK G, 1986, CARBOHYD RES, V154, P239; Twining BS, 2003, ANAL CHEM, V75, P3806, DOI 10.1021/ac034227z; Winkelmann G., 1997, TRANSITION METALS MI; Yun W, 1999, REV SCI INSTRUM, V70, P2238, DOI 10.1063/1.1149744	18	134	140	0	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					686	687		10.1126/science.1103524	http://dx.doi.org/10.1126/science.1103524			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499017				2022-12-28	WOS:000224756700051
J	Luft, AR; McCombe-Waller, S; Whitall, J; Forrester, LW; Macko, R; Sorkin, JD; Schulz, JB; Goldberg, AP; Hanley, DF				Luft, AR; McCombe-Waller, S; Whitall, J; Forrester, LW; Macko, R; Sorkin, JD; Schulz, JB; Goldberg, AP; Hanley, DF			Repetitive bilateral arm training and motor cortex activation in chronic stroke - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED MOVEMENT THERAPY; CORTICAL REORGANIZATION; FUNCTIONAL MRI; HEMIPLEGIC STROKE; BRAIN ACTIVATION; LIMB MOVEMENT; RECOVERY; PLASTICITY; EVOLUTION; FMRI	Context Reorganization in central motor networks occurs during early recovery from hemiparetic stroke. In chronic stroke survivors, specific rehabilitation therapy can improve upper extremity function. Objective To test the hypothesis that in patients who have chronic motor impairment following stroke, specific rehabilitation therapy that improves arm function is associated with reorganization of cortical networks. Design, Setting, and Patients A randomized controlled clinical trial conducted in a US ambulatory rehabilitation program with 21 patients (median [IQR], 50.3 [34.8-77.3] months after unilateral stroke). Data were collected between 2001 and 2004. Interventions Patients were randomly assigned to bilateral arm training with rhythmic auditory cueing (BATRAC) (n=9) or standardized dose-matched therapeutic exercises (DMTE) (n=12). Both were conducted for 1 hour, 3 times a week, for 6 weeks. Main Outcome Measures Within 2 weeks before and after the intervention, brain activation during elbow movement assessed by functional magnetic resonance imaging (fMRI) and functional outcome assessed using arm function scores. Results Patients in the BATRAC group but not in the DMTE group increased hemispheric activation during paretic arm movement (P=.03). Changes in activation were observed in the contralesional cerebrum and ipsilesional cerebellum (P=.009). BATRAC was associated with significant increases in activation in precentral (P<.001) and postcentral gyri (P=.03) and the cerebellum (P<.001), although 3 BATRAC patients showed no fMRI changes. Considering all patients, there were no differences in functional outcome between groups. When only BATRAC patients with fMRI response were included (n=6), BATRAC improved arm function more than DMTE did (P=.02). Conclusions These preliminary findings suggest that BATRAC induces reorganization in contralesional motor networks and provide biological plausibility for repetitive bilateral training as a potential therapy for upper extremity rehabilitation in hemiparetic stroke.	Univ Maryland, Sch Med, Dept Phys Therapy & Rehabil Sci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Div Gerontol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; Johns Hopkins Univ, Dept Neurol, Div Brain Injury Outcome, Baltimore, MD 21218 USA; Univ Tubingen, Hertie Inst Clin Brain Res, Dept Gen Neurol, Tubingen, Germany; Baltimore Vet Affairs Maryland Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Geriatric Research Education & Clinical Center	Whitall, J (corresponding author), Univ Maryland, Sch Med, Dept Phys Therapy & Rehabil Sci, 100 Penn St, Baltimore, MD 21201 USA.	Jwhitall@som.umaryland.edu	Schulz, Jörg B/D-9786-2012	Schulz, Jörg B/0000-0002-8903-0593; Hanley, Daniel/0000-0002-9536-4258	NIA NIH HHS [P60 AG012583, P60AG 12583, P60 AG012583-08] Funding Source: Medline; NINDS NIH HHS [R01 NS024282, 1R01 NS 24282-08] Funding Source: Medline; PHS HHS [M01-00052] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG012583] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Calautti C, 2003, STROKE, V34, P1553, DOI 10.1161/01.STR.0000071761.36075.A6; Cao Y, 1998, STROKE, V29, P112, DOI 10.1161/01.STR.29.1.112; Carey JR, 2002, BRAIN, V125, P773, DOI 10.1093/brain/awf091; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Classen J, 1997, BRAIN, V120, P605, DOI 10.1093/brain/120.4.605; Cramer SC, 1997, STROKE, V28, P2518, DOI 10.1161/01.STR.28.12.2518; Cramer SC, 2000, NEUROPHARMACOLOGY, V39, P842, DOI 10.1016/S0028-3908(99)00258-0; Cuadrado ML, 1999, CEREBROVASC DIS, V9, P337, DOI 10.1159/000016009; DAVIES PM, 2000, STEPS FOLLOW COMPREH, V7, P2; Feydy A, 2002, STROKE, V33, P1610, DOI 10.1161/01.STR.0000017100.68294.52; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Friston Karl J., 1996, P363; Geyer S, 2000, ANAT EMBRYOL, V202, P443, DOI 10.1007/s004290000127; GOWLAND C, 1992, PHYS THER, V72, P624, DOI 10.1093/ptj/72.9.624; Green JB, 1999, STROKE, V30, P2659, DOI 10.1161/01.STR.30.12.2659; GRESHAM GE, 1979, ARCH PHYS MED REHAB, V60, P487; Hallett M, 2001, BRAIN RES REV, V36, P169, DOI 10.1016/S0165-0173(01)00092-3; Herholz K, 2000, J CEREBR BLOOD F MET, V20, P1619, DOI 10.1097/00004647-200012000-00001; Honda M, 1997, J NEUROL SCI, V146, P117, DOI 10.1016/S0022-510X(96)00291-2; Jang SH, 2003, NEUROREPORT, V14, P1305, DOI 10.1097/01.wnr.0000078700.79393.09; Jang SH, 2003, NEUROREPORT, V14, P137, DOI 10.1097/00001756-200301200-00025; Johansen-Berg H, 2002, BRAIN, V125, P2731, DOI 10.1093/brain/awf282; Johansen-Berg H, 2002, P NATL ACAD SCI USA, V99, P14518, DOI 10.1073/pnas.222536799; Jorgensen H S, 1999, Phys Med Rehabil Clin N Am, V10, P887; Levy CE, 2001, AM J PHYS MED REHAB, V80, P4, DOI 10.1097/00002060-200101000-00003; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; Luft AR, 2002, HUM BRAIN MAPP, V17, P131, DOI 10.1002/hbm.10058; Luft AR, 1998, HUM BRAIN MAPP, V6, P105, DOI 10.1002/(SICI)1097-0193(1998)6:2<105::AID-HBM3>3.0.CO;2-7; Luft AR, 2004, NEUROIMAGE, V21, P924, DOI 10.1016/j.neuroimage.2003.10.026; Marshall RS, 2000, STROKE, V31, P656, DOI 10.1161/01.STR.31.3.656; Mayo NE, 1999, DISABIL REHABIL, V21, P258; Murase N, 2004, ANN NEUROL, V55, P400, DOI 10.1002/ana.10848; Nelles G, 1999, ANN NEUROL, V46, P901, DOI 10.1002/1531-8249(199912)46:6<901::AID-ANA13>3.0.CO;2-7; PARLOW SE, 1991, BEHAV BRAIN RES, V46, P1, DOI 10.1016/S0166-4328(05)80091-9; SANFORD J, 1993, PHYS THER, V73, P447, DOI 10.1093/ptj/73.7.447; Schaechter JD, 2002, NEUROREHAB NEURAL RE, V16, P326, DOI 10.1177/154596830201600403; Small SL, 2002, BRAIN, V125, P1544, DOI 10.1093/brain/awf148; Taub E, 1999, J REHABIL RES DEV, V36, P237; Thaut MH, 2002, NEUROPSYCHOLOGIA, V40, P1073, DOI 10.1016/S0028-3932(01)00141-5; Turton A, 1996, ELECTROMYOGR MOTOR C, V101, P316, DOI 10.1016/0924-980X(96)95560-5; UGAWA Y, 1993, NEUROSCI LETT, V160, P153, DOI 10.1016/0304-3940(93)90401-6; Ward NS, 2003, BRAIN, V126, P1430, DOI 10.1093/brain/awg145; Ward NS, 2003, BRAIN, V126, P2476, DOI 10.1093/brain/awg245; Werhahn KJ, 2003, ANN NEUROL, V54, P464, DOI 10.1002/ana.10686; Whitall J, 2000, STROKE, V31, P2390, DOI 10.1161/01.STR.31.10.2390; Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635	46	399	418	0	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2004	292	15					1853	1861		10.1001/jama.292.15.1853	http://dx.doi.org/10.1001/jama.292.15.1853			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IV	15494583	Bronze, Green Accepted			2022-12-28	WOS:000224485100024
J	Clase, CM; Garg, AX; Kiberd, BA				Clase, CM; Garg, AX; Kiberd, BA			Classifying kidney problems: can we avoid framing risks as diseases?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							3RD NATIONAL-HEALTH; STAGE RENAL-DISEASE; INSUFFICIENCY; PROTEINURIA; INHIBITION; PREVALENCE; OUTCOMES; FAILURE	A new international classification system for kidney problems is currently being developed. How can it meet the challenges of avoiding labelling all patients with low function as having kidney disease and being usable in countries with limited resources?	McMaster Univ, Dept Med, Hamilton, ON, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Dalhousie Univ, Dept Med, Halifax, NS, Canada	McMaster University; Western University (University of Western Ontario); Dalhousie University	Clase, CM (corresponding author), Suite 708,25 Charlton Ave E, Hamilton, ON L8N 1Y2, Canada.	clase@mcmaster.ca	Garg, Amit X/G-3295-2011	Clase, Catherine/0000-0002-4538-5958				Clase CM, 2002, J AM SOC NEPHROL, V13, P2812; Clase CM, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013291.78621.26; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; *ERA EDTA REG, 2003, ANN REP 2003; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; Hsu C, 2000, AM J KIDNEY DIS, V36, P415, DOI 10.1053/ajkd.2000.8996; Iseki K, 2003, KIDNEY INT, V63, P1468, DOI 10.1046/j.1523-1755.2003.00868.x; Iseki K, 1996, KIDNEY INT, V49, P800, DOI 10.1038/ki.1996.111; Iseki K, 1997, KIDNEY INT, V51, P850, DOI 10.1038/ki.1997.119; John R, 2004, AM J KIDNEY DIS, V43, P825, DOI 10.1053/j.ajkd.2003.12.046; KANNEL WB, 1984, AM HEART J, V108, P1347, DOI 10.1016/0002-8703(84)90763-4; KHAN IH, 1995, NEPHROL DIAL TRANSPL, V10, P684; Lamping DL, 2000, LANCET, V356, P1543, DOI 10.1016/S0140-6736(00)03123-8; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LINDEMAN RD, 1985, J AM GERIATR SOC, V33, P278, DOI 10.1111/j.1532-5415.1985.tb07117.x; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; Moynihan R, 2002, BRIT MED J, V324, P886, DOI 10.1136/bmj.324.7342.886; Ruggenenti P, 1999, LANCET, V354, P359, DOI 10.1016/S0140-6736(98)10363-X; Trivedi HS, 2002, AM J KIDNEY DIS, V39, P721, DOI 10.1053/ajkd.2002.31990	20	39	39	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	2004	329	7471					912	915		10.1136/bmj.329.7471.912	http://dx.doi.org/10.1136/bmj.329.7471.912			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863MU	15485978	Green Published			2022-12-28	WOS:000224566800029
J	Gelman, R; Gallistel, CR				Gelman, R; Gallistel, CR			Language and the origin of numerical concepts	SCIENCE			English	Editorial Material								Reports of research with the Piraha and Munduruku Amazonian Indians of Brazil lend themselves to discussions of the role of language in the origin of numerical concepts. The research findings indicate that, whether or not humans have an extensive counting list, they share with nonverbal animals a language-independent representation of number, with limited, scale-invariant precision. What causal role, then, does knowledge of the language of counting serve? We consider the strong Whorfian proposal, that of linguistic determinism; the weak Whorfian hypothesis, that language influences how we think; and that the "language of thought" maps to spoken language or symbol systems.	Rutgers State Univ, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Gelman, R (corresponding author), Rutgers State Univ, 152 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	rgelman@ruccs.rutgers.edu; Galliste@ruccs.rutgers.edu	Gallistel, Charles/K-4701-2019					Brannon EM, 2002, COGNITIVE ANIMAL, P197; BUCKLEY PB, 1974, J EXP PSYCHOL, V103, P1131, DOI 10.1037/h0037361; Butterworth B., 1999, MATH BRAIN; Carey S, 2004, DAEDALUS-US, V133, P59, DOI 10.1162/001152604772746701; DAVIS H, 1988, BEHAV BRAIN SCI, V11, P561, DOI 10.1017/S0140525X00053437; Dehaene S., 1997, NUMBER SENSE; Fodor J. A., 1975, LANGUAGE THOUGHT; Gallistel C. R., 1990, ORG LEARNING; GALLISTEL CR, IN PRESS HDB THINKIN; Gelman R., 2001, LANGUAGE BRAIN COGNI, P279; GELMAN R, IN PRESS TRENDS COGN; Gentner D, 2003, BRADFORD BOOKS, P1; GLEITMAN L, IN PRESS HDB THINKIN; GLEITMAN L, IN PRESS LANG LEARN; Gordon P, 2004, SCIENCE, V306, P496, DOI 10.1126/science.1094492; LEVINSON SC, 1996, LANGUAGE SPACE, pCH4; Pica P, 2004, SCIENCE, V306, P499, DOI 10.1126/science.1102085; VONGLASERSFELD E, 1993, DEV NUMERICAL COMPET, P225	18	109	109	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					441	443		10.1126/science.1105144	http://dx.doi.org/10.1126/science.1105144			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486289				2022-12-28	WOS:000224626500040
J	Kinane, TB; Westra, SJ				Kinane, TB; Westra, SJ			A four-year-old boy with hypoxemia - Hepatopulmonary syndrome due to the Abernethy malformation, type 1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PULMONARY ARTERIOVENOUS-MALFORMATIONS; HEREDITARY HEMORRHAGIC TELANGIECTASIA; LIVER-TRANSPLANTATION; CONGENITAL ABSENCE; PORTAL-VEIN; ANGIOGRAPHY; CT; CIRRHOSIS; DISEASE; SHUNT		Massachusetts Gen Hosp, Serv Pediat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Kinane, TB (corresponding author), Massachusetts Gen Hosp, Serv Pediat, Boston, MA 02114 USA.							Alvarez AE, 2002, PEDIATR PULM, V34, P391, DOI 10.1002/ppul.10182; Arguedas MR, 2003, HEPATOLOGY, V37, P192, DOI 10.1053/jhep.2003.50023; Badler R, 2002, PEDIATR RADIOL, V32, P28, DOI 10.1007/s00247-001-0590-6; BERNSTEIN D, 2000, NELSON TXB PEDIAT, P337; Churton T., 1897, BMJ-BRIT MED J, V1, P1223; Engelke C, 2002, RADIOGRAPHICS, V22, P739, DOI 10.1148/radiographics.22.4.g02jl01739; Engelke C, 2002, RADIOGRAPHICS, V22, P1516; Gossage JR, 1998, AM J RESP CRIT CARE, V158, P643, DOI 10.1164/ajrccm.158.2.9711041; HAITJEMA T, 1995, AM J MED, V99, P519, DOI 10.1016/S0002-9343(99)80229-0; HOPKINS WE, 1992, AM J CARDIOL, V70, P516, DOI 10.1016/0002-9149(92)91200-N; Howard ER, 1997, J PEDIATR SURG, V32, P494, DOI 10.1016/S0022-3468(97)90614-X; Kohda E, 1999, PEDIATR RADIOL, V29, P235, DOI 10.1007/s002470050580; KROWKA MJ, 1994, CHEST, V105, P1528, DOI 10.1378/chest.105.5.1528; Lange PA, 1996, CLIN CHEST MED, V17, P115, DOI 10.1016/S0272-5231(05)70302-6; LANGE PA, 1995, ANN INTERN MED, V122, P521, DOI 10.7326/0003-4819-122-7-199504010-00008; Lee J, 1998, ANN THORAC SURG, V65, P848, DOI 10.1016/S0003-4975(98)00011-3; Lee KN, 1999, RADIOLOGY, V211, P549, DOI 10.1148/radiology.211.2.r99ma46549; McAdams HP, 1996, AM J ROENTGENOL, V166, P1379, DOI 10.2214/ajr.166.6.8633451; PLAUCHU H, 1989, AM J MED GENET, V32, P291, DOI 10.1002/ajmg.1320320302; REMY J, 1992, RADIOLOGY, V182, P809, DOI 10.1148/radiology.182.3.1535899; RODRIGUEZROISIN R, 1987, AM REV RESPIR DIS, V135, P1085; Ryu JK, 2003, CLIN IMAG, V27, P97, DOI 10.1016/S0899-7071(02)00511-9; SLOAN RD, 1953, AM J ROENTGENOL, V70, P183; SRIVASTAVA D, 1995, CIRCULATION, V92, P1217, DOI 10.1161/01.CIR.92.5.1217; Taille C, 2003, TRANSPLANTATION, V75, P1482, DOI 10.1097/01.TP.0000061612.78954.6C; Usuki N, 1998, J COMPUT ASSIST TOMO, V22, P728, DOI 10.1097/00004728-199809000-00011; VASE P, 1985, ACTA MED SCAND, V218, P105; WEST JB, 1995, RESP PHYSL ESSENTIAL, P45; WHYTE MKB, 1992, THORAX, V47, P790, DOI 10.1136/thx.47.10.790	29	30	31	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1667	1675		10.1056/NEJMcpc049023	http://dx.doi.org/10.1056/NEJMcpc049023			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483286				2022-12-28	WOS:000224427300015
J	Ottenbacher, KJ; Smith, PM; Illig, SB; Linn, RT; Ostir, GV; Granger, CV				Ottenbacher, KJ; Smith, PM; Illig, SB; Linn, RT; Ostir, GV; Granger, CV			Trends in length of stay, living setting, functional outcome, and mortality following medical rehabilitation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNIFORM DATA SYSTEM; INDEPENDENCE MEASURE; ASSESSMENT SCALES; STROKE PATIENTS; 1ST ADMISSIONS; RELIABILITY; DISABILITY; AGREEMENT; TELEPHONE; COSTS	Content Changes in reimbursement have reduced length of stay (LOS) for patients receiving inpatient medical rehabilitation. The impact of decreased LOS on functional status, living setting, and mortality is not known. Objective To examine changes in LOS, functional status, living setting, and mortality in patients completing inpatient rehabilitation. Design Retrospective cohort study from 1994 through 2001 using information submitted to the Uniform Data System for Medical Rehabilitation. Setting and Participants Data were analyzed from 744 inpatient medical rehabilitation hospitals and centers located in 48 US states. A total of 148807 patient records from 5 impairment groups (stroke, brain dysfunction, spinal cord dysfunction, other neurologic conditions, and orthopedic conditions) were examined. Patients' mean age was 67.8 (SD, 15.8) years; the sample was 59% female and 81% non-Hispanic white. Main Outcome Measures Discharge setting, follow-up living setting, change in functional status, and mortality. Results Median LOS decreased from 20 to 12 days (P<.001) from 1994 to 2001. The proportional decrease in median LOS was greatest (42%) for patients with orthopedic conditions. Mean days to follow-up remained constant from 89 in 1994 to 90 in 2001. Functional status was clinically stable, while efficiency (functional status change divided by LOS) increased significantly (P<.001). Rates of discharge to home and living at home at follow-up remained stable, ranging from 81% to 93%. However, mortality at 80- to 180-day follow-up increased from less than 1% in 1994 to 4.7% in 2001. Conclusions Length of stay for inpatient rehabilitation decreased substantially from 1994 to 2001. Effectiveness as measured by change in functional status did not change clinically, and living setting did not change. Efficiency for functional outcomes improved but mortality at follow-up increased.	Univ Texas, Med Branch, Div Rehabil Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Div Geriatr, Sealy Ctr Aging, Galveston, TX 77555 USA; SUNY Buffalo, Uniform Data Syst Med Rehabil, Buffalo, NY 14260 USA; SUNY Buffalo, Dept Rehabil Med, Buffalo, NY 14260 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ottenbacher, KJ (corresponding author), Univ Texas, Med Branch, Div Rehabil Sci, 301 Univ Blvd, Galveston, TX 77555 USA.	kottenba@utmb.edu		Ottenbacher, Kenneth/0000-0001-5990-3982	NIA NIH HHS [P30 AG024832, KO2 AG019736] Funding Source: Medline; NICHD NIH HHS [R01 HD34622] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K02AG019736, P30AG024832] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson GF, 1999, HEALTH AFFAIR, V18, P178, DOI 10.1377/hlthaff.18.3.178; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Buchanan JL, 2003, HEALTH CARE FINANC R, V24, P45; Buchanan JL., 1997, CLASSIFICATION SYSTE; Carter GM, 2003, HEALTH CARE FINANC R, V24, P25; CARTER GM, 1997, PROSPECTIVE PAYMENT; Carter GM, 2002, ANAL INITIAL IMPLEME; Chan L, 2002, ARCH PHYS MED REHAB, V83, P1196, DOI 10.1053/apmr.2002.34811; Cotterill PG, 2002, HEALTH CARE FINANC R, V24, P1; *CTR MED MED SERV, 2000, FIN RUL INP REH FAC; Fiedler RC, 1998, AM J PHYS MED REHAB, V77, P444, DOI 10.1097/00002060-199809000-00019; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P87, DOI 10.1097/00002060-200001000-00017; Gage B, 1999, HEALTH CARE FINANC R, V20, P103; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Hamilton B. B., 1987, REHABILITATION OUTCO, P137; Hamilton BB, 1999, ARCH PHYS MED REHAB, V80, P385, DOI 10.1016/S0003-9993(99)90274-5; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Heffler S, 2002, HEALTH AFFAIR, V21, P207, DOI 10.1377/hlthaff.21.2.207; HEYDE CC, 1997, QUASILIKELIHOOD ANAL, pCH10; JARO MA, 1995, STAT MED, V14, P491, DOI 10.1002/sim.4780140510; Johnson MF, 2000, J AM GERIATR SOC, V48, P1389, DOI 10.1111/j.1532-5415.2000.tb02627.x; KANE R, 1994, STUDY POST ACUTE CAR; KEPPEL G, 1973, DESIGN ANAL RES HDB, P105; Law M, 2002, EVIDENCE BASED REHAB; Lu WS, 1996, STAT MED, V15, P1397, DOI 10.1002/(SICI)1097-0258(19960715)15:13&lt;1397::AID-SIM272&gt;3.0.CO;2-6; Musicco M, 2003, ARCH PHYS MED REHAB, V84, P551, DOI 10.1053/apmr.2003.50084; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Ottenbacher KJ, 2000, AM J PUBLIC HEALTH, V90, P1920, DOI 10.2105/AJPH.90.12.1920; OTTERNESS P, 1994, NEW YORK HIST, V75, P133; Raudenbush SW, 2002, HIERARCHICAL LINEAR; Schafer JL., 1997, ANAL INCOMPLETE MULT, DOI 10.1201/9781439821862; Segal ME, 1996, AM J PHYS MED REHAB, V75, P208, DOI 10.1097/00002060-199605000-00013; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; *STAT U NEW YORK B, 1997, GUID UN DAT MED REH; STINEMAN MG, 1994, MED CARE, V32, P366, DOI 10.1097/00005650-199404000-00005; STINEMAN MG, 1994, ARCH PHYS MED REHAB, V75, P1277; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Tesio L, 2002, AM J PHYS MED REHAB, V81, P168, DOI 10.1097/00002060-200203000-00003; WEDDERBURN RWM, 1974, BIOMETRIKA, V61, P439, DOI 10.2307/2334725; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	42	184	185	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2004	292	14					1687	1695		10.1001/jama.292.14.1687	http://dx.doi.org/10.1001/jama.292.14.1687			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	861JS	15479933				2022-12-28	WOS:000224413400027
J	Sipos, A; Rasmussen, F; Harrison, G; Tynelius, P; Lewis, G; Leon, DA; Gunnell, D				Sipos, A; Rasmussen, F; Harrison, G; Tynelius, P; Lewis, G; Leon, DA; Gunnell, D			Paternal age and schizophrenia: a population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARENTAL AGE; RISK; BIRTH; ASSOCIATION; PSYCHOSIS; MUTATIONS; PATTERNS; GROWTH; CANCER	Objective To investigate the association of paternal age at conception with the risk of offspring developing schizophrenia. Design A population based cohort study. Setting Sweden. Subjects 754 330 people born in Sweden between 1973 and 1980 and still alive and resident in Sweden at age 16 years. Main outcome measures Hospital admission with schizophrenia or non-schizophrenic non-affective psychosis. Results After adjustment for birth related exposures, socioeconomic factors, family history of psychosis, and early parental death the overall hazard ratio for each 10 year increase in paternal age was 1.47 (95% confidence interval 1.23 to 1.76) for schizophrenia and 1.12 (0.98 to 1.29) for non-schizophrenic non-affective psychosis. This association between paternal age and schizophrenia was present in those with no family history of the disorder (hazard ratio for each 10 year increase in paternal age 1.60, 1.32 to 1.92), but not in those with a family history (0.91, 0.44 to 1.89) (P = 0.04 for interaction). Conclusions Advancing paternal age is an important independent risk factor for schizophrenia. The stronger association between paternal age and schizophrenia in people without a family history provides further evidence that accumulation of de novo mutations in paternal sperm contributes to the overall risk of schizophrenia.	Karolinska Inst, Dept Publ Hlth Sci, SE-17176 Stockholm, Sweden; Univ Bristol, Acad Unit Psychiat, Bristol BS6 6JL, Avon, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England; Dept Social Med, Bristol BS8 2PR, Avon, England	Karolinska Institutet; University of Bristol; University of London; London School of Hygiene & Tropical Medicine	Rasmussen, F (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, SE-17176 Stockholm, Sweden.	finn.rasmussen@phs.ki.se	Lewis, Glyn/E-9944-2012; Leon, David A/G-2195-2010; Gunnell, David/ABE-6653-2020	Lewis, Glyn/0000-0001-5205-8245; Leon, David A/0000-0001-9747-1762; Gunnell, David/0000-0002-0829-6470; Rasmussen, Finn/0000-0001-7915-7809; Tynelius, Per/0000-0001-8155-7406				Brewin J, 1997, BRIT J PSYCHIAT, V171, P140, DOI 10.1192/bjp.171.2.140; Brown AS, 2002, AM J PSYCHIAT, V159, P1528, DOI 10.1176/appi.ajp.159.9.1528; Byrne M, 2003, ARCH GEN PSYCHIAT, V60, P673, DOI 10.1001/archpsyc.60.7.673; Crow JF, 1997, P NATL ACAD SCI USA, V94, P8380, DOI 10.1073/pnas.94.16.8380; Crow JF, 2003, SCIENCE, V301, P606, DOI 10.1126/science.1088552; Dalman C, 2002, SOC PSYCH PSYCH EPID, V37, P527, DOI 10.1007/s00127-002-0582-3; Dalman C, 2002, AM J PSYCHIAT, V159, P1591, DOI 10.1176/appi.ajp.159.9.1591; Dalman C, 2001, BRIT J PSYCHIAT, V179, P403, DOI 10.1192/bjp.179.5.403; David AS, 1997, PSYCHOL MED, V27, P1311, DOI 10.1017/S0033291797005680; El-Saadi O, 2004, SCHIZOPHR RES, V67, P227, DOI 10.1016/S0920-9964(03)00100-2; Gunnell D, 2003, AM J EPIDEMIOL, V158, P291, DOI 10.1093/aje/kwg118; Harrison G, 2003, PSYCHOL MED, V33, P723, DOI 10.1017/S0033291703007591; Hemminki K, 1999, EPIDEMIOLOGY, V10, P747, DOI 10.1097/00001648-199911000-00016; Malaspina D, 2001, ARCH GEN PSYCHIAT, V58, P361, DOI 10.1001/archpsyc.58.4.361; Malaspina D, 2002, AM J MED GENET, V114, P299, DOI 10.1002/ajmg.1701; *OFF NAT STAT, 2002, BIRTH STAT REV REG G; Pearlson GD, 2000, ANN NEUROL, V48, P556, DOI 10.1002/1531-8249(200010)48:4<556::AID-ANA2>3.3.CO;2-U; Sipos A, 2001, BRIT J PSYCHIAT, V178, P518, DOI 10.1192/bjp.178.6.518; Velakoulis D, 2000, AUST NZ J PSYCHIAT, V34, pS113, DOI 10.1080/000486700231; Wilkin DJ, 1998, AM J HUM GENET, V63, P711, DOI 10.1086/302000; Zammit S, 2003, BRIT J PSYCHIAT, V183, P405, DOI 10.1192/bjp.183.5.405; Zhang YQ, 1999, AM J EPIDEMIOL, V150, P1208	22	212	218	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	2004	329	7474					1070	1073		10.1136/bmj.38243.672396.55	http://dx.doi.org/10.1136/bmj.38243.672396.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PN	15501901	Green Published, Green Submitted, Green Accepted, Bronze			2022-12-28	WOS:000225070300016
J	Butler, D				Butler, D			The fertility riddle	NATURE			English	News Item							UNITED-STATES											Azziz R, 2004, REPROD BIOMED ONLINE, V8, P644, DOI 10.1016/S1472-6483(10)61644-6; Chandra A, 1998, FAM PLANN PERSPECT, V30, P34, DOI 10.2307/2991524; Joffe M, 2000, LANCET, V355, P1961, DOI 10.1016/S0140-6736(00)02328-X; Miller WC, 2004, JAMA-J AM MED ASSOC, V291, P2229, DOI 10.1001/jama.291.18.2229; *MPHPT, 2004, STAT HDB JAP 2004; Sharpe RM, 2002, NAT CELL BIOL, V4, pS33, DOI 10.1038/ncb-nm-fertilityS33; Tingen C, 2004, ENVIRON HEALTH PERSP, V112, P87, DOI 10.1289/ehp.6263; Tong S, 1998, HUM REPROD, V13, P95, DOI 10.1093/humrep/13.1.95; *UN DEP EC SOC AFF, 2004, WORLD FERT REP 2003	9	24	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	2004	432	7013					38	39		10.1038/432038a	http://dx.doi.org/10.1038/432038a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525975				2022-12-28	WOS:000224854900032
J	English, M; Esamai, F; Wasunna, A; Were, F; Ogutu, B; Wamae, A; Snow, RW; Peshu, N				English, M; Esamai, F; Wasunna, A; Were, F; Ogutu, B; Wamae, A; Snow, RW; Peshu, N			Delivery of paediatric care at the first-referral level in Kenya	LANCET			English	Article							SERIOUSLY ILL CHILDREN; HEALTH; HOSPITALS	We aimed to investigate provision of paediatric care in government admission, district hospitals in Kenya. We surveyed 14 first. referral level hospitals from seven of Kenya's eight provinces and obtained data for workload, outcome of infrastructure, and resources and the views of hospital staff and caretakers of admitted children. Paediatric admission rates varied almost ten-fold. Basic anti-infective drugs, clinical supplies, and laboratory tests were available in at least 12 hospitals, although these might be charged for on discharge. In at least 11 hospitals, antistaphylococcal drugs, appropriate treatment for malnutrition, newborn feeds, and measurement of bilirubin were rarely or never available. Staff highlighted infrastructure and human and consumable resources as problems. However, a strong sense of commitment, support for the work of the hospital, and a desire for improvement were expressed. Caretakers' views were generally positive, although dissatisfaction with the physical environment in which care took place was common. The capacity of the district hospital in Kenya needs strengthening by comprehensive policies that address real needs if current or new interventions and services at this level of care are to enhance child survival.	KEMRI, Wellcome Trust Collaborat Programme, Nairobi 00100, Kenya; KEMRI, Ctr Geog Med Res Coast, Kilifi, Kenya; Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Ctr Trop Med, Oxford OX3 9DU, England; Moi Univ & Moi Teaching & Referral Hosp, Coll Hlth Sci, Dept Paediat & Child Hlth, Eldoret, Kenya; Univ Nairobi, Kenyatta Natl Hosp, Dept Paediat & Child Hlth, Nairobi, Kenya; KEMRI Kisumu, USAMRU, KEMRI Ctr Clin Res, Kisumu, Kenya; Minist Hlth, Dept Prevent & Promot Hlth, Div Child Hlth, Nairobi, Kenya	University of Oxford; University of Oxford; Kenyatta National Hospital; University of Nairobi	English, M (corresponding author), KEMRI, Wellcome Trust Collaborat Programme, POB 43640, Nairobi 00100, Kenya.	menglish@wtnairobi.mimcorn.net	Snow, Robert William/AFR-1436-2022; ESAMAI, FABIAN/AAI-3268-2020	Snow, Robert William/0000-0003-3725-6088; English, Michael/0000-0002-7427-0826				[Anonymous], MILL DEV GOALS; [Anonymous], HOSP HLTH ALL; Barnum H., 1993, PUBLIC HOSP DEV COUN; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; Duke T, 2004, LANCET, V363, P1922, DOI 10.1016/S0140-6736(04)16438-6; English M, 2004, LANCET, V363, P1948, DOI 10.1016/S0140-6736(04)16408-8; English M, 2003, ARCH DIS CHILD, V88, P438, DOI 10.1136/adc.88.5.438; *GOV KEN, 1994, CLIN GUID; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Lee JW, 2003, LANCET, V362, P262, DOI 10.1016/S0140-6736(03)14006-8; *MIN HLTH REP KEN, 2001, 1 NAT C QUAL IMPR HL; Narasimhan V, 2004, LANCET, V363, P1469, DOI 10.1016/S0140-6736(04)16108-4; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; Noor AM, 2004, ACTA TROP, V91, P239, DOI 10.1016/j.actatropica.2004.05.003; Peterson S, 2004, LANCET, V363, P1955, DOI 10.1016/S0140-6736(04)16411-8; *WHO, 2002, IMPR QUAL PAED CAR A	18	84	85	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	2004	364	9445					1622	1629		10.1016/S0140-6736(04)17318-2	http://dx.doi.org/10.1016/S0140-6736(04)17318-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866IQ	15519635				2022-12-28	WOS:000224767600030
J	Lockwood, S				Lockwood, S			"Evidence of me" in evidence based medicine?	BRITISH MEDICAL JOURNAL			English	Article									Breast Canc Act Grp, Fairfield, Vic 3130, Australia		Lockwood, S (corresponding author), Breast Canc Act Grp, POB 281, Fairfield, Vic 3130, Australia.	lockwod@bigpond.com						Bastian H, 1998, INT J TECHNOL ASSESS, V14, P3, DOI 10.1017/S0266462300010485; *DIPEX ORG, PERS EXP HLTH ILLN; *NAT BREAST CANC C, 2004, NAT SURV WOM EARL BR; *NAT HLTH MRC, 1999, PSYCH CLIN PRACT GUI, P17; *NHMRC NAT BREAST, 1995, CLIN PRACT GUID TREA; Sackett D., 2000, EVIDENCE BASED MED P, DOI DOI 10.1136/BMJ.H3089; WHITE V, IN PRESS CANCER	7	18	21	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 30	2004	329	7473					1033	1035		10.1136/bmj.329.7473.1033	http://dx.doi.org/10.1136/bmj.329.7473.1033			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514354	Green Published			2022-12-28	WOS:000224852400031
J	McCoy, D; Sanders, D; Baum, F; Narayan, T; Legge, D				McCoy, D; Sanders, D; Baum, F; Narayan, T; Legge, D			Pushing the international health research agenda towards equity and effectiveness	LANCET			English	Editorial Material									Community Hlth Cell, Peoples Hlth Movement, Bangalore, Karnataka, India		McCoy, D (corresponding author), Community Hlth Cell, Peoples Hlth Movement, Bangalore, Karnataka, India.	davidmccoy@xyx.demon.co.uk	Baum, Fran/AAJ-1896-2021; Baum, Fran/AGN-4014-2022	Baum, Fran/0000-0002-2294-1368; Sanders, David/0000-0003-1094-7655				Global Forum for Health Research, 2005, 10 90 REP HLTH RES 2, P25; LABONTE R, 2004, FATAL INDIFFERENCE G; Lomas J, 2000, HEALTH AFFAIR, V19, P236, DOI 10.1377/hlthaff.19.3.236; MARTIN KA, 1996, PUBERTY SEXUALITY SE, P1; Michalos A. C., 1997, GOOD TAXES CASE TAXI; Minkler M., 2003, COMMUNITY BASED PART; PADARATH A, 2003, CIRCULATION CONVECTI; SANDERS D, IN PRESS WHO B; STECHER H, 1999, TIME TOBIN TAX SOME; *TAX JUST NEWT, 2003, DECL TAX JUST NEWT; Winter R, 2001, HDB ACTION RES HLTH, P9; 2003, LANCET, V362, P2033; 2004, LANCET, V363, P1745	13	29	30	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	2004	364	9445					1630	1631		10.1016/S0140-6736(04)17319-4	http://dx.doi.org/10.1016/S0140-6736(04)17319-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866IQ	15519636				2022-12-28	WOS:000224767600031
J	Ogawa, S; Glass, CK				Ogawa, S; Glass, CK			Factor XIIIA (Cross)links AT, receptors to atherosclerosis	CELL			English	Editorial Material								Angiotensin II, a small peptide hormone that plays key roles in the regulation of blood pressure, also contributes to inflammatory processes that promote the development of atherosclerosis. In this issue of Cell, AbdAlla et al. (2004) provide evidence that pathogenic actions of angiotensin II involve covalent crosslinking of angiotensin AT(1) receptors by factor XIIIA transglutaminase, resulting in stable receptor dimers with enhanced signaling properties.	Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ogawa, S (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592				AbdAlla S, 2004, CELL, V119, P343, DOI 10.1016/j.cell.2004.10.006; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Daugherty A, 2004, TRENDS CARDIOVAS MED, V14, P117, DOI 10.1016/j.tcm.2004.01.002; Franco R, 2003, TRENDS BIOCHEM SCI, V28, P238, DOI 10.1016/S0968-0004(03)00065-3; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Hansen JL, 2004, J BIOL CHEM, V279, P24108, DOI 10.1074/jbc.M400092200; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014	9	3	3	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2004	119	3					313	314		10.1016/j.cell.2004.10.008	http://dx.doi.org/10.1016/j.cell.2004.10.008			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	868IW	15507203	Bronze			2022-12-28	WOS:000224908300002
J	Nair, SR; Pearson, SB				Nair, SR; Pearson, SB			Pathologic fracture and lytic lesions in multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Gen Infirm, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary	Nair, SR (corresponding author), Gen Infirm, Leeds LS1 3EX, W Yorkshire, England.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1874	1874		10.1056/NEJMicm031146	http://dx.doi.org/10.1056/NEJMicm031146			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509820				2022-12-28	WOS:000224723100010
J	Matsukevich, DN; Kuzmich, A				Matsukevich, DN; Kuzmich, A			Quantum state transfer between matter and light	SCIENCE			English	Article							TELEPORTATION; COMMUNICATION; ENTANGLEMENT	We report on the coherent quantum state transfer from a two-level atomic system to a single photon. Entanglement between a single photon (signal) and a two-component ensemble of cold rubidium atoms is used to project the quantum memory element (the atomic ensemble) onto any desired state by measuring the signal in a suitable basis. The atomic qubit is read out by stimulating directional emission of a single photon (idler) from the (entangled) collective state of the ensemble. Faithful atomic memory preparation and readout are verified by the observed correlations between the signal and the idler photons. These results enable implementation of distributed quantum networking.	Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Kuzmich, A (corresponding author), Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA.	alex.kuzmich@physics.gatech.edu	Matsukevich, Dzmitry/C-9134-2009	Matsukevich, Dzmitry/0000-0002-7679-0569				BARRETT SD, QUANTPH0408040, P63615; Bennett CH, 1996, PHYS REV A, V54, P3824, DOI 10.1103/PhysRevA.54.3824; Blinov BB, 2004, NATURE, V428, P153, DOI 10.1038/nature02377; Bose S, 1999, PHYS REV LETT, V83, P5158, DOI 10.1103/PhysRevLett.83.5158; Chou CW, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.213601; CHUANG M, 2000, QUANTUM COMPUTATION; Duan LM, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.023818; Duan LM, 2001, NATURE, V414, P413, DOI 10.1038/35106500; HAROCHE S, 2002, EXPT QUANTUM COMPUTA, P37; Jiang W, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.043819; Kimble HJ, 1998, PHYS SCRIPTA, VT76, P127, DOI 10.1238/Physica.Topical.076a00127; Kuzmich A, 2003, QUANTUM INFORMATION WITH CONTINUOUS VARIABLES, P231; Kuzmich A, 2003, NATURE, V423, P731, DOI 10.1038/nature01714; Kuzmich A, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.030407; LIM YL, QUANTPH0408043; Lukin MD, 2003, REV MOD PHYS, V75, P457, DOI 10.1103/RevModPhys.75.457; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; van der Wal CH, 2003, SCIENCE, V301, P196, DOI 10.1126/science.1085946	21	294	300	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					663	666		10.1126/science.1103346	http://dx.doi.org/10.1126/science.1103346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499014	Green Submitted			2022-12-28	WOS:000224756700044
J	Sparing, R; Kosinski, CM; Krings, T; Schiefer, J				Sparing, R; Kosinski, CM; Krings, T; Schiefer, J			Eyelid oedema and headache	LANCET			English	Editorial Material									Univ Aachen, Dept Neurol & Neuroradiol, D-52074 Aachen, Germany	RWTH Aachen University	Sparing, R (corresponding author), Univ Aachen, Dept Neurol & Neuroradiol, D-52074 Aachen, Germany.	roland.sparing@rwth-aachen.de							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	2004	364	9443					1438	1438		10.1016/S0140-6736(04)17227-9	http://dx.doi.org/10.1016/S0140-6736(04)17227-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488220				2022-12-28	WOS:000224485300031
J	Ango, F; di Cristo, G; Higashiyama, H; Bennett, V; Wu, P; Huang, ZJ				Ango, F; di Cristo, G; Higashiyama, H; Bennett, V; Wu, P; Huang, ZJ			Ankyrin-based subcellular gradient of neurofascin, an immunoglobulin family protein, directs GABAergic innervation at Purkinje axon initial segment	CELL			English	Article							ADHESION MOLECULES; TRANSGENIC MICE; INTERNEURONS; L1; SPECTRIN; HIPPOCAMPUS; INHIBITION; CORTEX; DIVERSITY; GUIDANCE	Distinct classes of GABAergic synapses are segregated into subcellular domains (i.e., dendrite, soma, and axon initial segment-AIS), thereby differentially regulating the input, integration, and output of principal neurons. In cerebellum, for example, basket interneurons make exquisitely precise "pinceau synapses" on AIS of Purkinje neurons, but the underlying mechanism is unknown. Using BAC transgenic reporter mice, we found that basket axons always contacted Purkinje soma before innervating AIS. This synapse targeting process followed the establishment of a subcellular gradient of neurofascin186 (NF186), an L1 family immunoglobulin cell adhesion molecule (L1 CAM), along the Purkinje AIS-soma axis. This gradient was dependent on ankyrinG, an AIS-restricted membrane adaptor protein that recruits NF186. In the absence of neurofascin gradient, basket axons lost directional growth along Purkinje neurons and precisely followed NF186 to ectopic locations. Disruption of NF186-ankyrinG interactions at AIS reduced pinceau synapse formation. These results implicate ankyrin-based localization of L1CAMs in subcellular organization of GABAergic synapses.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem & Cell Biol, Durham, NC 27710 USA	Cold Spring Harbor Laboratory; Duke University; Howard Hughes Medical Institute	Huang, ZJ (corresponding author), Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.	huangj@cshl.edu		Huang, Z. Josh/0000-0003-0592-028X; Ango, Fabrice/0000-0002-5548-209X				BAYER SA, 1987, PROG NEUROBIOL, V29, P57, DOI 10.1016/0301-0082(87)90015-3; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; CAJAL SRY, 1911, MALOINE, P1909; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; Cohen NR, 1998, CURR BIOL, V8, P26, DOI 10.1016/S0960-9822(98)70017-X; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DAVIS JQ, 1984, J BIOL CHEM, V259, P1874; DICRISTO G, 2004, IN PRESS NAT NEUROSC; ESCLAPEZ M, 1994, J NEUROSCI, V14, P1834, DOI 10.1523/JNEUROSCI.14-03-01834.1994; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; GREIF KF, 1991, NEUROCHEM RES, V16, P235, DOI 10.1007/BF00966086; Heintz N, 2001, NAT REV NEUROSCI, V2, P861, DOI 10.1038/35104049; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; Hummel T, 2003, NEURON, V37, P221, DOI 10.1016/S0896-6273(02)01183-2; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Kapfer C, 2002, NAT NEUROSCI, V5, P247, DOI 10.1038/nn810; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Klausberger T, 2003, NATURE, V421, P844, DOI 10.1038/nature01374; Knott GW, 2002, NEURON, V34, P265, DOI 10.1016/S0896-6273(02)00663-3; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; Montag-Sallaz M, 2002, MOL CELL BIOL, V22, P7967, DOI 10.1128/MCB.22.22.7967-7981.2002; Palay S.L., 1974, CEREBELLAR CORTEX; Porter JT, 2001, J NEUROSCI, V21, P2699, DOI 10.1523/JNEUROSCI.21-08-02699.2001; Pouille F, 2004, NATURE, V429, P717, DOI 10.1038/nature02615; RATHJEN FG, 1987, CELL, V51, P841, DOI 10.1016/0092-8674(87)90107-3; Rosina A, 1999, NEUROREPORT, V10, P1613, DOI 10.1097/00001756-199905140-00041; Rougon G, 2003, ANNU REV NEUROSCI, V26, P207, DOI 10.1146/annurev.neuro.26.041002.131014; Sakurai T, 2001, J CELL BIOL, V154, P1259, DOI 10.1083/jcb.200104122; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Shen K, 2004, CELL, V116, P869, DOI 10.1016/S0092-8674(04)00251-X; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Swadlow HA, 2003, CEREB CORTEX, V13, P25, DOI 10.1093/cercor/13.1.25; Tamas G, 2003, SCIENCE, V299, P1902, DOI 10.1126/science.1082053; Tamas G, 2000, NAT NEUROSCI, V3, P366, DOI 10.1038/73936; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tuvia S, 1997, P NATL ACAD SCI USA, V94, P12957, DOI 10.1073/pnas.94.24.12957; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; Volkmer H, 1998, J CELL BIOL, V142, P1083, DOI 10.1083/jcb.142.4.1083; Yamagata M, 2002, CELL, V110, P649, DOI 10.1016/S0092-8674(02)00910-8; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Yi SJ, 1997, BIOCHEMISTRY-US, V36, P9596, DOI 10.1021/bi9704966; Zhang L, 1996, NEURON, V16, P47, DOI 10.1016/S0896-6273(00)80022-7; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	49	271	277	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2004	119	2					257	272		10.1016/j.cell.2004.10.004	http://dx.doi.org/10.1016/j.cell.2004.10.004			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479642	Bronze			2022-12-28	WOS:000224577200013
J	Emoto, K; He, Y; Ye, B; Grueber, WB; Adler, PN; Jan, LY; Jan, YN				Emoto, K; He, Y; Ye, B; Grueber, WB; Adler, PN; Jan, LY; Jan, YN			Control of dendritic branching and tiling by the tricornered-kinase/furry signaling pathway in Drosophila sensory neurons	CELL			English	Article							RETINAL GANGLION-CELLS; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; ACTIN CYTOSKELETON; PERIPHERAL NEURONS; SMALL GTPASES; RHO-GTPASES; MORPHOGENESIS; GENE; GROWTH	To cover the receptive field completely but without redundancy, neurons of certain functional groups exhibit tiling of their dendrites via dendritic repulsion. Here we show that two evolutionarily conserved proteins, the Tricornered (Trc) kinase and Furry (Fry), are essential for tiling and branching control of Drosophila sensory neuron dendrites. Dendrites of fry and trc mutants display excessive terminal branching and fail to avoid homologous dendritic branches, resulting in significant overlap of the dendritic fields. Trc control of dendritic branching involves regulation of RacGTPase, a pathway distinct from the action of Trc in tiling. Time-lapse analysis further reveals a specific loss of the ability of growing dendrites to turn away from nearby dendritic branches in fry mutants, suggestive of a defect in like-repels-like avoidance. Thus, the Trc/ Fry signaling pathway plays a key role in patterning dendritic fields by promoting avoidance between homologous dendrites as well as by limiting dendritic branching.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol & Biochem, San Francisco, CA 94143 USA; Univ Virginia, Dept Biol, Charlottesville, VA 22903 USA; Univ Virginia, Ctr Canc, Charlottesville, VA 22903 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Virginia; University of Virginia	Jan, YN (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol & Biochem, 1550 4th St, San Francisco, CA 94143 USA.	ynjan@itsa.ucsf.edu	EMOTO, KAZUO/G-4992-2014; He, Ying/B-3952-2010; Ye, Bing/V-1306-2018	He, Ying/0000-0002-2052-8350; Ye, Bing/0000-0002-8828-4065; Grueber, Wesley/0000-0001-6751-256X; Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299	NIGMS NIH HHS [R01 GM053498] Funding Source: Medline; NINDS NIH HHS [F32 NS046847-02, F32 NS046847, F32 NS046847-01, F32 NS046847-03, R01NS40929] Funding Source: Medline; PHS HHS [R0153498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040929, F32NS046847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; Brenman JE, 2001, DEV CELL, V1, P667, DOI 10.1016/S1534-5807(01)00072-7; Cline HT, 2001, CURR OPIN NEUROBIOL, V11, P118, DOI 10.1016/S0959-4388(00)00182-3; Colman-Lerner A, 2001, CELL, V107, P739, DOI 10.1016/S0092-8674(01)00596-7; Cong JL, 2001, DEVELOPMENT, V128, P2793; DeVries SH, 1997, J NEUROPHYSIOL, V78, P2048, DOI 10.1152/jn.1997.78.4.2048; Devroe E, 2004, J BIOL CHEM, V279, P24444, DOI 10.1074/jbc.M401999200; Du LL, 2002, MOL BIOL CELL, V13, P503, DOI 10.1091/mbc.01-07-0365; Gallegos ME, 2004, NEURON, V44, P239, DOI 10.1016/j.neuron.2004.09.021; Gao FB, 1999, GENE DEV, V13, P2549, DOI 10.1101/gad.13.19.2549; Gao FB, 2000, NEURON, V28, P91, DOI 10.1016/S0896-6273(00)00088-X; Geisbrecht ER, 2004, CELL, V118, P111, DOI 10.1016/j.cell.2004.06.020; Geng W, 2000, GENETICS, V156, P1817; Grueber WB, 2003, CELL, V112, P805, DOI 10.1016/S0092-8674(03)00160-0; Grueber WB, 2001, J COMP NEUROL, V440, P271, DOI 10.1002/cne.1385; Grueber WB, 2003, CURR BIOL, V13, P618, DOI 10.1016/S0960-9822(03)00207-0; Grueber WB, 2002, DEVELOPMENT, V129, P2867; Grueber WB, 2004, CURR OPIN NEUROBIOL, V14, P74, DOI 10.1016/j.conb.2004.01.001; Hirata D, 2002, EMBO J, V21, P4863, DOI 10.1093/emboj/cdf495; Jan YN, 2003, NEURON, V40, P229, DOI 10.1016/S0896-6273(03)00631-7; Kaufmann WE, 2000, CEREB CORTEX, V10, P981, DOI 10.1093/cercor/10.10.981; Lee A, 2003, DEVELOPMENT, V130, P5543, DOI 10.1242/dev.00792; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lee TM, 2000, NEURON, V25, P307, DOI 10.1016/S0896-6273(00)80896-X; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Lohmann C, 2001, J NEUROBIOL, V48, P150, DOI 10.1002/neu.1048; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MacNeil MA, 1998, NEURON, V20, P971, DOI 10.1016/S0896-6273(00)80478-X; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Nelson B, 2003, MOL BIOL CELL, V14, P3782, DOI 10.1091/mbc.E03-01-0018; PERRY VH, 1982, NATURE, V297, P683, DOI 10.1038/297683a0; PURPURA DP, 1975, ADV NEUROL, V12, P91; Redmond L, 2001, CURR OPIN NEUROBIOL, V11, P111, DOI 10.1016/S0959-4388(00)00181-1; Scott EK, 2001, NAT NEUROSCI, V4, P359, DOI 10.1038/86006; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Sugimura K, 2003, J NEUROSCI, V23, P3752; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; Van Aelst L, 2004, CURR OPIN NEUROBIOL, V14, P297, DOI 10.1016/j.conb.2004.05.012; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; WASSLE H, 1981, NATURE, V292, P344, DOI 10.1038/292344a0; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; Weiss EL, 2002, J CELL BIOL, V158, P885, DOI 10.1083/jcb.200203094; Whitford KL, 2002, ANNU REV NEUROSCI, V25, P127, DOI 10.1146/annurev.neuro.25.112701.142932; Winter CG, 2001, CELL, V105, P81, DOI 10.1016/S0092-8674(01)00298-7; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x; Ye B, 2004, CURR BIOL, V14, P314, DOI 10.1016/j.cub.2004.01.052; Zallen JA, 2000, MOL BIOL CELL, V11, P3177, DOI 10.1091/mbc.11.9.3177	51	177	180	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2004	119	2					245	256		10.1016/j.cell.2004.09.036	http://dx.doi.org/10.1016/j.cell.2004.09.036			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479641	Bronze			2022-12-28	WOS:000224577200012
J	Misteli, T				Misteli, T			Spatial positioning: A new dimension in genome function	CELL			English	Review							DOUBLE-STRAND BREAKS; NUCLEAR-ORGANIZATION; GENES; CHROMATIN; DNA; TRANSCRIPTION; LOCALIZATION; DROSOPHILA; INTERPHASE; DOMAINS	The eukaryotic cell nucleus is a heterogeneous organelle. Chromosomes are nonrandomly positioned within the nuclear space, and individual gene loci experience distinct local environments due to the presence of chromatin domains and subnuclear compartments. Recent observations have highlighted the important yet still largely mysterious role of spatial positioning in genome activity and stability.	NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Misteli, T (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.	mistelit@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010309, Z01BC010309] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Bressan DA, 2004, J CELL BIOL, V164, P361, DOI 10.1083/jcb.200311063; Casolari JM, 2004, CELL, V117, P427, DOI 10.1016/S0092-8674(04)00448-9; Gasser SM, 2001, CELL, V104, P639, DOI 10.1016/S0092-8674(01)00259-8; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Ishii K, 2002, CELL, V109, P551, DOI 10.1016/S0092-8674(02)00756-0; Kim SH, 2004, CYTOGENET GENOME RES, V105, P292, DOI 10.1159/000078201; Kosak ST, 2002, SCIENCE, V296, P158, DOI 10.1126/science.1068768; Lisby M, 2003, NAT CELL BIOL, V5, P572, DOI 10.1038/ncb997; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Parada LA, 2002, TRENDS CELL BIOL, V12, P425, DOI 10.1016/S0962-8924(02)02351-6; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; Sage BT, 2003, GENETICS, V165, P1183; Shopland LS, 2003, J CELL BIOL, V162, P981, DOI 10.1083/jcb.200303131; Su RC, 2004, NAT GENET, V36, P502, DOI 10.1038/ng1351; Thompson M, 2003, SCIENCE, V302, P1399, DOI 10.1126/science.1089814; Vazquez J, 2001, CURR BIOL, V11, P1227, DOI 10.1016/S0960-9822(01)00390-6; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; Zink D, 2004, J CELL BIOL, V166, P815, DOI 10.1083/jcb.200404107	19	130	142	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	2004	119	2					153	156		10.1016/j.cell.2004.09.035	http://dx.doi.org/10.1016/j.cell.2004.09.035			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479633	Bronze			2022-12-28	WOS:000224577200004
J	Bayindir, M; Sorin, F; Abouraddy, AF; Viens, J; Hart, SD; Joannopoulos, JD; Fink, Y				Bayindir, M; Sorin, F; Abouraddy, AF; Viens, J; Hart, SD; Joannopoulos, JD; Fink, Y			Metal-insulator-semiconductor optoelectronic fibres	NATURE			English	Article							PHOTONIC CRYSTAL FIBERS; HOLLOW WAVE-GUIDES; OPTICAL-FIBER; MULTILAYER	The combination of conductors, semiconductors and insulators with well-defined geometries and at prescribed length scales, while forming intimate interfaces, is essential in most functional electronic and optoelectronic devices. These are typically produced using a variety of elaborate wafer-based processes, which allow for small features, but are restricted to planar geometries and limited coverage area(1-3). In contrast, the technique of fibre drawing from a preformed reel or tube is simpler and yields extended lengths of highly uniform fibres with well-controlled geometries and good optical transport characteristics(4). So far, this technique has been restricted to particular materials(5-7) and larger features(8-12). Here we report on the design, fabrication and characterization of fibres made of conducting, semiconducting and insulating materials in intimate contact and in a variety of geometries. We demonstrate that this approach can be used to construct a tunable fibre photodetector comprising an amorphous semiconductor core contacted by metallic microwires, and surrounded by a cylindrical-shell resonant optical cavity. Such a fibre is sensitive to illumination along its entire length ( tens of meters), thus forming a photodetecting element of dimensionality one. We also construct a grid of such fibres that can identify the location of an illumination point. The advantage of this type of photodetector array is that it needs a number of elements of only order N, in contrast to the conventional order N-2 for detector arrays made of photodetecting elements of dimensionality zero.	MIT, Elect Res Lab, Cambridge, MA 02139 USA; MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA; MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; MIT, Dept Phys, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Fink, Y (corresponding author), MIT, Elect Res Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	mehmet@mit.edu; yoel@mit.edu	Joannopoulos, John D/E-6401-2013; Abouraddy, Ayman/I-7963-2012	Bayindir, Mehmet/0000-0003-0233-6870				Allan DC, 2001, NATO SCI SER II-MATH, V563, P305; Broeng J, 1999, OPT FIBER TECHNOL, V5, P305, DOI 10.1006/ofte.1998.0279; Chuang S. L, 2009, PHYS PHOTONIC DEVICE, V2nd; Eggleton BJ, 2001, OPT EXPRESS, V9, P698, DOI 10.1364/OE.9.000698; Fink Y, 1998, SCIENCE, V282, P1679, DOI 10.1126/science.282.5394.1679; Harrington JA, 2000, FIBER INTEGRATED OPT, V19, P211, DOI 10.1080/01468030050058794; Hart SD, 2002, SCIENCE, V296, P510, DOI 10.1126/science.1070050; Katagiri T, 2002, APPL OPTICS, V41, P7603, DOI 10.1364/AO.41.007603; Knight JC, 2003, NATURE, V424, P847, DOI 10.1038/nature01940; Kuriki K, 2004, OPT EXPRESS, V12, P1510, DOI 10.1364/OPEX.12.001510; LARGE M, 2003, P 29 EUR C OPT COMM, P1014; Sanghera J., 1998, INFRARED FIBER OPTIC; Sedra A. S., 2003, MICROELECTRONIC CIRC, V5th; Sze S.M., 2002, SEMICONDUCTOR DEVICE, V2nd; Temelkuran B, 2002, NATURE, V420, P650, DOI 10.1038/nature01275; van Eijkelenborg MA, 2001, OPT EXPRESS, V9, P319, DOI 10.1364/OE.9.000319; YEH P, 1978, J OPT SOC AM, V68, P1196, DOI 10.1364/JOSA.68.001196	17	172	188	5	136	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					826	829		10.1038/nature02937	http://dx.doi.org/10.1038/nature02937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483607				2022-12-28	WOS:000224435500042
J	Braithwaite, J; Spruit, HC				Braithwaite, J; Spruit, HC			A fossil origin for the magnetic field in A stars and white dwarfs	NATURE			English	Article							ADIABATIC STABILITY; POLOIDAL FIELDS; CP STARS; HELICITY; MODELS	Some main-sequence stars of spectral type A are observed to have a strong (0.03 - 3 tesla), static, large-scale magnetic field, of a chiefly dipolar shape: they are known as 'Ap stars'(1-4), such as Alioth, the fifth star in the Big Dipper. Following the discovery of these fields, it was proposed that they are remnants of the star's formation, a 'fossil' field(5,6). An alternative suggestion is that they could be generated by a dynamo process in the star's convective core(7). The dynamo hypothesis, however, has difficulty explaining high field strengths and the observed lack of a correlation with rotation. The weakness of the fossil-field theory has been the absence of field configurations stable enough to survive in a star over its lifetime. Here we report numerical simulations that show that stable magnetic field configurations, with properties agreeing with those observed, can develop through evolution from arbitrary, unstable initial fields. The results are applicable equally to Ap stars, magnetic white dwarfs and some highly magnetized neutron stars known as magnetars. This establishes fossil fields as the natural, unifying explanation for the magnetism of all these stars.	Max Planck Inst Astrophys, D-85741 Garching, Germany	Max Planck Society	Spruit, HC (corresponding author), Max Planck Inst Astrophys, Postfach 1317, D-85741 Garching, Germany.	henk@mpa-garching.mpg.de						BABCOCK HW, 1947, ASTROPHYS J, V105, P105, DOI 10.1086/144887; Bagnulo S, 2001, ASTRON ASTROPHYS, V369, P889, DOI 10.1051/0004-6361:20010101; BORRA EF, 1982, ANNU REV ASTRON ASTR, V20, P191, DOI 10.1146/annurev.aa.20.090182.001203; Charbonneau P, 2001, ASTROPHYS J, V559, P1094, DOI 10.1086/322417; Chui AYK, 1995, P R SOC-MATH PHYS SC, V451, P609, DOI 10.1098/rspa.1995.0146; COWLING TG, 1945, MON NOT R ASTRON SOC, V105, P166, DOI 10.1093/mnras/105.3.166; DUNCAN RC, 1992, APJ, V392, P9; FLOWERS E, 1977, ASTROPHYS J, V215, P302, DOI 10.1086/155359; Hsu SC, 2002, MON NOT R ASTRON SOC, V334, P257, DOI 10.1046/j.1365-8711.2002.05422.x; Hubrig S, 2000, ASTROPHYS J, V539, P352, DOI 10.1086/309189; KAMCHATNOV AM, 1982, ZH EKSP TEOR FIZ+, V82, P117; Kochukhov O, 2004, ASTRON ASTROPHYS, V414, P613, DOI 10.1051/0004-6361:20031595; Landstreet JD, 2000, ASTRON ASTROPHYS, V359, P213; MARKEY P, 1973, MON NOT R ASTRON SOC, V163, P77, DOI 10.1093/mnras/163.1.77; MARKEY P, 1974, MON NOT R ASTRON SOC, V168, P505, DOI 10.1093/mnras/168.3.505; Mazets EP, 1999, ASTRON LETT+, V25, P635; Mereghetti S., 1995, APJ, V442, P17; MOSS D, 1987, MON NOT R ASTRON SOC, V226, P297, DOI 10.1093/mnras/226.2.297; PRENDERGAST KH, 1956, ASTROPHYS J, V123, P498, DOI 10.1086/146186; Putney A, 1999, ASTR SOC P, V169, P195; TAYLER RJ, 1973, MON NOT R ASTRON SOC, V161, P365, DOI 10.1093/mnras/161.4.365; THOMPSON C, 1995, MON NOT R ASTRON SOC, V275, P255, DOI 10.1093/mnras/275.2.255; Wickramasinghe DT, 2000, PUBL ASTRON SOC PAC, V112, P873, DOI 10.1086/316593; WRIGHT GAE, 1973, MON NOT R ASTRON SOC, V162, P339, DOI 10.1093/mnras/162.4.339; Zhang M, 2003, ASTROPHYS J, V584, P479, DOI 10.1086/345615	25	342	344	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					819	821		10.1038/nature02934	http://dx.doi.org/10.1038/nature02934			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483604				2022-12-28	WOS:000224435500039
J	Rao, JVRP; Ganguly, NK; Mehendale, SM; Bollinger, RC				Rao, JVRP; Ganguly, NK; Mehendale, SM; Bollinger, RC			India's response to the HIV epidemic	LANCET			English	Editorial Material									Govt India, Minist Hlth & Family Welf, New Delhi 110011, India; Indian Council Med Res, New Delhi, India; Natl AIDS Res Inst, Pune, Maharashtra, India; Johns Hopkins Univ, Baltimore, MD USA	Indian Council of Medical Research (ICMR); Indian Council of Medical Research (ICMR); ICMR - National AIDS Research Institute (NARI); Johns Hopkins University	Rao, JVRP (corresponding author), Govt India, Minist Hlth & Family Welf, New Delhi 110011, India.	secyhlth@hub.nic.in		Bollinger, Robert/0000-0002-6798-6834				BECKER N E, 1986, Health and Social Work, V11, P26; Celentano D, 2004, 15 INT AIDS C BANGK; MAHAPATRA, 2004, SEATTLE POST IN 0916; *NAT AIDS CONTR OR, 2001, NAT BAS GEN POP BEH; SIMOES EAF, 1987, INDIAN J MED RES, V85, P335; *UNAIDS WHO, S AFR EP FACT SHEET; *UNAIDS WHO, IND EP FACT SHEET HI; White R, 2000, AIDS, V14, P2323, DOI 10.1097/00002030-200010200-00013	8	32	32	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2004	364	9442					1296	1297		10.1016/S0140-6736(04)17205-X	http://dx.doi.org/10.1016/S0140-6736(04)17205-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474121				2022-12-28	WOS:000224349700008
J	Chuikov, S; Kurash, JK; Wilson, JR; Xiao, B; Justin, N; Ivanov, GS; McKinney, K; Tempst, P; Prives, C; Gamblin, SJ; Barlev, NA; Reinberg, D				Chuikov, S; Kurash, JK; Wilson, JR; Xiao, B; Justin, N; Ivanov, GS; McKinney, K; Tempst, P; Prives, C; Gamblin, SJ; Barlev, NA; Reinberg, D			Regulation of p53 activity through lysine methylation	NATURE			English	Article							HISTONE METHYLTRANSFERASE; DNA-BINDING; ACETYLATION; ACTIVATION; PROTEIN; PHOSPHORYLATION; UBIQUITINATION; TRANSCRIPTION; MDM2	p53 is a tumour suppressor that regulates the cellular response to genotoxic stresses. p53 is a short-lived protein and its activity is regulated mostly by stabilization via different post-translational modifications. Here we report a novel mechanism of p53 regulation through lysine methylation by Set9 methyltransferase. Set9 specifically methylates p53 at one residue within the carboxyl-terminus regulatory region. Methylated p53 is restricted to the nucleus and the modification positively affects its stability. Set9 regulates the expression of p53 target genes in a manner dependent on the p53-methylation site. The crystal structure of a ternary complex of Set9 with a p53 peptide and the cofactor product S-adenosyl-L-homocysteine (AdoHcy) provides the molecular basis for recognition of p53 by this lysine methyltransferase.	Robert Wood Johnson Med Sch, Dept Biochem, Howard Hughes Med Inst, Div Nucl Acids Enzymol, Piscataway, NJ 08854 USA; NEMC Tufts Sch Med, Mol Oncol Res Inst, Boston, MA 02111 USA; Natl Inst Med Res, MRC, Struct Biol Grp, London NW7 1AA, England; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Tufts Medical Center; MRC National Institute for Medical Research; Columbia University; Memorial Sloan Kettering Cancer Center	Barlev, NA (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, Howard Hughes Med Inst, Div Nucl Acids Enzymol, Piscataway, NJ 08854 USA.	nbarlev@tufts-nemc.org; reinbedf@UMDNJ.EDU	Ivanov, Gleb/AAD-6785-2022; Wilson, Jon R/B-7362-2019; Barlev, Nikolai A/K-5268-2017; Ivanov, Gleb/AAB-5447-2020; Justin, Neil/E-1774-2011	Wilson, Jon R/0000-0002-5157-5432; Barlev, Nikolai A/0000-0001-7111-2446; Gamblin, Steve/0000-0001-5331-639X; Reinberg, Danny/0000-0003-4288-2016; Tempst, Paul/0000-0002-6680-3987				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GRAND RJA, 1995, VIROLOGY, V210, P323, DOI 10.1006/viro.1995.1349; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gu Wei, 2004, Novartis Found Symp, V259, P197; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P552; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378	22	601	629	0	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					353	360		10.1038/nature03117	http://dx.doi.org/10.1038/nature03117			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15525938				2022-12-28	WOS:000225161400046
J	Hoffman, RJ; Dhaliwal, G; Gilden, DJ; Saint, S				Hoffman, RJ; Dhaliwal, G; Gilden, DJ; Saint, S			Special cure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IRON-DEFICIENCY ANEMIA; CELIAC-DISEASE; PREVALENCE; SPRUE; RISK		Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA; Legacy Emanuel Hosp, Dept Med, Portland, OR USA; Legacy Good Samaritan Hosp, Dept Med, Portland, OR USA; Univ Calif San Francisco, Sch Med, San Francisco, CA USA; Ann Arbor Vet Affairs Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA; Univ Michigan Hlth Syst, Patient Safety Enhancement Program, Ann Arbor, MI USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dhaliwal, G (corresponding author), Vet Affairs Med Ctr, Dept Med, 4150 Clement St 111, San Francisco, CA 94121 USA.	gurpreet.dhaliwal@med.va.gov	Saint, Sanjay/AAF-5126-2019		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER; AHRQ HHS [P20-HS11540] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		CORAZZA GR, 1995, SCAND J GASTROENTERO, V30, P153, DOI 10.3109/00365529509093254; COUNSELL CE, 1994, GUT, V35, P844, DOI 10.1136/gut.35.6.844; Farrell RJ, 2002, NEW ENGL J MED, V346, P180, DOI 10.1056/NEJMra010852; Fasano A, 2003, ARCH INTERN MED, V163, P286, DOI 10.1001/archinte.163.3.286; Fine KD, 1996, NEW ENGL J MED, V334, P1163, DOI 10.1056/NEJM199605023341804; Fine KD, 2001, AM J GASTROENTEROL, V96, P138, DOI 10.1111/j.1572-0241.2001.03464.x; Green PHR, 2003, AM J MED, V115, P191, DOI 10.1016/S0002-9343(03)00302-4; Hin H, 1999, BMJ-BRIT MED J, V318, P164, DOI 10.1136/bmj.318.7177.164; HIN H, 1999, BMJ-BRIT MED J, V318, P857; Karnam US, 2004, SOUTH MED J, V97, P30, DOI 10.1097/01.SMJ.0000051059.23259.56; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; Maki M, 2003, NEW ENGL J MED, V348, P2517, DOI 10.1056/NEJMoa021687; MCINTYRE AS, 1993, GUT, V34, P1102, DOI 10.1136/gut.34.8.1102; McManus R, 2003, NEW ENGL J MED, V348, P2573, DOI 10.1056/NEJMcibr035033; Oxentenko AS, 2002, AM J GASTROENTEROL, V97, P933	15	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1997	2002		10.1056/NEJMcps040877	http://dx.doi.org/10.1056/NEJMcps040877			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525726				2022-12-28	WOS:000224851300014
J	Okuonzi, SA				Okuonzi, SA			Dying for economic growth? Evidence of a flawed economic policy in Uganda	LANCET			English	Editorial Material							SECTOR		Natl Council Children, Kampala, Uganda		Okuonzi, SA (corresponding author), Natl Council Children, POB 21456, Kampala, Uganda.	sokuonzi@infocom.co.ug						Abel-Smith B., 1994, INTRO HLTH POLICY PL; ADETUNJI J, 2000, B WORLD HEALTH ORGAN, V78, P1002; [Anonymous], 2001, UG DEM HLTH SURV 200; [Anonymous], 1996, UNICEF REVISED 1990; [Anonymous], 2002, 2002 STAT ABSTR; Brownbridge Martin, 2004, HLTH POLICY DEV, V2, P40; EBANYAT F, 2002, UGANDA HLTH B, V8, P259; *GOV UG, 2004, POV ER ACT PLAN DRAF; *GOV UG, 2003, INF MAT MORT UG CAUS; *GOV UG, 1999, VIS 2025 STRAT FRAM; *GOV UG, 2003, HLTH SECT REV REP; *GOV UG, 2003, STAT EM OBST CAR EMO; *GOV UG, 2004, UG NAT HIV AIDS POL; *GOV UG, 2004, IMPL UN CONV RIGHTS; *GOV UG, 2004, UG PART ASS UG POV; Government of Uganda, 2004, BACKGR BUDG FIN YEAR; Jeppsson A, 2000, INT J HEALTH PLAN M, V15, P273, DOI 10.1002/hpm.597; KIYONGA C, 2001, UGANDA HLTH B, V7, P31; Ministry of Finance. Planning and Economic Development Uganda Macro International, 1996, UG DEM HLTH SURV 199; MOLLER LC, 2002, UGANDA HLTH B, V8, P211; MWENDA A, 2004, MONITOR KAMPALA 0725, P14; OKUONZI SA, 1995, HEALTH POLICY PLANN, V10, P122, DOI 10.1093/heapol/10.2.122; Okuonzi SA, 2000, INT J HEALTH PLAN M, V15, P201; OKUONZI SA, 2002, UGANDA HLTH B, V8, P228; RANNANELIYA, STRATEGIES IMPROVING; RICE T, 1998, HLTH EC RECONSIDERED; ROSS L, 1998, PROMOTING QUALITY MA; SACHS JD, 2002, UGANDA HLTH B, V8, P113; Saito F., 2003, DECENTRALIZATION DEV; SHUTT R, 1998, TROUBLE CAPITALISM E; Stigliz J., 2002, GLOBALISATION ITS DI; WEISBROT M, 2001, SCOREBOARD GLOBALISA; World Health Organization, 2003, WORLD HLTH REP SHAP; World Health Organization, 1986, OTT CHART GES; YATES R, 2004, HLTH POLICY DEV, V2, P48	35	25	25	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	2004	364	9445					1632	1637		10.1016/S0140-6736(04)17320-0	http://dx.doi.org/10.1016/S0140-6736(04)17320-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	866IQ	15519637				2022-12-28	WOS:000224767600032
J	Otto, GA; Puglisi, JD				Otto, GA; Puglisi, JD			The pathway of HCVIRES-mediated translation initiation	CELL			English	Article							HEPATITIS-C VIRUS; RIBOSOME ENTRY SITE; INTERNAL INITIATION; NONTRANSLATED REGIONS; MUTATIONAL ANALYSIS; DOMAIN-II; RNA; SUBUNITS; ELEMENT; BINDING	The HCV internal ribosome entry site (IRES) directly regulates the assembly of translation initiation complexes on viral mRNA by a sequential pathway that is distinct from canonical eukaryotic initiation. The HCV IRES can form a binary complex with an eIF-free 40S ribosomal subunit. Next, a 48S-like complex assembles at the AUG initiation codon upon association of eIF3 and ternary complex. 80S complex formation is rate limiting and follows the GTP-dependent association of the 60S subunit. Efficient assembly of the 48S-like and 80S complexes on the IRES mRNA is dependent upon maintenance of the highly conserved HCV IRES structure. This revised model of HCV IRES translation initiation provides a context to understand the function of different HCV IRES domains during translation initiation.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University; Stanford University	Puglisi, JD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	puglisi@stanford.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI047365, R01AI047365] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47365] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; BROWN EA, 1992, NUCLEIC ACIDS RES, V20, P5041, DOI 10.1093/nar/20.19.5041; Buratti E, 1998, NUCLEIC ACIDS RES, V26, P3179, DOI 10.1093/nar/26.13.3179; Dmitriev SE, 2003, FEBS LETT, V533, P99, DOI 10.1016/S0014-5793(02)03776-6; Fletcher SP, 2002, RNA, V8, P1558, DOI 10.1017/S1355838202023038; Fukushi S, 2001, J BIOL CHEM, V276, P20824, DOI 10.1074/jbc.C100206200; He YP, 2002, VIRAL IMMUNOL, V15, P95, DOI 10.1089/088282402317340260; Hellen CUT, 1999, J VIRAL HEPATITIS, V6, P79, DOI 10.1046/j.1365-2893.1999.00150.x; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Honda M, 1999, J VIROL, V73, P1165, DOI 10.1128/JVI.73.2.1165-1174.1999; Honda M, 1996, RNA, V2, P955; Jubin R, 2000, J VIROL, V74, P10430, DOI 10.1128/JVI.74.22.10430-10437.2000; Kieft JS, 2002, NAT STRUCT BIOL, V9, P370, DOI 10.1038/nsb781; Kieft JS, 2001, RNA, V7, P194, DOI 10.1017/S1355838201001790; Kolupaeva VG, 2000, J VIROL, V74, P6242, DOI 10.1128/JVI.74.14.6242-6250.2000; Kong LK, 2002, J VIROL, V76, P12457, DOI 10.1128/JVI.76.24.12457-12462.2002; Kruger M, 2000, P NATL ACAD SCI USA, V97, P8566, DOI 10.1073/pnas.97.15.8566; Lorsch JR, 1999, EMBO J, V18, P6705, DOI 10.1093/emboj/18.23.6705; Lukavsky PJ, 2000, NAT STRUCT BIOL, V7, P1105; Lukavsky PJ, 2003, NAT STRUCT BIOL, V10, P1033, DOI 10.1038/nsb1004; Lytle JR, 2001, J VIROL, V75, P7629, DOI 10.1128/JVI.75.16.7629-7636.2001; Otto GA, 2002, RNA, V8, P913, DOI 10.1017/S1355838202022057; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Psaridi L, 1999, FEBS LETT, V453, P49, DOI 10.1016/S0014-5793(99)00662-6; Reynolds JE, 1996, RNA, V2, P867; Rijnbrand R, 2000, J VIROL, V74, P773, DOI 10.1128/JVI.74.2.773-783.2000; Safer B, 1979, Methods Enzymol, V60, P61; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; WANG CY, 1994, J VIROL, V68, P7301, DOI 10.1128/JVI.68.11.7301-7307.1994; WANG CY, 1995, RNA, V1, P526; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; Wood J, 2001, J VIROL, V75, P1348, DOI 10.1128/JVI.75.3.1348-1358.2001; Zhao WD, 2001, J VIROL, V75, P3719, DOI 10.1128/JVI.75.8.3719-3730.2001	35	204	215	2	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2004	119	3					369	380		10.1016/j.cell.2004.09.038	http://dx.doi.org/10.1016/j.cell.2004.09.038			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	868IW	15507208	Green Submitted, Bronze			2022-12-28	WOS:000224908300008
J	Dyall, SD; Yan, WH; Delgadillo-Correa, MG; Lunceford, A; Loo, JA; Clarke, CF; Johnson, PJ				Dyall, SD; Yan, WH; Delgadillo-Correa, MG; Lunceford, A; Loo, JA; Clarke, CF; Johnson, PJ			Non-mitochondrial complex I proteins in a hydrogenosomal oxidoreductase complex	NATURE			English	Article							NADH-QUINONE OXIDOREDUCTASE; TRICHOMONAS-VAGINALIS; FERREDOXIN OXIDOREDUCTASE; PARACOCCUS-DENITRIFICANS; ANAEROBIC EUKARYOTES; NUCLEAR GENOMES; MITOCHONDRIA; EVOLUTION; ORIGIN; GENES	Trichomonas vaginalis is a unicellular microaerophilic eukaryote that lacks mitochondria yet contains an alternative organelle, the hydrogenosome, involved in pyruvate metabolism. Pathways between the two organelles differ substantially: in hydrogenosomes, pyruvate oxidation is catalysed by pyruvate: ferredoxin oxidoreductase (PFOR), with electrons donated to an [ Fe]hydrogenase which produces hydrogen. ATP is generated exclusively by substrate-level phosphorylation in hydrogenosomes, as opposed to oxidative phosphorylation in mitochondria(1). PFOR and hydrogenase are found in eubacteria and amitochondriate eukaryotes, but not in typical mitochondria(2-4). Analyses of mitochondrial genomes indicate that mitochondria have a single endosymbiotic origin from an alpha-proteobacterial-type progenitor(5). The absence of a genome in trichomonad hydrogenosomes(6) precludes such comparisons, leaving the endosymbiotic history of this organelle unclear(7). Although phylogenetic reconstructions of a few proteins indicate that trichomonad hydrogenosomes share a common origin with mitochondria(8-11), others do not(2-4,7). Here we describe a novel NADH dehydrogenase module of respiratory complex I that is coupled to the central hydrogenosomal fermentative pathway to form a hydrogenosomal oxidoreductase complex that seems to function independently of quinones. Phylogenetic analyses of hydrogenosomal complex I-like proteins Ndh51 and Ndh24 reveal that neither has a common origin with mitochondrial homologues. These studies argue against a vertical origin of trichomonad hydrogenosomes from the proto-mitochondrial endosymbiont.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; NASA, Astrobiol Inst, Ctr Astrobiol, IGPP, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; National Aeronautics & Space Administration (NASA); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Johnson, PJ (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 1602 Mol Sci Bldg,609 Charles E Young Dr E, Los Angeles, CA 90095 USA.	johnsonp@ucla.edu						Akhmanova A, 1998, NATURE, V396, P527, DOI 10.1038/25023; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Bui ETN, 1996, P NATL ACAD SCI USA, V93, P9651, DOI 10.1073/pnas.93.18.9651; Clemens DL, 2000, MOL BIOCHEM PARASIT, V106, P307, DOI 10.1016/S0166-6851(99)00220-0; Dolezal P, 2004, GENE, V329, P81, DOI 10.1016/j.gene.2003.12.022; Doolittle WE, 1998, TRENDS GENET, V14, P307; Doolittle WF, 2003, PHILOS T R SOC B, V358, P39, DOI 10.1098/rstb.2002.1185; Dyall SD, 2000, MOL CELL BIOL, V20, P2488, DOI 10.1128/MCB.20.7.2488-2497.2000; Dyall SD, 2004, SCIENCE, V304, P253, DOI 10.1126/science.1094884; Embley TM, 2003, PHILOS T R SOC B, V358, P191, DOI 10.1098/rstb.2002.1190; FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I; Friedrich T, 2004, BBA-BIOENERGETICS, V1608, P1, DOI 10.1016/j.bbabio.2003.10.002; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Horner DS, 2000, MOL BIOL EVOL, V17, P1695, DOI 10.1093/oxfordjournals.molbev.a026268; Horner DS, 1999, MOL BIOL EVOL, V16, P1280, DOI 10.1093/oxfordjournals.molbev.a026218; Horner DS, 1996, P ROY SOC B-BIOL SCI, V263, P1053, DOI 10.1098/rspb.1996.0155; HRDY I, 1995, J MOL EVOL, V41, P388, DOI 10.1007/BF01215186; HRDY I, 1995, J EUKARYOT MICROBIOL, V42, P593, DOI 10.1111/j.1550-7408.1995.tb05913.x; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Jonassen T, 2003, J BIOL CHEM, V278, P51735, DOI 10.1074/jbc.M308760200; Land KM, 2004, MOL MICROBIOL, V51, P115, DOI 10.1046/j.1365-2958.2003.03791.x; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Massanz C, 1998, J BACTERIOL, V180, P1023, DOI 10.1128/JB.180.5.1023-1029.1998; Meganathan R, 2001, FEMS MICROBIOL LETT, V203, P131, DOI 10.1016/S0378-1097(01)00330-5; MULLER M, 1993, J GEN MICROBIOL, V139, P2879, DOI 10.1099/00221287-139-12-2879; Roger AJ, 1996, P NATL ACAD SCI USA, V93, P14618, DOI 10.1073/pnas.93.25.14618; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; YANO T, 1994, FEBS LETT, V354, P160, DOI 10.1016/0014-5793(94)01107-9	30	67	71	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1103	1107		10.1038/nature02990	http://dx.doi.org/10.1038/nature02990			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15510149				2022-12-28	WOS:000224730800042
J	Samatey, FA; Matsunami, H; Imada, K; Nagashima, S; Shaikh, TR; Thomas, DR; Chen, JZ; DeRosier, DJ; Kitao, A; Namba, K				Samatey, FA; Matsunami, H; Imada, K; Nagashima, S; Shaikh, TR; Thomas, DR; Chen, JZ; DeRosier, DJ; Kitao, A; Namba, K			Structure of the bacterial flagellar hook and implication for the molecular universal joint mechanism	NATURE			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; PROTEIN; FILAMENT; ROTATION; TRANSFORMATIONS; ORGANIZATION; CAULOBACTER; REFINEMENT; RESOLUTION	The bacterial flagellum is a motile organelle, and the flagellar hook is a short, highly curved tubular structure that connects the flagellar motor to the long filament acting as a helical propeller. The hook is made of about 120 copies of a single protein, FlgE, and its function as a nano-sized universal joint is essential for dynamic and efficient bacterial motility and taxis. It transmits the motor torque to the helical propeller over a wide range of its orientation for swimming and tumbling. Here we report a partial atomic model of the hook obtained by X-ray crystallography of FlgE31, a major proteolytic fragment of FlgE lacking unfolded terminal regions, and by electron cryomicroscopy and three-dimensional helical image reconstruction of the hook. The model reveals the intricate molecular interactions and a plausible switching mechanism for the hook to be flexible in bending but rigid against twisting for its universal joint function.	JST, ICORP, Dynam Nanomachine Project, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; JST, ERATO, Photon Nanomachine Project, Kyoto, Japan; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, WM Keck Inst Cellular Visualizat, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Univ Tokyo, Inst Mol & Cellular Biolsci, Bunkyo Ku, Tokyo 1130032, Japan	Japan Science & Technology Agency (JST); Osaka University; Japan Science & Technology Agency (JST); Brandeis University; Brandeis University; University of Tokyo	Namba, K (corresponding author), JST, ICORP, Dynam Nanomachine Project, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.	keiichi@fbs.osaka-u.ac.jp	Namba, Keiichi/A-9406-2016; Matsunami, Hideyuki/E-6632-2010; Kitao, Akio/B-8371-2008; Matsunami, Hideyuki/GOK-2037-2022; Samatey, Fadel/A-3204-2012	Matsunami, Hideyuki/0000-0001-5814-3766; Kitao, Akio/0000-0002-5221-0806; Matsunami, Hideyuki/0000-0001-5814-3766; Imada, Katsumi/0000-0003-1342-8885; Samatey, Fadel/0000-0002-0733-2863				AIZAWA S, 1980, J MOL BIOL, V137, P437, DOI 10.1016/0022-2836(80)90168-0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berg HC, 2003, ANNU REV BIOCHEM, V72, P19, DOI 10.1146/annurev.biochem.72.121801.161737; BERG HC, 1973, NATURE, V245, P380, DOI 10.1038/245380a0; CASE DA, 2002, AMBER7; Chen JZ, 2003, J STRUCT BIOL, V144, P144, DOI 10.1016/j.jsb.2003.09.008; DEPAMPHI.ML, 1971, J BACTERIOL, V105, P384, DOI 10.1128/JB.105.1.384-395.1971; DEPAMPHI.ML, 1971, J BACTERIOL, V105, P376, DOI 10.1128/JB.105.1.376-383.1971; FAHRNER KA, 1994, J MOL BIOL, V238, P173, DOI 10.1006/jmbi.1994.1279; FRANCIS NR, 1994, J MOL BIOL, V235, P1261, DOI 10.1006/jmbi.1994.1079; Hasegawa K, 1998, BIOPHYS J, V74, P569, DOI 10.1016/S0006-3495(98)77815-4; HIRANO T, 1994, J BACTERIOL, V176, P5439, DOI 10.1128/JB.176.17.5439-5449.1994; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOMMA M, 1990, J MOL BIOL, V213, P819, DOI 10.1016/S0022-2836(05)80266-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAGAWA H, 1979, J MOL BIOL, V129, P333, DOI 10.1016/0022-2836(79)90286-9; KATO S, 1984, J MOL BIOL, V173, P463, DOI 10.1016/0022-2836(84)90391-7; Kojima S, 2004, INT REV CYTOL, V233, P93, DOI 10.1016/S0074-7696(04)33003-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUDO S, 1990, NATURE, V346, P677, DOI 10.1038/346677a0; KUTSUKAKE K, 1979, J BACTERIOL, V140, P267, DOI 10.1128/JB.140.1.267-275.1979; LOWE G, 1987, NATURE, V325, P637, DOI 10.1038/325637a0; MACNAB RM, 1977, J MOL BIOL, V112, P1, DOI 10.1016/S0022-2836(77)80153-8; Macnab RM, 2003, ANNU REV MICROBIOL, V57, P77, DOI 10.1146/annurev.micro.57.030502.090832; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORGAN DG, 1995, J MOL BIOL, V249, P88, DOI 10.1006/jmbi.1995.0282; MORGAN DG, 1993, J MOL BIOL, V229, P79, DOI 10.1006/jmbi.1993.1009; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Namba K, 1997, Q REV BIOPHYS, V30, P1, DOI 10.1017/S0033583596003319; Otwinowski Z., 1997, PROCESSING XRAY DIFF; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; Samatey FA, 2000, J STRUCT BIOL, V132, P106, DOI 10.1006/jsbi.2000.4312; Samatey FA, 2001, NATURE, V410, P331, DOI 10.1038/35066504; SAMATEY FA, IN PRESS ACTA CRYS D; SILVERMAN M, 1974, NATURE, V249, P73, DOI 10.1038/249073a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Turner L, 2000, J BACTERIOL, V182, P2793, DOI 10.1128/JB.182.10.2793-2801.2000; VONDERVISZT F, 1992, J MOL BIOL, V226, P575, DOI 10.1016/0022-2836(92)90616-R; VONDERVISZT F, 1995, J MOL BIOL, V251, P520, DOI 10.1006/jmbi.1995.0453; WAGENKNECHT T, 1982, J MOL BIOL, V162, P69, DOI 10.1016/0022-2836(82)90162-0; WAGENKNECHT T, 1981, J MOL BIOL, V151, P439, DOI 10.1016/0022-2836(81)90005-X; Williams AW, 1996, J BACTERIOL, V178, P2960, DOI 10.1128/jb.178.10.2960-2970.1996; Yamashita I, 1998, NAT STRUCT BIOL, V5, P125; Yonekura K, 2003, NATURE, V424, P643, DOI 10.1038/nature01830	46	149	151	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1062	1068		10.1038/nature02997	http://dx.doi.org/10.1038/nature02997			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15510139				2022-12-28	WOS:000224730800031
J	Tomkins, JL; Brown, GS				Tomkins, JL; Brown, GS			Population density drives the local evolution of a threshold dimorphism	NATURE			English	Article							MALE-MALE COMPETITION; SEXUAL SELECTION; EARWIG; SIZE; TACTICS	Evolution can favour more than one reproductive tactic among conspecifics of the same sex(1,2). Under the conditional evolutionarily stable strategy, individuals adopt the tactic that generates the highest fitness return for their status: large males guard females, whereas small males sneak copulations(3,4). Tactics change at the status at which fitness benefits switch from favouring one tactic to favouring the alternative(1,5). This 'switchpoint' is expressed in many species as a threshold between divergent morphologies(3). Environmental and demographic parameters that influence the relative fitness of male tactics are predicted to determine a population's switchpoint(1,5) and consequently whether the population is monomorphic or dimorphic. Here we show threshold evolution in the forceps dimorphism of the European earwig Forficula auricularia and document the transition from completely monomorphic to classical male-dimorphic populations over a distance of only 40 km. Because the superior fighting ability of the dominant morph(6) will be more frequently rewarded at high encounter rates, population density is likely to be a key determinant of the relative fitness of the alternative tactics, and consequently the threshold. We show that, as predicted, population density correlates strongly with the shift in threshold, and that this factor drives the local evolution of the male dimorphism in these island populations. Our data provide evidence for the origin of phenotypic diversity within populations(7-9), through the evolution of a switchpoint in a conditional strategy that has responded to local population density.	Univ St Andrews, Div Environm & Evolutionary Biol, St Andrews KY16 9TH, Fife, Scotland	University of St Andrews	Tomkins, JL (corresponding author), Univ St Andrews, Div Environm & Evolutionary Biol, Sir Harold Mitchell Bldg, St Andrews KY16 9TH, Fife, Scotland.	jlt1@st-andrews.ac.uk	Tomkins, Joseph L/A-8091-2011	Tomkins, Joseph L/0000-0003-1259-7898				Bateson W., 1892, Proceedings of the Zoological Society, P585; EBERHARD WG, 1991, EVOLUTION, V45, P18, DOI 10.1111/j.1558-5646.1991.tb05262.x; Emlen DJ, 1997, BEHAV ECOL SOCIOBIOL, V41, P335, DOI 10.1007/s002650050393; Emlen DJ, 1996, EVOLUTION, V50, P1219, DOI [10.1111/j.1558-5646.1996.tb02362.x, 10.2307/2410662]; EMLEN ST, 1977, SCIENCE, V197, P215, DOI 10.1126/science.327542; Forslund P, 2000, ANIM BEHAV, V59, P753, DOI 10.1006/anbe.1999.1359; Gross MR, 1996, TRENDS ECOL EVOL, V11, P92, DOI 10.1016/0169-5347(96)81050-0; HAZEL WN, 1990, P ROY SOC B-BIOL SCI, V242, P181, DOI 10.1098/rspb.1990.0122; Hunt J, 2001, P ROY SOC B-BIOL SCI, V268, P2409, DOI 10.1098/rspb.2001.1758; Huxley JS, 1927, J GENET, V17, P309, DOI 10.1007/BF02983133; Kotiaho JS, 2001, BEHAV ECOL, V12, P553, DOI 10.1093/beheco/12.5.553; Maynard Smith J., 1982, pi; Moczek AP, 2003, BEHAV ECOL, V14, P841, DOI 10.1093/beheco/arg062; Moczek AP, 2002, EVOL ECOL RES, V4, P587; RADESATER T, 1993, ETHOLOGY, V95, P89, DOI 10.1111/j.1439-0310.1993.tb00460.x; Roff D.A., 1997, EVOLUTIONARY QUANTIT; Roff DA, 1996, Q REV BIOL, V71, P3, DOI 10.1086/419266; SCHLUTER D, 1988, EVOLUTION, V42, P849, DOI [10.2307/2408904, 10.1111/j.1558-5646.1988.tb02507.x]; SHUSTER SM, 2003, MG BEH ECOL, pR7; Snow D.W., 1998, BIRDS W PALEARCTIC; Tomkins JL, 1998, ANIM BEHAV, V56, P347, DOI 10.1006/anbe.1998.0838; Tomkins JL, 1999, BEHAV ECOL SOCIOBIOL, V47, P1, DOI 10.1007/s002650050643; TOMKINS JL, IN PRESS J EVOL BIOL; Unrug J, 2004, P ROY SOC B-BIOL SCI, V271, P1401, DOI 10.1098/rspb.2004.2729; West-Eberhard Mary Jane, 2003, pi; WESTEBERHARD MJ, 1986, P NATL ACAD SCI USA, V83, P1388, DOI 10.1073/pnas.83.5.1388; WESTEBERHARD MJ, 1989, ANNU REV ECOL SYST, V20, P249, DOI 10.1146/annurev.es.20.110189.001341; Zar J.H., 1999, ZAR KUHR 5 2019, V4th	28	118	120	2	51	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1099	1103		10.1038/nature02918	http://dx.doi.org/10.1038/nature02918			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15510148				2022-12-28	WOS:000224730800041
J	MacMahon, S; Neal, B; Rodgers, A; Chalmers, J				MacMahon, S; Neal, B; Rodgers, A; Chalmers, J			Commentary: The PROGRESS trial three years later: time for more action, less distraction	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; STROKE		Univ Sydney, George Inst Int Hlth, Sydney, NSW 2050, Australia; Univ Auckland, Clin Trials Res Unit, Auckland 1, New Zealand	University of Sydney; University of Auckland	MacMahon, S (corresponding author), Univ Sydney, George Inst Int Hlth, POB M201, Sydney, NSW 2050, Australia.	smacmahon@thegeorgeinstitute.org		Neal, Bruce/0000-0002-0490-7465; MacMahon, Stephen/0000-0003-2064-7699; Chalmers, John/0000-0002-9931-0580; Rodgers, Anthony/0000-0003-1282-1896				Chalmers J, 2003, STROKE, V34, P2333, DOI 10.1161/01.STR.0000091397.81767.40; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; *INT WORK PART STR, 2002, NAT CLIN GUID STROK; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; Muir KW, 2004, BMJ-BRIT MED J, V328, P297, DOI 10.1136/bmj.328.7435.297; *PROGRESS COLL GRO, 2002, EUR HEART J, V24, P475; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; Psaty BM, 2002, AM J HYPERTENS, V15, P472, DOI 10.1016/S0895-7061(02)02928-X; Rodgers A, 1996, BRIT MED J, V313, P147, DOI 10.1136/bmj.313.7050.147; Turnbull F, 2003, LANCET, V362, P1527; Wennberg R, 2004, BMJ-BRIT MED J, V329, P968, DOI 10.1136/bmj.329.7472.968	11	11	11	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 23	2004	329	7472					970	971		10.1136/bmj.329.7472.970	http://dx.doi.org/10.1136/bmj.329.7472.970			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866KU	15499117	Green Published			2022-12-28	WOS:000224773200024
J	Sharp, D				Sharp, D			Not-for-pro-fit drugs - no longer an oxymoron?	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Sharp, D (corresponding author), Lancet, London NW1 7BY, England.							*B M GAT FDN, 2004, ANN REP 2003 RESP NE; *MED MAL VENT, 2004, CUR MAL TOG ANN REP; Stix G, 2004, SCI AM, V290, P28, DOI 10.1038/scientificamerican0204-28; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; Vennerstrom JL, 2004, NATURE, V430, P900, DOI 10.1038/nature02779; Wheeler C, 2001, B WORLD HEALTH ORGAN, V79, P728; Widdus R., 2004, COMBATING DIS ASS PO	7	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1472	1474		10.1016/S0140-6736(04)17291-7	http://dx.doi.org/10.1016/S0140-6736(04)17291-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500876				2022-12-28	WOS:000224645500009
J	Pastinen, T; Hudson, TJ				Pastinen, T; Hudson, TJ			Cis-acting regulatory variation in the human genome	SCIENCE			English	Review							HUMAN GENE-EXPRESSION; SINGLE-NUCLEOTIDE POLYMORPHISM; ALLELIC EXPRESSION; LINKAGE DISEQUILIBRIUM; MARFAN-SYNDROME; LACTASE GENE; IDENTIFICATION; REGION; TRANSCRIPTION; MECHANISM	The systematic screening of the human genome for genetic variants that affect gene regulation should advance our fundamental understanding of phenotypic diversity and lead to the identification of alleles that modify disease risk. There are several challenges in localizing regulatory polymorphisms, including the wide spectrum of cis-acting regulatory mechanisms, the inconsistent effects of regulatory variants in different tissues, and the difficulty in isolating the causal variants that are in linkage disequilibrium with many other variants. We discuss the current state of knowledge and technologies used for mapping and characterizing genetic variation controlling human gene expression.	McGill Univ, Montreal, PQ H3A 1A4, Canada; Genome Quebec Innovat Ctr, Montreal, PQ H3A 1A4, Canada	McGill University	Hudson, TJ (corresponding author), McGill Univ, 740 Dr Penfield Ave, Montreal, PQ H3A 1A4, Canada.	tom.hudson@mcgill.ca	Hu, Ruogu/B-2203-2008					Bersaglieri T, 2004, AM J HUM GENET, V74, P1111, DOI 10.1086/421051; Carter AM, 2002, THROMB HAEMOSTASIS, V87, P846, DOI 10.1055/s-0037-1613095; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Enattah NS, 2002, NAT GENET, V30, P233, DOI 10.1038/ng826; *ENCODE PROJ CONS, 2004, SCIENCE, V306, P647; Ferguson-Smith A, 2003, SEMIN CELL DEV BIOL, V14, P43, DOI 10.1016/S1084-9521(02)00171-4; Gehring NH, 2001, NAT GENET, V28, P389, DOI 10.1038/ng578; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; HEWETT D, 1994, AM J HUM GENET, V55, P447; Hoogendoorn B, 2003, HUM MOL GENET, V12, P2249, DOI 10.1093/hmg/ddg246; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hu JF, 2000, BBA-GENE STRUCT EXPR, V1491, P49, DOI 10.1016/S0167-4781(00)00017-8; Hutchinson S, 2003, HUM MOL GENET, V12, P2269, DOI 10.1093/hmg/ddg241; Ingrosso D, 2003, LANCET, V361, P1693, DOI 10.1016/S0140-6736(03)13372-7; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Knight JC, 2003, NAT GENET, V33, P469, DOI 10.1038/ng1124; Knight JC, 2004, NAT GENET, V36, P394, DOI 10.1038/ng1331; Li J, 2004, P NATL ACAD SCI USA, V101, P7341, DOI 10.1073/pnas.0308195101; Lin ZW, 2002, PHYSIOL GENOMICS, V11, P235, DOI 10.1152/physiolgenomics.00061.2002; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Mulcare CA, 2004, AM J HUM GENET, V74, P1102, DOI 10.1086/421050; Ober C, 2003, AM J HUM GENET, V72, P1425, DOI 10.1086/375501; Ohlsson R, 1998, TRENDS GENET, V14, P435, DOI 10.1016/S0168-9525(98)01583-2; Olds LC, 2003, HUM MOL GENET, V12, P2333, DOI 10.1093/hmg/ddg244; Pastinen T, 2004, PHYSIOL GENOMICS, V16, P184, DOI 10.1152/physiolgenomics.00163.2003; Poulter M, 2003, ANN HUM GENET, V67, P298, DOI 10.1046/j.1469-1809.2003.00048.x; Rockman MV, 2002, MOL BIOL EVOL, V19, P1991, DOI 10.1093/oxfordjournals.molbev.a004023; Rosok O, 2004, NAT BIOTECHNOL, V22, P104, DOI 10.1038/nbt925; Rutter JL, 1998, CANCER RES, V58, P5321; Sakatani T, 2001, BIOCHEM BIOPH RES CO, V283, P1124, DOI 10.1006/bbrc.2001.4916; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Singer-Sam J, 1992, PCR Methods Appl, V1, P160; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Wade-Martins R, 2003, MOL THER, V7, P604, DOI 10.1016/S1525-0016(03)00060-1; Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315; Willing MC, 1996, AM J HUM GENET, V59, P799; Xu Y, 1999, J LIPID RES, V40, P50; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545	40	206	217	2	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					647	650		10.1126/science.1101659	http://dx.doi.org/10.1126/science.1101659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499010				2022-12-28	WOS:000224756700040
J	Ito, K; Hirao, A; Arai, F; Matsuoka, S; Takubo, K; Hamaguchi, I; Nomiyama, K; Hosokawa, K; Sakurada, K; Nakagata, N; Ikeda, Y; Mak, TW; Suda, T				Ito, K; Hirao, A; Arai, F; Matsuoka, S; Takubo, K; Hamaguchi, I; Nomiyama, K; Hosokawa, K; Sakurada, K; Nakagata, N; Ikeda, Y; Mak, TW; Suda, T			Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells	NATURE			English	Article							ATAXIA-TELANGIECTASIA GENE; SERIAL TRANSPLANTATION; DEFICIENT MICE; DNA-DAMAGE; BMI-1; PROLIFERATION; TELOMERASE; QUIESCENCE; CAPACITY; PRODUCT	The 'ataxia telangiectasia mutated' (Atm) gene maintains genomic stability by activating a key cell-cycle checkpoint in response to DNA damage, telomeric instability or oxidative stress(1,2). Mutational inactivation of the gene causes an autosomal recessive disorder, ataxia-telangiectasia, characterized by immunodeficiency, progressive cerebellar ataxia, oculocutaneous telangiectasia, defective spermatogenesis, premature ageing and a high incidence of lymphoma(3,4). Here we show that ATM has an essential function in the reconstitutive capacity of haematopoietic stem cells (HSCs) but is not as important for the proliferation or differentiation of progenitors, in a telomere-independent manner. Atm(-/-) mice older than 24 weeks showed progressive bone marrow failure resulting from a defect in HSC function that was associated with elevated reactive oxygen species. Treatment with anti-oxidative agents restored the reconstitutive capacity of Atm(-/-) HSCs, resulting in the prevention of bone marrow failure. Activation of the p16(INK4a)-retinoblastoma (Rb) gene product pathway in response to elevated reactive oxygen species led to the failure of Atm(-/-) HSCs. These results show that the self-renewal capacity of HSCs depends on ATM-mediated inhibition of oxidative stress.	Keio Univ, Sch Med, Dept Cell Differentiat, Sakaguchi Lab Dev Biol,Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Internal Med, Div Hematol,Shinjuku Ku, Tokyo 1608582, Japan; Kyowa Hakko Kogyo Co Ltd, Biofrontier Labs, Machida, Tokyo 1948533, Japan; Kumamoto Univ, Ctr Anim Resources & Dev, Div Reprod Engn, Kumamoto 8600811, Japan; Univ Toronto, Adv Med Discovery Inst, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Adv Med Discovery Inst, Ontario Canc Inst, Dept Immunol, Toronto, ON M5G 2C1, Canada	Keio University; Keio University; Kyowa Kirin Ltd; Kumamoto University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Suda, T (corresponding author), Keio Univ, Sch Med, Dept Cell Differentiat, Sakaguchi Lab Dev Biol,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	ahirao@sc.itc.keio.ac.jp; sudato@sc.itc.keio.ac.jp	Arai, Fumio/J-5241-2013; Suda, Toshio/H-6761-2013; Sakurada, Kazuhiro/AAH-2281-2021; Takubo, Keiyo/AAX-5546-2020	Arai, Fumio/0000-0003-1936-4907; Suda, Toshio/0000-0001-7540-1771; Sakurada, Kazuhiro/0000-0002-4858-2607; Takubo, Keiyo/0000-0002-1736-7592; Nakagata, Naomi/0000-0002-5737-9993				Allsopp RC, 2003, BLOOD, V102, P517, DOI 10.1182/blood-2002-07-2334; Allsopp RC, 2003, NAT MED, V9, P369, DOI 10.1038/nm0403-369; Allsopp RC, 2001, J EXP MED, V193, P917, DOI 10.1084/jem.193.8.917; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Ema H, 2000, J EXP MED, V192, P1281, DOI 10.1084/jem.192.9.1281; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MEYN MS, 1995, CANCER RES, V55, P5991; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Randall TD, 1997, BLOOD, V89, P3596, DOI 10.1182/blood.V89.10.3596.3596_3596_3606; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Samper E, 2002, BLOOD, V99, P2767, DOI 10.1182/blood.V99.8.2767; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 1996, J CLIN IMMUNOL, V16, P254, DOI 10.1007/BF01541389; Wong KK, 2003, NATURE, V421, P643, DOI 10.1038/nature01385; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yan MS, 2001, FASEB J, V15, P1132, DOI 10.1096/fj.00-0601com; Yuan YZ, 2004, NAT CELL BIOL, V6, P436, DOI 10.1038/ncb1126	30	906	945	2	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					997	1002		10.1038/nature02989	http://dx.doi.org/10.1038/nature02989			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496926				2022-12-28	WOS:000224585600047
J	Oguma, T; Palmer, LJ; Birben, E; Sonna, LA; Asano, K; Lilly, CM				Oguma, T; Palmer, LJ; Birben, E; Sonna, LA; Asano, K; Lilly, CM			Role of prostanoid DP receptor variants in susceptibility to asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIONAL CLONING; GENE; LINKAGE; EOTAXIN; CELLS	BACKGROUND: Previous genetic studies have associated the region of the human genome (14q22.1) containing the gene for the prostanoid DP receptor (PTGDR) with asthma. A study of a mouse model suggests that the receptor is required for the expression of the asthma phenotype. Our associations of asthma with functional genetic variants of PTGDR link these observations. METHODS: We identified and evaluated combinations of genetic variants that influence PTGDR transcription for disease association in case-control studies of 518 white patients with asthma and 175 white controls and 80 black patients with asthma and 45 black controls. RESULTS: We identified four novel and two previously reported single-nucleotide polymorphisms (SNPs) in PTGDR and its vicinity. These define four common three-SNP haplotypes, which vary in their ability to support transcription of PTGDR and have distinct DNA-binding-protein affinity profiles. Individual PTGDR SNPs were significantly associated with asthma in both populations. Specific PTGDR haplotypes were significantly associated with a diagnosis of asthma in a large case-control study of whites (P=0.002); we confirmed these findings in a second population of blacks (P=0.01). Multivariate analysis of the haplotype combinations (diplotypes) demonstrated that both whites (odds ratio, 0.55; 95 percent confidence interval, 0.38 to 0.80; P=0.002) and blacks (odds ratio, 0.32; 95 percent confidence interval, 0.12 to 0.89; P=0.03) who had at least one copy of the haplotype with a low transcriptional efficiency had a lower risk of asthma than subjects with no copies of the haplotype. CONCLUSIONS: Our functional and genetic findings identify PTGDR as an asthma-susceptibility gene.	Brigham & Womens Hosp, Div Pulm & Crit Care, Combined Program Pulm & Crit Care Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Western Australian Inst Med Res, Perth, WA, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6009, Australia; USA, Inst Environm Med, Natick, MA 01760 USA; Keio Univ, Sch Med, Dept Med, Cardiopulm Div, Tokyo 160, Japan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Western Australia; University of Western Australia; Keio University	Lilly, CM (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care, Combined Program Pulm & Crit Care Med, 75 Francis St,Thorn 826C, Boston, MA 02115 USA.	clilly@partners.org	Palmer, Lyle John/K-3196-2014; Palmer, Lyle John/N-1948-2019	Palmer, Lyle John/0000-0002-1628-3055; Palmer, Lyle John/0000-0002-1628-3055; BIRBEN, ESRA/0000-0003-1192-309X				Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; BOIE Y, 1995, J BIOL CHEM, V270, P18910, DOI 10.1074/jbc.270.32.18910; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; Hakonarson H, 2002, AM J HUM GENET, V71, P483, DOI 10.1086/342205; Hall IP, 1998, CLIN EXP ALLERGY, V28, P74; HALL IP, 1998, CLIN EXP ALLERGY S1, V28, P80; Jedrzkiewicz S, 2000, AM J PHYSIOL-LUNG C, V279, pL1058, DOI 10.1152/ajplung.2000.279.6.L1058; JOHNSTON SL, 1995, EUR RESPIR J, V8, P411, DOI 10.1183/09031936.95.08030411; Kobayashi T, 2002, PROSTAG OTH LIPID M, V68-9, P557, DOI 10.1016/S0090-6980(02)00055-2; Malerba G, 2001, J ALLERGY CLIN IMMUN, V107, P654, DOI 10.1067/mai.2001.113865; Mansur AH, 1999, AM J RESP CRIT CARE, V159, P1796, DOI 10.1164/ajrccm.159.6.9804036; Marsh DG, 1997, NAT GENET, V15, P389; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; McCullagh P, 2019, GEN LINEAR MODELS, DOI [10.1201/9780203753736, DOI 10.1007/978-1-4899-3242-6, DOI 10.1201/9780203753736]; Mehta C R, 1994, Stat Methods Med Res, V3, P135, DOI 10.1177/096228029400300203; Nakamura H, 2001, J ALLERGY CLIN IMMUN, V108, P946, DOI 10.1067/mai.2001.120135; Oguma T, 2002, AM J RESP CRIT CARE, V165, P382, DOI 10.1164/ajrccm.165.3.2103093; Palmer LJ, 2000, GENOME RES, V10, P1280, DOI 10.1101/gr.143400; Pritchard JK, 1999, AM J HUM GENET, V65, P220, DOI 10.1086/302449; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; Shikanai T, 2002, J APPL PHYSIOL, V93, P37, DOI 10.1152/japplphysiol.00993.2001; Silverman ES, 1998, AM J RESP CELL MOL, V19, P316, DOI 10.1165/ajrcmb.19.2.3154; Slatkin M, 1996, HEREDITY, V76, P377, DOI 10.1038/hdy.1996.55; Sonna LA, 2001, CHEST, V119, P1676, DOI 10.1378/chest.119.6.1676; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166; 1997, GUIDELINES DIAGNOSIS, P1	33	113	126	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2004	351	17					1752	1763		10.1056/NEJMoa031785	http://dx.doi.org/10.1056/NEJMoa031785			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863TH	15496624				2022-12-28	WOS:000224585200010
J	Brewster, LM; van Montfrans, GA; Kleijnen, J				Brewster, LM; van Montfrans, GA; Kleijnen, J			Systematic review: Antihypertensive drug therapy in black patients	ANNALS OF INTERNAL MEDICINE			English	Review							LEFT-VENTRICULAR HYPERTROPHY; CONVERTING-ENZYME-INHIBITOR; BASE-LINE CHARACTERISTICS; LIPID-LOWERING TREATMENT; END-POINT REDUCTION; ESSENTIAL-HYPERTENSION; BLOOD-PRESSURE; LOSARTAN INTERVENTION; AFRICAN-AMERICANS; KIDNEY-DISEASE	Background: Hypertension occurs more frequently and is generally more severe in black persons than in white persons, leading to excess morbidity and mortality. Purpose: To systematically review the efficacy of different anti-hypertensive drugs in reducing blood pressure, morbidity, and mortality in hypertensive black adults. Data Sources: The following databases were searched from their inception through November 2003: MEDLINE, EMBASE, LILACS (Literatura Latino-Americana y del Caribe en Ciencias de la Salud), African Index Medicus, and the Cochrane Library. PubMed was also searched from September 2003 through March 2004. Searches were conducted without language restriction. Study Selection: Randomized, controlled trials of drugs versus placebo (blood pressure outcomes) or drugs versus placebo or other drugs (morbidity and mortality outcomes). Data Extraction: 2 reviewers independently extracted data. Data Synthesis: The efficacy of beta-blockers in reducing systolic blood pressure and the efficacy of angiotensin-converting enzyme inhibitors in achieving diastolic blood pressure goals did not significantly differ from that of placebo (weighted mean difference for beta-blockers, -3.53 mm Hg [95% CI, -7.51 to 0.45 mm Hg]; relative risk for angiotensin-converting enzyme inhibitors, 1.35 [CI, 0.81 to 2.26]). In the pooled analyses, other reviewed drugs (calcium-channel blockers, diuretics, central sympatholytics, alpha-blockers, and angiotensin II receptor blockers) were more effective than placebo in reducing blood pressure, but only calcium-channel blockers remained effective in all prespecified subgroups, including patients with a baseline diastolic blood pressure of 110 mm Hg or greater. Main morbidity and mortality outcomes did not differ significantly between treatment groups when drugs were combined to reach blood pressure goals. However, trial results indicated a greater occurrence of diabetes with diuretics and a higher risk for cardiovascular events with drug regimens that included angiotensin-converting enzyme inhibitors. Limitations: This meta-analysis evaluated the blood pressure lowering-efficacy of monotherapy only. Conclusions: Drugs differ in their efficacy for reducing blood pressure in black patients, but there is no solid evidence that efficacy for reducing morbidity and mortality outcomes differs once patients achieve the blood pressure goal.	Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Brewster, LM (corresponding author), Acad Med Ctr, Dept Internal Med, F4-253,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Brewster, Lizzy M/K-7675-2019	Brewster, Lizzy M/0000-0002-7434-0038				Afridi I, 2003, J HYPERTENS, V21, P1983, DOI 10.1097/01.hjh.0000084751-37215.d2; Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; Altman D.G., 1991, PRACTICAL STAT MED R; [Anonymous], 1988, J Clin Epidemiol, V41, P1197; BLACK HR, 1993, HYPERTENSION, V21, P335; Brewster LM, 2000, J HYPERTENS, V18, P1537, DOI 10.1097/00004872-200018110-00002; BREWSTER LM, IN PRESS COCHRANE LI; BREWSTER LM, 2001, COCHRANE LIB; CLEOPHAS TJM, 1988, ANGIOLOGY, V39, P587, DOI 10.1177/000331978803900706; Conlin PR, 2003, AM J HYPERTENS, V16, P337, DOI 10.1016/S0895-7061(03)00056-6; COOPER R, 1994, J HYPERTENS, V12, P215; COOPER R, 1986, J HEALTH POLIT POLIC, V11, P97, DOI 10.1215/03616878-11-1-97; Dahlof B, 1997, AM J HYPERTENS, V10, P705; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; DAVIS BR, 1989, CONTROL CLIN TRIALS, V10, P11; Dean G, 1971, S Afr Med J, V45, P323; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; Douglas JG, 2003, ARCH INTERN MED, V163, P525, DOI 10.1001/archinte.163.5.525; DRAYER JIM, 1976, AM J MED, V60, P897, DOI 10.1016/0002-9343(76)90911-6; DRAYER JIM, 1983, HYPERTENSION, V5, P108; FADAYOMI MO, 1986, J CARDIOVASC PHARM, V8, P466, DOI 10.1097/00005344-198605000-00004; FIDDES R, 1994, CLIN THER, V16, P209; Flack JM, 2003, J AM COLL CARDIOL, V41, P1148, DOI 10.1016/S0735-1097(03)00054-8; Flack JM, 2001, CLIN THER, V23, P1193, DOI 10.1016/S0149-2918(01)80101-6; FRAY JCS, 1993, PATHOPHYSIOLOGY HYPE; FRISHMAN WH, 1995, J CLIN PHARMACOL, V35, P182, DOI 10.1002/j.1552-4604.1995.tb05009.x; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Gassman JJ, 2003, J AM SOC NEPHROL, V14, pS154, DOI 10.1097/01.ASN.0000070080.21680.CB; Grimm RH, 2001, HYPERTENSION, V37, P19, DOI 10.1161/01.HYP.37.1.19; GRIMM RH, 1997, ABC DIGEST URBAN NOV, P10; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HUMPHREYS GS, 1968, BMJ-BRIT MED J, V2, P601, DOI 10.1136/bmj.2.5605.601; IAJJ, 2003, JAMA-J AM MED ASSOC, V290, P199; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jamerson KA, 2000, AM J KIDNEY DIS, V36, pS24, DOI 10.1053/ajkd.2000.9688; *JOINT NAT COMM PR, 7 JOINT NAT COMM PRE; Julius S, 2004, J AM COLL CARDIOL, V43, P1047, DOI 10.1016/j.jacc.2003.11.029; Lemogoum D, 2003, J HYPERTENS, V21, P1993, DOI 10.1097/00004872-200311000-00003; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MATERSON BJ, 1995, AM J HYPERTENS, V8, P189, DOI 10.1016/0895-7061(94)00196-I; MOSER M, 1984, J CARDIOVASC PHARM, V6, P1085; MOSER M, 1982, CLIN PHARMACOL THER, V32, P307, DOI 10.1038/clpt.1982.165; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; Okin PM, 2000, HYPERTENSION, V36, P766, DOI 10.1161/01.HYP.36.5.766; Opie LH, 1997, AM J HYPERTENS, V10, P250, DOI 10.1016/S0895-7061(96)00384-6; Reisin E, 1997, HYPERTENSION, V30, P140, DOI 10.1161/01.HYP.30.1.140; ROSE M, 1990, AM J HYPERTENS, V3, P151, DOI 10.1093/ajh/3.2.151; SALAKO LA, 1979, CURR MED RES OPIN, V6, P358, DOI 10.1185/03007997909109451; SAUNDERS E, 1990, ARCH INTERN MED, V150, P1707, DOI 10.1001/archinte.150.8.1707; Schmid CH, 1998, STAT MED, V17, P1923, DOI 10.1002/(SICI)1097-0258(19980915)17:17<1923::AID-SIM874>3.0.CO;2-6; SEEDAT YK, 1980, CURR MED RES OPIN, V7, P68, DOI 10.1185/03007998009116518; SEEDAT YK, 1980, BRIT MED J, V281, P1241, DOI 10.1136/bmj.281.6250.1241; Seedat YK, 2000, J HUM HYPERTENS, V14, P739, DOI 10.1038/sj.jhh.1001059; Sehgal AR, 2004, HYPERTENSION, V43, P566, DOI 10.1161/01.HYP.0000118019.28487.9c; STEIN CM, 1992, INT J CARDIOL, V37, P231, DOI 10.1016/0167-5273(92)90213-M; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; VENTER C P, 1991, Medical Science Research, V19, P217; VENTER CP, 1991, S AFR MED J, V80, P324; VENTER CP, 1990, J CLIN PHARMACOL, V30, P533, DOI 10.1002/j.1552-4604.1990.tb03616.x; Wassertheil-Smoller S, 1991, CARDIOVASCULAR RISK, V1, P3; Weir MR, 1998, HYPERTENSION, V31, P1088, DOI 10.1161/01.HYP.31.5.1088; Weir MR, 1998, J HUM HYPERTENS, V12, P189, DOI 10.1038/sj.jhh.1000578; Weir MR, 1999, AM J HYPERTENS, V12, p195S; Williams B, 2004, J HUM HYPERTENS, V18, P139, DOI 10.1038/sj.jhh.1001683; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; 2000, HEART DIS, V23, P392	67	138	142	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	2004	141	8					614	627		10.7326/0003-4819-141-8-200410190-00009	http://dx.doi.org/10.7326/0003-4819-141-8-200410190-00009			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864SD	15492341				2022-12-28	WOS:000224652300005
J	Arrasate, M; Mitra, S; Schweitzer, ES; Segal, MR; Finkbeiner, S				Arrasate, M; Mitra, S; Schweitzer, ES; Segal, MR; Finkbeiner, S			Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death	NATURE			English	Article							GREEN FLUORESCENT PROTEIN; INTRANUCLEAR INCLUSIONS; POLYGLUTAMINE EXPANSIONS; NEUROLOGICAL PHENOTYPE; IN-VITRO; AGGREGATION; DISEASE; NUCLEAR; REPEAT; FRAGMENTS	Huntington's disease is caused by an abnormal polyglutamine expansion within the protein huntingtin and is characterized by microscopic inclusion bodies of aggregated huntingtin and by the death of selected types of neuron. Whether inclusion bodies are pathogenic, incidental or a beneficial coping response is controversial. To resolve this issue we have developed an automated microscope that returns to precisely the same neuron after arbitrary intervals, even after cells have been removed from the microscope stage. Here we show, by survival analysis, that neurons die in a time-independent fashion but one that is dependent on mutant huntingtin dose and polyglutamine expansion; many neurons die without forming an inclusion body. Rather, the amount of diffuse intracellular huntingtin predicts whether and when inclusion body formation or death will occur. Surprisingly, inclusion body formation predicts improved survival and leads to decreased levels of mutant huntingtin elsewhere in a neuron. Thus, inclusion body formation can function as a coping response to toxic mutant huntingtin.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94141 USA; Univ Calif San Francisco, Program Biomed Sci, San Francisco, CA 94141 USA; Univ Calif San Francisco, Med Sci Training Program, San Francisco, CA 94141 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Calif San Francisco, Div Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol & Physiol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Finkbeiner, S (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA.	sfinkbeiner@gladstone.ucsf.edu	Arrasate, Montserrat/ABB-4450-2020	Arrasate, Montserrat/0000-0002-8911-8990; Mitra, Siddhartha/0000-0003-3967-1496				Aiken CT, 2004, NEUROBIOL DIS, V16, P546, DOI 10.1016/j.nbd.2004.04.001; Apostol BL, 2003, P NATL ACAD SCI USA, V100, P5950, DOI 10.1073/pnas.2628045100; ARRASATE M, 2003, SOC NEUR ABSTR, V29; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; Collett D., 1994, MODELING SURVIVAL DA; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hack NJ, 2000, J NEUROSCI METH, V95, P177, DOI 10.1016/S0165-0270(99)00178-8; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kegel KB, 2002, J BIOL CHEM, V277, P7466, DOI 10.1074/jbc.M103946200; Kim M, 1999, J NEUROSCI, V19, P964; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kuemmerle S, 1999, ANN NEUROL, V46, P842; MACDONALD ME, 1998, TRINUCLEOTIDE DIS IN, P47; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Mende-Mueller LM, 2001, J NEUROSCI, V21, P1830, DOI 10.1523/JNEUROSCI.21-06-01830.2001; Moulder KL, 1999, J NEUROSCI, V19, P705; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Persichetti F, 1996, NEUROBIOL DIS, V3, P183, DOI 10.1006/nbdi.1996.0018; Perutz MF, 2001, NATURE, V412, P143, DOI 10.1038/35084141; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Preisinger E, 1999, PHILOS T ROY SOC B, V354, P1029, DOI 10.1098/rstb.1999.0455; Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; Richfield EK, 1995, ANN NEUROL, V38, P852, DOI 10.1002/ana.410380605; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shimohata T, 2002, NEUROSCI LETT, V323, P215, DOI 10.1016/S0304-3940(02)00162-3; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Strebel A, 2001, CYTOMETRY, V43, P126, DOI 10.1002/1097-0320(20010201)43:2<126::AID-CYTO1027>3.0.CO;2-J; Tanaka M, 2004, NAT MED, V10, P148, DOI 10.1038/nm985; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Therneau TM, 2000, MODELING SURVIVAL DA; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Yoo SY, 2003, NEURON, V37, P383, DOI 10.1016/S0896-6273(02)01190-X	50	1480	1510	2	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					805	810		10.1038/nature02998	http://dx.doi.org/10.1038/nature02998			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483602	Bronze			2022-12-28	WOS:000224435500037
J	Yamamoto, Y; Stock, DW; Jeffery, WR				Yamamoto, Y; Stock, DW; Jeffery, WR			Hedgehog signalling controls eye degeneration in blind cavefish	NATURE			English	Article							SONIC HEDGEHOG; GENE; ASTYANAX; EXPRESSION; EVOLUTION; SYSTEM; RETINA; PAX2	Hedgehog (Hh) proteins are responsible for critical signalling events during development(1) but their evolutionary roles remain to be determined. Here we show that hh gene expression at the embryonic midline controls eye degeneration in blind cavefish. We use the teleost Astyanax mexicanus, a single species with an eyed surface-dwelling form ( surface fish) and many blind cave forms ( cavefish) 2, to study the evolution of eye degeneration. Small eye primordia are formed during cavefish embryogenesis, which later arrest in development, degenerate and sink into the orbits. Eye degeneration is caused by apoptosis of the embryonic lens, and transplanting a surface fish embryonic lens into a cavefish optic cup can restore a complete eye(3-5). Here we show that sonic hedgehog (shh) and tiggy-winkle hedgehog ( twhh) gene expression is expanded along the anterior embryonic midline in several different cavefish populations. The expansion of hh signalling results in hyperactivation of downstream genes, lens apoptosis and arrested eye growth and development. These features can be mimicked in surface fish by twhh and/or shh overexpression, supporting the role of hh signalling in the evolution of cavefish eye regression.	Univ Maryland, Dept Biol, College Pk, MD 20742 USA; Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA	University System of Maryland; University of Maryland College Park; University of Colorado System; University of Colorado Boulder	Jeffery, WR (corresponding author), Univ Maryland, Dept Biol, College Pk, MD 20742 USA.	jeffery@umd.edu	Zebrafish, UCL/A-3125-2009	Yamamoto, Yoshiyuki/0000-0003-4830-5703	NATIONAL EYE INSTITUTE [R01EY014619] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY014619] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKIMENKO MA, 1994, J NEUROSCI, V14, P3475; Culver DC, 1982, CAVE LIFE EVOLUTION; Dowling TE, 2002, MOL BIOL EVOL, V19, P446, DOI 10.1093/oxfordjournals.molbev.a004100; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hallonet M, 1999, GENE DEV, V13, P3106, DOI 10.1101/gad.13.23.3106; Incardona JP, 1998, DEVELOPMENT, V125, P3553; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jeffery WR, 2003, INTEGR COMP BIOL, V43, P531, DOI 10.1093/icb/43.4.531; Jeffery WR, 2001, DEV BIOL, V231, P1, DOI 10.1006/dbio.2000.0121; Jeffery WR, 1998, AM ZOOL, V38, P685; KELLY GM, 1995, DEV GENET, V17, P129, DOI 10.1002/dvg.1020170205; Li HS, 1997, DEVELOPMENT, V124, P603; MACDONALD JM, 1995, VET DERMATOL, V6, P121, DOI 10.1111/j.1365-3164.1995.tb00055.x; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MITCHELL RW, 1977, SPEC PUBL MUS TEXAS, V12, P1; Neumann CJ, 2000, SCIENCE, V289, P2137, DOI 10.1126/science.289.5487.2137; Pabst O, 2000, DEV GENES EVOL, V210, P47, DOI 10.1007/PL00008188; Schwarz M, 2000, DEVELOPMENT, V127, P4325; Stenkamp DL, 2000, DEV BIOL, V220, P238, DOI 10.1006/dbio.2000.9629; Strecker U, 2003, MOL ECOL, V12, P699, DOI 10.1046/j.1365-294X.2003.01753.x; Strickler AG, 2001, DEV GENES EVOL, V211, P138, DOI 10.1007/s004270000123; Take-uchi M, 2003, DEVELOPMENT, V130, P955, DOI 10.1242/dev.00305; Wilkens H, 1988, EVOL BIOL, V23, P271, DOI [10.1007/978-1-4613-1043-3_8, DOI 10.1007/978-1-4613-1043-3_]; Yamamoto Y, 2003, EVOL DEV, V5, P435, DOI 10.1046/j.1525-142X.2003.03050.x; Yamamoto Y, 2000, SCIENCE, V289, P631, DOI 10.1126/science.289.5479.631	26	182	187	2	98	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					844	847		10.1038/nature02864	http://dx.doi.org/10.1038/nature02864			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483612				2022-12-28	WOS:000224435500047
J	Buckner, M				Buckner, M			Sickle-cell disease: from sierra Leone to southeast London	LANCET			English	Editorial Material																			0	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	2004	364	9442					1361	1361		10.1016/S0140-6736(04)17193-6	http://dx.doi.org/10.1016/S0140-6736(04)17193-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474139				2022-12-28	WOS:000224349700032
J	Kuma, A; Hatano, M; Matsui, M; Yamamoto, A; Nakaya, H; Yoshimori, T; Ohsumi, Y; Tokuhisa, T; Mizushima, N				Kuma, A; Hatano, M; Matsui, M; Yamamoto, A; Nakaya, H; Yoshimori, T; Ohsumi, Y; Tokuhisa, T; Mizushima, N			The role of autophagy during the early neonatal starvation period	NATURE			English	Article							PROTEIN CONJUGATION SYSTEM; KINASE CASCADE; GENE; CELLS; DISRUPTION; SENESCENCE; BECLIN-1; RECEPTOR; HOMOLOG; LC3	At birth the trans-placental nutrient supply is suddenly interrupted, and neonates face severe starvation until supply can be restored through milk nutrients(1). Here, we show that neonates adapt to this adverse circumstance by inducing autophagy. Autophagy is the primary means for the degradation of cytoplasmic constituents within lysosomes(2-4). The level of autophagy in mice remains low during embryogenesis; however, autophagy is immediately upregulated in various tissues after birth and is maintained at high levels for 3 - 12 h before returning to basal levels within 1 - 2 days. Mice deficient for Atg5, which is essential for autophagosome formation, appear almost normal at birth but die within 1 day of delivery. The survival time of starved Atg5-deficient neonates (similar to 12 h) is much shorter than that of wild-type mice (similar to21 h) but can be prolonged by forced milk feeding. Atg5-deficient neonates exhibit reduced amino acid concentrations in plasma and tissues, and display signs of energy depletion. These results suggest that the production of amino acids by autophagic degradation of 'self' proteins, which allows for the maintenance of energy homeostasis, is important for survival during neonatal starvation.	Japan Sci & Technol Agcy, PRESTO, Times Arrow & Biosignaling, Kawaguchi 3320012, Japan; Chiba Univ, Dept Dev Genet H2, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Pharmacol F2, Chiba 2608670, Japan; Chiba Univ, Biomed Res Ctr, Chiba 2608670, Japan; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 444, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan; Tokyo Metropolitan Inst Med Sci, Dept Bioregulat & Metab, Tokyo 1138613, Japan; Nagahama Inst Biosci & Technol, Dept Biosci, Nagahama 5260829, Japan; Natl Inst Genet, Dept Cell Genet, Mishima, Shizuoka 4118540, Japan	Japan Science & Technology Agency (JST); Chiba University; Chiba University; Chiba University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan; Tokyo Metropolitan Institute of Medical Science; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Mizushima, N (corresponding author), Japan Sci & Technol Agcy, PRESTO, Times Arrow & Biosignaling, Kawaguchi 3320012, Japan.	nmizu@rinshoken.or.jp	Ohsumi, Yoshinori/C-6449-2009; Mizushima, Noboru/C-3635-2009	Ohsumi, Yoshinori/0000-0003-2384-2166; Mizushima, Noboru/0000-0002-6258-6444				Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Doelling JH, 2002, J BIOL CHEM, V277, P33105, DOI 10.1074/jbc.M204630200; Hanaoka H, 2002, PLANT PHYSIOL, V129, P1181, DOI 10.1104/pp.011024; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Juhasz G, 2003, FEBS LETT, V543, P154, DOI 10.1016/S0014-5793(03)00431-9; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; MEDINA JM, 1992, PERINATAL BIOCH, P233; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0; YAMAMOTO A, 1991, CELL STRUCT FUNCT, V16, P419, DOI 10.1247/csf.16.419; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	27	2307	2402	8	349	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 23	2004	432	7020					1032	1036		10.1038/nature03029	http://dx.doi.org/10.1038/nature03029			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881RL	15525940				2022-12-28	WOS:000225887000043
J	Hanan, BB; Blichert-Toft, J; Pyle, DG; Christie, DM				Hanan, BB; Blichert-Toft, J; Pyle, DG; Christie, DM			Contrasting origins of the upper mantle revealed by hafnium and lead isotopes from the Southeast Indian Ridge	NATURE			English	Article							LOWER CRUSTAL XENOLITHS; TRACE-ELEMENT; LU-HF; GEOCHEMISTRY; GEOCHRONOLOGY; CONSTRAINTS; EVOLUTION; BOUNDARY; BASALTS; LAVAS	The origin of the isotopic signature of Indian mid-ocean ridge basalts has remained enigmatic, because the geochemical composition of these basalts is consistent either with pollution from recycled, ancient altered oceanic crust and sediments, or with ancient continental crust or lithosphere. The radiogenic isotopic signature may therefore be the result of contamination of the upper mantle by plumes containing recycled altered ancient oceanic crust and sediments(1), detachment and dispersal of continental material into the shallow mantle during rifting and breakup of Gondwana(2), or contamination of the upper mantle by ancient subduction processes(3,4). The identification of a process operating on a scale large enough to affect major portions of the Indian mid-ocean ridge basalt source region has been a longstanding problem. Here we present hafnium and lead isotope data from across the Indian - Pacific mantle boundary at the Australian - Antarctic discordance region of the Southeast Indian Ridge, which demonstrate that the Pacific and Indian upper mantle basalt source domains were each affected by different mechanisms. We infer that the Indian upper-mantle isotope signature in this region is affected mainly by lower continental crust entrained during Gondwana rifting, whereas the isotope signature of the Pacific upper mantle is influenced predominantly by ocean floor subduction-related processes.	San Diego State Univ, Dept Geol Sci, San Diego, CA 92182 USA; Ecole Normale Super Lyon, Lab Sci Terre, CNRS, UMR 5570, F-69364 Lyon 7, France; Univ Hawaii, Sch Ocean & Earth Sci Technol, Honolulu, HI 96822 USA; Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA	California State University System; San Diego State University; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); University of Hawaii System; Oregon State University	Hanan, BB (corresponding author), San Diego State Univ, Dept Geol Sci, 5500 Campanile Dr, San Diego, CA 92182 USA.	Barry.Hanan@sdsu.edu	Blichert-Toft, Janne/C-8280-2012	Blichert-Toft, Janne/0000-0002-4932-4079; Hanan, Barry/0000-0002-8240-2200				ALLEGRE CJ, 1987, EARTH PLANET SC LETT, V81, P319, DOI 10.1016/0012-821X(87)90120-8; ARNDT NT, 1989, TECTONOPHYSICS, V161, P201, DOI 10.1016/0040-1951(89)90154-6; BENOTHMAN D, 1989, EARTH PLANET SC LETT, V94, P1, DOI 10.1016/0012-821X(89)90079-4; Chauvel C, 2001, EARTH PLANET SC LETT, V190, P137, DOI 10.1016/S0012-821X(01)00379-X; Christie DM, 1998, NATURE, V394, P637, DOI 10.1038/29226; Gurnis M, 1998, SCIENCE, V279, P1499, DOI 10.1126/science.279.5356.1499; HAMELIN B, 1985, NATURE, V315, P196, DOI 10.1038/315196a0; Hanan B. B., 2000, J C ABSTR, V5, P478; Hanan BB, 1996, SCIENCE, V272, P991, DOI 10.1126/science.272.5264.991; HART SR, 1992, SCIENCE, V256, P517, DOI 10.1126/science.256.5056.517; HART SR, 1986, GEOCHIM COSMOCHIM AC, V50, P1551, DOI 10.1016/0016-7037(86)90329-7; HART SR, 1984, NATURE, V309, P753, DOI 10.1038/309753a0; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; Kamenetsky VS, 2001, GEOLOGY, V29, P243, DOI 10.1130/0091-7613(2001)029<0243:ROGCLI>2.0.CO;2; Kempton PD, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2002GC000320; MAHONEY J, 1991, EARTH PLANET SC LETT, V104, P350, DOI 10.1016/0012-821X(91)90215-4; Mahoney JJ, 1996, GEOLOGY, V24, P615, DOI 10.1130/0091-7613(1996)024<0615:BELFAN>2.3.CO;2; PEARSON DG, 1995, NATURE, V374, P711, DOI 10.1038/374711a0; PYLE DG, 1992, EARTH PLANET SC LETT, V112, P161, DOI 10.1016/0012-821X(92)90014-M; PYLE DG, 1995, J GEOPHYS RES-SOL EA, V100, P22261, DOI 10.1029/95JB01424; Rehkamper M, 1997, EARTH PLANET SC LETT, V147, P93, DOI 10.1016/S0012-821X(97)00009-5; RUDNICK RL, 1990, EARTH PLANET SC LETT, V98, P192, DOI 10.1016/0012-821X(90)90059-7; Salters VJM, 1998, CHEM GEOL, V145, P447, DOI 10.1016/S0009-2541(97)00154-X; Salters VJM, 2002, NATURE, V418, P68, DOI 10.1038/nature00798; Scherer EE, 1997, CHEM GEOL, V142, P63, DOI 10.1016/S0009-2541(97)00076-4; Soffer G, 2004, GEOCHIM COSMOCHIM AC, V68, pA692; STOREY M, 1989, NATURE, V338, P574, DOI 10.1038/338574a0; Vervoort JD, 1999, EARTH PLANET SC LETT, V168, P79, DOI 10.1016/S0012-821X(99)00047-3; Vervoort JD, 2000, EARTH PLANET SC LETT, V181, P115, DOI 10.1016/S0012-821X(00)00170-9; WEAVER BL, 1991, EARTH PLANET SC LETT, V104, P381, DOI 10.1016/0012-821X(91)90217-6; Wendt JI, 1999, EARTH PLANET SC LETT, V173, P271, DOI 10.1016/S0012-821X(99)00236-8; ZINDLER A, 1986, ANNU REV EARTH PL SC, V14, P493, DOI 10.1146/annurev.ea.14.050186.002425	32	149	154	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					91	94		10.1038/nature03026	http://dx.doi.org/10.1038/nature03026			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525986				2022-12-28	WOS:000224854900045
J	Lydon-Rochelle, MT				Lydon-Rochelle, MT			Minimal intervention - Nurse-midwives in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Washington, Sch Nursing, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lydon-Rochelle, MT (corresponding author), Univ Washington, Sch Nursing, Seattle, WA 98195 USA.							Declercq E, 2004, J MIDWIFERY WOM HEAL, V49, P78, DOI 10.1016/j.jmwh.2003.11.006; Martin Joyce A, 2003, Natl Vital Stat Rep, V52, P1; Shoemaker M., 1984, HIST NURSE MIDWIFERY	3	3	3	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1929	1931		10.1056/NEJMp048111	http://dx.doi.org/10.1056/NEJMp048111			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525718				2022-12-28	WOS:000224851300002
J	Marshall, DA; Levy, AR; Vidaillet, H; Fenwick, E; Slee, A; Blackhouse, G; Greene, HL; Wyse, G; Nichol, G; O'Brien, BJ				Marshall, DA; Levy, AR; Vidaillet, H; Fenwick, E; Slee, A; Blackhouse, G; Greene, HL; Wyse, G; Nichol, G; O'Brien, BJ		AFFIRM CORE Investigators	Cost-effectiveness of rhythm versus rate control in atrial fibrillation	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; RISK-FACTORS; CARDIOVASCULAR MEDICINE; CONFIDENCE-INTERVALS; EFFECTIVENESS PLANE; STROKE PREVENTION; CLINICAL-PRACTICE; USERS GUIDES; ANTICOAGULATION; CARDIOVERSION	Background: Atrial fibrillation is the most common type of sustained cardiac arrhythmia, but recent trials have identified no clear advantage of rhythm control over rate control. Consequently, economic factors often play a role in guiding treatment selection. Objective: To estimate the cost-effectiveness of rhythm-control versus rate-control strategies for atrial fibrillation in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM). Design: Retrospective economic evaluation. Nonparametric boot-strapping was used to estimate the distribution of incremental costs and effects on the cost-effectiveness plane. Data Sources: Data on survival and use of health care resources were obtained for all 4060 AFFIRM participants. Unit costs were estimated from various U.S. databases. Target Population: Patients with atrial fibrillation who were 65 years of age or who had other risk factors for stroke or death, similar to those enrolled in AFFIRM. Time Horizon: mean follow-up of 3.5 years. Perspective: Third-party payer. Interventions: management of patients with atrial fibrillation with antiarrhythmic drugs (rhythm control) compared with drugs that control heart rate (rate control). Outcome Measures: Mean survival, resource use, costs, and cost-effectiveness. Results of Base-Case Analysis: A mean survival gain of 0.08 year (P = 0.10) was observed for rate control. Patients in the rate-control group used fewer resources (hospital days, pacemaker procedures, cardioversions, and short-stay and emergency department visits). Rate control costs $5077 less per person than rhythm control. Results of Sensitivity Analysis: Cost savings ranged from $2189 to $5481 per person. Rhythm control was more costly and less effective than rate control in 95% of the bootstrap replicates over a wide range of cost assumptions. Limitations: Resource use was limited to key items collected in AFFIRM, and the results are generalizable only to similar patient populations with atrial fibrillation. Conclusion: Rate control is a cost-effective approach to the management of atrial fibrillation compared with maintenance of sinus rhythm in patients with atrial fibrillation similar to those enrolled in AFFIRM.	McMaster Univ, Ctr Evaluat Med, Hamilton, ON L6B 1H1, Canada	McMaster University	Marshall, DA (corresponding author), McMaster Univ, Ctr Evaluat Med, 25 Main St W,Suite 2000, Hamilton, ON L6B 1H1, Canada.	marshd@mcmaster.ca	Nichol, Graham/Z-4996-2019; Marshall, Deborah/J-7248-2015	Marshall, Deborah/0000-0002-8467-8008; Corley, Scott/0000-0001-5288-9188	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055139] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55139] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdelhafiz AH, 2001, CLIN THER, V23, P1628, DOI 10.1016/S0149-2918(01)80134-X; *AFFIRM INV, 2004, IN PRESS AM HEART J; *AG HLTH CAR POL R, 1995, HEALTHC COST UT PROJ; *AM MED ASS, 1998, PHYS CURR PROC TERM; Aronow WS, 1999, J AM GERIATR SOC, V47, P740, DOI 10.1111/j.1532-5415.1999.tb01602.x; BLACK WC, 1990, MED DECIS MAKING, V10, P212, DOI 10.1177/0272989X9001000308; Blackhouse G, 2002, MED DECIS MAKING, V22, P173, DOI 10.1177/02729890222063053; Briggs A, 1998, HEALTH ECON, V7, P723, DOI 10.1002/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.3.CO;2-F; Briggs AH, 1997, HEALTH ECON, V6, P327, DOI 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W; Briggs AH, 2001, HEALTH ECON, V10, P179, DOI 10.1002/hec.584; Briggs AH, 2000, PHARMACOECONOMICS, V17, P479, DOI 10.2165/00019053-200017050-00006; Catherwood E, 1999, ANN INTERN MED, V130, P625, DOI 10.7326/0003-4819-130-8-199904200-00002; Connolly ST, 2000, BRIT MED J, V320, P1219, DOI 10.1136/bmj.320.7244.1219; *CTR MED MED SERV, CMS FIL DOWLOAD MED; *CTR MED MED SERV, CMS FIL DOWNL MED PA; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; Drummond MF, 2015, METHODS EC EVALUATIO; Eckman MH, 1998, ARCH INTERN MED, V158, P1669, DOI 10.1001/archinte.158.15.1669; EFRON B, 1997, INTRO BOOTSTRAP; Epstein AE, 2002, AM HEART J, V143, P991, DOI 10.1067/mhj.2002.122875; FURBERG CD, 1994, AM J CARDIOL, V74, P236, DOI 10.1016/0002-9149(94)90363-8; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Gold MR, 1996, COST EFFECTIVENESS H; Golzari H, 1996, ANN INTERN MED, V125, P311, DOI 10.7326/0003-4819-125-4-199608150-00010; GRAVES EJ, 1992, VITAL HLTH STAT, V13, P112; Gronefeld GC, 2003, EUR HEART J, V24, P1430, DOI 10.1016/S0195-668X(03)00261-6; Hagens VE, 2004, J AM COLL CARDIOL, V43, P241, DOI 10.1016/j.jacc.2003.08.037; Hlatky MA, 1997, NEW ENGL J MED, V336, P92, DOI 10.1056/NEJM199701093360203; Johannesson M, 1997, NEW ENGL J MED, V336, P332, DOI 10.1056/NEJM199701303360503; Kalra L, 2000, BMJ-BRIT MED J, V320, P1236, DOI 10.1136/bmj.320.7244.1236; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karlsson G, 1996, PHARMACOECONOMICS, V9, P113, DOI 10.2165/00019053-199609020-00003; Laupacis A, 1996, Can J Cardiol, V12 Suppl A, p14A; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lin HJ, 1996, STROKE, V27, P1760, DOI 10.1161/01.STR.27.10.1760; Mark DB, 2002, CIRCULATION, V106, P516, DOI 10.1161/01.CIR.0000021407.93752.7B; Mark DB, 2002, CIRCULATION, V106, P626, DOI 10.1161/01.CIR.0000021408.40925.63; OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; Psaty BM, 1997, CIRCULATION, V96, P2455; RUSSELL LB, 1997, VITAL HLTH STAT, V2, P1; Sendi PP, 2001, HEALTH ECON, V10, P675; Stearne MR, 1998, BMJ-BRIT MED J, V317, P720; US Department of Labor. Bureau of Labor Statistics, CONS PRIC IND; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; Vidaillet H, 2002, AM J MED, V113, P365, DOI 10.1016/S0002-9343(02)01253-6; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; Wonderling D, 1996, BRIT MED J, V312, P1274, DOI 10.1136/bmj.312.7041.1274; Wyse DG, 1997, AM J CARDIOL, V79, P1198; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; 2002, RED BOOK	52	87	90	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2004	141	9					653	661		10.7326/0003-4819-141-9-200411020-00005	http://dx.doi.org/10.7326/0003-4819-141-9-200411020-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867JT	15520421				2022-12-28	WOS:000224839600001
J	Kurita, R; Tanaka, H				Kurita, R; Tanaka, H			Critical-like phenomena associated with liquid-liquid transition in a molecular liquid	SCIENCE			English	Article							PHASE-TRANSITION	Contrary to the conventional wisdom that there is only one unique liquid state for any material, recent evidence suggests that there can be more than two liquid states even for a single-component substance. The transition between these liquid states is called a liquid-liquid phase transition. We report the detailed experimental investigation on the kinetics of the continuous spinodal-decomposition-type transformation of one liquid into another for triphenyl phosphite. From the analysis of the linear regime, we found that the correlation length, xi, of fluctuations of the relevant order parameter diverges as xi=xi(0)[T-SD-T)/T-SD](-nu)(where xi(0)=60 nm and nu=0.5) while approaching the spinodal temperature, T-SD. This is an indication of a critical-like anomaly associated with the liquid-liquid transition. We also revealed that the order parameter governing the liquid-liquid transition must be of a nonconserved nature.	Univ Tokyo, Inst Ind Sci, Meguro Ku, Tokyo 1538505, Japan	University of Tokyo	Tanaka, H (corresponding author), Univ Tokyo, Inst Ind Sci, Meguro Ku, 4-6-1 Komaba, Tokyo 1538505, Japan.	tanaka@iis.u-tokyo.ac.jp	Kurita, Rei/S-1694-2017; Tanaka, Hajime/ABF-1451-2021; Tanaka, Hajime/A-9653-2008	Kurita, Rei/0000-0001-9346-9390; Tanaka, Hajime/0000-0002-4444-1890; Tanaka, Hajime/0000-0002-4444-1890				AASLAND S, 1994, NATURE, V369, P633, DOI 10.1038/369633a0; Angell CA, 2003, BIOPHYS CHEM, V105, P621, DOI 10.1016/S0301-4622(03)00093-0; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; BINDER K, 1984, PHYS REV A, V29, P341, DOI 10.1103/PhysRevA.29.341; Brazhkin VV, 2003, J PHYS-CONDENS MAT, V15, P6059, DOI 10.1088/0953-8984/15/36/301; Cohen I, 1996, J PHYS CHEM-US, V100, P8518, DOI 10.1021/jp953785h; Deb SK, 2001, NATURE, V414, P528, DOI 10.1038/35107036; Debenedetti P. G., 1997, METASTABLE LIQUIDS; Katayama Y, 2000, NATURE, V403, P170, DOI 10.1038/35003143; McMillan PF, 2004, J MATER CHEM, V14, P1506, DOI 10.1039/b401308p; Mishima O, 1998, NATURE, V396, P329, DOI 10.1038/24540; Monaco G, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.255701; Onuki A, 2002, PHASE TRANSITION DYN; Ponyatovsky EG, 2003, J PHYS-CONDENS MAT, V15, P6123, DOI 10.1088/0953-8984/15/36/304; Poole PH, 1997, SCIENCE, V275, P322, DOI 10.1126/science.275.5298.322; RAPOPORT E, 1967, J CHEM PHYS, V46, P2891, DOI 10.1063/1.1841150; Saika-Voivod I, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.041503; Sastry S, 2003, NAT MATER, V2, P739, DOI 10.1038/nmat994; TANAKA H, 1990, PHYS REV LETT, V65, P3136, DOI 10.1103/PhysRevLett.65.3136; Tanaka H, 1998, PHYS REV LETT, V80, P5750, DOI 10.1103/PhysRevLett.80.5750; Tanaka H, 2000, EUROPHYS LETT, V50, P340, DOI 10.1209/epl/i2000-00276-4; Tanaka H, 2000, PHYS REV E, V62, P6968, DOI 10.1103/PhysRevE.62.6968; Tanaka H, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.025701; TANAKA H, 1986, J APPL PHYS, V59, P3627, DOI 10.1063/1.336795; TANAKA H, 1987, PHYS REV LETT, V59, P692, DOI 10.1103/PhysRevLett.59.692; Wilson M, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.054206	26	189	190	1	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					845	848		10.1126/science.1103073	http://dx.doi.org/10.1126/science.1103073			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514150				2022-12-28	WOS:000224969400038
J	Collins, FS; Lander, ES; Rogers, J; Waterston, RH				Collins, FS; Lander, ES; Rogers, J; Waterston, RH		Int Human Genome Sequencing Conso	Finishing the euchromatic sequence of the human genome	NATURE			English	Article							RECENT SEGMENTAL DUPLICATIONS; COMPREHENSIVE GENETIC-MAP; DNA-SEQUENCE; PHYSICAL MAP; MOUSE GENOME; SACCHAROMYCES GENOMES; LINKAGE MAP; CHROMOSOME; HUMAN-CHROMOSOME-13; SELECTION	The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers similar to99% of the euchromatic genome and is accurate to an error rate of similar to1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human genome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead.				fc23a@nih.gov; lander@broad.mit.edu; jrh@sanger.ac.uk; waterston@gs.washington.edu	Ponting, Chris/AAV-2621-2021; Deloukas, Panos/B-2922-2013; Hubbard, Tim J/C-2567-2008; Lewis, Ernest K/B-3821-2012; Xiong, Yuqing/D-5404-2009; Vastrik, Imre/C-2690-2009; Glöckner, Gernot/A-7800-2010; Chothia, Tom/HDM-3159-2022; Santoyo-Lopez, Javier/C-9714-2012; Cuomo, Christina/L-2222-2019; Hubbard, Tim J.P./AAT-4571-2020; Taylor, Todd/A-7121-2009; Li, Wei/A-8544-2009; Seaman, Steven/A-2755-2013; Wilson, Richard K./AAF-4139-2019; Andrews, Dan/ABG-4815-2020; Itoh, Takehiko/E-8873-2014; Fernandez, Xose/ABA-7117-2020; Couronne, Olivier Couronne/G-1244-2012; Eyras, Eduardo/ABG-7144-2020; Smith, Andy/A-7512-2011; Schmutz, Jeremy/N-3173-2013; 郑, 征/C-8514-2011; Severin, Jessica/AAQ-2723-2020; Redon, Richard/F-3303-2014; Rodriguez, Joseph/I-9277-2014; dobson, richard/C-9269-2011	Deloukas, Panos/0000-0001-9251-070X; Hubbard, Tim J/0000-0002-1767-9318; Lewis, Ernest K/0000-0003-3905-8691; Xiong, Yuqing/0000-0001-5826-3696; Glöckner, Gernot/0000-0002-9061-1061; Santoyo-Lopez, Javier/0000-0003-1988-5059; Cuomo, Christina/0000-0002-5778-960X; Hubbard, Tim J.P./0000-0002-1767-9318; Taylor, Todd/0000-0003-4247-6253; Seaman, Steven/0000-0003-3349-3334; Wilson, Richard K./0000-0002-1992-1358; Itoh, Takehiko/0000-0002-6113-557X; Fernandez, Xose/0000-0001-7139-6215; Eyras, Eduardo/0000-0003-0793-6218; Smith, Andy/0000-0001-8580-278X; Schmutz, Jeremy/0000-0001-8062-9172; Severin, Jessica/0000-0003-1274-208X; Pitesky, Maurice/0000-0003-0084-6404; de Berardinis, Veronique/0000-0002-3273-4135; Maslen, Gareth/0000-0001-7318-3678; Keenan, Stephen/0000-0002-9141-7690; Redon, Richard/0000-0001-7751-2280; Bonfield, James/0000-0002-6447-4112; Dunham, Ian/0000-0003-2525-5598; Flanagan, Judith/0000-0002-4053-3288; Wollard, Jessica/0000-0002-9329-2609; Rigby, Rachel Elizabeth/0000-0001-5201-9422; Rodriguez, Joseph/0000-0002-6017-1376; Benkahla, Alia/0000-0001-9988-3250; Webber, Caleb/0000-0001-8063-7674; Kay, Mike/0000-0002-3282-0834; Pruitt, Kim/0000-0001-7950-1374; Steward, Charles/0000-0001-8829-5349; MCLELLAN, MICHAEL/0000-0002-2703-8784; Malfatti, Stephanie/0000-0003-4225-9857; Siepel, Adam/0000-0002-3557-7219; Schuster, Michael/0000-0003-2975-8969; Hinrichs, Angie/0000-0002-1697-1130; Hughes, Jaime/0000-0001-6045-4053; Lindsay, Sarah/0000-0002-0965-3070; Nicol, Robert/0000-0003-1932-1392; dobson, richard/0000-0003-4224-9245; Petit, Jean-Louis/0000-0002-8566-0571; Ito, Fumiaki/0000-0002-4129-4899; Clarke, Laura/0000-0002-5989-6898; Whittaker, Charles/0000-0002-2400-0094; Leongamornlert, Daniel/0000-0002-3486-3168; Gammon, Stuart/0000-0002-8651-6897; Palaniappan, Krishnaveni/0000-0003-4484-7505; Mott, Richard/0000-0002-1022-9330; Andrews, Dan/0000-0003-3922-6376	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003273] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adams M., 2002, GENOME BIOL, V3, DOI DOI 10.1186/GB-2002; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bailey JA, 2004, GENOME RES, V14, P789, DOI 10.1101/gr.2238404; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Bailey JA, 2002, AM J HUM GENET, V70, P83, DOI 10.1086/338458; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Cliften PF, 2001, GENOME RES, V11, P1175, DOI 10.1101/gr.182901; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Collins JE, 2003, GENOME RES, V13, P27, DOI 10.1101/gr.695703; Deloukas P, 2004, NATURE, V429, P375, DOI 10.1038/nature02462; Deloukas P, 2001, NATURE, V414, P865, DOI 10.1038/414865a; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Dunham A, 2004, NATURE, V428, P522, DOI 10.1038/nature02379; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Eichler EE, 2004, NAT REV GENET, V5, P345, DOI 10.1038/nrg1322; Felsenfeld A, 1999, GENOME RES, V9, P1; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FUREY TS, IN PRESS GENOME RES; Glusman G, 2001, GENOME RES, V11, P685, DOI 10.1101/gr.171001; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gordon D, 2001, GENOME RES, V11, P614, DOI 10.1101/gr.171401; Gregory SG, 2002, NATURE, V418, P743, DOI 10.1038/nature00957; Grimwood J, 2004, NATURE, V428, P529, DOI 10.1038/nature02399; GUYER M, 1992, SCIENCE, V258, P67; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Heilig R, 2003, NATURE, V421, P601, DOI 10.1038/nature01348; Heiner CR, 1998, GENOME RES, V8, P557, DOI 10.1101/gr.8.5.557; Hillier LW, 2003, NATURE, V424, P157, DOI 10.1038/nature01782; Horvath JE, 2001, HUM MOL GENET, V10, P2215, DOI 10.1093/hmg/10.20.2215; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Humphray SJ, 2004, NATURE, V429, P369, DOI 10.1038/nature02465; Istrail S, 2004, P NATL ACAD SCI USA, V101, P1916, DOI 10.1073/pnas.0307971100; Johnson ME, 2001, NATURE, V413, P514, DOI 10.1038/35097067; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Lai ZW, 1999, NAT GENET, V23, P309, DOI 10.1038/15484; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee C, 1997, HUM GENET, V100, P291, DOI 10.1007/s004390050508; Loftus BJ, 1999, GENOMICS, V60, P295, DOI 10.1006/geno.1999.5927; MADAN K, 1974, ANN GENET-PARIS, V17, P81; Maston GA, 2002, MOL BIOL EVOL, V19, P320, DOI 10.1093/oxfordjournals.molbev.a004085; McMurray AA, 1998, GENOME RES, V8, P562, DOI 10.1101/gr.8.5.562; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; Mungall AJ, 2003, NATURE, V425, P805, DOI 10.1038/nature02055; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Nilsson M, 1997, NAT GENET, V16, P252, DOI 10.1038/ng0797-252; Pruitt KD, 2003, NUCLEIC ACIDS RES, V31, P34, DOI 10.1093/nar/gkg111; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; Roest Crollius H, 2000, NAT GENET, V25, P235, DOI 10.1038/76118; RUDD MK, IN PRESS TRENDS GENE; Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x; Schmutz J, 2004, NATURE, V431, P268, DOI 10.1038/nature02919; Schmutz J, 2004, NATURE, V429, P365, DOI 10.1038/nature02390; She XW, 2004, NATURE, V430, P857, DOI 10.1038/nature02806; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Stankiewicz P, 2002, TRENDS GENET, V18, P74, DOI 10.1016/S0168-9525(02)02592-1; Storz G, 2002, SCIENCE, V296, P1260, DOI 10.1126/science.1072249; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Szymanski M, 2003, NUCLEIC ACIDS RES, V31, P429, DOI 10.1093/nar/gkg124; Torrents D, 2003, GENOME RES, V13, P2559, DOI 10.1101/gr.1455503; Tuzun E, 2004, GENOME RES, V14, P493, DOI 10.1101/gr.1907504; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	71	3341	3747	6	324	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					931	945		10.1038/nature03001	http://dx.doi.org/10.1038/nature03001			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496913	Bronze, Green Published			2022-12-28	WOS:000224585600034
J	Newhouse, JP				Newhouse, JP			Election 2004: Financing medicare in the next administration	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Newhouse, JP (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.		Newhouse, Joseph/AGJ-5632-2022					Blendon RJ, 1997, JAMA-J AM MED ASSOC, V277, P1253, DOI 10.1001/jama.277.15.1253; *C BUDG OFF, 2004, BUDG EC OUTL; Jamieson Amie, 2002, CURRENT POPULATION R; *ORG EC COOP DEV, 2000, HLTH DAT; 2004, CBOS CURRENT BUDGET	5	8	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2004	351	17					1714	1716		10.1056/NEJMp048161	http://dx.doi.org/10.1056/NEJMp048161			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863TH	15496618				2022-12-28	WOS:000224585200004
J	She, XW; Jiang, ZX; Clark, RL; Liu, G; Cheng, Z; Tuzun, E; Church, DM; Sutton, G; Halpern, AL; Eichler, EE				She, XW; Jiang, ZX; Clark, RL; Liu, G; Cheng, Z; Tuzun, E; Church, DM; Sutton, G; Halpern, AL; Eichler, EE			Shotgun sequence assembly and recent segmental duplications within the human genome	NATURE			English	Article								Complex eukaryotic genomes are now being sequenced at an accelerated pace primarily using whole-genome shotgun (WGS) sequence assembly approaches. WGS assembly was initially criticized because of its perceived inability to resolve repeat structures within genomes. Here, we quantify the effect of WGS sequence assembly on large, highly similar repeats by comparison Of the segmental duplication content of two different human genome assemblies. Our analysis shows that large (>15 kilobases) and highly identical (>97%) duplications are not adequately resolved by WGS assembly. This leads to significant reduction in genome length and the loss of genes embedded within duplications. Comparable analyses of mouse genome assemblies confirm that strict WGS sequence assembly will oversimplify our understanding of mammalian genome structure and evolution; a hybrid strategy using a targeted clone-by-clone approach to resolve duplications is proposed.	Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA 98195 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; Appl Biosyst Inc, Rockville, MD 20850 USA; Ctr Advancement Genom, Rockville, MD 20850 USA	University of Washington; University of Washington Seattle; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Thermo Fisher Scientific; Applied Biosystems; J. Craig Venter Institute	Eichler, EE (corresponding author), Univ Washington, Sch Med, Dept Genome Sci, 1705 NE Pacific St, Seattle, WA 98195 USA.	eee@gs.washington.edu	Tuzun, Eray/AAD-7282-2021; Tuzun, Eray/B-5949-2018	Tuzun, Eray/0000-0002-5550-7816; Tuzun, Eray/0000-0002-5550-7816				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Armengol L, 2003, HUM MOL GENET, V12, P2201, DOI 10.1093/hmg/ddg223; Bailey JA, 2004, GENOME RES, V14, P789, DOI 10.1101/gr.2238404; Bailey JA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-r23; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Bailey JA, 2001, GENOME RES, V11, P1005, DOI 10.1101/gr.GR-1871R; Batzoglou S, 2002, GENOME RES, V12, P177, DOI 10.1101/gr.208902; Cheung J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r25; Cheung VG, 2001, NATURE, V409, P953, DOI 10.1038/35057192; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Green P, 1997, GENOME RES, V7, P410, DOI 10.1101/gr.7.5.410; Hillier LW, 2003, NATURE, V424, P157, DOI 10.1038/nature01782; Huang XQ, 2003, GENOME RES, V13, P2164, DOI 10.1101/gr.1390403; Istrail S, 2004, P NATL ACAD SCI USA, V101, P1916, DOI 10.1073/pnas.0307971100; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Stankiewicz P, 2002, TRENDS GENET, V18, P74, DOI 10.1016/S0168-9525(02)02592-1; Tuzun E, 2004, GENOME RES, V14, P493, DOI 10.1101/gr.1907504; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Waterston RH, 2003, P NATL ACAD SCI USA, V100, P3022, DOI 10.1073/pnas.0634129100; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401	22	185	192	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					927	930		10.1038/nature03062	http://dx.doi.org/10.1038/nature03062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496912	Bronze			2022-12-28	WOS:000224585600033
J	Bulte, E; Damania, R; Gillson, L; Lindsay, K				Bulte, E; Damania, R; Gillson, L; Lindsay, K			Space - The final frontier for economists and elephants	SCIENCE			English	Editorial Material							BIODIVERSITY; SERENGETI		Tilburg Univ, Dept Econ, NL-5000 LE Tilburg, Netherlands; Univ Adelaide, Sch Econ, Adelaide, SA 5005, Australia; Univ Oxford, Dept Zool, Environm Change Inst, Biodivers Res Grp, Oxford OX1 3PS, England; Amboseli Trust Elephants, Amboseli Elephant Res Project, Nairobi 00519, Kenya	Tilburg University; University of Adelaide; University of Oxford	Bulte, E (corresponding author), Tilburg Univ, Dept Econ, POB 90153, NL-5000 LE Tilburg, Netherlands.		Gillson, Lindsey/AAR-6531-2020	Gillson, Lindsey/0000-0001-9607-6760; Bulte, Erwin/0000-0001-9491-5268				Barbier E.B., 1990, ELEPHANTS EC IVORY; BARNES J, 1990, FUTURE BOTSWANAS ELE, P60; Barrett CB, 1998, LAND ECON, V74, P449, DOI 10.2307/3146878; BRANDER J, 1997, CAN J ECON, V50, P526; Bulte EH, 1999, AM J AGR ECON, V81, P453, DOI 10.2307/1244594; DUBLIN HT, 1990, J ANIM ECOL, V59, P1147, DOI 10.2307/5037; Finnoff D, 2003, J ENVIRON ECON MANAG, V45, P589, DOI 10.1016/S0095-0696(02)00025-6; Rogers KH., 2003, KRUGER EXPERIENCE EC, P41; Ross M. L., 2001, TIMBER BOOMS I BREAK; Sanchirico JN, 1999, J ENVIRON ECON MANAG, V37, P129, DOI 10.1006/jeem.1998.1060; Saphores JD, 2003, J ECON DYN CONTROL, V28, P509, DOI 10.1016/S0165-1889(03)00033-2; Smith RJ, 2003, NATURE, V426, P67, DOI 10.1038/nature02025; SWANSON TM, 1994, OXFORD ECON PAP, V46, P800, DOI 10.1093/oep/46.Supplement_1.800; 2004, CONT INT TRAD END SP	15	12	13	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2004	306	5695					420	421		10.1126/science.1105392	http://dx.doi.org/10.1126/science.1105392			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	864IF	15486280				2022-12-28	WOS:000224626500032
J	Kah, LC; Lyons, TW; Frank, TD				Kah, LC; Lyons, TW; Frank, TD			Low marine sulphate and protracted oxygenation of the proterozoic biosphere	NATURE			English	Article							SULFUR ISOTOPIC COMPOSITION; OCEAN CHEMISTRY; SEAWATER; BASIN; GEOCHEMISTRY; RISE	Progressive oxygenation of the Earth's early biosphere is thought to have resulted in increased sulphide oxidation during continental weathering, leading to a corresponding increase in marine sulphate concentration(1). Accurate reconstruction of marine sulphate reservoir size is therefore important for interpreting the oxygenation history of early Earth environments. Few data, however, specifically constrain how sulphate concentrations may have changed during the Proterozoic era (2.5 - 0.54 Gyr ago). Prior to 2.2 Gyr ago, when oxygen began to accumulate in the Earth's atmosphere(2,3), sulphate concentrations are inferred to have been <1 mM and possibly < 200 muM, on the basis of limited isotopic variability preserved in sedimentary sulphides(4) and experimental data showing suppressed isotopic fractionation at extremely low sulphate concentrations(1,5). By 0.8 Gyr ago, oxygen and thus sulphate levels may have risen significantly(6,7). Here we report large stratigraphic variations in the sulphur isotope composition of marine carbonate-associated sulphate, and use a rate-dependent model for sulphur isotope change that allows us to track changes in marine sulphate concentrations throughout the Proterozoic. Our calculations indicate sulphate levels between 1.5 and 4.5 mM, or 5 - 15 per cent of modern values, for more than 1 Gyr after initial oxygenation of the Earth's biosphere. Persistence of low oceanic sulphate demonstrates the protracted nature of Earth's oxygenation. It links biospheric evolution to temporal patterns in the depositional behaviour of marine iron- and sulphur-bearing minerals(4), biological cycling of redox-sensitive elements(6) and availability of trace metals essential to eukaryotic development(8).	Univ Tennessee, Dept Earth & Planetary Sci, Knoxville, TN 37996 USA; Univ Missouri, Dept Geol Sci, Columbia, MO 65211 USA; Univ Nebraska, Dept Geosci, Lincoln, NE 68588 USA	University of Tennessee System; University of Tennessee Knoxville; University of Missouri System; University of Missouri Columbia; University of Nebraska System; University of Nebraska Lincoln	Kah, LC (corresponding author), Univ Tennessee, Dept Earth & Planetary Sci, Knoxville, TN 37996 USA.	lckah@utk.edu	Kah, Linda C/J-3754-2019	Kah, Linda C/0000-0001-7172-2033; Frank, Tracy/0000-0002-8422-7389				Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; Azmy K, 2001, PRECAMBRIAN RES, V112, P303, DOI 10.1016/S0301-9268(01)00194-2; Berner RA, 2001, GEOCHIM COSMOCHIM AC, V65, P685, DOI 10.1016/S0016-7037(00)00572-X; BOSSCHER H, 1993, J GEOL, V101, P345, DOI 10.1086/648228; Brennan ST, 2004, GEOLOGY, V32, P473, DOI 10.1130/g20251.1; BURDETT JW, 1989, EARTH PLANET SC LETT, V94, P189, DOI 10.1016/0012-821X(89)90138-6; Canfield DE, 2000, SCIENCE, V288, P658, DOI 10.1126/science.288.5466.658; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; Farquhar J, 2000, SCIENCE, V289, P756, DOI 10.1126/science.289.5480.756; Frank TD, 2003, GEOL MAG, V140, P397, DOI 10.1017/S0016756803007830; GELLATLY AM, IN PRESS GEOCHIM COS; GROTZINGER JP, 1989, SOC ECON PA, V44, P79, DOI 10.2110/pec.89.44.0079; Habicht KS, 2002, SCIENCE, V298, P2372, DOI 10.1126/science.1078265; Habicht KS, 2001, GEOLOGY, V29, P555, DOI 10.1130/0091-7613(2001)029<0555:IFBSRN>2.0.CO;2; Hurtgen MT, 2002, EARTH PLANET SC LETT, V203, P413, DOI 10.1016/S0012-821X(02)00804-X; Kah LC, 2001, PRECAMBRIAN RES, V111, P203, DOI 10.1016/S0301-9268(01)00161-9; Kampschulte A, 2001, CHEM GEOL, V175, P149, DOI 10.1016/S0009-2541(00)00367-3; Karhu JA, 1996, GEOLOGY, V24, P867, DOI 10.1130/0091-7613(1996)024<0867:CIATRO>2.3.CO;2; KNOLL AH, 1986, NATURE, V321, P832, DOI 10.1038/321832a0; Kump LR, 1999, CHEM GEOL, V161, P181, DOI 10.1016/S0009-2541(99)00086-8; Luepke JJ, 2001, PRECAMBRIAN RES, V111, P79, DOI 10.1016/S0301-9268(01)00157-7; Lyons TW, 2000, GEOCHIM COSMOCHIM AC, V64, P427, DOI 10.1016/S0016-7037(99)00323-3; Paytan A, 1998, SCIENCE, V282, P1459, DOI 10.1126/science.282.5393.1459; Schlesinger WH, 1997, BIOGEOCHEMISTRY; Shen Y, 2003, NATURE, V423, P632, DOI 10.1038/nature01651; Shen YN, 2002, AM J SCI, V302, P81, DOI 10.2475/ajs.302.2.81; Staudt WJ, 1995, ACS SYM SER, V612, P332; Strauss H, 1997, PALAEOGEOGR PALAEOCL, V132, P97, DOI 10.1016/S0031-0182(97)00067-9; WHELAN JF, 1990, AM J SCI, V290, P396, DOI 10.2475/ajs.290.4.396	30	345	364	4	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					834	838		10.1038/nature02974	http://dx.doi.org/10.1038/nature02974			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483609	Green Published			2022-12-28	WOS:000224435500044
J	Raabe, R; Sida, JL; Charvet, JL; Alamanos, N; Angulo, C; Casandjian, JM; Courtin, S; Drouart, A; Durand, DJC; Figuera, P; Gillibert, A; Heinrich, S; Jouanne, C; Lapoux, V; Lepine-Szily, A; Musumarra, A; Nalpas, L; Pierroutsakou, D; Romoli, M; Rusek, K; Trotta, M				Raabe, R; Sida, JL; Charvet, JL; Alamanos, N; Angulo, C; Casandjian, JM; Courtin, S; Drouart, A; Durand, DJC; Figuera, P; Gillibert, A; Heinrich, S; Jouanne, C; Lapoux, V; Lepine-Szily, A; Musumarra, A; Nalpas, L; Pierroutsakou, D; Romoli, M; Rusek, K; Trotta, M			No enhancement of fusion probability by the neutron halo of He-6	NATURE			English	Article							SUB-BARRIER FUSION; HEAVY-ION FUSION; SUBBARRIER FUSION; COULOMB BARRIER; NUCLEI; BREAKUP; LI-11	Quantum tunnelling through a potential barrier ( such as occurs in nuclear fusion) is very sensitive to the detailed structure of the system and its intrinsic degrees of freedom(1,2). A strong increase of the fusion probability has been observed for heavy deformed nuclei(3). In light exotic nuclei such as He-6, Li-11 and Be-11 ( termed 'halo' nuclei(4)), the neutron matter extends much further than the usual nuclear interaction scale. However, understanding the effect of the neutron halo on fusion has been controversial - it could induce a large enhancement of fusion(5), but alternatively the weak binding energy of the nuclei could inhibit the process(6). Other reaction channels known as direct processes ( usually negligible for ordinary nuclei) are also important: for example, a fragment of the halo nucleus could transfer to the target nucleus through a diminished potential barrier. Here we study the reactions of the halo nucleus He-6 with a U-238 target, at energies near the fusion barrier. Most of these reactions lead to fission of the system, which we use as an experimental signature to identify the contribution of the fusion and transfer channels to the total cross-section. At energies below the fusion barrier, we find no evidence for a substantial enhancement of fusion. Rather, the ( large) fission yield is due to a two-neutron transfer reaction, with other direct processes possibly also involved.	CEA Saclay, DSM, DAPNIA, F-91191 Gif Sur Yvette, France; Katholieke Univ Leuven, Inst Kern & Stralingsfys, B-3001 Louvain, Belgium; Catholic Univ Louvain, Ctr Rech Cyclotron, B-1348 Louvain, Belgium; GANIL, F-14076 Caen 5, France; CNRS, IN2P3, Inst Rech Subatom, F-67037 Strasbourg 2, France; Ist Nazl Fis Nucl, Lab Nazl Sud, I-95123 Catania, Italy; Univ Sao Paulo, Inst Fis, BR-05389970 Sao Paulo, Brazil; Univ Naples Federico II, I-80125 Naples, Italy; Ist Nazl Fis Nucl, Sez Napoli, I-80125 Naples, Italy; Andrzej Soltan Inst Nucl Studies, Dept Nucl React, PL-00681 Warsaw, Poland	CEA; UDICE-French Research Universities; Universite Paris Saclay; KU Leuven; Universite Catholique Louvain; CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Istituto Nazionale di Fisica Nucleare (INFN); Universidade de Sao Paulo; University of Naples Federico II; Istituto Nazionale di Fisica Nucleare (INFN); Soltan Institute for Nuclear Studies	Raabe, R (corresponding author), CEA Saclay, DSM, DAPNIA, F-91191 Gif Sur Yvette, France.	riccardo.raabe@fys.kuleuven.ac.be	Drouart, Antoine/Q-3171-2017; Lepine-Szily, Alinka/I-3325-2012	Lepine-Szily, Alinka/0000-0001-6640-8824; Rusek, Krzysztof/0000-0001-7513-0596; Courtin, Sandrine/0000-0001-6972-2798; Pierroutsakou, Dimitra/0000-0001-8556-0338; Raabe, Riccardo/0000-0003-4105-9802; Musumarra, Agatino/0000-0002-5766-9069; Lapoux, Valerie/0000-0002-2014-199X; Heinrich, Sophie/0000-0003-3132-1803				Aguilera EF, 2000, PHYS REV LETT, V84, P5058, DOI 10.1103/PhysRevLett.84.5058; AUSTIN SM, 1995, SCI AM, V272, P90, DOI 10.1038/scientificamerican0695-90; BECKERMAN M, 1988, REP PROG PHYS, V51, P1047, DOI 10.1088/0034-4885/51/8/001; CALDEIRA AO, 1981, PHYS REV LETT, V46, P211, DOI 10.1103/PhysRevLett.46.211; Canto LF, 1998, PHYS REV C, V58, P1107, DOI 10.1103/PhysRevC.58.1107; Dasgupta M, 1999, PHYS REV LETT, V82, P1395, DOI 10.1103/PhysRevLett.82.1395; DASSO CH, 1994, PHYS REV C, V50, pR12, DOI 10.1103/PhysRevC.50.R12; Dasso CH, 1996, NUCL PHYS A, V597, P473, DOI 10.1016/0375-9474(95)00459-9; DASSO CH, 1983, NUCL PHYS A, V405, P381, DOI 10.1016/0375-9474(83)90578-X; DIPIETRO A, 2004, PHYS REV C, V67; Hagino K, 2000, PHYS REV C, V61, DOI 10.1103/PhysRevC.61.037602; HANSEN PG, 1987, EUROPHYS LETT, V4, P409, DOI 10.1209/0295-5075/4/4/005; Hinde DJ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.272701; HUSSEIN MS, 1992, PHYS REV C, V46, P377, DOI 10.1103/PhysRevC.46.377; Kolata JJ, 1998, PHYS REV LETT, V81, P4580, DOI 10.1103/PhysRevLett.81.4580; RHOADESBROWN MJ, 1984, PHYS LETT B, V136, P19, DOI 10.1016/0370-2693(84)92047-1; Rusek K, 2003, PHYS REV C, V67, DOI 10.1103/PhysRevC.67.041604; Ryckewaert G, 2002, NUCL PHYS A, V701, p323C, DOI 10.1016/S0375-9474(01)01605-0; STOKSTAD RG, 1978, PHYS REV LETT, V41, P465, DOI 10.1103/PhysRevLett.41.465; Takahashi J, 1997, PHYS REV LETT, V78, P30, DOI 10.1103/PhysRevLett.78.30; TAKIGAWA N, 1993, PHYS REV C, V47, pR2470, DOI 10.1103/PhysRevC.47.R2470; Tamura T., 1974, Physics Reports. Physics Letters Section C, V14c, P59, DOI 10.1016/0370-1573(74)90028-3; TANIHATA I, 1985, PHYS REV LETT, V55, P2676, DOI 10.1103/PhysRevLett.55.2676; THOMPSON IJ, 1988, COMPUT PHYS REP, V7, P167, DOI 10.1016/0167-7977(88)90005-6; Trotta M, 2000, PHYS REV LETT, V84, P2342, DOI 10.1103/PhysRevLett.84.2342; TSUKADA M, 1993, JPN J APPL PHYS 9; VANDENBOSCH R, 1973, NUCL FISSION, P463; ZHUKOV MV, 1993, PHYS REP, V231, P151, DOI 10.1016/0370-1573(93)90141-Y	29	189	191	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					823	826		10.1038/nature02984	http://dx.doi.org/10.1038/nature02984			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483606				2022-12-28	WOS:000224435500041
J	Fotin, A; Cheng, YF; Grigorieff, N; Walz, T; Harrison, SC; Kirchhausen, T				Fotin, A; Cheng, YF; Grigorieff, N; Walz, T; Harrison, SC; Kirchhausen, T			Structure of an auxilin-bound clathrin coat and its implications for the mechanism of uncoating	NATURE			English	Article							IN-VIVO; DISSOCIATION; VESICLES; HSC70; IDENTIFICATION; COMPLEX; ATPASE	Clathrin-coated pits invaginate from specific membrane compartments and pinch off as coated vesicles. These vesicles then uncoat rapidly once released. The Hsc70 molecular chaperone effects the uncoating reaction, and is guided to appropriate locations on clathrin lattices by the J-domain-containing co-chaperone molecule auxilin(1-4). This raises the question of how a local event such as ATP hydrolysis by Hsc70 can catalyse a global disassembly. Here, we have used electron cryomicroscopy to determine 12-Angstrom-resolution structures of in-vitro-assembled clathrin coats in association with a carboxy-terminal fragment of auxilin that contains both the clathrin-binding region and the J domain. We have located the auxilin fragment by computing differences between these structures and those lacking auxilin (described in an accompanying paper(5)). Auxilin binds within the clathrin lattice near contacts between an inward-projecting C-terminal helical tripod and the crossing of two 'ankle' segments; it also contacts the terminal domain of yet another clathrin 'leg'. It therefore recruits Hsc70 to the neighbourhood of a set of critical interactions. Auxilin binding produces a local change in heavy-chain contacts, creating a detectable global distortion of the clathrin coat. We propose a mechanism by which local destabilization of the lattice promotes general uncoating.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Biophys Grad Program, Boston, MA 02115 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Howard Hughes Med Inst, Waltham, MA 02454 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biochem, Waltham, MA 02454 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Brandeis University; Howard Hughes Medical Institute; Brandeis University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Kirchhausen, T (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 200 Longwood Ave, Boston, MA 02115 USA.	Kirchhausen@crystal.harvard.edu	Gimenez, Luis E Diaz/D-9291-2011	Grigorieff, Nikolaus/0000-0002-1506-909X; Walz, Thomas/0000-0003-2606-2835; Cheng, Yifan/0000-0001-9535-0369				Barouch W, 1997, BIOCHEMISTRY-US, V36, P4303, DOI 10.1021/bi962727z; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; FOTIN A, NATURE; Greener T, 2001, NAT CELL BIOL, V3, P215, DOI 10.1038/35055137; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Gruschus JM, 2004, BIOCHEMISTRY-US, V43, P3111, DOI 10.1021/bi0354740; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; Jiang JW, 2003, BIOCHEMISTRY-US, V42, P5748, DOI 10.1021/bi034270g; Ma YC, 2002, J BIOL CHEM, V277, P49267, DOI 10.1074/jbc.M203695200; Pishvaee B, 2000, NAT CELL BIOL, V2, P958, DOI 10.1038/35046619; Scheele U, 2001, J BIOL CHEM, V276, P36131, DOI 10.1074/jbc.M106511200; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHRODER S, 1995, EUR J BIOCHEM, V228, P297, DOI 10.1111/j.1432-1033.1995.tb20263.x; Smith CJ, 2004, J MOL BIOL, V336, P461, DOI 10.1016/j.jmb.2003.12.006; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; Umeda A, 2000, EUR J CELL BIOL, V79, P336, DOI 10.1078/S0171-9335(04)70037-0; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0	18	120	124	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	2004	432	7017					649	653		10.1038/nature03078	http://dx.doi.org/10.1038/nature03078			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875PL	15502813				2022-12-28	WOS:000225433200052
J	Atkinson, A; Siegel, V; Pakhomov, E; Rothery, P				Atkinson, A; Siegel, V; Pakhomov, E; Rothery, P			Long-term decline in krill stock and increase in salps within the Southern Ocean	NATURE			English	Article							SEA-ICE EXTENT; ANTARCTIC KRILL; EUPHAUSIA-SUPERBA; ABUNDANCE; ECOSYSTEM; CARBON	Antarctic krill ( Euphausia superba) and salps ( mainly Salpa thompsoni) are major grazers in the Southern Ocean(1-4), and krill support commercial fisheries(5). Their density distributions(1,3,4,6) have been described in the period 1926 - 51, while recent localized studies(7-10) suggest short-term changes. To examine spatial and temporal changes over larger scales, we have combined all available scientific net sampling data from 1926 to 2003. This database shows that the productive southwest Atlantic sector contains > 50% of Southern Ocean krill stocks, but here their density has declined since the 1970s. Spatially, within their habitat, summer krill density correlates positively with chlorophyll concentrations. Temporally, within the southwest Atlantic, summer krill densities correlate positively with sea-ice extent the previous winter. Summer food and the extent of winter sea ice are thus key factors in the high krill densities observed in the southwest Atlantic Ocean. Krill need the summer phytoplankton blooms of this sector, where winters of extensive sea ice mean plentiful winter food from ice algae, promoting larval recruitment(7-11) and replenishing the stock. Salps, by contrast, occupy the extensive lower-productivity regions of the Southern Ocean and tolerate warmer water than krill(2-4,12). As krill densities decreased last century, salps appear to have increased in the southern part of their range. These changes have had profound effects within the Southern Ocean food web(10,13).	British Antarctic Survey, NERC, Cambridge CB3 OET, England; Sea Fisheries Res Inst, D-22767 Hamburg, Germany; Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z4, Canada; Univ Ft Hare, Fac Sci & Technol, Dept Zool, ZA-5700 Alice, South Africa; NERC, Ctr Ecol & Hydrol, Huntingdon PE28 2LS, England	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey; University of British Columbia; University of Fort Hare; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Atkinson, A (corresponding author), British Antarctic Survey, NERC, High Cross,Madingley Rd, Cambridge CB3 OET, England.	aat@bas.ac.uk						Arrigo KR, 1998, J GEOPHYS RES-OCEANS, V103, P15587, DOI 10.1029/98JC00930; Baker A. de C., 1954, Discovery Reports, V27, P201; Brierley AS, 2002, SCIENCE, V295, P1890, DOI 10.1126/science.1068574; Clarke A, 2003, ENVIRON CONSERV, V30, P1, DOI 10.1017/S0376892903000018; Constable AJ, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2001JC001270; Curran MAJ, 2003, SCIENCE, V302, P1203, DOI 10.1126/science.1087888; delaMare WK, 1997, NATURE, V389, P57, DOI 10.1038/37956; Everson E., 2000, KRILL BIOL ECOLOGY F; Foxton P., 1966, Discovery Reports, V34, P1; Fraser WR, 2003, MAR ECOL PROG SER, V265, P1, DOI 10.3354/meps265001; Gille ST, 2002, SCIENCE, V295, P1275, DOI 10.1126/science.1065863; Hofmann EE, 1998, ANTARCT SCI, V10, P406, DOI 10.1017/S0954102098000492; Hofmann EE, 2003, DEEP-SEA RES PT II, V50, P3121, DOI 10.1016/j.dsr2.2003.07.012; LAWS RM, 1985, AM SCI, V73, P26; Le Fevre J, 1998, J MARINE SYST, V17, P325, DOI 10.1016/S0924-7963(98)00047-5; Loeb V, 1997, NATURE, V387, P897, DOI 10.1038/43174; Marr J.W.S., 1962, DISCOVERY REP, VXXXII, P33; Moore JK, 1999, J GEOPHYS RES-OCEANS, V104, P3059, DOI 10.1029/1998JC900032; MURPHY EJ, 1995, J ANIM ECOL, V64, P333, DOI 10.2307/5895; Nicol S, 2000, NATURE, V406, P504, DOI 10.1038/35020053; Nicol S, 2000, CCAMLR SCI, V7, P87; ORSI AH, 1995, DEEP-SEA RES PT I, V42, P641, DOI 10.1016/0967-0637(95)00021-W; Pakhomov EA, 2002, DEEP-SEA RES PT II, V49, P1881, DOI 10.1016/S0967-0645(02)00017-6; Parkinson CL, 2002, ANN GLACIOL, V34, P435, DOI 10.3189/172756402781817482; Quetin Langdon B., 1996, Antarctic Research Series, V70, P357; Quetin LB, 2003, MAR ECOL PROG SER, V259, P185, DOI 10.3354/meps259185; Reid K, 2001, P ROY SOC B-BIOL SCI, V268, P377, DOI 10.1098/rspb.2000.1371; Siegel V, 2000, CAN J FISH AQUAT SCI, V57, P151, DOI 10.1139/cjfas-57-S3-151; Smetacek V., 1990, P103; Tynan CT, 1998, NATURE, V392, P708, DOI 10.1038/33675	30	801	867	16	414	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					100	103		10.1038/nature02996	http://dx.doi.org/10.1038/nature02996			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525989				2022-12-28	WOS:000224854900048
J	Bhatt, DL; Roe, MT; Peterson, ED; Li, Y; Chen, AY; Harrington, RA; Greenbaum, AB; Berger, PB; Cannon, CP; Cohen, DJ; Gibson, CM; Saucedo, JF; Kleiman, NS; Hochman, JS; Boden, WE; Brindis, RG; Peacock, WF; Smith, SC; Pollack, CV; Gibler, WB; Ohman, EM				Bhatt, DL; Roe, MT; Peterson, ED; Li, Y; Chen, AY; Harrington, RA; Greenbaum, AB; Berger, PB; Cannon, CP; Cohen, DJ; Gibson, CM; Saucedo, JF; Kleiman, NS; Hochman, JS; Boden, WE; Brindis, RG; Peacock, WF; Smith, SC; Pollack, CV; Gibler, WB; Ohman, EM		CRUSADE Investigators	Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes - Results from the CRUSADE quality improvement initiative	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLATELET GLYCOPROTEIN IIB/IIIA; ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; ARTERY-DISEASE; ACC/AHA GUIDELINES; HEART-ASSOCIATION; ELDERLY-PATIENTS; TRIAL; CARE; ANGIOGRAPHY	Context The American College of Cardiology/American Heart Association (ACC/ AHA) guidelines for the management of non-ST-segment elevation acute coronary syndromes (NSTE ACS) recommend early invasive management for high-risk patients, given the benefits with this approach demonstrated in randomized clinical trials. Objectives To determine the use and predictors of early invasive management strategies (cardiac catheterization <48 hours following presentation) in high-risk patients with NSTE ACS and to examine the association of early invasive management with mortality. Design, Setting, and Patients The CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Quality Improvement Initiative evaluated care patterns and outcomes for 17926 high-risk NSTE ACS patients (positive cardiac markers and/or ischemic electrocardiographic changes) based on ACC/AHA guidelines recommendations at 248 US hospitals with catheterization and revascularization facilities between March 2000 and September 2002. Main Outcome Measures Use of early invasive management within 48 hours of presentation, predictors of early invasive management, and in-hospital mortality. Results Of the 17926 patients analyzed, 8037 (44.8%) underwent early cardiac catheterization less than 48 hours following presentation. Predictors of early invasive management included cardiology care, younger age, lack of prior or current congestive heart failure, lack of renal insufficiency, ischemic electrocardiographic changes, positive cardiac markers, white race, and male sex. Patients treated with early invasive management were more likely to be treated with medications and interventions recommended by the ACC/AHA guidelines and had a lower risk of in-hospital mortality after adjusting for differences in clinical characteristics and after comparing propensity-matched pairs (2.5% vs 3.7%, P<.001). Conclusions An early invasive management strategy is not utilized in the majority of high-risk patients with NSTE ACS. This strategy appears to be reserved for patients without significant comorbidities and those cared for by cardiologists and is associated with a lower risk of in-hospital mortality.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Duke Clin Res Inst, Durham, NC USA; Henry Ford Heart & Vasc Inst, Detroit, MI USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, TIMI Study Grp, Boston, MA USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; Baylor Coll Med, Houston, TX 77030 USA; NYU, Sch Med, New York, NY USA; Univ Connecticut, Hartford, CT 06112 USA; Kaiser Permanente Hlth Syst, San Francisco, CA USA; Univ N Carolina, Chapel Hill, NC USA; Penn Hosp, Philadelphia, PA 19107 USA; Univ Cincinnati, Cincinnati, OH USA	Cleveland Clinic Foundation; Duke University; Henry Ford Health System; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Oklahoma System; University of Oklahoma Health Sciences Center; Baylor College of Medicine; New York University; University of Connecticut; Kaiser Permanente; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; Pennsylvania Medicine; University System of Ohio; University of Cincinnati	Bhatt, DL (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, Desk F25,9500 Euclid Ave, Cleveland, OH 44195 USA.	bhattd@ccf.org	Peterson, Eric David/ABF-5033-2021; Gibson, C. Michael/AAE-8212-2019	Hochman, Judith/0000-0002-5889-5981				Antman EM, 1999, CIRCULATION, V100, P1593, DOI 10.1161/01.CIR.100.15.1593; Bach RG, 2004, ANN INTERN MED, V141, P186, DOI 10.7326/0003-4819-141-3-200408030-00007; Bassand JP, 2000, EUR HEART J, V21, P1289, DOI 10.1053/euhj.2000.2256; Bavry AA, 2004, AM J CARDIOL, V93, P830, DOI 10.1016/j.amjcard.2003.12.019; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Bhatt DL, 2000, JAMA-J AM MED ASSOC, V284, P1549, DOI 10.1001/jama.284.12.1549; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boersma E, 2000, CIRCULATION, V101, P2557, DOI 10.1161/01.CIR.101.22.2557; Braunwald E, 2002, J AM COLL CARDIOL, V40, P1366, DOI 10.1016/S0735-1097(02)02336-7; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Chen J, 2000, AM J MED, V108, P460, DOI 10.1016/S0002-9343(00)00331-4; Cho L, 2003, AM J MED, V114, P106, DOI 10.1016/S0002-9343(02)01446-8; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; Denton TA, 2003, ANN THORAC SURG, V75, P758, DOI 10.1016/S0003-4975(02)04885-3; Garg PP, 2002, MED CARE, V40, P614, DOI 10.1097/00005650-200207000-00008; Hoekstra JW, 2002, ACAD EMERG MED, V9, P1146, DOI 10.1111/j.1553-2712.2002.tb01569.x; Januzzi JL, 2002, AM J CARDIOL, V90, P1246, DOI 10.1016/S0002-9149(02)02844-8; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; Keeley EC, 2003, AM J CARDIOL, V92, P509, DOI 10.1016/S0002-9149(03)00716-1; Leape LL, 2002, JAMA-J AM MED ASSOC, V288, P501, DOI 10.1001/jama.288.4.501; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Mehta RH, 2002, JAMA-J AM MED ASSOC, V287, P1269, DOI 10.1001/jama.287.10.1269; Parsons, 2001, P 26 ANN SAS US GROU; Petersen LA, 2003, NEW ENGL J MED, V348, P2209, DOI 10.1056/NEJMsa021725; Pollack CV, 2003, ANN EMERG MED, V41, P355, DOI 10.1067/mem.2003.88; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Sabatine MS, 2004, CIRCULATION, V109, P874, DOI 10.1161/01.CIR.0000112604.74713.35; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Sharis PJ, 2002, AM J CARDIOL, V90, P1154, DOI 10.1016/S0002-9149(02)02788-1; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 2003, CIRCULATION, V107, P1463, DOI 10.1161/01.CIR.0000063680.45780.A0; Wallentin L, 1999, LANCET, V354, P708; Wallentin L, 2000, LANCET, V356, P9, DOI 10.1016/S0140-6736(00)02427-2; Yusuf S, 2001, NEW ENGL J MED, V345, P494	36	447	469	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2004	292	17					2096	2104		10.1001/jama.292.17.2096	http://dx.doi.org/10.1001/jama.292.17.2096			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868OC	15523070	Bronze			2022-12-28	WOS:000224921900022
J	Alter, MJ; Seeff, LB; Bacon, BR; Thomas, DL; Rigsby, MO; Di Bisceglie, AM				Alter, MJ; Seeff, LB; Bacon, BR; Thomas, DL; Rigsby, MO; Di Bisceglie, AM			Testing for hepatitis C virus infection should be routine for persons at increased risk for infection	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CHRONIC LIVER-DISEASE; PLUS RIBAVIRIN; UNITED-STATES; ALCOHOL; MORTALITY; THERAPY	In the United States, chronic hepatitis C virus (HCV) infection affects an estimated 3 million persons, most younger than 50 years of age. It is one of the leading causes of chronic liver disease morbidity and mortality and the most common indication for liver transplantation. Effective treatment can eradicate the virus and eliminate or reduce liver inflammation and fibrosis, and counseling and immunization can modify or prevent the adverse effect of cofactors (for example, alcohol consumption or co-infections) on disease progression. However, controversy surrounds the need to routinely identify asymptomatic HCV-infected persons. Because no data currently demonstrate that treatment or other interventions will reduce future cases of HCV-related chronic disease and deaths, the U.S. Preventive Services Task Force found insufficient evidence to recommend for or against routine screening for HCV infection in adults at high risk. Chronic hepatitis C would require many years of follow-up to determine the incidence of complication after treatment of or other interventions in asymptomatic persons. It seems inappropriate to wait several decades to measure the impact of early identification of this viral infection when current data support a positive therapeutic effect that points to long-term benefits. In addition, treatment and other interventions must be provided before cirrhosis or liver failure occurs. Therefore, medical and public health professionals should continue the practice of screening persons for risk factors; offering testing to those at increased risk for HCV infection; and providing infected persons with appropriate counseling, medical evaluation, and treatment.	Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Alter, MJ (corresponding author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Mailstop D66, Atlanta, GA 30333 USA.							[Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 2002, HEPATOLOGY, V36, pS3, DOI 10.1053/jhep.2002.37117; [Anonymous], 1997, HEPATOLOGY, V26, pS2; Berg AO, 2004, ANN INTERN MED, V140, P462, DOI 10.7326/0003-4819-140-6-200403160-00013; Centers for Disease Control and Prevention (CDC) HIPAA Privacy Rule and Public Health, 2003, MMWR-MORBID MORTAL W, V52, P1; Chou R, 2004, ANN INTERN MED, V140, P465, DOI 10.7326/0003-4819-140-6-200403160-00014; Corrao G, 1998, HEPATOLOGY, V27, P914, DOI 10.1002/hep.510270404; Di Bisceglie AM, 2002, HEPATOLOGY, V36, pS121, DOI 10.1053/jhep.2002.36228; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Frieden TR, 1999, HEPATOLOGY, V29, P883, DOI 10.1002/hep.510290308; Gunn RA, 2003, SEX TRANSM DIS, V30, P340, DOI 10.1097/00007435-200304000-00013; Lau DTY, 1998, HEPATOLOGY, V28, P1121, DOI 10.1002/hep.510280430; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Roberts MS, 2004, LIVER TRANSPLANT, V10, P886, DOI 10.1002/lt.20137; Seeff LB, 2001, HEPATOLOGY, V33, P455, DOI 10.1053/jhep.2001.21905; Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119; Thomas DL, 2002, HEPATOLOGY, V36, pS201, DOI 10.1053/jhep.2002.36380; Vento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503; *VET HLTH ADM, 2003, FEDERAL PRACTITIO S5, V20, P7; Vong S, 2004, HEPATOLOGY, V39, P476, DOI 10.1002/hep.20049; Wiley TE, 1998, HEPATOLOGY, V28, P805, DOI 10.1002/hep.510280330	21	69	69	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2004	141	9					715	717		10.7326/0003-4819-141-9-200411020-00013	http://dx.doi.org/10.7326/0003-4819-141-9-200411020-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867JT	15520428				2022-12-28	WOS:000224839600008
J	Zimetbaum, P; Josephson, ME				Zimetbaum, P; Josephson, ME			Is there a role for maintaining sinus rhythm in patients with atrial fibrillation?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TORSADE-DE-POINTES; QUALITY-OF-LIFE; RANDOMIZED-TRIAL; DUAL-CHAMBER; FOLLOW-UP; CATHETER ABLATION; ELDERLY-PATIENTS; MANAGEMENT; THERAPY; AMIODARONE	Recent studies have indicated that outcomes in patients with atrial fibrillation who are managed with rate control and anticoagulation are similar to those in patients who have maintenance of sinus rhythm. These studies did not include important groups of patients with atrial fibrillation in whom antiarrhythmic therapy may be appropriate. This perspective argues for the maintenance of sinus rhythm and for the use of antiarrhythmic therapy that includes medications, invasive procedures, and a combination of both in appropriate patients.	Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Zimetbaum, P (corresponding author), Beth Israel Deaconess Med Ctr, 185 Pilgram Rd, Boston, MA 02215 USA.							Andersen HR, 1997, LANCET, V350, P1210, DOI 10.1016/S0140-6736(97)03425-9; [Anonymous], 1989, NEW ENGL J MED, V321, P406; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; Carlsson J, 2003, J AM COLL CARDIOL, V41, P1690, DOI 10.1016/S0735-1097(03)00332-2; Chiang CE, 2000, J AM COLL CARDIOL, V36, P1, DOI 10.1016/S0735-1097(00)00716-6; Corley SD, 2004, CIRCULATION, V109, P1509, DOI 10.1161/01.CIR.0000121736.16643.11; CRIJNS HJ, 1988, AM J CARDIOL, V62, P1303, DOI 10.1016/0002-9149(88)90282-2; Essebag V, 2003, J AM COLL CARDIOL, V41, P249, DOI 10.1016/S0735-1097(02)02709-2; Franz MR, 1997, J AM COLL CARDIOL, V30, P1785, DOI 10.1016/S0735-1097(97)00385-9; Friedman PL, 1998, AM J CARDIOL, V82, p50N, DOI 10.1016/S0002-9149(98)00586-4; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Goldschlager N, 2000, ARCH INTERN MED, V160, P1741, DOI 10.1001/archinte.160.12.1741; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; Hauser TH, 2003, AM J CARDIOL, V91, P1437, DOI 10.1016/S0002-9149(03)00395-3; Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X; HOHNLOSER SH, 1994, ANN INTERN MED, V121, P529, DOI 10.7326/0003-4819-121-7-199410010-00009; Huang DT, 1998, J CARDIOVASC ELECTR, V9, P462, DOI 10.1111/j.1540-8167.1998.tb01837.x; KERR CR, 2002, PACE, V25, P553; Kochiadakis GE, 1999, J AM COLL CARDIOL, V33, P966, DOI 10.1016/S0735-1097(98)00678-0; Kochiadakis GE, 1999, AM J CARDIOL, V83, P58, DOI 10.1016/S0002-9149(98)00783-8; Kondo N, 2003, ANN THORAC SURG, V75, P1490, DOI 10.1016/S0003-4975(02)04900-7; Kowey PR, 2003, AM J CARDIOL, V91, p33D, DOI 10.1016/S0002-9149(02)03377-5; Lamas GA, 2002, NEW ENGL J MED, V346, P1854, DOI 10.1056/NEJMoa013040; Lamas GA, 1998, NEW ENGL J MED, V338, P1097, DOI 10.1056/NEJM199804163381602; Lee MA, 2003, J AM COLL CARDIOL, V41, P1926, DOI 10.1016/S0735-1097(03)00426-1; McNamara RL, 2003, ANN INTERN MED, V139, P1018, DOI 10.7326/0003-4819-139-12-200312160-00012; Natale A, 2000, J AM COLL CARDIOL, V35, P1898, DOI 10.1016/S0735-1097(00)00635-5; Olivotto I, 2001, CIRCULATION, V104, P2517, DOI 10.1161/hc4601.097997; Oral H, 2003, CIRCULATION, V108, P2355, DOI 10.1161/01.CIR.0000095796.45180.88; Oral H, 2002, CIRCULATION, V105, P1077, DOI 10.1161/hc0902.104712; Pappone C, 2004, CIRCULATION, V109, P2724, DOI 10.1161/01.CIR.0000131866.44650.46; Pappone C, 2003, J AM COLL CARDIOL, V42, P185, DOI 10.1016/S0735-1097(03)00577-1; Priori SG, 1999, CIRCULATION, V99, P518, DOI 10.1161/01.CIR.99.4.518; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; Roy D, 2000, NEW ENGL J MED, V342, P913, DOI 10.1056/NEJM200003303421302; Saad EB, 2003, ANN INTERN MED, V138, P634, DOI 10.7326/0003-4819-138-8-200304150-00010; SALATA JJ, 1995, CIRC RES, V76, P110, DOI 10.1161/01.RES.76.1.110; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; Stabile G, 2001, J AM COLL CARDIOL, V37, P1639, DOI 10.1016/S0735-1097(01)01214-1; Steinberg JS, 2004, CIRCULATION, V109, P1973, DOI 10.1161/01.CIR.0000118472.77237.FA; STEVENSON WG, 1985, PACE, V8, P528, DOI 10.1111/j.1540-8159.1985.tb05854.x; Sweeney MO, 2003, CIRCULATION, V107, P2932, DOI 10.1161/01.CIR.0000072769.17295.B1; Tieleman RG, 1997, AM J CARDIOL, V79, P53, DOI 10.1016/S0002-9149(96)00675-3; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; VanGelder IC, 1996, ARCH INTERN MED, V156, P2585, DOI 10.1001/archinte.156.22.2585; Weerasooriya R, 2003, J AM COLL CARDIOL, V41, P1697, DOI 10.1016/S0735-1097(03)00338-3; Wijffels MCEF, 2003, J CARDIOVASC ELECTR, V14, pS40, DOI 10.1046/j.1540-8167.14.s9.20.x; Wilkoff BL, 2002, JAMA-J AM MED ASSOC, V288, P3115; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; Yang P, 2002, CIRCULATION, V105, P1943, DOI 10.1161/01.CIR.0000014448.19052.4C; Yang T, 1996, CIRCULATION, V93, P407, DOI 10.1161/01.CIR.93.3.407; Zimetbaum P, 2001, Heart Dis, V3, P148, DOI 10.1097/00132580-200105000-00004; Zimetbaum P, 2003, AM J CARDIOL, V91, P81, DOI 10.1016/S0002-9149(02)03004-7; 2001, CIRCULATION, V104, P2990; 2003, J AM COLL CARDIOL, V42, P20, DOI DOI 10.1016/S0735-1097(03)00559-X	56	11	12	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2004	141	9					720	726		10.7326/0003-4819-141-9-200411020-00015	http://dx.doi.org/10.7326/0003-4819-141-9-200411020-00015			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867JT	15520430				2022-12-28	WOS:000224839600010
J	Donaldson, L				Donaldson, L			When will health care pass the orange-wire test?	LANCET			English	Editorial Material							ADVERSE EVENTS; HOSPITALIZED-PATIENTS		WHO, World Alliance Patient Safety, CH-1211 Geneva, Switzerland	World Health Organization	Donaldson, L (corresponding author), WHO, World Alliance Patient Safety, CH-1211 Geneva, Switzerland.	philipp@who.int						Baker GR, 2004, CAN MED ASSOC J, V170, P1678, DOI 10.1503/cmaj.1040498; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Davis P., 2003, NEW ZEAL MED J, V116, P624; Davis P., 2002, NEW ZEAL MED J, V115, P271; Donaldson L., 2005, ORG MEMORY REPORT EX; Gawande AA, 1999, SURGERY, V126, P66, DOI 10.1067/msy.1999.98664; ISSAKOV A, 1994, MED DEVICES INT PERS; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; Schioler T, 2001, Ugeskr Laeger, V163, P5370; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; *WHO, 2002, 55 WORLD HLTH ASS GE, V1; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x; World Health Organization, 2000, WHOEDM20002; World Health Organization, 2004, WORLD ALL PAT SAF PR	16	25	25	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	2004	364	9445					1567	1568		10.1016/S0140-6736(04)17330-3	http://dx.doi.org/10.1016/S0140-6736(04)17330-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866IQ	15519618				2022-12-28	WOS:000224767600009
J	Peeling, RW; Mabey, D; Fitzgerald, DW; Watson-Jones, D				Peeling, RW; Mabey, D; Fitzgerald, DW; Watson-Jones, D			Avoiding HIV and dying of syphilis	LANCET			English	Editorial Material							SUB-SAHARAN AFRICA; CONGENITAL-SYPHILIS; ANTENATAL SYPHILIS; COST-EFFECTIVENESS; PREGNANCY; HAITI; TRANSMISSION; EXPERIENCE; NEVIRAPINE; TANZANIA		WHO, WHO Special Programme Res & Training Trop Dis, UNICEF UNDP World Bank, Diagnost Res & Dev, CH-1211 Geneva 27, Switzerland; London Sch Hyg & Trop Med, London WC1, England; Grp Haitien Etud Sarcome Kaposi & Infect Opportun, Port Au Prince, Haiti	The World Bank; World Health Organization; University of London; London School of Hygiene & Tropical Medicine	Peeling, RW (corresponding author), WHO, WHO Special Programme Res & Training Trop Dis, UNICEF UNDP World Bank, Diagnost Res & Dev, CH-1211 Geneva 27, Switzerland.	peelingr@who.int		Mabey, David/0000-0002-0031-8276				Fitzgerald D W, 1998, Int J Infect Dis, V2, P127, DOI 10.1016/S1201-9712(98)90113-8; Fitzgerald DW, 2003, AM J PUBLIC HEALTH, V93, P444, DOI 10.2105/AJPH.93.3.444; *GLOB FOR HLTH RES, 2004, 10 90 REP HLTH RES 2, P23; Gloyd S, 2001, HEALTH POLICY PLANN, V16, P29, DOI 10.1093/heapol/16.1.29; HIRA SK, 1990, GENITOURIN MED, V66, P159; Hook EW, 2002, SEX TRANSM DIS, V29, P486, DOI 10.1097/00007435-200208000-00010; Koenig SP, 2004, AIDS, V18, pS21, DOI 10.1097/00002030-200406003-00005; Marseille E, 1999, LANCET, V354, P803, DOI 10.1016/S0140-6736(99)80009-9; Oliff M, 2003, REPROD HEALTH MATTER, V11, P37, DOI 10.1016/S096-88080(03)02174-8; Peck R, 2003, JAIDS-J ACQ IMM DEF, V33, P470, DOI 10.1097/00126334-200308010-00007; Peeling RW, 2004, B WORLD HEALTH ORGAN, V82, P439; Schmid G, 2004, B WORLD HEALTH ORGAN, V82, P402; SCHULZ KF, 1987, GENITOURIN MED, V63, P320; Sweat MD, 2004, AIDS, V18, P1661, DOI 10.1097/01.aids.0000131353.06784.8f; Temmerman M, 1999, INT J STD AIDS, V10, P405, DOI 10.1258/0956462991914339; Terris-Prestholt F, 2003, SEX TRANSM INFECT, V79, P375, DOI 10.1136/sti.79.5.375; Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0; *UNICEF, 2002, MOTH TO CHILD TRANSM; Watson-Jones D, 2002, J INFECT DIS, V186, P940, DOI 10.1086/342952; *WHO UNICEF, 2004, FAR MOR PREGN WOM GE; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Health Organisation (WHO), SEX TRANSM DIS DIAGN	22	49	51	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	2004	364	9445					1561	1563		10.1016/S0140-6736(04)17327-3	http://dx.doi.org/10.1016/S0140-6736(04)17327-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	866IQ	15519615				2022-12-28	WOS:000224767600006
J	Kyle, RA; Rajkumar, SV				Kyle, RA; Rajkumar, SV			Drug therapy: Multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							STEM-CELL TRANSPLANTATION; HIGH-DOSE THERAPY; PROTEASOME INHIBITOR PS-341; TANDEM AUTOLOGOUS TRANSPLANTATION; THALIDOMIDE PLUS DEXAMETHASONE; BONE-MARROW-TRANSPLANTATION; RANDOMIZED-TRIAL; FOLLOW-UP; PHASE-II; RECEIVING THALIDOMIDE		Mayo Clin, Div Hematol & Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Kyle, RA (corresponding author), Mayo Clin, Div Hematol & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.	kyle.robert@mayo.edu	Rajkumar, S. Vincent/AAV-1834-2021	Rajkumar, S. Vincent/0000-0002-5862-1833	NATIONAL CANCER INSTITUTE [R21CA085818, R01CA093842, P01CA062242, R01CA107476, R01CA100080] Funding Source: NIH RePORTER; NCI NIH HHS [CA62242, CA107476, CA100080, CA85818, CA93842] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202; Adams J, 1999, CANCER RES, V59, P2615; ALEXANIAN R, 1986, ANN INTERN MED, V105, P8, DOI 10.7326/0003-4819-105-1-8; ALEXANIAN R, 1990, AM J HEMATOL, V33, P86, DOI 10.1002/ajh.2830330203; ALEXANIAN R, 1989, EUR J HAEMATOL, V43, P140; ALEXANIAN R, 1992, BLOOD, V80, P887; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Anagnostopoulos A, 2003, BRIT J HAEMATOL, V121, P768, DOI 10.1046/j.1365-2141.2003.04345.x; Anderson KC, 2003, MAYO CLIN PROC, V78, P15, DOI 10.4065/78.1.15; Attal M, 2003, NEW ENGL J MED, V349, P2495, DOI 10.1056/NEJMoa032290; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Attal M, 2004, NEW ENGL J MED, V350, P2628; Barbui AM, 2002, BRIT J HAEMATOL, V116, P202, DOI 10.1046/j.0007-1048.2001.03189.x; Barlogie B, 2003, BLOOD, V102, p42A; Barlogie B, 1997, BLOOD, V89, P789, DOI 10.1182/blood.V89.3.789; Barlogie B, 1999, BLOOD, V93, P55, DOI 10.1182/blood.V93.1.55.401k04_55_65; Barlogie B, 2001, BLOOD, V98, P492, DOI 10.1182/blood.V98.2.492; Bauer KS, 1998, BIOCHEM PHARMACOL, V55, P1827, DOI 10.1016/S0006-2952(98)00046-X; BENSINGER W, 2003, HEMATOL J S1, V4, pS215; BERENSON J, 2003, P AN M AM SOC CLIN, V22, P581; Berenson JR, 2002, BLOOD, V99, P3163, DOI 10.1182/blood.V99.9.3163; Berenson JR, 2001, CANCER-AM CANCER SOC, V91, P1956, DOI 10.1002/1097-0142(20010515)91:10<1956::AID-CNCR1219>3.0.CO;2-F; Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0; Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802; Blade J, 2003, BLOOD, V102, P3469, DOI 10.1182/blood-2003-01-0073; Blade J, 2003, BLOOD, V102, p42A; Blade J, 2000, ACTA ONCOL, V39, P843; Blade J, 2001, BRIT J HAEMATOL, V113, P422, DOI 10.1046/j.1365-2141.2001.02765.x; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; Casassus P, 2001, BRIT J HAEMATOL, V113, P1020; CAVO M, 1988, EUR J HAEMATOL, V40, P168; Cavo M, 2002, BLOOD, V100, p179A; Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340; Dimopoulos MA, 2003, J CLIN ONCOL, V21, P4444, DOI 10.1200/JCO.2003.07.200; Dimopoulos MA, 2001, ANN ONCOL, V12, P991, DOI 10.1023/A:1011132808904; Dispenzieri A, 2003, BLOOD, V102, p982A; Dredge K, 2002, BRIT J CANCER, V87, P1166, DOI 10.1038/sj.bjc.6600607; Einsele H, 2003, BRIT J HAEMATOL, V121, P411, DOI 10.1046/j.1365-2141.2003.04299.x; Eriksson T, 2001, EUR J CLIN PHARMACOL, V57, P365, DOI 10.1007/s002280100320; Facon T., 1996, Blood, V88, p685A; Fermand JP, 1998, BLOOD, V92, P3131, DOI 10.1182/blood.V92.9.3131.421k30_3131_3136; Fermand JP, 1999, BLOOD, V94, p396A; Fermand JP, 2003, HEMATOL J S1, V4, pS59; Gahrton G, 2001, BRIT J HAEMATOL, V113, P209, DOI 10.1046/j.1365-2141.2001.02726.x; Garcia-Sanz Ramon, 2002, Hematol J, V3, P43; Gertz MA, 1999, BONE MARROW TRANSPL, V23, P221, DOI 10.1038/sj.bmt.1701559; Gertz MA, 1995, LEUKEMIA, V9, P2115; Ghobrial IM, 2003, BONE MARROW TRANSPL, V32, P587, DOI 10.1038/sj.bmt.1704173; Ghobrial Irene M, 2003, J Support Oncol, V1, P194; Goldschmidt H, 1997, BRIT J HAEMATOL, V98, P736, DOI 10.1046/j.1365-2141.1997.2783095.x; Goldschmidt H, 2003, HEMATOL J S1, V4, pS61; GRABSTAL.H, 1965, CLIN PHARMACOL THER, V6, P298; Grignani G, 1996, BRIT J CANCER, V73, P1101, DOI 10.1038/bjc.1996.212; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2001, SEMIN ONCOL, V28, P607, DOI 10.1053/sonc.2001.28608; HJORTH M, 1993, EUR J HAEMATOL, V50, P95; Hussein MA, 2002, CANCER-AM CANCER SOC, V95, P2160, DOI 10.1002/cncr.10946; JAGANNATH S, 2003, P AN M AM SOC CLIN, V22, P582; Juliusson G, 2000, BRIT J HAEMATOL, V109, P89, DOI 10.1046/j.1365-2141.2000.01983.x; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Kumar A, 2003, LANCET ONCOL, V4, P293, DOI 10.1016/S1470-2045(03)01077-5; Kumar S, 2003, MAYO CLIN PROC, V78, P34, DOI 10.4065/78.1.34; Kyle RA, 2003, BRIT J HAEMATOL, V121, P749; Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21; Kyle RA, 2002, NEW ENGL J MED, V346, P564, DOI 10.1056/NEJMoa01133202; Kyle RA, 2004, CECIL TXB MED, P1184; LeBlanc R, 2002, CANCER RES, V62, P4996; LEE S, 2003, P AN M AM SOC CLIN, V22, P582; LENZ W, 1962, LANCET, V1, P45; Lokhorst HM, 2003, J CLIN ONCOL, V21, P1728, DOI 10.1200/JCO.2003.04.033; Maloney DG, 2003, BLOOD, V102, P3447, DOI 10.1182/blood-2002-09-2955; Maloney DG, 2001, BLOOD, V98, p434A; Mehta J, 1998, BONE MARROW TRANSPL, V22, P835, DOI 10.1038/sj.bmt.1701459; Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Moreau P, 2003, BLOOD, V102, p43A; Moreau P, 2002, BLOOD, V99, P731, DOI 10.1182/blood.V99.3.731; Munshi NC, 2001, ONCOLOGIST, V6, P17, DOI 10.1634/theoncologist.6-suppl_2-17; OLSON KB, 1965, CLIN PHARMACOL THER, V6, P292; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; ORLOWSKI RZ, 2003, P AN M AM SOC CLIN, V22, P200; Osman K, 2001, NEW ENGL J MED, V344, P1951, DOI 10.1056/NEJM200106213442516; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Palumbo A, 2003, BLOOD, V102, p148A; Palumbo A, 2003, BLOOD, V102, p984A; Palumbo A, 2001, HAEMATOLOGICA, V86, P399; Pasquali S, 1998, J CLIN ONCOL, V16, P3832; Rajkumar SV, 2000, MAYO CLIN PROC, V75, P897, DOI 10.4065/75.9.897; Rajkumar SV, 1999, HEMATOL ONCOL CLIN N, V13, P1295, DOI 10.1016/S0889-8588(05)70128-3; Rajkumar SV, 1999, BONE MARROW TRANSPL, V23, P1267, DOI 10.1038/sj.bmt.1701805; Rajkumar SV, 2003, LEUKEMIA, V17, P775, DOI 10.1038/sj.leu.2402866; Rajkumar SV, 2002, J HEMATOTH STEM CELL, V11, P33, DOI 10.1089/152581602753448522; Rajkumar SV, 2002, CLIN CANCER RES, V8, P2210; Rajkumar SV, 2002, MAYO CLIN PROC, V77, P813, DOI 10.4065/77.8.813; Rajkumar SV, 2002, J CLIN ONCOL, V20, P4319, DOI 10.1200/JCO.2002.02.116; Rajkumar SV, 2001, LEUKEMIA, V15, P1274, DOI 10.1038/sj.leu.2402183; RAJKUMAR SV, 2004, P AN M AM SOC CLIN, V23, P558; Richardson P, 2003, CANCER TREAT REV, V29, P33, DOI 10.1016/S0305-7372(03)00080-X; RICHARDSON P, 2004, P AN M AM SOC CLIN, V23, P558; RICHARDSON P, 2003, P AM SOC CLIN ONCL, V22, P581; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Richardson PG, 2003, BLOOD, V102, p235A; Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood-2002-03-0996; Roodman GD, 2002, J BONE MINER RES, V17, P1921, DOI 10.1359/jbmr.2002.17.11.1921; Seidl S, 2003, LANCET ONCOL, V4, P557, DOI 10.1016/S1470-2045(03)01195-1; Shaughnessy J, 2003, MAYO CLIN PROC, V78, P1098, DOI 10.4065/78.9.1098; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Singhal S, 2000, NEW ENGL J MED, V342, P364; Sirohi B, 2001, BLOOD, V98, p402A; Srkalovic G, 2002, MED ONCOL, V19, P219, DOI 10.1385/MO:19:4:219; Stewart AK, 2001, J CLIN ONCOL, V19, P3771, DOI 10.1200/JCO.2001.19.17.3771; Streetly M, 2003, BLOOD, V102, p236A; Weber D, 2003, J CLIN ONCOL, V21, P16, DOI 10.1200/JCO.2003.03.139; Weber DM, 2000, BLOOD, V96, p167A; YANG H, 2003, P AN M AM SOC CLIN, V22, P582; Zangari M, 2002, BLOOD, V100, P1168, DOI 10.1182/blood-2002-01-0335; Zangari M, 2001, BLOOD, V98, p775A; Zangari M, 2001, BLOOD, V98, P1614, DOI 10.1182/blood.V98.5.1614; Zeldis JB, 1999, CLIN THER, V21, P319, DOI 10.1016/S0149-2918(00)88289-2	123	1136	1215	0	122	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1860	1873		10.1056/NEJMra041875	http://dx.doi.org/10.1056/NEJMra041875			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509819				2022-12-28	WOS:000224723100009
J	Ali, K; Bilancio, A; Thomas, M; Pearce, W; Gilfillan, AM; Tkaczyk, C; Kuehn, N; Gray, A; Giddings, J; Peskett, E; Fox, R; Bruce, I; Walker, C; Sawyer, C; Okkenhaug, K; Finan, P; Vanhaesebroeck, B				Ali, K; Bilancio, A; Thomas, M; Pearce, W; Gilfillan, AM; Tkaczyk, C; Kuehn, N; Gray, A; Giddings, J; Peskett, E; Fox, R; Bruce, I; Walker, C; Sawyer, C; Okkenhaug, K; Finan, P; Vanhaesebroeck, B			Essential role for the p110 delta phosphoinositide 3-kinase in the allergic response	NATURE			English	Article							FC-EPSILON-RI; INCREASED INSULIN SENSITIVITY; MAST-CELL ACTIVATION; MICE LACKING; P85-ALPHA SUBUNIT; P110 DELTA; KIT; DIFFERENTIATION; HYPOGLYCEMIA; SURVIVAL	Inflammatory substances released by mast cells induce and maintain the allergic response(1,2). Mast cell differentiation and activation are regulated, respectively, by stem cell factor (SCF; also known as Kit ligand) and by allergen in complex with allergen-specific immunoglobulin E (IgE)(2,3). Activated SCF receptors and high-affinity receptors for IgE (FcepsilonRI) engage phosphoinositide 3-kinases (PI(3)Ks) to generate intracellular lipid second messenger signals(2-5). Here, we report that genetic or pharmacological inactivation of the p110delta isoform of PI(3) K in mast cells leads to defective SCF-mediated in vitro proliferation, adhesion and migration, and to impaired allergen-IgE-induced degranulation and cytokine release. Inactivation of p110delta protects mice against anaphylactic allergic responses. These results identify p110delta as a new target for therapeutic intervention in allergy and mast-cell-related pathologies.	Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Novartis Inst Biomed Res, Horsham RH12 5AB, W Sussex, England; NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; Frimorfo, CH-1705 Fribourg, Switzerland; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland	Ludwig Institute for Cancer Research; University of London; University College London; Novartis; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Dundee	Vanhaesebroeck, B (corresponding author), Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	bartvanh@ludwig.ucl.ac.uk	Okkenhaug, Klaus/D-5149-2012; Okkenhaug, Klaus/H-3154-2019	Okkenhaug, Klaus/0000-0002-9432-4051; Okkenhaug, Klaus/0000-0002-9432-4051; Pearce, Wayne/0000-0001-5407-4767; Thomas, Matthew/0000-0003-3472-3904; Peskett, Emma/0000-0002-0978-5401; Box, Carol/0000-0002-8919-8724; Gray, Alexander/0000-0001-9227-0363; BILANCIO, Antonio/0000-0002-5118-3359	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000850] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; Campbell E, 1999, AM J PATHOL, V154, P1259, DOI 10.1016/S0002-9440(10)65377-1; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Chen D, 2004, MOL CELL BIOL, V24, P320, DOI 10.1128/MCB.24.1.320-329.2004; Fruman DA, 2000, NAT GENET, V26, P379, DOI 10.1038/81715; Fukao T, 2003, J MOL MED, V81, P524, DOI 10.1007/s00109-003-0475-2; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Gray A, 2003, ANAL BIOCHEM, V313, P234, DOI 10.1016/S0003-2697(02)00607-3; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Hundley TR, 2004, BLOOD, V104, P2410, DOI 10.1182/blood-2004-02-0631; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Lu-Kuo JM, 2000, J BIOL CHEM, V275, P6022, DOI 10.1074/jbc.275.8.6022; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; Okayama Y, 2003, EUR J IMMUNOL, V33, P1450, DOI 10.1002/eji.200323563; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Okkenhaug K, 2002, SCIENCE, V297, P1031; Rivera J, 2002, MOL IMMUNOL, V38, P1253, DOI 10.1016/S0161-5890(02)00072-X; Sadhu C, 2003, BIOCHEM BIOPH RES CO, V308, P764, DOI 10.1016/S0006-291X(03)01480-3; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Tan BL, 2003, BLOOD, V101, P4725, DOI 10.1182/blood-2002-08-2521; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Tilley SL, 2000, J CLIN INVEST, V105, P361, DOI 10.1172/JCI8253; Tkaczyk C, 2003, J BIOL CHEM, V278, P48474, DOI 10.1074/jbc.M301350200; Ueki K, 2002, P NATL ACAD SCI USA, V99, P419, DOI 10.1073/pnas.012581799; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Wedemeyer J, 2000, BRIT MED BULL, V56, P936, DOI 10.1258/0007142001903616; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9	30	336	413	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					1007	1011		10.1038/nature02991	http://dx.doi.org/10.1038/nature02991			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496927	Bronze			2022-12-28	WOS:000224585600049
J	Yamamoto, KR				Yamamoto, KR			Bankrolling stem-cell research with California dollars	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Yamamoto, KR (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.								0	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2004	351	17					1711	1713		10.1056/NEJMp048224	http://dx.doi.org/10.1056/NEJMp048224			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	863TH	15496617				2022-12-28	WOS:000224585200003
J	Martin, MD				Martin, MD			Shower time	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Martin, MD (corresponding author), 2901 Montopolis Dr, Austin, TX 78741 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	2004	141	8					647	647		10.7326/0003-4819-141-8-200410190-00017	http://dx.doi.org/10.7326/0003-4819-141-8-200410190-00017			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864SD	15492347				2022-12-28	WOS:000224652300011
J	Fowlie, PW; Booth, P; Skeoch, CH				Fowlie, PW; Booth, P; Skeoch, CH			ABC of preterm birth - Moving the preterm infant	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LONG-TERM METHYLPHENIDATE; CHILDREN; ADHD		Perth Royal Infirm, Perth, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Aberdeen Matern Hosp, Aberdeen, Scotland; Princess Royal Matern Hosp, Glasgow, Lanark, Scotland	University of Dundee; University of Aberdeen	Fowlie, PW (corresponding author), Perth Royal Infirm, Perth, Scotland.							Abikoff H, 2004, J AM ACAD CHILD PSY, V43, P802, DOI 10.1097/01.chi.0000128791.10014.ac; BARRY P, 2003, PAEDIAT NEONATAL CRI; *BRIT ASS PER MED, 1996, STAND HOSP PROV NEON; Davis PJ, 2001, ACTA PAEDIATR, V90, P1068; Hechtman L, 2004, J AM ACAD CHILD PSY, V43, P812, DOI 10.1097/01.chi.0000128796.84202.eb; Jensen PS, 1999, J AM ACAD CHILD PSY, V38, P797, DOI 10.1097/00004583-199907000-00008; Leslie AJ, 1997, ACTA PAEDIATR, V86, P1253, DOI 10.1111/j.1651-2227.1997.tb14856.x; *MED DEV AG, 1995, REP TLNA COMM; PHILP AV, 2002, MENTAL HLTH SCOTLAND, P55; RHODES SM, 2004, PSYCHOPHARMACOL 0508; Shlossman PA, 1997, AM J PERINAT, V14, P449, DOI 10.1055/s-2007-994178; TANNOCK R, 1995, J ABNORM CHILD PSYCH, V23, P235, DOI 10.1007/BF01447091; Wolraich ML, 2003, J CHILD PSYCHOL PSYC, V44, P159, DOI 10.1111/1469-7610.00110	13	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	2004	329	7471					904	906A		10.1136/bmj.329.7471.904	http://dx.doi.org/10.1136/bmj.329.7471.904			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863MU	15485974	Green Published			2022-12-28	WOS:000224566800026
J	Hahnestad, YS; Lie, RT; Rortveit, G; Hunskaar, S				Hahnestad, YS; Lie, RT; Rortveit, G; Hunskaar, S			Familial risk of urinary incontinence in women: population based cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							NORWEGIAN EPINCONT; EPIDEMIOLOGIC SURVEY; COMMON OUTCOMES; RELATIVE RISK; PREVALENCE; COMMUNITY; HISTORY; COHORT; INDEX; LIFE	Objective To determine whether there is an increased risk of urinary incontinence in daughters and sisters of incontinent women. Design Population based cross sectional study. Setting EPINCONT (the epidemiology of incontinence in the count), of Nord-Trondelag studyy, a substudy of HUNT 2 (die Norwegian Nord-Trondelag health survey 2),1995-7. Participants 6021 mothers, 7629 daughters, 332 granddaughters, and 2104 older sisters of 2426 sisters. Main outcome measures Adjusted relative risks for urinary incontinence. Results The daughters of mothers with urinary incontinence had an increased risk for urinary incontinence (1.3, 95% confidence interval 1.2 to 1.4; absolute risk 23.3%), stress incontinence (1.5,1.3 to 1.8; 14.6%), mixed incontinence (1.6,1.2 to 2.0; 8.3%), and urge incontinence (1.8, 0.8 to 3.9; 2.6%). If mothers had severe symptoms then their daughters were likely to have such symptoms (1.9, 1.3 to 3.0; 4.0%). The younger sisters of female siblings with urinary incontinence, stress incontinence, or mixed incontinence had increased relative risks of, respectively, 1.6 (1.3 to 1.9; absolute risk 29.6%),1.8 (1.3 to 2.3; 18.3%), and 1.7 (1.1 to 2.8; 10.8%). Conclusion Women are more likely to develop urinary incontinence if their mother or older sisters are incontinent.	Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Sect Gen Practice, N-5018 Bergen, Norway; Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Sect Epidemiol & Med Stat, N-5018 Bergen, Norway	University of Bergen; University of Bergen	Hahnestad, YS (corresponding author), Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Sect Gen Practice, Kalfarveien 31, N-5018 Bergen, Norway.	Yngvild.hahnestad@isf.uib.no						Elia G, 2002, AM J OBSTET GYNECOL, V187, P53, DOI 10.1067/mob.2002.124842; FitzGerald MP, 2002, NEUROUROL URODYNAM, V21, P30, DOI 10.1002/nau.2116; Hannestad YS, 2003, BJOG-INT J OBSTET GY, V110, P247, DOI 10.1016/S1470-0328(02)02927-0; Hannestad YS, 2002, SCAND J PRIM HEALTH, V20, P102, DOI 10.1080/713796408; Hannestad YS, 2000, J CLIN EPIDEMIOL, V53, P1150, DOI 10.1016/S0895-4356(00)00232-8; Hunskaar S, 2000, INT UROGYNECOL J, V11, P301, DOI 10.1007/s001920070021; JENSEN JK, 1994, OBSTET GYNECOL, V83, P904; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; MOMMSEN S, 1994, WORLD J UROL, V12, P319; Mushkat Y, 1996, AM J OBSTET GYNECOL, V174, P617, DOI 10.1016/S0002-9378(96)70437-4; REKERS H, 1992, EUR J OBSTET GYN R B, V43, P229, DOI 10.1016/0028-2243(92)90178-2; Rortveit G, 2001, OBSTET GYNECOL, V98, P1004, DOI 10.1016/S0029-7844(01)01566-6; Rortveit G, 2003, NEW ENGL J MED, V348, P900, DOI 10.1056/NEJMoa021788; Sandvik H, 2000, NEUROUROL URODYNAM, V19, P137, DOI 10.1002/(SICI)1520-6777(2000)19:2<137::AID-NAU4>3.0.CO;2-G; SANDVIK H, 1995, J CLIN EPIDEMIOL, V48, P339, DOI 10.1016/0895-4356(94)00147-I; Schulman C, 1997, EUR UROL, V32, P315; Thom D, 1998, J AM GERIATR SOC, V46, P473, DOI 10.1111/j.1532-5415.1998.tb02469.x; Thom DH, 1997, OBSTET GYNECOL, V90, P983, DOI 10.1016/S0029-7844(97)00537-1; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	19	77	80	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 16	2004	329	7471					889	891		10.1136/bmj.329.7471.889	http://dx.doi.org/10.1136/bmj.329.7471.889			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863MU	15485965	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000224566800017
J	Grima, B; Chelot, E; Xia, RH; Rouyer, F				Grima, B; Chelot, E; Xia, RH; Rouyer, F			Morning and evening peaks of activity rely on different clock neurons of the Drosophila brain	NATURE			English	Article							CIRCADIAN PACEMAKER CELLS; BEHAVIORAL RHYTHMS; NERVOUS-SYSTEM; PERIOD; GENE; MELANOGASTER; OSCILLATIONS; NEUROPEPTIDE; PROJECTIONS; MUTATION	In Drosophila, a 'clock' situated in the brain controls circadian rhythms of locomotor activity. This clock relies on several groups of neurons that express the Period ( PER) protein, including the ventral lateral neurons (LN(v)s), which express the Pigment-dispersing factor (PDF) neuropeptide, and the PDF-negative dorsal lateral neurons (LN(d)s)(1). In normal cycles of day and night, adult flies exhibit morning and evening peaks of activity(1,2); however, the contribution of the different clock neurons to the rest activity pattern remains unknown. Here, we have used targeted expression of PER to restore the clock function of specific subsets of lateral neurons in arrhythmic per 0 mutant flies. We show that PER expression restricted to the LNvs only restores the morning activity, whereas expression of PER in both the LNvs and LNds also restores the evening activity. This provides the first neuronal bases for 'morning' and 'evening' oscillators in the Drosophila brain. Furthermore, we show that the LNvs alone can generate 24 h activity rhythms in constant darkness, indicating that the morning oscillator is sufficient to drive the circadian system.	CNRS, UPR 2216, NGI, Inst Neurobiol Alfred Fessard, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Rouyer, F (corresponding author), CNRS, UPR 2216, NGI, Inst Neurobiol Alfred Fessard, Av Terrasse, F-91198 Gif Sur Yvette, France.	rouyer@iaf.cnrs-gif.fr	Rouyer, François/L-9043-2018	Rouyer, François/0000-0001-5641-397X				Blanchardon E, 2001, EUR J NEUROSCI, V13, P871, DOI 10.1046/j.0953-816x.2000.01450.x; Cheng YZ, 1998, J NEUROSCI, V18, P741; de la Iglesia HO, 2000, SCIENCE, V290, P799, DOI 10.1126/science.290.5492.799; Dunlap J.C., 2004, CHRONOBIOLOGY BIOL T; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; HALLIBURTON IW, 1980, J GEN VIROL, V48, P1, DOI 10.1099/0022-1317-48-1-1; Helfrich-Forster C, 2000, J BIOL RHYTHM, V15, P135, DOI 10.1177/074873040001500208; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; ITO K, 1995, ROUX ARCH DEV BIOL, V204, P284, DOI 10.1007/BF02179499; Jagota A, 2000, NAT NEUROSCI, V3, P372, DOI 10.1038/73943; Kaneko M, 2000, J COMP NEUROL, V422, P66, DOI 10.1002/(SICI)1096-9861(20000619)422:1<66::AID-CNE5>3.0.CO;2-2; Kaneko M, 2000, J NEUROBIOL, V43, P207, DOI 10.1002/(SICI)1097-4695(20000605)43:3<207::AID-NEU1>3.0.CO;2-0; Klarsfeld A, 2004, J NEUROSCI, V24, P1468, DOI 10.1523/JNEUROSCI.3661-03.2004; Klarsfeld A, 2003, BEHAV PROCESS, V64, P161, DOI 10.1016/S0376-6357(03)00133-5; Malpel S, 2002, DEVELOPMENT, V129, P1443; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P333, DOI 10.1007/BF01417860; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Siegmund T, 2001, J COMP NEUROL, V431, P481, DOI 10.1002/1096-9861(20010319)431:4<481::AID-CNE1084>3.0.CO;2-7; Taghert PH, 2001, J NEUROSCI, V21, P6673, DOI 10.1523/JNEUROSCI.21-17-06673.2001; Yang ZH, 2001, NEURON, V29, P453, DOI 10.1016/S0896-6273(01)00218-5; Yoshii T, 2004, J INSECT PHYSIOL, V50, P479, DOI 10.1016/j.jinsphys.2004.02.011	21	484	495	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					869	873		10.1038/nature02935	http://dx.doi.org/10.1038/nature02935			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483616				2022-12-28	WOS:000224435500052
J	Heekeren, HR; Marrett, S; Bandettini, PA; Ungerleider, LG				Heekeren, HR; Marrett, S; Bandettini, PA; Ungerleider, LG			A general mechanism for perceptual decision-making in the human brain	NATURE			English	Article							HUMAN EXTRASTRIATE CORTEX; PREFRONTAL CORTEX; NEURAL BASIS; REPRESENTATION; ATTENTION; OBJECTS; MICROSTIMULATION; MEMORY; FACES; AREA	Findings from single-cell recording studies suggest that a comparison of the outputs of different pools of selectively tuned lower-level sensory neurons may be a general mechanism by which higher-level brain regions compute perceptual decisions. For example, when monkeys must decide whether a noisy field of dots is moving upward or downward, a decision can be formed by computing the difference in responses between lower-level neurons sensitive to upward motion and those sensitive to downward motion(1-4). Here we use functional magnetic resonance imaging and a categorization task in which subjects decide whether an image presented is a face or a house to test whether a similar mechanism is also at work for more complex decisions in the human brain and, if so, where in the brain this computation might be performed. Activity within the left dorsolateral prefrontal cortex is greater during easy decisions than during difficult decisions, covaries with the difference signal between face- and house-selective regions in the ventral temporal cortex, and predicts behavioural performance in the categorization task. These findings show that even for complex object categories, the comparison of the outputs of different pools of selectively tuned neurons could be a general mechanism by which the human brain computes perceptual decisions.	NIMH, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA; NIMH, Funct MRI Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Heekeren, HR (corresponding author), NIMH, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA.	hauke@nih.gov	Heekeren, Hauke/B-7739-2008; Bandettini, Peter A./F-5871-2012	Heekeren, Hauke/0000-0001-7912-6826; Marrett, Sean/0000-0001-8179-6511	NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002035, Z01MH002035, ZIAMH002783, Z01MH002783] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Ditterich J, 2003, NAT NEUROSCI, V6, P891, DOI 10.1038/nn1094; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; Gold JI, 2001, TRENDS COGN SCI, V5, P10, DOI 10.1016/S1364-6613(00)01567-9; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; HAXBY JV, 1994, J NEUROSCI, V14, P6336; HEEKEREN HR, 2002, SOC NEUR ABSTR; Hernandez A, 2002, NEURON, V33, P959, DOI 10.1016/S0896-6273(02)00613-X; Ishai A, 1999, P NATL ACAD SCI USA, V96, P9379, DOI 10.1073/pnas.96.16.9379; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kim JN, 1999, NAT NEUROSCI, V2, P176, DOI 10.1038/5739; Koechlin E, 2003, SCIENCE, V302, P1181, DOI 10.1126/science.1088545; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; McCarthy G, 1997, J COGNITIVE NEUROSCI, V9, P605, DOI 10.1162/jocn.1997.9.5.605; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; Pessoa L, 2003, J NEUROSCI, V23, P3990; PETRIDES M, 1985, BEHAV BRAIN RES, V16, P95, DOI 10.1016/0166-4328(85)90085-3; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; Rainer G, 2000, NEURON, V27, P179, DOI 10.1016/S0896-6273(00)00019-2; Romo R, 2003, NAT REV NEUROSCI, V4, P203, DOI 10.1038/nrn1058; Romo R, 2003, NEURON, V38, P649, DOI 10.1016/S0896-6273(03)00287-3; SALZMAN CD, 1990, NATURE, V346, P174, DOI 10.1038/346174a0; Schall JD, 2001, NAT REV NEUROSCI, V2, P33, DOI 10.1038/35049054; Shadlen MN, 2001, J NEUROPHYSIOL, V86, P1916, DOI 10.1152/jn.2001.86.4.1916; Shadlen MN, 1996, J NEUROSCI, V16, P1486; Sharma J, 2003, SCIENCE, V300, P1758, DOI 10.1126/science.1081721; Sugrue LP, 2004, SCIENCE, V304, P1782, DOI 10.1126/science.1094765; Woolrich MW, 2001, NEUROIMAGE, V14, P1370, DOI 10.1006/nimg.2001.0931	31	506	512	2	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					859	862		10.1038/nature02966	http://dx.doi.org/10.1038/nature02966			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483614				2022-12-28	WOS:000224435500050
J	Montague, PR; Hyman, SE; Cohen, JD				Montague, PR; Hyman, SE; Cohen, JD			Computational roles for dopamine in behavioural control	NATURE			English	Article							MEDIAL FRONTAL-CORTEX; PREFRONTAL CORTEX; NEURAL RESPONSES; HUMAN BRAIN; TEMPORAL PREDICTION; MONETARY GAINS; REWARD; ERROR; REINFORCEMENT; ADDICTION	Neuromodulators such as dopamine have a central role in cognitive disorders. In the past decade, biological findings on dopamine function have been infused with concepts taken from computational theories of reinforcement learning. These more abstract approaches have now been applied to describe the biological algorithms at play in our brains when we form value judgements and make choices. The application of such quantitative models has opened up new fields, ripe for attack by young synthesizers and theoreticians.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Harvard Univ, Cambridge, MA 02138 USA; Princeton Univ, Ctr Study Brain Mind & Behav, Dept Psychol, Princeton, NJ 08544 USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA	Baylor College of Medicine; Baylor College of Medicine; Harvard University; Princeton University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Montague, PR (corresponding author), Baylor Coll Med, Div Neurosci, 1 Baylor Plaza, Houston, TX 77030 USA.	read@bcm.tmc.edu; seh@harvard.edu; jdc@princeton.edu						Aharon I, 2001, NEURON, V32, P537, DOI 10.1016/S0896-6273(01)00491-3; [Anonymous], 1996, NEURO DYNAMIC PROGRA; Balleine BW, 2000, J NEUROSCI, V20, P8954; BAYER HM, 2002, SOC NEUR ABSTR, V28; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Berns GS, 2001, J NEUROSCI, V21, P2793, DOI 10.1523/JNEUROSCI.21-08-02793.2001; Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; Berridge KC, 2001, PSYCHOL LEARN MOTIV, V40, P223, DOI 10.1016/s0079-7421(00)80022-5; Braver TS, 2000, CONTROL OF COGNITIVE PROCESSES: ATTENTION AND PERFORMANCE XVIII, P713; Breiter HC, 2001, NEURON, V30, P619, DOI 10.1016/S0896-6273(01)00303-8; Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8; COHEN B M, 1981, Mclean Hospital Journal, V6, P95; Daw ND, 2002, NEURAL NETWORKS, V15, P603, DOI 10.1016/S0893-6080(02)00052-7; Dayan P, 2002, NEURON, V36, P285, DOI 10.1016/S0896-6273(02)00963-7; Dayan P., 2001, THEORETICAL NEUROSCI, P331; Delgado MR, 2000, J NEUROPHYSIOL, V84, P3072, DOI 10.1152/jn.2000.84.6.3072; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; Doya K, 2002, NEURAL NETWORKS, V15, P495, DOI 10.1016/S0893-6080(02)00044-8; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; Egelman DM, 1998, J COGNITIVE NEUROSCI, V10, P623, DOI 10.1162/089892998563022; Elliott R, 2000, J NEUROSCI, V20, P6159, DOI 10.1523/JNEUROSCI.20-16-06159.2000; Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x; Falkenstein M, 1995, EEG CL N SU, P287; FRISTON KJ, 1994, NEUROSCIENCE, V59, P229, DOI 10.1016/0306-4522(94)90592-4; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gehring WJ, 2002, SCIENCE, V295, P2279, DOI 10.1126/science.1066893; Hollerman JR, 1998, NAT NEUROSCI, V1, P304, DOI 10.1038/1124; Holroyd CB, 2004, NAT NEUROSCI, V7, P497, DOI 10.1038/nn1238; Holroyd CB, 2004, PSYCHOPHYSIOLOGY, V41, P245, DOI 10.1111/j.1469-8986.2004.00152.x; Holroyd CB, 2003, NEUROREPORT, V14, P2481, DOI 10.1097/00001756-200312190-00037; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Houk JC, 1995, MODELS INFORMATION P, P249; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; Ikemoto S, 1999, BRAIN RES REV, V31, P6, DOI 10.1016/S0165-0173(99)00023-5; Ikemoto S, 1996, BEHAV NEUROSCI, V110, P331, DOI 10.1037/0735-7044.110.2.331; Knutson B, 2000, NEUROIMAGE, V12, P20, DOI 10.1006/nimg.2000.0593; KNUTSON B, 2001, J NEUROSCI, V15, P1; Koechlin E, 2003, SCIENCE, V302, P1181, DOI 10.1126/science.1088545; McClure SM, 2003, NEURON, V38, P339, DOI 10.1016/S0896-6273(03)00154-5; McClure SM, 2003, TRENDS NEUROSCI, V26, P423, DOI 10.1016/S0166-2236(03)00177-2; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; Miller EK, 1996, J NEUROSCI, V16, P5154; Montague PR, 2002, NEURON, V36, P265, DOI 10.1016/S0896-6273(02)00974-1; Montague PR, 2004, J NEUROSCI, V24, P1754, DOI 10.1523/JNEUROSCI.4279-03.2004; Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996; Nieuwenhuis S, 2004, CEREB CORTEX, V14, P741, DOI 10.1093/cercor/bhh034; O'Doherty J, 2004, SCIENCE, V304, P452, DOI 10.1126/science.1094285; O'Doherty JP, 2002, NEURON, V33, P815, DOI 10.1016/S0896-6273(02)00603-7; O'Doherty JP, 2003, NEURON, V38, P329, DOI 10.1016/S0896-6273(03)00169-7; O'Reilly RC, 2002, CEREB CORTEX, V12, P246, DOI 10.1093/cercor/12.3.246; OReilly R., 1999, MODELS WORKING MEMOR, P375, DOI [10.1017/cbo9781139174909.014, DOI 10.1017/CBO9781139174909.014]; Pagnoni G, 2002, NAT NEUROSCI, V5, P97, DOI 10.1038/nn802; Potenza MN, 2003, ARCH GEN PSYCHIAT, V60, P828, DOI 10.1001/archpsyc.60.8.828; Redgrave P, 1999, TRENDS NEUROSCI, V22, P146, DOI 10.1016/S0166-2236(98)01373-3; Rescorla R.A., 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1101/GR.110528.110; Rougier NP, 2002, COGNITIVE SCI, V26, P503, DOI 10.1207/s15516709cog2604_4; Salamone JD, 2002, BEHAV BRAIN RES, V137, P3, DOI 10.1016/S0166-4328(02)00282-6; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1; SCHULTZ W, 1993, J NEUROSCI, V13, P900; SERVANSCHREIBER D, 1990, SCIENCE, V249, P892, DOI 10.1126/science.2392679; Shallice T., 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; SKINNER BF, 1963, SCIENCE, V140, P951, DOI 10.1126/science.140.3570.951; Stuss D. T., 2002, PR FRONTAL LOBE FUNC, P392; Sutton R. S., 1988, Machine Learning, V3, P9, DOI 10.1023/A:1022633531479; Thut G, 1997, NEUROREPORT, V8, P1225, DOI 10.1097/00001756-199703240-00033; Ullsperger M, 2003, J NEUROSCI, V23, P4308, DOI 10.1523/jneurosci.23-10-04308.2003; Waelti P, 2001, NATURE, V412, P43, DOI 10.1038/35083500; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469	72	641	660	3	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					760	767		10.1038/nature03015	http://dx.doi.org/10.1038/nature03015			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	861RE	15483596				2022-12-28	WOS:000224435500031
J	Hawton, K; Simkin, S; Deeks, J; Cooper, J; Johnston, A; Waters, K; Arundel, M; Bernal, W; Gunson, B; Hudson, M; Suri, D; Simpson, K				Hawton, K; Simkin, S; Deeks, J; Cooper, J; Johnston, A; Waters, K; Arundel, M; Bernal, W; Gunson, B; Hudson, M; Suri, D; Simpson, K			UK legislation on analgesic packs: before and after study of long term effect on poisonings	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DELIBERATE SELF-HARM; UNITED-KINGDOM; PARACETAMOL; OVERDOSE; AVAILABILITY; SUICIDE; RESTRICTION; ADOLESCENTS; PREVENTION; REDUCTION	Objective To evaluate the long term effect of legislation limiting the size of packs of analgesics sold over the counter. Design Before and after study. Setting Suicides in England and Wales, data from six liver units in England and Scotland and five general hospitals in England, and UK data on sales of analgesics, between September 1993 and September 2002. Data sources Office for National Statistics; six liver units in England and Scotland; monitoring systems in general hospitals in Oxford, Manchester, and Derby; and Intercontinental Medical Statistics Health UK. Main outcome measures Deaths by suicidal overdose with paracetamol, salicylates, or ibuprofen; numbers of patients admitted to liver units, listed for liver transplant, and undergoing transplantations for paracetamol induced hepatotoxicity; non-fatal self poisonings with analgesics and numbers of tablets taken; and sales figures for analgesics. Results Suicide deaths from paracetamol and salicylates were reduced by 22% (95% confidence interval 11% to 32%) in the year after the change in legislation on 16 September 1998, and this reduction persisted in the next two years. Liver unit admissions and liver transplants for paracetamol induced hepatotoxicity were reduced by around 30% in the four years after the legislation. Numbers of paracetamol and salicylate tablets in non-fatal overdoses were reduced in the three years after the legislation. Large overdoses were reduced by 20% (9% to 29%) for paracetamol and by 39% (14% to 57%) for salicylates in the second and third years after the legislation. Ibuprofen overdoses increased after the legislation, but with little or no effect on deaths. Conclusion Legislation restricting pack sizes of analgesics in the United Kingdom has been beneficial. A further reduction in pack sizes could prevent more deaths.	Univ Oxford, Warneford Hosp, Dept Psychiat, Ctr Suicide Res, Oxford OX3 7JX, England; Univ Manchester, Ctr Suicide Prevent, Manchester M13 9PL, Lancs, England; Derbyshire Royal Infirm, Mental Hlth Resource Ctr, Derby DE1 2QY, England; St James Univ Hosp, Dept Hepatol, Leeds LS9 7TF, W Yorkshire, England; Kings Coll Hosp London, Inst Liver Studies, London SE5 9RS, England; Queen Elizabeth Hosp, Liver Labs, Birmingham B15 2TH, W Midlands, England; Freeman Rd Hosp, Liver Unit, Newcastle Upon Tyne NE7 7ND, Tyne & Wear, England; Royal Free Hosp, London NW3 2QG, England; Univ Edinburgh, Royal Infirm, Dept Med, Edinburgh EH3 9YW, Midlothian, Scotland	University of Oxford; University of Manchester; Saint James's University Hospital; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Birmingham; Newcastle Freeman Hospital; Newcastle University - UK; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Royal Infirmary of Edinburgh; University of Edinburgh	Hawton, K (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Ctr Suicide Res, Oxford OX3 7JX, England.	keith.hawton@psych.ox.ac.uk	Deeks, Jon/AAV-5745-2020; Waters, Keith/AAH-5503-2019	Deeks, Jon/0000-0002-8850-1971; Waters, Keith/0000-0002-5031-0870; Gunson, Bridget/0000-0001-6149-9915				Bialas MC, 1996, QJM-INT J MED, V89, P893; Borna P, 2001, NORD J PSYCHIAT, V55, P325, DOI 10.1080/080394801317080828; BUCKLEY NA, 1995, MED J AUSTRALIA, V162, P190, DOI 10.5694/j.1326-5377.1995.tb126020.x; Gunnell D, 1997, J EPIDEMIOL COMMUN H, V51, P175, DOI 10.1136/jech.51.2.175; Gunnell D, 1997, CURRENT PROBLEMS PHA, V23, P9; HAWTON K, 1995, BRIT MED J, V310, P164, DOI 10.1136/bmj.310.6973.164; Hawton K, 2002, SUICIDE LIFE-THREAT, V32, P223, DOI 10.1521/suli.32.3.223.22169; Hawton K, 2001, BMJ-BRIT MED J, V322, P1203, DOI 10.1136/bmj.322.7296.1203; Hawton K, 1997, BRIT J PSYCHIAT, V171, P556, DOI 10.1192/bjp.171.6.556; HAWTON K, 1982, BRIT J PSYCHIAT, V141, P286, DOI 10.1192/bjp.141.3.286; Hawton K, 1996, BRIT J PSYCHIAT, V168, P43, DOI 10.1192/bjp.168.1.43; Laffoy M, 2001, Ir Med J, V94, P212; *OFF NAT STAT, 2003, HLTH STAT Q, V17, P65; *OFF NAT STAT, 2003, MORT STAT CAUS DH2, V29; OGRADY J, 1999, MEDICINE, V27, P80; Ostapowicz G, 2002, ANN INTERN MED, V137, P947, DOI 10.7326/0003-4819-137-12-200212170-00007; OTT P, 1990, J INTERN MED, V227, P423, DOI 10.1111/j.1365-2796.1990.tb00181.x; PRESCOTT LF, 1983, DRUGS, V25, P290, DOI 10.2165/00003495-198325030-00002; Prince MI, 2000, LANCET, V355, P2047, DOI 10.1016/S0140-6736(00)02354-0; Robinson D, 2000, BRIT MED J, V321, P926, DOI 10.1136/bmj.321.7266.926; Sheen CL, 2002, PHARMACOEPIDEM DR S, V11, P329, DOI 10.1002/pds.701; SMOLINSKE SC, 1990, DRUG SAFETY, V5, P252, DOI 10.2165/00002018-199005040-00003; Turvill JL, 2000, LANCET, V355, P2048, DOI 10.1016/S0140-6736(00)02355-2	23	175	177	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	2004	329	7474					1076	1079		10.1136/bmj.38253.572581.7C	http://dx.doi.org/10.1136/bmj.38253.572581.7C			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PN	15516343	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000225070300022
J	Hurwitz, CA; Duncan, J; Wolfe, J				Hurwitz, CA; Duncan, J; Wolfe, J			Caring for the child with cancer at the close of life - "There are people who make it, and I'm hoping I'm one of them"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEDIATRIC PALLIATIVE CARE; MALIGNANT-DISEASE; TERMINAL CANCER; ILL PATIENTS; SYMPTOMS; END; PAIN; METHYLPHENIDATE; HYDRATION; DYSPNEA	Approximately 25% of children with cancer die of their disease. Early in the course of a patient's illness, it is often impossible to determine whether the disease will be cured with cancer-directed treatment. When potentially curative therapy is no longer an option, the patient, family, and oncology team face enormous medical, psychological, and spiritual challenges. Optimal palliative care requires willingness on the part of the physician and caregiver team to engage the patient and family in discussions of their hopes and fears and to provide solace and support for emotional and physical pain. Using the comments of a child in the terminal phase of acute leukemia, his mother, and his physician, we describe opportunities and important lessons often revealed only when families and their caregivers face the end of a child's life. A broad-minded assessment of the patient's and family's physical, emotional, and spiritual needs and clarification of realistic goals and hopes not only improves the clinical care that the patient receives but also contributes to the sense of satisfaction and meaning that the physician can gain from the experience of caring for children at the end of life.	Dana Farber Canc Inst, Dept Pediat Oncol, Pediat Adv Care Team, Boston, MA 02115 USA; Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Maine Med Ctr, Maine Childrens Canc Program, Portland, ME USA; Maine Med Ctr, Barbara Bush Childrens Hosp, Portland, ME USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Maine Medical Center; Maine Medical Center	Wolfe, J (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, Pediat Adv Care Team, 44 Binney St, Boston, MA 02115 USA.	joanne_wolfe@dfci.harvard.edu						Abrahm J, 2000, PHYS GUIDE PAIN SYMP; ADAMS VD, 1986, J WATER POLLUT CON F, V58, P449; ADAMS-GREENLY M, 1991, Pediatrician, V18, P3; Allard P, 1999, J PAIN SYMPTOM MANAG, V17, P256, DOI 10.1016/S0885-3924(98)00157-2; ANGELL M, 1982, NEW ENGL J MED, V306, P98, DOI 10.1056/NEJM198201143060210; Back Anthony L, 2003, Ann Intern Med, V138, P439; Berger AM, 2002, PRINCIPLES PRACTICE; Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; BLUEBLONDLANGNE.M, 1978, PRIVATE WORLDS DYING; BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P365, DOI 10.1016/0885-3924(92)90091-U; BRUERA E, 1987, CANCER TREAT REP, V71, P67; Bruera E, 1996, SUPPORT CARE CANCER, V4, P147, DOI 10.1007/BF01845764; BRUERA E, 1993, ANN INTERN MED, V119, P906, DOI 10.7326/0003-4819-119-9-199311010-00007; Bruera Eduardo, 2002, J Palliat Med, V5, P127, DOI 10.1089/10966210252785097; BUCHAN ML, 1995, J CLIN ETHIC, V6, P53; Burns J P, 1997, New Horiz, V5, P72; Carrese JA, 2000, J GEN INTERN MED, V15, P92, DOI 10.1046/j.1525-1497.2000.03399.x; CHRIST G, 1984, CHILDHOOD CANCER IMP, P109; Christ GH, 2002, JAMA-J AM MED ASSOC, V288, P1269, DOI 10.1001/jama.288.10.1269; Christ GH, 2000, CANCER PRACT, V8, P72, DOI 10.1046/j.1523-5394.2000.82005.x; Collins JJ, 2000, J PAIN SYMPTOM MANAG, V19, P363, DOI 10.1016/S0885-3924(00)00127-5; Contro N, 2002, ARCH PEDIAT ADOL MED, V156, P14, DOI 10.1001/archpedi.156.1.14; Davis B, 2001, TXB PALLIATIVE NURSI, P363; Davis CL, 1997, BRIT MED J, V315, P931; Drake R, 2003, J PAIN SYMPTOM MANAG, V26, P594, DOI 10.1016/S0885-3924(03)00202-1; Escalante CP, 1996, CANCER, V78, P1314, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1314::AID-CNCR21>3.0.CO;2-2; Feudtner C, 2002, PEDIATRICS, V109, P887, DOI 10.1542/peds.109.5.887; Field M.J., 2003, CHILDREN DIE IMPROVI; HAIN RDW, 1995, PALLIATIVE MED, V9, P201, DOI 10.1177/026921639500900305; Hilden JM, 2001, IMPROVING PALLIATIVE, P161; Himelstein BP, 2004, NEW ENGL J MED, V350, P1752, DOI 10.1056/NEJMra030334; Hinds PS, 2001, CANCER NURS, V24, P122, DOI 10.1097/00002820-200104000-00007; Hongo T, 2003, PEDIATR INT, V45, P60, DOI 10.1046/j.1442-200X.2003.01668.x; Ingham J M, 1998, Hosp J, V13, P89; Jecker Nancy S, 1995, Rep Inst Philos Public Policy, V15, P10; KANE JR, 2002, PRINCIPLES PRACTICE, P1044; KOREN G, 1989, PEDIATR CLIN N AM, V36, P1141; Kreicbergs U, 2004, NEW ENGL J MED, V351, P1175, DOI 10.1056/NEJMoa040366; Mack JW, 2004, J CLIN ONCOL, V22, P563, DOI 10.1200/JCO.2004.04.078; MACK JW, 2004, 40 ANN M AM SOC CLIN; Mancini I, 1998, SUPPORT CARE CANCER, V6, P356, DOI 10.1007/s005200050177; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Meares C J, 1994, Am J Hosp Palliat Care, V11, P10, DOI 10.1177/104990919401100304; Miaskowski C, 1998, PRINC PR SUPPORT ONC, V1, P1; Mock V, 1997, Oncol Nurs Forum, V24, P991; MOUNT BM, 1986, J CLIN ONCOL, V4, P1127, DOI 10.1200/JCO.1986.4.7.1127; Nelson RM, 2000, PEDIATRICS, V106, P351; Ng K, 1998, J PAIN SYMPTOM MANAG, V16, P307, DOI 10.1016/S0885-3924(98)00097-9; Nitschke R, 2001, J CLIN ONCOL, V19, P595, DOI 10.1200/JCO.2001.19.2.595; Portenoy R K, 1991, J Palliat Care, V7, P13; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; Rozans M, 2002, J CLIN ONCOL, V20, P335, DOI 10.1200/JCO.20.1.335; Rusy LM, 2000, PEDIATR CLIN N AM, V47, P589, DOI 10.1016/S0031-3955(05)70227-3; SHAPIRO DL, 1984, JAMA-J AM MED ASSOC, V252, P2031, DOI 10.1001/jama.252.15.2031; Sirkia K, 1998, J PAIN SYMPTOM MANAG, V15, P220, DOI 10.1016/S0885-3924(98)00366-2; SOURKES B M, 1991, Journal of Psychosocial Oncology, V9, P81, DOI 10.1300/J077v09n02_06; Sourkes BM, 1996, J PALLIATIVE CARE, V12, P56, DOI 10.1177/082585979601200312; Steiner N, 1998, J PALLIAT CARE, V14, P6, DOI 10.1177/082585979801400202; Stevens M.M., 1998, OXFORD TXB PALLIATIV, P1045; TAKETOMO CK, 2003, PEDIAT DOSAGE HDB; Tobias JD, 2000, PEDIATR CLIN N AM, V47, P527, DOI 10.1016/S0031-3955(05)70224-8; Vullo-Navich K, 1998, Am J Hosp Palliat Care, V15, P77, DOI 10.1177/104990919801500205; Waller A, 1994, Am J Hosp Palliat Care, V11, P22; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WHIPPEN DA, 1991, J CLIN ONCOL, V9, P1916, DOI 10.1200/JCO.1991.9.10.1916; WILWERDING MB, 1995, SUPPORT CARE CANCER, V3, P135, DOI 10.1007/BF00365854; Wolfe J, 2002, PEDIATR CLIN N AM, V49, P1043, DOI 10.1016/S0031-3955(02)00034-2; Wolfe J, 2000, NEW ENGL J MED, V342, P326, DOI 10.1056/NEJM200002033420506; Wolfe J, 2000, JAMA-J AM MED ASSOC, V284, P2469, DOI 10.1001/jama.284.19.2469; Wolfe J, 2000, J CLIN ETHIC, V11, P157; Worden JW., 1996, CHILDREN GRIEF PAREN; 2000, EVIDENCE BASED SYMPT	72	70	70	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2004	292	17					2141	2149		10.1001/jama.292.17.2141	http://dx.doi.org/10.1001/jama.292.17.2141			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868OC	15523075				2022-12-28	WOS:000224921900027
J	Freemantle, N				Freemantle, N			Commentary: Is NICE delivering the goods?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Birmingham, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Freemantle, N (corresponding author), Univ Birmingham, Birmingham B15 2TT, W Midlands, England.	N.Freemantle@bham.ac.uk		Freemantle, Nick/0000-0001-5807-5740				Cover, 2004, BMJ, V329; Freemantle N, 2004, EVALUATING PHARM HLT; Maynard A, 2004, BMJ-BRIT MED J, V329, P227, DOI 10.1136/bmj.329.7459.227; *NAT I CLIN EXC, 2004, SUPP IMPL NICE GUID; Sheldon TA, 2004, BRIT MED J, V329, P999, DOI 10.1136/bmj.329.7473.999	5	11	11	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 30	2004	329	7473					1003	1004		10.1136/bmj.329.7473.1003	http://dx.doi.org/10.1136/bmj.329.7473.1003			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514343	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000224852400016
J	Schellenberg, JRMA; Adam, T; Mshinda, H; Masanja, H; Kabadi, G; Mukasa, O; John, T; Charles, S; Nathan, R; Wilczynska, K; Mgalula, L; Mbuya, C; Mswia, R; Manzi, F; de Savigny, D; Schellenberg, D; Victora, C				Schellenberg, JRMA; Adam, T; Mshinda, H; Masanja, H; Kabadi, G; Mukasa, O; John, T; Charles, S; Nathan, R; Wilczynska, K; Mgalula, L; Mbuya, C; Mswia, R; Manzi, F; de Savigny, D; Schellenberg, D; Victora, C			Effectiveness and cost of facility-based Integrated Management of Childhood Illness (IMCI) in Tanzania	LANCET			English	Article							PUBLIC-HEALTH; MORTALITY	Background The Integrated Management of Childhood Illness (IMCI) strategy is designed to address major causes of child mortality at the levels of community, health facility, and health system. We assessed the effectiveness of facility-based IMCI in rural Tanzania. Methods We compared two districts with facility-based IMCI and two neighbouring comparison districts without IMCI, from 1997 to 2002, in a non-randomised study. We assessed quality of case-management for children's illness, drug and vaccine availability, and supervision involving case-management, through a health-facility survey in 2000. Household surveys were used to assess child-health indicators in 1999 and 2002. Survival of children was tracked through demographic surveillance over a predefined 2-year period from mid 2000. Further information on contextual factors was gathered through interviews and record review. The economic cost of health care for children in IMCI and comparison districts was estimated through interviews and record review at national, district, facility, and household levels. Findings During the IMCI phase-in period, mortality rates in children under 5 years old were almost identical in IMCI and comparison districts. Over the next 2 years, the mortality rate was 13% lower in IMCI than in comparison districts (95% CI -7 to 30 or 5 to 21, depending on how adjustment is made for district-level clustering), with a rate difference of 3.8 fewer deaths per 1000 child-years. Contextual factors, such as use of mosquito nets, all favoured the comparison districts. Costs of children's health care with IMCI were similar to or lower than those for case-management without IMCI. Interpretation Our findings indicate that facility-based IMCI is good value for money, and support widespread implementation in the context of health-sector reform, basket funding, good facility access, and high utilisation of health facilities.	London Sch Hyg & Trop Med, Gates Malaria Partnership, London WC1B 3DP, England; Ifakara Hlth Res & Dev Ctr, Ifakara, Tanzania; Swiss Trop Inst, CH-4002 Basel, Switzerland; WHO, CH-1211 Geneva, Switzerland; Minist Hlth, Dar Es Salaam, Tanzania; WHO, Country Off, Dar Es Salaam, Tanzania; WHO, Reg Off Africa, Harare, Zimbabwe; Int Dev Res Ctr, Ottawa, ON, Canada; Hosp Clin Barcelona, Barcelona, Spain; Univ Pelotas, Pelotas, Brazil	University of London; London School of Hygiene & Tropical Medicine; Ifakara Health Institute; University of Basel; Swiss Tropical & Public Health Institute; World Health Organization; World Health Organization; World Health Organization; University of Barcelona; Hospital Clinic de Barcelona	Schellenberg, JRMA (corresponding author), London Sch Hyg & Trop Med, Gates Malaria Partnership, 50 Bedford Sq, London WC1B 3DP, England.	dajobelo@aol.com	Victora, Cesar G/D-4476-2013; Victora, Cesar Gomes/Y-2455-2019	Victora, Cesar G/0000-0002-2465-2180; Victora, Cesar Gomes/0000-0002-2465-2180; Schellenberg, David/0000-0001-8222-0186; Schellenberg, Joanna/0000-0002-0708-3676				ADAM T, IN PRESS B WHO; ADAM T, 2003, MULTICOUNTRY EVALUAT; BENNETT S, 1994, INT J EPIDEMIOL, V23, P1282, DOI 10.1093/ije/23.6.1282; Binka FN, 1999, J BIOSOC SCI, V31, P375, DOI 10.1017/S0021932099003752; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Bryce J, 2004, AM J PUBLIC HEALTH, V94, P406, DOI 10.2105/AJPH.94.3.406; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Cassels A, 1997, WHOARA9712; DESAVIGNY D, 2004, FOCUS FIXING HLTH SY; Font Fidel, 2002, BMC Int Health Hum Rights, V2, P4, DOI 10.1186/1472-698X-2-4; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7; Habicht JP, 1999, INT J EPIDEMIOL, V28, P10, DOI 10.1093/ije/28.1.10; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; *IDRC CRDI, 2002, INDEPTH MON SER DEM, V1; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Muela SH, 2000, HEALTH POLICY PLANN, V15, P296, DOI 10.1093/heapol/15.3.296; *NAT BUR STAT MACR, 2000, MEASURE EV TECHN REP, V7; Naturvardsverket, 2002, HOUS BIDG SURV 2000, V1; Schellenberg JA, 2004, HEALTH POLICY PLANN, V19, P1, DOI 10.1093/heapol/czh001; Schellenberg JA, 2003, LANCET, V361, P561, DOI 10.1016/S0140-6736(03)12515-9; *TANZ MIN HLTH, 2001, NAT HLTH ACC DRAFT F; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; Victora CG, 2004, AM J PUBLIC HEALTH, V94, P400, DOI 10.2105/AJPH.94.3.400; Walker N, 2002, LANCET, V360, P284, DOI 10.1016/S0140-6736(02)09550-8; *WHO DEP CHILD AD, GLOB MON IMCI IMPL; *WHO EXP COMM NUTR, 1995, WHO TECHN REP SER, V854; World Bank, 1993, INV HLTH WORLD DEV R; 2001, UNDP HUM DEV REPORT	28	205	207	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	2004	364	9445					1583	1594		10.1016/S0140-6736(04)17311-X	http://dx.doi.org/10.1016/S0140-6736(04)17311-X			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866IQ	15519628				2022-12-28	WOS:000224767600023
J	Sedrakyan, A; van der Meulen, J; Lewsey, J; Treasure, T				Sedrakyan, A; van der Meulen, J; Lewsey, J; Treasure, T			Variation in use of video assisted thoracic surgery in the United Kingdom	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE		Guys Hosp, Cardiothorac Unit, London SE1 9RT, England; Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Serv Res Unit, London WC1E 7HT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine	Treasure, T (corresponding author), Guys Hosp, Cardiothorac Unit, London SE1 9RT, England.	tom.treasure@gstt.sthames.nhs.uk	Lewsey, James/F-7546-2010	van der Meulen, Jan/0000-0002-9451-2335				DETSKY AS, 1995, NEW ENGL J MED, V333, P589, DOI 10.1056/NEJM199508313330911; Laycock WS, 2000, ARCH SURG-CHICAGO, V135, P457, DOI 10.1001/archsurg.135.4.457; LEWIS RJ, 1992, ANN THORAC SURG, V54, P421, DOI 10.1016/0003-4975(92)90431-3; SEDRAKYAN A, 2004, BMJ, V329; Wennberg JE, 1999, NEW ENGL J MED, V340, P52, DOI 10.1056/NEJM199901073400111	5	15	15	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	2004	329	7473					1011	1012		10.1136/bmj.329.7473.1011	http://dx.doi.org/10.1136/bmj.329.7473.1011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514345	Green Submitted, Green Published, Green Accepted, Bronze			2022-12-28	WOS:000224852400019
J	Frank, RAW; Titman, CM; Pratap, JV; Luisi, BF; Perham, RN				Frank, RAW; Titman, CM; Pratap, JV; Luisi, BF; Perham, RN			A molecular switch and proton wire synchronize the active sites in thiamine enzymes	SCIENCE			English	Article							DEHYDROGENASE MULTIENZYME COMPLEX; YEAST PYRUVATE-DECARBOXYLASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; BACILLUS-STEAROTHERMOPHILUS; 3-DIMENSIONAL STRUCTURE; REGULATORY PROPERTIES; ANGSTROM RESOLUTION; STRUCTURAL BASIS; E1 COMPONENT	Thiamine diphosphate (ThDP) is used as a cofactor in many key metabolic enzymes. We present evidence that the ThDPs in the two active sites of the E1 (EC 1.2.4.1) component of the pyruvate dehydrogenase complex communicate over a distance of 20 angstroms by reversibly shuttling a proton through an acidic tunnel in the protein. This "proton wire" permits the cofactors to serve reciprocally as general acid/base in catalysis and to switch the conformation of crucial active-site peptide loops. This synchronizes the progression of chemical events and can account for the oligomeric organization, conformational asymmetry, and "ping-pong" kinetic properties of E1 and other thiamine-dependent enzymes.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge	Luisi, BF (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	ben@cryst.bioc.cam.ac.uk; r.n.perham@bioc.cam.ac.uk	Titman, Christopher M/M-2223-2013	Titman, Christopher M/0000-0001-8698-8352; Frank, Rene/0000-0001-9724-9547				AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; BISSWANGER H, 1971, EUR J BIOCHEM, V24, P376, DOI 10.1111/j.1432-1033.1971.tb19696.x; BRESLOW R, 1957, J AM CHEM SOC, V79, P1762, DOI 10.1021/ja01564a064; Caines MEC, 2004, J BIOL CHEM, V279, P5685, DOI 10.1074/jbc.M310803200; Chauhan HJ, 2000, EUR J BIOCHEM, V267, P7158, DOI 10.1046/j.1432-1327.2000.01820.x; Ciszak EM, 2003, J BIOL CHEM, V278, P21240, DOI 10.1074/jbc.M300339200; FRANK R, UNPUB; Fries M, 2003, BIOCHEMISTRY-US, V42, P6996, DOI 10.1021/bi027397z; Hawksley D, 2001, J CHEM SOC PERK T 1, P144, DOI 10.1039/b006962k; HORN F, 1983, J BIOL CHEM, V258, P6912; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; Jones DD, 2001, J MOL BIOL, V305, P49, DOI 10.1006/jmbi.2000.4257; Jordan F, 2003, NAT PROD REP, V20, P184, DOI 10.1039/b111348h; Jordan F, 2003, J AM CHEM SOC, V125, P12732, DOI 10.1021/ja0346126; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; Latimer WM, 1920, J AM CHEM SOC, V42, P1419, DOI 10.1021/ja01452a015; Lessard IAD, 1996, BIOCHEMISTRY-US, V35, P16863, DOI 10.1021/bi961683r; Levitzki A, 1976, Curr Top Cell Regul, V10, P1; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; Lu GG, 2000, EUR J BIOCHEM, V267, P861, DOI 10.1046/j.1432-1327.2000.01070.x; Nagradova NK, 2001, FEBS LETT, V487, P327, DOI 10.1016/S0014-5793(00)02338-3; Nakai T, 2004, J MOL BIOL, V337, P1011, DOI 10.1016/j.jmb.2004.02.011; Nemeria N, 2002, BIOCHEMISTRY-US, V41, P15459, DOI 10.1021/bi0205909; NIKKOLA M, 1994, J MOL BIOL, V238, P387, DOI 10.1006/jmbi.1994.1299; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Schellenberger A, 1998, BBA-PROTEIN STRUCT M, V1385, P177, DOI 10.1016/S0167-4838(98)00067-3; Schellenberger A, 1997, METHOD ENZYMOL, V279, P131; Sergienko EA, 2002, BIOCHEMISTRY-US, V41, P3952, DOI 10.1021/bi011860a; SUGDEN PH, 1978, BIOCHEM J, V173, P659, DOI 10.1042/bj1730659; SUNDSTROM M, 1992, FEBS LETT, V313, P229, DOI 10.1016/0014-5793(92)81197-T; Szoke A, 2003, FEBS LETT, V553, P18, DOI 10.1016/S0014-5793(03)01008-1	33	144	146	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					872	876		10.1126/science.1101030	http://dx.doi.org/10.1126/science.1101030			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514159				2022-12-28	WOS:000224969400047
J	Katayama, Y; Inamura, Y; Mizutani, T; Yamakata, M; Utsumi, W; Shimomura, O				Katayama, Y; Inamura, Y; Mizutani, T; Yamakata, M; Utsumi, W; Shimomura, O			Macroscopic separation of dense fluid phase and liquid phase of phosphorus	SCIENCE			English	Article							HIGH-PRESSURE; TRANSITION; TRANSFORMATIONS	Structural transformation between a dense molecular fluid and a polymeric liquid of phosphorus that occurred at about 1 gigapascal and 1000degreesC was investigated by in situ x-ray radiography. When the low-pressure fluid was compressed, dark and round objects appeared in the radiograph. X-ray diffraction measurements confirmed that these objects were the high-pressure liquid. The drops grew and eventually filled the sample space. Decompressing caused the reverse process. The macroscopic phase separation supported the existence of a first-order phase transition between two stable disordered phases besides the liquid-gas transition. X-ray absorption measurements revealed that the change in density at the transition corresponds to about 40% of the density of the high-pressure liquid.	Japan Atom Energy Res Inst, Synchrotron Radiat Res Ctr, Sayo, Hyogo 6795148, Japan; Japan Synchrotron Radiat Res Inst, Sayo, Hyogo 6795198, Japan	Japan Atomic Energy Agency; Japan Synchrotron Radiation Research Institute; Japan Synchrotron Radiation Research Institute	Katayama, Y (corresponding author), Japan Atom Energy Res Inst, Synchrotron Radiat Res Ctr, 1-1-1 Mikazuki, Sayo, Hyogo 6795148, Japan.	katayama@spring8.or.jp						AASLAND S, 1994, NATURE, V369, P633, DOI 10.1038/369633a0; Brazhkin VV, 2002, NATO SCI SER II MATH, V81, P239; Brazhkin VV, 1997, HIGH PRESSURE RES, V15, P267, DOI 10.1080/08957959708240477; ENDO S, 1982, JPN J APPL PHYS 2, V21, pL482, DOI 10.1143/JJAP.21.L482; Funakoshi K, 2002, J PHYS-CONDENS MAT, V14, P11343, DOI 10.1088/0953-8984/14/44/479; HOHL D, 1994, PHYS REV B, V50, P17047, DOI 10.1103/PhysRevB.50.17047; Hutchinson E, 1943, T FARADAY SOC, V39, P0229, DOI 10.1039/tf9433900229; Katayama Y, 2003, J PHYS-CONDENS MAT, V15, P6085, DOI 10.1088/0953-8984/15/36/302; Katayama Y, 2002, J NON-CRYST SOLIDS, V312-14, P8, DOI 10.1016/S0022-3093(02)01641-1; Katayama Y, 1998, J SYNCHROTRON RADIAT, V5, P1023, DOI 10.1107/S0909049597015239; Katayama Y, 2000, NATURE, V403, P170, DOI 10.1038/35003143; McMillan PF, 2004, J MATER CHEM, V14, P1506, DOI 10.1039/b401308p; Mishima O, 2002, NATURE, V419, P599, DOI 10.1038/nature01106; Mishima O, 1998, NATURE, V396, P329, DOI 10.1038/24540; MISHIMA O, 1991, SCIENCE, V254, P406, DOI 10.1126/science.254.5030.406; MIZUTANI T, 2000, SCI TECHNOLOGY HIGH, P525; Monaco G, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.255701; Morishita T, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.105701; PECK DR, 1971, MELLORS COMPREHEN S3, V8, P149; Poole PH, 1997, SCIENCE, V275, P322, DOI 10.1126/science.275.5298.322; Senda Y, 2002, J PHYS-CONDENS MAT, V14, P3715, DOI 10.1088/0953-8984/14/14/304; Soper AK, 2000, PHYS REV LETT, V84, P2881, DOI 10.1103/PhysRevLett.84.2881; Urquidi J, 1999, PHYS REV LETT, V83, P2348, DOI 10.1103/PhysRevLett.83.2348; Utsumi W, 2002, J PHYS-CONDENS MAT, V14, P10497, DOI 10.1088/0953-8984/14/44/322; Yao M, 1996, J NON-CRYST SOLIDS, V205, P85, DOI 10.1016/S0022-3093(96)00216-5	25	137	142	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					848	851		10.1126/science.1102735	http://dx.doi.org/10.1126/science.1102735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514151				2022-12-28	WOS:000224969400039
J	Ruiz-Lapuente, P; Comeron, F; Mendez, J; Canal, R; Smartt, SJ; Filippenko, AV; Kurucz, RL; Chornock, R; Foley, RJ; Stanishev, V; Ibata, R				Ruiz-Lapuente, P; Comeron, F; Mendez, J; Canal, R; Smartt, SJ; Filippenko, AV; Kurucz, RL; Chornock, R; Foley, RJ; Stanishev, V; Ibata, R			The binary progenitor of Tycho Brahe's 1572 supernova	NATURE			English	Article							IA SUPERNOVAE; REMNANT; SYSTEMS; STARS; MODEL	The brightness of type Ia supernovae, and their homogeneity as a class, makes them powerful tools in cosmology, yet little is known about the progenitor systems of these explosions. They are thought to arise when a white dwarf accretes matter from a companion star, is compressed and undergoes a thermonuclear explosion(1-3). Unless the companion star is another white dwarf ( in which case it should be destroyed by the mass-transfer process itself), it should survive and show distinguishing properties. Tycho's supernova(4,5) is one of only two type Ia supernovae observed in our Galaxy, and so provides an opportunity to address observationally the identification of the surviving companion. Here we report a survey of the central region of its remnant, around the position of the explosion, which excludes red giants as the mass donor of the exploding white dwarf. We found a type G0 - G2 star, similar to our Sun in surface temperature and luminosity ( but lower surface gravity), moving at more than three times the mean velocity of the stars at that distance, which appears to be the surviving companion of the supernova.	Univ Barcelona, Dept Astron, E-08028 Barcelona, Spain; Max Planck Inst Astrophys, D-85748 Garching, Germany; European So Observ, D-85748 Garching, Germany; Isaac Newton Grp, E-38780 Tenerife, Canary Islands, Spain; Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Stockholm Univ, AlbaNova Univ Ctr, Dept Phys, SE-10891 Stockholm, Sweden; Observ Strasbourg, F-67000 Strasbourg, France	University of Barcelona; Max Planck Society; European Southern Observatory; Isaac Newton Group of Telescopes; University of Cambridge; University of California System; University of California Berkeley; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; Stockholm University	Ruiz-Lapuente, P (corresponding author), Univ Barcelona, Dept Astron, Marti & Franques 1, E-08028 Barcelona, Spain.	pilar@am.ub.es	Canal, Ramón/N-7351-2018; Stanishev, Vallery/M-8930-2013; Ruiz-Lapuente, Pilar/N-7475-2018	Stanishev, Vallery/0000-0002-7626-1181; Canal, Ramon/0000-0002-0465-2829; Foley, Ryan/0000-0002-2445-5275; Ibata, Rodrigo/0000-0002-3292-9709; Chornock, Ryan/0000-0002-7706-5668				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BAADE W, 1945, ASTROPHYS J, V102, P309, DOI 10.1086/144761; Baldwin J. E., 1957, OBSERVATORY, V77, P139; BRAHE T, 1972, OPERA OMNIA, V2, P307; BRANCH D, 1995, PUBL ASTRON SOC PAC, V107, P1019, DOI 10.1086/133657; BRAND J, 1993, ASTRON ASTROPHYS, V275, P67; Canal R, 2001, ASTROPHYS J, V550, pL53, DOI 10.1086/319479; Decourchelle A, 2001, ASTRON ASTROPHYS, V365, pL218, DOI 10.1051/0004-6361:20000115; Dehnen W, 1998, MON NOT R ASTRON SOC, V298, P387, DOI 10.1046/j.1365-8711.1998.01600.x; Hachisu I, 1996, ASTROPHYS J, V470, pL97, DOI 10.1086/310303; HUGHES JP, 1995, ASTROPHYS J, V444, pL81, DOI 10.1086/187865; Hughes JP, 2000, ASTROPHYS J, V545, pL53, DOI 10.1086/317337; Kurucz R. L., 1993, ATLAS9 STELLAR ATMOS; LEJEUNE T, 1997, A AS, V125, P246; Li XD, 1997, ASTRON ASTROPHYS, V322, pL9; LIVIO M, 2000, TYPE IA SUPERNOVAE T, P33; Marietta E, 2000, ASTROPHYS J SUPPL S, V128, P615, DOI 10.1086/313392; Podsiadlowski P., 2003, EVOLUTION APPEARANCE; Ruiz-Lapuente P, 2004, ASTROPHYS J, V612, P357, DOI 10.1086/422419; Ruiz-Lapuente P, 2003, ESO ASTROPHY SYMP, P140, DOI 10.1007/10828549_19; RuizLapuente P, 1997, NATO ADV SCI I C-MAT, V486, P205; RUIZLAPUENTE P, 2003, PROBING NATURE TYPE; RUIZLAPUENTE P, 2003, IN PRESS P C ASTR MO; SCHMIDTKALER T, 1982, LANDOLTBORNSTEIN, V2, P1; [No title captured]	27	195	198	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1069	1072		10.1038/nature03006	http://dx.doi.org/10.1038/nature03006			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15510140	Green Submitted			2022-12-28	WOS:000224730800032
J	Novoselov, KS; Geim, AK; Morozov, SV; Jiang, D; Zhang, Y; Dubonos, SV; Grigorieva, IV; Firsov, AA				Novoselov, KS; Geim, AK; Morozov, SV; Jiang, D; Zhang, Y; Dubonos, SV; Grigorieva, IV; Firsov, AA			Electric field effect in atomically thin carbon films	SCIENCE			English	Article							GRAPHITE; NANOTUBES; GRAPHENE; DEVICES	We describe monocrystalline graphitic films, which are a few atoms thick but are nonetheless stable under ambient conditions, metallic, and of remarkably high quality. The films are found to be a two-dimensional semimetal with a tiny overlap between valence and conductance bands, and they exhibit a strong ambipolar electric field effect such that electrons and holes in concentrations up to 10(13) per square centimeter and with room-temperature mobilities of similar to10,000 square centimeters per volt-second can be induced by applying gate voltage.	Univ Manchester, Dept Phys, Manchester M13 9PL, Lancs, England; Russian Acad Sci, Inst Microelect Technol, Chernogolovka 142432, Russia	University of Manchester; Russian Academy of Sciences	Geim, AK (corresponding author), Univ Manchester, Dept Phys, Manchester M13 9PL, Lancs, England.	geim@man.ac.uk	Jiang, Da/GZL-0534-2022; Li, jiayu/H-3827-2014; Novoselov, Kostya S/G-9581-2014; Ma, Jun/D-8971-2011; Geim, Andre K/J-7888-2012; Morozov, Sergey V/H-3171-2014; kuzmina, Ekaterina/ABG-2028-2021; Jiang, Da/E-3543-2013; Firsov, Anatoly/E-8090-2017	Jiang, Da/0000-0002-4341-2289; Li, jiayu/0000-0003-2639-213X; Novoselov, Kostya S/0000-0003-4972-5371; Geim, Andre K/0000-0003-2861-8331; Morozov, Sergey V/0000-0003-3075-7787; hai yan, he/0000-0003-0366-6185	Engineering and Physical Sciences Research Council [GR/R73621/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Affoune AM, 2001, CHEM PHYS LETT, V348, P17, DOI 10.1016/S0009-2614(01)01066-1; Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; Butenko AV, 2000, J APPL PHYS, V88, P2634, DOI 10.1063/1.1288166; Dimitrakopoulos CD, 2001, IBM J RES DEV, V45, P11, DOI 10.1147/rd.451.0011; Dresselhaus MS, 2002, ADV PHYS, V51, P1, DOI [10.1080/00018730110113644, 10.1080/00018738100101367]; Dujardin E, 2001, APPL PHYS LETT, V79, P2474, DOI 10.1063/1.1407306; Harigaya K, 2002, J PHYS-CONDENS MAT, V14, pL605, DOI 10.1088/0953-8984/14/36/102; Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622; Krishnan A, 1997, NATURE, V388, P451, DOI 10.1038/41284; Kruger M, 2003, NEW J PHYS, V5, DOI 10.1088/1367-2630/5/1/138; LAND TA, 1992, SURF SCI, V264, P261, DOI 10.1016/0039-6028(92)90183-7; Rotkin SV, 2004, APPL PHYS LETT, V84, P3139, DOI 10.1063/1.1710717; Shenderova OA, 2002, CRIT REV SOLID STATE, V27, P227, DOI 10.1080/10408430208500497; Shioyama H, 2001, J MATER SCI LETT, V20, P499, DOI 10.1023/A:1010907928709; SPAIN IL, 1981, CHEM PHYS CARBON, V16, P119; Stan MR, 2003, P IEEE, V91, P1940, DOI 10.1109/JPROC.2003.818327	16	48844	50970	1365	31336	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					666	669		10.1126/science.1102896	http://dx.doi.org/10.1126/science.1102896			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499015	Green Submitted			2022-12-28	WOS:000224756700045
J	Schulz, B; Frommer, WB				Schulz, B; Frommer, WB			A plant ABC transporter takes the lotus seat	SCIENCE			English	Editorial Material							ARABIDOPSIS		Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47907 USA; Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Carnegie Institution for Science	Schulz, B (corresponding author), Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47907 USA.	wfrommer@stanford.edu	Frommer, Wolf B/K-5042-2017; Frommer, Wolf B/A-8256-2008	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115				Barthlott W, 1997, PLANTA, V202, P1, DOI 10.1007/s004250050096; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Higgins CF, 2001, SCIENCE, V293, P1782, DOI 10.1126/science.1065588; Kol MA, 2003, J BIOL CHEM, V278, P24586, DOI 10.1074/jbc.M301875200; Kunst L, 2003, PROG LIPID RES, V42, P51, DOI 10.1016/S0163-7827(02)00045-0; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Martinoia E, 2002, PLANTA, V214, P345, DOI 10.1007/s004250100661; Pighin JA, 2004, SCIENCE, V306, P702, DOI 10.1126/science.1102331; Rashotte AM, 2004, PLANTA, V219, P5, DOI 10.1007/s00425-003-1197-y; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; Schmidt A, 2004, J BIOL CHEM, V279, P44817, DOI 10.1074/jbc.M405433200; VALLE D, 1993, NATURE, V361, P682, DOI 10.1038/361682a0; Xu CC, 2003, EMBO J, V22, P2370, DOI 10.1093/emboj/cdg234; Zolman BK, 2001, PLANT PHYSIOL, V127, P1266, DOI 10.1104/pp.010550	14	26	29	2	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					622	+		10.1126/science.1105227	http://dx.doi.org/10.1126/science.1105227			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499001				2022-12-28	WOS:000224756700032
J	Stone, PH				Stone, PH			Triggering myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARDIOVASCULAR-DISEASE		Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Stone, PH (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA.							Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; Stone PH, 2003, CURR OPIN CARDIOL, V18, P458, DOI 10.1097/00001573-200311000-00007; Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262	5	35	37	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2004	351	17					1716	1718		10.1056/NEJMp048245	http://dx.doi.org/10.1056/NEJMp048245			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863TH	15496619				2022-12-28	WOS:000224585200005
J	Rathore, SS; Krumholz, HM				Rathore, SS; Krumholz, HM			Differences, disparities, and biases: Clarifying racial variations in health care use	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; ISCHEMIC HEART-DISEASE; MEDICAL-CARE; CARDIOVASCULAR PROCEDURES; RACE; SEX; DISCRIMINATION; INEQUALITIES; EQUITY; ACCESS	Studies documenting racial differences in health care use are common in the medical literature. However, observational studies of racial differences in health care use lack a framework for interpreting reports of variations in health care use, leading to various terms, ranging from "variations" to "bias," that suggest different causes, consequences, and, ultimately, remedies for such variations in treatment. We propose criteria to assess racial differences in health care use by using a clinical equity (equal treatment based on equal clinical need) framework. This framework differentiates between initial reports of racial differences and subsequent classifications of their findings as racial disparities or racial bias in health care use. Racial variations in health care use may be considered disparities after demonstrating that racial differences are not attributable to treatment eligibility, clinical contraindications, patient preferences, or confounding by other clinical factors and are associated with adverse consequences. Racial bias with adverse consequences in health care may be inferred if a racial variation in treatment that has been characterized as a disparity persists after accounting for health care system factors (for example, type of hospital at which the patient was treated). We apply this framework to published reports of racial differences in treatment to determine which studies provide evidence of differences, disparities, and bias. We discuss the use of such a framework in directing policy interventions for alleviating inappropriate racial variations in health care use.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT USA	Yale University; Yale University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Room Cedar St,POB 208088, New Haven, CT 06520 USA.		, Harlan/AAI-2875-2020		NIGMS NIH HHS [GM07205] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAY LA, 1981, MED CARE, V19, P4, DOI 10.1097/00005650-198112001-00004; Bach PB, 2004, NEW ENGL J MED, V351, P575, DOI 10.1056/NEJMsa040609; Balsa AI, 2001, J HEALTH ECON, V20, P881, DOI 10.1016/S0167-6296(01)00101-1; Canto JG, 2000, NEW ENGL J MED, V342, P1094, DOI 10.1056/NEJM200004133421505; Chang WC, 2002, J EPIDEMIOL COMMUN H, V56, P488, DOI 10.1136/jech.56.7.488; Davidoff F, 1999, NEW ENGL J MED, V341, P285; Epstein AM, 2001, NEW ENGL J MED, V344, P1471, DOI 10.1056/NEJM200105103441911; Fisher ES, 1999, JAMA-J AM MED ASSOC, V281, P446, DOI 10.1001/jama.281.5.446; Geiger HJ, 1996, NEW ENGL J MED, V335, P815, DOI 10.1056/NEJM199609123351110; HOLMES MD, 1989, JAMA-J AM MED ASSOC, V261, P3242, DOI 10.1001/jama.261.22.3242; Huber TS, 1999, J VASC SURG, V30, P417, DOI 10.1016/S0741-5214(99)70068-6; HULKA BS, 1985, MED CARE, V23, P438, DOI 10.1097/00005650-198505000-00009; *I MED, 2002, UN TREATM CONFR RAC; Kravitz RL, 1999, ANN INTERN MED, V130, P231, DOI 10.7326/0003-4819-130-3-199902020-00028; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; McMahon LF, 1999, MED CARE, V37, P712, DOI 10.1097/00005650-199907000-00011; Mooney G H, 1983, Eff Health Care, V1, P179; Rathore SS, 2000, CIRCULATION, V102, P642, DOI 10.1161/01.CIR.102.6.642; Rathore SS, 2003, JAMA-J AM MED ASSOC, V289, P2517, DOI 10.1001/jama.289.19.2517; Rathore SS, 2002, AM HEART J, V144, P1052, DOI 10.1067/mhj.2002.126122; SULLIVAN LW, 1991, JAMA-J AM MED ASSOC, V266, P2674, DOI 10.1001/jama.266.19.2674; *US COMM CIV RIGHT, 1999, HLTH CAR CHALL ACKN; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907	24	86	86	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	2004	141	8					635	638		10.7326/0003-4819-141-8-200410190-00011	http://dx.doi.org/10.7326/0003-4819-141-8-200410190-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864SD	15492343				2022-12-28	WOS:000224652300007
J	Madara, J				Madara, J			Building an intestine - Architectural contributions of commensal bacteria	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Chicago	Madara, J (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.							Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002	4	30	36	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1685	1686		10.1056/NEJMcibr042621	http://dx.doi.org/10.1056/NEJMcibr042621			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483290				2022-12-28	WOS:000224427300019
J	Noskov, SY; Berneche, S; Roux, B				Noskov, SY; Berneche, S; Roux, B			Control of ion selectivity in potassium channels by electrostatic and dynamic properties of carbonyl ligands	NATURE			English	Article							K+ CHANNEL; CONDUCTION; PERMEATION; ENERGY; FILTER; NA+; SIMULATIONS; MUTATIONS; OCCUPANCY; PROTEINS	Potassium channels are essential for maintaining a normal ionic balance across cell membranes. Central to this function is the ability of such channels to support transmembrane ion conduction at nearly diffusion-limited rates while discriminating for K+ over Na+ by more than a thousand-fold. This selectivity arises because the transfer of the K+ ion into the channel pore is energetically favoured, a feature commonly attributed to a structurally precise fit between the K+ ion and carbonyl groups lining the rigid and narrow pore(1). But proteins are relatively flexible structures(2,3) that undergo rapid thermal atomic fluctuations larger than the small difference in ionic radius between K+ and Na+. Here we present molecular dynamics simulations for the potassium channel KcsA, which show that the carbonyl groups coordinating the ion in the narrow pore are indeed very dynamic ('liquid-like') and that their intrinsic electrostatic properties control ion selectivity. This finding highlights the importance of the classical concept of field strength(4). Selectivity for K+ is seen to emerge as a robust feature of a flexible fluctuating pore lined by carbonyl groups.	Cornell Univ, Weill Med Coll, Dept Biochem & Struct Biol, New York, NY 10021 USA; Univ Basel, Biozentrum, Div Struct Biol, CH-4056 Basel, Switzerland	Cornell University; University of Basel	Roux, B (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem & Struct Biol, 1300 York Ave, New York, NY 10021 USA.	benoit.roux@med.cornell.edu	Noskov, Sergei/B-3654-2010; Bernèche, Simon/L-6389-2013	Bernèche, Simon/0000-0002-6274-4094; Noskov, Sergei/0000-0001-7769-335X				Allen TW, 2000, J CHEM PHYS, V112, P8191, DOI 10.1063/1.481420; ALLEN TW, IN PRESS J GEN PHYSL; Aqvist J, 2000, NATURE, V404, P881, DOI 10.1038/35009114; AQVIST J, 1992, J PHYS CHEM-US, V96, P10019, DOI 10.1021/j100203a079; Berneche S, 2001, NATURE, V414, P73, DOI 10.1038/35102067; Berneche S, 2003, P NATL ACAD SCI USA, V100, P8644, DOI 10.1073/pnas.1431750100; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; EISENMAN G, 1962, Biophys J, V2, P259; Guidoni L, 1999, BIOCHEMISTRY-US, V38, P8599, DOI 10.1021/bi990540c; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B, 1999, NAT MED, V5, P1105, DOI 10.1038/13415; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; LeMasurier M, 2001, J GEN PHYSIOL, V118, P303, DOI 10.1085/jgp.118.3.303; Loboda A, 2001, BIOPHYS J, V80, P2704, DOI 10.1016/S0006-3495(01)76239-X; Lu T, 2001, NAT NEUROSCI, V4, P239, DOI 10.1038/85080; Luzhkov VB, 2001, BBA-PROTEIN STRUCT M, V1548, P194, DOI 10.1016/S0167-4838(01)00213-8; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MARRONE TJ, 1995, J AM CHEM SOC, V117, P779, DOI 10.1021/ja00107a022; Morais-Cabral JH, 2001, NATURE, V414, P37, DOI 10.1038/35102000; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; Nimigean CM, 2002, J GEN PHYSIOL, V120, P323, DOI 10.1085/jgp.20028614; Pauling L, 1960, NATURE CHEM BOND, VThird, P644; Shrivastava IH, 2002, BIOPHYS J, V83, P633, DOI 10.1016/S0006-3495(02)75197-7; WEEKS JD, 1971, J CHEM PHYS, V54, P5237, DOI 10.1063/1.1674820; YAMASHITA MM, 1990, P NATL ACAD SCI USA, V87, P5648, DOI 10.1073/pnas.87.15.5648; Zaccai G, 2000, SCIENCE, V288, P1604, DOI 10.1126/science.288.5471.1604; Zhou YF, 2003, J MOL BIOL, V333, P965, DOI 10.1016/j.jmb.2003.09.022; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	32	426	436	4	106	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					830	834		10.1038/nature02943	http://dx.doi.org/10.1038/nature02943			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483608				2022-12-28	WOS:000224435500043
J	Xu, X; Norell, MA				Xu, X; Norell, MA			A new troodontid dinosaur from China with avian-like sleeping posture	NATURE			English	Article							EVOLUTION; THEROPODA; SKULL	Discovering evidence of behaviour in fossilized vertebrates is rare. Even rarer is evidence of behaviour in non-avialan dinosaurs that directly relates to stereotypical behaviour seen in extant birds (avians) and not previously predicted in non-avialan dinosaurs(1,2). Here we report the discovery of a new troodontid taxon from the Early Cretaceous Yixian Formation of western Liaoning, China. Numerous other three-dimensionally preserved vertebrate fossils have been recovered recently at this locality, including some specimens preserving behavioural information(3). The new troodontid preserves several features that have been implicated in avialan origins. Notably, the specimen is preserved in the stereotypical sleeping or resting posture found in extant Aves(4). Evidence of this behaviour outside of the crown group Aves further demonstrates that many bird features occurred early in dinosaurian evolution(5,6).	Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China; Amer Museum Nat Hist, New York, NY 10024 USA	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS; American Museum of Natural History (AMNH)	Xu, X (corresponding author), Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, POB 643, Beijing 100044, Peoples R China.	xu@amnh.org; xingxu@vip.sina.com						Barsbold R, 1999, ACTA PALAEONTOL POL, V44, P189; Chang M., 2003, JEHOL BIOTA; Chiappe LM, 1998, NATURE, V392, P275, DOI 10.1038/32642; Chiappe LM, 1999, B AM MUS NAT HIST, P3; Clark James M., 1999, American Museum Novitates, V3265, P1; Currie P.J., 1987, Journal of Vertebrate Paleontology, V7, P72; Currie PJ, 2001, CAN J EARTH SCI, V38, P1753, DOI 10.1139/e01-065; Elzanowski Andrzej, 2002, P129; Guo ZF, 2003, SCI CHINA SER D, V46, P1261, DOI 10.1360/03yd0071; HILL RW, 1980, PHYSIOL ZOOL, V53, P305, DOI 10.1086/physzool.53.3.30155793; Hwang SH, 2002, AM MUS NOVIT, P1, DOI 10.1206/0003-0082(2002)381<0001:NSOMZT>2.0.CO;2; Hwang Sunny H., 2004, Journal of Systematic Palaeontology, V2, P13, DOI 10.1017/S1477201903001081; Ji Q, 2003, AM MUS NOVIT, P1, DOI 10.1206/0003-0082(2003)420<0001:AEODAI>2.0.CO;2; Jones TD, 2000, NATURE, V406, P716, DOI 10.1038/35021041; Loope DB, 1998, GEOLOGY, V26, P27, DOI 10.1130/0091-7613(1998)026<0027:LADIAL>2.3.CO;2; Makovicky PJ, 2003, AM MUS NOVIT, P1; Marsh R.L., 1989, Advances in Comparative and Environmental Physiology, V4, P205; Meng QJ, 2004, NATURE, V431, P145, DOI 10.1038/431145a; NORELL MA, 1995, NATURE, V378, P774, DOI 10.1038/378774a0; Norell MA, 2000, J VERTEBR PALEONTOL, V20, P7, DOI 10.1671/0272-4634(2000)020[0007:ANTTFU]2.0.CO;2; Norell Mark A., 1997, American Museum Novitates, V3215, P1; RUSSELL DA, 1993, CAN J EARTH SCI, V30, P2163, DOI 10.1139/e93-187; Schweitzer MH, 2001, J EXP ZOOL, V291, P317, DOI 10.1002/jez.1132; Sereno PC, 1999, SCIENCE, V284, P2137, DOI 10.1126/science.284.5423.2137; Swisher CC, 2002, CHINESE SCI BULL, V47, P135; Varricchio DJ, 1997, NATURE, V385, P247, DOI 10.1038/385247a0; WING LW, 1956, NATURAL HIST BIRDS; Xu X, 2000, NATURE, V408, P705, DOI 10.1038/35047056; Xu X, 2002, NATURE, V415, P780, DOI 10.1038/415780a; Xu X., 2002, THESIS CHINESE ACAD	30	164	181	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					838	841		10.1038/nature02898	http://dx.doi.org/10.1038/nature02898			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483610				2022-12-28	WOS:000224435500045
J	Heffner, LJ				Heffner, LJ			Advanced maternal age - How old is too old?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OUTCOMES		Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA	Boston University	Heffner, LJ (corresponding author), Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA.			Heffner, Linda/0000-0001-9623-7210				Andersen AMN, 2000, BRIT MED J, V320, P1708, DOI 10.1136/bmj.320.7251.1708; HOOK EB, 1983, JAMA-J AM MED ASSOC, V249, P2034, DOI 10.1001/jama.249.15.2034; MENKEN J, 1986, SCIENCE, V234, P413; MENKEN J, 1986, SCIENCE, V233, P1389, DOI 10.1126/science.3755843; Paulson RJ, 2002, JAMA-J AM MED ASSOC, V288, P2320, DOI 10.1001/jama.288.18.2320; Salihu HM, 2003, OBSTET GYNECOL, V102, P1006, DOI 10.1016/S0029-7844(03)00739-7	6	309	335	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1927	1929		10.1056/NEJMp048087	http://dx.doi.org/10.1056/NEJMp048087			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525717				2022-12-28	WOS:000224851300001
J	Molinari, NAM				Molinari, NAM			The effect of health care on population health	LANCET			English	Editorial Material							BIOMEDICAL-RESEARCH; BIRTH-WEIGHT; MORTALITY; DEMAND		Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Immunizat Program, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Molinari, NAM (corresponding author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Immunizat Program, Atlanta, GA 30341 USA.	NMolinari@cdc.gov	Molinari, NoelleAngelique Maria/F-3630-2017	Molinari, NoelleAngelique Maria/0000-0002-2758-3133				ATKINSON SE, 1992, J ENVIRON ECON MANAG, V22, P12, DOI 10.1016/0095-0696(92)90016-P; AUSTER RD, 1981, J HUM RESOUR, V16, P328, DOI 10.2307/145624; Fuchs V., 1974, WHO SHALL LIVE; GROSSMAN M, 1990, J POLIT ECON, V98, P983, DOI 10.1086/261716; HADLEY J, 1988, INQUIRY-J HEALTH CAR, V25, P485; HADLEY J, 1982, MORE MED CARE BETTER; HITIRIS T, 1992, J HEALTH ECON, V11, P173, DOI 10.1016/0167-6296(92)90033-W; KREMER M, 1993, Q J ECON, V108, P551, DOI 10.2307/2118400; McKeown Thomas, 1976, MODERN RISE POPULATI; MCKINLAY JB, 1977, MILBANK FUND Q, V55, P405, DOI 10.2307/3349539; ROSENZWEIG MR, 1983, J POLIT ECON, V91, P723, DOI 10.1086/261179; SCHNEYER S, 1981, MILBANK FUND Q, V59, P44, DOI 10.2307/3349775; Selma J.Mushkin, 1979, BIOMEDICAL RES COSTS; Sickles RC, 1998, J BUS ECON STAT, V16, P187, DOI 10.2307/1392574; VEHORN CL, 1982, RES POLICY, V11, P3, DOI 10.1016/0048-7333(82)90003-8; WOLFE BL, 1986, SOC SCI MED, V22, P993, DOI 10.1016/0277-9536(86)90199-1	16	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	2004	364	9445					1558	1560		10.1016/S0140-6736(04)17325-X	http://dx.doi.org/10.1016/S0140-6736(04)17325-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	866IQ	15519613				2022-12-28	WOS:000224767600004
J	Arendt, D; Tessmar-Raible, K; Snyman, H; Dorresteijn, AW; Wittbrodt, J				Arendt, D; Tessmar-Raible, K; Snyman, H; Dorresteijn, AW; Wittbrodt, J			Ciliary photoreceptors with a vertebrate-type opsin in an invertebrate brain	SCIENCE			English	Article							CIRCADIAN-RHYTHMS; HOMEOBOX GENE; PINEAL-GLAND; EYE; TRANSDUCIN; EXPRESSION; ZEBRAFISH; RHODOPSIN; EVOLUTION; LOOP	For vision, insect and vertebrate eyes use rhabdomeric and ciliary photoreceptor cells, respectively. These cells show distinct architecture and transduce the light signal by different phototransductory cascades. In the marine rag-worm Platynereis, we find both cell types: rhabdomeric photoreceptor cells in the eyes and ciliary photoreceptor cells in the brain. The latter use a photopigment closely related to vertebrate rod and cone opsins. Comparative analysis indicates that both types of photoreceptors, with distinct opsins, coexisted in Urbilateria, the last common ancestor of insects and vertebrates, and sheds new light on vertebrate eye evolution.	European Mol Biol Lab, Dept Dev Biol, D-69012 Heidelberg, Germany; Univ Marburg, Inst Spezielle Zool, D-35032 Marburg, Germany; Univ Giessen, Inst Allgemeine & Spezielle Zool, D-35390 Giessen, Germany	European Molecular Biology Laboratory (EMBL); Philipps University Marburg; Justus Liebig University Giessen	Arendt, D (corresponding author), European Mol Biol Lab, Dept Dev Biol, Meyerhofstr 1, D-69012 Heidelberg, Germany.	detlev.arendt@embl.de; jochen.wittbrodt@embl.de	Wittbrodt, Joachim/D-4735-2014; Tessmar-Raible, Kristin/F-9642-2011	Wittbrodt, Joachim/0000-0001-8550-7377; Tessmar-Raible, Kristin/0000-0002-8038-1741; Dorresteijn, Adriaan/0000-0003-2314-1634				Arendt D, 2003, INT J DEV BIOL, V47, P563; Arendt D, 2002, DEVELOPMENT, V129, P1143; Casarosa S, 1997, MECH DEVELOP, V61, P187, DOI 10.1016/S0925-4773(96)00640-5; Chen CMA, 2002, DEVELOPMENT, V129, P5363, DOI 10.1242/dev.00114; Chuang JC, 1999, MECH DEVELOP, V84, P195, DOI 10.1016/S0925-4773(99)00077-5; Deschet K, 1999, MECH DEVELOP, V83, P179, DOI 10.1016/S0925-4773(99)00037-4; DHAINAUT.N, 1965, CR HEBD ACAD SCI, V261, P1085; EDWARDS PR, COMMUNICATION; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Fukada Y, 2002, MOL NEUROBIOL, V25, P19, DOI 10.1385/MN:25:1:019; Gehring W, 2003, J MOL EVOL, V57, pS286, DOI 10.1007/s00239-003-0038-8; Hill CA, 2002, SCIENCE, V298, P176, DOI 10.1126/science.1076196; Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; Perron M, 1998, DEV BIOL, V199, P185, DOI 10.1006/dbio.1998.8939; Raible F, 2004, CURR BIOL, V14, pR106, DOI 10.1016/j.cub.2004.01.015; Tessmar-Raible K, 2003, CURR OPIN GENET DEV, V13, P331, DOI 10.1016/S0959-437X(03)00086-8; Van Gelder RN, 2003, SCIENCE, V300, P1534, DOI 10.1126/science.1085446; VERNET G, 1974, Annales des Sciences Naturelles Zoologie et Biologie Animale, V16, P27; Vigh B, 2002, HISTOL HISTOPATHOL, V17, P555, DOI 10.14670/HH-17.555; von Salvini-Plawen L, 1977, EVOLUTIONARY BIOL, P207; WHITTLE AC, 1974, CELL TISSUE RES, V154, P379; WILSON SW, 1991, DEVELOPMENT, V112, P723	24	277	285	5	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					869	871		10.1126/science.1099955	http://dx.doi.org/10.1126/science.1099955			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514158				2022-12-28	WOS:000224969400046
J	Schrag, DP; Alley, RB				Schrag, DP; Alley, RB			Physics - Ancient lessons for our future climate	SCIENCE			English	Editorial Material							ICE-CORE; CARBON; END		Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA	Harvard University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Schrag, DP (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.	schrag@eps.harvard.edu; ralley@mcfeely.geosc.psu.edu						DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; GREENWOOD DR, 1995, GEOLOGY, V23, P1044, DOI 10.1130/0091-7613(1995)023<1044:ECCALT>2.3.CO;2; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; Kerr RA, 2004, SCIENCE, V305, P932, DOI 10.1126/science.305.5686.932; Kirk-Davidoff DB, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL014659; Kurtz AC, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2003PA000908; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; LORIUS C, 1990, NATURE, V347, P139, DOI 10.1038/347139a0; Moritz RE, 2002, SCIENCE, V297, P1497, DOI 10.1126/science.1076522; Pagani M, 1999, PALEOCEANOGRAPHY, V14, P273, DOI 10.1029/1999PA900006; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Pinot S, 1999, CLIM DYNAM, V15, P857, DOI 10.1007/s003820050318; Rignot E, 2002, SCIENCE, V297, P1502, DOI 10.1126/science.1073888; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Sloan LC, 1998, GEOPHYS RES LETT, V25, P3517, DOI 10.1029/98GL02492; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	16	12	13	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					821	822		10.1126/science.1103025	http://dx.doi.org/10.1126/science.1103025			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514146				2022-12-28	WOS:000224969400033
J	Gil, L; Fuentes-Utrilla, P; Soto, A; Cervera, MT; Collada, C				Gil, L; Fuentes-Utrilla, P; Soto, A; Cervera, MT; Collada, C			English elm is a 2,000-year-old Roman clone	NATURE			English	Editorial Material									UPM, Escuela Tecn Super Ingenieros Montes, Dept Silvopascicultura, Madrid 28040, Spain; UPM, Escuela Tecn Super Ingenieros Montes, Dept Biotecnol, Madrid 28040, Spain; Inst Nacl Invest Agr, Madrid 28040, Spain	Universidad Politecnica de Madrid; Universidad Politecnica de Madrid; Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA)	Gil, L (corresponding author), UPM, Escuela Tecn Super Ingenieros Montes, Dept Silvopascicultura, Ciudad Univ S-N, Madrid 28040, Spain.	lgil@montes.upm.es	Cervera, M. Teresa/G-9181-2012; Gil, Luis/E-3216-2014; Collada, Carmen/H-1529-2015; Soto, Alvaro/E-3737-2012	Cervera, M. Teresa/0000-0001-6797-2347; Gil, Luis/0000-0002-5252-2607; Collada, Carmen/0000-0003-0236-1312; Soto, Alvaro/0000-0002-0144-1399				ASH HB, 1941, LJ MODERATUS COLUMEL; BRASIER CM, 1996, FOREST COMM REP FORE, P20; Brown AG, 2001, ANTIQUITY, V75, P745, DOI 10.1017/S0003598X00089250; COLLADA C, IN PRESS MOL ECOL NO; DumolinLapegue S, 1997, GENETICS, V146, P1475; FORSTER ES, 1954, LJ MODERATUS COLUMEL, V2; Hewitt GM, 1999, BIOL J LINN SOC, V68, P87, DOI 10.1111/j.1095-8312.1999.tb01160.x; HEYBROEK HM, 2000, FORESTRY COMPENDIUM; Lopez-Almansa JC, 2003, AM J BOT, V90, P603, DOI 10.3732/ajb.90.4.603; MARTIN R, 1971, RECH ARONOMES LATINS; Richens RH., 1983, ELM; Tovar A, 1975, HOMENAJE NACL LJ MOD, P93	12	69	75	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	2004	431	7012					1053	1053		10.1038/4311053a	http://dx.doi.org/10.1038/4311053a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15510138				2022-12-28	WOS:000224730800029
J	Solanki, SK; Usoskin, IG; Kromer, B; Schussler, M; Beer, J				Solanki, SK; Usoskin, IG; Kromer, B; Schussler, M; Beer, J			Unusual activity of the Sun during recent decades compared to the previous 11,000 years	NATURE			English	Article							SOLAR MODULATION; BE-10; C-14; FIELD	Direct observations of sunspot numbers are available for the past four centuries(1,2), but longer time series are required, for example, for the identification of a possible solar influence on climate and for testing models of the solar dynamo. Here we report a reconstruction of the sunspot number covering the past 11,400 years, based on dendrochronologically dated radiocarbon concentrations. We combine physics-based models for each of the processes connecting the radiocarbon concentration with sunspot number. According to our reconstruction, the level of solar activity during the past 70 years is exceptional, and the previous period of equally high activity occurred more than 8,000 years ago. We find that during the past 11,400 years the Sun spent only of the order of 10% of the time at a similarly high level of magnetic activity and almost all of the earlier high-activity periods were shorter than the present episode. Although the rarity of the current episode of high average sunspot numbers may indicate that the Sun has contributed to the unusual climate change during the twentieth century, we point out that solar variability is unlikely to have been the dominant cause of the strong warming during the past three decades(3).	Max Planck Inst Sonnensyst Forsch, D-37191 Katlenburg Lindau, Germany; Univ Oulu, Oulu Unit, Sodankyla Geophys Observ, Oulu, Finland; Heidelberger Akad Wissensch, Inst Umweltphys, D-69120 Heidelberg, Germany; EAWAG, Dept Surface Waters, CH-8600 Dubendorf, Switzerland	Max Planck Society; University of Oulu; Ruprecht Karls University Heidelberg; Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG)	Solanki, SK (corresponding author), Max Planck Inst Sonnensyst Forsch, D-37191 Katlenburg Lindau, Germany.	solanki@mps.mpg.de	Usoskin, Ilya G./E-5089-2014; Solanki, Sami K/E-2487-2013	Usoskin, Ilya G./0000-0001-8227-9081; Solanki, Sami K/0000-0002-3418-8449				Bard E, 1997, EARTH PLANET SC LETT, V150, P453, DOI 10.1016/S0012-821X(97)00082-4; Beer J, 2000, SPACE SCI REV, V94, P53, DOI 10.1023/A:1026778013901; BEER J, 1990, NATURE, V347, P164, DOI 10.1038/347164a0; Bond G, 2001, SCIENCE, V294, P2130, DOI 10.1126/science.1065680; BROECKER WS, 1994, NATURE, V367, P414, DOI 10.1038/367414a0; CASTAGNOLI G, 1980, RADIOCARBON, V22, P133, DOI 10.1017/S0033822200009413; Damon P.E., 1991, SUN TIME, P360; EDDY JA, 1976, SCIENCE, V192, P1189, DOI 10.1126/science.192.4245.1189; ELSASSER W, 1956, NATURE, V178, P1226, DOI 10.1038/1781226a0; Hongre L, 1998, PHYS EARTH PLANET IN, V106, P311, DOI 10.1016/S0031-9201(97)00115-5; Hoyt DV, 1998, SOL PHYS, V179, P189, DOI 10.1023/A:1005007527816; MUSCHELER R, 2003, ESA, P305; Solanki SK, 2003, J GEOPHYS RES-SPACE, V108, DOI 10.1029/2002JA009753; Solanki SK, 2002, ASTRON ASTROPHYS, V383, P706, DOI 10.1051/0004-6361:20011790; Solanki SK, 2000, NATURE, V408, P445, DOI 10.1038/35044027; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; STUIVER M, 1989, NATURE, V338, P405, DOI [10.1038/338405a0, 10.1038/286868a0]; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Stuiver M., 1993, HOLOCENE, V3, P289, DOI DOI 10.1177/095968369300300401; SUESS HE, 1955, SCIENCE, V122, P415, DOI 10.1126/science.122.3166.415-a; Usoskin IG, 2004, ASTRON ASTROPHYS, V413, P745, DOI 10.1051/0004-6361:20031533; Usoskin IG, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.211101; Usoskin IG, 2002, J GEOPHYS RES-SPACE, V107, DOI 10.1029/2002JA009343; Usoskin IG, 2002, SOL PHYS, V207, P389, DOI 10.1023/A:1016266801300; USOSKIN IG, IN PRESS RADIOCARBON; Yang S, 2000, GEOPHYS J INT, V140, P158, DOI 10.1046/j.1365-246x.2000.00011.x	26	643	681	9	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1084	1087		10.1038/nature02995	http://dx.doi.org/10.1038/nature02995			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15510145				2022-12-28	WOS:000224730800037
J	Cook, H				Cook, H			Historical keywords - Health	LANCET			English	Editorial Material									UCL, Wellcome Trust Ctr Hist Med, London, England	University of London; University College London	Cook, H (corresponding author), UCL, Wellcome Trust Ctr Hist Med, London, England.	h.cook@ucl.ac.uk							0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	2004	364	9444					1481	1481		10.1016/S0140-6736(04)17255-3	http://dx.doi.org/10.1016/S0140-6736(04)17255-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500880				2022-12-28	WOS:000224645500011
J	Gallagher, AG; Cates, CU				Gallagher, AG; Cates, CU			Virtual reality training for the operating room and cardiac catheterisation laboratory	LANCET			English	Review							SKILLS	Context High-profile cases of medical errors in the USA and UK, and major reports from organisations such as the US Institute of Medicine and UK Senate of Surgery, have sensitised the public and medical profession. Training is a key area that must be tackled to positively affect the problem of medical errors, especially in surgery and interventional cardiology. Despite the radically novel skills required for minimally invasive surgery or interventional cardiology, current training has gone largely unchanged. At the end of the 20th century, the public and the medical profession have concluded that training on patients is no longer acceptable. Starting point Recently, Teodor Grantcharov and colleagues (Br J Surg 2004; 91: 146-50) did a randomised double-blind trial which showed that training by virtual reality (VR) significantly reduces objectively assessed intraoperative errors in laparoscopic cholecystectomy. They used a low-fidelity VR simulator. Much more sophisticated VR simulators exist for endoscopy, gynaecology, laparoscopy, orthopaedics, otolaryngology, robotics, and urology. There are few studies on the efficacy of these simulators in improving the safety of procedures on patients. Where next There needs to be more large and multicentre studies. Technical skills training for procedural based medicine continues to be an ad-hoc mentor-based experience for the trainee, with experience gained by practising on patients. The skills required now are so difficult to learn that this type of training is no longer acceptable. VR-simulator-based training does work, but further empirical evidence is required to convince the more conservative members of the medical community.	Emory Univ Hosp, Dept Cardiol, Ctr Heart, Atlanta, GA 30322 USA; Emory Univ Hosp, Dept Surg, Emory Endosurg Unit, Atlanta, GA 30322 USA	Emory University; Emory University	Cates, CU (corresponding author), Emory Univ Hosp, Dept Cardiol, Ctr Heart, 1364 Clifton Rd NE, Atlanta, GA 30322 USA.	christopher_cates@emoryhealthcare.org		Gallagher, Anthony G./0000-0003-0887-5613				Adamsen S, 2000, ENDOSCOPY, V32, P895, DOI 10.1055/s-2000-8091; Cotin S, 2000, Stud Health Technol Inform, V70, P59; Cuschieri A, 2000, SURG ENDOSC-ULTRAS, V14, P1, DOI 10.1007/s004649900001; Eysenck Micahel, 2002, FDN COGNITIVE PSYCHO, P363; Gallagher AG, 2002, SURG ENDOSC, V16, P1746, DOI 10.1007/s00464-001-8215-6; Gallagher AG, 1998, ENDOSCOPY, V30, P617, DOI 10.1055/s-2007-1001366; Grantcharov TP, 2004, BRIT J SURG, V91, P146, DOI 10.1002/bjs.4407; Haluck RS, 2000, ARCH SURG-CHICAGO, V135, P786, DOI 10.1001/archsurg.135.7.786; Healy Gerald B, 2002, Bull Am Coll Surg, V87, P10; Kneebone RL, 2002, MED EDUC, V36, P1093, DOI 10.1046/j.1365-2923.2002.135410.x; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; Riva G, 2003, METHOD INFORM MED, V42, P524; Rogers DA, 2002, AM J SURG, V183, P242, DOI 10.1016/S0002-9610(02)00798-5; SATAVA RM, 1993, SURG ENDOSC-ULTRAS, V7, P203, DOI 10.1007/BF00594110; *SEN SURG GREAT BR, 1998, 5 SEN SURG GREAT BRI; Seymour NE, 2002, ANN SURG, V236, P458, DOI 10.1097/00000658-200210000-00008; Soler L, 2000, Stud Health Technol Inform, V70, P316; Yadav Jay S, 2004, Cleve Clin J Med, V71 Suppl 1, pS45	18	131	135	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1538	1540		10.1016/S0140-6736(04)17278-4	http://dx.doi.org/10.1016/S0140-6736(04)17278-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500900				2022-12-28	WOS:000224645500033
J	Wright, P				Wright, P			Maurice HF Wilkins - Obituary	LANCET			English	Biographical-Item												xeq87@dial.pipex.com							0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1482	1482		10.1016/S0140-6736(04)17258-9	http://dx.doi.org/10.1016/S0140-6736(04)17258-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15505895				2022-12-28	WOS:000224645500013
J	Jaillon, O; Aury, JM; Brunet, F; Petit, JL; Stange-Thomann, N; Mauceli, E; Bouneau, L; Fischer, C; Ozouf-Costaz, C; Bernot, A; Nicaud, S; Jaffe, D; Fisher, S; Lutfalla, G; Dossat, C; Segurens, B; Dasilva, C; Salanoubat, M; Levy, M; Boudet, N; Castellano, S; Anthouard, R; Jubin, C; Castelli, V; Katinka, M; Vacherie, B; Biemont, C; Skalli, Z; Cattolico, L; Poulain, J; de Berardinis, V; Cruaud, C; Duprat, S; Brottier, P; Coutanceau, JP; Gouzy, J; Parra, G; Lardier, G; Chapple, C; McKernan, KJ; McEwan, P; Bosak, S; Kellis, M; Volff, JN; Guigo, R; Zody, MC; Mesirov, J; Lindblad-Toh, K; Birren, B; Nusbaum, C; Kahn, D; Robinson-Rechavi, M; Laudet, V; Schachter, V; Quetier, F; Saurin, W; Scarpelli, C; Wincker, P; Lander, ES; Weissenbach, J; Roest Crollius, H				Jaillon, O; Aury, JM; Brunet, F; Petit, JL; Stange-Thomann, N; Mauceli, E; Bouneau, L; Fischer, C; Ozouf-Costaz, C; Bernot, A; Nicaud, S; Jaffe, D; Fisher, S; Lutfalla, G; Dossat, C; Segurens, B; Dasilva, C; Salanoubat, M; Levy, M; Boudet, N; Castellano, S; Anthouard, R; Jubin, C; Castelli, V; Katinka, M; Vacherie, B; Biemont, C; Skalli, Z; Cattolico, L; Poulain, J; de Berardinis, V; Cruaud, C; Duprat, S; Brottier, P; Coutanceau, JP; Gouzy, J; Parra, G; Lardier, G; Chapple, C; McKernan, KJ; McEwan, P; Bosak, S; Kellis, M; Volff, JN; Guigo, R; Zody, MC; Mesirov, J; Lindblad-Toh, K; Birren, B; Nusbaum, C; Kahn, D; Robinson-Rechavi, M; Laudet, V; Schachter, V; Quetier, F; Saurin, W; Scarpelli, C; Wincker, P; Lander, ES; Weissenbach, J; Roest Crollius, H			Genome duplication in the teleost fish Tetraodon nigroviridis reveals the early vertebrate proto-karyotype	NATURE			English	Article							RAY-FINNED FISHES; DNA-SEQUENCE; GENE DUPLICATION; SACCHAROMYCES-CEREVISIAE; COMPACT GENOME; ANIMAL GENOMES; EVOLUTION; CHROMOSOME; NUCLEOTIDE; ORIGIN	Tetraodon nigroviridis is a freshwater puffer fish with the smallest known vertebrate genome. Here, we report a draft genome sequence with long-range linkage and substantial anchoring to the 21 Tetraodon chromosomes. Genome analysis provides a greatly improved fish gene catalogue, including identifying key genes previously thought to be absent in fish. Comparison with other vertebrates and a urochordate indicates that fish proteins have diverged markedly faster than their mammalian homologues. Comparison with the human genome suggests similar to900 previously unannotated human genes. Analysis of the Tetraodon and human genomes shows that whole-genome duplication occurred in the teleost fish lineage, subsequent to its divergence from mammals. The analysis also makes it possible to infer the basic structure of the ancestral bony vertebrate genome, which was composed of 12 chromosomes, and to reconstruct much of the evolutionary history of ancient and recent chromosome rearrangements leading to the modern human karyotype.	CNRS, UMR Genoscope 8030, F-91057 Evry, France; Univ Evry, F-91057 Evry, France; Ecole Normale Super Lyon, Mol & Cellular Biol Lab, CNRS, UMR 5161,INRA,UMR 1237, F-69364 Lyon 07, France; MIT, Broad Inst, Cambridge, MA 02141 USA; Harvard, Cambridge, MA 02141 USA; Museum Natl Hist Nat, Dept Systemat & Evolut, Serv Systemat Mol, CNRS,IFR 101, F-75231 Paris, France; CNRS, UMR 5124, F-34293 Montpellier 5, France; UPF, IMIM, Grp Recerca Informat Biomed, Barcelona, Catalonia, Spain; Programa Bioinformat & Genom, Barcelona, Catalonia, Spain; Univ Lyon 1, CNRS, UMR Biometrie & Biol Evolut 5558, F-69622 Villeurbanne, France; INRA, CNRS, Lab Interact Plantes Microorganismes, F-31326 Castanet Tolosan, France; Agencourt Biosci Corp, Beverly, MA 01915 USA; Univ Wurzburg, Biozentrum, Biofuture Res Grp, D-97074 Wurzburg, Germany; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); Institut Hospital del Mar d'Investigacions Mediques (IMIM); Pompeu Fabra University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS); University of Wurzburg; Massachusetts Institute of Technology (MIT); Whitehead Institute	Weissenbach, J (corresponding author), CNRS, UMR Genoscope 8030, 2 Rue Gaston Cremieux, F-91057 Evry, France.	jsbach@genoscope.cns.fr	Kellis, Manolis/ABE-7385-2020; Jaillon, Olivier/GRY-6287-2022; Lutfalla, Georges/AAW-9386-2021; Guigo, Roderic/D-1303-2010; Gouzy, Jerome/AAH-4977-2020; Robinson-Rechavi, Marc/E-9727-2011; Kahn, Daniel/B-9393-2013; Aury, Jean-Marc/N-1621-2019; Gasull, Martina/J-4076-2019; Mesirov, Jill/AGF-7626-2022; Castellano, Sergi/A-7437-2016	Kellis, Manolis/0000-0001-7113-9630; Guigo, Roderic/0000-0002-5738-4477; Gouzy, Jerome/0000-0001-5695-4557; Robinson-Rechavi, Marc/0000-0002-3437-3329; Kahn, Daniel/0000-0001-8093-0854; Aury, Jean-Marc/0000-0003-1718-3010; LUTFALLA, Georges/0000-0002-6591-7894; Poulain, Julie/0000-0002-8744-3116; Petit, Jean-Louis/0000-0002-8566-0571; Jaillon, Olivier/0000-0002-7237-9596; de Berardinis, Veronique/0000-0002-3273-4135; Cruaud, Corinne/0000-0002-4752-7278; Brunet, Frederic/0000-0001-5145-8925; Castellano, Sergi/0000-0002-5819-4210; ROEST CROLLIUS, Hugues/0000-0002-8209-173X; McKernan, Kevin/0000-0002-3908-1122; Parra, Genis/0000-0002-0575-2936; Vacherie, Benoit/0000-0002-1564-0575				Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Artiguenave F, 2000, FEBS LETT, V487, P13, DOI 10.1016/S0014-5793(00)02273-0; Batzoglou S, 2002, GENOME RES, V12, P177, DOI 10.1101/gr.208902; Boulay JL, 2003, IMMUNITY, V19, P159, DOI 10.1016/S1074-7613(03)00211-5; Bouneau L, 2003, GENOME RES, V13, P1686, DOI 10.1101/gr.726003; Chiu CH, 2004, GENOME RES, V14, P11, DOI 10.1101/gr.1712904; Christoffels A, 2004, MOL BIOL EVOL, V21, P1146, DOI 10.1093/molbev/msh114; Collins JE, 2003, GENOME RES, V13, P27, DOI 10.1101/gr.695703; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Deloukas P, 2001, NATURE, V414, P865, DOI 10.1038/414865a; Dietrich FS, 2004, SCIENCE, V304, P304, DOI 10.1126/science.1095781; Fischer C, 2000, CYTOGENET CELL GENET, V88, P50, DOI 10.1159/000015484; Friedman R, 2001, GENOME RES, V11, P1842, DOI 10.1101/gr.200601; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Graves JAM, 2002, CYTOGENET GENOME RES, V99, P141, DOI 10.1159/000071585; Grutzner F, 1999, CHROMOSOME RES, V7, P655, DOI 10.1023/A:1009292220760; Gu X, 1996, P NATL ACAD SCI USA, V93, P4671, DOI 10.1073/pnas.93.10.4671; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Hatfield D. L., 2001, SELENIUM ITS MOL BIO; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Heilig R, 2003, NATURE, V421, P601, DOI 10.1038/nature01348; Holland PWH, 1999, SEMIN CELL DEV BIOL, V10, P515, DOI 10.1006/scdb.1999.0331; HOLLAND PWH, 1994, DEVELOPMENT, P125; Howe KL, 2002, GENOME RES, V12, P1418, DOI 10.1101/gr.149502; Hughes AL, 2001, GENOME RES, V11, P771, DOI 10.1101/gr.GR-1600R; Jaffe DB, 2003, GENOME RES, V13, P91, DOI 10.1101/gr.828403; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LI WH, 1985, MOL BIOL EVOL, V2, P150; Martin A, 2001, MOL BIOL EVOL, V18, P89, DOI 10.1093/oxfordjournals.molbev.a003723; McLysaght A, 2002, NAT GENET, V31, P200, DOI 10.1038/ng884; Mulder Nicola J, 2002, Brief Bioinform, V3, P225; Naruse K, 2004, GENOME RES, V14, P820, DOI 10.1101/gr.2004004; OHNO S, 1968, HEREDITAS-GENETISK A, V59, P169; Ojima Y., 1983, P111; PAMILO P, 1993, MOL BIOL EVOL, V10, P271; Panopoulou G, 2003, GENOME RES, V13, P1056, DOI 10.1101/gr.874803; Prohaska SJ, 2004, THEOR BIOSCI, V123, P89, DOI 10.1016/j.thbio.2004.03.004; Richard F, 2003, CHROMOSOME RES, V11, P605, DOI 10.1023/A:1024957002755; Robinson-Rechavi M, 2001, CURR BIOL, V11, pR458, DOI 10.1016/S0960-9822(01)00280-9; Roest Crollius H, 2000, NAT GENET, V25, P235, DOI 10.1038/76118; Roest Crollius H, 2000, GENOME RES, V10, P939, DOI 10.1101/gr.10.7.939; Spring J, 1997, FEBS LETT, V400, P2, DOI 10.1016/S0014-5793(96)01351-8; Tavare S., 1986, LECT MATH LIFE SCI, V17, P57; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; Torrents D, 2003, GENOME RES, V13, P2559, DOI 10.1101/gr.1455503; Vandepoele K, 2004, P NATL ACAD SCI USA, V101, P1638, DOI 10.1073/pnas.0307968100; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wolfe KH, 2001, NAT REV GENET, V2, P333, DOI 10.1038/35072009; Woods IG, 2000, GENOME RES, V10, P1903, DOI 10.1101/gr.10.12.1903; YUNIS JJ, 1982, SCIENCE, V215, P1525, DOI 10.1126/science.7063861; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847	57	1476	1578	3	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					946	957		10.1038/nature03025	http://dx.doi.org/10.1038/nature03025			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496914	Bronze			2022-12-28	WOS:000224585600035
J	Zhang, FC; Zhou, ZH				Zhang, FC; Zhou, ZH			Leg feathers in an Early Cretaceous bird	NATURE			English	Editorial Material							DINOSAURS		Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS	Zhang, FC (corresponding author), Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, POB 643, Beijing 100044, Peoples R China.	fuchengzhang@yeah.net						Chang M., 2003, JEHOL BIOTA; Chiappe LM, 1999, B AM MUS NAT HIST, P3; Christiansen P, 2004, CR PALEVOL, V3, P99, DOI 10.1016/j.crpv.2003.12.001; Feduccia A., 1999, ORIGIN EVOLUTION BIR, V2; Gatesy SM, 2001, NEW PERSPECTIVES ON THE ORIGIN AND EARLY EVOLUTION OF BIRDS, P333; Norberg R.A., 1985, P303; Norberg U., 1990, VERTEBRATE FLIGHT ME; Padian K, 1998, BIOL REV, V73, P1, DOI 10.1111/j.1469-185X.1997.tb00024.x; PENNYCUICK CJ, 1972, ANIMAL FLIGHT; Prum RO, 2003, NATURE, V421, P323, DOI 10.1038/421323a; Witmer Lawrence M., 2002, P3; Xu X, 2003, NATURE, V421, P335, DOI 10.1038/nature01342; Zhou ZH, 2003, NATURE, V421, P807, DOI 10.1038/nature01420	13	35	39	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					925	925		10.1038/431925a	http://dx.doi.org/10.1038/431925a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496911	Green Published, Bronze			2022-12-28	WOS:000224585600032
J	Glimcher, PW; Rustichini, A				Glimcher, PW; Rustichini, A			Neuroeconomics: The consilience of brain and decision	SCIENCE			English	Review							PARIETAL CORTEX; PERCEPTUAL DECISION; NEURAL BASIS; RISK; REPRESENTATION; RESPONSES; BEHAVIOR; STRATEGY; AXIOMS; REWARD	Economics, psychology, and neuroscience are converging today into a single, unified discipline with the ultimate aim of providing a single, general theory of human behavior. This is the emerging field of neuroeconomics in which consilience, the accordance of two or more inductions drawn from different groups of phenomena, seems to be operating. Economists and psychologists are providing rich conceptual tools for understanding and modeling behavior, white neurobiologists provide toots for the study of mechanism. The goat of this discipline is thus to understand the processes that connect sensation and action by revealing the neurobiological mechanisms by which decisions are made. This review describes recent developments in neuroeconomics from both behavioral and biological perspectives.	NYU, Ctr Neural Sci, New York, NY 10003 USA; Univ Minnesota, Dept Econ, Minneapolis, MN 55455 USA	New York University; University of Minnesota System; University of Minnesota Twin Cities	Glimcher, PW (corresponding author), NYU, Ctr Neural Sci, New York, NY 10003 USA.	glimcher@cns.nyu.edu						Allais M, 1953, ECONOMETRICA, V21, P503, DOI 10.2307/1907921; Andersen RA, 1997, ANNU REV NEUROSCI, V20, P303, DOI 10.1146/annurev.neuro.20.1.303; Barlow H.B., 1961, CURRENT PROBLEMS ANI; Barraclough DJ, 2004, NAT NEUROSCI, V7, P404, DOI 10.1038/nn1209; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Bernoulli D, 1954, ECONOMETRICA, V22, P23, DOI 10.2307/1909829; Breiter HC, 2001, NEURON, V30, P619, DOI 10.1016/S0896-6273(01)00303-8; CARACO T, 1980, ANIM BEHAV, V28, P820, DOI 10.1016/S0003-3472(80)80142-4; Coe B, 2002, J NEUROSCI, V22, P5081, DOI 10.1523/JNEUROSCI.22-12-05081.2002; Colby CL, 1999, ANNU REV NEUROSCI, V22, P319, DOI 10.1146/annurev.neuro.22.1.319; CONOVER K, IN PRESS GAMES EC BE; Dickhaut J, 2003, P NATL ACAD SCI USA, V100, P3536, DOI 10.1073/pnas.0530279100; DORRIS MC, IN PRESS NEURON; ELLSBERG D, 1961, Q J ECON, V75, P643, DOI 10.2307/1884324; Frith CD, 1999, SCIENCE, V286, P1692, DOI 10.1126/science.286.5445.1692; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; GALLISTEL CR, 1994, COGNITION, V50, P151, DOI 10.1016/0010-0277(94)90026-4; Gigerenzer G., 2002, BOUNDED RATIONALITY; Glimcher PW, 2003, BRADFORD BOOKS, P1; Gold JI, 2000, NATURE, V404, P390, DOI 10.1038/35006062; Gold JI, 2001, TRENDS COGN SCI, V5, P10, DOI 10.1016/S1364-6613(00)01567-9; GUTH W, 1982, J ECON BEHAV ORGAN, V3, P367, DOI 10.1016/0167-2681(82)90011-7; JANSSEN P, 2003, SOC NEUR ABSTR, V767, P2; Kacelnik A, 1997, TRENDS COGN SCI, V1, P304, DOI 10.1016/S1364-6613(97)01093-0; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; Kahneman D., 1982, JUDGEMENT UNCERTAINT; Knutson B, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0002.2001; LUCE D, 2000, SCI PSYCHOL SERIES, V8; McCabe K, 2001, P NATL ACAD SCI USA, V98, P11832, DOI 10.1073/pnas.211415698; Montague PR, 2002, NEUROIMAGE, V16, P1159, DOI 10.1006/nimg.2002.1150; NASH J, 1951, ANN MATH, V54, P286, DOI 10.2307/1969529; NASH JF, 1950, P NATL ACAD SCI USA, V36, P48, DOI 10.1073/pnas.36.1.48; Nash JF, 1950, ECONOMETRICA, V18, P155, DOI 10.2307/1907266; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; NEWSOME WT, 1990, COLD SPRING HARB SYM, V55, P697; O'Doherty J, 2001, NAT NEUROSCI, V4, P95, DOI 10.1038/82959; Paulus MP, 2001, NEUROIMAGE, V13, P91, DOI 10.1006/nimg.2000.0667; Pavlov I.P., 1927, CONDITIONED REFLEXES; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; Robson A, 2001, J POLIT ECON, V109, P900, DOI 10.1086/322083; RUSTICHINI A, IN PRESS GAMES EC BE; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; Shadlen MN, 2001, J NEUROPHYSIOL, V86, P1916, DOI 10.1152/jn.2001.86.4.1916; Shadlen MN, 1996, J NEUROSCI, V16, P1486; Sherrington C, 1906, INTEGRATIVE ACTION N; Sugrue LP, 2004, SCIENCE, V304, P1782, DOI 10.1126/science.1094765; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; Wilson E.O, 1998, CONSILIENCE; [No title captured]	49	409	420	2	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					447	452		10.1126/science.1102566	http://dx.doi.org/10.1126/science.1102566			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486291				2022-12-28	WOS:000224626500042
J	Farber, HW; Loscalzo, J				Farber, HW; Loscalzo, J			Mechanisms of disease: Pulmonary arterial hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							VASOACTIVE-INTESTINAL-PEPTIDE; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE-CELLS; PROTEIN-RECEPTOR-II; PORTOPULMONARY HYPERTENSION; PLEXIFORM LESIONS; EXPRESSION; SEROTONIN; PLASMA; ADRENOMEDULLIN		Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Loscalzo, J (corresponding author), Boston Univ, Sch Med, Evans Dept Med, 88 E Newton St, Boston, MA 02118 USA.	jloscalz@bu.edu	Loscalzo, Joseph/ABD-8980-2021	Farber, Harrison/0000-0002-0297-7902				Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; ALBERTSON TE, 1995, CHEST, V108, P1140, DOI 10.1378/chest.108.4.1140; ALLEN SW, 1993, AM REV RESPIR DIS, V148, P519, DOI 10.1164/ajrccm/148.2.519; Aslan M, 2001, P NATL ACAD SCI USA, V98, P15215, DOI 10.1073/pnas.221292098; Barst RJ, 2001, CLIN CHEST MED, V22, P509, DOI 10.1016/S0272-5231(05)70287-2; Battle RW, 1996, CHEST, V110, P1515, DOI 10.1378/chest.110.6.1515; BOLSTER MB, 1993, BAILLIERE CLIN RHEUM, V7, P79, DOI 10.1016/S0950-3579(05)80269-9; Castro M, 1996, MAYO CLIN PROC, V71, P543, DOI 10.4065/71.6.543; Castro O, 2003, BLOOD, V101, P1257, DOI 10.1182/blood-2002-03-0948; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; Cool CD, 2003, NEW ENGL J MED, V349, P1113, DOI 10.1056/NEJMoa035115; COX CP, 1984, PEPTIDES, V5, P325, DOI 10.1016/0196-9781(84)90228-6; Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059; Dingli D, 2001, CHEST, V120, P801, DOI 10.1378/chest.120.3.801; Donovan CL, 1996, TRANSPLANTATION, V61, P1180, DOI 10.1097/00007890-199604270-00011; Du Lingling, 2003, New England Journal of Medicine, V348, P500, DOI 10.1056/NEJMoa021650; Dumas JP, 1999, GEN PHARMACOL, V33, P289, DOI 10.1016/S0306-3623(99)00026-9; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI12805; Fallon MB, 2003, HEPATOLOGY, V37, P253, DOI 10.1053/jhep.2003.50090; Farber H W, 2001, AIDS Clin Care, V13, P53; Foletta VC, 2003, J CELL BIOL, V163, P421; Foletta VC, 2003, J CELL BIOL, V162, P1089, DOI 10.1083/jcb.200212060; Gaine SP, 1999, LANCET, V353, P74; Gaine SP, 1998, LANCET, V352, P719, DOI 10.1016/S0140-6736(98)02111-4; Galie Nazzareno, 2003, Am J Respir Med, V2, P123; Garcia-Manero G, 1999, AM J HEMATOL, V60, P130, DOI 10.1002/(SICI)1096-8652(199902)60:2<130::AID-AJH8>3.0.CO;2-Z; GERBER JG, 1980, J APPL PHYSIOL, V49, P107, DOI 10.1152/jappl.1980.49.1.107; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056/NEJMoa035477; GRISARU D, 1990, CHEST, V98, P1138, DOI 10.1378/chest.98.5.1138; Gunaydin S, 2002, CARDIOVASC SURG, V10, P138, DOI 10.1016/S0967-2109(01)00126-0; GURTNER HP, 1985, COR VASA, V27, P160; HASSOUN PM, 1992, P SOC EXP BIOL MED, V199, P165; HERVE P, 1990, AM J MED, V89, P117, DOI 10.1016/0002-9343(90)90111-P; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; Hill G, 1996, AUST NZ J MED, V26, P852, DOI 10.1111/j.1445-5994.1996.tb00642.x; HILLIKER KS, 1984, AM J PHYSIOL, V246, pH747, DOI 10.1152/ajpheart.1984.246.6.H747; Kakishita M, 1999, CLIN SCI, V96, P33, DOI 10.1042/CS19980070; Klings ES, 2001, RESP RES, V2, P280, DOI 10.1186/rr70; KOREN A, 1987, AM J DIS CHILD, V141, P93, DOI 10.1001/archpedi.1987.04460010093035; Launay JM, 2002, NAT MED, V8, P1129, DOI 10.1038/nm764; LEE SL, 1994, AM J PHYSIOL, V266, pL46, DOI 10.1152/ajplung.1994.266.1.L46; LIU F, 1995, MOL CELL BIOL, V15, P3479; Loscalzo J, 2001, NEW ENGL J MED, V345, P367, DOI 10.1056/NEJM200108023450511; Marcos E, 2003, AM J RESP CRIT CARE, V168, P487, DOI 10.1164/rccm.200210-1212OC; Mark EJ, 1997, NEW ENGL J MED, V337, P1483; Mark EJ, 1997, NEW ENGL J MED, V337, P602, DOI 10.1056/NEJM199708283370904; MARUNO K, 1995, AM J PHYSIOL-LUNG C, V268, pL1047, DOI 10.1152/ajplung.1995.268.6.L1047; MARVIN KS, 1993, CHEST, V103, P642, DOI 10.1378/chest.103.2.642; Mason NA, 1998, J PATHOL, V185, P313, DOI 10.1002/(SICI)1096-9896(199807)185:3<313::AID-PATH93>3.0.CO;2-8; MCDONNELL PJ, 1983, AM REV RESPIR DIS, V127, P437, DOI 10.1164/arrd.1983.127.4.437; MCQUILLAN LP, 1994, AM J PHYSIOL-HEART C, V267, pH1921; MCQUILLAN LP, 1995, AM J PHYSL H, V268; Mehta S, 2003, CHEST, V124, P2045, DOI 10.1378/chest.124.6.2045; Minter KR, 2001, AM J RESP CRIT CARE, V164, P2016, DOI 10.1164/ajrccm.164.11.2104101; MOLDEN D, 1982, ARCH PATHOL LAB MED, V106, P328; MURRAY RJ, 1989, CHEST, V96, P1050, DOI 10.1378/chest.96.5.1050; Newman JH, 2004, J AM COLL CARDIOL, V43, p33S, DOI 10.1016/j.jacc.2004.02.028; Newman JH, 2002, NEW ENGL J MED, V346, P1258; Newman JH, 2001, NEW ENGL J MED, V345, P319, DOI 10.1056/NEJM200108023450502; NEWMAN JH, 2001, NEW ENGL J MED, V345, P1502; Nicholls MG, 2001, PEPTIDES, V22, P1745, DOI 10.1016/S0196-9781(01)00508-3; Nishikimi T, 1997, HEART, V78, P390, DOI 10.1136/hrt.78.4.390; Peacock AJ, 1999, THORAX, V54, P1107, DOI 10.1136/thx.54.12.1107; Peacock AJ, 2000, THORAX, V55, P254; Petkov V, 2003, J CLIN INVEST, V111, P1339, DOI 10.1172/JCI200317500; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; Rudge JS, 2003, CIRC RES, V92, P947, DOI 10.1161/01.RES.0000074031.94558.99; SCHAIBERGER PH, 1993, CHEST, V104, P614, DOI 10.1378/chest.104.2.614; SHIMOKUBO T, 1995, LIFE SCI, V57, P1771, DOI 10.1016/0024-3205(95)02155-C; Shishido Naohiko, 2002, Nihon Kokyuki Gakkai Zasshi, V40, P574; Silver RM, 1996, RHEUM DIS CLIN N AM, V22, P825, DOI 10.1016/S0889-857X(05)70303-3; Simonneau G, 1998, CHEST, V114, p195S, DOI 10.1378/chest.114.3_Supplement.195S; Simonneau G, 2004, J AM COLL CARDIOL, V43, p5S, DOI 10.1016/j.jacc.2004.02.037; SODERMAN C, 1993, CLIN PHYSIOL, V13, P677, DOI 10.1111/j.1475-097X.1993.tb00482.x; SPEICH R, 1991, CHEST, V100, P1268, DOI 10.1378/chest.100.5.1268; STELZNER TJ, 1992, AM J PHYSIOL, V262, pL614, DOI 10.1152/ajplung.1992.262.5.L614; Sweeney M, 2000, Respir Res, V1, P40, DOI 10.1186/rr11; TRELL E, 1972, AM J MED, V53, P50, DOI 10.1016/0002-9343(72)90115-5; Trembath RC, 2001, NEW ENGL J MED, V345, P325, DOI 10.1056/NEJM200108023450503; Tuder RM, 1999, AM J RESP CRIT CARE, V159, P1925, DOI 10.1164/ajrccm.159.6.9804054; Tuder RM, 2001, J PATHOL, V195, P367, DOI 10.1002/path.953; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; VINCENT JA, 1993, AM J CARDIOL, V71, P1204, DOI 10.1016/0002-9149(93)90646-T; Weiss R A, 1998, J Natl Cancer Inst Monogr, P51; Yang YY, 2001, J GASTROENTEROL, V36, P181, DOI 10.1007/s005350170126; Zhao YD, 2003, CIRC RES, V92, P984, DOI 10.1161/01.RES.0000070587.79937.F0	90	917	981	8	94	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1655	1665		10.1056/NEJMra035488	http://dx.doi.org/10.1056/NEJMra035488			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483284				2022-12-28	WOS:000224427300012
J	Reber, M; Burrola, P; Lemke, G				Reber, M; Burrola, P; Lemke, G			A relative signalling model for the formation of a topographic neural map	NATURE			English	Article							RETINAL AXON GUIDANCE; GANGLION-CELL AXONS; VISUAL-SYSTEM; EPH RECEPTORS; IN-VITRO; PROJECTION; KINASE; ELF-1; CONNECTIONS; MODULATION	The highly ordered wiring of retinal ganglion cell (RGC) neurons in the eye to their synaptic targets in the superior colliculus of the midbrain has long served as the dominant experimental system for the analysis of topographic neural maps(1-3). Here we describe a quantitative model for the development of one arm of this map the wiring of the nasal - temporal axis of the retina to the caudal rostral axis of the superior colliculus. The model is based on RGC - RGC competition that is governed by comparisons of EphA receptor signalling intensity, which are made using ratios of, rather than absolute differences in, EphA signalling between RGCs(4). Molecular genetic experiments, exploiting a combinatorial series of EphA receptor knock-in and knockout mice, confirm the salient predictions of the model, and show that it both describes and predicts topographic mapping.	Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA	Salk Institute	Lemke, G (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA.	lemke@salk.edu	Reber, Michael/D-6250-2012	Reber, Michael/0000-0001-8842-7276				Brown A, 2000, CELL, V102, P77, DOI 10.1016/S0092-8674(00)00012-X; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Cohen-Cory S, 2002, SCIENCE, V298, P770, DOI 10.1126/science.1075510; Connor RJ, 1998, DEV BIOL, V193, P21, DOI 10.1006/dbio.1997.8786; Cutforth T, 2003, CELL, V114, P311, DOI 10.1016/S0092-8674(03)00568-3; Dottori M, 1998, P NATL ACAD SCI USA, V95, P13248, DOI 10.1073/pnas.95.22.13248; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Feldheim DA, 1998, NEURON, V21, P1303, DOI 10.1016/S0896-6273(00)80650-9; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; FRASER SE, 1980, ANNU REV NEUROSCI, V3, P319, DOI 10.1146/annurev.ne.03.030180.001535; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; Goodhill GJ, 1998, TRENDS NEUROSCI, V21, P226, DOI 10.1016/S0166-2236(97)01203-4; Hindges R, 2002, NEURON, V35, P475, DOI 10.1016/S0896-6273(02)00799-7; Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896-6273(00)80732-1; Kaas JH, 1997, BRAIN RES BULL, V44, P107, DOI 10.1016/S0361-9230(97)00094-4; McLaughlin T, 2003, NEURON, V40, P1147, DOI 10.1016/S0896-6273(03)00790-6; McLaughlin T, 2003, CURR OPIN NEUROBIOL, V13, P57, DOI 10.1016/S0959-4388(03)00014-X; Menzel P, 2001, DEV BIOL, V230, P74, DOI 10.1006/dbio.2000.0109; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; Mui SH, 2002, DEVELOPMENT, V129, P797; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; O'Leary DDM, 1999, CELL, V96, P255, DOI 10.1016/S0092-8674(00)80565-6; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; PRESTIGE MC, 1975, PROC R SOC SER B-BIO, V190, P77, DOI 10.1098/rspb.1975.0080; SIMON DK, 1992, J NEUROSCI, V12, P1212; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; WALTER J, 1987, DEVELOPMENT, V101, P685; Yates PA, 2001, J NEUROSCI, V21, P8548, DOI 10.1523/JNEUROSCI.21-21-08548.2001	30	95	97	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					847	853		10.1038/nature02957	http://dx.doi.org/10.1038/nature02957			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483613				2022-12-28	WOS:000224435500048
J	Rothman, RL; DeWalt, DA; Malone, R; Bryant, B; Shintani, A; Crigler, B; Weinberger, M; Pignone, M				Rothman, RL; DeWalt, DA; Malone, R; Bryant, B; Shintani, A; Crigler, B; Weinberger, M; Pignone, M			Influence of patient literacy on the effectiveness of a primary care-based diabetes disease management program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FUNCTIONAL HEALTH LITERACY; GLYCEMIC CONTROL; COMPREHENSION; KNOWLEDGE; IMPROVE; SKILLS	Context Low literacy is an important barrier for patients with diabetes, but interventions to address low literacy have not been well examined. Objective To examine the role of literacy on the effectiveness of a comprehensive disease management program for patients with diabetes. Design, Setting, and Participants Analysis of the influence of literacy on glycemic control and systolic blood pressure using data from a randomized controlled trial (conducted from February 2001 through April 2003) of a comprehensive diabetes management program. Participants were 217 patients aged 18 years or older with type 2 diabetes and poor glycemic control (glycosylated hemoglobin [HbA(1c)] levels greater than or equal to8.0%) and presenting to a US academic general internal medicine practice. Interventions All communication to patients was individualized and delivered to enhance comprehension among patients with low literacy. Intervention patients received intensive disease management from a multidisciplinary team. Control patients received an initial management session and continued with usual care. Main Outcome Measures Achievement of goal HbA(1c) levels and systolic blood pressure at 12-month follow-up for control and intervention patients stratified by literacy status. Results Complete 12-month data were available for 193 patients (89%). Among patients with low literacy, intervention patients were more likely than control patients to achieve goal HbA(1c) levels (less than or equal to7.0%) (42% vs 15%, respectively; adjusted odds ratio [OR], 4.6; 95% confidence interval [CI], 1.3 to 17.2; P=.02). Patients with higher literacy had similar odds of achieving goal HbA(1c) levels regardless of intervention status (24% vs 23%; adjusted OR, 1.0; 95% CI, 0.4 to 2.5; P=38). Improvements in systolic blood pressure were similar by literacy status. Conclusions Literacy may be an important factor for predicting who will benefit from an intervention for diabetes management. A diabetes disease management program that addresses literacy may be particularly beneficial for patients with low literacy, and increasing access to such a program could help reduce health disparities.	Vanderbilt Univ, Med Ctr, Ctr Hlth Serv Res, Dept Med,Div Gen Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Diabet Res & Training, Nashville, TN 37232 USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA; Univ N Carolina, Dept Hlth Policy & Adm, Chapel Hill, NC USA; Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Rothman, RL (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Hlth Serv Res, Dept Med,Div Gen Med, Suite 6000,Med Ctr E, Nashville, TN 37232 USA.	russell.rothman@vanderbilt.edu		DeWalt, Darren/0000-0003-2270-751X; Pignone, Michael/0000-0002-6657-7342; Rothman, Russsell/0000-0002-1506-3990				American Diabetes Association, 2000, DIABETES CARE S1, V23, pS1; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; Baker DW, 1998, J GEN INTERN MED, V13, P791, DOI 10.1046/j.1525-1497.1998.00242.x; Baker DW, 1997, AM J PUBLIC HEALTH, V87, P1027, DOI 10.2105/AJPH.87.6.1027; BERKMAN ND, 2004, 8704E0072 AG HEALTHC; Comings J., 2001, BUILDING LEVEL PLAYI; Davis T C, 1993, Fam Med, V25, P391; Davis TC, 1998, HEALTH EDUC BEHAV, V25, P613, DOI 10.1177/109019819802500508; Davis TC, 1996, PEDIATRICS, V97, P804; Doak CC, 1998, CA-CANCER J CLIN, V48, P151, DOI 10.3322/canjclin.48.3.151; DOAK CC, PFIZER HLTH LITERACY; Doak L G, 1996, Oncol Nurs Forum, V23, P1305; Doak L G, 1987, Promot Health, V8, P6; DOAK LG, 1980, PATIENT COUNS HEALTH, V2, P101, DOI 10.1016/S0738-3991(80)80049-8; Fain J A, 1990, Diabetes Educ, V16, P11, DOI 10.1177/014572179001600101; Gazmararian JA, 1999, JAMA-J AM MED ASSOC, V281, P545, DOI 10.1001/jama.281.6.545; Hawthorne K, 1999, DIABETIC MED, V16, P591, DOI 10.1046/j.1464-5491.1999.00102.x; *I MED COMM HLTH L, 2004, HLTH LIT PRESCR END; Kicklighter J R, 1993, Diabetes Educ, V19, P40; Kolstad A., 2002, ADULT LITERACY AM; Krein SL, 2004, AM J MED, V116, P732, DOI 10.1016/j.amjmed.2003.11.028; *NAT DIAB DAT GROU, 1995, DIAB AM; *NAT DIAB INF CLEA, 2002, NAT DIAB STAT DIAB S; Nurss JR, 1997, DIABETES EDUCATOR, V23, P563, DOI 10.1177/014572179702300508; Parker RM, 1999, JAMA-J AM MED ASSOC, V281, P552; Piette JD, 2000, AM J MED, V108, P20, DOI 10.1016/S0002-9343(99)00298-3; Renders CM, 2001, DIABETES CARE, V24, P1821, DOI 10.2337/diacare.24.10.1821; Rothman R, 2004, DIABETES EDUCATOR, V30, P263, DOI 10.1177/014572170403000219; Rothman R, 2002, JAMA-J AM MED ASSOC, V288, P2687, DOI 10.1001/jama.288.21.2687-a; ROTHMAN RL, IN PRESS AM J MED; Schillinger D, 2002, JAMA-J AM MED ASSOC, V288, P475, DOI 10.1001/jama.288.4.475; Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83; Weiss BD, 1998, J FAM PRACTICE, V46, P168; Weiss BD., 2003, HLTH LITERACY MANUAL; Williams MV, 1998, CHEST, V114, P1008, DOI 10.1378/chest.114.4.1008; Williams MV, 1998, ARCH INTERN MED, V158, P166, DOI 10.1001/archinte.158.2.166	36	261	262	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2004	292	14					1711	1716		10.1001/jama.292.14.1711	http://dx.doi.org/10.1001/jama.292.14.1711			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861JS	15479936	Bronze			2022-12-28	WOS:000224413400030
J	Depoortere, E; Checchi, F; Broillet, F; Gerstl, S; Minetti, A; Gayraud, O; Briet, V; Pahl, J; Defourny, I; Tatay, M; Brown, V				Depoortere, E; Checchi, F; Broillet, F; Gerstl, S; Minetti, A; Gayraud, O; Briet, V; Pahl, J; Defourny, I; Tatay, M; Brown, V			Violence and mortality in West Darfur, Sudan (2003-04): epidemiological evidence from four surveys	LANCET			English	Article							HEALTH; CONGO; WAR	Background Violence in Darfur, Sudan, has rendered more than one million people internally displaced. An epidemiological study of the effect of armed incursions on mortality in Darfur was needed to provide a basis for appropriate assistance to internally displaced people. Methods Between April and June, 2004, we did retrospective cluster surveys among 215 400 internally displaced people in four sites of West Darfur (Zalingei, Murnei, Niertiti, El Geneina). Mortality recall periods covered both the predisplacement and post-displacement periods in Zalingei, Murnei, and Niertiti, but not in El Geneina. Heads of households provided dates, causes, and places of deaths, and described the family structure. Findings Before arrival at displacement sites, mortality rates (expressed as deaths per 10 000 per day), were 5.9 (95% CI 2.2-14.9) in Zalingei, 9.5 (6.4-14.0) in Murnei, and 7.3 (3.2-15.7) in Niertiti. Violence caused 68-93% of these deaths. People who were killed were mostly adult men (relative risk 29.1-117.9 compared with children younger than 15 years), but included women and children. Most households fled because of direct village attacks. in camps, mortality rates fell but remained above the emergency benchmark, with a peak of 5.6 in El Geneina. Violence persisted even after displacement. Age and sex pyramids of surviving populations were skewed, with a deficit in men. Interpretation This study, which was done in a difficult setting, provides epidemiological evidence of this conflict's effect on civilians, confirming the serious nature of the crisis, and reinforcing findings from other war contexts.	Epictr, Paris, France; Med Sans Frontieres, Paris, France	Doctors Without Borders	Depoortere, E (corresponding author), Epictr, Paris, France.	evelyn.depoortere@brussels.msf.org		Checchi, Francesco/0000-0001-9030-5382				*AG FRANC PRESS, 2004, SUD PLAYS DEATH TOLL; *AG FRANC PRESS, 2004, SUD DARF CALM BEC NO; Amnesty International, 2004, SUD DARF RAP WEAP WA; *BBC, 2004, US HOUS CALLS DARF G; Brown V, 2002, LANCET, V359, P161, DOI 10.1016/S0140-6736(02)07378-6; Brown V, 2001, DISASTERS, V25, P164, DOI 10.1111/1467-7717.00168; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Grein T, 2003, BRIT MED J, V327, P650, DOI 10.1136/bmj.327.7416.650; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; *HUM RIGHTS WATCH, 2004, DARF DESTR ETHN CLEA; Legros D, 2001, LANCET, V357, P1429, DOI 10.1016/S0140-6736(00)04569-4; Murray CJL, 2002, BRIT MED J, V324, P346, DOI 10.1136/bmj.324.7333.346; Nathan N, 2004, LANCET, V363, P1402, DOI 10.1016/S0140-6736(04)16070-4; *OFF UN HIGH COMM, 2004, REP UN HIGH COMM HUM; *OFF UN HUM RES CO, 2004, DARF HUM PROF 5; Roberts L, 1999, LANCET, V353, P2249, DOI 10.1016/S0140-6736(05)76308-X; Salignon P, 2000, LANCET, V356, P1762, DOI 10.1016/S0140-6736(00)03217-7; Singh JA, 2004, LANCET, V364, P230, DOI 10.1016/S0140-6736(04)16691-9; Spiegel PB, 2000, LANCET, V355, P2204, DOI 10.1016/S0140-6736(00)02404-1; Tomczyk B, 2004, EMERGENCY NUTR MORTA; *UN HIGH COMM REF, 2004, DARF IDP EV CHAD SEC; UN. High Commission for Refugees, 1999, HDB EM; United Nations General Assembly, 1948, CONV PREV PUN CRIM G; *US AG INT DEV, 2004, SUD DARF CHAD BORD R; *WHO, 2004, RETR MORT SURV INT D; WOODRUFF BA, 2002, FIELD EXCHANGE, V17, P16	26	83	83	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	2004	364	9442					1315	1320		10.1016/S0140-6736(04)17187-0	http://dx.doi.org/10.1016/S0140-6736(04)17187-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474133				2022-12-28	WOS:000224349700026
J	Pincock, S				Pincock, S			William Carlisle Reeves - Obituary	LANCET			English	Biographical-Item												stephenpincock@blueyonder.co.uk		Pincock, Stephen/0000-0003-1655-2902					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	2004	364	9442					1308	1308		10.1016/S0140-6736(04)17175-4	http://dx.doi.org/10.1016/S0140-6736(04)17175-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15517695				2022-12-28	WOS:000224349700014
J	Sfeir, MY; Wang, F; Huang, LM; Chuang, CC; Hone, J; O'Brien, SP; Heinz, TF; Brus, LE				Sfeir, MY; Wang, F; Huang, LM; Chuang, CC; Hone, J; O'Brien, SP; Heinz, TF; Brus, LE			Probing electronic transitions in individual carbon nanotubes by Rayleigh scattering	SCIENCE			English	Article							RAMAN-SCATTERING; FLUORESCENCE; BUNDLES	Rayleigh scattering spectra were obtained from individual single-waited carbon nanotubes with the use of a laser-generated visible and near-infrared supercontinuum. This diagnostic method is noninvasive and general for nanoscale objects. The approach permits clear identification of excited states in arbitrary metallic and semiconducting nanotubes. We analyzed spectral lineshapes in relation to the role of excitonic effects and correlated the results with Raman scattering data on individual tubes. The nanotube structure remained the same over distances of tens of micrometers. Small nanotube bundles retained distinct Rayleigh spectroscopic signatures of their component nanotubes, thus allowing the probing of nanotube-nanotube interactions.	Columbia Univ, Dept Phys, New York, NY 10027 USA; Columbia Univ, Dept Chem, New York, NY 10027 USA; Columbia Univ, Dept Elect Engn, New York, NY 10027 USA; Columbia Univ, Dept Appl Math & Phys, New York, NY 10027 USA; Columbia Univ, Dept Mech Engn, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Heinz, TF (corresponding author), Columbia Univ, Dept Phys, 3000 Broadway, New York, NY 10027 USA.	tony.heinz@columbia.edu; leb26@columbia.edu	Heinz, Tony/K-7797-2015; Sfeir, Matthew/AAE-7390-2019; wang, Feng/I-5727-2015; O'Brien, Stephen/D-7682-2013; Huang, Limin/J-6211-2014; bartelsdoe, ludwig/F-8008-2011; OBrien, Stephen/O-8814-2019; Hone, James C/E-1879-2011	Heinz, Tony/0000-0003-1365-9464; Sfeir, Matthew/0000-0001-5619-5722; wang, Feng/0000-0001-8369-6194; O'Brien, Stephen/0000-0001-7531-8900; Huang, Limin/0000-0003-3053-0160; OBrien, Stephen/0000-0001-7531-8900; Hone, James C/0000-0002-8084-3301				AJIKI H, 1994, PHYSICA B, V201, P349, DOI 10.1016/0921-4526(94)91112-6; An L, 2002, J AM CHEM SOC, V124, P13688, DOI 10.1021/ja0274958; Ando T, 1997, J PHYS SOC JPN, V66, P1066, DOI 10.1143/JPSJ.66.1066; Bohren C., 2008, ABSORPTION SCATTERIN; Cheung CL, 2002, J PHYS CHEM B, V106, P2429, DOI 10.1021/jp0142278; Duesberg GS, 2000, PHYS REV LETT, V85, P5436, DOI 10.1103/PhysRevLett.85.5436; Fantini C, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.087401; Hartschuh A, 2003, SCIENCE, V301, P1354, DOI 10.1126/science.1087118; Huang SM, 2003, J AM CHEM SOC, V125, P5636, DOI 10.1021/ja034475c; Jorio A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.107403; Jorio A, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.121402; Jorio A, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.245416; Jorio A, 2001, PHYS REV LETT, V86, P1118, DOI 10.1103/PhysRevLett.86.1118; Kane CL, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.207401; Kim P, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.215502; Knight JC, 1996, OPT LETT, V21, P1547, DOI 10.1364/OL.21.001547; Lefebvre J, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.217401; Lin MF, 2000, PHYS REV B, V62, P13153, DOI 10.1103/PhysRevB.62.13153; LIN MF, 1994, PHYS REV B, V50, P17744, DOI 10.1103/PhysRevB.50.17744; Maruyama S, 2002, CHEM PHYS LETT, V360, P229, DOI 10.1016/S0009-2614(02)00838-2; O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631; Saito R, 2000, PHYS REV B, V61, P2981, DOI 10.1103/PhysRevB.61.2981; Saito R, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.085312; Saito R, 1998, PHYS PROPERTIES CARB; Spataru CD, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.077402; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Treacy MMJ, 1996, NATURE, V381, P678, DOI 10.1038/381678a0; Yu ZH, 2001, J PHYS CHEM B, V105, P1123, DOI 10.1021/jp003081u; Yu ZH, 2001, J PHYS CHEM B, V105, P6831, DOI 10.1021/jp010853t	29	199	205	4	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	2004	306	5701					1540	1543		10.1126/science.1103294	http://dx.doi.org/10.1126/science.1103294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15514117				2022-12-28	WOS:000225442700054
J	Treanor, J				Treanor, J			Weathering the influenza vaccine crisis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Rochester, Med Ctr, Infect Dis Unit, Rochester, NY 14642 USA	University of Rochester	Treanor, J (corresponding author), Univ Rochester, Med Ctr, Infect Dis Unit, Rochester, NY 14642 USA.							*CDCP, 2004, INT EST POP TARG INF; Gubareva LV, 2000, LANCET, V355, P827, DOI 10.1016/S0140-6736(99)11433-8; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Treanor J, 2002, VACCINE, V20, P1099, DOI 10.1016/S0264-410X(01)00440-6; WOOD JM, 1998, TXB INFLUENZA, P333	5	34	35	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2037	2040		10.1056/NEJMp048290	http://dx.doi.org/10.1056/NEJMp048290			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15492296	Bronze			2022-12-28	WOS:000225007200002
J	Abrescia, NGA; Cockburn, JJB; Grimes, JM; Sutton, GC; Diprose, JM; Butcher, SJ; Fuller, SD; Martin, CS; Burnett, RM; Stuart, DI; Bamford, DH; Bamford, JKH				Abrescia, NGA; Cockburn, JJB; Grimes, JM; Sutton, GC; Diprose, JM; Butcher, SJ; Fuller, SD; Martin, CS; Burnett, RM; Stuart, DI; Bamford, DH; Bamford, JKH			Insights into assembly from structural analysis of bacteriophage PRD1	NATURE			English	Article							CRYSTAL-STRUCTURE; CAPSID PROTEIN; COAT PROTEIN; VIRUS PRD1; WILD-TYPE; MEMBRANE; ADENOVIRUS; EVOLUTION; VERTEX; RESOLUTION	The structure of the membrane-containing bacteriophage PRD1 has been determined by X-ray crystallography at about 4 Angstrom resolution. Here we describe the structure and location of proteins P3, P16, P30 and P31. Different structural proteins seem to have specialist roles in controlling virus assembly. The linearly extended P30 appears to nucleate the formation of the icosahedral facets ( composed of trimers of the major capsid protein, P3) and acts as a molecular tape-measure, defining the size of the virus and cementing the facets together. Pentamers of P31 form the vertex base, interlocking with subunits of P3 and interacting with the membrane protein P16. The architectural similarities with adenovirus and one of the largest known virus particles PBCV-1 support the notion that the mechanism of assembly of PRD1 is scaleable and applies across the major viral lineage formed by these viruses.	Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England; Univ Oxford, Cent Chem Lab, Oxford Ctr Mol Sci, Oxford OX1 3QT, England; Univ Helsinki, Inst Biotechnol, Viikinkaari 5 00014, Finland; Univ Helsinki, Fac Biosci, Viikki Bioctr, Viikinkaari 5 00014, Finland; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Helsinki; University of Helsinki; The Wistar Institute	Stuart, DI (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Roosevelt Dr, Oxford OX3 7BN, England.	dave@strubi.ox.ac.uk	Abrescia, Nicola Gerardo/AAY-2323-2020; Butcher, Sarah J/H-5579-2012; San Martín, Carmen/A-4074-2010; Abrescia, Nicola GA/F-5898-2011	Abrescia, Nicola Gerardo/0000-0001-5559-1918; San Martín, Carmen/0000-0001-9799-175X; Stuart, David/0000-0002-3426-4210; Cockburn, Joseph/0000-0003-4730-1436; Butcher, Sarah/0000-0001-7060-5871; Bamford, Dennis/0000-0002-6438-8118; Grimes, Jonathan Mark/0000-0001-9698-0389				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAMFORD D, 1982, J VIROL, V44, P1031, DOI 10.1128/JVI.44.3.1031-1038.1982; BAMFORD DH, 1995, ADV VIRUS RES, V45, P281, DOI 10.1016/S0065-3527(08)60064-0; Bamford DH, 2002, THEOR POPUL BIOL, V61, P461, DOI 10.1006/tpbi.2002.1591; BAMFORD JKH, 1991, VIROLOGY, V183, P658, DOI 10.1016/0042-6822(91)90995-N; Bamford JKH, 2002, J STRUCT BIOL, V139, P103, DOI 10.1016/S1047-8477(02)00562-2; Belnap DM, 2000, TRENDS MICROBIOL, V8, P91, DOI 10.1016/S0966-842X(00)01704-2; Benson SD, 2002, ACTA CRYSTALLOGR D, V58, P39, DOI 10.1107/S0907444901017279; Benson SD, 1999, CELL, V98, P825, DOI 10.1016/S0092-8674(00)81516-0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURNETT RM, 1985, J MOL BIOL, V185, P125, DOI 10.1016/0022-2836(85)90187-1; Butcher SJ, 1995, EMBO J, V14, P6078, DOI 10.1002/j.1460-2075.1995.tb00298.x; Caldentey J, 2000, BIOCHEMISTRY-US, V39, P10566, DOI 10.1021/bi000711+; CHIU W, 1997, STRUCTURAL BIOL VIRU, P209; Cockburn JJB, 2003, ACTA CRYSTALLOGR D, V59, P538, DOI 10.1107/S0907444902023491; DELANO WL, 1995, ACTA CRYSTALLOGR D, V51, P740, DOI 10.1107/S0907444995001284; Diprose JM, 2001, EMBO J, V20, P7229, DOI 10.1093/emboj/20.24.7229; Esnouf RM, 1997, ACTA CRYSTALLOGR D, V53, P665, DOI 10.1107/S0907444997005829; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; Gowen B, 2003, J VIROL, V77, P7863, DOI 10.1128/JVI.77.14.7863-7871.2003; Grahn AM, 2002, MOL MICROBIOL, V46, P1199, DOI 10.1046/j.1365-2958.2002.03250.x; Grahn AM, 2002, J VIROL, V76, P4866, DOI 10.1128/JVI.76.10.4866-4872.2002; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Jaatinen ST, 2004, J VIROL, V78, P9790, DOI 10.1128/JVI.78.18.9790-9797.2004; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Journet L, 2003, SCIENCE, V302, P1757, DOI 10.1126/science.1091422; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LUO C, 1993, VIROLOGY, V194, P564, DOI 10.1006/viro.1993.1295; MINDICH L, 1982, J VIROL, V44, P1021, DOI 10.1128/JVI.44.3.1021-1030.1982; Morais MC, 2003, NAT STRUCT BIOL, V10, P572, DOI 10.1038/nsb939; Nandhagopal N, 2002, P NATL ACAD SCI USA, V99, P14758, DOI 10.1073/pnas.232580699; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rydman PS, 2002, J BACTERIOL, V184, P104, DOI 10.1128/JB.184.1.104-110.2002; Rydman PS, 1999, J MOL BIOL, V291, P575, DOI 10.1006/jmbi.1999.2978; Rydman PS, 2001, J MOL BIOL, V313, P785, DOI 10.1006/jmbi.2001.5068; Rydman PS, 2000, MOL MICROBIOL, V37, P356, DOI 10.1046/j.1365-2958.2000.01996.x; Sambrook J., 2001, MOL CLONING LAB MANU; San Martin C, 2002, NAT STRUCT BIOL, V9, P756, DOI 10.1038/nsb837; San Martin C, 2001, STRUCTURE, V9, P917, DOI 10.1016/S0969-2126(01)00642-6; Sokolova A, 2001, J BIOL CHEM, V276, P46187, DOI 10.1074/jbc.M106848200; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; STEWART PL, 1993, EMBO J, V12, P2589, DOI 10.1002/j.1460-2075.1993.tb05919.x; Stromsten NJ, 2003, J VIROL, V77, P6314, DOI 10.1128/JVI.77.11.6314-6321.2003; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Thuman-Commike PA, 1999, BIOPHYS J, V76, P3267, DOI 10.1016/S0006-3495(99)77479-5; Xu L, 2003, STRUCTURE, V11, P309, DOI 10.1016/S0969-2126(03)00023-6; Yan XD, 2000, NAT STRUCT BIOL, V7, P101, DOI 10.1038/72360	48	204	210	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					68	74		10.1038/nature03056	http://dx.doi.org/10.1038/nature03056			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525981				2022-12-28	WOS:000224854900039
J	Prange, R; Pallier, L; Hansen, KC; Howard, R; Vourlidas, A; Courtin, G; Parkinson, C				Prange, R; Pallier, L; Hansen, KC; Howard, R; Vourlidas, A; Courtin, G; Parkinson, C			An interplanetary shock traced by planetary auroral storms from the Sun to Saturn	NATURE			English	Article							EXTREME ULTRAVIOLET OBSERVATIONS; SOLAR-WIND; KILOMETRIC RADIATION; VOYAGER-1 ENCOUNTER; RADIO-EMISSION; CONVECTION; DYNAMICS; JUPITER; CAMERA; FIELD	A relationship between solar activity and aurorae on Earth was postulated(1,2) long before space probes directly detected plasma propagating outwards from the Sun(3). Violent solar eruption events trigger interplanetary shocks(4) that compress Earth's magnetosphere, leading to increased energetic particle precipitation into the ionosphere and subsequent auroral storms(5,6). Monitoring shocks is now part of the 'Space Weather' forecast programme aimed at predicting solar-activity-related environmental hazards. The outer planets also experience aurorae, and here we report the discovery of a strong transient polar emission on Saturn, tentatively attributed to the passage of an interplanetary shock - and ultimately to a series of solar coronal mass ejection (CME) events. We could trace the shock-triggered events from Earth, where auroral storms were recorded, to Jupiter, where the auroral activity was strongly enhanced, and to Saturn, where it activated the unusual polar source. This establishes that shocks retain their properties and their ability to trigger planetary auroral activity thoughout the Solar System. Our results also reveal differences in the planetary auroral responses on the passing shock, especially in their latitudinal and local time dependences.	Observ Paris, LESIA, F-92195 Meudon, France; Univ Michigan, Dept Atmospher Ocean & Space Sci, Ann Arbor, MI 48109 USA; USN, Res Lab, Washington, DC 20375 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91125 USA; NASA, Astrobiol Inst, Pasadena, CA 91125 USA	UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; University of Michigan System; University of Michigan; United States Department of Defense; United States Navy; Naval Research Laboratory; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Aeronautics & Space Administration (NASA)	Prange, R (corresponding author), Observ Paris, LESIA, 5 Pl Jules Janssen, F-92195 Meudon, France.	renee.prange@obspm.fr	Hansen, Kenneth C/F-3693-2011; Vourlidas, Angelos/C-8231-2009	Hansen, Kenneth C/0000-0002-8502-1980; Vourlidas, Angelos/0000-0002-8164-5948; Howard, Russell A./0000-0001-9027-8249				AXFORD WI, 1962, J GEOPHYS RES, V67, P3791, DOI 10.1029/JZ067i010p03791; BROADFOOT AL, 1981, SCIENCE, V212, P206, DOI 10.1126/science.212.4491.206; BROADFOOT AL, 1979, SCIENCE, V204, P979, DOI 10.1126/science.204.4396.979; Carr T. D., 1972, Physics of the Earth and Planetary Interiors, V6, P21, DOI 10.1016/0031-9201(72)90027-1; Chapman S, 1930, NATURE, V126, P129, DOI 10.1038/126129a0; CLARKE JT, 1980, ASTROPHYS J, V240, P696, DOI 10.1086/158277; COWLEY SHW, 2004, ANN GEOPHYS, V22, P2685; DEMAIRAN JJ, 1733, TRAITE PHYS HIST AUR, P245; DESCH MD, 1984, J GEOPHYS RES-SPACE, V89, P6819, DOI 10.1029/JA089iA08p06819; DESCH MD, 1983, J GEOPHYS RES-SPACE, V88, P8999, DOI 10.1029/JA088iA11p08999; FRANK LA, 1988, REV GEOPHYS, V26, P249, DOI 10.1029/RG026i002p00249; GALLAGHER DL, 1981, GEOPHYS RES LETT, V8, P1087, DOI 10.1029/GL008i010p01087; GALOPEAU PHM, 1998, J GEOPHYS RES, V100, P26337; GREENSTADT EW, 1965, J GEOPHYS RES, V70, P5451, DOI 10.1029/JZ070i021p05451; Gurnett DA, 2002, NATURE, V415, P985, DOI 10.1038/415985a; Hanlon P.G., 2004, J GEOPHYS RES, V109; LICHT AL, 1960, J GEOPHYS RES, V65, P1397, DOI 10.1029/JZ065i005p01397; LOCKWOOD M, 1990, J GEOPHYS RES-SPACE, V95, P17113, DOI 10.1029/JA095iA10p17113; Milan SE, 2000, ANN GEOPHYS-ATM HYDR, V18, P436, DOI 10.1007/s00585-000-0436-9; Pallier L, 2001, PLANET SPACE SCI, V49, P1159, DOI 10.1016/S0032-0633(01)00023-X; Prange R, 1998, J GEOPHYS RES-PLANET, V103, P20195, DOI 10.1029/98JE01128; RABL GKF, 1993, PLANET SPACE SCI, V41, P1079, DOI 10.1016/0032-0633(93)90111-E; Sandholt PE, 1998, GEOPHYS RES LETT, V25, P4313, DOI 10.1029/1998GL900113; SNYDER CW, 1963, J GEOPHYS RES, V68, P6361, DOI 10.1029/JZ068i024p06361; TOTH G, 1994, VERSATILE ADVECTION; Trauger JT, 1998, J GEOPHYS RES-PLANET, V103, P20237, DOI 10.1029/98JE01324; VASYLIUNAS VM, 1990, PHYS JOVIAN MAGNETOS, P395; Zarka P, 1998, J GEOPHYS RES-PLANET, V103, P20159, DOI 10.1029/98JE01323; ZARKA P, 1983, NATURE, V306, P767, DOI 10.1038/306767a0	29	102	102	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	2004	432	7013					78	81		10.1038/nature02986	http://dx.doi.org/10.1038/nature02986			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525983	Green Published			2022-12-28	WOS:000224854900041
J	Kraus, CK; Suarez, TA				Kraus, CK; Suarez, TA			Is there a doctor in the house? ... Or the senate? Physicians in US Congress, 1960-2004	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; UNHAPPY	Context The legislative and fiscal influences of Congress, as well as the continuing overall growth in health care spending as a portion of the gross domestic product, make congressional representation by physicians important because physicians have unique expertise in the impact of legislation on patient care and medical practice. Objectives To describe physician representation in the US Congress between 1960 and 2004 and relate the results to past representation of physicians in Congress. Design and Setting A retrospective observational study of members of the US Congress from all 50 states and all represented territories, who served from January 1960 to April 2004 (including 108th Congress), using data available in public access databases and congressional biographical records. Main Outcome Measures Physician representation in Congress, including occupation before taking office, state/territory of representation, sex, party affiliation, and time served. Results During the past 44 years, 25 (1.1%) of 2196 members of Congress were physicians. Physicians in Congress were more likely to be members of the Republican Party (60% vs 45.1% of all members, P=.007) and were similar to other members of Congress in mean years of service (9.2 years for physicians vs 12.3 years for all members, P=.09) and in sex distribution (4.0% female physicians vs 6.8% all female members, P=.57). Physicians in Congress represented 17 states, the Virgin Islands, and Puerto Rico. Conclusions Physician representation in Congress is low and is in stark contrast with physician roles during the first century of the United States. However, the 8 physicians currently serving in Congress may be indicative of a shift toward more direct influence of physicians in national politics.	Johns Hopkins Univ, Sinai Hosp, Div Cardiac Anesthesiol, Dept Anesthesiol, Baltimore, MD 21215 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Johns Hopkins Univ, Dept Emergency Med, Baltimore, MD USA	Johns Hopkins University; Sinai Hospital of Baltimore; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Suarez, TA (corresponding author), Johns Hopkins Univ, Sinai Hosp, Div Cardiac Anesthesiol, Dept Anesthesiol, 2401 W Belvedere Ave, Baltimore, MD 21215 USA.	tom_suarez_cabot-md@post.harvard.edu						*AM BAR ASS, NAT LAW POP STAT; *AM MED ASS, 2004 HLTH CAR TRENDS; *AM MED ASS, MED LIAB REF NOW COM; [Anonymous], FORTUNE MAGAZINE; Blendon RJ, 2001, HEALTH AFFAIR, V20, P33, DOI 10.1377/hlthaff.20.2.33; BROOKS D, 2004, SEATTLE POST IN 0630, pB6; Chernew ME, 2003, HEALTH AFFAIR, V22, P15, DOI 10.1377/hlthaff.22.4.15; *CONGR, C PAY RAT; Edwards N, 2002, BMJ-BRIT MED J, V324, P835, DOI 10.1136/bmj.324.7341.835; Gifford GE, 1976, PHYS SIGNERS DECLARA; HEFFLER S, 2004, HLTH AFFAIRS WE 0211; Iglehart JK, 2004, NEW ENGL J MED, V350, P826, DOI 10.1056/NEJMhpr045002; JAMESON MG, 1983, JAMA-J AM MED ASSOC, V249, P929; JENKINS CL, 2004, WASHINGTON POST 0205; Kereiakes DJ, 2004, CIRCULATION, V109, P2939, DOI 10.1161/01.CIR.0000133603.83150.CB; Landers SH, 2000, ARCH INTERN MED, V160, P3248, DOI 10.1001/archinte.160.21.3248; McHugh PR, 2004, NEW ENGL J MED, V351, P209, DOI 10.1056/NEJMp048147; Reinhardt UE, 2004, HEALTH AFFAIR, V23, P10, DOI 10.1377/hlthaff.23.3.10; Sandel MJ, 2004, NEW ENGL J MED, V351, P207, DOI 10.1056/NEJMp048145; Smith R, 2001, BMJ-BRIT MED J, V322, P1073, DOI 10.1136/bmj.322.7294.1073; Stolberg Sheryl Gay, 2004, NY TIMES, pA1; STONE A, 2004, US TODAY        0609, pA5; STRUNK BC, TRACKING HLTH CARE C; United States. Congress, BIOGR DIR US C 1774; *US CENS BUR, 2000, 65 YEARS POP 2000 CE; *US DEP LAB BUR LA, MAY 2003 NAT OCC EMP; Weiss Rick, 2004, WASH POST, pA19	27	13	13	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2004	292	17					2125	2129		10.1001/jama.292.17.2125	http://dx.doi.org/10.1001/jama.292.17.2125			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868OC	15523073				2022-12-28	WOS:000224921900025
J	Zapka, JG; Lemon, SC; Puleo, E; Estabrook, B; Luckmann, R; Erban, S				Zapka, JG; Lemon, SC; Puleo, E; Estabrook, B; Luckmann, R; Erban, S			Patient education for colon cancer screening: A randomized trial of a video mailed before a physical examination	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY-CARE PHYSICIANS; SERVICES TASK-FORCE; COLORECTAL-CANCER; DECISION-MAKING; FLEXIBLE SIGMOIDOSCOPY; PREVENTIVE SERVICES; LITERACY SKILLS; WOMEN; ADHERENCE; RISK	Background: Colorectal cancer screening is underused, and primary care clinicians are challenged to provide patient education within the constraints of busy practices. Objective: To test the effect of an educational video, mailed to patients' homes before a physical examination, on performance of colorectal cancer screening, particularly sigmoidoscopy. Design: Randomized, controlled trial. Setting: 5 primary care practices in central Massachusetts. Participants: 938 patients age 50 to 74 years who were scheduled for an upcoming physical examination, had no personal history of colorectal cancer, and were eligible for lower-endoscopy screening according to current guidelines. Intervention: Participants were randomly assigned to receive usual care (n = 488) or a video about colorectal cancer, the importance of early detection, and screening options (n = 450). Measurements: Baseline and 6-month follow-up telephone assessments were conducted. A dependent variable classified screening since baseline as 1) sigmoidoscopy with or without other tests, 2) another test or test combination, or 3) no tests. Results: Overall screening rates were the same in the intervention and control groups (55%). In regression modeling, intervention participants were nonsignificantly more likely to complete sigmoidoscopy alone or in combination with another test (odds ratio, 1.22 [95% CI, 0.88 to 1.70]). Intervention dose (viewing at least half of the video) was significantly related to receiving sigmoidoscopy with or without another test (odds ratio, 2.81 [CI, 1.85 to 4.26]). Recruitment records showed that at least 23% of people coming for periodic health assessments were currently screened by a lower-endoscopy procedure and therefore were not eligible. Limitations: The primary care sample studied consisted primarily of middle-class white persons who had high screening rates at baseline. The results may not be generalizable to other populations. The trial was conducted during a period of increased health insurance coverage for lower-endoscopy procedures and public media attention to colon cancer screening. Conclusions: A mailed video had no effect on the overall rate of colorectal cancer screening and only modestly improved sigmoidoscopy screening rates among patients in primary care practices.	Univ Massachusetts, Sch Med, Div Prevent & Behav Med, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Zapka, JG (corresponding author), Univ Massachusetts, Sch Med, Div Prevent & Behav Med, 55 Lake Ave N, Worcester, MA 01655 USA.		Wilkins, Thad/G-2541-2010		NCI NIH HHS [CA69653] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069653] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRE P, 1994, GASTROINTEST ENDOSC, V40, P271, DOI 10.1016/S0016-5107(94)70054-0; *AM AC FAM PHYS, 2001, SUMM POL REC PER HLT; *AM COLL OBST GYN, 2000, PRIM PREV CAR PER AS; Ashford A, 2000, AM J PREV MED, V19, P59, DOI 10.1016/S0749-3797(00)00152-5; Baier M, 2000, CANCER EPIDEM BIOMAR, V9, P229; Balas EA, 2000, ARCH INTERN MED, V160, P301, DOI 10.1001/archinte.160.3.301; Bandura A., 1986, SOCIAL FDN THOUGHT A; Barry MJ, 1999, JAMA-J AM MED ASSOC, V282, P2356, DOI 10.1001/jama.282.24.2356; Bejes C, 1992, Fam Pract Res J, V12, P83; BOSTICK RM, 1993, PREV MED, V22, P65, DOI 10.1006/pmed.1993.1005; Braddock CH, 1998, AM J MED, V105, P354; Braddock CH, 1999, JAMA-J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313; Breen N, 2001, J NATL CANCER I, V93, P1704, DOI 10.1093/jnci/93.22.1704; Brenes GA, 2000, PREV MED, V31, P410, DOI 10.1006/pmed.2000.0729; BURACK RC, 1987, PREV MED, V16, P739, DOI 10.1016/0091-7435(87)90014-4; Codori AM, 2001, PREV MED, V33, P128, DOI 10.1006/pmed.2001.0862; Cooper GS, 1998, CANCER, V82, P1476, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1476::AID-CNCR7>3.3.CO;2-D; Cram P, 2003, ARCH INTERN MED, V163, P1601, DOI 10.1001/archinte.163.13.1601; Curry SJ, 2003, FULFILLING POTENTIAL; Davis TC, 2001, CANCER INVEST, V19, P193, DOI 10.1081/CNV-100000154; Davis TC, 1998, J GEN INTERN MED, V13, P230, DOI 10.1046/j.1525-1497.1998.00072.x; Dunn AS, 2001, AM J PREV MED, V20, P130, DOI 10.1016/S0749-3797(00)00288-9; EDDY DM, 1987, GASTROENTEROLOGY, V92, P682, DOI 10.1016/0016-5085(87)90018-7; Erban S, 2001, Eff Clin Pract, V4, P10; Fishbein M., 1975, ATTITUDE INTENTION B; Flood AB, 1996, J GEN INTERN MED, V11, P342, DOI 10.1007/BF02600045; Friedman LC, 1999, PREV MED, V29, P119, DOI 10.1006/pmed.1999.0508; Friedman LC, 2001, J CANCER EDUC, V16, P85; Frosch DL, 2001, J GEN INTERN MED, V16, P391, DOI 10.1046/j.1525-1497.2001.016006391.x; GAGLIANO ME, 1988, J MED EDUC, V63, P785; GATCHEL RJ, 1986, J AM DENT ASSOC, V112, P218, DOI 10.14219/jada.archive.1986.0320; GORDON NP, 1993, J NATL CANCER I, V85, P566, DOI 10.1093/jnci/85.7.566; GORMAN C, 2000, TIME            0313, P70; Green L. W., 1999, HLTH PROMOTION PLANN; Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity, 2001, GUID DOC US IN VITR; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; Imperiale TF, 2002, NEW ENGL J MED, V346, P1781, DOI 10.1056/NEJM200206063462304; James AS, 2002, CANCER EPIDEM BIOMAR, V11, P529; KELLY RB, 1992, MED CARE, V30, P1029, DOI 10.1097/00005650-199211000-00006; Klabunde CN, 2003, PREV MED, V36, P352, DOI 10.1016/S0091-7435(02)00066-X; KOTTKE TE, 1993, MAYO CLIN PROC, V68, P785, DOI 10.1016/S0025-6196(12)60638-7; Lemon SC, 2003, AM J GASTROENTEROL, V98, P915, DOI 10.1016/S0002-9270(03)00024-8; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; Ling BS, 2001, J GEN INTERN MED, V16, P822, DOI 10.1046/j.1525-1497.2001.10337.x; Magnan S, 1997, J Ambul Care Manage, V20, P32; Mandelson MT, 2000, AM J PREV MED, V19, P149, DOI 10.1016/S0749-3797(00)00193-8; McCaffery K, 2001, SOC SCI MED, V53, P679, DOI 10.1016/S0277-9536(00)00375-0; MEAD VP, 1995, J FAM PRACTICE, V40, P363; MEADE CD, 1994, AM J PUBLIC HEALTH, V84, P119, DOI 10.2105/AJPH.84.1.119; MELAMED BG, 1978, J CONSULT CLIN PSYCH, V46, P1357, DOI 10.1037/0022-006X.46.6.1357; Michielutte R, 1999, J HEALTH CARE POOR U, V10, P281; MYERS RE, 1994, PREV MED, V23, P142, DOI 10.1006/pmed.1994.1020; MYERS RE, 1991, MED CARE, V29, P1039, DOI 10.1097/00005650-199110000-00009; NEALE AV, 1989, J OCCUP ENVIRON MED, V31, P1007, DOI 10.1097/00043764-198912000-00015; PETRAVAGE J, 1988, J FAM PRACTICE, V27, P387; Phillips KA, 1998, HEALTH SERV RES, V33, P571; Pignone M, 2000, ANN INTERN MED, V133, P761, DOI 10.7326/0003-4819-133-10-200011210-00008; Pignone M, 2002, ANN INTERN MED, V137, P132, DOI 10.7326/0003-4819-137-2-200207160-00015; Pignone M, 2002, ANN INTERN MED, V137, P96, DOI 10.7326/0003-4819-137-2-200207160-00007; Powe B D, 1999, Oncol Nurs Forum, V26, P583; Price J H, 1993, J Community Health, V18, P347, DOI 10.1007/BF01323966; Rawl SM, 2000, CANCER PRACT, V8, P32, DOI 10.1046/j.1523-5394.2000.81006.x; Richards C, 1998, AM J PREV MED, V15, P246, DOI 10.1016/S0749-3797(98)00075-0; Safran DG, 1998, MED CARE, V36, P728, DOI 10.1097/00005650-199805000-00012; Schroy PC, 1999, GASTROENTEROLOGY, V117, P304, DOI 10.1053/gast.1999.0029900304; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P595; Sieber WJ, 2000, CONTROL CLIN TRIALS, V21, p233S, DOI 10.1016/S0197-2456(00)00084-2; Smith RA, 2003, CA-CANCER J CLIN, V53, P27, DOI 10.3322/canjclin.53.1.27; STILLWATER B, 1995, PUBLIC HEALTH REP, V110, P211; Tang TS, 2001, CANCER PRACT, V9, P277, DOI 10.1046/j.1523-5394.2001.96008.x; THOMPSON RS, 1986, MED CARE, V24, P904, DOI 10.1097/00005650-198610000-00004; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; Walsh JME, 2003, JAMA-J AM MED ASSOC, V289, P1297, DOI 10.1001/jama.289.10.1297; Walsh JME, 2003, JAMA-J AM MED ASSOC, V289, P1288, DOI 10.1001/jama.289.10.1288; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weitzman ER, 2001, PREV MED, V32, P502, DOI 10.1006/pmed.2001.0838; WENDER RC, 2002, ENDOSC CLIN N AM, V12, P145; Woolf SH, 2000, NEW ENGL J MED, V343, P1641, DOI 10.1056/NEJM200011303432211; Yancey A K, 1994, J Cancer Educ, V9, P46; YANCEY AK, 1995, PREV MED, V24, P142, DOI 10.1006/pmed.1995.1027; Zapka JG, 2002, AM J PREV MED, V23, P28, DOI 10.1016/S0749-3797(02)00444-0; 2003, MMWR MORB MORTAL WKL, V52, P193	83	65	63	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2004	141	9					683	692		10.7326/0003-4819-141-9-200411020-00009	http://dx.doi.org/10.7326/0003-4819-141-9-200411020-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867JT	15520425				2022-12-28	WOS:000224839600005
J	Gillespie, DG				Gillespie, DG			The meeting that did not happen: Cairo, 10 years on	LANCET			English	Editorial Material									Johns Hopkins Sch Publ Hlth, Bill & Melinda Gates Inst Populat & Reprod Hlth, Baltimore, MD 21205 USA	Bill & Melinda Gates Foundation; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Gillespie, DG (corresponding author), Johns Hopkins Sch Publ Hlth, Bill & Melinda Gates Inst Populat & Reprod Hlth, Baltimore, MD 21205 USA.	dgillesp@jhsph.edu						BUSH GW, 2001, COMMUNICATION   0122; ETHELSTON S, 2004, FAMILY CARE INT NEW, P38; *INT PLANN PAR FED, 2004, COUNTD 2015 GLOB ROU; PAI, 2005, ACC DEN US RESTR INT; United Nations Population Fund (UNFPA), 1994, INT C POP DEV NEW YO; *US DEP STAT, 2004, PRES FISC YEAR 2005; WIRTH T, 2004, COUNTD 2015 GLOB ROU	7	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	2004	364	9445					1566	1567		10.1016/S0140-6736(04)17329-7	http://dx.doi.org/10.1016/S0140-6736(04)17329-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866IQ	15519617				2022-12-28	WOS:000224767600008
J	Gwatkin, DR				Gwatkin, DR			Integrating the management of childhood illness	LANCET			English	Editorial Material											Gwatkin, DR (corresponding author), 6483 Wishbone Terrace, Cabin John, MD 20818 USA.	dgwatkin@comcast.net						[Anonymous], BURDEN DIS GLOBAL PO; Bryce J, 2004, AM J PUBLIC HEALTH, V94, P406, DOI 10.2105/AJPH.94.3.406; Gwatkin DR, 1980, CAN HLTH NUTR INTERV; GWATKIN DR, 2000, SOCIOECONOMIC DIFFER; Tulloch J., 1999, Lancet (British edition), V354, P16, DOI 10.1016/S0140-6736(99)90252-0; *WHI DEP CHILD AD, 2002, MULT EV IMCI EFF COS; *WHO DEP CHILD AD, 2002, IMPL IMCI COMP 1 2 S	7	11	11	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	2004	364	9445					1557	1558		10.1016/S0140-6736(04)17324-8	http://dx.doi.org/10.1016/S0140-6736(04)17324-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	866IQ	15519612				2022-12-28	WOS:000224767600003
J	Daley, GQ				Daley, GQ			Chronic myeloid leukemia: Proving ground for cancer stem cells	CELL			English	Editorial Material							CHRONIC MYELOGENOUS LEUKEMIA; MICE; PROGENITORS; GENE	A central question in cancer biology is whether malignancy arises in self-renewing tissue stem cells that suffer oncogene activation or in differentiated cells that acquire properties of unremitting self-renewal? In two papers, Weissman and colleagues document both mechanisms: chronic leukemia arising by mutation affecting the hematopoietic stem cell (HSC) and acute leukemia evolving from committed granulocyte-macrophage progenitors that have acquired the self-renewal machinery of HSCs.	Harvard Univ, Sch Med, Childrens Hosp, Dept Biol Chem & Mol Pharmacol,Div Pediat Hematol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	Daley, GQ (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Biol Chem & Mol Pharmacol,Div Pediat Hematol, Boston, MA 02115 USA.							BIEMAUX C, 1996, BONE MARROW TRANSPL, V17, pS45; Bose S, 1998, BLOOD, V92, P3362, DOI 10.1182/blood.V92.9.3362; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593	9	27	29	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	2004	119	3					314	316		10.1016/j.cell.2004.10.015	http://dx.doi.org/10.1016/j.cell.2004.10.015			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	868IW	15507204	Bronze			2022-12-28	WOS:000224908300003
J	Gestwicki, JE; Crabtree, GR; Graef, IA				Gestwicki, JE; Crabtree, GR; Graef, IA			Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation	SCIENCE			English	Article							ALZHEIMERS-DISEASE THERAPIES; LIGANDS; TOXICITY; TARGETS; BINDING; DRUGS; FKBP	Protein aggregation is involved in the pathogenesis of neurodegenerative diseases and hence is considered an attractive target for therapeutic intervention. However, protein-protein interactions are exceedingly difficult to inhibit. Small molecules tack sufficient steric bulk to prevent interactions between large peptide surfaces. To yield potent inhibitors of beta-amyloid (Abeta) aggregation, we synthesized small molecules that increase their steric bulk by binding to chaperones but also have a moiety available for interaction with Abeta. This strategy yields potent inhibitors of Abeta aggregation and could lead to therapeutics for Alzheimer's disease and other forms of neurodegeneration.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Graef, IA (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol, Stanford, CA 94305 USA.	graef@cmgm.stanford.edu			NINDS NIH HHS [NS046789] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046789] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Braun PD, 2003, J AM CHEM SOC, V125, P7575, DOI 10.1021/ja035176q; Briesewitz R, 1999, P NATL ACAD SCI USA, V96, P1953, DOI 10.1073/pnas.96.5.1953; Citron M, 2002, NEUROBIOL AGING, V23, P1017, DOI 10.1016/S0197-4580(02)00122-7; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; Findeis MA, 2000, BBA-MOL BASIS DIS, V1502, P76, DOI 10.1016/S0925-4439(00)00034-X; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; HOLT DA, 1993, J AM CHEM SOC, V115, P9925, DOI 10.1021/ja00075a008; Janus C, 2000, BBA-MOL BASIS DIS, V1502, P63, DOI 10.1016/S0925-4439(00)00033-8; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klein WL, 2002, NEUROCHEM INT, V41, P345, DOI 10.1016/S0197-0186(02)00050-5; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Lee VMY, 2002, NEUROBIOL AGING, V23, P1039, DOI 10.1016/S0197-4580(02)00121-5; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Michaelis ML, 2003, J PHARMACOL EXP THER, V304, P897, DOI 10.1124/jpet.102.035840; Pollock R, 2002, NAT BIOTECHNOL, V20, P729, DOI 10.1038/nbt0702-729; Sacchettini JC, 2002, NAT REV DRUG DISCOV, V1, P267, DOI 10.1038/nrd769; Selkoe DJ, 2002, ANNU REV GENOM HUM G, V3, P67, DOI 10.1146/annurev.genom.3.022502.103022; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; Stankunas K, 2003, MOL CELL, V12, P1615, DOI 10.1016/S1097-2765(03)00491-X; Veselovsky AV, 2002, J MOL RECOGNIT, V15, P405, DOI 10.1002/jmr.597; Wong SS, 1998, J AM CHEM SOC, V120, P603, DOI 10.1021/ja9737735	26	160	171	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					865	869		10.1126/science.1101262	http://dx.doi.org/10.1126/science.1101262			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	869FS	15514157				2022-12-28	WOS:000224969400045
J	Blumenthal, D				Blumenthal, D			Doctors and drug companies	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHARMACEUTICAL-INDUSTRY; PHYSICIANS; GIFTS; REPRESENTATIVES; PRACTITIONERS; PERSPECTIVE; GUIDELINES; ETHICS; PIZZA; PAYS		Massachusetts Gen Hosp, Partners Hlth Care Syst, Inst Hlth Policy, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Partners Healthcare System	Blumenthal, D (corresponding author), Massachusetts Gen Hosp, Partners Hlth Care Syst, Inst Hlth Policy, Boston, MA 02114 USA.							*ACCME, 2003, ACCME ANN REP DAT 20; *ACCR COUNC CONT M, 2004, STAND COMM SUPP; Brett AS, 2003, ARCH INTERN MED, V163, P2213, DOI 10.1001/archinte.163.18.2213; Choudhry NK, 2002, JAMA-J AM MED ASSOC, V287, P612, DOI 10.1001/jama.287.5.612; Chren MM, 1999, AM J MED, V107, P182; Coyle SL, 2002, ANN INTERN MED, V136, P396, DOI 10.7326/0003-4819-136-5-200203050-00014; Dana J, 2003, JAMA-J AM MED ASSOC, V290, P252, DOI 10.1001/jama.290.2.252; DARVES B, 2003, ACP OBSERVER     JUL, P1; DEMBNER A, 2004, BOSTON GLOBE    0420, P1; Ferguson RP, 1999, AM J MED, V107, P149, DOI 10.1016/S0002-9343(99)00192-8; Gibbons RV, 1998, J GEN INTERN MED, V13, P151, DOI 10.1046/j.1525-1497.1998.00048.x; GILPIN KN, 2004, INT HERALD TRIB 0514, P11; Grande D, 2003, JAMA-J AM MED ASSOC, V290, P1150, DOI 10.1001/jama.290.9.1150-c; *KAIS FAM FDN, 2002, NAT SURV PHYS 2; Katz D, 2003, AM J BIOETHICS, V3, P39, DOI 10.1162/15265160360706552; Keim SM, 2004, ACAD EMERG MED, V11, P19, DOI 10.1197/S1069-6563(03)00580-3; Komesaroff PA, 2002, MED J AUSTRALIA, V176, P118, DOI 10.5694/j.1326-5377.2002.tb04318.x; KOWALCZYK L, 2003, BOSTON GLOBE    0525, P1; Levit K, 2004, HEALTH AFFAIR, V23, P147, DOI 10.1377/hlthaff.23.1.147; Moynihan R, 2003, BRIT MED J, V326, P1193, DOI 10.1136/bmj.326.7400.1193; Moynihan R, 2003, BMJ-BRIT MED J, V326, P1189, DOI 10.1136/bmj.326.7400.1189; Pear Robert, 2002, NY TIMES        0517, pA1; Petersen Melody, 2002, N Y Times Web, pC2; *PHRMA, 2002, PHRMA AD NEW MARK CO; Reinhardt UE, 2004, HEALTH AFFAIR, V23, P107, DOI 10.1377/hlthaff.23.1.107; Relman AS, 2002, NEW REPUBLIC, V227, P27; Relman AS, 2001, JAMA-J AM MED ASSOC, V285, P2009, DOI 10.1001/jama.285.15.2009; ROBEZNIEKS A, 2004, AM MED NEWS     0301, P1; Rogers WA, 2004, MED J AUSTRALIA, V180, P411, DOI 10.5694/j.1326-5377.2004.tb05995.x; SORRELL WH, 2004, PHARM MARKETING DISC; Studdert DM, 2004, NEW ENGL J MED, V351, P1891, DOI 10.1056/NEJMlim042229; Wager E, 2003, BRIT MED J, V326, P1196, DOI 10.1136/bmj.326.7400.1196; Watkins C, 2003, BRIT MED J, V326, P1178, DOI 10.1136/bmj.326.7400.1178; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; 2002, US TODAY        1014, pA14; 2003, N ENGL J MED, V349, P1866	36	162	169	1	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1885	1890		10.1056/NEJMhpr042734	http://dx.doi.org/10.1056/NEJMhpr042734			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509823				2022-12-28	WOS:000224723100014
J	Landrigan, CP; Rothschild, JM; Cronin, JW; Kaushal, R; Burdick, E; Katz, JT; Lilly, CM; Stone, PH; Lockley, SW; Bates, DW; Czeisler, CA				Landrigan, CP; Rothschild, JM; Cronin, JW; Kaushal, R; Burdick, E; Katz, JT; Lilly, CM; Stone, PH; Lockley, SW; Bates, DW; Czeisler, CA		Harvard Work Hours, Hlth Safety Gr	Effect of reducing interns' work hours on serious medical errors in intensive care units	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SLEEP-DEPRIVATION; HOUSE STAFF; PERFORMANCE; FATIGUE; NIGHT; COMPLICATIONS; ALERTNESS; EVENTS; IMPACT; SAFETY	BACKGROUND: Although sleep deprivation has been shown to impair neurobehavioral performance, few studies have measured its effects on medical errors. METHODS: We conducted a prospective, randomized study comparing the rates of serious medical errors made by interns while they were working according to a traditional schedule with extended (24 hours or more) work shifts every other shift (an ``every third night'' call schedule) and while they were working according to an intervention schedule that eliminated extended work shifts and reduced the number of hours worked per week. Incidents were identified by means of a multidisciplinary, four-pronged approach that included direct, continuous observation. Two physicians who were unaware of the interns' schedule assignments independently rated each incident. RESULTS: During a total of 2203 patient-days involving 634 admissions, interns made 35.9 percent more serious medical errors during the traditional schedule than during the intervention schedule (136.0 vs. 100.1 per 1000 patient-days, P<0.001), including 56.6 percent more nonintercepted serious errors (P<0.001). The total rate of serious errors on the critical care units was 22.0 percent higher during the traditional schedule than during the intervention schedule (193.2 vs. 158.4 per 1000 patient-days, P<0.001). Interns made 20.8 percent more serious medication errors during the traditional schedule than during the intervention schedule (99.7 vs. 82.5 per 1000 patient-days, P=0.03). Interns also made 5.6 times as many serious diagnostic errors during the traditional schedule as during the intervention schedule (18.6 vs. 3.3 per 1000 patient-days, P<0.001). CONCLUSIONS: Interns made substantially more serious medical errors when they worked frequent shifts of 24 hours or more than when they worked shorter shifts. Eliminating extended work shifts and reducing the number of hours interns work per week can reduce serious medical errors in the intensive care unit.	Brigham & Womens Hosp, Dept Med, Div Sleep Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Cardiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Internal Med Residency Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Sleep Med, Boston, MA USA; Childrens Hosp, Dept Med, Dept Med, Div Gen Pediat, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Landrigan, CP (corresponding author), Brigham & Womens Hosp, Dept Med, Div Sleep Med, 221 Longwood Ave, Boston, MA 02115 USA.	clandrigan@rics.bwh.harvard.edu		Landrigan, Christopher/0000-0001-8386-4100; Czeisler, Charles Andrew/0000-0002-7408-1849	AHRQ HHS [K08 HS13333, R01 HS12032, F32 HS14130] Funding Source: Medline; NCRR NIH HHS [M01 RR02635] Funding Source: Medline; NHLBI NIH HHS [T32 HL079010] Funding Source: Medline; NIOSH CDC HHS [R01 OH07567] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS013333, R01HS012032, F32HS014130] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH007567] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIOSH CDC HHS; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH))		*ACCR COUNC GRAD M, 2005, NUMB PROGR FILL POS; Baldwin DC, 2003, ACAD MED, V78, P1154, DOI 10.1097/00001888-200311000-00018; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Cavallo A, 2003, ERGONOMICS, V46, P653, DOI 10.1080/0014013031000085671; CZEISLER CA, 1990, NEW ENGL J MED, V322, P1253, DOI 10.1056/NEJM199005033221801; CZEISLER CA, 1982, SCIENCE, V217, P460, DOI 10.1126/science.7089576; Dawson D, 1997, NATURE, V388, P235, DOI 10.1038/40775; DINGES DF, 1990, SLEEP AND COGNITION, P159, DOI 10.1037/10499-012; DONCHIN Y, 1995, CRIT CARE MED, V23, P294, DOI 10.1097/00003246-199502000-00015; Eastridge BJ, 2003, AM J SURG, V186, P169, DOI 10.1016/S0002-9610(03)00183-1; FRIEDMAN RC, 1971, NEW ENGL J MED, V285, P201, DOI 10.1056/NEJM197107222850405; Gaba DM, 2002, NEW ENGL J MED, V347, P1249, DOI 10.1056/NEJMsa020846; GIRAUD T, 1993, CRIT CARE MED, V21, P40, DOI 10.1097/00003246-199301000-00011; GOTTLIEB DJ, 1991, ARCH INTERN MED, V151, P2065, DOI 10.1001/archinte.151.10.2065; Grantcharov TP, 2001, BRIT MED J, V323, P1222, DOI 10.1136/bmj.323.7323.1222; Jewett ME, 1999, J BIOL RHYTHM, V14, P588, DOI 10.1177/074873099129000920; Kaushal R, 2001, JAMA-J AM MED ASSOC, V285, P2114, DOI 10.1001/jama.285.16.2114; KOHN LT, 1999, ERR HUMAN BUILDING S; LAINE C, 1993, JAMA-J AM MED ASSOC, V269, P374, DOI 10.1001/jama.269.3.374; Lamberg L, 2002, JAMA-J AM MED ASSOC, V287, P303, DOI 10.1001/jama.287.3.303; Leape LL, 2002, JAMA-J AM MED ASSOC, V288, P501, DOI 10.1001/jama.288.4.501; Leape LL, 2000, JAMA-J AM MED ASSOC, V283, P1293; Lockley SW, 2004, NEW ENGL J MED, V351, P1829, DOI 10.1056/NEJMoa041404; Lockley SW, 2003, J CLIN ENDOCR METAB, V88, P4502, DOI 10.1210/jc.2003-030570; Monk TH, 2003, SLEEP, V26, P208, DOI 10.1093/sleep/26.2.208; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; Richardson GS, 1996, SLEEP, V19, P718; RUBINS HB, 1990, J GEN INTERN MED, V5, P104, DOI 10.1007/BF02600508; SAMKOFF JS, 1991, ACAD MED, V66, P687, DOI 10.1097/00001888-199111000-00013; SCHWARTZ RJ, 1992, ARCH SURG-CHICAGO, V127, P778; Veasey S, 2002, JAMA-J AM MED ASSOC, V288, P1116, DOI 10.1001/jama.288.9.1116; Weinger MB, 2002, JAMA-J AM MED ASSOC, V287, P955, DOI 10.1001/jama.287.8.955; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; Wyatt JK, 2004, SLEEP, V27, P374, DOI 10.1093/sleep/27.3.374; Wyatt JK, 1999, AM J PHYSIOL-REG I, V277, pR1152	39	1218	1239	0	130	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1838	1848		10.1056/NEJMoa041406	http://dx.doi.org/10.1056/NEJMoa041406			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509817				2022-12-28	WOS:000224723100007
J	Israel, E; Chinchilli, VM; Ford, JG; Boushey, HA; Cherniack, R; Craig, TJ; Deykin, A; Fagan, JK; Fahy, JV; Fish, J; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Liggett, SB; Martin, RJ; Mitra, N; Peters, SP; Silverman, E; Sorkness, C; Szefler, SJ; Wechsler, ME; Weiss, ST; Drazen, JM				Israel, E; Chinchilli, VM; Ford, JG; Boushey, HA; Cherniack, R; Craig, TJ; Deykin, A; Fagan, JK; Fahy, JV; Fish, J; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Liggett, SB; Martin, RJ; Mitra, N; Peters, SP; Silverman, E; Sorkness, C; Szefler, SJ; Wechsler, ME; Weiss, ST; Drazen, JM		Natl Heart Lung Blood Inst Asthma	Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial	LANCET			English	Article							BETA(2)-ADRENERGIC RECEPTOR HAPLOTYPES; INHALED BETA-AGONIST; MILD; POLYMORPHISMS; MODERATE; EXACERBATIONS	Background The issue of whether regular use of an inhaled beta(2)-adrenergic agonist worsens airflow and clinical outcomes in asthma is controversial. Retrospective studies have suggested that adverse effects occur in patients with a genetic polymorphism that results in homozygosity for arginine (Arg/Arg), rather than glycine (Gly/Gly), at aminoacid residue 16 of the beta(2)-adrenergic receptor. However, the existence of any genotype-dependent difference has not been tested in a prospective clinical trial. Methods Patients with mild asthma, not using a controller medication, were enrolled in pairs matched for forced expiratory volume in 1 s (FEV1) according to whether they had the Arg/Arg (n=37; four of 41 matches withdrew before randomisation) or Gly/Gly (n=41) genotype. Regularly scheduled treatment with albuterol or placebo was given in a masked, cross-over design, for 16-week periods. During the, study, as-needed albuterol use was discontinued and ipratropium bromide was used as needed. Morning peak expiratory flow rate (PEFR) was the primary outcome variable. The primary comparisons were between treatment period for each genotype; the secondary outcome was a treatment by genotype effect. Analyses were by intention to treat. Findings During the run-in period, when albuterol use was kept to a minimum, patients with the Arg/Arg genotype had an increase in morning PEFR of 23 L/min (p=0.0162); the change in patients with the Gly/Gly genotype was not significant (2 L/min; p=0.8399). During randomised treatment, patients with the Gly/Gly genotype had an increase in morning PEFR during treatment with regularly scheduled albuterol compared with placebo (14 L/min [95% CI 3 to 251; p=0.0175). By contrast, patients with the Arg/Arg genotype had lower morning PEFR during treatment with albuterol than during the placebo period, when albuterol use was limited (-10 L/min [49 to -2]; p=0.0209). The genotype-attributable treatment difference was therefore -24 L/min (-37 to -12; p=0.0003). There were similar genotype-specific effects in FEV1, symptoms, and use of supplementary reliever medication. Interpretation Genotype at the 16th aminoacid residue of the beta(2)-adrenergic receptor affects the long-term response to albuterol use. Bronchodilator treatments avoiding albuterol may be appropriate for patients with the Arg/Arg genotype.	Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Penn State Univ, Coll Med, Hershey, PA USA; Harlem Lung Ctr, New York, NY USA; Columbia Univ, New York, NY USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Univ Wisconsin, Madison, WI USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Columbia University; University of California System; University of California San Francisco; National Jewish Health; Jefferson University; University of Wisconsin System; University of Wisconsin Madison; University System of Ohio; University of Cincinnati	Israel, E (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	eisraelasst@partners.org	Wechsler, Michael/AAC-5506-2019; liggett, stephen b/E-7453-2012; Drazen, Jeffrey M/E-5841-2012; Wechsler, Michael/B-3979-2013	Wechsler, Michael/0000-0003-3505-2946; Liggett, Stephen B./0000-0002-0128-3669	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL051823, U10HL051843, U10HL051834, U10HL051810, U10HL051831, U10HL056443] Funding Source: NIH RePORTER; NHLBI NIH HHS [5 U10 HL056443, 5 U10 HL051831, 5 U10 HL051823, 5 U10 HL051810, 5 U10 HL051834, 5 U10 HL05184, 5 U10 HL051843] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Dennis SM, 2000, LANCET, V355, P1675, DOI 10.1016/S0140-6736(00)02238-8; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Martin RJ, 2001, CONTROL CLIN TRIALS, V22, p207S, DOI 10.1016/S0197-2456(01)00164-7; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; McGraw DW, 2003, J CLIN INVEST, V112, P619, DOI 10.1172/JCI200318193; *NAT ASTHM ED PROG, 1997, GUID DIAGN TREATM AS, V2; *NAT HEART LUNG BL, 1995, PUBL NAT HEART LUNG; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; Ross P, 1998, NAT BIOTECHNOL, V16, P1347, DOI 10.1038/4328; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Shore SA, 2003, J CLIN INVEST, V112, P495, DOI 10.1172/JCI200319642; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; Weir TD, 1998, AM J RESP CRIT CARE, V158, P787, DOI 10.1164/ajrccm.158.3.9801035	23	474	495	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1505	1512		10.1016/S0140-6736(04)17273-5	http://dx.doi.org/10.1016/S0140-6736(04)17273-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500895				2022-12-28	WOS:000224645500028
J	Alonso, PL; Sacarlal, J; Aponte, JJ; Leach, A; Macete, E; Milman, J; Mandomando, I; Spiessens, B; Guinovart, C; Espasa, M; Bassat, Q; Aide, P; Ofori-Anyinam, O; Navia, MM; Corachan, S; Ceuppens, M; Dubois, MC; Demoitie, MA; Dubovsky, F; Menendez, C; Tornieporth, N; Ballou, WR; Thompson, R; Cohen, J				Alonso, PL; Sacarlal, J; Aponte, JJ; Leach, A; Macete, E; Milman, J; Mandomando, I; Spiessens, B; Guinovart, C; Espasa, M; Bassat, Q; Aide, P; Ofori-Anyinam, O; Navia, MM; Corachan, S; Ceuppens, M; Dubois, MC; Demoitie, MA; Dubovsky, F; Menendez, C; Tornieporth, N; Ballou, WR; Thompson, R; Cohen, J			Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial	LANCET			English	Article							CIRCUMSPOROZOITE PROTEIN VACCINE; MALARIA VACCINE; SPF66 VACCINE; IMMUNOGENICITY; RTS,S	Background Development of an effective malaria vaccine could greatly contribute to disease control. RTS,S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium falciparum circumsporozoite surface antigen. We aimed to assess vaccine efficacy, immunogenicity, and safety in young African children. Methods We did a double-blind, phase IIb, randomised controlled trial in Mozambique in 2022 children aged 1-4 years. The study included two cohorts of children living in two separate areas which underwent different follow-up schemes. Participants were randomly allocated three doses of either RTS,S/AS02A candidate malaria vaccine or control vaccines. The primary endpoint, determined in cohort 1 (n=1605), was time to first clinical episode of P falciparum malaria (axillary temperature greater than or equal to37.5degreesC and P falciparum asexual parasitaemia >2500 per muL) over a 6-month surveillance period. Efficacy for prevention of new infections was determined in cohort 2 (n=417). Analysis was per protocol. Findings 115 children in cohort 1 and 50 in cohort 2 did not receive all three doses and were excluded from the perprotocol analysis. Vaccine efficacy for the first clinical episodes was 29.9% (95% CI 11.0-44.8; p=0.004). At the end of the 6-month observation period, prevalence of P falciparum infection was 37% lower in the RTS,S/AS02A group compared with the control group (11.9% VS 18.9%; p=0.0003). Vaccine efficacy for severe malaria was 57.7% (95% CI 16.2-80.6; p=0.019). In cohort 2, vaccine efficacy for extending time to first infection was 45.0 % (31.4-55.9; p<0.0001). Interpretation The RTS,S/AS02A vaccine was safe, well tolerated, and immunogenic. Our results show development of an effective vaccine against malaria is feasible.	Univ Barcelona, Hosp Clin, IDIBAPS, Ctr Salut Int, E-08036 Barcelona, Spain; Minist Saude, Invest Saude Manhica, Maputo 1929, Mozambique; Univ Eduardo Mondlane, Fac Med, Maputo, Mozambique; Minist Saude, Inst Nacl Saude, Maputo, Mozambique; Minist Saude, Direccao NAcl Saude, Maputo, Mozambique; GlaxoSmithKline Biol, Rixensart, Belgium; PATH, Malaria Vaccine Initiat, Rockville, MD USA	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Centro de Investigacao em Saude de Manhica; Eduardo Mondlane University; GlaxoSmithKline	Alonso, PL (corresponding author), Univ Barcelona, Hosp Clin, IDIBAPS, Ctr Salut Int, Villarroel 170, E-08036 Barcelona, Spain.	palonso@clinic.ub.es	Guinovart, Caterina/ABH-2981-2020; Bassat, Quique/P-2341-2016; Leach, Amanda/AAS-1120-2020; Sacarlal, Jahit/R-3172-2016; ESPASA, MATEU/L-4587-2014; Alonso, Pedro L/AAZ-3645-2020; Menéndez, Clara/Q-3446-2016; Mandomando, Inacio/ABD-8007-2020; Aide, Pedro/D-8771-2018	Bassat, Quique/0000-0003-0875-7596; Leach, Amanda/0000-0002-7114-9967; Sacarlal, Jahit/0000-0003-1059-217X; ESPASA, MATEU/0000-0003-4822-1024; Alonso, Pedro L/0000-0003-3292-3443; Menéndez, Clara/0000-0002-2641-6907; Mandomando, Inacio/0000-0002-1078-2187; 				Acosta CJ, 1999, TROP MED INT HEALTH, V4, P368, DOI 10.1046/j.1365-3156.1999.00406.x; ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; Alonso PL, 2002, POPULATION HLTH DEV, P189; Ballou WR, 2004, AM J TROP MED HYG, V71, P239; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; Breman JG, 2004, AM J TROP MED HYG, V71, P1; DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1; Doherty JF, 1999, AM J TROP MED HYG, V61, P865, DOI 10.4269/ajtmh.1999.61.865; ENEA V, 1984, SCIENCE, V225, P628, DOI 10.1126/science.6204384; Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342; GRAVES P, 2003, COCHRANE LIB; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; HESS KR, 1995, STAT MED, V14, P1707, DOI 10.1002/sim.4780141510; Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534; Klausner R, 2004, NATURE, V430, P930, DOI 10.1038/430930a; Loscertales MP, 2002, PEDIATR INFECT DIS J, V21, P148, DOI 10.1097/00006454-200202000-00013; Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0; SAUTE F, IN PRESS T R SOC TRO; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; Sun PF, 2003, J IMMUNOL, V171, P6961, DOI 10.4049/jimmunol.171.12.6961; Therneau TM, 2000, MODELING SURVIVAL DA; VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W; WIRTZ RA, 1987, EXP PARASITOL, V63, P166, DOI 10.1016/0014-4894(87)90158-5; World Health Organization, MAN SEV MAL PRACT HD, V3rd	25	585	610	0	46	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2004	364	9443					1411	1420		10.1016/S0140-6736(04)17223-1	http://dx.doi.org/10.1016/S0140-6736(04)17223-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488216				2022-12-28	WOS:000224485300027
J	Ainslie, G; Monterosso, J				Ainslie, G; Monterosso, J			A marketplace in the brain?	SCIENCE			English	Editorial Material							SELF-CONTROL; REWARD; ANTICIPATION; PARIETAL		Coatesville Vet Affairs Med Ctr, Coatesville, PA 19320 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Ainslie, G (corresponding author), Coatesville Vet Affairs Med Ctr, Coatesville, PA 19320 USA.	george.ainslie@med.va.gov		Monterosso, John/0000-0002-5613-3182; Ainslie, George/0000-0001-9201-9144				Ainslie G, 2003, CHOICE, BEHAVIOURAL ECONOMICS AND ADDICTION, P35, DOI 10.1016/B978-008044056-9/50043-9; Ainslie G, 2003, J EXP ANAL BEHAV, V79, P37, DOI 10.1901/jeab.2003.79-37; AINSLIE G, IN PRESS DISORDERS V; AINSLIE GW, 1974, J EXP ANAL BEHAV, V21, P485, DOI 10.1901/jeab.1974.21-485; Berns GS, 2001, J NEUROSCI, V21, P2793, DOI 10.1523/JNEUROSCI.21-08-02793.2001; Bunge SA, 2002, NEUROIMAGE, V17, P1562, DOI 10.1006/nimg.2002.1252; DELUTY MZ, 1983, BEHAV ANAL LETT, V3, P213; Frederick S, 2002, J ECON LIT, V40, P351, DOI 10.1257/002205102320161311; GIBBON J, 1977, PSYCHOL REV, V84, P279, DOI 10.1037/0033-295X.84.3.279; Green L, 2004, PSYCHOL BULL, V130, P769, DOI 10.1037/0033-2909.130.5.769; Hume D., 1968, TREATISE HUMAN NATUR; Kirby KN, 2001, J EXP PSYCHOL-APPL, V7, P154, DOI 10.1037//1076-898X.7.2.154; Knutson B, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0002.2001; Laibson D, 1997, Q J ECON, V112, P443, DOI 10.1162/003355397555253; Loewenstein G, 1996, ORGAN BEHAV HUM DEC, V65, P272, DOI 10.1006/obhd.1996.0028; Mather M, 2004, PSYCHOL SCI, V15, P259, DOI 10.1111/j.0956-7976.2004.00662.x; McClure SM, 2004, SCIENCE, V306, P503, DOI 10.1126/science.1100907; Montague PR, 2002, NEURON, V36, P265, DOI 10.1016/S0896-6273(02)00974-1; Paulus MP, 2001, NEUROIMAGE, V13, P91, DOI 10.1006/nimg.2000.0667; RESCORLA RA, 1988, AM PSYCHOL, V43, P151, DOI 10.1037/0003-066X.43.3.151; SCHULTZ W, 1992, J NEUROSCI, V12, P4595, DOI 10.1523/jneurosci.12-12-04595.1992	22	26	27	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2004	306	5695					421	423		10.1126/science.1104884	http://dx.doi.org/10.1126/science.1104884			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	864IF	15486281				2022-12-28	WOS:000224626500033
J	Imanishi, Y; Sato, T; Higashi, T; Sun, WK; Okubo, S				Imanishi, Y; Sato, T; Higashi, T; Sun, WK; Okubo, S			A network of superconducting gravimeters detects submicrogal coseismic gravity changes	SCIENCE			English	Article							INTERNAL DISLOCATIONS; SPHERICAL EARTH	With high-resolution continuous gravity recordings from a regional network of superconducting gravimeters, we have detected permanent changes in gravity acceleration associated with a recent large earthquake. Detected changes in gravity acceleration are smaller than 10(-8) meters seconds(-2) (1 micro-Galileo, about 10(-9) times the surface gravity acceleration) and agree with theoretical values calculated from a dislocation model. Superconducting gravimetry can contribute to the studies of secular gravity changes associated with tectonic processes.	Univ Tokyo, Ocean Res Inst, Nakano Ku, Tokyo 1648639, Japan; Natl Astron Observ Japan, Mizusawa, Iwate 0230861, Japan; Kyoto Univ, Grad Sch Sci, Dept Geophys, Sakyo Ku, Kyoto 6068502, Japan; Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); Kyoto University; University of Tokyo	Imanishi, Y (corresponding author), Univ Tokyo, Ocean Res Inst, Nakano Ku, 1-15-1 Minamidai, Tokyo 1648639, Japan.	imanishi@ori.u-tokyo.ac.jp	Okubo, Shuhei/AAX-1431-2021	Okubo, Shuhei/0000-0002-7015-3120				Aki K., 2002, QUANTITATIVE SEISMOL, Vsecond; BARNES DF, 1966, J GEOPHYS RES, V71, P451, DOI 10.1029/JZ071i002p00451; Boy JP, 2002, GEOPHYS J INT, V149, P534, DOI 10.1046/j.1365-246X.2002.01667.x; Crossley D, 2003, ADV GEOSCIENCES, V1, P65; CROSSLEY D, 1999, EOS, V80; Furuya M, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001989; *GEOGR SURV I JAP, UNPUB; GILBERT F, 1975, PHILOS T R SOC A, V278, P187, DOI 10.1098/rsta.1975.0025; Goodkind JM, 1999, REV SCI INSTRUM, V70, P4131, DOI 10.1063/1.1150092; HIGASHI T, 1996, MEM FS KYOTO U PAGC, V39, P313; IMANISHI Y, 2000, CAHIERS CTR EUROPEEN, V17, P97; IMANISHI Y, UNPUB; OKUBO S, 1993, GEOPHYS J INT, V115, P921, DOI 10.1111/j.1365-246X.1993.tb01501.x; OKUBO S, 1992, J GEOPHYS RES-SOL EA, V97, P7137, DOI 10.1029/92JB00178; PROTHERO WA, 1968, REV SCI INSTRUM, V39, P1257, DOI 10.1063/1.1683645; Rosat S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018304; SATO T, 1991, NONTIDAL GRAVITY CHA, V3, P109; SMYLIE DE, 1992, SCIENCE, V255, P1678, DOI 10.1126/science.255.5052.1678; Sun W, 1998, GEOPHYS J INT, V132, P79, DOI 10.1046/j.1365-246x.1998.00400.x; SUN WK, 1993, GEOPHYS J INT, V114, P569, DOI 10.1111/j.1365-246X.1993.tb06988.x; Tanaka Y, 2001, GEOPHYS RES LETT, V28, P2979, DOI 10.1029/2000GL012590; VIRTANEN H, 2001, J GEODETIC SOC JAPAN, V47, P328; WARBURTON RJ, 1977, GEOPHYS J ROY ASTR S, V48, P281, DOI 10.1111/j.1365-246X.1977.tb03672.x; Yamanaka Y, 2003, EARTH PLANETS SPACE, V55, pE21, DOI 10.1186/BF03352479	24	112	135	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					476	478		10.1126/science.1101875	http://dx.doi.org/10.1126/science.1101875			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486297				2022-12-28	WOS:000224626500050
J	Korenjak, M; Taylor-Harding, B; Binne, UK; Satterlee, JS; Stevaux, O; Aasland, R; White-Cooper, H; Dyson, N; Brehm, A				Korenjak, M; Taylor-Harding, B; Binne, UK; Satterlee, JS; Stevaux, O; Aasland, R; White-Cooper, H; Dyson, N; Brehm, A			Native E2F/RBF complexes contain Myb-interacting proteins and repress transcription of developmentally controlled E2F target genes	CELL			English	Article							DNA-REPLICATION; CELL-CYCLE; RETINOBLASTOMA PROTEIN; NEGATIVE REGULATOR; RB; CHROMATIN; RAS; LOCALIZATION; MECHANISMS; TRANSITION	The retinoblastoma tumor suppressor protein (pRb) regulates gene transcription by binding E2F transcription factors. pRb can recruit several repressor complexes to E2F bound promoters; however, native pRb repressor complexes have not been isolated. We have purified E2F/RBF repressor complexes from Drosophila embryo extracts and characterized their roles in E2F regulation. These complexes contain RBF, E2F and Myb-interacting proteins that have previously been shown to control developmentally regulated patterns of DNA replication in follicle cells. The complexes localize to transcriptionally silent sites on polytene chromosomes and mediate stable repression of a specific set of E2F targets that have sex- and differentiation-specific expression patterns. Strikingly, seven of eight complex subunits are structurally and functionally related to C. elegans synMuv class B genes, which cooperate to control vulval differentiation in the worm. These results reveal an extensive evolutionary conservation of specific pRb repressor complexes that physically combine subunits with established roles in the regulation of transcription, DNA replication, and chromatin structure.	Univ Munich, Adolf Butenandt Inst, Lehrstuhl Mol Biol, Munich, Germany; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Univ Bergen, Dept Mol Biol, Bergen, Norway; Univ Bergen, Computat Biol Unit, Bergen, Norway; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Munich; Harvard University; Massachusetts General Hospital; University of Bergen; University of Bergen; University of Oxford	Brehm, A (corresponding author), Univ Munich, Adolf Butenandt Inst, Lehrstuhl Mol Biol, Munich, Germany.	abrehm@lmu.de	White-Cooper, Helen/A-4633-2010	White-Cooper, Helen/0000-0002-3373-8023; Nolan-Stevaux, Olivier/0000-0002-5934-4786	NCI NIH HHS [CA64402, P01 CA95281, CA95281] Funding Source: Medline; NIGMS NIH HHS [GM53203] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA095281, R01CA064402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BD, 2004, NATURE, V430, P372, DOI 10.1038/nature02694; Ait-Si-Ali S, 2004, EMBO J, V23, P605, DOI 10.1038/sj.emboj.7600074; Angus SP, 2004, MOL CELL BIOL, V24, P5404, DOI 10.1128/MCB.24.12.5404-5420.2004; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Beall EL, 2002, NATURE, V420, P833, DOI 10.1038/nature01228; BEALL EL, 2004, GENES DEV; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Bouazoune K, 2002, EMBO J, V21, P2430, DOI 10.1093/emboj/21.10.2430; Calvi BR, 1998, GENE DEV, V12, P734, DOI 10.1101/gad.12.5.734; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Cayirlioglu P, 2001, DEVELOPMENT, V128, P5085; Ceol CJ, 2004, DEV CELL, V6, P563, DOI 10.1016/S1534-5807(04)00065-6; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Frolov MV, 2003, GENE DEV, V17, P723, DOI 10.1101/gad.1031803; Frolov MV, 2001, GENE DEV, V15, P2146, DOI 10.1101/gad.903901; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Joaquin M, 2002, ONCOGENE, V21, P7923, DOI 10.1038/sj.onc.1206001; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nicolas E, 2000, J BIOL CHEM, V275, P9797, DOI 10.1074/jbc.275.13.9797; Owen AB, 2003, GENOME RES, V13, P1828, DOI 10.1101/gr.1125403; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Shen WH, 2002, TRENDS PLANT SCI, V7, P505, DOI 10.1016/S1360-1385(02)02351-8; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stevaux O, 2002, EMBO J, V21, P4927, DOI 10.1093/emboj/cdf501; Storre J, 2002, EMBO REP, V3, P695, DOI 10.1093/embo-reports/kvf141; Sullivan W., 2000, DROSOPHILA PROTOCOLS; Taylor-Harding B, 2004, MOL CELL BIOL, V24, P9124, DOI 10.1128/MCB.24.20.9124-9136.2004; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White-Cooper H, 2000, DEVELOPMENT, V127, P5463; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338	46	231	240	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2004	119	2					181	193		10.1016/j.cell.2004.09.034	http://dx.doi.org/10.1016/j.cell.2004.09.034			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479636	Bronze			2022-12-28	WOS:000224577200007
J	Norman, G				Norman, G			Commentary: A conceptual framework may be of limited value	BRITISH MEDICAL JOURNAL			English	Editorial Material							EVIDENCE-BASED MEDICINE		McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada	McMaster University	Norman, G (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.	norman@mcmaster.ca						Hatala R, 2002, JAMA-J AM MED ASSOC, V288, P1110, DOI 10.1001/jama.288.9.1110; Norman G, 2003, MED EDUC, V37, P582, DOI 10.1046/j.1365-2923.2003.01586.x; Norman GR, 1998, CAN MED ASSOC J, V158, P177; Straus SE, 2000, CAN MED ASSOC J, V163, P837; Straus SE, 2004, BRIT MED J, V329, P1029, DOI 10.1136/bmj.329.7473.1029	5	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 30	2004	329	7473					1032	1032		10.1136/bmj.329.7473.1032	http://dx.doi.org/10.1136/bmj.329.7473.1032			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514353	Green Published			2022-12-28	WOS:000224852400030
J	Straus, SE; Green, ML; Bell, DS; Badgett, R; Davis, D; Gerrity, M; Ortiz, E; Shaneyfelt, TM; Whelan, C; Mangrulkar, R				Straus, SE; Green, ML; Bell, DS; Badgett, R; Davis, D; Gerrity, M; Ortiz, E; Shaneyfelt, TM; Whelan, C; Mangrulkar, R		Soc General Internal Med Evidence	Evaluating the teaching of evidence based medicine: conceptual framework	BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE; VALIDATION; SKILLS		Toronto Gen Hosp, Dept Med, Toronto, ON M5G 2C4, Canada; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Washington DC VA, Med Ctr, Washington, DC USA; VA Med Affairs, Dept Med, Birmingham, AL USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48104 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Yale University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Texas System; University of Texas Health San Antonio; University of Toronto; Oregon Health & Science University; University of Chicago; University of Michigan System; University of Michigan	Straus, SE (corresponding author), Toronto Gen Hosp, Dept Med, 200 Elizabeth St,9ES-407, Toronto, ON M5G 2C4, Canada.	sharon.straus@utoronto.ca	Bell, Douglas S/G-6702-2013; Greenhalgh, Trisha/B-1825-2015	Bell, Douglas S/0000-0002-5063-8294; Greenhalgh, Trisha/0000-0003-2369-8088; Gerrity, Martha/0000-0002-8772-4591				Fritsche L, 2002, BMJ-BRIT MED J, V325, P1338, DOI 10.1136/bmj.325.7376.1338; Green ML, 1999, ACAD MED, V74, P686, DOI 10.1097/00001888-199906000-00017; Greenhalgh T, 1997, J Eval Clin Pract, V3, P161, DOI 10.1046/j.1365-2753.1997.00082.x; Hatala R, 2002, JAMA-J AM MED ASSOC, V288, P1110, DOI 10.1001/jama.288.9.1110; Kunz R, 2001, Z Arztl Fortbild Qualitatssich, V95, P371; McAlister FA, 1999, J GEN INTERN MED, V14, P236, DOI 10.1046/j.1525-1497.1999.00323.x; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; Miller GE, 1990, ACAD MED S, V9, P63; Ramos KD, 2003, BRIT MED J, V326, P319, DOI 10.1136/bmj.326.7384.319; Rosenberg WMC, 1998, J ROY COLL PHYS LOND, V32, P557; Ross R, 2003, ACAD MED, V78, P412, DOI 10.1097/00001888-200304000-00019; Sackett D., 2000, EVIDENCE BASED MED P, DOI DOI 10.1136/BMJ.H3089; *SOC GEN INT MED, EV BAS MED; Straus SE, 2000, CAN MED ASSOC J, V163, P837; [No title captured], DOI DOI 10.1002/14651858.CD001270	15	79	81	1	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 30	2004	329	7473					1029	1032		10.1136/bmj.329.7473.1029	http://dx.doi.org/10.1136/bmj.329.7473.1029			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514352	Green Published			2022-12-28	WOS:000224852400029
J	Birnbaum, SG; Yuan, PX; Wang, M; Vijayraghavan, S; Bloom, AK; Davis, DJ; Gobeske, KT; Sweatt, JD; Manji, HK; Arnsten, AFT				Birnbaum, SG; Yuan, PX; Wang, M; Vijayraghavan, S; Bloom, AK; Davis, DJ; Gobeske, KT; Sweatt, JD; Manji, HK; Arnsten, AFT			Protein kinase C overactivity impairs prefrontal cortical regulation of working memory	SCIENCE			English	Article							BIPOLAR DISORDER; ALPHA-1-ADRENERGIC AGONIST; AUDITORY HALLUCINATIONS; CORTEX; SCHIZOPHRENIA; PERFORMANCE; MONKEYS	The prefrontal cortex is a higher brain region that regulates thought, behavior, and emotion using representational knowledge, operations often referred to as working memory. We tested the influence of protein kinase C (PKC) intracellular signaling on prefrontal cortical cognitive function and showed that high levels of PKC activity in prefrontal cortex, as seen for example during stress exposure, markedly impair behavioral and electrophysiological measures of working memory. These data suggest that excessive PKC activation can disrupt prefrontal cortical regulation of behavior and thought, possibly contributing to signs of prefrontal cortical dysfunction such as distractibility, impaired judgment, impulsivity, and thought disorder.	Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA; Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; NIMH, Mol Pathophysiol Lab, Bethesda, MD 20892 USA	Yale University; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Arnsten, AFT (corresponding author), Yale Univ, Sch Med, Dept Neurobiol, 333 Cedar St, New Haven, CT 06520 USA.	amy.arnsten@yale.edu		Sweatt, J. David/0000-0003-3567-485X	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH068789] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006036, R37AG006036] Funding Source: NIH RePORTER; NIA NIH HHS [AG06036] Funding Source: Medline; NIMH NIH HHS [P50 MH068789] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arnsten AFT, 1999, BIOL PSYCHIAT, V45, P26, DOI 10.1016/S0006-3223(98)00296-0; Arnsten AFT, 1998, SCIENCE, V280, P1711, DOI 10.1126/science.280.5370.1711; Arnsten AFT, 1997, PHARMACOL BIOCHEM BE, V58, P55, DOI 10.1016/S0091-3057(96)00477-7; Birnbaum S, 1999, BIOL PSYCHIAT, V46, P1266, DOI 10.1016/S0006-3223(99)00138-9; Blumberg HP, 1999, AM J PSYCHIAT, V156, P1986; Coyle JT, 2002, NAT MED, V8, P557, DOI 10.1038/nm0602-557; ELLICOTT A, 1990, AM J PSYCHIAT, V147, P1194; Frith C, 1996, PHILOS T R SOC B, V351, P1505, DOI 10.1098/rstb.1996.0136; GOLDMANRAKIC PS, 1991, AM PSYCHOP, P1; Koh PO, 2003, ARCH GEN PSYCHIAT, V60, P311, DOI 10.1001/archpsyc.60.3.311; KROWCHUK HV, 1995, ANN REV NURSING, V13, P87; Lawrie SM, 2002, BIOL PSYCHIAT, V51, P1008, DOI 10.1016/S0006-3223(02)01316-1; Manji HK, 1999, BIOL PSYCHIAT, V46, P1328, DOI 10.1016/S0006-3223(99)00235-8; Mao ZM, 1999, BIOL PSYCHIAT, V46, P1259, DOI 10.1016/S0006-3223(99)00139-0; MARKOVAC J, 1988, NATURE, V334, P71, DOI 10.1038/334071a0; Mazure, 1995, DOES STRESS CAUSE PS, V46; Mirnics K, 2001, MOL PSYCHIATR, V6, P293, DOI 10.1038/sj.mp.4000866; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607	18	228	238	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					882	884		10.1126/science.1100021	http://dx.doi.org/10.1126/science.1100021			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514161				2022-12-28	WOS:000224969400050
J	Keller, M; Lange, B; Hayasaka, K; Lange, W; Walther, H				Keller, M; Lange, B; Hayasaka, K; Lange, W; Walther, H			Continuous generation of single photons with controlled waveform in an ion-trap cavity system	NATURE			English	Article							DETERMINISTIC GENERATION; FLUORESCENCE; ENTANGLEMENT; DECOHERENCE; MOLECULE; DEMAND; SCHEME	The controlled production of single photons is of fundamental and practical interest; they represent the lowest excited quantum states of the radiation field, and have applications in quantum cryptography(1) and quantum information processing(2). Common approaches use the fluorescence of single ions(3), single molecules(4,5), colour centres(6,7) and semiconductor quantum dots(8-12). However, the lack of control over such irreversible emission processes precludes the use of these sources in applications ( such as quantum networks(13)) that require coherent exchange of quantum states between atoms and photons. The necessary control may be achieved in principle in cavity quantum electrodynamics. Although this approach has been used for the production of single photons from atoms(14-16), such experiments are compromised by limited trapping times, fluctuating atom - field coupling and multi-atom effects. Here we demonstrate a single-photon source based on a strongly localized single ion in an optical cavity. The ion is optimally coupled to a well-defined field mode, resulting in the generation of single-photon pulses with precisely defined shape and timing. We have confirmed the suppression of two-photon events up to the limit imposed by fluctuations in the rate of detector dark counts. The stream of emitted photons is uninterrupted over the storage time of the ion, as demonstrated by a measurement of photon correlations over 90 min.	Max Planck Inst Quantum Opt, D-85748 Garching, Germany; Natl Inst Informat & Commun Technol, Nishi Ku, Kobe, Hyogo 6512492, Japan; Univ Munich, Sekt Phys, D-85748 Garching, Germany	Max Planck Society; National Institute of Information & Communications Technology (NICT) - Japan; University of Munich	Lange, W (corresponding author), Max Planck Inst Quantum Opt, Hans Kopfermann Str 1, D-85748 Garching, Germany.	Wolfgang.Lange@mpq.mpg.de						BASCHE T, 1992, PHYS REV LETT, V69, P1516, DOI 10.1103/PhysRevLett.69.1516; Beige A, 2000, PHYS REV LETT, V85, P1762, DOI 10.1103/PhysRevLett.85.1762; Bennett CH., 1984, P IEEE INT C COMP SY, P175; Brattke S, 2001, PHYS REV LETT, V86, P3534, DOI 10.1103/PhysRevLett.86.3534; Brendel J, 1999, PHYS REV LETT, V82, P2594, DOI 10.1103/PhysRevLett.82.2594; Brouri R, 2000, OPT LETT, V25, P1294, DOI 10.1364/OL.25.001294; Cirac JI, 1997, PHYS REV LETT, V78, P3221, DOI 10.1103/PhysRevLett.78.3221; DIEDRICH F, 1987, PHYS REV LETT, V58, P203, DOI 10.1103/PhysRevLett.58.203; Duan LM, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.032305; Guthohrlein GR, 2001, NATURE, V414, P49, DOI 10.1038/35102129; Keller M, 2004, NEW J PHYS, V6, DOI 10.1088/1367-2630/6/1/095; Keller M, 2003, APPL PHYS B-LASERS O, V76, P125, DOI 10.1007/s00340-003-1114-x; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Kuhn A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.067901; Kurtsiefer C, 2000, PHYS REV LETT, V85, P290, DOI 10.1103/PhysRevLett.85.290; Law CK, 1997, J MOD OPTIC, V44, P2067, DOI 10.1080/095003497152357; Lounis B, 2000, NATURE, V407, P491, DOI 10.1038/35035032; McKeever J, 2004, SCIENCE, V303, P1992, DOI 10.1126/science.1095232; Michler P, 2000, SCIENCE, V290, P2282, DOI 10.1126/science.290.5500.2282; Moreau E, 2001, APPL PHYS LETT, V79, P2865, DOI 10.1063/1.1415346; PELLIZZARI T, 1995, PHYS REV LETT, V75, P3788, DOI 10.1103/PhysRevLett.75.3788; Santori C, 2001, PHYS REV LETT, V86, P1502, DOI 10.1103/PhysRevLett.86.1502; Yuan ZL, 2002, SCIENCE, V295, P102, DOI 10.1126/science.1066790; Zheng SB, 2000, PHYS REV LETT, V85, P2392, DOI 10.1103/PhysRevLett.85.2392	25	469	476	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1075	1078		10.1038/nature02961	http://dx.doi.org/10.1038/nature02961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15510142				2022-12-28	WOS:000224730800034
J	Nelson, DE; Ihekwaba, AEC; Elliott, M; Johnson, JR; Gibney, CA; Foreman, BE; Nelson, G; See, V; Horton, CA; Spiller, DG; Edwards, SW; McDowell, HP; Unitt, JF; Sullivan, E; Grimley, R; Benson, N; Broomhead, D; Kell, DB; White, MRH				Nelson, DE; Ihekwaba, AEC; Elliott, M; Johnson, JR; Gibney, CA; Foreman, BE; Nelson, G; See, V; Horton, CA; Spiller, DG; Edwards, SW; McDowell, HP; Unitt, JF; Sullivan, E; Grimley, R; Benson, N; Broomhead, D; Kell, DB; White, MRH			Oscillations in NF-kappa B signaling control the dynamics of gene expression	SCIENCE			English	Article							P65 SUBUNIT; TRANSCRIPTION; ALPHA; CELLS; PHOSPHORYLATION; ACTIVATION; TIME; ACETYLATION; MECHANISMS; SERINE-536	Signaling by the transcription factor nuclear factor kappa B (NF-kappaB) involves its release from inhibitor kappa B (IkappaB) in the cytosol, followed by translocation into the nucleus. NF-kappaB regulation Of IkappaBalpha transcription represents a delayed negative feedback loop that drives oscillations in NF-kappaB translocation. Single-cell time-lapse imaging band computational modeling of NF-kappaB (RelA) localization showed asynchronous oscillations following cell stimulation that decreased in frequency with increased IkappaBalpha transcription. Transcription of target genes depended on oscillation persistence, involving cycles of RelA phosphorytation and dephosphorylation. The functional consequences of NF-kappaB signaling may thus depend on number, period, and amplitude of oscillations.	Ctr Cell Imaging, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Manchester, Inst Sci & Technol, Dept Chem, Manchester M60 1QD, Lancs, England; Univ Manchester, Inst Sci & Technol, Dept Math, Manchester M60 1QD, Lancs, England; Alder Hey Childrens Hosp, Royal Liverpool Childrens Natl Hlth Serv Trust, Liverpool L12 2AP, Merseyside, England; AstraZeneca Res & Dev Charnwood, Dept Biol Mol, Loughborough LE11 5RH, Leics, England; Pfizer Ltd, Cent Res, Sandwich CT13 9NJ, Kent, England; AstraZeneca Res & Dev Charnwood, Adv Sci & Technol Lab, Loughborough LE11 5RH, Leics, England	University of Liverpool; University of Manchester; University of Manchester; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; AstraZeneca; Pfizer; AstraZeneca	White, MRH (corresponding author), Ctr Cell Imaging, Sch Biol Sci, Biosci Res Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	mwhite@liv.ac.uk	Johnson, James R/D-9721-2014; Kell, Douglas/E-8318-2011; nelson, glyn/A-6346-2009; Johnson, James R/A-8174-2012; Spiller, David G/I-3645-2012; Broomhead, David S/C-6836-2009	Johnson, James R/0000-0002-8849-0993; Kell, Douglas/0000-0001-5838-7963; nelson, glyn/0000-0002-1895-4772; Edwards, Steven/0000-0002-7074-0552; Spiller, David Geoffrey/0000-0003-2502-6787; Nelson, David/0000-0002-5034-0885; Ihekwaba, Adaoha/0000-0003-2787-7286; White, Michael/0000-0002-3617-3232				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; Bian X, 2002, J BIOL CHEM, V277, P42144, DOI 10.1074/jbc.M203891200; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Kell DB, 2004, CURR OPIN MICROBIOL, V7, P296, DOI 10.1016/j.mib.2004.04.012; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Lewis RS, 2003, BIOCHEM SOC T, V31, P925; McFerran DW, 2001, ENDOCRINOLOGY, V142, P3255, DOI 10.1210/en.142.7.3255; Monk NAM, 2003, CURR BIOL, V13, P1409, DOI 10.1016/S0960-9822(03)00494-9; Nelson G, 2002, J CELL SCI, V115, P1137; Nelson G, 2003, J CELL SCI, V116, P2495, DOI 10.1242/jcs.00461; Pourquie O, 2003, SCIENCE, V301, P328, DOI 10.1126/science.1085887; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Ting AY, 2002, SCIENCE, V298, P1189, DOI 10.1126/science.1079331; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	27	907	925	3	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					704	708		10.1126/science.1099962	http://dx.doi.org/10.1126/science.1099962			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499023				2022-12-28	WOS:000224756700057
J	Donald, PR; Schoeman, JF				Donald, PR; Schoeman, JF			Tuberculous meningitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PATHOGENESIS		Univ Stellenbosch, Fac Hlth Sci, Dept Pediat & Child Hlth, ZA-7505 Tygerberg, South Africa	Stellenbosch University	Donald, PR (corresponding author), Univ Stellenbosch, Fac Hlth Sci, Dept Pediat & Child Hlth, ZA-7505 Tygerberg, South Africa.							Rich AR, 1929, B JOHNS HOPKINS HOSP, V44, P273; Rich AR, 1933, B JOHNS HOPKINS HOSP, V52, P5	2	64	77	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2004	351	17					1719	1720		10.1056/NEJMp048227	http://dx.doi.org/10.1056/NEJMp048227			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863TH	15496620				2022-12-28	WOS:000224585200006
J	Majeed, A; Williams, S; Jarman, B; Aylin, P				Majeed, A; Williams, S; Jarman, B; Aylin, P			Prescribing of antibiotics and admissions for respiratory tract infections in England	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England	Imperial College London	Majeed, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England.		Aylin, Paul/A-1073-2014	Majeed, Azeem/0000-0002-2357-9858; Aylin, Paul/0000-0003-4589-1743					0	22	23	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 16	2004	329	7471					879	879		10.1136/bmj.329.7471.879	http://dx.doi.org/10.1136/bmj.329.7471.879			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863MU	15485964	Green Published			2022-12-28	WOS:000224566800013
J	Chen, HT; Hahn, S				Chen, HT; Hahn, S			Mapping the location of TFIIB within the RNA polymerase II transcription preinitiation complex: A model for the structure of PIC	CELL			English	Article							N-TERMINAL DOMAIN; TATA-BOX; ZINC RIBBON; PROMOTER DNA; START SITE; INITIATION; BINDING; PROTEIN; IDENTIFICATION; HOLOENZYME	Biochemical probes positioned on the surface of the general transcription factor TFIIB were used to probe the architecture of the RNA polymerase II (Pol II) transcription preinitiation complex (PIC). In PICs, the TFIIB linker and core domains are positioned over the central cleft and wall of Pol II. This positioning is not observed in the smaller Pol II-TFIIB complex. These results lead to a new model for the structure of the PIC, which agrees with most previously documented protein-DNA interactions within Pol II and archaea PICs. Specific interaction of the TFIIB core domain with Pol II positions and orients the promoter DNA over the Pol II central cleft, and TBP-DNA bending leads to bending of the promoter around the surface of Pol II. The TFIIF subunit Tfg1 was found in close proximity to the TFIIB B finger, linker, and core domains, suggesting that these two factors closely cooperate during initiation.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Howard Hughes Med Inst, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Hahn, S (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	shahn@fhcrc.org	Chen, Hung-Ta/ABC-8094-2021	Chen, Hung-Ta/0000-0003-1192-0382; Hahn, Steven/0000-0001-7240-2533	NIGMS NIH HHS [R01 GM053451-07, R01 GM053451-08, R01 GM053451-09] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053451] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; Bartlett MS, 2004, J BIOL CHEM, V279, P5894, DOI 10.1074/jbc.M311429200; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Bell SD, 1998, COLD SPRING HARB SYM, V63, P41, DOI 10.1101/sqb.1998.63.41; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Chen HT, 2000, PROTEIN SCI, V9, P1743, DOI 10.1110/ps.9.9.1743; Chen HT, 2003, MOL CELL, V12, P437, DOI 10.1016/S1097-2765(03)00306-X; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; Chung WH, 2003, MOL CELL, V12, P1003, DOI 10.1016/S1097-2765(03)00387-3; Craighead JL, 2002, STRUCTURE, V10, P1117, DOI 10.1016/S0969-2126(02)00813-4; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Datwyler SA, 2000, TRENDS BIOCHEM SCI, V25, P408, DOI 10.1016/S0968-0004(00)01652-2; Davis JA, 2002, MOL CELL, V10, P409, DOI 10.1016/S1097-2765(02)00598-1; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; Forget D, 2004, MOL CELL BIOL, V24, P1122, DOI 10.1128/MCB.24.3.1122-1131.2004; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; Hahn S, 2000, GENE DEV, V14, P719; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Kettenberger H, 2003, CELL, V114, P347, DOI 10.1016/S0092-8674(03)00598-1; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lei L, 1998, MOL CELL BIOL, V18, P2130, DOI 10.1128/MCB.18.4.2130; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Ohler U., 2002, GENOME BIOL, V3, pRESEARCH0087, DOI [10.1186/gb-2002-3-12-research0087, DOI 10.1186/GB-2002-3-12-RESEARCH0087]; Okuda M, 2000, EMBO J, V19, P1346, DOI 10.1093/emboj/19.6.1346; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Renfrow MB, 2004, J BIOL CHEM, V279, P2825, DOI 10.1074/jbc.M311433200; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; SUN ZW, 1995, P NATL ACAD SCI USA, V92, P3127, DOI 10.1073/pnas.92.8.3127; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; Warfield L, 2004, GENE DEV, V18, P1022, DOI 10.1101/gad.1192204; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	49	105	110	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2004	119	2					169	180		10.1016/j.cell.2004.09.028	http://dx.doi.org/10.1016/j.cell.2004.09.028			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479635	Bronze			2022-12-28	WOS:000224577200006
J	Muoio, DM; Newgard, CB				Muoio, DM; Newgard, CB			Insulin resistance takes a trip through the ER	SCIENCE			English	Editorial Material							TRANSLATIONAL CONTROL; INFLAMMATION; OBESITY		Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Muoio, DM (corresponding author), Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA.	newga002@mc.duke.edu	Muoio, Debbie Marie/E-1147-2012	Muoio, Deborah/0000-0003-3760-9277				Engelgau MM, 2004, ANN INTERN MED, V140, P945, DOI 10.7326/0003-4819-140-11-200406010-00035; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Perseghin G, 2003, INT J OBESITY, V27, pS6, DOI 10.1038/sj.ijo.0802491; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shoelson SE, 2003, INT J OBESITY, V27, pS49, DOI 10.1038/sj.ijo.0802501; Szegezdi E, 2003, ANN NY ACAD SCI, V1010, P186, DOI 10.1196/annals.1299.032; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	10	35	46	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2004	306	5695					425	426		10.1126/science.1104680	http://dx.doi.org/10.1126/science.1104680			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486283				2022-12-28	WOS:000224626500035
J	Palmer, N; Mueller, DH; Gilson, L; Mills, A; Haines, A				Palmer, N; Mueller, DH; Gilson, L; Mills, A; Haines, A			Health financing to promote access in low income settings - how much do we know?	LANCET			English	Review							USER FEES PLUS; SERVICE UTILIZATION; PUBLIC-HEALTH; IMPACT; CARE; QUALITY; COST; DISTRICT; CHARGES; ATTENDANCE	In this article we outline research since 1995 on the impact of various financing strategies on access to health services or health outcomes in low income countries. The limited evidence available suggests, in general, that user fees deterred utilisation. Prepayment or insurance schemes offered potential for improving access, but are very limited in scope. Conditional cash payments showed promise for improving uptake of interventions, but could also create a perverse incentive. The largely African origin of the reports of user fees, and the evidence from Latin America on conditional cash transfers, demonstrate the importance of the context in which studies are done. There is a need for improved quality of research in this area. Larger scale, upfront funding for evaluation of health financing initiatives is necessary to ensure an evidence base that corresponds to the importance of this issue for achieving development goals.	Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England; Univ Witwatersrand, Ctr Hlth Policy, Johannesburg, South Africa	University of London; London School of Hygiene & Tropical Medicine; University of Witwatersrand	Palmer, N (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.	natasha.palmer@lshtm.ac.uk	Gilson, Lucy/R-8846-2019	Gilson, Lucy/0000-0002-2775-7703; Mills, Anne/0000-0001-9863-9950; Haines, Andy/0000-0002-8053-4605				Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Alliance for Health Policy and Systems Research, 2004, STRENGTH HLTH SYST R; [Anonymous], 1987, CANCER RES, V47, P5782; Blas E, 2001, HEALTH POLICY PLANN, V16, P19, DOI 10.1093/heapol/16.suppl_2.19; Castano RA, 2002, HEALTH POLICY PLANN, V17, P5, DOI 10.1093/heapol/17.suppl_1.5; Chawla M, 2000, HEALTH POLICY PLANN, V15, P76, DOI 10.1093/heapol/15.1.76; *COCHR EFF PRACT O, 2003, EFF PRACT ORG CAR; Collins D, 1996, HEALTH POLICY PLANN, V11, P52, DOI 10.1093/heapol/11.1.52; Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361; DIOP F, 1995, HEALTH POLICY PLANN, V10, P223, DOI 10.1093/heapol/10.3.223; Dow WH, 2003, SOC SCI MED, V57, P975, DOI 10.1016/S0277-9536(02)00464-1; Ekman B, 2004, HEALTH POLICY PLANN, V19, P249, DOI 10.1093/heapol/czh031; GERTLER P, 2000, IMPACT PROGR HLTH FI; Gilson L, 1997, HEALTH POLICY PLANN, V12, P273, DOI 10.1093/oxfordjournals.heapol.a018882; Gwatkin DR, 2003, LANCET, V361, P540, DOI 10.1016/S0140-6736(03)12558-5; Gwatkin DR, 2004, LANCET, V364, P1273, DOI 10.1016/S0140-6736(04)17145-6; HADDAD S, 1995, SOC SCI MED, V40, P743, DOI 10.1016/0277-9536(94)00134-F; Hardeman W, 2004, HEALTH POLICY PLANN, V19, P22, DOI 10.1093/heapol/czh003; *INT LAB ORG, 2002, EXT SOC PROT HLTH CO; Keen J., 1999, QUALITATIVE RES HLTH; Kipp W, 2001, B WORLD HEALTH ORGAN, V79, P1032; LITVACK JI, 1993, SOC SCI MED, V37, P369, DOI 10.1016/0277-9536(93)90267-8; MBUGUA JK, 1995, SOC SCI MED, V41, P829, DOI 10.1016/0277-9536(94)00400-N; Meuwissen LE, 2002, HEALTH POLICY PLANN, V17, P304, DOI 10.1093/heapol/17.3.304; MITCHELL JC, 1983, SOCIOL REV, V31, P187, DOI 10.1111/j.1467-954X.1983.tb00387.x; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; MORRIS S, CONDITIONAL CASH TRA; MORRIS S, IN PRESS LANCET; Mushi AK, 2003, HEALTH POLICY PLANN, V18, P163, DOI 10.1093/heapol/czg021; MWABU G, 1995, HEALTH POLICY PLANN, V10, P164, DOI 10.1093/heapol/10.2.164; Nolan B., 1995, COST RECOVERY PUBLIC; Nyonator F, 1999, HEALTH POLICY PLANN, V14, P329, DOI 10.1093/heapol/14.4.329; Rivera JA, 2004, JAMA-J AM MED ASSOC, V291, P2563, DOI 10.1001/jama.291.21.2563; SCHNEIDER P, 2004, THESIS LONDON SCH HY; Schwartz B., 2002, ACHIEVING TWIN OBJEC; Seale C., 1999, QUALITY QUALITATIVE; Soeters R, 2003, HEALTH POLICY PLANN, V18, P74, DOI 10.1093/heapol/18.1.74; Towse A, 2004, BRIT MED J, V328, P103, DOI 10.1136/bmj.328.7431.103; Victora CG, 2004, AM J PUBLIC HEALTH, V94, P400, DOI 10.2105/AJPH.94.3.400; Waddington C. J., 1989, International Journal of Health Planning and Management, V4, P17, DOI 10.1002/hpm.4740040104; WAGSTAFF A, 2001, 5 CMH; Wilkinson D, 2001, B WORLD HEALTH ORGAN, V79, P665; *WORLD BANK, 1999, CAMB PUBL EXP REV; World Health Organization, 2001, MACR HLTH INV HLTH E; Yin R. K., 1994, CASE STUDY RES DESIG	45	142	142	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2004	364	9442					1365	1370		10.1016/S0140-6736(04)17195-X	http://dx.doi.org/10.1016/S0140-6736(04)17195-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	860NG	15474141				2022-12-28	WOS:000224349700034
J	Evershed, RP; Berstan, R; Grew, F; Copley, MS; Charmant, AJH; Barham, E; Mottram, HR; Brown, G				Evershed, RP; Berstan, R; Grew, F; Copley, MS; Charmant, AJH; Barham, E; Mottram, HR; Brown, G			Formulation of a Roman cosmetic	NATURE			English	Editorial Material									Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England; Sci Museum London, London EC2Y 5HN, England; Preconstruct Archaeol, London SE4 2PD, England	University of Bristol	Evershed, RP (corresponding author), Univ Bristol, Sch Chem, Cantocks Close, Bristol BS8 1TS, Avon, England.	r.p.evershed@bristol.ac.uk						Beagrie N., 1989, BRITANNIA-CAMBRIDGE, V20, P169; BLAKENEY AB, 1983, CARBOHYD RES, V113, P291, DOI 10.1016/0008-6215(83)88244-5; CERT A, 1994, FOOD CHEM, V49, P287, DOI 10.1016/0308-8146(94)90173-2; Copley MS, 2003, P NATL ACAD SCI USA, V100, P1524, DOI 10.1073/pnas.0335955100; Durrani N., 2004, CURRENT ARCHAEOLOGY, V192, P540; *INT CTR DIFFR DAT, 1999, PDF 2 POWD DIFFR DAT; RACKHAM H, 1944, PLINY NATURAL HIST, P9; RALPH J, 1991, J AGR FOOD CHEM, V39, P1426, DOI 10.1021/jf00008a014; RIDDLE JM, 1985, DISCORIDES PHARM MED, P153; *US PHS, 2003, TOX PROF TIN TIN COM	10	37	40	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	2004	432	7013					35	36		10.1038/432035a	http://dx.doi.org/10.1038/432035a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525972				2022-12-28	WOS:000224854900029
J	Lee, VC; Rhew, DC; Dylan, M; Badamgarav, E; Braunstein, GD; Weingarten, SR				Lee, VC; Rhew, DC; Dylan, M; Badamgarav, E; Braunstein, GD; Weingarten, SR			Meta-analysis: Angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Review							CONVERTING ENZYME-INHIBITORS; LEFT-VENTRICULAR DYSFUNCTION; RANDOMIZED-TRIAL; CANDESARTAN CILEXETIL; ACE-INHIBITOR; EXERCISE CAPACITY; CLINICAL-TRIALS; LOSARTAN; ENALAPRIL; THERAPY	Background: The role of angiotensin-receptor blockers (ARBs) in treating patients with chronic heart failure and high-risk acute myocardial infarction (MI) has been controversial, and recent clinical trials provide more information on this topic. Purpose: To quantify the effect of ARBs when compared with placebo (with and without background angiotensin-converting enzyme [ACE] inhibitors) and ACE inhibitors on all-cause mortality and heart failure hospitalizations in patients with chronic heart failure and high-risk acute MI. Data Sources: Data from original research published through 13 November 2003. Study Selection: Predefined criteria were used to identify 24 trials. Data Extraction: 2 reviewers independently collected information on study characteristics and data on all-cause mortality and heart failure hospitalization. Data Synthesis: 24 trials involving 38 080 patients were included. Analysis of chronic heart failure trials revealed that 1) ARBs were associated with reduced all-cause mortality (odds ratio [OR], 0.83 [95% CI, 0.69 to 1.00]) and heart failure hospitalizations (OR, 0.64 [CI, 0.53 to 0.781) as compared with placebo; 2) for ARBs versus ACE inhibitors, all-cause mortality (OR, 1.06 [CI, 0.90 to 1.26]) and heart failure hospitalization (OR, 0.95 [CI, 0.80 to 1.13]) did not differ; 3) and for combinations of ARBs plus ACE inhibitors versus ACE inhibitors alone, all-cause mortality was not reduced (OR, 0.97 [CI, 0.87 to 1.08]) but heart failure hospitalizations were reduced (OR, 0.77 [CI, 0.69 to 0.87]). For patients with high-risk acute MI, 2 randomized trials compared ARBs with ACE inhibitors but did not reveal differences in all-cause mortality or heart failure hospitalization. Limitations: Comparative economic data between ARBs and ACE inhibitors are lacking. Conclusions: Because ACE inhibitors and ARBs do not differ in efficacy for reducing all-cause mortality and heart failure hospitalizations in patients with chronic heart failure and in patients with high-risk acute MI, ARBs should be regarded as suitable alternatives to ACE inhibitors.	Zynx Hlth Inc, Los Angeles, CA 90024 USA		Lee, VC (corresponding author), Zynx Hlth Inc, 10880 Wilshire Blvd,Suite 1450, Los Angeles, CA 90024 USA.	vlee@zynx.com						Adams KF, 1999, J CARD FAIL, V5, P357; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Barrowman Nicholas J, 2003, BMC Med Res Methodol, V3, P13, DOI 10.1186/1471-2288-3-13; Baruch L, 1999, CIRCULATION, V99, P2658, DOI 10.1161/01.CIR.99.20.2658; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; CROZIER I, 1995, CIRCULATION, V91, P691, DOI 10.1161/01.CIR.91.3.691; *CTR MED MED SERV, 2004, HOSP QUAL IN OV; Dasbach EJ, 1999, CARDIOLOGY, V91, P189, DOI 10.1159/000006908; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DICKSTEIN K, 1995, J AM COLL CARDIOL, V26, P438, DOI 10.1016/0735-1097(95)80020-H; Dickstein K, 2002, LANCET, V360, P752, DOI 10.1016/S0140-6736(02)09895-1; Dunselman PHJM, 2001, INT J CARDIOL, V77, P131, DOI 10.1016/S0167-5273(00)00426-5; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Goodfriend TL, 1996, NEW ENGL J MED, V334, P1649, DOI 10.1056/NEJM199606203342507; GOTTLIEB SS, 1993, CIRCULATION, V88, P1602, DOI 10.1161/01.CIR.88.4.1602; Granger CB, 2000, AM HEART J, V139, P609, DOI 10.1016/S0002-8703(00)90037-1; Hamroff G, 1999, CIRCULATION, V99, P990, DOI 10.1161/01.CIR.99.8.990; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; *JOINT COMM ACCR H, 2002, OV HEART FAIL HF COR; Jong P, 2002, J AM COLL CARDIOL, V39, P463, DOI 10.1016/S0735-1097(01)01775-2; Konstam MA, 2004, J CARD FAIL, V10, P4, DOI 10.1016/j.cardfail.2004.01.006; Lang RM, 1997, J AM COLL CARDIOL, V30, P983, DOI 10.1016/S0735-1097(97)00253-2; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; Mann DL, 2002, CARDIOVASC DRUG THER, V16, P7, DOI 10.1023/A:1015355112501; MANTEL N, 1959, J NATL CANCER I, V22, P719; Matsumori A, 2003, EUR J HEART FAIL, V5, P669, DOI 10.1016/S1388-9842(03)00162-4; Mazayev VP, 1998, INT J CARDIOL, V65, P239, DOI 10.1016/S0167-5273(98)00149-1; McKelvie RS, 1999, CIRCULATION, V100, P1056, DOI 10.1161/01.CIR.100.10.1056; Mitrovic V, 2003, AM HEART J, V145, DOI 10.1067/mhj.2003.161; Murdoch DR, 2001, AM HEART J, V141, P800, DOI 10.1067/mhj.2001.114802; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; Phillips M Ian, 2002, Curr Opin Investig Drugs, V3, P569; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Riegger GAJ, 1999, CIRCULATION, V100, P2224, DOI 10.1161/01.CIR.100.22.2224; Schieffer B, 2003, AM J CARDIOL, V91, p12H, DOI 10.1016/S0002-9149(03)00429-6; Sharma D, 2000, AM J CARDIOL, V85, P187, DOI 10.1016/S0002-9149(99)00646-3; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; Tonkon M, 2000, INT J CLIN PRACT, V54, P11; Unger T, 2003, AM J CARDIOL, V91, p28G, DOI 10.1016/S0002-9149(03)00230-3; Weber M, 1997, CLIN THER, V19, P604, DOI 10.1016/S0149-2918(97)80086-0; Willenheimer R, 2002, INT J CARDIOL, V85, P261, DOI 10.1016/S0167-5273(02)00154-7; Wong M, 2002, J AM COLL CARDIOL, V40, P970, DOI 10.1016/S0735-1097(02)02063-6	46	141	148	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2004	141	9					693	704		10.7326/0003-4819-141-9-200411020-00011	http://dx.doi.org/10.7326/0003-4819-141-9-200411020-00011			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867JT	15520426				2022-12-28	WOS:000224839600006
J	Ponsky, TA; Huang, ZHJ; Kittle, K; Eichelberger, MR; Gilbert, JC; Brody, F; Newman, KD				Ponsky, TA; Huang, ZHJ; Kittle, K; Eichelberger, MR; Gilbert, JC; Brody, F; Newman, KD			Hospital- and patient-level characteristics and the risk of appendiceal rupture and negative appendectomy in children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPUTED-TOMOGRAPHY; QUALITY; IMPACT; CT; EPIDEMIOLOGY; CARE	Context The rates of appendiceal rupture and negative appendectomy in children remain high despite efforts to reduce them. Both outcomes are used as measures of hospital quality. Little is known about the factors that influence these rates. Objective To investigate the association between hospital- and patient-level characteristics and the rates of appendiceal rupture and negative appendectomy in children. Design, Setting, and Patients Retrospective review using the Pediatric Health Information System database containing information on 24 411 appendectomies performed on children aged 5 to 17 years at 36 pediatric hospitals in the United States between 1997 and 2002. Main Outcome Measures Rates of negative appendectomy and appendiceal rupture; the odds ratio (OR) of negative appendectomy and appendiceal rupture by hospital patient age, race, and health insurance status, and hospital fiscal year and appendectomy volume. Negative appendectomy rate was defined as the number of patients with appendectomy but without appendicitis divided by the total number of appendectomies. Results The median negative appendectomy rate was 3.06% (range, 1%-12%) and the median appendiceal rupture rate was 35.08% (range, 22%-62%). The adjusted OR for appendiceal rupture was higher in Asian children (1.66; 95% confidence interval [CI], 1.24-2.23) and black children (1.13; 95 % CI, 1.01-1.30) compared with white children. Children without health insurance and children with public insurance had increased odds of appendiceal rupture compared with children who had private health insurance (adjusted OR, 1.36; 95% Cl, 1.22-1.53 for self-insured; adjusted OR, 1, 48; 95% CI, 1.34-1.64 for public insurance). No correlation existed between negative appendectomy rate and race, health insurance status, or hospital appendiceal rupture rate. The negative appendectomy rate improved as the hospital appendectomy volume increased. Conclusion The rate of appendiceal rupture in school-aged children was associated with race and health insurance status and not with negative appendectomy rate and therefore is more likely to be associated with prehospitalization factors such as access to care, quality of care, and patient or physician education.	Childrens Natl Med Ctr, Dept Surg, Washington, DC 20010 USA; Childrens Natl Med Ctr, Dept Biostat, Washington, DC 20010 USA; George Washington Univ, Med Ctr, Washington, DC 20037 USA; Child Hlth Corp Amer, Overland Pk, KS USA	Children's National Health System; Children's National Health System; George Washington University	Newman, KD (corresponding author), Childrens Natl Med Ctr, Dept Surg, 111 Michigan Ave,West Wing,4th Floor,Suite 200, Washington, DC 20010 USA.	knewman@cnmc.org	Ponsky, Todd/J-1214-2014	Ponsky, Todd/0000-0001-7195-1493				ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; [Anonymous], US CENSUS BUREAU PRO; Applegate KE, 2001, RADIOLOGY, V220, P103, DOI 10.1148/radiology.220.1.r01jl17103; Balthazar EJ, 1998, AM J GASTROENTEROL, V93, P768; Bratton SL, 2000, PEDIATRICS, V106, P75, DOI 10.1542/peds.106.1.75; BRAVEMAN P, 1994, NEW ENGL J MED, V331, P444, DOI 10.1056/NEJM199408183310706; BRENDER JD, 1985, PEDIATRICS, V76, P301; DEZIEL DJ, 2002, CONTEMP SURG, V58, P286; Diez-Roux AV, 2000, ANNU REV PUBL HEALTH, V21, P171, DOI 10.1146/annurev.publhealth.21.1.171; Duncan C, 1998, SOC SCI MED, V46, P97, DOI 10.1016/S0277-9536(97)00148-2; Flum DR, 2001, JAMA-J AM MED ASSOC, V286, P1748, DOI 10.1001/jama.286.14.1748; Fuchs JR, 2002, J SURG RES, V106, P131, DOI 10.1006/jsre.2002.6441; Guagliardo MF, 2003, ACAD EMERG MED, V10, P1218, DOI 10.1197/S1069-6563(03)00492-5; Hale DA, 1997, ARCH SURG-CHICAGO, V132, P153; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; Kaiser S, 2002, RADIOLOGY, V223, P633, DOI 10.1148/radiol.2233011076; LUCKMANN R, 1991, EPIDEMIOLOGY, V2, P323, DOI 10.1097/00001648-199109000-00003; McDonald GP, 2001, AM SURGEON, V67, P1017; Norton VC, 1997, ANN EMERG MED, V29, P467, DOI 10.1016/S0196-0644(97)70218-X; Pena BMG, 2002, PEDIATRICS, V110, P1088, DOI 10.1542/peds.110.6.1088; Pittman-Waller VA, 2000, AM SURGEON, V66, P548; Rao PM, 1999, ANN SURG, V229, P344, DOI 10.1097/00000658-199903000-00007; Rao PM, 1998, NEW ENGL J MED, V338, P141, DOI 10.1056/NEJM199801153380301; ROTHROCK SG, 1991, ANN EMERG MED, V20, P45, DOI 10.1016/S0196-0644(05)81117-5; SCHER KS, 1980, SOUTHERN MED J, V73, P1561, DOI 10.1097/00007611-198012000-00005; VELANOVICH V, 1992, AM SURGEON, V58, P264; WONG ML, 1994, J PEDIATR SURG, V29, P1356, DOI 10.1016/0022-3468(94)90115-5; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	28	185	185	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2004	292	16					1977	1982		10.1001/jama.292.16.1977	http://dx.doi.org/10.1001/jama.292.16.1977			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865DO	15507583	Bronze			2022-12-28	WOS:000224682900022
J	Hooper, L; Brown, TJ; Elliott, RA; Payne, K; Roberts, C; Symmons, D				Hooper, L; Brown, TJ; Elliott, RA; Payne, K; Roberts, C; Symmons, D			The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced lay non-steroidal anti-inflammatory drugs: systematic review	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIALS; METAANALYSIS; ARTHRITIS; QUALITY; BIAS	Objectives To assess the effectiveness of five gastroprotective strategies for people taking non-steroidal anti-inflammatory drugs (NSAIDs) -H-2 receptor antagonists plus non-selective (or cyclo-oxygenase-1) NSAIDs; proton pump inhibitors plus non-selective NSAIDs; misoprostol plus non-selective NSAIDs; COX-2 selective NSAIDs; or COX-2 specific NSAIDs-in reducing serious gastrointestinal complications, symptomatic ulcers, serious cardiovascular or renal disease, and deaths, and improving quality of life. Data sources The Cochrane Library, Medline, Embase, Current Controlled Trials, and System for Information on Grey Literature in Europe (SIGLE) were searched to May 2002. Bibliographies and author contacts were used to identify further studies; non-English articles were included. Review methods Trial selection, data extraction, and quality assessment were performed independently, in duplicate. Articles were rejected only if the study was not a randomised controlled trial; did not assess a gastroprotective strategy versus placebo; included exclusively children or healthy volunteers; lasted less than 21 days; or did not measure review outcomes. Quality assessment included allocation concealment and baseline similarity. Random effects meta-analysis, meta-regression and subgrouping were used to pool effects and analyse associations with length of follow up, mean age, and baseline gastrointestinal status. Heterogeneity was examined and sensitivity analyses performed. Results Of 112 included randomised controlled trials (74 666 participants), five were judged to be at low risk of bias, and 138 deaths and 248 serious gastrointestinal events were reported overall. On comparing gastroprotective strategies versus placebo we found no evidence of effectiveness of H-2 receptor antagonists for any primary outcomes (few events reported); proton pump inhibitors may reduce the risk of symptomatic ulcers (relative risk 0.09,95% confidence interval 0.02 to 0.47); misoprostol reduces the risk of serious gastrointestinal complications (0.57, 0.36 to 0.91) and symptomatic ulcers (0.36, 0.20 to 0.67); COX-2 selectives reduce the risk of symptomatic ulcers (0.41, 0.26 to 0.65) and COX-2 specifics reduce the risk of symptomatic ulcers (0.49, 0.38 to 0.62) and possibly serious gastrointestinal complications (0.55, 0.38 to 0.80). All strategies except COX-2 selectives reduce the risk of endoscopic ulcers (at least 3 mm in diameter). Conclusions Misoprostol, COX-2 specific and selective NSAIDs, and probably proton pump inhibitors significantly reduce the risk of symptomatic ulcers, and misoprostol and probably COX-2 specifics significantly reduce the risk of serious gastrointestinal complications, but data quality is low. More data on H-2 receptor antagonists and proton pump inhibitors are needed, as is better reporting of rare but important outcomes.	Univ Manchester, Cochrane Oral Hlth Grp, Manchester M15 6FH, Lancs, England; Univ Dent Hosp, Manchester Dent Educ Ctr, Cent Manchester & Manchester Childrens Univ Healt, Manchester M15 6FH, Lancs, England; Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England; NW Genet Knowledge Pk, Manchester, Lancs, England; Univ Manchester, Sch Epidemiol & Hlth Sci, Biostat Grp, Manchester M13 9PL, Lancs, England; Univ Manchester, ARC Epidemiol Unit, Manchester M13 9PL, Lancs, England	University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester	Hooper, L (corresponding author), Univ Manchester, Cochrane Oral Hlth Grp, Manchester M15 6FH, Lancs, England.	lee.hooper@man.ac.uk	Elliott, Rachel/P-5894-2018; Payne, Katherine/AAJ-3728-2020; Hooper, Lee/D-2795-2009	Elliott, Rachel/0000-0002-3650-0168; Payne, Katherine/0000-0002-3938-4350; Hooper, Lee/0000-0002-7904-3331; Symmons, Deborah/0000-0002-8625-1200				Altman D.G., 1991, PRACTICAL STAT MED R; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Blower AL, 1997, ALIMENT PHARM THERAP, V11, P283, DOI 10.1046/j.1365-2036.1997.d01-604.x; *BRIT MED ASS, 2003, BRIT NATL FORM; *COCHR COLL, 2000, COCHR REV HDB 4 1; Deeks JJ, 2002, BRIT MED J, V325, P619, DOI 10.1136/bmj.325.7365.619; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dieppe P, 2004, BMJ-BRIT MED J, V329, P31, DOI 10.1136/bmj.329.7456.31; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eversmeyer W, 1993, Am J Med, V95, p10S, DOI 10.1016/0002-9343(93)90391-2; Juni P, 2001, SYSTEMATIC REV HLTH, P87; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Lister B J, 1993, Am J Med, V95, p2S, DOI 10.1016/0002-9343(93)90390-B; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; *NAT I CLIN EXC, 2001, 27 NICE; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; Rostom A, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002296, DOI 10.1002/14651858.CD002296]; Sterne J. A. C., 2008, SYSTEMATIC REV HLTH, V323, P189, DOI [10.1002/9780470693926.ch11, DOI 10.1002/9780470693926.CH11]; Sterne JAC, 2001, SYSTEMATIC REV HLTH, P347, DOI [DOI 10.1002/9780470693926.CH18, 10.1002/9780470693926.ch18]	19	160	164	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 23	2004	329	7472					948	952		10.1136/bmj.38232.680567.EB	http://dx.doi.org/10.1136/bmj.38232.680567.EB			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866KU	15475342	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000224773200017
J	Venn, A; Bruinsma, F; Werther, G; Pyett, P; Baird, D; Jones, P; Rayner, P; Lumley, J				Venn, A; Bruinsma, F; Werther, G; Pyett, P; Baird, D; Jones, P; Rayner, P; Lumley, J			Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility	LANCET			English	Article							SEX STEROID TREATMENT; MANAGEMENT; STATURE	Background Treatment with oestrogen to reduce the adult height of tall girls has been available since the 1950s. We undertook a retrospective cohort study to assess the long-term effects of this treatment on fertility. Methods Eligible participants were identified from the records of Australian paediatric endocrinologists who assessed tall girls from 1959 to 1993, and from self-referrals. Individuals included girls who had received oestrogen treatment (diethylstilboestrol or ethinyl oestradiol) (treated group) and those who were assessed but not treated (untreated group). Information about reproductive history was sought by telephone interview. Findings 1432 eligible individuals were identified, of whom 1243 (87%) could be traced. Of these, 780 (63%) completed interviews: 651 were identified from endocrinologists' records, 129 were self-referred. Treated (n=371) and untreated (n=409) women were similar in socioeconomic and other characteristics. After adjustment for age, treated women were more likely to have ever tried for 12 months or more to become pregnant without success (relative risk [RR] 1.80, 95% CI 1.40-2-30); more likely to have seen a doctor because they were having difficulty becoming pregnant (RR 1.80, 1.39-2.32); and more likely to have ever taken fertility drugs (RR 2.05, 1.39-3.04). Time to first pregnancy analysis showed that the treated group was 40% less likely to conceive in any given menstrual cycle of unprotected intercourse (age-adjusted fecundability ratio 0.59, 95% CI 0.46-0.76). These associations persisted when self-referred women were excluded. Interpretation High-dose oestrogen treatment in adolescence seems to reduce female fertility in later life. This finding has implications for current treatment practices and for our understanding of reproductive biology.	Univ Tasmania, Menzies Res Inst, Hobart, Tas 7001, Australia; La Trobe Univ, Bundoora, Vic, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Ctr Hormone Res, Melbourne, Vic, Australia; NIEHS, Res Triangle Pk, NC 27709 USA	University of Tasmania; Menzies Institute for Medical Research; La Trobe University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Venn, A (corresponding author), Univ Tasmania, Menzies Res Inst, Private Bag 23, Hobart, Tas 7001, Australia.	Alison.Venn@utas.edu.au	Rayner, Jo-Anne/B-4934-2016; Venn, Alison J/J-2803-2013; Baird, Donna D/D-5214-2017; Werther, George/B-3784-2012	Rayner, Jo-Anne/0000-0001-8622-9997; Baird, Donna D/0000-0002-5544-2653; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES049003, Z01ES049003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barnard Neal D, 2002, J Pediatr Adolesc Gynecol, V15, P23, DOI 10.1016/S1083-3188(01)00135-8; BAYLEY N, 1952, J PEDIATR-US, V40, P423, DOI 10.1016/S0022-3476(52)80205-7; CONTE FA, 1978, PEDIATRICS, V62, P1091; CRAWFORD JD, 1978, PEDIATRICS, V62, P1189; DEWAAL WJ, 1995, ARCH DIS CHILD, V73, P311, DOI 10.1136/adc.73.4.311; Drop SLS, 1998, ENDOCR REV, V19, P540, DOI 10.1210/er.19.5.540; GOLDZIEHER MA, 1956, J CLIN ENDOCR METAB, V16, P249, DOI 10.1210/jcem-16-2-249; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; NORMANN EK, 1991, ARCH DIS CHILD, V66, P1275, DOI 10.1136/adc.66.11.1275; Smith AMA, 2003, AUST NZ J PUBL HEAL, V27, P204, DOI 10.1111/j.1467-842X.2003.tb00809.x; TRYGSTAD O, 1986, ACTA ENDOCRINOL-COP, V113, P170; WEINBERG CR, 1993, STAT MED, V12, P867, DOI 10.1002/sim.4780120906; WETTENHALL HNB, 1975, J PEDIATR-US, V86, P602; WETTENHALL HNB, 1981, CLIN PAEDIAT ENDOCRI, P134	14	65	65	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1513	1518		10.1016/S0140-6736(04)17274-7	http://dx.doi.org/10.1016/S0140-6736(04)17274-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500896				2022-12-28	WOS:000224645500029
J	Rakhilin, SV; Olson, PA; Nishi, A; Starkova, NN; Fienberg, AA; Nairn, AC; Surmeier, DJ; Greengard, P				Rakhilin, SV; Olson, PA; Nishi, A; Starkova, NN; Fienberg, AA; Nairn, AC; Surmeier, DJ; Greengard, P			A network of control mediated by regulator of calcium/calmodulin-dependent signaling	SCIENCE			English	Article							INNERVATED BRAIN-REGIONS; RAT STRIATAL NEURONS; MEDIUM SPINY NEURONS; CYCLIC-AMP; DOPAMINE-RECEPTORS; CA2+ CURRENTS; INTACT-CELLS; PHOSPHORYLATION; CALMODULIN; ARPP-21	Calmodulin (CaM) is A major effector for the intracellular actions of Ca2+ in nearly all cell types. We identified a CaM-binding protein, designated regulator of calmodulin signaling (RCS). G protein-coupled receptor (GPCR)-dependent activation of protein kinase A (PKA) led to phosphorylation of RCS at Ser(55) and increased its binding to CaM. Phospho RCS acted as a competitive inhibitor of CaM-dependent enzymes, including protein phosphatase 2B (PP2B, also called calcineurin). Increasing RCS phosphorylation blocked GPCR- and PP2B-mediated suppression of L-type Ca2+ currents in striatal neurons. Conversely, genetic deletion of RCS significantly increased this modulation. Through a molecular mechanism that amplifies GPCR- and PKA-mediated signaling and attenuates GPCR- and PP2B-mediated signaling, RCS synergistically increases the phosphorylation of key proteins whose phosphorylation is regulated by PKA and PP2B.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA; Kurume Univ, Sch Med, Dept Pharmacol, Fukuoka 8300011, Japan; Intra Cellular Therapies Inc, New York, NY 10032 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA	Rockefeller University; Northwestern University; Feinberg School of Medicine; Kurume University; Yale University	Nairn, AC (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA.	angus.nairn@yale.edu; j-surmeier@northwestern.edu; greengard@rockefeller.edu		Nairn, Angus/0000-0002-7075-0195	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034696, R37NS034696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012958, P01DA010044] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10044, DA12958, P01 DA010044] Funding Source: Medline; NIMH NIH HHS [MH40899] Funding Source: Medline; NINDS NIH HHS [NS34696] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBEAU A, 1962, CAN MED ASSOC J, V87, P802; BERNARD V, 1992, J NEUROSCI, V12, P3591; Bibb JA, 2000, P NATL ACAD SCI USA, V97, P6809, DOI 10.1073/pnas.120166397; Black DJ, 2004, CELL CALCIUM, V35, P415, DOI 10.1016/j.ceca.2003.10.005; BRENE S, 1994, J NEUROSCI, V14, P985, DOI 10.1523/JNEUROSCI.14-03-00985.1994; Caporaso GL, 2000, NEUROPHARMACOLOGY, V39, P1637, DOI 10.1016/S0028-3908(99)00230-0; DUVOISIN RC, 1967, ARCH NEUROL-CHICAGO, V17, P124, DOI 10.1001/archneur.1967.00470260014002; Gerber DJ, 2003, P NATL ACAD SCI USA, V100, P8993, DOI 10.1073/pnas.1432927100; GIRAULT JA, 1990, NEUROSCIENCE, V37, P317; HEMMINGS HC, 1989, J BIOL CHEM, V264, P7726; Hernandez-Lopez S, 2000, J NEUROSCI, V20, P8987; HERSCH SM, 1994, J NEUROSCI, V14, P3351; Hornykiewicz O, 1987, Adv Neurol, V45, P19; HOWE AR, 1995, J NEUROSCI, V15, P458; Kim J, 2004, NEURON, V41, P745, DOI 10.1016/S0896-6273(04)00081-9; Kisielow J, 2001, EUR J IMMUNOL, V31, P1141, DOI 10.1002/1521-4141(200104)31:4<1141::AID-IMMU1141>3.0.CO;2-R; Miyakawa T, 2003, P NATL ACAD SCI USA, V100, P8987, DOI 10.1073/pnas.1432926100; Nishi A, 1997, J NEUROSCI, V17, P8147; OUIMET CC, 1989, J NEUROSCI, V9, P865; Persechini A, 2002, TRENDS CARDIOVAS MED, V12, P32, DOI 10.1016/S1050-1738(01)00144-X; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; RAKHILIN SV, UNPUB; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415; Zainelli GM, 2004, J NEUROSCI, V24, P1954, DOI 10.1523/JNEUROSCI.4424-03.2004	25	79	85	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					698	701		10.1126/science.1099961	http://dx.doi.org/10.1126/science.1099961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499021				2022-12-28	WOS:000224756700055
J	Kolaczkowski, B; Thornton, JW				Kolaczkowski, B; Thornton, JW			Performance of maximum parsimony and likelihood phylogenetics when evolution is heterogeneous	NATURE			English	Article							MITOCHONDRIAL-DNA; COVARIOTIDE MODEL; INFERENCE; SEQUENCES; ACCURACY; BIAS	All inferences in comparative biology depend on accurate estimates of evolutionary relationships. Recent phylogenetic analyses have turned away from maximum parsimony towards the probabilistic techniques of maximum likelihood and bayesian Markov chain Monte Carlo (BMCMC). These probabilistic techniques represent a parametric approach to statistical phylogenetics, because their criterion for evaluating a topology-the probability of the data, given the tree-is calculated with reference to an explicit evolutionary model from which the data are assumed to be identically distributed. Maximum parsimony can be considered nonparametric, because trees are evaluated on the basis of a general metric-the minimum number of character state changes required to generate the data on a given tree-without assuming a specific distribution(1). The shift to parametric methods was spurred, in large part, by studies showing that although both approaches perform well most of the time(2), maximum parsimony is strongly biased towards recovering an incorrect tree under certain combinations of branch lengths, whereas maximum likelihood is not(3-6). All these evaluations simulated sequences by a largely homogeneous evolutionary process in which data are identically distributed. There is ample evidence, however, that real-world gene sequences evolve heterogeneously and are not identically distributed(7-16). Here we show that maximum likelihood and BMCMC can become strongly biased and statistically inconsistent when the rates at which sequence sites evolve change non-identically over time. Maximum parsimony performs substantially better than current parametric methods over a wide range of conditions tested, including moderate heterogeneity and phylogenetic problems not normally considered difficult.	Univ Oregon, Ctr Ecol & Evolutionary Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Comp & Informat Sci, Eugene, OR 97403 USA	University of Oregon; University of Oregon	Thornton, JW (corresponding author), Univ Oregon, Ctr Ecol & Evolutionary Biol, Eugene, OR 97403 USA.	joet@uoregon.edu	Thornton, Joseph/GSN-4190-2022					Chang JT, 1996, MATH BIOSCI, V134, P189, DOI 10.1016/0025-5564(95)00172-7; Delarbre C, 2002, MOL PHYLOGENET EVOL, V22, P184, DOI 10.1006/mpev.2001.1045; DONALDSON TS, 1968, J AM STAT ASSOC, V63, P660, DOI 10.2307/2284037; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FITCH WM, 1976, J MOL EVOL, V8, P13, DOI 10.1007/BF01738880; GAUT BS, 1995, MOL BIOL EVOL, V12, P152, DOI 10.1093/oxfordjournals.molbev.a040183; HILLIS DM, 1994, SCIENCE, V264, P671, DOI 10.1126/science.8171318; Hillis DM, 1998, SYST BIOL, V47, P3, DOI 10.1080/106351598260987; Huelsenbeck JP, 1998, SYST BIOL, V47, P519; Huelsenbeck JP, 2002, MOL BIOL EVOL, V19, P698, DOI 10.1093/oxfordjournals.molbev.a004128; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Inagaki Y, 2004, MOL BIOL EVOL, V21, P1340, DOI 10.1093/molbev/msh130; KUHNER MK, 1994, MOL BIOL EVOL, V11, P459; Lockhart PJ, 1998, MOL BIOL EVOL, V15, P1183, DOI 10.1093/oxfordjournals.molbev.a026025; Lopez P, 2002, MOL BIOL EVOL, V19, P1; Misof B, 2002, J MOL EVOL, V55, P460, DOI 10.1007/s00239-002-2341-1; MIYAMOTO MM, 1995, MOL BIOL EVOL, V12, P503; Naylor GJP, 1998, SYST BIOL, V47, P61, DOI 10.1080/106351598261030; Philippe H, 2001, TRENDS BIOCHEM SCI, V26, P414, DOI 10.1016/S0968-0004(01)01877-1; Pollock DD, 1999, J MOL BIOL, V287, P187, DOI 10.1006/jmbi.1998.2601; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Pupko T, 2002, P ROY SOC B-BIOL SCI, V269, P1313, DOI 10.1098/rspb.2002.2025; Rokas A, 2003, NATURE, V425, P798, DOI 10.1038/nature02053; Russo CAM, 1996, MOL BIOL EVOL, V13, P525, DOI 10.1093/oxfordjournals.molbev.a025613; Sanderson MJ, 2000, SYST BIOL, V49, P817, DOI 10.1080/106351500750049860; Sullivan J, 2001, SYST BIOL, V50, P723, DOI 10.1080/106351501753328848; Swofford D. L., 1998, PAUP PHYLOGENETIC AN; Swofford DL, 2001, SYST BIOL, V50, P525, DOI 10.1080/106351501750435086; Tuffley C, 1997, B MATH BIOL, V59, P581, DOI 10.1016/S0092-8240(97)00001-3; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	30	410	422	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					980	984		10.1038/nature02917	http://dx.doi.org/10.1038/nature02917			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496922				2022-12-28	WOS:000224585600043
J	Nobrega, MA; Zhu, YW; Plajzer-Frick, I; Afzal, V; Rubin, EM				Nobrega, MA; Zhu, YW; Plajzer-Frick, I; Afzal, V; Rubin, EM			Megabase deletions of gene deserts result in viable mice	NATURE			English	Article							DNA-SEQUENCE; EXPRESSION; SKELETAL; INTERVAL; ENHANCER; NUMBER	The functional importance of the roughly 98% of mammalian genomes not corresponding to protein coding sequences remains largely undetermined(1). Here we show that some large-scale deletions of the non-coding DNA referred to as gene deserts(2-4) can be well tolerated by an organism. We deleted two large non-coding intervals, 1,511 kilobases and 845 kilobases in length, from the mouse genome. Viable mice homozygous for the deletions were generated and were indistinguishable from wildtype littermates with regard to morphology, reproductive fitness, growth, longevity and a variety of parameters assaying general homeostasis. Further detailed analysis of the expression of multiple genes bracketing the deletions revealed only minor expression differences in homozygous deletion and wild-type mice. Together, the two deleted segments harbour 1,243 non-coding sequences conserved between humans and rodents (more than 100 base pairs, 70% identity). Some of the deleted sequences might encode for functions unidentified in our screen; nonetheless, these studies further support the existence of potentially 'disposable DNA' in the genomes of mammals.	DOE Joint Genome Inst Walnut Creek, Walnut Creek, CA 94598 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Genom Div, Berkeley, CA 94720 USA	United States Department of Energy (DOE); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Rubin, EM (corresponding author), DOE Joint Genome Inst Walnut Creek, Walnut Creek, CA 94598 USA.	emrubin@lbl.gov						Anderson JP, 2004, MOL CELL BIOL, V24, P3757, DOI 10.1128/MCB.24.9.3757-3768.2004; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Bentley DR, 2004, NATURE, V429, P440, DOI 10.1038/nature02622; Boffelli D, 2004, NAT REV GENET, V5, P456, DOI 10.1038/nrg1350; Dodou E, 2003, MECH DEVELOP, V120, P1021, DOI 10.1016/S0925-4773(03)00178-3; Dunham A, 2004, NATURE, V428, P522, DOI 10.1038/nature02379; Frazer KA, 2004, GENOME RES, V14, P367, DOI 10.1101/gr.1961204; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Gu ZL, 2003, NATURE, V421, P63, DOI 10.1038/nature01198; Hogan B, 1994, MANIPULATING MOUSE E; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Jasny BR, 2001, SCIENCE, V291, P1153, DOI 10.1126/science.291.5506.1153; Kimura-Yoshida C, 2004, DEVELOPMENT, V131, P57, DOI 10.1242/dev.00877; KOTHARY R, 1989, DEVELOPMENT, V105, P707; Lettice LA, 2003, HUM MOL GENET, V12, P1725, DOI 10.1093/hmg/ddg180; Nelson CE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-r25; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; OVCHARENKO I, IN PRESS GENOMICS; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; SAUER B, 1990, New Biologist, V2, P441; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yu YJ, 2001, NAT REV GENET, V2, P780, DOI 10.1038/35093564; Zerucha T, 2000, J NEUROSCI, V20, P709, DOI 10.1523/JNEUROSCI.20-02-00709.2000; Zhu YW, 2000, P NATL ACAD SCI USA, V97, P1137, DOI 10.1073/pnas.97.3.1137	28	127	141	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					988	993		10.1038/nature03022	http://dx.doi.org/10.1038/nature03022			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496924	Green Submitted			2022-12-28	WOS:000224585600045
J	Bonow, RO				Bonow, RO			Update in cardiology	ANNALS OF INTERNAL MEDICINE			English	Review							CARDIOVASCULAR EVENTS		Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Bonow, RO (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Cardiol, 201 E Huron St,Suite 10-240, Chicago, IL 60611 USA.							Albert MA, 2003, CIRCULATION, V108, P161, DOI 10.1161/01.CIR.0000080289.72166.CF; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; Hjalmarson A, 1999, LANCET, V353, P2001; Manson JE, 2002, NEW ENGL J MED, V347, P716, DOI 10.1056/NEJMoa021067; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Yusuf S, 2000, NEW ENGL J MED, V342, P145	6	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	2004	141	8					628	634		10.7326/0003-4819-141-8-200410190-00010	http://dx.doi.org/10.7326/0003-4819-141-8-200410190-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864SD	15492342				2022-12-28	WOS:000224652300006
J	Sampath, P; Mazumder, B; Seshadri, V; Gerber, CA; Chavatte, L; Kinter, M; Ting, SM; Dignam, JD; Kim, S; Driscoll, DM; Fox, PL				Sampath, P; Mazumder, B; Seshadri, V; Gerber, CA; Chavatte, L; Kinter, M; Ting, SM; Dignam, JD; Kim, S; Driscoll, DM; Fox, PL			Noncanonical function of glutamyl-prolyi-tRNA synthetase: Gene-specific silencing of translation	CELL			English	Article							PROTEIN-PROTEIN INTERACTIONS; MESSENGER-RNA; GAMMA-INTERFERON; MACROMOLECULAR ASSEMBLAGE; MONOCYTIC CELLS; IFN-GAMMA; KINASE-C; COMPLEX; CERULOPLASMIN; IDENTIFICATION	Aminoacyl tRNA synthetases (ARS) catalyze the ligation of amino acids to cognate tRNAs. Chordate ARSs have evolved distinctive features absent from ancestral forms, including compartmentalization in a multisynthetase complex (MSC), noncatalytic peptide appendages, and ancillary functions unrelated to aminoacylation. Here, we show that glutamyl-prolyl-tRNA synthetase (GluProRS), a bifunctional ARS of the MSC, has a regulated, noncanonical activity that blocks synthesis of a specific protein. GluProRS was identified as a component of the interferon (IFN)gamma-activated inhibitor of translation (GAIT) complex by RNA affinity chromatography using the ceruloplasmin (Cp) GAIT element as ligand. In response to IFN-gamma, GluProRS is phosphorylated and released from the MSC, binds the Cp 3'-untranslated region in an mRNP containing three additional proteins, and silences Cp mRNA translation. Thus, GluProRS has divergent functions in protein synthesis: in the MSC, its aminoacylation activity supports global translation, but translocation of GluProRS to an inflammation-responsive mRNP causes gene-specific translational silencing.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Biol, Cleveland, OH 44115 USA; Natl Ctr Cell Sci, Pune 411007, Maharashtra, India; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA; Seoul Natl Univ, Coll Pharm, Ctr ARS Network, Seoul 151742, South Korea	Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); Seoul National University (SNU)	Fox, PL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	foxp@ccf.org	Kim, Sunghoon/AAE-8314-2020	Mazumder, Barsanjit/0000-0003-3069-7833; Chavatte, Laurent/0000-0001-7696-2431; Kinter, Michael/0000-0001-7409-8918	NHLBI NIH HHS [HL67725, HL76491, HL29582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582, P01HL076491, R01HL067725] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonellis A, 2003, AM J HUM GENET, V72, P1293, DOI 10.1086/375039; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; BERG BH, 1990, BIOCHIM BIOPHYS ACTA, V1038, P391, DOI 10.1016/0167-4838(90)90254-D; Bielli P, 2002, CELL MOL LIFE SCI, V59, P1413, DOI 10.1007/s00018-002-8519-2; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; Cahuzac B, 2000, EMBO J, V19, P445, DOI 10.1093/emboj/19.3.445; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CLEMENS MJ, 1990, TRENDS BIOCHEM SCI, V15, P172, DOI 10.1016/0968-0004(90)90153-3; de Pouplana LR, 2001, TRENDS BIOCHEM SCI, V26, P591, DOI 10.1016/S0968-0004(01)01932-6; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; ELGLAYAR S, 2003, J IMMUNOL, V171, P4561; FETT R, 1991, J BIOL CHEM, V266, P1448; Francklyn C, 2002, RNA, V8, P1363, DOI 10.1017/S1355838202021180; Galani K, 2001, EMBO J, V20, P6889, DOI 10.1093/emboj/20.23.6889; Garcia GE, 2003, KIDNEY INT, V64, P160, DOI 10.1046/j.1523-1755.2003.00077.x; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Han JM, 2003, BIOCHEM BIOPH RES CO, V303, P985, DOI 10.1016/S0006-291X(03)00485-6; Harris CE, 1999, J VIROL, V73, P72, DOI 10.1128/JVI.73.1.72-80.1999; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; Howard OMZ, 2002, J EXP MED, V196, P781, DOI 10.1084/jem.20020186; Jeong EJ, 2000, BIOCHEMISTRY-US, V39, P15775, DOI 10.1021/bi001393h; Kaminska M, 2001, BIOCHEMISTRY-US, V40, P14309, DOI 10.1021/bi015670b; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Kim JY, 2002, P NATL ACAD SCI USA, V99, P7912, DOI 10.1073/pnas.122110199; Kim MJ, 2003, NAT GENET, V34, P330, DOI 10.1038/ng1182; KLEBANOFF SJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P302, DOI 10.1016/0003-9861(92)90522-X; Ko YG, 2002, PROTEOMICS, V2, P1304, DOI 10.1002/1615-9861(200209)2:9<1304::AID-PROT1304>3.0.CO;2-E; Ko YG, 2001, J BIOL CHEM, V276, P6030, DOI 10.1074/jbc.M006189200; Ko YG, 2000, J CELL BIOL, V149, P567, DOI 10.1083/jcb.149.3.567; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Mazumder B, 1997, J IMMUNOL, V159, P1938; Mazumder B, 1999, MOL CELL BIOL, V19, P6898; Mazumder B, 2003, CELL, V115, P187, DOI 10.1016/S0092-8674(03)00773-6; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; MAZUMDER B, 2003, CELL, V28, P91; MIRANDE M, 1985, EUR J BIOCHEM, V147, P281, DOI 10.1111/j.1432-1033.1985.tb08748.x; Mourelatos Z, 2001, EMBO J, V20, P5443, DOI 10.1093/emboj/20.19.5443; Mukhopadhyay CK, 1997, P NATL ACAD SCI USA, V94, P11546, DOI 10.1073/pnas.94.21.11546; Otani A, 2002, P NATL ACAD SCI USA, V99, P178, DOI 10.1073/pnas.012601899; PENDERGAST AM, 1987, J BIOL CHEM, V262, P5939; PENDERGAST AM, 1985, J BIOL CHEM, V260, P1769; Preiss T, 2003, BIOESSAYS, V25, P1201, DOI 10.1002/bies.10362; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Robinson JC, 2000, J MOL BIOL, V304, P983, DOI 10.1006/jmbi.2000.4242; Sampath P, 2003, MOL CELL BIOL, V23, P1509, DOI 10.1128/MCB.23.5.1509-1519.2003; SCHRAY B, 1991, NUCLEIC ACIDS RES, V19, P5307, DOI 10.1093/nar/19.19.5307; Shiba K, 2002, J MOL EVOL, V55, P727, DOI 10.1007/s00239-002-2368-3; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; TING SM, 1992, J BIOL CHEM, V267, P17701; VENEMA RC, 1991, J BIOL CHEM, V266, P5298; Wakasugi K, 2002, J BIOL CHEM, V277, P20124, DOI 10.1074/jbc.C200126200; Wu H, 1995, BIOCHEMISTRY-US, V34, P16327, DOI 10.1021/bi00050a013; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X	56	199	215	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2004	119	2					195	208		10.1016/j.cell.2004.09.030	http://dx.doi.org/10.1016/j.cell.2004.09.030			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479637	Bronze			2022-12-28	WOS:000224577200008
J	Madden, MEE; Bodnar, RJ; Rimstidt, JD				Madden, MEE; Bodnar, RJ; Rimstidt, JD			Jarosite as an indicator of water-limited chemical weathering on Mars	NATURE			English	Article							MARTIAN REGOLITH; METEORITES; CLIMATE; SOIL; CHEMISTRY; SULFUR; BASALT; SALTS; ROCKS	The Mars Exploration Rover Opportunity identified the ferric sulphate mineral jarosite and possible relicts of gypsum at the Meridiani Planum landing site(1). On Earth, jarosite has been found to form in acid mine drainage environments, during the oxidation of sulphide minerals(2), and during alteration of volcanic rocks by acidic, sulphur-rich fluids near volcanic vents(3). Jarosite formation is thus thought to require a wet, oxidizing and acidic environment. But jarosite on Earth only persists over geologically relevant time periods in arid environments because it rapidly decomposes to produce ferric oxyhydroxides in more humid climates(4). Here we present equilibrium thermodynamic reaction-path simulations that constrain the range of possible conditions under which such aqueous alteration phases are likely to have formed on Mars. These calculations simulate the chemical weathering of basalt at relevant martian conditions. We conclude that the presence of jarosite combined with residual basalt at Meridiani Planum indicates that the alteration process did not proceed to completion, and that following jarosite formation, arid conditions must have prevailed.	Virginia Tech, Dept Geosci, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University	Madden, MEE (corresponding author), Virginia Tech, Dept Geosci, 4044 Derring Hall, Blacksburg, VA 24061 USA.	melwood@vt.edu	Bodnar, Robert J/A-1916-2009; Rimstidt, James/N-8910-2013; Elwood Madden, Megan/C-3381-2009	Elwood Madden, Megan/0000-0002-6735-4554				Banin A, 1997, J GEOPHYS RES-PLANET, V102, P13341, DOI 10.1029/97JE01160; Bethke C., 1996, GEOCHEMICAL REACTION; Bridges JC, 2001, SPACE SCI REV, V96, P365, DOI 10.1023/A:1011965826553; Catling DC, 1999, J GEOPHYS RES-PLANET, V104, P16453, DOI 10.1029/1998JE001020; Chyba C.F., 1994, HAZARDS DUE COMETS A, P9; CLARK BC, 1981, ICARUS, V45, P370, DOI 10.1016/0019-1035(81)90041-5; CLARK BC, 1993, GEOCHIM COSMOCHIM AC, V57, P4575, DOI 10.1016/0016-7037(93)90183-W; CLARK BC, 1979, J GEOPHYS RES, V84, P8395, DOI 10.1029/JB084iB14p08395; Farquhar J, 2000, NATURE, V404, P50, DOI 10.1038/35003517; Fieldes M., 1975, Soil components. Volume 2. Inorganic components (Gieseking, J.E., Ed)., P351; Fulignati P, 2002, J VOLCANOL GEOTH RES, V115, P397, DOI 10.1016/S0377-0273(02)00209-3; GOODING JL, 1978, ICARUS, V33, P483, DOI 10.1016/0019-1035(78)90186-0; GOODING JL, 1992, ICARUS, V99, P28, DOI 10.1016/0019-1035(92)90168-7; HEMLEY JJ, 1986, GEOLOGY, V14, P377, DOI 10.1130/0091-7613(1986)14<377:EOPOOM>2.0.CO;2; Herbert RB, 1997, CLAY CLAY MINER, V45, P261, DOI 10.1346/CCMN.1997.0450214; JAKOSKY BM, 1995, J GEOPHYS RES-PLANET, V100, P1579, DOI 10.1029/94JE02801; Langmuir D., 1996, AQUEOUS ENV GEOCHEMI; Levine J.S., 1985, PHOTOCHEMISTRY ATMOS, P337; Linke W.F., 1958, SOLUBILITIES INORGAN, VI; Marion GM, 2003, GEOCHIM COSMOCHIM AC, V67, P4251, DOI 10.1016/S0016-7037(03)00372-7; McSween HY, 2000, GEOCHIM COSMOCHIM AC, V64, P2155, DOI 10.1016/S0016-7037(99)00401-9; MORRIS R, 2004, LUN PLAN SCI C, V35; Owen T., 1992, COMPOSITION EARLY HI, P818; Phillips RJ, 2001, SCIENCE, V291, P2587, DOI 10.1126/science.1058701; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; ROSENBAUER RJ, 1983, ECON GEOL, V78, P1701, DOI 10.2113/gsecongeo.78.8.1701; SETTLE M, 1979, J GEOPHYS RES, V84, P8343, DOI 10.1029/JB084iB14p08343; Sharp T. G., 2003, GEOPHYS RES LETT, V30; Wanke H, 2001, SPACE SCI REV, V96, P317, DOI 10.1023/A:1011961725645; Ziegler K, 2003, CHEM GEOL, V202, P461, DOI 10.1016/j.chemgeo.2002.06.001	30	214	219	1	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					821	823		10.1038/nature02971	http://dx.doi.org/10.1038/nature02971			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483605				2022-12-28	WOS:000224435500040
J	Kenney, RT; Frech, SA; Muenz, LR; Villar, CP; Glenn, GM				Kenney, RT; Frech, SA; Muenz, LR; Villar, CP; Glenn, GM			Dose sparing with intradermal injection of influenza vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-VACCINE; HEPATITIS-B; ANTIBODY-RESPONSES; ADULTS; HEMAGGLUTININ; PROTECTION; CHALLENGE; SERUM	BACKGROUND The loss of half the U. S. supply of influenza vaccine due to contamination has created a critical shortage. Dose-sparing strategies that use intradermal delivery of vaccines may be one approach to consider. METHODS We conducted a randomized, open-label trial outside the influenza season in 100 healthy adults 18 to 40 years of age to compare the immunogenicity and safety of intradermal immunization with influenza vaccine with standard intramuscular immunization. Subjects were randomly assigned to receive either a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 mug of hemagglutinin per strain, by means of a prefilled syringe or a single intradermal dose of 0.1 ml, containing at least 3 mug of hemagglutinin per strain, by means of a fine-gauge needle; both injections were in the deltoid region. Changes in the hemagglutination-inhibition (HAI) antibody titer were assessed by comparing geometric mean titers and fold increases relative to baseline values and by comparing changes in the seroconversion and seroprotection rates. Local and systemic adverse events were assessed after both types of vaccination. RESULTS Subjects who received an intradermal injection with one fifth the standard dose of influenza vaccine had increases in the geometric mean HAI titer by a factor of 15.2 for the H1N1 strain in the vaccine, 19.0 for the H3N2 strain, and 12.4 for the B strain on day 21, as compared with respective increases by a factor of 14.9, 7.1, and 15.3 for the intramuscular injection of the standard dose. Seroconversion and seroprotection rates were similar in the two groups on day 21, ranging from 66 to 82 percent and 84 to 100 percent, respectively. Local reactions were significantly more frequent among recipients of intradermal injections than among recipients of intramuscular injections, but such reactions were mild and transient. CONCLUSIONS In this study of young adults, intradermal administration of one fifth the standard intramuscular dose of an influenza vaccine elicited immunogenicity that was similar to or better than that elicited by intramuscular injection. Intradermal administration could be used to expand the supplies of influenza vaccine, but further studies are needed before this strategy can be recommended for routine use.	Iomai, Gaithersburg, MD 20878 USA		Glenn, GM (corresponding author), Iomai, 20 Firstfield Rd,Suite 250, Gaithersburg, MD 20878 USA.	gglenn@iomai.com			NIAID NIH HHS [1R43-AI060071-01, 2R44-AI45264-02A2] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R44AI045264, R43AI060071] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Briggs DJ, 2000, B WORLD HEALTH ORGAN, V78, P693; BROWN H, 1977, J INFECT DIS, V136, pS466, DOI 10.1093/infdis/136.Supplement_3.S466; BRYAN JP, 1992, CLIN INFECT DIS, V14, P697, DOI 10.1093/clinids/14.3.697; CANTER J, 1990, ARCH INTERN MED, V150, P1923, DOI 10.1001/archinte.150.9.1923; DAVIES JR, 1989, EPIDEMIOL INFECT, V103, P217; DAVIES JR, 1989, EPIDEMIOL INFECT, V102, P325, DOI 10.1017/S0950268800030004; DOWDLE WR, 1973, POSTGRAD MED J, V49, P159, DOI 10.1136/pgmj.49.569.159; Glenn GM, 2003, IMMUNOL ALLERGY CLIN, V23, P787, DOI 10.1016/S0889-8561(03)00094-8; HALPERIN W, 1979, AM J PUBLIC HEALTH, V69, P1247, DOI 10.2105/AJPH.69.12.1247; HERBERT FA, 1979, J INFECT DIS, V140, P234, DOI 10.1093/infdis/140.2.234; HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610; Jackson LA, 2001, VACCINE, V19, P4703, DOI 10.1016/S0264-410X(01)00225-0; Jakob T, 1999, Adv Dermatol, V14, P209; KEITEL WA, 1994, J CLIN MICROBIOL, V32, P2468, DOI 10.1128/JCM.32.10.2468-2473.1994; Keitel WA, 1996, CLIN DIAGN LAB IMMUN, V3, P507, DOI 10.1128/CDLI.3.5.507-510.1996; Niculescu I T, 1981, Arch Roum Pathol Exp Microbiol, V40, P67; Pollack Andrew, 2004, N Y Times Web, pC3; REDFIELD RR, 1985, JAMA-J AM MED ASSOC, V254, P3203, DOI 10.1001/jama.254.22.3203; SALISBURY DM, 1996, IMMUNIZATION INFECT, P219; Treanor J, 2002, VACCINE, V20, P1099, DOI 10.1016/S0264-410X(01)00440-6; World Health Organization, 1980, GLOB ER SMALLP FIN R; 1997, CPMPBWP21496, P1	22	343	363	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2295	2301		10.1056/NEJMoa043540	http://dx.doi.org/10.1056/NEJMoa043540			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15525714	Bronze			2022-12-28	WOS:000225298100008
J	Huyen, Y; Zgheib, O; DiTullio, RA; Gorgoulis, VG; Zacharatos, P; Petty, TJ; Sheston, EA; Mellert, HS; Stavridi, ES; Halazonetis, TD				Huyen, Y; Zgheib, O; DiTullio, RA; Gorgoulis, VG; Zacharatos, P; Petty, TJ; Sheston, EA; Mellert, HS; Stavridi, ES; Halazonetis, TD			Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks	NATURE			English	Article							SMN TUDOR DOMAIN; DAMAGE; PROTEIN; CHECKPOINT; PHOSPHORYLATION; GENE; RECOGNITION; BINDING; MOTIF; ATM	The mechanisms by which eukaryotic cells sense DNA double-strand breaks (DSBs) in order to initiate checkpoint responses are poorly understood. 53BP1 is a conserved checkpoint protein with properties of a DNA DSB sensor(1-5). Here, we solved the structure of the domain of 53BP1 that recruits it to sites of DSBs. This domain consists of two tandem tudor folds with a deep pocket at their interface formed by residues conserved in the budding yeast Rad9 and fission yeast Rhp9/Crb2 orthologues. In vitro, the 53BP1 tandem tudor domain bound histone H3 methylated on Lys 79 using residues that form the walls of the pocket; these residues were also required for recruitment of 53BP1 to DSBs. Suppression of DOT1L, the enzyme that methylates Lys 79 of histone H3, also inhibited recruitment of 53BP1 to DSBs. Because methylation of histone H3 Lys 79 was unaltered in response to DNA damage, we propose that 53BP1 senses DSBs indirectly through changes in higher-order chromatin structure that expose the 53BP1 binding site.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Biomed Grad Studies Program, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Athens, Sch Med, Dept Histol & Embryol, Athens 11527, Greece	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; Athens Medical School; National & Kapodistrian University of Athens	Halazonetis, TD (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	halazonetis@wistar.upenn.edu	Petty, Tom/A-6758-2011; Gorgoulis, Vassilis/AAD-3630-2019; Halazonetis, Thanos/D-7923-2011; ZACHARATOS, PANAGIOTIS V/G-9954-2014	Petty, Tom/0000-0002-4007-6515; Gorgoulis, Vassilis/0000-0001-9001-4112; ZACHARATOS, PANAGIOTIS V/0000-0001-8324-5481				Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Charier G, 2004, STRUCTURE, V12, P1551, DOI 10.1016/j.str.2004.06.014; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; GAME JC, 2004, GENETICS        0915, DOI DOI 10.1534/GENETICS.104.028613; Huyen Y, 2004, STRUCTURE, V12, P1237, DOI 10.1016/j.str.2004.05.007; Iwabuchi K, 2003, J BIOL CHEM, V278, P36487, DOI 10.1074/jbc.M304066200; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mochan TA, 2003, CANCER RES, V63, P8586; Mozziconacci J, 2003, J STRUCT BIOL, V143, P72, DOI 10.1016/S1047-8477(03)00102-3; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; San-Segundo PA, 2000, MOL BIOL CELL, V11, P3601, DOI 10.1091/mbc.11.10.3601; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Sprangers R, 2003, J MOL BIOL, V327, P507, DOI 10.1016/S0022-2836(03)00148-7; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Willson J, 1997, NUCLEIC ACIDS RES, V25, P2138, DOI 10.1093/nar/25.11.2138; Xia ZF, 2001, J BIOL CHEM, V276, P2708, DOI 10.1074/jbc.M007665200	30	671	709	0	39	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					406	411		10.1038/nature03114	http://dx.doi.org/10.1038/nature03114			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15525939				2022-12-28	WOS:000225161400059
J	Wilson, FH; Hariri, A; Farhi, A; Zhao, HY; Petersen, KF; Toka, HR; Nelson-Williams, C; Raja, KM; Kashgarian, CM; Shulman, GI; Scheinman, SJ; Lifton, RP				Wilson, FH; Hariri, A; Farhi, A; Zhao, HY; Petersen, KF; Toka, HR; Nelson-Williams, C; Raja, KM; Kashgarian, CM; Shulman, GI; Scheinman, SJ; Lifton, RP			A cluster of metabolic defects caused by mutation in a mitochondrial tRNA	SCIENCE			English	Article							INSULIN-RESISTANCE; DIETARY MAGNESIUM; HYPERTENSION; RISK; CHOLESTEROL; DISEASE; SERUM; OBESITY	Hypertension and dyslipidemia are risk factors for atherosclerosis and occur together more often than expected by chance. Although this clustering suggests shared causation, unifying factors remain unknown. We describe a large kindred with a syndrome including hypertension, hypercholesterolemia, and hypomagnesemia. Each phenotype is transmitted on the maternal lineage with a pattern indicating mitochondrial inheritance. Analysis of the mitochondrial genome of the maternal lineage identified a homoplasmic mutation substituting cytidine for uridine immediately S' to the mitochondrial transfer RNA(Ite) anticodon. Uridine at this position is nearly invariate among transfer RNAs because of its role in stabilizing the anticodon loop. Given the known loss of mitochondrial function with aging, these findings may have implications for the common clustering of these metabolic disorders.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Biostat, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell & Mol Physiol, New Haven, CT 06510 USA; SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Lifton, RP (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA.	richard.lifton@yale.edu	Toka, Hakan/AAQ-2162-2021; Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668; Wilson, Frederick/0000-0002-5019-0186	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023686] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR-00125, M01 RR000125] Funding Source: Medline; NHLBI NIH HHS [P50 HL055007, P50 HL-55007] Funding Source: Medline; NIA NIH HHS [R01 AG023686-01A1, R01 AG023686-02, R01 AG023686-04, R01 AG023686, R01 AG023686-03] Funding Source: Medline; NIDDK NIH HHS [R01 DK049230, R01 DK-49230] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529; Atlante A, 1998, INT J MOL MED, V1, P709; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6; CRIQUI MH, 1986, CIRCULATION S1, V73, P140; George S, 2004, SCIENCE, V304, P1325, DOI 10.1126/science.1096706; Goldstein JL, 2001, SCIENCE, V292, P1310, DOI 10.1126/science.1061815; Guerrero-Romero F, 2002, ACTA DIABETOL, V39, P209, DOI 10.1007/s005920200036; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; Konrad M, 2004, AM J PHYSIOL-RENAL, V286, pF599, DOI 10.1152/ajprenal.00312.2003; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Mizushima S, 1998, J HUM HYPERTENS, V12, P447, DOI 10.1038/sj.jhh.1000641; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mosterd A, 1999, NEW ENGL J MED, V340, P1221, DOI 10.1056/NEJM199904223401601; O'Rahilly S, 2003, ENDOCRINOLOGY, V144, P3757, DOI 10.1210/en.2003-0373; Peacock JM, 1999, ANN EPIDEMIOL, V9, P159, DOI 10.1016/S1047-2797(98)00040-4; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Reilly RF, 2000, PHYSIOL REV, V80, P277, DOI 10.1152/physrev.2000.80.1.277; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WILLIAMS RR, 1988, JAMA-J AM MED ASSOC, V259, P3579, DOI 10.1001/jama.259.24.3579; WINGARD DL, 1983, AM J EPIDEMIOL, V117, P19, DOI 10.1093/oxfordjournals.aje.a113510; Zager RA, 2003, AM J PHYSIOL-RENAL, V285, pF1092, DOI 10.1152/ajprenal.00187.2003	31	254	273	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1190	1194		10.1126/science.1102521	http://dx.doi.org/10.1126/science.1102521			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15498972	Green Accepted			2022-12-28	WOS:000225193100052
J	El Arifeen, S; Blum, LS; Hoque, DME; Chowdhury, EK; Khan, R; Black, RE; Victora, CG; Bryce, J				El Arifeen, S; Blum, LS; Hoque, DME; Chowdhury, EK; Khan, R; Black, RE; Victora, CG; Bryce, J			Integrated Management of Childhood Illness (IMCI) in Bangladesh: early findings from a cluster-randomised study	LANCET			English	Article							MULTICOUNTRY EVALUATION; PUBLIC-HEALTH; CHILDREN; CARE	Background We report the preliminary findings from a continuing cluster randomised evaluation of the integrated Management of Childhood Illness (IMCI) strategy in Bangladesh. Methods 20 first-level outpatient facilities in the Madab sub-district and their catchment areas were randomised to either IMCI or standard care. Surveys were done in households and in health facilities at baseline and were repeated about 2 years after implementation. Data on use of health facilities were recorded. IMCI implementation included health worker training, health systems support, and community level activities guided by formative research. Findings 94% of health workers in the intervention facilities were trained in IMCI. Health systems supports were generally available, but implementation of the community activities was slow. The mean index of correct treatment for sick children was 54 in IMCI facilities compared with 9 in comparison facilities (range 0-100). Use of the IMCI facilities increased from 0.6 visits per child per year at baseline to 1.9 visits per child per year about 21 months after IMCI introduction. 19% of sick children in the IMCI area were taken to a health worker compared with 9% in the non-IMCI area. Interpretation 2 years into the assessment, the results show improvements in the quality of care in health facilities, increases in use of facilities, and gains in the proportion of sick children taken to an appropriate health care provider. These findings are being used to strengthen child health care nationwide. They suggest that low levels of use of health facilities could be improved by investing in quality of care and health systems support.	Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Univ Fed Pelotas, Pelotas, Brazil	International Centre for Diarrhoeal Disease Research (ICDDR); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Universidade Federal de Pelotas	El Arifeen, S (corresponding author), Int Ctr Diarrhoeal Dis Res, GPO Box 128, Dhaka 1000, Bangladesh.	shams@icddrb.org	Hoque, Dewan Md. Emdadul/J-1999-2019; Victora, Cesar Gomes/Y-2455-2019; Victora, Cesar G/D-4476-2013; Hoque, Dewan/O-3606-2015; Chowdhury, Enayet/I-1267-2019	Hoque, Dewan Md. Emdadul/0000-0001-8219-9196; Victora, Cesar Gomes/0000-0002-2465-2180; Victora, Cesar G/0000-0002-2465-2180; Hoque, Dewan/0000-0001-8219-9196; Chowdhury, Enayet/0000-0002-9709-794X; Arifeen, Shams/0000-0002-5372-5932; Black, Robert/0000-0001-9926-7984				Ahmed S, 2001, J TROP PEDIATRICS, V47, P98, DOI 10.1093/tropej/47.2.98; Baqui AH, 2001, ACTA PAEDIATR, V90, P682, DOI 10.1080/080352501750258775; Bryce J, 2004, AM J PUBLIC HEALTH, V94, P406, DOI 10.2105/AJPH.94.3.406; Chowdhury AMR, 2003, J HEALTH POPUL NUTR, V21, P193; Gouws E, 2004, B WORLD HEALTH ORGAN, V82, P509; GOUWS E, IN PRESS SOC SCI MED; Henry F J, 1993, Ann Epidemiol, V3, P382, DOI 10.1016/1047-2797(93)90065-C; HUICHO L, IN PRESS HLTH POLICY; Hussain A, 1999, TROP MED INT HEALTH, V4, P758, DOI 10.1046/j.1365-3156.1999.00485.x; MOSTAFA G, 1996, 79 ICDDR B; MOSTAFA G, 1996, 77 ICDDR B; National Institute of Population Research and Training (NIPORT) ORC Macro John Hopkins University ICDDRB, 2003, BANGL MAT HLTH SERV; Rousham EK, 1996, EUR J CLIN NUTR, V50, P560; Schellenberg JA, 2004, HEALTH POLICY PLANN, V19, P1, DOI 10.1093/heapol/czh001; Schellenberg JA, 2003, LANCET, V361, P561, DOI 10.1016/S0140-6736(03)12515-9; Schellenberg JRMA, 2004, LANCET, V364, P1583, DOI 10.1016/S0140-6736(04)17311-X; Tulloch J., 1999, Lancet (British edition), V354, P16, DOI 10.1016/S0140-6736(99)90252-0; Victora CG, 2004, LANCET, V364, P1541, DOI 10.1016/S0140-6736(04)17279-6; Victora CG, 2004, AM J PUBLIC HEALTH, V94, P400, DOI 10.2105/AJPH.94.3.400; *WHO, 2004, WHOFCHCAH991; *WHO, WHOCDR9335; *WHO UNICEF, RES INT MAN CHILDH I	22	124	128	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	2004	364	9445					1595	1602						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866IQ	15519629				2022-12-28	WOS:000224767600024
J	Green, ML				Green, ML			Commentary: The fool wonders, the wise (women) ask ... about tropical diseases in their practice	BRITISH MEDICAL JOURNAL			English	Editorial Material							MEDICINE CURRICULUM		Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University	Green, ML (corresponding author), Waterbury Hosp & Hlth Ctr, Primary Care Residency Program, 64 Robbins St, Waterbury, CT 06721 USA.	ruichael.green@yale.edu						ELLIS J, 1995, LANCET, V346, P407, DOI 10.1016/S0140-6736(95)92781-6; Green ML, 1997, J GEN INTERN MED, V12, P742, DOI 10.1046/j.1525-1497.1997.07159.x; Lockwood DNJ, 2004, BRIT MED J, V329, P1020, DOI 10.1136/bmj.329.7473.1020; Ross R, 2003, ACAD MED, V78, P412, DOI 10.1097/00001888-200304000-00019; Smith CA, 2000, J GEN INTERN MED, V15, P710, DOI 10.1046/j.1525-1497.2000.91026.x	5	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 30	2004	329	7473					1023	1023		10.1136/bmj.38257.549653.55	http://dx.doi.org/10.1136/bmj.38257.549653.55			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514350	Green Published			2022-12-28	WOS:000224852400027
J	Steinbrook, R				Steinbrook, R			Registration of clinical trials - Voluntary or mandatory?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*COUNC SCI AFF, 2004, FEAT CSA REP INFL FU; De Angelis C, 2004, NEW ENGL J MED, V351, P1250, DOI 10.1056/NEJMe048225; Steinbrook R, 2004, NEW ENGL J MED, V351, P315, DOI 10.1056/NEJMp048191	3	21	24	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1820	1822		10.1056/NEJMp048264	http://dx.doi.org/10.1056/NEJMp048264			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509812				2022-12-28	WOS:000224723100002
J	Andersson, N; Ho-Foster, A; Matthis, J; Marokoane, N; Mashiane, V; Mhatre, S; Mitchell, S; Mokoena, T; Monasta, L; Ngxowa, N; Salcedo, MP; Sonnekus, H				Andersson, N; Ho-Foster, A; Matthis, J; Marokoane, N; Mashiane, V; Mhatre, S; Mitchell, S; Mokoena, T; Monasta, L; Ngxowa, N; Salcedo, MP; Sonnekus, H			National cross sectional study of views on sexual violence and risk of HIV infection and AIDS among South African school pupils	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENDER; WOMEN; PREVENTION; PREVALENCE; EDUCATION; BEHAVIOR; HEALTH; RAPE	Objective To investigate the views of school pupils on sexual violence and on the risk of HIV infection and AIDS and their experiences of sexual violence. Design National cross sectional study. Setting 5162 classes in 1418 South African schools. Participants 269 705 pupils aged 10-19 years in grades 6-11. Main outcome measure Answers to questions about sexual violence and about the risk of HIV infection and AIDS. Results Misconceptions about: sexual violence were common among both sexes, but more females held views that would put them at high risk of HIV infection. One third of the respondents thought they might be HIV positive. This was associated with misconceptions about sexual violence and about the risk of HIV infection and AIDS. Around 11% of males and 4% of females claimed to have forced someone else to have sex; 66% of these males and 71% of these females had themselves been forced to have sex. A history of forced sex was a powerful determinant of views on sexual violence and risk of HIV infection. Conclusions The views of South African youth on sexual violence and on the risk of HIV infection and AIDS were compatible with acceptance of sexual coercion and "adaptive" attitudes to survival in a violent society. Views differed little between the sexes.	Univ Autonoma Guerrero, CIET, Acapulco, Mexico; CIETafrica, ZA-2041 Houghton, South Africa		Andersson, N (corresponding author), Univ Autonoma Guerrero, CIET, Apdo Postal 182, Acapulco, Mexico.	neil@ciet.org	Ho-Foster, Ari/AAM-9225-2021; Monasta, Lorenzo/B-1388-2012; Andersson, Neil/G-2248-2011	Ho-Foster, Ari/0000-0001-9817-8090; Monasta, Lorenzo/0000-0001-7774-548X; 				Andersson N, 2002, CIETMAP FREE GIS EPI; ARMSTRONG S, 1993, WORLD AIDS, P27; Blumenthal S, 1999, CHILD ABUSE NEGLECT, V23, P129, DOI 10.1016/S0145-2134(98)00117-3; Bowley DM, 2002, SAMJ S AFR MED J, V92, P744; Buzi RS, 2003, J SCHOOL HEALTH, V73, P191, DOI 10.1111/j.1746-1561.2003.tb03602.x; Campbell C, 2002, SOC SCI MED, V55, P331, DOI 10.1016/S0277-9536(01)00289-1; Eaton L, 2003, SOC SCI MED, V56, P149, DOI 10.1016/S0277-9536(02)00017-5; Garcia-Moreno C, 2000, AIDS, V14, pS253; Hartung TK, 2002, INT J STD AIDS, V13, P829, DOI 10.1258/095646202321020107; Jewkes R, 2002, SOC SCI MED, V55, P1603, DOI 10.1016/S0277-9536(01)00294-5; Jewkes R, 2002, SOC SCI MED, V55, P1231, DOI 10.1016/S0277-9536(01)00242-8; Kim J, 2002, SOC SCI MED, V54, P1243, DOI 10.1016/S0277-9536(01)00093-4; Koenig MA, 2004, SOC SCI MED, V58, P787, DOI 10.1016/S0277-9536(03)00244-2; MANTEL N, 1959, J NATL CANCER I, V22, P719; Mitchell C, 2003, CULT HEALTH SEX, V5, P513, DOI 10.1080/13691050110149909; Peltzer K, 2000, PSYCHOL REP, V87, P593; Taylor M, 2003, J SCHOOL HEALTH, V73, P97, DOI 10.1111/j.1746-1561.2003.tb03580.x; Varga CA, 2003, STUD FAMILY PLANN, V34, P160, DOI 10.1111/j.1728-4465.2003.00160.x; Watts C, 2002, LANCET, V359, P1232, DOI 10.1016/S0140-6736(02)08221-1; Wood K, 1998, SOC SCI MED, V47, P233, DOI 10.1016/S0277-9536(98)00057-4	20	43	44	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 23	2004	329	7472					952	954A		10.1136/bmj.38226.617454.7C	http://dx.doi.org/10.1136/bmj.38226.617454.7C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	866KU	15485935	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000224773200018
J	Lenton, TM; Schellnhuber, HJ; Szathmary, E				Lenton, TM; Schellnhuber, HJ; Szathmary, E			Climbing the co-evolution ladder	NATURE			English	Editorial Material									Tyndall Ctr, Southampton, Hants, England; Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England; Collegium Budapest, H-1014 Budapest, Hungary	University of Southampton; University of East Anglia	Lenton, TM (corresponding author), Tyndall Ctr, Southampton, Hants, England.		Szathmáry, Eörs/A-5007-2011; Lenton, Tim M/X-1893-2018; Schellnhuber, Hans Joachim/B-2607-2012; Schellnhuber, Hans Joachim/O-3873-2019; Szathmary, Eors/AAS-1202-2021	Lenton, Tim M/0000-0002-6725-7498; Schellnhuber, Hans Joachim/0000-0001-7453-4935; Schellnhuber, Hans Joachim/0000-0001-7453-4935; Szathmary, Eors/0000-0001-5227-2997				Crutzen PJ, 2002, NATURE, V415, P23, DOI 10.1038/415023a; Lenton TM, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018802; Lovelock J, 1988, AGES GAIA BIOGRAPHY; Schellnhuber HJ, 1999, NATURE, V402, pC19, DOI 10.1038/35011515; SCHELLNHUBER HJ, 2004, DAHLEM WORKSHOP REPO, V91; Szathmary E, 1995, MAJOR TRANSITIONS EV	6	29	33	3	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	2004	431	7011					913	913		10.1038/431913a	http://dx.doi.org/10.1038/431913a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496901	Bronze			2022-12-28	WOS:000224585600024
J	Saposnik, G; Young, B; Silver, B; Di Legge, S; Webster, F; Beletsky, V; Jain, V; Nilanont, Y; Hachinski, V				Saposnik, G; Young, B; Silver, B; Di Legge, S; Webster, F; Beletsky, V; Jain, V; Nilanont, Y; Hachinski, V			Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy - Predictors and association with outcome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; EARLY RECANALIZATION; RELIABILITY; PREVALENCE; RECOVERY; NEGLECT; BRAIN; UNIT	Context The focus of thrombolytic therapy in acute stroke has been on favorable outcome at 3 months. Few studies have analyzed outcome at 24 hours. An early and reliable prediction of poor outcome has implications for clinical management and discharge planning. Objective To evaluate predictors of lack of improvement at 24 hours after receiving alteplase and their relationship with poor outcome at 3 months. Design, Setting, and Participants Prospective cohort of consecutive patients with acute stroke who received alteplase and were admitted to a university hospital from January 1999 to March 2003. Participants were recruited from 2 academic centers in a major city in Ontario and 33 affiliated hospitals from 7 counties. Main Outcome Measures Lack of improvement defined as a difference between the National Institutes of Health Stroke Scale score at baseline and at 24 hours of 3 points or less. Poor outcome at 3 months defined by a modified Rankin Scale score of 3 to 5 or death. Results Among 216 patients with acute stroke who were treated with alteplase, 111 (51.4%) had a lack of improvement at 24 hours. After adjusting for age, sex, and stroke severity, baseline glucose level on admission (odds ratio [OR] 2.89; 95% confidence interval [CI], 1.40-5.99 for a glucose level >144 mg/dL [>8 mmol/L]), cortical involvement (OR, 2.66; 95% Cl, 1.36-5.20), and time to treatment (OR, 1.01; 95% Cl, 1.0-1.02 for each 1 minute increase in time to treatment) were independent predictors of lack of improvement. At 3 months, 43 patients (20.2%) had died; of the 170 survivors, 75 patients (44%) had poor outcomes. After adjusting for age, sex, and stroke severity, lack of improvement at 24 hours was an independent predictor of poor outcome (OR, 12.9; 95% Cl, 5.7-29.6) and death (OR, 7.5; 95% Cl, 2.9-19.6). Patients with a lack of improvement had longer lengths of hospitalization (14.5 vs 9.6 days; P=.02). Conclusions Among patients with acute stroke treated with thrombolytic therapy, lack of improvement at 24 hours is associated with poor outcome and death at 3 months. Elevated glucose level, time to thrombolytic therapy, and cortical involvement were predictors of lack of improvement.	Univ Western Ontario, London Hlth Sci Ctr, Stroke Serv, Dept Clin Neurol Sci,Stroke Program, London, ON N6A 5A5, Canada; Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA	London Health Sciences Centre; Western University (University of Western Ontario); Henry Ford Health System; Henry Ford Hospital	Saposnik, G (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Stroke Serv, Dept Clin Neurol Sci,Stroke Program, 339 Windermere Rd,Off 7-GE5, London, ON N6A 5A5, Canada.	gsaposni@uwo.ca	Webster, Fiona/AAK-3253-2020; Saposnik, Gustavo/M-3937-2017	Saposnik, Gustavo/0000-0002-5950-9886; Webster, Fiona/0000-0002-7318-7713				Adams HP, 1996, STROKE, V27, P1711; Alexandrov AV, 2004, STROKE, V35, P449, DOI 10.1161/01.STR.0000113737.58014.B4; Alvarez-Sabin J, 2003, STROKE, V34, P1235, DOI 10.1161/01.STR.0000068406.30514.31; Arenillas JF, 2002, STROKE, V33, P2197, DOI 10.1161/01.STR.0000027861.75884.DF; Baird AE, 2001, LANCET, V357, P2095, DOI 10.1016/S0140-6736(00)05183-7; BROTT T, 1989, STROKE, V20, P871, DOI 10.1161/01.STR.20.7.871; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Brown DL, 2004, STROKE, V35, P147, DOI 10.1161/01.STR.000010539.93273.72; Buxbaum LJ, 2004, NEUROLOGY, V62, P749, DOI 10.1212/01.WNL.0000113730.73031.F4; Chang KC, 2002, STROKE, V33, P2670, DOI 10.1161/01.STR.0000034396.68980.39; del Zoppo GJ, 2004, CEREBROVASC DIS, V17, P144, DOI 10.1159/000074807; Delsing BJP, 2001, PEDIATR NEUROL, V24, P283, DOI 10.1016/S0887-8994(01)00245-4; Demchuk AM, 2001, NEUROLOGY, V57, P474, DOI 10.1212/WNL.57.3.474; Demchuk AM, 2001, STROKE, V32, P89, DOI 10.1161/01.STR.32.1.89; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; Felberg RA, 2002, STROKE, V33, P1301, DOI 10.1161/01.STR.0000015556.48283.74; Foell RBT, 2003, CAN MED ASSOC J, V169, P193; Ganesan V, 2000, DEV MED CHILD NEUROL, V42, P455, DOI 10.1017/S0012162200000852; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; Grotta JC, 2001, STROKE, V32, P661, DOI 10.1161/01.STR.32.3.661; Hillis AE, 2004, NEURORADIOLOGY, V46, P31, DOI 10.1007/s00234-002-0918-4; Kalra L, 1997, STROKE, V28, P1386, DOI 10.1161/01.STR.28.7.1386; Kucinski T, 2003, NEURORADIOLOGY, V45, P11, DOI 10.1007/s00234-002-0881-0; Labiche LA, 2003, STROKE, V34, P695, DOI 10.1161/01.STR.0000055940.00316.6B; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; Martinez-Vila E, 2004, CEREBROVASC DIS, V17, P124, DOI 10.1159/000074804; Mendizabal JE, 2001, J NEUROIMAGING, V11, P101, DOI 10.1111/j.1552-6569.2001.tb00018.x; Merino JG, 2002, STROKE, V33, P141, DOI 10.1161/hs0102.100481; Poungvarin N, 1998, LANCET, V352, pSIII19; Saposnik G, 2003, STROKE, V34, P2103, DOI 10.1161/01.STR.0000088063.74250.DB; Schellinger PD, 2004, CURR OPIN NEUROL, V17, P69, DOI 10.1097/00019052-200402000-00012; Shafqat S, 1999, STROKE, V30, P2141, DOI 10.1161/01.STR.30.10.2141; *STAT CAN, POP DEM DAT TABL; Steiner T, 2004, STROKE, V35, P1018, DOI 10.1161/01.STR.0000120953.78592.72; Sulter G, 2003, STROKE, V34, P101, DOI 10.1161/01.STR.0000048148.09143.6C; Trouillas P, 1998, STROKE, V29, P2529, DOI 10.1161/01.STR.29.12.2529; Wardlaw JM, 2003, STROKE, V34, P1437, DOI 10.1161/01.STR.0000072513.72262.7E; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362	39	63	64	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2004	292	15					1839	1844		10.1001/jama.292.15.1839	http://dx.doi.org/10.1001/jama.292.15.1839			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IV	15494581	Bronze			2022-12-28	WOS:000224485100022
J	Takats, Z; Wiseman, JM; Gologan, B; Cooks, RG				Takats, Z; Wiseman, JM; Gologan, B; Cooks, RG			Mass spectrometry sampling under ambient conditions with desorption electrospray ionization	SCIENCE			English	Article							ASSISTED-LASER-DESORPTION/IONIZATION; CLUSTER-IMPACT; LARGE BIOMOLECULES; TISSUE; SIMS; MS	A new method of desorption ionization is described and applied to the ionization of various compounds, including peptides and proteins present on metal, polymer, and mineral surfaces. Desorption electrospray ionization (DESI) is carried out by directing electrosprayed charged droplets and ions of solvent onto the surface to be analyzed. The impact of the charged particles on the surface produces gaseous ions of material originally present on the surface. The resulting mass spectra are similar to normal ESI mass spectra in that they show mainly singly or multiply charged molecular ions of the analytes. The DESI phenomenon was observed both in the case of conductive and insulator surfaces and for compounds ranging from nonpolar small molecules such as lycopene, the alkaloid coniceine, and small drugs, through polar compounds such as peptides and proteins. Changes in the solution that is sprayed can be used to selectively ionize particular compounds, including those in biological matrices. in vivo analysis is demonstrated.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Cooks, RG (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.	cooks@purdue.edu	Cockshutt, Naomi/AAJ-2721-2020; Cooks, R Graham/G-1051-2015	Cooks, R Graham/0000-0002-9581-9603				Aksyonov SA, 2001, RAPID COMMUN MASS SP, V15, P2001, DOI 10.1002/rcm.470; BENNINGHOVEN A, 1987, CHEM ANAL SERIES MON, V86; BLAIN MG, 1989, J PHYS-PARIS, V50, P85, DOI 10.1051/jphyscol:1989216; Chaurand P, 2004, ANAL CHEM, V76, p86A, DOI 10.1021/ac0415197; CORNETT DS, 1994, RAPID COMMUN MASS SP, V8, P996; Daniel JM, 2002, INT J MASS SPECTROM, V216, P1, DOI 10.1016/S1387-3806(02)00585-7; FABRIS D, 1995, J MASS SPECTROM, V30, P140, DOI 10.1002/jms.1190300121; FENN JB, 1990, MASS SPECTROM REV, V9, P37, DOI 10.1002/mas.1280090103; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Filippi A, 2000, INT J MASS SPECTROM, V198, P137, DOI 10.1016/S1387-3806(00)00196-2; Gresham GL, 2001, INT J MASS SPECTROM, V208, P135, DOI 10.1016/S1387-3806(01)00388-8; He F, 1999, INT J MASS SPECTROM, V193, P103, DOI 10.1016/S1387-3806(99)00167-0; Laiko VV, 2000, ANAL CHEM, V72, P5239, DOI 10.1021/ac000530d; Laiko VV, 2000, ANAL CHEM, V72, P652, DOI 10.1021/ac990998k; MAHONEY JF, 1991, RAPID COMMUN MASS SP, V5, P441, DOI 10.1002/rcm.1290051004; MAHONEY JF, 1994, RAPID COMMUN MASS SP, V8, P403, DOI 10.1002/rcm.1290080513; Stockle R, 2001, ANAL CHEM, V73, P1399, DOI 10.1021/ac001440b; Stoeckli M, 2001, NAT MED, V7, P493, DOI 10.1038/86573; Tao WA, 2003, ANAL CHEM, V75, p25A, DOI 10.1021/ac0312110; Todd PJ, 2001, J MASS SPECTROM, V36, P355, DOI 10.1002/jms.153; Touboul D, 2004, ANAL CHEM, V76, P1550, DOI 10.1021/ac035243z; Wei J, 1999, NATURE, V399, P243, DOI 10.1038/20400; Winograd N, 2003, APPL SURF SCI, V203, P13, DOI 10.1016/S0169-4332(02)00633-5	23	2440	2686	52	1583	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2004	306	5695					471	473		10.1126/science.1104404	http://dx.doi.org/10.1126/science.1104404			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486296				2022-12-28	WOS:000224626500048
J	Bird, SM				Bird, SM			Attributable testing for abnormal prion protein, database linkage, and blood-borne vCJD risks	LANCET			English	Review							BOVINE SPONGIFORM ENCEPHALOPATHY; CREUTZFELDT-JAKOB-DISEASE; VARIANT; UK; TRANSMISSION; ACCUMULATION; APPENDIX; EPIDEMIOLOGY; TRANSFUSION; CATTLE	Context National prospective collection of tonsillar tissue to be tested anonymously for abnormal lymphoreticular accumulation of prion protein (PrP) was approved to begin in the UK in 2004. The UK is not, however, testing autopsy specimens attributably for abnormal PrP (PrPsc) so that recipients at risk after a blood transfusion from, or exposed to surgical instruments from, a deceased carrier of variant Creutzfeldt-Jakob disease (vCJD) can be followed up to quantify transmission risks. In Switzerland, surveillance for subclinical vCJD includes unconsented testing in autopsies: consented testing of tonsillar tissue is potentially attributable to interrupt human-to-human vCJD transmission or treat it. Starting point The UK announced its first case of probable blood-borne vCJD transmission in December, 2003, and first detected a case of probable blood-borne subclinical vCJD in July, 2004. To reduce the possible risk of onward transmission to other people, UK patients who had received vCJD-implicated plasma products are being contacted. They, and their general practitioner, are asked to inform anyone giving them medical, surgical, or dental treatment, and the patients must refrain from donating blood, tissues, or organs. Where next? Prudent additional surveillance options for human PrPsc-particularly at autopsy or to sanction the release of quarantined operation sets pending effective decontamination--can be costed by reference to results for cattle and sheep. Some ethical or legal impediments to the UK's potentially-attributable testing for PrPsc may yet be rued.	Univ Forvie Site, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England	MRC Biostatistics Unit; University of Cambridge	Bird, SM (corresponding author), Univ Forvie Site, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England.	sheila.bird@mrc-bsu.cam.ac.uk						Arnold M, 2003, P ROY SOC B-BIOL SCI, V270, P2141, DOI 10.1098/rspb.2003.2494; Bird SM, 2004, BMJ-BRIT MED J, V328, P118, DOI 10.1136/bmj.328.7432.118; Bird SM, 2003, STAT METHODS MED RES, V12, P261, DOI 10.1191/0962280203sm331ra; Cooper JD, 2003, INT J EPIDEMIOL, V32, P784, DOI 10.1093/ije/dyg248; Doherr MG, 1999, VET REC, V145, P155, DOI 10.1136/vr.145.6.155; Donnelly CA, 2003, STAT METHODS MED RES, V12, P177, DOI 10.1191/0962280203sm337ra; Ferguson NM, 2003, P ROY SOC B-BIOL SCI, V270, P1579, DOI 10.1098/rspb.2003.2484; Fichet G, 2004, LANCET, V364, P521, DOI 10.1016/S0140-6736(04)16810-4; Frosh A, 2004, LANCET, V364, P1260, DOI 10.1016/S0140-6736(04)17143-2; Ghani AC, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-4; Glatzel M, 2003, LANCET NEUROL, V2, P757, DOI 10.1016/S1474-4422(03)00588-X; Gore SM, 1996, BRIT MED J, V312, P791, DOI 10.1136/bmj.312.7034.791; Herzog C, 2004, LANCET, V363, P422, DOI 10.1016/S0140-6736(04)15487-1; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hilton DA, 2002, BRIT MED J, V325, P633, DOI 10.1136/bmj.325.7365.633; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; Hilton DA, 2004, J PATHOL, V203, P733, DOI 10.1002/path.1580; *HLTH PROT AG, 2004, CREUTZF JAK DIS CJD; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; Hunter N, 2002, J GEN VIROL, V83, P2897, DOI 10.1099/0022-1317-83-11-2897; Ironside JW, 2000, LANCET, V355, P1693, DOI 10.1016/S0140-6736(00)02243-1; KIRKUP B, 2003, REPORT INCIDENT 0228; Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X; MCDOUGALL L, 2004, SUNDAY HERALD   0905; Peden AH, 2004, LANCET, V364, P527, DOI 10.1016/S0140-6736(04)16811-6; *SCI STEER COMM, 2001, OP REQ STAT AUTH BSE; *SCI STEER COMM, 2003, OP BSE UK CATTL BORN; Wilesmith JW, 1997, VET REC, V141, P239, DOI 10.1136/vr.141.10.239; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	29	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2004	364	9442					1362	1364		10.1016/S0140-6736(04)17194-8	http://dx.doi.org/10.1016/S0140-6736(04)17194-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474140				2022-12-28	WOS:000224349700033
J	Stuart, MJ; Nagel, RL				Stuart, MJ; Nagel, RL			Sickle-cell disease	LANCET			English	Review							ACUTE CHEST SYNDROME; RED-BLOOD-CELLS; MEMBRANE PHOSPHOLIPID ASYMMETRY; NITRIC-OXIDE BIOAVAILABILITY; BONE-MARROW-TRANSPLANTATION; ACUTE VASOOCCLUSIVE CRISIS; FETAL-HEMOGLOBIN LEVELS; ENDOTHELIAL-CELLS; RISK-FACTOR; PULMONARY-HYPERTENSION	With the global scope of sickle-cell disease, knowledge of the countless clinical presentations and treatment of this disorder need to be familiar to generalists, haematologists, internists, and paediatricians alike. Additionally, an underlying grasp of sickle-cell pathophysiology, which has rapidly accrued new knowledge in areas related to erythrocyte and extra-erythrocyte events, is crucial to an understanding of the complexity of this molecular disease with protean manifestations. We highlight studies from past decades related to such translational research as the use of hydroxyurea in treatment, as well as the therapeutic promise of red-cell ion-channel blockers, and antiadhesion and anti-inflammatory therapy. The novel role of nitric oxide in sickle-cell pathophysiology and the range of its potential use in treatment are also reviewed. Understanding of disease as the result of a continuing interaction between basic scientists and clinical researchers is best exemplified by this entity.	Thomas Jefferson Univ, Dept Pediat, Div Hematol, Marian Anderson Sickle Cell Anemia Res Hematol La, Philadelphia, PA 19107 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Hematol,Bronx Sickle Cell Ctr, Bronx, NY 10467 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10467 USA	Jefferson University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Stuart, MJ (corresponding author), Thomas Jefferson Univ, Dept Pediat, Div Hematol, Marian Anderson Sickle Cell Anemia Res Hematol La, Philadelphia, PA 19107 USA.	marie.stuart@jefferson.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR012248] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073944, P60HL062148, U54HL070585, R01HL068962] Funding Source: NIH RePORTER; NCRR NIH HHS [RR12248] Funding Source: Medline; NHLBI NIH HHS [HL70585, HL62148, HL709994, HL68962, HL55435, HL73944] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Adams RJ, 2000, CURR OPIN HEMATOL, V7, P101, DOI 10.1097/00062752-200003000-00005; Aldrich TK, 1996, J APPL PHYSIOL, V80, P531, DOI 10.1152/jappl.1996.80.2.531; ARMOLIA P, 2003, BRIT J HAEMATOL, V120, P725; Aslan M, 2001, P NATL ACAD SCI USA, V98, P15215, DOI 10.1073/pnas.221292098; Atweh GF, 1999, BLOOD, V93, P1790; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Ballas Samir K., 1994, P745; Belcher JD, 2003, BLOOD, V101, P3953, DOI 10.1182/blood-2002-10-3313; BELLET PS, 1995, NEW ENGL J MED, V333, P699, DOI 10.1056/NEJM199509143331104; Benjamin LJ, 2000, BLOOD, V95, P1130, DOI 10.1182/blood.V95.4.1130.003k03a_1130_1136; Benkerrou M, 2002, BLOOD, V99, P2297, DOI 10.1182/blood.V99.7.2297; Bernini JC, 1998, BLOOD, V92, P3082, DOI 10.1182/blood.V92.9.3082.421k15_3082_3089; Bialecki ES, 2002, AM J MED, V113, P252, DOI 10.1016/S0002-9343(02)01165-8; BOOKCHIN RM, 1977, NATURE, V269, P526, DOI 10.1038/269526a0; Bookchin RM, 2002, CURR OPIN HEMATOL, V9, P107, DOI 10.1097/00062752-200203000-00004; Brittain JE, 2001, BLOOD, V97, P2159, DOI 10.1182/blood.V97.7.2159; Brugnara C, 2001, BLOOD CELL MOL DIS, V27, P71, DOI 10.1006/bcmd.2000.0366; CASTRO O, 1994, BLOOD, V84, P643, DOI 10.1182/blood.V84.2.643.643; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Chui DHK, 2001, CURR OPIN PEDIATR, V13, P22, DOI 10.1097/00008480-200102000-00004; Clarkson P, 1996, J CLIN INVEST, V97, P1989, DOI 10.1172/JCI118632; COHEN AR, 1992, BLOOD, V79, P1657; Cohen AR, 1998, NEW ENGL J MED, V339, P42, DOI 10.1056/NEJM199807023390109; CUNNINGHAM G, 1998, MMWR-MORBID MORTAL W, V47, P169; Dampier C, 2002, J PAIN, V3, P461, DOI 10.1054/jpai.2002.128064; de Franceschi L, 2003, BLOOD, V102, P1087, DOI 10.1182/blood-2002-07-2135; de Jong K, 2001, BLOOD, V98, P860, DOI 10.1182/blood.V98.3.860; DeSimone J, 2002, BLOOD, V99, P3905, DOI 10.1182/blood.V99.11.3905; Diallo D, 2002, CURR OPIN HEMATOL, V9, P111, DOI 10.1097/00062752-200203000-00005; Ducrocq R, 2001, J MED SCREEN, V8, P8, DOI 10.1136/jms.8.1.8; Duits AJ, 1996, CLIN IMMUNOL IMMUNOP, V81, P96, DOI 10.1006/clin.1996.0163; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; Fadlon E, 1998, BLOOD, V91, P266, DOI 10.1182/blood.V91.1.266.266_266_274; FERRONE F, 2001, DISORDERS HEMOGLOBIN, P577; Ferster A, 2001, BLOOD, V97, P3628, DOI 10.1182/blood.V97.11.3628; FRANCK PFH, 1985, J CLIN INVEST, V75, P183, DOI 10.1172/JCI111672; Frenette PS, 2002, CURR OPIN HEMATOL, V9, P101, DOI 10.1097/00062752-200203000-00003; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; Gbadoe AD, 2001, ARCH DIS CHILD, V85, P52, DOI 10.1136/adc.85.1.52; GEE BE, 1995, BLOOD, V85, P268, DOI 10.1182/blood.V85.1.268.bloodjournal851268; Gibson JS, 2002, BLOOD CELL MOL DIS, V28, P303, DOI 10.1006/bcmd.2002.0515; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056/NEJMoa035477; Gladwin MT, 2003, CIRCULATION, V107, P271, DOI 10.1161/01.CIR.0000044943.12533.A8; Gladwin MT, 2001, SEMIN HEMATOL, V38, P333, DOI 10.1053/shem.2001.27574; GREENBERG J, 1983, J PEDIATR-US, V102, P781, DOI 10.1016/S0022-3476(83)80258-3; GRIFFIN TC, 1993, J PEDIATR SURG, V28, P681, DOI 10.1016/0022-3468(93)90031-F; GRIFFIN TC, 1994, NEW ENGL J MED, V330, P733, DOI 10.1056/NEJM199403173301101; Gupta K, 1999, BBA-MOL BASIS DIS, V1453, P63, DOI 10.1016/S0925-4439(98)00085-4; Haque AK, 2002, HUM PATHOL, V33, P1037, DOI 10.1053/hupa.2002.128059; Harlan JM, 2000, BLOOD, V95, P365, DOI 10.1182/blood.V95.2.365; HEBBEL RP, 1980, NEW ENGL J MED, V302, P992, DOI 10.1056/NEJM198005013021803; Herrick J.B., 1910, ARCH INTERN MED, V6, P517; Hillery CA, 1996, BLOOD, V87, P4879, DOI 10.1182/blood.V87.11.4879.bloodjournal87114879; Hines PC, 2003, BLOOD, V101, P3281, DOI 10.1182/blood-2001-12-0289; HOOVER R, 1979, BLOOD, V54, P872; Hoppe C, 2003, BLOOD, V101, P2865, DOI 10.1182/blood-2002-09-2791; Hoppe CC, 2001, CURR OPIN ONCOL, V13, P85, DOI 10.1097/00001622-200103000-00001; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; Jacobson SJ, 1997, LANCET, V350, P1358, DOI 10.1016/S0140-6736(97)08462-6; JONECKIS CC, 1993, BLOOD, V82, P3548; Kassim AA, 2000, BLOOD, V95, P1878, DOI 10.1182/blood.V95.5.1878; Kaul DK, 2000, J CLIN INVEST, V106, P411, DOI 10.1172/JCI9225; Kaul DK, 2000, BLOOD, V95, P368, DOI 10.1182/blood.V95.2.368; KAUL DK, 1989, P NATL ACAD SCI USA, V86, P3356, DOI 10.1073/pnas.86.9.3356; Key NS, 1998, BLOOD, V91, P4216, DOI 10.1182/blood.V91.11.4216.411k15_4216_4223; Kinney TR, 1999, PEDIATRICS, V103, P640, DOI 10.1542/peds.103.3.640; KINNEY TR, 1990, J PEDIATR-US, V117, P194, DOI 10.1016/S0022-3476(05)80529-3; Kirkham FJ, 2001, LANCET, V357, P1656, DOI 10.1016/S0140-6736(00)04821-2; Klings ES, 2001, AM J RESP CRIT CARE, V164, P1248, DOI 10.1164/ajrccm.164.7.2101020; KOSHY M, 1988, NEW ENGL J MED, V319, P1447, DOI 10.1056/NEJM198812013192204; KOSHY M, 1995, BLOOD, V86, P3676, DOI 10.1182/blood.V86.10.3676.bloodjournal86103676; Kuypers FA, 1996, BLOOD, V87, P1179, DOI 10.1182/blood.V87.3.1179.bloodjournal8731179; Lard LR, 1999, J LEUKOCYTE BIOL, V66, P411, DOI 10.1002/jlb.66.3.411; Lowenthal EA, 1996, AM J HEMATOL, V51, P207, DOI 10.1002/(SICI)1096-8652(199603)51:3<207::AID-AJH5>3.3.CO;2-B; Maier-Redelsperger M, 1999, Curr Opin Hematol, V6, P115, DOI 10.1097/00062752-199903000-00010; Manodori AB, 1998, BLOOD, V92, P3445, DOI 10.1182/blood.V92.9.3445.421k24_3445_3454; Mantadakis E, 2000, BLOOD, V95, P78, DOI 10.1182/blood.V95.1.78.001k36_78_82; Matsui NM, 2002, BLOOD, V100, P3790, DOI 10.1182/blood-2002-02-0626; Matsui NM, 2001, BLOOD, V98, P1955, DOI 10.1182/blood.V98.6.1955; Melman A, 2000, INT J IMPOT RES, V12, pS133, DOI 10.1038/sj.ijir.3900592; MERKEL KHH, 1978, STROKE, V9, P45, DOI 10.1161/01.STR.9.1.45; Miller MK, 2001, J PEDIAT HEMATOL ONC, V23, P306, DOI 10.1097/00043426-200106000-00014; Miller ST, 2001, J PEDIATR-US, V139, P385, DOI 10.1067/mpd.2001.117580; Miller ST, 2000, NEW ENGL J MED, V342, P83, DOI 10.1056/NEJM200001133420203; Mollapour E, 1998, BLOOD, V91, P3423, DOI 10.1182/blood.V91.9.3423.3423_3423_3429; Morris CR, 2000, BRIT J HAEMATOL, V111, P498, DOI 10.1046/j.1365-2141.2000.02403.x; Morris CR, 2003, AM J RESP CRIT CARE, V168, P63, DOI 10.1164/rccm.200208-967OC; Morris CR, 2000, J PEDIAT HEMATOL ONC, V22, P515, DOI 10.1097/00043426-200011000-00009; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; Nagel RL, 2001, BRIT J HAEMATOL, V112, P19, DOI 10.1046/j.1365-2141.2001.02286.x; NAGEL RL, 2001, DISORDERS HEMOGLOBIN, P117; Nagel RL, 2001, DISORDERS HEMOGLOBIN; Ohene-Frempong K, 1998, BLOOD, V91, P288; Old JM., 2001, DISORDERS HEMOGLOBIN, P941; ONWUBALILI JK, 1983, LANCET, V2, P503; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; Orringer EP, 2001, JAMA-J AM MED ASSOC, V286, P2099, DOI 10.1001/jama.286.17.2099; Osarogiagbon UR, 2000, BLOOD, V96, P314, DOI 10.1182/blood.V96.1.314.013k39_314_320; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; Pawliuk R, 2001, SCIENCE, V294, P2368, DOI 10.1126/science.1065806; PEARSON HA, 1985, PEDIATRICS, V76, P392; PEGELOW CH, 1995, J PEDIATR-US, V126, P896, DOI 10.1016/S0022-3476(95)70204-0; PERUTZ MF, 1960, NATURE, V185, P416, DOI 10.1038/185416a0; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; POWARS DR, 1986, OBSTET GYNECOL, V67, P217, DOI 10.1097/00006250-198602000-00012; Rahimy MC, 2000, BLOOD, V96, P1685, DOI 10.1182/blood.V96.5.1685.h8001685_1685_1689; RAO S, 1985, AM J PEDIAT HEMATOL, V7, P298; Rees DC, 2003, BRIT J HAEMATOL, V120, P744, DOI 10.1046/j.1365-2141.2003.04193.x; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Robinson SD, 1999, P NATL ACAD SCI USA, V96, P11452, DOI 10.1073/pnas.96.20.11452; Romero JR, 2002, BLOOD, V99, P1103, DOI 10.1182/blood.V99.4.1103; ROTHMAN SM, 1986, ANN NEUROL, V20, P684, DOI 10.1002/ana.410200606; Saunthararajah Y, 2003, BLOOD, V102, P3865, DOI 10.1182/blood-2003-05-1738; SEMPLE MJ, 1984, THROMB HAEMOSTASIS, V51, P303; Serjeant GR, 1997, BRIT J HAEMATOL, V97, P253, DOI 10.1046/j.1365-2141.1997.02701.x; Serjeant GR, 2004, OBSTET GYNECOL, V103, P1278, DOI 10.1097/01.AOG.0000127433.23611.54; SERJEANT GR, 1993, LANCET, V341, P1237, DOI 10.1016/0140-6736(93)91145-C; Setty BNY, 2003, LANCET, V362, P1450, DOI 10.1016/S0140-6736(03)14689-2; Setty BNY, 2002, J LAB CLIN MED, V139, P80, DOI 10.1067/mlc.2002.121200; Setty BNY, 2002, BLOOD, V99, P1564, DOI 10.1182/blood.V99.5.1564; Setty BNY, 2001, BLOOD, V97, P2568, DOI 10.1182/blood.V97.9.2568; Setty BNY, 1996, BLOOD, V88, P2311, DOI 10.1182/blood.V88.6.2311.bloodjournal8862311; Setty BNY, 2001, BLOOD, V98, P3228, DOI 10.1182/blood.V98.12.3228; Setty BNY, 2000, BLOOD, V96, P1119, DOI 10.1182/blood.V96.3.1119; Solovey A, 1997, NEW ENGL J MED, V337, P1584, DOI 10.1056/NEJM199711273372203; Solovey A, 1998, J CLIN INVEST, V101, P1899, DOI 10.1172/JCI1932; Solovey AA, 2001, BLOOD, V97, P1937, DOI 10.1182/blood.V97.7.1937; SOWEMIMOCOKER SO, 1989, AM J HEMATOL, V31, P263, DOI 10.1002/ajh.2830310409; Steinberg MH, 2003, JAMA-J AM MED ASSOC, V289, P1645, DOI 10.1001/jama.289.13.1645; Steinberg MH, 1999, NEW ENGL J MED, V340, P1021, DOI 10.1056/NEJM199904013401307; Steinberg MH, 2001, MEDICINE, V80, P328, DOI 10.1097/00005792-200109000-00007; Steinberg MH, 1997, BRIT J HAEMATOL, V98, P838, DOI 10.1046/j.1365-2141.1997.3173132.x; STOCKMAN JA, 1972, NEW ENGL J MED, V287, P846, DOI 10.1056/NEJM197210262871703; Stuart MJ, 1999, BLOOD, V94, P1555, DOI 10.1182/blood.V94.5.1555.417k36_1555_1560; Stuart MJ, 2001, CURR OPIN HEMATOL, V8, P111, DOI 10.1097/00062752-200103000-00009; Stuart MJ, 2001, PEDIATR PATHOL MOL M, V20, P27, DOI 10.1080/15513810109168816; STYLES L, 1997, BLOOD, V90, P604; Styles LA, 2000, BLOOD, V96, P3276; Styles LA, 1996, BLOOD, V87, P2573, DOI 10.1182/blood.V87.6.2573.bloodjournal8762573; Styles LA, 1997, BLOOD, V89, P2554, DOI 10.1182/blood.V89.7.2554; Styles LA, 2000, BLOOD, V95, P3562, DOI 10.1182/blood.V95.11.3562.011k49_3562_3567; Sullivan KJ, 2001, AM J RESP CRIT CARE, V164, P2186, DOI 10.1164/ajrccm.164.12.2012090; SWERLICK RA, 1993, BLOOD, V82, P1891; TAIT JF, 1994, J LAB CLIN MED, V123, P741; Taylor JG, 2002, BLOOD, V100, P4303, DOI 10.1182/blood-2001-12-0306; Telen MJ, 2001, SEMIN HEMATOL, V38, P315, DOI 10.1053/shem.2001.27575; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; Tomer A, 2001, J LAB CLIN MED, V137, P398, DOI 10.1067/mlc.2001.115450; Tomer A, 2001, THROMB HAEMOSTASIS, V85, P966, DOI 10.1055/s-0037-1615948; Turhan A, 2002, P NATL ACAD SCI USA, V99, P3047, DOI 10.1073/pnas.052522799; Udani M, 1998, J CLIN INVEST, V101, P2550, DOI 10.1172/JCI1204; Vichinsky E, 2002, LANCET, V360, P629, DOI 10.1016/S0140-6736(02)09776-3; Vichinsky E, 2001, SEMIN HEMATOL, V38, P1, DOI 10.1016/S0037-1963(01)90053-8; Vichinsky EP, 2000, NEW ENGL J MED, V342, P1855, DOI 10.1056/NEJM200006223422502; VICHINSKY EP, 1995, NEW ENGL J MED, V333, P206, DOI 10.1056/NEJM199507273330402; Vichinsky EP, 1997, BLOOD, V89, P1787, DOI 10.1182/blood.V89.5.1787.1787_1787_1792; Vichinsky EP, 2001, TRANSFUSION, V41, P1086, DOI 10.1046/j.1537-2995.2001.41091086.x; Walters MC, 2000, BLOOD, V95, P1918; Wang WC, 2001, J PEDIATR-US, V139, P790, DOI 10.1067/mpd.2001.119590; Ware MA, 1999, BRIT J HAEMATOL, V104, P93, DOI 10.1046/j.1365-2141.1999.01160.x; Ware RE, 2002, BLOOD, V99, P10, DOI 10.1182/blood.V99.1.10; Ware RE, 1999, BLOOD, V94, P3022, DOI 10.1182/blood.V94.9.3022.421k17_3022_3026; WATSON J, 1948, AM J MED SCI, V215, P419, DOI 10.1097/00000441-194804000-00008; Wei A, 2001, BLOOD, V97, P3998, DOI 10.1182/blood.V97.12.3998; Weiner DL, 2003, JAMA-J AM MED ASSOC, V289, P1136, DOI 10.1001/jama.289.9.1136; Westerman MP, 1999, J LAB CLIN MED, V134, P352, DOI 10.1016/S0022-2143(99)90149-X; WICK TM, 1993, AM J HEMATOL, V42, P284, DOI 10.1002/ajh.2830420308; Wun T, 1997, J LAB CLIN MED, V129, P507, DOI 10.1016/S0022-2143(97)90005-6; Yasin Z, 2003, BLOOD, V102, P365, DOI 10.1182/blood-2002-11-3416; ZIMMERMAN SA, 2002, 30 NAT SICKL CELL M; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	174	522	562	0	83	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2004	364	9442					1343	1360		10.1016/S0140-6736(04)17192-4	http://dx.doi.org/10.1016/S0140-6736(04)17192-4			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474138				2022-12-28	WOS:000224349700031
J	Strauss, JF; Kafrissen, M				Strauss, JF; Kafrissen, M			Waiting for the second coming	NATURE			English	Editorial Material									Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Ortho McNeil Pharmaceut, Clin Affairs, Raritan, NJ 08869 USA	University of Pennsylvania; Pennsylvania Medicine; Johnson & Johnson; Johnson & Johnson USA	Strauss, JF (corresponding author), Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA.							HARRISON PF, 1996, CONTRACEPTIVE RES DE; Mastroianni Jr Luigi, 1990, DEV NEW CONTRACEPTIV; NASS S, 2004, NEW FRONTIERS CONTRA	3	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	2004	432	7013					43	45		10.1038/432043a	http://dx.doi.org/10.1038/432043a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525977				2022-12-28	WOS:000224854900034
J	Mimura, S; Seki, T; Tanaka, S; Diffley, JFX				Mimura, S; Seki, T; Tanaka, S; Diffley, JFX			Phosphorylation-dependent binding of mitotic cyclins to Cdc6 contributes to DNA replication control	NATURE			English	Article							S-PHASE; MOLECULAR-BASIS; PROTEIN; PROTEOLYSIS; DOMAIN; SPECIFICITY; COMPONENT; KINASES; TARGETS	Cyclin-dependent kinases (CDKs) limit the activation of DNA replication origins to once per cell cycle by preventing the assembly of pre-replicative complexes (pre-RCs) during S, G2 and M phases of the cell cycle in the budding yeast Saccharomyces cerevisiae(1,2). CDKs inhibit each pre-RC component (ORC, Cdc6, Cdt1/Mcm2-7) by different mechanisms. We show here that the mitotic CDK, Clb2/Cdc28, binds tightly to an amino-terminal domain (NTD) of Cdc6, and that Cdc6 in this complex is unable to assemble pre-RCs. We present evidence indicating that this Clb2-dependent mechanism contributes to preventing rereplication in vivo. CDK interaction with the NTD of Cdc6 is mediated by the cyclin subunit Clb2, and could be reconstituted with recombinant Clb2 protein and synthetic NTD peptides. Tight Clb2 binding occurred only when the NTD was phosphorylated on CDK consensus sites. Human CDKs containing cyclins A, B and E also bound specifically to phospho-NTD peptides. We propose that direct binding of cyclins to phosphopeptide motifs may be a widespread phenomenon contributing to the targeting of CDKs to substrates.	Canc Res UK London Res Inst, Clare Hall Labs, Potters Bar EN6 3LD, Herts, England	Cancer Research UK	Diffley, JFX (corresponding author), Canc Res UK London Res Inst, Clare Hall Labs, Blanche Lane, Potters Bar EN6 3LD, Herts, England.	john.diffley@cancer.org.uk	Tanaka, Seiji/Q-8601-2019	Tanaka, Seiji/0000-0003-3882-3494; Diffley, John/0000-0001-5184-7680				Adams PD, 1999, MOL CELL BIOL, V19, P1068; Archambault V, 2003, MOL BIOL CELL, V14, P4592, DOI 10.1091/mbc.E03-06-0384; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Desdouets C, 1998, EMBO J, V17, P4139, DOI 10.1093/emboj/17.14.4139; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Drury LS, 2000, CURR BIOL, V10, P231, DOI 10.1016/S0960-9822(00)00355-9; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; HALFORD KA, 2003, BIOCH ANAL YEAST PRE; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Perkins G, 2001, EMBO J, V20, P4836, DOI 10.1093/emboj/20.17.4836; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Seki T, 2000, P NATL ACAD SCI USA, V97, P14115, DOI 10.1073/pnas.97.26.14115; Weinreich M, 2001, P NATL ACAD SCI USA, V98, P11211, DOI 10.1073/pnas.201387198; Wilmes GM, 2004, GENE DEV, V18, P981, DOI 10.1101/gad.1202304	23	90	90	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1118	1123		10.1038/nature03024	http://dx.doi.org/10.1038/nature03024			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15496876				2022-12-28	WOS:000224730800045
J	Morwood, MJ; Soejono, RP; Roberts, RG; Sutikna, T; Turney, CSM; Westaway, KE; Rink, WJ; Zhao, JX; van den Bergh, GD; Due, RA; Hobbs, DR; Moore, MW; Bird, MI; Fifield, LK				Morwood, MJ; Soejono, RP; Roberts, RG; Sutikna, T; Turney, CSM; Westaway, KE; Rink, WJ; Zhao, JX; van den Bergh, GD; Due, RA; Hobbs, DR; Moore, MW; Bird, MI; Fifield, LK			Archaeology and age of a new hominin from Flores in eastern Indonesia	NATURE			English	Article							HUMAN OCCUPATION; AUSTRALIA; COLONIZATION; QUARTZ	Excavations at Liang Bua, a large limestone cave on the island of Flores in eastern Indonesia, have yielded evidence for a population of tiny hominins, sufficiently distinct anatomically to be assigned to a new species, Homo floresiensis(1). The finds comprise the cranial and some post-cranial remains of one individual, as well as a premolar from another individual in older deposits. Here we describe their context, implications and the remaining archaeological uncertainties. Dating by radiocarbon (C-14), luminescence, uranium-series and electron spin resonance (ESR) methods indicates that H. floresiensis existed from before 38,000 years ago (kyr) until at least 18 kyr. Associated deposits contain stone artefacts and animal remains, including Komodo dragon and an endemic, dwarfed species of Stegodon. H. floresiensis originated from an early dispersal of Homo erectus ( including specimens referred to as Homo ergaster and Homo georgicus)(1) that reached Flores, and then survived on this island refuge until relatively recently. It overlapped significantly in time with Homo sapiens in the region(2,3), but we do not know if or how the two species interacted.	Univ New England, Sch Human & Environm Studies, Armidale, NSW 2351, Australia; Indonesian Ctr Archaeol, Jakarta 12001, Indonesia; Univ Wollongong, Sch Earth & Environm Sci, GeoQuEST Res Ctr, Wollongong, NSW 2522, Australia; McMaster Univ, Sch Geog & Geol, Hamilton, ON L8S 4K1, Canada; Univ Queensland, ACQUIRE, Brisbane, Qld 4072, Australia; Netherlands Inst Sea Res, NL-1790 AB Den Burg, Texel, Netherlands; Univ St Andrews, Sch Geog & Geosci, St Andrews KY16 9AL, Fife, Scotland; Australian Natl Univ, Res Sch Phys Sci & Engn, Canberra, ACT 0200, Australia	University of New England; University of Wollongong; McMaster University; University of Queensland; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ); University of St Andrews; Australian National University	Morwood, MJ (corresponding author), Univ New England, Sch Human & Environm Studies, Armidale, NSW 2351, Australia.	mmorwood@pobox.une.edu.au; rgrob@uow.edu.au	Bird, Michael/G-5364-2010; van den Bergh, Gerrit D/I-7670-2016; Zhao, Jian-xin/A-5938-2008; Turney, Chris S M/P-8701-2018; Moore, Mark W/B-4729-2015; Roberts, Richard Graham/B-8245-2013; Sutikna, Thomas/C-4709-2018	Bird, Michael/0000-0003-1801-8703; Zhao, Jian-xin/0000-0002-2413-6178; Turney, Chris S M/0000-0001-6733-0993; Moore, Mark W/0000-0003-4768-5329; Roberts, Richard Graham/0000-0002-0128-4119; van den Bergh, Gerrit Dirk/0000-0003-1507-3336; Westaway, Kira/0000-0001-5315-778X; Sutikna, Thomas/0000-0002-9742-4226; Fifield, Leslie/0000-0003-2866-4944				Aitken M.J., 1998, INTRO OPTICAL DATING; Badang Dana, 2001, SARAWAK MUS J, V56, P37; Bird MI, 1999, RADIOCARBON, V41, P127, DOI 10.1017/S0033822200019482; Botter-Jensen L., 2003, OPTICALLY STIMULATED; Bowler JM, 2003, NATURE, V421, P837, DOI 10.1038/nature01383; Brown P, 2004, NATURE, V431, P1055, DOI 10.1038/nature02999; Franklin AD, 2000, RADIAT MEAS, V32, P633, DOI 10.1016/S1350-4487(00)00050-0; Gillespie R, 2002, RADIOCARBON, V44, P455, DOI 10.1017/S0033822200031830; Huntley DJ, 2001, CAN J EARTH SCI, V38, P1093, DOI 10.1139/e01-013; MARINGER J, 1970, ANTHROPOS, V65, P229; Morwood MJ, 1999, ANTIQUITY, V73, P273, DOI 10.1017/S0003598X00088244; Morwood MJ, 1998, NATURE, V392, P173, DOI 10.1038/32401; O'Connell JF, 2004, J ARCHAEOL SCI, V31, P835, DOI 10.1016/j.jas.2003.11.005; O'Connor S, 2002, ANTIQUITY, V76, P45, DOI 10.1017/S0003598X0008978X; O'Sullivan PB, 2001, GEOLOGY, V29, P607, DOI 10.1130/0091-7613(2001)029<0607:AIOTGA>2.0.CO;2; ROBERTS RG, 1994, QUATERNARY SCI REV, V13, P575, DOI 10.1016/0277-3791(94)90080-9; ROBERTS RG, 1990, NATURE, V345, P153, DOI 10.1038/345153a0; SONDAAR PY, 1994, CR ACAD SCI II, V319, P1255; Stokes S, 2003, RADIAT MEAS, V37, P383, DOI 10.1016/S1350-4487(03)00060-X; Turney CSM, 2001, QUATERNARY RES, V55, P3, DOI 10.1006/qres.2000.2195; van den Bergh Gert D., 1999, Scripta Geologica, V117, P1	21	282	294	1	141	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1087	1091		10.1038/nature02956	http://dx.doi.org/10.1038/nature02956			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	865VB	15510146				2022-12-28	WOS:000224730800038
J	Vernick, KD; Waters, AP				Vernick, KD; Waters, AP			Genomics and malaria control	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Minnesota, Ctr Microbial & Plant Genom, St Paul, MN 55108 USA; Univ Minnesota, Dept Microbiol, St Paul, MN 55108 USA; Leiden Univ, Med Ctr, Ctr Infect Dis, Dept Parasitol, Leiden, Netherlands	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Vernick, KD (corresponding author), Univ Minnesota, Ctr Microbial & Plant Genom, St Paul, MN 55108 USA.		Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982				Doolan DL, 2003, J EXP BIOL, V206, P3789, DOI 10.1242/jeb.00615; Justice RW, 2003, BIOESSAYS, V25, P1011, DOI 10.1002/bies.10331; Osta MA, 2004, J EXP BIOL, V207, P2551, DOI 10.1242/jeb.01066; Rosenthal PJ, 2003, J EXP BIOL, V206, P3735, DOI 10.1242/jeb.00589	4	18	20	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1901	1904		10.1056/NEJMcibr042899	http://dx.doi.org/10.1056/NEJMcibr042899			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509825				2022-12-28	WOS:000224723100016
J	Kerry, J				Kerry, J			Ensuring access to health care - The Kerry plan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2004	292	16					2007	2009		10.1001/jama.292.16.2007	http://dx.doi.org/10.1001/jama.292.16.2007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865DO	15507587				2022-12-28	WOS:000224682900026
J	Manikoth, P; George, M; Vaishnav, A; Sajwani, MJ				Manikoth, P; George, M; Vaishnav, A; Sajwani, MJ			Omphalitis	LANCET			English	Editorial Material									Royal Hosp, Neonatal Intens Care Unit, Seeb, Oman; Royal Hosp, Dept Paediat Surg, Seeb, Oman	The Royal Hospital, Sultanate of Oman; The Royal Hospital, Sultanate of Oman	Manikoth, P (corresponding author), Royal Hosp, Neonatal Intens Care Unit, Seeb, Oman.	manikoth@omantel.net.om		Manikoth, Prakash/0000-0002-9406-5678					0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	2004	364	9444					1522	1522		10.1016/S0140-6736(04)17276-0	http://dx.doi.org/10.1016/S0140-6736(04)17276-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500898				2022-12-28	WOS:000224645500031
J	Sanders, CJG; Canninga-van Dijk, MR; Borleffs, JC				Sanders, CJG; Canninga-van Dijk, MR; Borleffs, JC			Kaposi's sarcoma	LANCET			English	Editorial Material							AIDS		Univ Med Ctr, Dept Dermatol Allergol, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr, Dept Pathol, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr, Dept Internal Med, Div Infect Dis, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Sanders, CJG (corresponding author), Univ Med Ctr, Dept Dermatol Allergol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	c.sanders@azu.nl						Antman K, 2000, NEW ENGL J MED, V342, P1027, DOI 10.1056/NEJM200004063421407; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; FRIEDMANKIEN AE, 1982, ANN INTERN MED, V96, P693, DOI 10.7326/0003-4819-96-6-693; Hengge UR, 2002, LANCET INFECT DIS, V2, P281, DOI 10.1016/S1473-3099(02)00263-3; HOLUBAR K, 1981, AM J DERMATOPATH, V3, P349, DOI 10.1097/00000372-198100340-00003; Kaposi M., 1872, ARCH DERMATOL SYPHIL, V4, P265, DOI 10.1007/BF01830024; KAPOSI M, 1882, WIEN MED JB, P619; PENN I, 1979, TRANSPLANTATION, V27, P8, DOI 10.1097/00007890-197901000-00003; Sanders CJG, 1997, GENITOURIN MED, V73, P571; SLAVIN G, 1970, J PATHOL, V100, P187, DOI 10.1002/path.1711000307; SPIEGLER E, 1902, ARCH DERMATOL SYPHIL, V60, P1; THIJS A, 1957, Ann Soc Belg Med Trop (1920), V37, P295	13	16	16	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	2004	364	9444					1549	1552		10.1016/S0140-6736(04)17280-2	http://dx.doi.org/10.1016/S0140-6736(04)17280-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500902				2022-12-28	WOS:000224645500035
J	Senn, S				Senn, S			Individual response to treatment: is it a valid assumption?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED-TRIALS	Most drug trials assume that patients respond consistently to treatment, but the assumption is rarely tested. If patients vary randomly in their response to a drug rather than some patients never responding, searches for a genetic basis for non-response are futile.	Univ Glasgow, Dept Stat, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Senn, S (corresponding author), Univ Glasgow, Dept Stat, Glasgow G12 8QQ, Lanark, Scotland.	stephen@stats.gla.ac.uk	Senn, Stephen J/A-8101-2008; Senn, Stephen/B-2903-2013	Senn, Stephen/0000-0002-7558-8473				Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Horwitz RI, 1996, J CLIN EPIDEMIOL, V49, P395, DOI 10.1016/0895-4356(95)00058-5; Kalow W, 1998, PHARMACOGENETICS, V8, P283; Senn S, 1998, J CLIN EPIDEMIOL, V51, P1367; Senn S, 2003, DRUG INF J, V37, P7, DOI 10.1177/009286150303700103; Senn S, 1998, BRIT MED J, V317, P537; Senn S, 2001, DRUG INF J, V35, P1479, DOI 10.1177/009286150103500443; Senn S, 1997, J CLIN EPIDEMIOL, V50, P749; Smith R, 2003, BMJ, V327, P0	9	97	97	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 23	2004	329	7472					966	+		10.1136/bmj.329.7472.966	http://dx.doi.org/10.1136/bmj.329.7472.966			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866KU	15499115	Green Published			2022-12-28	WOS:000224773200022
J	Kosak, ST; Groudine, M				Kosak, ST; Groudine, M			Gene order and dynamic domains	SCIENCE			English	Editorial Material							SPATIAL-ORGANIZATION; CHROMOSOMAL DOMAINS; COEXPRESSED GENES; EXPRESSED GENES; GENOME; CHROMATIN; TRANSCRIPTION; HETEROCHROMATIN; DIFFERENTIATION; ACTIVATION	When considering the daunting complexity of eukaryotic genomes, some comfort can be found in the fact that the human genome may contain only 30,000 to 40,000 genes. Moreover, growing evidence suggests that genomes may be organized in such a way as to take advantage of space. A gene's location in the linear DNA sequence and its position in the three-dimensional nucleus can both be important in its regulation. Contrary to prevailing notions in this postgenomic era, the bacteriophage lambda, a paragon of simplicity, may stilt have a few things to teach us with respect to these facets of nonrandom genomes.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Radiat Oncol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Groudine, M (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.	markg@fhcrc.org		Kosak, Steven/0000-0002-3329-9032				Belmont A, 2003, CURR OPIN CELL BIOL, V15, P304, DOI 10.1016/S0955-0674(03)00045-0; Boutanaev AM, 2002, NATURE, V420, P666, DOI 10.1038/nature01216; Boyle S, 2001, HUM MOL GENET, V10, P211, DOI 10.1093/hmg/10.3.211; Brand M, 2004, NAT STRUCT MOL BIOL, V11, P73, DOI 10.1038/nsmb713; BRAND M, UNPUB; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Chowdhury D, 2004, IMMUNOL REV, V200, P182, DOI 10.1111/j.0105-2896.2004.00177.x; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898; Gerlich D, 2003, CELL, V112, P751, DOI 10.1016/S0092-8674(03)00189-2; Greil F, 2003, GENE DEV, V17, P2825, DOI 10.1101/gad.281503; Hurst LD, 2004, NAT REV GENET, V5, P299, DOI 10.1038/nrg1319; Kosak ST, 2004, GENE DEV, V18, P1371, DOI 10.1101/gad.1209304; Kosak ST, 2002, SCIENCE, V296, P158, DOI 10.1126/science.1068768; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; Leung AKL, 2003, CRIT REV EUKAR GENE, V13, P39, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i1.40; Mann RS, 1997, BIOESSAYS, V19, P661, DOI 10.1002/bies.950190804; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Parada LA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-r44; PTASHNE M, 2004, GENETIC SWITCH; Ragoczy T, 2003, CHROMOSOME RES, V11, P513, DOI 10.1023/A:1024939130361; Roy PJ, 2002, NATURE, V418, P975, DOI 10.1038/nature01012; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Spellman Paul T, 2002, J Biol, V1, P5, DOI 10.1186/1475-4924-1-5; Thompson M, 2003, SCIENCE, V302, P1399, DOI 10.1126/science.1089814; Volpi EV, 2000, J CELL SCI, V113, P1565; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	35	106	108	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					644	647		10.1126/science.1103864	http://dx.doi.org/10.1126/science.1103864			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499009				2022-12-28	WOS:000224756700039
J	Stolc, V; Gauhar, Z; Mason, C; Halasz, G; van Batenburg, MF; Rifkin, SA; Hua, SJ; Herreman, T; Tongprasit, W; Barbano, PE; Bussemaker, HJ; White, KP				Stolc, V; Gauhar, Z; Mason, C; Halasz, G; van Batenburg, MF; Rifkin, SA; Hua, SJ; Herreman, T; Tongprasit, W; Barbano, PE; Bussemaker, HJ; White, KP			A gene expression map for the euchromatic genome of Drosophila melanogaster	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVITY; SEQUENCE; DOMAINS	We used a maskless photolithography method to produce DNA oligonucleotide microarrays with unique probe sequences tiled throughout the genome of Drosophila melanogaster and across predicted splice junctions. RNA expression of protein coding and nonprotein coding sequences was determined for each major stage of the life cycle, including adult mates and females. We detected transcriptional activity for 93% of annotated genes and RNA expression for 41% of the probes in intronic and intergenic sequences. Comparison to genome-wide RNA interference data and to gene annotations revealed distinguishable levels of expression for different classes of genes and higher levels of expression for genes with essential cellular functions. Differential splicing was observed in about 40% of predicted genes, and 5440 previously unknown splice forms were detected. Genes within, conserved regions of synteny with D. pseudoobscura had highly correlated expression; these regions ranged in length from 10 to 900 kilobase pairs. The expressed intergenic and intronic sequences are more likely to be evolutionarily conserved than nonexpressed ones, and about 15% of them appear to be developmentally regulated. Our results provide a draft expression map for the entire nonrepetitive genome, which reveals a much more extensive and diverse set of expressed sequences than was previously predicted.	Yale Univ, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA; Yale Univ, Dept Math, New Haven, CT 06520 USA; NASA, Ames Res Ctr, Genome Res Facil, Moffett Field, CA 94035 USA; Eloret Corp, Sunnyvale, CA 94087 USA; Columbia Univ, Ctr Computat Biol & Bioinformat, New York, NY 10027 USA; Univ Amsterdam, Acad Med Ctr, Bioinformat Lab, NL-1100 DE Amsterdam, Netherlands; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Yale University; Yale University; Yale University; Yale University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Columbia University; University of Amsterdam; Academic Medical Center Amsterdam; Columbia University	White, KP (corresponding author), Yale Univ, Dept Genet, New Haven, CT 06520 USA.	kevin.white@yale.edu		Rifkin, Scott/0000-0001-8476-3256	NIGMS NIH HHS [T32GM008224-17] Funding Source: Medline; NLM NIH HHS [P20LM007276-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008224] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [P20LM007276] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Arbeitman MN, 2002, SCIENCE, V297, P2270, DOI 10.1126/science.1072152; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ashburner M, 1999, GENETICS, V153, P179; BENDER W, 1985, COLD SPRING HARB SYM, V50, P173, DOI 10.1101/SQB.1985.050.01.023; Bender W, 2002, DEVELOPMENT, V129, P4923; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868; Fisher RH, 1950, STAT METHODS RES WOR, P99; HALASZ G, UNPUB; Hild M, 2004, GENOME BIOL, V5; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Kerr MK, 2001, P NATL ACAD SCI USA, V98, P8961, DOI 10.1073/pnas.161273698; Li TR, 2003, DEV CELL, V5, P59, DOI 10.1016/S1534-5807(03)00192-8; LIPSHITZ HD, 1987, GENE DEV, V1, P307, DOI 10.1101/gad.1.3.307; MISRA S, 2002, GENOME BIOL, V3, P83, DOI [DOI 10.1186/GB-2002-3-12-RESEARCH0083, 10.1186/gb-2002-3-12-research0083]; Nuwaysir EF, 2002, GENOME RES, V12, P1749, DOI 10.1101/gr.362402; Parisi M, 2003, SCIENCE, V299, P697, DOI 10.1126/science.1079190; Pletcher SD, 2002, CURR BIOL, V12, P712, DOI 10.1016/S0960-9822(02)00808-4; Reinke V, 2002, ANNU REV GENOM HUM G, V3, P153, DOI 10.1146/annurev.genom.3.031302.100922; RICHARDS S, UNPUB; Rifkin SA, 2003, NAT GENET, V33, P138, DOI 10.1038/ng1086; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516; Singh-Gasson S, 1999, NAT BIOTECHNOL, V17, P974, DOI 10.1038/13664; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Yamada K, 2003, SCIENCE, V302, P842, DOI 10.1126/science.1088305	32	239	254	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					655	660		10.1126/science.1101312	http://dx.doi.org/10.1126/science.1101312			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499012	Green Submitted			2022-12-28	WOS:000224756700042
J	Zavatta, A; Viciani, S; Bellini, M				Zavatta, A; Viciani, S; Bellini, M			Quantum-to-classical transition with single-photon-added coherent states of light	SCIENCE			English	Article							HOMODYNE TOMOGRAPHY; AMPLIFICATION; INTERFERENCE; CLONING	Single-photon-added coherent states are the result of the most elementary amplification process of classical light fields by a single quantum of excitation. Being intermediate between a single-photon Fock state (fully quantum-mechanical) and a coherent (classical) one, these states offer the opportunity to closely follow the smooth transition between the particle-like and the wavelike behavior of tight. We report the experimental generation of single-photon-added coherent states and their complete characterization by quantum tomography. Besides visualizing the evolution of the quantum-to-classical transition, these states allow one to witness the gradual change from the spontaneous to the stimulated regimes of light emission.	Ist Nazl Ott Applicata, I-50125 Florence, Italy; Univ Florence, LENS, I-50019 Florence, Italy; Univ Florence, Dept Phys, I-50019 Florence, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale di Ottica (INO-CNR); University of Florence; University of Florence	Bellini, M (corresponding author), Ist Nazl Ott Applicata, Largo Enrico Fermi 6, I-50125 Florence, Italy.	bellini@ino.it	Zavatta, Alessandro/O-1592-2019; Bellini, Marco/J-4990-2013; VICIANI, SILVIA/AAY-2203-2020; Zavatta, Alessandro/C-1130-2009	Zavatta, Alessandro/0000-0002-1359-7956; Bellini, Marco/0000-0001-7352-1366; VICIANI, SILVIA/0000-0003-2260-094X; Zavatta, Alessandro/0000-0002-1359-7956				AGARWAL GS, 1991, PHYS REV A, V43, P492, DOI 10.1103/PhysRevA.43.492; Aichele T, 2002, EUR PHYS J D, V18, P237, DOI 10.1140/epjd/e20020028; Bellini M, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.043602; Breitenbach G, 1997, NATURE, V387, P471, DOI 10.1038/387471a0; De Martini F, 2000, OPT COMMUN, V179, P581, DOI 10.1016/S0030-4018(00)00611-8; Lamas-Linares A, 2002, SCIENCE, V296, P712, DOI 10.1126/science.1068972; Leonhardt U., 1997, MEASURING QUANTUM ST; Lvovsky AI, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.011801; Lvovsky AI, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.050402; Mandel L, 1995, OPTICAL COHERENCE QU; Montina A, 1998, PHYS REV A, V58, P3472, DOI 10.1103/PhysRevA.58.3472; Ou ZY, 1997, QUANTUM SEMICL OPT, V9, P599, DOI 10.1088/1355-5111/9/4/009; OU ZY, 1990, J OPT SOC AM B, V7, P211, DOI 10.1364/JOSAB.7.000211; Resch KJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.113601; REYNAUD S, 1992, PROG OPTICS, V30, P1, DOI 10.1016/S0079-6638(08)70096-9; SMITHEY DT, 1993, PHYS REV LETT, V70, P1244, DOI 10.1103/PhysRevLett.70.1244; Viciani S, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.053801; Walls D. F., 1994, QUANTUM OPT; Zavatta A, 2002, J OPT SOC AM B, V19, P1189, DOI 10.1364/JOSAB.19.001189; ZAVATTA A, IN PRESS PHYS REV A	20	548	553	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					660	662		10.1126/science.1103190	http://dx.doi.org/10.1126/science.1103190			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499013				2022-12-28	WOS:000224756700043
J	Sauer, R; Becker, H; Hohenberger, W; Rodel, C; Wittekind, C; Fietkau, R; Martus, P; Tschmelitsch, J; Hager, E; Hess, CF; Karstens, JH; Liersch, T; Schmidberger, H; Raab, R				Sauer, R; Becker, H; Hohenberger, W; Rodel, C; Wittekind, C; Fietkau, R; Martus, P; Tschmelitsch, J; Hager, E; Hess, CF; Karstens, JH; Liersch, T; Schmidberger, H; Raab, R		German Rectal Canc Study Grp	Preoperative versus postoperative chemoradiotherapy for rectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGRESS REPORT; ADJUVANT; THERAPY; TRIAL; RADIOTHERAPY	BACKGROUND: Postoperative chemoradiotherapy is the recommended standard therapy for patients with locally advanced rectal cancer. In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative chemoradiotherapy with postoperative chemoradiotherapy for locally advanced rectal cancer. METHODS: We randomly assigned patients with clinical stage T3 or T4 or node-positive disease to receive either preoperative or postoperative chemoradiotherapy. The preoperative treatment consisted of 5040 cGy delivered in fractions of 180 cGy per day, five days per week, and fluorouracil, given in a 120-hour continuous intravenous infusion at a dose of 1000 mg per square meter of body-surface area per day during the first and fifth weeks of radiotherapy. Surgery was performed six weeks after the completion of chemoradiotherapy. One month after surgery, four five-day cycles of fluorouracil (500 mg per square meter per day) were given. Chemoradiotherapy was identical in the postoperative-treatment group, except for the delivery of a boost of 540 cGy. The primary end point was overall survival. RESULTS: Four hundred twenty-one patients were randomly assigned to receive preoperative chemoradiotherapy and 402 patients to receive postoperative chemoradiotherapy. The overall five-year survival rates were 76 percent and 74 percent, respectively (P=0.80).The five-year cumulative incidence of local relapse was 6 percent for patients assigned to preoperative chemoradiotherapy and 13 percent in the postoperative-treatment group (P=0.006).Grade 3 or 4 acute toxic effects occurred in 27 percent of the patients in the preoperative-treatment group, as compared with 40 percent of the patients in the postoperative-treatment group (P=0.001); the corresponding rates of long-term toxic effects were 14 percent and 24 percent, respectively (P=0.01). CONCLUSIONS: Preoperative chemoradiotherapy, as compared with postoperative chemoradiotherapy, improved local control and was associated with reduced toxicity but did not improve overall survival.	Univ Erlangen Nurnberg, Dept Radiat Therapy, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Surg, D-91054 Erlangen, Germany; Univ Gottingen, Dept Surg, D-3400 Gottingen, Germany; Univ Gottingen, Dept Radiat Therapy, D-3400 Gottingen, Germany; Univ Leipzig, Inst Pathol, Leipzig, Germany; Univ Rostock, Dept Radiat Therapy, Rostock, Germany; Charite Univ Med Berlin, Inst Med Informat Biometry & Epidemiol, Berlin, Germany; Krankenhaus Barmherzigen Bruder, Dept Surg, St Veit An Der Glan, Austria; Landeskrankenhaus Klagenfurt, Inst Radiotherapy, Klagenfurt, Austria; Hannover Med Sch, Dept Radiat Therapy, Hannover, Germany; Klinikum Oldenburg, Dept Surg, Oldenburg, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Gottingen; University of Gottingen; Leipzig University; University of Rostock; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Konventhospital Der Barmherzigen Bruder; Hannover Medical School; Klinikum Oldenburg	Sauer, R (corresponding author), Univ Erlangen Nurnberg, Dept Radiat Therapy, Univ Str 27, D-91054 Erlangen, Germany.	sekretariat@strahlen.med.uni-erlangen.de	Fietkau, Rainer/A-9632-2017					[Anonymous], 1985, NEW ENGL J MED, V312, P1465; Beets-Tan R G H, 2003, Colorectal Dis, V5, P392, DOI 10.1046/j.1463-1318.2003.00518.x; BRESLOW NE, 1980, IARC SCI PUBL, V32, P51; Camma C, 2000, JAMA-J AM MED ASSOC, V284, P1008, DOI 10.1001/jama.284.8.1008; Gray R, 2001, LANCET, V358, P1291; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; HERMANEK P, 2000, CHALLENGES COLORECTA, P81; Hunerbein M, 2003, Colorectal Dis, V5, P402, DOI 10.1046/j.1463-1318.2003.00516.x; Hyams DM, 1997, DIS COLON RECTUM, V40, P131, DOI 10.1007/BF02054976; Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; MINSKY BD, 1992, J CLIN ONCOL, V10, P1218, DOI 10.1200/JCO.1992.10.8.1218; Pahlman L, 1997, NEW ENGL J MED, V336, P1539; Pahlman L, 1997, NEW ENGL J MED, V336, P980; Pijl MEJ, 2002, EUR J CANCER, V38, P887, DOI 10.1016/S0959-8049(02)00052-7; Rodel C, 2003, J CLIN ONCOL, V21, P3098, DOI 10.1200/JCO.2003.02.505; SAID S, 1994, CHIRURG, V65, P680; Sauer R, 2001, STRAHLENTHER ONKOL, V177, P173, DOI 10.1007/PL00002396; Seegenschmiedt M. H., 1993, Strahlentherapie und Onkologie, V169, P83; ZELEN M, 1990, STAT MED, V9, P645, DOI 10.1002/sim.4780090611	20	4308	4583	4	123	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2004	351	17					1731	1740		10.1056/NEJMoa040694	http://dx.doi.org/10.1056/NEJMoa040694			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863TH	15496622				2022-12-28	WOS:000224585200008
J	Currie, MP; Karwatowski, SP; Perera, J; Langford, EJ				Currie, MP; Karwatowski, SP; Perera, J; Langford, EJ			Introduction of nurse led DC cardioversion service in day surgery unit: prospective audit	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE PATIENTS; ATRIAL-FIBRILLATION; SUICIDAL IDEATION; AMERICAN-COLLEGE; TASK-FORCE; OLDER; DEPRESSION; BEHAVIOR; SOCIETY; PEOPLE	Problem Atrial fibrillation is the most common persistent arrhythmia in adults and carries an increased risk of thromboembolism and stroke. Electrical (DC) cardioversion is an effective treatment, but logistical difficulties in many institutions lead to problems providing a prompt service. This reduces the rate of long term success, delays relief of symptoms, and increases the burden on anticoagulation clinics. Design Prospective audit of introduction of a collaborative, nurse led DC cardioversion service in a day surgery unit. Setting Day surgery unit 5 km from an acute hospital in southeast London. Key measures for improvement Waiting times, success of procedures, and complication rates. Strategies for change Collaborative working across traditional specialty boundaries; empowerment of patients within the process; using a nurse consultant as a single point of reference to coordinate the service. Effects of change Sinus rhythm was restored in 131 (92%) of the first 143 patients treated. Three patients needed hospital admission; all were discharged uneventfully within 24 hours. No important complications occurred. Waiting times were reduced from 27 weeks to eight weeks for patients eligible for the service. Lessons learnt Elective DC cardioversion under general anaesthesia can be safely done by an appropriately trained nurse in a day surgery unit remote from an acute general hospital. This model of care is effective and can reduce waiting times and relieve pressure on acute beds and junior doctors.	Princess Royal Univ Hosp, Bromley Hosp NHS Trust, Dept Cardiol, Orpington BR6 8ND, Kent, England; Bromley Hosp NHS Trust, Dept Anaesthet, Day Surg Unit, Bromley, England		Currie, MP (corresponding author), Princess Royal Univ Hosp, Bromley Hosp NHS Trust, Dept Cardiol, Orpington BR6 8ND, Kent, England.	mary.currie@bromleyhospitals.nhs.uk						Alexopoulos GS, 1999, ARCH GEN PSYCHIAT, V56, P1048, DOI 10.1001/archpsyc.56.11.1048; Bartels SJ, 2002, AM J GERIAT PSYCHIAT, V10, P417, DOI 10.1176/appi.ajgp.10.4.417; Beautrais AL, 2002, SUICIDE LIFE-THREAT, V32, P1, DOI 10.1521/suli.32.1.1.22184; Callahan CM, 1996, J AM GERIATR SOC, V44, P1205, DOI 10.1111/j.1532-5415.1996.tb01370.x; CONWELL Y, 1990, J AM GERIATR SOC, V38, P640, DOI 10.1111/j.1532-5415.1990.tb01422.x; Cook JM, 2002, AM J GERIAT PSYCHIAT, V10, P437, DOI 10.1176/appi.ajgp.10.4.437; De Leo D, 2002, BRIT J PSYCHIAT, V181, P226, DOI 10.1192/bjp.181.3.226; De Leo D, 1990, DEPRESSION SUICIDE L; DEBEAUVOIR S, 1972, COMING AGE, P522; Department of Health, 2001, REF GUID CONS EX TRE; Duberstein PR, 2004, PSYCHOL MED, V34, P137, DOI 10.1017/S0033291703008584; Erlangsen A, 2003, J GERONTOL B-PSYCHOL, V58, pS314, DOI 10.1093/geronb/58.5.S314; FOSTER JR, 1984, HDB STUDIES PSYCHIAT, P265; Fuster V, 2001, EUR HEART J, V22, P1852, DOI 10.1053/euhj.2001.2983; Gallo JJ, 1994, J GERONTOL, V49, P251; HARRIS EC, 1994, MEDICINE, V73, P281, DOI 10.1097/00005792-199411000-00001; Harwood D, 2001, INT J GERIATR PSYCH, V16, P155, DOI 10.1002/1099-1166(200102)16:2<155::AID-GPS289>3.0.CO;2-0; Jackson A, 2002, NURS TIMES, V98, P34; JONES JS, 1990, AM J PSYCHIAT, V147, P1225; JORM AF, 1995, AGE AGEING, V24, P389, DOI 10.1093/ageing/24.5.389; Lykouras L, 2002, J AFFECT DISORDERS, V69, P225, DOI 10.1016/S0165-0327(00)00322-0; NAKRA B, 1990, VERWOERDTS CLIN GERO, P107; Quinn T, 1998, Nurs Crit Care, V3, P59; RAO R, 1998, BRIT MED J, V317, pB1016; Rubio A, 2001, BIOL PSYCHIAT, V49, P137, DOI 10.1016/S0006-3223(00)00952-5; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; Skoog I, 1996, AM J PSYCHIAT, V153, P1015; Thomas AJ, 2004, J AFFECT DISORDERS, V79, P81, DOI 10.1016/S0165-0327(02)00349-x; Tracy CM, 2000, J AM COLL CARDIOL, V36, P1725, DOI 10.1016/S0735-1097(00)01085-8; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	30	15	15	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 16	2004	329	7471					892	895B		10.1136/bmj.329.7471.892	http://dx.doi.org/10.1136/bmj.329.7471.892			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	863MU	15485966	Green Published			2022-12-28	WOS:000224566800018
J	Afshar, K; Willard, FS; Colombo, K; Johnston, CA; McCudden, CR; Siderovski, DP; Gonczy, P				Afshar, K; Willard, FS; Colombo, K; Johnston, CA; McCudden, CR; Siderovski, DP; Gonczy, P			RIC-8 is required for GPR-1/2-Dependent G alpha function during asymmetric division of C-elegans embryos	CELL			English	Article							CELL-DIVISION; GOLOCO MOTIF; G-PROTEINS; DROSOPHILA NEUROBLAST; GUANINE-NUCLEOTIDES; SPINDLE POSITION; DISTINCT ROLES; BETA-GAMMA; COMPLEX; ORIENTATION	Heterotrimeric G proteins are crucial for asymmetric cell division, but the mechanisms of signal activation remain poorly understood. Here, we establish that the evolutionarily conserved protein RIC-8 is required for proper asymmetric division of one-cell stage C. elegans embryos. Spindle severing experiments demonstrate that RIC-8 is required for generation of substantial pulling forces on astral microtubules. RIC-8 physically interacts with GOA-1 and GPA-16, two Galpha subunits that act in a partially redundant manner in one-cell stage embryos. RIC-8 preferentially binds to GDP bound GOA-1 and is a guanine nucleotide exchange factor (GEF) for GOA-1. Our analysis suggests that RIC-8 acts before the GoLoco protein GPR-1/2 in the sequence of events leading to Galpha activation. Furthermore, coimmunoprecipitation and in vivo epistasis demonstrate that inactivation of the Gbeta subunit GPB-1 alleviates the need for RIC-8 in one-cell stage embryos. Our findings suggest a mechanism in which RIC-8 favors generation of Galpha free from Gbetagamma and enables GPR-1/2 to mediate asymmetric cell division.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA	Swiss Institute Experimental Cancer Research; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Gonczy, P (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.	pierre.gonczy@isrec.unil.ch	Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210; McCudden, Christopher/0000-0002-4172-4641; Gonczy, Pierre/0000-0002-6305-6883	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM065533, R01GM062338] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62338, GM065533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brauchle M, 2003, CURR BIOL, V13, P819, DOI 10.1016/S0960-9822(03)00295-1; Broadus J, 1997, CURR BIOL, V7, P827, DOI 10.1016/S0960-9822(06)00370-8; Cai Y, 2003, CELL, V112, P51, DOI 10.1016/S0092-8674(02)01170-4; Colombo K, 2003, SCIENCE, V300, P1957, DOI 10.1126/science.1084146; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; Fuse N, 2003, CURR BIOL, V13, P947, DOI 10.1016/S0960-9822(03)00334-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gonczy P, 1999, J CELL BIOL, V144, P927, DOI 10.1083/jcb.144.5.927; Gonczy P, 2001, DEV CELL, V1, P363, DOI 10.1016/S1534-5807(01)00046-6; Gonczy P, 2002, TRENDS CELL BIOL, V12, P332, DOI 10.1016/S0962-8924(02)02306-1; Gotta M, 2003, CURR BIOL, V13, P1029, DOI 10.1016/S0960-9822(03)00371-3; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Grill SW, 2001, NATURE, V409, P630, DOI 10.1038/35054572; Grill SW, 2003, SCIENCE, V301, P518, DOI 10.1126/science.1086560; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kawasaki I, 1998, CELL, V94, P635, DOI 10.1016/S0092-8674(00)81605-0; Kimple RJ, 2004, BIOCHEM J, V378, P801, DOI 10.1042/BJ20031686; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Miller KG, 2000, NEURON, V27, P289, DOI 10.1016/S0896-6273(00)00037-4; Miller KG, 2000, GENETICS, V156, P1649; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Oxford GS, 2004, METHOD ENZYMOL, V390, P437; Pichler S, 2000, DEVELOPMENT, V127, P2063; Praitis V, 2001, GENETICS, V157, P1217; Robatzek M, 2000, GENETICS, V156, P1069; Ross EM, 1999, CRC METH SIG TRANS, P123; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Srinivasan DG, 2003, GENE DEV, V17, P1225, DOI 10.1101/gad.1081203; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; Tsou MFB, 2003, DEVELOPMENT, V130, P5717, DOI 10.1242/dev.00790; Willard FS, 2004, ANNU REV BIOCHEM, V73, P925, DOI 10.1146/annurev.biochem.73.011303.073756; Yu FW, 2003, J CELL BIOL, V162, P623, DOI 10.1083/jcb.200303174; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	38	148	155	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2004	119	2					219	230		10.1016/j.cell.2004.09.026	http://dx.doi.org/10.1016/j.cell.2004.09.026			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479639	Bronze, Green Published			2022-12-28	WOS:000224577200010
J	Miller, SD; David-Bajar, K				Miller, SD; David-Bajar, K			A brilliant case of erythrasma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Waccamaw Dermatol, Myrtle Beach, SC 29572 USA; Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA	San Antonio Military Medical Center; United States Department of Defense; United States Army	Miller, SD (corresponding author), Waccamaw Dermatol, Myrtle Beach, SC 29572 USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1666	1666		10.1056/NEJMicm010811	http://dx.doi.org/10.1056/NEJMicm010811			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483285				2022-12-28	WOS:000224427300013
J	Oransky, I				Oransky, I			Elisabeth Kubler-Ross - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com						KUBLERROSS E, PUBLICATION LIST	1	3	3	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	2004	364	9440					1120	1120		10.1016/S0140-6736(04)17087-6	http://dx.doi.org/10.1016/S0140-6736(04)17087-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	857FT	15481104				2022-12-28	WOS:000224102400015
J	Calonge, N; Randhawa, G				Calonge, N; Randhawa, G			The meaning of the US Preventive Services Task Force grade I recommendation: Screening for hepatitis C virus infection	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								The U.S. Preventive Services Task Force (USPSTF) formulates evidence-based recommendations for clinical preventive services. These recommendations are communicated by letter grades that reflect the quality of evidence and the magnitude of net health benefit expected from delivering the preventive service. When the USPSTF finds insufficient evidence to determine the balance of health benefits or harms of delivering a preventive service, because of a lack of studies, poor-quality studies, or good-quality studies with conflicting results, the USPSTF assigns the service an I letter grade. The USPSTF found insufficient evidence to recommend for or against screening for hepatitis C virus infection in high-risk individuals (I letter grade). This recommendation reflects the need for further research that would provide adequate evidence to assess the net health benefit for persons screened for hepatitis C virus infection.										Berg AO, 2004, ANN INTERN MED, V140, P462, DOI 10.7326/0003-4819-140-6-200403160-00013; Chou R, 2004, ANN INTERN MED, V140, P465, DOI 10.7326/0003-4819-140-6-200403160-00014	2	18	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2004	141	9					718	719		10.7326/0003-4819-141-9-200411020-00014	http://dx.doi.org/10.7326/0003-4819-141-9-200411020-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867JT	15520429				2022-12-28	WOS:000224839600009
J	Leung, GM; Hedley, AJ; Ho, LM; Chau, P; Wong, IOL; Thach, TQ; Ghani, AC; Donnelly, CA; Fraser, C; Riley, S; Ferguson, NM; Anderson, RM; Tsang, T; Leung, PY; Wong, V; Chan, JCK; Tsui, E; Lo, SV; Lam, TH				Leung, GM; Hedley, AJ; Ho, LM; Chau, P; Wong, IOL; Thach, TQ; Ghani, AC; Donnelly, CA; Fraser, C; Riley, S; Ferguson, NM; Anderson, RM; Tsang, T; Leung, PY; Wong, V; Chan, JCK; Tsui, E; Lo, SV; Lam, TH			The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: An analysis of all 1755 patients	ANNALS OF INTERNAL MEDICINE			English	Article							TRANSMISSION DYNAMICS; CORONAVIRUS INFECTION; SARS CORONAVIRUS; LABORATORY TESTS; OUTBREAK; TORONTO; CHILDREN; IMPACT; AGENT; CHINA	Background: As yet, no one has written a comprehensive epidemiologic account of a severe acute respiratory syndrome (SARS) outbreak from an affected country. Objective: To provide a comprehensive epidemiologic account of a SARS outbreak from an affected territory. Design: Epidemiologic analysis. Setting: The 2003 Hong Kong SARS outbreak. Participants: All 1755 cases and 302 deaths. Measurements: Sociodemographic characteristics; infection clusters by time, occupation, setting, and workplace; and geospatial relationships were determined. The mean and variance in the time from infection to onset (incubation period) were estimated in a small group of patients with known exposure. The mean and variance in time from onset to admission, from admission to discharge, or from admission to death were calculated. Logistic regression was used to identify important predictors of case fatality. Results: 49.3% of patients were infected in clinics, hospitals, or elderly or nursing homes, and the Amoy Gardens cluster accounted for 18.8% of cases. The ratio of women to men among infected individuals was 5:4. Health care workers accounted for 23.1% of all reported cases. The estimated mean incubation period was 4.6 days (95% CI, 3.8 to 5.8 days). Mean time from symptom onset to hospitalization varied between 2 and 8 days, decreasing over the course of the epidemic. Mean time from onset to death was 23.7 days (CI, 22.0 to 25.3 days), and mean time from onset to discharge was 26.5 days (CI, 25.8 to 27.2 days). Increasing age, male sex, atypical presenting symptoms, presence of comorbid conditions, and high lactate dehydrogenase level on admission were associated with a greater risk for death. Limitations: Estimates of the incubation period relied on statistical assumptions because few patients had known exposure times. Temporal changes in case management as the epidemic progressed, unavailable treatment information, and several potentially important factors that could not be thoroughly analyzed because of the limited sample size complicate interpretation of factors related to case fatality. Conclusions: This analysis of the complete data on the 2003 SARS epidemic in Hong Kong has revealed key epidemiologic features of the epidemic as it evolved.	Univ Hong Kong, Dept Community Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Lam, TH (corresponding author), Univ Hong Kong, Dept Community Med, 21 Sassoon Rd,Fac Med Bldg,Pokfulam, Hong Kong, Hong Kong, Peoples R China.	commed@hkucc.hku.hk	Leung, Gabriel Matthew/C-4336-2009; Ferguson, Neil/B-8578-2008; Hedley, Anthony J/A-9113-2013; Riley, Steven/C-4384-2009; Hedley, Anthony/C-4305-2009; Fraser, Christophe/A-8109-2008; Ghani, Azra/B-8560-2009; Thach, Thuan-Quoc/C-4416-2009; Lam, Tai Hing/C-4317-2009	Ferguson, Neil/0000-0002-1154-8093; Fraser, Christophe/0000-0003-2399-9657; Thach, Thuan-Quoc/0000-0003-3404-3888; Anderson, Roy/0000-0002-9528-3175; ho, lm/0000-0002-2709-927X; Leung, Gabriel/0000-0002-2503-6283; Riley, Steven/0000-0001-7904-4804; Ghani, Azra/0000-0002-0007-4910; Donnelly, Christl/0000-0002-0195-2463; Lam, Tai Hing/0000-0002-2033-9971				[Anonymous], 2013, WHOCDSCSRGAR2003; Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Center for Disease Control and Prevention, 2004, PUBL HLTH GUID COMM; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Fouchier RAM, 2004, CAN MED ASSOC J, V170, P63; Fraser C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/pnas.0307506101; Gomez G, 2004, STAT PAP, V45, P139, DOI 10.1007/BF02777221; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Hon KLE, 2003, LANCET, V361, P1701, DOI 10.1016/S0140-6736(03)13364-8; HONAKER J, 2004, AMELIA PROGRAM MISSI; Hong Kong SAR Government, 2020, VACC PASS Q A; Hsieh YH, 2004, EMERG INFECT DIS, V10, P201, DOI 10.3201/eid1002.030515; King G, 2001, AM POLIT SCI REV, V95, P49, DOI 10.1017/S0003055401000235; LAI PC, 2004, IN PRESS ENV HLTH PE; Lam TH, 2003, INT J EPIDEMIOL, V32, P178, DOI 10.1093/ije/dyg067; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Leung GM, 2004, EMERG INFECT DIS, V10, P1653, DOI 10.3201/eid1009.040155; Leung GM, 2004, ANN INTERN MED, V141, P333, DOI 10.7326/0003-4819-141-5-200409070-00106; Leung GM, 2003, J EPIDEMIOL COMMUN H, V57, P857, DOI 10.1136/jech.57.11.857; Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616; Naylor CD, 2004, JAMA-J AM MED ASSOC, V291, P2483, DOI 10.1001/jama.291.20.2483; Ng PC, 2004, PEDIATRICS, V113, pE7, DOI 10.1542/peds.113.1.e7; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Poon LLM, 2003, J CLIN VIROL, V28, P233, DOI 10.1016/j.jcv.2003.08.004; Rainer TH, 2004, ANN INTERN MED, V140, P614, DOI 10.7326/0003-4819-140-8-200404200-00008; Rainer TH, 2003, BRIT MED J, V326, P1354, DOI 10.1136/bmj.326.7403.1354; Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; Stuart A, 1994, KENDALLS ADV THEORY; Tai D Y, 2003, Ann Acad Med Singap, V32, pS34; Tang P, 2004, CAN MED ASSOC J, V170, P47; Wand M.P., 1994, KERNEL SMOOTHING; WHO, 2002, SUMM PROB SARS CAS O; WHO, 2003, US LAB METH SARS DIA; Wong Wing-Wai, 2003, J Chin Med Assoc, V66, P323; Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2	36	223	233	1	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2004	141	9					662	673		10.7326/0003-4819-141-9-200411020-00006	http://dx.doi.org/10.7326/0003-4819-141-9-200411020-00006			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867JT	15520422				2022-12-28	WOS:000224839600002
J	Vasbinder, GBC; Nelemans, PJ; Kessels, AGH; Kroon, AA; Maki, JH; Leiner, T; Beek, FJA; Korst, MBJM; Flobbe, K; de Haan, MW; van Zwam, WH; Postma, CT; Hunink, M; de Leeuw, PW; van Engelshoven, JMA				Vasbinder, GBC; Nelemans, PJ; Kessels, AGH; Kroon, AA; Maki, JH; Leiner, T; Beek, FJA; Korst, MBJM; Flobbe, K; de Haan, MW; van Zwam, WH; Postma, CT; Hunink, M; de Leeuw, PW; van Engelshoven, JMA		RADISH Study Grp	Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis	ANNALS OF INTERNAL MEDICINE			English	Article							DIGITAL-SUBTRACTION-ANGIOGRAPHY; ENHANCED MR-ANGIOGRAPHY; SPIRAL CT ANGIOGRAPHY; INTEROBSERVER VARIABILITY; BREATH-HOLD; RENOVASCULAR HYPERTENSION; TESTS; COMPLICATIONS; PREDICTION; DOPPLER	Background: Timely, accurate detection of renal artery stenosis is important because this disorder may be a potentially curable cause of hypertension and renal impairment. Objective: To determine the validity of computed tomographic angiography (CTA) and magnetic resonance angiography (MRA) compared with digital subtraction angiography (DSA) for detection of renal artery stenosis. Design: Prospective multicenter comparative study conducted from 1998 to 2001. Two panels of 3 observers judged CTA and MRA image data and were blinded to all other results. Digital subtraction angiography images were evaluated by consensus. Setting: 3 large teaching hospitals and 3 university hospitals in the Netherlands. Patients: 402 hypertensive patients with suspected renal artery stenosis were included. A group of 356 patients who underwent all 3 diagnostic tests was used for analysis. Measurements: Reproducibility was assessed by calculating interobserver agreement. Diagnostic performance was evaluated in terms of sensitivity, specificity, and other diagnostic variables. Atherosclerotic stenoses of 50% or greater and fibromuscular dysplasia were considered clinically relevant. Results: Twenty percent of patients who underwent all 3 tests had clinically relevant renal artery stenosis. Moderate interobserver agreement was found, with kappa values ranging from 0.59 to 0.64 for CTA and 0.40 to 0.51 for MRA. The combined sensitivity and specificity were 64% (95% CI, 55% to 73%) and 92% (CI, 90% to 95%) for CTA and 62% (CI, 54% to 71%) and 84% (CI, 81% to 87%) for MRA. Limitations: Eighteen percent of the patients were included nonconsecutively. Digital subtraction angiography may be an imperfect reference test. Conclusion: Computed tomographic angiography and MRA are not reproducible or sensitive enough to rule out renal artery stenosis in hypertensive patients. Therefore, DSA remains the diagnostic method of choice.	Maastricht Univ Hosp, Dept Radiol, CARIM, NL-6202 AZ Maastricht, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC)	Vasbinder, GBC (corresponding author), Maastricht Univ Hosp, Dept Radiol, CARIM, POB 5800, NL-6202 AZ Maastricht, Netherlands.	vasbinder@rad.unimaas.nl	de Leeuw, Peter W./J-4552-2016; Postma, C.T./L-4585-2015	de Leeuw, Peter W./0000-0002-4949-5812; 				ANDERSON GH, 1988, AM J HYPERTENS, V1, P301, DOI 10.1093/ajh/1.3.301; [Anonymous], 1987, ARCH INTERN MED, V147, P820; Bongers V, 2000, CLIN RADIOL, V55, P346, DOI 10.1053/crad.2000.0435; BOYKO EJ, 1988, J GEN INTERN MED, V3, P476, DOI 10.1007/BF02595925; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; De Cobelli F, 2000, RADIOLOGY, V214, P373, DOI 10.1148/radiology.214.2.r00fe14373; DENEEF P, 1987, MED DECIS MAKING, V7, P92, DOI 10.1177/0272989X8700700205; DEVRIES AR, 1984, DIAGN IMAG CLIN MED, V53, P277; Equine O, 1999, ARCH MAL COEUR VAISS, V92, P1043; Farres MT, 1996, CARDIOVASC INTER RAD, V19, P101; GALANSKI M, 1994, ROFO FORTSCHR RONTG, V161, P519, DOI 10.1055/s-2008-1032579; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Kaatee R, 1997, RADIOLOGY, V205, P121, DOI 10.1148/radiology.205.1.9314973; Kim TS, 1998, J VASC INTERV RADIOL, V9, P553, DOI 10.1016/S1051-0443(98)70320-3; Klingenbeck-Regn K, 1999, EUR J RADIOL, V31, P110, DOI 10.1016/S0720-048X(99)00086-8; Korst MBJM, 2000, AM J ROENTGENOL, V174, P629, DOI 10.2214/ajr.174.3.1740629; Krijnen P, 1998, ANN INTERN MED, V129, P705, DOI 10.7326/0003-4819-129-9-199811010-00005; Leung DA, 1998, JMRI-J MAGN RESON IM, V8, P598, DOI 10.1002/jmri.1880080313; Lufft V, 2002, AM J KIDNEY DIS, V40, P236, DOI 10.1053/ajkd.2002.34501; OLBRICT CJ, 1995, KIDNEY INT, V48, P1332, DOI 10.1038/ki.1995.418; Paul JF, 1999, AM J ROENTGENOL, V173, P1285, DOI 10.2214/ajr.173.5.10541106; POHL MA, 1985, AM J KIDNEY DIS, V5, pA120, DOI 10.1016/S0272-6386(85)80074-3; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.0.CO;2-S; Rieumont MJ, 1997, AM J ROENTGENOL, V169, P39, DOI 10.2214/ajr.169.1.9207498; Safian RD, 2001, NEW ENGL J MED, V344, P431, DOI 10.1056/NEJM200102083440607; Schoenberg SO, 2002, J AM SOC NEPHROL, V13, P158, DOI 10.1681/ASN.V131158; Schreij G, 1999, J HYPERTENS, V17, P1737, DOI 10.1097/00004872-199917120-00011; SHELLOCK FG, 1991, JMRI-J MAGN RESON IM, V1, P97, DOI 10.1002/jmri.1880010114; Thornton J, 1999, EUR RADIOL, V9, P930, DOI 10.1007/s003300050769; VACEK PM, 1985, BIOMETRICS, V41, P959, DOI 10.2307/2530967; van Jaarsveld BC, 1999, J HYPERTENS, V17, P1731, DOI 10.1097/00004872-199917120-00010; Vasbinder GBC, 2001, ANN INTERN MED, V135, P401, DOI 10.7326/0003-4819-135-6-200109180-00009; Vasbinder GBC, 2002, J MAGN RESON IMAGING, V16, P685, DOI 10.1002/jmri.10214; WAUGH JR, 1992, RADIOLOGY, V182, P243, DOI 10.1148/radiology.182.1.1727290; Wittenberg G, 1999, EUR RADIOL, V9, P546, DOI 10.1007/s003300050707; Young N, 2002, CARDIOVASC INTER RAD, V25, P123, DOI 10.1007/s00270-001-0105-8; 2003, SURVEY DATA REFERENC, P65	37	230	239	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2004	141	9					674	682		10.7326/0003-4819-141-9-200411020-00007	http://dx.doi.org/10.7326/0003-4819-141-9-200411020-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867JT	15520423				2022-12-28	WOS:000224839600003
J	Gerrienne, P; Meyer-Berthaud, B; Fairon-Demaret, M; Streel, M; Steemans, P				Gerrienne, P; Meyer-Berthaud, B; Fairon-Demaret, M; Streel, M; Steemans, P			Runcaria, a middle Devonian seed plant precursor	SCIENCE			English	Article							GYMNOSPERM EVOLUTION; ORIGIN; HETEROSPORY; HABIT; NOV; GEN	The emergence of the seed habit in the Middle Pateozoic was a decisive evolutionary breakthrough. Today, seed plants are the most successful plant lineage, with more than 250,000 living species. We have identified a middle Givetian (385 million years ago) seed precursor from Belgium predating the earliest seeds by about 20 million years. Runcaria is a small, radially symmetrical, integumented megasporangium surrounded by a cupule. The megasporangium bears an unopened distal extension protruding above the multilobed integument. This extension is assumed to be involved in anemophilous pollination. Runcaria sheds new light on the sequence of character acquisition leading to the seed.	Univ Liege, Dept Geol, Liege 1, Belgium; Ctr Cooperat Int Rech Agron Dev, F-34398 Montpellier 5, France	University of Liege; CIRAD	Gerrienne, P (corresponding author), Univ Liege, Dept Geol, B18, Liege 1, Belgium.	p.gerrienne@ulg.ac.be	Gerrienne, Philippe/C-8362-2009	Steemans, Philippe/0000-0003-1183-6324				Arkhangelskaya AD, 2003, REV PALAEOBOT PALYNO, V127, P45, DOI 10.1016/S0034-6667(03)00093-9; BATEMAN RM, 1994, BIOL REV, V69, P345, DOI 10.1111/j.1469-185X.1994.tb01276.x; Beck C.B., 1988, ORIGIN EVOLUTION GYM, P1; CHALONER WG, 1977, NATURE, V265, P233, DOI 10.1038/265233a0; DIMICHELE WA, 1989, TAXON, V38, P1, DOI 10.2307/1220881; Fairon-Demaret M, 1987, B I R SCI NAT BELG, V57, P183; FaironDemaret M, 1996, REV PALAEOBOT PALYNO, V93, P217, DOI 10.1016/0034-6667(95)00127-1; GALTIER J, 1989, NATURE, V340, P225, DOI 10.1038/340225a0; HAIG D, 1989, BIOL J LINN SOC, V38, P215, DOI 10.1111/j.1095-8312.1989.tb01576.x; Hemsley Alan R., 1993, Palaeontographica Abteilung B Palaeophytologie, V229, P135; Hilton J, 1996, REV PALAEOBOT PALYNO, V93, P235, DOI 10.1016/0034-6667(95)00128-X; Hilton J, 1998, ACTA BOT SIN, V40, P981; Kaufmann B, 2004, J GEOL, V112, P495, DOI 10.1086/421077; Li CS, 1997, BOT J LINN SOC, V123, P133; Marshall JEA, 2003, PALAEONTOLOGY, V46, P647, DOI 10.1111/1475-4983.00314; Niklas KJ., 1992, PLANT BIOMECHANICS E, DOI DOI 10.1007/BF01875445; Rothwell G. W, 1988, ORIGIN EVOLUTION GYM, P85; ROTHWELL GW, 1994, SYST BOT, V19, P443, DOI 10.2307/2419767; ROTHWELL GW, 1987, AM J BOT, V74, P970, DOI 10.2307/2443879; ROTHWELL GW, 1989, BOT GAZ, V150, P170, DOI 10.1086/337763; Rowe NP, 1997, PALAEONTOLOGY, V40, P575; Soltis PS, 2002, P NATL ACAD SCI USA, V99, P4430, DOI 10.1073/pnas.032087199; Stockmans F, 1968, I ROYAL SCI NATURELL, V159, P1; STREEL M, 1987, REV PALAEOBOT PALYNO, V50, P211, DOI 10.1016/0034-6667(87)90001-7; Tucker RD, 1998, EARTH PLANET SC LETT, V158, P175, DOI 10.1016/S0012-821X(98)00050-8	25	69	82	3	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2004	306	5697					856	858		10.1126/science.1102491	http://dx.doi.org/10.1126/science.1102491			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514154				2022-12-28	WOS:000224969400042
J	Newman, S; Steed, L; Mulligan, K				Newman, S; Steed, L; Mulligan, K			Self-management interventions for chronic illness	LANCET			English	Review							RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; INTENSIVE PATIENT EDUCATION; COGNITIVE-BEHAVIOR THERAPY; TYPE-2 DIABETES-MELLITUS; JOINT PROTECTION PROGRAM; RHEUMATOID-ARTHRITIS; ECONOMIC-EVALUATION; STRESS MANAGEMENT; CHRONIC DISEASE	An increasing number of interventions have been developed for patients to better manage their chronic illnesses. They are characterised by substantial responsibility taken by patients, and are commonly referred to as self. management interventions. We examine the background, content, and efficacy of such interventions for type 2 diabetes, arthritis, and asthma. Although the content and intensity of the programmes were affected by the objectives of management of the illness, the interventions differed substantially even within the three illnesses. When comparing across conditions, it is important to recognise the different objectives of the interventions and the complexity of the issues that they are attempting to tackle. For both diabetes and asthma, the objectives are concerned with the underlying control of the condition with clear strategies to achieve the desired outcome. By contrast, strategies to deal with symptoms of pain and the consequences of disability in arthritis can be more complex. The interventions that were efficacious provide some guidance as to the components needed in future programmes to achieve the best results. But to ensure that these results endure over time remains an important issue for self-management interventions.	UCL, Ctr Behav & Social Sci Med, Unit Hlth Psychol, London W1W 7EY, England	University of London; University College London	Newman, S (corresponding author), UCL, Ctr Behav & Social Sci Med, Unit Hlth Psychol, 2nd Floor,Wolfson Bldg,48 Riding House St, London W1W 7EY, England.	s.newman@uci.ac.uk	Mulligan, Kathleen/M-6670-2019; Newman, Stanton P/D-3972-2011	Newman, Stanton/0000-0001-6712-6079; Mulligan, Kathleen/0000-0002-6003-3029				AgursCollins TD, 1997, DIABETES CARE, V20, P1503, DOI 10.2337/diacare.20.10.1503; Aikens JE, 1997, PSYCHOTHER PSYCHOSOM, V66, P302, DOI 10.1159/000289152; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Astin JA, 2002, ARTHRIT RHEUM-ARTHR, V47, P291, DOI 10.1002/art.10416; Bailey WC, 1999, ARCH INTERN MED, V159, P2422, DOI 10.1001/archinte.159.20.2422; Bandura A., 1986, SOCIAL FDN THOUGHT A; Barlow J, 2002, PATIENT EDUC COUNS, V48, P177, DOI 10.1016/S0738-3991(02)00032-0; Barlow JH, 2000, HEALTH EDUC RES, V15, P665, DOI 10.1093/her/15.6.665; Bell MJ, 1998, J RHEUMATOL, V25, P231; Berg J, 1997, Clin Nurs Res, V6, P225, DOI 10.1177/105477389700600304; Blixen CE, 2001, J ASTHMA, V38, P23, DOI 10.1081/JAS-10000000264; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; BROWN SA, 1992, RES NURS HEALTH, V15, P409, DOI 10.1002/nur.4770150603; Brown SA, 2002, DIABETES CARE, V25, P259, DOI 10.2337/diacare.25.2.259; Brown SA, 1999, DIABETES EDUCATOR, V25, P52, DOI 10.1177/014572179902500623; Brus HLM, 1998, ANN RHEUM DIS, V57, P146, DOI 10.1136/ard.57.3.146; Cline CMJ, 1999, EUR J HEART FAIL, V1, P145, DOI 10.1016/S1388-9842(99)00014-8; Coates VE, 1996, PATIENT EDUC COUNS, V29, P99, DOI 10.1016/0738-3991(96)00938-X; Cochrane GM, 1999, RESP MED, V93, P763, DOI 10.1016/S0954-6111(99)90260-3; COHEN JL, 1986, ARTHRITIS RHEUM, V29, P388, DOI 10.1002/art.1780290312; Cote J, 2000, Can Respir J, V7, P395; Cote J, 2001, AM J RESP CRIT CARE, V163, P1415, DOI 10.1164/ajrccm.163.6.2006069; Couturaud F, 2002, J ASTHMA, V39, P493, DOI 10.1081/JAS-120004913; Cronan TA, 1997, ARTHRIT CARE RES, V10, P99, DOI 10.1002/art.1790100205; de Oliveira MA, 1999, EUR RESPIR J, V14, P908, DOI 10.1034/j.1399-3003.1999.14d30.x; Denollet J, 2001, CIRCULATION, V104, P2018, DOI 10.1161/hc4201.097940; DeRubeis RJ, 1998, J CONSULT CLIN PSYCH, V66, P37, DOI 10.1037/0022-006X.66.1.37; Epping-Jordan J, 2001, BMJ-BRIT MED J, V323, P947, DOI 10.1136/bmj.323.7319.947; Evers AWM, 2002, PAIN, V100, P141, DOI 10.1016/S0304-3959(02)00274-9; FOLKMAN S, 1984, J PERS SOC PSYCHOL, V46, P839, DOI 10.1037/0022-3514.46.4.839; Freeman K, 2002, CLIN REHABIL, V16, P828, DOI 10.1191/0269215502cr565oa; Fries JF, 1997, J RHEUMATOL, V24, P1378; Gallefoss F, 1999, AM J RESP CRIT CARE, V159, P812, DOI 10.1164/ajrccm.159.3.9804047; Gallefoss F, 2001, EUR RESPIR J, V17, P206, DOI 10.1183/09031936.01.17202060; George MR, 1999, ARCH INTERN MED, V159, P1710, DOI 10.1001/archinte.159.15.1710; Gibson PG, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001005, DOI 10.1002/14651858.CD001005]; Gibson PG, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001117], 10.1002/14651858.CD001117]; GLASGOW RE, 1992, DIABETES CARE, V15, P1423, DOI 10.2337/diacare.15.10.1423; Glasgow RE, 2000, MED CARE, V38, P1062, DOI 10.1097/00005650-200011000-00002; Glasgow RE, 1999, ANN BEHAV MED, V21, P159, DOI 10.1007/BF02908297; Glasgow RE, 2002, PATIENT EDUC COUNS, V48, P115, DOI 10.1016/S0738-3991(02)00025-3; GLASGOW RE, 1991, PATIENT COMPLIANCE M, P209; GRIFFIN S, 1989, ED PSYCHOSOCIAL INTE; Hammond A, 2001, RHEUMATOLOGY, V40, P1044, DOI 10.1093/rheumatology/40.9.1044; Hammond A, 1999, PATIENT EDUC COUNS, V37, P19, DOI 10.1016/S0738-3991(98)00093-7; Harish Z, 2001, ANN ALLERG ASTHMA IM, V86, P185, DOI 10.1016/S1081-1206(10)62689-0; HAWLEY DJ, 1993, J RHEUMATOL, V20, P2025; HAWLEY DJ, 1995, BAILLIERE CLIN RHEUM, V9, P803, DOI 10.1016/S0950-3579(05)80315-2; Helliwell PS, 1999, RHEUMATOLOGY, V38, P303, DOI 10.1093/rheumatology/38.4.303; Henry JL, 1997, PSYCHOL HEALTH MED, V2, P109; Hill J, 2001, ANN RHEUM DIS, V60, P869; Hockemeyer J, 2002, BEHAV MED, V27, P161, DOI 10.1080/08964280209596041; Holman H, 2000, BRIT MED J, V320, P526, DOI 10.1136/bmj.320.7234.526; Hopman-Rock M, 2000, J RHEUMATOL, V27, P1947; Jablon SL, 1997, APPL PSYCHOPHYS BIOF, V22, P155, DOI 10.1023/A:1026259725197; Juenger J, 2002, HEART, V87, P235, DOI 10.1136/heart.87.3.235; Kauppinen R, 1998, RESP MED, V92, P300, DOI 10.1016/S0954-6111(98)90113-5; Kauppinen R, 1999, RESP MED, V93, P283, DOI 10.1016/S0954-6111(99)90026-4; Kauppinen R, 2001, RESP MED, V95, P56, DOI 10.1053/rmed.2000.0971; Keefe FJ, 1999, ARTHRIT CARE RES, V12, P101, DOI 10.1002/1529-0131(199904)12:2<101::AID-ART5>3.0.CO;2-9; KEEFE FJ, 1996, CLIN CARE RHEUMATIC; Kenardy J, 2002, DIABETIC MED, V19, P234, DOI 10.1046/j.1464-5491.2002.00679.x; Keyserling TC, 2000, DIABETES EDUCATOR, V26, P796, DOI 10.1177/014572170002600508; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Kirk AF, 2001, DIABETIC MED, V18, P877, DOI 10.1046/j.0742-3071.2001.00570.x; Klein JJ, 2001, EUR RESPIR J, V17, P386, DOI 10.1183/09031936.01.17303860; KRAVITZ RL, 1993, ARCH INTERN MED, V153, P1869, DOI 10.1001/archinte.153.16.1869; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Lazarus R S, 1992, WHO Reg Publ Eur Ser, V44, P11; Lehrer P, 2002, J CONSULT CLIN PSYCH, V70, P691, DOI 10.1037//0022-006X.70.3.691; Leibing E, 1999, CLIN J PAIN, V15, P58, DOI 10.1097/00002508-199903000-00009; Levetan CS, 2002, DIABETES CARE, V25, P2, DOI 10.2337/diacare.25.1.2; Levy ML, 2000, RESP MED, V94, P900, DOI 10.1053/rmed.2000.0861; Lindroth Y, 1997, ARTHRIT CARE RES, V10, P325, DOI 10.1002/art.1790100507; Lord J, 1999, Health Technol Assess, V3, P1; Lorig K, 1995, HMO Pract, V9, P60; LORIG K, 1989, ARTHRITIS RHEUM, V32, P91, DOI 10.1002/anr.1780320116; LORIG K, 1986, J RHEUMATOL, V13, P763; LORIG K, 1987, PATIENT EDUC COUNS, V10, P207, DOI 10.1016/0738-3991(87)90126-1; Lorig K R, 2001, Eff Clin Pract, V4, P256; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Lundgren S, 1999, SCAND J RHEUMATOL, V28, P47; Lustman PJ, 1998, ANN INTERN MED, V129, P613, DOI 10.7326/0003-4819-129-8-199810150-00005; Marabini A, 2002, RESP MED, V96, P993, DOI 10.1053/rmed.2002.1394; Maurer BT, 1999, ARCH PHYS MED REHAB, V80, P1293, DOI 10.1016/S0003-9993(99)90032-1; McKay HG, 2002, REHABIL PSYCHOL, V47, P31, DOI 10.1037/0090-5550.47.1.31; McKay HG, 2001, DIABETES CARE, V24, P1328, DOI 10.2337/diacare.24.8.1328; Mensing C, 2003, DIABETES CARE, V26, P149; Miller CK, 2002, PREV MED, V34, P252, DOI 10.1006/pmed.2001.0985; Morley S, 1999, PAIN, V80, P1, DOI 10.1016/S0304-3959(98)00255-3; Multon KD, 2001, ARTHRIT RHEUM-ARTHR, V45, P122, DOI 10.1002/1529-0131(200104)45:2<122::AID-ANR163>3.3.CO;2-Z; Neinstein LS, 2001, WESTERN J MED, V175, P293, DOI 10.1136/ewjm.175.5.293; Norris SL, 2002, DIABETES CARE, V25, P1159, DOI 10.2337/diacare.25.7.1159; Norris SL, 2001, DIABETES CARE, V24, P561, DOI 10.2337/diacare.24.3.561; PADGETT D, 1988, J CLIN EPIDEMIOL, V41, P1007, DOI 10.1016/0895-4356(88)90040-6; PARCEL GS, 1986, SELF MANAGEMENT CHRO, P3; Perneger TV, 2002, AM J MED, V113, P7, DOI 10.1016/S0002-9343(02)01136-1; Peterman AH, 1998, HDB HLTH BEHAV CHANG, P462; Pincus T, 1996, BRIT J RHEUMATOL, V35, P879; PROCHASKA JO, 1992, BRIT J ADDICT, V87, P825; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; Ray NF, 1998, DIABETES CARE, V21, P296; Rickheim PL, 2002, DIABETES CARE, V25, P269, DOI 10.2337/diacare.25.2.269; Ridgeway NA, 1999, SOUTHERN MED J, V92, P667, DOI 10.1097/00007611-199907000-00004; RIEMSMA RP, 2002, PATIENT ED ADULTS RH; Rubin RR, 1999, DIABETES-METAB RES, V15, P205, DOI 10.1002/(SICI)1520-7560(199905/06)15:3<205::AID-DMRR29>3.0.CO;2-O; Samaras K, 1997, DIABETES RES CLIN PR, V37, P121, DOI 10.1016/S0168-8227(97)00061-2; Schmaling KB, 2001, J CLIN PSYCHOL MED S, V8, P167, DOI 10.1023/A:1011365519345; Scholten C, 1999, ARCH PHYS MED REHAB, V80, P1282, DOI 10.1016/S0003-9993(99)90030-8; Sharpe L, 2001, PAIN, V89, P275, DOI 10.1016/S0304-3959(00)00379-1; Smith DE, 1997, DIABETES CARE, V20, P52, DOI 10.2337/diacare.20.1.52; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; Smyth JM, 1999, JAMA-J AM MED ASSOC, V281, P1304, DOI 10.1001/jama.281.14.1304; Snoek FJ, 2002, DIABETIC MED, V19, P265, DOI 10.1046/j.1464-5491.2002.00678.x; Solomon DH, 2002, J RHEUMATOL, V29, P362; STEED L, 2002, DIABETIC MED, V19, P22; Sudre P, 1999, THORAX, V54, P681, DOI 10.1136/thx.54.8.681; Surwit RS, 2002, DIABETES CARE, V25, P30, DOI 10.2337/diacare.25.1.30; Taal E, 1997, SEMIN ARTHRITIS RHEU, V26, P805, DOI 10.1016/S0049-0172(97)80024-8; Thomas KS, 2002, BMJ-BRIT MED J, V325, P752, DOI 10.1136/bmj.325.7367.752; Trento M, 2002, DIABETOLOGIA, V45, P1231, DOI 10.1007/s00125-002-0904-8; Turner MO, 1998, AM J RESP CRIT CARE, V157, P540, DOI 10.1164/ajrccm.157.2.9703060; United Nations department of economic and social affairs, 2001, WORLD POP PROSP 2000; van der Palen J, 2001, PATIENT EDUC COUNS, V43, P161, DOI 10.1016/S0738-3991(00)00155-5; vantSpijker A, 1997, PSYCHOSOM MED, V59, P280, DOI 10.1097/00006842-199705000-00011; Vazquez IM, 1998, AM J HEALTH PROMOT, V13, P116, DOI 10.4278/0890-1171-13.2.116; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; *WHO, 2000, 206 WHO; 1991, J ALLERGY CLIN IMMUN, V88, P425	130	581	595	2	113	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1523	1537		10.1016/S0140-6736(04)17277-2	http://dx.doi.org/10.1016/S0140-6736(04)17277-2			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	864PN	15500899				2022-12-28	WOS:000224645500032
J	Kidwell, CS; Chalela, JA; Saver, JL; Starkman, S; Hill, MD; Demchuk, AM; Butman, JA; Patronas, N; Alger, JR; Latour, LL; Luby, ML; Baird, AE; Leary, MC; Tremwel, M; Ovbiagele, B; Fredieu, A; Suzuki, S; Villablanca, JP; Davis, S; Dunn, B; Todd, JW; Ezzeddine, MA; Haymore, J; Lynch, JK; Davis, U; Warach, S				Kidwell, CS; Chalela, JA; Saver, JL; Starkman, S; Hill, MD; Demchuk, AM; Butman, JA; Patronas, N; Alger, JR; Latour, LL; Luby, ML; Baird, AE; Leary, MC; Tremwel, M; Ovbiagele, B; Fredieu, A; Suzuki, S; Villablanca, JP; Davis, S; Dunn, B; Todd, JW; Ezzeddine, MA; Haymore, J; Lynch, JK; Davis, U; Warach, S			Comparison of MRI and CT for detection of acute intracerebral hemorrhage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE ISCHEMIC-STROKE; SUBARACHNOID HEMORRHAGE; CEREBRAL MICROBLEEDS; RISK-FACTOR; MANAGEMENT; ASSOCIATION; GUIDELINES; STATEMENT; HEMATOMA; COUNCIL	Context Noncontrast computed tomography (CT) is the standard brain imaging study for the initial evaluation of patients with acute stroke symptoms. Multimodal magnetic resonance imaging (MRI) has been proposed as an alternative to CT in the emergency stroke setting. However, the accuracy of MRI relative to CT for the detection of hyperacute intracerebral hemorrhage has not been demonstrated. Objective To compare the accuracy of MRI and CT for detection of acute intracerebral hemorrhage in patients presenting with acute focal stroke symptoms. Design, Setting, and Patients A prospective, multicenter study was performed at 2 stroke centers (UCLA Medical Center and Suburban Hospital, Bethesda, Md), between October 2000 and February 2003. Patients presenting with focal stroke symptoms within 6 hours of onset underwent brain MRI followed by noncontrast CT. Main Outcome Measures Acute intracerebral hemorrhage and any intracerebral hemorrhage diagnosed on gradient recalled echo (GRE) MRI and CT scans by a consensus of 4 blinded readers. Results The study was stopped early, after 200 patients were enrolled, when it became apparent at the time of an unplanned interim analysis that MRI was detecting cases of hemorrhagic transformation not detected by CT. For the diagnosis of any hemorrhage, MRI was positive in 71 patients with CT positive in 29 (P<.001). For the diagnosis of acute hemorrhage, MRI and CT were equivalent (96% concordance). Acute hemorrhage was diagnosed in 25 patients on both MRI and CT. In 4 other patients, acute hemorrhage was present on MRI but not on the corresponding CT-each of these 4 cases was interpreted as hemorrhagic transformation of an ischemic infarct. In 3 patients, regions interpreted as acute hemorrhage on CT were interpreted as chronic hemorrhage on MRI. In 1 patient, subarachnoid hemorrhage was diagnosed on CT but not on MRI. In 49 patients, chronic hemorrhage, most often microbleeds, was visualized on MRI but not on CT. Conclusion MRI maybe as accurate as CT for the detection of acute hemorrhage in patients presenting with acute focal stroke symptoms and is more accurate than CT for the detection of chronic intracerebral hemorrhage.	Univ Calif Los Angeles, Med Ctr, Stroke Ctr, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Med Ctr, Dept Neurol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Med Ctr, Dept Emergency Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Med Ctr, Dept Radiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Med Ctr, Ahmanson Lovelace Brain Mapping Ctr, Los Angeles, CA 90024 USA; Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA; Univ Calgary, Foothills Hosp, Dept Clin Neurosci, Calgary Stroke Program, Calgary, AB, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; NIH, Dept Diagnost Radiol, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Beth Israel Deaconess Med Ctr, Div Stroke & Vasc Neurol, Boston, MA 02215 USA; Sparks Neurol Ctr, Ft Smith, AR USA; Royal Melbourne Hosp, Parkville, Vic 3050, Australia; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; Washington Adventist Hosp, Ctr Neurosci Serv, Takoma Pk, MD USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Calgary; University of Calgary; University of Calgary; National Institutes of Health (NIH) - USA; Harvard University; Beth Israel Deaconess Medical Center; Royal Melbourne Hospital; Emory University	Kidwell, CS (corresponding author), Washington Hosp Ctr, Stroke Ctr, 100 Irving St NW,East Bldg Room 6126, Washington, DC 20010 USA.	ckidwell@ucla.edu	Hill, Michael D/C-9073-2012; Butman, John/J-2780-2013; Latour, Larry/AAH-5663-2021; Luby, Marie/AEX-9494-2022; Davis, Stephen M/L-5260-2013; Butman, John A/A-2694-2008; Warach, Steven/R-5074-2019; Demchuk, Andrew M/E-1103-2012	Hill, Michael D/0000-0002-6269-1543; Butman, John/0000-0002-1547-9195; Latour, Larry/0000-0001-6160-5263; Davis, Stephen M/0000-0003-0962-2300; Demchuk, Andrew M/0000-0002-4930-7789; Saver, Jeffrey/0000-0001-9141-2251	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002891, K24NS002092, Z01NS002995, Z01NS002975, K23NS002088, R01NS039498] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB 002087] Funding Source: Medline; NINDS NIH HHS [NS 39498, K24 NS 02092, K23 NS 02088] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Albers GW, 1999, STROKE, V30, P2230, DOI 10.1161/01.STR.30.10.2230; Atlas SW, 1998, AM J NEURORADIOL, V19, P1471; Baird AE, 1998, J CEREBR BLOOD F MET, V18, P583, DOI 10.1097/00004647-199806000-00001; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Chalela JA, 2004, J NEUROIMAGING, V14, P54, DOI 10.1177/1051228403258673; EDELMAN RR, 1986, AM J NEURORADIOL, V7, P751; Fan YH, 2003, STROKE, V34, P2459, DOI 10.1161/01.STR.0000090841.90286.81; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; Fiebach JB, 2004, STROKE, V35, P502, DOI 10.1161/01.STR.0000114203.75678.88; Hermier M, 2004, STROKE, V35, P1989, DOI 10.1161/01.STR.0000133341.74387.96; Kidwell CS, 2003, STROKE, V34, P2995, DOI 10.1161/01.STR.0000098902.69855.A9; Kidwell CS, 2002, STROKE, V33, P95, DOI 10.1161/hs0102.101792; Kidwell CS, 2001, NEUROLOGY, V57, P1611, DOI 10.1212/WNL.57.9.1611; Liebeskind DS, 2003, STROKE, V34, P255; Linfante I, 1999, STROKE, V30, P2263, DOI 10.1161/01.STR.30.11.2263; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mitchell P, 2001, J NEUROL NEUROSUR PS, V70, P205, DOI 10.1136/jnnp.70.2.205; Nakada T, 1996, J NEUROIMAGING, V6, P119, DOI 10.1111/jon199662119; Packard AS, 2003, ARCH NEUROL-CHICAGO, V60, P1156, DOI 10.1001/archneur.60.8.1156; Patel MR, 1996, STROKE, V27, P2321, DOI 10.1161/01.STR.27.12.2321; Roob G, 2000, CURR OPIN NEUROL, V13, P69, DOI 10.1097/00019052-200002000-00013; Ruland S, 2002, STROKE, V33, P1334, DOI 10.1161/01.STR.0000014609.44258.AD; SANDERCOCK P, 1986, LANCET, V1, P506; Schellinger PD, 1999, STROKE, V30, P765, DOI 10.1161/01.STR.30.4.765; Singer MB, 1998, RADIOLOGY, V208, P417, DOI 10.1148/radiology.208.2.9680570; Wiesmann M, 2002, J NEUROSURG, V96, P684, DOI 10.3171/jns.2002.96.4.0684; Wong KS, 2003, NEUROLOGY, V60, P511, DOI 10.1212/01.WNL.0000046583.40125.20	28	458	484	3	49	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2004	292	15					1823	1830		10.1001/jama.292.15.1823	http://dx.doi.org/10.1001/jama.292.15.1823			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IV	15494579	Bronze			2022-12-28	WOS:000224485100020
J	Clark, M; Price, PE				Clark, M; Price, PE			Is wound healing a true science or a clinical art?	LANCET			English	Editorial Material							GENE-TRANSFER		Cardiff Univ, Cardiff Medictr, Wound Healing Res Unit, Cardiff CF14 4UJ, S Glam, Wales	Cardiff University	Clark, M (corresponding author), Cardiff Univ, Cardiff Medictr, Wound Healing Res Unit, Heath Pk, Cardiff CF14 4UJ, S Glam, Wales.	clarkm@whru.co.uk						Andreadis ST, 2004, EXPERT OPIN BIOL TH, V4, P783, DOI 10.1517/14712598.4.6.783; Appleton I, 2003, IDRUGS, V6, P1067; Cullum N, 2004, COCHRANE LIB; Eming SA, 2004, EXPERT OPIN BIOL TH, V4, P1373, DOI 10.1517/14712598.4.9.1373; Galko MJ, 2004, PLOS BIOL, V2, P1114, DOI 10.1371/journal.pbio.0020239; Mustoe T, 2004, AM J SURG, V187, p65S, DOI 10.1016/S0002-9610(03)00306-4; Severens Johan L, 2002, Adv Skin Wound Care, V15, P72, DOI 10.1097/00129334-200203000-00008; Tomic-Canic M, 2004, AM J SURG, V188, p67S, DOI 10.1016/S0002-9610(03)00293-9	8	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2004	364	9443					1388	1389		10.1016/S0140-6736(04)17240-1	http://dx.doi.org/10.1016/S0140-6736(04)17240-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488204				2022-12-28	WOS:000224485300009
J	Malasarn, D; Saltikov, W; Campbell, KM; Santini, JM; Hering, JG; Newman, DK				Malasarn, D; Saltikov, W; Campbell, KM; Santini, JM; Hering, JG; Newman, DK			arrA is a reliable marker for As(V) respiration	SCIENCE			English	Article									CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; La Trobe Univ, Dept Microbiol, Bundoora, Vic 3086, Australia	California Institute of Technology; California Institute of Technology; California Institute of Technology; La Trobe University	Newman, DK (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.	dkn@caltech.edu		Campbell, Kate/0000-0002-8715-5544				Akai J, 2004, APPL GEOCHEM, V19, P215, DOI 10.1016/j.apgeochem.2003.09.008; Harvey CF, 2002, SCIENCE, V298, P1602, DOI 10.1126/science.1076978; Islam FS, 2004, NATURE, V430, P68, DOI 10.1038/nature02638; Kneebone PE, 2002, ENVIRON SCI TECHNOL, V36, P381, DOI 10.1021/es010922h; Oremland RS, 2003, SCIENCE, V300, P939, DOI 10.1126/science.1081903; Saltikov CW, 2003, P NATL ACAD SCI USA, V100, P10983, DOI 10.1073/pnas.1834303100; Smith AH, 2000, B WORLD HEALTH ORGAN, V78, P1093	7	190	198	9	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					455	455		10.1126/science.1102374	http://dx.doi.org/10.1126/science.1102374			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486292				2022-12-28	WOS:000224626500043
J	Aitken, RJ; Koopman, P; Lewis, SEM				Aitken, RJ; Koopman, P; Lewis, SEM			Seeds of concern	NATURE			English	Article							PARENTAL OCCUPATIONAL-EXPOSURE; TESTICULAR DYSGENESIS SYNDROME; SEMEN QUALITY; SPERM; RISK; ABNORMALITIES; FREQUENCY; ESTROGENS; CANCER; TIME		Univ Newcastle, Sch Environm & Life Sci, Discipline Biol Sci, Callaghan, NSW 2308, Australia; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Queens Univ Belfast, Belfast BT12 6BJ, Antrim, North Ireland	University of Newcastle; University of Queensland; Queens University Belfast	Aitken, RJ (corresponding author), Univ Newcastle, Sch Environm & Life Sci, Discipline Biol Sci, Callaghan, NSW 2308, Australia.	jaitken@mail.newcastle.edu.au	Aitken, Robert John/AAY-8238-2020; Lewis, Sheena E M/ABI-8338-2020; Koopman, Peter A/C-9416-2009	Aitken, Robert John/0000-0002-9152-156X; Koopman, Peter A/0000-0001-6939-0914				AITKEN RJ, IN PRESS INT J ANDRO; AITKEN RJ, IN PESS REPROD FERTI; Andersen AG, 2000, HUM REPROD, V15, P366, DOI 10.1093/humrep/15.2.366; Anderson D, 2003, MUTAT RES-REV MUTAT, V544, P173, DOI 10.1016/j.mrrev.2003.06.016; Anderson D, 2002, ADV EXP MED BIOL, V518, P11; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; Chitra K. C., 2004, Indian Journal of Experimental Biology, V42, P220; Fisher JS, 2003, HUM REPROD, V18, P1383, DOI 10.1093/humrep/deg273; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; Handelsman DJ, 2001, REPROD FERT DEVELOP, V13, P317, DOI 10.1071/RD00103; Hill KA, 2004, ENVIRON MOL MUTAGEN, V43, P110, DOI 10.1002/em.20004; Irvine S, 1996, BMJ-BRIT MED J, V312, P467, DOI 10.1136/bmj.312.7029.467; Jobling S, 2004, AQUAT TOXICOL, V66, P205, DOI 10.1016/j.aquatox.2004.01.001; Klaassen C.D., 2001, CASARETT DOULLS TOXI; Knight JA, 1997, J OCCUP ENVIRON MED, V39, P333, DOI 10.1097/00043764-199704000-00011; Kodama H, 1997, FERTIL STERIL, V68, P519, DOI 10.1016/S0015-0282(97)00236-7; Kuhnert B, 2004, HUM REPROD UPDATE, V10, P327, DOI 10.1093/humupd/dmh030; Oliva A, 2001, HUM REPROD, V16, P1768, DOI 10.1093/humrep/16.8.1768; Pettersson A, 2004, INT J CANCER, V109, P941, DOI 10.1002/ijc.20088; ROBAIRE B, 2003, ADV MALE MED DEV TOX; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; Schuppe HC, 2000, ANDROLOGIA, V32, P255, DOI 10.1046/j.1439-0272.2000.00393.x; Semenza JC, 1997, ENVIRON HEALTH PERSP, V105, P1030, DOI 10.2307/3433835; Sharpe RM, 2003, INT J ANDROL, V26, P2, DOI 10.1046/j.1365-2605.2003.00367.x; Shu XO, 1999, CANCER EPIDEM BIOMAR, V8, P783; Singh NP, 2003, FERTIL STERIL, V80, P1420, DOI 10.1016/j.fertnstert.2003.04.002; Skakkebaek NE, 2004, INT J ANDROL, V27, P189, DOI 10.1111/j.1365-2605.2004.00488.x; Slama R, 2002, HUM REPROD, V17, P503, DOI 10.1093/humrep/17.2.503; Swan SH, 2000, ENVIRON HEALTH PERSP, V108, P961, DOI 10.2307/3435055; TRACEY E, 2004, CANC NEW S WALES INC; WHORTON D, 1979, J OCCUP ENVIRON MED, V21, P161	31	247	250	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					48	52		10.1038/432048a	http://dx.doi.org/10.1038/432048a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525979	Bronze			2022-12-28	WOS:000224854900036
J	Fakhouri, F; Matignon, M; Therby, A; Mejean, A; Correas, JM; Challier, S; Knebelmann, B				Fakhouri, F; Matignon, M; Therby, A; Mejean, A; Correas, JM; Challier, S; Knebelmann, B			The man with "milk-shake" urine	LANCET			English	Editorial Material							LYMPHATIC FILARIASIS		Hop Necker Enfants Malad, AP HP, Dept Nephrol, Paris, France; Hop Necker Enfants Malad, AP HP, Dept Infect Dis, Paris, France; Hop Necker Enfants Malad, AP HP, Dept Urol, Paris, France; Hop Necker Enfants Malad, AP HP, Dept Radiol, Paris, France; Hop Necker Enfants Malad, AP HP, Dept Bacteriol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Fakhouri, F (corresponding author), Hop Necker Enfants Malad, AP HP, Dept Nephrol, Paris, France.	Fadi-fakhouri@nck.ap-hop-paris.fr	Matignon, Marie B/Q-8091-2018					Cox FEG, 2000, PARASITOL TODAY, V16, P135, DOI 10.1016/S0169-4758(00)01647-1; DUFOUR B, 1978, J UROL NEPHROL, V84, P231; Melrose WD, 2002, INT J PARASITOL, V32, P947, DOI 10.1016/S0020-7519(02)00062-0	3	1	1	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	2004	364	9445					1638	1638		10.1016/S0140-6736(04)17321-2	http://dx.doi.org/10.1016/S0140-6736(04)17321-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866IQ	15519638				2022-12-28	WOS:000224767600033
J	Bush, GW				Bush, GW			Ensuring access to health care - The Bush plan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2004	292	16					2010	2011		10.1001/jama.292.16.2010	http://dx.doi.org/10.1001/jama.292.16.2010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865DO	15507588				2022-12-28	WOS:000224682900027
J	Gray, JAM				Gray, JAM			Self-management in chronic illness	LANCET			English	Editorial Material									Inst Hlth Sci, UK Natl Screening Comm, Oxford OX3 7LF, England	University of Oxford	Gray, JAM (corresponding author), Inst Hlth Sci, UK Natl Screening Comm, Oxford OX3 7LF, England.							Coulter A, 2002, AUTONOMOUS PATIENT; GRAY JAM, 2002, RESOURCEFUL PATIENT; Holman H, 2004, JAMA-J AM MED ASSOC, V292, P1057, DOI 10.1001/jama.292.9.1057; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731	4	8	8	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	2004	364	9444					1467	1468		10.1016/S0140-6736(04)17288-7	http://dx.doi.org/10.1016/S0140-6736(04)17288-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500873				2022-12-28	WOS:000224645500006
J	Zhou, ZH; Zhang, FC				Zhou, ZH; Zhang, FC			A precocial avian embryo from the Lower Cretaceous of China	SCIENCE			English	Article									Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS	Zhou, ZH (corresponding author), Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, POB 643, Beijing 100044, Peoples R China.	zhonghe@yeah.net						Horner JR, 1996, NATURE, V383, P103, DOI 10.1038/383103b0; Norell Mark A., 2001, American Museum Novitates, V3315, P1, DOI 10.1206/0003-0082(2001)315<0001:AEODTF>2.0.CO;2; RICKLEFS RE, 1998, AVIAN GROWTH DEV EVO, P31; Schweitzer MH, 2002, J VERTEBR PALEONTOL, V22, P191, DOI 10.1671/0272-4634(2002)022[0191:LCAEWE]2.0.CO;2; Sibley C.G., 1990, PHYLOGENY CLASSIFICA; Starck J.M., 1993, Current Ornithology, V10, P275; [No title captured]	7	62	74	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					653	653		10.1126/science.1100000	http://dx.doi.org/10.1126/science.1100000			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499011				2022-12-28	WOS:000224756700041
J	Stevenson, M				Stevenson, M			Therapeutic potential of RNA interference	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ABL GENE-EXPRESSION; SILENCING SUPPRESSOR; TRANSGENIC PLANTS; HIV-1; INHIBITION; REPLICATION; INFLUENZA; CELLS; TRANSCRIPTS; MODULATION		Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Stevenson, M (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St,Suite 319, Worcester, MA 01605 USA.	mario.stevenson@umassmed.edu						Angell SM, 1997, EMBO J, V16, P3675, DOI 10.1093/emboj/16.12.3675; Belfort R, 2002, AM J OPHTHALMOL, V133, P467; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Bucher E, 2004, J GEN VIROL, V85, P983, DOI 10.1099/vir.0.19734-0; Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002; Delgadillo MO, 2004, J GEN VIROL, V85, P993, DOI 10.1099/vir.0.19735-0; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757; Hu WY, 2002, CURR BIOL, V12, P1301, DOI 10.1016/S0960-9822(02)00975-2; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948; Li WX, 2004, P NATL ACAD SCI USA, V101, P1350, DOI 10.1073/pnas.0308308100; LINDBO JA, 1992, VIROLOGY, V189, P725, DOI 10.1016/0042-6822(92)90595-G; McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; Nieth C, 2003, FEBS LETT, V545, P144, DOI 10.1016/S0014-5793(03)00523-4; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Scherr M, 2003, BLOOD, V101, P1566, DOI 10.1182/blood-2002-06-1685; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Stevenson M, 2003, NAT REV IMMUNOL, V3, P851, DOI 10.1038/nri1227; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Surabhi RM, 2002, J VIROL, V76, P12963, DOI 10.1128/JVI.76.24.12963-12973.2002; Tijsterman M, 2004, CELL, V117, P1, DOI 10.1016/S0092-8674(04)00293-4; Ullu E, 2004, CELL MICROBIOL, V6, P509, DOI 10.1111/j.1462-5822.2004.00399.x; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Wohlbold L, 2003, BLOOD, V102, P2236, DOI 10.1182/blood-2002-12-3899; Zamore PD, 2004, CURR BIOL, V14, pR198, DOI 10.1016/j.cub.2004.02.021; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100; Zeng Y, 2002, RNA, V8, P855, DOI 10.1017/S1355838202020071	49	162	191	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2004	351	17					1772	1777		10.1056/NEJMra045004	http://dx.doi.org/10.1056/NEJMra045004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863TH	15496626				2022-12-28	WOS:000224585200012
J	Wood, C; Clauss, M				Wood, C; Clauss, M			Panda phlebotomies? The need for comparative screening for haemochromatosis	LANCET			English	Editorial Material							IRON; LEMURS; STORES		Inst Anim Physiol, D-5764 Oberschleissheim, Germany; Zhejiang Univ, Coll Life Sci, Hangzhou 310027, Zhejiang, Peoples R China; Zhejiang Univ, Minist Educ, Key Lab Conservat Genet & Reprod Biol Endangered, Hangzhou 310027, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Clauss, M (corresponding author), Inst Anim Physiol, D-5764 Oberschleissheim, Germany.	clauss@tiph.vetmed.uni-muenchen.de	Clauss, Marcus/GRR-7996-2022; Clauss, Marcus/A-4710-2008; Clauss, Marcus/M-8702-2019	Clauss, Marcus/0000-0003-3841-6207; Clauss, Marcus/0000-0003-3841-6207; Clauss, Marcus/0000-0003-3841-6207; Wood, Christopher/0000-0002-5517-9496				BENIRSCHKE K, 1985, ADV VET SCI COMP MED, V30, P167; Clauss M., 2002, P EUROPEAN ASS ZOO W, V4, P123; Dutton CJ, 2003, J ZOO WILDLIFE MED, V34, P16, DOI 10.1638/1042-7260(2003)34[0016:BEOFRL]2.0.CO;2; GONZALES J, 1984, ZOO BIOL, V3, P255, DOI 10.1002/zoo.1430030308; Lowenstine Linda J., 1999, P260; Mazzaro LM, 2004, ZOO BIOL, V23, P205, DOI 10.1002/zoo.10126; O'Toole D, 2001, VET PATHOL, V38, P372, DOI 10.1354/vp.38-4-372; Paglia DE, 1999, P AM ASS ZOO VET ANN, P163; Paglia DE, 2000, P AM ASS ZOO VET, P124; Pietrangelo A, 2004, NEW ENGL J MED, V350, P2383, DOI 10.1056/NEJMra031573; WEEKS BR, 1989, AM J VET RES, V50, P198; Wood C, 2003, AM J PRIMATOL, V61, P101, DOI 10.1002/ajp.10113; ZHANG H, 1993, INT S PROT GIANT PAN, P351	13	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2004	364	9443					1384	1385		10.1016/S0140-6736(04)17237-1	http://dx.doi.org/10.1016/S0140-6736(04)17237-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488201				2022-12-28	WOS:000224485300006
J	Cuello, LG; Cortes, DM; Perozo, E				Cuello, LG; Cortes, DM; Perozo, E			Molecular architecture of the KvAP voltage-dependent K+ channel in a lipid bilayer	SCIENCE			English	Article							GATED SODIUM-CHANNELS; POTASSIUM CHANNEL; TRANSMEMBRANE SEGMENT; CRYSTAL-STRUCTURE; CHARGE MOVEMENT; SHAKER; S4; CONDUCTION; MECHANISM; SENSOR	We have analyzed the local structure and dynamics of the prokaryotic voltage-dependent K+ channel (KvAP) at 0 millivolts, using site-directed spin labeling and electron paramagnetic resonance spectroscopy. We show that the S4 segment is located at the protein/lipid interface, with most of its charges protected from the lipid environment. Structurally, S4 is highly dynamic and is separated into two short helices by a flexible linker. Accessibility and dynamics data indicate that the S1 segment is surrounded by other parts of the protein. We propose that S1 is at the contact interface between the voltage-sensing and pore domains. These results establish the general principles of voltage-dependent channel structure in a biological membrane.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA	University of Virginia	Perozo, E (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA.	eperozo@virginia.edu						Bell DC, 2004, J GEN PHYSIOL, V123, P5, DOI 10.1085/jgp.200308918; Berneche S, 2003, P NATL ACAD SCI USA, V100, P8644, DOI 10.1073/pnas.1431750100; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; Elinder F, 2001, BIOPHYS J, V80, P1802, DOI 10.1016/S0006-3495(01)76150-4; Goldstein SAN, 1996, NEURON, V16, P717, DOI 10.1016/S0896-6273(00)80092-6; Gross A, 1999, BIOCHEMISTRY-US, V38, P10324, DOI 10.1021/bi990856k; Hong KH, 2000, J GEN PHYSIOL, V115, P51, DOI 10.1085/jgp.115.1.51; Huang C C, 2000, Pac Symp Biocomput, P230; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Jin TH, 2002, MOL CELL, V10, P469, DOI 10.1016/S1097-2765(02)00659-7; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Laine M, 2004, FEBS LETT, V564, P257, DOI 10.1016/S0014-5793(04)00273-X; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; MCHAOURAB HS, 2000, DISTANCE MEASUREMENT; Monks SA, 1999, J GEN PHYSIOL, V113, P415, DOI 10.1085/jgp.113.3.415; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Starace DM, 2004, NATURE, V427, P548, DOI 10.1038/nature02270; Steinhoff HJ, 2003, METHODS, V29, P188, DOI 10.1016/S1046-2023(02)00309-2; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	33	190	195	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2004	306	5695					491	495		10.1126/science.1101373	http://dx.doi.org/10.1126/science.1101373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486302				2022-12-28	WOS:000224626500055
J	Edmunds, LH				Edmunds, LH			Cardiopulmonary bypass after 50 years	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hosp Univ Penn, Dept Surg, Div Cardiothorac Surg, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Edmunds, LH (corresponding author), Hosp Univ Penn, Dept Surg, Div Cardiothorac Surg, 3400 Spruce St, Philadelphia, PA 19104 USA.							*AM HEART ASS, 2003, HEART DIS STROK STAT, P3; Centers for Disease Control and Prevention, LIF EXP BIRTH 65 YEA; GIBBON JH, 1978, AM J SURG, V135, P608, DOI 10.1016/0002-9610(78)90119-8	3	27	29	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1603	1606		10.1056/NEJMp048212	http://dx.doi.org/10.1056/NEJMp048212			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483278				2022-12-28	WOS:000224427300006
J	Garber, AM				Garber, AM			Business and medicine: Corporate treatment for the ills of academic medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stanford Univ, Stanford, CA 94305 USA; Dept Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Garber, AM (corresponding author), Dept Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.		Garber, Alan M/F-1476-2010						0	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1601	1603		10.1056/NEJMp048215	http://dx.doi.org/10.1056/NEJMp048215			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483277	Green Published			2022-12-28	WOS:000224427300005
J	Reijneveld, SA; van der Wal, MF; Brugman, E; Sing, RAH; Verloove-Vanhorick, SP				Reijneveld, SA; van der Wal, MF; Brugman, E; Sing, RAH; Verloove-Vanhorick, SP			Infant crying and abuse	LANCET			English	Article							CHILDREN; IMPACT	Child abuse and neglect are important causes of child morbidity and death. We assessed potentially detrimental parental actions induced by infant crying in 3259 infants aged 1-6 months, in the Netherlands. In infants aged 6 months, 5.6% (95% CI 4.2-7.0) of parents reported having smothered, slapped, or shaken their baby at least once because of its crying. The risks of detrimental actions were highest for parents from non-industrialised countries, those with either no job or a job with short working hours, and those who judged their infant's crying to be excessive. Clinicians should be aware of the risks of abuse in children known to cry a lot and should target interventions at parents to help them cope with this crying.	Univ Groningen, Dept Hlth Sci, NL-9700 AD Groningen, Netherlands; TNO Netherlands Org Appl Sci Res Prevent & Hlth, Leiden, Netherlands; Amsterdam Municipal Hlth Serv, Dept Epidemiol & Hlth Promot, Amsterdam, Netherlands; VU Univ Med Ctr, Inst Res Extramural Med, Dept Social Med, Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Paediat, Leiden, Netherlands	University of Groningen; Netherlands Organization Applied Science Research; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Reijneveld, SA (corresponding author), Univ Groningen, Dept Hlth Sci, POB 196, NL-9700 AD Groningen, Netherlands.	s.a.reijneveld@med.rug.nl		Reijneveld, Sijmen/0000-0002-1206-7523				Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Krugman R D, 1983, Pediatrician, V12, P68; Reijneveld SA, 2001, PEDIATRICS, V108, P893, DOI 10.1542/peds.108.4.893; UNICEF, 2003, LEAG TABL CHILD MALT; van der Wal MF, 1998, ARCH DIS CHILD, V79, P312, DOI 10.1136/adc.79.4.312	6	201	207	0	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	2004	364	9442					1340	1342		10.1016/S0140-6736(04)17191-2	http://dx.doi.org/10.1016/S0140-6736(04)17191-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	860NG	15474137				2022-12-28	WOS:000224349700030
J	Cockburn, JJB; Abrescia, NGA; Grimes, JM; Sutton, GC; Diprose, JM; Benevides, JM; Thomas, GJ; Bamford, JKH; Bamford, DH; Stuart, DI				Cockburn, JJB; Abrescia, NGA; Grimes, JM; Sutton, GC; Diprose, JM; Benevides, JM; Thomas, GJ; Bamford, JKH; Bamford, DH; Stuart, DI			Membrane structure and interactions with protein and DNA in bacteriophage PRD1	NATURE			English	Article							VIRAL MEMBRANE; INTERNAL MEMBRANE; CRYOELECTRON MICROSCOPY; BACTERIAL-VIRUS; UNIQUE VERTEX; PRD1; ORGANIZATION; MODEL	Membranes are essential for selectively controlling the passage of molecules in and out of cells and mediating the response of cells to their environment. Biological membranes and their associated proteins present considerable difficulties for structural analysis. Although enveloped viruses have been imaged at about 9 Angstrom resolution by cryo-electron microscopy and image reconstruction(1,2), no detailed crystallographic structure of a membrane system has been described. The structure of the bacteriophage PRD1 particle, determined by X-ray crystallography at about 4 Angstrom resolution, allows the first detailed analysis of a membrane-containing virus(3). The architecture of the viral capsid and its implications for virus assembly are presented in the accompanying paper(3). Here we show that the electron density also reveals the icosahedral lipid bilayer, beneath the protein capsid, enveloping the viral DNA. The viral membrane contains about 26,000 lipid molecules asymmetrically distributed between the membrane leaflets. The inner leaflet is composed predominantly of zwitterionic phosphatidylethanolamine molecules, facilitating a very close interaction with the viral DNA, which we estimate to be packaged to a pressure of about 45 atm, factors that are likely to be important during membrane-mediated DNA translocation into the host cell. In contrast, the outer leaflet is enriched in phosphatidylglycerol and cardiolipin, which show a marked lateral segregation within the icosahedral asymmetric unit. In addition, the lipid headgroups show a surprising degree of order.	Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England; Univ Oxford, Cent Chem Lab, Oxford Ctr Mol Sci, Oxford OX1 3QT, England; Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Fac Biosci, Viikki Bioctr, FIN-00014 Helsinki, Finland	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Missouri System; University of Missouri Kansas City; University of Helsinki; University of Helsinki	Stuart, DI (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Roosevelt Dr, Oxford OX3 7BN, England.	dave@strubi.ox.ac.uk	Abrescia, Nicola Gerardo/AAY-2323-2020; Abrescia, Nicola GA/F-5898-2011	Abrescia, Nicola Gerardo/0000-0001-5559-1918; Cockburn, Joseph/0000-0003-4730-1436; Stuart, David/0000-0002-3426-4210; Grimes, Jonathan Mark/0000-0001-9698-0389				BAMFORD D, 1982, J VIROL, V44, P1031, DOI 10.1128/JVI.44.3.1031-1038.1982; BAMFORD DH, 1995, ADV VIRUS RES, V45, P281, DOI 10.1016/S0065-3527(08)60064-0; Bamford JKH, 2002, J STRUCT BIOL, V139, P103, DOI 10.1016/S1047-8477(02)00562-2; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Butcher SJ, 1995, EMBO J, V14, P6078, DOI 10.1002/j.1460-2075.1995.tb00298.x; CASPAR DLD, 1971, NATURE-NEW BIOL, V231, P46, DOI 10.1038/newbio231046a0; Cerritelli ME, 1997, CELL, V91, P271, DOI 10.1016/S0092-8674(00)80409-2; DAVIS TN, 1982, VIROLOGY, V120, P287, DOI 10.1016/0042-6822(82)90031-9; Evans E, 2003, BIOPHYS J, V85, P2342, DOI 10.1016/S0006-3495(03)74658-X; Gowen B, 2003, J VIROL, V77, P7863, DOI 10.1128/JVI.77.14.7863-7871.2003; Grahn AM, 1999, J BACTERIOL, V181, P6689, DOI 10.1128/JB.181.21.6689-6696.1999; Grahn AM, 2002, MOL MICROBIOL, V46, P1199, DOI 10.1046/j.1365-2958.2002.03250.x; Laurinavicius S, 2004, VIROLOGY, V322, P328, DOI 10.1016/j.virol.2004.02.009; Livolant F, 1996, PROG POLYM SCI, V21, P1115, DOI 10.1016/S0079-6700(96)00016-0; Mancini EJ, 2000, MOL CELL, V5, P255, DOI 10.1016/S1097-2765(00)80421-9; Nagle JF, 2000, BBA-REV BIOMEMBRANES, V1469, P159, DOI 10.1016/S0304-4157(00)00016-2; Rydman PS, 2002, J BACTERIOL, V184, P104, DOI 10.1128/JB.184.1.104-110.2002; Rydman PS, 1999, J MOL BIOL, V291, P575, DOI 10.1006/jmbi.1999.2978; Rydman PS, 2001, J MOL BIOL, V313, P785, DOI 10.1006/jmbi.2001.5068; Rydman PS, 2000, MOL MICROBIOL, V37, P356, DOI 10.1046/j.1365-2958.2000.01996.x; San Martin C, 2001, STRUCTURE, V9, P917, DOI 10.1016/S0969-2126(01)00642-6; Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581; Stromsten NJ, 2003, J VIROL, V77, P6314, DOI 10.1128/JVI.77.11.6314-6321.2003; STRUTH B, 2002, PHYS REV LETT, V88, P55023; Tao YZ, 1998, CELL, V95, P431, DOI 10.1016/S0092-8674(00)81773-0; Tuma R, 1996, J MOL BIOL, V257, P102, DOI 10.1006/jmbi.1996.0150; Zhang W, 2003, NAT STRUCT BIOL, V10, P907, DOI 10.1038/nsb990	28	111	114	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					122	125		10.1038/nature03053	http://dx.doi.org/10.1038/nature03053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525993				2022-12-28	WOS:000224854900053
J	Yeomans, DK; Veverka, J				Yeomans, DK; Veverka, J			Fred Lawrence Whipple (1906-2004) - Obituary	NATURE			English	Biographical-Item									CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Cornell Univ, Ctr Radio Phys & Space Res, Ithaca, NY 14850 USA; Cornell Univ, Planetary Studies Lab, Ithaca, NY 14850 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Cornell University; Cornell University	Yeomans, DK (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	donald.k.yeomans@jpl.nasa.gov; jfv4@cornell.edu							0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					31	31		10.1038/432031a	http://dx.doi.org/10.1038/432031a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525970				2022-12-28	WOS:000224854900028
J	Voordouw, ACG; Sturkenboom, MCJM; Dieleman, JP; Stijnen, T; Smith, DJ; van der Lei, J; Stricker, BHC				Voordouw, ACG; Sturkenboom, MCJM; Dieleman, JP; Stijnen, T; Smith, DJ; van der Lei, J; Stricker, BHC			Annual revaccination against influenza and mortality risk in community-dwelling elderly parsons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VACCINE USE; EFFICACY; DISEASE; EPIDEMIC; REDUCTION; IMPACT	Context Although large-scale observational studies have demonstrated the effectiveness of influenza vaccination, no large studies have systematically addressed the clinical benefit of annual revaccinations. Objective To investigate the effect of annual influenza revaccination on mortality in community-dwelling elderly persons. Design, Setting, and Participants A population-based cohort study using the computerized Integrated Primary Care Information (IPCI) database in the Netherlands including community-dwelling individuals aged 65 years or older from 1996 through 2002. For each year, we computed the individual cumulative exposure to influenza vaccination since study start. Main Outcome Measure Association between the number of consecutive influenza vaccinations and all-cause mortality vs no vaccination after adjusting forage, sex, chronic respiratory and cardiovascular disease, hypertension, diabetes mellitus, renal failure, and cancer. Results The study population included 26071 individuals, of whom 3485 died during follow-up. Overall, a first vaccination was associated with a nonsignificant annual reduction of mortality risk of 10% (hazard ratio [HR], 0.90; 95% confidence interval [CI], 0.78-1.03) while revaccination was associated with a reduced mortality risk of 24% (HR, 0.76; 95% Cl, 0.70-0.83). Compared with a first vaccination, revaccination was associated with a reduced annual mortality risk of 15% (HR, 0.85; 95% Cl, 0.75-0.96). During the epidemic periods this reduction was 28% (HR, 0.72; 95% Cl, 0.53-0.96). Similar estimates were obtained for persons with and without chronic comorbidity and those aged 70 years or older at baseline. overall, influenza vaccination is estimated to prevent 1 death for every 302 vaccinees at a vaccination coverage that varied between 64% and 74%. Conclusion Annual influenza vaccination is associated with a reduction in all-cause mortality risk in a population of community-dwelling elderly persons, particularly in older individuals.	Erasmus Univ, Med Ctr, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Internal Med, Pharmacoepidemiol Unit, Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Med Informat, Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Virol, Rotterdam, Netherlands; Inspectorate Hlth Care, Med Evaluat Board, The Hague, Netherlands; Inspectorate Hlth Care, Drug Safety Unit, The Hague, Netherlands; Univ Cambridge, Dept Zool, Cambridge, England	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Cambridge	Stricker, BHC (corresponding author), Erasmus Univ, Med Ctr, Dept Epidemiol & Biostat, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Smith, Derek/Z-3075-2019	Smith, Derek/0000-0002-2393-1890				AHMED AEH, 1995, LANCET, V346, P591, DOI 10.1016/S0140-6736(95)91434-X; ARDEN N, 1995, AM J PUBLIC HEALTH, V85, P399, DOI 10.2105/AJPH.85.3.399; Beyer WEP, 1999, ARCH INTERN MED, V159, P182, DOI 10.1001/archinte.159.2.182; Beyer WEP, 1996, VACCINE, V14, P1331, DOI 10.1016/S0264-410X(96)00058-8; CARRAT F, 1995, J EPIDEMIOL COMMUN H, V49, P419, DOI 10.1136/jech.49.4.419; CLAYTON D, 1993, STAT MODELS EPIDEMIO, P307; de Jong JC, 2000, J MED VIROL, V61, P94, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;94::AID-JMV15&gt;3.0.CO;2-C; deBruijn IA, 1997, VACCINE, V15, P1323, DOI 10.1016/S0264-410X(97)00019-4; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Hak E, 2002, CLIN INFECT DIS, V35, P370, DOI 10.1086/341403; HOSKINS TW, 1979, LANCET, V1, P33; Keitel WA, 1997, VACCINE, V15, P1114, DOI 10.1016/S0264-410X(97)00003-0; KEITEL WA, 1988, AM J EPIDEMIOL, V127, P353, DOI 10.1093/oxfordjournals.aje.a114809; Lamberts H, 2002, FAM PRACT, V19, P433, DOI 10.1093/fampra/19.5.433; MCELHANEY JE, 1992, J GERONTOL, V47, pM3, DOI 10.1093/geronj/47.1.M3; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; Nichol KL, 1999, ANN INTERN MED, V130, P397, DOI 10.7326/0003-4819-130-5-199903020-00003; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; SAAH AJ, 1986, ARCH INTERN MED, V146, P2353, DOI 10.1001/archinte.146.12.2353; Smith DJ, 1999, P NATL ACAD SCI USA, V96, P14001, DOI 10.1073/pnas.96.24.14001; SPRENGER MJW, 1993, INT J EPIDEMIOL, V22, P334, DOI 10.1093/ije/22.2.334; van Essen GA, 2003, VACCINE, V21, P1780, DOI 10.1016/S0264-410X(03)00072-0; vanEssen GA, 1997, AGE AGEING, V26, P275; Vlug AE, 1999, METHOD INFORM MED, V38, P339; Voordouw BCG, 2003, ARCH INTERN MED, V163, P1089, DOI 10.1001/archinte.163.9.1089	27	118	121	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2004	292	17					2089	2095		10.1001/jama.292.17.2089	http://dx.doi.org/10.1001/jama.292.17.2089			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868OC	15523069	Bronze			2022-12-28	WOS:000224921900021
J	Beverley, SM; Dobson, DE				Beverley, SM; Dobson, DE			Flypaper for parasites	CELL			English	Editorial Material							LEISHMANIASIS	In this issue, Kamhawi et al. (2004) describe the identification of an insect galectin as the receptor for the stage-specific Leishmania adhesin lipophosphoglycan (LPG). This interaction is critical for parasite survival in the midgut of its sand fly vector. The results open new avenues for studies of insect immunity, transmission binding vaccines, and host-parasite co-evolution.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Beverley, SM (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave, St Louis, MO 63110 USA.			Beverley, Stephen/0000-0001-5319-0811				Beverley SM, 1998, TRENDS MICROBIOL, V6, P35, DOI 10.1016/S0966-842X(97)01180-3; Enserink M, 2000, SCIENCE, V290, P1881, DOI 10.1126/science.290.5498.1881; Kamhawi S, 2004, CELL, V119, P329, DOI 10.1016/j.cell.2004.10.009; Pelletier I, 2003, J BIOL CHEM, V278, P22223, DOI 10.1074/jbc.M302693200; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Rogers ME, 2004, NATURE, V430, P463, DOI 10.1038/nature02675; Sacks D, 2001, ANNU REV MICROBIOL, V55, P453, DOI 10.1146/annurev.micro.55.1.453	7	5	5	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	2004	119	3					311	312		10.1016/j.cell.2004.10.013	http://dx.doi.org/10.1016/j.cell.2004.10.013			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	868IW	15507202	Bronze			2022-12-28	WOS:000224908300001
J	Fraser, J; Walls, M; McGuire, W				Fraser, J; Walls, M; McGuire, W			ABC of preterm birth - Respiratory complications of preterm birth	BRITISH MEDICAL JOURNAL			English	Review									Univ Dundee, Ninewells Hosp & Med Sch, Neonatal Intens Care Unit, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Fraser, J (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Neonatal Intens Care Unit, Dundee DD1 9SY, Scotland.			McGuire, William/0000-0001-8572-3467				BRION LP, 2003, COCHRANE DB SYST REV; CROWLEY P, 2003, COCHRANE DATABASE SY, DOI UNSP CD000065; GREENOUGH A, 2003, COCHRANE LIB, DOI UNSP CD000456; Halliday HL, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001144; HENDERSONSMART DJ, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000104; SOLL RF, 2003, COCHRANE DATABASE SY, DOI UNSP CD000510; WANG EEL, 2003, COCHRANE DATABASE SY, DOI UNSP CD001725	7	33	37	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 23	2004	329	7472					962	965		10.1136/bmj.329.7472.962	http://dx.doi.org/10.1136/bmj.329.7472.962			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866KU	15499114	Green Published			2022-12-28	WOS:000224773200021
J	Clayden, J; Lund, A; Vallverdu, LS; Helliwell, M				Clayden, J; Lund, A; Vallverdu, LS; Helliwell, M			Ultra-remote stereocontrol by conformational communication of information along a carbon chain	NATURE			English	Article							ASYMMETRIC INDUCTION; THERMODYNAMIC CONTROL; ATROPISOMERIC AMIDES; DYNAMIC RESOLUTION; KETO ESTERS; STEREOCHEMISTRY; (-)-EPHEDRINE; OXAZOLIDINE; AUXILIARY; ALDEHYDES	Many receptors(1) and allosteric proteins(2) function through binding of a molecule to induce a conformational change, which then influences a remote active site. In synthetic systems, comparable intramolecular information transfer can be effected by using the shape of one part of a molecule to control the stereoselectivity of reactions occurring some distance away(3). However, the need for direct communication with the reaction site usually limits such remote stereocontrol to distances of not more than about five bond lengths. Cyclic structures overcome this problem by allowing the controlling centre and the reaction site(4,5) to approach each other, but the information transfer spans only short absolute distances. Truly remote stereocontrol can, however, be achieved with rigid compounds containing amide groups: the conformation of the amides can be controlled by stereogenic centres(6-9) and responds to that of neighbouring amide groups(10-12) and in turn influences stereoselective reactions(13). This strategy has allowed remote stereocontrol spanning 8 (ref. 11) or 9 (ref. 12) bonds. Here we demonstrate stereocontrol over a reaction taking place more than 20 bond lengths from the controlling centre, corresponding to a linear distance of over 2.5 nm. This transmission of information, achieved by conformational changes relayed through the molecule, provides a chemical model of allostery and might serve as a molecular mechanism for communicating and processing information(14-16).	Univ Manchester, Dept Chem, Manchester M13 9PL, Lancs, England	University of Manchester	Clayden, J (corresponding author), Univ Manchester, Dept Chem, Oxford Rd, Manchester M13 9PL, Lancs, England.	clayden@man.ac.uk		Clayden, Jonathan/0000-0001-5080-9535	Engineering and Physical Sciences Research Council [GR/S05144/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		AGAMI C, 1985, TETRAHEDRON, V41, P537, DOI 10.1016/S0040-4020(01)96496-8; Ahmed A, 1998, TETRAHEDRON, V54, P13277, DOI 10.1016/S0040-4020(98)00814-X; Balzani V, 2002, CHEM-EUR J, V8, P5524, DOI 10.1002/1521-3765(20021216)8:24<5524::AID-CHEM5524>3.0.CO;2-J; Bowles P, 1997, J CHEM SOC PERK T 1, P2607, DOI 10.1039/a701671i; Clayden J, 2004, TETRAHEDRON, V60, P4399, DOI 10.1016/j.tet.2004.01.101; Clayden J, 2001, ORG LETT, V3, P4133, DOI 10.1021/ol0167457; Clayden J, 2002, J AM CHEM SOC, V124, P5266, DOI 10.1021/ja017702o; Clayden J, 1998, TETRAHEDRON LETT, V39, P105, DOI 10.1016/S0040-4039(97)10443-9; Clayden J, 2000, TETRAHEDRON LETT, V41, P5171, DOI 10.1016/S0040-4039(00)00833-9; Clayden J, 2001, TETRAHEDRON-ASYMMETR, V12, P695, DOI 10.1016/S0957-4166(01)00110-0; Clayden J, 2001, TETRAHEDRON LETT, V42, P3163, DOI 10.1016/S0040-4039(01)00416-6; Clayden J, 1999, ANGEW CHEM INT EDIT, V38, P2556, DOI 10.1002/(SICI)1521-3773(19990903)38:17<2556::AID-ANIE2556>3.0.CO;2-Q; Clayden J, 1998, SYNLETT, P810; Clayden J, 2000, J CHEM SOC PERK T 1, P1363, DOI 10.1039/b000669f; CUYEGKENG MA, 1987, CHEM BER-RECL, V120, P803, DOI 10.1002/cber.19871200519; Date M, 2001, J CHEM SOC PERK T 1, P645, DOI 10.1039/b100497m; ELIEL EL, 1994, STEREOCHEMISTRY ORGA, pCH12; Heinemann C, 1999, J AM CHEM SOC, V121, P4894, DOI 10.1021/ja984035z; Krauss G., 1999, BIOCH SIGNAL TRANSDU; Krauss R, 2003, SYNLETT, P598; Linnane P, 1997, NATURE, V385, P799, DOI 10.1038/385799a0; Magnus N, 1997, TETRAHEDRON LETT, V38, P3491, DOI 10.1016/S0040-4039(97)00704-1; Mikami K, 2001, TETRAHEDRON, V57, P2917, DOI 10.1016/S0040-4020(01)00036-9; Perutz M. F., 1990, MECH COOPERATIVITY; Sauvage JP, 1998, ACCOUNTS CHEM RES, V31, P611, DOI 10.1021/ar960263r; SNIECKUS V, 1990, CHEM REV, V90, P879, DOI 10.1021/cr00104a001; Tamai Y, 1999, J CHEM SOC PERK T 1, P1141, DOI 10.1039/a901978b; Yin JJ, 2002, J AM CHEM SOC, V124, P1162, DOI 10.1021/ja017082r	28	174	175	3	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	2004	431	7011					966	971		10.1038/nature02933	http://dx.doi.org/10.1038/nature02933			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	863TI	15496918				2022-12-28	WOS:000224585600039
J	Ira, G; Pellicioli, A; Balijja, A; Wang, X; Fiorani, S; Carotenuto, W; Liberi, G; Bressan, D; Wan, LH; Hollingsworth, NM; Haber, JE; Foiani, M				Ira, G; Pellicioli, A; Balijja, A; Wang, X; Fiorani, S; Carotenuto, W; Liberi, G; Bressan, D; Wan, LH; Hollingsworth, NM; Haber, JE; Foiani, M			DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1	NATURE			English	Article							DOUBLE-STRAND BREAKS; CELL-CYCLE; DEPENDENT PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; G2/M ARREST; REPAIR; KINASE; ADAPTATION; PROTEIN	A single double-strand break (DSB) induced by HO endonuclease triggers both repair by homologous recombination and activation of the Mec1-dependent DNA damage checkpoint in budding yeast(1-6). Here we report that DNA damage checkpoint activation by a DSB requires the cyclin-dependent kinase CDK1 (Cdc28) in budding yeast. CDK1 is also required for DSB-induced homologous recombination at any cell cycle stage. Inhibition of homologous recombination by using an analogue-sensitive CDK1 protein(7,8) results in a compensatory increase in non-homologous end joining. CDK1 is required for efficient 5' to 3' resection of DSB ends and for the recruitment of both the single-stranded DNA-binding complex, RPA, and the Rad51 recombination protein. In contrast, Mre11 protein, part of the MRX complex, accumulates at unresected DSB ends. CDK1 is not required when the DNA damage checkpoint is initiated by lesions that are processed by nucleotide excision repair. Maintenance of the DSB-induced checkpoint requires continuing CDK1 activity that ensures continuing end resection. CDK1 is also important for a later step in homologous recombination, after strand invasion and before the initiation of new DNA synthesis.	FIRC Inst Mol Oncol Fdn, I-20139 Milan, Italy; Brandeis Univ, Rosenstiel Ctr, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20122 Milan, Italy; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	IFOM - FIRC Institute of Molecular Oncology; Brandeis University; Brandeis University; University of Milan; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Haber, JE (corresponding author), FIRC Inst Mol Oncol Fdn, Via Adamello 16, I-20139 Milan, Italy.	haber@brandeis.edu; marco.foiani@ifom-ieo-campus.it	Pellicioli, Achille/B-8765-2017; Foiani, Marco/M-8234-2014; LIBERI, GIORDANO/AAY-7273-2020; Ira, Grzegorz/B-7912-2010	Pellicioli, Achille/0000-0002-1528-9009; Foiani, Marco/0000-0003-4795-834X; LIBERI, GIORDANO/0000-0003-3160-2242; Haber, James/0000-0002-1878-0610	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080600, R01GM050717] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI044009, AI44009] Funding Source: Medline; NIGMS NIH HHS [R01 GM080600, R01 GM050717] Funding Source: Medline; Telethon [GGP030412] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon)		Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Caspari T, 2002, GENE DEV, V16, P1195, DOI 10.1101/gad.221402; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; Diede SJ, 2001, CURR BIOL, V11, P1336, DOI 10.1016/S0960-9822(01)00400-6; FOIANI M, 1995, MOL CELL BIOL, V15, P883; Frank-Vaillant M, 2002, MOL CELL, V10, P1189, DOI 10.1016/S1097-2765(02)00705-0; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; Karathanasis E, 2002, GENETICS, V161, P1015; Lee J, 1999, IMMUNITY, V11, P771, DOI 10.1016/S1074-7613(00)80151-X; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Liberles DA, 2001, GENOME BIOL, V2; Lisby M, 2003, NAT CELL BIOL, V5, P572, DOI 10.1038/ncb997; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Naiki T, 2004, MOL CELL BIOL, V24, P3277, DOI 10.1128/MCB.24.8.3277-3285.2004; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sugawara N, 2003, MOL CELL, V12, P209, DOI 10.1016/S1097-2765(03)00269-7; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Toh GWL, 2003, BIOCHEM SOC T, V31, P242, DOI 10.1042/bst0310242; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Wang X, 2004, PLOS BIOL, V2, P104, DOI 10.1371/journal.pbio.0020021; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	29	559	572	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	2004	431	7011					1011	1017		10.1038/nature02964	http://dx.doi.org/10.1038/nature02964			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496928	Green Accepted			2022-12-28	WOS:000224585600050
J	Spagnoli, LG; Mauriello, A; Sangiorgi, G; Fratoni, S; Bonanno, E; Schwartz, RS; Piepgras, DG; Pistolese, R; Ippoliti, A; Holmes, DR				Spagnoli, LG; Mauriello, A; Sangiorgi, G; Fratoni, S; Bonanno, E; Schwartz, RS; Piepgras, DG; Pistolese, R; Ippoliti, A; Holmes, DR			Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATHEROSCLEROTIC PLAQUES; INFLAMMATION; ENDARTERECTOMY; PATHOGENESIS; ULCERATION; THROMBOSIS; MORPHOLOGY; DISEASE; PROTEIN; LESIONS	Context Recent studies suggest that factors other than the degree of carotid stenosis are involved in ischemic stroke pathogenesis, especially modifications of plaque composition and related complications. Objective To examine the role of carotid plaque rupture and thrombosis in ischemic stroke pathogenesis in patients undergoing carotid endarterectomy, excluding those with possible cardiac embolization or with severe stenosis of the circle of Willis. Design, Setting, and Patients A total of 269 carotid plaques selected from an interinstitutional Carotid Tissue Bank were studied by histology after surgical endarterectomy between January 1995 and December 2002. A total of 96 plaques were from patients with ipsilateral major stroke, 91 plaques from patients with transient ischemic attack (TIA), and 82 plaques from patients without symptoms. Main Outcome Measures Differences in the frequency of thrombosis, cap rupture, cap erosion, inflammatory infiltrate, and major cardiovascular risk factors between study groups. Results A thrombotically active carotid plaque associated with high inflammatory infiltrate was observed in 71 (74.0%) of 96 patients with ipsilateral major stroke (and in all 32 plaques from patients operated within 2 months of symptom onset) compared with 32 (35.2%) of 91 patients with TIA (P<.001) or 12 (14.6%) of 82 patients who were without symptoms (P<.001). In addition, a fresh thrombus was observed in 53.8% of patients with stroke operated 13 to 24 months after the cerebrovascular event, An acute thrombus was associated with cap rupture in 64 (90.1%) of 71 thrombosed plaques from patients with stroke and with cap erosion in the remaining 7 cases (9.9%). Ruptured plaques of patients affected by stroke were characterized by the presence of a more severe inflammatory infiltrate, constituted by monocytes, macrophages, and T lymphocyte cells compared with that observed in the TIA and asymptomatic groups (P=.001). There was no significant difference between groups in major cardiovascular risk factors. Conclusion These results demonstrate a major role of carotid thrombosis and inflammation in ischemic stroke in patients affected by carotid atherosclerotic disease.	Univ Roma Tor Vergata, Dept Cardiovasc Dis, Div Vasc Surg, I-00133 Rome, Italy; Minneapolis Cardiovasc Res Inst, Minneapolis, MN USA; Mayo Clin & Mayo Fdn, Dept Neurol Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Cardiovasc Dis, Rochester, MN 55905 USA	University of Rome Tor Vergata; Mayo Clinic; Mayo Clinic; Mayo Clinic	Spagnoli, LG (corresponding author), Univ Roma Tor Vergata, Dipartimento Biopatol & Diagnost Immagini, Cattedra Anat & Istol Patol, Via Montpellier 1, I-00133 Rome, Italy.	spagnoli@uniroma2.it	MAURIELLO, ALESSANDRO/K-4705-2016; Sangiorgi, Giuseppe M/H-5141-2019	MAURIELLO, ALESSANDRO/0000-0002-7351-5676; Sangiorgi, Giuseppe M/0000-0001-5862-1967; IPPOLITI, ARNALDO/0000-0001-5311-8203; bonanno, elena/0000-0002-0222-0141; Spagnoli, Luigi Giusto/0000-0002-0684-5501; ippoliti, arnaldo/0000-0002-2804-0157				Acalovschi D, 2003, STROKE, V34, P1864, DOI 10.1161/01.STR.0000079815.38626.44; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; BARNETT HJM, 1978, NEUROLOGY, V28, P769; Bassiouny HS, 1997, J VASC SURG, V26, P585, DOI 10.1016/S0741-5214(97)70056-9; Bayes-Genis A, 2001, NEW ENGL J MED, V345, P1022, DOI 10.1056/NEJMoa003147; Carr S, 1996, J VASC SURG, V23, P755, DOI 10.1016/S0741-5214(96)70237-9; Chamorro A, 2004, CEREBROVASC DIS, V17, P1, DOI 10.1159/000075297; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; ELIASZIW M, 1994, STROKE, V25, P304, DOI 10.1161/01.STR.25.2.304; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Frijns CJM, 2002, STROKE, V33, P2115, DOI 10.1161/01.STR.0000021902.33129.69; Fujii K, 2003, CIRCULATION, V108, P2473, DOI 10.1161/01.CIR.0000097121.95451.39; Goldstein LB, 2003, STROKE, V34, P2767, DOI 10.1161/01.STR.0000097803.90702.31; Golledge J, 2000, STROKE, V31, P774, DOI 10.1161/01.STR.31.3.774; GOMEZ CR, 1990, STROKE, V21, P148, DOI 10.1161/01.STR.21.1.148; Gorelick PB, 2002, STROKE, V33, P862, DOI 10.1161/hs0302.103657; Hatsukami TS, 1997, STROKE, V28, P95, DOI 10.1161/01.STR.28.1.95; Inzitari D, 2000, NEW ENGL J MED, V342, P1693, DOI 10.1056/NEJM200006083422302; Libby P, 2001, CIRCULATION, V103, P1718, DOI 10.1161/01.CIR.103.13.1718; Mathiesen EB, 2001, CIRCULATION, V103, P2171; Mauriello A, 2000, CIRCULATION, V101, P744, DOI 10.1161/01.CIR.101.7.744; Naghavi M, 2003, CIRCULATION, V108, P1772, DOI 10.1161/01.CIR.0000087481.55887.C9; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; SITZER M, 1995, STROKE, V26, P1231, DOI 10.1161/01.STR.26.7.1231; SPAGNOLI LG, 1994, ATHEROSCLEROSIS, V108, P39, DOI 10.1016/0021-9150(94)90036-1; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; SUNDT TM, 1981, MAYO CLIN PROC, V56, P533; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Tilton RG, 2002, DRUG NEWS PERSPECT, V15, P351, DOI 10.1358/dnp.2002.15.6.701654; VANDAMME H, 1993, INT ANGIOL, V12, P299; Verheye S, 2002, CIRCULATION, V105, P1596, DOI 10.1161/01.CIR.0000012527.94843.BF; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; ZHENG Z, 2003, CURR MOL MED, V361, P372	38	335	364	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2004	292	15					1845	1852		10.1001/jama.292.15.1845	http://dx.doi.org/10.1001/jama.292.15.1845			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IV	15494582	Bronze			2022-12-28	WOS:000224485100023
J	Bianco, PR				Bianco, PR			Hepatitis CNS3 helicase unwinds RNA in leaps and bounds	LANCET			English	Editorial Material							C VIRUS; MACROMOLECULAR MACHINES; STEP-SIZE; MECHANISMS		SUNY Buffalo, Dept Microbiol & Immunol, Ctr Single Mol Biophys, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Bianco, PR (corresponding author), SUNY Buffalo, Dept Microbiol & Immunol, Ctr Single Mol Biophys, Buffalo, NY 14214 USA.	pbianco@buffalo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066831] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM66831-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Bianco PR, 2000, NATURE, V405, P368, DOI 10.1038/35012652; Borowski P, 2003, EUR J BIOCHEM, V270, P1645, DOI 10.1046/j.1432-1033.2003.03540.x; Delagoutte E, 2003, Q REV BIOPHYS, V36, P1, DOI 10.1017/S0033583502003864; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; Dev Anouk, 2004, Curr Gastroenterol Rep, V6, P77, DOI 10.1007/s11894-004-0030-5; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Lucius AL, 2002, J MOL BIOL, V324, P409, DOI 10.1016/S0022-2836(02)01067-7; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Serebrov V, 2004, NATURE, V430, P476, DOI 10.1038/nature02704; Tan SL, 2002, NAT REV DRUG DISCOV, V1, P867, DOI 10.1038/nrd937; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88	14	2	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	2004	364	9443					1385	1387		10.1016/S0140-6736(04)17238-3	http://dx.doi.org/10.1016/S0140-6736(04)17238-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488202				2022-12-28	WOS:000224485300007
J	Stevenson, J; Abernethy, AP; Miller, C; Currow, DC				Stevenson, J; Abernethy, AP; Miller, C; Currow, DC			Managing comorbidities in patients at the end of life	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG-REACTIONS; THERAPY	Chronic conditions require careful management in patients who develop a life limiting illness. Doctors need to consider both the physical and psychological effects of treatment.	Flinders Univ S Australia, Dept Palliat & Support Serv, Adelaide, SA 5001, Australia; Repatriat Gen Hosp, So Adelaide Palliat Serv, Daw Pk, SA 5041, Australia; Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA; Repatriat Gen Hosp, Div Gen Med, Daw Pk, SA, Australia	Flinders University South Australia; Duke University	Currow, DC (corresponding author), Flinders Univ S Australia, Dept Palliat & Support Serv, Adelaide, SA 5001, Australia.	david.currow@rgh.sa.gov.au		Currow, David/0000-0003-1988-1250				Chalmers J, 1999, J HYPERTENS, V17, P151; Coebergh JWW, 1999, J CLIN EPIDEMIOL, V52, P1131, DOI 10.1016/S0895-4356(99)00098-0; Colven R, 2000, ANN INTERN MED, V133, P430, DOI 10.7326/0003-4819-133-6-200009190-00010; Diabet Control Complications Trial Res Grp, 1995, DIABETES CARE, V18, P1415; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; Goldberg RM, 1996, AM J EMERG MED, V14, P447, DOI 10.1016/S0735-6757(96)90147-3; Hensrud DD, 2000, MAYO CLIN PROC, V75, P165; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Kotler DP, 2000, ANN INTERN MED, V133, P622, DOI 10.7326/0003-4819-133-8-200010170-00015; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Mannesse CK, 2000, AGE AGEING, V29, P35, DOI 10.1093/ageing/29.1.35; Mayfield E, 1999, SOC WORK HEALTH CARE, V29, P21, DOI 10.1300/J010v29n02_02; Neal B, 2000, LANCET, V356, P1955; Olsen H, 1999, BLOOD PRESSURE, V8, P94; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WARD SE, 1992, NURS RES, V41, P362; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Yusuf S, 2000, NEW ENGL J MED, V342, P145	20	98	100	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	2004	329	7471					909	912		10.1136/bmj.329.7471.909	http://dx.doi.org/10.1136/bmj.329.7471.909			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863MU	15485977	Green Published			2022-12-28	WOS:000224566800028
J	Bossuyt, F; Meegaskumbura, M; Beenaerts, N; Gower, DJ; Pethiyagoda, R; Roelants, K; Mannaert, A; Wilkinson, M; Bahir, MM; Manamendra-Arachchi, K; Ng, PKL; Schneider, CJ; Oommen, OV; Milinkovitch, MC				Bossuyt, F; Meegaskumbura, M; Beenaerts, N; Gower, DJ; Pethiyagoda, R; Roelants, K; Mannaert, A; Wilkinson, M; Bahir, MM; Manamendra-Arachchi, K; Ng, PKL; Schneider, CJ; Oommen, OV; Milinkovitch, MC			Local endemism within the western Ghats-Sri Lanka biodiversity hotspot	SCIENCE			English	Article							EVOLUTION	The apparent biotic affinities between the mainland and the island in the Western Ghats-Sri Lanka biodiversity hotspot have been interpreted as the result of frequent migrations during recent periods of low sea level. We show, using molecular phylogenies of two invertebrate and four vertebrate groups, that biotic interchange between these areas has been much more limited than hitherto assumed. Despite several extended periods of land connection during the past 500,000 years, Sri Lanka has maintained a fauna that is largely distinct from that of the Indian mainland. Future conservation programs for the subcontinent should take into account such patterns of local endemism at the finest scale at which they may occur.	Free Univ Brussels, Dept Biol, Unit Ecol & Systemat, B-1050 Brussels, Belgium; Free Univ Brussels, Inst Mol Biol & Med, Lab Evolutionary Genet, B-6041 Gosselies, Belgium; Boston Univ, Dept Biol, Boston, MA 02215 USA; Wildlife Heritage Trust, Colombo 8, Sri Lanka; Nat Hist Museum, Dept Zool, London SW7 5BD, England; Natl Univ Singapore, Dept Biol Sci, Singapore 119260, Singapore; Univ Kerala, Dept Zool, Thiruvananthapuram 695581, Kerala, India	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Boston University; Natural History Museum London; National University of Singapore; University of Kerala	Bossuyt, F (corresponding author), Free Univ Brussels, Dept Biol, Unit Ecol & Systemat, Pleinlaan 2, B-1050 Brussels, Belgium.	fbossuyt@vub.ac.be	Meegaskumbura, Madhava/F-8782-2013; Ng, Peter/J-7393-2012; Pethiyagoda, Rohan/C-2307-2009; Wilkinson, Mark/J-2026-2014; Beenaerts, Natalie/AAC-5579-2021	Meegaskumbura, Madhava/0000-0002-4599-6724; Wilkinson, Mark/0000-0002-9459-8976; Milinkovitch, Michel/0000-0002-2553-0724; Roelants, Kim/0000-0001-5367-5958; Beenaerts, Natalie/0000-0001-5655-5943; Pethiyagoda, Rohan/0000-0001-7215-9617; Bossuyt, Franky/0000-0001-6804-9271				BOTT R, 1970, ARK ZOOL, V22, P627; BOTT R, 1970, Abhandlungen der Senckenbergischen Naturforschenden Gesellschaft, V526, P1; CADLE JE, 1990, BIOL J LINN SOC, V40, P293, DOI 10.1111/j.1095-8312.1990.tb00541.x; Daniels RJR, 2001, CURR SCI INDIA, V81, P240; Darlington P.J., 1957, ZOOGEOGRAPHY GEOGRAP; Erdelen W., 1990, VEGETATION EROSION, P491; Gillespie RG, 2002, ANNU REV ENTOMOL, V47, P595, DOI 10.1146/annurev.ento.47.091201.145244; INGER R F, 1984, Journal of the Bombay Natural History Society, V81, P551; KIRTISINGHE P, 1957, AMPHIBIAN FAUNA CEYL; MacArthur R, 1967, THEORY ISLAND BIOGEO; Meegaskumbura M, 2002, SCIENCE, V298, P379, DOI 10.1126/science.298.5592.379; Moritz Craig, 1997, P442; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Ng Peter K.L., 1995, Journal of South Asian Natural History, V1, P129; Ng Peter K. L., 2001, Zeylanica, V6, P113; Pan GB, 1997, CLIMATES S ASIA; Pethiyagoda R., 1991, FRESHWATER FISHES SR, DOI DOI 10.1093/sysbio/syw095; Pethiyagoda R, 1998, OCC PAP WILDL HERITA, V2, P1; PRENDERGAST JR, 1993, NATURE, V365, P335, DOI 10.1038/365335a0; Rodrigues ASL, 2004, NATURE, V428, P640, DOI 10.1038/nature02422; Rohling EJ, 1998, NATURE, V394, P162, DOI 10.1038/28134; Schubart CD, 1998, NATURE, V393, P363, DOI 10.1038/30724; SENANAYAKE FR, 1977, NATURE, V265, P351, DOI 10.1038/265351a0; SMITH MA, 1943, SERPENTES FAUNA BRIT, V3; Somasekaram T., 1997, ATLAS SRI LANKA; Vaz GG, 2000, CURR SCI INDIA, V79, P228; Wallace, 1876, GEOGRAPHICAL DISTRIB	27	247	273	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					479	481		10.1126/science.1100167	http://dx.doi.org/10.1126/science.1100167			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486298				2022-12-28	WOS:000224626500051
J	Miyashita, Y				Miyashita, Y			Cognitive memory: Cellular and network machineries and their top-down control	SCIENCE			English	Review							LONG-TERM-MEMORY; INFERIOR TEMPORAL CORTEX; EPISODIC-LIKE MEMORY; CA3 NMDA RECEPTORS; PREFRONTAL CORTEX; ASSOCIATIVE MEMORY; RECOGNITION MEMORY; PERIRHINAL NEURONS; EXECUTIVE CONTROL; MONKEY	A brain-wide distributed network orchestrates cognitive memorizing and remembering of explicit memory (i.e., memory of facts and events). The network was initially identified in humans and is being systematically investigated in molecular/genetic, single-unit, lesion, and imaging studies in animals. The types of memory identified in humans are extended into animals as episodic-like (event) memory or semantic-like (fact) memory. The unique configurational association between environmental stimuli and behavioral context, which is likely the basis of episodic-like memory, depends on neural circuits in the medial temporal lobe, whereas memory traces representing repeated associations, which is likely the basis of semantic-like memory, are consolidated in the domain-specific regions in the temporal cortex. These regions are reactivated during remembering and contribute to the contents of a memory. Two types of retrieval signal reach the cortical representations. one runs from the frontal cortex for active (or effortful) retrieval (top-down signal), and the other spreads backward from the medial temporal lobe for automatic retrieval. By sending the top-down signal to the temporal cortex, frontal regions manipulate and organize to-be-remembered information, devise strategies for retrieval, and also monitor the outcome, with dissociated frontal regions making functionally separate contributions. The challenge is to understand the hierarchical interactions between these multiple cortical areas, not only with a correlational analysis but also with an interventional study demonstrating the causal necessity and the direction of the causality.	Univ Tokyo, Sch Med, Dept Physiol, Tokyo 1130033, Japan	University of Tokyo	Miyashita, Y (corresponding author), Univ Tokyo, Sch Med, Dept Physiol, Tokyo 1130033, Japan.	yasushi_miyashita@m.u-tokyo.ac.jp	Miyashita, Yasushi/B-7171-2019	Miyashita, Yasushi/0000-0003-3496-8637				AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Anderson J.R., 1995, COGNITIVE PSYCHOL IT, V4th; [Anonymous], 1983, CANADIAN PSYCHOL; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brown MW, 2001, NAT REV NEUROSCI, V2, P51, DOI 10.1038/35049064; Buckner RL, 2001, NAT REV NEUROSCI, V2, P624, DOI 10.1038/35090048; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Burgess PW, 1996, MEMORY, V4, P359, DOI 10.1080/096582196388906; Clayton NS, 1998, NATURE, V395, P272, DOI 10.1038/26216; Clayton NS, 2003, NAT REV NEUROSCI, V4, P685, DOI 10.1038/nrn1180; D 'Esposito M, 2000, SEMIN NEUROL, V20, P487, DOI 10.1055/s-2000-13182; Day M, 2003, NATURE, V424, P205, DOI 10.1038/nature01769; Dobbins IG, 2002, NEURON, V35, P989, DOI 10.1016/S0896-6273(02)00858-9; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; Erickson CA, 1999, J NEUROSCI, V19, P10404; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Freedman DJ, 2001, SCIENCE, V291, P312, DOI 10.1126/science.291.5502.312; Fuster J., 2015, PREFRONTAL CORTEX, V5th; Hampton RR, 2004, CURR OPIN NEUROBIOL, V14, P192, DOI 10.1016/j.conb.2004.03.006; Hampton RR, 2001, P NATL ACAD SCI USA, V98, P5359, DOI 10.1073/pnas.071600998; Hasegawa I, 1998, SCIENCE, V281, P814, DOI 10.1126/science.281.5378.814; Ishai A, 2000, NEURON, V28, P979, DOI 10.1016/S0896-6273(00)00168-9; JANOWSKY JS, 1989, NEUROPSYCHOLOGIA, V27, P1043, DOI 10.1016/0028-3932(89)90184-X; Kahn I, 2004, J NEUROSCI, V24, P4172, DOI 10.1523/JNEUROSCI.0624-04.2004; Kikyo H, 2002, NEURON, V36, P177, DOI 10.1016/S0896-6273(02)00939-X; Koechlin E, 2003, SCIENCE, V302, P1181, DOI 10.1126/science.1088545; Koriat A, 2001, J EXP PSYCHOL LEARN, V27, P34, DOI 10.1037//0278-7393.27.1.34; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Maril A, 2003, NEUROIMAGE, V18, P827, DOI 10.1016/S1053-8119(03)00014-4; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miller EK, 2002, PHILOS T R SOC B, V357, P1123, DOI 10.1098/rstb.2002.1099; MILNER B, 1991, NEUROPSYCHOLOGIA, V29, P601, DOI 10.1016/0028-3932(91)90013-X; Mishkin M, 1997, PHILOS T R SOC B, V352, P1461, DOI 10.1098/rstb.1997.0132; Miyashita Y, 2000, CURR OPIN NEUROBIOL, V10, P187, DOI 10.1016/S0959-4388(00)00071-4; MIYASHITA Y, 1993, ANNU REV NEUROSCI, V16, P245, DOI 10.1146/annurev.ne.16.030193.001333; MIYASHITA Y, 1988, NATURE, V335, P817, DOI 10.1038/335817a0; Morris RGM, 2001, PHILOS T R SOC B, V356, P1453, DOI 10.1098/rstb.2001.0945; Nadel L, 1997, CURR OPIN NEUROBIOL, V7, P217, DOI 10.1016/S0959-4388(97)80010-4; Nakahara K, 2002, SCIENCE, V295, P1532, DOI 10.1126/science.1067653; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; Nakazawa K, 2003, NEURON, V38, P305, DOI 10.1016/S0896-6273(03)00165-X; Naya Y, 1996, P NATL ACAD SCI USA, V93, P2664, DOI 10.1073/pnas.93.7.2664; Naya Y, 2003, J NEUROSCI, V23, P2861; Naya Y, 2001, SCIENCE, V291, P661, DOI 10.1126/science.291.5504.661; O'Craven KM, 2000, J COGNITIVE NEUROSCI, V12, P1013, DOI 10.1162/08989290051137549; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Ohbayashi M, 2003, SCIENCE, V301, P233, DOI 10.1126/science.1084884; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; Petrides M., 2000, HDB NEUROPSYCHOLOGY; Poldrack RA, 2001, NATURE, V414, P546, DOI 10.1038/35107080; Roberts William A., 1998, PRINCIPLES ANIMAL CO; Rolls ET, 1996, HIPPOCAMPUS, V6, P601, DOI 10.1002/(SICI)1098-1063(1996)6:6<601::AID-HIPO5>3.0.CO;2-J; Rugg MD, 2003, TRENDS COGN SCI, V7, P313, DOI 10.1016/S1364-6613(03)00131-1; Sakai K, 2003, NAT NEUROSCI, V6, P75, DOI 10.1038/nn987; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; Saleem KS, 1996, J NEUROSCI, V16, P4757; Schacter DL, 1998, ANNU REV PSYCHOL, V49, P289, DOI 10.1146/annurev.psych.49.1.289; SHIFFRIN RM, 1984, PSYCHOL REV, V91, P269, DOI 10.1037/0033-295X.91.2.269; SIDTIS JJ, 1981, SCIENCE, V212, P344, DOI 10.1126/science.6782673; Sigala N, 2002, NATURE, V415, P318, DOI 10.1038/415318a; Squire L.R., 2002, NEUROPSYCHOLOGY MEMO; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Steele RJ, 1999, HIPPOCAMPUS, V9, P118, DOI 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8; Stuss D.T., 1986, FRONTAL LOBES; Suzuki WA, 2003, J COMP NEUROL, V463, P67, DOI 10.1002/cne.10744; Tokuyama W, 2000, NAT NEUROSCI, V3, P1134, DOI 10.1038/80655; Tomita H, 1999, NATURE, V401, P699, DOI 10.1038/44372; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; Wagner AD, 2001, CURR BIOL, V11, pR964, DOI 10.1016/S0960-9822(01)00575-9; Wheeler ME, 2000, P NATL ACAD SCI USA, V97, P11125, DOI 10.1073/pnas.97.20.11125; Wirth S, 2003, SCIENCE, V300, P1578, DOI 10.1126/science.1084324; Yakovlev V, 1998, NAT NEUROSCI, V1, P310, DOI 10.1038/1131; Yoshida M, 2003, P NATL ACAD SCI USA, V100, P4257, DOI 10.1073/pnas.0736457100	79	192	198	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					435	440		10.1126/science.1101864	http://dx.doi.org/10.1126/science.1101864			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486288				2022-12-28	WOS:000224626500039
J	Weissman, DE				Weissman, DE			Decision making at a time of crisis near the end of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TERMINALLY ILL PATIENTS; CANCER-PATIENTS; PATIENTS PREFERENCES; FAMILY CAREGIVERS; ADVANCED DEMENTIA; DYING PATIENTS; CARE; PHYSICIAN; PATIENT; COMMUNICATION	As patients approach the end of life, their disease process may create an immediate life-threatening emergency, yet invasive interventions may be less likely to provide benefit while carrying the same or greater risks. Knowing when it is time to shift from life-prolonging to more palliative approaches, focused on quality of life and comfort, is emotionally and clinically challenging for patients, families, and physicians. Key factors in the decision process include prognosis, risk-benefit analysis of the proposed intervention, current symptom burden, temporal pattern of the illness, patient's age and life stage, and the patient's goals of care. A structured approach to decision making includes assessing the patient's physical, psychological, and spiritual needs; assessing the patient's support system; discussing prognosis; and assessing patient-specific goals. Physicians can best help patients decide which treatments are appropriate by taking the necessary time to explore all curative and palliative care options, providing honest and timely prognostic information, making clear recommendations, facilitating patient-family discussions, and affirming patient choices.	Med Coll Wisconsin, Palliat Care Ctr, Div Neoplast & Related Disorders, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Weissman, DE (corresponding author), Froedtert Hosp, Div Neoplast Dis & Related Disorders, Room 3961,9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	dweissma@mail.mcw.edu						Ahronheim JC, 1996, ARCH INTERN MED, V156, P2094, DOI 10.1001/archinte.156.18.2094; Back Anthony L, 2003, Ann Intern Med, V138, P439; Baile WF, 1999, ONCOLOGY-NY, V13, P1021; Bascom P B, 1997, Am J Hosp Palliat Care, V14, P57, DOI 10.1177/104990919701400202; Billings J A, 1998, J Palliat Med, V1, P73, DOI 10.1089/jpm.1998.1.73; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; CARLSON RW, 1988, JAMA-J AM MED ASSOC, V259, P378, DOI 10.1001/jama.259.3.378; Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; Coulehan JL, 2001, ANN INTERN MED, V135, P221, DOI 10.7326/0003-4819-135-3-200108070-00022; Curtis JR, 2001, CRIT CARE MED, V29, pN26, DOI 10.1097/00003246-200102001-00006; Curtis JR, 2001, J GEN INTERN MED, V16, P41; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Fallowfield LJ, 2002, PALLIATIVE MED, V16, P297, DOI 10.1191/0269216302pm575oa; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; Fried Terri R, 2003, J Palliat Med, V6, P237, DOI 10.1089/109662103764978489; GERLE B, 1960, CANCER, V13, P1206, DOI 10.1002/1097-0142(196011/12)13:6<1206::AID-CNCR2820130609>3.0.CO;2-F; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; Hotopf M, 2002, PALLIATIVE MED, V16, P81, DOI 10.1191/02169216302pm507oa; HUANG Z, 2002, PRINCIPLES PRACTICE, P956; Jenkins C, 1998, J PALLIATIVE CARE, V14, P18, DOI 10.1177/082585979801400104; Kagawa-Singer M, 2001, JAMA-J AM MED ASSOC, V286, P2993, DOI 10.1001/jama.286.23.2993; KUSHNER K, 1989, J FAM PRACTICE, V28, P73; Lamont E, 2002, PRINCIPLES PRACTICE, P607; Lamont EB, 2001, ANN INTERN MED, V134, P1096, DOI 10.7326/0003-4819-134-12-200106190-00009; Lamont EB, 2003, JAMA-J AM MED ASSOC, V290, P98, DOI 10.1001/jama.290.1.98; Larson DG, 2000, JAMA-J AM MED ASSOC, V284, P1573, DOI 10.1001/jama.284.12.1573; Loprinzi CL, 2000, J CLIN ONCOL, V18, P699, DOI 10.1200/JCO.2000.18.3.699; Luce JM, 2001, JAMA-J AM MED ASSOC, V285, P1331, DOI 10.1001/jama.285.10.1331; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; McCahill LE, 2002, J AM COLL SURGEONS, V195, P411, DOI 10.1016/S1072-7515(02)01306-6; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Miettinen TT, 1999, J PALLIATIVE CARE, V15, P26, DOI 10.1177/082585979901500205; MUIR JC, 2002, PRINCIPLES PRACTICE, P653; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; *NAT AC SCI I MED, 1997, APPR DEATH IMPR CAR; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; Roter DL, 2002, JAMA-J AM MED ASSOC, V288, P756, DOI 10.1001/jama.288.6.756; Rousseau Paul, 2002, J Palliat Med, V5, P657, DOI 10.1089/109662102320880444; SCHNEIDERMAN LJ, 1993, J CLIN ETHIC, V4, P28; Schulz R, 2003, NEW ENGL J MED, V349, P1936, DOI 10.1056/NEJMsa035373; Tang ST, 2001, CANCER INVEST, V19, P165, DOI 10.1081/CNV-100000151; Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; von Gunten C F, 1998, J Palliat Med, V1, P45; von Gunten CF, 2000, JAMA-J AM MED ASSOC, V284, P3051, DOI 10.1001/jama.284.23.3051; Walsh T D, 1990, J Pain Symptom Manage, V5, P273, DOI 10.1016/0885-3924(90)90043-J; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Weissman David E, 2003, J Palliat Med, V6, P1, DOI 10.1089/10966210360510046; Weissman DE, 1997, ARCH INTERN MED, V157, P733, DOI 10.1001/archinte.157.7.733; Wenrich MD, 2001, ARCH INTERN MED, V161, P868, DOI 10.1001/archinte.161.6.868	58	83	85	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2004	292	14					1738	1743		10.1001/jama.292.14.1738	http://dx.doi.org/10.1001/jama.292.14.1738			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861JS	15479939				2022-12-28	WOS:000224413400033
J	Berlo, K; Blundy, J; Turner, S; Cashman, K; Hawkesworth, C; Black, S				Berlo, K; Blundy, J; Turner, S; Cashman, K; Hawkesworth, C; Black, S			Geochemical precursors to volcanic activity at Mount St. Helens, USA	SCIENCE			English	Article							CRYSTALLIZATION; DIFFUSION; ERUPTIONS; DYNAMICS; ASCENT; DACITE; MAGMAS	The importance of the interplay between degassing and crystallization before and after the eruption of Mount St. Helens (Washington, USA) in 1980 is well established. Here, we show that degassing occurred over a period of decades to days before eruptions and that the manner of degassing, as deduced from geochemicai signatures within the magma, was characteristic of the eruptive style. Trace element (lithium) and short-lived radioactive isotope (lead-210 and radium-226) data show that ascending magma stalled within the conduit, leading to the accumulation of volatiles and the formation of lead-210 excesses, which signals the presence of degassing magma at depth.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Macquarie Univ, Dept Earth & Planetary Sci, GEMOC, Sydney, NSW 2109, Australia; Univ Oregon, Dept Geol Sci, Eugene, OR 97403 USA; Univ Reading, Dept Archaeol, Sch Human & Environm Sci, Reading RG6 6AB, Berks, England	University of Bristol; Macquarie University; University of Oregon; University of Reading	Berlo, K (corresponding author), Univ Bristol, Dept Earth Sci, Wills Mem Bldg,Queens Rd, Bristol BS8 1RJ, Avon, England.	Kim.Berlo@bristol.ac.uk	Facility, Edinburgh Ion Microprobe/AAD-8512-2020; Black, Stuart/A-1099-2014; Turner, Simon/0000-0002-6426-6495	Facility, Edinburgh Ion Microprobe/0000-0001-6248-6657; Black, Stuart/0000-0003-1396-4821; Turner, Simon/0000-0002-6426-6495				Barnes H., 1997, GEOCHEMISTRY HYDROTH; BENNETT JT, 1982, EARTH PLANET SC LETT, V60, P61, DOI 10.1016/0012-821X(82)90020-6; Blundy J, 2001, CONTRIB MINERAL PETR, V140, P631, DOI 10.1007/s004100000219; BLUNDY J, UNPUB; CASADEVALL T, 1983, SCIENCE, V221, P1383, DOI 10.1126/science.221.4618.1383; Cashman KV, 2004, GEOLOGY, V32, P141, DOI 10.1130/G20078.1; CASHMAN KV, 1992, CONTRIB MINERAL PETR, V109, P431, DOI 10.1007/BF00306547; EICHELBERGER JC, 1986, NATURE, V323, P598, DOI 10.1038/323598a0; Gauthier PJ, 1999, EARTH PLANET SC LETT, V172, P111, DOI 10.1016/S0012-821X(99)00195-8; GESCHWIND CH, 1995, B VOLCANOL, V57, P356, DOI 10.1007/BF00301293; Giletti BJ, 1997, CHEM GEOL, V139, P3, DOI 10.1016/S0009-2541(97)00026-0; Klug C, 1996, B VOLCANOL, V58, P87, DOI 10.1007/s004450050128; LIPMAN PW, 1981, US GEOL SURV PROF PA, V1250, P93; Newman S, 2002, COMPUT GEOSCI-UK, V28, P597, DOI 10.1016/S0098-3004(01)00081-4; Richter FM, 2003, GEOCHIM COSMOCHIM AC, V67, P3905, DOI 10.1016/S0016-7037(03)00174-1; Rust AC, 2004, GEOLOGY, V32, P349, DOI 10.1130/G20388.2; RUTHERFORD MJ, 1993, J GEOPHYS RES, V98, P667; SCANDONE R, 1985, J VOLCANOL GEOTH RES, V23, P239, DOI 10.1016/0377-0273(85)90036-8; Signorelli S, 2000, GEOCHIM COSMOCHIM AC, V64, P2851, DOI 10.1016/S0016-7037(00)00386-0; Stevenson DS, 1998, B VOLCANOL, V60, P307, DOI 10.1007/s004450050234; TAYLOR BE, 1983, NATURE, V306, P541, DOI 10.1038/306541a0; WEBSTER JD, 1989, ECON GEOL, V84, P116, DOI 10.2113/gsecongeo.84.1.116	22	93	93	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2004	306	5699					1167	1169		10.1126/science.1103869	http://dx.doi.org/10.1126/science.1103869			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15486253				2022-12-28	WOS:000225193100043
J	Cochran, ES; Vidale, JE; Tanaka, S				Cochran, ES; Vidale, JE; Tanaka, S			Earth tides can trigger shallow thrust fault earthquakes	SCIENCE			English	Article							STRESS; SEISMICITY	We show a correlation between the occurrence of shallow thrust earthquakes and the occurrence of the strongest tides. The rate of earthquakes varies from the background rate by a factor of 3 with the tidal stress. The highest correlation is found when we assume a coefficient of friction of mu = 0.4 for the crust, although we see good correlation for mu between 0.2 and 0.6. Our results quantify the effect of applied stress on earthquake triggering, a key factor in understanding earthquake nucleation and cascades whereby one earthquake triggers others.	Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; Tohoku Univ, Grad Sch Sci, Dept Geophys, Sendai, Miyagi 9808578, Japan	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Tohoku University	Cochran, ES (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.	cochran@moho.ess.ucla.edu	Vidale, John/H-4965-2011; Cochran, Elizabeth/AAA-8460-2022	Vidale, John/0000-0002-3658-818X; Cochran, Elizabeth/0000-0003-2485-4484				Custodio SIS, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL016991; DIETERICH JH, 1987, TECTONOPHYSICS, V144, P127, DOI 10.1016/0040-1951(87)90012-6; DZIEWONSKI AM, 1981, J GEOPHYS RES, V86, P2825, DOI 10.1029/JB086iB04p02825; Emter D, 1997, LECT NOTES EARTH SCI, V66, P293; Hardebeck JL, 1998, J GEOPHYS RES-SOL EA, V103, P24427, DOI 10.1029/98JB00573; HARTZELL S, 1989, B SEISMOL SOC AM, V79, P1282; Main IG, 1999, GEOPHYS J INT, V139, pF1, DOI 10.1046/j.1365-246x.1999.00004.x; Matsumoto K., 2000, J OCEANOGR, V56, P567, DOI [10.1023/A:1011157212596, 10.1023/A:1011157212596,, DOI 10.1023/A:1011157212596]; Saar MO, 2003, EARTH PLANET SC LETT, V214, P605, DOI 10.1016/S0012-821X(03)00418-7; Stein RS, 1999, NATURE, V402, P605, DOI 10.1038/45144; Stein RS, 2003, SCI AM, V288, P72, DOI 10.1038/scientificamerican0103-72; Tanaka S, 2004, EARTH PLANETS SPACE, V56, P511, DOI 10.1186/BF03352510; Tanaka S, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB001577; TANAKA S, 2002, GEOPHYS RES LETT, V29; Tolstoy M, 2002, GEOLOGY, V30, P503, DOI 10.1130/0091-7613(2002)030<0503:BOTSTC>2.0.CO;2; Vidale JE, 1998, J GEOPHYS RES-SOL EA, V103, P24567, DOI 10.1029/98JB00594; Wilcock WSD, 2001, GEOPHYS RES LETT, V28, P3999, DOI 10.1029/2001GL013370; [No title captured]	18	223	249	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2004	306	5699					1164	1166		10.1126/science.1103961	http://dx.doi.org/10.1126/science.1103961			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15498971				2022-12-28	WOS:000225193100042
J	Lamb, NE; Hassold, TJ				Lamb, NE; Hassold, TJ			Nondisjunction - A view from ringside	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Emory University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Lamb, NE (corresponding author), Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA.							Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Lamb NE, 1997, HUM MOL GENET, V6, P1391, DOI 10.1093/hmg/6.9.1391	2	26	28	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1931	1934		10.1056/NEJMp048118	http://dx.doi.org/10.1056/NEJMp048118			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525719				2022-12-28	WOS:000224851300003
J	Coomarasamy, A; Khan, KS				Coomarasamy, A; Khan, KS			What is the evidence that postgraduate teaching in evidence based medicine changes anything? A systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CRITICAL-APPRAISAL SKILLS; JOURNAL CLUB; CONTROLLED-TRIAL; REAL-TIME; RESIDENTS; CURRICULUM; KNOWLEDGE; CARE; EPIDEMIOLOGY; INSTRUCTION	Objective To evaluate the effects of standalone versus clinically integrated teaching in evidence based medicine on various outcomes in postgraduates. Design Systematic review of randomised and non-randomised controlled trials and before and after comparison studies. Data sources Medline, Embase, ERIC, Cochrane Library, DARE, HTA database, Best Evidence, BEME, and SCI. Study selection 23 studies: four randomised trials, seven non-randomised controlled studies, and 12 before and after comparison studies. 18 studies (including two randomised trials) evaluated a standalone teaching method, and five studies (including two randomised trials) evaluated a clinically integrated teaching method. Main outcome measures Knowledge, critical appraisal skills, attitudes, and behaviour. Results Standalone teaching improved knowledge but not skills, attitudes, or behaviour. Clinically integrated teaching improved knowledge, skills, attitudes, and behaviour. Conclusion Teaching of evidence based medicine should be moved from classrooms to clinical practice to achieve improvements in substantial outcomes.	Birmingham Womens Hosp, Educ Resource Ctr, Birmingham B15 2TG, W Midlands, England	Birmingham Women's Hospital	Coomarasamy, A (corresponding author), Birmingham Womens Hosp, Educ Resource Ctr, Birmingham B15 2TG, W Midlands, England.	arricoomar@blueyonder.co.uk	Khan, Khalid S/AAT-8824-2020	Khan, Khalid S/0000-0001-5084-7312				Bazarian JJ, 1999, ANN EMERG MED, V34, P148, DOI 10.1016/S0196-0644(99)70222-2; Bradley DR, 2002, J MED LIBR ASSOC, V90, P194; CAUDILL TS, 1993, CLIN RES, V41, pA816; Coomarasamy A, 2003, MED TEACH, V25, P77, DOI 10.1080/0142159021000061468; Deshpande Neelima, 2003, Health Info Libr J, V20, P86, DOI 10.1046/j.1471-1842.2003.00422.x; Dwarakanath LS, 2000, HOSP MED, V61, P425, DOI 10.12968/hosp.2000.61.6.1360; Fu CHY, 1999, ACAD PSYCHIATR, V23, P205, DOI 10.1007/BF03340056; GEHLBACH SH, 1980, J MED EDUC, V55, P362; Grad R, 2001, FAM MED, V33, P602; Green ML, 1997, J GEN INTERN MED, V12, P742, DOI 10.1046/j.1525-1497.1997.07159.x; Haines SJ, 2003, J AM COLL SURGEONS, V197, P285, DOI 10.1016/S1072-7515(03)00114-5; HILLSON SD, 1993, CLIN RES, V41, pA559; Ibbotson T, 1998, MED EDUC, V32, P486; Kellum JA, 2000, CRIT CARE MED, V28, P3067, DOI 10.1097/00003246-200008000-00065; Khan K. S., 1999, Journal of Obstetrics and Gynaecology (Abingdon), V19, P231; KITCHENS JM, 1989, J GEN INTERN MED, V4, P384, DOI 10.1007/BF02599686; KNOWLES MS, 1998, TEACHING ASSESSING C, P23; Langkamp D L, 1992, Fam Med, V24, P528; LINZER M, 1988, JAMA-J AM MED ASSOC, V260, P2537, DOI 10.1001/jama.260.17.2537; McGinn T, 2002, ACAD MED, V77, P1150, DOI 10.1097/00001888-200211000-00019; MULVIHILL MN, 1981, MT SINAI J MED, V48, P350; Norman GR, 1998, CAN MED ASSOC J, V158, P177; Ross R, 2003, ACAD MED, V78, P412, DOI 10.1097/00001888-200304000-00019; Sackett D., 2000, EVIDENCE BASED MED P, DOI DOI 10.1136/BMJ.H3089; Sackett DL, 1998, JAMA-J AM MED ASSOC, V280, P1336, DOI 10.1001/jama.280.15.1336; Schoenfeld P, 2000, ACAD MED, V75, P1212, DOI 10.1097/00001888-200012000-00019; SEELIG CB, 1991, J GEN INTERN MED, V6, P330; SEELIG CB, 1993, SOUTH MED J, V86, P780, DOI 10.1097/00007611-199307000-00013; Smith CA, 2000, J GEN INTERN MED, V15, P710, DOI 10.1046/j.1525-1497.2000.91026.x; Taylor R, 2000, MED EDUC, V34, P120, DOI 10.1046/j.1365-2923.2000.00574.x; [No title captured], DOI DOI 10.1002/14651858.CD001270	31	416	428	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	2004	329	7473					1017	1019		10.1136/bmj.329.7473.1017	http://dx.doi.org/10.1136/bmj.329.7473.1017			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514348	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000224852400023
J	Sheldon, TA; Cullum, N; Dawson, D; Lankshear, A; Lowson, K; Watt, I; West, P; Wright, D; Wright, J				Sheldon, TA; Cullum, N; Dawson, D; Lankshear, A; Lowson, K; Watt, I; West, P; Wright, D; Wright, J			What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews	BRITISH MEDICAL JOURNAL			English	Article								Objectives To assess the extent and pattern of implementation of guidance issued by the National Institute for Clinical Excellence (NICE). Design Interrupted time series analysis, review of case notes, survey. and interviews. Setting Acute and primary care trusts in England and Wales. Participants All primary care prescribing, hospital pharmacies: a random sample of 20 acute trusts, 17 mental health trusts, and 21 primary care trusts; and senior clinicians and managers from five acute trusts. Main outcome measures Rates of prescribing and use of procedures and medical devices relative to evidence based guidance. Results 6308 usable patient audit forms were returned. Implementation of NICE guidance varied by trust and by topic. Prescribing of some taxanes for cancer (P<0.002) and orlistat for obesity (P<0.001) significantly increased in line with guidance. Prescribing of drugs for Alzheimer's disease and prophylactic extraction of wisdom teeth showed trends consistent With, but not obviously a consequence of the guidance. Prescribing practice often did not accord with the details of the guidance. No change was apparent in the use of hearing aids, hip prostheses, implantable cardioverter defibrillators, laparoscopic hernia repair, and laparoscopic colorectal cancer surgery after NICE guidance had been issued. Conclusions Implementation of NICE guidance has been variable. Guidance seems more likely to be adopted when there is strong professional support, a stable and convincing evidence base, mid no increased or unfunded costs, in organisations that have established good systems for tracking guidance implementation and where the professionals involved are not isolated. Guidance needs to be clear and reflect the clinical context.	Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; Univ York, York Hlth Econ Consortium, York YO10 5DD, N Yorkshire, England; Bradford Royal Infirm, Bradford BD9 6RJ, W Yorkshire, England	University of York - UK; University of York - UK; University of York - UK; Bradford Royal Infirmary	Sheldon, TA (corresponding author), Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.	tas5@york.ac.uk	Cullum, Nicky A/F-2438-2011; Lankshear, Annette J/C-9953-2010; Sheldon, Trevor/AAK-7088-2021; Wright, John/H-1624-2012; Cullum, Nicky/AAT-5888-2020	Cullum, Nicky A/0000-0003-2631-123X; Sheldon, Trevor/0000-0002-7479-5913; Wright, John/0000-0001-9572-7293; Cullum, Nicky/0000-0003-2631-123X; Lankshear, Annette/0000-0002-2418-3783				Bloor K, 2003, BRIT MED J, V326, P578, DOI 10.1136/bmj.326.7389.578; BOX G, 1984, TIME SERIES ANAL FOR; Brock David M, 1999, RESTRUCTURING PROFES; *DEP HLTH, 1999, FAST ACC MOD TREATM; DILLON A, 2001, INFORMING JUDGMENT C; Fitzgerald L, 2002, HUM RELAT, V55, P1429, DOI 10.1177/001872602128782213; Grimshaw JM, 2004, HLTH TECHNOL ASSESS, V8; MACE S, 2002, PHARM J, V269, P680; Mays N., 1999, QUALITATIVE RES HLTH; McDowall D., 1980, INTERRUPTED TIME SER; McDowall D., 1980, INTERRUPTED TIME SER, V21; Miles M., 2013, QUALITATIVE DATA ANA; PARK RE, 1989, AM J PUBLIC HEALTH, V79, P445, DOI 10.2105/AJPH.79.4.445; Plummer CJ, 2003, HEART, V89, P787, DOI 10.1136/heart.89.7.787; Roger E.M, 2003, DIFFUSION INNOVATION, V5th; Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607; Silverman D., 2017, DOING QUALITATIVE RE, V5th; Strauss A., 1998, BASICS QUALITATIVE R	18	279	281	0	20	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 30	2004	329	7473					999	1003		10.1136/bmj.329.7473.999	http://dx.doi.org/10.1136/bmj.329.7473.999			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514342	Green Accepted, Green Published			2022-12-28	WOS:000224852400015
J	Almeida, VR; Barrios, CA; Panepucci, RR; Lipson, M				Almeida, VR; Barrios, CA; Panepucci, RR; Lipson, M			All-optical control of light on a silicon chip	NATURE			English	Article							WAVE-GUIDE DEVICES; MODULATION; SI	Photonic circuits, in which beams of light redirect the flow of other beams of light, are a long-standing goal for developing highly integrated optical communication components(1-3). Furthermore, it is highly desirable to use silicon - the dominant material in the microelectronic industry - as the platform for such circuits. Photonic structures that bend, split, couple and filter light have recently been demonstrated in silicon(4,5), but the flow of light in these structures is predetermined and cannot be readily modulated during operation. All-optical switches and modulators have been demonstrated with III-V compound semiconductors(6,7), but achieving the same in silicon is challenging owing to its relatively weak nonlinear optical properties. Indeed, all-optical switching in silicon has only been achieved by using extremely high powers(8-15) in large or non-planar structures, where the modulated light is propagating out-of-plane. Such high powers, large dimensions and non-planar geometries are inappropriate for effective on-chip integration. Here we present the experimental demonstration of fast all-optical switching on silicon using highly light-confining structures to enhance the sensitivity of light to small changes in refractive index. The transmission of the structure can be modulated by up to 94% in less than 500 ps using light pulses with energies as low as 25 pJ. These results confirm the recent theoretical prediction(16) of efficient optical switching in silicon using resonant structures.	Cornell Univ, Sch Elect & Comp Engn, Ithaca, NY 14853 USA	Cornell University	Lipson, M (corresponding author), Cornell Univ, Sch Elect & Comp Engn, Ithaca, NY 14853 USA.	lipson@ece.cornell.edu	Barrios, Carlos Angulo/D-8786-2014; Almeida, Vilson R/A-9005-2013; Panepucci, Roberto/A-3356-2015	Barrios, Carlos Angulo/0000-0002-2496-5443; Almeida, Vilson R/0000-0001-9077-2941; Panepucci, Roberto/0000-0002-6792-7711				Almeida VR, 2003, OPT LETT, V28, P1302, DOI 10.1364/OL.28.001302; Barrios CA, 2003, J LIGHTWAVE TECHNOL, V21, P1089, DOI 10.1109/JLT.2003.810090; Cheben P, 2003, P SOC PHOTO-OPT INS, V5117, P147, DOI 10.1117/12.498795; Chin A, 1996, APPL PHYS LETT, V69, P653, DOI 10.1063/1.117795; Cocorullo G, 2000, J NON-CRYST SOLIDS, V266, P1247, DOI 10.1016/S0022-3093(99)00932-1; Hache A, 2000, APPL PHYS LETT, V77, P4089, DOI 10.1063/1.1332823; HENARI FZ, 1995, APPL PHYS LETT, V67, P323, DOI 10.1063/1.115432; Ibrahim TA, 2003, IEEE PHOTONIC TECH L, V15, P36, DOI 10.1109/LPT.2002.805877; Krauss TF, 2003, PHYS STATUS SOLIDI A, V197, P688, DOI 10.1002/pssa.200303117; LEONARD SW, 2001, QUANT EL LAS SCI C P, P159; Liu AS, 2004, NATURE, V427, P615, DOI 10.1038/nature02310; Loncar M, 2000, J LIGHTWAVE TECHNOL, V18, P1402, DOI 10.1109/50.887192; Meindl JD, 2002, IBM J RES DEV, V46, P245, DOI 10.1147/rd.462.0245; Miller DAB, 2000, IEEE J SEL TOP QUANT, V6, P1312, DOI 10.1109/2944.902184; NORMANDIN R, 1989, CAN J PHYS, V67, P412, DOI 10.1139/p89-073; Pardo F, 2003, P SOC PHOTO-OPT INS, V5116, P435, DOI 10.1117/12.499075; Soljacic M, 2003, OPT LETT, V28, P637, DOI 10.1364/OL.28.000637; Soref R. A., 1987, PROC SPIE, V704, P32; SOREF RA, 1989, OSA INT GUID WAV OPT, P86; Stepanov S, 2003, APPL PHYS LETT, V83, P5151, DOI 10.1063/1.1636518; TAN HW, 2004, C LAS EL 2004 OPT SO; Tsang HK, 2002, APPL PHYS LETT, V80, P416, DOI 10.1063/1.1435801; Van V, 2002, IEEE PHOTONIC TECH L, V14, P74, DOI 10.1109/68.974166; VERDEYEN JT, 2000, LASER ELECT, P153; Vlasov YA, 2004, OPT EXPRESS, V12, P1622, DOI 10.1364/OPEX.12.001622; Wada K, 2002, PROC SPIE, V4870, P437, DOI 10.1117/12.475558; Weiss SM, 2003, APPL PHYS LETT, V83, P1980, DOI 10.1063/1.1609249; Yablonovitch E, 2001, SCI AM, V285, P46, DOI 10.1038/scientificamerican1201-46; ZHAO CZ, 1995, APPL PHYS LETT, V67, P2448, DOI 10.1063/1.114603	29	1201	1248	24	476	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1081	1084		10.1038/nature02921	http://dx.doi.org/10.1038/nature02921			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15510144				2022-12-28	WOS:000224730800036
J	Lin, J				Lin, J			Falciform-ligament sign of pneumoperitoneum	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									E Da Hosp, Kaohsiung 824, Taiwan	E-Da Hospital	Lin, J (corresponding author), E Da Hosp, Kaohsiung 824, Taiwan.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					E16	E16		10.1056/ENEJMicm030659	http://dx.doi.org/10.1056/ENEJMicm030659			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509810				2022-12-28	WOS:000224723100011
J	Miller, DH				Miller, DH			Brain atrophy, interferon beta, and treatment trials in multiple sclerosis	LANCET			English	Editorial Material							RELAPSING-REMITTING MS; CEREBRAL ATROPHY; MATTER		UCL, Inst Neurol, Dept Neuroinflammat, NMR Res Unit, London WC1N 3BG, England	University of London; University College London	Miller, DH (corresponding author), UCL, Inst Neurol, Dept Neuroinflammat, NMR Res Unit, London WC1N 3BG, England.	dmiller@saturn.nmr.ion.ucl.ac.uk			Multiple Sclerosis Society [748] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society)		Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Dalton CM, 2004, BRAIN, V127, P1101, DOI 10.1093/brain/awh126; Evangelou N, 2000, ANN NEUROL, V47, P391, DOI 10.1002/1531-8249(200003)47:3<391::AID-ANA20>3.0.CO;2-J; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Jones CK, 2001, NEUROLOGY, V56, pA379; Miller David H, 2004, NeuroRx, V1, P284, DOI 10.1602/neurorx.1.2.284; Miller DH, 2002, BRAIN, V125, P1676, DOI 10.1093/brain/awf177; Molyneux PD, 2000, BRAIN, V123, P2256, DOI 10.1093/brain/123.11.2256; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Rudick RA, 1999, NEUROLOGY, V53, P1698, DOI 10.1212/WNL.53.8.1698; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040	12	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 23	2004	364	9444					1463	1464		10.1016/S0140-6736(04)17285-1	http://dx.doi.org/10.1016/S0140-6736(04)17285-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500870				2022-12-28	WOS:000224645500003
J	Nelson, DL; Gibbs, RA				Nelson, DL; Gibbs, RA			The critical region in trisomy 21	SCIENCE			English	Editorial Material							DOWN-SYNDROME; TS65DN MOUSE; MODEL; PHENOTYPES; BEHAVIOR; MICE		Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Nelson, DL (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	nelson@bcm.tmc.edu						Adams DJ, 2004, NAT GENET, V36, P867, DOI 10.1038/ng1388; Baxter LL, 2000, HUM MOL GENET, V9, P195, DOI 10.1093/hmg/9.2.195; CoussonsRead ME, 1996, BEHAV GENET, V26, P7, DOI 10.1007/BF02361154; KORENBERG JR, 1994, P NATL ACAD SCI USA, V91, P4997, DOI 10.1073/pnas.91.11.4997; Lindsay EA, 1999, NATURE, V401, P379, DOI 10.1038/43900; MCCORMICK MK, 1989, GENOMICS, V5, P325, DOI 10.1016/0888-7543(89)90065-7; Olson LE, 2004, SCIENCE, V306, P687, DOI 10.1126/science.1098992; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; REEVES RH, 1995, NAT GENET, V11, P177, DOI 10.1038/ng1095-177; Sago H, 1998, P NATL ACAD SCI USA, V95, P6256, DOI 10.1073/pnas.95.11.6256	10	28	31	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					619	+		10.1126/science.1105226	http://dx.doi.org/10.1126/science.1105226			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499000				2022-12-28	WOS:000224756700030
J	Peters, A; von Klot, S; Heier, M; Trentinaglia, I; Hormann, A; Wichmann, HE; Lowel, H				Peters, A; von Klot, S; Heier, M; Trentinaglia, I; Hormann, A; Wichmann, HE; Lowel, H		Cooperative Hlth Res Region Augsbu	Exposure to traffic and the onset of myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARTICULATE AIR-POLLUTION; HEART-RATE-VARIABILITY; HEAVY PHYSICAL EXERTION; CASE-CROSSOVER; BLOOD MARKERS; CAR DRIVERS; MORTALITY; RISK; ASSOCIATION; DISEASE	BACKGROUND: An association between exposure to vehicular traffic in urban areas and the exacerbation of cardiovascular disease has been suggested in previous studies. This study was designed to assess whether exposure to traffic can trigger myocardial infarction. METHODS: We conducted a case-crossover study in which cases of myocardial infarction were identified with the use of data from the Cooperative Health Research in the Region of Augsburg Myocardial Infarction Registry in Augsburg, in southern Germany, for the period from February 1999 to July 2001. There were 691 subjects for whom the date and time of the myocardial infarction were known who had survived for at least 24 hours after the event, completed the registry's standardized interview, and provided information on factors that may have triggered the myocardial infarction. Data on subjects' activities during the four days preceding the onset of symptoms were collected with the use of patient diaries. RESULTS: An association was found between exposure to traffic and the onset of a myocardial infarction within one hour afterward (odds ratio, 2.92; 95 percent confidence interval, 2.22 to 3.83; P<0.001). The time the subjects spent in cars, on public transportation, or on motorcycles or bicycles was consistently linked with an increase in the risk of myocardial infarction. Adjusting for the level of exercise on a bicycle or for getting up in the morning changed the estimated effect of exposure to traffic only slightly (odds ratio for myocardial infarction, 2.73; 95 percent confidence interval, 2.06 to 3.61; P<0.001). The subject's use of a car was the most common source of exposure to traffic; nevertheless, there was also an association between time spent on public transportation and the onset of a myocardial infarction one hour later. CONCLUSIONS: Transient exposure to traffic may increase the risk of myocardial infarction in susceptible persons.	GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-87564 Neuherberg, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Hlth Econ, D-87564 Neuherberg, Germany; Univ Munich, Fac Med, Dept Epidemiol, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Peters, A (corresponding author), GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Ingolstadter Landstr 1, D-87564 Neuherberg, Germany.	peters@gsf.de	Heier, Margit/AAT-5280-2020; Peters, Annette/A-6117-2011; Wichmann, Heinz Erich/AAA-5695-2022	Peters, Annette/0000-0001-6645-0985; 				Adams HS, 2001, SCI TOTAL ENVIRON, V279, P29, DOI 10.1016/S0048-9697(01)00723-9; Akiyama T, 2001, NEW ENGL J MED, V345, P391, DOI 10.1056/NEJM200108093450601; BEVAN MAJ, 1991, ENVIRON SCI TECHNOL, V25, P788, DOI 10.1021/es00016a026; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Brook RD, 2002, CIRCULATION, V105, P1534, DOI 10.1161/01.CIR.0000013838.94747.64; FORASTIERE F, 1994, AM J IND MED, V26, P785, DOI 10.1002/ajim.4700260607; Gold DR, 2000, CIRCULATION, V101, P1267, DOI 10.1161/01.CIR.101.11.1267; Hallqvist J, 2000, AM J EPIDEMIOL, V151, P459, DOI 10.1093/oxfordjournals.aje.a010231; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Ising Hartmut, 1999, Noise Health, V1, P37; Liao DP, 1999, ENVIRON HEALTH PERSP, V107, P521, DOI 10.2307/3434393; LOWEL H, 1991, J CLIN EPIDEMIOL, V44, P249, DOI 10.1016/0895-4356(91)90036-9; Maclure M, 2000, ANNU REV PUBL HEALTH, V21, P193, DOI 10.1146/annurev.publhealth.21.1.193; Magari SR, 2001, CIRCULATION, V104, P986, DOI 10.1161/hc3401.095038; Mittleman MA, 1999, CIRCULATION, V99, P2737, DOI 10.1161/01.CIR.99.21.2737; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91, DOI 10.1093/oxfordjournals.aje.a117550; Mittleman MA, 2001, CIRCULATION, V103, P2805; MULLER JE, 1994, J AM COLL CARDIOL, V23, P809, DOI 10.1016/0735-1097(94)90772-2; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; Pekkanen J, 2000, OCCUP ENVIRON MED, V57, P818, DOI 10.1136/oem.57.12.818; Peters A, 2002, LANCET, V360, P1184, DOI 10.1016/S0140-6736(02)11289-X; Peters A, 2001, EUR HEART J, V22, P1198, DOI 10.1053/euhj.2000.2483; Peters A, 2001, CIRCULATION, V103, P2810; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; Pope CA, 1999, AM HEART J, V138, P890, DOI 10.1016/S0002-8703(99)70014-1; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Pope CA, 2004, ENVIRON HEALTH PERSP, V112, P339, DOI 10.1289/ehp.6588; Praml G, 2000, INT ARCH OCC ENV HEA, V73, P209, DOI 10.1007/s004200050029; Rank J, 2001, SCI TOTAL ENVIRON, V279, P131, DOI 10.1016/S0048-9697(01)00758-6; Riediker M, 2004, AM J RESP CRIT CARE, V169, P934, DOI 10.1164/rccm.200310-1463OC; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Schwartz J, 2001, ENVIRON HEALTH PERSP, V109, P405, DOI 10.2307/3434788; VANWIJNEN JH, 1995, INT ARCH OCC ENV HEA, V67, P187, DOI 10.1007/BF00626351; Verrier Richard L., 1996, Cardiology Clinics, V14, P289; Williams JE, 2000, CIRCULATION, V101, P2034, DOI 10.1161/01.CIR.101.17.2034; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302; [No title captured]	38	688	705	0	79	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2004	351	17					1721	1730		10.1056/NEJMoa040203	http://dx.doi.org/10.1056/NEJMoa040203			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863TH	15496621				2022-12-28	WOS:000224585200007
J	Lederman, MM; Veazey, RS; Offord, R; Mosier, DE; Dufour, J; Mefford, M; Piatak, M; Lifson, JD; Salkowitz, JR; Rodriguez, B; Blauvelt, A; Hartley, O				Lederman, MM; Veazey, RS; Offord, R; Mosier, DE; Dufour, J; Mefford, M; Piatak, M; Lifson, JD; Salkowitz, JR; Rodriguez, B; Blauvelt, A; Hartley, O			Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5	SCIENCE			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; HIV-1 INFECTION; PRIMATE LENTIVIRUSES; LANGERHANS CELLS; RANTES ANALOGS; DC-SIGN; CORECEPTOR; INTERNALIZATION; RESISTANCE; RECEPTORS	Topical agents, such as microbicides, that can protect against human immunodeficiency virus (HIV) transmission are urgently needed. Using a chimeric simian/human immunodeficiency virus (SHIV SF162), which is tropic for the chemokine receptor CCR5, we report that topical application of high doses of PSC-RANTES, an amino terminus-modified analog of the chemokine RANTES, provided potent protection against vaginal challenge in rhesus macaques. These experimental findings have potentially important implications for understanding vaginal transmission of HIV and the design of strategies for its prevention.	Case Western Reserve Univ, Univ Hosp, Dept Med, Cleveland, OH 44106 USA; Tulane Natl Primate Res Ctr, Covington, LA 70433 USA; Univ Geneva, Fac Med, Dept Struct Biol & Bioinformat, CH-1211 Geneva 4, Switzerland; Scripps Res Inst, La Jolla, CA 92037 USA; NCI, AIDS Vaccine Program, SAIC Frederick Inc, Frederick, MD 21702 USA; NCI, Dermatol Branch, Bethesda, MD 20892 USA	Case Western Reserve University; University Hospitals of Cleveland; Tulane University; University of Geneva; Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lederman, MM (corresponding author), Case Western Reserve Univ, Univ Hosp, Dept Med, 2061 Cornell Rd, Cleveland, OH 44106 USA.	MXL6@case.edu	Rodriguez, Benigno/C-3365-2009	Rodriguez, Benigno/0000-0001-9736-7957; Mefford, Megan/0000-0003-4441-7134	NCI NIH HHS [N01-CO-124000] Funding Source: Medline; NIAID NIH HHS [AI 51649, AI 36219] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI051649, P30AI036219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Clapham PR, 2002, J GEN VIROL, V83, P1809, DOI 10.1099/0022-1317-83-8-1809; Davis CW, 2004, J EXP MED, V199, P1037, DOI 10.1084/jem.20040426; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; Hartley O, 2003, J VIROL, V77, P6637, DOI 10.1128/JVI.77.12.6637-6644.2003; HARTLEY O, UNPUB; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kawamura T, 2000, J EXP MED, V192, P1491, DOI 10.1084/jem.192.10.1491; Kawamura T, 2003, P NATL ACAD SCI USA, V100, P8401, DOI 10.1073/pnas.1432450100; Lifson JD, 2001, J VIROL, V75, P10187, DOI 10.1128/JVI.75.21.10187-10199.2001; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Miller CJ, 2003, MICROBES INFECT, V5, P59, DOI 10.1016/S1286-4579(02)00056-4; Mosier DE, 1999, J VIROL, V73, P3544, DOI 10.1128/JVI.73.5.3544-3550.1999; MOSIER DE, UNPUB; Pastore C, 2003, ANTIMICROB AGENTS CH, V47, P509, DOI 10.1128/AAC.47.2.509-517.2003; Pope M, 2003, NAT MED, V9, P847, DOI 10.1038/nm0703-847; Sabbe R, 2001, J VIROL, V75, P661, DOI 10.1128/JVI.75.2.661-671.2001; Salkowitz JR, 2001, CLIN IMMUNOL, V98, P200, DOI 10.1006/clim.2000.4969; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Torre VS, 2000, J VIROL, V74, P4868, DOI 10.1128/JVI.74.10.4868-4876.2000; Tsai CC, 2004, AIDS RES HUM RETROV, V20, P11, DOI 10.1089/088922204322749459; Turville SG, 2001, BLOOD, V98, P2482, DOI 10.1182/blood.V98.8.2482; Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833; Veazey RS, 2003, J EXP MED, V198, P1551, DOI 10.1084/jem.20031266; VEAZEY RS, UNPUB; Wu L, 2002, P NATL ACAD SCI USA, V99, P1568, DOI 10.1073/pnas.032654399; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	33	304	324	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					485	487		10.1126/science.1099288	http://dx.doi.org/10.1126/science.1099288			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486300				2022-12-28	WOS:000224626500053
J	McClure, SM; Laibson, DI; Loewenstein, G; Cohen, JD				McClure, SM; Laibson, DI; Loewenstein, G; Cohen, JD			Separate neural systems value immediate and delayed monetary rewards	SCIENCE			English	Article							FMRI; PREDICTION; BRAIN; ANTICIPATION; CIRCUITRY; TIME	When humans are offered the choice between rewards available at different points in time, the relative values of the options are discounted according to their expected delays until delivery. Using functional magnetic resonance imaging, we examined the neural correlates of time discounting while subjects made a series of choices between monetary reward options that varied by delay to delivery. We demonstrate that two separate systems are involved in such decisions. Parts of the limbic system associated with the midbrain dopamine system, including paralimbic cortex, are preferentially activated by decisions involving immediately available rewards. In contrast, regions of the lateral prefrontal. cortex and posterior parietal cortex are engaged uniformly by intertemporal choices irrespective of delay. Furthermore, the relative engagement of the two systems is directly associated with subjects' choices, with greater relative fronto-parietal activity when subjects choose longer term options.	Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA; Princeton Univ, Ctr Study Brain Mind & Behav, Princeton, NJ 08544 USA; Harvard Univ, Dept Econ, Cambridge, MA 02138 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA; Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA	Princeton University; Princeton University; Harvard University; National Bureau of Economic Research; Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	McClure, SM (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.	smcclure@princeton.edu	Laibson, David/AAA-7362-2022; Loewenstein, George/G-7616-2014	Loewenstein, George/0000-0003-2790-0474	NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH065214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG005842] Funding Source: NIH RePORTER; NIA NIH HHS [AG05842] Funding Source: Medline; NIMH NIH HHS [MH065214, MH132804] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aharon I, 2001, NEURON, V32, P537, DOI 10.1016/S0896-6273(01)00491-3; AINSLIE G, 1975, PSYCHOL BULL, V82, P463, DOI 10.1037/h0076860; Ainslie G., 1992, PICOECONOMICS; Angeletos GM, 2001, J ECON PERSPECT, V15, P47, DOI 10.1257/jep.15.3.47; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Benabou R, 2002, ECON LETT, V77, P419, DOI 10.1016/S0165-1765(02)00158-1; BIEDERMAN J, 2002, J ATTEN DISORD, V6, pS1; Breiter HC, 1999, ANN NY ACAD SCI, V877, P523, DOI 10.1111/j.1749-6632.1999.tb09287.x; Dehaene S, 1998, TRENDS NEUROSCI, V21, P355, DOI 10.1016/S0166-2236(98)01263-6; Elster J, 1979, ULYSSES SIRENS STUDI; Frederick S, 2002, J ECON LIT, V40, P351, DOI 10.1257/002205102320161311; Giordano LA, 2002, PSYCHOPHARMACOLOGY, V163, P174, DOI 10.1007/s00213-002-1159-2; Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872; Herrnstein R. J., 1997, MATCHING LAW PAPERS; HOEBEL BG, 1985, AM J CLIN NUTR, V42, P1133, DOI 10.1093/ajcn/42.5.1133; Kagel John H., 1995, EC CHOICE THEORY EXP; Knutson B, 2001, NEUROREPORT, V12, P3683, DOI 10.1097/00001756-200112040-00016; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; KOOPMANS TC, 1964, ECONOMETRICA, V32, P82, DOI 10.2307/1913736; Laibson D, 1997, Q J ECON, V112, P443, DOI 10.1162/003355397555253; Loewenstein G, 1996, ORGAN BEHAV HUM DEC, V65, P272, DOI 10.1006/obhd.1996.0028; MACMILLAN M, 1992, BRAIN COGNITION, V19, P72, DOI 10.1016/0278-2626(92)90038-N; McClure SM, 2003, NEURON, V38, P339, DOI 10.1016/S0896-6273(03)00154-5; Meck WH, 2002, BRAIN COGNITION, V48, P195, DOI 10.1006/brcg.2001.1313; Metcalfe J, 1999, PSYCHOL REV, V106, P3, DOI 10.1037/0033-295X.106.1.3; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Montague PR, 2002, NEURON, V36, P265, DOI 10.1016/S0896-6273(02)00974-1; O'Donoghue T, 1999, AM ECON REV, V89, P103, DOI 10.1257/aer.89.1.103; Ochsner KN, 2002, J COGNITIVE NEUROSCI, V14, P1215, DOI 10.1162/089892902760807212; OLDS J, 1958, SCIENCE, V127, P315, DOI 10.1126/science.127.3294.315; PHELPS ES, 1968, REV ECON STUD, V35, P185, DOI 10.2307/2296547; Rachlin H., 2004, SCI SELF CONTROL, DOI 10.4159/9780674042513; RACHLIN H, 1989, JUDGMENT DECISION CH, pCH7; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Seymour B, 2004, NATURE, V429, P664, DOI 10.1038/nature02581; SHEFRIN HM, 1988, ECON INQ, V26, P609, DOI 10.1111/j.1465-7295.1988.tb01520.x; Smith Adam, 1966, THEORY MORAL SENTIME; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Tanaka SC, 2004, NAT NEUROSCI, V7, P887, DOI 10.1038/nn1279; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065	41	1890	1947	17	354	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					503	507		10.1126/science.1100907	http://dx.doi.org/10.1126/science.1100907			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486304				2022-12-28	WOS:000224626500058
J	Lu, XW; le Noble, F; Yuan, L; Jiang, QJ; de Lafarge, B; Sugiyama, D; Breant, C; Claes, F; De Smet, F; Thomas, JL; Autiero, M; Carmeliet, P; Tessier-Lavigne, M; Eichmann, A				Lu, XW; le Noble, F; Yuan, L; Jiang, QJ; de Lafarge, B; Sugiyama, D; Breant, C; Claes, F; De Smet, F; Thomas, JL; Autiero, M; Carmeliet, P; Tessier-Lavigne, M; Eichmann, A			The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system	NATURE			English	Article							C-ELEGANS; ENDOTHELIAL-CELLS; CARDIOVASCULAR DEVELOPMENT; BRANCHING MORPHOGENESIS; EXPRESSION PATTERNS; AXON OUTGROWTH; MUTANT MICE; DCC; FAMILY; UNC-5	Blood vessels and nerves are complex, branched structures that share a high degree of anatomical similarity. Guidance of vessels and nerves has to be exquisitely regulated to ensure proper wiring of both systems. Several regulators of axon guidance have been identified and some of these are also expressed in endothelial cells; however, the extent to which their guidance functions are conserved in the vascular system is still incompletely understood. We show here that the repulsive netrin receptor UNC5B is expressed by endothelial tip cells of the vascular system. Disruption of the Unc5b gene in mice, or of Unc5b or netrin-1a in zebrafish, leads to aberrant extension of endothelial tip cell filopodia, excessive vessel branching and abnormal navigation. Netrin-1 causes endothelial filopodial retraction, but only when UNC5B is present. Thus, UNC5B functions as a repulsive netrin receptor in endothelial cells controlling morphogenesis of the vascular system.	Coll France, INSERM, U36, F-75005 Paris, France; Stanford Univ, Howard Hughes Med Inst, Dept Biol Sci, Stanford, CA 94305 USA; Univ Paris 06, CNRS, UMR 7622, F-75252 Paris, France; Univ Louvain VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Univ Paris 06, Hop La Pitie Salpetriere, INSERM,U495, IFR Neurosci, F-75651 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Howard Hughes Medical Institute; Stanford University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Flanders Institute for Biotechnology (VIB); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Tessier-Lavigne, M (corresponding author), Coll France, INSERM, U36, 11 Pl Marcelin Berthelot, F-75005 Paris, France.	tessier-lavigne.marc@gene.com; anne.eichmann@college-de.france.fr	le Noble, Ferdinand/L-7867-2017; Carmeliet, Peter/AAQ-5140-2020; De Smet, Frederik/Q-7808-2016	Carmeliet, Peter/0000-0001-7961-1821; De Smet, Frederik/0000-0002-6669-3335				Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Barallobre MJ, 2000, DEVELOPMENT, V127, P4797; Barrett C, 2001, MECH DEVELOP, V106, P163, DOI 10.1016/S0925-4773(01)00415-4; Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Cohen-Cory S, 2002, NAT NEUROSCI, V5, P926, DOI 10.1038/nn1002-926; Corset V, 2000, NATURE, V407, P747, DOI 10.1038/35037600; Deiner MS, 1997, NEURON, V19, P575, DOI 10.1016/S0896-6273(00)80373-6; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Engelkamp D, 2002, MECH DEVELOP, V118, P191, DOI 10.1016/S0925-4773(02)00248-4; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gitler AD, 2004, DEV CELL, V7, P107, DOI 10.1016/j.devcel.2004.06.002; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Jiang Y, 2003, DEV BIOL, V258, P364, DOI 10.1016/S0012-1606(03)00136-2; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Keleman K, 2001, NEURON, V32, P605, DOI 10.1016/S0896-6273(01)00505-0; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Koch M, 2000, J CELL BIOL, V151, P221, DOI 10.1083/jcb.151.2.221; Lauderdale JD, 1997, MOL CELL NEUROSCI, V9, P293, DOI 10.1006/mcne.1997.0624; Lawson ND, 2002, NAT REV GENET, V3, P674, DOI 10.1038/nrg888; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Leighton PA, 2001, NATURE, V410, P174, DOI 10.1038/35065539; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Liu Y, 2004, CURR BIOL, V14, P897, DOI 10.1016/j.cub.2004.05.020; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Moyon D, 2001, DEVELOPMENT, V128, P3359; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Przyborski SA, 1998, DEVELOPMENT, V125, P41; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shirasaki R, 1996, NEURON, V17, P1079, DOI 10.1016/S0896-6273(00)80241-X; Stalmans I, 2003, NAT MED, V9, P173, DOI 10.1038/nm819; Sugiyama D, 2003, BLOOD, V101, P4733, DOI 10.1182/blood-2002-09-2799; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Torres-Vazquez J, 2004, DEV CELL, V7, P117, DOI 10.1016/j.devcel.2004.06.008; Van Der Zwaag B, 2002, DEV DYNAM, V225, P336, DOI 10.1002/dvdy.10159; Wang H, 1999, J NEUROSCI, V19, P4938; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Westerfield M, 1994, ZEBRAFISH BOOK GUIDE; Yin Y, 2000, MECH DEVELOP, V96, P115, DOI 10.1016/S0925-4773(00)00369-5; Yuan L, 2002, DEVELOPMENT, V129, P4797	48	388	420	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2004	432	7014					179	186		10.1038/nature03080	http://dx.doi.org/10.1038/nature03080			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15510105				2022-12-28	WOS:000225020200036
J	Saito, Y; Takao, H; Tani, T; Nonoyama, T; Takatori, K; Homma, T; Nagaya, T; Nakamura, M				Saito, Y; Takao, H; Tani, T; Nonoyama, T; Takatori, K; Homma, T; Nagaya, T; Nakamura, M			Lead-free piezoceramics	NATURE			English	Article							TEMPLATED GRAIN-GROWTH; FERROELECTRIC CERAMICS; BISMUTH TITANATE; PIEZOELECTRIC CERAMICS; PREFERRED ORIENTATION; NIOBATES; SYSTEM; OXIDES	Lead has recently been expelled from many commercial applications and materials ( for example, from solder, glass and pottery glaze) owing to concerns regarding its toxicity. Lead zirconium titanate (PZT) ceramics are high-performance piezoelectric materials, which are widely used in sensors, actuators and other electronic devices; they contain more than 60 weight per cent lead. Although there has been a concerted effort to develop lead-free piezoelectric ceramics, no effective alternative to PZT has yet been found(1-14). Here we report a lead-free piezoelectric ceramic with an electric-field-induced strain comparable to typical actuator-grade PZT. We achieved this through the combination of the discovery of a morphotropic phase boundary in an alkaline niobate-based perovskite solid solution, and the development of a processing route leading to highly [001] textured polycrystals. The ceramic exhibits a piezoelectric constant d(33) ( the induced charge per unit force applied in the same direction) of above 300 picocoulombs per newton (pCN(-1)), and texturing the material leads to a peak d(33) of 416 pCN(-1). The textured material also exhibits temperature-independent field-induced strain characteristics.	Toyota Cent Res & Dev Labs Inc, Aichi 4801192, Japan; DENSO Corp, Aichi 4488861, Japan	Toyota Central R&D Labs Inc; DENSO	Saito, Y (corresponding author), Toyota Cent Res & Dev Labs Inc, Aichi 4801192, Japan.	ysaito@mosk.tytlabs.co.jp	Tani, Toshihiko/D-5810-2012; Ye, Shukai/A-2089-2009					AURIVILLIUS B, 1950, ARK KEMI, V1, P499; BRAHMAROUTU B, 1996, P 10 IEEE INT S APPL, V2, P883; BUHRER CF, 1962, J CHEM PHYS, V36, P798, DOI 10.1063/1.1732613; COHEN RE, 1992, NATURE, V358, P136, DOI 10.1038/358136a0; DUNGAN RH, 1965, J AM CERAM SOC, V48, P601, DOI 10.1111/j.1151-2916.1965.tb14682.x; HAERTLING GH, 1967, J AM CERAM SOC, V50, P329, DOI 10.1111/j.1151-2916.1967.tb15121.x; Haertling GH, 1999, J AM CERAM SOC, V82, P797, DOI 10.1111/j.1151-2916.1999.tb01840.x; Hellwege K. N., 1981, CRYSTAL SOLID STATE, V16a; Horn JA, 1999, J AM CERAM SOC, V82, P921, DOI 10.1111/j.1151-2916.1999.tb01854.x; JAEGER RE, 1962, J AM CERAM SOC, V45, P209, DOI 10.1111/j.1151-2916.1962.tb11127.x; JAFFE B, 1955, J RES NAT BUR STAND, V55, P239, DOI 10.6028/jres.055.028; Jaffe B, 1971, PIEZOELECTRIC CERAMI; KIMURA T, 1989, J AM CERAM SOC, V72, P85, DOI 10.1111/j.1151-2916.1989.tb05958.x; LOTGERING FK, 1959, J INORG NUCL CHEM, V9, P113, DOI 10.1016/0022-1902(59)80070-1; MITSUI T, 1990, CRYSTAL SOLID STAT S, V28; NITTA T, 1968, J AM CERAM SOC, V51, P626, DOI 10.1111/j.1151-2916.1968.tb12633.x; SAITO Y, 1995, JPN J APPL PHYS 1, V34, P5313, DOI 10.1143/JJAP.34.5313; Saito Y, 1996, JPN J APPL PHYS 1, V35, P5168, DOI 10.1143/JJAP.35.5168; Saito Y, 1997, JPN J APPL PHYS 1, V36, P5963, DOI 10.1143/JJAP.36.5963; SCOTT BA, 1968, MATER RES BULL, V3, P831, DOI 10.1016/0025-5408(68)90100-1; Sugawara T, 2003, CERAM TRANS, V136, P389; Takenaka T, 1999, KEY ENG MAT, V157-1, P57, DOI 10.4028/www.scientific.net/KEM.157-158.57; TAKENAKA T, 1980, JPN J APPL PHYS, V19, P31, DOI 10.1143/JJAP.19.31; TAKENAKA T, 2003, 11 US JAP SEM DIEL P, P237; Takeuchi T, 1999, JPN J APPL PHYS 1, V38, P5553, DOI 10.1143/JJAP.38.5553; Tani T, 1998, J KOREAN PHYS SOC, V32, pS1217; WATANABE H, 1991, J AM CERAM SOC, V74, P139, DOI 10.1111/j.1151-2916.1991.tb07309.x; WOOD EA, 1951, ACTA CRYSTALLOGR, V4, P353, DOI 10.1107/S0365110X51001112; Zhang SJ, 2003, APPL PHYS LETT, V83, P3150, DOI 10.1063/1.1619207; [No title captured]	30	4352	4558	90	2371	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	2004	432	7013					84	87		10.1038/nature03028	http://dx.doi.org/10.1038/nature03028			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15516921				2022-12-28	WOS:000224854900043
J	Challine, D; Pellegrin, B; Bouvier-Alias, M; Rigot, P; Laperche, L; Pawlotsky, JM				Challine, D; Pellegrin, B; Bouvier-Alias, M; Rigot, P; Laperche, L; Pawlotsky, JM			HIV and hepatitis C virus RNA in seronegative organ and tissue donors	LANCET			English	Article							HCV	The objective of our study was to determine whether nucleic acid testing could detect HIV RNA or hepatitis C virus (HCV) RNA in a large series of seronegative organ and tissue donors, and whether this technique should be routinely used to improve viral safety of grafts. We studied 2236 organ donors, 636 tissue donors, and 177 cornea donors. We identified five HCV RNA-positive donors in 2119 HCV-seronegative organ donors, and one HCV RNA-positive donor in 631 HCV-seronegative tissue donors. No HIV-seronegative, HIV RNA-positive donor was identified. Our data suggest that routine nucleic acid testing of organ and tissue donors might increase viral safety in transplantation.	Univ Paris 12, Hop Henri Mondor, Serv Virol,INSERM,U635, Viral Emergency & Organ Tissue & Cell Donoe Scree, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Pawlotsky, JM (corresponding author), Univ Paris 12, Hop Henri Mondor, Serv Virol,INSERM,U635, Viral Emergency & Organ Tissue & Cell Donoe Scree, 51 Ave Marechal Lattre Tassigny, F-94010 Creteil, France.	jean-michel.pawlotsky@hmn.aphp.fr	Bouvier-Alias, Magali/S-5631-2018; Challine, Dominique/U-2652-2018; Pawlotsky, Jean-Michel/R-8159-2018	Bouvier-Alias, Magali/0000-0003-1590-5980; Pawlotsky, Jean-Michel/0000-0003-0745-7559				CIESLAK PR, 2003, MMWR-MORBID MORTAL W, V52, P273; EASTLUND T, 1995, CELL TRANSPLANT, V4, P455, DOI 10.1016/0963-6897(95)00035-V; Jackson BR, 2003, TRANSFUSION, V43, P721, DOI 10.1046/j.1537-2995.2003.00392.x; Lefrere JJ, 1997, TRANSFUSION, V37, P565, DOI 10.1046/j.1537-2995.1997.37597293892.x; Lelie PN, 2002, TRANSFUSION, V42, P527, DOI 10.1046/j.1537-2995.2002.00101.x	5	25	25	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	2004	364	9445					1611	1612		10.1016/S0140-6736(04)17315-7	http://dx.doi.org/10.1016/S0140-6736(04)17315-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866IQ	15519632				2022-12-28	WOS:000224767600027
J	Fang, S; Bagtharia, R; Kumar, R; Costeloe, KL; Bush, A; Millar, MR; Adams, GGW				Fang, S; Bagtharia, R; Kumar, R; Costeloe, KL; Bush, A; Millar, MR; Adams, GGW			Pneumatocoele and conjunctivitis in a newborn	LANCET			English	Editorial Material									Homerton Univ Hosp Fdn Trust, Neonatol Unit, London E9 6SR, England; Royal Brompton Hosp NHS Trust, London, England; Barts & London NHS Trust, London, England; Moorfields Eye Hosp, London, England	Royal Brompton Hospital; Barts Health NHS Trust; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust	Fang, S (corresponding author), Homerton Univ Hosp Fdn Trust, Neonatol Unit, London E9 6SR, England.	Swee.Fang@homerton.nhs.ok							0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	2004	364	9445					1610	1610		10.1016/S0140-6736(04)17314-5	http://dx.doi.org/10.1016/S0140-6736(04)17314-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866IQ	15519631				2022-12-28	WOS:000224767600026
J	Krug, EG				Krug, EG			Injury surveillance is key to preventing injuries	LANCET			English	Editorial Material									WHO, Dept Injuries & Violence Prevent, CH-1211 Geneva OK, Switzerland	World Health Organization	Krug, EG (corresponding author), WHO, Dept Injuries & Violence Prevent, CH-1211 Geneva OK, Switzerland.	kruge@who.int						*AD HOC COMM HLTH, 1996, TDRGEN961 WHO AD HOC; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Holder Y., 2001, INJURY SURVEILLANCE; Ichikawa M, 2003, ACCIDENT ANAL PREV, V35, P183, DOI 10.1016/S0001-4575(01)00102-6; Peden M, 2004, WORLD REP ROAD TRAFF; Sethi D., 2004, GUIDELINES CONDUCTIN; Vyrostek Sara B., 2004, Morbidity and Mortality Weekly Report, V53, P1; World Health Organization, 2000, INJ LEAD CAUS GLOB B; World Health Organization, 2002, WORLD REPORT VIOLENC; *WORLD HLTH ASS, 2003, 5624 WHA WHO; *WORLD HLTH ASS, 2004, 5710 WHA WHO	11	56	60	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	2004	364	9445					1563	1566		10.1016/S0140-6736(04)17328-5	http://dx.doi.org/10.1016/S0140-6736(04)17328-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866IQ	15519616				2022-12-28	WOS:000224767600007
J	Lockwood, DNJ; Armstrong, M; Grant, AD				Lockwood, DNJ; Armstrong, M; Grant, AD			Integrating evidence based medicine into routine clinical practice: seven years' experience at the Hospital for Tropical Diseases, London	BRITISH MEDICAL JOURNAL			English	Article								Problem Introduction and evaluation of evidence based medicine (EBM) into routine hospital practice. Strategy for change Routine EBM meetings introduced in 1997. Design Review of outcomes of meetings from 1997 to 2004, focusing on their effect on clinical practice. Setting Referral centre for tropical and domestic infectious diseases. Key measure for improvement Outcome of meetings, classified as resulting in a change in practice; confirmation or clarification of existing practice; identification of a need for more evidence; and outcome unclear. Effects of change Examples include a change from inpatient to day case treatment of New World cutaneous leishmaniasis; development of guidelines on the treatment of coinfection with visceral leishmaniasis and HIV; and identification of the need for more data on the efficacy and toxicity of atovaquone-proguanil (Malarone) compared with quinine plus sulfadoxine-pyrimethamine (Fansidar) in the treatment of uncomplicated falciparum malaria, which resulted in a clinical trial being set up. Lessons learnt Incorporation of EBM meetings into our routine practice has resulted in treatment guidelines being more closely based on published evidence and improvements to care of patients. Written summaries of the meetings are important to facilitate change.	UCL Hosp NHS Trust, Hosp Trop Dis, London WC1E 6AU, England	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; University College London	Grant, AD (corresponding author), UCL Hosp NHS Trust, Hosp Trop Dis, Mortimer Market Ctr, London WC1E 6AU, England.	alison.grant@lshtm.ac.uk							0	14	14	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 30	2004	329	7473					1020	1023		10.1136/bmj.329.7473.1020	http://dx.doi.org/10.1136/bmj.329.7473.1020			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514349	Green Published, Green Accepted			2022-12-28	WOS:000224852400026
J	Doebeli, M; Hauert, C; Killingback, T				Doebeli, M; Hauert, C; Killingback, T			The evolutionary origin of cooperators and defectors	SCIENCE			English	Article							CONTINUOUS PRISONERS-DILEMMA	Coexistence of cooperators and defectors is common in nature, yet the evolutionary origin of such social diversification is unclear. Many models have been studied on the basis of the assumption that benefits of cooperative acts only accrue to others. Here, we analyze the continuous snowdrift game, in which cooperative investments are costly but yield benefits to others as well as to the cooperator. Adaptive dynamics of investment levels often result in evolutionary diversification from initially uniform populations to a stable state in which cooperators making large investments coexist with defectors who invest very little. Thus, when individuals benefit from their own actions, large asymmetries in cooperative investments can evolve.	Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Math, Vancouver, BC V6T 1Z4, Canada; Coll William & Mary, Dept Math, Williamsburg, VA 23187 USA	University of British Columbia; University of British Columbia; William & Mary	Doebeli, M (corresponding author), Univ British Columbia, Dept Zool, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.	doebeli@zoology.ubc.ca	Hauert, Christoph/E-5369-2011; Doebeli, Michael/D-5391-2012	Hauert, Christoph/0000-0002-1239-281X; 				AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Clutton-Brock TH, 1999, SCIENCE, V284, P1640, DOI 10.1126/science.284.5420.1640; Dieckmann U, 1996, J MATH BIOL, V34, P579, DOI 10.1007/BF02409751; Doebeli M, 1998, P NATL ACAD SCI USA, V95, P8676, DOI 10.1073/pnas.95.15.8676; Dugatkin L.A., 1997, COOPERATION ANIMALS; Frank, 1998, FDN SOCIAL EVOLUTION; Geritz SAH, 1998, EVOL ECOL, V12, P35, DOI 10.1023/A:1006554906681; GREIG D, 2004, BIOL LETT, V217, P525; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Hauert C, 2004, NATURE, V428, P643, DOI 10.1038/nature02360; Hauert C, 2002, SCIENCE, V296, P1129, DOI 10.1126/science.1070582; HOEKSTRA RF, 1980, J THEOR BIOL, V87, P785, DOI 10.1016/0022-5193(80)90117-4; Hofbauer J, 1998, EVOLUTIONARY GAMES P; Huang A. S., 1977, COMPREHENSIVE VIROLO, V10, P73; Killingback T, 2002, AM NAT, V160, P421, DOI 10.1086/342070; MAIRE N, 2001, SELECTION, V2, P119, DOI DOI 10.1556/SELECT.2.2001.1-2.9; Metz J. A. J., 1996, STOCHASTIC SPATIAL S, P183; Nowak MA, 2004, SCIENCE, V303, P793, DOI 10.1126/science.1093411; Nowak MA, 1998, NATURE, V393, P573, DOI 10.1038/31225; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; Packer C, 1997, SCI AM, V276, P52, DOI 10.1038/scientificamerican0597-52; PITCHER T, 1992, NETH J ZOOL, V42, P371, DOI 10.1163/156854291X00397; SMITH JM, 1973, NATURE, V246, P15, DOI 10.1038/246015a0; Sober E., 1998, OTHERS EVOLUTION PSY; Sugden R, 1986, EC RIGHTS COOPERATIO; Szathmary E, 1995, MAJOR TRANSITIONS EV; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; Turner PE, 2003, AM NAT, V161, P497, DOI 10.1086/367880; Wahl LM, 1999, J THEOR BIOL, V200, P307, DOI 10.1006/jtbi.1999.0996	29	225	228	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					859	862		10.1126/science.1101456	http://dx.doi.org/10.1126/science.1101456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514155	Green Submitted			2022-12-28	WOS:000224969400043
J	Abbamonte, P; Blumberg, G; Rusydi, A; Gozar, A; Evans, PG; Siegrist, T; Venema, L; Eisaki, H; Isaacs, ED; Sawatzky, GA				Abbamonte, P; Blumberg, G; Rusydi, A; Gozar, A; Evans, PG; Siegrist, T; Venema, L; Eisaki, H; Isaacs, ED; Sawatzky, GA			Crystallization of charge holes in the spin ladder of Sr14Cu24O41	NATURE			English	Article							DOPED HOLES; SUPERCONDUCTIVITY; WAVE	Determining the nature of the electronic phases that compete with superconductivity in high-transition-temperature (high-T-c) superconductors is one of the deepest problems in condensed matter physics. One candidate is the 'stripe' phase(1-3), in which the charge carriers ( holes) condense into rivers of charge that separate regions of antiferromagnetism. A related but lesser known system is the 'spin ladder', which consists of two coupled chains of magnetic ions forming an array of rungs. A doped ladder can be thought of as a high-T-c material with lower dimensionality, and has been predicted to exhibit both superconductivity(4-6) and an insulating 'hole crystal'(4,7,8) phase in which the carriers are localized through many-body interactions. The competition between the two resembles that believed to operate between stripes and superconductivity in high-T-c materials(9). Here we report the existence of a hole crystal in the doped spin ladder of Sr14Cu24O41 using a resonant X-ray scattering technique(10). This phase exists without a detectable distortion in the structural lattice, indicating that it arises from many-body electronic effects. Our measurements confirm theoretical predictions(4,7,8), and support the picture that proximity to charge ordered states is a general property of superconductivity in copper oxides.	Brookhaven Natl Lab, Natl Synchrotron Light Source, Upton, NY 11973 USA; SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA; Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; Univ Groningen, NL-9747 AG Groningen, Netherlands; Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Wisconsin, Dept Mat Sci & Engn, Madison, WI 53706 USA; AIST, Nanoelectr Res Inst, Tsukuba, Ibaraki 3058568, Japan; Argonne Natl Lab, Ctr Nanoscale Mat, Argonne, IL 60439 USA; Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z1, Canada	State University of New York (SUNY) System; United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Alcatel-Lucent; Lucent Technologies; AT&T; University of Groningen; University of Illinois System; University of Illinois Urbana-Champaign; University of Wisconsin System; University of Wisconsin Madison; National Institute of Advanced Industrial Science & Technology (AIST); United States Department of Energy (DOE); Argonne National Laboratory; University of British Columbia	Abbamonte, P (corresponding author), Brookhaven Natl Lab, Natl Synchrotron Light Source, Upton, NY 11973 USA.	abbamonte@bnl.gov	Evans, Paul G/A-9260-2009; Siegrist, Theo/R-3855-2019; Eisaki, Hiroshi/F-6317-2018; Sawatzky, George A/D-2997-2012; Rusydi, Andrivo/I-1849-2016	Evans, Paul G/0000-0003-0421-6792; Siegrist, Theo/0000-0001-5368-1442; Eisaki, Hiroshi/0000-0002-8299-6416; Rusydi, Andrivo/0000-0001-8054-3934; Blumberg, Girsh/0000-0003-0388-8327				Abbamonte P, 2002, SCIENCE, V297, P581, DOI 10.1126/science.1070903; Blumberg G, 2002, SCIENCE, V297, P584, DOI 10.1126/science.1070481; Carr ST, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.195121; CHEN CT, 1992, PHYS REV LETT, V68, P2543, DOI 10.1103/PhysRevLett.68.2543; Cox GR, 1998, J PALLIATIVE CARE, V14, P57, DOI 10.1177/082585979801400113; DAGOTTO E, 1992, PHYS REV B, V45, P5744, DOI 10.1103/PhysRevB.45.5744; Dagotto E, 1996, SCIENCE, V271, P618, DOI 10.1126/science.271.5249.618; Durr HA, 1999, SCIENCE, V284, P2166, DOI 10.1126/science.284.5423.2166; Etrillard J, 2004, PHYSICA C, V403, P290, DOI 10.1016/j.physc.2004.01.003; Fukuda T, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.012104; Gorshunov B, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.060508; Gruner G., 1994, DENSITY WAVES SOLIDS; Hiroi Z, 1996, PHYS REV B, V54, P15849, DOI 10.1103/PhysRevB.54.15849; KAO C, 1990, PHYS REV LETT, V65, P373, DOI 10.1103/PhysRevLett.65.373; Kitano H, 2001, EUROPHYS LETT, V56, P434, DOI 10.1209/epl/i2001-00537-2; LOW U, 1994, PHYS REV LETT, V72, P1918, DOI 10.1103/PhysRevLett.72.1918; Matsuda M, 1997, PHYS REV B, V56, P14499, DOI 10.1103/PhysRevB.56.14499; Motoyama N, 1997, PHYS REV B, V55, pR3386, DOI 10.1103/PhysRevB.55.R3386; Nucker N, 2000, PHYS REV B, V62, P14384, DOI 10.1103/PhysRevB.62.14384; Osafune T, 1997, PHYS REV LETT, V78, P1980, DOI 10.1103/PhysRevLett.78.1980; SIGRIST M, 1994, PHYS REV B, V49, P12058, DOI 10.1103/PhysRevB.49.12058; Tranquada JM, 1997, PHYS REV LETT, V78, P338, DOI 10.1103/PhysRevLett.78.338; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; Uehara M, 1996, J PHYS SOC JPN, V65, P2764, DOI 10.1143/JPSJ.65.2764; van Smaalen S, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.026101; Vuletic T, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.257002; White SR, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.165122; Wigner E, 1934, PHYS REV, V46, P1002, DOI 10.1103/PhysRev.46.1002; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391	29	155	155	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1078	1081		10.1038/nature02925	http://dx.doi.org/10.1038/nature02925			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15510143	Green Submitted			2022-12-28	WOS:000224730800035
J	Taylor, RS; Drummond, MF; Salkeld, G; Sullivan, SD				Taylor, RS; Drummond, MF; Salkeld, G; Sullivan, SD			Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NICE; GUIDANCE		Univ Birmingham, Dept Publ Hlth & Epidemiol, Birmingham B15 2TT, W Midlands, England; Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia; Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA	University of Birmingham; University of York - UK; University of Sydney; University of Washington; University of Washington Seattle	Taylor, RS (corresponding author), Univ Birmingham, Dept Publ Hlth & Epidemiol, Birmingham B15 2TT, W Midlands, England.	r.s.taylor@bham.ac.uk						Anis AH, 1998, PHARMACOECONOMICS, V13, P119, DOI 10.2165/00019053-199813010-00011; *AUSTR GOV DEP HLT, 2004, SCHED PHARM BEN; Benjamin I, 2002, LANCET, V359, P2120, DOI 10.1016/S0140-6736(02)08933-X; *BUR IND EC, 1991, 11 BIE; Commonwealth Department of Health Housing and Community Services, 1992, GUID PHARM IND PREP; Drummond MF, 2003, EUR J HEALTH ECON, V4, P67, DOI [10.1007/s10198-003-0174-5, DOI 10.1007/S10198-003-0174-5]; Drummond Michael, 2002, Appl Health Econ Health Policy, V1, P53; Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453; George B, 2001, PHARMACOECONOMICS, V19, P1103, DOI 10.2165/00019053-200119110-00004; Guillen AM, 2003, INT J HEALTH SERV, V33, P1, DOI 10.2190/1JC6-FRL4-QM2L-QN6E; Haffner ME, 2002, NAT REV DRUG DISCOV, V1, P821, DOI 10.1038/nrd919; Hill SR, 2000, JAMA-J AM MED ASSOC, V283, P2116, DOI 10.1001/jama.283.16.2116; Hjelmgren J, 2001, Value Health, V4, P225, DOI 10.1046/j.1524-4733.2001.43040.x; HUTTON J, 2000, HEALTH ECON, V9, pS9; Javitz HS, 2004, AM J MANAG CARE, V10, P217; Kumar K, 2002, J NEUROSURG, V97, P803, DOI 10.3171/jns.2002.97.4.0803; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Mason J, 1998, HLTH TRENDS, V30, P120; Mather DB, 1999, AM J MANAG CARE, V5, P277; McKee M, 2003, J ROY SOC MED, V96, P1, DOI 10.1258/jrsm.96.1.1; MITCHELL AS, 2002, INT J RISK SAFETY ME, V15, P77; *NAT I CLIN EXC, 2003, TECHN APPR GUID, V58; *NAT I CLIN EXC, TECHN APPR GUID, V36; *NAT I CLIN EXC, 2003, TECHN APPR GUID, V55; *NAT I CLIN EXC, 2002, TECHN APPR GUID, V30; National Institute for Clinical Excellence, 2004, GUID METH TECHN APPR; Nurnberg H George, 2004, Am J Ther, V11, P9, DOI 10.1097/00045391-200401000-00005; Oliver A, 2003, HEALTH POLICY, V63, P197, DOI 10.1016/S0168-8510(02)00066-0; OLSEN JA, 2001, HEALTH ECON, V10, P201; *ONT DRUG BEN PROG, ONT GUID DRUG SUBM E; Park SJ, 2003, NEW ENGL J MED, V348, P1537, DOI 10.1056/NEJMoa021007; *PROD COMM, 2001, INT PHARM PRIC DIFF; Raftery J, 2001, BRIT MED J, V323, P1300, DOI 10.1136/bmj.323.7324.1300; Salkeld G., 1999, EC AUSTR HLTH POLICY, P115; Scuffham P, 2003, DIABETIC MED, V20, P586, DOI 10.1046/j.1464-5491.2003.00991.x; Stevens A, 2003, J PUBLIC HEALTH MED, V25, P98, DOI 10.1093/pubmed/fdg022; SULLIVAN SD, 2001, J MANAGE CARE PHARM, V7, P272; Taylor RS, 2002, PHARMACOECONOMICS, V20, P1031, DOI 10.2165/00019053-200220150-00001	38	129	133	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 23	2004	329	7472					972	975		10.1136/bmj.329.7472.972	http://dx.doi.org/10.1136/bmj.329.7472.972			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866KU	15499118	Green Published, Green Submitted			2022-12-28	WOS:000224773200025
J	Feingold, EA; Good, PJ; Guyer, MS; Kamholz, S; Liefer, L; Wetterstrand, K; Collins, FS; Gingeras, TR; Kampa, D; Sekinger, EA; Cheng, J; Hirsch, H; Ghosh, S; Zhu, Z; Pate, S; Piccolboni, A; Yang, A; Tammana, H; Bekiranov, S; Kapranov, P; Harrison, R; Church, G; Struhl, K; Ren, B; Kim, TH; Barrera, LO; Qu, C; Van Calcar, S; Luna, R; Glass, CK; Rosenfeld, MG; Guigo, R; Antonarakis, SE; Birney, E; Brent, M; Pachter, L; Reymond, A; Dermitzakis, ET; Dewey, C; Keefe, D; Denoeud, F; Lagarde, J; Ashurst, J; Hubbard, T; Wesselink, JJ; Castelo, R; Eyras, E; Myers, RM; Sidow, A; Batzoglou, S; Trinklein, ND; Hartman, SJ; Aldred, SF; Anton, E; Schroeder, DI; Marticke, SS; Nguyen, L; Schmutz, J; Grimwood, J; Dickson, M; Cooper, GM; Stone, EA; Asimenos, G; Brudno, M; Dutta, A; Karnani, N; Taylor, CM; Kim, HK; Robins, G; Stamatoyannopoulos, G; Stamatoyannopoulos, JA; Dorschner, M; Sabo, P; Hawrytycz, M; Humbert, R; Wallace, J; Yu, M; Navas, PA; McArthur, M; Noble, WS; Dunham, I; Koch, CM; Andrews, RM; Clelland, GK; Wilcox, S; Fowler, JC; James, KD; Groth, P; Dovey, OM; Ellis, PD; Wraight, VL; Mungall, AJ; Dhami, P; Fiegler, H; Langford, CF; Carter, NP; Vetrie, D; Snyder, M; Euskirchen, G; Urban, AE; Nagalakshmi, U; Rinn, J; Popescu, G; Bertone, P; Hartman, S; Rozowsky, J; Emanuelsson, O; Royce, T; Chung, S; Gerstein, M; Lian, Z; Lian, J; Nakayama, Y; Weissman, S; Stoic, V; Tongprasit, W; Sethi, H; Jones, S; Marra, M; Shin, H; Schein, J; Clamp, M; Lindblad-Toh, K; Chang, J; Jaffe, DB; Kamal, ES; Lander, ES; Mikkelsen, TS; Vinson, J; Zody, MC; de Jong, PJ; Osoegawa, K; Nefedov, M; Zhu, B; Baxevanis, AD; Wolfsberg, TG; Collins, FS; Crawford, GE; Holt, E; Vasicek, TJ; Zhou, D; Luo, S; Green, ED; Bouffard, GG; Margulies, EH; Portnoy, ME; Hansen, NF; Thomas, PJ; Mcdowell, JC; Maskeri, B; Young, AC; Idol, JR; Blakesley, RW; Schuler, G; Miller, W; Hardison, R; Elnitski, L; Shah, P; Salzberg, SL; Pertea, M; Majoros, WH; Haussler, D; Thomas, D; Rosenbloom, KR; Clawson, H; Siepe, A; Kent, WJ; Weng, Z; Jin, S; Halees, A; Burden, H; Karaoz, U; Fu, Y; Yu, Y; Ding, C; Cantor, CR; Kingston, RE; Dennis, J; Green, RD; Singer, MA; Richmond, TA; Norton, JE; Farnham, PJ; Oberley, MJ; Inman, DR; McCormick, MR; Kim, H; Middle, CL; Pirrung, MC; Fu, XD; Kwon, YS; Ye, Z; Dekker, J; Tabuchi, TM; Gheldof, N; Dostie, J; Harvey, SC				Feingold, EA; Good, PJ; Guyer, MS; Kamholz, S; Liefer, L; Wetterstrand, K; Collins, FS; Gingeras, TR; Kampa, D; Sekinger, EA; Cheng, J; Hirsch, H; Ghosh, S; Zhu, Z; Pate, S; Piccolboni, A; Yang, A; Tammana, H; Bekiranov, S; Kapranov, P; Harrison, R; Church, G; Struhl, K; Ren, B; Kim, TH; Barrera, LO; Qu, C; Van Calcar, S; Luna, R; Glass, CK; Rosenfeld, MG; Guigo, R; Antonarakis, SE; Birney, E; Brent, M; Pachter, L; Reymond, A; Dermitzakis, ET; Dewey, C; Keefe, D; Denoeud, F; Lagarde, J; Ashurst, J; Hubbard, T; Wesselink, JJ; Castelo, R; Eyras, E; Myers, RM; Sidow, A; Batzoglou, S; Trinklein, ND; Hartman, SJ; Aldred, SF; Anton, E; Schroeder, DI; Marticke, SS; Nguyen, L; Schmutz, J; Grimwood, J; Dickson, M; Cooper, GM; Stone, EA; Asimenos, G; Brudno, M; Dutta, A; Karnani, N; Taylor, CM; Kim, HK; Robins, G; Stamatoyannopoulos, G; Stamatoyannopoulos, JA; Dorschner, M; Sabo, P; Hawrytycz, M; Humbert, R; Wallace, J; Yu, M; Navas, PA; McArthur, M; Noble, WS; Dunham, I; Koch, CM; Andrews, RM; Clelland, GK; Wilcox, S; Fowler, JC; James, KD; Groth, P; Dovey, OM; Ellis, PD; Wraight, VL; Mungall, AJ; Dhami, P; Fiegler, H; Langford, CF; Carter, NP; Vetrie, D; Snyder, M; Euskirchen, G; Urban, AE; Nagalakshmi, U; Rinn, J; Popescu, G; Bertone, P; Hartman, S; Rozowsky, J; Emanuelsson, O; Royce, T; Chung, S; Gerstein, M; Lian, Z; Lian, J; Nakayama, Y; Weissman, S; Stoic, V; Tongprasit, W; Sethi, H; Jones, S; Marra, M; Shin, H; Schein, J; Clamp, M; Lindblad-Toh, K; Chang, J; Jaffe, DB; Kamal, ES; Lander, ES; Mikkelsen, TS; Vinson, J; Zody, MC; de Jong, PJ; Osoegawa, K; Nefedov, M; Zhu, B; Baxevanis, AD; Wolfsberg, TG; Collins, FS; Crawford, GE; Holt, E; Vasicek, TJ; Zhou, D; Luo, S; Green, ED; Bouffard, GG; Margulies, EH; Portnoy, ME; Hansen, NF; Thomas, PJ; Mcdowell, JC; Maskeri, B; Young, AC; Idol, JR; Blakesley, RW; Schuler, G; Miller, W; Hardison, R; Elnitski, L; Shah, P; Salzberg, SL; Pertea, M; Majoros, WH; Haussler, D; Thomas, D; Rosenbloom, KR; Clawson, H; Siepe, A; Kent, WJ; Weng, Z; Jin, S; Halees, A; Burden, H; Karaoz, U; Fu, Y; Yu, Y; Ding, C; Cantor, CR; Kingston, RE; Dennis, J; Green, RD; Singer, MA; Richmond, TA; Norton, JE; Farnham, PJ; Oberley, MJ; Inman, DR; McCormick, MR; Kim, H; Middle, CL; Pirrung, MC; Fu, XD; Kwon, YS; Ye, Z; Dekker, J; Tabuchi, TM; Gheldof, N; Dostie, J; Harvey, SC		ENCODE Project Consortium	The ENCODE (ENCyclopedia of DNA elements) Project	SCIENCE			English	Editorial Material							INTERNATIONAL HAPMAP PROJECT; HUMAN-GENOME; SEQUENCE; TRANSCRIPTION; ANNOTATION; QUALITY; CDNAS	The ENCyclopedia Of DNA Elements (ENCODE) Project aims to identify all functional elements in the human genome sequence. The pilot phase of the Project is focused on a specified 30 megabases (similar to1%) of the human genome sequence and is organized as an international consortium of computational and laboratory-based scientists working to develop and apply high-throughput approaches for detecting all sequence elements that confer biological function. The results of this pilot phase will guide future efforts to analyze the entire human genome.	NHGRI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Feingold, EA (corresponding author), NHGRI, Bethesda, MD 20892 USA.	elise_feingold@nih.gov	Wolfsberg, Tyra/D-8296-2017; Schroeder, Diane/I-2200-2015; Hubbard, Tim J.P./AAT-4571-2020; Clawson, Hiram/ABE-6101-2020; Antonarakis, Stylianos E/N-8866-2014; Bertone, Paul/A-6600-2013; Jin, Shengnan/I-6264-2012; Lagarde, Julien/AAI-1686-2020; Ding, Chunming/B-2593-2008; Jones, Steven J/C-3621-2009; Cooper, Gregory/D-6914-2011; Mikkelsen, Tarjei S/A-1306-2007; Elnitski, Laura/AAD-3595-2021; Oberley, Matthew/I-8107-2019; Pertea, Mihaela/AAT-2705-2021; Taylor, Christopher M./AAF-5480-2020; Bertone, Paul/Z-3734-2019; Grimwood, Jane/ABD-5737-2021; Marra, Marco A/B-5987-2008; Castelo, Robert/A-4679-2010; Guigo, Roderic/D-1303-2010; Karaoz, Ulas/J-7093-2014; Popescu, George/B-7013-2008; Hubbard, Tim J/C-2567-2008; Popescu, George/N-2193-2019; Eyras, Eduardo/A-1560-2010; Salzberg, Steven L/F-6162-2011; Eduardo, Eyras/L-1053-2014; Salzberg, Steven/Q-6514-2019; Oberley, Matthew/L-4326-2019; Schein, Jacquie E/G-3674-2015; Mungall, Andrew J./U-7067-2018; Dermitzakis, Emmanouil/B-7687-2013; Schmutz, Jeremy/N-3173-2013; Gasull, Martina/J-4076-2019; Eyras, Eduardo/ABG-7144-2020; Karnani, Neerja/G-2539-2012; Hardison, Ross C/G-1142-2010; Brent, Michael/AAK-3702-2020; Sandelin, Albin/G-2881-2011	Wolfsberg, Tyra/0000-0001-5646-9455; Schroeder, Diane/0000-0003-2282-9912; Hubbard, Tim J.P./0000-0002-1767-9318; Antonarakis, Stylianos E/0000-0001-8907-5823; Bertone, Paul/0000-0001-5059-4829; Jin, Shengnan/0000-0003-0467-6502; Lagarde, Julien/0000-0002-0290-7445; Ding, Chunming/0000-0002-2063-5594; Jones, Steven J/0000-0003-3394-2208; Cooper, Gregory/0000-0001-5509-9923; Mikkelsen, Tarjei S/0000-0002-8133-3135; Oberley, Matthew/0000-0001-6419-2513; Pertea, Mihaela/0000-0003-0762-8637; Taylor, Christopher M./0000-0002-7983-5275; Bertone, Paul/0000-0001-5059-4829; Marra, Marco A/0000-0001-7146-7175; Castelo, Robert/0000-0003-2229-4508; Guigo, Roderic/0000-0002-5738-4477; Karaoz, Ulas/0000-0002-8238-6757; Popescu, George/0000-0002-7580-6792; Hubbard, Tim J/0000-0002-1767-9318; Popescu, George/0000-0002-7580-6792; Salzberg, Steven L/0000-0002-8859-7432; Eduardo, Eyras/0000-0003-0793-6218; Salzberg, Steven/0000-0002-8859-7432; Mungall, Andrew J./0000-0002-0905-2742; Schmutz, Jeremy/0000-0001-8062-9172; Eyras, Eduardo/0000-0003-0793-6218; Hardison, Ross C/0000-0003-4084-7516; Brent, Michael/0000-0002-8689-0299; Koch, Christof/0000-0001-6482-8067; Cooper, Sara/0000-0002-9627-0309; Dutta, Anindya/0000-0002-4319-0073; Stone, Eric/0000-0002-2725-4209; Gingeras, Thomas/0000-0001-9106-3573; Clawson, Hiram/0000-0002-0480-0545; Baxevanis, Andy/0000-0002-5370-0014; Siepel, Adam/0000-0002-3557-7219; church, george/0000-0001-6232-9969; Elnitski, Laura/0000-0003-1065-019X; Rinn, John/0000-0002-7231-7539; Dunham, Ian/0000-0003-2525-5598; Pachter, Lior/0000-0002-9164-6231; Halees, Anason/0000-0001-5880-7067; Sandelin, Albin/0000-0002-7109-7378	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG200304, R01HG003143] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Blakesley RW, 2004, GENOME RES, V14, P2235, DOI 10.1101/gr.2648404; Blanchette M, 2004, GENOME RES, V14, P708, DOI 10.1101/gr.1933104; Boffelli D, 2004, NAT REV GENET, V5, P456, DOI 10.1038/nrg1350; *ENCODE CONS, UNPUB; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; Felsenfeld A, 1999, GENOME RES, V9, P1; Foster MW, 2004, NAT REV GENET, V5, P467, DOI 10.1038/nrg1351; Gerhard DS, 2004, GENOME RES, V14, P2121, DOI 10.1101/gr.2596504; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Imanishi T, 2004, PLOS BIOL, V2, P856, DOI 10.1371/journal.pbio.0020162; *INT HUM GEN SEQ C, IN PRESS NATURE; Kapronov Philipp, 2003, Briefings in Functional Genomics & Proteomics, V2, P47, DOI 10.1093/bfgp/2.1.47; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Pruitt KD, 2003, NUCLEIC ACIDS RES, V31, P34, DOI 10.1093/nar/gkg111; Ren B, 2004, METHOD ENZYMOL, V376, P304; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SIEPEL A, IN PRESS STAT METHOD; Spellman PT, 2002, GENOME BIOL, V3; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Trinklein ND, 2004, GENOME RES, V14, P62, DOI 10.1101/gr.1982804; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	28	1570	1630	7	160	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					636	640		10.1126/science.1105136	http://dx.doi.org/10.1126/science.1105136			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499007				2022-12-28	WOS:000224756700037
J	Schulman, SP				Schulman, SP			Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; GLYCOPROTEIN IIB/IIIA INHIBITORS; UNSTABLE ANGINA; ASPIRIN RESISTANCE; PLATELET-AGGREGATION; CLOPIDOGREL RESISTANCE; IIIA POLYMORPHISM; PROGNOSTIC VALUE; RISK; INTERVENTION		Johns Hopkins Univ Hosp, Coronary Care Unit, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Schulman, SP (corresponding author), Johns Hopkins Univ Hosp, Coronary Care Unit, 601 N Wolfe St,Carnegie 568, Baltimore, MD 21287 USA.	ssch-ulm@jhmi.edu						Alexander JH, 1999, AM J CARDIOL, V83, P1147, DOI 10.1016/S0002-9149(99)00049-1; AMBROSE JA, 1992, J AM COLL CARDIOL, V19, P1653, DOI 10.1016/0735-1097(92)90632-W; Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Barrabes JA, 2003, CIRCULATION, V108, P814, DOI 10.1161/01.CIR.0000084553.92734.83; Bhatt DL, 2004, J AM COLL CARDIOL, V43, P1127, DOI 10.1016/j.jacc.2004.01.022; Boersma E, 1999, CIRCULATION, V100, P2045, DOI 10.1161/01.CIR.100.20.2045; Boersma E, 2002, LANCET, V359, P189, DOI 10.1016/S0140-6736(02)07442-1; BOGATY P, 1994, CIRCULATION, V90, P5, DOI 10.1161/01.CIR.90.1.5; Braunwald E, 2003, CIRCULATION, V108, P28; Braunwald E, 2002, CIRCULATION, V106, P1893, DOI 10.1161/01.CIR.0000037106.76139.53; Buffon A, 2002, NEW ENGL J MED, V347, P5, DOI 10.1056/NEJMoa012295; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Catella-Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199; Chen WH, 2004, J AM COLL CARDIOL, V43, P1122, DOI 10.1016/j.jacc.2003.12.034; Cipollone F, 2000, CIRCULATION, V102, P1007, DOI 10.1161/01.CIR.102.9.1007; Dalby M, 2004, J AM COLL CARDIOL, V43, P162, DOI 10.1016/j.jacc.2003.08.033; Fontana P, 2003, CIRCULATION, V108, P989, DOI 10.1161/01.CIR.0000085073.69189.88; Gawaz M, 1996, CIRCULATION, V93, P229, DOI 10.1161/01.CIR.93.2.229; Gum PA, 2003, J AM COLL CARDIOL, V41, P961, DOI 10.1016/S0735-1097(02)03014-0; Gurbel PA, 2003, CIRCULATION, V107, P2908, DOI 10.1161/01.CIR.0000072771.11429.83; Halcox JPJ, 2002, CIRCULATION, V106, P653, DOI 10.1161/01.CIR.0000025404.78001.D8; Kastrati A, 2004, NEW ENGL J MED, V350, P232, DOI 10.1056/NEJMoa031859; Kimmel SE, 2004, J AM COLL CARDIOL, V43, P985, DOI 10.1016/j.jacc.2003.08.064; Kurth T, 2003, CIRCULATION, V108, P1191, DOI 10.1161/01.CIR.0000087593.07533.9B; Landmesser U, 2004, CIRCULATION, V109, P27, DOI 10.1161/01.CIR.0000129501.88485.1f; Lau WC, 2003, CIRCULATION, V107, P32, DOI 10.1161/01.CIR.0000047060.60595.CC; Lau WC, 2004, CIRCULATION, V109, P166, DOI 10.1161/01.CIR.0000112378.09325.F9; Matetzky S, 2004, CIRCULATION, V109, P3171, DOI 10.1161/01.CIR.0000130846.46168.03; Muller I, 2003, CIRCULATION, V108, P2195, DOI 10.1161/01.CIR.0000099507.32936.C0; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; Nair S, 2002, PLATELETS, V13, P387, DOI 10.1080/0953710021000024394; O'Donnell CJ, 2001, CIRCULATION, V103, P3051, DOI 10.1161/01.CIR.103.25.3051; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; Peters RJG, 2003, CIRCULATION, V108, P1682, DOI 10.1161/01.CIR.0000091201.39590.CB; Peterson ED, 2003, J AM COLL CARDIOL, V42, P45, DOI 10.1016/S0735-1097(03)00514-X; Quinn MJ, 2004, J AM COLL CARDIOL, V43, P972, DOI 10.1016/j.jacc.2003.09.059; Rioufol G, 2002, CIRCULATION, V106, P804, DOI 10.1161/01.CIR.0000025609.13806.31; Samani NJ, 1997, CARDIOVASC RES, V33, P693, DOI 10.1016/S0008-6363(96)00222-2; Saw J, 2003, CIRCULATION, V108, P921, DOI 10.1161/01.CIR.0000088780.57432.43; Simoons ML, 2001, LANCET, V357, P1915; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Steinhubl SR, 2001, CIRCULATION, V103, P2572; Undas A, 1999, LANCET, V353, P982, DOI 10.1016/S0140-6736(98)05054-5; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; Yusuf S, 2003, CIRCULATION, V107, P966, DOI 10.1161/01.CIR.0000051362.96946.15; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Zimmermann N, 2003, CIRCULATION, V108, P542, DOI 10.1161/01.CIR.0000081770.51929.5A	48	34	37	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2004	292	15					1875	1882		10.1001/jama.292.15.1875	http://dx.doi.org/10.1001/jama.292.15.1875			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IV	15494586				2022-12-28	WOS:000224485100027
J	Alexander, RB; Propert, KJ; Schaeffer, AJ; Landis, JR; Nickel, JC; O'Leary, MP; Pontari, MA; McNaughton-Collins, M; Shoskes, DA; Comiter, CV; Datta, NS; Fowler, JE; Nadler, RB; Zeitlin, SI; Knauss, JS; Wang, YL; Kusek, JW; Nyberg, LM; Litwin, MS				Alexander, RB; Propert, KJ; Schaeffer, AJ; Landis, JR; Nickel, JC; O'Leary, MP; Pontari, MA; McNaughton-Collins, M; Shoskes, DA; Comiter, CV; Datta, NS; Fowler, JE; Nadler, RB; Zeitlin, SI; Knauss, JS; Wang, YL; Kusek, JW; Nyberg, LM; Litwin, MS		Chronic Prostatitis Collaborative	Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome - A randomized, double-blind trial	ANNALS OF INTERNAL MEDICINE			English	Article							NATIONAL-INSTITUTES; SYMPTOM INDEX; CLINICAL-TRIAL; PREVALENCE; DIAGNOSIS; COHORT; VALIDATION; THERAPY	Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in men is principally defined by pain in the pelvic region lasting more than 3 months. No cause of the disease has been established, and therapies are empirical and mostly untested. Antimicrobial agents and alpha-adrenergic receptor blockers are frequently used. Objective: To determine whether 6-week therapy with ciprofloxacin or tamsulosin is more effective than placebo at improving symptoms in men with refractory, long-standing CP/CPPS. Design: Randomized, double-blind trial with a 2 x 2 factorial design comparing 6 weeks of therapy with ciprofloxacin, tamsulosin, both drugs, or placebo. Setting: Urology outpatient clinics at 10 tertiary care medical centers in North America. Patients: Patients were identified from referral-based practices of urologists. One hundred ninety-six men with a National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score of at least 15 and a mean of 6.2 years of symptoms were enrolled. Patients had received substantial previous treatment. Measurements: The authors evaluated NIH-CPSI total score and subscores, patient-reported global response assessment, a generic measure of quality of life, and adverse events. Interventions: Ciprofloxacin, 500 mg twice daily; tamsulosin, 0.4 mg once daily; a combination of the 2 drugs; or placebo. Results: The NIH-CPSI total score decreased modestly in all treatment groups. No statistically significant difference in the primary outcome was seen for ciprofloxacin versus no ciprofloxacin (P = 0.15) or tamsulosin versus no tamsulosin (P > 0.2). Treatments also did not differ significantly for any of the secondary outcomes. Limitations: Treatment lasting longer than 6 weeks was not tested. Patients who had received less pretreatment may have responded differently. Conclusion: Ciprofloxacin and tamsulosin did not substantially reduce symptoms in men with long-standing CP/CPPS who had at least moderate symptoms.	Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Univ Penn, Philadelphia, PA 19104 USA; Temple Univ, Philadelphia, PA 19104 USA; Northwestern Univ, Chicago, IL 60611 USA; Queens Univ, Kingston, ON, Canada; Brigham & Womens Hosp, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Cleveland Clin Florida, Weston, FL USA; Univ Arizona, Tucson, AZ USA; Charles Drew Univ, Los Angeles, CA USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Mississippi, Jackson, MS 39216 USA; Natl Inst Diabet & Digest & Kidney Dis, Bethesda, MD USA	University System of Maryland; University of Maryland Baltimore; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Northwestern University; Queens University - Canada; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Cleveland Clinic Foundation; University of Arizona; Charles R. Drew University of Medicine & Science; University of California System; University of California Los Angeles; University of Mississippi; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Alexander, RB (corresponding author), Vet Affairs Maryland Hlth Care Syst, 10 N Greene St, Baltimore, MD 21201 USA.	ralexander@smail.umaryland.edu	Landis, J. Richard/A-9330-2010	Litwin, Mark/0000-0002-2318-344X; Landis, J Richard/0000-0001-8099-0988	NIDDK NIH HHS [U01 DK53572, U01 DK53730, U01 DK53732, U01 DK53746, U01 DK53738, U01 DK53734, U01 DK53736] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK053746, U01DK053734, U01DK053730, U01DK053738, U01DK053732, U01DK053736] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander RB, 1996, UROLOGY, V48, P568, DOI 10.1016/S0090-4295(96)00234-8; Calhoun EA, 2004, ARCH INTERN MED, V164, P1231; Cheah PY, 2003, J UROLOGY, V169, P592, DOI 10.1016/S0022-5347(05)63960-2; Collins MM, 2000, ANN INTERN MED, V133, P367, DOI 10.7326/0003-4819-133-5-200009050-00013; Collins MM, 2001, J UROLOGY, V166, P1800, DOI 10.1016/S0022-5347(05)65678-9; Collins MM, 2001, J GEN INTERN MED, V16, P656; Collins MM, 1998, J UROLOGY, V159, P1224, DOI 10.1016/S0022-5347(01)63564-X; DIGGLKE PJ, 1994, ANAL LONGITUDINAL DA; Goto T, 1998, Int J Urol, V5, P243, DOI 10.1111/j.1442-2042.1998.tb00597.x; GRANADOS EA, 1992, J UROLOGY, V148, P80, DOI 10.1016/S0022-5347(17)36516-3; Krieger JN, 1999, JAMA-J AM MED ASSOC, V282, P236, DOI 10.1001/jama.282.3.236; Krieger JN, 1996, UROLOGY, V48, P715, DOI 10.1016/S0090-4295(96)00421-9; Litwin MS, 1999, J UROLOGY, V162, P369, DOI 10.1016/S0022-5347(05)68562-X; Mehik A, 2003, UROLOGY, V62, P425, DOI 10.1016/S0090-4295(03)00466-7; MEHTA C, 1997, P STATX SAS US STAT; Nickel JC, 2001, J UROLOGY, V165, P1539, DOI 10.1016/S0022-5347(05)66344-6; Nickel JC, 2003, UROLOGY, V62, P614, DOI 10.1016/S0090-4295(03)00583-1; Nickel JC, 2003, J UROLOGY, V170, P818, DOI 10.1097/01.ju.0000082252.49374.e9; Nickel JC, 2001, J UROLOGY, V165, P842, DOI 10.1016/S0022-5347(05)66541-X; Propert KJ, 2002, UROLOGY, V59, P870, DOI 10.1016/S0090-4295(02)01601-1; Roberts RO, 1998, UROLOGY, V51, P578, DOI 10.1016/S0090-4295(98)00034-X; Roberts RO, 2002, J UROLOGY, V168, P2467, DOI 10.1016/S0022-5347(05)64170-5; Schaeffer AJ, 2002, J UROLOGY, V168, P1048, DOI 10.1016/S0022-5347(05)64572-7; Schaeffer AJ, 2002, J UROLOGY, V168, P593, DOI 10.1016/S0022-5347(05)64686-1; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wilt TJ, 2002, J UROLOGY, V167, P177, DOI 10.1016/S0022-5347(05)65407-9	26	152	168	1	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	2004	141	8					581	589		10.7326/0003-4819-141-8-200410190-00005	http://dx.doi.org/10.7326/0003-4819-141-8-200410190-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864SD	15492337				2022-12-28	WOS:000224652300001
J	Kenney, LB; Yasui, Y; Inskip, PD; Hammond, S; Neglia, JP; Mertens, AC; Meadows, AT; Friedman, D; Robison, LL; Diller, L				Kenney, LB; Yasui, Y; Inskip, PD; Hammond, S; Neglia, JP; Mertens, AC; Meadows, AT; Friedman, D; Robison, LL; Diller, L			Breast cancer after childhood cancer: A report from the childhood cancer survivor study	ANNALS OF INTERNAL MEDICINE			English	Article							2ND MALIGNANT NEOPLASMS; LONG-TERM SURVIVORS; INVOLVED-FIELD RADIATION; HODGKINS-DISEASE; RISK-FACTORS; YOUNG-WOMEN; ADOLESCENCE; CHEMOTHERAPY; COHORT; PROBABILITIES	Background: Survivors of childhood cancer are at risk for secondary breast cancer. Other than previous chest radiation therapy, risk factors for secondary breast cancer have not been established. Objective: To identify risk factors for breast cancer among female survivors of childhood cancer. Design: Retrospective cohort study. Setting: The Childhood Cancer Survivor Study (CCSS), a multicenter study of persons who survived more than 5 years after childhood cancer diagnosed from 1970 to 1986. Participants: Among 6068 women in the CCSS, 95 women had 111 confirmed cases of breast cancer. Measurements: Standardized incidence ratios for breast cancer were calculated by using age-specific incidence rates in the general population. Breast cancer incidence was evaluated with respect to primary cancer diagnosis and therapy, age at and time since primary diagnosis, menstrual and reproductive history, and family history of cancer. Results: Breast cancer risk was increased in survivors who were treated with chest radiation therapy (standardized incidence ratio, 24.7 [95% CI, 19.3 to 31.0]) and survivors of bone and soft-tissue sarcoma who were not treated with chest radiation therapy (standardized incidence ratios, 6.7 and 7.6, respectively). Family history of breast cancer (relative rate, 2.7 [CI, 1.3 to 5.0]) and history of thyroid disease (relative rate, 1.7 [CI, 1.1 to 2.6]) were independently associated with increased risk, and exposure to pelvic radiation was protective (relative rate, 0.6 [CI, 0.4 to 0.9]). Age at primary cancer diagnosis and menstrual and reproductive histories did not statistically significantly modify risk. Limitations: This cohort has not yet attained an age at which breast cancer risk is greatest. Conclusion: Survivors of childhood sarcomas and those who received chest radiation therapy are at risk for secondary breast cancer. When assessing a survivor's risk, clinicians should consider primary diagnosis, previous radiation therapy, family cancer history, and history of thyroid disease.	Dana Farber Canc Inst, Qual Life Clin, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA USA; Univ Washington, Sch Med, Seattle, WA 98195 USA; NCI, Bethesda, MD USA; Ohio State Univ, Coll Med & Publ Hlth, Columbus, OH USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Ohio; Ohio State University; University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania	Kenney, LB (corresponding author), Dana Farber Canc Inst, Qual Life Clin, 44 Binney St, Boston, MA 02115 USA.	Lisa_Kenney@DFCI.harvard.edu	Friedman, Danielle Novetsky/B-7551-2016; Robison, Leslie/N-8122-2018; Yasui, Yutaka/E-2564-2015	Friedman, Danielle Novetsky/0000-0003-4668-9176; Yasui, Yutaka/0000-0002-7717-8638; Neglia, Joseph/0000-0002-5525-0598	NCI NIH HHS [CA 55727, U24 CA055727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U24CA055727, U01CA055727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aisenberg AC, 1997, CANCER, V79, P1203, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1203::AID-CNCR20>3.0.CO;2-2; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; Boice JD, 2001, MED PEDIATR ONCOL, V36, P508, DOI 10.1002/mpo.1122; BRESLOW NE, 1995, J CLIN ONCOL, V13, P1851, DOI 10.1200/JCO.1995.13.8.1851; BRESLOW NE, 1987, INT AGENCY RES CANC, V82; BYRNE J, 1992, AM J OBSTET GYNECOL, V166, P788, DOI 10.1016/0002-9378(92)91335-8; Colditz GA, 1996, J NATL CANCER I, V88, P365, DOI 10.1093/jnci/88.6.365; Dawson LA, 1998, EUR J CANCER, V34, P2000, DOI 10.1016/S0959-8049(98)00208-1; Diller L, 2002, J CLIN ONCOL, V20, P2085, DOI 10.1200/JCO.2002.08.031; Donaldson SS, 2002, J CLIN ONCOL, V20, P3081, DOI 10.1200/JCO.2002.12.101; Friedmann AM, 2002, J CLIN ONCOL, V20, P3088, DOI 10.1200/JCO.2002.03.051; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GARBER JE, 1991, CANCER RES, V51, P6094; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O; Green DM, 2000, J CLIN ONCOL, V18, P1492, DOI 10.1200/JCO.2000.18.7.1492; HANCOCK SL, 1993, J NATL CANCER I, V85, P25, DOI 10.1093/jnci/85.1.25; HELZLSOUER KJ, 1995, INT J CANCER, V64, P14, DOI 10.1002/ijc.2910640105; Jernstrom H, 1999, LANCET, V354, P1846, DOI 10.1016/S0140-6736(99)04336-6; Li CI, 2003, ARCH INTERN MED, V163, P49, DOI 10.1001/archinte.163.1.49; MacKarem G, 2001, Breast J, V7, P34, DOI 10.1046/j.1524-4741.2001.007001034.x; MADIGAN MP, 1995, J NATL CANCER I, V87, P1681, DOI 10.1093/jnci/87.22.1681; Metayer C, 2000, J CLIN ONCOL, V18, P2435, DOI 10.1200/JCO.2000.18.12.2435; *NAT CANC I, 2002, SURV EP END RES SEER; Neglia JP, 2001, J NATL CANCER I, V93, P618, DOI 10.1093/jnci/93.8.618; Ng AK, 2002, BLOOD, V100, P1989, DOI 10.1182/blood-2002-02-0634; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; Sankila R, 1996, J CLIN ONCOL, V14, P1442, DOI 10.1200/JCO.1996.14.5.1442; SCARADAVOU A, 1995, CANCER, V76, P1860, DOI 10.1002/1097-0142(19951115)76:10<1860::AID-CNCR2820761027>3.0.CO;2-I; Sklar C, 2000, J CLIN ENDOCR METAB, V85, P3227, DOI 10.1210/jc.85.9.3227; Swerdlow AJ, 2000, J CLIN ONCOL, V18, P498, DOI 10.1200/JCO.2000.18.3.498; Travis LB, 2003, JAMA-J AM MED ASSOC, V290, P465, DOI 10.1001/jama.290.4.465; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; van Leeuwen FE, 2000, J CLIN ONCOL, V18, P487, DOI 10.1200/JCO.2000.18.3.487; van Leeuwen FE, 2003, JNCI-J NATL CANCER I, V95, P971, DOI 10.1093/jnci/95.13.971; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041; Wolden SL, 2000, J CLIN ONCOL, V18, P765, DOI 10.1200/JCO.2000.18.4.765; YAHALOM J, 1992, J CLIN ONCOL, V10, P1674, DOI 10.1200/JCO.1992.10.11.1674	37	169	174	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	2004	141	8					590	597		10.7326/0003-4819-141-8-200410190-00006	http://dx.doi.org/10.7326/0003-4819-141-8-200410190-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864SD	15492338				2022-12-28	WOS:000224652300002
J	Pica, P; Lemer, C; Izard, W; Dehaene, S				Pica, P; Lemer, C; Izard, W; Dehaene, S			Exact and approximate arithmetic in an Amazonian indigene group	SCIENCE			English	Article							NUMBER; SYSTEMS; REPRESENTATIONS; LANGUAGE; BRAIN	Is calculation possible without language? Or is the human ability for arithmetic dependent on the language faculty? To clarify the relation between language and arithmetic, we studied numerical cognition in speakers of Munduruku, an Amazonian language with a very small lexicon of number words. Although the Munduruku lack words for numbers beyond 5, they are able to compare and add large approximate numbers that are far beyond their naming range. However, they fail in exact arithmetic with numbers larger than 4 or 5. Our results imply a distinction between a nonverbal system of number approximation and a language-based counting system for exact number and arithmetic.	Serv Hosp Frederic Joliot, CEA, DSV, INSERM,U562,Unite Cognit Neuroimaging, F-91401 Orsay, France; CNRS, Unite Mixte Rech Formal Struct Language 7023, Paris, France; Univ Paris 08, Paris, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Universite Paris-VIII	Dehaene, S (corresponding author), Serv Hosp Frederic Joliot, CEA, DSV, INSERM,U562,Unite Cognit Neuroimaging, F-91401 Orsay, France.	dehaene@shfj.cea.fr	Pica, Pierre/H-9523-2012; Pica, Pierre/N-1342-2019; Henrich, Joseph/A-2403-2009	Pica, Pierre/0000-0001-9452-5446; Pica, Pierre/0000-0001-9452-5446; 				ALLIK J, 1991, PERCEPT PSYCHOPHYS, V49, P303, DOI 10.3758/BF03205986; Barth H, 2003, COGNITION, V86, P201, DOI 10.1016/S0010-0277(02)00178-6; Brannon EM, 2000, J EXP PSYCHOL ANIM B, V26, P31, DOI 10.1037/0097-7403.26.1.31; BUCKLEY PB, 1974, J EXP PSYCHOL, V103, P1131, DOI 10.1037/h0037361; Butterworth B., 1999, MATH BRAIN; Carey S, 1998, SCIENCE, V282, P641, DOI 10.1126/science.282.5389.641; CHOMSKY N, 1988, LANGUAGE PROBLEMS KN, P169; DEHAENE S, 1991, NEUROPSYCHOLOGIA, V29, P1045, DOI 10.1016/0028-3932(91)90076-K; Dehaene S, 1999, SCIENCE, V284, P970, DOI 10.1126/science.284.5416.970; Dehaene S, 1998, TRENDS NEUROSCI, V21, P355, DOI 10.1016/S0166-2236(98)01263-6; Dehaene S., 1997, NUMBER SENSE; Feigenson L, 2004, TRENDS COGN SCI, V8, P307, DOI 10.1016/j.tics.2004.05.002; GALLISTEL CR, 1992, COGNITION, V44, P43, DOI 10.1016/0010-0277(92)90050-R; Gordon P, 2004, SCIENCE, V306, P496, DOI 10.1126/science.1094492; Hurford JamesR., 1987, LANGUAGE NUMBER; Lemer C, 2003, NEUROPSYCHOLOGIA, V41, P1942, DOI 10.1016/S0028-3932(03)00123-4; MOYER RS, 1967, NATURE, V215, P1519, DOI 10.1038/2151519a0; Nieder A, 2004, P NATL ACAD SCI USA, V101, P7457, DOI 10.1073/pnas.0402239101; Pollmann T, 1996, COGNITION, V59, P219, DOI 10.1016/0010-0277(95)00704-0; Spelke ES, 2001, COGNITION, V78, P45, DOI 10.1016/S0010-0277(00)00108-6; SPELKE ES, 2001, LANG ACQUIS, P70, DOI DOI 10.1017/CB09780511620669.005; STROMER C, 1932, SPRACHE MUNDURUKU; Sulkowski GM, 2001, COGNITION, V79, P239, DOI 10.1016/S0010-0277(00)00112-8; Whalen J, 1999, PSYCHOL SCI, V10, P130, DOI 10.1111/1467-9280.00120; Wiese H, 2003, NUMBERS LANGUAGE HUM; WYNN K, 1992, NATURE, V358, P749, DOI 10.1038/358749a0; WYNN K, 1990, COGNITION, V36, P155, DOI 10.1016/0010-0277(90)90003-3; [No title captured]	29	726	739	4	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					499	503		10.1126/science.1102085	http://dx.doi.org/10.1126/science.1102085			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486303	Green Published, Green Submitted			2022-12-28	WOS:000224626500057
J	Pierard, LA; Lancellotti, P				Pierard, LA; Lancellotti, P			The role of ischemic mitral regurgitation in the pathogenesis of acute pulmonary edema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; EXERCISE-INDUCED CHANGES; CORONARY-ARTERY-DISEASE; HEART-FAILURE; DETERMINANTS; MECHANISM; HYPERTENSION; INSIGHTS	BACKGROUND: Acute mitral regurgitation may cause pulmonary edema, but the pathogenetic role of chronic ischemic mitral regurgitation, a dynamic condition, has not yet been characterized. METHODS: We prospectively studied 28 patients (mean [+/-SD] age, 65+/-11 years) with acute pulmonary edema and left ventricular systolic dysfunction and 46 patients without a history of acute pulmonary edema. The two groups were matched for all baseline characteristics. Patients underwent quantitative Doppler echocardiography during exercise. Exercise-induced changes in the left ventricular volume, the ejection fraction, the mitral regurgitant volume, the effective regurgitant orifice area, and the transtricuspid pressure gradient were compared in patients with and without acute pulmonary edema. RESULTS: The two groups had similar clinical and baseline echocardiographic characteristics. They also had similar exercise-induced changes in heart rate, systolic blood pressure, and left ventricular volumes. In the univariate analysis, patients with recent pulmonary edema had a much higher increase than did the patients without pulmonary edema in mitral regurgitant volume (26+/-14 ml vs. 5+/-14 ml, P<0.001), the effective regurgitant orifice area (16+/-10 mm(sup 2) vs. 2+/-9 mm(sup 2), P<0.001), and the transtricuspid pressure gradient (29+/-10 mm Hg vs. 13+/-11 mm Hg, P<0.001). In the multivariate analysis, exercise-induced changes in the effective regurgitant orifice area (P<0.001), in the transtricuspid pressure gradient (P=0.001), and in the left ventricular ejection fraction (P=0.02) were independently associated with a history of recent pulmonary edema. CONCLUSIONS: In patients with left ventricular systolic dysfunction, acute pulmonary edema is associated with the dynamic changes in ischemic mitral regurgitation and the resulting increase in pulmonary vascular pressure.	Univ Hosp Liege, Div Cardiol, Liege, Belgium	University of Liege	Pierard, LA (corresponding author), Univ Hosp Sart Tilman, Dept Cardiol, B-4000 Liege, Belgium.	lpierard@chu.ulg.ac.be						Agostoni P, 2003, CIRCULATION, V108, P2666, DOI 10.1161/01.CIR.0000097115.61309.59; Bentancur AG, 2002, AM J MED SCI, V323, P238, DOI 10.1097/00000441-200205000-00002; Cotter G, 1998, LANCET, V351, P389, DOI 10.1016/S0140-6736(97)08417-1; EnriquezSarano M, 1997, J AM COLL CARDIOL, V29, P153, DOI 10.1016/S0735-1097(96)00436-6; Gandhi SK, 2001, NEW ENGL J MED, V344, P17, DOI 10.1056/NEJM200101043440103; Grigioni F, 2001, CIRCULATION, V103, P1759, DOI 10.1161/01.CIR.103.13.1759; He SQ, 1997, CIRCULATION, V96, P1826, DOI 10.1161/01.CIR.96.6.1826; Hung J, 1999, J AM COLL CARDIOL, V33, P538, DOI 10.1016/S0735-1097(98)00570-1; Irvine T, 2002, HEART, V88, piv11; KEREN G, 1986, AM HEART J, V112, P517, DOI 10.1016/0002-8703(86)90516-8; Lancellotti P, 2003, CIRCULATION, V108, P1713, DOI 10.1161/01.CIR.0000087599.49332.05; Lancellotti P, 2003, J AM COLL CARDIOL, V42, P1921, DOI 10.1016/j.jacc.2003.04.002; Lebrun F, 2001, J AM COLL CARDIOL, V38, P1685, DOI 10.1016/S0735-1097(01)01605-9; Levine RA, 2003, J AM COLL CARDIOL, V42, P1929, DOI 10.1016/j.jacc.2003.09.004; Otsuji Y, 1997, CIRCULATION, V96, P1999, DOI 10.1161/01.CIR.96.6.1999; STONE GW, 1991, AM J CARDIOL, V67, P37, DOI 10.1016/0002-9149(91)90095-3; TCHENG JE, 1992, ANN INTERN MED, V117, P18, DOI 10.7326/0003-4819-117-1-18; Yiu SF, 2000, CIRCULATION, V102, P1400, DOI 10.1161/01.CIR.102.12.1400	18	201	209	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1627	1634		10.1056/NEJMoa040532	http://dx.doi.org/10.1056/NEJMoa040532			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483281	Bronze			2022-12-28	WOS:000224427300009
J	Davis, PG; Tan, A; O'Donnell, CPF; Schulze, A				Davis, PG; Tan, A; O'Donnell, CPF; Schulze, A			Resuscitation of newborn infants with 100% oxygen or air: a systematic review and meta-analysis	LANCET			English	Review							ROOM-AIR; OXIDATIVE STRESS; TERM INFANTS; 21-PERCENT; CONSENSUS	Background International consensus statements for resuscitation of newborn infants recommend provision of 100% oxygen with positive pressure if assisted ventilation is required. However, 100% oxygen exacerbates reperfusion injury in animals and reduces cerebral perfusion in newborn babies. We aimed to establish whether resuscitation with air decreased mortality or neurological disability in newborn infants compared with 100% oxygen. Methods We did a systematic review and meta-analysis of trials that compared resuscitation with air versus 100% oxygen, using the methods of the Cochrane Collaboration. We combined data for similar outcomes in the analysis where appropriate, using a fixed-effects model. Findings Five trials (two masked and three unmasked), consisting of 1302 newborn infants, fulfilled the inclusion criteria. Most babies were born at or near term in developing countries. In the three unmasked studies, infants resuscitated with room air who remained cyanotic and bradycardic were switched to 100% oxygen at 90 s. The masked studies allowed crossover to the other gas during the first minutes of life. Although no individual trial showed a difference in mortality, the pooled analysis showed a significant benefit for infants resuscitated with air (relative risk 0.71 [95% CI 0.54 to 0.94], risk difference -0.05 [-0.08 to -0.01]). The effect on long-term development could not be reliably determined because of methodological limitations in the one study that followed up infants beyond 12 months of age. Interpretation For term and near-term infants, we can reasonably conclude that air should be used initially, with oxygen as backup if initial resuscitation fails. The effect of intermediate concentrations of oxygen at resuscitation needs to be investigated. Future trials should include and stratify for premature infants.	Royal Hosp Women, Melbourne, Vic, Australia; Univ Melbourne, Melbourne, Vic, Australia; Booth Hall Childrens Hosp, Manchester, Lancs, England; Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany	University of Melbourne; Royal Manchester Children's Hospital; University of Munich	Davis, PG (corresponding author), Royal Hosp Women, 132 Grattan St, Carlton, Vic 3053, Australia.	pgd@unimelb.edu.au		O'donnell, Colm/0000-0002-8004-450X				AINLEYWALKER JC, 1979, BRIT MED J, V2, P1590, DOI 10.1136/bmj.2.6204.1590-b; [Anonymous], 2 KINGS, V4; [Anonymous], GENESIS; DEEKS JJ, ANAL PRESENTING RESU; Hammerman C, 1998, CLIN PERINATOL, V25, P757, DOI 10.1016/S0095-5108(18)30110-6; Kattwinkel J, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.4.e56; Kattwinkel J, 2003, J PEDIATR-US, V142, P221, DOI 10.1067/mpd.2003.147; Kutzsche S, 2001, PEDIATR RES, V49, P834, DOI 10.1203/00006450-200106000-00020; LUNDSTROM K, 1995, ARCH DIS CHILD, V73, P81; Milner AD, 1998, EUR J PEDIATR, V157, P524, DOI 10.1007/s004310050870; Niermeyer S, 2000, PEDIATRICS, V106; NIIJIMA S, 1988, ARCH DIS CHILD-FETAL, V63, P1126, DOI 10.1136/adc.63.10_Spec_No.1126; Ramji S, 2003, Indian Pediatr, V40, P510; RAMJI S, 1993, PEDIATR RES, V34, P809, DOI 10.1203/00006450-199312000-00023; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Saugstad OD, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e1; Saugstad OD, 2003, PEDIATRICS, V112, P296, DOI 10.1542/peds.112.2.296; Saugstad OD, 2001, PEDIATRICS, V108, P1203, DOI 10.1542/peds.108.5.1203; Saugstad OD, 1998, CLIN PERINATOL, V25, P741, DOI 10.1016/S0095-5108(18)30109-X; Silverman WA, 2004, PEDIATRICS, V113, P394, DOI 10.1542/peds.113.2.394; Soll R, 1999, LANCET, V354, P4, DOI 10.1016/S0140-6736(99)00149-X; TAN A, 2004, COCHRANE LIB; Tin W, 2001, ARCH DIS CHILD-FETAL, V84, pF106, DOI 10.1136/fn.84.2.F106; Van Marter LJ, 2000, PEDIATRICS, V105, P1194, DOI 10.1542/peds.105.6.1194; Vento M, 2003, J PEDIATR-US, V142, P240, DOI 10.1067/mpd.2003.91; Vento M, 2001, PEDIATRICS, V107, P642, DOI 10.1542/peds.107.4.642; Vento M, 2001, BIOL NEONATE, V79, P261	27	242	248	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	2004	364	9442					1329	1333		10.1016/S0140-6736(04)17189-4	http://dx.doi.org/10.1016/S0140-6736(04)17189-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474135				2022-12-28	WOS:000224349700028
J	Zhao, XB; Xiao, B; Fletcher, AJ; Thomas, KM; Bradshaw, D; Rosseinsky, MJ				Zhao, XB; Xiao, B; Fletcher, AJ; Thomas, KM; Bradshaw, D; Rosseinsky, MJ			Hysteretic adsorption and desorption of hydrogen by nanoporous metal-organic frameworks	SCIENCE			English	Article							COORDINATION-POLYMER; CRYSTAL-STRUCTURE; SORPTION; MOLECULES; CHEMISTRY; POROSITY; KINETICS	Adsorption and desorption of hydrogen from nanoporous materials, such as activated carbon, is usually fully reversible. We have prepared nanoporous metal-organic framework materials with flexible linkers in which the pore openings, as characterized in the static structures, appear to be too small to allow H-2 to pass. We observe hysteresis in their adsorption and desorption kinetics above the supercritical temperature of H-2 that reflects the dynamical opening of the "windows" between pores. This behavior would allow H-2 to be adsorbed at high pressures but stored at lower pressures.	Newcastle Univ, Sch Nat Sci, No Carbon Res Labs, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Liverpool, Dept Chem, Liverpool, Merseyside, England	Newcastle University - UK; University of Liverpool	Thomas, KM (corresponding author), Newcastle Univ, Sch Nat Sci, No Carbon Res Labs, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	mark.thomas@ncl.ac.uk	Fletcher, Ashleigh/B-8636-2009; Bradshaw, Darren/D-6174-2013; Thomas, Keith M/E-7832-2011; Zhao, Xuebo/U-1425-2017	Fletcher, Ashleigh/0000-0003-3915-8887; Thomas, Keith M/0000-0002-8661-3099; Zhao, Xuebo/0000-0002-5352-0953; Xiao, Bo/0000-0001-9286-7477	Engineering and Physical Sciences Research Council [EP/C511794/1] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Bradshaw D, 2004, J AM CHEM SOC, V126, P6106, DOI 10.1021/ja0316420; Cussen EJ, 2002, J AM CHEM SOC, V124, P9574, DOI 10.1021/ja0262737; Dybtsev DN, 2004, J AM CHEM SOC, V126, P32, DOI 10.1021/ja038678c; Eddaoudi M, 2001, ACCOUNTS CHEM RES, V34, P319, DOI 10.1021/ar000034b; Endo K, 1997, J AM CHEM SOC, V119, P4117, DOI 10.1021/ja964198s; Ferey G, 2003, CHEM COMMUN, P2976, DOI 10.1039/b308903g; Fletcher AJ, 2004, J AM CHEM SOC, V126, P9750, DOI 10.1021/ja0490267; Fletcher AJ, 2001, J AM CHEM SOC, V123, P10001, DOI 10.1021/ja0109895; Fletcher AJ, 2000, LANGMUIR, V16, P6253, DOI 10.1021/la9916528; GUNDIAH G, 2003, J MATER SCI, V85, P209; James SL, 2003, CHEM SOC REV, V32, P276, DOI 10.1039/b200393g; Kepert CJ, 1999, CHEM COMMUN, P375, DOI 10.1039/a809746a; Kitaura R, 2003, ANGEW CHEM INT EDIT, V42, P428, DOI 10.1002/anie.200390130; Kondo M, 1997, ANGEW CHEM INT EDIT, V36, P1725, DOI 10.1002/anie.199717251; Losier P, 1996, ANGEW CHEM INT EDIT, V35, P2779, DOI 10.1002/anie.199627791; Pan L, 2004, J AM CHEM SOC, V126, P1308, DOI 10.1021/ja0392871; Power KN, 1998, NEW J CHEM, V22, P177; Reid CR, 2001, J PHYS CHEM B, V105, P10619, DOI 10.1021/jp0108263; Rowsell JLC, 2004, J AM CHEM SOC, V126, P5666, DOI 10.1021/ja049408c; SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603; Yaghi OM, 1998, ACCOUNTS CHEM RES, V31, P474, DOI 10.1021/ar970151f	21	1109	1134	15	354	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					1012	1015		10.1126/science.1101982	http://dx.doi.org/10.1126/science.1101982			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15486255				2022-12-28	WOS:000225001100037
J	Amrani, N; Ganesan, R; Kervestin, S; Mangus, DA; Ghosh, S; Jacobson, A				Amrani, N; Ganesan, R; Kervestin, S; Mangus, DA; Ghosh, S; Jacobson, A			A faux 3 '-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay	NATURE			English	Article							TRANSLATION TERMINATION; POLY(A)-BINDING PROTEIN; INITIATION; YEAST; SURVEILLANCE; RECOGNITION; EFFICIENCY; SEQUENCES; UPSTREAM; POLY(A)	Nonsense-mediated messenger RNA decay (NMD) is triggered by premature translation termination(1-3), but the features distinguishing premature from normal termination are unknown. One model for NMD suggests that decay-inducing factors bound to mRNAs during early processing events are routinely removed by elongating ribosomes but remain associated with mRNAs when termination is premature, triggering rapid turnover(4). Recent experiments(5-7) challenge this notion and suggest a model that posits that mRNA decay is activated by the intrinsically aberrant nature of premature termination(8,9). Here we use a primer extension inhibition ( toeprinting) assay(10) to delineate ribosome positioning and find that premature translation termination in yeast extracts is indeed aberrant. Ribosomes encountering premature UAA or UGA codons in the CAN1 mRNA fail to release and, instead, migrate to upstream AUGs. This anomaly depends on prior nonsense codon recognition and is eliminated in extracts derived from cells lacking the principal NMD factor, Upf1p, or by flanking the nonsense codon with a normal 3' - untranslated region (UTR). Tethered poly(A)-binding protein (Pab1p), used as a mimic of a normal 3'-UTR, recruits the termination factor Sup35p (eRF3) and stabilizes nonsense-containing mRNAs. These findings indicate that efficient termination and mRNA stability are dependent on a properly configured 3'-UTR.	Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Jacobson, A (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA.	allan.jacobson@umassmed.edu			NIGMS NIH HHS [R01 GM027757, R37 GM027757] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027757, R01GM027757] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONETTI B, 1995, J MOL BIOL, V251, P334, DOI 10.1006/jmbi.1995.0438; Coller JM, 1998, GENE DEV, V12, P3226, DOI 10.1101/gad.12.20.3226; Cosson B, 2002, MOL CELL BIOL, V22, P3301, DOI 10.1128/MCB.22.10.3301-3315.2002; Dmitriev SE, 2003, FEBS LETT, V533, P99, DOI 10.1016/S0014-5793(02)03776-6; Gatfield D, 2003, EMBO J, V22, P3960, DOI 10.1093/emboj/cdg371; Gehring NH, 2003, MOL CELL, V11, P939, DOI 10.1016/S1097-2765(03)00142-4; Gonzalez CI, 2001, GENE, V274, P15, DOI 10.1016/S0378-1119(01)00552-2; Hilleren P, 1999, RNA, V5, P711, DOI 10.1017/S1355838299990519; Hosoda N, 2003, J BIOL CHEM, V278, P38287, DOI 10.1074/jbc.C300300200; Iizuka N, 1997, METHODS, V11, P353, DOI 10.1006/meth.1996.0433; Jacobson A, 2000, COLD SPRING HARBOR M, V39, P827; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Kozak M, 1998, NUCLEIC ACIDS RES, V26, P4853, DOI 10.1093/nar/26.21.4853; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; LeBlanc JJ, 2004, J VIROL, V78, P5139, DOI 10.1128/JVI.78.10.5139-5146.2004; Maderazo AB, 2003, MOL CELL BIOL, V23, P842, DOI 10.1128/MCB.23.3.842-851.2003; Maderazo AB, 2000, MOL CELL BIOL, V20, P4591, DOI 10.1128/MCB.20.13.4591-4603.2000; Mangus DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-223; MAQUAT LE, 1995, RNA, V1, P453; Muhlrad D, 1999, MOL BIOL CELL, V10, P3971, DOI 10.1091/mbc.10.11.3971; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; Sachs MS, 2002, METHODS, V26, P105, DOI 10.1016/S1046-2023(02)00013-0; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; Stansfield I, 1997, EUR J BIOCHEM, V245, P557, DOI 10.1111/j.1432-1033.1997.00557.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; THOMAS KR, 1986, NATURE, V324, P34, DOI 10.1038/324034a0; Uchida N, 2002, J BIOL CHEM, V277, P50286, DOI 10.1074/jbc.M203029200	30	368	381	5	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					112	118		10.1038/nature03060	http://dx.doi.org/10.1038/nature03060			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525991				2022-12-28	WOS:000224854900051
J	Kroutvar, M; Ducommun, Y; Heiss, D; Bichler, M; Schuh, D; Abstreiter, G; Finley, JJ				Kroutvar, M; Ducommun, Y; Heiss, D; Bichler, M; Schuh, D; Abstreiter, G; Finley, JJ			Optically programmable electron spin memory using semiconductor quantum dots	NATURE			English	Article							CHARGE STORAGE	The spin of a single electron subject to a static magnetic field provides a natural two-level system that is suitable for use as a quantum bit, the fundamental logical unit in a quantum computer(1-3). Semiconductor quantum dots fabricated by strain driven self-assembly(4) are particularly attractive for the realization of spin quantum bits, as they can be controllably positioned(5), electronically coupled(6) and embedded into active devices(7-10). It has been predicted that the atomic-like electronic structure(4) of such quantum dots suppresses coupling of the spin to the solid-state quantum dot environment(11-14), thus protecting the 'spin' quantum information against decoherence(15,16). Here we demonstrate a single electron spin memory device in which the electron spin can be programmed by frequency selective optical excitation. We use the device to prepare single electron spins in semiconductor quantum dots with a well defined orientation, and directly measure the intrinsic spin flip time and its dependence on magnetic field. A very long spin lifetime is obtained, with a lower limit of about 20 milliseconds at a magnetic field of 4 tesla and at 1 kelvin.	Tech Univ Munich, Walter Schottky Inst, D-85748 Garching, Germany	Technical University of Munich	Finley, JJ (corresponding author), Tech Univ Munich, Walter Schottky Inst, Coulombwall 3, D-85748 Garching, Germany.	finley@wsi.tum.de	Finley, Jonathan j/L-4164-2015; Heiss, Dominik/C-6319-2008	Finley, Jonathan j/0000-0003-3036-529X; Heiss, Dominik/0000-0002-8047-0699				ARAKAWA Y, 2003, PHYS STATUS SOLIDI B, V238, P229; Bayer M, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.195315; Bayer M, 2001, SCIENCE, V291, P451, DOI 10.1126/science.291.5503.451; CULTON R, 2002, PHYS REV B, V66; De Franceschi S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.156801; Elzerman JM, 2004, NATURE, V430, P431, DOI 10.1039/nature02693; Finley JJ, 1998, APPL PHYS LETT, V73, P2618, DOI 10.1063/1.122524; Finley JJ, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.073307; Fujisawa T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.236802; Fujisawa T, 2002, NATURE, V419, P278, DOI 10.1038/nature00976; Gupta JA, 1999, PHYS REV B, V59, P10421, DOI 10.1103/PhysRevB.59.R10421; Heidemeyer H, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.196103; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; Khaetskii A, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.195329; Khaetskii AV, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.125316; Khaetskii AV, 2000, PHYS REV B, V61, P12639, DOI 10.1103/PhysRevB.61.12639; Kroutvar M, 2003, APPL PHYS LETT, V83, P443, DOI 10.1063/1.1588368; Langbein W, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.161301; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Meier F., 1984, MODERN PROBLEMS COND, V8; Oulton R, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.235301; Woods LM, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.161318; Zrenner A, 2002, NATURE, V418, P612, DOI 10.1038/nature00912	24	823	829	2	151	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					81	84		10.1038/nature03008	http://dx.doi.org/10.1038/nature03008			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525984				2022-12-28	WOS:000224854900042
J	Lickert, H; Takeuchi, JK; von Both, I; Walls, JR; McAuliffe, F; Adamson, SL; Henkelman, RM; Wrana, JL; Rossant, J; Bruneau, BG				Lickert, H; Takeuchi, JK; von Both, I; Walls, JR; McAuliffe, F; Adamson, SL; Henkelman, RM; Wrana, JL; Rossant, J; Bruneau, BG			Baf60c is essential for function of BAF chromatin remodelling complexes in heart development	NATURE			English	Article							MAMMALIAN SWI/SNF COMPLEXES; TRANSCRIPTION FACTORS; MUSCLE DIFFERENTIATION; MUTUAL COFACTORS; MOUSE HEART; IN-VIVO; NKX2-5; PROLIFERATION; CARDIOGENESIS; EXPRESSION	Tissue-specific transcription factors regulate several important aspects of embryonic development. They must function in the context of DNA assembled into the higher-order structure of chromatin. Enzymatic complexes such as the Swi/Snf-like BAF complexes remodel chromatin to allow the transcriptional machinery access to gene regulatory elements(1,2). Here we show that Smarcd3, encoding Baf60c, a subunit of the BAF complexes, is expressed specifically in the heart and somites in the early mouse embryo. Smarcd3 silencing by RNA interference in mouse embryos derived from embryonic stem cells causes defects in heart morphogenesis that reflect impaired expansion of the anterior/secondary heart field, and also results in abnormal cardiac and skeletal muscle differentiation. An intermediate reduction in Smarcd3 expression leads to defects in outflow tract remodelling reminiscent of human congenital heart defects. Baf60c overexpressed in cell culture can mediate interactions between cardiac transcription factors and the BAF complex ATPase Brg1, thereby potentiating the activation of target genes. These results reveal tissue-specific and dose-dependent roles for Baf60c in recruiting BAF chromatin remodelling complexes to heart-specific enhancers, providing a novel mechanism to ensure transcriptional regulation during organogenesis.	Hosp Sick Children, Mouse Imaging Ctr, Toronto, ON M5G 1X8, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Coll Dublin, Dept Obstet & Gynaecol, Natl Matern Hosp, Dublin 2, Ireland; Univ Toronto, Dept Obstet & Gynecol, Toronto, ON M5G 1L4, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; National Maternity Hospital, Dublin; University College Dublin; University of Toronto	Rossant, J (corresponding author), Hosp Sick Children, Mouse Imaging Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	rossant@mshri.on.ca; bbruneau@sickkids.ca	Lickert, Heiko/K-9045-2013; Wrana, Jeffrey/F-8857-2013; HENKELMAN, MARK/W-6847-2019; Adamson, S. Lee/E-4581-2013	Adamson, S. Lee/0000-0002-7340-3041; Bruneau, Benoit/0000-0002-0804-7597				Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Biben C, 1996, DEV BIOL, V173, P200, DOI 10.1006/dbio.1996.0017; Brown CO, 2004, J BIOL CHEM, V279, P10659, DOI 10.1074/jbc.M301648200; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Cai CL, 2003, DEV CELL, V5, P877, DOI 10.1016/S1534-5807(03)00363-0; Chen HY, 2004, DEVELOPMENT, V131, P2219, DOI 10.1242/dev.01094; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Debril MB, 2004, J BIOL CHEM, V279, P16677, DOI 10.1074/jbc.M312288200; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kunath T, 2003, NAT BIOTECHNOL, V21, P559, DOI 10.1038/nbt813; Liu W, 2004, P NATL ACAD SCI USA, V101, P4489, DOI 10.1073/pnas.0308466101; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Meilhac SM, 2004, DEV CELL, V6, P685, DOI 10.1016/S1534-5807(04)00133-9; Meilhac SM, 2003, DEVELOPMENT, V130, P3877, DOI 10.1242/dev.00580; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Roy K, 2002, J BIOL CHEM, V277, P33818, DOI 10.1074/jbc.M205159200; Sharpe J, 2002, SCIENCE, V296, P541, DOI 10.1126/science.1068206; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Toyoda M, 2003, DEV CELL, V5, P85, DOI 10.1016/S1534-5807(03)00189-8; von Both I, 2004, DEV CELL, V7, P331, DOI 10.1016/j.devcel.2004.07.023; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Zhou YQ, 2002, PHYSIOL GENOMICS, V10, P113, DOI 10.1152/physiolgenomics.00119.2001	30	382	394	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					107	112		10.1038/nature03071	http://dx.doi.org/10.1038/nature03071			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525990				2022-12-28	WOS:000224854900050
J	Thoma, R; Schulz-Gasch, T; D'Arcy, B; Benz, J; Aebi, J; Dehmlow, H; Hennig, M; Stihle, M; Ruf, A				Thoma, R; Schulz-Gasch, T; D'Arcy, B; Benz, J; Aebi, J; Dehmlow, H; Hennig, M; Stihle, M; Ruf, A			Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase	NATURE			English	Article							LANOSTEROL SYNTHASE; SQUALENE CYCLASE; CRYSTAL-STRUCTURE; 2,3-OXIDOSQUALENE; CATION; REFINEMENT; INHIBITORS	In higher organisms the formation of the steroid scaffold is catalysed exclusively by the membrane-bound oxidosqualene cyclase (OSC; lanosterol synthase). In a highly selective cyclization reaction OSC forms lanosterol with seven chiral centres starting from the linear substrate 2,3-oxidosqualene. Valuable data on the mechanism of the complex cyclization cascade have been collected during the past 50 years using suicide inhibitors, mutagenesis studies and homology modelling. Nevertheless it is still not fully understood how the enzyme catalyses the reaction(1,2). Because of the decisive role of OSC in cholesterol biosynthesis it represents a target for the discovery of novel anticholesteraemic drugs that could complement the widely used statins(3). Here we present two crystal structures of the human membrane protein OSC: the target protein with an inhibitor that showed cholesterol lowering in vivo opens the way for the structure-based design of new OSC inhibitors. The complex with the reaction product lanosterol gives a clear picture of the way in which the enzyme achieves product specificity in this highly exothermic cyclization reaction.	Hoffmann La Roche Ag, Pharma Res Discovery Chem, CH-4070 Basel, Switzerland	Roche Holding	Ruf, A (corresponding author), Hoffmann La Roche Ag, Pharma Res Discovery Chem, CH-4070 Basel, Switzerland.	armin.ruf@roche.com						Abe I, 1998, BIOCHEMISTRY-US, V37, P5779, DOI 10.1021/bi980366c; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Brown GR, 1999, J MED CHEM, V42, P1306, DOI 10.1021/jm990038q; Corey EJ, 1996, BIOCHEM BIOPH RES CO, V219, P327, DOI 10.1006/bbrc.1996.0232; Corey EJ, 1997, J AM CHEM SOC, V119, P1277, DOI 10.1021/ja963227w; Corey EJ, 1997, J AM CHEM SOC, V119, P1289, DOI 10.1021/ja963228o; Dehmlow H, 2003, J MED CHEM, V46, P3354, DOI 10.1021/jm021120f; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; GANDOUR RD, 1981, BIOORG CHEM, V10, P169, DOI 10.1016/0045-2068(81)90020-1; GERBER PR, 1992, BIOPOLYMERS, V32, P1003, DOI 10.1002/bip.360320811; Hoshino T, 2002, CHEM COMMUN, P291, DOI 10.1039/b108995c; Jolidon S., 1993, P223; Lenhart A, 2002, CHEM BIOL, V9, P639, DOI 10.1016/S1074-5521(02)00138-2; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Miklis PC, 1998, J AM CHEM SOC, V120, P10482, DOI 10.1021/ja980505d; Milla P, 2002, EUR J BIOCHEM, V269, P2108, DOI 10.1046/j.1432-1033.2002.02861.x; Morand OH, 1997, J LIPID RES, V38, P373; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PORALLA K, 1994, TRENDS BIOCHEM SCI, V19, P157, DOI 10.1016/0968-0004(94)90276-3; Reinert DJ, 2004, CHEM BIOL, V11, P121, DOI 10.1016/j.chembiol.2003.12.013; Roversi P, 2000, ACTA CRYSTALLOGR D, V56, P1316, DOI 10.1107/S0907444900008490; Ruf A, 2004, BIOCHEM BIOPH RES CO, V315, P247, DOI 10.1016/j.bbrc.2004.01.052; Schulz-Gasch T, 2003, J COMPUT CHEM, V24, P741, DOI 10.1002/jcc.10147; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wendt KU, 2000, ANGEW CHEM INT EDIT, V39, P2812, DOI 10.1002/1521-3773(20000818)39:16<2812::AID-ANIE2812>3.0.CO;2-#; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; Wendt KU, 1999, J MOL BIOL, V286, P175, DOI 10.1006/jmbi.1998.2470; Zoltewicz JA, 1998, J ORG CHEM, V63, P4985, DOI 10.1021/jo9801465	30	252	261	4	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					118	122		10.1038/nature02993	http://dx.doi.org/10.1038/nature02993			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525992				2022-12-28	WOS:000224854900052
J	Canagarajah, B; Leskow, FC; Ho, JYS; Mischak, H; Saidi, LF; Kazanietz, MG; Hurley, JH				Canagarajah, B; Leskow, FC; Ho, JYS; Mischak, H; Saidi, LF; Kazanietz, MG; Hurley, JH			Structural mechanism for lipid activation of the Rac-specific GAP, beta 2-chimaerin	CELL			English	Article							PROTEIN-KINASE-C; PHORBOL ESTER RECEPTOR; CYSTEINE-RICH REGION; CRYSTAL-STRUCTURE; N-CHIMAERIN; SUBCELLULAR-LOCALIZATION; INDUCED TRANSLOCATION; MEMBRANE-BINDING; NIH 3T3-CELLS; DOMAIN	The lipid second messenger diacylglycerol acts by binding to the C1 domains of target proteins, which translocate to cell membranes and are allosterically activated. Here we report the crystal structure at 3.2 Angstrom resolution of one such protein, beta2-chimaerin, a GTPase-activating protein for the small GTPase Rac, in its inactive conformation. The structure shows that in the inactive state, the N terminus of beta2-chimaerin protrudes into the active site of the RacGAP domain, sterically blocking Rac binding. The diacylglycerol and phospholipid membrane binding site on the C1 domain is buried by contacts with the four different regions of beta2-chimaerin: the N terminus, SH2 domain, RacGAP domain, and the linker between the SH2 and C1 domains. Phospholipid binding to the C1 domain triggers the cooperative dissociation of these interactions, allowing the N terminus to move out of the active site and thereby activating the enzyme.	NIDDKD, Mol Biol Lab, NIH, US Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Pennsylvania; University of Pennsylvania	Hurley, JH (corresponding author), NIDDKD, Mol Biol Lab, NIH, US Dept Hlth & Human Serv, Bethesda, MD 20892 USA.	hurley@helix.nih.gov	Mischak, Harald/E-8685-2011	Mischak, Harald/0000-0003-0323-0306	NCI NIH HHS [R01-CA74197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1993, J BIOL CHEM, V268, P10709; Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; ARECES LB, 1994, J BIOL CHEM, V269, P19553; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bogi K, 1999, FEBS LETT, V456, P27, DOI 10.1016/S0014-5793(99)00927-8; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; Caloca MJ, 2003, BIOCHEM J, V375, P313, DOI 10.1042/BJ20030727; Caloca MJ, 1997, J BIOL CHEM, V272, P26488, DOI 10.1074/jbc.272.42.26488; Caloca MJ, 2001, J BIOL CHEM, V276, P18303, DOI 10.1074/jbc.M011368200; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; Hurley James H, 2003, Methods Mol Biol, V233, P289; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Hurley JH, 1997, PROTEIN SCI, V6, P477; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P14679, DOI 10.1074/jbc.270.24.14679; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LEUNG T, 1994, J BIOL CHEM, V269, P12888; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Slater SJ, 1999, BIOCHEMISTRY-US, V38, P3804, DOI 10.1021/bi982778r; Soltis SM, 1997, J APPL CRYSTALLOGR, V30, P190, DOI 10.1107/S0021889896012939; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Wurtele M, 2001, NAT STRUCT BIOL, V8, P23; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YUAN SX, 1995, CANCER RES, V55, P3456; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	60	105	106	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2004	119	3					407	418		10.1016/j.cell.2004.10.012	http://dx.doi.org/10.1016/j.cell.2004.10.012			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	868IW	15507211	Bronze			2022-12-28	WOS:000224908300011
J	Jordan, F				Jordan, F			Biochemistry - How active sites communicate in thiamine enzymes	SCIENCE			English	Editorial Material							PYRUVATE-DEHYDROGENASE; ANGSTROM RESOLUTION; DIPHOSPHATE; COMPLEX; PYROPHOSPHATE; COMPONENT		Rutgers State Univ, Dept Chem, Newark, NJ 07102 USA	Rutgers State University Newark; Rutgers State University New Brunswick	Jordan, F (corresponding author), Rutgers State Univ, Dept Chem, Newark, NJ 07102 USA.	frjordan@newark.rutgers.edu			NIGMS NIH HHS [GM-50380, GM-62330] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; Ciszak EM, 2003, J BIOL CHEM, V278, P21240, DOI 10.1074/jbc.M300339200; Frank RAW, 2004, SCIENCE, V306, P872, DOI 10.1126/science.1101030; JORDAN F, 2004, THIAMINE CATALYTIC M, P1; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KHAILOVA LS, 1985, BIOCHEM INT, V11, P509; NEET KE, 1983, CONT ENZYME KINETICS, P267; Nemeria N, 2004, BIOCHEMISTRY-US, V43, P6565, DOI 10.1021/bi049549r	9	17	17	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					818	820		10.1126/science.1105457	http://dx.doi.org/10.1126/science.1105457			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514144				2022-12-28	WOS:000224969400031
J	van de Beek, D; de Gans, J; Spanjaard, L; Weisfelt, M; Reitsma, JB; Vermeulen, M				van de Beek, D; de Gans, J; Spanjaard, L; Weisfelt, M; Reitsma, JB; Vermeulen, M			Clinical features and prognostic factors in adults with bacterial meningitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE-UNIT; PNEUMOCOCCAL MENINGITIS; STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL THERAPY; LUMBAR PUNCTURE; DEXAMETHASONE; SUSCEPTIBILITY; COMPLICATIONS; NETHERLANDS; CHILDREN	BACKGROUND: We conducted a nationwide study in the Netherlands to determine clinical features and prognostic factors in adults with community-acquired acute bacterial meningitis. METHODS: From October 1998 to April 2002, all Dutch patients with community-acquired acute bacterial meningitis, confirmed by cerebrospinal fluid cultures, were prospectively evaluated. All patients underwent a neurologic examination on admission and at discharge, and outcomes were classified as unfavorable (defined by a Glasgow Outcome Scale score of 1 to 4 points at discharge) or favorable (a score of 5). Predictors of an unfavorable outcome were identified through logistic-regression analysis. RESULTS: We evaluated 696 episodes of community-acquired acute bacterial meningitis. The most common pathogens were Streptococcus pneumoniae (51 percent of episodes) and Neisseria meningitidis (37 percent). The classic triad of fever, neck stiffness, and a change in mental status was present in only 44 percent of episodes; however, 95 percent had at least two of the four symptoms of headache, fever, neck stiffness, and altered mental status. On admission, 14 percent of patients were comatose and 33 percent had focal neurologic abnormalities. The overall mortality rate was 21 percent. The mortality rate was higher among patients with pneumococcal meningitis than among those with meningococcal meningitis (30 percent vs. 7 percent, P<0.001). The outcome was unfavorable in 34 percent of episodes. Risk factors for an unfavorable outcome were advanced age, presence of otitis or sinusitis, absence of rash, a low score on the Glasgow Coma Scale on admission, tachycardia, a positive blood culture, an elevated erythrocyte sedimentation rate, thrombocytopenia, and a low cerebrospinal fluid white-cell count. CONCLUSIONS: In adults presenting with community-acquired acute bacterial meningitis, the sensitivity of the classic triad of fever, neck stiffness, and altered mental status is low, but almost all present with at least two of the four symptoms of headache, fever, neck stiffness, and altered mental status. The mortality associated with bacterial meningitis remains high, and the strongest risk factors for an unfavorable outcome are those that are indicative of systemic compromise, a low level of consciousness, and infection with S. pneumoniae.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Netherlands Reference Lab Bacterial Meningitis, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van de Beek, D (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol H2, POB 22660, NL-1100 DD Amsterdam, Netherlands.	d.vandebeek@amc.uva.nl	van de beek, diederik/A-2935-2010; van de Beek, Diederik/Y-2713-2019	van de Beek, Diederik/0000-0002-4571-044X				Arditi M, 1998, PEDIATRICS, V102, P1087, DOI 10.1542/peds.102.5.1087; Arnold AM, 2003, AM J EPIDEMIOL, V157, P74, DOI 10.1093/aje/kwf156; Aronin SI, 1998, ANN INTERN MED, V129, P862, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00004; Aronin Steven I, 2002, Expert Opin Pharmacother, V3, P121, DOI 10.1517/14656566.3.2.121; Attia J, 1999, JAMA-J AM MED ASSOC, V282, P175, DOI 10.1001/jama.282.2.175; Auburtin M, 2002, AM J RESP CRIT CARE, V165, P713, DOI 10.1164/ajrccm.165.5.2105110; BOHR V, 1985, J INFECTION, V10, P143, DOI 10.1016/S0163-4453(85)91585-3; BRUYN GAW, 1989, EUR J CLIN MICROBIOL, V8, P695, DOI 10.1007/BF01963754; de Gans J, 2002, NEW ENGL J MED, V347, P1549, DOI 10.1056/NEJMoa021334; de Gans J, 2003, NEW ENGL J MED, V348, P955; DODGE PR, 1965, NEW ENGL J MED, V272, P954, DOI 10.1056/NEJM196505062721806; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; Flores-Cordero JM, 2003, INTENS CARE MED, V29, P1967, DOI 10.1007/s00134-003-1935-4; Hasbun R, 2001, NEW ENGL J MED, V345, P1727, DOI 10.1056/NEJMoa010399; Hoen B, 1993, Eur J Med, V2, P28; Hussein AS, 2000, MEDICINE, V79, P360, DOI 10.1097/00005792-200011000-00002; Jennett B., 1981, MANAGEMENT HEAD INJU; Kastenbauer S, 2003, BRAIN, V126, P1015, DOI 10.1093/brain/awg113; Kellner JD, 2002, PEDIATR INFECT DIS J, V21, P903, DOI 10.1097/00006454-200210000-00004; KIRKPATRICK B, 1994, J INFECTION, V29, P171, DOI 10.1016/S0163-4453(94)90698-X; KRAGSBJERG P, 1994, SCAND J INFECT DIS, V26, P659, DOI 10.3109/00365549409008633; Little R. J. A., 1987, STAT ANAL MISSING DA; Lu CH, 2002, CLIN NEUROL NEUROSUR, V104, P352, DOI 10.1016/S0303-8467(02)00052-5; Magnussen C R, 1980, N Y State J Med, V80, P901; McMillan DA, 2001, CLIN INFECT DIS, V33, P969, DOI 10.1086/322612; *NETH REF LAB BACT, 2003, BACT MEN NETH ANN RE; OLSSON RA, 1961, ANN INTERN MED, V55, P545, DOI 10.7326/0003-4819-55-4-545; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; Sigurdardottir B, 1997, ARCH INTERN MED, V157, P425, DOI 10.1001/archinte.157.4.425; SPANOS A, 1989, JAMA-J AM MED ASSOC, V262, P2700, DOI 10.1001/jama.262.19.2700; *STAT METH, 2001, STATL; TAUBER MG, 1992, AM J PATHOL, V141, P53; TUNKEL AR, 2001, BACTERIAL MENINGITIS; van Crevel H, 2002, J NEUROL, V249, P129, DOI 10.1007/PL00007855; van de Beek D, 2004, LANCET INFECT DIS, V4, P139, DOI 10.1016/S1473-3099(04)00937-5; van de Beek D, 2002, J INFECT DIS, V186, P1047, DOI 10.1086/344229; van de Beek D, 2002, J ANTIMICROB CHEMOTH, V49, P661, DOI 10.1093/jac/49.4.661; van de Beek D, 2004, ANN INTERN MED, V141, P327, DOI 10.7326/0003-4819-141-4-200408170-00028; van de Beek D, 1997, J ANTIMICROB CHEMOTH, V40, P895, DOI 10.1093/jac/40.6.895; WEISS W, 1967, ARCH INTERN MED, V120, P517, DOI 10.1001/archinte.120.5.517; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823	42	916	932	1	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1849	1859		10.1056/NEJMoa040845	http://dx.doi.org/10.1056/NEJMoa040845			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509818	Green Published			2022-12-28	WOS:000224723100008
J	Mortimer, NJ; Mills, J				Mortimer, NJ; Mills, J			Beau's lines	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Leicester Royal Infirm, Leicester LE1 5WW, Leics, England	University of Leicester	Mortimer, NJ (corresponding author), Leicester Royal Infirm, Leicester LE1 5WW, Leics, England.			Mills, James/0000-0003-4496-332X					0	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2004	351	17					1778	1778		10.1056/NEJMicm040187	http://dx.doi.org/10.1056/NEJMicm040187			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863TH	15496627				2022-12-28	WOS:000224585200013
J	Mermin, J; Lule, J; Ekwaru, JP; Malamba, S; Downing, R; Ransom, R; Kaharuza, F; Culver, D; Kizito, F; Bunnell, R; Kigozi, A; Nakanjako, D; Wafula, W; Quick, R				Mermin, J; Lule, J; Ekwaru, JP; Malamba, S; Downing, R; Ransom, R; Kaharuza, F; Culver, D; Kizito, F; Bunnell, R; Kigozi, A; Nakanjako, D; Wafula, W; Quick, R			Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda	LANCET			English	Article							TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS; PNEUMOCYSTIS-CARINII-PNEUMONIA; IMMUNODEFICIENCY-VIRUS DISEASE; PLASMODIUM-FALCIPARUM; BACTERIAL PNEUMONIA; RANDOMIZED-TRIAL; COTE-DIVOIRE; OPPORTUNISTIC INFECTIONS; HIV-1-INFECTED ADULTS; IMMUNE ACTIVATION	Background Prophylaxis with co-trimoxazole (trimethoprim-sulphamethoxazole) is recommended for people with HIV infection or AIDS but is rarely used in Africa. We assessed the effect of such prophylaxis on morbidity, mortality, CD4-cell count, and viral load among people with HIV infection living in rural Uganda, an area with high rates of bacterial resistance to co-trimoxazole. Methods Between April, 2001, and March, 2003, we enrolled, and followed up with weekly home visits, 509 individuals with HIV-1 infection and their 1522 HIV-negative household members. After 5 months of follow-up, HIV-positive participants were offered daily co-trimoxazole prophylaxis (800 mg trimethoprim, 160 mg sulphamethoxazole) and followed up for a further 1 - 5 years. We assessed rates of malaria, diarrhoea, hospital admission, and death. Findings Co-trimoxazole was well tolerated with rare (<2% per person-year) adverse reactions. Even though rates of resistance in diarrhoeal pathogens were high (76%), co-trimoxazole prophylaxis was associated with a 46% reduction in mortality (hazard ratio 0.54 [95% CI 0.35-0.84], p=0.006) and lower rates of malaria (multivariate incidence rate ratio 0.28 [0.19-0.40], p<0.0001), diarrhoea (0.65 [0.53-0.81], p<0.0001), and hospital admission (0.69 [0.48-0.98), p=0.04). The annual rate of decline in CD4-cell count was less during prophylaxis than before (77 vs 203 cells per mu L, p<0.0001), and the annual rate of increase in viral load was lower (0.08 vs 0 - 90 logo copies per mL, p=0.01). Interpretation Daily co-trimoxazole prophylaxis was associated with reduced morbidity and mortality and had beneficial effects on CD4-cell count and viral load. Co-trimoxazole prophylaxis is a readily available, effective intervention for people with HIV infection in Africa.	Ctr Dis Control & Prevent, CDC Uganda, Global AIDS Program, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA; Ctr Dis Control & Prevent, Hepatitis Branch, Div Viral Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA; AIDS Support Org, Kampala, Uganda	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Mermin, J (corresponding author), Uganda Virus Res Inst, POB 49, Entebbe, Uganda.	jhm7@cdc.gov	Mermin, Jonathan/J-9847-2012	Nakanjako, Damalie/0000-0002-0935-2112				Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Anglaret X, 2001, LANCET, V358, P1027, DOI 10.1016/S0140-6736(01)06227-4; Badri M, 1999, LANCET, V354, P334, DOI 10.1016/S0140-6736(05)75237-5; Badri M, 2001, AIDS, V15, P1143, DOI 10.1097/00002030-200106150-00009; Brou H, 2003, AIDS CARE, V15, P629, DOI 10.1080/09540120310001595113; Bush CE, 1996, J ACQ IMMUN DEF SYND, V13, P23, DOI 10.1097/00042560-199609000-00004; Chaisson RE, 1998, AIDS, V12, P29, DOI 10.1097/00002030-199801000-00004; Donovan RM, 1996, J INFECT DIS, V174, P401, DOI 10.1093/infdis/174.2.401; Dorsey G, 2002, LANCET, V360, P2031, DOI 10.1016/S0140-6736(02)12021-6; El-Sadr WM, 1999, CLIN INFECT DIS, V29, P775, DOI 10.1086/520433; Hoffman IF, 1999, AIDS, V13, P487, DOI 10.1097/00002030-199903110-00007; Iyer JK, 2001, LANCET, V358, P1066, DOI 10.1016/S0140-6736(01)06201-8; Kaplan JE, 1999, CLIN INFECT DIS, V29, P544, DOI 10.1086/598630; KAPLAN JE, 2002, GUIDELINES PREVENTIN; Kilian AHD, 1998, T ROY SOC TROP MED H, V92, P197, DOI 10.1016/S0035-9203(98)90748-9; Maynart M, 2001, J ACQ IMMUN DEF SYND, V26, P130, DOI 10.1097/00126334-200102010-00004; Mole L, 1997, J INFECT DIS, V176, P766, DOI 10.1086/517297; Mwansa J, 2002, EMERG INFECT DIS, V8, P92, DOI 10.3201/eid0801.010018; *NCCLS, 1998, NCCLS PERF STAND ANT; Osmond DH, 1999, CLIN INFECT DIS, V29, P536, DOI 10.1086/598629; Rabaud C, 2001, SCAND J INFECT DIS, V33, P759, DOI 10.1080/003655401317074581; Rapuoda B, 2003, TROP MED INT HEALTH, V8, P860, DOI 10.1046/j.1360-2276.2003.01114.x; Salazar-Gonzalez JF, 1998, J INFECT DIS, V178, P423, DOI 10.1086/515629; Seage GR, 2002, J ACQ IMMUN DEF SYND, V30, P421, DOI [10.1097/01.QAI.0000021700.48448.69, 10.1097/00042560-200208010-00008]; UNAIDS/WHO, 2000, PROV WHO UNAIDS SECR; Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3; Weissman D, 1996, J EXP MED, V183, P687, DOI 10.1084/jem.183.2.687; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; Wolday D, 2002, JAIDS-J ACQ IMM DEF, V31, P56, DOI 10.1097/00126334-200209010-00008; Xiao LH, 1998, J INFECT DIS, V177, P437, DOI 10.1086/514212; Yoshimine H, 2001, AM J TROP MED HYG, V64, P172; Zachariah R, 2003, AIDS, V17, P1053, DOI 10.1097/00002030-200305020-00015; Zar H J, 2001, SADJ, V56, P617	34	265	272	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2004	364	9443					1428	1434		10.1016/S0140-6736(04)17225-5	http://dx.doi.org/10.1016/S0140-6736(04)17225-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488218	Green Submitted			2022-12-28	WOS:000224485300029
J	Berggren, PO; Yang, SN; Murakami, M; Efanov, AM; Uhles, S; Kohler, M; Moede, T; Fernstrom, A; Appelskog, LB; Aspinwall, CA; Zaitsev, SV; Larsson, O; de Vargas, LM; Fecher-Trost, C; Weissgerber, P; Ludwig, A; Leibiger, B; Juntti-Berggren, L; Barker, CJ; Gromada, J; Freichel, M; Leibiger, IB; Flockerzi, V				Berggren, PO; Yang, SN; Murakami, M; Efanov, AM; Uhles, S; Kohler, M; Moede, T; Fernstrom, A; Appelskog, LB; Aspinwall, CA; Zaitsev, SV; Larsson, O; de Vargas, LM; Fecher-Trost, C; Weissgerber, P; Ludwig, A; Leibiger, B; Juntti-Berggren, L; Barker, CJ; Gromada, J; Freichel, M; Leibiger, IB; Flockerzi, V			Removal of Ca2+ channel beta(3) Subunit enhances Ca2+ oscillation frequency and insulin exocytosis	CELL			English	Article							PANCREATIC BETA-CELLS; GATED CALCIUM-CHANNELS; INOSITOL 1,4,5-TRISPHOSPHATE; FUNCTIONAL EXPRESSION; SUBUNIT; COMPLEX; GLUCOSE; TRANSCRIPTION; MODULATION; ACTIVATION	An oscillatory increase in pancreatic beta cell cytoplasmic free Ca2+ concentration, [Ca2+](i), is a key feature in glucose-induced insulin release. The role of the voltage-gated Ca2+ channel beta(3) subunit in the molecular regulation of these [Ca2+](i) oscillations has now been clarified by using beta(3) subunit-deficient beta cells. beta(3) knockout mice showed a more efficient glucose homeostasis compared to wild-type mice due to increased glucose-stimulated insulin secretion. This resulted from an increased glucose-induced [Ca2+](i) oscillation frequency in beta cells lacking the beta(3) subunit, an effect accounted for by enhanced formation of inositol 1,4,5-trisphosphate (InsP(3)) and increased Ca2+ mobilization from intracellular stores. Hence, the beta(3) subunit negatively modulated InsP(3)-induced Ca2+ release, which is not paralleled by any effect on the voltage-gated L type Ca2+ channel. Since the increase in insulin release was manifested only at high glucose concentrations, blocking the beta(3) subunit in the beta cell may constitute the basis for a novel diabetes therapy.	Karolinska Univ Hosp SOlna, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden; Univ Saarland, D-66421 Homburg, Germany; Lilly Res Labs, D-22419 Hamburg, Germany; Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Boston Univ, Sch Med, Evans BIomed Res Ctr, Boston, MA 02118 USA; Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	Karolinska Institutet; Karolinska University Hospital; Saarland University; Eli Lilly; Lilly Deutschland GmbH; Lomonosov Moscow State University; Boston University; Technical University of Munich	Berggren, PO (corresponding author), Karolinska Univ Hosp SOlna, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden.	per-olof.berggren@molmed.ki.se	Tuluc, Petronel/C-2527-2011; Efanov, Alexander/R-3630-2019	Efanov, Alexander/0000-0002-8630-1503; Berggren, Per-Olof/0000-0001-8991-413X; Uhles, Sabine/0000-0002-2836-8726; Kohler, Martin/0000-0001-6487-4303; Aspinwall, Craig/0000-0002-4359-5812; Moede, Tilo/0000-0002-2045-9244	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; BARKER CJ, 1995, BIOCHEM J, V306, P557, DOI 10.1042/bj3060557; BARKER CJ, 1994, BIOCHEM J, V297, P265, DOI 10.1042/bj2970265; Barker CJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE1113, DOI 10.1152/ajpendo.00088.2002; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Dolphin AC, 2003, PHARMACOL REV, V55, P607, DOI 10.1124/pr.55.4.3; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hibino H, 2003, P NATL ACAD SCI USA, V100, P307, DOI 10.1073/pnas.0136791100; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; IHARA Y, 1995, MOL ENDOCRINOL, V9, P121, DOI 10.1210/me.9.1.121; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Murakami M, 2002, J BIOL CHEM, V277, P40342, DOI 10.1074/jbc.M203425200; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; ROE MW, 1993, J BIOL CHEM, V268, P9953; Roe MW, 1998, J BIOL CHEM, V273, P10402, DOI 10.1074/jbc.273.17.10402; Scholze A, 2001, MOL ENDOCRINOL, V15, P1211, DOI 10.1210/me.15.7.1211; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; STADDON JM, 1991, J BIOL CHEM, V266, P4840; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Wang XZ, 2000, J VIROL, V74, P11296, DOI 10.1128/JVI.74.23.11296-11303.2000; Yang SN, 1999, P NATL ACAD SCI USA, V96, P10164, DOI 10.1073/pnas.96.18.10164; Yasuda T, 2004, J GEN PHYSIOL, V123, P401, DOI 10.1085/jgp.200308967; Yu J, 2003, J BIOL CHEM, V278, P46210, DOI 10.1074/jbc.M303743200; Zaitsev SV, 2001, DIABETES, V50, pS70, DOI 10.2337/diabetes.50.2007.S70	34	89	97	0	13	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	2004	119	2					273	284		10.1016/j.cell.2004.09.033	http://dx.doi.org/10.1016/j.cell.2004.09.033			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479643	Bronze			2022-12-28	WOS:000224577200014
J	Ozcan, U; Cao, Q; Yilmaz, E; Lee, AH; Iwakoshi, NN; Ozdelen, E; Tuncman, G; Gorgun, C; Glimcher, LH; Hotamisligil, GS				Ozcan, U; Cao, Q; Yilmaz, E; Lee, AH; Iwakoshi, NN; Ozdelen, E; Tuncman, G; Gorgun, C; Glimcher, LH; Hotamisligil, GS			Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes	SCIENCE			English	Article							UNFOLDED PROTEIN RESPONSE; TRANSLATIONAL CONTROL; TRANSCRIPTION FACTOR; MESSENGER-RNA; ER STRESS; KINASE; RESISTANCE; XBP-1; IRE1; JNK	Obesity contributes to the development of type 2 diabetes, but the underlying mechanisms are poorly understood. Using cell culture and mouse models, we show that obesity causes endoplasmic reticulum (ER) stress. This stress in turn leads to suppression of insulin receptor signaling through hyperactivation of c-Jun N-terminal kinase (JNK) and subsequent serine phosphorylation of insulin receptor substrate-1 (IRS-1). Mice deficient in X-box-binding protein-1 (XBP-1), a transcription factor that modulates the ER stress response, develop insulin resistance. These findings demonstrate that ER stress is a central feature of peripheral insulin resistance and type 2 diabetes at the molecular, cellular, and organismal levels. Pharmacologic manipulation of this pathway may offer novel opportunities for treating these common diseases.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Hotamisligil, GS (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	ghotamis@hsph.harvard.edu	Longo, Kenneth A/A-5631-2010; YILMAZ, ERKAN/O-1592-2014	YILMAZ, ERKAN/0000-0001-7355-3878	NATIONAL CANCER INSTITUTE [P50CA100707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007703, R01DK052539] Funding Source: NIH RePORTER; NCI NIH HHS [P05-CA100707] Funding Source: Medline; NIAID NIH HHS [AI32412] Funding Source: Medline; NIDDK NIH HHS [T32-DK07703, DK52539] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; Hampton RY, 2000, CURR BIOL, V10, pR518, DOI 10.1016/S0960-9822(00)00583-2; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hotamisligin G. S., 2003, DIABETES MELLITUS, P953; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; KHARROUBI I, 2004, ENDOCRINOLOGY   0805, DOI DOI 10.1210/EN.2004-0478; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; OZCAN U, UNPUB; Reimold AM, 2000, GENE DEV, V14, P152; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shi YG, 2003, ENDOCR REV, V24, P91, DOI 10.1210/er.2002-0018; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	26	2805	2968	12	363	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					457	461		10.1126/science.1103160	http://dx.doi.org/10.1126/science.1103160			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486293				2022-12-28	WOS:000224626500044
J	Yohe, G; Andronova, N; Schlesinger, M				Yohe, G; Andronova, N; Schlesinger, M			Climate - To hedge or not against an uncertain climate	SCIENCE			English	Editorial Material									Wesleyan Univ, Dept Econ, Middletown, CT 06459 USA; Univ Illinois, Dept Atmospher Sci, Climate Res Grp, Urbana, IL 61801 USA	Wesleyan University; University of Illinois System; University of Illinois Urbana-Champaign	Yohe, G (corresponding author), Wesleyan Univ, Dept Econ, Middletown, CT 06459 USA.	gyohe@wesleyan.edu	Andronova, Natalia/I-8983-2012					Andronova NG, 2001, J GEOPHYS RES-ATMOS, V106, P22605, DOI 10.1029/2000JD000259; *IPCC, 2001, CLIM CHANG 2001 IMP, pCH19; Jones PD, 2003, J CLIMATE, V16, P206, DOI 10.1175/1520-0442(2003)016<0206:HALSSA>2.0.CO;2; Lempert RJ, 2000, CLIMATIC CHANGE, V45, P387, DOI 10.1023/A:1005698407365; Manne A. S., 1995, SUMMARY POLL RESULTS; Nordhaus W. D., 2001, WARMING WORLD EC MOD; NORDHAUS WD, 1991, ECON J, V101, P920, DOI 10.2307/2233864; SCHNEIDER S, 2003, ENVEPOCGSP200313 OEC; SMITH J, 2003, ENVEPOCGSP200312 OEC; Yohe G, 1996, GLOBAL ENVIRON CHANG, V6, P87, DOI 10.1016/0959-3780(96)00004-0	10	99	100	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2004	306	5695					416	417		10.1126/science.1101170	http://dx.doi.org/10.1126/science.1101170			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486278				2022-12-28	WOS:000224626500030
J	Abbott, LF; Regehr, WG				Abbott, LF; Regehr, WG			Synaptic computation	NATURE			English	Article							LONG-TERM POTENTIATION; ENDOGENOUS CANNABINOIDS; RECEPTOR DESENSITIZATION; RETROGRADE INHIBITION; DEPRESSION; SYNAPSES; PLASTICITY; RELEASE; CALCIUM; INFORMATION	Neurons are often considered to be the computational engines of the brain, with synapses acting solely as conveyers of information. But the diverse types of synaptic plasticity and the range of timescales over which they operate suggest that synapses have a more active role in information processing. Long-term changes in the transmission properties of synapses provide a physiological substrate for learning and memory, whereas short-term changes support a variety of computations. By expressing several forms of synaptic plasticity, a single neuron can convey an array of different signals to the neural circuit in which it operates.	Brandeis Univ, Volcani Ctr, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Brandeis University; Brandeis University; Harvard University; Harvard Medical School	Abbott, LF (corresponding author), Brandeis Univ, Volcani Ctr, Waltham, MA 02454 USA.	abbott@brandeis.edu						Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; Auger C, 2000, J PHYSIOL-LONDON, V526, P3, DOI 10.1111/j.1469-7793.2000.t01-3-00003.x; Blitz DM, 2003, J NEUROPHYSIOL, V90, P2438, DOI 10.1152/jn.00562.2003; Brenowitz S, 1998, NEURON, V20, P135, DOI 10.1016/S0896-6273(00)80441-9; Brenowitz S, 2001, J NEUROSCI, V21, P1857, DOI 10.1523/JNEUROSCI.21-06-01857.2001; Brenowitz SD, 2003, J NEUROSCI, V23, P6373; Brown RE, 2003, NAT REV NEUROSCI, V4, P1013, DOI 10.1038/nrn1257; Brown SP, 2003, NAT NEUROSCI, V6, P1048, DOI 10.1038/nn1126; Burrone J, 2003, CURR OPIN NEUROBIOL, V13, P560, DOI 10.1016/j.conb.2003.09.007; Carandini M, 2002, J NEUROSCI, V22, P10053; CHANDRAN PKG, 1985, ADV CAPD, V1, P18; Chavkin C, 2000, PROG BRAIN RES, V125, P363; Chen CF, 2002, NEURON, V33, P779, DOI 10.1016/S0896-6273(02)00611-6; Chevaleyre V, 2003, NEURON, V38, P461, DOI 10.1016/S0896-6273(03)00235-6; Chung S, 2002, NEURON, V34, P437, DOI 10.1016/S0896-6273(02)00659-1; Conn PJ, 2003, ANN NY ACAD SCI, V1003, P12, DOI 10.1196/annals.1300.002; Cook DL, 2003, NATURE, V421, P66, DOI 10.1038/nature01248; Craig AM, 2001, NAT NEUROSCI, V4, P569, DOI 10.1038/88388; Dittman JS, 2000, J NEUROSCI, V20, P1374; Eccles, 2013, PHYSL SYNAPSES; Fitzsimonds RM, 1998, PHYSIOL REV, V78, P143, DOI 10.1152/physrev.1998.78.1.143; Fortune ES, 2002, J PHYSIOLOGY-PARIS, V96, P539, DOI 10.1016/S0928-4257(03)00009-3; Freeman TCB, 2002, NEURON, V35, P759, DOI 10.1016/S0896-6273(02)00819-X; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Fuhrmann G, 2002, J NEUROPHYSIOL, V87, P140, DOI 10.1152/jn.00258.2001; Gerdeman GL, 2002, NAT NEUROSCI, V5, P446, DOI 10.1038/nn832; Goldman MS, 2002, J NEUROSCI, V22, P584, DOI 10.1523/JNEUROSCI.22-02-00584.2002; GROSSBERG S, 1994, BRAIN INFORMATION EV, P58; Hausser M, 2000, SCIENCE, V290, P739, DOI 10.1126/science.290.5492.739; Hopfield JJ, 2004, P NATL ACAD SCI USA, V101, P337, DOI 10.1073/pnas.2536316100; Johnston D, 2003, PHILOS T ROY SOC B, V358, P667, DOI 10.1098/rstb.2002.1248; Jones MV, 1996, TRENDS NEUROSCI, V19, P96, DOI 10.1016/S0166-2236(96)80037-3; Kandel E., 2000, PRINCIPLES NEURAL SC, P1414; Katz B., 1966, NERVE MUSCLE SYNAPSE; Kombian SB, 1997, NEURON, V19, P903, DOI 10.1016/S0896-6273(00)80971-X; Konishi M, 2003, ANNU REV NEUROSCI, V26, P31, DOI 10.1146/annurev.neuro.26.041002.131123; Kreitzer AC, 2001, NEURON, V29, P717, DOI 10.1016/S0896-6273(01)00246-X; Kreitzer AC, 2002, CURR OPIN NEUROBIOL, V12, P324, DOI 10.1016/S0959-4388(02)00328-8; Kuba H, 2002, EUR J NEUROSCI, V15, P984, DOI 10.1046/j.1460-9568.2002.01933.x; Liaw JS, 1996, HIPPOCAMPUS, V6, P591; Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9; LLANO I, 1991, NEURON, V6, P565, DOI 10.1016/0896-6273(91)90059-9; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Maass W, 2002, NEURAL NETWORKS, V15, P155, DOI 10.1016/S0893-6080(01)00144-7; Maass W, 1999, NEURAL COMPUT, V11, P903, DOI 10.1162/089976699300016494; MAGLEBY KL, 1987, SYNAPTIC FUNCTION, P21; Markram H, 1998, P NATL ACAD SCI USA, V95, P5323, DOI 10.1073/pnas.95.9.5323; Markram H, 1998, NEUROBIOL LEARN MEM, V70, P101, DOI 10.1006/nlme.1998.3841; Markram H, 1998, NEUROPHARMACOLOGY, V37, P489, DOI 10.1016/S0028-3908(98)00049-5; Melamed O, 2004, TRENDS NEUROSCI, V27, P11, DOI 10.1016/j.tins.2003.10.014; Morris RGM, 2003, PHILOS T ROY SOC B, V358, P643, DOI 10.1098/rstb.2002.1230; ODonovan MJ, 1997, TRENDS NEUROSCI, V20, P431, DOI 10.1016/S0166-2236(97)01124-7; Ohno-Shosaku T, 2001, NEURON, V29, P729, DOI 10.1016/S0896-6273(01)00247-1; Okatan M, 2000, NEURAL NETWORKS, V13, P699, DOI 10.1016/S0893-6080(00)00036-8; PITLER TA, 1992, J NEUROSCI, V12, P4122; Reyes A, 1998, NAT NEUROSCI, V1, P279, DOI 10.1038/1092; Sandberg A, 2003, NETWORK-COMP NEURAL, V14, P789, DOI 10.1088/0954-898X/14/4/309; Schultz W, 2000, ANNU REV NEUROSCI, V23, P473, DOI 10.1146/annurev.neuro.23.1.473; Silberberg G, 2004, J PHYSIOL-LONDON, V556, P19, DOI 10.1113/jphysiol.2004.060962; Sjostrom PJ, 2003, NEURON, V39, P641, DOI 10.1016/S0896-6273(03)00476-8; Tao HZW, 2001, P NATL ACAD SCI USA, V98, P11009, DOI 10.1073/pnas.191351698; Thomson AM, 2003, J COMPUT NEUROSCI, V15, P159, DOI 10.1023/A:1025812808362; Thomson AM, 2002, PHILOS T R SOC B, V357, P1781, DOI 10.1098/rstb.2002.1163; Trommershauser J, 2003, BIOPHYS J, V84, P1563, DOI 10.1016/S0006-3495(03)74967-4; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; Wilson RI, 2001, NATURE, V410, P588, DOI 10.1038/35069076; Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545; Xu-Friedman MA, 2003, J NEUROSCI, V23, P2182; Zador AM, 1997, NEURON, V19, P1, DOI 10.1016/S0896-6273(00)80341-4; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	75	1076	1096	33	301	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					796	803		10.1038/nature03010	http://dx.doi.org/10.1038/nature03010			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483601				2022-12-28	WOS:000224435500036
J	Buchwald, H; Avidor, Y; Braunwald, E; Jensen, MD; Pories, W; Fahrbach, K; Schoelles, K				Buchwald, H; Avidor, Y; Braunwald, E; Jensen, MD; Pories, W; Fahrbach, K; Schoelles, K			Bariatric surgery: A systematic review and meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MORBIDLY OBESE-PATIENTS; GASTRIC BYPASS-SURGERY; QUALITY-OF-LIFE; VERTICAL BANDED GASTROPLASTY; TYPE-2 DIABETES-MELLITUS; OBSTRUCTIVE SLEEP-APNEA; INTENTIONAL WEIGHT-LOSS; LONG-TERM; BILIOPANCREATIC DIVERSION; UNITED-STATES	Context About 5% of the US population is morbidly obese. This disease remains largely refractory to diet and drug therapy, but generally responds well to bariatric surgery. Objective To determine the impact of bariatric surgery on weight loss, operative mortality outcome, and 4 obesity comorbidities (diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea). Data Sources and Study Selection Electronic literature search of MEDLINE, Current Contents, and the Cochrane Library databases plus manual reference checks of all articles on bariatric surgery published in the English language between 1990 and 2003. Two levels of screening were used on 2738 citations. Data Extraction A total of 136 fully extracted studies, which included 91 overlapping patient populations (kin studies), were included for a total of 22094 patients. Nineteen percent of the patients were men and 72.6% were women, with a mean age of 39 years (range, 16-64 years). Sex was not reported for 1537 patients (8%). The baseline mean body mass index for 16 944 patients was 46.9 (range, 32.3-68.8). Data Synthesis A random effects model was used in the meta-analysis. The mean (95% confidence interval) percentage of excess weight loss was 61.2% (58.1%-64.4%) for all patients; 47.5% (40.7%-54.2%) for patients who underwent gastric banding; 61.6% (56.7%-66.5%), gastric bypass; 68.2% (61.5%-74.8%), gastroplasty; and 70.1% (66.3%-73.9%), biliopancreatic diversion or duodenal switch. Operative mortality (less than or equal to30 days) in the extracted studies was 0.1% for the purely restrictive procedures, 0.5% for gastric bypass, and 1.1% for biliopancreatic diversion or duodenal switch. Diabetes was completely resolved in 76.8% of patients and resolved or improved in 86.0%. Hyperlipidemia improved in 70% or more of patients. Hypertension was resolved in 61.7% of patients and resolved or improved in 78.5%. Obstructive sleep apnea was resolved in 85.7% of patients and was resolved or improved in 83.6% of patients. Conclusions Effective weight loss was achieved in morbidly obese patients after undergoing bariatric surgery. A substantial majority of patients with diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea experienced complete resolution or improvement.	Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA; Ethicon Endosurg Inc, Cincinnati, OH USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Mayo Clin, Coll Med, Dept Med, Rochester, MN USA; E Carolina Univ, Sch Med, Dept Surg, Greenville, NC 27858 USA; MetaWorks Inc, Medford, MA USA	University of Minnesota System; University of Minnesota Twin Cities; Johnson & Johnson; Johnson & Johnson USA; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Mayo Clinic; University of North Carolina; East Carolina University	Buchwald, H (corresponding author), Univ Minnesota, Dept Surg, 420 Delaware St SE,MMC 290, Minneapolis, MN 55455 USA.	buchw001@umn.edu	Kohn, Geoffrey P/A-9056-2009					[Anonymous], 1990, Arch Intern Med, V150, P153, DOI 10.1001/archinte.150.1.153; Ashy ARA, 1998, INT SURG, V83, P108; BROLIN RE, 1990, INT J OBESITY, V14, P939; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; Buchwald H, 2002, OBES SURG, V12, P733, DOI 10.1381/096089202320995484; Buchwald H, 2002, OBES SURG, V12, P705, DOI 10.1381/096089202321019747; BUFFINGTON CK, 1994, OBES SURG, V4, P328, DOI 10.1381/096089294765558287; Ceelen W, 2003, ANN SURG, V237, P10, DOI 10.1097/00000658-200301000-00002; Christou NV, 2004, ANN SURG, V240, P416, DOI 10.1097/01.sla.0000137343.63376.19; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; Cowan GSM, 1998, WORLD J SURG, V22, P987, DOI 10.1007/s002689900504; Cummings DE, 2002, NEW ENGL J MED, V346, P1623, DOI 10.1056/NEJMoa012908; Deitel M, 2003, OBES SURG, V13, P329, DOI 10.1381/096089203765887598; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dixon JB, 2003, DIABETIC MED, V20, P127, DOI 10.1046/j.1464-5491.2003.00889.x; DORNFELD LP, 1985, INT J OBESITY, V9, P381; Dymek MP, 2001, OBES SURG, V11, P32, DOI 10.1381/096089201321454088; Faraj M, 2003, J CLIN ENDOCR METAB, V88, P1594, DOI 10.1210/jc.2002-021309; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; GELONEZE B, 2003, CIRCULATING CONCENTR; GLEYSTEEN JJ, 1992, AM J CLIN NUTR, V55, P591; GRUNDY SM, 1991, ANN INTERN MED, V115, P956; HALL JC, 1990, ANN SURG, V211, P419, DOI 10.1097/00000658-199004000-00007; Hanusch-Enserer U, 2003, NEW ENGL J MED, V348, P2159, DOI 10.1056/NEJM200305223482125; HEDGES L, 1985, STAT METHODS METAANA, P230; Hess DS, 1998, OBES SURG, V8, P267, DOI 10.1381/096089298765554476; Hickey MS, 1998, ANN SURG, V227, P637, DOI 10.1097/00000658-199805000-00004; *INT OB TASK FORC, 2003, CALL OB REV OV NUMB; Kalfarentzos F, 1999, OBES SURG, V9, P433, DOI 10.1381/096089299765552701; Karlsson J, 1998, INT J OBESITY, V22, P113, DOI 10.1038/sj.ijo.0800553; KELLUM JM, 1990, ANN SURG, V211, P763, DOI 10.1097/00000658-199006000-00016; Kopp HP, 2003, ARTERIOSCL THROM VAS, V23, P1042, DOI 10.1161/01.ATV.0000073313.16135.21; Kral J G, 1995, Int J Risk Saf Med, V7, P111, DOI 10.3233/JRS-1995-7204; MacDonald K G Jr, 1997, J Gastrointest Surg, V1, P213, DOI 10.1016/S1091-255X(97)80112-6; Marceau P, 1998, WORLD J SURG, V22, P947, DOI 10.1007/s002689900498; Mingrone G, 2002, ATHEROSCLEROSIS, V161, P455, DOI 10.1016/S0021-9150(01)00667-0; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; Monteforte MJ, 2000, OBES SURG, V10, P391, DOI 10.1381/096089200321594246; MULROW CD, 1997, COCHRANE COLLABORATI; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; *N AM ASS STUD OB, 2000, NIH PUBL; *NAASO NAT HEART, 1998, NIH PUBL; *NAT CTR HLTH STAT, NHANES 4; Nguyen NT, 2001, ANN SURG, V234, P279, DOI 10.1097/00000658-200109000-00002; NIGHTENGALE ML, 1991, MAYO CLIN PROC, V66, P773, DOI 10.1016/S0025-6196(12)61194-X; O'Brien PE, 2002, OBES SURG, V12, P652, DOI 10.1381/096089202321019639; Polyzogopoulou EV, 2003, DIABETES, V52, P1098, DOI 10.2337/diabetes.52.5.1098; PORIES WJ, 1995, ANN SURG, V222, P339, DOI 10.1097/00000658-199509000-00011; Pories WJ, 2001, WORLD J SURG, V25, P527, DOI 10.1007/s002680020348; RAJALA R, 1991, J INTERN MED, V230, P125, DOI 10.1111/j.1365-2796.1991.tb00419.x; RAND CSW, 1990, SOUTHERN MED J, V83, P1390, DOI 10.1097/00007611-199012000-00006; Rasheid S, 2003, OBES SURG, V13, P58, DOI 10.1381/096089203321136593; REISIN E, 1982, J CHRON DIS, V35, P887, DOI 10.1016/0021-9681(82)90119-9; Rubino FA, 2004, ANN SURG, V239, P1, DOI 10.1097/01.sla.0000102989.54824.fc; Schauer PR, 2003, ANN SURG, V238, P467, DOI 10.1097/01.sla.0000089851.41115.1b; Scopinaro N, 1998, WORLD J SURG, V22, P936, DOI 10.1007/s002689900497; Sjostrom CD, 1999, OBES RES, V7, P477; Smith SC, 1996, OBES SURG, V6, P345, DOI 10.1381/096089296765556674; Sturm R, 2003, ARCH INTERN MED, V163, P2146, DOI 10.1001/archinte.163.18.2146; Sugerman H, 1997, J INTERN MED, V241, P71, DOI 10.1046/j.1365-2796.1997.89104000.x; Sugerman HJ, 2003, ANN SURG, V237, P751, DOI 10.1097/00000658-200306000-00002; Thorne A, 2002, INT J OBESITY, V26, P193, DOI 10.1038/sj.ijo.0801871; van Gemert WG, 1998, AM J CLIN NUTR, V67, P197, DOI 10.1093/ajcn/67.2.197; WATERS GS, 1991, AM J SURG, V161, P154, DOI 10.1016/0002-9610(91)90377-P; Weiner P, 1998, THORAX, V53, P39, DOI 10.1136/thx.53.1.39; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Yannakoulia M, 2003, J CLIN ENDOCR METAB, V88, P1730, DOI 10.1210/jc.2002-021604; Zinzindohoue F, 2003, ANN SURG, V237, P1, DOI 10.1097/00000658-200301000-00001; 2000, ARCH INTERN MED, V160, P898	72	3481	3555	14	154	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2004	292	14					1724	1737		10.1001/jama.292.14.1724	http://dx.doi.org/10.1001/jama.292.14.1724			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861JS	15479938				2022-12-28	WOS:000224413400032
J	Markowitz, AJ; Rabow, MW				Markowitz, AJ; Rabow, MW			Palliative care for patients with heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Pantilat SZ, 2004, JAMA-J AM MED ASSOC, V291, P2476, DOI 10.1001/jama.291.20.2476	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2004	292	14					1744	1744		10.1001/jama.292.14.1744	http://dx.doi.org/10.1001/jama.292.14.1744			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861JS	15479940				2022-12-28	WOS:000224413400034
J	Nemeth, E; Tuttle, MS; Powelson, J; Vaughn, MB; Donovan, A; Ward, DM; Ganz, T; Kaplan, J				Nemeth, E; Tuttle, MS; Powelson, J; Vaughn, MB; Donovan, A; Ward, DM; Ganz, T; Kaplan, J			Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization	SCIENCE			English	Article							INFLAMMATION; TRANSPORTER; EXPRESSION; PROTEIN-2; MEDIATOR; HORMONE; ANEMIA	Hepcidin is a peptide hormone secreted by the liver in response to iron loading and inflammation. Decreased hepcidin leads to tissue iron overload, whereas hepcidin overproduction leads to hypoferremia and the anemia of inflammation. Ferroportin is an iron exporter present on the surface of absorptive enterocytes, macrophages, hepatocytes, and placental cells. Here we report that hepcidin bound to ferroportin in tissue culture cells. After binding, ferroportin was internalized and degraded, leading to decreased export of cellular iron. The posttranslational regulation of ferroportin by hepcidin may thus complete a homeostatic loop: Iron regulates the secretion of hepcidin, which in turn controls the concentration of ferroportin on the cell surface.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA; Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA; Childrens Hosp, Dept Hematol, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Utah System of Higher Education; University of Utah; Harvard University; Boston Children's Hospital	Ganz, T (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA.	TGanz@mednet.ucla.edu; jerry.kaplan@path.utah.edu	Ganz, Tomas/AAN-3308-2020; Ganz, Tomas/D-4567-2009	Nemeth, Elizabeta/0000-0002-3477-2397; Ganz, Tomas/0000-0002-2830-5469; Tuttle, Marie/0000-0003-1198-2727	NHLBI NIH HHS [HL26922, T35HL007744] Funding Source: Medline; NIDDK NIH HHS [DK065029, DK30534] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026922, R37HL026922, T35HL007744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030534, R01DK030534, R01DK065029] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Aumelas A, 1996, EUR J BIOCHEM, V237, P575, DOI 10.1111/j.1432-1033.1996.0575p.x; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Frazer DM, 2002, GASTROENTEROLOGY, V123, P835, DOI 10.1053/gast.2002.35353; Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hunter HN, 2002, J BIOL CHEM, V277, P37597, DOI 10.1074/jbc.M205305200; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Mok H, 2004, DEVELOPMENT, V131, P1859, DOI 10.1242/dev.01081; Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Nicolas G, 2002, BLOOD CELL MOL DIS, V29, P327, DOI 10.1006/bcmd.2002.0573; Pietrangelo A, 2004, NEW ENGL J MED, V350, P2383, DOI 10.1056/NEJMra031573; RYSER HJP, 1967, NATURE, V215, P934, DOI 10.1038/215934a0; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Yang FM, 2002, J BIOL CHEM, V277, P39786, DOI 10.1074/jbc.M201485200; Yeh KY, 2004, AM J PHYSIOL-GASTR L, V286, pG385, DOI 10.1152/ajpgi.00246.2003	19	3372	3572	15	345	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	2004	306	5704					2090	2093		10.1126/science.1104742	http://dx.doi.org/10.1126/science.1104742			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881CM	15514116				2022-12-28	WOS:000225841000062
J	Grutzner, F; Rens, W; Tsend-Ayush, E; El-Mogharbel, N; O'Brien, PCM; Jones, RC; Ferguson-Smith, MA; Graves, JAM				Grutzner, F; Rens, W; Tsend-Ayush, E; El-Mogharbel, N; O'Brien, PCM; Jones, RC; Ferguson-Smith, MA; Graves, JAM			In the platypus a meiotic chain of ten sex chromosomes shares genes with the bird Z and mammal X chromosomes	NATURE			English	Article							DETERMINING REGION; Y-CHROMOSOME; DMRT1; MONOTREMATA; DIFFERENTIATION; MARSUPIALS; EVOLUTION; SYSTEM; MEDAKA; DNA	Two centuries after the duck-billed platypus was discovered, monotreme chromosome systems remain deeply puzzling. Karyotypes of males(1), or of both sexes(2-4), were claimed to contain several unpaired chromosomes ( including the X chromosome) that form a multi-chromosomal chain at meiosis. Such meiotic chains exist in plants(5) and insects(6) but are rare in vertebrates(7). How the platypus chromosome system works to determine sex and produce balanced gametes has been controversial for decades(1-4). Here we demonstrate that platypus have five male-specific chromosomes (Y chromosomes) and five chromosomes present in one copy in males and two copies in females ( X chromosomes). These ten chromosomes form a multivalent chain at male meiosis, adopting an alternating pattern to segregate into XXXXX-bearing and YYYYY-bearing sperm. Which, if any, of these sex chromosomes bears one or more sex-determining genes remains unknown. The largest X chromosome, with homology to the human X chromosome, lies at one end of the chain, and a chromosome with homology to the bird Z chromosome lies near the other end. This suggests an evolutionary link between mammal and bird sex chromosome systems, which were previously thought to have evolved independently.	Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 2601, Australia; Univ Cambridge, Dept Vet Med, Ctr Vet Sci, Cambridge CB3 0ES, England; Univ Newcastle, Dept Biol Sci, Newcastle, NSW 2308, Australia	Australian National University; University of Cambridge; University of Newcastle	Grutzner, F (corresponding author), Australian Natl Univ, Res Sch Biol Sci, GPO Box 475, Canberra, ACT 2601, Australia.	frank.gruetzner@anu.edu.au	Grutzner, Frank/AAD-5834-2020; Graves, Jennifer A.M./A-1387-2008; Grutzner, Frank/ABB-2820-2021	Grutzner, Frank/0000-0002-3088-7314; Graves, Jennifer/0000-0001-6480-7856				BICK Y, 1992, MEIOTIC CHAIN CHROMO, P64; BICK YAE, 1975, CYTOBIOS, V14, P17; Brunner B, 2001, GENOMICS, V77, P8, DOI 10.1006/geno.2001.6615; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; CLELAND R, 1962, CYTOGENETICS OENOTHE; Eaker S, 2001, J CELL SCI, V114, P2953; FREDGA K, 1970, PHILOS T R SOC B, V259, P15, DOI 10.1098/rstb.1970.0042; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; GRIFFITHS R, 1991, P ROY SOC B-BIOL SCI, V244, P123, DOI 10.1098/rspb.1991.0060; Grutzner F, 2003, COMP BIOCHEM PHYS A, V136, P867, DOI 10.1016/j.cbpb.2003.09.014; Johannisson R, 1994, CHROMOSOME RES, V2, P137, DOI 10.1007/BF01553492; Matsuda M, 2002, NATURE, V417, P559, DOI 10.1038/nature751; Mizuno S, 2002, CYTOGENET GENOME RES, V99, P236, DOI 10.1159/000071599; MURTAGH CE, 1977, CHROMOSOMA, V65, P37, DOI 10.1007/BF00293129; Nanda I, 2002, P NATL ACAD SCI USA, V99, P11778, DOI 10.1073/pnas.182314699; Nanda I, 1999, NAT GENET, V21, P258, DOI 10.1038/6769; OHNO S, 1967, CHROMOSOMES SEX LINK; Rahn MI, 1996, CHROMOSOME RES, V4, P350, DOI 10.1007/BF02257270; Raymond CS, 2000, GENE DEV, V14, P2587, DOI 10.1101/gad.834100; Rens W, 1999, CHROMOSOME RES, V7, P461, DOI 10.1023/A:1009249813617; RENS W, IN PRESS P NATL ACAD; Shetty S, 2002, CYTOGENET GENOME RES, V99, P245, DOI 10.1159/000071600; SYREN RM, 1977, NATURE, V266, P167, DOI 10.1038/266167a0; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; Toder R, 1997, MAMM GENOME, V8, P418, DOI 10.1007/s003359900459; Watson J.M., 1992, P53; Woodburne MO, 2003, MOL PHYLOGENET EVOL, V28, P360, DOI 10.1016/S1055-7903(03)00113-1; WRIGLEY JM, 1984, IN VITRO CELL DEV B, V20, P321; WRIGLEY JM, 1988, CHROMOSOMA, V96, P231, DOI 10.1007/BF00302363	29	200	205	2	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	2004	432	7019					913	917		10.1038/nature03021	http://dx.doi.org/10.1038/nature03021			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	879QY	15502814				2022-12-28	WOS:000225733500056
J	Stomp, M; Huisman, J; de Jongh, F; Veraart, AJ; Gerla, D; Rijkeboer, M; Ibelings, BW; Wollenzien, UIA; Stal, LJ				Stomp, M; Huisman, J; de Jongh, F; Veraart, AJ; Gerla, D; Rijkeboer, M; Ibelings, BW; Wollenzien, UIA; Stal, LJ			Adaptive divergence in pigment composition promotes phytoplankton biodiversity	NATURE			English	Article							COMPETITION; MARINE; LIGHT; PHOTOTROPHY	The dazzling diversity of the phytoplankton has puzzled biologists for decades(1-5). The puzzle has been enlarged rather than solved by the progressive discovery of new phototrophic microorganisms in the oceans, including picocyanobacteria(6,7), pico-eukaryotes(8), and bacteriochlorophyll-based(9-11) and rhodopsin-based phototrophic bacteria(12,13). Physiological and genomic studies suggest that natural selection promotes niche differentiation among these phototrophic microorganisms, particularly with respect to their photosynthetic characteristics(14-16). We have analysed competition for light between two closely related picocyanobacteria of the Synechococcus group that we isolated from the Baltic Sea(17). One of these two has a red colour because it contains the pigment phycoerythrin, whereas the other is blue-green because it contains high contents of the pigment phycocyanin. Here we report theory and competition experiments that reveal stable coexistence of the two picocyanobacteria, owing to partitioning of the light spectrum. Further competition experiments with a third marine cyanobacterium, capable of adapting its pigment composition, show that this species persists by investing in the pigment that absorbs the colour not used by its competitors. These results demonstrate the adaptive significance of divergence in pigment composition of phototrophic microorganisms, which allows an efficient utilization of light energy and favours species coexistence.	Univ Amsterdam, Inst Biodivers & Ecosyst Dynam, NL-1018 WS Amsterdam, Netherlands; Netherlands Inst Ecol NIOO KNAW, Ctr Limnol, NL-3631 AC Nieuwersluis, Netherlands; Netherlands Inst Ecol NIOO KNAW, Ctr Estuarine & Marine Ecol, NL-4400 AC Yerseke, Netherlands	University of Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW); Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW)	Huisman, J (corresponding author), Univ Amsterdam, Inst Biodivers & Ecosyst Dynam, Nieuwe Achtergracht 127, NL-1018 WS Amsterdam, Netherlands.	jef.huisman@science.uva.nl	Huisman, Jef/A-1089-2013; Gerla, Daan/A-4170-2009; Veraart, Annelies J/E-1927-2014; Stal, Lucas J/B-3334-2011; Stomp, Maayke/J-1484-2012; Ibelings, Bas W/B-4237-2011	Huisman, Jef/0000-0001-9598-3211; Gerla, Daan/0000-0002-2847-5273; Veraart, Annelies J/0000-0001-6286-7484; Ibelings, Bas W/0000-0002-7213-7407				Abrams PA, 1999, AM NAT, V153, P83, DOI 10.1086/303154; Beja O, 2002, NATURE, V415, P630, DOI 10.1038/415630a; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Beja O, 2001, NATURE, V411, P786, DOI 10.1038/35081051; CHISHOLM SW, 1988, NATURE, V334, P340, DOI 10.1038/334340a0; DEMARSAC NT, 1977, J BACTERIOL, V130, P82, DOI 10.1128/JB.130.1.82-91.1977; Ernst A, 2003, MICROBIOL-SGM, V149, P217, DOI 10.1099/mic.0.25475-0; Falkowski P.G., 2013, AQUATIC PHOTOSYNTHES; Huisman J, 1999, ECOLOGY, V80, P211, DOI 10.1890/0012-9658(1999)080[0211:CFLBPS]2.0.CO;2; HUISMAN J, 1994, ECOLOGY, V75, P507, DOI 10.2307/1939554; Huisman J, 2004, ECOLOGY, V85, P2960, DOI 10.1890/03-0763; Huisman J, 1999, NATURE, V402, P407, DOI 10.1038/46540; HUTCHINSON G, 1961, AM NAT, V95, P137, DOI 10.1086/282171; Irigoien X, 2004, NATURE, V429, P863, DOI 10.1038/nature02593; Jonker RR, 1995, WATER SCI TECHNOL, V32, P177, DOI 10.1016/0273-1223(95)00696-6; Kirk J., 1983, LIGHT PHOTOSYNTHESIS; Kolber ZS, 2000, NATURE, V407, P177, DOI 10.1038/35025044; Kolber ZS, 2001, SCIENCE, V292, P2492, DOI 10.1126/science.1059707; METZ JAJ, 1992, TRENDS ECOL EVOL, V7, P198, DOI 10.1016/0169-5347(92)90073-K; Moon-van der Staay SY, 2001, NATURE, V409, P607, DOI 10.1038/35054541; Moore LR, 1998, NATURE, V393, P464, DOI 10.1038/30965; OHKI K, 1985, PLANT PHYSIOL, V79, P943, DOI 10.1104/pp.79.4.943; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; SATHYENDRANATH S, 1989, LIMNOL OCEANOGR, V34, P188, DOI 10.4319/lo.1989.34.1.0188; SOMMER U, 1985, LIMNOL OCEANOGR, V30, P335, DOI 10.4319/lo.1985.30.2.0335; Tilman D., 1982, Monographs in Population Biology, pi; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; WATERBURY JB, 1979, NATURE, V277, P293, DOI 10.1038/277293a0	28	207	214	9	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					104	107		10.1038/nature03044	http://dx.doi.org/10.1038/nature03044			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15475947				2022-12-28	WOS:000224854900049
J	Gill, TM; Allore, HG; Holford, TR; Guo, ZC				Gill, TM; Allore, HG; Holford, TR; Guo, ZC			Hospitalization, restricted activity, and the development of disability among older persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER-EXTREMITY FUNCTION; FUNCTIONAL DEPENDENCE; PHYSICAL PERFORMANCE; HOME CARE; SUBSEQUENT DISABILITY; COGNITIVE IMPAIRMENT; CONTROLLED-TRIAL; ELDERLY PERSONS; UNITED-STATES; NURSING-HOME	Context Preventing the development of disability in activities of daily living is an important goal in older adults, yet relatively little is known about the disabling process. Objectives To evaluate the relationship between 2 types of intervening events (hospitalization and restricted activity) and the development of disability and to determine whether this relationship is modified by the presence of physical frailty. Design, Setting, and Participants Prospective cohort study, conducted in the general community in greater New Haven, Conn, from March 1998 to March 2003, of 754 persons aged 70 years or older, who were not disabled (ie, required no personal assistance) in 4 essential activities of daily living: bathing, dressing, walking inside the house, and transferring from a chair. Participants were categorized into 2 groups according to the presence of physical frailty (defined on the basis of slow gait speed) and were followed up with monthly telephone interviews for up to 5 years to ascertain exposure to intervening events and determine the occurrence of disability. Main Outcome Measure Disability, defined as the need for personal assistance in bathing, dressing, walking inside the house, or transferring from a chair. Results During the 5-year follow-up period, disability developed among 417 (55.3%) participants, 372 (49.3%) were hospitalized and 600 (79.6%) had at least 1 episode of restricted activity. The multivariable hazard ratios for the development of disability were 61.8 (95% confidence interval [CI], 49.0-78.0) within a month of hospitalization and 5.54 (95% Cl, 4.27-7.19) within a month of restricted activity. Strong associations were observed for participants who were physically frail and those who were not physically frail. Hospital admissions for falls were most likely to lead to disability. Intervening events occurring more than a month prior to disability onset were not associated with the development of disability. The population-attributable fractions associated with new exposure to hospitalization and restricted activity, respectively, were 0.48 and 0.19; 0.40 and 0.20, respectively, for frail participants and 0.61 and 0.16, respectively, for nonfrail participants. Conclusions Illnesses and injuries leading to either hospitalization or restricted activity represent important sources of disability for older persons living in the community, regardless of the presence of physical frailty. These intervening events may be suitable targets for the prevention of disability.	Yale Univ, Sch Med, Dorothy Adler Geriatr Assessment Ctr, Dept Internal Med, New Haven, CT 06504 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA	Yale University; Yale University	Gill, TM (corresponding author), Yale Univ, Sch Med, Dorothy Adler Geriatr Assessment Ctr, Dept Internal Med, 20 York St, New Haven, CT 06504 USA.	gill@ynhh.org	Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368; Allore, Heather/0000-0001-7685-8175	NIA NIH HHS [R01AG17560, P30AG21342, K24AG021507] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG021342, K24AG021507, R01AG017560] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], TXB GERIATRIC MED GE; Binder EF, 2004, JAMA-J AM MED ASSOC, V292, P837, DOI 10.1001/jama.292.7.837; Bortz WM, 2002, J GERONTOL A-BIOL, V57, pM283, DOI 10.1093/gerona/57.5.M283; BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796; Campbell AJ, 1997, AGE AGEING, V26, P315, DOI 10.1093/ageing/26.4.315; Cohen HJ, 2002, NEW ENGL J MED, V346, P905, DOI 10.1056/NEJMsa010285; COUGHLIN TA, 1992, HEALTH SERV RES, V27, P453; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Cronin-Stubbs D, 2000, ARCH INTERN MED, V160, P3074, DOI 10.1001/archinte.160.20.3074; Ebrahim S, 1999, LANCET, V353, P1990, DOI 10.1016/S0140-6736(99)00195-6; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; GILL TM, 1995, J GERONTOL A-BIOL, V50, pM235, DOI 10.1093/gerona/50A.5.M235; Gill TM, 2002, NEW ENGL J MED, V347, P1068, DOI 10.1056/NEJMoa020423; Gill TM, 2004, AM J MED, V117, P484, DOI 10.1016/j.amjmed.2004.05.018; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; Gill TM, 2003, ARCH INTERN MED, V163, P1317, DOI 10.1001/archinte.163.11.1317; Gill TM, 2003, J GERONTOL A-BIOL, V58, P70; Gill TM, 1996, J GERONTOL A-BIOL, V51, pM283, DOI 10.1093/gerona/51A.6.M283; Gill TM, 1997, J GEN INTERN MED, V12, P757, DOI 10.1046/j.1525-1497.1997.07161.x; Gill TM, 2002, J AM GERIATR SOC, V50, P1492, DOI 10.1046/j.1532-5415.2002.50403.x; Gill TM, 2001, ANN INTERN MED, V135, P313, DOI 10.7326/0003-4819-135-5-200109040-00007; Gill TM, 1999, J GERONTOL A-BIOL, V54, pM377, DOI 10.1093/gerona/54.7.M377; Gill TM, 2001, J AM GERIATR SOC, V49, P1039, DOI 10.1046/j.1532-5415.2001.49206.x; Gill TM, 2004, ARCH PHYS MED REHAB, V85, P1043, DOI 10.1016/j.apmr.2003.10.021; Goodwin James S, 2002, Lancet, V359, P1358, DOI 10.1016/S0140-6736(02)08318-6; GRESHAM GE, 1995, CLIN PRACTICE GUIDEL, V16, P1; Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Guralnik JM, 2002, AM J PUBLIC HEALTH, V92, P1244, DOI 10.2105/AJPH.92.8.1244; Hamerman D, 1999, ANN INTERN MED, V130, P945, DOI 10.7326/0003-4819-130-11-199906010-00022; Hanley JA, 2001, J EPIDEMIOL COMMUN H, V55, P508, DOI 10.1136/jech.55.7.508; Hardy SE, 2004, JAMA-J AM MED ASSOC, V291, P1596, DOI 10.1001/jama.291.13.1596; Hoenig H, 1997, J AM GERIATR SOC, V45, P1371, DOI 10.1111/j.1532-5415.1997.tb02939.x; Hosmer D. W., 1999, APPL SURVIVAL ANAL; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; Keeley EC, 2004, JAMA-J AM MED ASSOC, V291, P736, DOI 10.1001/jama.291.6.736; KEMPER P, 1992, HEALTH SERV RES, V27, P421; Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202; Landefeld CS, 1998, J AM GERIATR SOC, V46, P1314, DOI 10.1111/j.1532-5415.1998.tb04553.x; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lauer MS, 2002, NEW ENGL J MED, V346, P1468, DOI 10.1056/NEJMcp012672; Levine C, 1999, NEW ENGL J MED, V340, P1587, DOI 10.1056/NEJM199905203402013; MacMahon B., 1996, EPIDEMIOLOGY PRINCIP, V2nd; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; Manton KG, 2001, P NATL ACAD SCI USA, V98, P6354, DOI 10.1073/pnas.111152298; MCKINLAY JB, 1995, J AGING HEALTH, V7, P497, DOI 10.1177/089826439500700403; Morley JE, 2002, J GERONTOL A-BIOL, V57, pM698, DOI 10.1093/gerona/57.11.M698; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rich MW, 2001, J GERONTOL A-BIOL, V56, pM88, DOI 10.1093/gerona/56.2.M88; ROCKWOOD K, 1994, CAN MED ASSOC J, V150, P489; Rodgers W, 1997, J GERONTOL B-PSYCHOL, V52, P21, DOI 10.1093/geronb/52B.Special_Issue.21; Rothman K., 1998, MODERN EPIDEMIOLOGY; RUDBERG MA, 1993, J GERONTOL, V48, pM261, DOI 10.1093/geronj/48.6.M261; SALIVE ME, 1994, J AM GERIATR SOC, V42, P287, DOI 10.1111/j.1532-5415.1994.tb01753.x; Sands LP, 2002, J GERONTOL A-BIOL, V57, pM449, DOI 10.1093/gerona/57.7.M449; SCHOLES D, 1991, AM J PUBLIC HEALTH, V81, P485, DOI 10.2105/AJPH.81.4.485; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; SPECTOR WD, 1987, J CHRON DIS, V40, P481, DOI 10.1016/0021-9681(87)90004-X; Straus SE, 2002, JAMA-J AM MED ASSOC, V288, P1396, DOI 10.1001/jama.288.11.1396; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; Tinetti ME, 2002, JAMA-J AM MED ASSOC, V287, P2098, DOI 10.1001/jama.287.16.2098; *US CENS BUR, 2003, AM FACTF	69	426	429	1	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2004	292	17					2115	2124		10.1001/jama.292.17.2115	http://dx.doi.org/10.1001/jama.292.17.2115			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	868OC	15523072				2022-12-28	WOS:000224921900024
J	Roberts, TG; Goulart, BH; Squitieri, L; Stallings, SC; Halpern, EF; Chabner, BA; Gazelle, GS; Finkelstein, SN; Clark, JW				Roberts, TG; Goulart, BH; Squitieri, L; Stallings, SC; Halpern, EF; Chabner, BA; Gazelle, GS; Finkelstein, SN; Clark, JW			Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	38th Annual Meeting of the American-Society-of-Clinical-Oncology	MAY 18-21, 2002	ORLANDO, FL	Amer Soc Clin Oncol			INFORMED-CONSENT; I TRIALS; ONCOLOGY; ETHICS; IMPACT; PERCEPTIONS; PHYSICIANS; THERAPY; QUALITY; AGENTS	Context In the past, cancer patients entering phase 1 studies confronted the prospects of high risk and unlikely benefit. Over the last decade, cancer drugs under development have become more targeted, and the clinical research environment has become more scrutinized. The impact of these changes on the risks and benefits to patients who participate in phase 1 cancer trials is unknown. Objective To determine trends in the rates of treatment-related (toxic) death, objective response, and serious toxicity and to identify factors associated with these outcomes. Data Sources We searched abstracts and journal articles reporting the results of phase 1 cancer treatment trials originally submitted to annual meetings of the American Society of Clinical Oncology (ASCO) from 1991 through 2002. Study Selection We focused on published single-agent trials that enrolled patients with advanced solid tumors and excluded studies testing agents already approved by the US Food and Drug Administration at the time of the ASCO presentation. Data Extraction Multiple observers independently extracted information on trial design, location, sponsorship, types of tumors treated, drug class, route of administration, and clinical outcomes. Data Synthesis The overall toxic death rate for 213 studies (involving 6474 cancer patients) published in peer-reviewed journals was 0.54%, while the overall objective response rate was 3.8%. Toxic death rates decreased over the study period, from 1.1% over the first 4 years of the study (1991-1994) to 0.06% over the most recent 4-year period (1999-2002) (P<.01). Response rates also decreased but by proportionally much less. After adjusting for characteristics of the experimental trials and the investigational agents, the odds of a patient dying from an experimental treatment while participating in a trial submitted during the most recent 4-year period were less than one tenth those of a patient participating in a trial submitted during the first 4-year period (odds ratio, 0.09; 95% confidence interval, 0.01-0.67; P=.009). In comparison, the adjusted odds of a patient experiencing an objective response over the same time periods decreased by approximately half (odds ratio, 0.46; 95% confidence interval, 0.32-0.66; P<.001). Conclusions The level of risk experienced by cancer patients who participate in phase 1 treatment trials appears to have improved over the 12-year period from 1991 through 2002. Because toxic death rates have decreased more quickly than have objective response rates, the ratio of risk to benefit may have also improved. These changes relate in part to the targeted and less-toxic nature of newer cancer drugs and are coincident with the increased attention that has been paid to the safety of clinical research over the time period we analyzed.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Hematol Oncol, Boston, MA 02114 USA; MIT, Program Pharmaceut Ind, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dana Farber Harvard Canc Ctr, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University	Roberts, TG (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Hematol Oncol, Cox 640,100 Blossom St, Boston, MA 02114 USA.	troberts@partners.org	Goulart, Bernardo Haddock Lobo/L-5514-2019		NATIONAL CANCER INSTITUTE [R25CA092203] Funding Source: NIH RePORTER; NCI NIH HHS [R25T CA 92203, R25 CA092203] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal M, 2003, JAMA-J AM MED ASSOC, V290, P1075, DOI 10.1001/jama.290.8.1075; *AM SOC CLIN ONC, ASCO ANN M; Bubley GJ, 1999, J CLIN ONCOL, V17, P3461, DOI 10.1200/JCO.1999.17.11.3461; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1401, DOI 10.1001/jama.263.10.1401; Cheng JD, 2000, J CLIN ONCOL, V18, P421, DOI 10.1200/JCO.2000.18.2.421; Cox K, 1996, Eur J Cancer Care (Engl), V5, P90, DOI 10.1111/j.1365-2354.1996.tb00214.x; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; Daugherty CK, 1999, J CLIN ONCOL, V17, P1601, DOI 10.1200/JCO.1999.17.5.1601; DAUGHERTY CK, 1995, ANN ONCOL, V6, P321, DOI 10.1093/oxfordjournals.annonc.a059178; Daugherty CK, 1997, ANN INTERN MED, V126, P892, DOI 10.7326/0003-4819-126-11-199706010-00008; DECOSTER G, 1990, ANN ONCOL, V1, P175, DOI 10.1093/oxfordjournals.annonc.a057716; EDGAR H, 1990, MILBANK Q, V68, P111, DOI 10.2307/3350178; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; EMANUEL EJ, 1995, J CLIN ONCOL, V13, P1049, DOI 10.1200/JCO.1995.13.5.1049; ESTEY E, 1986, CANCER TREAT REP, V70, P1105; Fox E, 2002, ONCOLOGIST, V7, P401, DOI 10.1634/theoncologist.7-5-401; GOLDMAN L, 1980, NEW ENGL J MED, V303, P255, DOI 10.1056/NEJM198007313030504; Horng S, 2002, NEW ENGL J MED, V347, P2134, DOI 10.1056/NEJMsa021182; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Joffe S, 2001, LANCET, V358, P1772, DOI 10.1016/S0140-6736(01)06805-2; Johnson JR, 2003, J CLIN ONCOL, V21, P1404, DOI 10.1200/JCO.2003.08.072; KODISH E, 1992, J CLIN ONCOL, V10, P1810, DOI 10.1200/JCO.1992.10.11.1810; Korn EL, 2001, J CLIN ONCOL, V19, P265, DOI 10.1200/JCO.2001.19.1.265; Krzyzanowska MK, 2003, JAMA-J AM MED ASSOC, V290, P495, DOI 10.1001/jama.290.4.495; LIPSETT MB, 1982, JAMA-J AM MED ASSOC, V248, P941, DOI 10.1001/jama.248.8.941; Lorman AJ, 2001, J BIOLAW BUS, V4, P23; MARKMAN M, 1986, CA-CANCER J CLIN, V36, P367, DOI 10.3322/canjclin.36.6.367; Massarelli E, 2003, LUNG CANCER-J IASLC, V39, P55, DOI 10.1016/S0169-5002(02)00308-2; Meropol NJ, 2003, J CLIN ONCOL, V21, P2589, DOI 10.1200/JCO.2003.10.072; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Miller M, 2000, HASTINGS CENT REP, V30, P34, DOI 10.2307/3527646; National Cancer Institute, 2006, COMM TERM CRIT ADV E; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; *PAR INT CORP, 2003, PAR PHARM R D STAT S; Roberts TG, 2003, J CLIN ONCOL, V21, P3683, DOI 10.1200/JCO.2003.01.204; Smith TL, 1996, J CLIN ONCOL, V14, P287, DOI 10.1200/JCO.1996.14.1.287; Steinbrook R, 2002, NEW ENGL J MED, V346, P1425, DOI 10.1056/NEJM200205023461828; Steinbrook R, 2002, NEW ENGL J MED, V346, P716, DOI 10.1056/NEJM200202283460924; VONHOFF DD, 1991, INVEST NEW DRUG, V9, P115, DOI 10.1007/BF00194562; WACHTER RM, 1992, NEW ENGL J MED, V326, P128, DOI 10.1056/NEJM199201093260209; Weir HK, 2003, JNCI-J NATL CANCER I, V95, P1276, DOI 10.1093/jnci/djg040; World Health Organization, 1979, WHO PUBL	42	222	280	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2004	292	17					2130	2140		10.1001/jama.292.17.2130	http://dx.doi.org/10.1001/jama.292.17.2130			11	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868OC	15523074				2022-12-28	WOS:000224921900026
J	Palmer, AR				Palmer, AR			Symmetry breaking and the evolution of development	SCIENCE			English	Review							LEFT-RIGHT ASYMMETRY; LEFT-RIGHT AXIS; NODAL-RELATED GENE; BILATERAL ASYMMETRY; SITUS-INVERSUS; FIDDLER-CRABS; EXPRESSION; EMBRYO; ESTABLISHMENT; SYSTEMATICS	Because of its simplicity, the binary-switch nature. of left-right asymmetry permits meaningful comparisons among many different organisms. Phylogenetic analyses of asymmetry variation, inheritance, and molecular. mechanisms reveal unexpected insights into how development evolves. First, directional asymmetry, an evolutionary novelty, arose from nonheritabie origins almost as often as from mutations, implying that genetic assimilation ("phenotype precedes genotype") is a common mode of evolution. Second, the molecular pathway directing hearts leftward-the nodal cascade-varies considerably among vertebrates (homology of form does not require homology of development) and was possibly co-opted from a preexisting asymmetrical chordate organ system. Finally, declining frequencies of spontaneous asymmetry reversal throughout vertebrate evolution suggest that heart development has become more canalized.	Univ Alberta, Dept Biol Sci, Systemat & Evolut Grp, Edmonton, AB T6G 2E9, Canada; Bamfield Marine Sci Ctr, Bamfield, BC V0R 1B0, Canada	University of Alberta; Simon Fraser University	Palmer, AR (corresponding author), Univ Alberta, Dept Biol Sci, Systemat & Evolut Grp, Edmonton, AB T6G 2E9, Canada.	rich.palmer@ualberta.ca	Palmer, A. Richard/A-3593-2010	Palmer, A. Richard/0000-0002-7579-3899				Abouheif E, 1997, TRENDS ECOL EVOL, V12, P405, DOI 10.1016/S0169-5347(97)01125-7; Amack JD, 2004, CURR BIOL, V14, P685, DOI 10.1016/j.cub.2004.04.002; Arthur W, 2002, NATURE, V415, P757, DOI 10.1038/415757a; Asami T, 1998, AM NAT, V152, P225, DOI 10.1086/286163; Boorman CJ, 2002, EVOL DEV, V4, P354, DOI 10.1046/j.1525-142X.2002.02021.x; Boorman CJ, 2002, BIOESSAYS, V24, P1004, DOI 10.1002/bies.10171; BROWN NA, 1990, DEVELOPMENT, V109, P1; Brueckner M, 2001, AM J MED GENET, V101, P339, DOI 10.1002/1096-8628(20010715)101:4<339::AID-AJMG1442>3.0.CO;2-P; Burighel P, 1997, MICROSCOPICAL ANATOM, V15, P221; Capdevila J, 2000, CELL, V101, P9, DOI 10.1016/S0092-8674(00)80619-4; Concha ML, 2001, J ANAT, V199, P63, DOI 10.1046/j.1469-7580.2001.19910063.x; COOK SA, 1968, EVOLUTION, V22, P496, DOI 10.1111/j.1558-5646.1968.tb03988.x; Cooke J, 2004, BIOL REV, V79, P377, DOI 10.1017/S1464793103006298; CRANE J, 1967, ZOOLOGICA-N Y, V52, P49; Dathe V, 2002, ANAT EMBRYOL, V205, P343, DOI 10.1007/s00429-002-0269-2; de Jong G, 2003, NATURE, V424, P16, DOI 10.1038/424016b; DUBOULE D, 1994, EVOLUTION DEV REGULA, P135; Essner JJ, 2002, NATURE, V418, P37, DOI 10.1038/418037a; Fischer A, 2002, CURR BIOL, V12, P1807, DOI 10.1016/S0960-9822(02)01222-8; Fishman MC, 1997, DEVELOPMENT, V124, P2099; Goldstein B, 1998, CURR BIOL, V8, P157, DOI 10.1016/S0960-9822(98)70062-4; GOVIND CK, 1992, J NEUROBIOL, V23, P1423, DOI 10.1002/neu.480231006; Gundersen GG, 2003, SCIENCE, V300, P2040, DOI 10.1126/science.1084938; Hall BK, 2001, BIOL PHILOS, V16, P215, DOI 10.1023/A:1006773408919; Hall BK, 1997, TRENDS ECOL EVOL, V12, P461, DOI 10.1016/S0169-5347(97)01222-6; Hall BK., 1999, EVOLUTIONARY DEV BIO, V2; Halpern ME, 2003, TRENDS NEUROSCI, V26, P308, DOI 10.1016/S0166-2236(03)00129-2; Hamada H, 2002, NAT REV GENET, V3, P103, DOI 10.1038/nrg732; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Heil M, 2004, NATURE, V430, P205, DOI 10.1038/nature02703; JANZEN FJ, 1991, EVOLUTION, V45, P435, DOI 10.1111/j.1558-5646.1991.tb04417.x; Jefferies R.P.S., 1986, ANCESTRY VERTEBRATES; Jeffery JE, 2002, EVOL DEV, V4, P292, DOI 10.1046/j.1525-142X.2002.02018.x; Jesson LK, 2003, INT J PLANT SCI, V164, pS237, DOI 10.1086/378537; Jesson LK, 2002, P ROY SOC B-BIOL SCI, V269, P1835, DOI 10.1098/rspb.2002.2068; Kennedy DN, 1999, NEUROLOGY, V53, P1260, DOI 10.1212/WNL.53.6.1260; Lacalli TC, 2002, ACTA ZOOL-STOCKHOLM, V83, P87, DOI 10.1046/j.1463-6395.2002.00101.x; Lall S, 2001, ANNU REV GENET, V35, P407, DOI 10.1146/annurev.genet.35.102401.090832; Levin M, 2004, CRIT REV ORAL BIOL M, V15, P197, DOI 10.1177/154411130401500403; Long S, 2003, DEVELOPMENT, V130, P2303, DOI 10.1242/dev.00436; Ludwig W., 1932, RECHTS LINKS PROBLEM; Manner J, 2000, ANAT RECORD, V259, P248, DOI 10.1002/1097-0185(20000701)259:3<248::AID-AR30>3.0.CO;2-K; McGrath J, 2003, CURR OPIN GENET DEV, V13, P385, DOI 10.1016/S0959-437X(03)00091-1; McGrath J, 2003, CELL, V114, P61, DOI 10.1016/S0092-8674(03)00511-7; McShea DW, 1998, ANNU REV ECOL SYST, V29, P293, DOI 10.1146/annurev.ecolsys.29.1.293; Meinhardt H, 2001, INT J DEV BIOL, V45, P177; Mercola M, 2003, J CELL SCI, V116, P3251, DOI 10.1242/jcs.00668; Minelli A, 2000, EVOL DEV, V2, P157, DOI 10.1046/j.1525-142x.2000.00054.x; Morokuma J, 2002, DEV GENES EVOL, V212, P439, DOI 10.1007/s00427-002-0242-3; Nijhout H. F., 2003, P3; Nonaka S, 2002, NATURE, V418, P96, DOI 10.1038/nature00849; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; Palmer AR, 1996, P NATL ACAD SCI USA, V93, P14279, DOI 10.1073/pnas.93.25.14279; PALMER AR, IN PRESS VARIATION; Parenti LR, 1996, COPEIA, P703; Piaget J., 1929, Revue Suisse de Zoologie, V36, P263; Pigliucci M, 2003, EVOLUTION, V57, P1455; Rosenberg MS, 2001, J CRUSTACEAN BIOL, V21, P839, DOI 10.1651/0278-0372(2001)021[0839:TSATOF]2.0.CO;2; ROY TA, 1994, AM J PHYS ANTHROPOL, V94, P203, DOI 10.1002/ajpa.1330940205; Ruppert EE, 1997, MICROSCOPIC ANATOMY, V15, P349; Shibazaki Y, 2004, CURR BIOL, V14, P1462, DOI 10.1016/j.cub.2004.08.018; Shimeld SM, 2004, TRENDS GENET, V20, P277, DOI 10.1016/j.tig.2004.04.010; SHINE R, 1988, J THEOR BIOL, V132, P43, DOI 10.1016/S0022-5193(88)80189-9; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; SIMPSON GG, 1953, EVOLUTION, V7, P110, DOI 10.2307/2405746; SMITH LD, 1994, SCIENCE, V264, P710, DOI 10.1126/science.264.5159.710; Smith WC, 1999, TRENDS GENET, V15, P3, DOI 10.1016/S0168-9525(98)01641-2; Stern CD, 2002, NATURE, V418, P29, DOI 10.1038/418029a; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Tabin CJ, 2003, GENE DEV, V17, P1, DOI 10.1101/gad.1053803; TRINKAUS E, 1994, AM J PHYS ANTHROPOL, V93, P1, DOI 10.1002/ajpa.1330930102; True JR, 2001, EVOL DEV, V3, P109, DOI 10.1046/j.1525-142x.2001.003002109.x; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; WADDINGTON CH, 1953, EVOLUTION, V7, P118, DOI 10.2307/2405747; West-Eberhard Mary Jane, 2003, pi; Wilkins A.S., 2002, EVOLUTION DEV PATHWA; Yost HJ, 1999, CURR OPIN GENET DEV, V9, P422; Yu JK, 2002, EVOL DEV, V4, P418, DOI 10.1046/j.1525-142X.2002.02030.x; Zile MH, 2000, DEV BIOL, V223, P323, DOI 10.1006/dbio.2000.9754	79	288	296	3	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					828	833		10.1126/science.1103707	http://dx.doi.org/10.1126/science.1103707			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514148				2022-12-28	WOS:000224969400035
J	Sondermann, H; Soisson, SM; Boykevisch, S; Yang, SS; Bar-Sagi, D; Kuriyan, J				Sondermann, H; Soisson, SM; Boykevisch, S; Yang, SS; Bar-Sagi, D; Kuriyan, J			Structural analysis of autoinhibition in the Ras activator son of sevenless	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; PLECKSTRIN HOMOLOGY DOMAINS; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; INTRAMOLECULAR INTERACTIONS; BINDING PROTEINS; N-TERMINUS; GRB2; COMPLEX; GTP	The classical model for the activation of the nucleotide exchange factor Son of sevenless (SOS) involves its recruitment to the membrane, where it engages Ras. The recent discovery that Ras.GTP is an allosteric activator of SOS indicated that the regulation of SOS is more complex than originally envisaged. We now present crystallographic and biochemical analyses of a construct of SOS that contains the DbI homology-pleckstrin homology (DH-PH) and catalytic domains and show that the DH-PH unit blocks the allosteric binding site for Ras and suppresses the activity of SOS. SOS is dependent on Ras binding to the allosteric site for both a lower level of activity, which is a result of Ras.GDP binding, and maximal activity, which requires Ras.GTP. The action of the DH-PH unit gates a reciprocal interaction between Ras and SOS, in which Ras converts SOS from low to high activity forms as Ras.GDP is converted to Ras.GTP by SOS.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Rockefeller University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kuriyan, J (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	kuriyan@berkeley.edu		Bar-Sagi, Dafna/0000-0003-2597-8948	NATIONAL CANCER INSTITUTE [R01CA096504, P01CA028146, R37CA055360] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA096504-02, 5P01 CA28146, 5R37CA55360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmadian Mohammad Reza, 2002, Methods Mol Biol, V189, P45; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Hall BE, 2002, FRONT BIOSCI, V7, pD288, DOI 10.2741/hall; Hall BE, 2001, J BIOL CHEM, V276, P27629, DOI 10.1074/jbc.M101727200; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Kim JH, 1998, ONCOGENE, V16, P2597, DOI 10.1038/sj.onc.1201822; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; Kraemer A, 2002, J MOL BIOL, V324, P763, DOI 10.1016/S0022-2836(02)01136-1; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NIMNUAL A, 2002, SCI STKE, pPE36, DOI DOI 10.1126/STKE.2002.145; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; Silver SJ, 2004, GENESIS, V39, P263, DOI 10.1002/gene.20054; Sini P, 2004, NAT CELL BIOL, V6, P268, DOI 10.1038/ncb1096; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sondermann H, 2003, STRUCTURE, V11, P1583, DOI 10.1016/j.str.2003.10.015; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	34	207	209	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2004	119	3					393	405		10.1016/j.cell.2004.10.005	http://dx.doi.org/10.1016/j.cell.2004.10.005			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	868IW	15507210	Bronze			2022-12-28	WOS:000224908300010
J	Studdert, DM; Mello, MM; Brennan, TA				Studdert, DM; Mello, MM; Brennan, TA			Financial conflicts of interest in physicians' relationships with the pharmaceutical industry - Self-regulation in the shadow of federal prosecution.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GIFTS		Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Brennan, TA (corresponding author), Brigham & Womens Hosp, 75 Francis St,PBB4, Boston, MA 02115 USA.	tabrennan@partners.org	Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537; Mello, Michelle/0000-0003-2877-4270				*ACCR COUNC CONT M, STAND COMM SUPP CONT; Altman DE, 2004, NEW ENGL J MED, V350, P9, DOI 10.1056/NEJMp038224; *AM MED ASS, E8061 AM MED ASS; Babcock L, 1997, J ECON PERSPECT, V11, P109, DOI 10.1257/jep.11.1.109; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Blumenthal D, 2004, NEW ENGL J MED, V351, P1885, DOI 10.1056/NEJMhpr042734; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; BROOKER GG, 2002, HAMLINE L REV, V25, P373; CHREN MM, 1994, JAMA-J AM MED ASSOC, V271, P684, DOI 10.1001/jama.271.9.684; Coyle SL, 2002, ANN INTERN MED, V136, P396, DOI 10.7326/0003-4819-136-5-200203050-00014; Dana J, 2003, JAMA-J AM MED ASSOC, V290, P252, DOI 10.1001/jama.290.2.252; DEMBNER A, 2004, BOSTON GLOBE    0305, pA1; *DEP HHS, 2003, FED REGISTER, V68, P23731; *DEP HHS DEP JUST, 2002, HLTH CAR FRAUD AB CO; *DEP HHS OFF INSP, 1992, OEI019000481 DEP HHS; Devlin Patrick, 1965, ENFORCEMENT MORALS; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; Greider K., 2003, BIG FIX PHARM IND RI; Harris Gardiner, 2004, N Y Times Web, pA19; Hart HLA, 1963, LAW LIBERTY MORALITY; HAVIGHURST CC, 1998, HLTH CARE LAW POLICY; Kassirer JP, 2000, JAMA-J AM MED ASSOC, V284, P2156, DOI 10.1001/jama.284.17.2156; Katz D, 2003, AM J BIOETHICS, V3, P39, DOI 10.1162/15265160360706552; KRAUSE JH, 2002, CARDOZO LAW REV, V23, P1363; Morin K, 2002, JAMA-J AM MED ASSOC, V287, P78, DOI 10.1001/jama.287.1.78; Moses HI, 2002, NEW ENGL J MED, V347, P1371, DOI 10.1056/NEJMsb021319; MURPHY S, 2004, BOSTON GLOBE    0715, pA1; PETERSEN M, 2003, NY TIMES        1204, pC1; Pharmaceutical Research and Manufacturers of America, COD INT HEALTHC PROF; RABECS RN, 2001, MICH ST L REV, P1; Relman AS, 2003, JAMA-J AM MED ASSOC, V289, P2418, DOI 10.1001/jama.289.18.2418; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; Steinman MA, 2001, AM J MED, V110, P551, DOI 10.1016/S0002-9343(01)00660-X; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	35	139	146	3	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1891	1900		10.1056/NEJMlim042229	http://dx.doi.org/10.1056/NEJMlim042229			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509824				2022-12-28	WOS:000224723100015
J	Liao, GC; Wang, JM; Guo, JS; Allard, J; Cheng, J; Ng, A; Shafer, S; Puech, A; McPherson, JD; Foernzler, D; Peltz, G; Usuka, J				Liao, GC; Wang, JM; Guo, JS; Allard, J; Cheng, J; Ng, A; Shafer, S; Puech, A; McPherson, JD; Foernzler, D; Peltz, G; Usuka, J			In silico genetics: Identification of a functional element regulating H2-E alpha gene expression	SCIENCE			English	Article							AH-RECEPTOR; PHENOTYPE; MOUSE; MHC	Computational tools can markedly accelerate the rate at which murine genetic models can be analyzed. We developed a computational method for mapping. phenotypic traits that vary among inbred strains onto haplotypic blocks. This method correctly predicted the genetic basis for strain-specific differences in several biologically important traits. It was also used to identify an allele-specific functional genomic element regulating H2-Ealpha gene expression. This functional element, which contained the binding sites for YY1 and a second transcription factor that is probably serum response factor, is located within the first intron of the H2-Ealpha gene. This computational method will greatly improve our ability to identify the genetic basis for a variety of phenotypic traits, ranging from qualitative trait information to quantitative gene expression data, which vary among inbred mouse strains.	Roche Palo Alto, Dept Genet & Genom, Palo Alto, CA 94304 USA; Stanford Univ, Med Ctr, Dept Anesthesia, Stanford, CA 94305 USA; Ctr Natl Genotypage, F-91057 Evry, France; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63108 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Roche Ctr Med Genom F Hoffmann La Roche, CH-4070 Basel, Switzerland	Roche Holding; Stanford University; CEA; UDICE-French Research Universities; Universite Paris Saclay; Washington University (WUSTL); Washington University (WUSTL); Roche Holding	Peltz, G (corresponding author), Roche Palo Alto, Dept Genet & Genom, 3431 Hillview Ave, Palo Alto, CA 94304 USA.	gary.peltz@roche.com	Shafer, Steven/AAH-4514-2021; McPherson, John D/D-2633-2017; PUECH, Anne/A-7470-2013	McPherson, John D/0000-0001-8049-9347; Shafer, Steven/0000-0002-0289-7793	NHGRI NIH HHS [1 R01 HG02322-01] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002322] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; EMA M, 1994, J BIOL CHEM, V269, P27337; Grupe A, 2001, SCIENCE, V292, P1915, DOI 10.1126/science.1058889; *JACKS LAB, 1998, 475 JACKS LAB; Maier A, 1998, ENVIRON HEALTH PERSP, V106, P421, DOI 10.2307/3434070; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NEBERT DW, 1982, GENETICS, V100, P79; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; OKEY AB, 1994, TOXICOL LETT, V70, P1, DOI 10.1016/0378-4274(94)90139-2; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; WANG J, 2004, COMPUTATIONAL GENETI; YANG Y, 1992, J BIOL CHEM, V267, P11669	14	96	97	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					690	695		10.1126/science.1100636	http://dx.doi.org/10.1126/science.1100636			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499019				2022-12-28	WOS:000224756700053
J	Cisek, P; Kalaska, JF				Cisek, P; Kalaska, JF			Neural correlates of mental rehearsal in dorsal premotor cortex	NATURE			English	Article							MOTOR IMAGERY; REPRESENTATION; MECHANISMS; MOVEMENTS; NEURONS	Behavioural and imaging studies suggest that when humans mentally rehearse a familiar action they execute some of the same neural operations used during overt motor performance(1-9). Similarly, neural activation is present during action observation in many of the same brain regions normally used for performance, including premotor cortex(6-9). Here we present behavioural evidence that monkeys also engage in mental rehearsal during the observation of sensory events associated with a well-learned motor task. Furthermore, most task-related neurons in dorsal premotor cortex exhibit the same activity patterns during observation as during performance, even during an instructed-delay period before any actual observed motion. This activity might be a single-neuron correlate of covert mental rehearsal.	Univ Montreal, Dept Physiol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Kalaska, JF (corresponding author), Univ Montreal, Dept Physiol, CP 6128 Succursale Centreville, Montreal, PQ H3C 3J7, Canada.	kalaskaj@physio.umontreal.ca	Cisek, Paul/H-2660-2012					Buccino G, 2001, EUR J NEUROSCI, V13, P400, DOI 10.1046/j.1460-9568.2001.01385.x; Cisek P, 2003, J NEUROPHYSIOL, V89, P922, DOI 10.1152/jn.00607.2002; Cisek P, 2002, J NEUROPHYSIOL, V87, P1149, DOI 10.1152/jn.00443.2001; Crammond DJ, 1997, TRENDS NEUROSCI, V20, P54, DOI 10.1016/S0166-2236(96)30019-2; DIPELLEGRINO G, 1992, EXP BRAIN RES, V91, P176, DOI 10.1007/BF00230027; Fadiga L, 2000, INT J PSYCHOPHYSIOL, V35, P165, DOI 10.1016/S0167-8760(99)00051-3; Ferrari PF, 2003, EUR J NEUROSCI, V17, P1703, DOI 10.1046/j.1460-9568.2003.02601.x; Flanagan JR, 2003, NATURE, V424, P769, DOI 10.1038/nature01861; Jeannerod M, 1995, CURR OPIN NEUROBIOL, V5, P727, DOI 10.1016/0959-4388(95)80099-9; Jeannerod M, 1999, Q J EXP PSYCHOL-A, V52, P1, DOI 10.1080/027249899391205; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; Jeannerod M, 2001, NEUROIMAGE, V14, pS103, DOI 10.1006/nimg.2001.0832; Johnson SH, 2002, NEUROIMAGE, V17, P1693, DOI 10.1006/nimg.2002.1265; Kohler E, 2002, SCIENCE, V297, P846, DOI 10.1126/science.1070311; Ochiai T, 2002, J NEUROPHYSIOL, V88, P2167, DOI 10.1152/jn.2002.88.4.2167; Papaxanthis C, 2002, EXP BRAIN RES, V143, P447, DOI 10.1007/s00221-002-1012-1; Ramnani N, 2004, NAT NEUROSCI, V7, P85, DOI 10.1038/nn1168; Rizzolatti G, 2001, NAT REV NEUROSCI, V2, P661, DOI 10.1038/35090060; Shen LM, 1997, J NEUROPHYSIOL, V77, P1195, DOI 10.1152/jn.1997.77.3.1195; SIRIGU A, 1995, NEUROREPORT, V6, P997, DOI 10.1097/00001756-199505090-00012; Sirigu A, 1996, SCIENCE, V273, P1564, DOI 10.1126/science.273.5281.1564; Umilta MA, 2001, NEURON, V31, P155, DOI 10.1016/S0896-6273(01)00337-3; Watanabe M, 2001, EXP BRAIN RES, V140, P511, DOI 10.1007/s002210100856	23	180	181	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					993	996		10.1038/nature03005	http://dx.doi.org/10.1038/nature03005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	863TI	15496925				2022-12-28	WOS:000224585600046
J	Hegedus, L				Hegedus, L			The thyroid nodule	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERCUTANEOUS ETHANOL INJECTION; NEEDLE-ASPIRATION BIOPSY; SUPPRESSIVE THERAPY; RADIOACTIVE IODINE; RANDOMIZED-TRIAL; DOUBLE-BLIND; MANAGEMENT; DISEASE; DIAGNOSIS; GOITER	A 42-year-old woman presents with a palpable mass on the left side of her neck. She has no neck pain and no symptoms of thyroid dysfunction. Physical examination reveals a solitary, mobile thyroid nodule, 2 cm by 3 cm, without lymphadenopathy. The patient has no family history of thyroid disease and no history of external irradiation. Which investigations should be performed? Assuming that the nodule is benign, which, if any, treatment should be recommended?	Odense Univ Hosp, Dept Endocrinol & Metab, DK-5000 Odense, Denmark	University of Southern Denmark; Odense University Hospital	Hegedus, L (corresponding author), Odense Univ Hosp, Dept Endocrinol & Metab, DK-5000 Odense, Denmark.	laszlo.hegedus@ouh.fyns-amt.dk						Alexander EK, 2003, ANN INTERN MED, V138, P315, DOI 10.7326/0003-4819-138-4-200302180-00010; Bennedbaek FN, 1999, CLIN ENDOCRINOL, V50, P357, DOI 10.1046/j.1365-2265.1999.00663.x; Bennedbaek FN, 1999, THYROID, V9, P225, DOI 10.1089/thy.1999.9.225; Bennedbaek FN, 2003, J CLIN ENDOCR METAB, V88, P5773, DOI 10.1210/jc.2003-031000; Bennedbaek FN, 1997, EUR J ENDOCRINOL, V136, P240, DOI 10.1530/eje.0.1360240; Bennedbaek FN, 2000, J CLIN ENDOCR METAB, V85, P2493, DOI 10.1210/jc.85.7.2493; BENNEDBAEK FN, 1998, J CLIN ENDOCR METAB, V83, P30; BURCH HB, 1995, ENDOCRIN METAB CLIN, V24, P663, DOI 10.1016/S0889-8529(18)30019-7; Castro MR, 2002, J CLIN ENDOCR METAB, V87, P4154, DOI 10.1210/jc.2001-011762; Danese D, 1998, THYROID, V8, P15, DOI 10.1089/thy.1998.8.15; Dossing H, 2002, RADIOLOGY, V225, P53, DOI 10.1148/radiol.2251011042; Elisei R, 2004, J CLIN ENDOCR METAB, V89, P163, DOI 10.1210/jc.2003-030550; Feld S, 1996, ENDOCR PRACT, V2, P78; Ferrari C, 1996, EUR J ENDOCRINOL, V135, P383, DOI 10.1530/eje.0.1350383; GHARIB H, 1993, ANN INTERN MED, V118, P282, DOI 10.7326/0003-4819-118-4-199302150-00007; HAMBURGER JI, 1980, J CLIN ENDOCR METAB, V50, P1089, DOI 10.1210/jcem-50-6-1089; HAMBURGER JI, 1994, J CLIN ENDOCR METAB, V79, P335, DOI 10.1210/jc.79.2.335; HAMMING JF, 1990, ARCH INTERN MED, V150, P1088; HAMMING JF, 1990, ARCH INTERN MED, V150, P113, DOI 10.1001/archinte.150.1.113; Hegedus L, 2003, ENDOCR REV, V24, P102, DOI 10.1210/er.2002-0016; Hegedus L, 2001, ENDOCRIN METAB CLIN, V30, P339, DOI 10.1016/S0889-8529(05)70190-0; HEGEDUS L, 1988, ARCH INTERN MED, V148, P1116, DOI 10.1001/archinte.148.5.1116; Hegedus L, 1999, J CLIN ENDOCR METAB, V84, P756, DOI 10.1210/jc.84.2.756; Ito Y, 2003, THYROID, V13, P381, DOI 10.1089/105072503321669875; Jarlov AE, 1998, THYROID, V8, P393, DOI 10.1089/thy.1998.8.393; Jennings A, 2001, ENDOCRIN METAB CLIN, V30, P401, DOI 10.1016/S0889-8529(05)70192-4; Kang KW, 2003, J CLIN ENDOCR METAB, V88, P4100, DOI 10.1210/jc.2003-030465; KUMA K, 1992, WORLD J SURG, V16, P583, DOI 10.1007/BF02067327; Lippi F, 1996, J CLIN ENDOCR METAB, V81, P3261, DOI 10.1210/jc.81.9.3261; Marqusee E, 2000, ANN INTERN MED, V133, P696, DOI 10.7326/0003-4819-133-9-200011070-00011; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; MCCOWEN KD, 1980, AM J MED, V68, P853, DOI 10.1016/0002-9343(80)90205-3; Nygaard B, 1999, CLIN ENDOCRINOL, V50, P197, DOI 10.1046/j.1365-2265.1999.00635.x; Papini E, 1998, J CLIN ENDOCR METAB, V83, P780, DOI 10.1210/jc.83.3.780; Papini E, 2002, J CLIN ENDOCR METAB, V87, P1941, DOI 10.1210/jc.87.5.1941; Pasieka JL, 2000, WORLD J SURG, V24, P966, DOI 10.1007/s002680010159; SANDROCK D, 1993, ACTA ENDOCRINOL-COP, V128, P51, DOI 10.1530/acta.0.1280051; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SHAMBAUGH GE, 1974, JAMA-J AM MED ASSOC, V228, P866, DOI 10.1001/jama.228.7.866; Singer PA, 1996, ARCH INTERN MED, V156, P2165, DOI 10.1001/archinte.156.19.2165; Songun I, 1999, EUR J SURG, V165, P839; Surks MI, 2004, JAMA-J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228; Uzzan B, 1996, J CLIN ENDOCR METAB, V81, P4278, DOI 10.1210/jc.81.12.4278; VERDE G, 1994, CLIN ENDOCRINOL, V41, P719, DOI 10.1111/j.1365-2265.1994.tb02785.x; Wong CKM, 2000, WORLD J SURG, V24, P934, DOI 10.1007/s002680010175; Zelmanovitz F, 1998, J CLIN ENDOCR METAB, V83, P3881, DOI 10.1210/jc.83.11.3881; Zingrillo M, 1998, J CLIN ENDOCR METAB, V83, P3905, DOI 10.1210/jc.83.11.3905	47	990	1080	2	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2004	351	17					1764	1771		10.1056/NEJMcp031436	http://dx.doi.org/10.1056/NEJMcp031436			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863TH	15496625				2022-12-28	WOS:000224585200011
J	Ryan, DP; Titton, RL; Harris, NL; Fletcher, CDM; Demetri, GD; Colvin, RB				Ryan, DP; Titton, RL; Harris, NL; Fletcher, CDM; Demetri, GD; Colvin, RB			Case 32-2004: A 68-year-old man with a large retroperitoneal mass - Gastrointestinal stromal tumor	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TYROSINE KINASE INHIBITOR; SOFT-TISSUE SARCOMAS; KIT CD117; C-KIT; IMATINIB MESYLATE; MUTATIONS; DIAGNOSIS; EFFICACY; STI571; SAFETY		Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Ryan, DP (corresponding author), Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA.							Borden EC, 2003, CLIN CANCER RES, V9, P1941; Corless CL, 2002, AM J PATHOL, V160, P1567, DOI 10.1016/S0002-9440(10)61103-0; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Demetri GD., 2004, J NATL COMPR CANC NE, V2, pS; Fletcher CDM, 2002, AM J CLIN PATHOL, V118, P163, DOI 10.1309/U1J7-AVTM-KV80-MTNG; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hornick JL, 2003, AM J CLIN PATHOL, V119, P325, DOI 10.1309/EJ3RY45QCYPUKQG4; Hornick JL, 2002, AM J CLIN PATHOL, V117, P188; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Kindblom LG, 1998, AM J PATHOL, V152, P1259; Medeiros F, 2004, AM J SURG PATHOL, V28, P889, DOI 10.1097/00000478-200407000-00007; Miettinen M, 2001, VIRCHOWS ARCH, V438, P1, DOI 10.1007/s004280000338; Rubin BP, 2001, CANCER RES, V61, P8118; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; Singer S, 2002, J CLIN ONCOL, V20, P3898, DOI 10.1200/JCO.2002.03.095; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; Weisberg E, 2003, DRUG RESIST UPDATE, V6, P231, DOI 10.1016/S1368-7646(03)00062-1	22	4	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2004	351	17					1779	1787		10.1056/NEJMcpc049024	http://dx.doi.org/10.1056/NEJMcpc049024			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863TH	15496628				2022-12-28	WOS:000224585200015
J	Karlawish, JH				Karlawish, JH			Competency in the age of assessment	LANCET			English	Editorial Material									Inst Aging, Philadelphia, PA 19104 USA		Karlawish, JH (corresponding author), Inst Aging, Philadelphia, PA 19104 USA.	jasonkar@mail.med.upenn.edu			NATIONAL INSTITUTE ON AGING [U19AG010483] Funding Source: NIH RePORTER; NIA NIH HHS [U19 AG010483] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Appelbaum PS, 2000, MACARTHUR COMPETENCE; Carpenter WT, 2000, ARCH GEN PSYCHIAT, V57, P533, DOI 10.1001/archpsyc.57.6.533; Grisso T, 1998, MACARTHUR COMPETENCE; GRISSO T, 1998, MAKING JUDGMENTS PAT, P127; HRISCHMAN KB, 2004, J GERIATR PSYCH NEUR, V75, P55; Kim SYH, 2002, AM J GERIAT PSYCHIAT, V10, P151, DOI 10.1176/appi.ajgp.10.2.151; POLYTHRESS N, 1999, MACARTHUR COMPETENCE; *U PA ALZH DIS CTR, DEV PRACT GUID VOT P	8	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2004	364	9443					1383	1384		10.1016/S0140-6736(04)17236-X	http://dx.doi.org/10.1016/S0140-6736(04)17236-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488200				2022-12-28	WOS:000224485300005
J	Smitz, J; Cortvrindt, R				Smitz, J; Cortvrindt, R			First childbirth from transplanted cryoreserve ovarian tissue brings hope for cancer survivors	LANCET			English	Editorial Material							CHILDHOOD-CANCER; FERTILITY PRESERVATION; RADIOTHERAPY		Free Univ Brussels, Akad Ziekenhuis, Ctr Reprod Med, Follicle Biol Lab, B-1090 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Smitz, J (corresponding author), Free Univ Brussels, Akad Ziekenhuis, Ctr Reprod Med, Follicle Biol Lab, B-1090 Brussels, Belgium.	johan.smitz@az.vub.ac.be		Smitz, Johan/0000-0002-5857-6542				Arav A, 2003, J ASSIST REPROD GEN, V20, P351; Baird DT, 1999, ENDOCRINOLOGY, V140, P462, DOI 10.1210/en.140.1.462; GOSDEN R, 1994, HUM REPROD, V9, P598; Hubner K, 2003, SCIENCE, V300, P1251, DOI 10.1126/science.1083452; Kim SS, 2001, HUM REPROD, V16, P2056, DOI 10.1093/humrep/16.10.2056; Larsen EC, 2003, HUM REPROD, V18, P417, DOI 10.1093/humrep/deg073; Larsen EC, 2004, ACTA OBSTET GYN SCAN, V83, P96, DOI 10.1111/j.1600-0412.2004.00332.x; Meirow D, 2001, HUM REPROD UPDATE, V7, P535, DOI 10.1093/humupd/7.6.535; Meirow D, 2001, HUM REPROD, V16, P632, DOI 10.1093/humrep/16.4.632; Morita Y, 2000, ANN NY ACAD SCI, V905, P209; Oktay K, 2000, NEW ENGL J MED, V342, P1919, DOI 10.1056/NEJM200006223422516; Oktay K, 2004, LANCET, V363, P837, DOI 10.1016/S0140-6736(04)15728-0; Shaw JM, 1996, HUM REPROD, V11, P1668; Smitz JEJ, 2002, REPRODUCTION, V123, P185, DOI 10.1530/rep.0.1230185; Sonmezer M, 2004, HUM REPROD UPDATE, V10, P251, DOI 10.1093/humupd/dmh021; Thomson AB, 2002, BEST PRACT RES CL EN, V16, P311, DOI 10.1053/beem.2002.0200	16	5	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	2004	364	9443					1379	1380		10.1016/S0140-6736(04)17234-6	http://dx.doi.org/10.1016/S0140-6736(04)17234-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488198				2022-12-28	WOS:000224485300003
J	Brent, DA				Brent, DA			Treating depression in children: Antidepressants and pediatric depression the risk of doing nothing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SUICIDE		Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Med Ctr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC	Brent, DA (corresponding author), Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Med Ctr, Pittsburgh, PA 15213 USA.							BRENT DA, 1988, ARCH GEN PSYCHIAT, V45, P581, DOI 10.1001/archpsyc.1988.01800300079011; March J, 2004, JAMA-J AM MED ASSOC, V292, P807; Martin A, 2004, ARCH PEDIAT ADOL MED, V158, P773, DOI 10.1001/archpedi.158.8.773; Olfson M, 2003, ARCH GEN PSYCHIAT, V60, P978, DOI 10.1001/archpsyc.60.9.978; Webster DW, 2004, JAMA-J AM MED ASSOC, V292, P594, DOI 10.1001/jama.292.5.594; WEBSTER DW, 2004, JAMA-J AM MED ASSOC, V292, P1178	6	86	86	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1598	1601						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483276				2022-12-28	WOS:000224427300004
J	Wise, RP; Iskander, J; Pratt, RD; Campbell, S; Ball, R; Pless, RP; Braun, MM				Wise, RP; Iskander, J; Pratt, RD; Campbell, S; Ball, R; Pless, RP; Braun, MM			Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EVENT-REPORTING-SYSTEM; INFANT-DEATH-SYNDROME; ADVERSE EVENTS; IMMUNIZATION; RISK; PERTUSSIS; VAERS; EPIDEMIOLOGY; EFFICACY; PURPURA	Context Clinical trials evaluate a vaccine's safety before approval, but some risks may escape detection or adequate characterization until larger population exposures occur after licensure. Objective To summarize reports of events occurring after vaccination with 7-valent pneumococcal conjugate vaccine (PCV), including those that may warrant further investigation to assess possible causation by PCV. Design Descriptive epidemiology of reports submitted to the Vaccine Adverse Event Reporting System (VAERS), a national passive surveillance database. Setting and Patients United States during first 2 years after licensure of PCV (February 2000 through February 2002). Reports studied were for children younger than 18 years and vaccinated with PCV. Main Outcome Measures Numbers and proportional distributions of reports. Results A total of 4154 reports of events following PCV were submitted to VAERS, for a rate of 13.2 reports per 100000 doses distributed. Multiple vaccines were given in 74.3% of reports. The most frequently reported symptoms and signs included fever, injection site reactions, fussiness, rashes, and urticaria. Serious events were described in 14.6% of reports. There were 117 deaths, 23 reports of positive rechallenges, and 34 cases of invasive pneumococcal infections possibly representing vaccine failure. Immune-mediated events occurred in 31.3% of reports. All 14 patients with anaphylactic or anaphylactoid reactions survived. Thrombocytopenia developed in 14 patients and serum sickness in 6 others. Neurologic symptoms occurred in 38% of reports. Seizures described in 393 reports included 94 febrile seizures. Conclusions The majority of reports to VAERS in the first 2 years after licensure of PCV described generally minor adverse events previously identified in clinical trials. The proportion of reports portraying serious events was similar to that for other vaccines. Although there are important limitations in passive surveillance data, and caution in their interpretation is necessary, symptoms experienced by a few children more than once after successive PCV doses, including allergic reactions, prolonged or abnormal crying, fussiness, dyspnea, and gastrointestinal distress, warrant continued surveillance, as do reports of rare but potentially serious events, such as seizures, anaphylactic or anaphylactoid reactions, serum sickness, and thrombocytopenia.	US FDA, Ctr Biol Evaluat & Res, Div Epidemiol, Off Biostat & Epidemiol, Rockville, MD 20852 USA; US FDA, Ctr Biol Evaluat & Res, Div Vaccines & Related Prod Applicat, Off Vaccines Res & Review, Rockville, MD 20852 USA; Ctr Dis Control & Prevent, Immunizat Safety Branch, Epidemiol & Surveillance Div, Natl Immunizat Program, Atlanta, GA USA; Ctr Infect Dis Prevent & Control Hlth Canada, Immunizat Safety Unit, Immunizat & Resp Infect Div, Ottawa, ON, Canada	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); Centers for Disease Control & Prevention - USA	Wise, RP (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Epidemiol, Off Biostat & Epidemiol, HFM-225,1401 Rockville Pike, Rockville, MD 20852 USA.	R.P.Wise@cber.fda.gov						[Anonymous], 2002, IMMUNIZATION SAFETY; Ball Robert, 2002, Expert Rev Vaccines, V1, P161, DOI 10.1586/14760584.1.2.161; Beeler J, 1996, PEDIATR INFECT DIS J, V15, P88, DOI 10.1097/00006454-199601000-00020; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Black SB, 2002, PEDIATR INFECT DIS J, V21, P568, DOI 10.1097/00006454-200206000-00018; Braun MM, 1997, J PEDIATR-US, V131, P529, DOI 10.1016/S0022-3476(97)70056-8; Byard RW, 1998, J PAEDIATR CHILD H, V34, P101; Byard RW, 1995, MED J AUSTRALIA, V163, P443, DOI 10.5694/j.1326-5377.1995.tb124675.x; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; Cohen AD, 1996, J AUTOIMMUN, V9, P699, DOI 10.1006/jaut.1996.0091; DeStefano F, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.6.e112; Ellenberg SS, 1997, PUBLIC HEALTH REP, V112, P10; *FDA PHS, 1995, COD COSTART SYMB THE; GRIFFIN MR, 1988, NEW ENGL J MED, V319, P618, DOI 10.1056/NEJM198809083191006; Halsey Neal A, 2002, Semin Pediatr Infect Dis, V13, P205, DOI 10.1053/spid.2002.125864; HOFFMAN HJ, 1987, PEDIATRICS, V79, P598; *I SAF MED PRACT, 2002, ISMP MED SAFETY ALER, V7, P2; Jefferson T, 1998, J EPIDEMIOL COMMUN H, V52, P674, DOI 10.1136/jech.52.10.674; Jonville-Bera AP, 2001, BRIT J CLIN PHARMACO, V51, P271, DOI 10.1046/j.1365-2125.2001.00341.x; Miller E, 2001, ARCH DIS CHILD, V84, P227, DOI 10.1136/adc.84.3.227; Rosenthal S, 1995, AM J PUBLIC HEALTH, V85, P1706, DOI 10.2105/AJPH.85.12.1706; Shetty AK, 2000, ARCH FAM MED, V9, P553, DOI 10.1001/archfami.9.6.553; Silvers LE, 2001, PHARMACOEPIDEM DR S, V10, P279, DOI 10.1002/pds.619; Singleton JA, 1999, VACCINE, V17, P2908, DOI 10.1016/S0264-410X(99)00132-2; Stratton K, 2003, IMMUNIZATION SAFETY; STRATTON KR, 1994, JAMA-J AM MED ASSOC, V271, P1602, DOI 10.1001/jama.271.20.1602; Verstraeten T, 2001, AM J EPIDEMIOL, V154, P1006, DOI 10.1093/aje/154.11.1006; WEBER RE, 1984, MOL PHYSIOL, V6, P1; Wise RP, 2000, JAMA-J AM MED ASSOC, V284, P1271, DOI 10.1001/jama.284.10.1271; Wise RP, 1997, JAMA-J AM MED ASSOC, V278, P1176, DOI 10.1001/jama.278.14.1176; Zhou Weigong, 2003, MMWR Surveill Summ, V52, P1; 1994, FED REG, V59, P54042; 2001, MMWR WEEKLY     1221, V50, P1140	33	53	56	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2004	292	14					1702	1710		10.1001/jama.292.14.1702	http://dx.doi.org/10.1001/jama.292.14.1702			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861JS	15479935	Bronze			2022-12-28	WOS:000224413400029
J	Constancia, M; Kelsey, G; Reik, W				Constancia, M; Kelsey, G; Reik, W			Resourceful imprinting	NATURE			English	Article							GENES; EXPRESSION; METABOLISM; GENOMES; MAMMALS; GROWTH; LOCUS		Babraham Inst, Lab Dev Genet & Imprinting, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Constancia, M (corresponding author), Babraham Inst, Lab Dev Genet & Imprinting, Cambridge CB2 4AT, England.	miguel.constancia@bbsrc.ac.uk; gavin.kelsey@bbsrc.ac.uk; wolf.reik@bbsrc.ac.uk	Reik, Wolf/I-6794-2012; Constancia, Miguel/F-6654-2013	Kelsey, Gavin/0000-0002-9762-5634; Constancia, Miguel/0000-0002-8976-1679; Reik, Wolf/0000-0003-0216-9881	Biotechnology and Biological Sciences Research Council [BB/B50118X/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Barker DJP, 2002, TRENDS ENDOCRIN MET, V13, P364, DOI 10.1016/S1043-2760(02)00689-6; BEECHEY CV, MOUSE IMPRINTING DAT; Brown WM, 2004, MED HYPOTHESES, V63, P377, DOI 10.1016/j.mehy.2004.05.010; Constancia M, 2002, NATURE, V417, P945, DOI 10.1038/nature00819; Curley JP, 2004, P ROY SOC B-BIOL SCI, V271, P1303, DOI 10.1098/rspb.2004.2725; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; Haig D, 2004, ANNU REV GENET, V38, P553, DOI 10.1146/annurev.genet.37.110801.142741; Isles AR, 2000, TRENDS COGN SCI, V4, P309, DOI 10.1016/S1364-6613(00)01504-7; Judson H, 2002, NATURE, V416, P539, DOI 10.1038/416539a; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; Killian JK, 2000, MOL CELL, V5, P707, DOI 10.1016/S1097-2765(00)80249-X; Ma D, 2004, J CLIN INVEST, V114, P339, DOI 10.1172/jci200419876; Maher ER, 2003, HUM REPROD, V18, P2508, DOI 10.1093/humrep/deg486; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; Morison IM, 2001, NUCLEIC ACIDS RES, V29, P275, DOI 10.1093/nar/29.1.275; Oudejans CBM, 2004, MOL HUM REPROD, V10, P589, DOI 10.1093/molehr/gah080; Plagge A, 2004, NAT GENET, V36, P818, DOI 10.1038/ng1397; Reik W, 2003, J PHYSIOL-LONDON, V547, P35, DOI 10.1113/jphysiol.2002.033274; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Sibley CP, 2004, P NATL ACAD SCI USA, V101, P8204, DOI 10.1073/pnas.0402508101; Skuse DH, 1997, NATURE, V387, P705, DOI 10.1038/42706; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342; Tsai CE, 2002, CURR BIOL, V12, P1221, DOI 10.1016/S0960-9822(02)00951-X; Tycko B, 2002, J CELL PHYSIOL, V192, P245, DOI 10.1002/jcp.10129; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Wilkins JF, 2003, NAT REV GENET, V4, P359, DOI 10.1038/nrg1062; Yu SH, 2000, J CLIN INVEST, V105, P615, DOI 10.1172/JCI8437	30	211	225	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	2004	432	7013					53	57		10.1038/432053a	http://dx.doi.org/10.1038/432053a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525980				2022-12-28	WOS:000224854900037
J	Gao, XF; Jiang, L				Gao, XF; Jiang, L			Water-repellent legs of water striders	NATURE			English	Editorial Material							LOCOMOTION		Chinese Acad Sci, Inst Chem, Key Lab Organ Solids, Beijing 100080, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing 100080, Peoples R China; Natl Ctr Nanosci & Nanotechnol, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Chemistry, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; National Center for Nanoscience & Technology - China	Gao, XF (corresponding author), Chinese Acad Sci, Inst Chem, Key Lab Organ Solids, Beijing 100080, Peoples R China.	jianglei@iccas.ac.cn	Jiang, Lei/B-1066-2011; jiang, lei/E-8437-2010; , 许永傲/AAC-2581-2019	gao, xue feng/0000-0001-6908-1361				CAPONIGRO MA, 1976, AM MIDL NAT, V95, P268, DOI 10.2307/2424392; Cassie ABD, 1944, T FARADAY SOC, V40, P0546, DOI 10.1039/tf9444000546; Dickinson M, 2003, NATURE, V424, P621, DOI 10.1038/424621a; Feng L, 2002, ADV MATER, V14, P1857, DOI 10.1002/adma.200290020; HOLDGATE MW, 1955, J EXP BIOL, V32, P591; Hu DL, 2003, NATURE, V424, P663, DOI 10.1038/nature01793; Tadanaga K, 1997, J AM CERAM SOC, V80, P1040, DOI 10.1111/j.1151-2916.1997.tb02943.x	7	2010	2151	92	1679	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					36	36		10.1038/432036a	http://dx.doi.org/10.1038/432036a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525973	Bronze			2022-12-28	WOS:000224854900030
J	Hauf, S; Watanabe, Y				Hauf, S; Watanabe, Y			Kinetochore orientation in mitosis and meiosis	CELL			English	Review							SISTER-CHROMATID COHESION; POLO-LIKE KINASE; REDUCTIONAL CHROMOSOME SEGREGATION; MAMMALIAN TISSUE-CELLS; 1ST MEIOTIC DIVISION; AURORA-B KINASE; FISSION YEAST; SPINDLE CHECKPOINT; BUDDING YEAST; MITOTIC SPINDLE	Kinetochores are the major point of contact between spindle microtubules and chromosomes. They are assemblies of more than 50 different proteins and take part in regulating and controlling their own interaction with the spindle. We review recent advance in understanding how kinetochores are properly placed onto the chromosome, and how their interaction with the microtubules of the spindle is regulated. Kinetochore orientation in meiosis I shows some particular features, and we also discuss similarities and differences between mitosis and meiosis I.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japan Sci & Technol Agcy, SORST, Tokyo 1130032, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Hauf, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.	silke@biochem.s.u-tokyo.ac.jp; ywatanab@iam.u-tokyo.ac.jp	Hauf, Silke/H-7321-2012	Hauf, Silke/0000-0001-5938-721X; Watanabe, Yoshinori/0000-0002-5488-4812				Amor DJ, 2004, TRENDS CELL BIOL, V14, P359, DOI 10.1016/j.tcb.2004.05.009; Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; Bajer A. S., 1972, SPINDLE DYNAMICS CHR; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Bernard P, 2001, NAT CELL BIOL, V3, P522, DOI 10.1038/35074598; Biggins S, 2003, CURR BIOL, V13, pR449, DOI 10.1016/S0960-9822(03)00369-5; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; Blower MD, 2002, DEV CELL, V2, P319, DOI 10.1016/S1534-5807(02)00135-1; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Cimini D, 2003, J CELL SCI, V116, P4213, DOI 10.1242/jcs.00716; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Clyne RK, 2003, NAT CELL BIOL, V5, P480, DOI 10.1038/ncb977; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; Dernburg AF, 1996, CELL, V86, P135, DOI 10.1016/S0092-8674(00)80084-7; Dernburg AF, 2001, J CELL BIOL, V153, pF33, DOI 10.1083/jcb.153.6.F33; Dewar H, 2004, NATURE, V428, P93, DOI 10.1038/nature02328; Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Gadde S, 2004, CURR BIOL, V14, pR797, DOI 10.1016/j.cub.2004.09.021; Gimenez-Abian JF, 2004, CURR BIOL, V14, P1187, DOI 10.1016/j.cub.2004.06.052; GOLDSTEIN LSB, 1981, CELL, V25, P591, DOI 10.1016/0092-8674(81)90167-7; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; Kaitna S, 2002, CURR BIOL, V12, P798, DOI 10.1016/S0960-9822(02)00820-5; Karpen GH, 1996, SCIENCE, V273, P118, DOI 10.1126/science.273.5271.118; Kemp B, 2004, GENE DEV, V18, P1946, DOI 10.1101/gad.1227304; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Kitagawa K, 2001, NAT REV MOL CELL BIO, V2, P678, DOI 10.1038/35089568; Kitajima TS, 2003, SCIENCE, V300, P1152, DOI 10.1126/science.1083634; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Lan WJ, 2004, CURR BIOL, V14, P273, DOI 10.1016/j.cub.2004.01.055; Lawrence CJ, 2004, J CELL BIOL, V167, P19, DOI 10.1083/jcb.200408113; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lee BH, 2002, GENE DEV, V16, P1672, DOI 10.1101/gad.989302; Lee J, 2000, MOL REPROD DEV, V56, P51, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;51::AID-MRD7&gt;3.0.CO;2-N; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; MAZIA D, 1961, MEIOSIS MITOSIS; McAinsh AD, 2003, ANNU REV CELL DEV BI, V19, P519, DOI 10.1146/annurev.cellbio.19.111301.155607; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; Molnar M, 2001, J CELL SCI, V114, P2843; Molnar M, 2001, GENETICS, V157, P519; Morishita J, 2001, GENES CELLS, V6, P743, DOI 10.1046/j.1365-2443.2001.00459.x; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; NICKLAS RB, 1969, J CELL BIOL, V43, P40, DOI 10.1083/jcb.43.1.40; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Ohi R, 2004, MOL BIOL CELL, V15, P2895, DOI 10.1091/mbc.E04-02-0082; Ono T, 2004, MOL BIOL CELL, V15, P3296, DOI 10.1091/mbc.E04-03-0242; Ono T, 2003, CELL, V115, P109, DOI 10.1016/S0092-8674(03)00724-4; OSTERGREN G, 1951, HEREDITAS, V37, P85; Paliulis LV, 2000, J CELL BIOL, V150, P1223, DOI 10.1083/jcb.150.6.1223; Parra MT, 2004, J CELL SCI, V117, P1221, DOI 10.1242/jcs.00947; Parra MT, 2003, J CELL SCI, V116, P961, DOI 10.1242/jcs.00330; Petersen J, 2001, J CELL SCI, V114, P4371; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Rabitsch KP, 2003, DEV CELL, V4, P535, DOI 10.1016/S1534-5807(03)00086-8; RIEDER CL, 1982, INT REV CYTOL, V79, P1, DOI 10.1016/S0074-7696(08)61672-1; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Schrader, 1953, MITOSIS MOVEMENT CHR; Shonn MA, 2000, SCIENCE, V289, P300, DOI 10.1126/science.289.5477.300; Shonn MA, 2003, CURR BIOL, V13, P1979, DOI 10.1016/j.cub.2003.10.057; Shonn MA, 2002, GENE DEV, V16, P1659, DOI 10.1101/gad.975802; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Sugimoto K, 2001, CELL STRUCT FUNCT, V26, P705, DOI 10.1247/csf.26.705; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; Tanaka TU, 2000, NAT CELL BIOL, V2, P492, DOI 10.1038/35019529; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Toth A, 2000, CELL, V103, P1155, DOI 10.1016/S0092-8674(00)00217-8; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Uhlmann F, 2004, EXP CELL RES, V296, P80, DOI 10.1016/j.yexcr.2004.03.005; Vagnarelli P, 2004, EMBO REP, V5, P167, DOI 10.1038/sj.embor.7400077; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774; Watanabe Y, 2001, NATURE, V409, P359, DOI 10.1038/35053103; Yamamoto A, 2003, EMBO J, V22, P2284, DOI 10.1093/emboj/cdg222; Yokobayashi S, 2003, MOL CELL BIOL, V23, P3965, DOI 10.1128/MCB.23.11.3965-3973.2003; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	89	92	95	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2004	119	3					317	327		10.1016/j.cell.2004.10.014	http://dx.doi.org/10.1016/j.cell.2004.10.014			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	868IW	15507205	Bronze			2022-12-28	WOS:000224908300004
J	Trampert, J; Deschamps, F; Resovsky, J; Yuen, D				Trampert, J; Deschamps, F; Resovsky, J; Yuen, D			Probabilistic tomography maps chemical heterogeneities throughout the lower mantle	SCIENCE			English	Article							SEISMIC TOMOGRAPHY; SHEAR VELOCITY; CONVECTION; PLUMES; CORE; DENSITY; INVERSION; BOUNDARY; HOTSPOTS; MODELS	We obtained likelihoods in the lower mantle for long-wavelength models of bulk sound and shear wave speed, density, and boundary topography, compatible with gravity constraints, from normal mode splitting functions and surface wave data. Taking into account the large uncertainties in Earth's thermodynamic reference state and the published range of mineral physics data, we converted the tomographic likelihoods into probability density functions for temperature, perovskite, and iron variations. Temperature and composition can be separated, showing that chemical variations contribute to the overall. buoyancy and are dominant in the lower 1000 kilometers of the mantle.	Univ Utrecht, Dept Earth Sci, NL-3508 TA Utrecht, Netherlands; Univ Minnesota, Dept Geophys, Minnesota Supercomp Inst, Minneapolis, MN 55455 USA	Utrecht University; University of Minnesota System; University of Minnesota Twin Cities	Trampert, J (corresponding author), Univ Utrecht, Dept Earth Sci, POB 80021, NL-3508 TA Utrecht, Netherlands.	jeannot@geo.uu.nl	Trampert, Jeannot/N-3240-2019; Deschamps, Frédéric/N-1994-2013; Trampert, Jeannot/B-8090-2015	Trampert, Jeannot/0000-0002-5868-9491; Deschamps, Frédéric/0000-0001-5110-2320; Trampert, Jeannot/0000-0002-5868-9491				Anderson DL, 2001, SCIENCE, V293, P2016, DOI 10.1126/science.1065448; ANDERSON OL, 1964, REV GEOPHYS SPACE PH, V6, P491; Bijwaard H, 1998, J GEOPHYS RES-SOL EA, V103, P30055, DOI 10.1029/98JB02467; CHRISTENSEN U, 1984, ANN GEOPHYS, V2, P311; CHRISTENSEN UR, 1989, PHILOS T R SOC A, V328, P417, DOI 10.1098/rsta.1989.0045; Courtillot V, 2003, EARTH PLANET SC LETT, V205, P295, DOI 10.1016/S0012-821X(02)01048-8; Davaille A, 1999, NATURE, V402, P756, DOI 10.1038/45461; DAVIES GF, 1986, GEOPHYS RES LETT, V13, P1517, DOI 10.1029/GL013i013p01517; Deschamps F, 2003, PHYS EARTH PLANET IN, V140, P277, DOI 10.1016/j.pepi.2003.09.004; Forte AM, 2001, NATURE, V410, P1049, DOI 10.1038/35074000; Grand SP., 1997, GSA TODAY, V7, P1; Gu YJ, 2001, J GEOPHYS RES-SOL EA, V106, P11169, DOI 10.1029/2001JB000340; GURNIS M, 1986, J GEOPHYS RES-SOLID, V91, P1407, DOI 10.1029/JB091iB11p11407; HAGER BH, 1985, NATURE, V313, P541, DOI 10.1038/313541a0; HANSEN U, 1988, NATURE, V334, P237, DOI 10.1038/334237a0; HANSEN U, 1995, DOUBLE DIFFUSE CONVE, P135; Ishii M, 1999, SCIENCE, V285, P1231, DOI 10.1126/science.285.5431.1231; KARATO S, 1993, GEOPHYS RES LETT, V20, P1623, DOI 10.1029/93GL01767; KARATO SL, 1999, J GEOPHYS RES, V106, P21771; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; KELLOGG LH, 1993, GEOPHYS RES LETT, V20, P379, DOI 10.1029/93GL00045; Kennett BLN, 1998, J GEOPHYS RES-SOL EA, V103, P12469, DOI 10.1029/98JB00150; Masters G., 2000, EARTHS DEEP INTERIOR, V117, P66; Montelli R, 2004, SCIENCE, V303, P338, DOI 10.1126/science.1092485; Murakami M, 2004, SCIENCE, V304, P855, DOI 10.1126/science.1095932; Ni SD, 2002, SCIENCE, V296, P1850, DOI 10.1126/science.1070698; OLSON P, 1982, J GEOPHYS RES, V87, P3993, DOI 10.1029/JB087iB05p03993; OLSON P, 1991, J GEOPHYS RES-SOLID, V96, P4347, DOI 10.1029/90JB02530; Resovsky J, 2003, EARTH PLANET SC LETT, V215, P121, DOI 10.1016/S0012-821X(03)00436-9; Ritsema J, 1999, SCIENCE, V286, P1925, DOI 10.1126/science.286.5446.1925; Romanowicz B, 2002, SCIENCE, V296, P513, DOI 10.1126/science.1069404; Saltzer RL, 2001, GEOPHYS RES LETT, V28, P1335, DOI 10.1029/2000GL012339; SALTZER RL, 2003, GEOPHYS RES LETT, V140, P277; Schott B, 2004, PHYS EARTH PLANET IN, V146, P139, DOI 10.1016/j.pepi.2003.07.026; Schubert G, 2001, MANTLE CONVECTION EA; SIDORIN I, 1998, OBSERVATIONAL THEORE, P209; SLEEP NH, 1988, GEOPHYS J INT, V95, P437, DOI 10.1111/j.1365-246X.1988.tb06695.x; Su WJ, 1997, PHYS EARTH PLANET IN, V100, P135, DOI 10.1016/S0031-9201(96)03236-0; SU WJ, 1994, J GEOPHYS RES-SOL EA, V99, P6945, DOI 10.1029/93JB03408; Tackley PJ, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000167; TACKLEY PJ, 1998, OBSERVATIONAL THEORE, P231; Tarantola A., 1987, INVERSE PROBLEM THEO; Tsuchiya T, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020278; van der Hilst RD, 1999, SCIENCE, V283, P1885, DOI 10.1126/science.283.5409.1885; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; WOODHOUSE JH, 1984, J GEOPHYS RES, V89, P5953, DOI 10.1029/JB089iB07p05953; YUEN DA, 1993, GEOPHYS RES LETT, V20, P899, DOI 10.1029/93GL00867	47	367	370	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					853	856		10.1126/science.1101996	http://dx.doi.org/10.1126/science.1101996			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514153				2022-12-28	WOS:000224969400041
J	Majumdar, SR; Almasi, EA; Stafford, RS				Majumdar, SR; Almasi, EA; Stafford, RS			Promotion and prescribing of hormone therapy after report of harm by the women's health initiative	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTINUING MEDICAL-EDUCATION; RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; NATIONAL TRENDS; UNITED-STATES; ESTROGEN; PUBLICATION; PHYSICIANS; INDUSTRY	Context Little is known about how the pharmaceutical industry responds to evidence of harm associated with its products, such as the publication in July 2002 of the Women's Health Initiative Estrogen Plus Progestin Trial (WHI E+P) report demonstrating that standard-dose Prempro produced significant harm and lacked net benefits. Objective To examine pharmaceutical industry response to the WHI E+P results by analyzing promotional expenditures for hormone therapy before and after July 2002. Design and Setting Nationally representative and prospectively collected longitudinal data (January 2001 through December 2003) on prescribing and promotion of hormone therapies were obtained from IMS Health and Consumer Media Reports. Main Outcome Measures Trends in quarterly prescriptions for hormone therapy and expenditures on 5 modes of drug promotion: samples, office-based detailing, hospital-based promotion, journal advertisements, and direct-to-consumer advertising. Results Prior to the WHI E+P report, prescribing rates and promotional spending for hormone therapy were stable. In the quarter before the WHI E+P report (April-June 2002), 22.4 million prescriptions for hormone therapy were dispensed and $71 million was spent on promotion (in annual terms, $350 per year per US physician). Within 9 months of the report's publication (quarter 1 of 2003), there was a 32% decrease in hormone therapy prescriptions, and a nadir had been reached for promotional spending (37% decrease compared with pre-WHI E+P levels). Spending decreased for all promotional activities and most hormone therapies. overall, the greatest declines were for samples (36% decrease as of quarter 1 of 2003) and direct-to-consumer advertising (100% decrease). The greatest declines in promotion occurred for standard-dose Prempro (61% decrease as of quarter 1 of 2003), the agent implicated by the WHI E+P report. More recently, promotional efforts have increased, particularly for lower-dose Prempro, a resurgence associated with modestly increased prescriptions for this newer agent. Conclusions Concordant with its widespread use, hormone therapy was among the most heavily promoted medications prior to the WHI E+P report. Following reporting of the evidence of harm from this trial, there was a substantial decline in promotional spending for hormone therapy, particularly for the agents most directly implicated in the trial. Interrelated with the impact of the trial results themselves and the ensuing media coverage, reduced promotion may have contributed to a substantial decline in hormone therapy prescriptions.	Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Stanford, CA 94305 USA; Univ Alberta, Dept Med, Edmonton, AB, Canada	Stanford University; University of Alberta	Stafford, RS (corresponding author), Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Hoover Pavil, Stanford, CA 94305 USA.	rstafford@stanford.edu	Stafford, Randall/F-3974-2017	Stafford, Randall/0000-0003-1805-1271	AHRQ HHS [R01-HS013405] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS013405] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Austin PC, 2003, JAMA-J AM MED ASSOC, V289, P3241, DOI 10.1001/jama.289.24.3241; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; GARDNER J, 1992, US NEWS WORLD RE NOV, V8, P71; Herrington DM, 2003, NEW ENGL J MED, V349, P519, DOI 10.1056/NEJMp038108; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Holmer AF, 2001, JAMA-J AM MED ASSOC, V285, P2012, DOI 10.1001/jama.285.15.2012; Katz Anne, 2003, Health Care Women Int, V24, P927, DOI 10.1080/07399330390244167; Lawton B, 2003, BRIT MED J, V327, P845, DOI 10.1136/bmj.327.7419.845; Levy R, 1994, Arch Fam Med, V3, P327, DOI 10.1001/archfami.3.4.327; Ma J, 2003, CLIN THER, V25, P1503, DOI 10.1016/S0149-2918(03)80136-4; Majumdar SR, 2003, AM J MED, V115, P467, DOI 10.1016/S0002-9343(03)00422-4; Majumdar SR, 2001, J GEN INTERN MED, V16, P351, DOI 10.1046/j.1525-1497.2001.016006351.x; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; *N AM MEN SOC, 2003, MENOPAUSE, V10, P6; Naylor CD, 2004, JAMA-J AM MED ASSOC, V291, P104, DOI 10.1001/jama.291.1.104; Petersen Melody, 2002, N Y Times Web, pC2; Relman AS, 2001, JAMA-J AM MED ASSOC, V285, P2009, DOI 10.1001/jama.285.15.2009; ROSSDEGNAN D, 1993, JAMA-J AM MED ASSOC, V270, P1937, DOI 10.1001/jama.270.16.1937; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schwartz LM, 2004, ANN INTERN MED, V140, P226, DOI 10.7326/0003-4819-140-3-200402030-00015; Smalley W, 2000, JAMA-J AM MED ASSOC, V284, P3036, DOI 10.1001/jama.284.23.3036; Stafford RS, 2004, JAMA-J AM MED ASSOC, V291, P54, DOI 10.1001/jama.291.1.54; Stafford RS, 2003, ARCH INTERN MED, V163, P1046, DOI 10.1001/archinte.163.9.1046; Wang TJ, 1999, CIRCULATION, V99, P2055, DOI 10.1161/01.CIR.99.15.2055; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; ZATE M, 2000, VENTURA COUNTY  0826; 1996, ADWEEK          1125, V46, P3	28	119	128	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2004	292	16					1983	1988		10.1001/jama.292.16.1983	http://dx.doi.org/10.1001/jama.292.16.1983			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865DO	15507584				2022-12-28	WOS:000224682900023
J	Victora, CG; Hanson, K; Bryce, J; Vaughan, JP				Victora, CG; Hanson, K; Bryce, J; Vaughan, JP			Achieving universal coverage,with health interventions	LANCET			English	Review							INTERMITTENT PREVENTIVE TREATMENT; CHILD-MORTALITY; PUBLIC-HEALTH; MALARIA; CARE; COUNTRIES; SYSTEMS	Cost-effective public health interventions are not reaching developing country populations who need them. Programmes to deliver these interventions are too often patchy, low quality, inequitable, and short-lived. we review the challenges of going to scale-ie, building on known, effective interventions to achieve universal coverage. One challenge is to choose interventions consistent with the epidemiological profile of the population. A second is to plan for context-specific delivery mechanisms effective in going to scale, and to avoid uniform approaches. A third is to develop innovative delivery mechanisms that move incrementally along the vertical-to-horizontal axis as health systems gain capacity in service delivery. The availability of sufficient funds is essential, but constraints to reaching universal coverage go well beyond financial issues. Accurate estimates of resource requirements need a full understanding of the factors that limit intervention delivery. Sound decisions need to be made about the choice of delivery mechanisms, the sequence of action, and the pace at which services can be expanded. Strong health systems are required, and the time frames and funding cycles of national and international agencies are often unrealistically short.	Univ Fed Pelotas, BR-96001970 Pelotas, RS, Brazil; London Sch Hyg & Trop Med, London WC1, England	Universidade Federal de Pelotas; University of London; London School of Hygiene & Tropical Medicine	Victora, CG (corresponding author), Univ Fed Pelotas, CP 464, BR-96001970 Pelotas, RS, Brazil.	cvictora@terra.com.br	Victora, Cesar G/D-4476-2013; Victora, Cesar Gomes/Y-2455-2019	Victora, Cesar G/0000-0002-2465-2180; Victora, Cesar Gomes/0000-0002-2465-2180				AMARAL J, IN PRESS EFFECT INTE; [Anonymous], 2001, MACR HLTH INV HLTH E; Becerra-Posada F, 2004, LANCET, V364, P997, DOI 10.1016/S0140-6736(04)17026-8; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Claeson M, 2000, B WORLD HEALTH ORGAN, V78, P1234; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; *DEP INT DEV, MACR AID POL PAP DEP; Devarajan S., 2002, PROSPECTS COSTS APRI; Glasgow RE, 2003, AM J PUBLIC HEALTH, V93, P1261, DOI 10.2105/AJPH.93.8.1261; Gupta R, 2004, LANCET, V363, P320, DOI 10.1016/S0140-6736(03)15394-9; Gwatkin DR, 2004, LANCET, V364, P1273, DOI 10.1016/S0140-6736(04)17145-6; HAINES A, IN PRESS B WHO; Hanson K, 2003, J INT DEV, V15, P1, DOI DOI 10.1002/JID.963; Hawley WA, 2003, AM J TROP MED HYG, V68, P121, DOI 10.4269/ajtmh.2003.68.121; Hongoro C, 2004, LANCET, V364, P1451, DOI 10.1016/S0140-6736(04)17229-2; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; KIKUMBIH N, IN PRESS SOC SCI MED; Kurowski C, 2004, HUMAN RESOURCES HLTH; MILLS A, COPENHAGEN CONSENSUS; MSUYA J, YHORIZONTAL VERTICAL; *NAT HLTH SERV, WHAT IS HERD IMM; NSUNGWASABIITI J, IN PRESS J HLTH POPU; Oliveira-Cruz V., 2003, J INT DEV, V15, P41, DOI [10.1002/jid.965, DOI 10.1002/JID.965]; Oliveira-Cruz V., 2003, J INT DEV, V15, P67, DOI [DOI 10.1002/JID.966, 10.1002/jid.966]; Palmer N, 2004, LANCET, V364, P1365, DOI 10.1016/S0140-6736(04)17195-X; Perry H B, 1999, J Health Popul Dev Ctries, V2, P45; RANSON MK, 2003, J INT DEV, V15, P41; Ranson MK, 2003, J INT DEV J DEV STUD, V15, P15, DOI DOI 10.1002/JID.964; Rifkin S, 1986, World Educ Rep, P8; Rosen JB, 2004, LANCET, V363, P1386, DOI 10.1016/S0140-6736(04)16052-2; Schellenberg JA, 2004, HEALTH POLICY PLANN, V19, P1, DOI 10.1093/heapol/czh001; Schreuder B, 2001, S AFR MED J, V91, P249; Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0; Tulloch J., 1999, Lancet (British edition), V354, P16, DOI 10.1016/S0140-6736(99)90252-0; van Eijk AM, 2004, TROP MED INT HEALTH, V9, P630, DOI 10.1111/j.1365-3156.2004.01242.x; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; Victora CG, 2004, AM J PUBLIC HEALTH, V94, P400, DOI 10.2105/AJPH.94.3.400; VICTORA CG, COCOVERAGE CHILD SUR; VICTORA CG, IN PRESS DIS CONTROL; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; *WHO, TREAT 3 MILL 2005 MA; *WHO, AN REV IMCI STRAT; WHO, 2003, WORLD HLTH REP; WHO Europe, 1978, DECL ALM AT; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Health Organization (WHO), 2001, PREV MOTH TO CHILD T	47	126	127	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1541	1548		10.1016/S0140-6736(04)17279-6	http://dx.doi.org/10.1016/S0140-6736(04)17279-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500901				2022-12-28	WOS:000224645500034
J	Hood, L; Heath, JR; Phelps, ME; Lin, BY				Hood, L; Heath, JR; Phelps, ME; Lin, BY			Systems biology and new technologies enable predictive and preventative medicine	SCIENCE			English	Editorial Material							NANOMECHANICAL CANTILEVER ARRAY; LASER-CAPTURE MICRODISSECTION; PROSTATE-CANCER; GENE-EXPRESSION; NANOWIRE NANOSENSORS; PROTEOMIC PATTERNS; MICROCHIP DEVICE; NETWORKS; DNA; BIOSENSORS	Systems approaches to disease are grounded in the idea that disease-perturbed protein and gene regulatory networks differ from their normal counterparts; we have been pursuing the possibility that these differences may be reflected by multiparameter measurements of the blood. Such concepts are transforming current diagnostic and therapeutic approaches to medicine and, together with new technologies, wilt enable a predictive and preventive medicine that will lead to personalized medicine.	Inst Syst Biol, Seattle, WA USA; CALTECH, Dept Chem, Pasadena, CA 91125 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA	Institute for Systems Biology (ISB); California Institute of Technology; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Hood, L (corresponding author), Inst Syst Biol, Seattle, WA USA.	lhood@systemsbiology.org	Crozier, Laura/A-7950-2013					Adam BL, 2002, CANCER RES, V62, P3609; Alon U, 2003, SCIENCE, V301, P1866, DOI 10.1126/science.1089072; Arntz Y, 2003, NANOTECHNOLOGY, V14, P86, DOI 10.1088/0957-4484/14/1/319; Braslavsky I, 2003, P NATL ACAD SCI USA, V100, P3960, DOI 10.1073/pnas.0230489100; Brenner S, 2000, NAT BIOTECHNOL, V18, P630, DOI 10.1038/76469; BUNIMOVICH Y, IN PRESS LANGMUIR; Carlson RH, 1997, PHYS REV LETT, V79, P2149, DOI 10.1103/PhysRevLett.79.2149; Chen RJ, 2003, P NATL ACAD SCI USA, V100, P4984, DOI 10.1073/pnas.0837064100; Choy G, 2003, BIOTECHNIQUES, V35, P1022, DOI 10.2144/03355rr02; CHURCH JG, 1993, CYTOMETRY, V14, P271, DOI 10.1002/cyto.990140306; Covitz PA, 2003, PHARMACOGENOMICS J, V3, P257, DOI 10.1038/sj.tpj.6500187; Craven RA, 2001, PROTEOMICS, V1, P1200; Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711; Davidson EH, 2003, P NATL ACAD SCI USA, V100, P1475, DOI 10.1073/pnas.0437746100; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Diamandis EP, 2003, CLIN CHEM, V49, P1272, DOI 10.1373/49.8.1272; Fritz J, 2000, SCIENCE, V288, P316, DOI 10.1126/science.288.5464.316; Fu AY, 2002, ANAL CHEM, V74, P2451, DOI 10.1021/ac0255330; Hadd AG, 1997, ANAL CHEM, V69, P3407, DOI 10.1021/ac970192p; Hahm J, 2004, NANO LETT, V4, P51, DOI 10.1021/nl034853b; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herschman HR, 2003, SCIENCE, V302, P605, DOI 10.1126/science.1090585; Hong JW, 2004, NAT BIOTECHNOL, V22, P435, DOI 10.1038/nbt951; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; JOHNSTONHALPERI.E, IN PRESS J APPL PHYS; KARUBE I, 1995, ANN NY ACAD SCI, V750, P101, DOI 10.1111/j.1749-6632.1995.tb19935.x; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Klein CA, 2004, CELL CYCLE, V3, P29; Lee KB, 2002, SCIENCE, V295, P1702, DOI 10.1126/science.1067172; LIN BC, UNPUB; Liu AY, 1997, P NATL ACAD SCI USA, V94, P10705, DOI 10.1073/pnas.94.20.10705; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; McKendry R, 2002, P NATL ACAD SCI USA, V99, P9783, DOI 10.1073/pnas.152330199; Melosh NA, 2003, SCIENCE, V300, P112, DOI 10.1126/science.1081940; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; PANTOJA R, 2004, IN PRESS BIOSEN 0506, DOI DOI 10.1016/J.BIOS.2004.02.020; Petricoin EF, 2002, J NATL CANCER I, V94, P1576; Phelps ME, 2000, P NATL ACAD SCI USA, V97, P9226, DOI 10.1073/pnas.97.16.9226; Phelps ME, 2004, PET MOL IMAGING BIOL; Qu YS, 2002, CLIN CHEM, V48, P1835; Rothenberg EV, 2003, INFEC DIS S, P61; Shah K, 2004, GENE THER, V11, P1175, DOI 10.1038/sj.gt.3302278; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; UTLEG AG, UNPUB; Waters LC, 1998, ANAL CHEM, V70, P158, DOI 10.1021/ac970642d; Weissleder R, 2001, RADIOLOGY, V219, P316, DOI 10.1148/radiology.219.2.r01ma19316; Weston AD, 2003, COLD SPRING HARB SYM, V68, P345, DOI 10.1101/sqb.2003.68.345; WHETSELL L, 1992, ONCOGENE, V7, P2355; Wickline SA, 2003, CIRCULATION, V107, P1092, DOI 10.1161/01.CIR.0000059651.17045.77; Wu GH, 2001, NAT BIOTECHNOL, V19, P856, DOI 10.1038/nbt0901-856; Zhang H, 2003, NAT BIOTECHNOL, V21, P660, DOI 10.1038/nbt827	52	769	839	1	202	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					640	643		10.1126/science.1104635	http://dx.doi.org/10.1126/science.1104635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499008				2022-12-28	WOS:000224756700038
J	Jordan, KD				Jordan, KD			A fresh look at electron hydration	SCIENCE			English	Editorial Material							WATER; SPECTROSCOPY; DYNAMICS; CLUSTER; ANIONS		Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jordan, KD (corresponding author), Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA.	jordan@pitt.edu						Bragg AE, 2004, SCIENCE, V306, P669, DOI 10.1126/science.1103527; Coe JV, 1997, J CHEM PHYS, V107, P6023, DOI 10.1063/1.474271; Hammer NI, 2004, SCIENCE, V306, P675, DOI 10.1126/science.1102792; HART EJ, 1962, J AM CHEM SOC, V84, P4090, DOI 10.1021/ja00880a025; Jordan KD, 2003, ANNU REV PHYS CHEM, V54, P367, DOI 10.1146/annurev.physchem.54.011002.103851; Lee HM, 2003, J CHEM PHYS, V119, P187, DOI 10.1063/1.1576757; Paik DH, 2004, SCIENCE, V306, P672, DOI 10.1126/science.1102827; Pshenichnikov MS, 2004, CHEM PHYS LETT, V389, P171, DOI 10.1016/j.cplett.2004.03.107; ROSSKY PJ, 1988, J PHYS CHEM-US, V92, P4277, DOI 10.1021/j100326a009; Turi L, 2002, J CHEM PHYS, V117, P6186, DOI 10.1063/1.1503308; Weber JM, 2001, CHEM PHYS LETT, V339, P337, DOI 10.1016/S0009-2614(01)00295-0; Yokoyama K, 1998, J PHYS CHEM A, V102, P6957, DOI 10.1021/jp981809p	12	65	68	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					618	619		10.1126/science.1104678	http://dx.doi.org/10.1126/science.1104678			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15498999				2022-12-28	WOS:000224756700029
J	Kassen, R; Llewellyn, M; Rainey, PB				Kassen, R; Llewellyn, M; Rainey, PB			Ecological constraints on diversification in a model adaptive radiation	NATURE			English	Article							DIVERSITY; EVOLUTION; PRODUCTIVITY; FITNESS	Taxonomic diversification commonly occurs through adaptive radiation, the rapid evolution of a single lineage into a range of genotypes or species each adapted to a different ecological niche(1,2). Radiation size (measured as the number of new types) varies widely between phylogenetically distinct taxa(2-4) and between replicate radiations within a single taxon where the ecological opportunities available seem to be identical(5,6). Here we show how variation in energy input (productivity) and environmental disturbance combine to determine the extent of diversification in a single radiating lineage of Pseudomonas fluorescens adapting to laboratory conditions. Diversity peaked at intermediate rates of both productivity and disturbance and declined towards the extremes in a manner reminiscent of well-known ecological patterns(7-9). The mechanism responsible for the decrease in diversity arises from pleiotropic fitness costs associated with niche specialization(10,11), the effects of which are modulated by gradients of productivity and disturbance. Our results indicate that ecological gradients may constrain the size of adaptive radiations, even in the presence of the strong diversifying selection associated with ecological opportunity, by decoupling evolutionary diversification from ecological coexistence.	Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England; Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Ctr Adv Res Environm Genom, Ottawa, ON K1N 6N5, Canada; Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand	University of Oxford; University of Ottawa; University of Ottawa; University of Auckland	Kassen, R (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.	rkassen@uottawa.ca	Rainey, Paul/A-3207-2008	Rainey, Paul/0000-0003-0879-5795				Buckling A, 2003, SCIENCE, V302, P2107, DOI 10.1126/science.1088848; Buckling A, 2000, NATURE, V408, P961, DOI 10.1038/35050080; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; Day T, 2004, BIOSCIENCE, V54, P101, DOI 10.1641/0006-3568(2004)054[0101:CAFED]2.0.CO;2; Doebeli M, 2003, NATURE, V421, P259, DOI 10.1038/nature01274; Gillespie R, 2004, SCIENCE, V303, P356, DOI 10.1126/science.1091875; Givnish Thomas J., 1997, P1; Holt RD, 1996, OIKOS, V75, P182, DOI 10.2307/3546242; Huston M.A., 1994, BIOL DIVERSITY; Kassen R, 2000, NATURE, V406, P508, DOI 10.1038/35020060; Kawecki TJ, 1997, J EVOLUTION BIOL, V10, P407, DOI 10.1007/s000360050032; Kondoh M, 2001, P ROY SOC B-BIOL SCI, V268, P269, DOI 10.1098/rspb.2000.1384; LEVENE H, 1953, AM NAT, V87, P331, DOI 10.1086/281792; Losos JB, 2000, NATURE, V408, P847, DOI 10.1038/35048558; MacLean RC, 2004, P NATL ACAD SCI USA, V101, P8072, DOI 10.1073/pnas.0307195101; MEYER W, 1993, HISTOL HISTOPATHOL, V8, P305; Morris SC, 1999, EVOLUTION OF BIOLOGICAL DIVERSITY, P283; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; Rainey PB, 2003, NATURE, V425, P72, DOI 10.1038/nature01906; RIEBESELL JF, 1974, ECOLOGY, V55, P183, DOI 10.2307/1934634; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; Seehausen O, 1997, SCIENCE, V277, P1808, DOI 10.1126/science.277.5333.1808; Simpson G. G., 1953, MAJOR FEATURES EVOLU, DOI DOI 10.7312/SIMP93764; SMITH JM, 1980, GENET RES, V35, P45, DOI 10.1017/S0016672300013926; Spiers AJ, 2003, MOL MICROBIOL, V50, P15, DOI 10.1046/j.1365-2958.2003.03670.x; Tilman D., 1982, Monographs in Population Biology, pi; Travisano M, 2000, AM NAT, V156, pS35, DOI 10.1086/303414; Williams EE., 1972, EVOL BIOL, V6, P47, DOI [DOI 10.1007/978-1-4684-9063-3_3, 10. 1007/978-1-4684-9063-3]; Worm B, 2002, NATURE, V417, P848, DOI 10.1038/nature00830	30	74	76	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					984	988		10.1038/nature02923	http://dx.doi.org/10.1038/nature02923			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496923				2022-12-28	WOS:000224585600044
J	Joseph, SB; Bradley, MN; Castrillo, A; Bruhn, KW; Mak, PA; Pei, LM; Hogenesch, J; O'Connell, RM; Cheng, GH; Saez, E; Miller, JF; Tontonoz, P				Joseph, SB; Bradley, MN; Castrillo, A; Bruhn, KW; Mak, PA; Pei, LM; Hogenesch, J; O'Connell, RM; Cheng, GH; Saez, E; Miller, JF; Tontonoz, P			LXR-dependent gene expression is important for macrophage survival and the innate immune response	CELL			English	Article							CELL-BINDING CHARACTERISTICS; NUCLEAR RECEPTOR LXR; SCAVENGER RECEPTORS; MOLECULAR-CLONING; MICE LACKING; APOPTOSIS; CHOLESTEROL; LISTERIA; AIM; ATHEROSCLEROSIS	The liver X receptors (LXRs) are nuclear receptors with established roles in the regulation of lipid metabolism. We now show that LXR signaling not only regulates macrophage cholesterol metabolism but also impacts antimicrobial responses. Mice lacking LXRs are highly susceptible to infection with the intracellular bacteria Listeria monocytogenes (LM). Bone marrow transplant studies point to altered macrophage function as the major determinant of susceptibility. LXR-null macrophages undergo accelerated apoptosis when challenged with LM and exhibit defective bacterial clearance in vivo. These defects result, at least in part, from loss of regulation of the antiapoptotic factor SPalpha, a direct target for regulation by LXRalpha. Expression of LXRalpha or SPalpha in macrophages inhibits apoptosis in the setting of LM infection. Our results demonstrate that LXR-dependent gene expression plays an unexpected role in innate immunity and suggest that common nuclear receptor pathways mediate macrophage responses to modified lipoproteins and intracellular pathogens.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Novartis	Tontonoz, P (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.	ptontonoz@mednet.ucla.edu	Bruhn, Kevin/F-9772-2013	Joseph, Sean/0000-0002-2602-8517	NATIONAL CANCER INSTITUTE [R01CA084008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066088, P01HL030568] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84008] Funding Source: Medline; NHLBI NIH HHS [HL 66088, HL 30568] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8; Edelson BT, 2000, CURR OPIN IMMUNOL, V12, P425, DOI 10.1016/S0952-7915(00)00112-6; Edelson BT, 2002, J IMMUNOL, V169, P3869, DOI 10.4049/jimmunol.169.7.3869; Fettucciari K, 2000, J IMMUNOL, V165, P3923, DOI 10.4049/jimmunol.165.7.3923; Gebe JA, 1997, J BIOL CHEM, V272, P6151, DOI 10.1074/jbc.272.10.6151; Gebe JA, 2000, IMMUNOLOGY, V99, P78, DOI 10.1046/j.1365-2567.2000.00903.x; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Guzman CA, 1996, MOL MICROBIOL, V20, P119, DOI 10.1111/j.1365-2958.1996.tb02494.x; Haruta I, 2001, J BIOL CHEM, V276, P22910, DOI 10.1074/jbc.M100324200; Hilbi H, 1997, INFECT IMMUN, V65, P5165, DOI 10.1128/IAI.65.12.5165-5170.1997; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Kuwata K, 2003, AM J PATHOL, V162, P837, DOI 10.1016/S0002-9440(10)63880-1; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lee CH, 2003, SCIENCE, V302, P453, DOI 10.1126/science.1087344; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Miyazaki T, 1999, J EXP MED, V189, P413, DOI 10.1084/jem.189.2.413; North RJ, 1997, IMMUNOL REV, V158, P27, DOI 10.1111/j.1600-065X.1997.tb00989.x; OCONNELL R, 2004, IN PRESS J EXP MED; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rojas M, 1997, J IMMUNOL, V159, P1352; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Terpstra V, 2000, ARTERIOSCL THROM VAS, V20, P1860, DOI 10.1161/01.ATV.20.8.1860; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; van der Laan LJW, 1999, J IMMUNOL, V162, P939; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Ziouzenkova O, 2003, P NATL ACAD SCI USA, V100, P2730, DOI 10.1073/pnas.0538015100	35	431	453	1	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2004	119	2					299	309		10.1016/j.cell.2004.09.032	http://dx.doi.org/10.1016/j.cell.2004.09.032			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479645	Bronze			2022-12-28	WOS:000224577200016
J	Spiegelman, BM; Heinrich, R				Spiegelman, BM; Heinrich, R			Biological control through regulated transcriptional coactivators	CELL			English	Review							STEROID-RECEPTOR COACTIVATOR-1; MESSENGER-RNA EXPRESSION; MUSCLE GENE-EXPRESSION; SERUM RESPONSE FACTOR; MITOCHONDRIAL BIOGENESIS; NUCLEAR RECEPTORS; OCA-B; PROTEIN METHYLTRANSFERASE; HISTONE ACETYLTRANSFERASE; HEPATIC GLUCONEOGENESIS	Gene activation in higher eukaryotes requires the concerted action of transcription factors and coactivator proteins. Coactivators exist in multiprotein complexes that dock on transcription factors and modify chromatin, allowing effective transcription to take place. While biological control focused at the level of the transcription factor is very common, it is now quite clear that a substantial component of gene control is directed at the expression of coactivators, involving pathways as diverse as B-cell development, smooth muscle differentiation, and hepatic gluconeogenesis. Quantitative control of coactivators allows the functional integration of multiple transcription factors and facilitates the formation of distinct biological programs. This coordination and acceleration of different steps in linked pathways has important kinetic considerations, enabling outputs of particular pathways to be increased far more than would otherwise be possible. These kinetic aspects suggest opportunities and concerns as coactivators become targets of therapeutic intervention.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Humboldt Univ, Sect Theoret Biophys, Inst Biol, D-10115 Berlin, Germany	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Humboldt University of Berlin	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu			NIDDK NIH HHS [DK61562, DK54477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK054477, R01DK061562, R01DK054477] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Clabby ML, 2003, J BIOL CHEM, V278, P5760, DOI 10.1074/jbc.M208173200; Coghlan MJ, 2003, MOL ENDOCRINOL, V17, P860, DOI 10.1210/me.2002-0355; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; Fell D., 1997, UNDERSTANDING CONTRO; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Fossett N, 2001, DIFFERENTIATION, V69, P83, DOI 10.1046/j.1432-0436.2001.690202.x; FU KL, 2003, MOL CELL BIOL, V23, P2425; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; Heinrich R., 1996, REGULATION CELLULAR; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Lehman JJ, 2002, CLIN EXP PHARMACOL P, V29, P339, DOI 10.1046/j.1440-1681.2002.03655.x; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Leonardsson G, 2004, P NATL ACAD SCI USA, V101, P8437, DOI 10.1073/pnas.0401013101; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2003, J BIOL CHEM, V278, P30843, DOI 10.1074/jbc.M303643200; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Luo Y, 1998, MOL CELL BIOL, V18, P3803, DOI 10.1128/MCB.18.7.3803; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; Norrbom J, 2004, J APPL PHYSIOL, V96, P189, DOI 10.1152/japplphysiol.00765.2003; Pal S, 2004, P NATL ACAD SCI USA, V101, P980, DOI 10.1073/pnas.0307612100; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Svensson EC, 2000, J BIOL CHEM, V275, P20762, DOI 10.1074/jbc.M001522200; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; TSANG AP, GENES DEV, V12, P1176; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; Wolstein O, 2000, J BIOL CHEM, V275, P16459, DOI 10.1074/jbc.275.22.16459; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Xu Jianming, 2002, Rev Endocr Metab Disord, V3, P185, DOI 10.1023/A:1020016208071; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Yu X, 2001, IMMUNITY, V14, P157, DOI 10.1016/S1074-7613(09)00090-9; Zhou G, 2003, MOL CELL BIOL, V23, P7742, DOI 10.1128/MCB.23.21.7742-7755.2003	84	277	284	1	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2004	119	2					157	167		10.1016/j.cell.2004.09.037	http://dx.doi.org/10.1016/j.cell.2004.09.037			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479634	Bronze			2022-12-28	WOS:000224577200005
J	Grotegut, CA				Grotegut, CA			Ureteral obstruction in pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Grotegut, CA (corresponding author), Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					E14	E14		10.1056/NEJMicm030958	http://dx.doi.org/10.1056/NEJMicm030958			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483272				2022-12-28	WOS:000224427300014
J	Poggio, T; Bizzi, E				Poggio, T; Bizzi, E			Generalization in vision and motor control	NATURE			English	Article							INFERIOR TEMPORAL NEURONS; RECEPTIVE-FIELDS; MODULAR ORGANIZATION; VISUAL AREAS; CORTEX; CELLS; REPRESENTATION; RESPONSES; MOVEMENT; DISCRIMINATION	Learning is more than memory. It is not simply the building of a look-up table of labelled images, or a phone-directory-like list of motor acts and the corresponding sequences of muscle activation. Central to learning and intelligence is the ability to predict, that is, to generalize to new situations, beyond the memory of specific examples. The key to generalization, in turn, is the architecture of the system, more than the rules of synaptic plasticity. We propose a specific architecture for generalization for both the motor and the visual systems, and argue for a canonical microcircuit underlying visual and motor learning.	MIT, McGovern Inst,Ctr Biol & Computat Learning, Dept Brain & Cognit Sci, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02142 USA; European Brain Res Inst, I-00143 Rome, Italy	Massachusetts Institute of Technology (MIT)	Poggio, T (corresponding author), MIT, McGovern Inst,Ctr Biol & Computat Learning, Dept Brain & Cognit Sci, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02142 USA.	tp@ai.mit.edu; ebizzi@mit.edu		/0000-0002-7644-4498				Amirikian B, 2003, P NATL ACAD SCI USA, V100, P12474, DOI 10.1073/pnas.2037719100; Aoyagi Y, 2004, IEEE T NEUR SYS REH, V12, P12, DOI 10.1109/TNSRE.2003.823265; BELKIN M, 2004, TR200405 U CHIC; BIZZI E, 1991, SCIENCE, V253, P287, DOI 10.1126/science.1857964; Booth MCA, 1998, CEREB CORTEX, V8, P510, DOI 10.1093/cercor/8.6.510; Borg-Graham LJ, 1998, NATURE, V393, P369, DOI 10.1038/30735; BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; BULTHOFF HH, 1992, P NATL ACAD SCI USA, V89, P60, DOI 10.1073/pnas.89.1.60; CARANDINI M, 1994, SCIENCE, V264, P1333, DOI 10.1126/science.8191289; Carandini M, 1997, J NEUROSCI, V17, P8621; Chance FS, 1999, NAT NEUROSCI, V2, P277, DOI 10.1038/6381; d'Avella A, 2003, NAT NEUROSCI, V6, P300, DOI 10.1038/nn1010; DiCarlo JJ, 2000, NAT NEUROSCI, V3, P814, DOI 10.1038/77722; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; Douglas RJ, 2004, ANNU REV NEUROSCI, V27, P419, DOI 10.1146/annurev.neuro.27.070203.144152; Gandolfo F, 2000, P NATL ACAD SCI USA, V97, P2259, DOI 10.1073/pnas.040567097; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; Giese MA, 2003, NAT REV NEUROSCI, V4, P179, DOI 10.1038/nrn1057; Gribble PL, 2002, NATURE, V417, P938, DOI 10.1038/nature00834; GRILLNER S, 1985, ANNU REV NEUROSCI, V8, P233, DOI 10.1146/annurev.ne.08.030185.001313; GRILLNER S, 1981, HDB PHYSL NERVOUS SY, V4, P1179; GROSS CG, 1973, HDB SENSORY PHYSL, V7; Hastie T., 2009, SPRINGER SERIES STAT, DOI 10.1007/978-0-387-84858-7; HIETANEN JK, 1992, EXP BRAIN RES, V89, P157; HOGAN N, 1984, J NEUROSCI, V4, P2745; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; Jing J, 2004, J NEUROSCI, V24, P6315, DOI 10.1523/JNEUROSCI.0965-04.2004; Kargo WJ, 2000, J NEUROSCI, V20, P409, DOI 10.1523/JNEUROSCI.20-01-00409.2000; Kobatake E, 1998, J NEUROPHYSIOL, V80, P324, DOI 10.1152/jn.1998.80.1.324; KOBATAKE E, 1994, J NEUROPHYSIOL, V71, P856, DOI 10.1152/jn.1994.71.3.856; Lemay MA, 2001, IEEE T NEUR SYS REH, V9, P12, DOI 10.1109/7333.918272; Li CSR, 2001, NEURON, V30, P593, DOI 10.1016/S0896-6273(01)00301-4; LOEB GE, 1985, J EXP BIOL, V115, P137; LOGOTHETIS NK, 1995, CURR BIOL, V5, P552, DOI 10.1016/S0960-9822(95)00108-4; Logothetis NK, 1996, ANNU REV NEUROSCI, V19, P577, DOI 10.1146/annurev.ne.19.030196.003045; MARUYAMA M, 1992, 1291 GRBF MLP MIT; MERZENICH MM, 1973, BRAIN RES, V50, P275, DOI 10.1016/0006-8993(73)90731-2; Missal M, 1997, CEREB CORTEX, V7, P758, DOI 10.1093/cercor/7.8.758; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; Mussa-Ivaldi FA, 2000, PHILOS T R SOC B, V355, P1755, DOI 10.1098/rstb.2000.0733; MussaIvaldi FA, 1997, 1997 IEEE INTERNATIONAL SYMPOSIUM ON COMPUTATIONAL INTELLIGENCE IN ROBOTICS AND AUTOMATION - CIRA '97, PROCEEDINGS, P84, DOI 10.1109/CIRA.1997.613842; MUSSAIVALDI FA, 1994, P NATL ACAD SCI USA, V91, P7534, DOI 10.1073/pnas.91.16.7534; Olshausen BA, 1996, NATURE, V381, P607, DOI 10.1038/381607a0; Palmeri TJ, 2004, NAT REV NEUROSCI, V5, P291, DOI 10.1038/nrn1364; Paz R, 2003, NAT NEUROSCI, V6, P882, DOI 10.1038/nn1097; PERRETT DI, 1991, EXP BRAIN RES, V86, P159; PERRETT DI, 1993, IMAGE VISION COMPUT, V11, P317, DOI 10.1016/0262-8856(93)90011-5; POGGIO T, 1990, COLD SPRING HARB SYM, V55, P899; Poggio Tomaso, 2003, NOTICES AM MATH SOC, V50, P537; Pouget A, 1997, J COGNITIVE NEUROSCI, V9, P222, DOI 10.1162/jocn.1997.9.2.222; Pouget A, 2003, ANNU REV NEUROSCI, V26, P381, DOI 10.1146/annurev.neuro.26.041002.131112; REICHARDT W, 1983, BIOL CYBERN, V46, P1, DOI 10.1007/BF00595226; Riesenhuber M, 1999, NAT NEUROSCI, V2, P1019, DOI 10.1038/14819; RIESENHUBER M, 2003, VISUAL NEUROSCIENCES, V2, P1640; RODMAN HR, 1993, J NEUROPHYSIOL, V70, P1115, DOI 10.1152/jn.1993.70.3.1115; SALINAS E, 1995, J NEUROSCI, V15, P6461; Saltiel P, 1998, J NEUROPHYSIOL, V80, P2323, DOI 10.1152/jn.1998.80.5.2323; SATO T, 1989, EXP BRAIN RES, V77, P23; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; STEIN PSG, 1995, J NEUROSCI, V15, P4343; TANAKA K, 1993, SCIENCE, V262, P685, DOI 10.1126/science.8235589; Thoroughman KA, 2000, NATURE, V407, P742, DOI 10.1038/35037588; Tresch MC, 1999, EXP BRAIN RES, V129, P401, DOI 10.1007/s002210050908; Vapnik V., 1998, STAT LEARNING THEORY; Wise SP, 1998, EXP BRAIN RES, V121, P285, DOI 10.1007/s002210050462; Yu AJ, 2002, NEURAL COMPUT, V14, P2857, DOI 10.1162/089976602760805313	67	213	218	0	33	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					768	774		10.1038/nature03014	http://dx.doi.org/10.1038/nature03014			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483597				2022-12-28	WOS:000224435500032
J	Tsodyks, M; Gilbert, C				Tsodyks, M; Gilbert, C			Neural networks and perceptual learning	NATURE			English	Article							PRIMARY VISUAL-CORTEX; ORIENTATION SELECTIVITY; DISCRIMINATION TASK; RESPONSE PROPERTIES; NUCLEUS BASALIS; MODEL; NEURONS; CONTEXT; VISION; V1	Sensory perception is a learned trait. The brain strategies we use to perceive the world are constantly modified by experience. With practice, we subconsciously become better at identifying familiar objects or distinguishing fine details in our environment. Current theoretical models simulate some properties of perceptual learning, but neglect the underlying cortical circuits. Future neural network models must incorporate the top-down alteration of cortical function by expectation or perceptual tasks. These newly found dynamic processes are challenging earlier views of static and feedforward processing of sensory information.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Rockefeller Univ, New York, NY 10021 USA	Weizmann Institute of Science; Rockefeller University	Tsodyks, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	misha@weizmann.ac.il; gilbert@mail.rockefeller.edu	tsodyks, misha/J-4430-2013	Tsodyks, Misha/0000-0002-5661-4349	NEI NIH HHS [R01 EY007968] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007968] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adini Y, 2002, NATURE, V415, P790, DOI 10.1038/415790a; ADINI Y, IN PRESS J VISION; AHISSAR M, 1993, P NATL ACAD SCI USA, V90, P5718, DOI 10.1073/pnas.90.12.5718; Bakin JS, 1996, P NATL ACAD SCI USA, V93, P11219, DOI 10.1073/pnas.93.20.11219; BARLOW H, 1989, COMP NEUR S, P54; BENYISHAI R, 1995, P NATL ACAD SCI USA, V92, P3844, DOI 10.1073/pnas.92.9.3844; Crist RE, 1997, J NEUROPHYSIOL, V78, P2889, DOI 10.1152/jn.1997.78.6.2889; Crist RE, 2001, NAT NEUROSCI, V4, P519, DOI 10.1038/87470; Dosher BA, 1998, P NATL ACAD SCI USA, V95, P13988, DOI 10.1073/pnas.95.23.13988; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; Dragoi V, 2000, NEURON, V28, P287, DOI 10.1016/S0896-6273(00)00103-3; Ghose GM, 2002, J NEUROPHYSIOL, V87, P1867, DOI 10.1152/jn.00690.2001; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; Hebb Donald O., 1949, ORG BEHAV; Hertz JA, 2018, INTRO THEORY NEURAL; Herzog MH, 1997, VISION RES, V37, P2133, DOI 10.1016/S0042-6989(97)00043-6; Herzog MH, 1998, BIOL CYBERN, V78, P107, DOI 10.1007/s004220050418; Hoshino O, 2004, NEURAL COMPUT, V16, P563, DOI 10.1162/089976604772744910; KARNI A, 1993, NATURE, V365, P250, DOI 10.1038/365250a0; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Li W, 2004, NAT NEUROSCI, V7, P651, DOI 10.1038/nn1255; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Mato G, 1996, NEURAL COMPUT, V8, P270, DOI 10.1162/neco.1996.8.2.270; MCKEE SP, 1978, PERCEPT PSYCHOPHYS, V24, P258, DOI 10.3758/BF03206097; MOSES Y, 1990, BIOL CYBERN, V63, P463, DOI 10.1007/BF00199579; POGGIO T, 1992, SCIENCE, V256, P1018, DOI 10.1126/science.1589770; POLAT U, 1994, P NATL ACAD SCI USA, V91, P1206, DOI 10.1073/pnas.91.4.1206; Polat U, 2004, P NATL ACAD SCI USA, V101, P6692, DOI 10.1073/pnas.0401200101; Rao RPN, 1997, NEURAL COMPUT, V9, P721, DOI 10.1162/neco.1997.9.4.721; RECANZONE GH, 1993, J NEUROSCI, V13, P87; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1057, DOI 10.1152/jn.1992.67.5.1057; Schoups A, 2001, NATURE, V412, P549, DOI 10.1038/35087601; Seitz AR, 2003, NATURE, V422, P36, DOI 10.1038/422036a; Senn W, 2001, NEURAL COMPUT, V13, P35, DOI 10.1162/089976601300014628; Seung HS, 2003, NEURON, V40, P1063, DOI 10.1016/S0896-6273(03)00761-X; SEUNG HS, 1992, PHYS REV A, V45, P6056, DOI 10.1103/PhysRevA.45.6056; Sigman M, 2000, NAT NEUROSCI, V3, P264, DOI 10.1038/72979; SOMERS DC, 1995, J NEUROSCI, V15, P5448; Teich AF, 2003, J NEUROPHYSIOL, V89, P2086, DOI 10.1152/jn.00970.2002; Tsodyks M, 2004, NEURAL NETWORKS, V17, P823, DOI 10.1016/j.neunet.2004.03.004; Ullman S, 2004, NEURAL NETWORKS, V17, P833, DOI 10.1016/j.neunet.2004.01.006; ULLMAN S, 1995, CEREB CORTEX, V5, P1, DOI 10.1093/cercor/5.1.1; WANG QQ, 1994, PERCEPT PSYCHOPHYS, V56, P495, DOI 10.3758/BF03206946; Watanabe T, 2001, NATURE, V413, P844, DOI 10.1038/35101601; WEISS Y, 1993, NEURAL COMPUT, V5, P695, DOI 10.1162/neco.1993.5.5.695; WILLIAMS RJ, 1992, MACH LEARN, V8, P229, DOI 10.1007/BF00992696; WILSON HR, 1972, BIOPHYS J, V12, P1, DOI 10.1016/S0006-3495(72)86068-5; Yu C, 2004, J VISION, V4, P169, DOI 10.1167/4.3.4; Zhaoping L, 2003, NETWORK-COMP NEURAL, V14, P233, DOI 10.1088/0954-898X/14/2/304	50	107	113	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					775	781		10.1038/nature03013	http://dx.doi.org/10.1038/nature03013			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483598	Green Accepted			2022-12-28	WOS:000224435500033
J	Zimmerli, W; Trampuz, A; Ochsner, PE				Zimmerli, W; Trampuz, A; Ochsner, PE			Current concepts: Prosthetic-joint infections	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TOTAL KNEE ARTHROPLASTY; TOTAL HIP-ARTHROPLASTY; FOREIGN-BODY INFECTION; 2-STAGE REIMPLANTATION; REVISION ARTHROPLASTY; IN-VITRO; DEBRIDEMENT; DEVICE; RETENTION; DIAGNOSIS		Univ Basel, Med Clin, Liestal, Switzerland; Mayo Clin, Coll Med, Dept Internal Med, Div Infect Dis, Rochester, MN USA; Kantonsspital Liestal, Clin Orthoped Surg, CH-4410 Liestal, Switzerland	University of Basel; Mayo Clinic; Kantonsspital Baselland	Zimmerli, W (corresponding author), Kantonsspital Liestal, Univ Med Clin, CH-4410 Liestal, Switzerland.	werner.zimmerli@unibas.ch	Trampuz, Andrej/K-9633-2013					*AM AC ORTH SURG, 2004, 1023 AM AC ORTH SURG; *AM AC ORTH SURG, 2004, ANT PROPH DENT PAT; Anderl JN, 2003, ANTIMICROB AGENTS CH, V47, P1251, DOI 10.1128/AAC.47.4.1251-1256.2003; Atkins BL, 1998, J CLIN MICROBIOL, V36, P2932, DOI 10.1128/JCM.36.10.2932-2939.1998; Berbari EF, 1998, CLIN INFECT DIS, V27, P1247, DOI 10.1086/514991; Brandt CM, 1997, CLIN INFECT DIS, V24, P914, DOI 10.1093/clinids/24.5.914; Callaghan JJ, 1999, CLIN ORTHOP RELAT R, P139; Ceri H, 1999, J CLIN MICROBIOL, V37, P1771, DOI 10.1128/JCM.37.6.1771-1776.1999; COLYER RA, 1994, CLIN ORTHOP RELAT R, P75; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Crockarell JR, 1998, J BONE JOINT SURG AM, V80A, P1306, DOI 10.2106/00004623-199809000-00009; Darouiche RO, 2004, NEW ENGL J MED, V350, P1422, DOI 10.1056/NEJMra035415; Darouiche RO, 2001, CLIN INFECT DIS, V33, P1567, DOI 10.1086/323130; Deirmengian C, 2003, J ARTHROPLASTY, V18, P22, DOI 10.1016/S0883-5403(03)00288-2; DRANCOURT M, 1993, ANTIMICROB AGENTS CH, V37, P1214, DOI 10.1128/AAC.37.6.1214; Drancourt M, 1997, J ANTIMICROB CHEMOTH, V39, P235, DOI 10.1093/jac/39.2.235; Fisman DN, 2001, CLIN INFECT DIS, V32, P419, DOI 10.1086/318502; Giulieri SG, 2004, INFECTION, V32, P222, DOI 10.1007/s15010-004-4020-1; GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258; Hain SF, 2002, J BONE JOINT SURG BR, V84B, P315, DOI 10.1302/0301-620X.84B3.12369; HARRIS WH, 1990, NEW ENGL J MED, V323, P801, DOI 10.1056/NEJM199009203231206; Hook M., 2000, INFECT ASS INDWELLIN, P27, DOI [10.1128/9781555818067.ch2, DOI 10.1128/9781555818067.CH2]; HOPE PG, 1989, J BONE JOINT SURG BR, V71, P851, DOI 10.1302/0301-620X.71B5.2584258; Ivancevic V, 2002, EUR J NUCL MED MOL I, V29, P835, DOI 10.1007/s00259-002-0857-7; Ivaneeviae V, 2002, EUR J NUCL MED MOL I, V29, P547, DOI 10.1007/s00259-001-0744-7; Kadurugamuwa JL, 2004, ANTIMICROB AGENTS CH, V48, P2283, DOI 10.1128/AAC.48.6.2283-2287.2004; Kaplan SS, 1999, INFECT IMMUN, V67, P1640; Langlais F, 2003, J BONE JOINT SURG BR, V85B, P637, DOI 10.1302/0301-620X.85B5.14413; Lew DP, 1997, NEW ENGL J MED, V336, P999, DOI 10.1056/NEJM199704033361406; Love, 2000, Clin Positron Imaging, V3, P159, DOI 10.1016/S1095-0397(00)00071-6; Maderazo EG, 1988, CLIN ORTHOP RELAT R, P131; Meehan AM, 2003, CLIN INFECT DIS, V36, P845, DOI 10.1086/368182; Murdoch DR, 2001, CLIN INFECT DIS, V32, P647, DOI 10.1086/318704; MURRAY DG, 1995, JAMA-J AM MED ASSOC, V273, P1950, DOI 10.1001/jama.1995.03520480070043; Osmon DR, 2002, CLIN ORTHOP RELAT R, P80, DOI 10.1097/01.blo.0000030171.56585.1d; Pandey R, 2000, ARCH ORTHOP TRAUM SU, V120, P570, DOI 10.1007/s004020000174; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PROCTOR RA, 2000, INFECT ASS INDWELLIN, P41; RAUT VV, 1994, J BONE JOINT SURG BR, V76B, P721, DOI 10.1302/0301-620X.76B5.8083258; Schafroth M, 2003, TOTAL HIP REPLACEMENT: IMPLANTATION TECHNIQUE AND LOCAL COMPLICATIONS, P65; SCHOIFET SD, 1990, J BONE JOINT SURG AM, V72A, P1383, DOI 10.2106/00004623-199072090-00018; Schwank S, 1998, ANTIMICROB AGENTS CH, V42, P895, DOI 10.1128/AAC.42.4.895; Segawa H, 1999, J BONE JOINT SURG AM, V81A, P1434, DOI 10.2106/00004623-199910000-00008; SHIH LY, 1987, CLIN ORTHOP RELAT R, V225, P238; Shirtliff ME, 2002, CLIN MICROBIOL REV, V15, P527, DOI 10.1128/CMR.15.4.527-544.2002; Smith SL, 2001, CLIN RADIOL, V56, P221, DOI 10.1053/crad.2000.0620; Spangehl MJ, 1999, J BONE JOINT SURG AM, V81A, P672, DOI 10.2106/00004623-199905000-00008; Sperling JW, 2001, CLIN ORTHOP RELAT R, P206, DOI 10.1097/00003086-200101000-00028; STECKELBERG JM, 2000, INFECT ASS INDWELLIN, P173; Tattevin P, 1999, CLIN INFECT DIS, V29, P292, DOI 10.1086/520202; TIGGES S, 1994, AM J ROENTGENOL, V163, P377, DOI 10.2214/ajr.163.2.8037035; Trampuz A, 2004, AM J MED, V117, P556, DOI 10.1016/j.amjmed.2004.06.022; Trampuz A, 2003, REV MED MICROBIOL, V14, P1; TREBSE R, IN PRESS J BONE JOIN; TRMAPUZ A, 2003, CLIN ORTHOP RELAT R, V414, P69; Tsukayama DT, 1996, J BONE JOINT SURG AM, V78A, P512, DOI 10.2106/00004623-199604000-00005; TSUKAYAMA DT, 1991, ORTHOPEDICS, V14, P841; Ure KJ, 1998, J BONE JOINT SURG AM, V80A, P961, DOI 10.2106/00004623-199807000-00004; Vuong C, 2003, J INFECT DIS, V188, P706, DOI 10.1086/377239; Westrich GH., 1999, REVISION TOTAL HIP A, P371; WIDMER AF, 1990, J INFECT DIS, V162, P96, DOI 10.1093/infdis/162.1.96; WIDMER AF, 1991, ANTIMICROB AGENTS CH, V35, P741, DOI 10.1128/AAC.35.4.741; WIDMER AF, 1992, CLIN INFECT DIS, V14, P1251, DOI 10.1093/clinids/14.6.1251; Williams RJ, 2002, INFECT IMMUN, V70, P6805, DOI 10.1128/IAI.70.12.6805-6810.2002; WINDSOR RE, 1990, J BONE JOINT SURG AM, V72A, P272, DOI 10.2106/00004623-199072020-00017; Wolz C, 2002, INFECT IMMUN, V70, P2758, DOI 10.1128/IAI.70.6.2758-2762.2002; Zimmerli W, 1998, JAMA-J AM MED ASSOC, V279, P1537, DOI 10.1001/jama.279.19.1537; ZIMMERLI W, 1984, J CLIN INVEST, V73, P1191, DOI 10.1172/JCI111305; ZIMMERLI W, 1982, J INFECT DIS, V146, P487, DOI 10.1093/infdis/146.4.487; ZIMMERLI W, 1985, SCAND J INFECT DIS, V17, P303, DOI 10.3109/inf.1985.17.issue-3.10; ZIMMERLI W, 1994, J ANTIMICROB CHEMOTH, V33, P959	71	1945	2008	5	169	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1645	1654		10.1056/NEJMra040181	http://dx.doi.org/10.1056/NEJMra040181			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483283				2022-12-28	WOS:000224427300011
J	Belshe, RB; Newman, FK; Cannon, J; Duane, C; Treanor, J; Van Hoecke, C; Howe, BJ; Dubin, G				Belshe, RB; Newman, FK; Cannon, J; Duane, C; Treanor, J; Van Hoecke, C; Howe, BJ; Dubin, G			Serum antibody responses after intradermal vaccination against influenza	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEPATITIS-B VACCINATION; VIRUS-VACCINE; BOOSTER; IMMUNOGENICITY	BACKGROUND If found to be safe and immunogenic, reduced doses of influenza vaccine given by the intradermal route could increase the number of available doses of vaccine. METHODS In an open-label study, we randomly assigned 119 subjects to receive an intradermal injection of trivalent inactivated influenza vaccine, containing 6 mug of hemagglutinin for each antigen ( 40 percent of the usual dose), and 119 to receive an intramuscular injection of the standard dose of 15 mug of hemagglutinin for each antigen. The two groups were subdivided according to age ( 18 to 60 years and older than 60 years). RESULTS Among subjects who were 18 to 60 years of age, serum antibody responses were vigorous and did not differ significantly between the intradermal and intramuscular groups, and all subjects had hemagglutination-inhibition (HAI) titers of at least 1: 40. Although the subjects who were older than 60 years of age also had a vigorous antibody response, there was a trend toward a better response in the intramuscular route, but this finding was significant only for antigen to the H3N2 strain. Nevertheless, 100 percent of older subjects in the intramuscular group and 93 percent of such subjects in the intradermal group had an HAI antibody titer to the H3N2 strain of more than 1: 40, and 100 percent in each group had a titer of this level for both the H1N1 and B strains. Local pain was significantly more common in the intramuscular group than in the intradermal group among subjects who were 18 to 60 years of age but not among subjects who were over 60 years old. Signs of local inflammation were significantly more common among subjects in the intradermal group than among those in the intramuscular group, in both age groups. CONCLUSIONS As compared with an intramuscular injection of full-dose influenza vaccine, an intradermal injection of a reduced dose resulted in similarly vigorous antibody responses among persons 18 to 60 years of age but not among those over the age of 60 years.	St Louis Univ, Dept Internal Med, Div Infect Dis & Immunol, St Louis, MO 63110 USA; Univ Rochester, Dept Internal Med, Div Infect Dis, Rochester, NY USA; GlaxoSmithKline Biol, Rixensart, Belgium; GlaxoSmithKline, King Of Prussia, PA USA	Saint Louis University; University of Rochester; GlaxoSmithKline; GlaxoSmithKline	Belshe, RB (corresponding author), St Louis Univ, Dept Internal Med, Div Infect Dis & Immunol, 3635 Vista Ave,FDT-8N, St Louis, MO 63110 USA.	belsherb@slu.edu						AYOOLA EA, 1986, ARCH VIROL, V91, P291, DOI 10.1007/BF01314288; Briggs DJ, 2000, B WORLD HEALTH ORGAN, V78, P693; BROWN H, 1977, J INFECT DIS, V136, pS466, DOI 10.1093/infdis/136.Supplement_3.S466; Chau KF, 2004, AM J KIDNEY DIS, V43, P910, DOI 10.1053/j.ajkd.2003.12.052; COLEMAN PJ, 1991, VACCINE, V9, P723, DOI 10.1016/0264-410X(91)90287-G; FRAZER IH, 1987, MED J AUSTRALIA, V146, P242, DOI 10.5694/j.1326-5377.1987.tb120230.x; Gherardin AW, 2001, J TRAVEL MED, V8, P122, DOI 10.2310/7060.2001.24445; GOLDWATER PN, 1986, NEW ZEAL MED J, V99, P703; Harper SA, 2004, MMWR RECOMM REP, V53, P743; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; Henderson EA, 2000, INFECT CONT HOSP EP, V21, P264, DOI 10.1086/501756; Jaijaroensup W, 1999, J TRAVEL MED, V6, P234, DOI 10.1111/j.1708-8305.1999.tb00524.x; JAIJAROENSUP W, 1998, VACCINE, V16, P1559; Janeway C.A., 1999, IMMUNOBIOLOGY IMMUNE; MILLER KD, 1983, LANCET, V2, P1454, DOI 10.1016/S0140-6736(83)90800-0; MILNE A, 1986, NEW ZEAL MED J, V99, P47; PAYLER DK, 1974, BRIT MED J, V2, P727, DOI 10.1136/bmj.2.5921.727-a; REDFIELD RR, 1985, JAMA-J AM MED ASSOC, V254, P3203, DOI 10.1001/jama.254.22.3203; Sabchareon A, 1998, PEDIATR INFECT DIS J, V17, P1001, DOI 10.1097/00006454-199811000-00007; Somboonsilp Wanida, 2003, Journal of the Medical Association of Thailand, V86, P1122; Tantawichien T, 1999, CLIN INFECT DIS, V28, P1100, DOI 10.1086/514737; TAURASO NM, 1969, B WORLD HEALTH ORGAN, V41, P507; Treanor J, 2002, VACCINE, V20, P1099, DOI 10.1016/S0264-410X(01)00440-6; WILKINS TD, 1990, MED J AUSTRALIA, V152, P140, DOI 10.5694/j.1326-5377.1990.tb125121.x	24	264	277	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2286	2294		10.1056/NEJMoa043555	http://dx.doi.org/10.1056/NEJMoa043555			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15525713	Bronze			2022-12-28	WOS:000225298100007
J	Craig, TK; Garety, P; Power, P; Rahaman, N; Colbert, S; Fornells-Ambrojo, M; Dunn, G				Craig, TK; Garety, P; Power, P; Rahaman, N; Colbert, S; Fornells-Ambrojo, M; Dunn, G			The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EARLY INTERVENTION; SCHIZOPHRENIC-PATIENTS; 1ST-EPISODE PSYCHOSIS; COGNITIVE THERAPY; DURATION; ADMISSION	Objective To evaluate the effectiveness of a service for early psychosis. Design Randomised controlled clinical trial. Setting Community mental health teams in one London borough. Participants 144 people aged 16-40 years presenting to mental health services for the first or second time with non-organic, non-affective psychosis. Interventions Assertive outreach with evidence based biopsychosocial interventions (specialised care group) and standard care (control group) delivered by community mental health teams. Primary outcome measures Rates of relapse and readmission to hospital. Results Compared with patients in the standard care group, those in the specialised care group were less likely to relapse (odds ratio 0.46, 95% confidence interval 0.22 to 0.97), were readmitted fewer times (beta 0.39, 0.10 to 0.68), and were less likely to drop out of the study (odds ratio 0.35, 0.15 to 0.81). When rates were adjusted for sex, previous psychotic episode, and ethnicity, the difference in relapse was no longer significant (odds ratio 0.55, 0.24 to 1.26); only total number of readmissions (beta 0.36, 0.04 to 0.66) and dropout rates (beta 0.28, 0.12 to 0.73) remained significant. Conclusions Limited evidence shows that a team delivering specialised care for patients with early psychosis is superior to standard care for maintaining contact with professionals and for reducing readmissions to hospital. No firm conclusions can, however, be drawn owing to the modest sample size.	Inst Psychiat, London SE5 8AF, England; S London & Maudsley NHS Trust, Onset Serv, London SW9 9NT, England; Univ Manchester, Sch Epidemiol & Hlth Sci, Biostat Grp, Manchester M13 9PT, Lancs, England	University of London; King's College London; South London & Maudsley NHS Trust; University of Manchester	Craig, TK (corresponding author), Inst Psychiat, De Crespigny Pk, London SE5 8AF, England.	t.craig@iop.kcl.ac.uk	Craig, Tom K J/A-9083-2011; Garety, Philippa A/B-2795-2009; Garety, Philippa A/F-9755-2014	Garety, Philippa A/0000-0002-5637-1340; Craig, Thomas/0000-0003-1442-0391; Fornells-Ambrojo, Miriam/0000-0001-5789-5675				Addington J, 2003, CAN J PSYCHIAT, V48, P204, DOI 10.1177/070674370304800309; AITCHISON KJ, 1999, 1 EPISODE PSYCHOSIS; Birchwood M, 1997, BRIT J PSYCHIAT, V170, P2, DOI 10.1192/bjp.170.1.2; Birchwood M, 1998, BRIT J PSYCHIAT, V172, P53, DOI 10.1192/S0007125000297663; Cullberg J, 2002, ACTA PSYCHIAT SCAND, V106, P276, DOI 10.1034/j.1600-0447.2002.02376.x; *DEP HLTH, 2001, COMP CLIN SOC IND; Department of Health, 2000, NHS PLAN PLAN INV PL; Department of Health, 2001, MENT HLTH POL IMPL G; Drake RJ, 2000, BRIT J PSYCHIAT, V177, P511, DOI 10.1192/bjp.177.6.511; Drury V, 1996, BRIT J PSYCHIAT, V169, P593, DOI 10.1192/bjp.169.5.593; *EARL PSYCH PREV I, 1997, EPPIC EARL PSYCH TRA; Edwards J, 2002, IMPLEMENTING EARLY I; GARETY PA, 2001, SOCIAL PSYCHIAT PSYC, V36, P1; Jablensky A, 1992, SCHIZOPHRENIA MANIFE; JABLENSKY S, 1992, SCHIZOPHRENIA MANIFE; Jackson H, 1998, BRIT J PSYCHIAT, V172, P93, DOI 10.1192/S0007125000297730; Jolley S, 2003, BEHAV COGN PSYCHOTH, V31, P473, DOI 10.1017/S1352465803004107; Lewis S, 2002, BRIT J PSYCHIAT, V181, pS91, DOI 10.1192/bjp.181.43.s91; Lieberman JA, 2003, AM J PSYCHIAT, V160, P1396, DOI 10.1176/appi.ajp.160.8.1396; Linszen D, 1996, PSYCHOL MED, V26, P333, DOI 10.1017/S0033291700034723; LOEBEL AD, 1992, AM J PSYCHIAT, V149, P1183; Malla A, 2003, AUST NZ J PSYCHIAT, V37, P407, DOI 10.1046/j.1440-1614.2003.01194.x; Malla AK, 2001, J CLIN PSYCHIAT, V62, P179, DOI 10.4088/JCP.v62n0308; McGorry PD, 1996, SCHIZOPHRENIA BULL, V22, P305, DOI 10.1093/schbul/22.2.305; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; Melle I, 2004, ARCH GEN PSYCHIAT, V61, P143, DOI 10.1001/archpsyc.61.2.143; Nordentoft M, 2002, BRIT J PSYCHIAT, V181, pS98, DOI 10.1192/bjp.181.43.s98; Pelosi A, 2003, BRIT J PSYCHIAT, V182, P196, DOI 10.1192/bjp.182.3.196; Wyatt RJ, 1997, PSYCHOL MED, V27, P261, DOI 10.1017/S0033291796004345; ZHANG ML, 1994, BRIT J PSYCHIAT, V165, P96, DOI 10.1192/S0007125000293045	30	415	418	2	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	2004	329	7474					1067	1070		10.1136/bmj.38246.594873.7C	http://dx.doi.org/10.1136/bmj.38246.594873.7C			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PN	15485934	Green Published, Green Submitted			2022-12-28	WOS:000225070300015
J	Barnett, AH; Bain, SC; Bouter, P; Karlberg, B; Madsbad, S; Jervell, J; Mustonen, J				Barnett, AH; Bain, SC; Bouter, P; Karlberg, B; Madsbad, S; Jervell, J; Mustonen, J		Diabetics Exposed Telmisartan Enal	Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; HEART-FAILURE; CAPTOPRIL; MORTALITY; LOSARTAN; PROTEINURIA; MICROALBUMINURIA; IRBESARTAN; ENALAPRIL; DISEASE	BACKGROUND: Few studies have directly compared the renoprotective effects of angiotensin II-receptor blockers and angiotensin-converting-enzyme (ACE) inhibitors in persons with type 2 diabetes. METHODS: In this prospective, multicenter, double-blind, five-year study, we randomly assigned 250 subjects with type 2 diabetes and early nephropathy to receive either the angiotensin II-receptor blocker telmisartan (80 mg daily, in 120 subjects) or the ACE inhibitor enalapril (20 mg daily, in 130 subjects). The primary end point was the change in the glomerular filtration rate (determined by measuring the plasma clearance of iohexol) between the baseline value and the last available value during the five-year treatment period. Secondary end points included the annual changes in the glomerular filtration rate, serum creatinine level, urinary albumin excretion, and blood pressure; the rates of end-stage renal disease and cardiovascular events; and the rate of death from all causes. RESULTS: After five years, the change in the glomerular filtration rate was -17.9 ml per minute per 1.73 m(sup 2) of body-surface area, where the minus sign denotes a decrement, with telmisartan (in 103 subjects), as compared with -14.9 ml per minute per 1.73 m(sup 2) with enalapril (in 113 subjects), for a treatment difference of -3.0 ml per minute per 1.73 m(sup 2) (95 percent confidence interval, -7.6 to 1.6 ml per minute per 1.73 m(sup 2)). The lower boundary of the confidence interval, in favor of enalapril, was greater than the predefined margin of -10.0 ml per minute per 1.73 m(sup 2), indicating that telmisartan was not inferior to enalapril. The effects of the two agents on the secondary end points were not significantly different after five years. CONCLUSIONS: Telmisartan is not inferior to enalapril in providing long-term renoprotection in persons with type 2 diabetes. These findings do not necessarily apply to persons with more advanced nephropathy, but they support the clinical equivalence of angiotensin II-receptor blockers and ACE inhibitors in persons with conditions that place them at high risk for cardiovascular events.	Univ Birmingham, Div Med Sci, Birmingham, W Midlands, England; Birmingham Heartlands & Solihull Natl Hlth Serv T, Birmingham, W Midlands, England; Bosch Med Ctr, Dept Internal Med, Den Bosch, Netherlands; Linkoping Univ Hosp, S-58185 Linkoping, Sweden; Univ Copenhagen, Hvidovre Hosp, Dept Endocrinol, DK-2650 Hvidovre, Denmark; Univ Hosp Oslo, Oslo, Norway; Tampere Univ Hosp, Dept Internal Med, Tampere, Finland	University of Birmingham; Linkoping University; University of Copenhagen; University of Oslo; Tampere University; Tampere University Hospital	Barnett, AH (corresponding author), Birmingham Heartlands Hosp, Undergrad Ctr, Bordesley Green E, Birmingham B9 5SS, W Midlands, England.	anthony.barnett@heartsol.wmids.nhs.uk		Madsbad, Sten/0000-0002-5017-1815				[Anonymous], 1999, STAT MED, V18, P1905; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Brown NJ, 1998, CIRCULATION, V97, P1411, DOI 10.1161/01.CIR.97.14.1411; Dickstein K, 2002, LANCET, V360, P752, DOI 10.1016/S0140-6736(02)09895-1; *INT DIAB FED, 2003, DIAB VOIC SPEC B INT; Jarrett R J, 1984, Diabet Med, V1, P17; KRUTZEN E, 1984, J LAB CLIN MED, V104, P955; LACOURCIERE Y, 1993, HYPERTENSION, V21, P786, DOI 10.1161/01.HYP.21.6.786; Lacourciere Y, 2000, KIDNEY INT, V58, P762, DOI 10.1046/j.1523-1755.2000.00224.x; LEBOWITZ HE, 1994, KIDNEY INT S45, V45, P150; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1994, NEW ENGL J MED, V330, P152; MACLEOD JM, 1995, DIABETOLOGIA, V38, P610, DOI 10.1007/BF00400732; Mattock MB, 1998, DIABETES, V47, P1786, DOI 10.2337/diabetes.47.11.1786; MOLITCH ME, 2004, DIABETES CARE S1, V27, pS79, DOI DOI 10.2337/DIACARE.27.5.1240-A; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; Rippin J, 2002, J DIABETES COMPLICAT, V16, P195, DOI 10.1016/S1056-8727(01)00165-9; Valmadrid CT, 2000, ARCH INTERN MED, V160, P1093, DOI 10.1001/archinte.160.8.1093	23	611	637	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1952	1961		10.1056/NEJMoa042274	http://dx.doi.org/10.1056/NEJMoa042274			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15516696				2022-12-28	WOS:000224851300007
J	Freeman, TM				Freeman, TM			Hypersensitivity to hymenoptera stings	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY SPASM; DISCONTINUING VENOM IMMUNOTHERAPY; WHOLE-BODY EXTRACTS; INSECT STINGS; RUSH IMMUNOTHERAPY; NATURAL-HISTORY; ALLERGY; ANAPHYLAXIS; SENSITIVITY; CHILDREN		Wilford Hall USAF Med Ctr, Dept Allergy & Immunol, Lackland AFB, San Antonio, TX 78023 USA	United States Department of Defense; United States Air Force	Freeman, TM (corresponding author), Wilford Hall USAF Med Ctr, Dept Allergy & Immunol, Lackland AFB, San Antonio, TX 78023 USA.	tfree95900@aol.com						BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BERNSTEIN JA, 1994, ANN ALLERGY, V73, P423; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; CHAFEE FH, 1970, ACTA ALLERGOL, V25, P292, DOI 10.1111/j.1398-9995.1970.tb01265.x; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Conraads VMA, 1998, CHEST, V113, P1417, DOI 10.1378/chest.113.5.1417; Duplantier JE, 1998, J ALLERGY CLIN IMMUN, V101, P855, DOI 10.1016/S0091-6749(98)70318-5; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; Freeman TM, 1997, ANN ALLERG ASTHMA IM, V78, P369, DOI 10.1016/S1081-1206(10)63198-5; Fujita Y, 2001, J CLIN ANESTH, V13, P221, DOI 10.1016/S0952-8180(01)00239-2; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; GODDARD J, 2003, PHYS GUIDE ARTHROPOD, P4; Goldberg A, 2001, J ALLERGY CLIN IMMUN, V107, P902, DOI 10.1067/mai.2001.114986; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1989, ALLERGY PROC, V10, P103, DOI 10.2500/108854189778960964; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P482, DOI 10.1016/0091-6749(81)90102-0; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI [10.1067/mai.2003.1606, 10.1016/S0091-6749(03)01537-9]; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Golden DBK, 2003, MONOGRAPH INSECT ALL, P63; GRAFT DF, 1984, J PEDIATR-US, V104, P664, DOI 10.1016/S0022-3476(84)80940-3; Gurlanick MW, 2003, MONOGRAPH INSECT ALL, P11; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; Hoffman D., 2003, MONOGRAPH INSECT ALL, P37; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; HOFFMAN DR, 1991, ANN ALLERGY, V66, P29; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Kontou-Fili K, 2002, CURR OPIN ALLERGY CL, V2, P353, DOI 10.1097/00130832-200208000-00010; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P391, DOI 10.1016/0091-6749(77)90024-0; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; Machiels JP, 1996, ANN EMERG MED, V27, P674; Matucci, 2002, ALLERGY, V57, P867; MCKENNA WR, 2003, MONOGRAPH INSECT ALL, P27; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; Reisman RE, 2001, J ALLERGY CLIN IMMUN, V107, P781, DOI 10.1067/mai.2001.115042; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V84, P331, DOI 10.1016/0091-6749(89)90417-X; Rueff F, 2001, J ALLERGY CLIN IMMUN, V108, P1027, DOI 10.1067/mai.2001.119154; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Simons FER., 2004, J ALLERGY CLIN IMMUN, V113, P1039; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5	53	54	60	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1978	1984		10.1056/NEJMcp042013	http://dx.doi.org/10.1056/NEJMcp042013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525723				2022-12-28	WOS:000224851300010
J	Lavis, JN; Posada, FB; Haines, A; Osei, E				Lavis, JN; Posada, FB; Haines, A; Osei, E			Use of research to inform public policymaking	LANCET			English	Article							HEALTH-SYSTEMS; KNOWLEDGE; IMPLEMENTATION; GAP	To improve health and reduce health inequalities, public policymakers need to find the best solutions to the most burdensome health problems, the best ways to fit these solutions into complex and often overstretched and underresourced health systems, and the best ways to bring about the desired changes in health systems. Systematic reviews can inform public policymaking by providing research-based answers to these questions. Public policymakers can encourage more informed policymaking by asking to see systematic reviews on priority issues, commissioning reviews when none exists, and placing more value on such work in their deliberations and in their interactions with stakeholders. Donors and international agencies can encourage more informed public policymaking by supporting national and regional efforts to undertake reviews and assess their local applicability, and by supporting regional or worldwide efforts to coordinate review and assessment processes.	McMaster Univ, Hlth Sci Ctr, Ctr Hlth Econ & Policy Anal, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Polit Sci, Hamilton, ON L8N 3Z5, Canada; Minist Hlth, Gen Coordinat Natl Inst Hlth, Mexico City, DF, Mexico; London Sch Hyg & Trop Med, London WC1, England	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; University of London; London School of Hygiene & Tropical Medicine	Lavis, JN (corresponding author), McMaster Univ, Hlth Sci Ctr, Ctr Hlth Econ & Policy Anal, Dept Clin Epidemiol & Biostat, Room 2D3,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	lavisj@mcmaster.ca	Lavis, John N/I-7555-2013	Lavis, John N/0000-0001-7917-3657; Haines, Andy/0000-0002-8053-4605				ALLEN C, 2003, P 11 COCHR C OCT 26, P44; [Anonymous], 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000363.PUB2; [Anonymous], MILL DEV GOALS; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Berwick DM, 2003, JAMA-J AM MED ASSOC, V289, P1969, DOI 10.1001/jama.289.15.1969; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Briggs CJ, 2001, COCHRANE DB SYST REV, V4; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; DANS A, 2004, USERS GUIDE INTERACT; Denis JL, 2001, ACAD MANAGE J, V44, P809, DOI 10.2307/3069417; Fontaine O, 2000, COCHRANE DB SYST REV, V2; Garner P, 1998, BRIT MED J, V317, P531; GRIMSHAW JM, 2001, MED CARE S, V39, P112; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Gwatkin DR, 2004, LANCET, V364, P1273, DOI 10.1016/S0140-6736(04)17145-6; Hahn S., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002847; Haines A, 2004, B WORLD HEALTH ORGAN, V82, P724; Hanney Stephen R., 2003, HEALTH RES POLICY SY, V1, P1, DOI DOI 10.1186/1478-4505-1-2; Haynes B, 1999, BRIT MED J, V319, P652, DOI 10.1136/bmj.319.7211.652; Hongoro C, 2004, LANCET, V364, P1451, DOI 10.1016/S0140-6736(04)17229-2; Iles V., 2001, ORGANISATIONAL CHANG; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Lavis JN, 2003, MILBANK Q, V81, P221, DOI 10.1111/1468-0009.t01-1-00052; Lavis JN, 2002, MILBANK Q, V80, P125, DOI 10.1111/1468-0009.00005; MAHER D, WHAT IS DOTS GUIDE U; Mason J, 2001, JAMA-J AM MED ASSOC, V286, P2988, DOI 10.1001/jama.286.23.2988; McAuley LM, 2003, BRIT MED J, V327, P106, DOI 10.1136/bmj.327.7406.106; Palmer N, 2004, LANCET, V364, P1365, DOI 10.1016/S0140-6736(04)17195-X; Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0; Victora CG, 2004, LANCET, V364, P1541, DOI 10.1016/S0140-6736(04)17279-6; Volmink J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003510.pub2	31	208	216	1	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	2004	364	9445					1615	1621		10.1016/S0140-6736(04)17317-0	http://dx.doi.org/10.1016/S0140-6736(04)17317-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866IQ	15519634				2022-12-28	WOS:000224767600029
J	Kaplinsky, NJ; Barton, MK				Kaplinsky, NJ; Barton, MK			Plant biology - Plant acupuncture: Sticking PINs in the right places	SCIENCE			English	Editorial Material							POLAR AUXIN TRANSPORT; ARABIDOPSIS; GRADIENTS		Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA	Carnegie Institution for Science	Kaplinsky, NJ (corresponding author), Carnegie Inst Washington, Dept Plant Biol, 290 Panama St, Stanford, CA 94305 USA.	barton@andrew2.stanford.edu		Kaplinsky, Nick/0000-0002-1759-1826				Benjamins R, 2001, DEVELOPMENT, V128, P4057; Benkova E, 2003, CELL, V115, P591, DOI 10.1016/S0092-8674(03)00924-3; BENNETT SRM, 1995, PLANT J, V8, P505, DOI 10.1046/j.1365-313X.1995.8040505.x; Blakeslee JJ, 2004, PLANT PHYSIOL, V134, P28, DOI 10.1104/pp.103.031690; Blancaflor EB, 2003, PLANT PHYSIOL, V133, P1677, DOI 10.1104/pp.103.032169; Christensen SK, 2000, CELL, V100, P469, DOI 10.1016/S0092-8674(00)80682-0; Friml J, 2004, SCIENCE, V306, P862, DOI 10.1126/science.1100618; Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Geldner N, 2004, DEVELOPMENT, V131, P389, DOI 10.1242/dev.00926; OKADA K, 1991, PLANT CELL, V3, P677, DOI 10.1105/tpc.3.7.677; Reinhardt D, 2003, NATURE, V426, P255, DOI 10.1038/nature02081	12	10	10	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					822	823		10.1126/science.1105534	http://dx.doi.org/10.1126/science.1105534			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514147				2022-12-28	WOS:000224969400034
J	Matsumoto, Y; Maller, JL				Matsumoto, Y; Maller, JL			A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry	SCIENCE			English	Article							XENOPUS EGG EXTRACTS; MAMMALIAN-CELLS; CDK2; TRANSITION; PROGRESSION; CDK2-CYCLIN; DUPLICATION; PROTEIN; KINASE; MICE	Excess cyclin E-Cdk2 accelerates entry into S phase of the cell cycle and promotes polyploidy, which may contribute to genomic instability in cancer cells. We identified 20 amino acids in cyclin E as a centrosomal localization signal (CLS) essential for both centrosomal targeting and promoting DNA synthesis. Expressed wild-type, but not mutant, CLS peptides localized on the centrosome, prevented endogenous cyclin E and cyclin A from localizing to the centrosome, and inhibited DNA synthesis. Ectopic cyclin E localized to the centrosome and accelerated S phase entry even with mutations that abolish Cdk2 binding, but not with a mutation in the CLS. These results suggest that cyclin E has a modular centrosomal-targeting domain essential for promoting S phase entry in a Cdk2-independent manner.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.	Jim.Maller@uchsc.edu						Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumoto Y., UNPUB; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Moroy T, 2004, INT J BIOCHEM CELL B, V36, P1424, DOI 10.1016/S1357-2725(03)00432-1; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rialland M, 2002, J CELL SCI, V115, P1435; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strausfeld UP, 1996, J CELL SCI, V109, P1555; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468	22	158	162	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					885	888		10.1126/science.1103544	http://dx.doi.org/10.1126/science.1103544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514162				2022-12-28	WOS:000224969400051
J	Eisenberg, MJ				Eisenberg, MJ			Drug-eluting stents: some bare facts	LANCET			English	Editorial Material							CORONARY-ARTERY-DISEASE; WASHINGTON RADIATION; BALLOON ANGIOPLASTY; GAMMA-RADIATION; WRIST-PLUS; THROMBOSIS; RESTENOSIS; THERAPY; IMPLANTATION; CLOPIDOGREL		Jewish Gen Hosp, Div Cardiol & Clin Epidemiol, Montreal, PQ H3T 1EZ, Canada	McGill University	Eisenberg, MJ (corresponding author), Jewish Gen Hosp, Div Cardiol & Clin Epidemiol, Montreal, PQ H3T 1EZ, Canada.	marke@epid.jgh.mcgill.ca						Babapulle MN, 2002, CIRCULATION, V106, P2859, DOI 10.1161/01.CIR.0000038984.30279.89; Cheneau E, 2003, CIRCULATION, V107, P2153, DOI 10.1161/01.CIR.0000062648.39025.09; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Kerner A, 2003, CATHETER CARDIO INTE, V60, P505, DOI 10.1002/ccd.10712; Liistro F, 2001, HEART, V86, P262, DOI 10.1136/heart.86.3.262; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441; Waksman R, 2001, CIRCULATION, V103, P2332; Waksman R, 2002, CIRCULATION, V106, P776, DOI 10.1161/01.CIR.0000028605.04359.FE	11	27	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1466	1467		10.1016/S0140-6736(04)17287-5	http://dx.doi.org/10.1016/S0140-6736(04)17287-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500872				2022-12-28	WOS:000224645500005
J	Pighin, JA; Zheng, HQ; Balakshin, LJ; Goodman, IP; Western, TL; Jetter, R; Kunst, L; Samuels, AL				Pighin, JA; Zheng, HQ; Balakshin, LJ; Goodman, IP; Western, TL; Jetter, R; Kunst, L; Samuels, AL			Plant cuticular lipid export requires an ABC transporter	SCIENCE			English	Article							CANCER RESISTANCE PROTEIN; ARABIDOPSIS-THALIANA; MUTANTS	A waxy protective cuticle coats all primary aerial plant tissues. Its synthesis requires extensive export of lipids from epidermal cells to the plant surface. Arabidopsis cer5 mutants had reduced stem cuticular wax loads and accumulated sheetlike inclusions in the cytoplasm of wax-secreting cells. These inclusions represented abnormal deposits of cuticular wax and resembled inclusions found in a human disorder caused by a defective peroxisomal adenosine triphosphate binding cassette (ABC) transporter. We found that the CER5 gene encodes an ABC transporter localized in the plasma membrane of epidermal cells and conclude that it is required for wax export to the cuticle.	Univ British Columbia, Dept Bot, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	University of British Columbia; University of British Columbia	Samuels, AL (corresponding author), Univ British Columbia, Dept Bot, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.	lsamuels@interchange.ubc.ca	Samuels, Anne Lacey/C-9767-2012; zheng, Huanquan/G-4739-2011	Samuels, Anne Lacey/0000-0002-0606-8933; Zheng, Huanquan/0000-0003-2986-725X				Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Jasinski M, 2003, PLANT PHYSIOL, V131, P1169, DOI 10.1104/pp.102.014720; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; KOORNNEEF M, 1989, J HERED, V80, P118, DOI 10.1093/oxfordjournals.jhered.a110808; Otsu CT, 2004, J EXP BOT, V55, P1643, DOI 10.1093/jxb/erh195; POWELL H, 1975, ARCH NEUROL-CHICAGO, V32, P250, DOI 10.1001/archneur.1975.00490460066009; Rashotte AM, 2001, PHYTOCHEMISTRY, V57, P115, DOI 10.1016/S0031-9422(00)00513-6; REA PA, 2003, ABC PROTEINS BACTERI, P335; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; Scheffer GL, 2000, CANCER RES, V60, P2589	10	380	421	4	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					702	704		10.1126/science.1102331	http://dx.doi.org/10.1126/science.1102331			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499022				2022-12-28	WOS:000224756700056
J	Ciufolini, I; Pavlis, EC				Ciufolini, I; Pavlis, EC			A confirmation of the general relativistic prediction of the Lense-Thirring effect	NATURE			English	Article							LAGEOS; SATELLITE; DRAG	An important early prediction of Einstein's general relativity(1-3) was the advance of the perihelion of Mercury's orbit, whose measurement provided one of the classical tests of Einstein's theory(4). The advance of the orbital point-of-closest-approach also applies to a binary pulsar system(5,6) and to an Earth-orbiting satellite(3). General relativity also predicts that the rotation of a body like Earth will drag the local inertial frames of reference around it(3,7), which will affect the orbit of a satellite(8). This Lense-Thirring effect has hitherto not been detected with high accuracy(9), but its detection with an error of about 1 per cent is the main goal of Gravity Probe B-an ongoing space mission using orbiting gyroscopes(10). Here we report a measurement of the Lense-Thirring effect on two Earth satellites: it is 99+/-5 per cent of the value predicted by general relativity; the uncertainty of this measurement includes all known random and systematic errors, but we allow for a total +/-10 per cent uncertainty to include underestimated and unknown sources of error.	Univ Lecce, Dipartimento Ingn Innovaz, I-73100 Lecce, Italy; Ist Nazl Fis Nucl, Sez Lecce, I-73100 Lecce, Italy; Univ Maryland Baltimore Cty, Joint Ctr Earth Syst Technol, Baltimore, MD USA	University of Salento; Istituto Nazionale di Fisica Nucleare (INFN); University System of Maryland; University of Maryland Baltimore County	Ciufolini, I (corresponding author), Univ Lecce, Dipartimento Ingn Innovaz, Via Monteroni, I-73100 Lecce, Italy.	ignazio.ciufolini@unile.it	Pavlis, Erricos C./AAF-4151-2019; Ciufolini, Ignazio/AAX-6592-2021	Pavlis, Erricos C./0000-0002-9726-7064; 				Andres JI, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002692; BENDER P, 1979, P 2 INT S US ART SAT, V2, P145; BERTOTTI B, 2003, PHYS EARTH SOLAR SYS; CIUFOLINI I, 1986, PHYS REV LETT, V56, P278, DOI 10.1103/PhysRevLett.56.278; CIUFOLINI I, 1989, INT J MOD PHYS A, V4, P3083, DOI 10.1142/S0217751X89001266; CIUFOLINI I, 2004, WEBER SAT LARES STUD; CIUFOLINI I, 2003, RELATIVISTIC SPACETI, P99; Ciufolini I., 1995, GRAVITATION INERTIA; FITCH VL, 1995, REV GRAVITY PROBE B; Genzel R, 2003, NATURE, V425, P934, DOI 10.1038/nature02065; HULSE RA, 1975, ASTROPHYS J, V195, pL51, DOI 10.1086/181708; *LAGEOS, 1985, J GEOPHYS RES B, V90, P9215; Lense J., 1918, PHYZ, V19, P156; Martin CF, 1996, J GEOPHYS RES-SOL EA, V101, P3215, DOI 10.1029/95JB02810; MCCARTHY D, 1996, 1996 IERS CONVENTION; Misner C. W., 1973, GRAVITATION; NOOMEN R, 2003, NASA CP; NORDTVEDT K, 1988, INT J THEOR PHYS, V27, P1395, DOI 10.1007/BF00671317; PAVLIS DE, 1998, GEODYN SYSTEMS DESCR, V3; Ray R. D., 1999, 209478 NASA GSFC; Rees MJ, 2001, ESO ASTROPHY SYMP, P351, DOI 10.1007/10720995_75; REIGBER C, IN PRESS J GEODYN; RIES JC, 1998, LARES PHASE A STUDY; RUBINCAM DP, 1988, J GEOPHYS RES-SOLID, V93, P13805, DOI 10.1029/JB093iB11p13805; RUBINCAM DP, 1995, J GEOPHYS RES-SOL EA, V100, P20285, DOI 10.1029/95JB02278; RUBINCAM DP, 1990, J GEOPHYS RES-SOLID, V95, P4881, DOI 10.1029/JB095iB04p04881; SHAPIRO II, 1988, PHYS REV LETT, V61, P2643, DOI 10.1103/PhysRevLett.61.2643; Thorne K.S., 1986, MEMBRANE PARADIGM; Weinberg S., 1972, GRAVITATION COSMOLOG; WILL CM, 1993, THEORY EXPT GRAVITAT; WILLIAMS JG, 2002, P 9 M GROSSM M, P1797	31	354	356	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					958	960		10.1038/nature03007	http://dx.doi.org/10.1038/nature03007			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496915				2022-12-28	WOS:000224585600036
J	Novikov, VN; Sokolov, AP				Novikov, VN; Sokolov, AP			Poisson's ratio and the fragility of glass-forming liquids	NATURE			English	Article							TRANSITION TEMPERATURE; SUPERCOOLED LIQUIDS; BOSON PEAK; RELAXATION; VISCOSITY; DYNAMICS; SCATTERING; FORMERS; SOLIDS	The nature of the transformation by which a supercooled liquid 'freezes' to a glass-the glass transition-is a central issue in condensed matter physics(1-3) but also affects many other fields, including biology(4). Substantial progress has been made in understanding this phenomenon over the past two decades, yet many key questions remain. In particular, the factors that control the temperature-dependent relaxation and viscous properties of the liquid phase as the glass transition is approached (that is, whether the glass-forming liquid is 'fragile' or 'strong'(5-7)) remain unclear. Here we show that the fragility of a glass-forming liquid is intimately linked to a very basic property of the corresponding glass phase: the relative strength of shear and bulk moduli, or Poisson's ratio.	Univ Akron, Dept Polymer Sci, Akron, OH 44325 USA; Russian Acad Sci, Inst Automat & Electrometry, Novosibirsk 630090, Russia	University System of Ohio; University of Akron; Institute of Automation & Electrometry SB RAS; Russian Academy of Sciences	Sokolov, AP (corresponding author), Univ Akron, Dept Polymer Sci, Akron, OH 44325 USA.	alexei@uakron.edu						ANDERSON PW, 1995, SCIENCE, V268, P1154, DOI 10.1126/science.268.5214.1154; ANGELL CA, 1985, J NON-CRYST SOLIDS, V73, P1, DOI 10.1016/0022-3093(85)90334-5; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; Barrer RM, 1943, T FARADAY SOC, V39, P0048, DOI 10.1039/tf9433900048; BORDAT P, 2004, ORGCONDMAT0401117; BUCHENAU U, 2004, ORGCONDMAT0401088; Courtens E, 2001, SOLID STATE COMMUN, V117, P187, DOI 10.1016/S0038-1098(00)00434-8; Debenedetti PG, 2001, NATURE, V410, P259, DOI 10.1038/35065704; DUVAL E, 1990, J PHYS-CONDENS MAT, V2, P10227, DOI 10.1088/0953-8984/2/51/001; Dyre JC, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.042501; FABELINSKII IL, 1968, MOLECULAR SCATTERING, pCH7; FOX KC, 1995, SCIENCE, V267, P1922, DOI 10.1126/science.7701317; Grigera TS, 2003, NATURE, V422, P289, DOI 10.1038/nature01475; MALINOVSKY VK, 1986, SOLID STATE COMMUN, V57, P757, DOI 10.1016/0038-1098(86)90854-9; Martinez LM, 2001, NATURE, V410, P663, DOI 10.1038/35070517; Nemilov S. V, 1995, THERMODYNAMIC KINETI; NEMILOV SV, 1968, RUSS J PHYS CH USSR, V42, P726; Novikov VN, 1998, PHYS REV B, V58, P8367, DOI 10.1103/PhysRevB.58.8367; Quitmann D, 1996, J NON-CRYST SOLIDS, V203, P12, DOI 10.1016/0022-3093(96)00328-6; Roland CM, 2003, J CHEM PHYS, V119, P1838, DOI 10.1063/1.1581850; Rossler E, 1998, J NON-CRYST SOLIDS, V223, P207, DOI 10.1016/S0022-3093(97)00365-7; Sanditov DS, 1998, GLASS PHYS CHEM+, V24, P539; Scopigno T, 2003, SCIENCE, V302, P849, DOI 10.1126/science.1089446; Sokolov AP, 1997, PHYS REV LETT, V78, P2405, DOI 10.1103/PhysRevLett.78.2405; SOKOLOV AP, 1993, PHYS REV LETT, V71, P2062, DOI 10.1103/PhysRevLett.71.2062; Stickel F, 1996, J CHEM PHYS, V104, P2043, DOI 10.1063/1.470961; Tobolsky A, 1943, FRONTIERS CHEM, V1, P125; Wang WH, 2003, J MATER RES, V18, P2747, DOI 10.1557/JMR.2003.0382	28	409	414	3	127	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					961	963		10.1038/nature02947	http://dx.doi.org/10.1038/nature02947			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496916				2022-12-28	WOS:000224585600037
J	Sun, WD; Arculus, RJ; Kamenetsky, VS; Binns, RA				Sun, WD; Arculus, RJ; Kamenetsky, VS; Binns, RA			Release of gold-bearing fluids in convergent margin magmas prompted by magnetite crystallization	NATURE			English	Article							BACK-ARC BASIN; VOLCANIC-ROCKS; MANUS BASIN; SEA-FLOOR; GLASSES; MANTLE; SOLUBILITY; ENRICHMENT; STABILITY; DEPOSITS	A relationship between convergent margin magmas and copper gold ore mineralization has long been recognized(1-6). The nature of the genetic link is controversial, particularly whether the link is due to high-oxygen-fugacity (f(O 2)) melts and fluids released from subducted slabs(5-7) or to brine exsolution during magmatic evolution4. For submarine, subduction-related volcanic glasses from the eastern Manus basin, Papua New Guinea, we here report abrupt decreases in gold and copper abundances, coupled with a switch in the behaviour of titanium and iron from concentration increases to decreases as SiO2 rises. We propose that the abrupt depletion in gold and copper results from concurrent sulphur reduction as a result of f(O 2) buffering, causing enhanced formation of copper-gold hydrosulphide complexes that become scavenged from crystallizing melts into cogenetic magmatic aqueous fluids. This process is particularly efficient in oxidized arc magmas with substantial sulphate. We infer that subsequent migration and cooling of exsolved aqueous fluids create links between copper-gold mineralization and arc magmatism in the Manus basin(8,9), and at convergent margins in general(1-6).	Australian Natl Univ, Dept Earth & Marine Sci, Canberra, ACT 0200, Australia; Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Max Planck Inst Chem, D-55020 Mainz, Germany; Univ Tasmania, Ctr Ore Deposit Res, Hobart, Tas 7001, Australia; Univ Tasmania, Sch Earth Sci, Hobart, Tas 7001, Australia; CSIRO Explorat & Min, N Ryde, NSW 1670, Australia	Australian National University; Australian National University; Max Planck Society; University of Tasmania; University of Tasmania; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Arculus, RJ (corresponding author), Australian Natl Univ, Dept Earth & Marine Sci, Canberra, ACT 0200, Australia.	richard.arculus@anu.edu.au	Kamenetsky, Vadim/CAF-7424-2022; Sun, Weidong/V-2014-2019; Sun, Weidong/AAJ-7430-2021; Kamenetsky, Vadim S/B-1019-2008; Kamenetsky, Vadim/K-2200-2019; Sun, Weidong/F-8482-2010	Sun, Weidong/0000-0002-8931-8407; Kamenetsky, Vadim S/0000-0002-2734-8790; Arculus, Richard/0000-0002-3432-392X				Archibald SM, 2001, GEOCHIM COSMOCHIM AC, V65, P4413, DOI 10.1016/S0016-7037(01)00730-X; Binns R.A., 2002, P OC DRILL PROGR IN, P1; BINNS RA, 1993, ECON GEOL BULL SOC, V88, P2226, DOI 10.2113/gsecongeo.88.8.2226; CARMICHAEL ISE, 1986, EARTH PLANET SC LETT, V78, P200, DOI 10.1016/0012-821X(86)90061-0; Gammons CH, 1997, ECON GEOL BULL SOC, V92, P45, DOI 10.2113/gsecongeo.92.1.45; Gibert F, 1998, GEOCHIM COSMOCHIM AC, V62, P2931, DOI 10.1016/S0016-7037(98)00209-9; Kamenetsky VS, 2002, CHEM GEOL, V183, P349, DOI 10.1016/S0009-2541(01)00383-7; Kamenetsky VS, 2001, EARTH PLANET SC LETT, V184, P685, DOI 10.1016/S0012-821X(00)00352-6; KEAYS RR, 1976, ECON GEOL, V71, P705, DOI 10.2113/gsecongeo.71.4.705; KILINC A, 1983, CONTRIB MINERAL PETR, V83, P136, DOI 10.1007/BF00373086; Loucks RR, 1999, SCIENCE, V284, P2159, DOI 10.1126/science.284.5423.2159; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; McInnes BIA, 1999, SCIENCE, V286, P512, DOI 10.1126/science.286.5439.512; Moss R, 2001, ECON GEOL BULL SOC, V96, P91, DOI 10.2113/96.1.91; MULLER D, 1993, ORE GEOL REV, V8, P383, DOI 10.1016/0169-1368(93)90035-W; Muller D, 2001, LITHOS, V57, P163, DOI 10.1016/S0024-4937(01)00035-4; Mungall JE, 2002, GEOLOGY, V30, P915, DOI 10.1130/0091-7613(2002)030<0915:RTMSMA>2.0.CO;2; Phillips GN, 2004, NATURE, V429, P860, DOI 10.1038/nature02644; RICHARDS JP, 1990, J GEOCHEM EXPLOR, V35, P141, DOI 10.1016/0375-6742(90)90038-C; Roberts S, 2003, GEOLOGY, V31, P805, DOI 10.1130/G19716.1; Sillitoe RH, 1997, AUST J EARTH SCI, V44, P373, DOI 10.1080/08120099708728318; Sun WD, 2003, GEOLOGY, V31, P845, DOI 10.1130/G19832.1; Sun WD, 2003, CHEM GEOL, V196, P259, DOI 10.1016/S0009-2541(02)00416-3; Sun WD, 2003, NATURE, V422, P294, DOI 10.1038/nature01482; Togashi S, 1997, GEOCHIM COSMOCHIM AC, V61, P543, DOI 10.1016/S0016-7037(96)00369-9; Ulrich T, 1999, NATURE, V399, P676, DOI 10.1038/21406; Williams-Jones A.E., 2002, WATER ROCK INTERACTI, V7, P279; Yang KH, 2002, ECON GEOL BULL SOC, V97, P1079, DOI 10.2113/97.5.1079; Yang KH, 1996, NATURE, V383, P420, DOI 10.1038/383420a0; ZENTILLI M, 1985, CHEM GEOL, V48, P17, DOI 10.1016/0009-2541(85)90032-4	30	291	357	0	129	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					975	978		10.1038/nature02972	http://dx.doi.org/10.1038/nature02972			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496920				2022-12-28	WOS:000224585600041
J	Tran, H; Anand, SS				Tran, H; Anand, SS			Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE MYOCARDIAL-INFARCTION; LOW-DOSE ASPIRIN; PRACTICE GUIDELINES COMMITTEE; ASSOCIATION TASK-FORCE; SECONDARY PREVENTION; CONTROLLED-TRIAL; UNSTABLE ANGINA; DOUBLE-BLIND; ACETYLSALICYLIC-ACID; ACC/AHA GUIDELINES	Context Atherothrombosis is a pathophysiologic process that results in clinical ischemic events affecting the cerebral, coronary, and peripheral arterial circulation. Antiplatelet agents, used alone or in combination, are effective in preventing recurrent vascular events among individuals with established vascular disease. Objective To summarize the current state of evidence regarding oral antiplatelet treatment in patients with cerebrovascular disease, coronary artery disease (CAD), and peripheral arterial disease. Evidence Acquisition Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina, aspirin, ticlopidine, dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004. We manually searched journals and abstract booklets; scrutinized reference lists of trials and review articles; and reviewed meta-analyses, scientific statements, and guidelines from official societies. Evidence Synthesis Appropriate oral first-line antiplatelet therapy is aspirin for individuals with ST-segment elevation myocardial infarction; aspirin or clopidogrel for those with TIA or stroke, chronic stable angina, or peripheral arterial disease; and aspirin combined with clopidogrel for those with non-ST-segment elevation acute coronary syndrome. Aspirin combined with dipyridamole is a possible alternative for patients who experience a first episode of TIA or stroke in the absence of clinically apparent CAD. Although ticlopidine has been shown to be of benefit in various vascular conditions, its adverse-effect profile has limited its use. Conclusions Aspirin, ticlopidine, clopidogrel, aspirin combined with clopidogrel, and aspirin combined with dipyridamole are effective in preventing recurrent vascular events among various subgroups of patients with vascular disease. Current clinical trial evidence favors the use of aspirin or clopidogrel as first-line agents for the majority of patients with vascular disease. Clinical trials evaluating combination antiplatelet therapies will direct future practice.	McMaster Univ, Med Ctr,Fac Hlth Sci, Dept Med, Thromboembolism Unit, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Fac Hlth Sci, Dept Med, Div Cardiol, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Anand, SS (corresponding author), McMaster Univ, Med Ctr,Fac Hlth Sci, Dept Med, Thromboembolism Unit, 1200 Main St W,Room 3W28A, Hamilton, ON L8N 3Z5, Canada.	anands@mcmaster.ca						ACHESON J, 1969, BMJ-BRIT MED J, V1, P614, DOI 10.1136/bmj.1.5644.614; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1991, Lancet, V338, P1345; *ANT TRIAL COLL, 2003, STROKE, V34, pE182; ARONOW WS, 1994, AM J CARDIOL, V74, P64, DOI 10.1016/0002-9149(94)90493-6; Baigent C, 1998, BMJ-BRIT MED J, V316, P1337, DOI 10.1136/bmj.316.7141.1337; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; Bennett CL, 1998, ANN INTERN MED, V128, P541, DOI 10.7326/0003-4819-128-7-199804010-00004; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; BOYSEN G, 1988, STROKE, V19, P1211, DOI 10.1161/01.STR.19.10.1211; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; Cairns JA, 2001, CHEST, V119, p228S, DOI 10.1378/chest.119.1_suppl.228S; Cannon CP, 2000, CIRCULATION, V102, P149, DOI 10.1161/01.CIR.102.2.149; CHIMOWITZ MI, 1992, STROKE, V23, P433, DOI 10.1161/01.STR.23.3.433; COLLINS R, 1987, EUR HEART J, V8, P634; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; DESCHRYVER EL, 2004, COCHRANE DB SYST REV, V1; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Diener HC, 2001, INT J CLIN PRACT, V55, P162; Elwood P C, 1979, J R Coll Gen Pract, V29, P413; ELWOOD PC, 1990, LANCET, V335, P486, DOI 10.1016/0140-6736(90)90728-N; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; FIELDS WS, 1985, STROKE, V16, P406; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gibbons RJ, 2003, CIRCULATION, V107, P149, DOI 10.1161/01.CIR.0000047041.66447.29; GUIRAUDCHAUMEIL B, 1982, REV NEUROL, V138, P367; GUSTAFSSON C, 1987, STROKE, V18, P299; HANKEY GJ, 2000, COCHRANE DB SYST REV, V2; Harker LA, 1999, DRUG SAFETY, V21, P325, DOI 10.2165/00002018-199921040-00007; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; JANZON L, 1990, J INTERN MED, V227, P301, DOI 10.1111/j.1365-2796.1990.tb00164.x; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; MAUTNER GC, 1992, AM J CARDIOL, V70, P1147, DOI 10.1016/0002-9149(92)90046-2; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Nenci GG, 1999, EUR HEART J SUPPL, V1, pA27; NYMAN I, 1992, LANCET, V340, P497, DOI 10.1016/0140-6736(92)91706-E; PETERS RZ, 2002, CIRCULATION, V106, pA2258; Popma JJ, 2001, CHEST, V119, p321S, DOI 10.1378/chest.119.1_suppl.321S; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; Smith SC, 2001, CIRCULATION, V103, P3019, DOI 10.1161/01.CIR.103.24.3019; SORENSEN PS, 1983, STROKE, V14, P15, DOI 10.1161/01.STR.14.1.15; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; Topol CE, 2000, LANCET, V355, P337; Topol EJ, 2003, CIRCULATION, V108, P399, DOI 10.1161/01.CIR.0000084501.48570.F6; TSUYA T, 1990, AM J CARDIOL, V66, P275, DOI 10.1016/0002-9149(90)90835-O; van Gijn J, 2003, THROMB RES, V110, P349, DOI 10.1016/S0049-3848(03)00414-6; VERHEUGT FWA, 1988, AM J CARDIOL, V61, P904, DOI 10.1016/0002-9149(88)90368-2; WALLENTIN L, 1990, LANCET, V336, P827; WALLENTIN LC, 1991, J AM COLL CARDIOL, V18, P1587, DOI 10.1016/0735-1097(91)90489-V; Yusuf S, 2001, NEW ENGL J MED, V345, P494	54	142	152	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2004	292	15					1867	1874		10.1001/jama.292.15.1867	http://dx.doi.org/10.1001/jama.292.15.1867			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IV	15494585				2022-12-28	WOS:000224485100026
J	Yardley, L; Donovan-Hall, M; Smith, HE; Walsh, BM; Mullee, M; Bronstein, AM				Yardley, L; Donovan-Hall, M; Smith, HE; Walsh, BM; Mullee, M; Bronstein, AM			Effectiveness of primary care-based vestibular rehabilitation for chronic dizziness	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; COMMUNITY SAMPLE; GENERAL-PRACTICE; OLDER-ADULTS; VERTIGO; PEOPLE; THERAPY; DIZZY; FEAR	Background: Dizziness is a very common symptom and is usually managed in primary care. Vestibular rehabilitation for dizziness is a simple treatment that may be suitable for primary care delivery, but its effectiveness has not yet been determined. Objective: To evaluate the effectiveness of nurse-delivered vestibular rehabilitation in primary care for patients with chronic dizziness. Design: Single-blind randomized, controlled trial. Setting: 20 general practices in southern England. Patients: 170 adult patients with chronic dizziness who were randomly assigned to vestibular rehabilitation (n = 83) or usual medical care (n = 87). Intervention: Each patient received one 30- to 40-minute appointment with a primary care nurse. The nurse taught the patient exercises to be carried out daily at home, with the support of a treatment booklet. Measurements: Primary outcome measures were baseline, 3-month, and 6-month assessment of self-reported spontaneous and provoked symptoms of dizziness, dizziness-related quality of life, and objective measurement of postural stability with eyes open and eyes closed. Results: At 3 months, improvement on all primary outcome measures in the vestibular rehabilitation group was significantly greater than in the usual medical care group; this improvement was maintained at 6 months. Of 83 treated patients, 56 (67%) reported clinically significant improvement compared with 33 of 87 (38%) usual care patients (relative risk, 1.78 [95% CI, 1.31 to 2.42]). Limitations: Psychological elements of the therapy may have contributed to outcomes, and the treatment may be effective only for well-motivated patients. Conclusions: Vestibular rehabilitation delivered by nurses in general practice improves symptoms, postural stability, and dizziness-related handicap in patients with chronic dizziness.	Univ Southampton, Sch Psychol, Southampton SO17 1BK, Hants, England; Brighton & Sussex Med Sch, Brighton, MA USA; Univ London Imperial Coll Sci & Technol, London, England	University of Southampton; Imperial College London	Yardley, L (corresponding author), Univ Southampton, Sch Psychol, Southampton SO17 1BK, Hants, England.	L.Yardley@soton.ac.uk	Smith, Helen E/M-2449-2016	Smith, Helen E/0000-0003-1883-6124; Walsh, Bronagh/0000-0003-1008-0545; Donovan-Hall, Margaret/0000-0003-3398-845X; Yardley, Lucy/0000-0002-3853-883X	MRC [MC_U950770497] Funding Source: UKRI; Medical Research Council [MC_U950770497] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Beidel DC, 2001, J ANXIETY DISORD, V15, P121, DOI 10.1016/S0887-6185(00)00046-3; Bird JC, 1998, BRIT J GEN PRACT, V48, P1828; Brandt T, 2000, J NEUROL, V247, P491, DOI 10.1007/s004150070146; BURKER EJ, 1995, PSYCHOL AGING, V10, P104, DOI 10.1037/0882-7974.10.1.104; Cohen HS, 2003, OTOLARYNG HEAD NECK, V128, P60, DOI 10.1067/mhn.2003.23; Colledge NR, 1996, BMJ-BRIT MED J, V313, P788; COOKSEY FS, 1946, P ROY SOC MED, V39, P273, DOI 10.1177/003591574603900523; Friedman SM, 2002, J AM GERIATR SOC, V50, P1329, DOI 10.1046/j.1532-5415.2002.50352.x; Hanley K, 2002, BRIT J GEN PRACT, V52, P809; Hanley K, 2001, BRIT J GEN PRACT, V51, P666; Herdman SJ, 1999, VESTIBULAR REHABILIT; Hoffman RM, 1999, AM J MED, V107, P468, DOI 10.1016/S0002-9343(99)00260-0; HORAK FB, 1992, OTOLARYNG HEAD NECK, V106, P175, DOI 10.1177/019459989210600220; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; Johansson M, 2001, OTOLARYNG HEAD NECK, V125, P151, DOI 10.1067/mhn.2001.118127; KREBSX DE, 2000, OTOLARYNGOL HEAD NEC, V128, P240; Kristinsdottir EK, 2000, SCAND J REHABIL MED, V32, P56; Kroenke K, 2000, SOUTH MED J, V93, P160; Myers LB, 1998, ADHERENCE TREATMENT; OJALA M, 1989, ACTA NEUROL SCAND, V80, P118, DOI 10.1111/j.1600-0404.1989.tb03852.x; Pocock S, 1983, CLIN TRIALS; RASCOL O, 1995, DRUGS, V50, P777, DOI 10.2165/00003495-199550050-00002; Resnick B, 2000, PATIENT EDUC COUNS, V39, P243, DOI 10.1016/S0738-3991(99)00039-7; SHEPARD NT, 1995, OTOLARYNG HEAD NECK, V112, P173, DOI 10.1016/S0194-5998(95)70317-9; SLOANE P, 1989, J AM GERIATR SOC, V37, P101, DOI 10.1111/j.1532-5415.1989.tb05867.x; Sloane PD, 2001, ANN INTERN MED, V134, P823, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00005; Steenerson RL, 1996, OTOLARYNG HEAD NECK, V114, P61, DOI 10.1016/S0194-5998(96)70284-X; Strupp M, 1998, NEUROLOGY, V51, P838, DOI 10.1212/WNL.51.3.838; Tinetti ME, 2000, ANN INTERN MED, V132, P337, DOI 10.7326/0003-4819-132-5-200003070-00002; Ware J., 2001, SF 36 PHYS MENTAL HL, P1994; Yardley L, 1998, BRIT J GEN PRACT, V48, P1131; Yardley L, 1998, CLIN OTOLARYNGOL, V23, P442, DOI 10.1046/j.1365-2273.1998.00179.x; Yardley L, 1998, J NEUROL NEUROSUR PS, V65, P679, DOI 10.1136/jnnp.65.5.679; Yardley L, 1998, BRIT J GEN PRACT, V48, P1136; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	37	139	144	1	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	2004	141	8					598	605		10.7326/0003-4819-141-8-200410190-00007	http://dx.doi.org/10.7326/0003-4819-141-8-200410190-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864SD	15492339	Green Published			2022-12-28	WOS:000224652300003
J	Dayan, L; Donovan, B				Dayan, L; Donovan, B			Chlamydia, gonorrhoea, and injectable progesterone	LANCET			English	Editorial Material							CONTRACEPTIVE USE; UNITED-STATES; DEPO-PROVERA; INFECTIONS; STORY		Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia; Royal N Shore Hosp, Sexual Hlth Serv, St Leonards, NSW 2065, Australia; Sydney Hosp, Sydney Sexual Hlth Ctr, Sydney, NSW, Australia	University of Sydney; Royal North Shore Hospital	Dayan, L (corresponding author), Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.	ldayan@doh.health.nsw.gov.au	Donovan, Basil J/K-1246-2012	Donovan, Basil J/0000-0001-8851-4126				Cromer BA, 1998, J ADOLESCENT HEALTH, V23, P74, DOI 10.1016/S1054-139X(98)00030-5; Fenton KA, 2004, SEX TRANSM INFECT, V80, P255, DOI 10.1136/sti.2004.009415; KLITSCH M, 1993, FAM PLANN PERSPECT, V25, P37, DOI 10.2307/2135992; Morrison CS, 2004, SEX TRANSM DIS, V31, P561, DOI 10.1097/01.olq.0000137904.56037.70; Oddens BJ, 1997, J BIOSOC SCI, V29, P437, DOI 10.1017/S0021932097004379; RICHARD BW, 1987, ANN INTERN MED, V106, P886, DOI 10.7326/0003-4819-106-6-886; Turner CF, 2002, JAMA-J AM MED ASSOC, V287, P726, DOI 10.1001/jama.287.6.726	7	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	2004	364	9443					1387	1388		10.1016/S0140-6736(04)17239-5	http://dx.doi.org/10.1016/S0140-6736(04)17239-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488203				2022-12-28	WOS:000224485300008
J	Friesema, ECH; Grueters, A; Biebermann, H; Krude, H; von Moers, A; Reeser, M; Barrett, TG; Mancilla, EE; Svensson, J; Kester, MHA; Kuiper, GGJM; Balkassmi, S; Uitterlinden, AG; Koehrle, J; Rodien, P; Halestrap, AP; Visser, T				Friesema, ECH; Grueters, A; Biebermann, H; Krude, H; von Moers, A; Reeser, M; Barrett, TG; Mancilla, EE; Svensson, J; Kester, MHA; Kuiper, GGJM; Balkassmi, S; Uitterlinden, AG; Koehrle, J; Rodien, P; Halestrap, AP; Visser, T			Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation	LANCET			English	Article								Monocarboxylate transporter 8 (MCT8) is a thyroid hormone transporter, the gene of which is located on the X chromosome. We tested whether mutations in MCT8 cause severe psychomotor retardation and high serum triiodothyronine (T,) concentrations in five unrelated young boys. The coding sequence of MCT8 was analysed by PCR and direct sequencing of its six exons. In two patients, gene deletions of 2.4 kb and 24 kb were recorded and in three patients missense mutations Ala150Va1, Arg171stop, and Leu397Pro were identified. We suggest that this novel syndrome of X-linked psychomotor retardation is due to a defect in T-3 entry into neurons through MCT8, resulting in impaired T-3 action and metabolism.	Erasmus MC, Dept Internal Med, Rotterdam, Netherlands; Humboldt Univ, Dept Paediat Endocrinol, Charite Childrens Hosp, Berlin, Germany; Juliana Childrens Hosp, Dept Paediat, The Hague, Netherlands; Birmingham Childrens Hosp, Dept Endocrinol, Birmingham, W Midlands, England; Univ Chile, Inst Biomed Sci, Santiago, Chile; Malmo Univ Hosp, Dept Paediat, Malmo, Sweden; Charite Univ Med Berlin, Inst Expt Endocrinol, Berlin, Germany; CHU Angers, INSERM, U0018, EMI, Angers, France; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	Erasmus University Rotterdam; Erasmus MC; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Birmingham; Universidad de Chile; Lund University; Skane University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; University of Bristol	Visser, T (corresponding author), Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.	t.j.visser@erasmusmc.nl	Visser, Theo J/C-8059-2013; Halestrap, Andrew P/G-7275-2011; Rodien, Patrice/AAT-7909-2021; Köhrle, Josef/AAH-6438-2020; Barrett, Timothy/F-1682-2010	Visser, Theo J/0000-0002-6997-284X; Köhrle, Josef/0000-0002-9187-9078; Barrett, Timothy/0000-0002-6873-0750; Halestrap, Andrew/0000-0001-5374-2778; Biebermann, Heike/0000-0002-2024-7778; Svensson, Johan/0000-0003-4313-1521				Bernal J, 2002, J ENDOCRINOL INVEST, V25, P268, DOI 10.1007/BF03344003; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; de Escobar GM, 2000, J CLIN ENDOCR METAB, V85, P3975, DOI 10.1210/jc.85.11.3975; Friesema ECH, 2003, J BIOL CHEM, V278, P40128, DOI 10.1074/jbc.M300909200; Hennemann G, 2001, ENDOCR REV, V22, P451, DOI 10.1210/er.22.4.451; LAFRENIERE RG, 1994, HUM MOL GENET, V3, P1133, DOI 10.1093/hmg/3.7.1133; Yen PM, 2003, TRENDS ENDOCRIN MET, V14, P327, DOI 10.1016/S1043-2760(03)00114-0	7	471	485	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2004	364	9443					1435	1437		10.1016/S0140-6736(04)17226-7	http://dx.doi.org/10.1016/S0140-6736(04)17226-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488219				2022-12-28	WOS:000224485300030
J	Raymont, V; Bingley, W; Buchanan, A; David, AS; Hayward, P; Wessely, S; Hotopf, M				Raymont, V; Bingley, W; Buchanan, A; David, AS; Hayward, P; Wessely, S; Hotopf, M			Prevalence of mental incapacity on medical inpatients and associated risk factors: cross-sectional study	LANCET			English	Article							ALZHEIMERS-DISEASE; INFORMED-CONSENT; PATIENTS CAPACITIES; TREATMENT DECISIONS; ILL PATIENTS; COMPETENCE; STATE; STANDARDS; MODEL	Background Although mental incapacity is becoming increasingly important in clinical practice, little information available on its frequency in medical inpatients. We aimed to estimate the prevalence of mental incapacity in admitted medical inpatients; to determine the frequency that medical teams recognised patients who did not mental capacity; and to identify factors associated with mental incapacity. Methods Over an 18-month period, we recruited 302 consecutive acute medical inpatients. Participants assessed with the MacArthur competence tool for treatment and by clinical interview. Cognitive impairment measured by the mini-mental state examination. Findings 72 (24%) patients were severely cognitively impaired, unconscious, or unable to express a choice and automatically assigned to the incapacity group. 71 (24%) refused to participate or could not speak English. 159 patients were interviewed. Of these, 31% (95% CI 24-38) were judged not to have mental capacity. For the sample (n=302), we estimated that at least 40% did not have mental capacity. Clinical teams rarely identified who did not have mental capacity: of 50 patients interviewed, 12 (24%) were rated as lacking capacity. associated with mental incapacity were increasing age and cognitive impairment. Interpretation Mental incapacity is common in acutely ill medical inpatients, and clinicians tend not to recognise Screening methods for cognitive impairment could be useful in detecting those with doubtful capacity to consent.	Kings Coll London, Inst Psychiat, Weston Educ Ctr, Dept Psychol, London SE5 9RS, England; Yale Univ, New Haven, CT USA; Univ Cent Lancashire, Preston PR1 2HE, Lancs, England	University of London; King's College London; Yale University; University of Central Lancashire	Hotopf, M (corresponding author), Kings Coll London, Inst Psychiat, Weston Educ Ctr, Dept Psychol, Cutcombe Rd, London SE5 9RS, England.	m.hotopf@iop.kcl.ac.uk	Hotopf, Matthew/E-4971-2010; David, Anthony S/C-1315-2011; Wessely, Simon C/A-8713-2008; David, Anthony/O-1750-2019	David, Anthony S/0000-0003-0967-774X; David, Anthony/0000-0003-0967-774X; Hotopf, Matthew/0000-0002-3980-4466; Wessely, Simon Charles/0000-0002-6743-9929				Appelbaum PS, 1997, PSYCHOSOMATICS, V38, P119, DOI 10.1016/S0033-3182(97)71480-4; *BRIT MED ASS ROYA, 2004, BRIT NAT FORM; Carpenter WT, 2000, ARCH GEN PSYCHIAT, V57, P533, DOI 10.1001/archpsyc.57.6.533; CHRISTENSEN K, 1995, B AM ACAD PSYCH LAW, V23, P353; Dyer C, 2002, BRIT MED J, V324, P753, DOI 10.1136/bmj.324.7340.753; Etchells E, 1999, J GEN INTERN MED, V14, P27, DOI 10.1046/j.1525-1497.1999.00277.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Grisso T, 1997, PSYCHIATR SERV, V48, P1415; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P149, DOI 10.1007/BF01499323; GRISSO T, 1995, AM J PSYCHIAT, V152, P1033; Grisso T, 1998, ASSESSING COMPETENCE; GRISSO T, 1992, MANUAL RATIONAL THIN; KATZ M, 1995, PSYCHOSOMATICS, V36, P33, DOI 10.1016/S0033-3182(95)71705-4; Kim SYH, 2002, AM J PSYCHIAT, V159, P797, DOI 10.1176/appi.ajp.159.5.797; Kim SYH, 2002, AM J GERIAT PSYCHIAT, V10, P151, DOI 10.1176/appi.ajgp.10.2.151; Kim SYH, 2001, AM J PSYCHIAT, V158, P712, DOI 10.1176/appi.ajp.158.5.712; Marson DC, 1996, NEUROLOGY, V46, P666, DOI 10.1212/WNL.46.3.666; ROTH LH, 1977, AM J PSYCHIAT, V134, P279; STROMBERG CD, 1983, HARVARD J LEGIS, V20, P275; SZMUKLER G, 1998, PSYCHIAT B, V0022, P00662, DOI DOI 10.1192/pb.22.11.662; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; VENTURA J, 1993, INT J METH PSYCH RES, V3, P221; Vollmann J, 2003, PSYCHOL MED, V33, P1463, DOI 10.1017/S0033291703008389; 2002, BMA NEWS	24	263	267	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	2004	364	9443					1421	1427		10.1016/S0140-6736(04)17224-3	http://dx.doi.org/10.1016/S0140-6736(04)17224-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488217				2022-12-28	WOS:000224485300028
J	Goodman, MB				Goodman, MB			Deconstructing C-elegans sensory mechanotransduction	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; SENSITIVITY; CHANNEL; NEURONS		Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Stanford University	Goodman, MB (corresponding author), Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.	mbgoodman@stanford.edu	Goodman, Miriam B./H-3036-2019	Goodman, Miriam B./0000-0002-5810-1272				Adrian ED, 1926, J PHYSIOL-LONDON, V61, P49, DOI 10.1113/jphysiol.1926.sp002273; Adrian ED, 1926, J PHYSIOL-LONDON, V61, P151, DOI 10.1113/jphysiol.1926.sp002281; Brown A, UNPUB; *CDCP, 2004, NAT DIAB FACT SHEET; CHALFIE M, 1985, J NEUROSCI, V5, P956; Chelur DS, 2002, NATURE, V420, P669, DOI 10.1038/nature01205; Ernstrom GG, 2002, ANNU REV GENET, V36, P411, DOI 10.1146/annurev.genet.36.061802.101708; Goodman MB, 2002, NATURE, V415, P1039, DOI 10.1038/4151039a; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; Hardie RC, 2001, J EXP BIOL, V204, P3403; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; MENDELSON M, 1964, SCIENCE, V144, P554, DOI 10.1126/science.144.3618.554; OHAGAN R, UNPUB; Suzuki H, 2003, NEURON, V39, P1005, DOI 10.1016/j.neuron.2003.08.015	14	1	2	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2004	306	5695					427	428		10.1126/science.1105624	http://dx.doi.org/10.1126/science.1105624			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486284				2022-12-28	WOS:000224626500036
J	Hall, DA; Zhu, H; Zhu, XW; Royce, T; Gerstein, M; Snyder, M				Hall, DA; Zhu, H; Zhu, XW; Royce, T; Gerstein, M; Snyder, M			Regulation of gene expression by a metabolic enzyme	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL-DNA; BUDDING YEAST; COMPLEX; IDENTIFICATION; TRANSCRIPTION; PROMOTER; PROTEINS; PROTEOME; BINDING	Gene expression in eukaryotes is normally believed to be controlled by transcriptional regulators that activate genes encoding structural proteins and enzymes. To identify previously unrecognized DNA binding activities, a yeast proteome microarray was screened with DNA probes; Arg5,6, a well-characterized mitochondrial enzyme involved in arginine biosynthesis, was identified. Chromatin immunoprecipitation experiments revealed that Arg5,6 is associated with specific nuclear and mitochondrial loci in vivo, and Arg5,6 binds to specific fragments in vitro. Deletion of Arg5,6 causes altered transcript levels of both nuclear and mitochondrial target genes. These results indicate that metabolic enzymes can directly regulate eukaryotic gene expression.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Snyder, M (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.	michael.snyder@yale.edu		Snyder, Michael/0000-0003-0784-7987; Zhu, Xiaowei/0000-0002-5731-3177				Abadjieva A, 2001, J BIOL CHEM, V276, P42869, DOI 10.1074/jbc.M103732200; Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Bailey TL, 1998, J COMPUT BIOL, V5, P211, DOI 10.1089/cmb.1998.5.211; Bateman JM, 2002, J BIOL CHEM, V277, P47946, DOI 10.1074/jbc.M209071200; Bateman JM, 2002, GENETICS, V161, P1043; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Guillamon JM, 2001, FEMS YEAST RES, V1, P169, DOI 10.1111/j.1567-1364.2001.tb00031.x; HICKE BJ, 1989, EMBO J, V8, P3843, DOI 10.1002/j.1460-2075.1989.tb08562.x; Hirose Y, 2000, GENE DEV, V14, P1415; Horak CE, 2002, P NATL ACAD SCI USA, V99, P2924, DOI 10.1073/pnas.052706999; Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197; Kusari AB, 2004, J CELL BIOL, V164, P267, DOI 10.1083/jcb.200310021; MacIver FH, 1997, CURR GENET, V31, P119, DOI 10.1007/s002940050184; Naithani S, 2003, MOL BIOL CELL, V14, P324, DOI 10.1091/mbc.E02-08-0490; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Pinsky BA, 2003, DEV CELL, V5, P735, DOI 10.1016/S1534-5807(03)00322-8; SCHMIDT WM, 1994, J MOL BIOL, V243, P157, DOI 10.1006/jmbi.1994.1642; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Turner BM, 2003, NAT CELL BIOL, V5, P390, DOI 10.1038/ncb0503-390; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191; [No title captured]	22	179	197	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2004	306	5695					482	484		10.1126/science.1096773	http://dx.doi.org/10.1126/science.1096773			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486299				2022-12-28	WOS:000224626500052
J	Chklovskii, DB; Mel, BW; Svoboda, K				Chklovskii, DB; Mel, BW; Svoboda, K			Cortical rewiring and information storage	NATURE			English	Article							RAT BARREL CORTEX; IN-VIVO; PYRAMIDAL NEURONS; VISUAL-CORTEX; DEPENDENT PLASTICITY; SYNAPTIC PLASTICITY; DENDRITIC SPINES; SILENT SYNAPSES; NMDA RECEPTOR; GLUTAMATERGIC SYNAPSE	Current thinking about long-term memory in the cortex is focused on changes in the strengths of connections between neurons. But ongoing structural plasticity in the adult brain, including synapse formation/elimination and remodelling of axons and dendrites, suggests that memory could also depend on learning-induced changes in the cortical 'wiring diagram'. Given that the cortex is sparsely connected, wiring plasticity could provide a substantial boost in storage capacity, although at a cost of more elaborate biological machinery and slower learning.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA; Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory; University of Southern California; Howard Hughes Medical Institute	Chklovskii, DB (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	mel@usc.edu						ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; Bishop CM., 1995, NEURAL NETWORKS PATT; Braitenberg V, 1991, ANATOMY CORTEX; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; CHANG FLF, 1982, BRAIN RES, V232, P283, DOI 10.1016/0006-8993(82)90274-8; Chklovskii DB, 2004, NEURON, V43, P609, DOI 10.1016/j.neuron.2004.08.012; Chklovskii DB, 2004, ANNU REV NEUROSCI, V27, P369, DOI 10.1146/annurev.neuro.27.070203.144226; CLINE HT, 1991, TRENDS NEUROSCI, V14, P104, DOI 10.1016/0166-2236(91)90071-2; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; Cui ZZ, 2004, NEURON, V41, P781, DOI 10.1016/S0896-6273(04)00072-8; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Faherty CJ, 2003, DEV BRAIN RES, V141, P55, DOI 10.1016/S0165-3806(02)00642-9; Finnerty GT, 1999, NATURE, V400, P367, DOI 10.1038/22553; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; Frankland PW, 2004, SCIENCE, V304, P881, DOI 10.1126/science.1094804; Frankland PW, 2001, NATURE, V411, P309, DOI 10.1038/35077089; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; GREENOUGH WT, 1973, EXP NEUROL, V41, P371, DOI 10.1016/0014-4886(73)90278-1; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; Hebb Donald O., 1949, ORG BEHAV; HEINEN SJ, 1991, EXP BRAIN RES, V83, P670; Hellwig B, 2000, BIOL CYBERN, V82, P111, DOI 10.1007/PL00007964; Heynen AJ, 2003, NAT NEUROSCI, V6, P854, DOI 10.1038/nn1100; Holmgren C, 2003, J PHYSIOL-LONDON, V551, P139, DOI 10.1113/jphysiol.2003.044784; HUBEL DH, 1959, J PHYSIOL-LONDON, V148, P574, DOI 10.1113/jphysiol.1959.sp006308; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Jones EG, 1998, SCIENCE, V282, P1121, DOI 10.1126/science.282.5391.1121; Jontes JD, 2000, NEURON, V27, P11, DOI 10.1016/S0896-6273(00)00003-9; Jourdain P, 2003, J NEUROSCI, V23, P10645; Kalisman N, 2003, BIOL CYBERN, V88, P210, DOI 10.1007/s00422-002-0377-3; KANDEL E, 1999, MEMORY MIND MOL; Knott GW, 2002, NEURON, V34, P265, DOI 10.1016/S0896-6273(02)00663-3; KOCH C, 1982, PHILOS T R SOC B, V298, P227, DOI 10.1098/rstb.1982.0084; Kolb B, 1998, ANNU REV PSYCHOL, V49, P43, DOI 10.1146/annurev.psych.49.1.43; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Levene MJ, 2004, J NEUROPHYSIOL, V91, P1908, DOI 10.1152/jn.01007.2003; Levy W.B., 1985, SYNAPTIC MODIFICATIO, P105; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Lisman J, 2003, NAT REV NEUROSCI, V4, P926, DOI 10.1038/nrn1259; Lisman J, 2001, NATURE, V411, P248, DOI 10.1038/35077185; MacKay D. J. C., 2019, INFORM THEORY INFERE; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Maravall M, 2004, CEREB CORTEX, V14, P655, DOI 10.1093/cercor/bhh026; Markram H, 1997, J PHYSIOL-LONDON, V500, P409, DOI 10.1113/jphysiol.1997.sp022031; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; McCaig CD, 2002, TRENDS NEUROSCI, V25, P354, DOI 10.1016/S0166-2236(02)02174-4; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; MCCLELLAND JL, 1985, J EXP PSYCHOL GEN, V114, P159, DOI 10.1037/0096-3445.114.2.159; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; MEL BW, 1992, ADV NEUR IN, V4, P35; MEL BW, 1993, J NEUROPHYSIOL, V70, P1086, DOI 10.1152/jn.1993.70.3.1086; Mel BW, 2002, NEURON, V34, P175, DOI 10.1016/S0896-6273(02)00669-4; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; Mizrahi A, 2003, NAT NEUROSCI, V6, P1201, DOI 10.1038/nn1133; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; Nimchinsky EA, 2004, J NEUROSCI, V24, P2054, DOI 10.1523/JNEUROSCI.5066-03.2004; Oertner TG, 2002, NAT NEUROSCI, V5, P657, DOI 10.1038/nn867; Oheim M, 2001, J NEUROSCI METH, V111, P29, DOI 10.1016/S0165-0270(01)00438-1; Petersen CCH, 1998, P NATL ACAD SCI USA, V95, P4732, DOI 10.1073/pnas.95.8.4732; Poirazi P, 2001, NEURON, V29, P779, DOI 10.1016/S0896-6273(01)00252-5; Poirazi P, 2003, NEURON, V37, P977, DOI 10.1016/S0896-6273(03)00148-X; Poirazi P, 2000, NEURAL COMPUT, V12, P1189, DOI 10.1162/089976600300015556; Polsky A, 2004, NAT NEUROSCI, V7, P621, DOI 10.1038/nn1253; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; Pratt KG, 2003, NEURON, V39, P269, DOI 10.1016/S0896-6273(03)00422-7; RALL W, 1987, SYNAPTIC FUNCTION, P603; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; Sabatini BL, 2000, NATURE, V408, P589, DOI 10.1038/35046076; SHEPHERD GM, 1987, NEUROSCIENCE, V21, P151, DOI 10.1016/0306-4522(87)90329-0; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Stepanyants A, 2002, NEURON, V34, P275, DOI 10.1016/S0896-6273(02)00652-9; Stepanyants A, 2004, NEURON, V43, P251, DOI 10.1016/j.neuron.2004.06.013; STEPANYANTS AB, 2003, SOC NEUR ANN M NEW O; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; Takahashi T, 2003, SCIENCE, V299, P1585, DOI 10.1126/science.1079886; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Toni N, 1999, NATURE, V402, P421, DOI 10.1038/46574; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; TURNER AM, 1985, BRAIN RES, V329, P195, DOI 10.1016/0006-8993(85)90525-6; VOLKMAR FR, 1972, SCIENCE, V176, P1445, DOI 10.1126/science.176.4042.1445; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222; Xiao MY, 2004, NAT NEUROSCI, V7, P236, DOI 10.1038/nn1196; Ziv NE, 2001, CURR OPIN NEUROBIOL, V11, P536, DOI 10.1016/S0959-4388(00)00246-4	90	497	507	3	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					782	788		10.1038/nature03012	http://dx.doi.org/10.1038/nature03012			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	861RE	15483599				2022-12-28	WOS:000224435500034
J	Destexhe, A; Marder, E				Destexhe, A; Marder, E			Plasticity in single neuron and circuit computations	NATURE			English	Article							INTRINSIC EXCITABILITY; SYNAPTIC PLASTICITY; DENDRITIC I(H); DYNAMIC CLAMP; SPARSE CODE; MODULATION; PRINCIPLES; SYSTEMS; NETWORK; MEMORY	Plasticity in neural circuits can result from alterations in synaptic strength or connectivity, as well as from changes in the excitability of the neurons themselves. To better understand the role of plasticity in the brain, we need to establish how brain circuits work and the kinds of computations that different circuit structures achieve. By linking theoretical and experimental studies, we are beginning to reveal the consequences of plasticity mechanisms for network dynamics, in both simple invertebrate circuits and the complex circuits of mammalian cerebral cortex.	CNRS, Integrat & Computat Neurosci Unit UNIC, F-91198 Gif Sur Yvette, France; Brandeis Univ, Volcani Ctr, Waltham, MA 02454 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Brandeis University	Destexhe, A (corresponding author), CNRS, Integrat & Computat Neurosci Unit UNIC, F-91198 Gif Sur Yvette, France.	Destexhe@iaf.cnrs-gif.fr; marder@brandeis.edu		Destexhe, Alain/0000-0001-7405-0455				Abbott LF, 2000, NAT NEUROSCI, V3, P1178, DOI 10.1038/81453; Abeles M., 1991, CORTICONICS NEURONAL; BARANYI A, 1978, EXP BRAIN RES, V33, P283; BARLOW H, 1989, COMP NEUR S, P54; Barlow H. B., 1985, Models of the visual cortex, P37; Barlow H. B., 1961, SENS COMMUN, P217, DOI DOI 10.7551/MITPRESS/9780262518420.003.0013; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; Bell CC, 1997, NATURE, V387, P278, DOI 10.1038/387278a0; BOWER J, 1994, BOOK GENESIS; Braitenberg V, 1998, CORTEX STAT GEOMETRY; BUONOMANO DV, 1995, SCIENCE, V267, P1028, DOI 10.1126/science.7863330; Cajal S.R., 1909, HISTOLOGIE SYSTEME N, P1909; Chance FS, 2002, NEURON, V35, P773, DOI 10.1016/S0896-6273(02)00820-6; Daoudal G, 2003, LEARN MEMORY, V10, P456, DOI 10.1101/lm.64103; Dayan P, 2001, COMPUTATIONAL NEUROS; Desai NS, 1999, NAT NEUROSCI, V2, P515, DOI 10.1038/9165; Destexhe A, 2003, NAT REV NEUROSCI, V4, P739, DOI 10.1038/nrn1198; Destexhe A, 2003, PHYSIOL REV, V83, P1401, DOI 10.1152/physrev.00012.2003; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; FOLDIAK P, 1990, BIOL CYBERN, V64, P165, DOI 10.1007/BF02331346; FREGNAC Y, 2002, HDB BRAIN THEORY NEU, P515; FRIESEN WO, 1994, NEUROSCI BIOBEHAV R, V18, P547; GETTING PA, 1989, ANNU REV NEUROSCI, V12, P185, DOI 10.1146/annurev.neuro.12.1.185; Golding NL, 2002, NATURE, V418, P326, DOI 10.1038/nature00854; Goldman MS, 2002, J NEUROSCI, V22, P584, DOI 10.1523/JNEUROSCI.22-02-00584.2002; Goldman MS, 2001, J NEUROSCI, V21, P5229, DOI 10.1523/JNEUROSCI.21-14-05229.2001; Golowasch J, 1999, J NEUROSCI, V19, part. no., DOI 10.1523/JNEUROSCI.19-20-j0004.1999; Gupta A, 2000, SCIENCE, V287, P273, DOI 10.1126/science.287.5451.273; Hahnloser RHR, 2002, NATURE, V419, P65, DOI 10.1038/nature00974; Harris-Warrick RM, 1998, ANN NY ACAD SCI, V860, P155, DOI 10.1111/j.1749-6632.1998.tb09046.x; Hebb Donald O., 1949, ORG BEHAV; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; HINTON GE, 1995, SCIENCE, V268, P1158, DOI 10.1126/science.7761831; Ho N, 2000, J NEUROPHYSIOL, V84, P1488, DOI 10.1152/jn.2000.84.3.1488; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; Ito M, 2001, PHYSIOL REV, V81, P1143, DOI 10.1152/physrev.2001.81.3.1143; Johnston D, 1996, ANNU REV NEUROSCI, V19, P165, DOI 10.1146/annurev.ne.19.030196.001121; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Katz PS, 1996, TRENDS NEUROSCI, V19, P54, DOI 10.1016/0166-2236(96)89621-4; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; Koch C., 1998, METHODS NEURONAL MOD, DOI 10.1016/s0898-1221(98)91179-8; Maass W, 2002, NEURAL COMPUT, V14, P2531, DOI 10.1162/089976602760407955; MacLean JN, 2003, NEURON, V37, P109, DOI 10.1016/S0896-6273(02)01104-2; Magee JC, 1999, NAT NEUROSCI, V2, P508, DOI 10.1038/9158; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; Marder E, 1996, PHYSIOL REV, V76, P687, DOI 10.1152/physrev.1996.76.3.687; Marder E, 2002, BIOESSAYS, V24, P1145, DOI 10.1002/bies.10185; Marder E, 2002, NEURAL NETWORKS, V15, P479, DOI 10.1016/S0893-6080(02)00043-6; Marder E, 1996, P NATL ACAD SCI USA, V93, P13481, DOI 10.1073/pnas.93.24.13481; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Martin KC, 2002, NAT REV NEUROSCI, V3, P813, DOI 10.1038/nrn942; MCCORMICK DA, 1989, TRENDS NEUROSCI, V12, P215, DOI 10.1016/0166-2236(89)90125-2; MEL BW, 1994, NEURAL COMPUT, V6, P1031, DOI 10.1162/neco.1994.6.6.1031; Migliore M, 2002, NAT REV NEUROSCI, V3, P362, DOI 10.1038/nrn810; Monier C, 2003, NEURON, V37, P663, DOI 10.1016/S0896-6273(03)00064-3; MOORE GP, 1966, ANNU REV PHYSIOL, V28, P493, DOI 10.1146/annurev.ph.28.030166.002425; Mountcastle V.B., 1979, NEUROSCIENCE 4 STUDY, P21; Nusbaum MP, 2002, NATURE, V417, P343, DOI 10.1038/417343a; Olshausen BA, 1996, NATURE, V381, P607, DOI 10.1038/381607a0; Perez-Orive J, 2002, SCIENCE, V297, P359, DOI 10.1126/science.1070502; PETERS A, 1993, CEREB CORTEX, V3, P49, DOI 10.1093/cercor/3.1.49; Prinz AA, 2004, TRENDS NEUROSCI, V27, P218, DOI 10.1016/j.tins.2004.02.004; RALL W, 1973, BIOPHYS J, V13, P648, DOI 10.1016/S0006-3495(73)86014-X; RALL W, 1969, BIOPHYS J, V9, P1483, DOI 10.1016/S0006-3495(69)86467-2; RALL W, 1967, J NEUROPHYSIOL, V30, P1138, DOI 10.1152/jn.1967.30.5.1138; Rao R. P., 2002, PROBABILISTIC MODELS; Roskies AL, 1999, NEURON, V24, P7, DOI 10.1016/S0896-6273(00)80817-X; Rudolph M, 2001, PHYS REV LETT, V86, P3662, DOI 10.1103/PhysRevLett.86.3662; Rudolph M, 2003, J NEUROSCI, V23, P2466; SCHWINDT PC, 1995, J NEUROPHYSIOL, V74, P2220, DOI 10.1152/jn.1995.74.5.2220; SELVERSTON AI, 1980, BEHAV BRAIN SCI, V3, P535, DOI 10.1017/S0140525X00006580; Shadlen MN, 1998, J NEUROSCI, V18, P3870; Sharp AA, 1996, J NEUROPHYSIOL, V76, P867, DOI 10.1152/jn.1996.76.2.867; SHEPHERD GM, 1987, NEUROSCIENCE, V21, P151, DOI 10.1016/0306-4522(87)90329-0; Shu YS, 2003, J NEUROSCI, V23, P10388; Shulz DE, 2000, NATURE, V403, P549, DOI 10.1038/35000586; Silberberg G, 2002, TRENDS NEUROSCI, V25, P227, DOI 10.1016/S0166-2236(02)02151-3; Sjostrom PJ, 2002, CURR OPIN NEUROBIOL, V12, P305, DOI 10.1016/S0959-4388(02)00325-2; SOFTKY W, 1994, NEUROSCIENCE, V58, P13, DOI 10.1016/0306-4522(94)90154-6; SRINIVASAN MV, 1982, PROC R SOC SER B-BIO, V216, P427, DOI 10.1098/rspb.1982.0085; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; Steriade M., 1997, THALAMUS; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Stuart G., 2000, DENDRITES; SZENTAGOTHAI J, 1983, REV PHYSIOL BIOCH P, V98, P11, DOI 10.1007/BFb0033866; Thomson AM, 2000, TRENDS NEUROSCI, V23, P305, DOI 10.1016/S0166-2236(00)01580-0; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Van Vreeswijk C, 1994, J Comput Neurosci, V1, P313; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; WANG XJ, 1992, NEURAL COMPUT, V4, P84, DOI 10.1162/neco.1992.4.1.84; Wang XJ, 2003, J NEUROPHYSIOL, V89, P3279, DOI 10.1152/jn.00242.2003; Wei DS, 2001, SCIENCE, V293, P2272, DOI 10.1126/science.1061198; White JA, 1998, J COMPUT NEUROSCI, V5, P5, DOI 10.1023/A:1008841325921; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; Williams SR, 2000, J NEUROPHYSIOL, V83, P3177, DOI 10.1152/jn.2000.83.5.3177; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4; Zhang W, 2003, NAT REV NEUROSCI, V4, P885, DOI 10.1038/nrn1248	100	187	191	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010					789	795		10.1038/nature03011	http://dx.doi.org/10.1038/nature03011			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483600				2022-12-28	WOS:000224435500035
J	Muni, NI; Gross, TP				Muni, NI; Gross, TP			Problems with drug-eluting coronary stents - The FDA perspective	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Muni, NI (corresponding author), US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA.							*FOOD DRUG ADM, 2004, TAXUS EXPR 2 PACL EL; *FOOD DRUG ADM, 2003, CYPHER SIR EL COR ST	2	40	46	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1593	1595		10.1056/NEJMp048262	http://dx.doi.org/10.1056/NEJMp048262			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483274				2022-12-28	WOS:000224427300002
J	Wang, J; Zhang, JG; Zheng, HK; Li, J; Liu, DY; Li, H; Samudrala, R; Yu, J; Wong, GKS				Wang, J; Zhang, JG; Zheng, HK; Li, J; Liu, DY; Li, H; Samudrala, R; Yu, J; Wong, GKS			Mouse transcriptome: Neutral evolution of 'non-coding' complementary DNAs	NATURE			English	Editorial Material							DATABASE; GENES; RNAS		Zhejiang Univ, Hangzhou Genom Inst, James D Watson Inst Genome Sci, Hangzhou 310007, Peoples R China; Chinese Acad Sci, Beijing Inst Genom, Beijing 101300, Peoples R China; Univ Washington, Dept Microbiol, Computat Genom Grp, Seattle, WA 98195 USA; Univ Washington, Genome Ctr, Dept Med, Seattle, WA 98195 USA	Zhejiang University; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Wang, J (corresponding author), Zhejiang Univ, Hangzhou Genom Inst, James D Watson Inst Genome Sci, Hangzhou 310007, Peoples R China.	gksw@genomics.org.cn	WONG, Gane Ka-Shu/G-5784-2013; 郑, 征/C-8514-2011; Li, Heng/D-9344-2011	WONG, Gane Ka-Shu/0000-0001-6108-5560; Li, Heng/0000-0003-4874-2874; Zhang, Jianguo/0000-0003-0723-1701; Li, Jun/0000-0001-7218-429X				Bono H, 2003, GENOME RES, V13, P1318, DOI 10.1101/gr.1075103; Eddy SR, 2002, CELL, V109, P137, DOI 10.1016/S0092-8674(02)00727-4; Griffiths-Jones S, 2003, NUCLEIC ACIDS RES, V31, P439, DOI 10.1093/nar/gkg006; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Nesterova TB, 2001, GENOME RES, V11, P833, DOI 10.1101/gr.174901; Numata K, 2003, GENOME RES, V13, P1301, DOI 10.1101/gr.1011603; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; Szymanski M, 2003, NUCLEIC ACIDS RES, V31, P429, DOI 10.1093/nar/gkg124; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	10	121	126	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2004	431	7010								10.1038/nature03016	http://dx.doi.org/10.1038/nature03016			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15495343				2022-12-28	WOS:000224435500028
J	Corey, DP; Garcia-Anoveros, J; Holt, JR; Kwan, KY; Lin, SY; Vollrath, MA; Amalfitano, A; Cheung, ELM; Derfler, BH; Duggan, A; Geleoc, GSG; Gray, PA; Hoffman, MP; Rehm, HL; Tamasauskas, D; Zhang, DS				Corey, DP; Garcia-Anoveros, J; Holt, JR; Kwan, KY; Lin, SY; Vollrath, MA; Amalfitano, A; Cheung, ELM; Derfler, BH; Duggan, A; Geleoc, GSG; Gray, PA; Hoffman, MP; Rehm, HL; Tamasauskas, D; Zhang, DS			TRPA1 is a candidate for the mechanosensitive transduction channel of vertebrate hair cells	NATURE			English	Article							ION CHANNELS; INNER-EAR; MECHANOELECTRICAL TRANSDUCTION; MECHANOTRANSDUCER CHANNEL; TIP LINKS; ADAPTATION; MUTATIONS; GENE; CADHERIN-23; ADENOVIRUS	Mechanical deflection of the sensory hair bundles of receptor cells in the inner ear causes ion channels located at the tips of the bundle to open, thereby initiating the perception of sound. Although some protein constituents of the transduction apparatus are known, the mechanically gated transduction channels have not been identified in higher vertebrates. Here, we investigate TRP ( transient receptor potential) ion channels as candidates and find one, TRPA1 ( also known as ANKTM1), that meets criteria for the transduction channel. The appearance of TRPA1 messenger RNA expression in hair cell epithelia coincides developmentally with the onset of mechanosensitivity. Antibodies to TRPA1 label hair bundles, especially at their tips, and tip labelling disappears when the transduction apparatus is chemically disrupted. Inhibition of TRPA1 protein expression in zebrafish and mouse inner ears inhibits receptor cell function, as assessed with electrical recording and with accumulation of a channel-permeant fluorescent dye. TRPA1 is probably a component of the transduction channel itself.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Northwestern Univ, Inst Neurosci, Dept Anesthesiol, Chicago, IL 60611 USA; Northwestern Univ, Inst Neurosci, Dept Neurol, Chicago, IL 60611 USA; Northwestern Univ, Inst Neurosci, Dept Physiol, Chicago, IL 60611 USA; Univ Virginia, Sch Med, Dept Neurosci, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Otolaryngol, Charlottesville, VA 22908 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Partners Genome Ctr, Mol Med Lab, Cambridge, MA 02139 USA; Duke Univ, Med Ctr, Dept Pediat, Div Med Genet, Durham, NC 27705 USA; NIDCR, Matrix & Morphogenesis Unit, CDBRB, NIH, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Northwestern University; Northwestern University; Northwestern University; University of Virginia; University of Virginia; Massachusetts Institute of Technology (MIT); Harvard University; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Corey, DP (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.	dcorey@hms.harvard.edu		Kwan, Kelvin/0000-0002-8617-5543; Garcia-Anoveros, Jaime/0000-0001-6561-9048; Rehm, Heidi L./0000-0002-6025-0015; Corey, David/0000-0003-4497-6016	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000707] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ASSAD JA, 1991, NEURON, V7, P985, DOI 10.1016/0896-6273(91)90343-X; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bermingham NA, 1999, SCIENCE, V284, P1837, DOI 10.1126/science.284.5421.1837; Clapham DE, 2003, PHARMACOL REV, V55, P591, DOI 10.1124/pr.55.4.6; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; COREY DP, 1983, J NEUROSCI, V3, P962; COREY DP, 1979, NATURE, V281, P675, DOI 10.1038/281675a0; Corey DP, 2004, NATURE, V428, P901, DOI 10.1038/428901a; Corey DP, 2003, NEURON, V39, P585, DOI 10.1016/S0896-6273(03)00505-1; COREY DP, 1979, BIOPHYS J, V26, P499, DOI 10.1016/S0006-3495(79)85267-4; Denman-Johnson K, 1999, J NEUROCYTOL, V28, P821, DOI 10.1023/A:1007061819934; Di Palma F, 2002, P NATL ACAD SCI USA, V99, P14994, DOI 10.1073/pnas.222425399; Duggan A, 2000, CURR BIOL, V10, pR384, DOI 10.1016/S0960-9822(00)00478-4; Farris HE, 2004, J PHYSIOL-LONDON, V558, P769, DOI 10.1113/jphysiol.2004.061267; Gale JE, 2001, J NEUROSCI, V21, P7013, DOI 10.1523/JNEUROSCI.21-18-07013.2001; Garcia-Anoveros J, 1998, NEURON, V20, P1231, DOI 10.1016/S0896-6273(00)80503-6; Geleoc GSG, 2003, NAT NEUROSCI, V6, P1019, DOI 10.1038/nn1120; Gillespie PG, 1997, NEURON, V19, P955, DOI 10.1016/S0896-6273(00)80387-6; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hodges BL, 2000, J GENE MED, V2, P250, DOI 10.1002/1521-2254(200007/08)2:4<250::AID-JGM113>3.0.CO;2-3; Holt JR, 1999, J NEUROPHYSIOL, V81, P1881, DOI 10.1152/jn.1999.81.4.1881; Holt JR, 2002, AUDIOL NEURO-OTOL, V7, P157, DOI 10.1159/000058302; Howard J, 2004, CURR BIOL, V14, pR224, DOI 10.1016/j.cub.2004.02.050; HOWARD J, 1988, NEURON, V1, P189, DOI 10.1016/0896-6273(88)90139-0; HUDSPETH AJ, 1977, P NATL ACAD SCI USA, V74, P2407, DOI 10.1073/pnas.74.6.2407; Hudspeth AJ, 2000, P NATL ACAD SCI USA, V97, P11765, DOI 10.1073/pnas.97.22.11765; HUDSPETH AJ, 1982, J NEUROSCI, V2, P1; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Kachar B, 2000, P NATL ACAD SCI USA, V97, P13336, DOI 10.1073/pnas.97.24.13336; Luebke AE, 2001, GENE THER, V8, P789, DOI 10.1038/sj.gt.3301445; Meyers JR, 2003, J NEUROSCI, V23, P4054; Michels KB, 2002, ANN EPIDEMIOL, V12, P21, DOI 10.1016/S1047-2797(01)00238-1; Reiners J, 2003, INVEST OPHTH VIS SCI, V44, P5006, DOI 10.1167/iovs.03-0483; Ricci AJ, 1998, J NEUROSCI, V18, P8261; Sidi S, 2003, SCIENCE, V301, P96, DOI 10.1126/science.1084370; Siemens J, 2004, NATURE, V428, P950, DOI 10.1038/nature02483; Sollner C, 2004, NATURE, V428, P955, DOI 10.1038/nature02484; Starr CJ, 2004, P NATL ACAD SCI USA, V101, P2572, DOI 10.1073/pnas.0308474100; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; SUKHAREV S, 2004, SCI STKE, pRE4; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229	42	497	559	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	2004	432	7018					723	730		10.1038/nature03066	http://dx.doi.org/10.1038/nature03066			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877UE	15483558				2022-12-28	WOS:000225597200040
J	Alberts, B				Alberts, B			A wake-up call	NATURE			English	Editorial Material									Natl Acad Sci, Washington, DC 20001 USA	National Academies of Sciences, Engineering & Medicine	Alberts, B (corresponding author), Natl Acad Sci, 500 5th St NW, Washington, DC 20001 USA.								0	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	2004	431	7012					1041	1041		10.1038/4311041a	http://dx.doi.org/10.1038/4311041a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15510128	Bronze			2022-12-28	WOS:000224730800021
J	Shachaf, CM; Kopelman, AM; Arvanitis, C; Karlsson, A; Beer, S; Mandl, S; Bachmann, MH; Borowsky, AD; Ruebner, B; Cardiff, RD; Yang, QW; Bishop, JM; Contag, CH; Felsher, DW				Shachaf, CM; Kopelman, AM; Arvanitis, C; Karlsson, A; Beer, S; Mandl, S; Bachmann, MH; Borowsky, AD; Ruebner, B; Cardiff, RD; Yang, QW; Bishop, JM; Contag, CH; Felsher, DW			MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer	NATURE			English	Article							LIVER-REGENERATION; STEM-CELLS; GROWTH; TUMORIGENESIS; ONCOGENES; NEOPLASIA	Hepatocellular carcinoma is generally refractory to clinical treatment(1). Here, we report that inactivation of the MYC oncogene is sufficient to induce sustained regression of invasive liver cancers. MYC inactivation resulted en masse in tumour cells differentiating into hepatocytes and biliary cells forming bile duct structures, and this was associated with rapid loss of expression of the tumour marker alpha-fetoprotein, the increase in expression of liver cell markers cytokeratin 8 and carcinoembryonic antigen, and in some cells the liver stem cell marker cytokeratin 19. Using in vivo bioluminescence imaging we found that many of these tumour cells remained dormant as long as MYC remain inactivated; however, MYC reactivation immediately restored their neoplastic features. Using array comparative genomic hybridization we confirmed that these dormant liver cells and the restored tumour retained the identical molecular signature and hence were clonally derived from the tumour cells. Our results show how oncogene inactivation may reverse tumorigenesis in the most clinically difficult cancers. Oncogene inactivation uncovers the pluripotent capacity of tumours to differentiate into normal cellular lineages and tissue structures, while retaining their latent potential to become cancerous, and hence existing in a state of tumour dormancy.	Stanford Univ, Dept Med, Div Med Oncol, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; Univ Calif Davis, Med Ctr, Dept Pathol, Davis, CA 95616 USA; Univ Calif San Francisco, GW Hooper Fdn, San Francisco, CA 94143 USA	Stanford University; Stanford University; Stanford University; University of California System; University of California Davis; University of California System; University of California San Francisco	Felsher, DW (corresponding author), Stanford Univ, Dept Med, Div Med Oncol, Stanford, CA 94305 USA.	dfelsher@stanford.edu	Borowsky, Alexander D/S-5404-2017; Bachmann, Michael Hubertus/N-9339-2016; Arvanitis, Constadina/C-5975-2013	Bachmann, Michael Hubertus/0000-0002-0204-3720; Arvanitis, Constadina/0000-0002-6311-0974; Contag, Christopher/0000-0002-1011-8278				Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Coleman WB, 2003, CURR MOL MED, V3, P573, DOI 10.2174/1566524033479546; Demicheli R, 2001, SEMIN CANCER BIOL, V11, P297, DOI 10.1006/scbi.2001.0385; Edinger M, 2003, BLOOD, V101, P640, DOI 10.1182/blood-2002-06-1751; Fausto N, 1990, CURR OPIN CELL BIOL, V2, P1036, DOI 10.1016/0955-0674(90)90153-6; Fausto N, 2003, MECH DEVELOP, V120, P117, DOI 10.1016/S0925-4773(02)00338-6; Felsher DW, 2003, NAT REV CANCER, V3, P375, DOI 10.1038/nrc1070; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Hardy J, 2001, EXP HEMATOL, V29, P1353, DOI 10.1016/S0301-472X(01)00756-1; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEFFERT KS, 1984, CELL CULTURE METHODS, P43; Lotem J, 2002, SEMIN CANCER BIOL, V12, P339, DOI 10.1016/S1044-579X(02)00054-8; MURAKAMI H, 1993, CANCER RES, V53, P1719; Naumov GN, 2001, SEMIN CANCER BIOL, V11, P271, DOI 10.1006/scbi.2001.0382; Nowak AK, 2004, EUR J CANCER, V40, P1474, DOI 10.1016/j.ejca.2004.02.027; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Riethmuller G, 2001, SEMIN CANCER BIOL, V11, P307, DOI 10.1006/scbi.2001.0386; SANDGREN EP, 1989, ONCOGENE, V4, P715; Simile MM, 2004, CARCINOGENESIS, V25, P333, DOI 10.1093/carcin/bgh014; Thorgeirsson SS, 1996, FASEB J, V10, P1249, DOI 10.1096/fasebj.10.11.8836038; UHR JW, 1991, CANCER RES, V51, pS5045; Uhr JW, 1997, NAT MED, V3, P505, DOI 10.1038/nm0597-505; Venook A P, 2000, Curr Treat Options Oncol, V1, P407, DOI 10.1007/s11864-000-0068-z; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wu YF, 2002, ONCOGENE, V21, P1518, DOI 10.1038/sj.onc.1205208	30	673	712	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1112	1117		10.1038/nature03043	http://dx.doi.org/10.1038/nature03043			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15475948				2022-12-28	WOS:000224730800044
J	March, JS; Foa, E; Gammon, P; Chrisman, A; Curry, J; Fitzgerald, D; Sullivan, K; Franklin, M; Huppert, J; Rynn, M; Zhao, N; Zoellner, L; Leonard, H; Garcia, A; Freeman, J; Tu, X				March, JS; Foa, E; Gammon, P; Chrisman, A; Curry, J; Fitzgerald, D; Sullivan, K; Franklin, M; Huppert, J; Rynn, M; Zhao, N; Zoellner, L; Leonard, H; Garcia, A; Freeman, J; Tu, X		POTS Team	Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder - The Pediatric OCD Treatment Study (POTS) randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTICENTER TRIAL; CLINICAL-TRIALS; DISSEMINATION; METAANALYSIS; INHIBITORS; CHILDHOOD	Context The empirical literature on treatment of obsessive-compulsive disorder (OCD) in children and adolescents supports the efficacy of short-term OCD-specific cognitive-behavior therapy (CBT) or medical management with selective serotonin reuptake inhibitors. However, little is known about their relative and combined efficacy. Objective To evaluate the efficacy of CBT alone and medical management with the selective serotonin reuptake inhibitor sertraline alone, or CBT and sertraline combined, as initial treatment for children and adolescents with OCD. Design, Setting, and Participants The Pediatric OCD Treatment Study, a balanced, masked randomized controlled trial conducted in 3 academic centers in the United States and enrolling a volunteer outpatient sample of 112 patients aged 7 through 17 years with a primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of OCD and a Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) score of 16 or higher. Patients were recruited between September 1997 and December 2002. Interventions Participants were randomly assigned to receive CBT alone, sertraline alone, combined CBT and sertraline, or pill placebo for 12 weeks. Main Outcome Measures Change in CY-BOCS score over 12 weeks as rated by an independent evaluator masked to treatment status; rate of clinical remission defined as a CY-BOCS score less than or equal to 10. Results Ninety-seven of 112 patients (87%) completed the full 12 weeks of treatment. Intent-to-treat random regression analyses indicated a statistically significant advantage for CBT alone (P=.003), sertraline alone (P=.007), and combined treatment (P=.001) compared with placebo. Combined treatment also proved superior to CBT alone (P=.008) and to sertraline alone (P=.006), which did not differ from each other. Site differences emerged for CBT and sertraline but not for combined treatment, suggesting that combined treatment is less susceptible to setting-specific variations. The rate of clinical remission for combined treatment was 53.6% (95% confidence interval [CI], 36%-70%); for CBT alone, 39.3% (95% Cl, 24%-58%); for sertraline alone, 21.4% (95% Cl, 10%-40%); and for placebo, 3.6% (95% CI, 0%-19%). The remission rate for combined treatment did not differ from that for CBT alone (P=.42) but did differ from sertraline alone (P=.03) and from placebo (P<.001). CBT alone did not differ from sertraline alone (P=.24) but did differ from placebo (P=.002), whereas sertraline alone did not (P=.10). The 3 active treatments proved acceptable and well tolerated, with no evidence of treatment-emergent harm to self or to others. Conclusion Children and adolescents with OCD should begin treatment with the combination of CBT plus a selective serotonin reuptake inhibitor or CBT alone.	Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA; Univ Penn, Philadelphia, PA 19104 USA; Brown Univ, Providence, RI 02912 USA	Duke University; University of Pennsylvania; Brown University	March, JS (corresponding author), Duke Univ, Med Ctr, Dept Psychiat, DUMC Box 3527, Durham, NC 27710 USA.	jsmarch@acpub.duke.edu			NIMH NIH HHS [R01 MH055121, R01 MH055126, 1 R01 MH55121, 1 R01 MH55126] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH055121, R01MH055126] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Barlow DH, 1999, BEHAV RES THER, V37, pS147, DOI 10.1016/S0005-7967(99)00054-6; Berger VW, 1999, CONTROL CLIN TRIALS, V20, P319, DOI 10.1016/S0197-2456(99)00014-8; de Haan E, 1992, Acta Paedopsychiatr, V55, P93; DEVEAUGHGEISS J, 1992, J AM ACAD CHILD PSY, V31, P45, DOI 10.1097/00004583-199201000-00008; FLAMENT MF, 1988, J AM ACAD CHILD PSY, V27, P764, DOI 10.1097/00004583-198811000-00018; Franklin M, 2003, J CHILD ADOL PSYCHOP, V13, pS39, DOI 10.1089/104454603322126331; Franklin M.E., 2002, CLIN BEHAV THERAPY A, P276; Franklin ME, 2000, J CONSULT CLIN PSYCH, V68, P594, DOI 10.1037//0022-006X.68.4.594; Franklin ME, 1998, J AM ACAD CHILD PSY, V37, P412, DOI 10.1097/00004583-199804000-00019; Geller D, 2000, DEPRESS ANXIETY, V11, P163, DOI 10.1002/1520-6394(2000)11:4<163::AID-DA3>3.3.CO;2-V; Geller DA, 2003, AM J PSYCHIAT, V160, P1919, DOI 10.1176/appi.ajp.160.11.1919; Geller DA, 2001, J AM ACAD CHILD PSY, V40, P773, DOI 10.1097/00004583-200107000-00011; GOODMAN WK, 1992, PSYCHIAT CLIN N AM, V15, P861; GREIST JH, 1995, ARCH GEN PSYCHIAT, V52, P53; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Kraemer HC, 2002, ARCH GEN PSYCHIAT, V59, P877, DOI 10.1001/archpsyc.59.10.877; March JS, 1998, JAMA-J AM MED ASSOC, V280, P1752, DOI 10.1001/jama.280.20.1752; MARCH JS, 1994, J AM ACAD CHILD PSY, V33, P333, DOI 10.1097/00004583-199403000-00006; March JS, 1998, OCD CHILDREN ADOLESC; Marchal IS, 1997, VET IMMUNOL IMMUNOP, V58, P1; Pocock SJ., 2013, CLIN TRIALS PRACTICA; Riddle MA, 2001, J AM ACAD CHILD PSY, V40, P222, DOI 10.1097/00004583-200102000-00017; Rosenthal R., 2000, CONTRASTS EFFECT SIZ; Sackett DL, 2000, EVIDENCE BASED MED; Scahill L, 1997, J AM ACAD CHILD PSY, V36, P844, DOI 10.1097/00004583-199706000-00023; Schoenwald SK, 2001, PSYCHIATR SERV, V52, P1190, DOI 10.1176/appi.ps.52.9.1190; SILVERMAN WK, 1996, ANXIETY DISORDERS IN; Vitiello B, 2004, NEW ENGL J MED, V350, P1489, DOI 10.1056/NEJMp038248; Wechsler D., 1991, WISC 3 WECHSLER INTE; Weinfurt K. P, 2000, READING UNDERSTANDIN, P317; Whittington CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1; 1998, J AM ACAD CHILD  S10, V37, P27	33	558	560	1	116	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2004	292	16					1969	1976						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865DO	15507582				2022-12-28	WOS:000224682900021
J	Wennberg, DE; Lucas, FL; Siewers, AE; Kellett, MA; Malenka, DJ				Wennberg, DE; Lucas, FL; Siewers, AE; Kellett, MA; Malenka, DJ			Outcomes of percutaneous coronary interventions performed at centers without and with onsite coronary artery bypass graft surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; SITE CARDIAC-SURGERY; GLYCOPROTEIN IIB/IIIA RECEPTOR; ON-SITE; PRIMARY ANGIOPLASTY; THROMBOLYTIC THERAPY; BALLOON ANGIOPLASTY; SURGICAL BACKUP; UNITED-KINGDOM; EXPERIENCE	Context An ongoing debate focuses on whether institutions should perform percutaneous coronary interventions (PCIs) without an onsite coronary artery bypass graft (CABG) surgery program. Objective To compare patient outcomes following PCI at US institutions performing this procedure without and with onsite cardiac surgery. Design, Setting, and Patients Medicare hospital (part A) data were used to identify PCIs performed on fee-for-service Medicare enrollees (n=625854) aged at least 65 years at acute care facilities between January 1, 1999, and December 1, 2001. Hospitals without and with onsite cardiac surgery were identified based on the presence of claims for CABG surgery. Patients were characterized as undergoing primary/rescue PCI, defined as an emergency procedure performed on the same day of admission for an acute myocardial infarction (MI), vs all other PCIs. Main Outcome Measures Post-PCI CABG surgery and combined in-hospital and 30-day mortality. Results A total of 178 hospitals performed PCIs without onsite cardiac surgery and 943 hospitals performed PCIs with onsite cardiac surgery. Patients undergoing PCIs in hospitals without onsite cardiac surgery were similar to those with onsite cardiac surgery with respect to age, sex, race, and measurable comorbidities; however, patients undergoing PCIs in hospitals without onsite cardiac surgery were more likely to have a primary/rescue PCI (22.0% vs 5.6%, P<.001). Patients undergoing PCIs in hospitals without cardiac surgery were more likely to die (6.0% vs 3.3%; adjusted odds ratio [OR], 1.29; 95% confidence interval [CI], 1.14-1.47; P<.001). After accounting for baseline differences, mortality for patients with primary/rescue PCI was similar in institutions without and with cardiac surgery (adjusted OR, 0.93; 95% Cl, 0.80-1.08; P=34). However, for the larger non-primary/rescue PCI population, mortality was higher in hospitals without onsite cardiac surgery (adjusted OR, 1.38; 95% Cl, 1.14-1.67; P=.001). This increase in mortality was primarily confined to hospitals performing 50 or less Medicare PCIs per year. Conclusions Percutaneous coronary interventions in hospitals without onsite cardiac surgery are often performed for reasons other than immediate treatment of an MI and are associated with a higher risk of adverse outcomes. Policies aimed at increasing access to primary/rescue PCI through promoting PCI in hospitals without cardiac surgery may inadvertently lead to an overall increase in mortality related to PCI.	Ctr Outcomes Res & Evaluat, Portland, ME 04101 USA; Maine Med Ctr, Dept Med, Portland, ME 04102 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Ctr Evaluat Clin Sci, Hanover, NH 03756 USA; Dartmouth Hitchcock Med Ctr, Dept Cardiol, Lebanon, NH 03766 USA	Maine Medical Center; Dartmouth College; Dartmouth College	Wennberg, DE (corresponding author), Ctr Outcomes Res & Evaluat, 139 Forest Ave, Portland, ME 04101 USA.	dwennberg@healthdialog.com						*AM HEART ASS, 2002, HEART DIS STROK STAT; Andersen HR, 2003, NEW ENGL J MED, V349, P733, DOI 10.1056/NEJMoa025142; [Anonymous], 1999, INT CLASS DIS; Aversano T, 2002, JAMA-J AM MED ASSOC, V287, P1943, DOI 10.1001/jama.287.15.1943; Brush JE, 1996, J INVASIVE CARDIOL, V8, P91; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Cannon CP, 2002, JAMA-J AM MED ASSOC, V287, P1987, DOI 10.1001/jama.287.15.1987; DELLAVALLE A, 1995, CORONARY ARTERY DIS, V6, P513; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Fisher ES, 2003, PERSPECT BIOL MED, V46, P69, DOI 10.1353/pbm.2003.0004; GEORGE J, 1998, PHILADELPHIA BU 0227; Gray HH, 2000, HEART, V83, P224; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; IANNONE LA, 1993, TEX HEART I J, V20, P99; Jollis JG, 1997, CIRCULATION, V95, P2485, DOI 10.1161/01.CIR.95.11.2485; KIMMEL SE, 1995, JAMA-J AM MED ASSOC, V274, P1137, DOI 10.1001/jama.274.14.1137; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; KLINKE WP, 1992, AM J CARDIOL, V70, P1520, DOI 10.1016/0002-9149(92)90451-4; Loubeyre C, 1999, CATHETER CARDIO INTE, V47, P441, DOI 10.1002/(SICI)1522-726X(199908)47:4<441::AID-CCD12>3.0.CO;2-S; Malenka DJ, 2002, J AM COLL CARDIOL, V40, P2092, DOI 10.1016/S0735-1097(02)02605-0; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; RAMSDALE DR, 1995, BRIT HEART J, V73, P414; RICHARDSON SG, 1990, BRIT MED J, V300, P355, DOI 10.1136/bmj.300.6721.355; Ritchie JL, 1999, AM HEART J, V138, P437, DOI 10.1016/S0002-8703(99)70144-4; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Schomig A, 2000, NEW ENGL J MED, V343, P385, DOI 10.1056/NEJM200008103430602; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Seshadri N, 2002, CIRCULATION, V106, P2346, DOI 10.1161/01.CIR.0000036595.92742.69; Smith SC, 2001, J AM COLL CARDIOL, V37, P2215, DOI 10.1016/S0735-1097(01)01344-4; Smyth DW, 1997, J INVASIVE CARDIOL, V9, P324; SOWTON E, 1991, BRIT HEART J, V66, P325; Ting HH, 2003, AM HEART J, V145, P278, DOI 10.1067/mhj.2003.61; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Vogt A, 1999, Semin Interv Cardiol, V4, P43; WEAVER WD, 1993, CIRCULATION, V88, P2067, DOI 10.1161/01.CIR.88.5.2067; Wennberg D, 1997, J Health Serv Res Policy, V2, P75; Wennberg D.E, 1999, DARTMOUTH ATLAS CARD; Wennberg DE, 1996, JAMA-J AM MED ASSOC, V275, P1161, DOI 10.1001/jama.275.15.1161; Wharton TP, 2004, J AM COLL CARDIOL, V43, P1943, DOI 10.1016/j.jacc.2004.03.013; Wharton TP, 1999, J AM COLL CARDIOL, V33, P1257, DOI 10.1016/S0735-1097(99)00009-1; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	41	87	88	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2004	292	16					1961	1968		10.1001/jama.292.16.1961	http://dx.doi.org/10.1001/jama.292.16.1961			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865DO	15507581	Bronze			2022-12-28	WOS:000224682900020
J	Burwinkel, M; Holtkamp, N; Baier, M				Burwinkel, M; Holtkamp, N; Baier, M			Biology of infectious proteins: lessons from yeast prions	LANCET			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; GENETIC-VARIATION; MECHANISM		Robert Koch Inst, Project Neurodegenerat Dis, D-13353 Berlin, Germany; Humboldt Univ, Inst Neuropathol, D-13353 Berlin, Germany	Robert Koch Institute; Humboldt University of Berlin	Baier, M (corresponding author), Robert Koch Inst, Project Neurodegenerat Dis, D-13353 Berlin, Germany.	baierm@rki.de		Burwinkel, Michael/0000-0003-4811-7323				Bailey CH, 2004, NEURON, V44, P49, DOI 10.1016/j.neuron.2004.09.017; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Eaglestone SS, 1999, EMBO J, V18, P1974, DOI 10.1093/emboj/18.7.1974; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Oidtmann B, 2003, FEBS LETT, V538, P96, DOI 10.1016/S0014-5793(03)00149-2; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; True HL, 2000, NATURE, V407, P477, DOI 10.1038/35035005; True HL, 2004, NATURE, V431, P184, DOI 10.1038/nature02885; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	12	6	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1471	1472		10.1016/S0140-6736(04)17290-5	http://dx.doi.org/10.1016/S0140-6736(04)17290-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500875				2022-12-28	WOS:000224645500008
J	Kong, M; Fox, CJ; Mu, J; Solt, L; Xu, A; Cinalli, RM; Birnbaum, MJ; Lindsten, T; Thompson, CB				Kong, M; Fox, CJ; Mu, J; Solt, L; Xu, A; Cinalli, RM; Birnbaum, MJ; Lindsten, T; Thompson, CB			The PP2A-associated protein alpha 4 is an essential inhibitor of apoptosis	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; PHOSPHATASE 2A; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; OPITZ-SYNDROME; BINDING; GENE; ASSOCIATION; SURVIVAL; TAP42	Despite evidence that protein kinases are regulators of apoptosis, a specific role for phosphatases in regulating cell survival has not been established. Here we show that alpha4, a noncatalytic subunit of protein phosphatase 2A (PP2A), is required to repress apoptosis in murine cells. alpha4 is a nonredundant regulator of the dephosphorylation of the transcription factors c-jun and p53. As a result of alpha4 deletion, multiple proapoptotic genes were transcribed. Either inhibition of new protein synthesis or Bcl-x(L) overexpression Suppressed apoptosis initiated by alpha4 deletion. Thus, mammalian cell viability depends on repression of transcription-initiated apoptosis mediated by a component of PP2A.	Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Thompson, CB (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu		Mu, James/0000-0001-8081-2401; Birnbaum, Morris/0000-0001-9972-8680				Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Chuang E, 2000, IMMUNITY, V13, P313, DOI 10.1016/S1074-7613(00)00031-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Duvel K, 2003, MOL CELL, V11, P1467, DOI 10.1016/S1097-2765(03)00228-4; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Everett AD, 2002, DEV DYNAM, V224, P461, DOI 10.1002/dvdy.10125; Hua DR, 2003, EUR J IMMUNOL, V33, P1899, DOI 10.1002/eji.200323720; INUI S, 1995, J IMMUNOL, V154, P2714; Inui S, 1998, BLOOD, V92, P539, DOI 10.1182/blood.V92.2.539.414k23_539_546; Inui S, 2002, INT IMMUNOL, V14, P177, DOI 10.1093/intimm/14.2.177; LINDSTEN T, UNPUB; Liu J, 2001, P NATL ACAD SCI USA, V98, P6650, DOI 10.1073/pnas.111154698; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rohlmann A, 1996, NAT BIOTECHNOL, V14, P1562, DOI 10.1038/nbt1196-1562; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	23	131	138	4	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					695	698		10.1126/science.1100537	http://dx.doi.org/10.1126/science.1100537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499020				2022-12-28	WOS:000224756700054
J	Bird, SM				Bird, SM			Prescribing sentence: time for evidence-based justice	LANCET			English	Editorial Material							MANDATORY DRUGS TESTS; PRISONS; SCOTLAND; DEATHS; NEED		MRC, Biostat Unit, Cambridge CB2 2SR, England; Univ Strathclyde, Dept Stat & Modeling Sci, Glasgow, Lanark, Scotland	MRC Biostatistics Unit; University of Strathclyde	Bird, SM (corresponding author), MRC, Biostat Unit, Cambridge CB2 2SR, England.	Sheila.bird@mrc-bsu.cam.ac.uk						Bird SM, 2003, DRUG-EDUC PREV POLIC, V10, P396, DOI 10.1080/0968763031000111626-131; Bird SM, 2003, LANCET, V362, P941, DOI 10.1016/S0140-6736(03)14362-0; Bird SM, 2003, ADDICTION, V98, P185, DOI 10.1046/j.1360-0443.2003.00264.x; BIRD SM, 2004, HERALD          0217, P15; BIRD SM, 2004, HERALD GLASGOW  0226, P19; Blunkett D., 2004, REDUCING CRIME CHANG; Bourn J., 2004, DRUG TREATMENT TESTI; Carter P., 2004, MANAGING OFFENDERS R; Committee on Data and Research for Policy on Illegal Drugs, 2001, INF AM POL ILL DRUGS; ELERY S, 2002, DRUG TREATMENT TESTI; Fitz-Gibbon C, 2004, J R STAT SOC A STAT, V167, P1, DOI 10.1046/j.0964-1998.2003.02047.x; GOGGINS P, 2004, POLICY REV       MAR, P10; Gore SM, 1998, BRIT MED J, V316, P1256, DOI 10.1136/bmj.316.7140.1256; Gore SM, 1996, BRIT MED J, V312, P1411; Gore SM, 1996, LANCET, V348, P1124, DOI 10.1016/S0140-6736(96)06318-0; GORE SM, 1995, BRIT MED J, V310, P595, DOI 10.1136/bmj.310.6979.595; *HOM OFF, 2004, ON CHARG DRUG TEST E; Hough M, 2003, IMPACT DRUG TREATMEN; KAY J, 2004, POLICY REV MAG   MAR, P14; NAYSMITH S, 2004, SUNDAY HERALD G 0229, P16; *ROYAL STAT SOC WO, PERF IND GOOD BAD UG; Singleton N., 2003, DRUG RELATED MORTALI; Smith AFM, 1996, J ROY STAT SOC A STA, V159, P367, DOI 10.2307/2983324; Turnbull PJ, 2000, DRUG TREATMENT TESTI	24	13	13	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	2004	364	9443					1457	1459		10.1016/S0140-6736(04)17230-9	http://dx.doi.org/10.1016/S0140-6736(04)17230-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488223				2022-12-28	WOS:000224485300034
J	Schaub, B; von Mutius, E				Schaub, B; von Mutius, E			The marketing of asthma and allergies	LANCET			English	Editorial Material							HOUSE-DUST MITE; CLINICAL MANAGEMENT; CHILDHOOD ASTHMA; SOLUBLE CD14; EXPOSURE; CHILDREN; PREVENTION; POLYMORPHISM; AVOIDANCE; ENCASINGS		Univ Childrens Hosp, D-80337 Munich, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich	Schaub, B (corresponding author), Univ Childrens Hosp, D-80337 Munich, Germany.	bianca.schaub@med.uni-muenchen.de	Schaub, Bianca/B-9935-2019	Schaub, Bianca/0000-0003-1652-8873; von Mutius, Erika/0000-0002-8893-4515				*AM CAT FANC ASS, SPHINX CAT; Arshad SH, 2004, CURR OPIN ALLERGY CL, V4, P119, DOI [10.1097/00130832-200404000-00009, 10.1097/01.all.0000123971.96233.65]; Asher I, 2004, INT ARCH ALLERGY IMM, V135, P83, DOI 10.1159/000080524; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P936, DOI 10.1067/mai.2003.1475; Bergquist P, 2001, EUR RESPIR J, V18, P248, DOI 10.1183/09031936.01.00239601; Bukstein DA, 2003, ANN ALLERG ASTHMA IM, V90, P543, DOI 10.1016/S1081-1206(10)61848-0; Cabana MD, 2004, J ALLERGY CLIN IMMUN, V114, P352, DOI 10.1016/j.jaci.2004.04.047; Capristo C, 2004, ALLERGY, V59, P53, DOI 10.1111/j.1398-9995.2004.00652.x; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; Halken S, 2003, J ALLERGY CLIN IMMUN, V111, P169, DOI 10.1067/mai.2003.5; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; Juniper EF, 2003, CURR OPIN PULM MED, V9, pS8, DOI 10.1097/00063198-200304001-00003; Kabesch M, 2004, ALLERGY, V59, P520, DOI 10.1111/j.1398-9995.2004.00439.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Maziak W, 2002, EUR RESPIR J, V20, P1476, DOI 10.1183/09031936.02.00281102; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Robinson AR, 2004, ARCH INTERN MED, V164, P427, DOI 10.1001/archinte.164.4.427; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x	22	2	2	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2004	364	9443					1389	1390		10.1016/S0140-6736(04)17241-3	http://dx.doi.org/10.1016/S0140-6736(04)17241-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488205				2022-12-28	WOS:000224485300010
J	Ridderinkhof, KR; Ullsperger, M; Crone, EA; Nieuwenhuis, S				Ridderinkhof, KR; Ullsperger, M; Crone, EA; Nieuwenhuis, S			The role of the medial frontal cortex in cognitive control	SCIENCE			English	Review						dsfsdf	ANTERIOR CINGULATE CORTEX; PREFRONTAL CORTEX; ERROR-DETECTION; MOTOR AREAS; REWARD; CONFLICT; BRAIN; INHIBITION; PUNISHMENT; POTENTIALS	Adaptive goal-directed behavior involves monitoring of ongoing actions and performance outcomes, and subsequent adjustments of behavior and learning. We evaluate new findings in cognitive neuroscience concerning cortical interactions that subserve the recruitment and implementation of such cognitive control. A review of primate and human studies, along with a meta-analysis of the human functional neuroimaging literature, suggest that the detection of unfavorable outcomes, response errors, response conflict, and decision uncertainty elicits largely overlapping clusters of activation foci in an extensive part of the posterior medial. frontal cortex (pMFC). A direct link is delineated between activity in this area and subsequent adjustments in performance. Emerging evidence points to functional interactions between the pMFC and the lateral prefrontal cortex (LPFC), so that monitoring-related pMFC activity serves as a signal that engages regulatory processes in the LPFC to implement performance adjustments.	Univ Amsterdam, Dept Psychol, Roetersstr 15, NL-1018 WB Amsterdam, Netherlands; Leiden Univ, Dept Psychol, NL-2333 AK Leiden, Netherlands; Max Planck Inst Human Cognit & Brain Sci, D-04103 Leipzig, Germany; Univ Calif Davis, Ctr Mind & Brain, Davis, CA 95616 USA; Free Univ Amsterdam, Dept Cognit Psychol, NL-1081 BT Amsterdam, Netherlands	University of Amsterdam; Leiden University; Leiden University - Excl LUMC; Max Planck Society; University of California System; University of California Davis; Vrije Universiteit Amsterdam	Ridderinkhof, KR (corresponding author), Univ Amsterdam, Dept Psychol, Roetersstr 15, NL-1018 WB Amsterdam, Netherlands.	K.R.Ridderinkhof@uva.nl	Zhang, Xiao/V-9027-2017; Ullsperger, Markus/I-4760-2019; Ullsperger, Markus/E-2797-2010	Zhang, Xiao/0000-0002-2932-5875; Ullsperger, Markus/0000-0003-3970-1982; Ullsperger, Markus/0000-0003-3970-1982				Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Badre D, 2004, NEURON, V41, P473, DOI 10.1016/S0896-6273(03)00851-1; BATES JF, 1993, J COMP NEUROL, V336, P211, DOI 10.1002/cne.903360205; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Bush G, 2002, P NATL ACAD SCI USA, V99, P523, DOI 10.1073/pnas.012470999; Cools R, 2002, J NEUROSCI, V22, P4563, DOI 10.1523/JNEUROSCI.22-11-04563.2002; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Fiehler K, 2004, EUR J NEUROSCI, V19, P3081, DOI 10.1111/j.0953-816X.2004.03414.x; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gehring WJ, 2000, NAT NEUROSCI, V3, P516, DOI 10.1038/74899; GEMBA H, 1986, NEUROSCI LETT, V70, P223, DOI 10.1016/0304-3940(86)90467-2; Hester R, 2004, CEREB CORTEX, V14, P986, DOI 10.1093/cercor/bhh059; Holroyd CB, 2004, NAT NEUROSCI, V7, P497, DOI 10.1038/nn1238; Holroyd CB, 2004, PSYCHOPHYSIOLOGY, V41, P245, DOI 10.1111/j.1469-8986.2004.00152.x; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; HOLROYD CB, IN PRESS COGNITIVE N; Ito S, 2003, SCIENCE, V302, P120, DOI 10.1126/science.1087847; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Knutson B, 2001, NEUROREPORT, V12, P3683, DOI 10.1097/00001756-200112040-00016; Koski L, 2000, EXP BRAIN RES, V133, P55, DOI 10.1007/s002210000400; Matsumoto K, 2004, CURR OPIN NEUROBIOL, V14, P178, DOI 10.1016/j.conb.2004.03.005; Matsumoto K, 2004, SCIENCE, V303, P969, DOI 10.1126/science.1094733; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; O'Doherty J, 2001, NAT NEUROSCI, V4, P95, DOI 10.1038/82959; O'Doherty J, 2003, J NEUROSCI, V23, P7931; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Petrides M, 1999, EUR J NEUROSCI, V11, P1011, DOI 10.1046/j.1460-9568.1999.00518.x; Picard N, 1996, CEREB CORTEX, V6, P342, DOI 10.1093/cercor/6.3.342; Posner MI, 1998, ATTENTIVE BRAIN, P401; Ridderinkhof KR, 2003, NEUROSCI LETT, V348, P1, DOI 10.1016/S0304-3940(03)00566-4; Ridderinkhof KR, 2002, SCIENCE, V298, P2209, DOI 10.1126/science.1076929; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Shidara M, 2002, SCIENCE, V296, P1709, DOI 10.1126/science.1069504; Shima K, 1998, SCIENCE, V282, P1335, DOI 10.1126/science.282.5392.1335; Stuphorn V, 2000, NATURE, V408, P857, DOI 10.1038/35048576; Ullsperger M, 2003, J NEUROSCI, V23, P4308, DOI 10.1523/jneurosci.23-10-04308.2003; ULLSPERGER M, IN PRESS CORTEX; YEUNG N, IN PRESS PSYCHOL REV	42	2139	2161	7	329	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					443	447		10.1126/science.1100301	http://dx.doi.org/10.1126/science.1100301			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486290	Green Published			2022-12-28	WOS:000224626500041
J	Schimmel, P; Ewalt, K				Schimmel, P; Ewalt, K			Translation silenced by fused pair of tRNA synthetases	CELL			English	Editorial Material							CERULOPLASMIN	In this issue of Cell, Sampath et al. (2004) discover gene-specific translational silencing as a novel function of the fused glutamyl- and prolyl-tRNA synthetase (GluProRS). GluProRS is released from a multisynthetase translation complex in response to gamma-interferon and forms a four-protein GAIT complex that silences translation of ceruloplasmin (Cp), a protein linked to the inflammatory response.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Bielli P, 2002, CELL MOL LIFE SCI, V59, P1413, DOI 10.1007/s00018-002-8519-2; FETT R, 1991, J BIOL CHEM, V266, P1448; Howard OMZ, 2002, J EXP MED, V196, P781, DOI 10.1084/jem.20020186; Jeong EJ, 2000, BIOCHEMISTRY-US, V39, P15775, DOI 10.1021/bi001393h; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; Norcum MT, 1999, J BIOL CHEM, V274, P12205, DOI 10.1074/jbc.274.18.12205; Sampath P, 2004, CELL, V119, P195, DOI 10.1016/j.cell.2004.09.030; Sampath P, 2003, MOL CELL BIOL, V23, P1509, DOI 10.1128/MCB.23.5.1509-1519.2003; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147	9	0	0	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	2004	119	2					147	148		10.1016/j.cell.2004.10.001	http://dx.doi.org/10.1016/j.cell.2004.10.001			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479630	Bronze			2022-12-28	WOS:000224577200001
J	Marcus, GF				Marcus, GF			Before the word - Language evolution: evolutionary vestiges may provide clues to the ultimate origins of human language.	NATURE			English	Editorial Material									NYU, Dept Psychol, New York, NY 10003 USA	New York University	Marcus, GF (corresponding author), NYU, Dept Psychol, 6 Washington Pl, New York, NY 10003 USA.							Christiansen M.H., 2003, LANGUAGE EVOLUTION; Gould Stephen J., 1980, PANDAS THUMB; Jackendoff R. S., 2002, FDN LANGUAGE BRAIN M; Marcus G., 2004, BIRTH MIND; McElree B, 2003, J MEM LANG, V48, P67, DOI 10.1016/S0749-596X(02)00515-6	5	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	2004	431	7010					745	745		10.1038/431745a	http://dx.doi.org/10.1038/431745a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483585				2022-12-28	WOS:000224435500020
J	Prinssen, M; Verhoeven, ELG; Buth, J; Cuypers, PWM; van Sambeek, MRHM; Balm, R; Buskens, E; Grobbee, DE; Blankensteijn, JD; Grobbee, DE; Blankensteijn, JD; Buth, J; Pattynama, PM; Verhoeven, ELG; van Voorthuisen, AE; Bak, AAA; Blankensteijn, JD; Prinssen, M; van Sambeek, MRHM; Verhoeven, ELG; Buth, J; Cuypers, PWM; Balm, R; Buskens, E; Grobbee, DE; Hunink, MG; van Engelshoven, JM; Jacobs, MJHM; de Mol, BAJM; van Bockel, JH; Balm, R; Reekers, J; Tielbeek, X; Verhoeven, ELG; Wisselink, W; Boekema, N; Sikking, I; Prinssen, M; Balm, R; Buth, J; van Sambeek, MRHM; Verhoeven, ELG; Blankensteijn, JD; Blankensteijn, JD; Prinssen, M; Buskens, E; Buth, J; Tielbeek, AV; Blankensteijn, JD; Balm, R; Reekers, JA; van Sambeek, MRHM; Pattynama, P; Verhoeven, ELG; Prins, T; van der Ham, AC; van der Velden, JJIM; van Sterkenburg, SMM; ten Haken, GB; Bruijninckx, CMA; van Overhagen, H; Nolthenius, RPT; Hendriksz, TR; Teijink, JAW; Odink, HF; de Smet, AAEA; Vroegindeweij, D; van Loenhout, RMM; Rutten, MJ; Hamming, JF; Lampmann, LEH; Bender, MHM; Pasmans, H; Vahl, AC; de Vries, C; Mackaay, AJC; van Dortmont, LMC; van der Vliet, D; Kool, LS; Boomsma, JHB; van Dop, HR; van Otterloo, JCAD; de Rooij, TPW; Smits, TM; Yilmaz, EN; Wisselink, W; van den Berg, FG; Visser, MJT; van der Linden, E; Schurink, GWH; de Haan, M; Smeets, HJ; Stabel, P; van Elst, F; Poniewierski, J; Vermassen, FEG				Prinssen, M; Verhoeven, ELG; Buth, J; Cuypers, PWM; van Sambeek, MRHM; Balm, R; Buskens, E; Grobbee, DE; Blankensteijn, JD; Grobbee, DE; Blankensteijn, JD; Buth, J; Pattynama, PM; Verhoeven, ELG; van Voorthuisen, AE; Bak, AAA; Blankensteijn, JD; Prinssen, M; van Sambeek, MRHM; Verhoeven, ELG; Buth, J; Cuypers, PWM; Balm, R; Buskens, E; Grobbee, DE; Hunink, MG; van Engelshoven, JM; Jacobs, MJHM; de Mol, BAJM; van Bockel, JH; Balm, R; Reekers, J; Tielbeek, X; Verhoeven, ELG; Wisselink, W; Boekema, N; Sikking, I; Prinssen, M; Balm, R; Buth, J; van Sambeek, MRHM; Verhoeven, ELG; Blankensteijn, JD; Blankensteijn, JD; Prinssen, M; Buskens, E; Buth, J; Tielbeek, AV; Blankensteijn, JD; Balm, R; Reekers, JA; van Sambeek, MRHM; Pattynama, P; Verhoeven, ELG; Prins, T; van der Ham, AC; van der Velden, JJIM; van Sterkenburg, SMM; ten Haken, GB; Bruijninckx, CMA; van Overhagen, H; Nolthenius, RPT; Hendriksz, TR; Teijink, JAW; Odink, HF; de Smet, AAEA; Vroegindeweij, D; van Loenhout, RMM; Rutten, MJ; Hamming, JF; Lampmann, LEH; Bender, MHM; Pasmans, H; Vahl, AC; de Vries, C; Mackaay, AJC; van Dortmont, LMC; van der Vliet, D; Kool, LS; Boomsma, JHB; van Dop, HR; van Otterloo, JCAD; de Rooij, TPW; Smits, TM; Yilmaz, EN; Wisselink, W; van den Berg, FG; Visser, MJT; van der Linden, E; Schurink, GWH; de Haan, M; Smeets, HJ; Stabel, P; van Elst, F; Poniewierski, J; Vermassen, FEG		DREAM Trial Grp	A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPEN SURGICAL REPAIR; DECISION-ANALYSIS MODEL; COST-EFFECTIVENESS; CLINICAL-TRIALS; STENT-GRAFT; AAA REPAIR; MORTALITY; SURVEILLANCE; SURGERY; LIFE	BACKGROUND: Although the initial results of endovascular repair of abdominal aortic aneurysms were promising, current evidence from controlled studies does not convincingly show a reduction in 30-day mortality relative to that achieved with open repair. METHODS: We conducted a multicenter, randomized trial comparing open repair with endovascular repair in 345 patients who had received a diagnosis of abdominal aortic aneurysm of at least 5 cm in diameter and who were considered suitable candidates for both techniques. The outcome events analyzed were operative (30-day) mortality and two composite end points of operative mortality and severe complications and operative mortality and moderate or severe complications. RESULTS: The operative mortality rate was 4.6 percent in the open-repair group (8 of 174 patients; 95 percent confidence interval, 2.0 to 8.9 percent) and 1.2 percent in the endovascular-repair group (2 of 171 patients; 95 percent confidence interval, 0.1 to 4.2 percent), resulting in a risk ratio of 3.9 (95 percent confidence interval, 0.9 to 32.9). The combined rate of operative mortality and severe complications was 9.8 percent in the open-repair group (17 of 174 patients; 95 percent confidence interval, 5.8 to 15.2 percent) and 4.7 percent in the endovascular-repair group (8 of 171 patients; 95 percent confidence interval, 2.0 to 9.0 percent), resulting in a risk ratio of 2.1 (95 percent confidence interval, 0.9 to 5.4). CONCLUSIONS: On the basis of the overall results of this trial, endovascular repair is preferable to open repair in patients who have an abdominal aortic aneurysm that is at least 5 cm in diameter. Long-term follow-up is needed to determine whether this advantage is sustained.	Univ Med Ctr, Dept Surg, Div Vasc Surg, Utrecht, Netherlands; Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; Univ Groningen, Univ Med Ctr Groningen, Acad Hosp, Dept Surg, Div Vasc Surg, Groningen, Netherlands; Catharina Hosp, Dept Surg, Eindhoven, Netherlands; Erasmus MC, Dept Surg, Div Vasc Surg, Rotterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Surg, Div Vasc Surg, NL-1105 AZ Amsterdam, Netherlands; Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Vasc Surg, NL-6500 HB Nijmegen, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Groningen; Catharina Hospital; Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen	Blankensteijn, JD (corresponding author), Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Vasc Surg 410, POB 9101, NL-6500 HB Nijmegen, Netherlands.	j.blankensteijn@chir.umcn.nl	Grobbee, Diederick/C-7651-2014; van Sambeek, marc/CAF-1289-2022; van der Velden, J./H-8101-2014; Blankensteijn, Jan D/Q-9291-2016; Reekers, Jim/ABF-7580-2021	Grobbee, Diederick/0000-0003-4472-4468; Blankensteijn, Jan D/0000-0002-2062-8749; buskens, erik/0000-0002-6463-1106				Adriaensen MEAPM, 2002, RADIOLOGY, V224, P739, DOI 10.1148/radiol.2243011675; Akkersdijk GJM, 2004, EUR J VASC ENDOVASC, V28, P41, DOI 10.1016/j.ejvs.2004.01.003; Anderson PL, 2004, J VASC SURG, V39, P10, DOI 10.1016/j.jvs.2003.07.020; Blankensteijn JD, 1998, BRIT J SURG, V85, P1624; Bolland K, 2000, STAT MED, V19, P2899, DOI 10.1002/1097-0258(20001115)19:21<2899::AID-SIM597>3.0.CO;2-O; Bosch JL, 2002, RADIOLOGY, V225, P337, DOI 10.1148/radiol.2252011687; Brady AR, 2002, NEW ENGL J MED, V346, P1445; Brewster DC, 2003, J VASC SURG, V37, P1106, DOI 10.1067/mva.2003.363; Carpenter JP, 2001, J VASC SURG, V34, P1050, DOI 10.1067/mva.2001.120037; Chaikof EL, 2002, J VASC SURG, V35, P1048, DOI 10.1067/mva.2002.123763; Forbes TL, 2002, CAN J SURG, V45, P420; Greenberg RK, 2004, J VASC SURG, V40, P23; Greenberg RK, 2004, J VASC SURG, V39, P1209, DOI 10.1016/j.jvs.2004.02.032; Greenhalgh RM, 2004, LANCET, V364, P843, DOI 10.1016/S0140-6736(04)16979-1; Harris PL, 1997, J ENDOVASC SURG, V4, P72, DOI 10.1583/1074-6218(1997)004<0072:TNFCTO>2.0.CO;2; Lederle FA, 2002, NEW ENGL J MED, V346, P1437, DOI 10.1056/NEJMoa012573; Lee WA, 2004, J VASC SURG, V39, P491, DOI 10.1016/j.jvs.2003.12.001; Maher MM, 2003, RADIOLOGY, V228, P647, DOI 10.1148/radiol.2283012185; Matsumura JS, 2003, J VASC SURG, V37, P262, DOI 10.1067/mva.2003.120; Moore WS, 2003, J VASC SURG, V38, P46, DOI 10.1016/S0741-5214(03)00410-5; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; Patel ST, 1999, J VASC SURG, V29, P958, DOI 10.1016/S0741-5214(99)70237-5; Powell JT, 1998, LANCET, V352, P1649; Prinssen M, 2004, EUR J VASC ENDOVASC, V27, P121, DOI 10.1016/j.ejvs.2003.11.006; Prinssen M, 2002, J CARDIOVASC SURG, V43, P379; Rutherford RB, 1997, J VASC SURG, V26, P517, DOI 10.1016/S0741-5214(97)70045-4; Rutherford RB, 2001, J VASC SURG, V33, P805; Schermerhorn ML, 2002, J VASC SURG, V36, P1112, DOI 10.1067/mva.2002.129646; Verhoeven ELG, 2004, EUR J VASC ENDOVASC, V27, P477, DOI 10.1016/j.ejvs.2003.09.007; Volodos N L, 1991, Vasa Suppl, V33, P93; Zarins CK, 1999, J VASC SURG, V29, P292, DOI 10.1016/S0741-5214(99)70382-4	31	1456	1530	2	88	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1607	1618		10.1056/NEJMoa042002	http://dx.doi.org/10.1056/NEJMoa042002			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483279	Green Published			2022-12-28	WOS:000224427300007
J	Alexander, LN; Seward, JF; Santibanez, TA; Pallansch, MA; Kew, OM; Prevots, DR; Strebel, PM; Cono, J; Wharton, M; Orenstein, WA; Sutter, RW				Alexander, LN; Seward, JF; Santibanez, TA; Pallansch, MA; Kew, OM; Prevots, DR; Strebel, PM; Cono, J; Wharton, M; Orenstein, WA; Sutter, RW			Vaccine policy changes and epidemiology of poliomyelitis in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INACTIVATED POLIOVIRUS VACCINE; PARALYTIC POLIOMYELITIS; IMPACT; IDENTIFICATION; SCHEDULE	Context The last case of poliomyelitis in the United States due to indigenously acquired wild poliovirus occurred in 1979; however, as a consequence of oral poliovirus vaccine (OPV) use that began in 1961, an average of 9 cases of vaccine-associated paralytic poliomyelitis (VAPP) were confirmed each year from 1961 through 1989. To reduce the VAPP burden, national vaccination policy changed in 1997 from reliance on OPV to options for a sequential schedule of inactivated poliovirus vaccine (IPV) followed by OPV. In 2000, an exclusive IPV schedule was adopted. Objective To review the epidemiology of paralytic poliomyelitis and document the association between the vaccine schedule changes and VAPP in the United States. Design and Setting Review of national surveillance data from 1990 through 2003 for cases of confirmed paralytic poliomyelitis. Main Outcome Measures Number of confirmed paralytic poliomyelitis cases, including VAPP, and ratio of VAPP cases to number of doses of OPV distributed that occurred before, during, and after implementation of policy changes. Results From 1990 through 1999, 61 cases of paralytic poliomyelitis were reported; 59 (97%) of these were VAPP (1 case per 2.9 million OPV doses distributed), 1 case was imported, and 1 case was indeterminate. Thirteen cases occurred during the 19971999 transitional policy period and were associated with the all-OPV schedule; none occurred with the IPV-OPV schedule. No cases occurred after the United States implemented the all-IPV policy in 2000. The last imported poliomyelitis case occurred in 1993 and the last case of VAPP occurred in 1999. Conclusion The change in polio vaccination policy from OPV to exclusive use of IPV was successfully implemented; this change led to the elimination of VAPP in the United States.	Ctr Dis Control & Prevent, Natl Immunizat Program, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Alexander, LN (corresponding author), Ctr Dis Control & Prevent, Natl Immunizat Program, Natl Ctr Infect Dis, 1600 Clifton Rd,MS E-61, Atlanta, GA 30333 USA.	lalexander@cdc.gov		Prevots, D Rebecca/0000-0003-0339-9873; Santibanez, Tammy A./0000-0002-5784-7427				Abramson JS, 1999, PEDIATRICS, V104, P1404, DOI 10.1542/peds.104.6.1404; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; CDC, 1981, CDC ANN SUMM REP MOR; Centers for Disease Control and Prevention, NAT IMM SURV; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P107; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1017; Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P180; DE L, 1995, J CLIN MICROBIOL, V33, P562, DOI 10.1128/JCM.33.3.562-571.1995; ESTEVES K, 1988, B WORLD HEALTH ORGAN, V66, P739; Halsey NA, 1999, PEDIATRICS, V103, P171, DOI 10.1542/peds.103.1.171; Halsey NA, 1997, PEDIATRICS, V99, P300, DOI 10.1542/peds.99.2.300; HENDERSON DA, 1964, JAMA-J AM MED ASSOC, V190, P41; *I MED, 1996, VACC SAF FOR OPT POL; *I MED, 1977, EV POL VACC, P75; *I MED, 1988, EV POL VACC POL VACC; JOCE R, 1992, BRIT MED J, V305, P79, DOI 10.1136/bmj.305.6845.79; KOHBERGER RC, 1995, I MED POL WORKSH JUN; Kolasa MS, 2001, PUBLIC HEALTH REP, V116, P282, DOI 10.1093/phr/116.4.282; Lindegren Mary Lou, 2004, Morbidity and Mortality Weekly Report, V53, P1; LUTHER T, 1962, ASS CASES POLIOMYELI, P1; Marwick C, 1996, JAMA-J AM MED ASSOC, V275, P827, DOI 10.1001/jama.275.11.827; NKOWANE BM, 1987, JAMA-J AM MED ASSOC, V257, P1335, DOI 10.1001/jama.257.10.1335; NOTTAY BK, 1981, VIROLOGY, V108, P405, DOI 10.1016/0042-6822(81)90448-7; Polich T., 1997, J CLIN GEROPSYCHOLOG, V3, P1; PREVOTS DR, 1994, ARCH PEDIAT ADOL MED, V148, P479, DOI 10.1001/archpedi.1994.02170050037007; RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8; Schmidt NJ, 1989, DIAGNOSTIC PROCEDURE, V6th, P51; Schonberger L B, 1978, Adv Neurol, V19, P217; SCHONBERGER LB, 1976, AM J EPIDEMIOL, V104, P202, DOI 10.1093/oxfordjournals.aje.a112290; STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568; Sutter R. W. C. S., 1999, VACCINES, P364; SUTTER RW, 1989, AM J PUBLIC HEALTH, V79, P495, DOI 10.2105/AJPH.79.4.495; SUTTER RW, 1994, INFECT MED, V11, P429; Sutter RW, 1994, INFECT MED, V11, P426; SUTTER RW, 1994, INFECT MED, V11, P435; Taylor JA, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e90; VARUGHESE PV, 1989, CAN J PUBLIC HEALTH, V80, P363; Ventura S J, 2001, Natl Vital Stat Rep, V49, P1; Wattigney WA, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.5.e83; Weibel RE, 1996, AM J PUBLIC HEALTH, V86, P734, DOI 10.2105/AJPH.86.5.734; YANG CF, 1991, VIRUS RES, V20, P159; Zimmerman RK, 1999, AM FAM PHYSICIAN, V59, P113; 1998, MMWR MORB MORTAL WKL, V46, P79	44	149	168	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2004	292	14					1696	1701		10.1001/jama.292.14.1696	http://dx.doi.org/10.1001/jama.292.14.1696			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861JS	15479934	Bronze			2022-12-28	WOS:000224413400028
J	Shahmanesh, M; Wayal, S				Shahmanesh, M; Wayal, S			Targeting commercial sex-workers in Goa, India: time for a strategic rethink?	LANCET			English	Editorial Material							SEXUALLY-TRANSMITTED-DISEASES; CONDOM PROMOTION; HIV; PREVENTION; PREVALENCE; INFECTION; DECLINE; IMPACT		UCL Royal Free & Univ Coll Med Sch, Ctr Sexual Hlth & HIV Res, London WC1E 6AU, England; Posit People, Panaji, Goa, India	University of London; University College London; UCL Medical School	Shahmanesh, M (corresponding author), UCL Royal Free & Univ Coll Med Sch, Ctr Sexual Hlth & HIV Res, London WC1E 6AU, England.	bamaryjoon@yahoo.co.uk		Shahmanesh, Maryam/0000-0001-7129-8535; Wayal, Sonali/0000-0002-5878-7665				Alary M, 2002, AIDS, V16, P463, DOI 10.1097/00002030-200202150-00019; BHAVE G, 1995, AIDS, V9, pS21; Boily MC, 2002, SEX TRANSM INFECT, V78, pI78, DOI 10.1136/sti.78.suppl_1.i78; Egger M, 2000, LANCET, V355, P2101, DOI 10.1016/S0140-6736(00)02376-X; Ghys PD, 2001, AIDS, V15, P1421, DOI 10.1097/00002030-200107270-00012; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; Jana S, 1998, AIDS, V12 Suppl B, pS101; Kaul R, 2002, J ACQ IMMUN DEF SYND, V30, P69, DOI 10.1097/00042560-200205010-00009; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; Parker RG, 2000, AIDS, V14, pS22, DOI 10.1097/00002030-200006001-00004; SHARMA R, 2004, FRONTLINE       0717; Steen R, 2000, SEX TRANSM DIS, V27, P1, DOI 10.1097/00007435-200001000-00001	13	18	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2004	364	9442					1297	1299		10.1016/S0140-6736(04)17206-1	http://dx.doi.org/10.1016/S0140-6736(04)17206-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474122				2022-12-28	WOS:000224349700009
J	Townsend, D; Lahankar, SA; Lee, SK; Chambreau, SD; Suits, AG; Zhang, X; Rheinecker, J; Harding, LB; Bowman, JM				Townsend, D; Lahankar, SA; Lee, SK; Chambreau, SD; Suits, AG; Zhang, X; Rheinecker, J; Harding, LB; Bowman, JM			The roaming atom: Straying from the reaction path in formaldehyde decomposition	SCIENCE			English	Article							QUANTUM-STATE CORRELATIONS; PHOTOFRAGMENTATION DYNAMICS; DISTRIBUTIONS; DISSOCIATION; H2CO->H-2+CO	We present a combined experimental and theoretical investigation of formaldehyde (H2CO) dissociation to H-2 and CO at energies just above the threshold for competing H elimination. High-resolution state-resolved imaging measurements of the CO velocity distributions reveal two dissociation pathways. The first proceeds through a well-established transition state to produce rotationally excited CO and vibrationally cold H-2. The second dissociation pathway yields rotationally cold CO in conjunction with highly vibrationally excited H-2. Quasi-classical trajectory calculations performed on a global potential energy surface for H2CO suggest that this second channel represents an intramolecular hydrogen abstraction mechanism: One hydrogen atom explores large regions of the potential energy surface before bonding with the second H atom, bypassing the saddle point entirely.	SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA; Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; Emory Univ, Dept Chem, Atlanta, GA 30322 USA; Emory Univ, Cherry L Emerson Ctr Sci Computat, Atlanta, GA 30322 USA; Argonne Natl Lab, Div Chem, Argonne, IL 60439 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; United States Department of Energy (DOE); Brookhaven National Laboratory; Wayne State University; Emory University; Emory University; United States Department of Energy (DOE); Argonne National Laboratory	Suits, AG (corresponding author), SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.	asuits@wayne.edu; jmbowma@emory.edu	Townsend, Dave/K-3461-2015					ATKINSON R, 1992, J PHYS CHEM REF DATA, V21, P1125, DOI 10.1063/1.555918; BAMFORD DJ, 1985, J CHEM PHYS, V82, P3032, DOI 10.1063/1.448252; BUTENHOFF TJ, 1990, J CHEM PHYS, V92, P377, DOI 10.1063/1.458440; BUTENHOFF TJ, 1989, J CHEM SOC FARAD T 2, V85, P1155, DOI 10.1039/f29898501155; CHANDLER DW, 1987, J CHEM PHYS, V87, P1445, DOI 10.1063/1.453276; CHANG YT, 1992, J CHEM PHYS, V96, P4341, DOI 10.1063/1.462826; CHEN W, 1994, CHEM PHYS LETT, V228, P436, DOI 10.1016/0009-2614(94)00939-2; DEBARRE D, 1985, J CHEM PHYS, V83, P4476, DOI 10.1063/1.449015; Eppink ATJB, 1997, REV SCI INSTRUM, V68, P3477, DOI 10.1063/1.1148310; HO P, 1982, J CHEM PHYS, V76, P3630, DOI 10.1063/1.443400; Li X., 2000, J CHEM PHYS, V113; Marcy TP, 2001, J PHYS CHEM A, V105, P8361, DOI 10.1021/jp010961f; Moore CB, 1995, FARADAY DISCUSS, V102, P1, DOI 10.1039/fd9950200001; MOORE CB, 1983, ANNU REV PHYS CHEM, V34, P525, DOI 10.1146/annurev.pc.34.100183.002521; RHEINECKER JL, UNPUB; Schinke R., 1993, PHOTODISSOCIATION DY; Sun LP, 2002, SCIENCE, V296, P875, DOI 10.1126/science.1068053; Townsend D, 2003, REV SCI INSTRUM, V74, P2530, DOI 10.1063/1.1544053; VANZEE RD, 1993, J CHEM PHYS, V99, P1664, DOI 10.1063/1.465335; YAN T, 2004, IN PRESS J PHYS A; Zhang XB, 2004, J PHYS CHEM A, V108, P8980, DOI [10.1021/jp048339l, 10.1021/jp0483391]	21	481	483	3	224	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1158	1161		10.1126/science.1104386	http://dx.doi.org/10.1126/science.1104386			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15498970				2022-12-28	WOS:000225193100040
J	Solomon, AW; Holland, MJ; Alexander, NDE; Massae, PA; Aguirre, A; Natividad-Sancho, A; Molina, S; Safari, S; Shao, JF; Courtright, P; Peeling, RW; West, SK; Bailey, RL; Foster, A; Mabey, DCW				Solomon, AW; Holland, MJ; Alexander, NDE; Massae, PA; Aguirre, A; Natividad-Sancho, A; Molina, S; Safari, S; Shao, JF; Courtright, P; Peeling, RW; West, SK; Bailey, RL; Foster, A; Mabey, DCW			Mass treatment with single-dose azithromycin for trachoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Meeting of the Royal-Society-of-Tropical-Medicine-and-Hygiene	DEC   12, 2002	LONDON, ENGLAND	Royal Soc Trop Med & Hyg			OCULAR CHLAMYDIAL INFECTION; CLINICAL-DIAGNOSIS; LOW-PREVALENCE; PREVENTION; BLINDNESS; NEPAL; AREAS	BACKGROUND Trachoma, caused by repeated ocular infection with Chlamydia trachomatis, is an important cause of blindness. Current recommended dosing intervals for mass azithromycin treatment for trachoma are based on a mathematical model. METHODS We collected conjunctival swabs for quantitative polymerase-chain-reaction assay of C. trachomatis before and 2, 6, 12, 18, and 24 months after mass treatment with azithromycin in a Tanzanian community in which trachoma was endemic. For ethical reasons, at 6, 12, and 18 months, we gave tetracycline eye ointment to residents who had clinically active trachoma. RESULTS: At baseline, 956 of 978 residents (97.8 percent) received either one oral dose of azithromycin or (if azithromycin was contraindicated) a course of tetracycline eye ointment. The prevalence of infection fell from 9.5 percent before mass treatment to 2.1 percent at 2 months and 0.1 percent at 24 months. The quantitative burden of ocular C. trachomatis infection in the community was 13.9 percent of the pretreatment level at 2 months and 0.8 percent at 24 months. At each time point after baseline, over 90 percent of the total community burden of C. trachomatis infection was found among subjects who had been positive the previous time they were tested. CONCLUSIONS: The prevalence and intensity of infection fell dramatically and remained low for two years after treatment. One round of very-high-coverage mass treatment with azithromycin, perhaps aided by subsequent periodic use of tetracycline eye ointment for persons with active disease, can interrupt the transmission of ocular C. trachomatis infection.	Univ London London Sch Hyg & Trop Med, Clin Res Unit, London WC1E 7HT, England; Tumaini Univ, Kilimanjaro Christian Med Coll, Moshi, Tanzania; Huruma Hosp, Mkuu, Rombo, Tanzania; MRC Labs, Fajara, Gambia; WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland; Hlth Canada, Natl Microbiol Lab, Winnipeg, MB, Canada; Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA	University of London; London School of Hygiene & Tropical Medicine; MRC Laboratory Molecular Biology; World Health Organization; Health Canada; Johns Hopkins University	Solomon, AW (corresponding author), Univ London London Sch Hyg & Trop Med, Clin Res Unit, Keppel St, London WC1E 7HT, England.	anthony.solomon@lshtm.ac.uk	Holland, Martin J/K-6502-2012	Holland, Martin J/0000-0002-5828-6318; Mabey, David/0000-0002-0031-8276; Solomon, Anthony/0000-0001-7101-6649; Foster, Allen/0000-0003-2368-4436; Andreasen, Aura/0000-0003-0664-7342	Wellcome Trust [098521, 059134] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9; Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461; Bird M, 2003, J INFECT DIS, V187, P1669, DOI 10.1086/374743; Bowman RJC, 2000, INVEST OPHTH VIS SCI, V41, P4074; Dawson CR, 1997, CLIN INFECT DIS, V24, P363, DOI 10.1093/clinids/24.3.363; Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2; Everett KDE, 1999, INT J SYST BACTERIOL, V49, P415, DOI 10.1099/00207713-49-2-415; FOSTER A, 1991, LANCET, V337, P1267, DOI 10.1016/0140-6736(91)92929-V; GRAYSTON JT, 1985, REV INFECT DIS, V7, P717; Jha H, 2002, CLIN INFECT DIS, V35, P765, DOI 10.1086/342298; Kirkwood B., 1988, BR K ESSENTIALS MED; Kuper H, 2003, LANCET INFECT DIS, V3, P372, DOI 10.1016/S1473-3099(03)00659-5; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451; Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1; Mabey Denise, 2003, Expert Rev Anti Infect Ther, V1, P209, DOI 10.1586/14787210.1.2.209; Rothman K., 1998, MODERN EPIDEMIOLOGY; SCHACHTER J, 1983, REV INFECT DIS, V5, pS562; SCHACHTER J, 1985, REV INFECT DIS, V7, P713; Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5; Shattock RM, 1998, SEX TRANSM INFECT, V74, P289, DOI 10.1136/sti.74.4.289; Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8; Tabbara KF, 1996, OPHTHALMOLOGY, V103, P842; TAYLOR HR, 1993, BRIT J OPHTHALMOL, V77, P66, DOI 10.1136/bjo.77.2.66; Thein J, 2002, OPHTHALMIC EPIDEMIOL, V9, P263, DOI 10.1076/opep.9.4.263.1508; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; THYLEFORS B, 1985, REV INFECT DIS, V7, P774; Thylefors B, 1998, WORLD HEALTH FORUM, V19, P53; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1; West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158; [No title captured]	32	190	193	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1962	1971		10.1056/NEJMoa040979	http://dx.doi.org/10.1056/NEJMoa040979			10	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525721	Bronze, Green Accepted			2022-12-28	WOS:000224851300008
J	Hurwitz, B				Hurwitz, B			How does evidence based guidance influence determinations of medical negligence?	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PRACTICE GUIDELINES		Kings Coll London, Sch Humanities, London WC2R 2LS, England	University of London; King's College London	Hurwitz, B (corresponding author), Kings Coll London, Sch Humanities, London WC2R 2LS, England.	brian.hurwitz@kcl.ac.uk						*DEP HLTH, 1999, DRUG MIS DEP GUID CL, pR15; EVANS JG, 1995, AGE AGEING, V24, P461, DOI 10.1093/ageing/24.6.461; FOSTER C, 2002, CLIN GUIDELINES LAW, P111; *GEN MED COUNC, 1998, MAINT GOOD MED PRACT, P4; Grilli R, 2000, LANCET, V355, P103, DOI 10.1016/S0140-6736(99)02171-6; Hall MA, 2004, JAMA-J AM MED ASSOC, V291, P1697, DOI 10.1001/jama.291.14.1697-c; Hampton JR, 2003, CLIN MED, V3, P279, DOI 10.7861/clinmedicine.3-3-279; HORTON RC, 1995, ANN INTERN MED, V123, P965, DOI 10.7326/0003-4819-123-12-199512150-00026; HURWITZ B, 2000, NICE CHI NHS REFORMS, P151; Hurwitz B, 1998, CLIN GUIDELINES LAW; HYAMS AL, 1995, ANN INTERN MED, V122, P450, DOI 10.7326/0003-4819-122-6-199503150-00008; MACNEE W, 2004, BMJ-BRIT MED J, V329, P111; McDonagh R J, 2003, J Obstet Gynaecol Can, V25, P139; Merenstein D, 2004, JAMA-J AM MED ASSOC, V291, P1698, DOI 10.1001/jama.291.14.1698-a; Merenstein D, 2004, JAMA-J AM MED ASSOC, V291, P15, DOI 10.1001/jama.291.1.15; Mulrow CD, 2001, J HEALTH POLIT POLIC, V26, P249, DOI 10.1215/03616878-26-2-249; RAZ J, 1984, AUTHORITY, P4; Samanta A, 2003, J ROY SOC MED, V96, P133, DOI 10.1258/jrsm.96.3.133; STRAUS SE, 2000, CMAJ, V153, P837; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; 2003, DRUG THER B, V41, P79	21	62	62	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	2004	329	7473					1024	1028		10.1136/bmj.329.7473.1024	http://dx.doi.org/10.1136/bmj.329.7473.1024			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514351	Green Published			2022-12-28	WOS:000224852400028
J	AbdAlla, S; Lother, H; Langer, A; el Faramawy, Y; Quitterer, U				AbdAlla, S; Lother, H; Langer, A; el Faramawy, Y; Quitterer, U			Factor XIIIA transglutaminase crosslinks AT(1) receptor dimers of monocytes at the onset of atherosclerosis	CELL			English	Article							PERIPHERAL-BLOOD MONOCYTES; ANGIOTENSIN-II; MEMBRANE; HETERODIMERS; EXPRESSION; DIMERIZATION; RECRUITMENT; ACTIVATION; DEFICIENT; PRESSURE	Many G protein-coupled receptors form dimers in cells. However, underlying mechanisms are barely understood. We report here that intracellular factor XIIIA transglutaminase crosslinks agonist-induced AT(1) receptor homodimers via glutamine(315) in the carboxyl-terminal tail of the AT(1) receptor. The crosslinked dimers displayed enhanced signaling and desensitization in vitro and in vivo. Inhibition of angiotensin II release or of factor XIIIA activity prevented formation of crosslinked AT(1) receptor dimers. In agreement with this finding, factor XIIIA-deficient individuals lacked crosslinked AT(1) dimers. Elevated levels of crosslinked AT(1) dimers were present on monocytes of patients with the common atherogenic risk factor hypertension and correlated with an enhanced angiotensin II-dependent monocyte adhesion to endothelial cells. Elevated levels of crosslinked AT(1) receptor dimers on monocytes could sustain the process of atherogenesis, because inhibition of angiotensin II generation or of intracellular factor XIIIA activity suppressed the appearance of crosslinked AT(1) receptors and symptoms of atherosclerosis in ApoE-deficient mice.	Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Inst Pharmakol, D-97078 Wurzburg, Germany	Heinrich Pette Institute; University of Wurzburg	Quitterer, U (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	toph029@rzbox.uni-wuerzburg.de						AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; ACHYUTHAN KE, 1993, J BIOL CHEM, V268, P21284; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Barki-Harrington L, 2003, CIRCULATION, V108, P1611, DOI 10.1161/01.CIR.0000092166.30360.78; Caimi G., 1997, Artery, V22, P328; Cayatte AJ, 2000, ARTERIOSCL THROM VAS, V20, P1724, DOI 10.1161/01.ATV.20.7.1724; Dinauer MC, 1999, BLOOD, V94, P914, DOI 10.1182/blood.V94.3.914.415a11_914_922; Dorffel Y, 1999, HYPERTENSION, V34, P113, DOI 10.1161/01.HYP.34.1.113; Dorffel Y, 2001, ATHEROSCLEROSIS, V157, P151, DOI 10.1016/S0021-9150(00)00674-2; DUGGAN J, 1992, AM J HYPERTENS, V5, P687; DUTTON A, 1975, P NATL ACAD SCI USA, V72, P2568, DOI 10.1073/pnas.72.7.2568; Dzau VJ, 2001, HYPERTENSION, V37, P1047, DOI 10.1161/01.HYP.37.4.1047; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Franco R, 2003, TRENDS BIOCHEM SCI, V28, P238, DOI 10.1016/S0968-0004(03)00065-3; GERRITY RG, 1985, ARTERIOSCLEROSIS, V5, P55, DOI 10.1161/01.ATV.5.1.55; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; Gosgnach W, 2000, CARDIOVASC RES, V45, P486, DOI 10.1016/S0008-6363(99)00269-2; Hayek T, 1998, J CARDIOVASC PHARM, V31, P540, DOI 10.1097/00005344-199804000-00011; Ishiguro H, 2001, J BIOL CHEM, V276, P36742, DOI 10.1074/jbc.M106027200; Kim CJ, 2000, ARTERIOSCL THROM VAS, V20, P1976, DOI 10.1161/01.ATV.20.8.1976; LAZARUS DS, 1994, BBA-MOL BASIS DIS, V1226, P12, DOI 10.1016/0925-4439(94)90052-3; LJUNGMAN S, 1983, HYPERTENSION, V5, P368, DOI 10.1161/01.HYP.5.3.368; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Ma J, 2003, J MOL CELL CARDIOL, V35, P993, DOI 10.1016/S0022-2828(03)00179-2; MUSZBEK L, 1988, THROMB HAEMOSTASIS, V59, P231; MUSZBEK L, 1995, THROMB HAEMOSTASIS, V73, P702; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; POLGAR J, 1990, BIOCHEM J, V267, P557, DOI 10.1042/bj2670557; POSTNOV YV, 1985, PHYSIOL REV, V65, P904, DOI 10.1152/physrev.1985.65.4.904; Quitterer U, 1999, J BIOL CHEM, V274, P14773, DOI 10.1074/jbc.274.21.14773; Quitterer U, 2004, SEMIN NEPHROL, V24, P115, DOI 10.1016/j.semnephrol.2003.11.007; Schiffrin EL, 2002, AM J HYPERTENS, V15, p115S, DOI 10.1016/S0895-7061(02)03006-6; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; WIDGREN BR, 1992, AM J HYPERTENS, V5, P167, DOI 10.1093/ajh/5.3.167; Zeng CY, 2003, HYPERTENSION, V42, P787, DOI 10.1161/01.HYP.0000085334.34963.4E; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288	40	154	160	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2004	119	3					343	354		10.1016/j.cell.2004.10.006	http://dx.doi.org/10.1016/j.cell.2004.10.006			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	868IW	15507206	Bronze			2022-12-28	WOS:000224908300006
J	Bush, GW; Kerry, JF				Bush, GW; Kerry, JF			Election 2004: Health care coverage and drug costs - The candidates speak out	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1815	1819		10.1056/NEJMp048272	http://dx.doi.org/10.1056/NEJMp048272			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509811				2022-12-28	WOS:000224723100001
J	Mukherjee, S				Mukherjee, S			Becoming a physician: A precarious exchange	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Dana Farber Partners Canc Care, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Mukherjee, S (corresponding author), Dana Farber Partners Canc Care, Boston, MA 02115 USA.							Halsted WS, 1904, J HOPKINS HOSP B, V15, P267; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008	3	57	58	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1822	1824		10.1056/NEJMp048085	http://dx.doi.org/10.1056/NEJMp048085			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509813				2022-12-28	WOS:000224723100003
J	Laheij, RJF; Sturkenboom, MCJM; Hassing, RJ; Dieleman, J; Stricker, BHC; Jansen, JBMJ				Laheij, RJF; Sturkenboom, MCJM; Hassing, RJ; Dieleman, J; Stricker, BHC; Jansen, JBMJ			Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BACTERIAL OVERGROWTH; PATIENT RECORDS; OMEPRAZOLE; CIMETIDINE; COLONIZATION; INFECTIONS; RANITIDINE; DYSPEPSIA; THERAPY; MUCOSA	Context Reduction of gastric acid secretion by acid-suppressive therapy allows pathogen colonization from the upper gastrointestinal tract. The bacteria and viruses in the contaminated stomach have been identified as species from the oral cavity. Objective To examine the association between the use of acid-suppressive drugs and occurrence of community-acquired pneumonia. Design, Setting, and Participants Incident acid-suppressive drug users with at least 1 year of valid database history were identified from the Integrated Primary Care Information database between January 1, 1995, and December 31, 2002. Incidence rates for pneumonia were calculated for unexposed and exposed individuals. To reduce confounding by indication, a case-control analysis was conducted nested in a cohort of incident users of acid-suppressive drugs. Cases were all individuals with incident pneumonia during or after stopping use of acid-suppressive drugs. Up to 10 controls were matched to each case for practice, year of birth, sex, and index date. Conditional logistic regression was used to compare the risk of community-acquired pneumonia between use of proton pump inhibitors (PPIs) and H-2-receptor antagonists. Main Outcome Measure Community-acquired pneumonia defined ascertain (proven by radiography or sputum culture) or probable (clinical symptoms consistent with pneumonia). Results The study population comprised 364683 individuals who developed 5551 first occurrences of pneumonia during follow-up. The incidence rates of pneumonia in non-acid-suppressive drug users and acid-suppressive drug users were 0.6 and 2.45 per 100 person-years, respectively. The adjusted relative risk for pneumonia among persons currently using PPIs compared with those who stopped using PPIs was 1.89 (95% confidence interval, 1.36-2.62). Current users of H-2-receptor antagonists had a 1.63-fold increased risk of pneumonia (95% confidence interval, 1.07-2.48) compared with those who stopped use. For current PPI users, a significant positive dose-response relationship was observed. For H-2-receptor antagonist users, the variation in dose was restricted. Conclusion Current use of gastric acid-suppressive therapy was associated with an increased risk of community-acquired pneumonia.	Radboud Univ Nijmegen Med Ctr, Dept Gastroenterol, NL-6500 HB Nijmegen, Netherlands; Erasmus MC Univ, Med Ctr Rotterdam, Dept Med Informat, Rotterdam, Netherlands; Erasmus MC Univ, Med Ctr Rotterdam, Dept Epidemiol & Biostat, Pharmacoepidemiol Unit, Rotterdam, Netherlands	Radboud University Nijmegen; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Laheij, RJF (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Gastroenterol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	R.Laheij@mdl.umcn.nl						*AM GASTR ASS, 1998, GASTROENTEROLOGY, V114, P579; AYBAY C, 1995, GEN PHARMACOL-VASC S, V26, P1413, DOI 10.1016/0306-3623(94)00301-3; BARTLETT JG, 1995, NEW ENGL J MED, V333, P1618, DOI 10.1056/NEJM199512143332408; Brummer RJM, 1996, DIGEST DIS SCI, V41, P2048, DOI 10.1007/BF02093609; DELANEY BC, 2000, COCHRANE DB SYST REV; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; GIANNELLA RA, 1973, ANN INTERN MED, V78, P271, DOI 10.7326/0003-4819-78-2-271; Hayase Y, 2002, J GASTROENTEROL, V37, P101, DOI 10.1007/s005350200003; HOWDEN CW, 1987, GUT, V28, P96, DOI 10.1136/gut.28.1.96; Hurst AF, 1934, BRIT MED J, V1934, P665, DOI 10.1136/bmj.2.3849.665; INGLIS TJJ, 1993, LANCET, V341, P911, DOI 10.1016/0140-6736(93)91208-4; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; Laheij RJF, 2003, ALIMENT PHARM THER, V18, P847, DOI 10.1046/j.1365-2036.2003.01744.x; LAMBERTS H, 1992, FAM PRACT, V9, P330, DOI 10.1093/fampra/9.3.330; LITTMAN A, 1990, LANCET, V335, P222, DOI 10.1016/0140-6736(90)90308-R; Martinez AC, 2000, EUR J CLIN MICROBIOL, V19, P96; Mikawa K, 1999, ANESTH ANALG, V89, P218, DOI 10.1097/00000539-199907000-00040; RUDDELL WSJ, 1980, LANCET, V1, P672; Ruhl CE, 2001, ANN EPIDEMIOL, V11, P477, DOI 10.1016/S1047-2797(01)00236-8; Sanduleanu S, 2001, ALIMENT PHARM THER, V15, P379, DOI 10.1046/j.1365-2036.2001.00888.x; Scaringi L, 1996, SCAND J IMMUNOL, V44, P204, DOI 10.1046/j.1365-3083.1996.d01-300.x; SIMMS HH, 1991, J TRAUMA, V31, P531, DOI 10.1097/00005373-199104000-00013; Thorens J, 1996, GUT, V39, P54, DOI 10.1136/gut.39.1.54; van Bommel MJJ, 2001, POSTGRAD MED J, V77, P514, DOI 10.1136/pmj.77.910.514; VANDERLEI J, 1993, ANN INTERN MED, V119, P1036, DOI 10.7326/0003-4819-119-10-199311150-00011; Vlug AE, 1999, METHOD INFORM MED, V38, P339; *WHO COLL CTR DRUG, 2002, ATC IND DDDS; WICKRAMASINGHE LSP, 1984, BRIT MED J, V289, P1272; Zedtwitz-Liebenstein K, 2002, CRIT CARE MED, V30, P1118, DOI 10.1097/00003246-200205000-00026	29	602	633	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2004	292	16					1955	1960		10.1001/jama.292.16.1955	http://dx.doi.org/10.1001/jama.292.16.1955			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865DO	15507580	Bronze			2022-12-28	WOS:000224682900019
J	Carlsson, J				Carlsson, J			A useless error?	LANCET			English	Editorial Material									Lanssjukhuset, Med Klin, S-39185 Kalmar, Sweden		Carlsson, J (corresponding author), Lanssjukhuset, Med Klin, S-39185 Kalmar, Sweden.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	2004	364	9444					1553	1553		10.1016/S0140-6736(04)17281-4	http://dx.doi.org/10.1016/S0140-6736(04)17281-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500903				2022-12-28	WOS:000224645500036
J	Lo, S; Noble, J; Bowler, I; Angus, B				Lo, S; Noble, J; Bowler, I; Angus, B			Dysuria and a headache	LANCET			English	Editorial Material							TUBERCULOSIS		John Radcliffe Hosp, Dept Med, Oxford OX3 9DU, England; Churchill Hosp, Dept Urol, Oxford OX3 7LJ, England; John Radcliffe Hosp, Dept Microbiol, Oxford OX3 9DU, England	University of Oxford; University of Oxford; University of Oxford	Angus, B (corresponding author), John Radcliffe Hosp, Dept Med, Oxford OX3 9DU, England.	brian.angus@ndm.ox.ac.uk	Angus, Brian/L-9246-2019	Angus, Brian/0000-0003-3598-7784				Benabdellah A, 2002, ANN UROL, V36, P26, DOI 10.1016/S0003-4401(01)00066-3; Benchekroun A, 1998, ANN UROL, V32, P89; GOW JG, 1984, BRIT J UROL, V56, P449; LANE DJ, 1982, MED INT, V1, P983; *STAT NOT COMM DIS, 1998, TUB	5	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1554	1554		10.1016/S0140-6736(04)17282-6	http://dx.doi.org/10.1016/S0140-6736(04)17282-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500904				2022-12-28	WOS:000224645500037
J	Palmer, L; Milhollin, G				Palmer, L; Milhollin, G			Nuclear safety - Brazil's nuclear puzzle	SCIENCE			English	Editorial Material									Wisconsin Project Nucl Arms Control, Washington, DC 20006 USA		Palmer, L (corresponding author), Wisconsin Project Nucl Arms Control, Washington, DC 20006 USA.	liz@wisconsinproject.org						BROOKE J, 1990, NY TIMES        1009, pA1; *CNN COM, 2004, BRAZ COMM NONPR SUSP; COCHRAN TB, 1987, NUCL WEAPONS DATABOO, V2, P127; HIBBS M, 1997, NUCL WEEK, V38, P17; HIBBS M, 2000, NUCL FUEL       0707; HIBBS M, 1998, NUCLEARFUEL, V23, P5; HIBBS M, 1996, NUCLEONICS WEEK, V37, P1; 2004, AGENCE FRANCE P 0405	8	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					617	617		10.1126/science.1104209	http://dx.doi.org/10.1126/science.1104209			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15498998				2022-12-28	WOS:000224756700028
J	Van de Perre, P; Dedet, JP				Van de Perre, P; Dedet, JP			Vaccine efficacy: winning a bathe (not war) against malaria	LANCET			English	Editorial Material									Univ Hosp Montpellier, Bacteriol Lab, F-34395 Montpellier 5, France; Univ Hosp Montpellier, Virol Lab, F-34395 Montpellier 5, France; Univ Hosp Montpellier, Parasitol Lab, F-34395 Montpellier 5, France; Inst Res & Dev, UMR, Montpellier, France; Univ Montpellier, F-34059 Montpellier, France; CNRS, UMR 5093, Montpellier, France	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS)	Van de Perre, P (corresponding author), Univ Hosp Montpellier, Bacteriol Lab, F-34395 Montpellier 5, France.	p-van_de_perre@chu-montpellier.fr	Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427				BALTOU WR, 2004, AM J TROP MED HYG S2, V71, P239; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; Greenwood B, 2004, NATURE, V430, P926, DOI 10.1038/430926a; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; Hoffman S, 2004, NATURE, V430, P940, DOI 10.1038/430940a; Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409; Kumar KA, 2004, J IMMUNOL METHODS, V292, P157, DOI 10.1016/j.jim.2004.06.017; Lyke KE, 2004, VACCINE, V22, P3169, DOI 10.1016/j.vaccine.2004.01.054; Moorthy VS, 2004, LANCET, V363, P150, DOI 10.1016/S0140-6736(03)15267-1; Moree M, 2004, AM J TROP MED HYG, V71, P248, DOI 10.4269/ajtmh.2004.71.248; Nussenzweig R S, 1977, Adv Exp Med Biol, V93, P75; Ter Kuile FO, 2004, AM J TROP MED HYG, V71, P41, DOI 10.4269/ajtmh.2004.71.41; *UNDP WORLD BANK W, 2000, MAL TRANSM BLOCK VAC	13	5	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2004	364	9443					1380	1383		10.1016/S0140-6736(04)17235-8	http://dx.doi.org/10.1016/S0140-6736(04)17235-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488199				2022-12-28	WOS:000224485300004
J	Cai, DS; Frantz, JD; Tawa, NE; Melendez, PA; Oh, BC; Lidov, HGW; Hasselgren, PO; Frontera, WR; Lee, J; Glass, DJ; Shoelson, SE				Cai, DS; Frantz, JD; Tawa, NE; Melendez, PA; Oh, BC; Lidov, HGW; Hasselgren, PO; Frontera, WR; Lee, J; Glass, DJ; Shoelson, SE			IKK beta/NF-kappa B activation causes severe muscle wasting in mice	CELL			English	Article							UBIQUITIN-PROTEASOME PATHWAY; FOXO TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR; SKELETAL-MUSCLE; TNF-ALPHA; PROTEIN BREAKDOWN; ATROPHY; KINASE; CACHEXIA; EXPRESSION	Muscle wasting,accompanies aging and pathological conditions ranging from cancer, cachexia, and diabetes to denervation and immobilization. We show that activation of NF-kappaB, through muscle-specific transgenic expression of activated IkappaB kinase beta (MIKK), causes profound muscle wasting that resembles clinical cachexia. In contrast, no overt phenotype was seen upon muscle-specific inhibition of NF-kappaB through expression of IkappaBalpha superrepressor (MISR). Muscle loss was due to accelerated protein breakdown through ubiquitin-dependent proteolysis. Expression of the E3 ligase MuRF1, a mediator of muscle atrophy, was increased in MIKK mice. Pharmacological or genetic inhibition of the IKKbeta/NF-kappaB/MuRF1 pathway reversed muscle atrophy. Denervation- and tumor-induced muscle loss were substantially reduced and survival rates improved by NF-kappaB inhibition in MISR mice, consistent with a critical role for NF-kappaB in the pathology of muscle wasting and establishing it as an important clinical target for the treatment of muscle atrophy.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Childrens Hosp, Div Genet, Boston, MA 02115 USA; Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; Regeneron Pharmaceut Inc, Muscle Program, Tarrytown, NY 10591 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Harvard University; Spaulding Rehabilitation Hospital; Regeneron; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Shoelson, SE (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	steven.shoelson@joslin.harvard.edu	Glass, David/AAI-3910-2021; Lee, Jongsoon/AAG-1674-2020; Glass, David/C-4782-2012	Oh, Byung-Chul/0000-0002-4277-7083; Lee, Jongsoon/0000-0002-0891-5059; Glass, David/0000-0001-6187-4164	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045943, R01DK051729, R37DK051729, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK051729-09, R01 DK051729-08, DK36836, R01 DK045943-08, R01 DK051729-07, R01 DK045943-07, DK45943, DK51729] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argiles JM, 1999, MED RES REV, V19, P223, DOI 10.1002/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Carpenter S, 2001, PATHOLOGY SKELETAL M; Coletti D, 2002, EMBO J, V21, P631, DOI 10.1093/emboj/21.4.631; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Donoviel DB, 1996, MOL CELL BIOL, V16, P1649; Fanelli FR, 1995, NUTRITION, V11, P595; Fang CH, 1998, INT J MOL MED, V1, P163; Fiorucci S, 2002, P NATL ACAD SCI USA, V99, P15770, DOI 10.1073/pnas.232583599; FONG Y, 1989, AM J PHYSIOL, V256, pR659, DOI 10.1152/ajpregu.1989.256.3.R659; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hunter RB, 2002, FASEB J, V16, P529, DOI 10.1096/fj.01-0866com; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Ladner KJ, 2003, J BIOL CHEM, V278, P2294, DOI 10.1074/jbc.M207129200; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; LARSSON L, 1993, J PHYSIOL-LONDON, V472, P595, DOI 10.1113/jphysiol.1993.sp019964; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC806, DOI 10.1152/ajpcell.00129.2003; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC370, DOI 10.1152/ajpcell.00453.2002; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; LopezSoriano J, 1996, MOL CELL BIOCHEM, V165, P17; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MOLDAWER LL, 1987, AM J PHYSIOL, V253, pC766, DOI 10.1152/ajpcell.1987.253.6.C766; MORA M, 1989, EUR HEART J, V10, P103, DOI 10.1093/eurheartj/10.suppl_D.103; MULLEN BJ, 1990, P SOC EXP BIOL MED, V193, P318; Penner CG, 2001, BIOCHEM BIOPH RES CO, V281, P1331, DOI 10.1006/bbrc.2001.4497; ROTHWARF DM, 2000, SCI STKE; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Stewart CEH, 2004, J CELL PHYSIOL, V198, P237, DOI 10.1002/jcp.10387; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; Tiao G, 1997, AM J PHYSIOL-REG I, V272, pR849, DOI 10.1152/ajpregu.1997.272.3.R849; Tisdale MJ, 1997, J NATL CANCER I, V89, P1763, DOI 10.1093/jnci/89.23.1763; VAN AD, 1996, SCIENCE, V274, P787; Wray CJ, 2003, INT J BIOCHEM CELL B, V35, P698, DOI 10.1016/S1357-2725(02)00341-2; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	45	994	1039	4	71	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2004	119	2					285	298		10.1016/j.cell.2004.09.027	http://dx.doi.org/10.1016/j.cell.2004.09.027			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479644	Bronze			2022-12-28	WOS:000224577200015
J	Florusse, LJ; Peters, CJ; Schoonman, J; Hester, KC; Koh, CA; Dec, SF; Marsh, KN; Sloan, ED				Florusse, LJ; Peters, CJ; Schoonman, J; Hester, KC; Koh, CA; Dec, SF; Marsh, KN; Sloan, ED			Stable low-pressure hydrogen clusters stored in a binary clathrate hydrate	SCIENCE			English	Article								Thermodynamic, x-ray diffraction, and Raman and nuclear magnetic resonance spectroscopy measurements show that clusters of H-2 can be stabilized and stored at low pressures in a sll binary clathrate hydrate. Clusters of H-2 molecules occupy small water cages, whereas large water cages are singly occupied by tetrahydrofuran. The presence of this second guest component stabilizes the clathrate at pressures of 5 megapascals at 279.6 kelvin, versus 300 megapascals at 280 kelvin for pure H-2 hydrate.	Colorado Sch Mines, Dept Chem Engn, Ctr Hydrate Res, Golden, CO 80401 USA; Delft Univ Technol, Fac Sci Appl, Dept Chem Technol Phys Chem & Mol Thermodynam, NL-2628 BL Delft, Netherlands; Delft Univ Technol, Delft Inst Sustainable Energy, Inorgan Chem Lab, NL-2628 BL Delft, Netherlands; Univ Canterbury, Dept Chem & Proc Engn, Christchurch 1, New Zealand	Colorado School of Mines; Delft University of Technology; Delft University of Technology; University of Canterbury	Sloan, ED (corresponding author), Colorado Sch Mines, Dept Chem Engn, Ctr Hydrate Res, Golden, CO 80401 USA.	esloan@mines.edu		Hester, Keith Christian/0000-0002-6134-5091				BARRER RM, 1962, T FARADAY SOC, V58, P2239, DOI 10.1039/tf9625802239; Dyadin YA, 1999, MENDELEEV COMMUN, P209; HOLDER GD, 1983, IND ENG CHEM PROC DD, V22, P170, DOI 10.1021/i200020a029; LOOS TW, 1980, J CHEM THERMODYN, V12, P193; Mao WL, 2004, P NATL ACAD SCI USA, V101, P708, DOI 10.1073/pnas.0307449100; Mao WL, 2002, SCIENCE, V297, P2247, DOI 10.1126/science.1075394; Raeissi S, 2001, J SUPERCRIT FLUID, V20, P221, DOI 10.1016/S0896-8446(01)00071-7; SANDFORD SA, 1993, SCIENCE, V262, P400, DOI 10.1126/science.11542874; Sloan E. D., 1998, CLATHRATE HYDRATES N; TSE JS, 1987, J PHYS-PARIS, V48, P543, DOI 10.1051/jphyscol:1987174; Tulk CA, 1998, J PHYS CHEM A, V102, P8734, DOI 10.1021/jp981497q; VOS WL, 1993, PHYS REV LETT, V71, P3150, DOI 10.1103/PhysRevLett.71.3150; Zhang SX, 2000, J CHEM ENG DATA, V45, P908, DOI 10.1021/je000076a; ZUGIK M, 2001, THESIS KINGS COLL LO	14	588	619	4	156	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					469	471		10.1126/science.1102076	http://dx.doi.org/10.1126/science.1102076			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486295				2022-12-28	WOS:000224626500047
J	Wong, CH; Tan, SH				Wong, CH; Tan, SH			Subacute necrotising fasciitis	LANCET			English	Editorial Material							CLINICAL-FEATURES		Singapore Gen Hosp, Dept Plast Surg, Singapore 169608, Singapore; Singapore Gen Hosp, Dept Hand Surg, Singapore 169608, Singapore	Singapore General Hospital; Singapore General Hospital	Wong, CH (corresponding author), Singapore Gen Hosp, Dept Plast Surg, Singapore 169608, Singapore.	wchinho@hotmail.com						BARKER FG, 1987, J CLIN PATHOL, V40, P335, DOI 10.1136/jcp.40.3.335; CHELSOM J, 1994, LANCET, V344, P1111, DOI 10.1016/S0140-6736(94)90629-7; Jarrett P, 1997, AUST NZ J MED, V27, P29, DOI 10.1111/j.1445-5994.1997.tb00910.x; Nichols RL, 2001, CLIN INFECT DIS, V33, pS84, DOI 10.1086/321862; Wong CH, 2003, J BONE JOINT SURG AM, V85A, P1454, DOI 10.2106/00004623-200308000-00005	5	11	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2004	364	9442					1376	1376		10.1016/S0140-6736(04)17197-3	http://dx.doi.org/10.1016/S0140-6736(04)17197-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474143				2022-12-28	WOS:000224349700036
J	Stuart, SN; Chanson, JS; Cox, NA; Young, BE; Rodrigues, ASL; Fischman, DL; Waller, RW				Stuart, SN; Chanson, JS; Cox, NA; Young, BE; Rodrigues, ASL; Fischman, DL; Waller, RW			Status and trends of amphibian declines and extinctions worldwide	SCIENCE			English	Article							POPULATION DECLINES; CENTRAL-AMERICA; CLIMATE; TOAD; BIODIVERSITY; MORTALITY; DISEASE; FROGS	The first global assessment of amphibians provides new context for the well-publicized phenomenon of amphibian declines. Amphibians are more threatened and are declining more rapidly than either birds or mammals. Although many declines are due to habitat loss and overutilization, other, unidentified processes threaten 48% of rapidly declining species and are driving species most quickly to extinction. Declines are nonrandom in terms of species' ecological preferences, geographic ranges, and taxonomic associations and are most prevalent among Neotropicai montane, stream-associated species. The lack of conservation remedies for these poorly understood declines means that hundreds of amphibian species now face extinction.	IUCN Species Survival Commiss Conservat, Int Ctr Appl Biodivers Sci, Biodivers Assessment Unit, Washington, DC 20036 USA; Natureserve, Monteverde, Puntarenas, Costa Rica; Conservat Int, Ctr Appl Biodivers Sci, Washington, DC 20036 USA	Conservation International	Stuart, SN (corresponding author), IUCN Species Survival Commiss Conservat, Int Ctr Appl Biodivers Sci, Biodivers Assessment Unit, 1919 M St NW, Washington, DC 20036 USA.	s.stuart@conservation.org	Rodrigues, Ana/GYQ-6273-2022; Fapesp, Biota/F-8655-2017; Rodrigues, Ana S.L./A-5914-2009	Fapesp, Biota/0000-0002-9887-8449; Rodrigues, Ana S.L./0000-0003-4775-0127				Berger L, 1998, P NATL ACAD SCI USA, V95, P9031, DOI 10.1073/pnas.95.15.9031; BirdLife International, 2004, STAT WORLDS BIRDS IN; Bosch J, 2001, BIOL CONSERV, V97, P331, DOI 10.1016/S0006-3207(00)00132-4; Burrowes PA, 2004, HERPETOLOGICA, V60, P141, DOI 10.1655/03-50; CZECHURA G V, 1990, Memoirs of the Queensland Museum, V29, P361; Daszak P, 2003, DIVERS DISTRIB, V9, P141, DOI 10.1046/j.1472-4642.2003.00016.x; DROST CA, 1996, CONSERV BIOL, V10, P415; Houlahan JE, 2000, NATURE, V404, P752, DOI 10.1038/35008052; IUCN CONSERVATION INTERNATIONAL AND NATURESERVE, 2004, GLOB AMPH ASS; *IUCN WORLD CONS U, 2003, 2003 IUCN RED LIST T; IUCN - The World Conservation Union, 2001, IUCN RED LIST CAT CR; Laurance WF, 1996, CONSERV BIOL, V10, P406, DOI 10.1046/j.1523-1739.1996.10020406.x; Lips KR, 1999, CONSERV BIOL, V13, P117, DOI 10.1046/j.1523-1739.1999.97185.x; Lips KR, 1998, CONSERV BIOL, V12, P106, DOI 10.1046/j.1523-1739.1998.96359.x; Lips KR, 2004, BIOL CONSERV, V119, P555, DOI 10.1016/j.biocon.2004.01.017; Lips KR, 2003, CONSERV BIOL, V17, P1078, DOI 10.1046/j.1523-1739.2003.01623.x; Lynch John D., 1998, Revista de la Academia Colombiana de Ciencias Exactas Fisicas y Naturales, V22, P149; Magin C, 2003, ORYX, V37, P406; MANZANILLA J, 2004, MEM FUND LA SALLE CI, V62, P5; PECHMANN JHK, 1994, HERPETOLOGICA, V50, P65; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; Pimm SL, 2000, NATURE, V403, P843, DOI 10.1038/35002708; Pounds JA, 2004, NATURE, V427, P107, DOI 10.1038/427107a; POUNDS JA, 1994, CONSERV BIOL, V8, P72, DOI 10.1046/j.1523-1739.1994.08010072.x; Pounds JA, 2001, NATURE, V410, P639, DOI 10.1038/35070683; Pounds JA, 1997, CONSERV BIOL, V11, P1307, DOI 10.1046/j.1523-1739.1997.95485.x; Ron SR, 2003, J HERPETOL, V37, P116, DOI 10.1670/0022-1511(2003)037[0116:PDOTJT]2.0.CO;2; SHERMAN CK, 1993, J HERPETOL, V27, P186, DOI 10.2307/1564935; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Young BE, 2001, CONSERV BIOL, V15, P1213, DOI 10.1046/j.1523-1739.2001.00218.x	30	3001	3325	29	1316	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	2004	306	5702					1783	1786		10.1126/science.1103538	http://dx.doi.org/10.1126/science.1103538			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878FA	15486254	Green Submitted			2022-12-28	WOS:000225630800055
J	Hassink, RJ; Doevendans, PA				Hassink, RJ; Doevendans, PA			Backscatter from lead	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Med Ctr Utrecht, NL-3584 CT Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Hassink, RJ (corresponding author), Univ Med Ctr Utrecht, NL-3584 CT Utrecht, Netherlands.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					E17	E17		10.1056/ENEJMicm030057	http://dx.doi.org/10.1056/ENEJMicm030057			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525716				2022-12-28	WOS:000224851300013
J	Smetacek, V; Mechsner, F				Smetacek, V; Mechsner, F			Making sense	NATURE			English	Editorial Material									Alfred Wegener Inst Polar & Marine Res, D-27570 Bremerhaven, Germany; Inst Occupat Physiol, D-44139 Dortmund, Germany; Inst Adv Study, Delmenhorst, Germany	Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research	Smetacek, V (corresponding author), Alfred Wegener Inst Polar & Marine Res, Handelshafen 12, D-27570 Bremerhaven, Germany.							Angelaki DE, 2004, NATURE, V430, P560, DOI 10.1038/nature02754; Cole J., 1995, PRIDE DAILY MARATHON; Sherrington C, 1906, INTEGRATIVE ACTION N; Smetacek V, 2002, NATURE, V415, P481, DOI 10.1038/415481a	4	20	20	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	2004	432	7013					21	21		10.1038/432021a	http://dx.doi.org/10.1038/432021a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525964	Bronze			2022-12-28	WOS:000224854900022
J	Filippi, M; Rovaris, M; Inglese, M; Barkhof, F; De Stefano, N; Smith, S; Comi, G				Filippi, M; Rovaris, M; Inglese, M; Barkhof, F; De Stefano, N; Smith, S; Comi, G		ETOMS Study Grp	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial	LANCET			English	Article							CLINICALLY ISOLATED SYNDROMES; ENHANCING LESIONS; VENTRICULAR ENLARGEMENT; MAGNETIZATION-TRANSFER; PROGNOSTIC VALUE; IMAGING FINDINGS; ATROPHY; VOLUME; MRI; DISABILITY	Background In patients who present with clinically isolated syndromes suggestive of multiple sclerosis, interferon beta-la is effective in delaying evolution to clinically definite disease and in reducing MRI-measured disease activity. We aimed to assess whether this drug can also reduce the rate of brain volume decrease in such patients enrolled in the ETOMS (early treatment of multiple sclerosis) trial. Methods MRI data for brain volume measurements at baseline, month 12, and month 24 were available from 131, 111, and 112 patients assigned treatment (22 mug interferon beta-la), and 132, 98, and 99 patients assigned placebo respectively. Normalised brain parenchymal volume (NBV) at baseline and percentage brain volume changes (PBVC) were measured with a fully-automated segmentation technique. The primary endpoint was conversion to clinically definite multiple sclerosis due to clinical relapse. Analysis was by intention to treat. Findings 41 (31%) of 131 patients on interferon beta-1a and 62 (47%) of 132 on placebo converted to clinically definite multiple sclerosis (odds ratio 0.52 [95% CI 0.31-0.86], p=0.0115). Mean PBVC for patients on placebo was -0.83% during the first year, -0.67% during the second year, and -1.68% during the entire study period. Respective values for treated patients were -0.62%, -0.61%, and -1.18%. The changes in brain volume were significant in both groups at all timepoints. A significant treatment effect was detected for month 24 versus baseline values (p=0.0031). The number of new T2 lesions formed during the first year correlated, weakly with, PBVC during the second year. Interpretation Early treatment with interferon beta-la is effective in reducing conversion to clinically definite multiple sclerosis and in slowing progressive loss of brain tissue in patients with clinically isolated syndromes. The modest correlation between new lesion formation and brain volume decrease suggests that inflammatory and neurodegenerative processes are, at least partly, dissociated from the earliest clinical stage of multiple sclerosis onwards.	Sci Inst & Univ Osped San Raffaele, Dept Neurol, Neuroimaging Res Unit, I-20132 Milan, Italy; Sci Inst & Univ Osped San Raffaele, Dept Neurol, Clin Trials Unit, I-20132 Milan, Italy; Vrije Univ Amsterdam Med Ctr, Dept Neuroradiol, Amsterdam, Netherlands; Univ Siena, Inst Neurol Sci, Neurometab Unit, I-53100 Siena, Italy; Univ Oxford, Funct Magnet Resonance Imaging Brain Ctr, Dept Clin Neurol, Oxford OX1 2JD, England	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Siena; University of Oxford	Filippi, M (corresponding author), Sci Inst & Univ Osped San Raffaele, Dept Neurol, Neuroimaging Res Unit, Via Olgettina 60, I-20132 Milan, Italy.	filippi.massimo@hsr.it	Rovaris, Marco/AAA-6040-2020; Filippi, Massimo/K-1755-2018; Barkhof, Frederik/AAJ-6226-2020; Macedo, Ana/L-9912-2018; Inglese, Matilde/AAH-3189-2020	Rovaris, Marco/0000-0001-9691-1957; Filippi, Massimo/0000-0002-5485-0479; Barkhof, Frederik/0000-0003-3543-3706; Macedo, Ana/0000-0002-6978-8989; Inglese, Matilde/0000-0002-9610-0297; Smith, Stephen/0000-0001-8166-069X	Engineering and Physical Sciences Research Council [GR/R77018/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		ALLEN IV, 1979, J NEUROL SCI, V41, P81, DOI 10.1016/0022-510X(79)90142-4; Brex PA, 2002, NEW ENGL J MED, V346, P158, DOI 10.1056/NEJMoa011341; Brex PA, 2000, NEUROLOGY, V54, P1689, DOI 10.1212/WNL.54.8.1689; Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Dalton CM, 2002, J NEUROL NEUROSUR PS, V73, P141, DOI 10.1136/jnnp.73.2.141; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; FILIPPI M, 1994, NEUROLOGY, V44, P635, DOI 10.1212/WNL.44.4.635; Filippi M, 2003, BRAIN, V126, P433, DOI 10.1093/brain/awg038; Fisher E, 2002, NEUROLOGY, V59, P1412, DOI 10.1212/01.WNL.0000036271.49066.06; Freeborough PA, 1997, IEEE T MED IMAGING, V16, P623, DOI 10.1109/42.640753; Gasperini C, 2000, MAGN RESON IMAGING, V18, P761, DOI 10.1016/S0730-725X(00)00156-9; Iannucci G, 2000, AM J NEURORADIOL, V21, P1034; Jacobs LD, 2000, NEW ENGL J MED, V343, P898, DOI 10.1056/NEJM200009283431301; Jones CK, 2001, NEUROLOGY, V56, pA379; Kalkers NF, 2002, ARCH NEUROL-CHICAGO, V59, P1572, DOI 10.1001/archneur.59.10.1572; Kalkers NF, 2001, NEUROLOGY, V57, P1253, DOI 10.1212/WNL.57.7.1253; Kaplan MR, 1997, NATURE, V386, P724, DOI 10.1038/386724a0; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Leist TP, 2001, ARCH NEUROL-CHICAGO, V58, P57, DOI 10.1001/archneur.58.1.57; Martino G, 2002, LANCET NEUROL, V1, P499, DOI 10.1016/S1474-4422(02)00223-5; Mastronardo G, 1999, AM J NEURORADIOL, V20, P1268; Miller DH, 2002, BRAIN, V125, P1676, DOI 10.1093/brain/awf177; MILLER DH, 1991, J NEUROL NEUROSUR PS, V54, P683, DOI 10.1136/jnnp.54.8.683; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; O'Riordan JI, 1998, BRAIN, V121, P495, DOI 10.1093/brain/121.3.495; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; Rao AB, 2002, NEUROLOGY, V59, P688, DOI 10.1212/WNL.59.5.688; Rovaris M, 1999, CURR OPIN NEUROL, V12, P337, DOI 10.1097/00019052-199906000-00012; Rovaris M, 2003, RADIOLOGY, V227, P731, DOI 10.1148/radiol.2273020721; Rovaris M, 1997, J NEUROL, V244, P266, DOI 10.1007/s004150050083; Rovaris M, 2001, BRAIN, V124, P1803, DOI 10.1093/brain/124.9.1803; Rudick RA, 1999, NEUROLOGY, V53, P1698, DOI 10.1212/WNL.53.8.1698; Rudick RA, 2000, MULT SCLER, V6, P365, DOI 10.1191/135245800701566322; Saindane AM, 2000, NEUROLOGY, V55, P61, DOI 10.1212/WNL.55.1.61; SIPE JC, 1984, NEUROLOGY, V34, P1368, DOI 10.1212/WNL.34.10.1368; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2001, J COMPUT ASSIST TOMO, V25, P466, DOI 10.1097/00004728-200105000-00022; Traboulsee A, 2002, NEUROLOGY, V59, P126, DOI 10.1212/WNL.59.1.126; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Trapp BD, 1999, NEUROSCIENTIST, V5, P48, DOI 10.1177/107385849900500107; Yong VW, 1998, NEUROLOGY, V51, P682; Zivadinov R, 2001, J NEUROL NEUROSUR PS, V70, P773, DOI 10.1136/jnnp.70.6.773	43	196	201	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1489	1496		10.1016/S0140-6736(04)17271-1	http://dx.doi.org/10.1016/S0140-6736(04)17271-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500893				2022-12-28	WOS:000224645500026
J	McFadden, EP; Stabile, E; Regar, E; Cheneau, E; Ong, ATL; Kinnaird, T; Suddath, WO; Weissman, NJ; Torguson, R; Kent, KM; Pichard, AD; Satler, LF; Waksman, R; Serruys, PW				McFadden, EP; Stabile, E; Regar, E; Cheneau, E; Ong, ATL; Kinnaird, T; Suddath, WO; Weissman, NJ; Torguson, R; Kent, KM; Pichard, AD; Satler, LF; Waksman, R; Serruys, PW			Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy	LANCET			English	Article							NONCARDIAC SURGERY; SLOW-RELEASE; PACLITAXEL	Although the safety profiles of coronary stents eluting sirolimus or paclitaxel do not seem to differ from those of bare metal stents in the short-to-medium term, concern has arisen about the potential for late stent thromboses related to delayed endothelialisation of the stent struts. We report four cases of angiographically-confirmed stent thrombosis that occurred late after elective implantation of polymer-based paxlitaxel-eluting (343 and 442 days) or sirolimus-eluting (335 and 375 days) stents, and resulted in myocardial infarction. All cases arose soon after antiplatelet therapy was interrupted. If confirmed in systematic long-term follow-up studies, our findings have potentially serious clinical implications.	Erasmus Univ, Thoraxctr, NL-3000 DR Rotterdam, Netherlands; Washington Hosp Ctr, Washington, DC 20010 USA	Erasmus University Rotterdam; Erasmus MC; MedStar Washington Hospital Center	Serruys, PW (corresponding author), Erasmus Univ, Thoraxctr, NL-3000 DR Rotterdam, Netherlands.	p.w.j.c.serruys@erasmusmc.nl	Regar, E/ABA-3301-2020; Regar, Evelyn/AAD-8201-2019	stabile, eugenio/0000-0001-9763-6010; stabile, eugenio/0000-0002-4544-3142				Carter AJ, 2004, CARDIOVASC RES, V63, P617, DOI 10.1016/j.cardiores.2004.04.029; Colombo A, 2003, CIRCULATION, V108, P788, DOI 10.1161/01.CIR.0000086926.62288.A6; Farb A, 2001, CIRCULATION, V104, P473, DOI 10.1161/hc3001.092037; Kaluza GL, 2000, J AM COLL CARDIOL, V35, P1288, DOI 10.1016/S0735-1097(00)00521-0; Schwartz RS, 2004, J AM COLL CARDIOL, V44, P1373, DOI 10.1016/j.jacc.2004.04.060; Wilson SH, 2003, J AM COLL CARDIOL, V42, P234, DOI 10.1016/S0735-1097(03)00622-3	7	1088	1168	0	40	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1519	1521		10.1016/S0140-6736(04)17275-9	http://dx.doi.org/10.1016/S0140-6736(04)17275-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500897				2022-12-28	WOS:000224645500030
J	Bronnimann, S; Luterbacher, J; Staehelin, J; Svendby, TM; Hansen, G; Svenoe, T				Bronnimann, S; Luterbacher, J; Staehelin, J; Svendby, TM; Hansen, G; Svenoe, T			Extreme climate of the global troposphere and stratosphere in 1940-42 related to El Nino	NATURE			English	Article							NORTHERN-HEMISPHERE; DATA SET; TEMPERATURE; ENSO; TELECONNECTIONS; OSCILLATION; ANOMALIES; TRENDS; WINTER	Although the El Nino/Southern Oscillation phenomenon is the most prominent mode of climate variability(1) and affects weather and climate in large parts of the world, its effects on Europe and the high-latitude stratosphere are controversial(2-5). Using historical observations and reconstruction techniques, we analyse the anomalous state of the troposphere and stratosphere in the Northern Hemisphere from 1940 to 1942 that occurred during a strong and long-lasting El Nino event. Exceptionally low surface temperatures in Europe and the north Pacific Ocean coincided with high temperatures in Alaska. In the lower stratosphere, our reconstructions show high temperatures over northern Eurasia and the north Pacific Ocean, and a weak polar vortex. In addition, there is observational evidence for frequent stratospheric warmings and high column ozone at Arctic and mid-latitude sites. We compare our historical data for the period 1940-42 with more recent data and a 650-year climate model simulation. We conclude that the observed anomalies constitute a recurring extreme state of the global troposphere-stratosphere system in northern winter that is related to strong El Nino events.	ETH, Inst Atmospher & Climate Sci, Honggerberg HPP, CH-8093 Zurich, Switzerland; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Univ Bern, NCCR Climate, CH-3012 Bern, Switzerland; Univ Bern, Inst Geog, CH-3012 Bern, Switzerland; Univ Oslo, Dept Phys, N-0316 Oslo, Norway; Norwegian Inst Air Res, Polar Environm Ctr, N-9296 Tromso, Norway; Norwegian Polar Res Inst, N-9171 Longyearbyen, Norway	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Arizona; University of Bern; University of Bern; University of Oslo; Norwegian Institute for Air Research; Norwegian Polar Institute	Bronnimann, S (corresponding author), ETH, Inst Atmospher & Climate Sci, Honggerberg HPP, CH-8093 Zurich, Switzerland.	stefan.broennimann@env.ethz.ch	Brönnimann, Stefan/A-5737-2008	Bronnimann, Stefan/0000-0001-9502-7991; Luterbacher, Juerg/0000-0002-8569-0973				Alexander MA, 2002, J CLIMATE, V15, P2205, DOI 10.1175/1520-0442(2002)015<2205:TABTIO>2.0.CO;2; Ambaum MHP, 2002, J CLIMATE, V15, P1969, DOI 10.1175/1520-0442(2002)015<1969:TNTSC>2.0.CO;2; ANGIONE RJ, 1983, J CLIM APPL METEOROL, V22, P1377, DOI 10.1175/1520-0450(1983)022<1377:BORFT>2.0.CO;2; Bronnimann S, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019611; Bronnimann S, 2004, CLIM DYNAM, V22, P499, DOI 10.1607/s00382-004-0391-3; Bronnimann S, 2003, Q J ROY METEOR SOC, V129, P2819, DOI 10.1256/qj.02.145; Bronnimann S, 2003, INT J CLIMATOL, V23, P769, DOI 10.1002/joc.914; Chavez FP, 2003, SCIENCE, V299, P217, DOI 10.1126/science.1075880; Diaz H.F., 2000, EL NINO SO OSCILLATI; FRAEDRICH K, 1992, INT J CLIMATOL, V12, P25, DOI 10.1002/joc.3370120104; GOLDSMITH P, 1973, NATURE, V244, P545, DOI 10.1038/244545a0; Greatbatch RJ, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018542; Hurrell J. W., 2003, N ATLANTIC OSCILLATI; Jones PD, 2003, J CLIMATE, V16, P206, DOI 10.1175/1520-0442(2003)016<0206:HALSSA>2.0.CO;2; Kaplan A, 1998, J GEOPHYS RES-OCEANS, V103, P18567, DOI 10.1029/97JC01734; Kistler R, 2001, B AM METEOROL SOC, V82, P247, DOI 10.1175/1520-0477(2001)082<0247:TNNYRM>2.3.CO;2; Labitzke K., 1999, STRATOSPHERE PHENOME; Labitzke K., 2000, SPARC NEWSL, V15, P11; Limpasuvan V, 2004, J CLIMATE, V17, P2584, DOI 10.1175/1520-0442(2004)017<2584:TLCOTN>2.0.CO;2; Mantua NJ, 1997, B AM METEOROL SOC, V78, P1069, DOI 10.1175/1520-0477(1997)078<1069:APICOW>2.0.CO;2; Merkel U, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013726; Newman PA, 2001, J GEOPHYS RES-ATMOS, V106, P19999, DOI 10.1029/2000JD000061; Pozo-Vazquez D, 2001, J CLIMATE, V14, P3408, DOI 10.1175/1520-0442(2001)014<3408:TABEAW>2.0.CO;2; Randel WJ, 2002, J METEOROL SOC JPN, V80, P849, DOI 10.2151/jmsj.80.849; Staehelin J, 2001, REV GEOPHYS, V39, P231, DOI 10.1029/1999RG000059; Staehelin J, 1998, J GEOPHYS RES-ATMOS, V103, P5827, DOI 10.1029/97JD02402; Svendby TM, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003963; Trenberth KE, 1998, J GEOPHYS RES-OCEANS, V103, P14291, DOI 10.1029/97JC01444; TRENBERTH KE, 1980, MON WEATHER REV, V108, P855, DOI 10.1175/1520-0493(1980)108<0855:TNHSLP>2.0.CO;2; TRENBERTH KE, 1994, CLIM DYNAM, V9, P303, DOI 10.1007/BF00204745; VANLOON H, 1987, MON WEATHER REV, V115, P357, DOI 10.1175/1520-0493(1987)115<0357:TSOPVT>2.0.CO;2	31	146	149	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					971	974		10.1038/nature02982	http://dx.doi.org/10.1038/nature02982			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496919				2022-12-28	WOS:000224585600040
J	Lynn, WA; Lightman, S				Lynn, WA; Lightman, S			The eye in systemic infection	LANCET			English	Review							ACUTE RETINAL NECROSIS; ENDOGENOUS BACTERIAL ENDOPHTHALMITIS; OCULAR FUNDUS FINDINGS; TOXOPLASMIC RETINOCHOROIDITIS; CYTOMEGALOVIRUS RETINITIS; CONGENITAL TOXOPLASMOSIS; CLINICAL CHARACTERISTICS; POSTERIOR SEGMENT; VIRUS TYPE-1; DISEASE	Bacterial, fungal, viral, and parasitic pathogens all cause systemic infection and can spread to the eye. Dissemination of pathogens via the bloodstream can lead to direct involvement of the eye. Visual loss is common in bacterial or fungal endophthalmitis, and toxoplasmosis is a major cause of ocular morbidity and poor vision after congenital or acquired infection. Some infections cause intraocular damage by indirect mechanisms (eg, HIV-mediated immunosuppression), leading to opportunistic infections such as cytomegalovirus infection, periocular nerve involvement due to leprosy, and hypersensitivity reactions in tuberculosis. Eye symptoms might indicate the outcome of an underlying infection, such as development of retinal ischaemia in severe malaria, which is associated with a poor prognosis. Successful outcome for patients with ocular infection depends on close collaboration between clinicians identifying and treating underlying disease, specialist ophthalmic review, and ophthalmic interventional skills (when needed).	Ealing Gen Hosp, Infect & Immun Unit, Dept Infect Dis, Southall UB1 3HW, Middx, England; Moorfields Eye Hosp, Inst Ophthalmol, London, England	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust	Lynn, WA (corresponding author), Ealing Gen Hosp, Infect & Immun Unit, Dept Infect Dis, Southall UB1 3HW, Middx, England.	william.lynn@eht.nhs.uk						Al-Abdulla NA, 2002, AM J OPHTHALMOL, V134, P912, DOI 10.1016/S0002-9394(02)01811-1; Aldave AJ, 2001, CURR OPIN OPHTHALMOL, V12, P433, DOI 10.1097/00055735-200112000-00008; Ang LPK, 2000, EYE, V14, P855, DOI 10.1038/eye.2000.236; Antsaklis A, 2002, PRENATAL DIAG, V22, P1107, DOI 10.1002/pd.476; Arcieri E S, 2001, Braz J Infect Dis, V5, P356, DOI 10.1590/S1413-86702001000600011; AVILA MP, 1984, ARCH OPHTHALMOL-CHIC, V102, P384; Bains HS, 2003, ARCH OPHTHALMOL-CHIC, V121, P205, DOI 10.1001/archopht.121.2.205; BARONDES MJ, 1992, ANN OPHTHALMOL, V24, P335; Batisse D, 1996, AIDS, V10, P55, DOI 10.1097/00002030-199601000-00008; Bayu S, 1997, CLIN INFECT DIS, V24, P1256, DOI 10.1086/513626; BEDROSSIAN RH, 1955, J PEDIATR-US, V46, P329, DOI 10.1016/S0022-3476(55)80292-2; Behrens GMN, 2000, IMMUNOBIOLOGY, V202, P186, DOI 10.1016/S0171-2985(00)80065-0; Betharia SM, 2002, OPHTHALMOLOGICA, V216, P300, DOI 10.1159/000063839; Bialasiewicz AA, 2001, OPHTHALMOLOGE, V98, P972, DOI 10.1007/s003470170047; BIGLAN AW, 1979, AM J OPHTHALMOL, V88, P898, DOI 10.1016/0002-9394(79)90568-3; Binder MI, 2003, MEDICINE, V82, P97, DOI 10.1097/00005792-200303000-00004; Bosch-Driessen EH, 1999, AM J OPHTHALMOL, V128, P421, DOI 10.1016/S0002-9394(99)00271-8; Bosch-Driessen LEH, 2002, OPHTHALMOLOGY, V109, P869, DOI 10.1016/S0161-6420(02)00990-9; Bosch-Driessen LH, 2002, AM J OPHTHALMOL, V134, P34, DOI 10.1016/S0002-9394(02)01537-4; Bouza E, 1997, MEDICINE, V76, P53, DOI 10.1097/00005792-199701000-00005; Boyer DS, 2002, AM J OPHTHALMOL, V133, P484; Brown D. H., 1970, Journal of Pediatric Ophthalmology, V7, P182; Brun SC, 1997, INT OPHTHALMOL CLIN, V37, P25, DOI 10.1097/00004397-199703740-00004; CARITHERS HA, 1978, AM J DIS CHILD, V132, P1195, DOI 10.1001/archpedi.1978.02120370043011; Chen YC, 2003, J ANTIMICROB CHEMOTH, V52, P71, DOI 10.1093/jac/dkg275; CHERUBINI TD, 1969, ARCH OPHTHALMOL-CHIC, V81, P363, DOI 10.1001/archopht.1969.00990010365012; Chippaux J P, 1999, Ophthalmic Epidemiol, V6, P229, DOI 10.1076/opep.6.4.229.4185; COHEN J, 1999, INFECT DIS; Comer JA, 2001, VECTOR-BORNE ZOONOT, V1, P91, DOI 10.1089/153036601316977714; Cook AJC, 2000, BRIT MED J, V321, P142, DOI 10.1136/bmj.321.7254.142; Courtright P, 2002, LEPROSY REV, V73, P225; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; CRUMP JRC, 1992, CLIN INFECT DIS, V14, P1069, DOI 10.1093/clinids/14.5.1069; Cunningham ET, 2000, AM J OPHTHALMOL, V130, P340, DOI 10.1016/S0002-9394(00)00573-0; DELAEY JJ, 1983, DOC OPHTHALMOL, V56, P11, DOI 10.1007/BF00154703; DENNING DW, 1990, REV INFECT DIS, V12, P1147; DUTTON GN, 1983, T OPHTHAL SOC UK, V103, P503; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Ejere H, 2001, COCHRANE DB SYST REV, V1; Feman SS, 2002, T AM OPHTHAL SOC, V100, P70; Feman Stephen S, 2002, Trans Am Ophthalmol Soc, V100, P67; FRIEDMAN.CT, 1969, ARCH OPHTHALMOL-CHIC, V81, P481; GARDNER BP, 1991, AM J OPHTHALMOL, V112, P567, DOI 10.1016/S0002-9394(14)76860-6; GERDE LS, 1982, SOUTHERN MED J, V75, P255, DOI 10.1097/00007611-198202000-00044; Gilbert R, 2003, BJOG-INT J OBSTET GY, V110, P112, DOI 10.1016/S1470-0328(02)02325-X; GILBERT RE, 2003, COCHRANE LIB; GLASNER PD, 1992, AM J OPHTHALMOL, V114, P136, DOI 10.1016/S0002-9394(14)73976-5; Gopal L, 2003, AM J OPHTHALMOL, V135, P93, DOI 10.1016/S0002-9394(02)01858-5; GRANT SM, 1990, DRUGS, V39, P877, DOI 10.2165/00003495-199039060-00006; Gungor K, 2002, EUR J OPHTHALMOL, V12, P232; Gupta A, 2001, RETINA-J RET VIT DIS, V21, P435, DOI 10.1097/00006982-200110000-00004; Hall LR, 1999, CLIN MICROBIOL REV, V12, P445, DOI 10.1128/CMR.12.3.445; Haritoglou C, 2000, OPHTHALMOLOGE, V97, P433, DOI 10.1007/s003470070094; Hero M, 1997, ARCH OPHTHALMOL-CHIC, V115, P997, DOI 10.1001/archopht.1997.01100160167005; HOGAN MJ, 1964, ARCH OPHTHALMOL-CHIC, V72, P592; Hoh H B, 1998, Med J Malaysia, V53, P288; HOLLAND GN, 1992, ARCH OPHTHALMOL-CHIC, V110, P1435, DOI 10.1001/archopht.1992.01080220097029; Jabs DA, 2003, AM J OPHTHALMOL, V135, P26, DOI 10.1016/S0002-9394(02)01759-2; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; Jones JL, 2001, OBSTET GYNECOL SURV, V56, P296, DOI 10.1097/00006254-200105000-00025; Jumper JM, 2000, RETINA-J RET VIT DIS, V20, P190, DOI 10.1097/00006982-200003000-00012; Kaimbo Wa Kaimbo D, 1999, Bull Soc Belge Ophtalmol, V271, P51; KARMA A, 1995, AM J OPHTHALMOL, V119, P127, DOI 10.1016/S0002-9394(14)73864-4; Kato T, 1997, JPN J OPHTHALMOL, V41, P196, DOI 10.1016/S0021-5155(97)00002-6; Kayembe DL, 2003, TROP MED INT HEALTH, V8, P83, DOI 10.1046/j.1365-3156.2003.00957.x; Kayikcioglu O, 2000, OCUL IMMUNOL INFLAMM, V8, P59, DOI 10.1076/0927-3948(200003)8:1;1-S;FT059; KESTELYN P, 1993, AM J OPHTHALMOL, V116, P721, DOI 10.1016/S0002-9394(14)73472-5; Khan Tajamul, 2002, J Ayub Med Coll Abbottabad, V14, P29; Khubchandani R, 2002, ARCH NEUROL-CHICAGO, V59, P1633, DOI 10.1001/archneur.59.10.1633; KLEMOLA E, 1965, BMJ-BRIT MED J, V2, P1099, DOI 10.1136/bmj.2.5470.1099; Kochar D K, 2000, J Assoc Physicians India, V48, P473; Kochar DK, 1998, QJM-INT J MED, V91, P845, DOI 10.1093/qjmed/91.12.845; Kontoyiannis DP, 2001, MYCOSES, V44, P125, DOI 10.1046/j.1439-0507.2001.00649.x; Kramer M, 2003, HOSP MED, V64, P421, DOI 10.12968/hosp.2003.64.7.2313; Krishna R, 2000, EYE, V14, P30, DOI 10.1038/eye.2000.7; Kuo IC, 1998, AM J OPHTHALMOL, V125, P306, DOI 10.1016/S0002-9394(99)80136-6; KUPPERMANN BD, 1993, AM J OPHTHALMOL, V115, P575, DOI 10.1016/S0002-9394(14)71453-9; Lalezari J, 2002, J ACQ IMMUN DEF SYND, V30, P392, DOI [10.1097/00042560-200208010-00004, 10.1097/01.QAI.0000018570.35064.1D]; Laverdiere M, 2002, J ANTIMICROB CHEMOTH, V50, P119, DOI 10.1093/jac/dkf074; Lee MS, 2003, AM J OPHTHALMOL, V135, P412, DOI 10.1016/S0002-9394(02)01945-1; Lee SY, 2002, OPHTHALMOLOGY, V109, P1879, DOI 10.1016/S0161-6420(02)01225-3; Lee WH, 2000, BRIT J OPHTHALMOL, V84, P667; Lewallen S, 1996, T ROY SOC TROP MED H, V90, P144, DOI 10.1016/S0035-9203(96)90116-9; Lewallen S, 1999, T ROY SOC TROP MED H, V93, P619, DOI 10.1016/S0035-9203(99)90071-8; Lewallen S, 2000, ARCH OPHTHALMOL-CHIC, V118, P924; Lewallen S, 1998, ARCH OPHTHALMOL-CHIC, V116, P293, DOI 10.1001/archopht.116.3.293; Lynn WA, 2004, LANCET INFECT DIS, V4, P456, DOI 10.1016/S1473-3099(04)01061-8; Maertzdorf J, 2000, ANN NEUROL, V48, P936, DOI 10.1002/1531-8249(200012)48:6<936::AID-ANA16>3.3.CO;2-Z; MAETZ HM, 1987, J INFECT DIS, V156, P414, DOI 10.1093/infdis/156.2.414; Mancel E, 1999, AUST NZ J OPHTHALMOL, V27, P380, DOI 10.1046/j.1440-1606.1999.00269.x; MANDELL GL, 2000, MANDELL DOUGLAS BENN; Margo C E, 1983, J Pediatr Ophthalmol Strabismus, V20, P180; Martin DF, 1999, AM J OPHTHALMOL, V127, P329; McCannel CA, 1996, AM J OPHTHALMOL, V121, P35, DOI 10.1016/S0002-9394(14)70532-X; Merle H, 2002, AM J OPHTHALMOL, V134, P190, DOI 10.1016/S0002-9394(02)01521-0; Mikkila HO, 2000, OPHTHALMOLOGY, V107, P581, DOI 10.1016/S0161-6420(99)00128-1; Nagaki Y, 2001, JPN J OPHTHALMOL, V45, P108, DOI 10.1016/S0021-5155(00)00293-8; Nakanishi F, 2000, JPN J OPHTHALMOL, V44, P561, DOI 10.1016/S0021-5155(00)00207-0; NI C, 1982, International Ophthalmology Clinics, V22, P103, DOI 10.1097/00004397-198202230-00009; ODAY DM, 1985, CURR EYE RES, V4, P131, DOI 10.3109/02713688508999978; OKADA AA, 1994, OPHTHALMOLOGY, V101, P832; Pepose JS, 1996, OCULAR INFECT IMMUNI, V1; Polic B, 1998, J EXP MED, V188, P1047, DOI 10.1084/jem.188.6.1047; Porges Y, 2003, CORNEA, V22, P1, DOI 10.1097/00003226-200301000-00001; Raina UK, 2000, AM J OPHTHALMOL, V130, P843, DOI 10.1016/S0002-9394(00)00646-2; Rao Narsing A., 1994, Indian Journal of Ophthalmology, V42, P51; Rathinam SR, 1999, OCUL IMMUNOL INFLAMM, V7, P109, DOI 10.1076/ocii.7.2.109.4020; RICHARDS FO, 1995, CLIN INFECT DIS, V21, pS49, DOI 10.1093/clinids/21.Supplement_1.S49; Rivero ME, 1999, ARCH OPHTHALMOL-CHIC, V117, P616; Rohatgi J, 2000, JPN J OPHTHALMOL, V44, P146, DOI 10.1016/S0021-5155(99)00185-9; Rosberger DF, 1998, AM J OPHTHALMOL, V125, P301, DOI 10.1016/S0002-9394(99)80135-4; ROSEN PH, 1990, EYE, V4, P486, DOI 10.1038/eye.1990.63; Sabrosa Nelson Alexandre, 2002, Ophthalmol Clin North Am, V15, P351, DOI 10.1016/S0896-1549(02)00024-X; Sabrosa NA, 2001, CURR OPIN OPHTHALMOL, V12, P450, DOI 10.1097/00055735-200112000-00010; Salomon N, 1999, Semin Respir Infect, V14, P353; Sarui H, 2002, AM J MED SCI, V324, P109, DOI 10.1097/00000441-200208000-00012; SCHANTZ PM, 1979, AM J TROP MED HYG, V28, P24, DOI 10.4269/ajtmh.1979.28.24; Schwartz EC, 1997, BRIT J OPHTHALMOL, V81, P443, DOI 10.1136/bjo.81.6.443; SEE RF, 2002, OPHTHALMOL CLIN N AM, V15, pR8; See Robert F, 2002, Ophthalmol Clin North Am, V15, P529, DOI 10.1016/S0896-1549(02)00048-2; SEKHAR GC, 1994, DOC OPHTHALMOL, V87, P211, DOI 10.1007/BF01203851; SEMBA RD, 1990, OPHTHALMOLOGY, V97, P1334; SHARKEY JA, 1993, BRIT J OPHTHALMOL, V77, P253, DOI 10.1136/bjo.77.4.253; Smiddy W E, 1998, Curr Opin Ophthalmol, V9, P66, DOI 10.1097/00055735-199806000-00012; SMITH RE, 1972, AM J OPHTHALMOL, V74, P1126, DOI 10.1016/0002-9394(72)90732-5; SMITH TW, 1977, AM J OPHTHALMOL, V84, P259, DOI 10.1016/0002-9394(77)90860-1; SPECHT CS, 1991, OPHTHALMOLOGY, V98, P1356, DOI 10.1016/S0161-6420(91)32126-2; Stanford MR, 2003, OPHTHALMOLOGY, V110, P926, DOI 10.1016/S0161-6420(03)00083-6; Steinemann TL, 1999, ARCH OPHTHALMOL-CHIC, V117, P132, DOI 10.1001/archopht.117.1.132; TABBARA KF, 1990, BRIT J OPHTHALMOL, V74, P249, DOI 10.1136/bjo.74.4.249; Tan SY, 2000, TRANSPLANT P, V32, P1965, DOI 10.1016/S0041-1345(00)01514-1; Tanaka M, 2001, RETINA-J RET VIT DIS, V21, P203, DOI 10.1097/00006982-200106000-00001; Tiribelli M, 2002, EUR J HAEMATOL, V68, P314, DOI 10.1034/j.1600-0609.2002.01674.x; Umeh R E, 1999, Ophthalmic Epidemiol, V6, P303, DOI 10.1076/opep.6.4.303.4187; UNINSKY E, 1983, OPHTHALMOLOGY, V90, P175; Uzun O, 2001, CLIN INFECT DIS, V32, P1713, DOI 10.1086/320757; van Voorst Vader PC, 1998, DERMATOL CLIN, V16, P699, DOI 10.1016/S0733-8635(05)70035-8; VANVELDEN DJJ, 1977, S AFR MED J, V51, P867; Vijayalakshmi P., 2002, Indian Journal of Ophthalmology, V50, P307; Villanueva AV, 2000, CLIN INFECT DIS, V30, P479, DOI 10.1086/313689; Vutova K, 2002, ANN TROP PAEDIATR, V22, P213, DOI 10.1179/027249302125001507; WADDELL KM, 1995, BRIT J OPHTHALMOL, V79, P250, DOI 10.1136/bjo.79.3.250; Walters G, 2001, CURR OPIN OPHTHALMOL, V12, P191, DOI 10.1097/00055735-200106000-00008; Weishaar PD, 1998, OPHTHALMOLOGY, V105, P57, DOI 10.1016/S0161-6420(98)71225-3; WILKINSON CP, 1971, AM J OPHTHALMOL, V71, P921, DOI 10.1016/0002-9394(71)90267-4; Wolff S M, 1972, Trans Am Ophthalmol Soc, V70, P577; Wong JS, 2000, OPHTHALMOLOGY, V107, P1483, DOI 10.1016/S0161-6420(00)00216-5; WONG KW, 1987, ARCH OPHTHALMOL-CHIC, V105, P788; WORKMAN DMS, 1990, AUST NZ J OPHTHALMOL, V18, P357, DOI 10.1111/j.1442-9071.1990.tb00634.x; Young S, 2000, LANCET, V355, P984, DOI 10.1016/S0140-6736(00)90017-5; ZAKKA KA, 1978, SURV OPHTHALMOL, V22, P313, DOI 10.1016/0039-6257(78)90176-5; Zambarakji HJ, 2002, OCUL IMMUNOL INFLAMM, V10, P41, DOI 10.1076/ocii.10.1.41.10327	152	36	36	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2004	364	9443					1439	1450		10.1016/S0140-6736(04)17228-0	http://dx.doi.org/10.1016/S0140-6736(04)17228-0			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IX	15488221				2022-12-28	WOS:000224485300032
J	Sosnick, TR				Sosnick, TR			Comment on "Force-clamp spectroscopy monitors the folding trajectory of a single protein"	SCIENCE			English	Editorial Material							HYDROGEN-EXCHANGE; UBIQUITIN; KINETICS; STABILITY; MUTANT; ENERGY; STATE	In a recent report on atomic force microscopy (AFM)-monitored protein folding, Fernandez and Li (Reports, 12 March 2004, p. 1674) concluded that the folding of the single-domain protein ubiquitin does not correspond to transitions between discrete states. The results are inconsistent with solution studies of ubiquitin folding and probably are due in part to chain-tangling in the tethered polyprotein construct used in the AFM studies.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago	Sosnick, TR (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58th St, Chicago, IL 60637 USA.		Freed, Karl F/J-7764-2018	Freed, Karl F/0000-0001-6240-2599				Benitez-Cardoza CG, 2004, BIOCHEMISTRY-US, V43, P5195, DOI 10.1021/bi0361620; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; Deniz AA, 2000, P NATL ACAD SCI USA, V97, P5179, DOI 10.1073/pnas.090104997; Fernandez JM, 2004, SCIENCE, V303, P1674, DOI 10.1126/science.1092497; Gladwin ST, 1996, FOLD DES, V1, P407, DOI 10.1016/S1359-0278(96)00057-0; Jacob J, 2004, J MOL BIOL, V338, P369, DOI 10.1016/j.jmb.2004.02.065; KHORASANIZADEH S, 1993, BIOCHEMISTRY-US, V32, P7054, DOI 10.1021/bi00078a034; Khorasanizadeh S, 1996, NAT STRUCT BIOL, V3, P193, DOI 10.1038/nsb0296-193; Krantz BA, 2000, NAT STRUCT BIOL, V7, P62; Krantz BA, 2000, BIOCHEMISTRY-US, V39, P11696, DOI 10.1021/bi000792+; Krantz BA, 2002, J MOL BIOL, V324, P359, DOI 10.1016/S0022-2836(02)01029-X; Krantz BA, 2004, J MOL BIOL, V337, P463, DOI 10.1016/j.jmb.2004.01.018; Lipman EA, 2003, SCIENCE, V301, P1233, DOI 10.1126/science.1085399; Platt GW, 2003, BIOCHEMISTRY-US, V42, P13762, DOI 10.1021/bi030147d; Sabelko J, 1999, P NATL ACAD SCI USA, V96, P6031, DOI 10.1073/pnas.96.11.6031; Sivaraman T, 2001, NAT STRUCT BIOL, V8, P331, DOI 10.1038/86208; Went HM, 2004, FEBS LETT, V567, P333, DOI 10.1016/j.febslet.2004.04.089	17	20	20	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2004	306	5695					411B	+		10.1126/science.1100962	http://dx.doi.org/10.1126/science.1100962			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486276				2022-12-28	WOS:000224626500021
J	Ahlgren, M; Melbye, M; Wohlfahrt, J; Sorensen, TIA				Ahlgren, M; Melbye, M; Wohlfahrt, J; Sorensen, TIA			Growth patterns and the risk of breast cancer in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BIRTH CHARACTERISTICS; DANISH MEASUREMENTS; SEXED TWINS; YOUNG-WOMEN; HEIGHT; WEIGHT; CHILDHOOD; POPULATION; COHORT; NORWAY	BACKGROUND: Adult height and body-mass index influence the risk of breast cancer in women. Whether these associations reflect growth patterns of the fetus or growth during childhood and adolescence is unknown. METHODS: We investigated the association between growth during childhood and the risk of breast cancer in a cohort of 117,415 Danish women. Birth weight, age at menarche, and annual measurements of height and weight were obtained from school health records. We used the data to model individual growth curves. Information on vital status, age at first childbirth, parity, and diagnosis of breast cancer was obtained through linkages to national registries. RESULTS: During 3,333,359 person-years of follow-up, 3340 cases of breast cancer were diagnosed. High birth weight, high stature at 14 years of age, low body-mass index (BMI) at 14 years of age, and peak growth at an early age were independent risk factors for breast cancer. Height at 8 years of age and the increase in height during puberty (8 to 14 years of age) were also associated with breast cancer. The attributable risks of birth weight, height at 14 years of age, BMI at 14 years of age, and age at peak growth were 7 percent, 15 percent, 15 percent, and 9 percent, respectively. No effect of adjusting for age at menarche, age at first childbirth, and parity was observed. CONCLUSIONS: Birth weight and growth during childhood and adolescence influence the risk of breast cancer.	Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark; Copenhagen Univ Hosp, Inst Prevent Med, Danish Epidemiol Sci Ctr, Copenhagen, Denmark	Aarhus University; Statens Serum Institut; Aarhus University; University of Copenhagen	Ahlgren, M (corresponding author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen S, Denmark.	abk@ssi.dk		melbye, mads/0000-0001-8264-6785				Ahlgren M, 2003, INT J CANCER, V107, P997, DOI 10.1002/ijc.11481; Andersson SW, 2001, BRIT J CANCER, V84, P1193, DOI 10.1054/bjoc.2000.1738; De Stavola BL, 2000, BRIT J CANCER, V83, P964, DOI 10.1054/bjoc.2000.1370; Ekbom A, 1997, JNCI-J NATL CANCER I, V89, P71, DOI 10.1093/jnci/89.1.71; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; Friedenreich CM, 2001, EUR J CANCER PREV, V10, P15, DOI 10.1097/00008469-200102000-00003; FRISCH RE, 1974, SCIENCE, V185, P949, DOI 10.1126/science.185.4155.949; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; Gunnell D, 2001, EPIDEMIOL REV, V23, P313, DOI 10.1093/oxfordjournals.epirev.a000809; He Q, 2001, PEDIATR RES, V49, P244, DOI 10.1203/00006450-200102000-00019; Herrinton LJ, 2001, AM J EPIDEMIOL, V154, P618, DOI 10.1093/aje/154.7.618; Hilakivi-Clarke L, 2001, BRIT J CANCER, V85, P1680, DOI 10.1054/bjoc.2001.2109; Howard BA, 2000, J MAMMARY GLAND BIOL, V5, P119, DOI 10.1023/A:1026487120779; Hubinette A, 2001, INT J CANCER, V91, P248, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1025>3.3.CO;2-H; Innes K, 2000, AM J EPIDEMIOL, V152, P1121, DOI 10.1093/aje/152.12.1121; Kaijser M, 2001, J NATL CANCER I, V93, P60, DOI 10.1093/jnci/93.1.60; KVALE G, 1988, CANCER-AM CANCER SOC, V62, P1625, DOI 10.1002/1097-0142(19881015)62:8<1625::AID-CNCR2820620828>3.0.CO;2-K; LEMARCHAND L, 1988, BRIT J CANCER, V57, P437, DOI 10.1038/bjc.1988.99; LEMARCHAND L, 1988, AM J EPIDEMIOL, V128, P137; Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9; Olson JE, 1997, AM J EPIDEMIOL, V145, P58; Petersen Tove Anne-Grete, 2002, Ugeskr Laeger, V164, P5006; Power C, 1997, AM J CLIN NUTR, V66, P1094, DOI 10.1093/ajcn/66.5.1094; Rasmussen Soren, 2002, Ugeskr Laeger, V164, P5011; Rostgaard K, 2000, CANCER CAUSE CONTROL, V11, P669, DOI 10.1023/A:1008928204121; Russo J, 1999, ONCOL RES, V11, P169; Sanderson M, 1998, PAEDIATR PERINAT EP, V12, P397; Sanderson M, 2002, BRIT J CANCER, V86, P84, DOI 10.1038/sj.bjc.6600009; Sanderson M, 1996, EPIDEMIOLOGY, V7, P34, DOI 10.1097/00001648-199601000-00007; SAS Institute, 2003, SAS STAT US GUID VER; Storm HH, 1997, DAN MED BULL, V44, P535; Titus-Ernstoff L, 2002, CANCER EPIDEM BIOMAR, V11, P207; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; Vatten LJ, 2002, BRIT J CANCER, V86, P89, DOI 10.1038/sj.bjc.6600011; 2003, STATA BASE REFERENCE	35	294	303	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1619	1626		10.1056/NEJMoa040576	http://dx.doi.org/10.1056/NEJMoa040576			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483280				2022-12-28	WOS:000224427300008
J	Thorpe, LE; Frieden, TR; Laserson, KF; Wells, C; Khatri, GR				Thorpe, LE; Frieden, TR; Laserson, KF; Wells, C; Khatri, GR			Seasonality of tuberculosis in India: is it real and what does it tell us?	LANCET			English	Article								India has a third of the world's tuberculosis cases. Large-scale expansion of a national programme in 1998 has allowed for population-based analyses of data from tuberculosis registries. We assessed seasonal trends using quarterly reports from districts with stable tuberculosis control programmes (population 115 million). In northern India, tuberculosis diagnoses peaked between April and June, and reached a nadir between October and December, whereas no seasonality was reported in the south. Overall, rates of new smear-positive tuberculosis cases were 57 per 100000 population in peak seasons versus 46 per 100000 in trough seasons. General health-seeking behaviour artifact was ruled out. Seasonality was highest in paediatric cases, suggesting variation in recent transmission.	NYC Dept Hlth & Mental Hyg, Div Epidemiol, New York, NY 10013 USA; Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Adult Community Hlth, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Appl Publ Hlth Training, Atlanta, GA USA; WHO, Reg Off SE Asia, Stop TB Unit, Delhi, India; Govt India, Minist Hlth & Family Welf, Directorate Gen Hlth Serv, New Delhi, India	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; World Health Organization	Thorpe, LE (corresponding author), NYC Dept Hlth & Mental Hyg, Div Epidemiol, CN6,125 Worth St, New York, NY 10013 USA.	lthorpe@health.nyc.gov		Frieden, Thomas/0000-0002-4759-2256				Douglas AS, 1996, THORAX, V51, P944, DOI 10.1136/thx.51.9.944; GRIGG ERN, 1958, AM REV TUBERC PULM, V78, P151; Rios M, 2000, EUR J EPIDEMIOL, V16, P483, DOI 10.1023/A:1007653329972; Schaaf HS, 1996, TUBERCLE LUNG DIS, V77, P43, DOI 10.1016/S0962-8479(96)90074-X; Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6	5	90	94	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	2004	364	9445					1613	1614		10.1016/S0140-6736(04)17316-9	http://dx.doi.org/10.1016/S0140-6736(04)17316-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866IQ	15519633	Green Submitted			2022-12-28	WOS:000224767600028
J	Claussen, E				Claussen, E			Climate policy - An effective approach to climate change	SCIENCE			English	Editorial Material									Pew Ctr Global Climate Change, Arlington, VA 22201 USA		Claussen, E (corresponding author), Pew Ctr Global Climate Change, Arlington, VA 22201 USA.	ClaussenE@pewclimate.org						Abraham S, 2004, SCIENCE, V305, P616, DOI 10.1126/science.1098630; Alic John A., 2003, US TECHNOLOGY INNOVA; *ENV PROT AG, 2002, EPA430R04003; National Research Council, 2002, EFF IMP CORP AV FUEL; *PEW CTR GLOB CLIM, 2004, IN PRESS WORKSH P 10; Smith J.B., 2004, SYNTHESIS POTENTIAL; Wetherald RT, 2001, GEOPHYS RES LETT, V28, P1535, DOI 10.1029/2000GL011786	7	6	9	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2004	306	5697					816	816		10.1126/science.1105702	http://dx.doi.org/10.1126/science.1105702			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514142				2022-12-28	WOS:000224969400029
J	Friml, J; Yang, X; Michniewicz, M; Weijers, D; Quint, A; Tietz, O; Benjamins, R; Ouwerkerk, PBF; Ljung, K; Sandberg, G; Hooykaas, PJJ; Palme, K; Offringa, R				Friml, J; Yang, X; Michniewicz, M; Weijers, D; Quint, A; Tietz, O; Benjamins, R; Ouwerkerk, PBF; Ljung, K; Sandberg, G; Hooykaas, PJJ; Palme, K; Offringa, R			A PINOID-dependent binary switch in apical-basal PIN polar targeting directs auxin efflux	SCIENCE			English	Article							ARABIDOPSIS; TRANSPORT; GRADIENTS; GNOM; MORPHOGENESIS	Polar transport-dependent local accumulation of auxin provides positional cues for multiple plant patterning processes. This directional auxin flow depends on the polar subcellular localization of the PIN auxin efflux regulators. Overexpression of the PINOID protein kinase induces a basal-to-apical shift in PIN localization, resulting in the toss of auxin gradients and strong defects in embryo and seedling roots. Conversely, pid loss of function induces an apical-to-basal. shift in PIN1 polar targeting at the inflorescence apex, accompanied by defective organogenesis. Our results show that a PINOID-dependent binary switch controls PIN polarity and mediates changes in auxin flow to create local gradients for patterning processes.	Leiden Univ, Clusius Lab, Inst Biol, NL-2333 AL Leiden, Netherlands; Univ Tubingen, Ctr Mol Biol Plants, D-72076 Tubingen, Germany; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Univ Freiburg, D-79104 Freiburg, Germany; Swedish Univ Agr Sci, Dept Forest & Plant Physiol, Umea Plant Sci Ctr, S-90183 Umea, Sweden; BOKU Univ Nat Resources & Appl Life Sci, Inst Appl Genet & Cell Biol, A-1190 Vienna, Austria	Leiden University; Leiden University - Excl LUMC; Eberhard Karls University of Tubingen; Peking University; University of Freiburg; Swedish University of Agricultural Sciences; Umea University; University of Natural Resources & Life Sciences, Vienna	Offringa, R (corresponding author), Leiden Univ, Clusius Lab, Inst Biol, Wassenaarseweg 64, NL-2333 AL Leiden, Netherlands.	offringa@rulbim.leidenuniv.nl	Hooykaas, Paul JJ/S-4256-2017; Weijers, Dolf/ABI-1332-2020; Weijers, Dolf/A-2076-2010; Ljung, Karin/AAE-8691-2019; Palme, Klaus/A-9524-2013; Friml, Jiri/D-9511-2012	Hooykaas, Paul JJ/0000-0002-9736-6927; Weijers, Dolf/0000-0003-4378-141X; Weijers, Dolf/0000-0003-4378-141X; Ljung, Karin/0000-0003-2901-189X; Palme, Klaus/0000-0002-2728-3835; Friml, Jiri/0000-0002-8302-7596				Benjamins R, 2001, DEVELOPMENT, V128, P4057; Benkova E, 2003, CELL, V115, P591, DOI 10.1016/S0092-8674(03)00924-3; BENNETT SRM, 1995, PLANT J, V8, P505, DOI 10.1046/j.1365-313X.1995.8040505.x; Berleth T, 2001, CURR OPIN PLANT BIOL, V4, P57, DOI 10.1016/S1369-5266(00)00136-9; Christensen SK, 2000, CELL, V100, P469, DOI 10.1016/S0092-8674(00)80682-0; Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a; Friml J, 2002, PLANT MOL BIOL, V49, P273, DOI 10.1023/A:1015248926412; Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6; Friml J, 2003, NATURE, V426, P147, DOI 10.1038/nature02085; Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5; Geldner N, 2004, DEVELOPMENT, V131, P389, DOI 10.1242/dev.00926; Ljung K, 2002, PLANT MOL BIOL, V50, P309, DOI 10.1023/A:1016024017872; Mattsson J, 2003, PLANT PHYSIOL, V131, P1327, DOI 10.1104/pp.013623; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; Ottenschlager I, 2003, P NATL ACAD SCI USA, V100, P2987, DOI 10.1073/pnas.0437936100; Reinhardt D, 2003, NATURE, V426, P255, DOI 10.1038/nature02081; Steinmann T, 1999, SCIENCE, V286, P316, DOI 10.1126/science.286.5438.316; Weijers D, 2001, DEVELOPMENT, V128, P4289; Weijers D, 2001, NATURE, V414, P709, DOI 10.1038/414709a	19	557	599	5	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2004	306	5697					862	865		10.1126/science.1100618	http://dx.doi.org/10.1126/science.1100618			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869FS	15514156				2022-12-28	WOS:000224969400044
J	Levrard, B; Forget, F; Montmessin, F; Laskar, J				Levrard, B; Forget, F; Montmessin, F; Laskar, J			Recent ice-rich deposits formed at high latitudes on Mars by sublimation of unstable equatorial ice during low obliquity	NATURE			English	Article							CHAOTIC OBLIQUITY; NEAR-SURFACE; CIRCULATION; HYDROGEN	Observations from the gamma-ray spectrometer instrument suite on the Mars Odyssey spacecraft have been interpreted as indicating the presence of vast reservoirs of near-surface ice in high latitudes of both martian hemispheres(1-5). Ice concentrations are estimated to range from 70 per cent at 60degrees latitude to 100 per cent near the poles, possibly overlain by a few centimetres of ice-free material in most places(4). This result is supported by morphological evidence of metres-thick layered deposits that are rich in water-ice(6-9) and periglacial-like features(10,11) found only difficult to accommodate with such processes(9,13,14). Alternatively, there are suggestions that ice-rich deposits form by transport of ice from polar reservoirs and direct redeposition in high latitudes during periods of higher obliquity(9,13), but these results have been difficult to reproduce with other models. Here we propose instead that, during periods of low obliquity ( less than 25degrees), high-latitude ice deposits form in both hemispheres by direct deposition of ice, as a result of sublimation from an equatorial ice reservoir that formed earlier, during a prolonged high-obliquity excursion. Using the ice accumulation rates estimated from global climate model simulations we show that, over the past ten million years, large variations of Mars' obliquity have allowed the formation of such metres-thick, sedimentary layered deposits in high latitude and polar regions.	IMC, CNRS, UMR 8028, F-75014 Paris, France; Univ Paris 06, Meteorol Dynam Lab, F-75005 Paris, France; NASA, Ames Res Ctr, Div Space Sci, Moffett Field, CA 94035 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Levrard, B (corresponding author), ENS Lyon, UCBL, UMR 5570, Lab Planetol & Teledetect, 43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.	blevrard@imcce.fr	Laskar, Jacques/E-1098-2011	Laskar, Jacques/0000-0003-2634-789X; Montmessin, Franck/0000-0002-4187-1457				Boynton WV, 2002, SCIENCE, V297, P81, DOI 10.1126/science.1073722; BOYNTON WV, 2003, AGU ALL M; Feldman WC, 2002, SCIENCE, V297, P75, DOI 10.1126/science.1073541; FELDMAN WC, 2004, J GEOPHYS RES-PLANET, V109, DOI DOI 10.1029/2003JE002160; Forget F, 1999, J GEOPHYS RES-PLANET, V104, P24155, DOI 10.1029/1999JE001025; HABERLE RM, 2000, LUN PLAN SCI C 31; HAYS JD, 1976, SCIENCE, V194, P1121, DOI 10.1126/science.194.4270.1121; Head JW, 2003, NATURE, V426, P797, DOI 10.1038/nature02114; Head JW, 2003, GEOLOGY, V31, P641, DOI 10.1130/0091-7613(2003)031<0641:CMGOMW>2.0.CO;2; HOURDIN F, 1993, J ATMOS SCI, V50, P3625, DOI 10.1175/1520-0469(1993)050<3625:MVATAS>2.0.CO;2; JAKOSKY BM, 1995, J GEOPHYS RES-PLANET, V100, P1579, DOI 10.1029/94JE02801; JAKOSKY BM, 1985, NATURE, V315, P559, DOI 10.1038/315559a0; Kreslavsky MA, 2000, J GEOPHYS RES-PLANET, V105, P26695, DOI 10.1029/2000JE001259; Kreslavsky MA, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015392; Laskar J, 2004, ICARUS, V170, P343, DOI 10.1016/j.icarus.2004.04.005; LASKAR J, 1993, NATURE, V361, P608, DOI 10.1038/361608a0; Laskar J, 2002, NATURE, V419, P375, DOI 10.1038/nature01066; MANGOLD N, 2003, 3 MARS POL SCI C; Mellon MT, 2004, ICARUS, V169, P324, DOI 10.1016/j.icarus.2003.10.022; Milliken RE, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE002005; Mischna MA, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002051; MISCHNA MA, 2003, 6 INT MARS C; Mitrofanov I, 2002, SCIENCE, V297, P78, DOI 10.1126/science.1073616; Montmessin F, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2004JE002284; Mustard JF, 2001, NATURE, V412, P411, DOI 10.1038/35086515; Richardson MI, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001536; Richardson MI, 2002, NATURE, V416, P298, DOI 10.1038/416298a; SHEAN DE, 2004, LUN PLAN SCI C 35; TOUMA J, 1993, SCIENCE, V259, P1294, DOI 10.1126/science.259.5099.1294; [No title captured], DOI DOI 10.1029/2001JE001522	30	161	162	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2004	431	7012					1072	1075		10.1038/nature03055	http://dx.doi.org/10.1038/nature03055			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865VB	15510141				2022-12-28	WOS:000224730800033
J	Olson, LE; Richtsmeier, JT; Leszl, J; Reeves, RH				Olson, LE; Richtsmeier, JT; Leszl, J; Reeves, RH			A chromosome 21 critical region does not cause specific down syndrome phenotypes	SCIENCE			English	Article								The "Down syndrome critical region" (DSCR) is a chromosome 21 segment purported to contain genes responsible for many features of Down syndrome (DS), including craniofacial dysmorphology. We used chromosome engineering to create mice that were trisomic or monosomic for only the mouse chromosome segment orthologous to the DSCR and assessed dysmorphologies of the craniofacial skeleton that show direct parallels with DS in mice with a larger segmental trisomy. The DSCR genes were not sufficient and were largely not necessary to produce the facial phenotype. These results refute specific predictions of the prevailing hypothesis of gene action in DS.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA; Penn State Univ, Genet Program, University Pk, PA 16802 USA	Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Reeves, RH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.	rreeves@jhmi.edu	Olson, Lisa Erin/AGX-7480-2022	Olson, Lisa Erin/0000-0003-0710-7583; Richtsmeier, Joan/0000-0002-0239-5822	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD038384] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F33DE005706] Funding Source: NIH RePORTER; NICHD NIH HHS [P01 HD024605, HD24605, HD38384, R01 HD038384] Funding Source: Medline; NIDCR NIH HHS [F33 DE005706] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		COHEN WI, 1999, DOWN SYNDROME Q, V4, P3; DAVISSON MT, COMMUNICATION; Delabar Jean-Maurice, 1993, European Journal of Human Genetics, V1, P114; Gardiner K, 2003, GENE, V318, P137, DOI 10.1016/S0378-1119(03)00769-8; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Kisling E, 1966, CRANIAL MORPHOLOGY D; KORENBERG JR, 1994, P NATL ACAD SCI USA, V91, P4997, DOI 10.1073/pnas.91.11.4997; MCCORMICK MK, 1989, GENOMICS, V5, P325, DOI 10.1016/0888-7543(89)90065-7; Mural RJ, 2002, SCIENCE, V296, P1661, DOI 10.1126/science.1069193; NIEBUHR E, 1974, HUMANGENETIK, V21, P99, DOI 10.1007/BF00278575; Olson LE, 2003, CANCER RES, V63, P6602; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Reeves RH, 2001, TRENDS GENET, V17, P83, DOI 10.1016/S0168-9525(00)02172-7; Richtsmeier J. T., 2001, INTER DISC; Richtsmeier JT, 2000, DEV DYNAM, V217, P137, DOI 10.1002/(SICI)1097-0177(200002)217:2<137::AID-DVDY1>3.0.CO;2-N; Sago H, 1998, P NATL ACAD SCI USA, V95, P6256, DOI 10.1073/pnas.95.11.6256; SHAPIRO BL, 1983, AM J MED GENET, V14, P241, DOI 10.1002/ajmg.1320140206	17	216	221	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2004	306	5696					687	690		10.1126/science.1098992	http://dx.doi.org/10.1126/science.1098992			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866EN	15499018	Green Accepted			2022-12-28	WOS:000224756700052
J	Halik, M; Klauk, H; Zschieschang, U; Schmid, G; Dehm, C; Schutz, M; Maisch, S; Effenberger, F; Brunnbauer, M; Stellacci, F				Halik, M; Klauk, H; Zschieschang, U; Schmid, G; Dehm, C; Schutz, M; Maisch, S; Effenberger, F; Brunnbauer, M; Stellacci, F			Low-voltage organic transistors with an amorphous molecular gate dielectric	NATURE			English	Article							SELF-ASSEMBLED MONOLAYER; PERFORMANCE; DISPLAYS	Organic thin film transistors (TFTs) are of interest for a variety of large-area electronic applications, such as displays(1-3,) sensors(4,5) and electronic barcodes(6-8). One of the key problems with existing organic TFTs is their large operating voltage, which often exceeds 20 V. This is due to poor capacitive coupling through relatively thick gate dielectric layers: these dielectrics are usually either inorganic oxides or nitrides(2-8), or insulating polymers(9), and are often thicker than 100 nm to minimize gate leakage currents. Here we demonstrate a manufacturing process for TFTs with a 2.5-nm-thick molecular self-assembled monolayer (SAM) gate dielectric and a high-mobility organic semiconductor (pentacene). These TFTs operate with supply voltages of less than 2 V, yet have gate currents that are lower than those of advanced silicon field-effect transistors with SiO2 dielectrics. These results should therefore increase the prospects of using organic TFTs in low-power applications (such as portable devices). Moreover, molecular SAMs may even be of interest for advanced silicon transistors where the continued reduction in dielectric thickness leads to ever greater gate leakage and power dissipation.	Infineon Technol AG, New Memory Platforms, Mat & Technol, D-91052 Erlangen, Germany; Univ Stuttgart, Dept Chem, D-70569 Stuttgart, Germany; MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA	Infineon Technologies; University of Stuttgart; Massachusetts Institute of Technology (MIT)	Halik, M (corresponding author), Infineon Technol AG, New Memory Platforms, Mat & Technol, Paul Gossen Str 100, D-91052 Erlangen, Germany.	marcus.halik@infineon.com	Stellacci, Francesco/B-1990-2008; Halik, Marcus/M-2556-2016	Stellacci, Francesco/0000-0003-4635-6080; Halik, Marcus/0000-0001-5976-0862				Bartic C, 2003, APPL PHYS LETT, V82, P475, DOI 10.1063/1.1527698; Baude PF, 2003, APPL PHYS LETT, V82, P3964, DOI 10.1063/1.1579554; Boulas C, 1996, PHYS REV LETT, V76, P4797, DOI 10.1103/PhysRevLett.76.4797; Collet J, 2000, APPL PHYS LETT, V76, P1941, DOI 10.1063/1.126219; Collett J, 1998, APPL PHYS LETT, V73, P2681, DOI 10.1063/1.122552; Crone B, 2000, NATURE, V403, P521, DOI 10.1038/35000530; Crone BK, 2002, J APPL PHYS, V91, P10140, DOI 10.1063/1.1476084; de Leeuw DM, 2002, INTERNATIONAL ELECTRON DEVICES 2002 MEETING, TECHNICAL DIGEST, P293, DOI 10.1109/IEDM.2002.1175836; FONTAINE P, 1993, APPL PHYS LETT, V62, P2256, DOI 10.1063/1.109433; Halik M, 2003, ADV MATER, V15, P917, DOI 10.1002/adma.200304654; Huitema HEA, 2001, NATURE, V414, P599, DOI 10.1038/414599a; Kelley TW, 2003, MATER RES SOC SYMP P, V771, P169; Kelley TW, 2003, J PHYS CHEM B, V107, P5877, DOI 10.1021/jp034352e; Klauk H, 2003, APPL PHYS LETT, V82, P4175, DOI 10.1063/1.1579870; Klauk H, 2002, J APPL PHYS, V92, P5259, DOI 10.1063/1.1511826; Lenfant S, 2003, NANO LETT, V3, P741, DOI 10.1021/nl034162f; Lo SH, 1997, IEEE ELECTR DEVICE L, V18, P209, DOI 10.1109/55.568766; Rogers JA, 2001, P NATL ACAD SCI USA, V98, P4835, DOI 10.1073/pnas.091588098; SCHUTZ M, 2002, THESIS U STUTTGART, P192; Sekine K, 2001, IEEE T ELECTRON DEV, V48, P1550, DOI 10.1109/16.936559; Sheraw CD, 2002, APPL PHYS LETT, V80, P1088, DOI 10.1063/1.1448659; Thompson S, 2002, INTERNATIONAL ELECTRON DEVICES 2002 MEETING, TECHNICAL DIGEST, P61, DOI 10.1109/IEDM.2002.1175779	22	706	749	5	322	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	2004	431	7011					963	966		10.1038/nature02987	http://dx.doi.org/10.1038/nature02987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863TI	15496917				2022-12-28	WOS:000224585600038
J	DeBusk, RF; Miller, NH; Parker, KM; Bandura, A; Kraemer, HC; Cher, DJ; West, JA; Fowler, MB; Greenwald, G				DeBusk, RF; Miller, NH; Parker, KM; Bandura, A; Kraemer, HC; Cher, DJ; West, JA; Fowler, MB; Greenwald, G			Care management for low-risk patients with heart failure - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							HOME-BASED INTERVENTION; SYSTOLIC FUNCTION; MULTIDISCIPLINARY; READMISSION; HOSPITALIZATION; PROGRAMS; EFFICACY; OUTCOMES; SYSTEM; ELDERS	Background: Nurse care management programs for patients with chronic illness have been shown to be safe and effective. Objective: To determine whether a telephone-mediated nurse care management program for heart failure reduced the rate of rehospitalization for heart failure and for all causes over a 1-year period. Design: Randomized, controlled trial of usual care with nurse management versus usual care alone in patients hospitalized for heart failure from May 1998 through October 2001. Setting: 5 northern California hospitals in a large health maintenance organization. Patients: Of 2786 patients screened, 462 met clinical criteria for heart failure and were randomly assigned (228 to intervention and 234 to usual care). Intervention: Nurse care management provided structured telephone surveillance and treatment for heart failure and coordination of patients' care with primary care physicians. Measurements: Time to first rehospitalization for heart failure or for any cause and time to a combined end point of first rehospitalization, emergency department visit, or death. Results: At 1 year, half of the patients had been rehospitalized at least once and 11% had died. only one third of rehospitalizations were for heart failure. The rate of first rehospitalization for heart failure was similar in both groups (proportional hazard, 0.85 [95% CI, 0.46 to 1.57]). The rate of all-cause rehospitalization was similar (proportional hazard, 0.98 [CI, 0.76 to 1.27]). Limitations: The findings of this study, conducted in a single health care system, may not be generalizable to other health care systems. The overall effect of the intervention was minor. Conclusions: Among patients with heart failure at low risk on the basis of sociodemographic and medical attributes, nurse care management did not statistically significantly reduce rehospitalizations for heart failure or for any cause. Such programs may be less effective for patients at low risk than those at high risk.	Stanford Univ, Sch Med, Palo Alto, CA 94304 USA	Stanford University	DeBusk, RF (corresponding author), Stanford Univ, Sch Med, 780 Welch Rd,106, Palo Alto, CA 94304 USA.	debusk@stanford.edu		Cher, Daniel/0000-0002-3747-7879	NHLBI NIH HHS [HL56950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Burns RB, 1997, J AM GERIATR SOC, V45, P276, DOI 10.1111/j.1532-5415.1997.tb00940.x; Chin MH, 1997, AM J PUBLIC HEALTH, V87, P643, DOI 10.2105/AJPH.87.4.643; Dauterman KW, 2001, J CARD FAIL, V7, P221, DOI 10.1054/jcaf.2001.26896; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.2307/2334377; Gottdiener JS, 2002, ANN INTERN MED, V137, P631, DOI 10.7326/0003-4819-137-8-200210150-00006; Grady KL, 2000, CIRCULATION, V102, P2443, DOI 10.1161/01.CIR.102.19.2443; Havranek EP, 2002, AM HEART J, V143, P412, DOI 10.1067/mhj.2002.120773; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Kasper EK, 2002, J AM COLL CARDIOL, V39, P471, DOI 10.1016/S0735-1097(01)01761-2; KONSTAM MA, 1994, ACHPR PUBLICATION; Krumholz HM, 1997, ARCH INTERN MED, V157, P99, DOI 10.1001/archinte.157.1.99; Masoudi Frederick A, 2002, Heart Fail Rev, V7, P9; Massie BM, 1997, AM HEART J, V133, P703, DOI 10.1016/S0002-8703(97)70173-X; McAlister FA, 2001, AM J MED, V110, P378, DOI 10.1016/S0002-9343(00)00743-9; Mion LC, 2003, ANN EMERG MED, V41, P57, DOI 10.1067/mem.2003.3; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Packer M, 1999, AM J CARDIOL, V83, p1A; Perry G, 1997, NEW ENGL J MED, V336, P525; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Rich MW, 2001, AM J MED, V110, P410, DOI 10.1016/S0002-9343(01)00632-5; Riegel B, 2002, ARCH INTERN MED, V162, P705, DOI 10.1001/archinte.162.6.705; Riegel B, 2000, J CARD FAIL, V6, P290, DOI 10.1054/jcaf.2000.19226; Rundall TG, 2002, BMJ-BRIT MED J, V325, P958, DOI 10.1136/bmj.325.7370.958; SHORTELL SM, 1993, HOSP HEALTH SERV ADM, V38, P447; Stewart S, 1999, LANCET, V354, P1077, DOI 10.1016/S0140-6736(99)03428-5; Stewart S, 1998, ARCH INTERN MED, V158, P1067, DOI 10.1001/archinte.158.10.1067; Stewart S, 2002, CIRCULATION, V105, P2861, DOI 10.1161/01.CIR.0000019067.99013.67; West JA, 1997, AM J CARDIOL, V79, P58, DOI 10.1016/S0002-9149(96)00676-5; WILLIAMS JF, 1995, J AM COLL CARDIOL, V26, P1376	31	150	152	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	2004	141	8					606	613		10.7326/0003-4819-141-8-200410190-00008	http://dx.doi.org/10.7326/0003-4819-141-8-200410190-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864SD	15492340				2022-12-28	WOS:000224652300004
J	Hess, HA; Roper, JC; Grill, SW; Koelle, MR				Hess, HA; Roper, JC; Grill, SW; Koelle, MR			RGS-7 completes a receptor-independent heterotrimeric G protein regulate mitotic spindle positioning in C-elegans	CELL			English	Article							CAENORHABDITIS-ELEGANS; G-ALPHA; POLARITY CUES; ORIENTATION; ASSOCIATION; MECHANISMS; SYNEMBRYN; DIVISIONS; G(O)ALPHA; PARTNER	Heterotrimeric G proteins promote microtubule forces that position mitotic spindles during asymmetric cell division in C. elegans embryos. While all previously studied G protein functions require activation by seven-transmembrane receptors, this function appears to be receptor independent. We found that mutating a regulator of G protein signaling, RGS-7, resulted in hyperasymmetric spindle movements due to decreased force on one spindle pole. RGS-7 is localized at the cell cortex, and its effects require two redundant Galpha(o)-related G proteins and their nonreceptor activators RIC-8 and GPR-1/2. Using recombinant proteins, we found that RIC-8 stimulates GTP binding by Galpha(o) and that the FIGS domain of RGS-7 stimulates GTP hydrolysis by Galpha(o), demonstrating that Galpha(o) passes through the GTP bound state during its activity cycle. While GTPase activators typically inactivate G proteins, RGS-7 instead appears to promote G protein function asymmetrically in the cell, perhaps acting as a G protein effector.	Max Planck Inst Cell Biol & Genet, D-01307 Dresden, Germany; Yale Univ, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Max Planck Society; Yale University; Yale University	Koelle, MR (corresponding author), Max Planck Inst Cell Biol & Genet, D-01307 Dresden, Germany.	michael.koelle@yale.edu	Grill, Stephan/D-9427-2012					Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; CARTY DJ, 1994, METHOD ENZYMOL, V237, P38; Colombo K, 2003, SCIENCE, V300, P1957, DOI 10.1126/science.1084146; Dong MQ, 2000, GENE DEV, V14, P2003; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Edgley M, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf051; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Ghosh M, 2003, J BIOL CHEM, V278, P34747, DOI 10.1074/jbc.C300271200; Gonczy P, 2002, TRENDS CELL BIOL, V12, P332, DOI 10.1016/S0962-8924(02)02306-1; Gotta M, 2003, CURR BIOL, V13, P1029, DOI 10.1016/S0960-9822(03)00371-3; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Grill SW, 2001, NATURE, V409, P630, DOI 10.1038/35054572; Hajdu-Cronin YM, 1999, GENE DEV, V13, P1780, DOI 10.1101/gad.13.14.1780; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Honda A, 2002, J BIOL CHEM, V277, P20234, DOI 10.1074/jbc.M112080200; Kehrl JH, 2002, GENOMICS, V79, P860, DOI 10.1006/geno.2002.6773; Kelly WG, 1997, GENETICS, V146, P227; Knust E, 2001, CELL, V107, P125, DOI 10.1016/S0092-8674(01)00534-7; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Krumins AM, 2002, METHOD ENZYMOL, V344, P673; Liu LX, 1999, GENOME RES, V9, P859, DOI 10.1101/gr.9.9.859; Miller KG, 2000, GENETICS, V156, P1649; Patikoglou GA, 2002, J BIOL CHEM, V277, P47004, DOI 10.1074/jbc.M208186200; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Rose LS, 1998, DEVELOPMENT, V125, P1337; Sato M, 2003, LIFE SCI, V73, P917, DOI 10.1016/S0024-3205(03)00355-2; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Schneider SQ, 2003, ANNU REV GENET, V37, P221, DOI 10.1146/annurev.genet.37.110801.142443; Srinivasan DG, 2003, GENE DEV, V17, P1225, DOI 10.1101/gad.1081203; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; Tsou MFB, 2003, DEVELOPMENT, V130, P5717, DOI 10.1242/dev.00790; Tsou MFB, 2002, DEVELOPMENT, V129, P4469; WU HC, 1994, LAB INVEST, V71, P175; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	38	84	87	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2004	119	2					209	218		10.1016/j.cell.2004.09.025	http://dx.doi.org/10.1016/j.cell.2004.09.025			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863QQ	15479638	Bronze			2022-12-28	WOS:000224577200009
J	Prelec, D				Prelec, D			A Bayesian truth serum for subjective data	SCIENCE			English	Article							EGOCENTRIC BIAS; CONSENSUS; INFORMATION	Subjective judgments, an essential information source for science and policy, are problematic because there are no public criteria for assessing judgmental truthfulness. I present a scoring method for eliciting truthful subjective data in situations where objective truth is unknowable. The method assigns high scores not to the most common answers but to the answers that are more common than collectively predicted, with predictions drawn from the same population. This simple adjustment in the scoring criterion removes all bias in favor of consensus: Truthful answers maximize expected score even for respondents who believe that their answer represents a minority view.	MIT, Alfred P Sloan Sch Management, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Prelec, D (corresponding author), MIT, Alfred P Sloan Sch Management, E56-320,38 Mem Dr, Cambridge, MA 02139 USA.	dprelec@mit.edu						[Anonymous], 1989, SIGNAL DETECTION THE; AUMANN RJ, 1987, ECONOMETRICA, V55, P1, DOI 10.2307/1911154; BATCHELDER WH, 1988, PSYCHOMETRIKA, V53, P71, DOI 10.1007/BF02294195; Berg J, 1997, UNDERSTANDING STRATEGIC INTERACTION, P444; Bernardo J., 2000, BAYESIAN THEORY, V15; BLACKWELL D, 1953, ANN MATH STAT, V24, P265, DOI 10.1214/aoms/1177729032; Camerer CF, 1999, J RISK UNCERTAINTY, V19, P7, DOI 10.1023/A:1007850605129; Cooke R. M., 1991, EXPERTS UNCERTAINTY; Cover TM., 2006, ELEMENTS INFORM THEO, DOI [10.1002/047174882X, DOI 10.1002/047174882X]; CREMER J, 1988, ECONOMETRICA, V56, P1247, DOI 10.2307/1913096; DASPREMONT C, 1979, J PUBLIC ECON, V11, P25, DOI 10.1016/0047-2727(79)90043-4; DAWES RM, 1989, J EXP SOC PSYCHOL, V25, P1, DOI 10.1016/0022-1031(89)90036-X; Dawes RobynM., 1990, INSIGHTS DECISION MA; EDWARDS W, 1961, PSYCHOL REV, V68, P275, DOI 10.1037/h0044699; HOCH SJ, 1987, J PERS SOC PSYCHOL, V53, P221, DOI 10.1037/0022-3514.53.2.221; JOHNSON S, 1990, ECONOMETRICA, V58, P873, DOI 10.2307/2938354; KRUEGER J, 1994, J PERS SOC PSYCHOL, V67, P596, DOI 10.1037/0022-3514.67.4.596; KULLBACK S, 1954, INFORMATION THEORY S; Linstone H.A., 1975, DELPHI METHOD; MARKS G, 1987, PSYCHOL BULL, V102, P72, DOI 10.1037/0033-2909.102.1.72; MCAFEE RP, 1992, ECONOMETRICA, V60, P395, DOI 10.2307/2951601; Rees M, 2003, OUR FINAL CENTURY; ROSS L, 1977, J EXP SOC PSYCHOL, V13, P279, DOI 10.1016/0022-1031(77)90049-X; SAVAGE LJ, 1971, J AM STAT ASSOC, V66, P783, DOI 10.2307/2284229; Tirole, 2000, GAME THEORY; Turner C. F., 1984, SURVEYING SUBJECTIVE, V1; WINKLER RL, 1969, J AM STAT ASSOC, V64, P1073, DOI 10.2307/2283486	27	201	204	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	2004	306	5695					462	466		10.1126/science.1102081	http://dx.doi.org/10.1126/science.1102081			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15486294				2022-12-28	WOS:000224626500045
J	Mou, SS; Giroir, BP; Molitor-Kirsch, EA; Leonard, SR; Nikaidoh, H; Nizzi, F; Town, DA; Roy, LC; Scott, W; Stromberg, D				Mou, SS; Giroir, BP; Molitor-Kirsch, EA; Leonard, SR; Nikaidoh, H; Nizzi, F; Town, DA; Roy, LC; Scott, W; Stromberg, D			Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE-UNIT; CARDIOPULMONARY BYPASS; INFLAMMATORY RESPONSE; NOSOCOMIAL INFECTIONS; CHILDREN; OPERATIONS; TRANSFUSION; COMPLEMENT; AGE	BACKGROUND: In an attempt to reduce the coagulopathic and inflammatory responses seen after cardiopulmonary bypass, the use of fresh whole blood during heart operations has become the standard of care for neonates and infants at many institutions. We compared the use of fresh whole blood with the use of a combination of packed red cells and fresh-frozen plasma (reconstituted blood) for priming of the cardiopulmonary bypass circuit. METHODS: We conducted a single-center, randomized, double-blind, controlled trial involving children less than one year of age who underwent open-heart surgery. Patients were assigned to receive either fresh whole blood that had been collected not more than 48 hours previously (96 patients) or reconstituted blood (104 patients) for bypass-circuit priming. Clinical outcomes and serologic measures of systemic inflammation and myocardial injury were compared between the groups. RESULTS: The group that received reconstituted blood had a shorter stay in the intensive care unit than the group that received fresh whole blood (70.5 hours vs. 97.0 hours, P=0.04). The group that received reconstituted blood also had a smaller cumulative fluid balance at 48 hours (-6.9 ml per kilogram of body weight vs. 28.8 ml per kilogram, P=0.003). Early postoperative chest-tube output, blood-product transfusion requirements, and levels of serum mediators of inflammation and cardiac troponin I were similar in the two groups. CONCLUSIONS: The use of fresh whole blood for cardiopulmonary bypass priming has no advantage over the use of a combination of packed red cells and fresh-frozen plasma during surgery for congenital heart disease. Moreover, circuit priming with fresh whole blood is associated with an increased length of stay in the intensive care unit and increased perioperative fluid overload.	Childrens Med Ctr, Div Cardiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX USA; Carter BloodCare, Dallas, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Stromberg, D (corresponding author), Childrens Med Ctr, Div Cardiol, 1935 Motor St, Dallas, TX 75235 USA.	daniel.stromberg@childrens.com						Chang RKR, 2003, CURR OPIN CARDIOL, V18, P98, DOI 10.1097/00001573-200303000-00004; ENGLAND MD, 1986, CIRCULATION, V74, P134; HARKER LA, 1980, BLOOD, V56, P824; Holmes JH, 2002, INFLAMM RES, V51, P579, DOI 10.1007/PL00012432; Ichinose F, 1999, ANESTH ANALG, V88, P258, DOI 10.1097/00000539-199902000-00006; KERN FH, 1992, ANN THORAC SURG, V54, P541, DOI 10.1016/0003-4975(92)90451-9; KIRKLIN JK, 1983, J THORAC CARDIOV SUR, V86, P845; Laine E, 2003, TRANSFUSION, V43, P322, DOI 10.1046/j.1537-2995.2003.00305.x; LAVEE J, 1989, J THORAC CARDIOV SUR, V97, P204; Lequier LL, 2000, CHEST, V117, P1706, DOI 10.1378/chest.117.6.1706; MANNO CS, 1991, BLOOD, V77, P930, DOI 10.1182/blood.V77.5.930.930; Miller BE, 1997, ANESTH ANALG, V85, P1196, DOI 10.1097/00000539-199712000-00003; MILLIKEN J, 1988, CRIT CARE MED, V16, P233, DOI 10.1097/00003246-198803000-00005; Newburger JW, 2003, J PEDIATR-US, V143, P67, DOI 10.1016/S0022-3476(03)00183-5; Nightingale S, 2003, TRANSFUSION, V43, P364, DOI 10.1046/j.1537-2995.2003.00324.x; PETAJA J, 1995, J THORAC CARDIOV SUR, V109, P524, DOI 10.1016/S0022-5223(95)70284-9; Pizarro C, 2001, EUR J CARDIO-THORAC, V19, P294, DOI 10.1016/S1010-7940(01)00575-9; Rosenzweig EB, 1999, CIRCULATION, V100, P182; SEGHAYE MC, 1993, J THORAC CARDIOV SUR, V106, P978, DOI 10.1016/S0022-5223(19)33968-6; Strong DM, 2002, TRENDS MOL MED, V8, P355, DOI 10.1016/S1471-4914(02)02361-4; Urrea M, 2003, PEDIATR INFECT DIS J, V22, P490, DOI 10.1097/00006454-200306000-00002; Wan S, 1997, CHEST, V112, P676, DOI 10.1378/chest.112.3.676; Williams GD, 1999, ANESTH ANALG, V89, P57, DOI 10.1097/00000539-199907000-00011; Williams GD, 1998, ANN THORAC SURG, V66, P870, DOI 10.1016/S0003-4975(98)00600-6	24	107	108	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1635	1644		10.1056/NEJMoa041065	http://dx.doi.org/10.1056/NEJMoa041065			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483282				2022-12-28	WOS:000224427300010
J	Newman, TB				Newman, TB			Treating depression in children: A black-box warning for antidressants in children?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Newman, TB (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.							March J, 2004, JAMA-J AM MED ASSOC, V292, P807; Whittington CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1	2	62	63	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2004	351	16					1595	1598						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861OU	15483275				2022-12-28	WOS:000224427300003
J	Stoleru, D; Peng, Y; Agosto, J; Rosbash, M				Stoleru, D; Peng, Y; Agosto, J; Rosbash, M			Coupled oscillators control morning and evening locomotor behaviour of Drosophila	NATURE			English	Article							SUPRACHIASMATIC NUCLEUS; CIRCADIAN-RHYTHMS; PACEMAKER NEURONS; CLOCK GENES; PERIOD; BRAIN; MELANOGASTER; NEUROPEPTIDE; LIGHT; PROJECTIONS	Daily rhythms of physiology and behaviour are precisely timed by an endogenous circadian clock(1,2). These include separate bouts of morning and evening activity, characteristic of Drosophila melanogaster and many other taxa, including mammals(3-5). Whereas multiple oscillators have long been proposed to orchestrate such complex behavioural programmes(6), their nature and interplay have remained elusive. By using cell-specific ablation, we show that the timing of morning and evening activity in Drosophila derives from two distinct groups of circadian neurons: morning activity from the ventral lateral neurons that express the neuropeptide PDF, and evening activity from another group of cells, including the dorsal lateral neurons. Although the two oscillators can function autonomously, cell-specific rescue experiments with circadian clock mutants indicate that they are functionally coupled.	Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA; Brandeis Univ, Natl Ctr Behav Genom, Dept Biol, Waltham, MA 02454 USA	Brandeis University; Howard Hughes Medical Institute; Brandeis University	Rosbash, M (corresponding author), Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA.	rosbash@brandeis.edu			NIGMS NIH HHS [T32 GM007122] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007122] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blanchardon E, 2001, EUR J NEUROSCI, V13, P871, DOI 10.1046/j.0953-816x.2000.01450.x; de la Iglesia HO, 2000, SCIENCE, V290, P799, DOI 10.1126/science.290.5492.799; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Emery P, 2000, NEURON, V26, P493, DOI 10.1016/S0896-6273(00)81181-2; HALLIBURTON IW, 1980, J GEN VIROL, V48, P1, DOI 10.1099/0022-1317-48-1-1; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Harmar AJ, 2002, CELL, V109, P497, DOI 10.1016/S0092-8674(02)00736-5; Helfrich-Forster C, 2000, J BIOL RHYTHM, V15, P135, DOI 10.1177/074873040001500208; Helfrich-Forster C, 2001, J INSECT PHYSIOL, V47, P877, DOI 10.1016/S0022-1910(01)00060-9; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; Jagota A, 2000, NAT NEUROSCI, V3, P372, DOI 10.1038/73943; Kaneko M, 2000, J COMP NEUROL, V422, P66, DOI 10.1002/(SICI)1096-9861(20000619)422:1<66::AID-CNE5>3.0.CO;2-2; Klarsfeld A, 2004, J NEUROSCI, V24, P1468, DOI 10.1523/JNEUROSCI.3661-03.2004; Lee HS, 2003, J BIOL RHYTHM, V18, P435, DOI 10.1177/0748730403259106; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Levine JD, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-5; Levine JD, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-1; Nitabach MN, 2002, CELL, V109, P485, DOI 10.1016/S0092-8674(02)00737-7; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Park JH, 2000, P NATL ACAD SCI USA, V97, P3608, DOI 10.1073/pnas.070036197; Peng Y, 2003, PLOS BIOL, V1, P32, DOI 10.1371/journal.pbio.0000013; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P333, DOI 10.1007/BF01417860; Rao S, 2001, J NEUROBIOL, V49, P159, DOI 10.1002/neu.1072; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Veleri S, 2003, CURR BIOL, V13, P1758, DOI 10.1016/j.cub.2003.09.030; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Yamaguchi S, 2003, SCIENCE, V302, P1408, DOI 10.1126/science.1089287; Yang ZH, 2001, NEURON, V29, P453, DOI 10.1016/S0896-6273(01)00218-5; Yoshii T, 2004, J INSECT PHYSIOL, V50, P479, DOI 10.1016/j.jinsphys.2004.02.011; Zhao J, 2003, CELL, V113, P755, DOI 10.1016/S0092-8674(03)00400-8	30	508	518	0	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	2004	431	7010					862	868		10.1038/nature02926	http://dx.doi.org/10.1038/nature02926			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861RE	15483615				2022-12-28	WOS:000224435500051
J	Burkle, FM; Burkleft, FM				Burkle, FM; Burkleft, FM			Health and politics in the 2003 war with Iraq: lessons learned	LANCET			English	Editorial Material									Johns Hopkins Univ Med Inst, Ctr Int Emergency Disaster & Refugee Studies, Baltimore, MD USA	Johns Hopkins University	Burkle, FM (corresponding author), Ctr Int Emergency Disaster & Refugee Studies, 452 Iana St, Kailua, HI USA.	fburkle@jhsph.edu	Burkle, Frederick/AAE-5423-2020					*AMN INT, IR RESP OCC POW; *AMN INT, IR LOOT LAWL HUM CON; BACON KH, 2003, WASHINGTON POST 0307, pA33; BLAKEMORE B, ROBBED HOSP LOOTERS; Burkle F M Jr, 2001, Prehosp Disaster Med, V16, P128; Burkle FM, 1999, BRIT MED J, V319, P422, DOI 10.1136/bmj.319.7207.422; *INT HOSP FED, INF IR HOSP PRESS LO; *INT STUD TEAM, 1991, HLTH WELF IR GULF CR; MCCAFFREY BR, WE NEED MORE TROOPS; McCarthy M, 2003, LANCET, V361, P629, DOI 10.1016/S0140-6736(03)12622-0; *OV DEV I, HUM PRINC CONFL IR; *PHYS HUM RIGHTS, RES INV B, V1; SCHMITT E, NOBODY LISTENED STAT; SHANKER T, 2003, NY TIMES        1118, P10; *UN OCHA, UN OCHA INT REG INF; *UNICEF, 1999, CHILD MAT MORT SURV; *UNICEF, 2002, INT NUTR STAT SURV 5; *UNICEF, 1996, MULT IND CLUST SAMPL; *USAID OFDA, 1998, NO IR HUM PROGR 1991, P3; Valenciano M, 2003, JAMA-J AM MED ASSOC, V290, P654, DOI 10.1001/jama.290.5.654; *WHO, 2003, COMM DIS PROF IR; *WHO, 2003, JUMP START HLTH SYST, P1; IRAQ BODY COUNT HAMI	23	15	15	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	2004	364	9442					1371	1375		10.1016/S0140-6736(04)17196-1	http://dx.doi.org/10.1016/S0140-6736(04)17196-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474142				2022-12-28	WOS:000224349700035
